PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Narod, SA				Narod, Steven A.			Ten types of breast cancer?	LANCET			English	Editorial Material									[Narod, Steven A.] Univ Toronto, Womens Coll, Res Inst, Toronto, ON M5G 1N8, Canada	University of Toronto; Women's College Research Institute	Narod, SA (corresponding author), Univ Toronto, Womens Coll, Res Inst, Toronto, ON M5G 1N8, Canada.	steven.narod@wchospital.ca	Narod, Steven A/AAA-6112-2022					Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Mehta R, 2011, CLIN BREAST CANCER, V11, P20, DOI 10.3816/CBC.2011.n.004; Nielsen TO, 2010, CLIN CANCER RES, V16, P5222, DOI 10.1158/1078-0432.CCR-10-1282; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prat A, 2012, NAT REV CLIN ONCOL, V9, P48, DOI 10.1038/nrclinonc.2011.178	6	2	2	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 6	2012	380	9849					1212	+		10.1016/S0140-6736(12)60781-8	http://dx.doi.org/10.1016/S0140-6736(12)60781-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	020NG	22781491				2022-12-28	WOS:000309817500008
J	Hirota, T; Lee, JW; St John, PC; Sawa, M; Iwaisako, K; Noguchi, T; Pongsawakul, PY; Sonntag, T; Welsh, DK; Brenner, DA; Doyle, FJ; Schultz, PG; Kay, SA				Hirota, Tsuyoshi; Lee, Jae Wook; St John, Peter C.; Sawa, Mariko; Iwaisako, Keiko; Noguchi, Takako; Pongsawakul, Pagkapol Y.; Sonntag, Tim; Welsh, David K.; Brenner, David A.; Doyle, Francis J., III; Schultz, Peter G.; Kay, Steve A.			Identification of Small Molecule Activators of Cryptochrome	SCIENCE			English	Article							MAMMALIAN CIRCADIAN CLOCK; CHEMICAL BIOLOGY; PERIOD; REVEALS; METABOLISM; PHOSPHORYLATION; OSCILLATIONS; DEGRADATION; HOMEOSTASIS; RHYTHMS	Impairment of the circadian clock has been associated with numerous disorders, including metabolic disease. Although small molecules that modulate clock function might offer therapeutic approaches to such diseases, only a few compounds have been identified that selectively target core clock proteins. From an unbiased cell-based circadian phenotypic screen, we identified KL001, a small molecule that specifically interacts with cryptochrome (CRY). KL001 prevented ubiquitin-dependent degradation of CRY, resulting in lengthening of the circadian period. In combination with mathematical modeling, our studies using KL001 revealed that CRY1 and CRY2 share a similar functional role in the period regulation. Furthermore, KL001-mediated CRY stabilization inhibited glucagon-induced gluconeogenesis in primary hepatocytes. KL001 thus provides a tool to study the regulation of CRY-dependent physiology and aid development of clock-based therapeutics of diabetes.	[Lee, Jae Wook; Schultz, Peter G.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; [Hirota, Tsuyoshi; Sawa, Mariko; Pongsawakul, Pagkapol Y.; Sonntag, Tim; Kay, Steve A.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; [St John, Peter C.; Doyle, Francis J., III] Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA; [Iwaisako, Keiko; Brenner, David A.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Noguchi, Takako; Welsh, David K.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Noguchi, Takako; Welsh, David K.] Univ Calif San Diego, Ctr Chronobiol, La Jolla, CA 92093 USA; [Welsh, David K.] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA; [Hirota, Tsuyoshi; Kay, Steve A.] Univ Calif San Diego, San Diego Ctr Syst Biol, La Jolla, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego; University of California System; University of California Santa Barbara; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego	Schultz, PG (corresponding author), Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.	schultz@scripps.edu; skay@ucsd.edu	St. John, Peter/AAQ-1508-2021; Pongsawakul, Pagkapol Y./GSD-2959-2022; Kay, Steve A/F-6025-2011; Hirota, Tsuyoshi/D-8158-2015	St. John, Peter/0000-0002-7928-3722; Kay, Steve A/0000-0002-0402-2878; Hirota, Tsuyoshi/0000-0003-4876-3608; Brenner, David/0000-0003-2573-525X	NIH [GM074868, MH051573, GM085764, GM096873, MH082945]; Skaggs Institute for Chemical Biology; U.S. Army Research Office [W911NF-09-0001]; Department of Veterans Affairs Career Development Award; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM085764, R01GM096873, R01GM074868, R01GM041804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH082945, R01MH051573] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Skaggs Institute for Chemical Biology; U.S. Army Research Office; Department of Veterans Affairs Career Development Award(US Department of Veterans Affairs); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank E. Peters, X. Liu, M. Garcia, C. Cho, and R. Glynne for assistance; C. Doherty for critical reading; and K. Lamia and J. Takahashi for reagents. This work was supported in part by grants from NIH (GM074868, MH051573, and GM085764 to S. A. K.; GM096873 to F. J. D.; and MH082945 to D. K. W.), Skaggs Institute for Chemical Biology (to P. G. S), the U.S. Army Research Office (W911NF-09-0001 to F. J. D.), and a Department of Veterans Affairs Career Development Award (to D. K. W.). S. A. K. and P. G. S. serve on the Board of Reset Therapeutics and are paid consultants.	Asher G, 2011, CELL METAB, V13, P125, DOI 10.1016/j.cmet.2011.01.006; Bass J, 2010, SCIENCE, V330, P1349, DOI 10.1126/science.1195027; Busino L, 2007, SCIENCE, V316, P900, DOI 10.1126/science.1141194; Chen Z, 2012, P NATL ACAD SCI USA, V109, P101, DOI 10.1073/pnas.1118034108; Dupuis J, 2010, NAT GENET, V42, P105, DOI 10.1038/ng.520; Godinho SIH, 2007, SCIENCE, V316, P897, DOI 10.1126/science.1141138; Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022; Hirota T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000559; Hirota T, 2009, CHEM BIOL, V16, P921, DOI 10.1016/j.chembiol.2009.09.002; Hirota T, 2008, P NATL ACAD SCI USA, V105, P20746, DOI 10.1073/pnas.0811410106; Hitomi K, 2009, P NATL ACAD SCI USA, V106, P6962, DOI 10.1073/pnas.0809180106; Isojima Y, 2009, P NATL ACAD SCI USA, V106, P15744, DOI 10.1073/pnas.0908733106; Kelly MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032670; Kurabayashi N, 2010, MOL CELL BIOL, V30, P1757, DOI 10.1128/MCB.01047-09; Lamia KA, 2011, NATURE, V480, P552, DOI 10.1038/nature10700; Lee JW, 2011, ANGEW CHEM INT EDIT, V50, P10608, DOI 10.1002/anie.201103915; Siepka SM, 2007, CELL, V129, P1011, DOI 10.1016/j.cell.2007.04.030; Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030; Solt LA, 2011, FUTURE MED CHEM, V3, P623, DOI [10.4155/FMC.11.9, 10.4155/fmc.11.9]; Yin L, 2007, SCIENCE, V318, P1786, DOI 10.1126/science.1150179; Yoo SH, 2005, P NATL ACAD SCI USA, V102, P2608, DOI 10.1073/pnas.0409763102; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Zhang EE, 2010, NAT MED, V16, P1152, DOI 10.1038/nm.2214; Zhang EE, 2009, CELL, V139, P199, DOI 10.1016/j.cell.2009.08.031	24	297	313	1	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 31	2012	337	6098					1094	1097		10.1126/science.1223710	http://dx.doi.org/10.1126/science.1223710			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	996WP	22798407	Green Accepted			2022-12-28	WOS:000308125800047
J	Lu, B; Nakamura, T; Inouye, K; Li, JH; Tang, YT; Lundback, P; Valdes-Ferrer, SI; Olofsson, PS; Kalb, T; Roth, J; Zou, YR; Erlandsson-Harris, H; Yang, H; Ting, JPY; Wang, HC; Andersson, U; Antoine, DJ; Chavan, SS; Hotamisligil, GS; Tracey, KJ				Lu, Ben; Nakamura, Takahisa; Inouye, Karen; Li, Jianhua; Tang, Yiting; Lundback, Peter; Valdes-Ferrer, Sergio I.; Olofsson, Peder S.; Kalb, Thomas; Roth, Jesse; Zou, Yongrui; Erlandsson-Harris, Helena; Yang, Huan; Ting, Jenny P. -Y.; Wang, Haichao; Andersson, Ulf; Antoine, Daniel J.; Chavan, Sangeeta S.; Hotamisligil, Goekhan S.; Tracey, Kevin J.			Novel role of PKR in inflammasome activation and HMGB1 release	NATURE			English	Article							PROTEIN-KINASE PKR; SUBSTRATE RECOGNITION; NLRP3 INFLAMMASOME; APOPTOSIS; ACID; ELF2-ALPHA; INFECTION; PATHWAYS; BINDING; STRESS	The inflammasome regulates the release of caspase activation-dependent cytokines, including interleukin (IL)-1 beta, IL-18 and high-mobility group box 1 (HMGB1)(1-5). By studying HMGB1 release mechanisms, here we identify a role for double-stranded RNA-dependent protein kinase (PKR, also known as EIF2AK2) in inflammasome activation. Exposure of macrophages to inflammasome agonists induced PKR autophosphorylation. PKR inactivation by genetic deletion or pharmacological inhibition severely impaired inflammasome activation in response to double-stranded RNA, ATP, monosodium urate, adjuvant aluminium, rotenone, live Escherichia coli, anthrax lethal toxin, DNA transfection and Salmonella typhimurium infection. PKR deficiency significantly inhibited the secretion of IL-1 beta, IL-18 and HMGB1 in E. coli-induced peritonitis. PKR physically interacts with several inflammasome components, including NOD-like receptor (NLR) family pyrin domain-containing 3 (NLRP3), NLRP1, NLR family CARD domain-containing protein 4 (NLRC4), absent in melanoma 2 (AIM2), and broadly regulates inflammasome activation. PKR autophosphorylation in a cell-free system with recombinant NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC, also known as PYCARD) and pro-caspase-1 reconstitutes inflammasome activity. These results show a crucial role for PKR in inflammasome activation, and indicate that it should be possible to pharmacologically target this molecule to treat inflammation.	[Lu, Ben; Li, Jianhua; Valdes-Ferrer, Sergio I.; Olofsson, Peder S.; Kalb, Thomas; Roth, Jesse; Yang, Huan; Chavan, Sangeeta S.; Tracey, Kevin J.] Feinstein Inst Med Res, Lab Biomed Sci, Manhasset, NY 11030 USA; [Lu, Ben; Valdes-Ferrer, Sergio I.; Tracey, Kevin J.] N Shore LIJ Hlth Syst, Elmezzi Grad Sch Mol Med, Manhasset, NY 11030 USA; [Nakamura, Takahisa; Inouye, Karen; Hotamisligil, Goekhan S.] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; [Tang, Yiting; Zou, Yongrui] Feinstein Inst Med Res, Ctr Autoimmun & Musculoskeletal Dis, New York, NY 11030 USA; [Lundback, Peter; Erlandsson-Harris, Helena] Karolinska Univ Hosp, Karolinska Inst, Dept Med, S-17176 Stockholm, Sweden; [Ting, Jenny P. -Y.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Wang, Haichao] N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY 11030 USA; [Antoine, Daniel J.] Univ Liverpool, Dept Mol & Clin Pharmacol, MRC Ctr Drug Safety Sci, Liverpool L69 3GE, Merseyside, England	Northwell Health; Northwell Health; Harvard University; Harvard T.H. Chan School of Public Health; Northwell Health; Karolinska Institutet; Karolinska University Hospital; University of North Carolina; University of North Carolina Chapel Hill; Northwell Health; North Shore University Hospital; University of Liverpool	Tracey, KJ (corresponding author), Feinstein Inst Med Res, Lab Biomed Sci, 350 Community Dr, Manhasset, NY 11030 USA.	blu@nshs.edu; kjtracey@nshs.edu	Lu, Ben/AAN-1068-2021; Valdés-Ferrer, Sergio Iván/ABD-1057-2020; Wang, Haichao/K-6310-2012; Wang, Haichao/AAU-2237-2021; Lundbäck, Peter/B-5010-2013; Andersson, Ulf/ABD-5162-2021	Lu, Ben/0000-0002-8597-0406; Valdés-Ferrer, Sergio Iván/0000-0002-4863-6484; Wang, Haichao/0000-0002-0211-9000; Wang, Haichao/0000-0002-0211-9000; Andersson, Ulf/0000-0003-0316-3860; Tracey, Kevin J/0000-0003-1884-6314; Nakamura, Takahisa/0000-0003-4922-4569; Lundback, Peter/0000-0003-0399-0399; Chavan, Sangeeta S./0000-0002-4822-3356	National Institutes of Health [RO1 GM62508, DK052539]; foundation of Elmezzi Graduate School of Molecular Medicine; International Human Frontier Science Program; American Heart Association; MRC [G0700654] Funding Source: UKRI; Medical Research Council [G0700654, G0700654B] Funding Source: researchfish; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057226, R01GM062508] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); foundation of Elmezzi Graduate School of Molecular Medicine; International Human Frontier Science Program(Human Frontier Science Program); American Heart Association(American Heart Association); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank H. LaQueta, M. Dancho, M. McCarty, E. Lau, D. Katz and J. Scheinerman for technical assistance. This work was supported in part by grants from the National Institutes of Health (RO1 GM62508 to K. J. T. and DK052539 to G. S. H.). B. L. and S.I.V.-F. are supported by the foundation of Elmezzi Graduate School of Molecular Medicine. T.N. is supported by fellowships from the International Human Frontier Science Program and a Career Development Award from the American Heart Association.	Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Bauernfeind F, 2011, J IMMUNOL, V187, P613, DOI 10.4049/jimmunol.1100613; Bennett RL, 2006, BLOOD, V108, P821, DOI 10.1182/blood-2005-11-006817; Dar AC, 2005, CELL, V122, P887, DOI 10.1016/j.cell.2005.06.044; Dey M, 2005, CELL, V122, P901, DOI 10.1016/j.cell.2005.06.041; Duncan JA, 2007, P NATL ACAD SCI USA, V104, P8041, DOI 10.1073/pnas.0611496104; Franchi L, 2012, NAT IMMUNOL, V13, P325, DOI 10.1038/ni.2231; Hsu LC, 2004, NATURE, V428, P341, DOI 10.1038/nature02405; Jiang WW, 2007, J IMMUNOL, V178, P6495, DOI 10.4049/jimmunol.178.10.6495; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; Lamkanfi M, 2011, J IMMUNOL, V187, P597, DOI 10.4049/jimmunol.1100229; Lamkanfi M, 2010, J IMMUNOL, V185, P4385, DOI 10.4049/jimmunol.1000803; Manfredi AA, 2008, J IMMUNOL, V180, P2270, DOI 10.4049/jimmunol.180.4.2270; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001; Ogura Y, 2006, CELL, V126, P659, DOI 10.1016/j.cell.2006.08.002; Qin SX, 2006, J EXP MED, V203, P1637, DOI 10.1084/jem.20052203; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; Sander LE, 2011, NATURE, V474, P385, DOI 10.1038/nature10072; Schattgen SA, 2011, IMMUNOL REV, V243, P109, DOI 10.1111/j.1600-065X.2011.01053.x; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Wen HT, 2012, NAT IMMUNOL, V13, P352, DOI 10.1038/ni.2228; Willingham SB, 2009, J IMMUNOL, V183, P2008, DOI 10.4049/jimmunol.0900138; Yanai H, 2009, NATURE, V462, P99, DOI 10.1038/nature08512; Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107	26	542	584	8	220	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 30	2012	488	7413					670	+		10.1038/nature11290	http://dx.doi.org/10.1038/nature11290			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	996NC	22801494	Green Submitted, Green Accepted			2022-12-28	WOS:000308095100059
J	Trapence, G; Collins, C; Avrett, S; Carr, R; Sanchez, H; Ayala, G; Diouf, D; Beyrer, C; Baral, SD				Trapence, Gift; Collins, Chris; Avrett, Sam; Carr, Robert; Sanchez, Hugo; Ayala, George; Diouf, Daouda; Beyrer, Chris; Baral, Stefan D.			From personal survival to public health: community leadership by men who have sex with men in the response to HIV	LANCET			English	Article							MIDDLE-INCOME COUNTRIES; HIV/AIDS PREVENTION; RISK BEHAVIOR; MPOWERMENT PROJECT; AFRICAN-AMERICANS; BISEXUAL MEN; YOUNG GAY; INFECTION; INTERVENTION; INVOLVEMENT	Community leadership and participation by gay men and men who have sex with men (MSM) have been central to the response to HIV since the beginning of the epidemic. Through a wide array of actions, engagement of MSM has been important in the protection of communities. The connection between personal and community health as drivers of health advocacy continue to be a powerful element. The passion and urgency brought by MSM communities have led to the targeting and expansion of HIV and AIDS research and programming, and have improved the synergy of health and human rights, sustainability, accountability, and health outcomes for all people affected by HIV. MSM are, however, frequently excluded from the evidence-based services that they helped to develop, despite them generally being the most effective actors in challenging environments. Without MSM community involvement, government-run health programmes might have little chance of effectively reaching communities or scaling up interventions to lessen, and ultimately end, the HIV pandemic.	[Baral, Stefan D.] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Ctr Publ Hlth & Human Rights, Baltimore, MD 21205 USA; [Trapence, Gift] Ctr Dev People, Lilongwe, Malawi; [Collins, Chris] AmfaR, Washington, DC USA; [Carr, Robert] Int Council AIDS Serv Org, Toronto, ON, Canada; [Sanchez, Hugo] Epictr, Lima, Peru; [Ayala, George] Global Forum MSM & HIV MSMGF, Oakland, CA USA; [Diouf, Daouda] Environm Dev Act Third World ENDA, Dakar, Senegal	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Baral, SD (corresponding author), Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Ctr Publ Hlth & Human Rights, E7146,615 N Wolfe St, Baltimore, MD 21205 USA.	sbaral@jhsph.edu	Ayala, George/AAF-6035-2021; Baral, Stefan/AAG-4818-2020; Baral, Stefan/D-2930-2013	Baral, Stefan/0000-0002-5482-2419; 	Ford Foundation; amFaR, The Foundation for AIDS Research; Bill & Melinda Gates Foundation; Johns Hopkins Center for AIDS Research (NIAID) [1P30AI094189-01A1]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI094189] Funding Source: NIH RePORTER	Ford Foundation; amFaR, The Foundation for AIDS Research; Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); Johns Hopkins Center for AIDS Research (NIAID); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding for in-country consultations was provided by the Ford Foundation. This paper and The Lancet HIV in MSM Series was supported by grants to the Center for Public Health and Human Rights at Johns Hopkins, from amFaR, The Foundation for AIDS Research, and the Bill & Melinda Gates Foundation. CB was partly supported by the Johns Hopkins Center for AIDS Research (NIAID, 1P30AI094189-01A1).	Adam PCG, 2009, JAIDS-J ACQ IMM DEF, V52, pS143, DOI 10.1097/QAI.0b013e3181baf111; ALTMAN DG, 1995, HEALTH PSYCHOL, V14, P526, DOI 10.1037/0278-6133.14.6.526; [amfAR IAVI Center for Public Health and Human Rights JHSPH], 2011, RESP PROT FULF BEST; [amfAR Johns Hopkins Bloomberg School of Public Health Center for Public Health and Human Rights], 2011, ACH AIDS FREE GEN GA; amfAR, 2008, MSM HIV ROAD UN ACC; amfAR, 2010, INT RIGHTS HLTH MSM; AmfAR M, 2010, LESSONS FRONT LINES; [Anonymous], BBC; [Anonymous], ECONOMIST; [Anonymous], 1983, DENV PRINC; APCOM, 2010, ORG MAPP PROJ HIV AI; Asthana S, 1996, SOC SCI MED, V43, P133, DOI 10.1016/0277-9536(95)00348-7; Baral SD, 2010, INT AIDS C VIENN AUS; Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339; Baral S, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-36; Baral S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004997; Barr D, 2008, RESTORING HOPE: DECENT CARE IN THE MIDST OF HIV/AIDS, P139; Berkowitz Richard, 1983, HAVE SEX EPIDEMIC ON; Beyrer C, 2011, DIR DEV, P1, DOI 10.1596/978-0-8213-8726-9; Beyrer C, 2012, LANCET; Beyrer C, 2011, LANCET, V378, P1619, DOI 10.1016/S0140-6736(11)61686-3; Brown P, 1995, NEW APPROACHES EVALU; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Burrage Joe, 2003, J Assoc Nurses AIDS Care, V14, P52, DOI 10.1177/1055329002239190; BUTTERFOSS FD, 1993, HEALTH EDUC RES, V8, P315, DOI 10.1093/her/8.3.315; Caceres CF, 2008, SEX TRANSM INFECT, V84, pI49, DOI 10.1136/sti.2008.030569; Chillag K, 2002, AIDS EDUC PREV, V14, P27, DOI 10.1521/aeap.14.4.27.23886; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Corbie-Smith G, 1999, J GEN INTERN MED, V14, P537, DOI 10.1046/j.1525-1497.1999.07048.x; Csete J, 2011, HUMAN RIGHTS GLOBAL; DeGruttola V, 2010, CLIN INFECT DIS, V50, pS102, DOI 10.1086/651480; Diouf D, 2007, HIV AIDS POLICY SENE; Dworkin SL, 2008, AM J COMMUN PSYCHOL, V42, P51, DOI 10.1007/s10464-008-9183-y; Earl L., 1995, PARTICIPATORY EVALUA; Easton D, 2007, AIDS EDUC PREV, V19, P465, DOI 10.1521/aeap.2007.19.6.465; EMMONS CA, 1986, HEALTH EDUC QUART, V13, P331, DOI 10.1177/109019818601300405; Frasca T, 2005, AIDS LATIN AM SEX CL; Galea S, 2001, PUBLIC HEALTH REP, V116, P530, DOI 10.1093/phr/116.6.530; Gamble VN, 1997, AM J PUBLIC HEALTH, V87, P1773, DOI 10.2105/AJPH.87.11.1773; Geibel S, 2008, SEX TRANSM DIS, V35, P746, DOI 10.1097/OLQ.0b013e318170589d; Godwin J, 2010, REPORT INT CONSULTAT; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Green LW, 2001, AM J PUBLIC HEALTH, V91, P1926, DOI 10.2105/AJPH.91.12.1926; GuentherGrey C, 1996, PUBLIC HEALTH REP, V111, P41; Hall B.L., 1992, AM SOCIOL, V23, P15, DOI [10.1007/BF02691928, DOI 10.1007/BF02691928]; Harrington M, 2009, JAIDS-J ACQ IMM DEF, V52, pS63, DOI 10.1097/QAI.0b013e3181bbcc56; Hays RB, 2003, AM J COMMUN PSYCHOL, V31, P301, DOI 10.1023/A:1023966905973; Hinsch B, 1992, PASSIONS CUT SLEEVE; Hoad Neville Wallace, 2005, SEX POLITICS S AFRIC; India HIV/AIDS Alliance, 2011, 1 YEAR PEHCH; International HIV/AIDS Alliance CHaAAG, 2010, EN LEG ENV EFF HIV R; International Woman's Rights Action Watch Asia Pacific (IWRAW), OCCASIONAL PAPERS SE, V7, P8; IRMA, 2010, PROM PROD ADV RECT M; Israel B A, 2001, Educ Health (Abingdon), V14, P182; ITP Coalition, 2008, CCM ADV REP MAK GLOB; Izazola-Licea JA, 2009, JAIDS-J ACQ IMM DEF, V52, pS119, DOI 10.1097/QAI.0b013e3181baeeda; Jaffe HW, 2007, JAMA-J AM MED ASSOC, V298, P2412, DOI 10.1001/jama.298.20.2412; Johnson CA, 2007, MAP HIV AIDS PROGRAM; Kahn JG, 2001, J ACQ IMMUN DEF SYND, V27, P482, DOI 10.1097/00126334-200108150-00010; Kelly KJ, 2010, AIDS CARE, V22, P1580, DOI 10.1080/09540121.2010.524191; Koblin B, 2004, LANCET, V364, P41, DOI 10.1016/S0140-6736(04)16588-4; Landers S, 2011, AIDS BEHAV, V15, pS101, DOI 10.1007/s10461-011-9896-z; Lane T, 2008, AIDS BEHAV, V12, pS78, DOI 10.1007/s10461-008-9389-x; Latkin C, 2010, AIDS BEHAV, V14, pS222, DOI 10.1007/s10461-010-9804-y; Mbali M., 2005, TAC HIST RIGHTS BASE; McGowan I, 2011, AIDS BEHAV, V15, pS66, DOI 10.1007/s10461-011-9899-9; Merson MH, 2008, LANCET, V372, P475, DOI 10.1016/S0140-6736(08)60884-3; Millett GA, 2012, LANCET; Munthali K, GAYS WORSE DOGS BING; Narayanan S, 2011, INT J DRUG POLICY, V22, P311, DOI 10.1016/j.drugpo.2011.01.002; Olukya G, D BAHATI UGANDA LAWM; Oosterhoff P, 2008, REPROD HEALTH MATTER, V16, P162, DOI 10.1016/S0968-8080(08)32408-2; Opuni M, 2002, AIDS, V16, pS53, DOI 10.1097/00002030-200216004-00008; OSTROW DG, 1986, PSYCHOPHARMACOL BULL, V22, P678; Palacios-Jimenez L, 1986, FACILITATORS GUIDE E; PEPFAR, 2011, TECHN GUID COMB HIV; Pitisuttithum P, 2004, JAIDS-J ACQ IMM DEF, V37, P1160, DOI 10.1097/01.qai.0000136091.72955.4b; Poteat T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028760; Ramirez-Valles J, 2003, AIDS EDUC PREV, V15, P90, DOI 10.1521/aeap.15.1.5.90.23606; Ramirez-Valles J, 2002, HEALTH EDUC RES, V17, P389, DOI 10.1093/her/17.4.389; Ramirez-Valles J, 2010, J HEALTH SOC BEHAV, V51, P30, DOI 10.1177/0022146509361176; Richter DL, 2006, AIDS EDUC PREV, V18, P362, DOI 10.1521/aeap.2006.18.4.362; Rodriguez-Garcia R, 2011, ANAL COMMUNITY RESP; Sandfort T, 2009, SOCIAL SILENCE SOCIA; SCHENSUL JJ, 2005, COMMUNITY INTERVENTI, P176; Schultz A, 2004, HDB SOCIAL WORK GROU; Schwartlander B, 2011, LANCET, V377, P2031, DOI 10.1016/S0140-6736(11)60702-2; Shernoff M, 1990, CHANGING FACE GAY ME; Sullivan PS, 2012, LANCET; Sweat M, 2011, LANCET INFECT DIS, V11, P525, DOI 10.1016/S1473-3099(11)70060-3; The Global Fund, 2010, GLOB FUND STRAT REL; THOMAS SB, 1991, AM J PUBLIC HEALTH, V81, P1498, DOI 10.2105/AJPH.81.11.1498; UN General Assembly, 1966, UN TREAT SER, V993, P3; UNDP, 2011, UN ACC EX MUN HIV PR; van Griensven F, 2010, JAIDS-J ACQ IMM DEF, V53, P234, DOI 10.1097/QAI.0b013e3181c2fc86; Wentzy James, 2002, FIGHT BACK FIGHT AID; Wohlfeiler D, 2002, SEX TRANSM INFECT, V78, pI176, DOI 10.1136/sti.78.suppl_1.i176; World Health Organization, 2011, PREVENTION TREATMENT; World Health Organization (WHO), 1978, ALM AT INT C PRIM HL; Zimmerman MA, 1997, HEALTH EDUC BEHAV, V24, P177, DOI 10.1177/109019819702400206	100	79	80	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 28	2012	380	9839					400	410		10.1016/S0140-6736(12)60834-4	http://dx.doi.org/10.1016/S0140-6736(12)60834-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819662	Green Accepted			2022-12-28	WOS:000306842800038
J	Bui, M; Dimitriadis, EK; Hoischen, C; An, E; Quenet, D; Giebe, S; Nita-Lazar, A; Diekmann, S; Dalal, Y				Bui, Minh; Dimitriadis, Emilios K.; Hoischen, Christian; An, Eunkyung; Quenet, Delphine; Giebe, Sindy; Nita-Lazar, Aleksandra; Diekmann, Stephan; Dalal, Yamini			Cell-Cycle-Dependent Structural Transitions in the Human CENP-A Nucleosome In Vivo	CELL			English	Article							CENTROMERIC CHROMATIN; BUDDING YEAST; NONHISTONE SCM3; TERMINAL DOMAIN; DNA; COMPLEX; HJURP; DYNAMICS; LOCALIZATION; PROPAGATION	In eukaryotes, DNA is packaged into chromatin by canonical histone proteins. The specialized histone H3 variant CENP-A provides an epigenetic and structural basis for chromosome segregation by replacing H3 at centromeres. Unlike exclusively octameric canonical H3 nucleosomes, CENP-A nucleosomes have been shown to exist as octamers, hexamers, and tetramers. An intriguing possibility reconciling these observations is that CENP-A nucleosomes cycle between octamers and tetramers in vivo. We tested this hypothesis by tracking CENP-A nucleosomal components, structure, chromatin folding, and covalent modifications across the human cell cycle. We report that CENP-A nucleosomes alter from tetramers to octamers before replication and revert to tetramers after replication. These structural transitions are accompanied by reversible chaperone binding, chromatin fiber folding changes, and previously undescribed modifications within the histone fold domains of CENP-A and H4. Our results reveal a cyclical nature to CENP-A nucleosome structure and have implications for the maintenance of epigenetic memory after centromere replication.	[Bui, Minh; Quenet, Delphine; Dalal, Yamini] NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA; [Dimitriadis, Emilios K.] Natl Inst Biomed Imaging & Bioengn, Lab Biomed Engn & Phys Sci, NIH, Bethesda, MD 20892 USA; [An, Eunkyung; Nita-Lazar, Aleksandra] NIAID, Lab Syst Biol, NIH, Bethesda, MD 20892 USA; [Hoischen, Christian; Giebe, Sindy; Diekmann, Stephan] Fritz Lipmann Inst, Jena, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Dalal, Y (corresponding author), NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA.	dalaly@mail.nih.gov	Nita-Lazar, Aleksandra/N-3740-2018	Nita-Lazar, Aleksandra/0000-0002-8523-605X; Dalal, Yamini/0000-0002-7655-6182; Bui, Minh/0000-0002-7984-3275	NIH/NCI; Deutsche Forschungsgemeinschaft; NATIONAL CANCER INSTITUTE [ZIABC011207, ZIABC011209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001085, ZIAAI001084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [ZICEB000085, ZICEB000070] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank Drs. Shiv Grewal, Tom Misteli, Gordon Hager, Sam John, and anonymous reviewers for insightful comments and suggestions, and P. Donlin-Asp for preliminary FRET experiments. The NIH/NCI Intramural Research Programs (Y.D., A.N.-L., and E.K.D.), and the Deutsche Forschungsgemeinschaft (S.D.) supported this work. We thank Jennifer Gerton for sharing unpublished work complementary to our findings in this manuscript.	Allshire RC, 2008, NAT REV GENET, V9, P923, DOI 10.1038/nrg2466; An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j; Ando S, 2002, MOL CELL BIOL, V22, P2229, DOI 10.1128/MCB.22.7.2229-2241.2002; Bintu L, 2011, NAT STRUCT MOL BIOL, V18, P1394, DOI 10.1038/nsmb.2164; Black BE, 2004, NATURE, V430, P578, DOI 10.1038/nature02766; Black B, 2011, CELL, V144, P471, DOI 10.1016/j.cell.2011.02.002; Bloom K, 2010, NATURE, V463, P446, DOI 10.1038/nature08912; Camahort R, 2009, MOL CELL, V35, P794, DOI 10.1016/j.molcel.2009.07.022; Carroll CW, 2010, J CELL BIOL, V189, P1143, DOI 10.1083/jcb.201001013; Dalai Y, 2010, CURR OPIN CELL BIOL, V22, P392, DOI 10.1016/j.ceb.2010.02.005; Dalal Y, 2005, NUCLEIC ACIDS RES, V33, P934, DOI 10.1093/nar/gki224; Dalal Y, 2007, PLOS BIOL, V5, P1798, DOI 10.1371/journal.pbio.0050218; Dechassa ML, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1320; Dimitriadis EK, 2010, P NATL ACAD SCI USA, V107, P20317, DOI 10.1073/pnas.1009563107; Dunleavy EM, 2011, NUCLEUS-PHILA, V2, P146, DOI 10.4161/nucl.2.2.15211; Dunleavy EM, 2009, CELL, V137, P485, DOI 10.1016/j.cell.2009.02.040; Foltz DR, 2009, CELL, V137, P472, DOI 10.1016/j.cell.2009.02.039; Furuyama T, 2009, CELL, V138, P104, DOI 10.1016/j.cell.2009.04.049; Hellwig D, 2011, J CELL SCI, V124, P3871, DOI 10.1242/jcs.088625; Hellwig D, 2008, J BIOPHOTONICS, V1, P245, DOI 10.1002/jbio.200810014; Hemmerich P, 2008, J CELL BIOL, V180, P1101, DOI 10.1083/jcb.200710052; Henikoff S, 2010, COLD SH Q B, V75, P51, DOI 10.1101/sqb.2010.75.001; Hu H, 2011, GENE DEV, V25, P901, DOI 10.1101/gad.2045111; Jansen LET, 2007, J CELL BIOL, V176, P795, DOI 10.1083/jcb.200701066; Kalitsis P, 2003, CHROMOSOME RES, V11, P345, DOI 10.1023/A:1024044008009; Marshall OJ, 2008, J CELL BIOL, V183, P1193, DOI 10.1083/jcb.200804078; Mizuguchi G, 2007, CELL, V129, P1153, DOI 10.1016/j.cell.2007.04.026; Neumann H, 2009, MOL CELL, V36, P153, DOI 10.1016/j.molcel.2009.07.027; Perpelescu M, 2009, J CELL BIOL, V185, P397, DOI 10.1083/jcb.200903088; Probst AV, 2009, NAT REV MOL CELL BIO, V10, P192, DOI 10.1038/nrm2640; Schuh M, 2007, CURR BIOL, V17, P237, DOI 10.1016/j.cub.2006.11.051; Screpanti E, 2011, CURR BIOL, V21, P391, DOI 10.1016/j.cub.2010.12.039; Sekulic N, 2010, NATURE, V467, P347, DOI 10.1038/nature09323; Shelby RD, 2000, J CELL BIOL, V151, P1113, DOI 10.1083/jcb.151.5.1113; Shuaib M, 2010, P NATL ACAD SCI USA, V107, P1349, DOI 10.1073/pnas.0913709107; Shukla MS, 2010, P NATL ACAD SCI USA, V107, P1936, DOI 10.1073/pnas.0904497107; Silva NCE, 2007, J MOL BIOL, V370, P555, DOI 10.1016/j.jmb.2007.04.064; Simon M, 2011, P NATL ACAD SCI USA, V108, P12711, DOI 10.1073/pnas.1106264108; Sullivan BA, 2004, NAT STRUCT MOL BIOL, V11, P1076, DOI 10.1038/nsmb845; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Tachiwana H, 2011, NATURE, V476, P232, DOI 10.1038/nature10258; Torigoe SE, 2011, MOL CELL, V43, P638, DOI 10.1016/j.molcel.2011.07.017; Trazzi S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005832; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Wan XH, 2009, CELL, V137, P672, DOI 10.1016/j.cell.2009.03.035; Wang HD, 2008, EPIGENET CHROMATIN, V1, DOI 10.1186/1756-8935-1-10; Xiao H, 2011, MOL CELL, V43, P369, DOI 10.1016/j.molcel.2011.07.009; Zhang WG, 2012, MOL CELL, V45, P263, DOI 10.1016/j.molcel.2011.12.010; Zlatanova J, 2006, MOL CELL, V24, P317, DOI 10.1016/j.molcel.2006.10.017	49	103	106	1	29	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 20	2012	150	2					317	326		10.1016/j.cell.2012.05.035	http://dx.doi.org/10.1016/j.cell.2012.05.035			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817894	Bronze, Green Accepted			2022-12-28	WOS:000306595700011
J	Svetlov, V; Nudler, E				Svetlov, Vladimir; Nudler, Evgeny			Unfolding the Bridge between Transcription and Translation	CELL			English	Editorial Material							RNA-POLYMERASE; ELONGATION; RIBOSOMES; RFAH		[Svetlov, Vladimir; Nudler, Evgeny] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA	New York University	Nudler, E (corresponding author), NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA.	evgeny.nudler@nyumc.org		Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058750] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058750, R01 GM58750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakshi S, 2012, MOL MICROBIOL, V85, P21, DOI 10.1111/j.1365-2958.2012.08081.x; Belogurov GA, 2007, MOL CELL, V26, P117, DOI 10.1016/j.molcel.2007.02.021; Belogurov GA, 2010, MOL MICROBIOL, V76, P286, DOI 10.1111/j.1365-2958.2010.07056.x; Belogurov GA, 2009, EMBO J, V28, P112, DOI 10.1038/emboj.2008.268; Bryan PN, 2010, CURR OPIN STRUC BIOL, V20, P482, DOI 10.1016/j.sbi.2010.06.002; Burmann BM, 2012, CELL, V150, P291, DOI 10.1016/j.cell.2012.05.042; Burmann BM, 2011, BIOCHEM J, V435, P783, DOI 10.1042/BJ20101679; Burmann BM, 2010, SCIENCE, V328, P501, DOI 10.1126/science.1184953; Proshkin S, 2010, SCIENCE, V328, P504, DOI 10.1126/science.1184939; Sevostyanova A, 2011, MOL CELL, V43, P253, DOI 10.1016/j.molcel.2011.05.026	10	9	9	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 20	2012	150	2					243	245		10.1016/j.cell.2012.06.025	http://dx.doi.org/10.1016/j.cell.2012.06.025			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817886	Green Accepted, Bronze			2022-12-28	WOS:000306595700003
J	Diehl, AK				Diehl, Andrew K.			Review: Daily aspirin reduces short-term risk for cancer and cancer mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Diehl, AK (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.							Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; US Preventive Services Task Force, 2007, ANN INTERN MED, V146, P361, DOI 10.7326/0003-4819-146-5-200703060-00008	3	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2							JC2-2	10.7326/0003-4819-157-2-201207170-02002	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-02002			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801694				2022-12-28	WOS:000307787900001
J	Spence, D				Spence, Des			Don't just blame big pharma	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						[Anonymous], 2012, TELEGRAPH; Cratty C., 2009, CNN             0902; Jack A., 2012, FINANCIAL TIMES; Neville S., 2012, GUARDIAN        0529; UNITED STATES. Department of Justice. Office of Public Affairs, 2012, US PHARM CO MERCK SH	5	0	0	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 17	2012	345								e4825	10.1136/bmj.e4825	http://dx.doi.org/10.1136/bmj.e4825			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978LQ	22807079				2022-12-28	WOS:000306742900006
J	Chapman, F; Blackmur, JP; Fotheringham, J; Watson, S; Whitworth, C; Dhaun, N				Chapman, Fiona; Blackmur, James P.; Fotheringham, James; Watson, Simon; Whitworth, Caroline; Dhaun, Neeraj			An uncommon cause of pleural effusions in a dialysis patient	LANCET			English	Editorial Material									[Chapman, Fiona; Blackmur, James P.; Watson, Simon; Whitworth, Caroline; Dhaun, Neeraj] Royal Infirm, Dept Renal Med, Edinburgh, Midlothian, Scotland; [Fotheringham, James] Univ Sheffield, Sheffield Kidney Inst, Sheffield, S Yorkshire, England; [Fotheringham, James] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England	Royal Infirmary of Edinburgh; University of Sheffield; University of Sheffield	Dhaun, N (corresponding author), Queens Med Res Inst, 3rd Floor E,Room E3-23,47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	bean.dhaun@ed.ac.uk	Blackmur, James/ABM-7695-2022	Blackmur, James/0000-0001-7267-837X				Dillard M G, 1979, J Natl Med Assoc, V71, P285; MacRae JM, 2004, AM J KIDNEY DIS, V43, DOI 10.1053/j.ajkd.2004.01.016; Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80; The Renal. Association, VASC ASSC HAEM; UK Renal Registry, 2010, 13 UK REN REG	5	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2012	380	9837					186	186		10.1016/S0140-6736(12)60403-6	http://dx.doi.org/10.1016/S0140-6736(12)60403-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	973KN	22794247				2022-12-28	WOS:000306359100047
J	Jaworski, CM; Myers, RC; Johnston-Halperin, E; Heremans, JP				Jaworski, C. M.; Myers, R. C.; Johnston-Halperin, E.; Heremans, J. P.			Giant spin Seebeck effect in a non-magnetic material	NATURE			English	Article								The spin Seebeck effect is observed when a thermal gradient applied to a spin-polarized material leads to a spatially varying transverse spin current in an adjacent non-spin-polarized material, where it gets converted into a measurable voltage. It has been previously observed with a magnitude of microvolts per kelvin in magnetically ordered materials, ferromagnetic metals(1), semiconductors(2) and insulators(3). Here we describe a signal in a non-magnetic semiconductor (InSb) that has the hallmarks of being produced by the spin Seebeck effect, but is three orders of magnitude larger (millivolts per kelvin). We refer to the phenomenon that produces it as the giant spin Seebeck effect. Quantizing magnetic fields spin-polarize conduction electrons in semiconductors by means of Zeeman splitting, which spin-orbit coupling amplifies by a factor of similar to 25 in InSb. We propose that the giant spin Seebeck effect is mediated by phonon-electron drag, which changes the electrons' momentum and directly modifies the spin-splitting energy through spin-orbit interactions. Owing to the simultaneously strong phonon-electron drag and spin-orbit coupling in InSb, the magnitude of the giant spin Seebeck voltage is comparable to the largest known classical thermopower values.	[Jaworski, C. M.; Heremans, J. P.] Ohio State Univ, Dept Mech Engn, Columbus, OH 43210 USA; [Myers, R. C.] Ohio State Univ, Dept Mat Sci & Engn, Columbus, OH 43210 USA; [Myers, R. C.; Johnston-Halperin, E.; Heremans, J. P.] Ohio State Univ, Dept Phys, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Heremans, JP (corresponding author), Ohio State Univ, Dept Mech Engn, Columbus, OH 43210 USA.	heremans.1@osu.edu	Myers, Roberto/B-4431-2008; Heremans, Joseph P/D-3298-2015; Johnston-Halperin, Ezekiel/B-5902-2012; Johnston-Halperin, Ezekiel/AAM-2564-2021	Myers, Roberto/0000-0002-3695-2244; Heremans, Joseph P/0000-0003-3996-2744; Johnston-Halperin, Ezekiel/0000-0002-6240-3505	NSF [CBET-1133589, DMR-0820414]; DOE GATE Center of Excellence [FG26 05NT42616]; Div Of Chem, Bioeng, Env, & Transp Sys [1133589] Funding Source: National Science Foundation	NSF(National Science Foundation (NSF)); DOE GATE Center of Excellence; Div Of Chem, Bioeng, Env, & Transp Sys(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG))	We thank Y. Kato, H. Adachi, S. Maekawa and D. Stroud for discussions, and K. Wickey for assistance. This work was supported by the NSF CBET-1133589 (data acquisition and interpretation) and by DMR-0820414 (sample preparation). C.M.J. has a fellowship from the DOE GATE Center of Excellence FG26 05NT42616.	Adachi H, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.094410; Adachi H, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3529944; Bosu S, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.224401; Jaworski CM, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.186601; Jaworski CM, 2010, NAT MATER, V9, P898, DOI [10.1038/nmat2860, 10.1038/NMAT2860]; Le Breton JC, 2011, NATURE, V475, P82, DOI 10.1038/nature10224; Madelung O., 1982, LANDOLT BORNSTEIN NU, V17; PURI SM, 1964, PHYS REV A-GEN PHYS, V136, P1767; Saitoh E, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2199473; Shoenberg D., 1984, MAGNETIC OSCILLATION; Tserkovnyak Y, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.224403; Uchida K, 2008, NATURE, V455, P778, DOI 10.1038/nature07321; Uchida K, 2010, NAT MATER, V9, P894, DOI [10.1038/NMAT2856, 10.1038/nmat2856]; Uchida K, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3507386; Valenzuela SO, 2006, NATURE, V442, P176, DOI 10.1038/nature04937; Weiler M, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.106602; Xiao J, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.214418; Yu HM, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.146601	19	147	148	6	237	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2012	487	7406					210	213		10.1038/nature11221	http://dx.doi.org/10.1038/nature11221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972LP	22785317				2022-12-28	WOS:000306278900034
J	Di Giuseppe, D; Alfredsson, L; Bottai, M; Askling, J; Wolk, A				Di Giuseppe, Daniela; Alfredsson, Lars; Bottai, Matteo; Askling, Johan; Wolk, Alicja			Long term alcohol intake and risk of rheumatoid arthritis in women: a population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							TIME-SCALE; CONSUMPTION; INFLAMMATION; CELL; QUESTIONNAIRE; INHIBITION; INDUCTION; RESPONSES; SMOKING; DISEASE	Objective To analyse the association between alcohol intake and incidence of rheumatoid arthritis in women. Design Prospective cohort study with repeated measurements. Setting The Swedish Mammography Cohort, a population based cohort from central Sweden. Participants 34 141 women born between 1914 and 1948, followed up from 1 January 2003 to 31 December 2009. Main outcome measures Newly diagnosed cases of rheumatoid arthritis identified by linkage with two Swedish national registers. Data on alcohol consumption were collected in 1987 and 1997. Results During the follow-up period (226 032 person years), 197 incident cases of rheumatoid arthritis were identified. There was a statistically significant 37% decrease in risk of rheumatoid arthritis among women who drank >4 glasses of alcohol (1 glass = 15 g of ethanol) per week compared with women who drank <1 glass per week or who never drank alcohol (relative risk 0.63 (95% confidence interval 0.42 to 0.96), P=0.04). Drinking of all types of alcohol (beer, wine, and liquor) was non-significantly inversely associated with the risk of rheumatoid arthritis. Analysis of long term alcohol consumption showed that women who reported drinking >3 glasses of alcohol per week in both 1987 and 1997 had a 52% decreased risk of rheumatoid arthritis compared with those who never drank (relative risk 0.48 (0.24 to 0.98)). Conclusion Moderate consumption of alcohol is associated with reduced risk of rheumatoid arthritis.	[Di Giuseppe, Daniela; Wolk, Alicja] Karolinska Inst, Inst Environm Med, Div Nutr Epidemiol, S-17177 Stockholm, Sweden; [Alfredsson, Lars] Karolinska Inst, Inst Environm Med, Div Cardiovasc Epidemiol, S-17177 Stockholm, Sweden; [Bottai, Matteo] Karolinska Inst, Inst Environm Med, Div Biostat, S-17177 Stockholm, Sweden; [Askling, Johan] Karolinska Hosp, Dept Med, Clin Epidemiol Unit, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Wolk, A (corresponding author), Karolinska Inst, Inst Environm Med, Div Nutr Epidemiol, Box 210, S-17177 Stockholm, Sweden.	Alicja.Wolk@ki.se	Alfredsson, Lars/AAC-9007-2019	Alfredsson, Lars/0000-0003-1688-6697; Di Giuseppe, Daniela/0000-0003-3817-8288	Swedish Research Council's Committee for Research Infrastructure; Karolinska Institute's Award for PhD students (KID)	Swedish Research Council's Committee for Research Infrastructure; Karolinska Institute's Award for PhD students (KID)	The study was supported by research grants from the Swedish Research Council's Committee for Research Infrastructure for maintenance of the Swedish Mammography Cohort, and from the Karolinska Institute's Award for PhD students (KID-funding).	AHO K, 1993, ANN RHEUM DIS, V52, P897, DOI 10.1136/ard.52.12.897-b; Baecklund E, 2006, ARTHRITIS RHEUM, V54, P692, DOI 10.1002/art.21675; Cerhan JR, 2002, J RHEUMATOL, V29, P246; Fan J, 2011, ALCOHOL CLIN EXP RES, V35, P47, DOI 10.1111/j.1530-0277.2010.01321.x; Friberg E, 2009, CANCER EPIDEM BIOMAR, V18, P355, DOI 10.1158/1055-9965.EPI-08-0993; Hansson LM, 2000, NUTR CANCER, V36, P1, DOI 10.1207/S15327914NC3601_1; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HAZES JMW, 1990, ANN RHEUM DIS, V49, P980, DOI 10.1136/ard.49.12.980; Heliovaara M, 2000, ANN RHEUM DIS, V59, P631, DOI 10.1136/ard.59.8.631; Imhof A, 2004, EUR HEART J, V25, P2092, DOI 10.1016/j.ehj.2004.09.032; Jonsson IM, 2007, P NATL ACAD SCI USA, V104, P258, DOI 10.1073/pnas.0608620104; Kallberg H, 2009, ANN RHEUM DIS, V68, P222, DOI 10.1136/ard.2007.086314; Knight A, 2010, J RHEUMATOL, V37, P2553, DOI 10.3899/jrheum.091280; Korn EL, 1997, AM J EPIDEMIOL, V145, P72; Lu B, 2010, ARTHRITIS RHEUM-US, V62, P3554, DOI 10.1002/art.27739; Ludvigsson JF, 2009, EUR J EPIDEMIOL, V24, P659, DOI 10.1007/s10654-009-9350-y; Mandrekar P, 2006, ALCOHOL CLIN EXP RES, V30, P135, DOI 10.1111/j.1530-0277.2006.00012.x; Mandrekar P, 2004, J IMMUNOL, V173, P3398, DOI 10.4049/jimmunol.173.5.3398; Maxwell JR, 2010, RHEUMATOLOGY, V49, P2140, DOI 10.1093/rheumatology/keq202; Messerer M, 2004, J NUTR, V134, P1800, DOI 10.1093/jn/134.7.1800; Neovius M, 2011, ANN RHEUM DIS, V70, P624, DOI 10.1136/ard.2010.133371; Pedersen M, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2022; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Thiebaut ACM, 2004, STAT MED, V23, P3803, DOI 10.1002/sim.2098; Verma Shilpi, 2008, V447, P295, DOI 10.1007/978-1-59745-242-7_20; VOIGT LF, 1994, EPIDEMIOLOGY, V5, P525; Waldschmidt TJ, 2006, ALCOHOL, V38, P121, DOI 10.1016/j.alcohol.2006.05.001	27	69	72	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 10	2012	345								e4230	10.1136/bmj.e4230	http://dx.doi.org/10.1136/bmj.e4230			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975NT	22782847	hybrid, Green Published			2022-12-28	WOS:000306518700001
J	Das, P				Das, Pamela			Profile Jim Kim: new President of the World Bank	LANCET			English	Biographical-Item																			0	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 7	2012	380	9836					19	19		10.1016/S0140-6736(12)61033-2	http://dx.doi.org/10.1016/S0140-6736(12)61033-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970GK	22760080	Bronze			2022-12-28	WOS:000306115900013
J	Bourassa, AE; Robock, A; Randel, WJ; Deshler, T; Rieger, LA; Lloyd, ND; Llewellyn, EJ; Degenstein, DA				Bourassa, Adam E.; Robock, Alan; Randel, William J.; Deshler, Terry; Rieger, Landon A.; Lloyd, Nicholas D.; Llewellyn, E. J. (Ted); Degenstein, Douglas A.			Large Volcanic Aerosol Load in the Stratosphere Linked to Asian Monsoon Transport	SCIENCE			English	Article							EL-CHICHON; ERUPTIONS	The Nabro stratovolcano in Eritrea, northeastern Africa, erupted on 13 June 2011, injecting approximately 1.3 teragrams of sulfur dioxide (SO2) to altitudes of 9 to 14 kilometers in the upper troposphere, which resulted in a large aerosol enhancement in the stratosphere. The SO2 was lofted into the lower stratosphere by deep convection and the circulation associated with the Asian summer monsoon while gradually converting to sulfate aerosol. This demonstrates that to affect climate, volcanic eruptions need not be strong enough to inject sulfur directly to the stratosphere.	[Bourassa, Adam E.; Rieger, Landon A.; Lloyd, Nicholas D.; Llewellyn, E. J. (Ted); Degenstein, Douglas A.] Univ Saskatchewan, Inst Space & Atmospher Studies, Saskatoon, SK S7N 5E2, Canada; [Robock, Alan] Rutgers State Univ, Dept Environm Sci, New Brunswick, NJ 08901 USA; [Randel, William J.] Natl Ctr Atmospher Res, Boulder, CO 80307 USA; [Deshler, Terry] Univ Wyoming, Dept Atmospher Sci, Laramie, WY 82071 USA	University of Saskatchewan; Rutgers State University New Brunswick; National Center Atmospheric Research (NCAR) - USA; University of Wyoming	Bourassa, AE (corresponding author), Univ Saskatchewan, Inst Space & Atmospher Studies, Saskatoon, SK S7N 5E2, Canada.	adam.bourassa@usask.ca	Robock, Alan/B-6385-2016; Randel, William J/K-3267-2016	Randel, William J/0000-0002-5999-7162; Robock, Alan/0000-0002-6319-5656	Natural Sciences and Engineering Research Council of Canada; Canadian Space Agency; U.S. National Science Foundation (NSF) [ATM-0730452]; NSF [ATM-1011827]; NSF; Div Atmospheric & Geospace Sciences [1011827] Funding Source: National Science Foundation	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian Space Agency(Canadian Space Agency); U.S. National Science Foundation (NSF)(National Science Foundation (NSF)); NSF(National Science Foundation (NSF)); NSF(National Science Foundation (NSF)); Div Atmospheric & Geospace Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	A.E.B., D.A.D., and E.J.L. are supported by the Natural Sciences and Engineering Research Council of Canada and the Canadian Space Agency. A.R. is supported by U.S. National Science Foundation (NSF) grant ATM-0730452. T.D. and the Wyoming in situ measurements are supported by NSF grant ATM-1011827. W.J.R. acknowledges support of the NASA Aura Science Team. The National Center for Atmospheric Research is sponsored by NSF. The authors thank the Keck Institute for Space Studies for providing a forum to discuss topics in this paper, and C. Roth and M. Park for help with creating the figures. OSIRIS data are publicly available at odin-osiris.usask.ca; CALIPSO data at http://eosweb.larc.nasa.gov/PRODOCS/calipso/table_calipso.html; GOME2 data at http://sacs.aeronomie.be/products.php; in situ balloon data at ftp://cat.uwyo.edu/pub/permanent/balloon/Aerosol_InSitu_Meas; and NCEP data at www.esrl.noaa.gov/psd/data/gridded/data.ncep.reanalysis.html.	[Anonymous], 2011, SCI HIGHLIGHTS   JUL; Bourassa AE, 2008, J QUANT SPECTROSC RA, V109, P52, DOI 10.1016/j.jqsrt.2007.07.007; Bourassa AE, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD008079; Bourassa AE, 2012, ATMOS CHEM PHYS, V12, P605, DOI 10.5194/acp-12-605-2012; Bourassa AE, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2009JD013274; Deshler T, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002514; DUTTON EG, 1992, GEOPHYS RES LETT, V19, P2313, DOI 10.1029/92GL02495; Fueglistaler S, 2009, REV GEOPHYS, V47, DOI 10.1029/2008RG000267; Hamill P, 1997, B AM METEOROL SOC, V78, P1395, DOI 10.1175/1520-0477(1997)078<1395:TLCOSA>2.0.CO;2; Haywood JM, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2010JD014447; Hofmann D, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039008; Kravitz B, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2009JD013525; Llewellyn E, 2004, CAN J PHYS, V82, P411, DOI 10.1139/P04-005; MCCORMICK MP, 1992, GEOPHYS RES LETT, V19, P155, DOI 10.1029/91GL02790; MCCORMICK MP, 1995, NATURE, V373, P399, DOI 10.1038/373399a0; Murtagh D, 2002, CAN J PHYS, V80, P309, DOI 10.1139/P01-157; Park M, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD008294; Plumb RA, 1996, J GEOPHYS RES-ATMOS, V101, P3957, DOI 10.1029/95JD03002; Prata AJ, 2007, ATMOS CHEM PHYS, V7, P5093, DOI 10.5194/acp-7-5093-2007; Randel WJ, 2010, SCIENCE, V328, P611, DOI 10.1126/science.1182274; Robock A, 2000, REV GEOPHYS, V38, P191, DOI 10.1029/1998RG000054; Solomon S, 2011, SCIENCE, V333, P866, DOI 10.1126/science.1206027; TREPTE CR, 1992, NATURE, V355, P626, DOI 10.1038/355626a0; Vernier JP, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047563; Vernier JP, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2010GL046614; YUE GK, 1991, J GEOPHYS RES-ATMOS, V96, P5209, DOI 10.1029/90JD02227	26	147	147	1	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2012	337	6090					78	81		10.1126/science.1219371	http://dx.doi.org/10.1126/science.1219371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767926				2022-12-28	WOS:000306053100047
J	Henry, AG; Ungar, PS; Passey, BH; Sponheimer, M; Rossouw, L; Bamford, M; Sandberg, P; de Ruiter, DJ; Berger, L				Henry, Amanda G.; Ungar, Peter S.; Passey, Benjamin H.; Sponheimer, Matt; Rossouw, Lloyd; Bamford, Marion; Sandberg, Paul; de Ruiter, Darryl J.; Berger, Lee			The diet of Australopithecus sediba	NATURE			English	Article							MICROWEAR TEXTURE ANALYSIS; STERKFONTEIN VALLEY; MOLAR MICROWEAR; PLEISTOCENE; HOMININS; BOISEI; FOODS	Specimens of Australopithecus sediba from the site of Malapa, South Africa (dating from approximately 2 million years (Myr) ago)(1) present a mix of primitive and derived traits that align the taxon with other Australopithecus species and with early Homo(2). Although much of the available cranial and postcranial material of Au. sediba has been described(3-6), its feeding ecology has not been investigated. Here we present results from the first extraction of plant phytoliths from dental calculus of an early hominin. We also consider stable carbon isotope and dental microwear texture data for Au. sediba in light of new palaeoenvironmental evidence. The two individuals examined consumed an almost exclusive C-3 diet that probably included harder foods, and both dicotyledons (for example, tree leaves, fruits, wood and bark) and monocotyledons (for example, grasses and sedges). Like Ardipithecus ramidus (approximately 4.4 Myr ago) and modern savanna chimpanzees, Au. sediba consumed C-3 foods in preference to widely available C-4 resources. The inferred consumption of C-3 monocotyledons, and wood or bark, increases the known variety of early hominin foods. The overall dietary pattern of these two individuals contrasts with available data for other hominins in the region and elsewhere.	[Henry, Amanda G.] Max Planck Inst Evolutionary Anthropol, Plant Foods & Hominin Dietary Ecol Res Grp, D-04103 Leipzig, Germany; [Ungar, Peter S.] Univ Arkansas, Dept Anthropol, Fayetteville, AR 72701 USA; [Ungar, Peter S.; Sponheimer, Matt; de Ruiter, Darryl J.; Berger, Lee] Univ Witwatersrand, Sch Geosci, Inst Human Evolut, ZA-2050 Johannesburg, South Africa; [Passey, Benjamin H.] Johns Hopkins Univ, Dept Earth & Planetary Sci, Baltimore, MD 21218 USA; [Sponheimer, Matt; Sandberg, Paul] Univ Colorado Boulder, Dept Anthropol, Boulder, CO 80309 USA; [Rossouw, Lloyd] Natl Museum Bloemfontein, Dept Archaeol, ZA-9300 Bloemfontein, South Africa; [Rossouw, Lloyd] Univ Free State, Dept Plant Sci, ZA-9300 Bloemfontein, South Africa; [Rossouw, Lloyd] Univ Washington, Dept Biol, Seattle, WA 98195 USA; [Bamford, Marion] Univ Witwatersrand, Sch Geosci, BPI Palaeontol, ZA-2050 Johannesburg, South Africa; [de Ruiter, Darryl J.] Texas A&M Univ, Dept Anthropol, College Stn, TX 77843 USA	Max Planck Society; University of Arkansas System; University of Arkansas Fayetteville; University of Witwatersrand; Johns Hopkins University; University of Colorado System; University of Colorado Boulder; University of the Free State; University of Washington; University of Washington Seattle; University of Witwatersrand; Texas A&M University System; Texas A&M University College Station	Henry, AG (corresponding author), Max Planck Inst Evolutionary Anthropol, Plant Foods & Hominin Dietary Ecol Res Grp, Deutsch Pl 6, D-04103 Leipzig, Germany.	amanda_henry@eva.mpg.de	Sponheimer, Matt/A-6075-2013; Berger, Lee Rogers/AAC-3484-2020	Sponheimer, Matt/0000-0002-8743-1123; Berger, Lee Rogers/0000-0002-0367-7629; Passey, Benjamin/0000-0002-3483-4148; Rossouw, Lloyd/0000-0001-9433-1430; de Ruiter, Darryl/0000-0003-1183-0352; Henry, Amanda/0000-0002-2923-4199	US National Science Foundation (NSF); Smithsonian Institution; Institute for Human Evolution of the University of the Witwatersrand; Max Planck Society; US Department of State Fulbright Scholarship Program; Malapa Project; Leakey Foundation; University of Colorado; Palaeontological Scientific Trust, South Africa; South African Department of Science and Technology; Wenner-Gren Foundation; Ray A. Rothrock Fellowship; Texas AM University; Gauteng Provincial Government; South Africa National Research Foundation; University of the Witwatersrand	US National Science Foundation (NSF)(National Science Foundation (NSF)); Smithsonian Institution(Smithsonian Institution); Institute for Human Evolution of the University of the Witwatersrand; Max Planck Society(Max Planck SocietyFoundation CELLEX); US Department of State Fulbright Scholarship Program; Malapa Project; Leakey Foundation; University of Colorado; Palaeontological Scientific Trust, South Africa; South African Department of Science and Technology; Wenner-Gren Foundation; Ray A. Rothrock Fellowship; Texas AM University; Gauteng Provincial Government; South Africa National Research Foundation(National Research Foundation - South Africa); University of the Witwatersrand	A.G.H. was funded in part by the US National Science Foundation (NSF), the Smithsonian Institution, the Malapa Project at the Institute for Human Evolution of the University of the Witwatersrand, and the Max Planck Society. P. S. U. was funded by the US Department of State Fulbright Scholarship Program, the Malapa Project and the US NSF. B. H. P. was supported by the US NSF. M. S. was funded by the US NSF, the Leakey Foundation and the University of Colorado Dean's Fund for Excellence. The phytolith reference material and processing of M. B. was funded by the Palaeontological Scientific Trust, South Africa, and the South African Department of Science and Technology. P. S. was supported by the Wenner-Gren Foundation. D.J.d.R. was funded by the Ray A. Rothrock Fellowship and the International Research Travel Assistance Grant of Texas A&M University. Extensive funding for the Malapa Project comes from the Gauteng Provincial Government, the South African Department of Science and Technology, the South Africa National Research Foundation, the University of the Witwatersrand, and many private and public donors. We thank K. Krueger for running the microwear texture data through ToothFrax and SFrax, and J. Leichliter and O. Paine for their work with the Malapa roost rodents.	Bamford M. K., 2010, Palaeontologia Africana, V45, P23; Berger LR, 2010, SCIENCE, V328, P195, DOI 10.1126/science.1184944; Carlson KJ, 2011, SCIENCE, V333, P1402, DOI 10.1126/science.1203922; Cerling TE, 2011, P NATL ACAD SCI USA, V108, P9337, DOI 10.1073/pnas.1104627108; Dirks PHGM, 2010, SCIENCE, V328, P205, DOI 10.1126/science.1184950; Grine FE, 2006, J HUM EVOL, V51, P297, DOI 10.1016/j.jhevol.2006.04.004; Henry AG, 2011, P NATL ACAD SCI USA, V108, P486, DOI 10.1073/pnas.1016868108; Kibii JM, 2011, SCIENCE, V333, P1407, DOI 10.1126/science.1202521; Kivell TL, 2011, SCIENCE, V333, P1411, DOI 10.1126/science.1202625; Lambert JE, 2004, AM J PHYS ANTHROPOL, V125, P363, DOI 10.1002/ajpa.10403; Lee-Thorp J, 2000, J HUM EVOL, V39, P565, DOI 10.1006/jhev.2000.0436; LEETHORP JA, 1994, J HUM EVOL, V27, P361, DOI 10.1006/jhev.1994.1050; Passey BH, 2006, CHEM GEOL, V235, P238, DOI 10.1016/j.chemgeo.2006.07.002; Pickering R, 2011, SCIENCE, V333, P1421, DOI 10.1126/science.1203697; Piperno D.R., 2006, PHYTOLITH COMPREHENS; Pontzer H, 2011, J HUM EVOL, V61, P683, DOI 10.1016/j.jhevol.2011.08.006; Rogers M. E, 1994, CURRENT PRIMATOLOGY, V1, P37; Schoeninger MJ, 1999, AM J PRIMATOL, V49, P297, DOI 10.1002/(SICI)1098-2345(199912)49:4<297::AID-AJP2>3.0.CO;2-N; Scott RS, 2005, NATURE, V436, P693, DOI 10.1038/nature03822; Smith CC, 2010, J HUM EVOL, V58, P43, DOI 10.1016/j.jhevol.2009.08.001; Sponheimer M, 2006, J HUM EVOL, V51, P128, DOI 10.1016/j.jhevol.2006.02.002; Sponheimer M, 2005, J HUM EVOL, V48, P301, DOI 10.1016/j.jhevol.2004.11.008; Ungar P.S., 2010, MAMMAL TEETH ORIGIN; Ungar PS, 2011, SCIENCE, V334, P190, DOI 10.1126/science.1207701; Ungar PS, 2010, PHILOS T R SOC B, V365, P3345, DOI 10.1098/rstb.2010.0033; van der Merwe NJ, 2008, S AFR J SCI, V104, P153; van der Merwe NJ, 2003, J HUM EVOL, V44, P581, DOI 10.1016/S0047-2484(03)00050-2; VOGEL JC, 1978, S AFR J SCI, V74, P298; White TD, 2009, SCIENCE, V326, P87, DOI 10.1126/science.1175822; Zipfel B, 2011, SCIENCE, V333, P1417, DOI 10.1126/science.1202703	30	120	124	1	176	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2012	487	7405					90	93		10.1038/nature11185	http://dx.doi.org/10.1038/nature11185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	968LM	22763449				2022-12-28	WOS:000305982900056
J	Albert, DM; Blanchard, JW; Knox, BL				Albert, Daniel M.; Blanchard, June Weisberger; Knox, Barbara L.			Ensuring Appropriate Expert Testimony for Cases Involving the "Shaken Baby"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ABUSIVE HEAD TRAUMA; INFANTS		[Albert, Daniel M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53792 USA; [Knox, Barbara L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53792 USA; [Blanchard, June Weisberger] Univ Wisconsin, Sch Law, Madison, WI 53792 USA; [Knox, Barbara L.] Amer Family Childrens Hosp, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Albert, DM (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 600 Highland Ave,F4-334 CSC, Madison, WI 53792 USA.	dalbert@ophth.wisc.edu			NATIONAL EYE INSTITUTE [P30EY016665] Funding Source: NIH RePORTER; NEI NIH HHS [P30-EY016665, P30 EY016665] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Chadwick D, 1997, CHILD MALTREATMENT, V2, P313, DOI DOI 10.1177/1077559597002004004; Christian CW, 2009, PEDIATRICS, V123, P1409, DOI 10.1542/peds.2009-0408; Findley KA, 2012, HOUSTON J HLTH POLIC; Fountain TR, 2008, ALBERT JAKOBIECS PRI, V4, P5425; Gallegos A., 2011, AM MED NEWS; Hewes HA, 2011, ARCH PEDIAT ADOL MED, V165, P918, DOI 10.1001/archpediatrics.2011.151; Parks S., 2012, PEDIAT ABUSIVE HEAD; Parks S, 2012, INJURY PREVENTION; Ricci L, 2003, CHILD ABUSE NEGLECT, V27, P271, DOI 10.1016/S0145-2134(03)00006-1; Rorke-Adams L, 2011, J PRIM HEALTH CARE, V3, P161, DOI 10.1071/HC11161	10	13	14	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2012	308	1					39	40		10.1001/jama.2012.6763	http://dx.doi.org/10.1001/jama.2012.6763			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971DD	22760288	Green Accepted			2022-12-28	WOS:000306183000020
J	Spence, D				Spence, Des			Bad medicine: chest examination	BRITISH MEDICAL JOURNAL			English	Editorial Material							PLEURAL EFFUSION; RELIABILITY; DIAGNOSIS; SIGNS					destwo@yahoo.co.uk						Benbassat J, 2010, J GEN INTERN MED, V25, P865, DOI 10.1007/s11606-010-1327-8; Kalantri S, 2007, RESP MED, V101, P431, DOI 10.1016/j.rmed.2006.07.014; Mangione S, 1997, JAMA-J AM MED ASSOC, V278, P717, DOI 10.1001/jama.278.9.717; Movahed MR, 2007, ECHOCARDIOGR-J CARD, V24, P447, DOI 10.1111/j.1540-8175.2007.00425.x; Rolston D, 2008, CLEV CLIN J MED, V75, P297; Wong CL, 2009, JAMA-J AM MED ASSOC, V301, P309, DOI 10.1001/jama.2008.937	6	7	7	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 4	2012	344								e4569	10.1136/bmj.e4569	http://dx.doi.org/10.1136/bmj.e4569			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972KE	22763573				2022-12-28	WOS:000306275200010
J	O'Reilly, KM; Durry, E; ul Islam, O; Quddus, A; Abid, N; Mir, TP; Tangermann, RH; Aylward, RB; Grassly, NC				O'Reilly, Kathleen M.; Durry, Elias; ul Islam, Obaid; Quddus, Arshad; Abid, Ni'ma; Mir, Tahir P.; Tangermann, Rudi H.; Aylward, R. Bruce; Grassly, Nicholas C.			The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001-11: a retrospective analysis	LANCET			English	Article							MONOVALENT; IMMUNOGENICITY; ERADICATION; STRATEGIES; COUNTRIES	Background Pakistan and Afghanistan are two of the three remaining countries yet to interrupt wild-type poliovirus transmission. The increasing incidence of poliomyelitis in these countries during 2010-11 led the Executive Board of WHO in January, 2012, to declare polio eradication a "programmatic emergency for global public health". We aimed to establish why incidence is rising in these countries despite programme innovations including the introduction of new vaccines. Methods We did a matched case-control analysis based on a database of 46 977 children aged 0-14 years with onset of acute flaccid paralysis between Jan 1, 2001, and Dec 31, 2011. The vaccination history of children with poliomyelitis was compared with that of children with acute flaccid paralysis due to other causes to estimate the clinical effectiveness of oral poliovirus vaccines (OPVs) in Afghanistan and Pakistan by conditional logistic regression. We estimated vaccine coverage and serotype-specific vaccine-induced population immunity in children aged 0-2 years and assessed their association with the incidence of poliomyelitis over time in seven regions of Afghanistan and Pakistan. Findings Between Jan 1, 2001, and Dec 31, 2011, there were 883 cases of serotype 1 poliomyelitis (710 in Pakistan and 173 in Afghanistan) and 272 cases of poliomyelitis serotype 3 (216 in Pakistan and 56 in Afghanistan). The estimated clinical effectiveness of a dose of trivalent OPV against serotype 1 poliomyelitis was 12.5% (95% CI 5.6-18.8) compared with 34.5% (16.1-48.9) for monovalent OPV (p=0.007) and 23.4% (10.4-34.6) for bivalent OPV (p=0.067). Bivalent OPV was non-inferior compared with monovalent OPV (p=0.21). Vaccination coverage decreased during 2006-11 in the Federally Administered Tribal Areas (FATA), Balochistan, and Khyber Pakhtunkhwa in Pakistan and in southern Afghanistan. Although partially mitigated by the use of more effective vaccines, these decreases in coverage resulted in lower vaccine-induced population immunity to poliovirus serotype 1 in FATA and Balochistan and associated increases in the incidence of poliomyelitis. Interpretation The effectiveness of bivalent OPV is comparable with monovalent OPV and can therefore be used in eradicating serotype 1 poliomyelitis whilst minimising the risks of serotype 3 outbreaks. However, decreases in vaccination coverage in parts of Pakistan and southern Afghanistan have severely limited the effect of this vaccine.	[O'Reilly, Kathleen M.; Grassly, Nicholas C.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, MRC, Ctr Outbreak Anal & Modelling,Sch Publ Hlth, London W2 1PG, England; [Durry, Elias; ul Islam, Obaid; Abid, Ni'ma] WHO Country Off, Islamabad, Pakistan; [Quddus, Arshad] WHO Country Off, Kabul, Afghanistan; [Mir, Tahir P.] WHO Eastern Mediterranean Reg, Polio Eradicat Initiat, Cairo, Egypt; [Tangermann, Rudi H.; Aylward, R. Bruce] WHO, Global Polio Eradicat Initiat, CH-1211 Geneva, Switzerland	Imperial College London; Egyptian Knowledge Bank (EKB); World Health Organization Egypt; World Health Organization	O'Reilly, KM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, MRC, Ctr Outbreak Anal & Modelling,Sch Publ Hlth, St Marys Campus,Norfolk Pl, London W2 1PG, England.	k.oreilly@imperial.ac.uk	O'Reilly, Kathleen/H-9170-2019; Grassly, Nicholas C/C-6381-2008	O'Reilly, Kathleen/0000-0002-4892-8022; Grassly, Nicholas C/0000-0001-6067-4507	Poliovirus Research subcommittee of WHO; Royal Society; Medical Research Council; Medical Research Council [G0600719B] Funding Source: researchfish	Poliovirus Research subcommittee of WHO; Royal Society(Royal Society of London); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Poliovirus Research subcommittee of WHO, Royal Society, and Medical Research Council.	Abid N, 2010, East Mediterr Health J, V16 Suppl, pS5; [Anonymous], 2011, Wkly Epidemiol Rec, V86, P277; [Anonymous], 2011, Wkly Epidemiol Rec, V86, P437; [Anonymous], 2000, Wkly Epidemiol Rec, V75, P274; [Anonymous], 2008, Wkly Epidemiol Rec, V83, P321; Barros AJD, 2012, LANCET, V379, P1225, DOI 10.1016/S0140-6736(12)60113-5; Caceres VM, 2001, CLIN INFECT DIS, V33, P531, DOI 10.1086/321905; Closser S, 2010, CHASING POLIO PAKIST; El-Sayed N, 2008, NEW ENGL J MED, V359, P1655, DOI 10.1056/NEJMoa0800390; Executive Board of WHO, POL INT GLOB ER IN; Federal Ministry of Health Government of Islamic Republic of Pakistan, NAT EM ACT PLAN 2011; Grassly NC, 2007, LANCET, V369, P1356, DOI 10.1016/S0140-6736(07)60531-5; Grassly NC, 2006, SCIENCE, V314, P1150, DOI 10.1126/science.1130388; Grassly NC, 2009, J INFECT DIS, V200, P794, DOI 10.1086/605330; Hilborn Ray, 1997, V28; Hills, 1993, STAT MODELS EPIDEMIO; Independent Monitoring Board of the Global Polio Eradication Initiative, 2012, 10 MONTHS COUNT; Independent Monitoring Board of the Global Polio Eradication Initiative, 2011, REP IND MON BOARD GL; Mushtaq MU, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-60; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; Posey DL, 1997, J INFECT DIS, V175, pS258, DOI 10.1093/infdis/175.Supplement_1.S258; Sutter RW, 2010, LANCET, V376, P1682, DOI 10.1016/S0140-6736(10)61230-5; Tangermann RH, 2000, B WORLD HEALTH ORGAN, V78, P330; WHO, POL CAS COUNT; World Health Organization, 2002, Weekly Epidemiological Record, V77, P205	25	43	45	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 4	2012	380	9840					491	498		10.1016/S0140-6736(12)60648-5	http://dx.doi.org/10.1016/S0140-6736(12)60648-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983GY	22766207	Green Published, Bronze			2022-12-28	WOS:000307109000030
J	Karim, SSA; Gray, GE; Martinson, N				Karim, Salim S. Abdool; Gray, Glenda E.; Martinson, Neil			Preexposure Prophylaxis for HIV Prevention	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MALE CIRCUMCISION; SOUTH-AFRICA; INFECTION; WOMEN; PREVALENCE; TRIAL; RISK		[Karim, Salim S. Abdool] CAPRISA, Durban, South Africa; [Karim, Salim S. Abdool] Univ KwaZulu Natal, Durban, South Africa; [Karim, Salim S. Abdool] Columbia Univ, New York, NY USA; [Gray, Glenda E.; Martinson, Neil] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa	University of Kwazulu Natal; Columbia University; University of Witwatersrand	Karim, SSA (corresponding author), CAPRISA, Durban, South Africa.		Karim, Salim Safurdeen Abdool/N-5947-2013; Karim, Salim Abdool/P-3117-2019; Karim, Salim Abdool/AAE-7118-2019	Karim, Salim Safurdeen Abdool/0000-0002-4986-2133; Karim, Salim Abdool/0000-0002-4986-2133; 				Auvert B, 2009, J INFECT DIS, V199, P14, DOI 10.1086/595566; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Department of Health, 2011, 2010 NAT ANT SENT HI; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Gust DA, 2010, AIDS, V24, P1135, DOI 10.1097/QAD.0b013e328337b8bd; Karim QA, 2011, INT J EPIDEMIOL, V40, P922, DOI 10.1093/ije/dyq176; Meyer-Rath G, 2010, 18 INT AIDS C VIENN; Microbicide Trials Network, 2011, MTN STAT DEC DISC US; The Southern African HIV Clinicians Society, 2012, GUID CLIN EXP TEN AB; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; Walensky RP, 2012, CLIN INFECT DIS, V54, P1504, DOI 10.1093/cid/cis225; Weiss HA, 2009, LANCET INFECT DIS, V9, P669, DOI 10.1016/S1473-3099(09)70235-X	13	10	10	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2012	367	5					462	465		10.1056/NEJMclde1207706	http://dx.doi.org/10.1056/NEJMclde1207706			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981VZ	22784042				2022-12-28	WOS:000307001900014
J	Kyomya, M; Todyrs, KW; Amon, JJ				Kyomya, Michael; Todyrs, Katherine W.; Amon, Joseph J.			Laws against sodomy and the HIV epidemic in African prisons	LANCET			English	Editorial Material									[Todyrs, Katherine W.; Amon, Joseph J.] Human Rights Watch, New York, NY 10118 USA; [Kyomya, Michael] Uganda Prisons Serv, Kampala, Uganda		Amon, JJ (corresponding author), Human Rights Watch, New York, NY 10118 USA.	amonj@hrw.org		Amon, Joseph/0000-0002-2455-6703				Human Rights Watch, 2010, UNJ UNH HIV TB AB ZA; Human Rights Watch, 2008, THIS AL LEG OR SOD L; Human Rights Watch, 2011, EV DEAD BOD MUST WOR; Lesotho Correctional Service, 2009, HIV AIDS POL; Simooya OO, 2001, AIDS, V15, P1741, DOI 10.1097/00002030-200109070-00023; Todrys KW, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001215; Todrys KW, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-8; Todrys KW., 2011, INT J PRISON HEALTH, V7, P10; Uganda Prisons Service, 2009, RAP SIT ASS HIV STI; Uganda Prisons Service, 2010, PROGR 04 PRIS MED SE; UN Office on Drugs and Crime UNAIDS World Bank, 2007, HIV PRIS SUBS AFR OP; World Health Organization, 2007, INT ADDR HIV PRIS PR; World Health Organization, 2011, PREVENTION TREATMENT	13	15	15	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 28	2012	380	9839					310	312		10.1016/S0140-6736(12)60682-5	http://dx.doi.org/10.1016/S0140-6736(12)60682-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819651				2022-12-28	WOS:000306842800005
J	Rozenblatt-Rosen, O; Deo, RC; Padi, M; Adelmant, G; Calderwood, MA; Rolland, T; Grace, M; Dricot, A; Askenazi, M; Tavares, M; Pevzner, SJ; Abderazzaq, F; Byrdsong, D; Carvunis, AR; Chen, AA; Cheng, JW; Correll, M; Duarte, M; Fan, CY; Feltkamp, MC; Ficarro, SB; Franchi, R; Garg, BK; Gulbahce, N; Hao, T; Holthaus, AM; James, R; Korkhin, A; Litovchick, L; Mar, JC; Pak, TR; Rabello, S; Rubio, R; Shen, Y; Singh, S; Spangle, JM; Tasan, M; Wanamaker, S; Webber, JT; Roecklein-Canfield, J; Johannsen, E; Barabasi, AL; Beroukhim, R; Kieff, E; Cusick, ME; Hill, DE; Munger, K; Marto, JA; Quackenbush, J; Roth, FP; DeCaprio, JA; Vidal, M				Rozenblatt-Rosen, Orit; Deo, Rahul C.; Padi, Megha; Adelmant, Guillaume; Calderwood, Michael A.; Rolland, Thomas; Grace, Miranda; Dricot, Amelie; Askenazi, Manor; Tavares, Maria; Pevzner, Samuel J.; Abderazzaq, Fieda; Byrdsong, Danielle; Carvunis, Anne-Ruxandra; Chen, Alyce A.; Cheng, Jingwei; Correll, Mick; Duarte, Melissa; Fan, Changyu; Feltkamp, Mariet C.; Ficarro, Scott B.; Franchi, Rachel; Garg, Brijesh K.; Gulbahce, Natali; Hao, Tong; Holthaus, Amy M.; James, Robert; Korkhin, Anna; Litovchick, Larisa; Mar, Jessica C.; Pak, Theodore R.; Rabello, Sabrina; Rubio, Renee; Shen, Yun; Singh, Saurav; Spangle, Jennifer M.; Tasan, Murat; Wanamaker, Shelly; Webber, James T.; Roecklein-Canfield, Jennifer; Johannsen, Eric; Barabasi, Albert-Laszlo; Beroukhim, Rameen; Kieff, Elliott; Cusick, Michael E.; Hill, David E.; Muenger, Karl; Marto, Jarrod A.; Quackenbush, John; Roth, Frederick P.; DeCaprio, James A.; Vidal, Marc			Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins	NATURE			English	Article							EPSTEIN-BARR-VIRUS; ASSOCIATION; COMPLEX	Genotypic differences greatly influence susceptibility and resistance to disease. Understanding genotype-phenotype relationships requires that phenotypes be viewed as manifestations of network properties, rather than simply as the result of individual genomic variations(1). Genome sequencing efforts have identified numerous germline mutations, and large numbers of somatic genomic alterations, associated with a predisposition to cancer(2). However, it remains difficult to distinguish background, or 'passenger', cancer mutations from causal, or 'driver', mutations in these data sets. Human viruses intrinsically depend on their host cell during the course of infection and can elicit pathological phenotypes similar to those arising from mutations(3). Here we test the hypothesis that genomic variations and tumour viruses may cause cancer through related mechanisms, by systematically examining host interactome and transcriptome network perturbations caused by DNA tumour virus proteins. The resulting integrated viral perturbation data reflects rewiring of the host cell networks, and highlights pathways, such as Notch signalling and apoptosis, that go awry in cancer. We show that systematic analyses of host targets of viral proteins can identify cancer genes with a success rate on a par with their identification through functional genomics and large-scale cataloguing of tumour mutations. Together, these complementary approaches increase the specificity of cancer gene identification. Combining systems-level studies of pathogen-encoded gene products with genomic approaches will facilitate the prioritization of cancer-causing driver genes to advance the understanding of the genetic basis of human cancer.	[Rozenblatt-Rosen, Orit; Deo, Rahul C.; Padi, Megha; Adelmant, Guillaume; Calderwood, Michael A.; Rolland, Thomas; Dricot, Amelie; Askenazi, Manor; Tavares, Maria; Abderazzaq, Fieda; Byrdsong, Danielle; Chen, Alyce A.; Duarte, Melissa; Fan, Changyu; Ficarro, Scott B.; Franchi, Rachel; Garg, Brijesh K.; Gulbahce, Natali; Hao, Tong; Holthaus, Amy M.; James, Robert; Korkhin, Anna; Litovchick, Larisa; Mar, Jessica C.; Rabello, Sabrina; Rubio, Renee; Shen, Yun; Spangle, Jennifer M.; Tasan, Murat; Johannsen, Eric; Barabasi, Albert-Laszlo; Kieff, Elliott; Cusick, Michael E.; Hill, David E.; Muenger, Karl; Marto, Jarrod A.; Quackenbush, John; Roth, Frederick P.; DeCaprio, James A.; Vidal, Marc] Dana Farber Canc Inst, CCSB, Genom Anal Network Perturbat Ctr Excellence Genom, Boston, MA 02215 USA; [Rozenblatt-Rosen, Orit; Tavares, Maria; Cheng, Jingwei; Korkhin, Anna; Litovchick, Larisa; Beroukhim, Rameen; DeCaprio, James A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Rozenblatt-Rosen, Orit; Tavares, Maria; Cheng, Jingwei; Korkhin, Anna; Litovchick, Larisa; Rabello, Sabrina; Barabasi, Albert-Laszlo; Beroukhim, Rameen; DeCaprio, James A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Deo, Rahul C.; Adelmant, Guillaume; Askenazi, Manor; Ficarro, Scott B.; Garg, Brijesh K.; Singh, Saurav; Tasan, Murat; Webber, James T.; Marto, Jarrod A.; Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Deo, Rahul C.] Univ Calif San Francisco, Dept Med, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Deo, Rahul C.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA; [Padi, Megha; Abderazzaq, Fieda; Correll, Mick; Mar, Jessica C.; Rubio, Renee; Quackenbush, John] Dana Farber Canc Inst, CCCB, Dept Biostat & Computat Biol, Boston, MA 02215 USA; [Padi, Megha; Adelmant, Guillaume; Calderwood, Michael A.; Rolland, Thomas; Dricot, Amelie; Askenazi, Manor; Tavares, Maria; Pevzner, Samuel J.; Abderazzaq, Fieda; Byrdsong, Danielle; Carvunis, Anne-Ruxandra; Correll, Mick; Duarte, Melissa; Fan, Changyu; Ficarro, Scott B.; Franchi, Rachel; Garg, Brijesh K.; Gulbahce, Natali; Hao, Tong; James, Robert; Mar, Jessica C.; Rabello, Sabrina; Rubio, Renee; Shen, Yun; Singh, Saurav; Wanamaker, Shelly; Webber, James T.; Roecklein-Canfield, Jennifer; Barabasi, Albert-Laszlo; Beroukhim, Rameen; Cusick, Michael E.; Hill, David E.; Marto, Jarrod A.; Quackenbush, John; Roth, Frederick P.; Vidal, Marc] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA; [Padi, Megha; Mar, Jessica C.; Quackenbush, John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Adelmant, Guillaume; Askenazi, Manor; Tavares, Maria; Ficarro, Scott B.; Garg, Brijesh K.; Singh, Saurav; Webber, James T.; Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02215 USA; [Calderwood, Michael A.; Rolland, Thomas; Dricot, Amelie; Pevzner, Samuel J.; Byrdsong, Danielle; Carvunis, Anne-Ruxandra; Fan, Changyu; Hao, Tong; James, Robert; Shen, Yun; Wanamaker, Shelly; Cusick, Michael E.; Hill, David E.; Vidal, Marc] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Calderwood, Michael A.; Duarte, Melissa; Holthaus, Amy M.; Johannsen, Eric; Kieff, Elliott] Brigham & Womens Hosp, Channing Lab, Div Infect Dis, Boston, MA 02115 USA; [Calderwood, Michael A.; Grace, Miranda; Chen, Alyce A.; Duarte, Melissa; Holthaus, Amy M.; Spangle, Jennifer M.; Johannsen, Eric; Kieff, Elliott; Muenger, Karl] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Calderwood, Michael A.; Duarte, Melissa; Holthaus, Amy M.; Johannsen, Eric; Kieff, Elliott] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA; [Pevzner, Samuel J.] Boston Univ, Dept Biomed Engn, Boston, MA 02118 USA; [Pevzner, Samuel J.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Feltkamp, Mariet C.] Leiden Univ, Med Ctr, Dept Med Microbiol, NL-2300 RC Leiden, Netherlands; [Franchi, Rachel; Wanamaker, Shelly; Roecklein-Canfield, Jennifer] Simmons Coll, Dept Chem, Boston, MA 02115 USA; [Gulbahce, Natali; Rabello, Sabrina; Barabasi, Albert-Laszlo] Northeastern Univ, CCNR, Boston, MA 02115 USA; [Gulbahce, Natali; Rabello, Sabrina; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Phys, Boston, MA 02115 USA; [Gulbahce, Natali] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Pak, Theodore R.; Tasan, Murat; Roth, Frederick P.] Univ Toronto, Donnelly Ctr, Toronto, ON M5G 1X5, Canada; [Pak, Theodore R.; Tasan, Murat; Roth, Frederick P.] Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1X5, Canada; [Pak, Theodore R.; Tasan, Murat; Roth, Frederick P.] Univ Toronto, Dept Comp Sci, Toronto, ON M5G 1X5, Canada; [Pak, Theodore R.; Tasan, Murat; Roth, Frederick P.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Beroukhim, Rameen] Broad Inst, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Boston University; Boston University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Simmons University; Northeastern University; Northeastern University; University of California System; University of California San Francisco; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Marto, JA (corresponding author), Dana Farber Canc Inst, CCSB, Genom Anal Network Perturbat Ctr Excellence Genom, Boston, MA 02215 USA.	jarrod_marto@dfci.harvard.edu; johnq@jimmy.harvard.edu; fritz.roth@utoronto.ca; james_decaprio@dfci.harvard.edu; marc_vidal@dfci.harvard.edu	Roth, Frederick P/H-6308-2011; Rozenblatt-Rosen, Orit/HDN-4182-2022; Calderwood, Mike/B-2475-2014; Hill, David E/B-6617-2011; Barabasi, Albert-Laszlo/S-6474-2017; Feltkamp, Mariet/A-3788-2010	Calderwood, Mike/0000-0001-6475-1418; Feltkamp, Mariet/0000-0001-5993-9846; Pak, Theodore/0000-0002-1676-2523; Roth, Frederick/0000-0002-6628-649X; Litovchick, Larisa/0000-0002-9540-597X; Munger, Karl/0000-0003-3288-9935; Trigg, Shelly/0000-0001-6904-4149; Chen, Alyce/0000-0002-5018-8908; Quackenbush, John/0000-0002-2702-5879; Askenazi, Manor/0000-0003-1646-833X; Webber, James/0000-0001-8594-9888; Mar, Jessica/0000-0002-5147-9299; Carvunis, Anne-Ruxandra/0000-0002-6474-6413; Barabasi, Albert/0000-0002-4028-3522; Rolland, Thomas/0000-0001-6468-8391	Center of Excellence in Genomic Science (CEGS) from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) [P50HG004233]; Institute Sponsored Research funds from the Dana-Farber Cancer Institute Strategic Initiative; NIH [R01HG001715, R01CA093804, R01CA063113, P01CA050661, R01CA081135, R01CA066980, U01CA141583, R01CA131354, R01CA047006, R01CA085180, T32HL007208, K08HL098361, K08CA122833, F32GM095284, K25HG006031]; Canada Excellence Research Chairs (CERC) Program, Canadian Institute for Advanced Research Fellowship and Ontario Research Fund; James S. McDonnell Foundation [220020084]; NATIONAL CANCER INSTITUTE [R01CA081135, R01CA047006, P01CA050661, R01CA085180, R01CA093804, R01CA063113, U01CA141583, R01CA066980, R01CA131354, K08CA122833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL098361, T32HL007208] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001715, P50HG004233, K25HG006031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM095284] Funding Source: NIH RePORTER	Center of Excellence in Genomic Science (CEGS) from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH); Institute Sponsored Research funds from the Dana-Farber Cancer Institute Strategic Initiative; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canada Excellence Research Chairs (CERC) Program, Canadian Institute for Advanced Research Fellowship and Ontario Research Fund; James S. McDonnell Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the Center for Cancer Systems Biology (CCSB) and J. Aster, M. Meyerson, W. Kaelin, G. Superti-Furga and S. Sunyaev for discussions, and J. W. Harper, W. Hahn, P. Howley, Y. Jacob, M. Imperiale, I. Koralnik, H. Pfister and D. Wang for reagents. This work was primarily supported by Center of Excellence in Genomic Science (CEGS) grant P50HG004233 from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) awarded to M. V. (principal investigator), A.-L. B., J. A. D., E. K., J. A. M., K. M., J. Q. and F. P. R. Additional funding included Institute Sponsored Research funds from the Dana-Farber Cancer Institute Strategic Initiative to M. V.; NIH grants R01HG001715 to M. V., D. E. H. and F. P. R.; R01CA093804, R01CA063113 and P01CA050661 to J. A. D.; R01CA081135, R01CA066980 and U01CA141583 to K. M.; R01CA131354, R01CA047006 and R01CA085180 to E. K.; T32HL007208 and K08HL098361 to R. C. D.; K08CA122833 to R. B.; F32GM095284 and K25HG006031 to M. P.; Canada Excellence Research Chairs (CERC) Program, Canadian Institute for Advanced Research Fellowship and Ontario Research Fund to F. P. R.; and James S. McDonnell Foundation grant 220020084 to A.-L. B. M. V. is a 'Chercheur Qualifie Honoraire' from the Fonds de la Recherche Scientifique (Wallonia-Brussels Federation, Belgium).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; [Anonymous], 2007, NAT GENET, V39, P423; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Berriz GF, 2003, BIOINFORMATICS, V19, P2502, DOI 10.1093/bioinformatics/btg363; Brimer N, 2012, ONCOGENE, V31, P4639, DOI 10.1038/onc.2011.589; Brimer N, 2007, VIROLOGY, V358, P303, DOI 10.1016/j.virol.2006.08.038; Calderwood MA, 2007, P NATL ACAD SCI USA, V104, P7606, DOI 10.1073/pnas.0702332104; Calderwood MA, 2011, VIROLOGY, V414, P19, DOI 10.1016/j.virol.2011.02.018; Copeland NG, 2010, NAT REV CANCER, V10, P696, DOI 10.1038/nrc2916; Dreze M, 2010, METHOD ENZYMOL, V470, P281, DOI 10.1016/S0076-6879(10)70012-4; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Foxman EF, 2011, NAT REV MICROBIOL, V9, P254, DOI 10.1038/nrmicro2541; Fujita KI, 2011, P NATL ACAD SCI USA, V108, P1427, DOI 10.1073/pnas.1014156108; Gulbahce N, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002531; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Howley PM, 2009, VIROLOGY, V384, P256, DOI 10.1016/j.virol.2008.12.006; Klinakis A, 2011, NATURE, V473, P230, DOI 10.1038/nature09999; Lamesch P, 2007, GENOMICS, V89, P307, DOI 10.1016/j.ygeno.2006.11.012; Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980; Marcuzzi GP, 2009, J GEN VIROL, V90, P2855, DOI 10.1099/vir.0.012872-0; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Shapira SD, 2009, CELL, V139, P1255, DOI 10.1016/j.cell.2009.12.018; Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yu HY, 2011, NAT METHODS, V8, P478, DOI [10.1038/NMETH.1597, 10.1038/nmeth.1597]; Zhou F, 2010, J PROTEOME RES, V9, P6242, DOI 10.1021/pr1004696	29	277	283	0	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 26	2012	487	7408					491	495		10.1038/nature11288	http://dx.doi.org/10.1038/nature11288			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979KD	22810586	Green Accepted, Green Submitted			2022-12-28	WOS:000306815300040
J	Rimmer, JH; Marques, AC				Rimmer, James H.; Marques, Alexandre C.			Physical activity for people with disabilities	LANCET			English	Editorial Material							RECREATION FACILITIES; PARTICIPATION; BARRIERS; CHILDREN; FITNESS		[Rimmer, James H.] Univ Alabama Birmingham, Birmingham, AL 35294 USA; [Rimmer, James H.] Lakeshore Fdn, Birmingham, AL 35294 USA; [Marques, Alexandre C.] Univ Fed Pelotas, Pelotas, Brazil	University of Alabama System; University of Alabama Birmingham; Universidade Federal de Pelotas	Rimmer, JH (corresponding author), Univ Alabama Birmingham, Birmingham, AL 35294 USA.	jrimmer@uab.edu						Barnes C, 2010, DISABIL SOC, V25, P771, DOI 10.1080/09687599.2010.520889; Ginis KAM, 2007, APPL PHYSIOL NUTR ME, V32, pS135, DOI 10.1139/H07-108; Murphy NA, 2008, PEDIATRICS, V121, P1057, DOI 10.1542/peds.2008-0566; Nortvedt MW, 2005, NEUROL SCI, V26, P334, DOI 10.1007/s10072-005-0498-2; Phillips M, 2009, CLIN REHABIL, V23, P746, DOI 10.1177/0269215509334838; Riley BB, 2008, J PHYS ACT HEALTH, V5, P158, DOI 10.1123/jpah.5.1.158; Rimmer J. H., 2007, Morbidity and Mortality Weekly Report, V56, P1021; Rimmer JA, 2008, DEV NEUROREHABIL, V11, P141, DOI 10.1080/17518420701688649; Rimmer JH, 2005, AM J HEALTH PROMOT, V19, P327, DOI 10.4278/0890-1171-19.5.327; Rimmer JH, 2004, AM J PREV MED, V26, P419, DOI 10.1016/j.amepre.2004.02.002; Rimmer JH, 2005, AM J HLTH PROMOT, V19, pii; Sit CHP, 2007, PREV MED, V45, P424, DOI 10.1016/j.ypmed.2007.02.003; United Nations (UN) General Assembly, 2007, CONV RIGHTS PERS DIS; WHO, 2011, WORLD REPORT ON DISABILITY, P1	14	103	103	1	39	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 21	2012	380	9838					193	195		10.1016/S0140-6736(12)61028-9	http://dx.doi.org/10.1016/S0140-6736(12)61028-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976TV	22818934				2022-12-28	WOS:000306609200007
J	Burmann, BM; Knauer, SH; Sevostyanova, A; Schweimer, K; Mooney, RA; Landick, R; Artsimovitch, I; Rosch, P				Burmann, Bjoern M.; Knauer, Stefan H.; Sevostyanova, Anastasia; Schweimer, Kristian; Mooney, Rachel A.; Landick, Robert; Artsimovitch, Irina; Roesch, Paul			An alpha Helix to beta Barrel Domain Switch Transforms the Transcription Factor RfaH into a Translation Factor	CELL			English	Article							POLYMERASE-II ELONGATION; RNA-POLYMERASE; ESCHERICHIA-COLI; FACTOR NUSG; IN-VITRO; CRYSTAL-STRUCTURE; OPS ELEMENT; PROTEIN; COMPLEX; ANTITERMINATION	NusG homologs regulate transcription and coupled processes in all living organisms. The Escherichia coli (E. coli) two-domain paralogs NusG and RfaH have conformationally identical N-terminal domains (NTDs) but dramatically different carboxy-terminal domains (CTDs), a beta barrel in NusG and an alpha hairpin in RfaH. Both NTDs interact with elongating RNA polymerase (RNAP) to reduce pausing. In NusG, NTD and CTD are completely independent, and NusG-CTD interacts with termination factor Rho or ribosomal protein S10. In contrast, RfaH-CTD makes extensive contacts with RfaH-NTD to mask an RNAP-binding site therein. Upon RfaH interaction with its DNA target, the operon polarity suppressor (ops) DNA, RfaH-CTD is released, allowing RfaH-NTD to bind to RNAP. Here, we show that the released RfaH-CTD completely refolds from an all-alpha to an all-beta conformation identical to that of NusG-CTD. As a consequence, RfaH-CTD binding to S10 is enabled and translation of RfaH-controlled operons is strongly potentiated.	[Sevostyanova, Anastasia; Artsimovitch, Irina] Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; [Sevostyanova, Anastasia; Artsimovitch, Irina] Ohio State Univ, RNA Grp, Columbus, OH 43210 USA; [Burmann, Bjoern M.; Knauer, Stefan H.; Schweimer, Kristian; Roesch, Paul] Univ Bayreuth, Lehrstuhl Biopolymere, D-95447 Bayreuth, Germany; [Burmann, Bjoern M.; Knauer, Stefan H.; Schweimer, Kristian; Roesch, Paul] Univ Bayreuth, Forschungszentrum Biomakromol, D-95447 Bayreuth, Germany; [Mooney, Rachel A.; Landick, Robert] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; [Landick, Robert] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Bayreuth; University of Bayreuth; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Artsimovitch, I (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12Th Ave, Columbus, OH 43210 USA.	artsimovitch1@osu.edu; roesch@unibt.de	Rösch, Paul/I-5445-2014; Burmann, Björn/M-8913-2015; Artsimovitch, Irina/L-3467-2019; Burmann, Björn M./AAI-7760-2021; Knauer, Stefan/GXG-9861-2022; Burmann, Björn M./AAR-7399-2020	Rösch, Paul/0000-0003-3330-2446; Burmann, Björn/0000-0002-3135-7964; Burmann, Björn M./0000-0002-3135-7964; Schweimer, Kristian/0000-0002-3837-8442; Knauer, Stefan/0000-0002-4143-0694	DFG [Ro617/18-1]; NIH [GM67153, GM38660]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038660, R29GM038660, R37GM038660, R01GM067153] Funding Source: NIH RePORTER	DFG(German Research Foundation (DFG)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank R. Heissmann for excellent technical assistance and H.K. Seoh and C. Squires for the generous gift of antibodies used for ChIP-chip experiments. This project was supported by DFG (Ro617/18-1 to P.R.) and NIH (GM67153 to I.A.; GM38660 to R.L.).	Alexander PA, 2009, P NATL ACAD SCI USA, V106, P21149, DOI 10.1073/pnas.0906408106; Andreeva A, 2006, CURR OPIN STRUC BIOL, V16, P399, DOI 10.1016/j.sbi.2006.04.003; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Artsimovitch I, 2002, CELL, V109, P193, DOI 10.1016/S0092-8674(02)00724-9; Bailey MJA, 1997, MOL MICROBIOL, V26, P845, DOI 10.1046/j.1365-2958.1997.6432014.x; Bailey MJA, 2000, MOL GEN GENET, V262, P1052, DOI 10.1007/PL00008648; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Belogurov GA, 2007, MOL CELL, V26, P117, DOI 10.1016/j.molcel.2007.02.021; Belogurov GA, 2010, MOL MICROBIOL, V76, P286, DOI 10.1111/j.1365-2958.2010.07056.x; Belogurov GA, 2009, EMBO J, V28, P112, DOI 10.1038/emboj.2008.268; Ben-Shem A, 2010, SCIENCE, V330, P1203, DOI 10.1126/science.1194294; Bryan PN, 2010, CURR OPIN STRUC BIOL, V20, P482, DOI 10.1016/j.sbi.2010.06.002; Burmann BM, 2011, BIOCHEM J, V435, P783, DOI 10.1042/BJ20101679; Burmann BM, 2010, SCIENCE, V328, P501, DOI 10.1126/science.1184953; Burns CM, 1998, J MOL BIOL, V278, P307, DOI 10.1006/jmbi.1998.1691; BURNS CM, 1995, P NATL ACAD SCI USA, V92, P4738, DOI 10.1073/pnas.92.11.4738; BUROVA E, 1995, J BACTERIOL, V177, P1388, DOI 10.1128/jb.177.5.1388-1392.1995; Carter HD, 2004, J BACTERIOL, V186, P2829, DOI 10.1128/JB.186.9.2829-2840.2004; Chalissery J, 2011, J MOL BIOL, V405, P49, DOI 10.1016/j.jmb.2010.10.044; Chen YX, 2009, GENE DEV, V23, P2765, DOI 10.1101/gad.1834709; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Greenwald J, 2010, STRUCTURE, V18, P1244, DOI 10.1016/j.str.2010.08.009; Hirtreiter A, 2010, NUCLEIC ACIDS RES, V38, P4040, DOI 10.1093/nar/gkq135; Klein BJ, 2011, P NATL ACAD SCI USA, V108, P546, DOI 10.1073/pnas.1013828108; Knowlton JR, 2003, BIOCHEMISTRY-US, V42, P2275, DOI 10.1021/bi0272508; Kyrpides NC, 1996, TRENDS BIOCHEM SCI, V21, P425, DOI 10.1016/S0968-0004(96)30036-4; LI J, 1993, GENE DEV, V7, P161, DOI 10.1101/gad.7.1.161; Littler DR, 2010, FEBS LETT, V584, P2093, DOI 10.1016/j.febslet.2010.01.027; Luo X, 2008, MOL CELL, V32, P791, DOI 10.1016/j.molcel.2008.10.028; Luo XL, 2004, NAT STRUCT MOL BIOL, V11, P338, DOI 10.1038/nsmb748; Martinez-Rucobo FW, 2011, EMBO J, V30, P1302, DOI 10.1038/emboj.2011.64; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; Mooney RA, 2009, MOL CELL, V33, P97, DOI 10.1016/j.molcel.2008.12.021; Mooney RA, 2009, J MOL BIOL, V391, P341, DOI 10.1016/j.jmb.2009.05.078; Reay P, 2004, PROTEINS, V56, P40, DOI 10.1002/prot.20054; Schneider DA, 2006, P NATL ACAD SCI USA, V103, P12707, DOI 10.1073/pnas.0605686103; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Sevostyanova A, 2011, MOL CELL, V43, P253, DOI 10.1016/j.molcel.2011.05.026; Squires CL, 2000, ANNU REV MICROBIOL, V54, P775, DOI 10.1146/annurev.micro.54.1.775; Steiner T, 2002, EMBO J, V21, P4641, DOI 10.1093/emboj/cdf455; SULLIVAN SL, 1992, J BACTERIOL, V174, P1339, DOI 10.1128/jb.174.4.1339-1344.1992; Surewicz WK, 2011, TOP CURR CHEM, V305, P135, DOI 10.1007/128_2011_165; Tokuriki N, 2009, SCIENCE, V324, P203, DOI 10.1126/science.1169375; Tuinstra RL, 2008, P NATL ACAD SCI USA, V105, P5057, DOI 10.1073/pnas.0709518105; Werner F, 2011, NAT REV MICROBIOL, V9, P85, DOI 10.1038/nrmicro2507; Zhou HH, 2009, PROTEINS, V76, P787, DOI 10.1002/prot.22465; Zhou K, 2009, P NATL ACAD SCI USA, V106, P6956, DOI 10.1073/pnas.0806302106	48	142	142	1	45	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 20	2012	150	2					291	303		10.1016/j.cell.2012.05.042	http://dx.doi.org/10.1016/j.cell.2012.05.042			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817892	Bronze, Green Accepted			2022-12-28	WOS:000306595700009
J	Welch, JS; Ley, TJ; Link, DC; Miller, CA; Larson, DE; Koboldt, DC; Wartman, LD; Lamprecht, TL; Liu, FL; Xia, J; Kandoth, C; Fulton, RS; McLellan, MD; Dooling, DJ; Wallis, JW; Chen, K; Harris, CC; Schmidt, HK; Kalicki-Veizer, JM; Lu, C; Zhang, QY; Lin, L; O'Laughlin, MD; McMichael, JF; Delehaunty, KD; Fulton, LA; Magrini, VJ; McGrath, SD; Demeter, RT; Vickery, TL; Hundal, J; Cook, LL; Swift, GW; Reed, JP; Alldredge, PA; Wylie, TN; Walker, JR; Watson, MA; Heath, SE; Shannon, WD; Varghese, N; Nagarajan, R; Payton, JE; Baty, JD; Kulkarni, S; Klco, JM; Tomasson, MH; Westervelt, P; Walter, MJ; Graubert, TA; DiPersio, JF; Ding, L; Mardis, ER; Wilson, RK				Welch, John S.; Ley, Timothy J.; Link, Daniel C.; Miller, Christopher A.; Larson, David E.; Koboldt, Daniel C.; Wartman, Lukas D.; Lamprecht, Tamara L.; Liu, Fulu; Xia, Jun; Kandoth, Cyriac; Fulton, Robert S.; McLellan, Michael D.; Dooling, David J.; Wallis, John W.; Chen, Ken; Harris, Christopher C.; Schmidt, Heather K.; Kalicki-Veizer, Joelle M.; Lu, Charles; Zhang, Qunyuan; Lin, Ling; O'Laughlin, Michelle D.; McMichael, Joshua F.; Delehaunty, Kim D.; Fulton, Lucinda A.; Magrini, Vincent J.; McGrath, Sean D.; Demeter, Ryan T.; Vickery, Tammi L.; Hundal, Jasreet; Cook, Lisa L.; Swift, Gary W.; Reed, Jerry P.; Alldredge, Patricia A.; Wylie, Todd N.; Walker, Jason R.; Watson, Mark A.; Heath, Sharon E.; Shannon, William D.; Varghese, Nobish; Nagarajan, Rakesh; Payton, Jacqueline E.; Baty, Jack D.; Kulkarni, Shashikant; Klco, Jeffery M.; Tomasson, Michael H.; Westervelt, Peter; Walter, Matthew J.; Graubert, Timothy A.; DiPersio, John F.; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.			The Origin and Evolution of Mutations in Acute Myeloid Leukemia	CELL			English	Article							INTERNAL TANDEM DUPLICATION; ALPHA CHIMERIC GENE; PML/RAR-ALPHA; PROMYELOCYTIC LEUKEMIA; CLONAL EVOLUTION; RETINOIC ACID; MOLECULAR-GENETICS; SOMATIC MUTATIONS; PROGNOSTIC IMPACT; DNMT3A MUTATIONS	Most mutations in cancer genomes are thought to be acquired after the initiating event, which may cause genomic instability and drive clonal evolution. However, for acute myeloid leukemia (AML), normal karyotypes are common, and genomic instability is unusual. To better understand clonal evolution in AML, we sequenced the genomes of M3-AML samples with a known initiating event (PML-RARA) versus the genomes of normal karyotype M1-AML samples and the exomes of hematopoietic stem/progenitor cells (HSPCs) from healthy people. Collectively, the data suggest that most of the mutations found in AML genomes are actually random events that occurred in HSPCs before they acquired the initiating mutation; the mutational history of that cell is "captured" as the clone expands. In many cases, only one or two additional, cooperating mutations are needed to generate the malignant founding clone. Cells from the founding clone can acquire additional cooperating mutations, yielding subclones that can contribute to disease progression and/or relapse.	[Welch, John S.; Ley, Timothy J.; Link, Daniel C.; Wartman, Lukas D.; Lamprecht, Tamara L.; Liu, Fulu; Xia, Jun; Heath, Sharon E.; Shannon, William D.; Tomasson, Michael H.; Westervelt, Peter; Walter, Matthew J.; Graubert, Timothy A.; DiPersio, John F.; Ding, Li] Washington Univ, Dept Med, St Louis, MO 63110 USA; [Welch, John S.; Ley, Timothy J.; Link, Daniel C.; Watson, Mark A.; Shannon, William D.; Nagarajan, Rakesh; Payton, Jacqueline E.; Kulkarni, Shashikant; Tomasson, Michael H.; Westervelt, Peter; Walter, Matthew J.; Graubert, Timothy A.; DiPersio, John F.; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Siteman Canc Ctr, St Louis, MO 63110 USA; [Ley, Timothy J.; Miller, Christopher A.; Larson, David E.; Koboldt, Daniel C.; Kandoth, Cyriac; Fulton, Robert S.; McLellan, Michael D.; Dooling, David J.; Wallis, John W.; Harris, Christopher C.; Schmidt, Heather K.; Kalicki-Veizer, Joelle M.; Lu, Charles; Lin, Ling; O'Laughlin, Michelle D.; McMichael, Joshua F.; Delehaunty, Kim D.; Fulton, Lucinda A.; Magrini, Vincent J.; McGrath, Sean D.; Demeter, Ryan T.; Vickery, Tammi L.; Hundal, Jasreet; Cook, Lisa L.; Swift, Gary W.; Reed, Jerry P.; Alldredge, Patricia A.; Wylie, Todd N.; Walker, Jason R.; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Genome Inst, St Louis, MO 63110 USA; [Watson, Mark A.; Varghese, Nobish; Nagarajan, Rakesh; Payton, Jacqueline E.; Kulkarni, Shashikant; Klco, Jeffery M.] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Baty, Jack D.] Washington Univ, Dept Biostat, St Louis, MO 63110 USA; [Zhang, Qunyuan; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Dept Genet, St Louis, MO 63110 USA; [Chen, Ken] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Texas System; UTMD Anderson Cancer Center	Ley, TJ (corresponding author), Washington Univ, Dept Med, St Louis, MO 63110 USA.	timley@wustl.edu	Mardis, Elaine/W-2202-2019; Weinstock, George M/C-6314-2013; Miller, Christopher A./A-1060-2009; Walter, Matthew J/S-7758-2018; Klco, Jeffery/M-9717-2018; Chen, Ken/AAU-1432-2021; McGrath, Sean David/AAT-3540-2020; Magrini, Vincent/AAT-5830-2020; Wilson, Richard K./AAF-4139-2019; Walker, Jason/A-9702-2013	Weinstock, George M/0000-0002-2997-4592; Miller, Christopher A./0000-0003-4266-6700; Klco, Jeffery/0000-0003-2961-6960; Chen, Ken/0000-0003-4013-5279; McGrath, Sean David/0000-0001-9064-8449; Magrini, Vincent/0000-0002-2019-4872; Wilson, Richard K./0000-0002-1992-1358; Walker, Jason/0000-0001-7547-5789; Westover, Tamara/0000-0002-1000-6698; Graubert, Timothy/0000-0002-7710-1171; MCLELLAN, MICHAEL/0000-0002-2703-8784; Tomasson, Michael/0000-0003-4518-7123; Larson, David/0000-0001-7934-5906; Kandoth, Cyriac/0000-0002-1345-3573	Washington University Cancer Genome Initiative; NCI Cancer Center [P30 CA91842]; Washington University in St. Louis; National Human Genome Research Institute [NHGRI U54 HG003079]; National Cancer Institute [K99 HL103975]; Barnes-Jewish Hospital Foundation [00335-0505-02]; NATIONAL CANCER INSTITUTE [R01CA083962, P30CA091842, P30CA016672, P01CA101937] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K99HL103975, R00HL103975] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003079] Funding Source: NIH RePORTER	Washington University Cancer Genome Initiative; NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Washington University in St. Louis; National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Barnes-Jewish Hospital Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank the Analysis Pipeline group for developing the automated sequence analysis pipelines; the LIMS group for developing tools and software to manage samples and sequencing; and the Systems group for providing the IT infrastructure and HPC solutions required for sequencing and analysis. We thank William S. Schierding and Nathan D. Dees for their help on tumor clonality analysis, Dr. David Spencer for help with pathway analysis, and Joshua McMichael for help with figure preparation. We also thank The Cancer Genome Atlas for allowing us to use unpublished data for this study, the Washington University Cancer Genome Initiative for their support, and the Siteman Cancer Center Flow Cytometry Core, which provided cell sorting service and is supported in part by an NCI Cancer Center Support grant P30 CA91842. This work was funded by grants to Richard K. Wilson from Washington University in St. Louis and the National Human Genome Research Institute (NHGRI U54 HG003079), and grants to John S. Welch (K99 HL103975) and Timothy J. Ley from the National Cancer Institute (PO1 CA101937) and the Barnes-Jewish Hospital Foundation (00335-0505-02).	Abkowitz JL, 2000, BLOOD, V96, P3399, DOI 10.1182/blood.V96.10.3399.h8003399_3399_3405; Abkowitz JL, 1996, NAT MED, V2, P190, DOI 10.1038/nm0296-190; Abramson Joseph H, 2011, Epidemiol Perspect Innov, V8, P1, DOI 10.1186/1742-5573-8-1; Allford S, 1999, BRIT J HAEMATOL, V105, P198; ARMITAGE P, 1957, BRIT J CANCER, V11, P161, DOI 10.1038/bjc.1957.22; Bacher U, 2010, CURR OPIN ONCOL, V22, P646, DOI 10.1097/CCO.0b013e32833ed806; Betz BL, 2010, ARCH PATHOL LAB MED, V134, P1427, DOI 10.1043/2010-0245-RA.1; Bullinger L, 2010, LEUKEMIA, V24, P438, DOI 10.1038/leu.2009.263; Calabrese P, 2004, AM J PATHOL, V164, P1337, DOI 10.1016/S0002-9440(10)63220-8; Carretero M, 2010, CURR OPIN CELL BIOL, V22, P781, DOI 10.1016/j.ceb.2010.07.004; Catlin SN, 2011, BLOOD, V117, P4460, DOI 10.1182/blood-2010-08-303537; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/NMETH.1363, 10.1038/nmeth.1363]; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Flex E, 2008, J EXP MED, V205, P751, DOI 10.1084/jem.20072182; Foudi A, 2009, NAT BIOTECHNOL, V27, P84, DOI 10.1038/nbt.1517; Funk RK, 2008, BLOOD, V112, P1434, DOI 10.1182/blood-2008-01-132084; Gilliland DG, 2002, SEMIN HEMATOL, V39, P6, DOI 10.1053/shem.2002.36921; Gundry M, 2012, MUTAT RES-FUND MOL M, V729, P1, DOI [10.1016/j.mrfmmm.2011.10.001, 10.1016/mrfmmm.2011.10.001]; Harvey RC, 2010, BLOOD, V115, P5312, DOI 10.1182/blood-2009-09-245944; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; Ishikawa Y, 2009, EUR J HAEMATOL, V83, P90, DOI 10.1111/j.1600-0609.2009.01261.x; Jeong EG, 2008, CLIN CANCER RES, V14, P3716, DOI 10.1158/1078-0432.CCR-07-4839; Kelly LM, 2002, P NATL ACAD SCI USA, V99, P8283, DOI 10.1073/pnas.122233699; Kogan SC, 2007, CURR TOP MICROBIOL, V313, P3; Larson DE, 2012, BIOINFORMATICS, V28, P311, DOI 10.1093/bioinformatics/btr665; Larson RA, 2011, MEDITERR J HEMATOL I, V3, DOI 10.4084/MJHID.2011.032; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Li L, 2008, BLOOD, V111, P3849, DOI 10.1182/blood-2007-08-109942; Lin J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026906; Link DC, 2011, JAMA-J AM MED ASSOC, V305, P1568, DOI 10.1001/jama.2011.473; LOEB LA, 1974, CANCER RES, V34, P2311; Lynch M, 2010, TRENDS GENET, V26, P345, DOI 10.1016/j.tig.2010.05.003; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Markova J, 2012, EUR J HAEMATOL, V88, P128, DOI 10.1111/j.1600-0609.2011.01716.x; McCormick SR, 2010, ARCH PATHOL LAB MED, V134, P1143, DOI 10.1043/2009-0292-OA.1; Millau JF, 2011, BIOCHEM CELL BIOL, V89, P505, DOI [10.1139/o11-052, 10.1139/O11-052]; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Mullighan CG, 2009, P NATL ACAD SCI USA, V106, P9414, DOI 10.1073/pnas.0811761106; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Payton JE, 2009, J CLIN INVEST, V119, P1714, DOI 10.1172/JCI38248; Pedersen-Bjergaard J, 2008, LEUKEMIA, V22, P240, DOI 10.1038/sj.leu.2405078; Pfeifer GP, 2006, CURR TOP MICROBIOL, V301, P259; Rocquain J, 2010, AM J HEMATOL, V85, P717, DOI 10.1002/ajh.21798; ROWLEY JD, 1977, INT J CANCER, V20, P869, DOI 10.1002/ijc.2910200608; Sallmyr A, 2008, BLOOD, V111, P3173, DOI 10.1182/blood-2007-05-092510; Sanz MA, 2009, BLOOD, V113, P1875, DOI 10.1182/blood-2008-04-150250; Shen Y, 2011, BLOOD, V118, P5593, DOI 10.1182/blood-2011-03-343988; Shih LY, 2004, CLIN CANCER RES, V10, P1326, DOI 10.1158/1078-0432.CCR-0835-03; Sohal J, 2003, BLOOD, V101, P3188, DOI 10.1182/blood-2002-06-1800; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Suela J, 2007, CYTOGENET GENOME RES, V118, P304, DOI 10.1159/000108314; Takayama N, 2001, EXP HEMATOL, V29, P864, DOI 10.1016/S0301-472X(01)00651-8; Takizawa H, 2011, J EXP MED, V208, P273, DOI 10.1084/jem.20101643; Tomasson MH, 2008, BLOOD, V111, P4797, DOI 10.1182/blood-2007-09-113027; Tomlinson IPM, 1996, P NATL ACAD SCI USA, V93, P14800, DOI 10.1073/pnas.93.25.14800; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Walter MJ, 2012, NEW ENGL J MED, V366, P1090, DOI 10.1056/NEJMoa1106968; Walter MJ, 2009, P NATL ACAD SCI USA, V106, P12950, DOI 10.1073/pnas.0903091106; Walter MJ, 2004, MOL CELL BIOL, V24, P10882, DOI 10.1128/MCB.24.24.10882-10893.2004; Wartman LD, 2011, J CLIN INVEST, V121, P1445, DOI 10.1172/JCI45284; Welch JS, 2011, JAMA-J AM MED ASSOC, V305, P1577, DOI 10.1001/jama.2011.497; Yamashita Y, 2010, ONCOGENE, V29, P3723, DOI 10.1038/onc.2010.117; Young MA, 2012, CELL STEM CELL, V10, P570, DOI 10.1016/j.stem.2012.03.002; Zheng XM, 2009, INT J ONCOL, V34, P1521, DOI 10.3892/ijo_00000281	67	1110	1136	3	154	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 20	2012	150	2					264	278		10.1016/j.cell.2012.06.023	http://dx.doi.org/10.1016/j.cell.2012.06.023			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817890	Green Accepted, Bronze			2022-12-28	WOS:000306595700007
J	Heneghan, C; Perera, R; Nunan, D; Mahtani, K; Gill, P				Heneghan, Carl; Perera, Rafael; Nunan, David; Mahtani, Kamal; Gill, Peter			Forty years of sports performance research and little insight gained	BRITISH MEDICAL JOURNAL			English	Editorial Material							CARBOHYDRATE-ELECTROLYTE SOLUTION; MARATHON RUNNING PERFORMANCE; PROLONGED EXERCISE; PSYCHOLOGICAL AFFECT; ENDURANCE CAPACITY; FLUID BALANCE; INTERMITTENT; INGESTION; ENVIRONMENT; GLUCOSE		[Heneghan, Carl; Perera, Rafael; Nunan, David; Mahtani, Kamal; Gill, Peter] Univ Oxford, Dept Primary Care Hlth Sci, Ctr Evidence Based Med, Oxford OX1 2ET, England	University of Oxford	Heneghan, C (corresponding author), Univ Oxford, Dept Primary Care Hlth Sci, Ctr Evidence Based Med, Oxford OX1 2ET, England.	carl.heneghan@phc.ox.ac.uk	Gill, Peter J./A-6021-2012	Gill, Peter J./0000-0002-6253-1312; Perera, Rafael/0000-0003-2418-2091	National Institute for Health Research [CL-2011-13-006] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Ali A, 2007, MED SCI SPORT EXER, V39, P1969, DOI 10.1249/mss.0b013e31814fb3e3; Arkinstall MJ, 2001, J APPL PHYSIOL, V91, P2125, DOI 10.1152/jappl.2001.91.5.2125; Atkinson G, 2011, INT J SPORTS MED, V32, P611, DOI 10.1055/s-0031-1273739; Atkinson G, 2001, J SPORT SCI, V19, P811, DOI 10.1080/026404101317015447; Betts JA, 2009, APPL PHYSIOL NUTR ME, V34, P773, DOI 10.1139/H09-070; Bilzon JLJ, 2000, EUR J APPL PHYSIOL, V82, P305, DOI 10.1007/s004210000206; Carter J, 2003, PFLUG ARCH EUR J PHY, V446, P211, DOI 10.1007/s00424-003-1020-4; Clarke ND, 2005, INT J SPORT NUTR EXE, V15, P625, DOI 10.1123/ijsnem.15.6.625; Currell K, 2006, EUR J APPL PHYSIOL, V98, P583, DOI 10.1007/s00421-006-0305-7; Eng J, 2003, RADIOLOGY, V227, P309, DOI 10.1148/radiol.2272012051; Foskett A, 2008, MED SCI SPORT EXER, V40, P96, DOI [10.1249/mss.0013e3181586b2c, 10.1249/mss.0b013e3181586b2c]; Galloway SDR, 2000, J SPORT SCI, V18, P339, DOI 10.1080/026404100402403; Galloway SDR, 2001, J APPL PHYSIOL, V91, P654, DOI 10.1152/jappl.2001.91.2.654; GREEN L F, 1972, Proceedings of the Nutrition Society, V31, P5; Green L.F., 1972, BRIT J SPORT MED, V6, P125; Heneghan C, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001702; Hooper S, 2004, J DENT, V32, P541, DOI 10.1016/j.jdent.2004.05.002; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Ioannidis JPA, 2001, BRIT MED J, V322, P879, DOI 10.1136/bmj.322.7291.879; Jentjens RLPG, 2005, BRIT J NUTR, V93, P485, DOI 10.1079/BJN20041368; Jeukendrup A, 1996, MED SCI SPORT EXER, V28, P266, DOI 10.1097/00005768-199602000-00017; Jeukendrup AE, 2010, SCAND J MED SCI SPOR, V20, P112, DOI 10.1111/j.1600-0838.2008.00862.x; Lancaster GI, 2005, J APPL PHYSIOL, V98, P565, DOI 10.1152/japplphysiol.00754.2004; Morris JG, 2003, J SPORT SCI, V21, P371, DOI 10.1080/0264041031000071191; MUCKLE DS, 1973, BRIT J SPORT MED, V7, P340; Nassis GP, 1998, BRIT J SPORT MED, V32, P248, DOI 10.1136/bjsm.32.3.248; Nicholas Ceri W., 1995, Journal of Sports Sciences, V13, P283, DOI 10.1080/02640419508732241; Nicholas CW, 1999, MED SCI SPORT EXER, V31, P1280, DOI 10.1097/00005768-199909000-00008; Noakes TD, 1998, MED SCI SPORT EXER, V30, P1381, DOI 10.1097/00005768-199809000-00007; Nuesch E, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3515; Peacock OJ, 2012, APPETITE, V58, P56, DOI 10.1016/j.appet.2011.08.023; Peacock OJ, 2011, J SPORT SCI, V29, P897, DOI 10.1080/02640414.2011.568511; Rollo I, 2011, MED SCI SPORT EXER, V43, P468, DOI 10.1249/MSS.0b013e3181f1cda3; TSINTZAS OK, 1995, EUR J APPL PHYSIOL O, V70, P154, DOI 10.1007/BF00361543; VIST GE, 1994, MED SCI SPORT EXER, V26, P1269; WIDRICK JJ, 1993, J APPL PHYSIOL, V74, P2998, DOI 10.1152/jappl.1993.74.6.2998; WILLIAMS C, 1990, EUR J APPL PHYSIOL O, V60, P112, DOI 10.1007/BF00846030	37	21	21	1	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 19	2012	345								e4797	10.1136/bmj.e4797	http://dx.doi.org/10.1136/bmj.e4797			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978MA	22810388				2022-12-28	WOS:000306744300011
J	Liu, MK; Hwang, HY; Tao, H; Strikwerda, AC; Fan, KB; Keiser, GR; Sternbach, AJ; West, KG; Kittiwatanakul, S; Lu, JW; Wolf, SA; Omenetto, FG; Zhang, X; Nelson, KA; Averitt, RD				Liu, Mengkun; Hwang, Harold Y.; Tao, Hu; Strikwerda, Andrew C.; Fan, Kebin; Keiser, George R.; Sternbach, Aaron J.; West, Kevin G.; Kittiwatanakul, Salinporn; Lu, Jiwei; Wolf, Stuart A.; Omenetto, Fiorenzo G.; Zhang, Xin; Nelson, Keith A.; Averitt, Richard D.			Terahertz-field-induced insulator-to-metal transition in vanadium dioxide metamaterial	NATURE			English	Article							MOTT TRANSITION; POOLE-FRENKEL; SPECTROSCOPY; ENHANCEMENT; ELECTRON; VO2	Electron-electron interactions can render an otherwise conducting material insulating(1), with the insulator-metal phase transition in correlated-electron materials being the canonical macroscopic manifestation of the competition between charge-carrier itinerancy and localization. The transition can arise from underlying microscopic interactions among the charge, lattice, orbital and spin degrees of freedom, the complexity of which leads to multiple phase-transition pathways. For example, in many transition metal oxides, the insulator-metal transition has been achieved with external stimuli, including temperature, light, electric field, mechanical strain or magnetic field(2-7). Vanadium dioxide is particularly intriguing because both the lattice and on-site Coulomb repulsion contribute to the insulator-to-metal transition at 340K (ref. 8). Thus, although the precise microscopic origin of the phase transition remains elusive, vanadium dioxide serves as a testbed for correlated-electron phase-transition dynamics. Here we report the observation of an insulator-metal transition in vanadium dioxide induced by a terahertz electric field. This is achieved using metamaterial-enhanced picosecond, high-field terahertz pulses to reduce the Coulomb-induced potential barrier for carrier transport(9). A nonlinear metamaterial response is observed through the phase transition, demonstrating that high-field terahertz pulses provide alternative pathways to induce collective electronic and structural rearrangements. The metamaterial resonators play a dual role, providing sub-wavelength field enhancement that locally drives the nonlinear response, and global sensitivity to the local changes, thereby enabling macroscopic observation of the dynamics(10,11). This methodology provides a powerful platform to investigate low-energy dynamics in condensed matter and, further, demonstrates that integration of metamaterials with complex matter is a viable pathway to realize functional nonlinear electromagnetic composites.	[Hwang, Harold Y.; Nelson, Keith A.] MIT, Dept Chem, Cambridge, MA 02139 USA; [Liu, Mengkun; Strikwerda, Andrew C.; Keiser, George R.; Sternbach, Aaron J.; Averitt, Richard D.] Boston Univ, Dept Phys, Boston, MA 02215 USA; [Tao, Hu; Omenetto, Fiorenzo G.] Tufts Univ, Medford, MA 02155 USA; [Fan, Kebin; Zhang, Xin] Boston Univ, Dept Mech Engn, Boston, MA 02215 USA; [West, Kevin G.; Kittiwatanakul, Salinporn; Lu, Jiwei; Wolf, Stuart A.] Univ Virginia, Dept Mat Sci & Engn, Charlottesville, VA 22904 USA; [Wolf, Stuart A.] Univ Virginia, Dept Phys, Charlottesville, VA 22904 USA	Massachusetts Institute of Technology (MIT); Boston University; Tufts University; Boston University; University of Virginia; University of Virginia	Nelson, KA (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	kanelson@mit.edu; raveritt@buphy.bu.edu	Tao, Hu/C-1528-2013; Liu, Mengkun/B-3241-2019; Fan, Kebin/ABC-5164-2020; Fan, Kebin/B-2984-2012; Averitt, Richard/AAX-4178-2021; Zhang, Xin/B-9244-2009	Liu, Mengkun/0000-0002-3512-9133; Fan, Kebin/0000-0002-0275-0871; Fan, Kebin/0000-0002-0275-0871; Zhang, Xin/0000-0002-4413-5084; Strikwerda, Andrew/0000-0001-8212-5891; Averitt, Richard/0000-0003-0451-1935	DOE-BES [DE-FG02-09ER46643]; ONR [N00014-09-1-1103]	DOE-BES(United States Department of Energy (DOE)); ONR(Office of Naval Research)	We acknowledge support from DOE-BES under grant DE-FG02-09ER46643 and from ONR grant N00014-09-1-1103.	Asamitsu A, 1997, NATURE, V388, P50, DOI 10.1038/40363; Basov DN, 2011, REV MOD PHYS, V83, P471, DOI 10.1103/RevModPhys.83.471; BERGLUND CN, 1969, PHYS REV, V185, P1022, DOI 10.1103/PhysRev.185.1022; Cao J, 2009, NAT NANOTECHNOL, V4, P732, DOI [10.1038/nnano.2009.266, 10.1038/NNANO.2009.266]; Cavalleri A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.237401; Chen HT, 2006, NATURE, V444, P597, DOI 10.1038/nature05343; Driscoll T, 2009, SCIENCE, V325, P1518, DOI 10.1126/science.1176580; GROENEVELD RHM, 1995, PHYS REV B, V51, P11433, DOI 10.1103/PhysRevB.51.11433; Hilton DJ, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.226401; Hirori H, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3560062; Hoffmann MC, 2009, J OPT SOC AM B, V26, pA29, DOI 10.1364/JOSAB.26.000A29; Hoffmann MC, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.161201; Kim HT, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/052; Kubler C, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.116401; Limelette P, 2003, SCIENCE, V302, P89, DOI 10.1126/science.1088386; Liu MK, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.066403; Merbold H, 2011, OPT EXPRESS, V19, P7262, DOI 10.1364/OE.19.007262; MORIN FJ, 1959, PHYS REV LETT, V3, P34, DOI 10.1103/PhysRevLett.3.34; Pashkin A, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.195120; Pergament AL, 2010, J PHYS CHEM SOLIDS, V71, P874, DOI 10.1016/j.jpcs.2010.03.032; Qazilbash MM, 2007, SCIENCE, V318, P1750, DOI 10.1126/science.1150124; Seo MA, 2009, NAT PHOTONICS, V3, P152, DOI 10.1038/NPHOTON.2009.22; Shalaby M, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3617476; SIMMONS JG, 1967, PHYS REV, V155, P657, DOI 10.1103/PhysRev.155.657; Stefanovich G, 2000, J PHYS-CONDENS MAT, V12, P8837, DOI 10.1088/0953-8984/12/41/310; Wang J, 2003, SCIENCE, V299, P1719, DOI 10.1126/science.1080615; Werley CA, 2012, OPT EXPRESS, V20, P8551, DOI 10.1364/OE.20.008551; West KG, 2008, J VAC SCI TECHNOL A, V26, P133, DOI 10.1116/1.2819268; YEARGAN JR, 1968, J APPL PHYS, V39, P5600, DOI 10.1063/1.1656022; Yeh KL, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2734374	30	862	875	73	1119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 19	2012	487	7407					345	348		10.1038/nature11231	http://dx.doi.org/10.1038/nature11231			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JB	22801506				2022-12-28	WOS:000306506500038
J	Winterstein, AG; Gerhard, T; Kubilis, P; Saidi, A; Linden, S; Crystal, S; Zito, J; Shuster, JJ; Olfson, M				Winterstein, Almut G.; Gerhard, Tobias; Kubilis, Paul; Saidi, Arwa; Linden, Stephan; Crystal, Stephen; Zito, Julie; Shuster, Jonathan J.; Olfson, Mark			Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TACHYCARDIA-INDUCED CARDIOMYOPATHY; AMBULATORY BLOOD-PRESSURE; PHARMACOLOGICAL-TREATMENT; ADHD DRUGS; MEDICATION; EVENTS; YOUTHS; ADULTS; RISK; METHYLPHENIDATE	Objectives To evaluate the cardiac safety of central nervous system stimulants in children and adolescents. Design Population based retrospective cohort study. Setting Automated healthcare claims data from 1 219 847 children and young people eligible for 28 state Medicaid programmes from 1999 to 2006 linked to the Social Security Death Master File and the National Death Index. Participants Children and young people age 3-18 entered the cohort at the first diagnosis of a mental health condition commonly treated with stimulants (such as attention-deficit/hyperactivity disorder) after a minimum period of six months' eligibility and were followed until loss of eligibility, their 19th birthday, admission to hospital for longer than 30 days, or death. Exclusion criteria included transplant recipients, receipt of dialysis, or claims indicating substance misuse. We retained high risk groups with similar use of stimulants as low risk children (such as children with congenital heart disease). Sociodemographic characteristics, cardiac risk factors, and psychiatric diagnoses obtained from before the index period were summarised with a propensity score. We used discrete survival analysis to estimate the relative risk for periods of stimulant use and non-use, adjusted for propensity score and antipsychotic use for the full cohort and the high risk and low risk groups. Main outcome measures Composite endpoint of stroke, acute myocardial infarction, or sudden cardiac death; a secondary composite endpoint added ventricular arrhythmia Results A total of 66 (95 including ventricular arrhythmia) events occurred during 2 321 311 years of follow-up. The odds ratio adjusted for propensity score and antipsychotic use for current versus no stimulant use was 0.62 (95% confidence interval 0.27 to 1.44), with a corresponding adjusted incidence rate of 2.2 and 3.5 per 100 000 patient years for current stimulant and non-use, respectively. Twenty six events occurred in high risk patients (incidence rate 63 per 100 000 patient years) with an odds ratio of 1.02 (0.28 to 3.69). Odds ratios for the secondary endpoint were similar to those for the primary endpoint (0.74, 0.38 to 1.46). Conclusions Treatment of children with central nervous stimulants is not significantly associated with an increase in the short term risk of severe cardiac events. Analyses cannot be generalised to children with long term use of stimulants. Furthermore, long term effects of slight increases in heart rate or blood pressure are unknown.	[Winterstein, Almut G.; Kubilis, Paul; Linden, Stephan] Univ Florida, Coll Pharm, Coll Med, Gainesville, FL 32611 USA; [Gerhard, Tobias] Rutgers State Univ, Ernest Mario Sch Pharm, New Brunswick, NJ 08901 USA; [Gerhard, Tobias] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08901 USA; [Shuster, Jonathan J.] Univ Florida, Coll Med, UF Clin Res Ctr, Dept Hlth Outcomes & Policy, Gainesville, FL 32611 USA; [Crystal, Stephen] Rutgers State Univ, Ctr Hlth Serv Res Pharmacotherapy Chron Dis Manag, New Brunswick, NJ 08901 USA; [Zito, Julie] Univ Maryland, Baltimore, MD 21201 USA; [Olfson, Mark] Columbia Univ, New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA; [Winterstein, Almut G.; Kubilis, Paul; Linden, Stephan] Univ Florida, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; Rutgers State University New Brunswick; Rutgers State University New Brunswick; State University System of Florida; University of Florida; Rutgers State University New Brunswick; University System of Maryland; University of Maryland Baltimore; Columbia University; New York State Psychiatry Institute; State University System of Florida; University of Florida	Winterstein, AG (corresponding author), Univ Florida, Coll Pharm, Coll Med, Gainesville, FL 32611 USA.	almut@cop.ufl.edu	Shuster, Jonathan/ABB-5773-2021; winterstein, almut/ABH-1838-2020; Olfson, Mark/AAA-8547-2021; winterstein, Almut/A-3017-2014	Shuster, Jonathan/0000-0001-9499-5616; winterstein, Almut/0000-0002-6518-5961; Gerhard, Tobias/0000-0002-8598-5771	Agency of Healthcare Research and Quality (AHRQ) [R01-HS0185606]; NIH from National Center for Advancing Translational Sciences [1UL1 TR000064]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS018506] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000064] Funding Source: NIH RePORTER	Agency of Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIH from National Center for Advancing Translational Sciences; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This study was funded by grant R01-HS0185606 from the Agency of Healthcare Research and Quality (AHRQ) and in part by NIH grant 1UL1 TR000064 from the National Center for Advancing Translational Sciences. AHRQ and NIH had no role in the design, conduct, or reporting of the study or in the decision to submit the manuscript for publication.	Belanger SA, 2009, PAED CHILD HEALT-CAN, V14, P579, DOI 10.1093/pch/14.9.579; Biederman J, 2006, BIOL PSYCHIAT, V59, P829, DOI 10.1016/j.biopsych.2005.09.011; Chen CY, 2009, J CHILD ADOL PSYCHOP, V19, P187, DOI 10.1089/cap.2008.096; Chung CP, 2010, PHARMACOEPIDEM DR S, V19, P563, DOI 10.1002/pds.1888; Cooper WO, 2011, NEW ENGL J MED, V365, P1896, DOI 10.1056/NEJMoa1110212; CORNFIELD J, 1951, J NATL CANCER I, V11, P1269; COX DR, 1972, J R STAT SOC B, V34, P187; El Hajjar M, 2004, ARCH PEDIATRIE, V11, P24, DOI 10.1016/j.arcped.2003.11.005; Findling RL, 2001, J AM ACAD CHILD PSY, V40, P525, DOI 10.1097/00004583-200105000-00011; Graham J, 2011, EUR CHILD ADOLES PSY, V20, P17, DOI 10.1007/s00787-010-0140-6; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; HERNDON JE, 1995, STAT MED, V14, P2119, DOI 10.1002/sim.4780141906; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; McCarthy S, 2009, DRUG SAFETY, V32, P1089, DOI 10.2165/11317630-000000000-00000; Nissen SE, 2006, NEW ENGL J MED, V354, P1445, DOI 10.1056/NEJMp068049; Olfson M, 2012, J AM ACAD CHILD PSY, V51, P147, DOI 10.1016/j.jaac.2011.11.008; Perrin JM, 2008, PEDIATRICS, V122, P451, DOI 10.1542/peds.2008-1573; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; Ray WA, 2001, ARCH GEN PSYCHIAT, V58, P1161, DOI 10.1001/archpsyc.58.12.1161; Ray WA, 2009, NEW ENGL J MED, V360, P225, DOI 10.1056/NEJMoa0806994; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Samuels JA, 2006, PEDIATR NEPHROL, V21, P92, DOI 10.1007/s00467-005-2051-1; Schelleman H, 2011, PEDIATRICS, V127, P1102, DOI 10.1542/peds.2010-3371; Shinbane JS, 1997, J AM COLL CARDIOL, V29, P709, DOI 10.1016/S0735-1097(96)00592-X; Stowe CD, 2002, ANN PHARMACOTHER, V36, P1142, DOI 10.1345/aph.1A367; Umana E, 2003, AM J MED, V114, P51, DOI 10.1016/S0002-9343(02)01472-9; Vetter VL, 2008, CIRCULATION, V117, P2407, DOI 10.1161/CIRCULATIONAHA.107.189473; Weisler RH, 2005, CNS SPECTRUMS, V10, P35, DOI 10.1017/S109285290000242X; Winterstein AG, 2008, ANN PHARMACOTHER, V42, P24, DOI 10.1345/aph.1K143; Winterstein AG, 2007, PEDIATRICS, V120, pE1494, DOI 10.1542/peds.2007-0675; Zito JM, 1999, ARCH PEDIAT ADOL MED, V153, P1257, DOI 10.1001/archpedi.153.12.1257	32	29	29	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 18	2012	345								e4627	10.1136/bmj.e4627	http://dx.doi.org/10.1136/bmj.e4627			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	978LU	22809800	Green Published, hybrid			2022-12-28	WOS:000306743400008
J	Catalona, WJ; D'Amico, AV; Fitzgibbons, WF; Kosoko-Lasaki, O; Leslie, SW; Lynch, HT; Moul, JW; Rendell, MS; Walsh, PC				Catalona, William J.; D'Amico, Anthony V.; Fitzgibbons, William F.; Kosoko-Lasaki, Omofolasade; Leslie, Stephen W.; Lynch, Henry T.; Moul, Judd W.; Rendell, Marc S.; Walsh, Patrick C.			What the US Preventive Services Task Force Missed in Its Prostate Cancer Screening Recommendation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							FOLLOW-UP; MORTALITY; TRIAL; LUNG		Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Creighton Univ, Sch Med, Omaha, NE USA; Duke Univ, Sch Med, Durham, NC USA; Duke Canc Inst, Durham, NC USA; Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA	Northwestern University; Feinberg School of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Creighton University; Duke University; Duke University; Johns Hopkins University; Johns Hopkins Medicine	Rendell, MS (corresponding author), Creighton Diabet Ctr, 601 N 30th St, Omaha, NE 68131 USA.	Rendell@asndi.com						Andriole GL, 2012, J NATL CANCER I, V104, P125, DOI 10.1093/jnci/djr500; Bill-Axelson A, 2011, NEW ENGL J MED, V364, P1708, DOI 10.1056/NEJMoa1011967; Chornokur G, 2011, PROSTATE, V71, P985, DOI 10.1002/pros.21314; Chou R, 2011, ANN INTERN MED, V155, P762, DOI 10.7326/0003-4819-155-11-201112060-00375; Etzioni R, 2008, CANCER CAUSE CONTROL, V19, P175, DOI 10.1007/s10552-007-9083-8; Ganz PA, 2012, ANN INTERN MED, V156, P591, DOI [10.7326/0003-4819-156-8-201204170-00401, 10.7326/0003-4819-156-8-201204170-00010]; Hugosson J, 2010, LANCET ONCOL, V11, P725, DOI 10.1016/S1470-2045(10)70146-7; Moyer VA, 2012, ANN INTERN MED, V157, P120, DOI 10.7326/0003-4819-157-2-201207170-00459; Pinsky PF, 2010, CLIN TRIALS, V7, P303, DOI 10.1177/1740774510374091; Roobol MJ, 2009, EUR UROL, V56, P584, DOI 10.1016/j.eururo.2009.07.018; Schroder FH, 2012, NEW ENGL J MED, V366, P981, DOI 10.1056/NEJMoa1113135; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084	12	56	56	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2					137	+		10.7326/0003-4819-157-2-201207170-00463	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00463			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801676				2022-12-28	WOS:000307787900019
J	Hoffman, RM				Hoffman, Richard M.			Periodic PSA-based screening in men 55 to 69 years of age reduced prostate cancer mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RECOMMENDATIONS		New Mexico VA Hlth Care Syst, Albuquerque, NM USA		Hoffman, RM (corresponding author), New Mexico VA Hlth Care Syst, Albuquerque, NM USA.			Hoffman, Richard/0000-0002-4714-7726				Andriole GL, 2012, J NATL CANCER I, V104, P125, DOI 10.1093/jnci/djr500; Chou R, 2011, JAMA-J AM MED ASSOC, V306, P2721, DOI 10.1001/jama.2011.1891; Loeb S, 2011, J CLIN ONCOL, V29, P464, DOI 10.1200/JCO.2010.30.6373; Moyer VA, 2012, ANN INTERN MED, V156, P880, DOI 10.7326/0003-4819-156-12-201206190-00424; Prasad SM, 2012, JAMA-J AM MED ASSOC, V307, P1692, DOI 10.1001/jama.2012.534; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084; Wolf AMD, 2010, CA-CANCER J CLIN, V60, P70, DOI 10.3322/caac.20066	7	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2							JC2-4	10.7326/0003-4819-157-2-201207170-02004	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-02004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801696				2022-12-28	WOS:000307787900003
J	Preda, A				Preda, Adrian			Review: Lithium is associated with adverse events in patients with mood disorders	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Calif Irvine Coll Med, Irvine, CA 92717 USA	University of California System; University of California Irvine	Preda, A (corresponding author), Univ Calif Irvine Coll Med, Irvine, CA 92717 USA.		Preda, Adrian/K-8889-2013	Preda, Adrian/0000-0003-3373-2438				Werneke U, 2012, ACTA PSYCHIAT SCAND	1	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2							JC2-10	10.7326/0003-4819-157-2-201207170-02010	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-02010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801701				2022-12-28	WOS:000307787900009
J	Singh, V				Singh, Vibhuti			Review: ACE-Is or ARBs reduce adverse CV outcomes regardless of baseline systolic blood pressure	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ S Florida, Coll Med, St Petersburg, FL 33701 USA	State University System of Florida; University of South Florida	Singh, V (corresponding author), Univ S Florida, Coll Med, St Petersburg, FL 33701 USA.							Fraker TD, 2007, J AM COLL CARDIOL, V50, P2264, DOI [10.1016/j.jacc.2007.08.002, 10.1161/CIRCULATIONAHA.107.187930]; Remme WJ, 2007, CARDIOVASC DRUG THER, V21, P405, DOI 10.1007/s10557-007-6071-x	2	1	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2							JC2-8	10.7326/0003-4819-157-2-201207170-02008	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-02008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801699				2022-12-28	WOS:000307787900007
J	Meldrum, M				Meldrum, Marcia			Women making contraceptive choices in 20th-century America	LANCET			English	Editorial Material									Univ Calif Los Angeles, UCLA Ctr Hlth Serv & Soc, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Meldrum, M (corresponding author), Univ Calif Los Angeles, UCLA Ctr Hlth Serv & Soc, Los Angeles, CA 90024 USA.	meldrum@history.ucla.edu		Meldrum, Marcia/0000-0003-0130-9299				Cook Hera, 2005, LONG SEXUAL REVOLUTI; Junod SW, 2002, J HIST MED ALL SCI, V57, P117, DOI 10.1093/jhmas/57.2.117; Meldrum ML, 1996, B HIST MED, V70, P266, DOI 10.1353/bhm.1996.0075; Siegel Watkins E., 1998, PILL SOCIAL HIST ORA; Tone Andrea, 2002, DEVICES DESIRES HIST; Watkins ES, 2010, J WOMENS HIST, V22, P88	6	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2012	380	9837					102	103		10.1016/S0140-6736(12)61166-0	http://dx.doi.org/10.1016/S0140-6736(12)61166-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22803208				2022-12-28	WOS:000306359100023
J	Rudkjobing, A; Olejaz, M; Birk, HO; Nielsen, AJ; Hernandez-Quevedo, C; Krasnik, A				Rudkjobing, Andreas; Olejaz, Maria; Birk, Hans Okkels; Nielsen, Annegrete Juul; Hernandez-Quevedo, Cristina; Krasnik, Allan			Integrated care: a Danish perspective	BRITISH MEDICAL JOURNAL			English	Editorial Material							DENMARK; HEALTH		[Rudkjobing, Andreas; Olejaz, Maria; Birk, Hans Okkels; Nielsen, Annegrete Juul; Krasnik, Allan] Univ Copenhagen, Dept Publ Hlth, Sect Hlth Serv Res, DK-1014 Copenhagen, Denmark; [Rudkjobing, Andreas; Krasnik, Allan] Univ Copenhagen, Ctr Hlth Ageing, DK-1168 Copenhagen, Denmark; [Hernandez-Quevedo, Cristina] London Sch Econ & Polit Sci, European Observ Hlth Syst & Policies, London, England	University of Copenhagen; University of Copenhagen; European Observatory on Health Systems & Policies; University of London; London School Economics & Political Science	Rudkjobing, A (corresponding author), Univ Copenhagen, Dept Publ Hlth, Sect Hlth Serv Res, Oster Farimagsgade 5, DK-1014 Copenhagen, Denmark.	anru@sund.ku.dk	Hernandez-Quevedo, Cristina/AAX-5316-2021	Olejaz, Maria/0000-0002-1310-308X				Bhanoo S. N., 2010, NY TIMES; Christensen AIDM, 2011, NATL HLTH PROFILE 20; Coleman MP, 2011, LANCET, V377, P127, DOI 10.1016/S0140-6736(10)62231-3; Curry N, 2010, CLIN SERVICE INTEGRA; Danish Quality Unit of General Practice, SENT DAT CAPT SEC SE; Diderichsen FAI, 2011, HLTH INEQUALITIES CA; Economist Intelligence Unit, 2011, FUT PROOF W EUR HEAL; Guldberg TL, 2011, DIABETIC MED, V28, P325, DOI 10.1111/j.1464-5491.2010.03178.x; Implement Consulting Group, 2011, EV HLTH CAR AGR; Lorig K R, 2001, Eff Clin Pract, V4, P256; Mackenbach JP, 2008, NEW ENGL J MED, V358, P2468, DOI 10.1056/NEJMsa0707519; Magnussen J, 2009, NORDIC HEALTHCARE SY; *MIN INT HLTH, 2004, STRUKT BET; National Board of Health, NAT INT CANC PATHW; OECD, 2012, DAT INC DISTR POV IN; Olejaz M, 2012, HLTH SYST TRANSIT, V14, pI; Probst HB, 2012, HEALTH POLICY, V105, P65, DOI 10.1016/j.healthpol.2011.11.001; Strandberg-Larsen Martin, 2007, Int J Integr Care, V7, pe35; WHO Regional Office for Europe, 2012, EUR HLTH ALL DAT HFA	19	21	21	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 13	2012	345								e4451	10.1136/bmj.e4451	http://dx.doi.org/10.1136/bmj.e4451			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NX	22797845	Green Accepted			2022-12-28	WOS:000306519100003
J	Warner, JH; Margine, ER; Mukai, M; Robertson, AW; Giustino, F; Kirkland, AI				Warner, Jamie H.; Margine, Elena Roxana; Mukai, Masaki; Robertson, Alexander W.; Giustino, Feliciano; Kirkland, Angus I.			Dislocation-Driven Deformations in Graphene	SCIENCE			English	Article							ELECTRON-MICROSCOPY; CARBON NANOTUBES; ATOMIC-STRUCTURE; HIGH-RESOLUTION; DEFECTS; STRAIN; STRENGTH; FIELDS; FILMS; TEM	The movement of dislocations in a crystal is the key mechanism for plastic deformation in all materials. Studies of dislocations have focused on three-dimensional materials, and there is little experimental evidence regarding the dynamics of dislocations and their impact at the atomic level on the lattice structure of graphene. We studied the dynamics of dislocation pairs in graphene, recorded with single-atom sensitivity. We examined stepwise dislocation movement along the zig-zag lattice direction mediated either by a single bond rotation or through the loss of two carbon atoms. The strain fields were determined, showing how dislocations deform graphene by elongation and compression of C-C bonds, shear, and lattice rotations.	[Warner, Jamie H.; Margine, Elena Roxana; Robertson, Alexander W.; Giustino, Feliciano; Kirkland, Angus I.] Univ Oxford, Dept Mat, Oxford OX1 3PH, England; [Mukai, Masaki] JEOL, Akishima, Tokyo 1968558, Japan	University of Oxford; Jeol Ltd; JEOL Japan	Warner, JH (corresponding author), Univ Oxford, Dept Mat, Parks Rd, Oxford OX1 3PH, England.	jamie.warner@materials.ox.ac.uk	Robertson, Alex W/J-5321-2014; Giustino, Feliciano/ABD-5408-2021; Giustino, Feliciano/F-6343-2013; Giustino, Feliciano/AAM-2551-2020	Robertson, Alex W/0000-0002-9521-6482; Giustino, Feliciano/0000-0001-9293-1176; Warner, Jamie/0000-0002-1271-2019; Margine, Elena Roxana/0000-0002-5573-9940	Royal Society; Balliol College; Engineering and Physical Sciences Research Council [EP/F028784/1]; Marie Curie Intra-Euronpean Fellowships project [FP7-PEOPLE-2009-IEF-252586]; European Research Council under EU [239578]; EPSRC [EP/F028784/1] Funding Source: UKRI	Royal Society(Royal Society of London); Balliol College; Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Marie Curie Intra-Euronpean Fellowships project; European Research Council under EU(European Research Council (ERC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	J.H.W. thanks the Royal Society and Balliol College for support. Financial support from the Engineering and Physical Sciences Research Council (grant EP/F028784/1) is gratefully acknowledged. E. R. M. was funded by Marie Curie Intra-Euronpean Fellowships project FP7-PEOPLE-2009-IEF-252586. F. G. acknowledges support from the European Research Council under EU FP7/ERC grant no. 239578. J.H.W. produced the samples; performed the HRTEM, GPA analysis, image simulations, and dislocation theory; analyzed the results; and wrote the paper. M. M. developed and installed the monochromator. A. I. K. developed the HRTEM methods and assisted with the analysis and writing the paper. A. W. R. assisted with the GPA analysis and HREM image simulations. E. R. M. and F. G. designed and analyzed the calculation and assisted with writing the paper. E. R. M. performed the calculations.	Carpio A, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.085406; Chen JH, 2011, NAT PHYS, V7, P535, DOI [10.1038/NPHYS1962, 10.1038/nphys1962]; Chen S, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.214103; Cockayne E, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.195425; Ding F, 2007, NANO LETT, V7, P681, DOI 10.1021/nl0627543; Gomez-Navarro C, 2010, NANO LETT, V10, P1144, DOI 10.1021/nl9031617; Grantab R, 2010, SCIENCE, V330, P946, DOI 10.1126/science.1196893; Haider M, 2010, MICROSC MICROANAL, V16, P393, DOI 10.1017/S1431927610013498; Hashimoto A, 2004, NATURE, V430, P870, DOI 10.1038/nature02817; Huang PY, 2011, NATURE, V469, P389, DOI 10.1038/nature09718; Hytch MJ, 1998, ULTRAMICROSCOPY, V74, P131, DOI 10.1016/S0304-3991(98)00035-7; Jeong BW, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.165403; Jinschek JR, 2011, CARBON, V49, P556, DOI 10.1016/j.carbon.2010.09.058; Kabius B, 2009, J ELECTRON MICROSC, V58, P147, DOI 10.1093/jmicro/dfp021; Kim Y, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.075445; Kotakoski J, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.105505; Krivanek OL, 2010, NATURE, V464, P571, DOI 10.1038/nature08879; Lee C, 2008, SCIENCE, V321, P385, DOI 10.1126/science.1157996; Levy N, 2010, SCIENCE, V329, P544, DOI 10.1126/science.1191700; Li XS, 2009, SCIENCE, V324, P1312, DOI 10.1126/science.1171245; Liu Z, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.015501; Mesaros A, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.155111; Meyer JC, 2008, NANO LETT, V8, P3582, DOI 10.1021/nl801386m; Meyer JC, 2011, NAT MATER, V10, P209, DOI 10.1038/NMAT2941; Mukai M., 2005, MICROSC MICROANAL, V11, P2134; Nair RR, 2012, NAT PHYS, V8, P199, DOI [10.1038/NPHYS2183, 10.1038/nphys2183]; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Robertson AW, 2011, ACS NANO, V5, P6610, DOI 10.1021/nn202051g; Suenaga K, 2010, NATURE, V468, P1088, DOI 10.1038/nature09664; Warner JH, 2011, NAT MATER, V10, P958, DOI [10.1038/NMAT3125, 10.1038/nmat3125]; Warner JH, 2009, NAT NANOTECHNOL, V4, P500, DOI [10.1038/NNANO.2009.194, 10.1038/nnano.2009.194]; Xu T, 2018, WOODH PUB SER ELECT, P137, DOI 10.1016/B978-0-08-102053-1.00005-3; Yazyev OV, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.195420	33	300	304	29	447	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2012	337	6091					209	212		10.1126/science.1217529	http://dx.doi.org/10.1126/science.1217529			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798609				2022-12-28	WOS:000306323500052
J	Yewdell, JW; Ince, WL				Yewdell, Jonathan W.; Ince, William L.			Frameshifting to PA-X Influenza	SCIENCE			English	Editorial Material							PROTEIN; PATHOGENESIS; EXPRESSION		[Yewdell, Jonathan W.; Ince, William L.] NIAID, Viral Dis Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Yewdell, JW (corresponding author), NIAID, Viral Dis Lab, Bethesda, MD 20892 USA.	jyewdell@niaid.nih.gov	yewdell, jyewdell@nih.gov jonathan/A-1702-2012		Intramural NIH HHS [ZIA AI001055-05] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001014] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; Boivin S, 2010, J BIOL CHEM, V285, P28411, DOI 10.1074/jbc.R110.117531; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Dittmar KA, 2006, PLOS GENET, V2, P2107, DOI 10.1371/journal.pgen.0020221; Jagger BW, 2012, SCIENCE, V337, P199, DOI 10.1126/science.1222213; Krumbholz A, 2011, MED MICROBIOL IMMUN, V200, P69, DOI 10.1007/s00430-010-0176-8; Kryazhimskiy S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001301; McAuley JL, 2007, CELL HOST MICROBE, V2, P240, DOI 10.1016/j.chom.2007.09.001; SANZEZQUERRO JJ, 1995, J VIROL, V69, P2420, DOI 10.1128/JVI.69.4.2420-2426.1995; Zamarin D, 2006, J VIROL, V80, P7976, DOI 10.1128/JVI.00415-06	10	22	24	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2012	337	6091					164	165		10.1126/science.1225539	http://dx.doi.org/10.1126/science.1225539			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798590	Green Accepted			2022-12-28	WOS:000306323500032
J	Kupfer, JM; Bond, EU				Kupfer, Joel M.; Bond, Edward U.			Patient Satisfaction and Patient-Centered Care Necessary but Not Equal	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; REQUESTS		[Kupfer, Joel M.] Methodist Med Ctr, Dept Cardiol, Peoria, IL 61603 USA; [Kupfer, Joel M.] Univ Illinois, Sch Med, Dept Med, Peoria, IL USA; [Bond, Edward U.] Bradley Univ, Dept Mkt, Peoria, IL 61625 USA	University of Illinois System; University of Illinois Peoria; Bradley University	Kupfer, JM (corresponding author), Methodist Med Ctr, Dept Cardiol, 221 NE Glenn Oak Ave, Peoria, IL 61603 USA.	jkupfer@mmci.org		Bond, Edward/0000-0002-6383-4972				Brett AS, 2012, JAMA-J AM MED ASSOC, V307, P149, DOI 10.1001/jama.2011.1999; Chang JT, 2006, ANN INTERN MED, V144, P665, DOI 10.7326/0003-4819-144-9-200605020-00010; Committee on Quality of Health Care in America, 2001, I MED CROSS QUAL CHA; Coulter A, 2012, J AMBUL CARE MANAG, V35, P80, DOI 10.1097/JAC.0b013e318249e0fd; Golder PN, WHAT IS QUALITY INTE; Hall Melvin F, 2008, Healthc Financ Manage, V62, P76; Jarvik JG, 2003, JAMA-J AM MED ASSOC, V289, P2810, DOI 10.1001/jama.289.21.2810; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V293, P1995, DOI 10.1001/jama.293.16.1995	8	100	104	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2012	308	2					139	140		10.1001/jama.2012.7381	http://dx.doi.org/10.1001/jama.2012.7381			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971QS	22782413				2022-12-28	WOS:000306219500024
J	Moriarty, B; Hay, R; Morris-Jones, R				Moriarty, Blaithin; Hay, Roderick; Morris-Jones, Rachael			The diagnosis and management of tinea	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SOUTH-EAST LONDON; SUPERFICIAL FUNGAL-INFECTIONS; TRICHOPHYTON-TONSURANS; SCALP RINGWORM; CAPITIS; EPIDEMIOLOGY; ONYCHOMYCOSIS; PREVALENCE; DERMATOPHYTOSES; WORLDWIDE		[Moriarty, Blaithin; Hay, Roderick; Morris-Jones, Rachael] Kings Coll Hosp London, Dept Dermatol, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Morris-Jones, R (corresponding author), Kings Coll Hosp London, Dept Dermatol, London SE5 9RS, England.	themojos@doctors.org.uk						Ameen M, 2010, CLIN DERMATOL, V28, P197, DOI 10.1016/j.clindermatol.2009.12.005; Borman AM, 2007, MED MYCOL, V45, P131, DOI 10.1080/13693780601070107; BRONSON DM, 1983, J AM ACAD DERMATOL, V8, P322, DOI 10.1016/S0190-9622(83)70034-4; Faergemann J, 2003, BRIT J DERMATOL, V149, P1, DOI 10.1046/j.1365-2133.149.s65.4.x; Foster KW, 2004, J AM ACAD DERMATOL, V50, P748, DOI 10.1016/S0190-9622(03)02117-0; Fuller LC, 1997, BRIT J DERMATOL, V136, P139, DOI 10.1111/j.1365-2133.1997.tb08771.x; Fuller LC, 2003, BMJ-BRIT MED J, V326, P539, DOI 10.1136/bmj.326.7388.539; Fuller LC, 2003, BRIT J DERMATOL, V148, P985, DOI 10.1046/j.1365-2133.2003.05022.x; Ginter-Hanselmayer G, 2007, MYCOSES, V50, P6, DOI 10.1111/j.1439-0507.2007.01424.x; Gupta AK, 2000, INT J DERMATOL, V39, P746, DOI 10.1046/j.1365-4362.2000.00012.x; Havlickova B, 2008, MYCOSES, V51, P2, DOI 10.1111/j.1439-0507.2008.01606.x; Hay RJ, 1996, BRIT J DERMATOL, V135, P955, DOI 10.1046/j.1365-2133.1996.d01-1101.x; Hay RJ, 2011, J AM ACAD DERMATOL, V65, P1219, DOI 10.1016/j.jaad.2010.09.730; Hay RJ, 2010, CLIN DERMATOL, V28, P190, DOI 10.1016/j.clindermatol.2010.01.001; Higgins EM, 2000, BRIT J DERMATOL, V143, P53, DOI 10.1046/j.1365-2133.2000.03530.x; Honig PJ, 1999, PEDIATR INFECT DIS J, V18, P211, DOI 10.1097/00006454-199902000-00030; Jahromi SB, 2006, MYCOSES, V49, P65, DOI 10.1111/j.1439-0507.2005.01182.x; Kuklova I, 2001, MYCOSES, V44, P493, DOI 10.1046/j.1439-0507.2001.00697.x; MACKENZIE DWR, 1963, BMJ-BRIT MED J, P363, DOI 10.1136/bmj.2.5353.363; Macura AB, 2010, MYCOSES, V53, P148, DOI 10.1111/j.1439-0507.2008.01684.x; Rodwell GEJ, 2008, INT J DERMATOL, V47, P339, DOI 10.1111/j.1365-4632.2008.03416.x; Tan Hiok-Hee, 2005, Nihon Ishinkin Gakkai Zasshi, V46, P77, DOI 10.3314/jjmm.46.77; WEITZMAN I, 1995, CLIN MICROBIOL REV, V8, P240, DOI 10.1128/CMR.8.2.240; Welsh O, 2006, MYCOSES, V49, P119, DOI 10.1111/j.1439-0507.2006.01199.x; White JML, 2007, J EUR ACAD DERMATOL, V21, P1061, DOI 10.1111/j.1468-3083.2007.02173.x; Woldeamanuel Y, 2005, MYCOSES, V48, P137, DOI 10.1111/j.1439-0507.2004.01081.x	26	50	50	2	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	2012	345								e4380	10.1136/bmj.e4380	http://dx.doi.org/10.1136/bmj.e4380			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975NT	22782730				2022-12-28	WOS:000306518700002
J	[Anonymous]				[Anonymous]			Care can't get better until complaints are heard	BRITISH MEDICAL JOURNAL			English	Editorial Material																		General Medical Council, 2012, RAIS ACT PAT SAF	1	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 2	2012	344								e4511	10.1136/bmj.e4511	http://dx.doi.org/10.1136/bmj.e4511			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972JV	22750471				2022-12-28	WOS:000306274300005
J	Steinbrook, R				Steinbrook, Robert			Preexposure Prophylaxis for HIV Infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University	Steinbrook, R (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,I-456 SHM,POB 208008, New Haven, CT 06520 USA.	rsteinbrook@attglobal.net						Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Centers for Disease Control and Prevention, 2012, HIV US GLANC; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Hallett TB, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001123; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; World Health Organization, GUID COUPL HIV TEST	8	5	5	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 5	2012	308	9					865	866		10.1001/jama.2012.9885	http://dx.doi.org/10.1001/jama.2012.9885			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	999ET	22820712				2022-12-28	WOS:000308292900012
J	Hochberg, MC; Yerges-Armstrong, L; Mitchell, BD				Hochberg, Marc C.; Yerges-Armstrong, Laura; Mitchell, Braxton D.			Osteoarthritis susceptibility genes continue trickling in	LANCET			English	Editorial Material							KNEE; MORTALITY; HIP		[Hochberg, Marc C.; Yerges-Armstrong, Laura; Mitchell, Braxton D.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Hochberg, MC (corresponding author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.	mhochber@umaryland.edu	Mitchell, Braxton/CAF-0876-2022	Mitchell, Braxton/0000-0003-4920-4744	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [RC2AR058950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072488] Funding Source: NIH RePORTER; NIAMS NIH HHS [RC2 AR058950] Funding Source: Medline; NIDDK NIH HHS [P30 DK072488] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[arcOGEN Consortium arcOGEN Collaborators], 2012, LANCET; Chaganti RK, 2011, CURR REV MUSCULOSKE, V4, P99, DOI 10.1007/s12178-011-9088-5; Day-Williams AG, 2011, AM J HUM GENET, V89, P446, DOI 10.1016/j.ajhg.2011.08.001; Evangelou E, 2011, ANN RHEUM DIS, V70, P349, DOI 10.1136/ard.2010.132787; Losina E, 2011, ANN INTERN MED, V154, P217, DOI 10.7326/0003-4819-154-4-201102150-00001; MacGregor AJ, 2009, RHEUMATOLOGY, V48, P277, DOI 10.1093/rheumatology/ken475; Nuesch E, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1165; Pereira D, 2011, OSTEOARTHR CARTILAGE, V19, P1270, DOI 10.1016/j.joca.2011.08.009; STECHER RM, 1948, ANN RHEUM DIS, V7, P1, DOI 10.1136/ard.7.1.1; Valdes AM, 2011, ANN RHEUM DIS, V70, P873, DOI 10.1136/ard.2010.134155; Valdes AM, 2011, NAT REV RHEUMATOL, V7, P23, DOI 10.1038/nrrheum.2010.191; Yerges-Armstrong LM, 2012, OSTEOARTHR CARTILAGE, V20, pS46, DOI 10.1016/j.joca.2012.02.590	12	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 1	2012	380	9844					785	787		10.1016/S0140-6736(12)60818-6	http://dx.doi.org/10.1016/S0140-6736(12)60818-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	000OP	22763109	Green Accepted			2022-12-28	WOS:000308396300006
J	Shen, Y; Yue, F; McCleary, DF; Ye, Z; Edsall, L; Kuan, S; Wagner, U; Dixon, J; Lee, L; Lobanenkov, VV; Ren, B				Shen, Yin; Yue, Feng; McCleary, David F.; Ye, Zhen; Edsall, Lee; Kuan, Samantha; Wagner, Ulrich; Dixon, Jesse; Lee, Leonard; Lobanenkov, Victor V.; Ren, Bing			A map of the cis-regulatory sequences in the mouse genome	NATURE			English	Article							FUNCTIONAL ELEMENTS; ENHANCERS; REVEALS; IDENTIFICATION; VERTEBRATE; PROMOTERS; DYNAMICS; DATABASE; DISTINCT	The laboratory mouse is the most widely used mammalian model organism in biomedical research. The 2.6 x 10(9) bases of the mouse genome possess a high degree of conservation with the human genome(1), so a thorough annotation of the mouse genome will be of significant value to understanding the function of the human genome. So far, most of the functional sequences in the mouse genome have yet to be found, and the cis-regulatory sequences in particular are still poorly annotated. Comparative genomics has been a powerful tool for the discovery of these sequences(2), but on its own it cannot resolve their temporal and spatial functions. Recently, ChIP-Seq has been developed to identify cis-regulatory elements in the genomes of several organisms including humans, Drosophila melanogaster and Caenorhabditis elegans(3-5). Here we apply the same experimental approach to a diverse set of 19 tissues and cell types in the mouse to produce a map of nearly 300,000 murine cis-regulatory sequences. The annotated sequences add up to 11% of the mouse [GRAPHICS] genome, and include more than 70% of conserved non-coding sequences. We define tissue-specific enhancers and identify potential transcription factors regulating gene expression in each tissue or cell type. Finally, we show that much of the mouse genome is organized into domains of coordinately regulated enhancers and promoters. Our results provide a resource for the annotation of functional elements in the mammalian genome and for the study of mechanisms regulating tissue-specific gene expression.	[Shen, Yin; Yue, Feng; McCleary, David F.; Ye, Zhen; Edsall, Lee; Kuan, Samantha; Wagner, Ulrich; Dixon, Jesse; Lee, Leonard; Ren, Bing] Ludwig Inst Canc Res, La Jolla, CA 92093 USA; [Dixon, Jesse] Univ Calif San Diego, Sch Med, Med Scientist Training Program, La Jolla, CA 92093 USA; [Dixon, Jesse] Univ Calif San Diego, Sch Med, Biomed Sci Grad Program, La Jolla, CA 92093 USA; [Lobanenkov, Victor V.] NIAID, Immunogenet Lab, Twinbrook NIAID Facil 1, Rockville, MD 20852 USA; [Ren, Bing] Univ Calif San Diego, Sch Med, Moores Canc Ctr, Dept Cellular & Mol Med,Inst Genom Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Diego	Ren, B (corresponding author), Ludwig Inst Canc Res, 9500 Gilman Dr, La Jolla, CA 92093 USA.	biren@ucsd.edu	Lobanenkov, Victor/ABD-5710-2021; Dixon, Jesse/AAT-2914-2020; Lobanenkov, Victor V./AGQ-8903-2022	Dixon, Jesse/0000-0002-6273-2181; Lobanenkov, Victor/0000-0001-6665-3635; Edsall, Lee Elizabeth/0000-0002-0326-2829	National Human Genome Research Institute [R01HG003991]; Ludwig Institute for Cancer Research; International Rett Syndrome Foundation; California Institute for Regenerative Medicine; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000860, ZIAAI001021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007198] Funding Source: NIH RePORTER	National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Ludwig Institute for Cancer Research; International Rett Syndrome Foundation; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank F. Jin, Y. Luu, S. Klugman, A. Y.-J. Kim, Q.-M. Ngo, B. A. Gomez and S. Selvaraj for consultation. The mESC line Bruce4 was a gift from UCSD Transgenic Core. Research funding was provided by the National Human Genome Research Institute (R01HG003991) and the Ludwig Institute for Cancer Research to B. R. Y. S. is supported by a postdoctoral fellowship from the International Rett Syndrome Foundation. J.D. is supported by a pre-doctoral fellowship from the California Institute for Regenerative Medicine.	Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Chepelev I, 2012, CELL RES, V22, P490, DOI 10.1038/cr.2012.15; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Gerstein MB, 2010, SCIENCE, V330, P1775, DOI 10.1126/science.1196914; Hawkins RD, 2010, CELL STEM CELL, V6, P479, DOI 10.1016/j.stem.2010.03.018; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380; Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014; Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369; Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046; Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049; Ong CT, 2011, NAT REV GENET, V12, P283, DOI 10.1038/nrg2957; Parkhomchuk D, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp596; Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Roy S, 2010, SCIENCE, V330, P1787, DOI 10.1126/science.1198374; Schmidt D, 2010, SCIENCE, V328, P1036, DOI 10.1126/science.1186176; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Splinter E, 2006, GENE DEV, V20, P2349, DOI 10.1101/gad.399506; Visel A, 2007, NUCLEIC ACIDS RES, V35, pD88, DOI 10.1093/nar/gkl822; Visel A, 2009, NATURE, V461, P199, DOI 10.1038/nature08451; Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	30	957	978	6	164	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 2	2012	488	7409					116	120		10.1038/nature11243	http://dx.doi.org/10.1038/nature11243			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981ZE	22763441	Green Accepted			2022-12-28	WOS:000307010700044
J	Kaufman, JJ; Tao, GM; Shabahang, S; Banaei, EH; Deng, DSS; Liang, XD; Johnson, SG; Fink, Y; Abouraddy, AF				Kaufman, Joshua J.; Tao, Guangming; Shabahang, Soroush; Banaei, Esmaeil-Hooman; Deng, Daosheng S.; Liang, Xiangdong; Johnson, Steven G.; Fink, Yoel; Abouraddy, Ayman F.			Structured spheres generated by an in-fibre fluid instability	NATURE			English	Article							MONODISPERSE; PARTICLES; ARRAYS; DEVICE	From drug delivery(1,2) to chemical and biological catalysis(3) and cosmetics(4), the need for efficient fabrication pathways for particles over a wide range of sizes, from a variety of materials, and in many different structures has been well established(5). Here we harness the inherent scalability of fibre production(6) and an in-fibre Plateau-Rayleigh capillary instability(7) for the fabrication of uniformly sized, structured spherical particles spanning an exceptionally wide range of sizes: from 2 mm down to 20 nm. Thermal processing of a multimaterial fibre(8) controllably induces the instability(9), resulting in a well-ordered, oriented emulsion(10) in three dimensions. The fibre core and cladding correspond to the dispersed and continuous phases, respectively, and are both frozen in situ on cooling, after which the particles are released when needed. By arranging a variety of structures and materials in a macroscopic scaled-up model of the fibre, we produce composite, structured, spherical particles, such as core-shell particles, two-compartment 'Janus' particles(11), and multi-sectioned 'beach ball' particles. Moreover, producing fibres with a high density of cores allows for an unprecedented level of parallelization. In principle, 10(8) 50-nm cores may be embedded in metres-long, 1-mm-diameter fibre, which can be induced to break up simultaneously throughout its length, into uniformly sized, structured spheres.	[Kaufman, Joshua J.; Tao, Guangming; Shabahang, Soroush; Banaei, Esmaeil-Hooman; Abouraddy, Ayman F.] Univ Cent Florida, CREOL, Coll Opt & Photon, Orlando, FL 32816 USA; [Banaei, Esmaeil-Hooman] Univ Cent Florida, Dept Elect Engn & Comp Sci, Orlando, FL 32816 USA; [Deng, Daosheng S.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA; [Liang, Xiangdong; Johnson, Steven G.] MIT, Dept Math, Cambridge, MA 02139 USA; [Fink, Yoel] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA	State University System of Florida; University of Central Florida; State University System of Florida; University of Central Florida; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Abouraddy, AF (corresponding author), Univ Cent Florida, CREOL, Coll Opt & Photon, Orlando, FL 32816 USA.	raddy@creol.ucf.edu	Tao, Guangming/AAH-2617-2021; Deng, Daosheng/S-5002-2018; Deng, Daosheng/AAN-1286-2020; Abouraddy, Ayman/I-7963-2012; Liang, Xiangdong/C-5903-2016	Tao, Guangming/0000-0002-1371-7735; Deng, Daosheng/0000-0002-4203-5119; Deng, Daosheng/0000-0002-4203-5119; Johnson, Steven/0000-0001-7327-4967	US National Science Foundation [ECCS-1002295]; Ralph E. Powe Junior Faculty Enhancement Award from the Oak Ridge Associated Universities (ORAU); US Air Force Office of Scientific Research (AFOSR) [FA-9550-12-1-0148]; CREOL; College of Optics Photonics; Materials Research Science and Engineering Program of the US NSF [DMR-0819762]; US Army Research Office through the Institute for Soldier Nanotechnologies [W911NF-07-D-0004]	US National Science Foundation(National Science Foundation (NSF)); Ralph E. Powe Junior Faculty Enhancement Award from the Oak Ridge Associated Universities (ORAU); US Air Force Office of Scientific Research (AFOSR)(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); CREOL; College of Optics Photonics; Materials Research Science and Engineering Program of the US NSF; US Army Research Office through the Institute for Soldier Nanotechnologies	Work at UCF was supported by the US National Science Foundation (award number ECCS-1002295), a Ralph E. Powe Junior Faculty Enhancement Award from the Oak Ridge Associated Universities (ORAU), in part by the US Air Force Office of Scientific Research (AFOSR) under contract FA-9550-12-1-0148, and by CREOL, The College of Optics & Photonics. Work at MIT was supported in part by the Materials Research Science and Engineering Program of the US NSF under award number DMR-0819762, and also in part by the US Army Research Office through the Institute for Soldier Nanotechnologies under contract number W911NF-07-D-0004. We thank Sasha Stolyarov, J. Manuel Perez, Sudipta Seal and Kirk Scammon for assistance. We especially thank M. J. Soileau, B. E. A. Saleh, D. N. Christodoulides and M. Z. Bazant for encouragement and support.	Abouraddy AF, 2007, NAT MATER, V6, P336, DOI 10.1038/nmat1889; [Anonymous], 1992, INTERMOLECULAR SURFA; Ballato J, 2010, OPT FIBER TECHNOL, V16, P399, DOI 10.1016/j.yofte.2010.08.006; Bell AT, 2003, SCIENCE, V299, P1688, DOI 10.1126/science.1083671; Cao G., 2004, NANOSTRUCTURES NANOM; DEGENNES PG, 1985, REV MOD PHYS, V57, P827, DOI 10.1103/RevModPhys.57.827; Dendukuri D, 2006, NAT MATER, V5, P365, DOI 10.1038/nmat1617; Dendukuri D, 2009, ADV MATER, V21, P4071, DOI 10.1002/adma.200803386; Deng DS, 2011, OPT EXPRESS, V19, P16273, DOI 10.1364/OE.19.016273; Deng DS, 2008, NANO LETT, V8, P4265, DOI 10.1021/nl801979w; Dussan V. E. B., 1979, ANNU REV FLUID MECH, V11, P371, DOI DOI 10.1146/ANNUREV.FL.11.010179.002103; Eggers J, 2008, REP PROG PHYS, V71, DOI 10.1088/0034-4885/71/3/036601; Hernandez CJ, 2007, J PHYS CHEM C, V111, P4477, DOI 10.1021/jp0672095; Kaufman JJ, 2011, NANO LETT, V11, P4768, DOI 10.1021/nl202583g; Li T, 1985, OPTICAL FIBER COMMUN, V1; Liang X, 2011, J FLUID MECH, V683, P235, DOI 10.1017/jfm.2011.260; Merkel TJ, 2010, LANGMUIR, V26, P13086, DOI 10.1021/la903890h; Nie ZH, 2008, MICROFLUID NANOFLUID, V5, P585, DOI 10.1007/s10404-008-0271-y; Nisisako T, 2008, LAB CHIP, V8, P287, DOI 10.1039/b713141k; Orf ND, 2011, P NATL ACAD SCI USA, V108, P4743, DOI 10.1073/pnas.1101160108; Rolland JP, 2005, J AM CHEM SOC, V127, P10096, DOI 10.1021/ja051977c; Rotello V. M., 2003, NANOPARTICLES BUILDI; Shabahang S, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3653247; Sjoblom J., 2001, ENCY HDB EMULSION TE; Smith KA, 2002, INTERFACE FREE BOUND, V4, P263; Souto E. B., 2008, International Journal of Cosmetic Science, V30, P157, DOI 10.1111/j.1468-2494.2008.00433.x; Timko BP, 2011, ANNU REV MATER RES, V41, P1, DOI 10.1146/annurev-matsci-062910-100359; Tomotika S., 1935, P ROY SOC LOND A MAT, V150, P322, DOI DOI 10.1098/RSPA.1935.0104; Utada AS, 2005, SCIENCE, V308, P537, DOI 10.1126/science.1109164; Vollath D., 2008, NANOMATERIALS INTRO; Walther A, 2008, SOFT MATTER, V4, P663, DOI 10.1039/b718131k; Wang J, 2011, SMALL, V7, P1919, DOI 10.1002/smll.201100442	32	143	147	9	258	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 26	2012	487	7408					463	467		10.1038/nature11215	http://dx.doi.org/10.1038/nature11215			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979KD	22810590				2022-12-28	WOS:000306815300034
J	Shivaraju, M; Unruh, JR; Slaughter, BD; Mattingly, M; Berman, J; Gerton, JL				Shivaraju, Manjunatha; Unruh, Jay R.; Slaughter, Brian D.; Mattingly, Mark; Berman, Judith; Gerton, Jennifer L.			Cell-Cycle-Coupled Structural Oscillation of Centromeric Nucleosomes in Yeast	CELL			English	Article							NUCLEAR-PORE COMPLEX; CENP-A NUCLEOSOME; BUDDING YEAST; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; MOLECULAR ARCHITECTURE; CHROMATIN REQUIRES; POINT CENTROMERES; NONHISTONE SCM3; CHAPERONE SCM3	The centromere is a specialized chromosomal structure that regulates chromosome segregation. Centromeres are marked by a histone H3 variant. In budding yeast, the histone H3 variant Cse4 is present in a single centromeric nucleosome. Experimental evidence supports several different models for the structure of centromeric nucleosomes. To investigate Cse4 copy number in live yeast, we developed a method coupling fluorescence correlation spectroscopy and calibrated imaging. We find that centromeric nucleosomes have one copy of Cse4 during most of the cell cycle, whereas two copies are detected at anaphase. The proposal of an anaphase-coupled structural change is supported by Cse4-Cse4 interactions, incorporation of Cse4, and the absence of Scm3 in anaphase. Nucleosome reconstitution and ChIP suggests both Cse4 structures contain H2A/H2B. The increase in Cse4 intensity and deposition at anaphase are also observed in Candida albicans. Our experimental evidence supports a cell-cycle-coupled oscillation of centromeric nucleosome structure in yeast.	[Shivaraju, Manjunatha; Unruh, Jay R.; Slaughter, Brian D.; Mattingly, Mark; Gerton, Jennifer L.] Stowers Inst Med Res, Kansas City, MO 64110 USA; [Shivaraju, Manjunatha] Open Univ, Milton Keynes MK7 6BJ, Bucks, England; [Berman, Judith] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; [Gerton, Jennifer L.] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	Stowers Institute for Medical Research; Open University - UK; University of Minnesota System; University of Minnesota Twin Cities; University of Kansas; University of Kansas Medical Center	Gerton, JL (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.	jeg@stowers.org	Shivaraju, manjunatha/J-5173-2014; Berman, Judith/ABA-8528-2021; Berman, Judith/AAS-5115-2021	Berman, Judith/0000-0002-8577-0084; Shivaraju, Manjunatha/0000-0001-6346-6279; Unruh, Jay/0000-0003-3077-4990	NIH [R01GM080477]; SIMR; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080477] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SIMR; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Jerry Workman, Christophe Lavelle, and Sue Jaspersen for valuable discussions. We thank Swaminathan Venkatesh for topoI. We thank Dan Bradford for technical assistance and all of the members of the Gerton lab for their help and support. We thank Yamini Dalal and Kerry Bloom for sharing unpublished data and valuable discussions and a special thanks to Minh Bui for composing the graphical abstract. This research was supported by NIH R01GM080477 and SIMR.	Alber F, 2007, NATURE, V450, P695, DOI 10.1038/nature06405; Allshire RC, 2008, NAT REV GENET, V9, P923, DOI 10.1038/nrg2466; Antonin W, 2008, FEBS LETT, V582, P2004, DOI 10.1016/j.febslet.2008.02.067; Bancaud A, 2007, MOL CELL, V27, P135, DOI 10.1016/j.molcel.2007.05.037; Black B, 2011, CELL, V144, P471, DOI 10.1016/j.cell.2011.02.002; Bui M, 2012, CELL, V150, P317, DOI 10.1016/j.cell.2012.05.035; Camahort R, 2007, MOL CELL, V26, P853, DOI 10.1016/j.molcel.2007.05.013; Camahort R, 2009, MOL CELL, V35, P794, DOI 10.1016/j.molcel.2009.07.022; Cho US, 2011, P NATL ACAD SCI USA, V108, P9367, DOI 10.1073/pnas.1106389108; Coffman VC, 2011, J CELL BIOL, V195, P563, DOI 10.1083/jcb.201106078; Cole HA, 2011, P NATL ACAD SCI USA, V108, P12687, DOI 10.1073/pnas.1104978108; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Dalal Y, 2007, PLOS BIOL, V5, P1798, DOI 10.1371/journal.pbio.0050218; Dechassa ML, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1320; Dimitriadis EK, 2010, P NATL ACAD SCI USA, V107, P20317, DOI 10.1073/pnas.1009563107; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; Foltz DR, 2006, NAT CELL BIOL, V8, P458, DOI 10.1038/ncb1397; Furuyama S, 2007, P NATL ACAD SCI USA, V104, P14706, DOI 10.1073/pnas.0706985104; Furuyama T, 2006, P NATL ACAD SCI USA, V103, P6172, DOI 10.1073/pnas.0601686103; Furuyama T, 2009, CELL, V138, P104, DOI 10.1016/j.cell.2009.04.049; He XW, 2000, CELL, V101, P763, DOI 10.1016/S0092-8674(00)80888-0; Henikoff S, 2005, CURR OPIN GENET DEV, V15, P177, DOI 10.1016/j.gde.2005.01.004; Henikoff S, 2012, GENETICS, V190, P1575, DOI 10.1534/genetics.111.137711; Hu H, 2011, GENE DEV, V25, P901, DOI 10.1101/gad.2045111; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jansen LET, 2007, J CELL BIOL, V176, P795, DOI 10.1083/jcb.200701066; Jin QW, 2000, J CELL SCI, V113, P1903; Jin QW, 1998, J CELL BIOL, V141, P21, DOI 10.1083/jcb.141.1.21; Joglekar AP, 2008, J CELL BIOL, V181, P587, DOI 10.1083/jcb.200803027; Kingston IJ, 2011, J BIOL CHEM, V286, P4021, DOI 10.1074/jbc.M110.189340; Krassovsky K, 2012, P NATL ACAD SCI USA, V109, P243, DOI 10.1073/pnas.1118898109; Lavelle C, 2009, CELL, V139, P1216, DOI 10.1016/j.cell.2009.12.014; Lawrimore J, 2011, J CELL BIOL, V195, P573, DOI 10.1083/jcb.201106036; Lermontova I, 2006, PLANT CELL, V18, P2443, DOI 10.1105/tpc.106.043174; Luger K, 1999, METHOD ENZYMOL, V304, P3; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Mellone BG, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002068; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; Mishra PK, 2007, MOL GENET GENOMICS, V278, P455, DOI 10.1007/s00438-007-0263-8; Mishra PK, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002303; Mizuguchi G, 2007, CELL, V129, P1153, DOI 10.1016/j.cell.2007.04.026; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; PALMER DK, 1985, MOL CELL BIOL, V5, P173, DOI 10.1128/MCB.5.1.173; Pavelka N, 2010, NATURE, V468, P321, DOI 10.1038/nature09529; Pearson CG, 2004, CURR BIOL, V14, P1962, DOI 10.1016/j.cub.2004.09.086; Pidoux AL, 2009, MOL CELL, V33, P299, DOI 10.1016/j.molcel.2009.01.019; Prunell A, 1998, BIOPHYS J, V74, P2531, DOI 10.1016/S0006-3495(98)77961-5; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Schuh M, 2007, CURR BIOL, V17, P237, DOI 10.1016/j.cub.2006.11.051; Sekulic N, 2010, NATURE, V467, P347, DOI 10.1038/nature09323; Shcheprova Z, 2008, NATURE, V454, P728, DOI 10.1038/nature07212; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; Shivaraju M, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.183640; Shuaib M, 2010, P NATL ACAD SCI USA, V107, P1349, DOI 10.1073/pnas.0913709107; Silva NCE, 2007, J MOL BIOL, V370, P555, DOI 10.1016/j.jmb.2007.04.064; Stoler S, 2007, P NATL ACAD SCI USA, V104, P10571, DOI 10.1073/pnas.0703178104; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Takahashi K, 2005, PHILOS T R SOC B, V360, P595, DOI 10.1098/rstb.2004.1614; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Takayama Y, 2008, MOL BIOL CELL, V19, P682, DOI 10.1091/mbc.E07-05-0504; Tanaka T, 2005, PHILOS T ROY SOC B, V360, P606; Wente SR, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000562; Wieland G, 2004, MOL CELL BIOL, V24, P6620, DOI 10.1128/mcb.24.15.6620-6630.2004; Williams JS, 2009, MOL CELL, V33, P287, DOI 10.1016/j.molcel.2009.01.017; Winey M, 1997, MOL BIOL CELL, V8, P2119, DOI 10.1091/mbc.8.11.2119; Xiao H, 2011, MOL CELL, V43, P369, DOI 10.1016/j.molcel.2011.07.009; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687; Yoda K, 2000, P NATL ACAD SCI USA, V97, P7266, DOI 10.1073/pnas.130189697; Zhou Z, 2011, NATURE, V472, P234, DOI 10.1038/nature09854	69	72	73	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 20	2012	150	2					304	316		10.1016/j.cell.2012.05.034	http://dx.doi.org/10.1016/j.cell.2012.05.034			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817893	Green Accepted, Bronze			2022-12-28	WOS:000306595700010
J	Enriquez, J; Gullans, S				Enriquez, Juan; Gullans, Steve			Genetically enhanced Olympics are coming	NATURE			English	Editorial Material							CONVERTING ENZYME GENOTYPE; HIGH-ALTITUDE; PERFORMANCE; GENE		[Enriquez, Juan; Gullans, Steve] Excel Venture Management, Boston, MA 02199 USA		Enriquez, J (corresponding author), Excel Venture Management, Boston, MA 02199 USA.	jenriquez@excelvm.com						Berman Y, 2010, PHYSIOLOGY, V25, P250, DOI 10.1152/physiol.00008.2010; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; Droma Y, 2008, WILD ENVIRON MED, V19, P22, DOI 10.1580/06-WEME-OR-073.1; Karkazis K, 2012, AM J BIOETHICS, V12, P3, DOI 10.1080/15265161.2012.680533; Myerson S, 1999, J APPL PHYSIOL, V87, P1313, DOI 10.1152/jappl.1999.87.4.1313; Ostrander EA, 2009, ANNU REV GENOM HUM G, V10, P407, DOI 10.1146/annurev-genom-082908-150058; Sonna LA, 2001, J APPL PHYSIOL, V91, P1355, DOI 10.1152/jappl.2001.91.3.1355; Thompson J, 2007, HIGH ALT MED BIOL, V8, P278, DOI 10.1089/ham.2007.1044	8	6	7	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 19	2012	487	7407					297	297		10.1038/487297a	http://dx.doi.org/10.1038/487297a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	975JB	22810679	Bronze			2022-12-28	WOS:000306506500017
J	Hergott, LJ				Hergott, Lawrence J.			Making It From Home to First	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Colorado, Denver, CO 80202 USA	University of Colorado System; University of Colorado Denver	Hergott, LJ (corresponding author), Univ Colorado, Denver, CO 80202 USA.	lhergott@comcast.net						Finley J, 2012, PERS STAT TRANSF TRA; Hergott LJ, 2009, JAMA-J AM MED ASSOC, V302, P2188, DOI 10.1001/jama.2009.1586; Hergott LJ, 2009, ANN INTERN MED, V151, P753; O'Donohue J., 2008, BLESS SPACE US	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2012	308	3					245	246		10.1001/jama.2012.7816	http://dx.doi.org/10.1001/jama.2012.7816			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975AC	22797641				2022-12-28	WOS:000306477900024
J	Jack, A				Jack, Andrew			Mea culpa: are multi-billion dollar fines forcing drug companies to clean up their act?	BRITISH MEDICAL JOURNAL			English	Editorial Material												andrew.jack@ft.com		Jack, Andrew/0000-0001-9679-2898				ALMASHAT S, 2010, RAPIDLY INCREASING C; GlaxoSmithKline, ASTHM PROM 2003 OP P; Jack A, 2012, GSK PAY 3BN SETTLE U; Jack A, 2012, GSK ILLS SYMPTOMATIC; Jack A, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6459; Wolfe S, 2012, GLAXOSMITHKLINE SETT	6	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 18	2012	345								e4865	10.1136/bmj.e4865	http://dx.doi.org/10.1136/bmj.e4865			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978LU	22809803				2022-12-28	WOS:000306743400012
J	Carr, B; Gates, MF; Mitchell, A; Shah, R				Carr, Bob; Gates, Melinda French; Mitchell, Andrew; Shah, Rajiv			Giving women the power to plan their families	LANCET			English	Editorial Material									[Carr, Bob] Dept Foreign Affairs & Trade, Barton Act, Australia; [Gates, Melinda French] Bill & Melinda Gates Fdn, Seattle, WA USA; [Mitchell, Andrew] Dept Int Dev, London, England; [Shah, Rajiv] US Agcy Int Dev, Washington, DC 20523 USA	Bill & Melinda Gates Foundation; United States Agency for International Development (USAID)	Carr, B (corresponding author), Dept Foreign Affairs & Trade, Barton Act, Australia.	pssofs@dfid.gov.uk						Bhutta ZA, 2010, LANCET, V375, P2032, DOI 10.1016/S0140-6736(10)60678-2; Bongaarts J, 2011, SCIENCE, V333, P574, DOI 10.1126/science.1207558; Cleland J, 2006, LANCET, V368, P1810, DOI 10.1016/S0140-6736(06)69480-4; Lloyd Cynthia B., 2005, GROWING GLOBAL CHANG; Ross John, 2004, UNDERSTANDING DEMOGR; Singh S, 2012, ADDING IT COSTS BENE; The Gates Institute Johns Hopkins Bloomberg School of Public Health, 2011, PRIM DEM DIV; UN Economic and Social Council, 2011, 44 SESS APR 11 15 20; United Nations, 2009, MILL DEV GOALS REP 2; United Nations Secretary-General Ban Ki-moon, 2010, GLOB STRAT WOM CHILD	10	35	35	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2012	380	9837					80	82		10.1016/S0140-6736(12)60905-2	http://dx.doi.org/10.1016/S0140-6736(12)60905-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784540				2022-12-28	WOS:000306359100007
J	Yeung, TSV				Yeung, Tsz-Shan Valerie			Olympic winning	LANCET			English	Editorial Material									Nottinghamshire Healthcare NHS Trust, Child & Family Therapy Serv, CAMHS, Mansfield NG18 1QJ, Notts, England		Yeung, TSV (corresponding author), Nottinghamshire Healthcare NHS Trust, Child & Family Therapy Serv, CAMHS, 17-19 St John St, Mansfield NG18 1QJ, Notts, England.	val.yeung@nhs.net							0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 7	2012	380	9836					72	73		10.1016/S0140-6736(12)60199-8	http://dx.doi.org/10.1016/S0140-6736(12)60199-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970GK	22770459				2022-12-28	WOS:000306115900036
J	Divakaruni, AS; Murphy, AN				Divakaruni, Ajit S.; Murphy, Anne N.			A Mitochondrial Mystery, Solved	SCIENCE			English	Editorial Material							RAT-LIVER; PYRUVATE CARRIER; TRANSPORT; IDENTIFICATION; INHIBITION; MECHANISM		[Divakaruni, Ajit S.; Murphy, Anne N.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Divakaruni, AS (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	anmurphy@ucsd.edu	Murphy, Anne N/H-3217-2016	Murphy, Anne N/0000-0002-5222-9902				Bricker DK, 2012, SCIENCE, V337, P96, DOI 10.1126/science.1218099; Denton R M, 1979, Essays Biochem, V15, P37; HALESTRAP AP, 1976, BIOCHEM J, V156, P181, DOI 10.1042/bj1560181; HALESTRAP AP, 1974, BIOCHEM J, V138, P313, DOI 10.1042/bj1380313; HALESTRAP AP, 1975, BIOCHEM J, V148, P85, DOI 10.1042/bj1480085; Herzig S, 2012, SCIENCE, V337, P93, DOI 10.1126/science.1218530; Hildyard JCW, 2003, BIOCHEM J, V374, P607, DOI 10.1042/BJ20030995; Palmieri F, 2008, BBA-BIOENERGETICS, V1777, P564, DOI 10.1016/j.bbabio.2008.03.008; PAPA S, 1974, EUR J BIOCHEM, V49, P265, DOI 10.1111/j.1432-1033.1974.tb03831.x; PARADIES G, 1975, FEBS LETT, V52, P149, DOI 10.1016/0014-5793(75)80659-4; Pfeffer G, 2012, COCHRANE DB SYST REV, V18, P4; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; Smith RAJ, 2012, TRENDS PHARMACOL SCI, V33, P341, DOI 10.1016/j.tips.2012.03.010; THOMAS AP, 1981, BIOCHEM J, V196, P471, DOI 10.1042/bj1960471; Wang F, 2010, MOL ASPECTS MED, V31, P75, DOI 10.1016/j.mam.2009.12.003	15	25	32	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2012	337	6090					41	43		10.1126/science.1225601	http://dx.doi.org/10.1126/science.1225601			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767917				2022-12-28	WOS:000306053100035
J	Bourke, J				Bourke, Joanna			The art of medicine Languages of pain	LANCET			English	Editorial Material									Univ London Birkbeck Coll, Dept Hist, London WC1E 7HX, England	University of London; Birkbeck University London	Bourke, J (corresponding author), Univ London Birkbeck Coll, Dept Hist, London WC1E 7HX, England.	J.Bourke@bbk.ac.uk			Wellcome Trust [092708] Funding Source: Medline	Wellcome Trust(Wellcome Trust)		Bourke Joanna, 2011, WHAT IT MEANS BE HUM; Burney F, 1986, F BURNEY SELECTED LE, P127; Coulehan J, 2009, PERSPECT BIOL MED, V52, P585, DOI 10.1353/pbm.0.0130; Edson M, 2008, BODIES BARRIERS DRAM; Howell JD, 1995, TECHNOLOGY HOSP TRAN; Lakof G., 1980, METAPHORS WE LIVE; REISER SJ, 1993, EMPATHY PRACTICE MED	7	7	7	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 30	2012	379	9835					2420	2421		10.1016/S0140-6736(12)61055-1	http://dx.doi.org/10.1016/S0140-6736(12)61055-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	967NV	22764375	Green Accepted			2022-12-28	WOS:000305915900014
J	Zeggini, E; Panoutsopoulou, K; Southam, L; Rayner, NW; Day-Williams, AG; Lopes, MC; Boraska, V; Esko, T; Evangelou, E; Hofman, A; Houwing-Duistermaat, JJ; Ingvarsson, T; Jonsdottir, I; Jonsson, H; Kerkhof, HJM; Kloppenburg, M; Bos, SD; Mangino, M; Metrustry, S; Slagboom, PE; Thorleifsson, G; Raine, EVA; Ratnayake, M; Ricketts, M; Beazley, C; Blackburn, H; Bumpstead, S; Elliott, KS; Hunt, SE; Potter, SC; Shin, SY; Yadav, VK; Zhai, GJ; Sherburn, K; Dixon, K; Arden, E; Aslam, N; Battley, PK; Carluke, I; Doherty, S; Gordon, A; Joseph, J; Keen, R; Koller, NC; Mitchell, S; O'Neill, F; Paling, E; Reed, MR; Rivadeneira, F; Swift, D; Walker, K; Watkins, B; Wheeler, M; Birrell, F; Ioannidis, JPA; Meulenbelt, I; Metspalu, A; Rai, A; Salter, D; Stefansson, K; Styrkarsdottir, U; Uitterlinden, AG; van Meurs, JBJ; Chapman, K; Deloukas, P; Ollier, WER; Wallis, GA; Arden, N; Carr, A; Doherty, M; McCaskie, A; Wilkinson, JM; Ralston, SH; Valdes, AM; Spector, TD; Loughlin, J				Zeggini, Eleftheria; Panoutsopoulou, Kalliope; Southam, Lorraine; Rayner, Nigel W.; Day-Williams, Aaron G.; Lopes, Margarida C.; Boraska, Vesna; Esko, Tonu; Evangelou, Evangelos; Hofman, Albert; Houwing-Duistermaat, Jeanine J.; Ingvarsson, Thorvaldur; Jonsdottir, Ingileif; Jonsson, Helgi; Kerkhof, Hanneke J. M.; Kloppenburg, Margreet; Bos, Steffan D.; Mangino, Massimo; Metrustry, Sarah; Slagboom, P. Eline; Thorleifsson, Gudmar; Raine, Emma V. A.; Ratnayake, Madhushika; Ricketts, Michelle; Beazley, Claude; Blackburn, Hannah; Bumpstead, Suzannah; Elliott, Katherine S.; Hunt, Sarah E.; Potter, Simon C.; Shin, So-Youn; Yadav, Vijay K.; Zhai, Guangju; Sherburn, Kate; Dixon, Kate; Arden, Elizabeth; Aslam, Nadim; Battley, Phillippa-Kate; Carluke, Ian; Doherty, Sally; Gordon, Andrew; Joseph, John; Keen, Richard; Koller, Nicola C.; Mitchell, Sheryl; O'Neill, Fiona; Paling, Ellen; Reed, Mike R.; Rivadeneira, Fernando; Swift, Diane; Walker, Kirsten; Watkins, Bridget; Wheeler, Maggie; Birrell, Fraser; Ioannidis, John P. A.; Meulenbelt, Ingrid; Metspalu, Andres; Rai, Ashok; Salter, Donald; Stefansson, Kari; Styrkarsdottir, Unnur; Uitterlinden, Andre G.; van Meurs, Joyce B. J.; Chapman, Kay; Deloukas, Panos; Ollier, William E. R.; Wallis, Gillian A.; Arden, Nigel; Carr, Andrew; Doherty, Michael; McCaskie, Andrew; Wilkinson, J. Mark; Ralston, Stuart H.; Valdes, Ana M.; Spector, Tim D.; Loughlin, John		arcOGEN Consortium & arcOGEN Colla	Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study	LANCET			English	Article							MESENCHYMAL STEM-CELLS; KNEE OSTEOARTHRITIS; BONE-MARROW; HIP; GENE; GDF5; NUCLEOSTEMIN; GROWTH; HAND; CHONDROITIN-4-SULFOTRANSFERASE-1	Background Osteoarthritis is the most common form of arthritis worldwide and is a major cause of pain and disability in elderly people. The health economic burden of osteoarthritis is increasing commensurate with obesity prevalence and longevity. Osteoarthritis has a strong genetic component but the success of previous genetic studies has been restricted due to insufficient sample sizes and phenotype heterogeneity. Methods We undertook a large genome-wide association study (GWAS) in 7410 unrelated and retrospectively and prospectively selected patients with severe osteoarthritis in the arcOGEN study, 80% of whom had undergone total joint replacement, and 11 009 unrelated controls from the UK. We replicated the most promising signals in an independent set of up to 7473 cases and 42 938 controls, from studies in Iceland, Estonia, the Netherlands, and the UK. All patients and controls were of European descent. Findings We identified five genome-wide significant loci (binomial test p <= 5.0x10(-8)) for association with osteoarthritis and three loci just below this threshold. The strongest association was on chromosome 3 with rs6976 (odds ratio 1.12 [95% CI 1.08-1.16]; p=7.24x10(-11)), which is in perfect linkage disequilibrium with rs11177. This SNP encodes a missense polymorphism within the nucleostemin-encoding gene GNL3. Levels of nucleostemin were raised in chondrocytes from patients with osteoarthritis in functional studies. Other significant loci were on chromosome 9 close to ASTN2, chromosome 6 between FILIP1 and SENP6, chromosome 12 close to KLHDC5 and PTHLH, and in another region of chromosome 12 close to CHST11. One of the signals close to genome-wide significance was within the FTO gene, which is involved in regulation of bodyweight-a strong risk factor for osteoarthritis. All risk variants were common in frequency and exerted small effects. Interpretation Our findings provide insight into the genetics of arthritis and identify new pathways that might be amenable to future therapeutic intervention.	[Zeggini, Eleftheria; Panoutsopoulou, Kalliope; Southam, Lorraine; Day-Williams, Aaron G.; Lopes, Margarida C.; Boraska, Vesna; Beazley, Claude; Blackburn, Hannah; Bumpstead, Suzannah; Hunt, Sarah E.; Potter, Simon C.; Shin, So-Youn; Yadav, Vijay K.; Deloukas, Panos] Sanger Inst, Hinxton, England; [Southam, Lorraine; Rayner, Nigel W.; Lopes, Margarida C.; Elliott, Katherine S.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [Rayner, Nigel W.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England; [Boraska, Vesna] Univ Split, Sch Med, Split, Croatia; [Esko, Tonu; Metspalu, Andres] Univ Tartu, Estonian Genome Ctr, EE-50090 Tartu, Estonia; [Esko, Tonu; Metspalu, Andres] Univ Tartu, Ctr Translat Genom, EE-50090 Tartu, Estonia; [Esko, Tonu; Metspalu, Andres] Univ Tartu, Inst Mol & Cell Biol, EE-50090 Tartu, Estonia; [Esko, Tonu; Metspalu, Andres] Estonian Bioctr, Tartu, Estonia; [Evangelou, Evangelos; Ioannidis, John P. A.] Univ Ioannina, Sch Med, GR-45110 Ioannina, Greece; [Hofman, Albert; Kerkhof, Hanneke J. M.; Rivadeneira, Fernando; Uitterlinden, Andre G.; van Meurs, Joyce B. J.] Erasmus MC, Rotterdam, Netherlands; [Houwing-Duistermaat, Jeanine J.; Kloppenburg, Margreet; Bos, Steffan D.; Slagboom, P. Eline; Meulenbelt, Ingrid] Leiden Univ, Med Ctr, Leiden, Netherlands; [Ingvarsson, Thorvaldur] Univ Akureyri, Akureyri, Iceland; [Ingvarsson, Thorvaldur; Jonsdottir, Ingileif; Jonsson, Helgi; Stefansson, Kari] Univ Iceland, Reykjavik, Iceland; [Jonsdottir, Ingileif; Thorleifsson, Gudmar; Stefansson, Kari; Styrkarsdottir, Unnur] deCODE Genet, Reykjavik, Iceland; [Mangino, Massimo; Metrustry, Sarah; Zhai, Guangju; O'Neill, Fiona; Valdes, Ana M.; Spector, Tim D.] Kings Coll London, London WC2R 2LS, England; [Raine, Emma V. A.; Ratnayake, Madhushika; Birrell, Fraser; McCaskie, Andrew; Loughlin, John] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Ricketts, Michelle; Koller, Nicola C.; Salter, Donald; Ralston, Stuart H.] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland; [Zhai, Guangju] Mem Univ Newfoundland, St John, NF, Canada; [Sherburn, Kate; Dixon, Kate; Ollier, William E. R.] Univ Manchester, Ctr Integrated Genom Med Res, Manchester, Lancs, England; [Arden, Elizabeth; Battley, Phillippa-Kate] Southampton Gen Hosp, Wellcome Trust Clin Res Facil, Southampton SO9 4XY, Hants, England; [Aslam, Nadim; Joseph, John; Rai, Ashok] Worcestershire Acute Hosp NHS Trust, Worcester, England; [Carluke, Ian; Reed, Mike R.; Walker, Kirsten; Birrell, Fraser] Wansbeck Gen Hosp, Ashington, England; [Doherty, Sally; Wheeler, Maggie; Doherty, Michael] Univ Nottingham, Nottingham NG7 2RD, England; [Gordon, Andrew; Paling, Ellen; Swift, Diane; Wilkinson, J. Mark] Univ Sheffield, Dept Human Metab, Acad Unit Bone Metab, Sheffield, S Yorkshire, England; [Keen, Richard] Royal Natl Orthopaed Hosp, Stanmore HA7 4LP, Middx, England; [Mitchell, Sheryl; McCaskie, Andrew] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Paling, Ellen; Swift, Diane; Wilkinson, J. Mark] No Gen Hosp, Sheffield Natl Inst Hlth Res, Musculoskeletal Biomed Res Unit, Sheffield S5 7AU, S Yorkshire, England; [Watkins, Bridget; Stefansson, Kari; Arden, Nigel; Carr, Andrew] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England; [Ioannidis, John P. A.] Tufts Clin & Translat Sci Inst, Boston, MA USA; [Ioannidis, John P. A.] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Ioannidis, John P. A.] Stanford Univ, Stanford Prevent Res Ctr, Sch Med, Stanford, CA 94305 USA; [Wallis, Gillian A.] Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester, Lancs, England; [Arden, Nigel] Univ Southampton, Med Res Council, Epidemiol Resource Ctr, Southampton, Hants, England	Wellcome Trust Sanger Institute; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Split; University of Tartu; University of Tartu; University of Tartu; Estonian Biocentre; University of Ioannina; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Akureyri; University of Iceland; University of London; King's College London; Newcastle University - UK; University of Edinburgh; Memorial University Newfoundland; University of Manchester; University of Southampton; University of Nottingham; University of Sheffield; University of London; University College London; Royal National Orthopaedic Hospital NHS Trust; Newcastle Freeman Hospital; Newcastle University - UK; Northern General Hospital; University of Oxford; Tufts University; Stanford University; University of Manchester; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Southampton	Zeggini, E (corresponding author), Wellcome Trust Sanger Inst, Morgan Bldg,Wellcome Trust Genome Campus, Cambridge CB10 1HH, England.	eleftheria@sanger.ac.uk; john.loughlin@ncl.ac.uk	Perica, Vesna Boraska/D-8230-2017; Meulenbelt, Ingrid/F-4756-2011; Ioannidis, John P. A./G-9836-2011; Slagboom, P. Eline/R-4790-2016; Houwing-Duistermaat, Jeanne/V-9048-2018; yadav, VIJAY k/Q-2540-2016; Bos, Steffan D/L-7896-2016; Deloukas, Panos/B-2922-2013; Rivadeneira, Fernando/O-5385-2015; Stefansson, Kari/AAE-7187-2019; Evangelou, Evangelos/C-3033-2013; Mangino, Massimo/F-5134-2011	Perica, Vesna Boraska/0000-0003-3999-1529; Meulenbelt, Ingrid/0000-0001-7786-7081; Slagboom, P. Eline/0000-0002-2875-4723; yadav, VIJAY k/0000-0003-2345-2846; Bos, Steffan D/0000-0002-2975-7520; Deloukas, Panos/0000-0001-9251-070X; Rivadeneira, Fernando/0000-0001-9435-9441; Evangelou, Evangelos/0000-0002-5488-2999; Mangino, Massimo/0000-0002-2167-7470; Zeggini, Eleftheria/0000-0003-4238-659X; Jonsson, Helgi/0000-0003-0187-8985; Loughlin, John/0000-0003-2018-3361; Birrell, Fraser/0000-0002-6163-6155; Houwing-Duistermaat, Jeanine/0000-0002-4505-7137; McCaskie, Andrew/0000-0001-6476-0832; van Meurs, Joyce/0000-0001-6245-2123; Raine, Emma/0000-0002-1896-2238; Styrkarsdottir, Unnur/0000-0001-8146-8278; Esko, Tonu/0000-0003-1982-6569; Valdes, Ana M./0000-0003-1141-4471; Panoutsopoulou, Kalliope/0000-0002-5460-8025; Reed, Michael/0000-0002-6309-2710; Hunt, Sarah/0000-0002-8350-1235; Doherty, Michael/0000-0002-5763-8326	Arthritis Research UK [18030]; Medical Research Council [G0100594, G0900753, MC_U122886349, G0600237, G0901461] Funding Source: researchfish; MRC [MC_U122886349, G0901461, G0100594, G0600237, G0900753] Funding Source: UKRI	Arthritis Research UK(Versus Arthritis); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	arcOGEN was funded by a special purpose grant from Arthritis Research UK (grant 18030). A full list of acknowledgements and funding sources are provided in the appendix p 9.	Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Beekman C, 2006, MOL CELL BIOL, V26, P9291, DOI 10.1128/MCB.01183-06; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Chapman K, 2008, HUM MOL GENET, V17, P1497, DOI 10.1093/hmg/ddn038; Chitnavis J, 1997, J BONE JOINT SURG BR, V79B, P660, DOI 10.1302/0301-620X.79B4.7437; Conneely KN, 2007, AM J HUM GENET, V81, P1158, DOI 10.1086/522036; Day-Williams AG, 2011, AM J HUM GENET, V89, P446, DOI 10.1016/j.ajhg.2011.08.001; Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140-6736(05)71086-2; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Evangelou E, 2011, ANN RHEUM DIS, V70, P349, DOI 10.1136/ard.2010.132787; Evangelou E, 2009, ARTHRITIS RHEUM-US, V60, P1710, DOI 10.1002/art.24524; Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634; Grcevic D, 2010, J RHEUMATOL, V37, P246, DOI 10.3899/jrheum.090167; Gregory KE, 2001, J BONE MINER RES, V16, P2005, DOI 10.1359/jbmr.2001.16.11.2005; Han CX, 2005, INT J MOL MED, V16, P205; Heinegard D, 2009, INT J EXP PATHOL, V90, P575, DOI 10.1111/j.1365-2613.2009.00695.x; Karlsson C, 2010, OSTEOARTHR CARTILAGE, V18, P581, DOI 10.1016/j.joca.2009.12.002; Kerkhof HJM, 2010, ARTHRITIS RHEUM-US, V62, P499, DOI 10.1002/art.27184; Kluppel M, 2010, PROG MOL BIOL TRANSL, V93, P113, DOI 10.1016/S1877-1173(10)93006-8; Kluppel M, 2005, DEVELOPMENT, V132, P3989, DOI 10.1242/dev.01948; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Lanyon P, 2000, BRIT MED J, V321, P1179, DOI 10.1136/bmj.321.7270.1179; Loughlin John, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009257; Ma HH, 2008, TRENDS CELL BIOL, V18, P575, DOI 10.1016/j.tcb.2008.09.003; MacGregor AJ, 2009, RHEUMATOLOGY, V48, P277, DOI 10.1093/rheumatology/ken475; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Miyamoto Y, 2007, NAT GENET, V39, P529, DOI 10.1038/2005; Neame RL, 2004, ANN RHEUM DIS, V63, P1022, DOI 10.1136/ard.2003.014498; Panoutsopoulou K, 2011, ANN RHEUM DIS, V70, P864, DOI 10.1136/ard.2010.141473; Pereira D, 2011, OSTEOARTHR CARTILAGE, V19, P1270, DOI 10.1016/j.joca.2011.08.009; Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676; Valdes AM, 2011, ANN RHEUM DIS, V70, P873, DOI 10.1136/ard.2010.134155; Valdes AM, 2011, NAT REV RHEUMATOL, V7, P23, DOI 10.1038/nrrheum.2010.191; Valdes AM, 2010, ARTHRITIS RHEUM-US, V62, P2688, DOI 10.1002/art.27574; Wilson PM, 2010, J NEUROSCI, V30, P8529, DOI 10.1523/JNEUROSCI.0032-10.2010; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Zhang W, 2010, OSTEOARTHR CARTILAGE, V18, P476, DOI 10.1016/j.joca.2010.01.013	37	264	272	3	73	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 1	2012	380	9844					815	823		10.1016/S0140-6736(12)60681-3	http://dx.doi.org/10.1016/S0140-6736(12)60681-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	000OP	22763110	Green Submitted, Green Published			2022-12-28	WOS:000308396300030
J	Minor, PD				Minor, Philip D.			Polio vaccines and the eradication of poliomyelitis	LANCET			English	Editorial Material							UNITED-STATES		Hlth Protect Agcy, Div Virol, Natl Inst Biol Stand & Control, S Mimms EN6 3QG, Herts, England	Health Protection Agency; National Institute for Biological Standards & Control	Minor, PD (corresponding author), Hlth Protect Agcy, Div Virol, Natl Inst Biol Stand & Control, S Mimms EN6 3QG, Herts, England.	philip.minor@nibsc.hpa.org.uk						Global Polio Eradication Initiative, INF COUNTR; Grassly NC, 2007, LANCET, V369, P1356, DOI 10.1016/S0140-6736(07)60531-5; Jacob TJ, 1984, REV INFECT DIS S2, V6, pS438; Kew O, 2002, SCIENCE, V296, P356, DOI 10.1126/science.1068284; Minor PD, 2012, J GEN VIROL, V93, P457, DOI 10.1099/vir.0.036988-0; NATHANSON N, 1963, AM J HYG, V78, P29, DOI 10.1093/oxfordjournals.aje.a120328; NATHANSON N, 1984, REV INFECT DIS, V6, pS308; NKOWANE BM, 1987, JAMA-J AM MED ASSOC, V257, P1335, DOI 10.1001/jama.257.10.1335; O'Reilly KM, 2012, LANCET; Office of Health Economics, 1963, PRIC POL; SABIN AB, 1984, REV INFECT DIS, V6, pS391	11	11	12	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 4	2012	380	9840					454	455		10.1016/S0140-6736(12)60921-0	http://dx.doi.org/10.1016/S0140-6736(12)60921-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	983GY	22766208				2022-12-28	WOS:000307109000007
J	Holmes, D				Holmes, David			Gregorio Millett: an improbable journey	LANCET			English	Biographical-Item																		MILLETT G, PUBLICATION LIST	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 28	2012	380	9839					331	331		10.1016/S0140-6736(12)61194-5	http://dx.doi.org/10.1016/S0140-6736(12)61194-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979TN	22819664				2022-12-28	WOS:000306842800016
J	Hodis, E; Watson, IR; Kryukov, GV; Arold, ST; Imielinski, M; Theurillat, JP; Nickerson, E; Auclair, D; Li, LR; Place, C; DiCara, D; Ramos, AH; Lawrence, MS; Cibulskis, K; Sivachenko, A; Voet, D; Saksena, G; Stransky, N; Onofrio, RC; Winckler, W; Ardlie, K; Wagle, N; Wargo, J; Chong, K; Morton, DL; Stemke-Hale, K; Chen, G; Noble, M; Meyerson, M; Ladbury, JE; Davies, MA; Gershenwald, JE; Wagner, SN; Hoon, DSB; Schadendorf, D; Lander, ES; Gabriel, SB; Getz, G; Garraway, LA; Chin, L				Hodis, Eran; Watson, Ian R.; Kryukov, Gregory V.; Arold, Stefan T.; Imielinski, Marcin; Theurillat, Jean-Philippe; Nickerson, Elizabeth; Auclair, Daniel; Li, Liren; Place, Chelsea; DiCara, Daniel; Ramos, Alex H.; Lawrence, Michael S.; Cibulskis, Kristian; Sivachenko, Andrey; Voet, Douglas; Saksena, Gordon; Stransky, Nicolas; Onofrio, Robert C.; Winckler, Wendy; Ardlie, Kristin; Wagle, Nikhil; Wargo, Jennifer; Chong, Kelly; Morton, Donald L.; Stemke-Hale, Katherine; Chen, Guo; Noble, Michael; Meyerson, Matthew; Ladbury, John E.; Davies, Michael A.; Gershenwald, Jeffrey E.; Wagner, Stephan N.; Hoon, Dave S. B.; Schadendorf, Dirk; Lander, Eric S.; Gabriel, Stacey B.; Getz, Gad; Garraway, Levi A.; Chin, Lynda			A Landscape of Driver Mutations in Melanoma	CELL			English	Article							SOMATIC MUTATIONS; HUMAN CANCER; PROTEIN COMPLEX; GENOME; RAS; AURORA; DISCOVERY; CATALOG	Despite recent insights into melanoma genetics, systematic surveys for driver mutations are challenged by an abundance of passenger mutations caused by carcinogenic UV light exposure. We developed a permutation-based framework to address this challenge, employing mutation data from intronic sequences to control for passenger mutational load on a per gene basis. Analysis of large-scale melanoma exome data by this approach discovered six novel melanoma genes (PPP6C, RAC1, SNX31, TACC1, STK19, and ARID2), three of which-RAC1, PPP6C, and STK19-harbored recurrent and potentially targetable mutations. Integration with chromosomal copy number data contextualized the landscape of driver mutations, providing oncogenic insights in BRAF- and NRAS-driven melanoma as well as those without known NRAS/BRAF mutations. The landscape also clarified a mutational basis for RB and p53 pathway deregulation in this malignancy. Finally, the spectrum of driver mutations provided unequivocal genomic evidence for a direct mutagenic role of UV light in melanoma pathogenesis.	[Hodis, Eran; Kryukov, Gregory V.; Imielinski, Marcin; Theurillat, Jean-Philippe; Nickerson, Elizabeth; Auclair, Daniel; DiCara, Daniel; Ramos, Alex H.; Lawrence, Michael S.; Cibulskis, Kristian; Sivachenko, Andrey; Voet, Douglas; Saksena, Gordon; Stransky, Nicolas; Onofrio, Robert C.; Winckler, Wendy; Ardlie, Kristin; Wagle, Nikhil; Noble, Michael; Meyerson, Matthew; Lander, Eric S.; Gabriel, Stacey B.; Getz, Gad; Garraway, Levi A.; Chin, Lynda] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA; [Hodis, Eran; Kryukov, Gregory V.; Ramos, Alex H.; Wagle, Nikhil; Meyerson, Matthew; Garraway, Levi A.; Chin, Lynda] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Watson, Ian R.; Li, Liren; Chin, Lynda] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Arold, Stefan T.; Ladbury, John E.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Arold, Stefan T.; Ladbury, John E.] Univ Texas MD Anderson Canc Ctr, Ctr Biomol Struct & Funct, Houston, TX 77030 USA; [Stemke-Hale, Katherine; Davies, Michael A.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Chen, Guo; Davies, Michael A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Gershenwald, Jeffrey E.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Gershenwald, Jeffrey E.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Chin, Lynda] Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77030 USA; [Watson, Ian R.; Li, Liren; Place, Chelsea; Meyerson, Matthew; Garraway, Levi A.; Chin, Lynda] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Meyerson, Matthew; Garraway, Levi A.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA; [Kryukov, Gregory V.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA; [Wargo, Jennifer] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Chong, Kelly; Hoon, Dave S. B.] John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA; [Morton, Donald L.] John Wayne Canc Inst, Melanoma Dept, Santa Monica, CA 90404 USA; [Wagner, Stephan N.] Med Univ Vienna, Div Immunol Allergy & Infect Dis, Dept Dermatol, A-1090 Vienna, Austria; [Wagner, Stephan N.] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1090 Vienna, Austria; [Schadendorf, Dirk] Univ Hosp Essen, Dept Dermatol, D-45122 Essen, Germany; [Lander, Eric S.] Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; John Wayne Cancer Institute; John Wayne Cancer Institute; Medical University of Vienna; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; University of Duisburg Essen; Massachusetts Institute of Technology (MIT); Whitehead Institute	Garraway, LA (corresponding author), Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.	levi_garraway@dfci.harvard.edu; lchin@mdanderson.org	Cibulskis, Kristian/AAC-7380-2019; Arold, Stefan/T-2612-2019; Kryukov, Gregory V/A-9592-2008; Hoon, Dave SB/C-7146-2018; Lawrence, Michael/AAC-8202-2020; Davies, Michael/GWV-2527-2022; Gershenwald, Jeff/AAX-4367-2020; Meyerson, Matthew L/E-7123-2012; Schadendorf, Dirk/AAE-8206-2019; Stemke-Hale, Katherine/K-9113-2013; Wagle, Nikhil/Q-7428-2019	Hoon, Dave SB/0000-0003-1915-3683; Gershenwald, Jeff/0000-0003-4519-5369; Stemke-Hale, Katherine/0000-0002-1231-4192; Cibulskis, Kristian/0000-0003-1343-1582; Watson, Ian/0000-0002-6025-3080; Wagner, Stephan/0000-0003-4941-7029; Meyerson, Matthew/0000-0002-9133-8108; Arold, Stefan T/0000-0001-5278-0668; Kryukov, Gregory/0000-0002-6131-9483; Ladbury, John/0000-0002-6328-7200	NHGRI [U54 HG003067]; Melanoma Research Alliance; University of Texas MD Anderson Cancer Center Melanoma Specialized Programs of Research Excellence and Melanoma Informatics, Tissue Resource, and Pathology [P50 CA93459]; NCI [CA-16672, R33CA126674, R01 CA093947]; Canadian Institutes of Health Research; Swiss National Science Foundation [PASMP3_134379/1]; G. Harold and Leila Y. Mathers Charitable Foundation; FWF-Austrian Science Fund [L590-B12]; NIH [DP2OD002750]; Starr Cancer Consortium; TCGA GDAC [U24 CA143845]; Milestein Innovation Award in Melanoma Research; Novartis; Austrian Science Fund (FWF) [L 590] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA093947, P50CA093459, P30CA016672, U24CA143845, T32CA009172, R33CA126674] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003067] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD002750] Funding Source: NIH RePORTER	NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Melanoma Research Alliance; University of Texas MD Anderson Cancer Center Melanoma Specialized Programs of Research Excellence and Melanoma Informatics, Tissue Resource, and Pathology; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); G. Harold and Leila Y. Mathers Charitable Foundation; FWF-Austrian Science Fund(Austrian Science Fund (FWF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Starr Cancer Consortium; TCGA GDAC; Milestein Innovation Award in Melanoma Research; Novartis(Novartis); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank L. Ambrogio and E. Bevilacuqa for management of sequencing data production. We thank A. McKenna, L. Zou, S.L. Carter, P. Stojanov, P. Lin, L. Lichtenstein, and the rest of the Broad Cancer Genome Analysis group. We thank C.Z. Zhang and C. Johannessen for helpful discussion, as well as the members of the Garraway and Chin labs. This work was supported by the NHGRI Large Scale Sequencing Program; grant U54 HG003067 to the Broad Institute (PI, E.S.L.); the Melanoma Research Alliance; The University of Texas MD Anderson Cancer Center Melanoma Specialized Programs of Research Excellence and Melanoma Informatics, Tissue Resource, and Pathology (core grant P50 CA93459) (PI, J.E.G., M.A.D.); and the NCI Support Grant (CA-16672). I.R.W. is a recipient of the Canadian Institutes of Health Research Fellowship. J.-P.T. is supported by the Swiss National Science Foundation (PASMP3_134379/1). J.E.L. is supported by The G. Harold and Leila Y. Mathers Charitable Foundation. S.N.W. was supported by the FWF-Austrian Science Fund (L590-B12). L.A.G. is supported by the NIH New Innovator Award (DP2OD002750), NCI (R33CA126674), the Melanoma Research Alliance, and the Starr Cancer Consortium. L.C. is supported by NCI RO1 (R01 CA093947), TCGA GDAC (U24 CA143845), and the Melanoma Research Alliance. L.C. is a recipient of the Milestein Innovation Award in Melanoma Research and is a CPRIT Scholar. N.W. is a consultant and shareholder in Foundation Medicine. L.A.G. is an equity holder and consultant in Foundation Medicine, a consultant to Novartis and Millennium/Takeda, and a recipient of a grant from Novartis.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Berger MF, 2010, GENOME RES, V20, P413, DOI 10.1101/gr.103697.109; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Cibulskis K, 2011, BIOINFORMATICS, V27, P2601, DOI 10.1093/bioinformatics/btr446; Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972; Cooper GM, 2011, NAT REV GENET, V12, P628, DOI 10.1038/nrg3046; Cully M, 2005, CANCER RES, V65, P10363, DOI 10.1158/0008-5472.CAN-05-1633; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Delaval B, 2004, ONCOGENE, V23, P4516, DOI 10.1038/sj.onc.1207593; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Flaherty KT, 2012, NAT REV CANCER, V12, P349, DOI 10.1038/nrc3218; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Garibyan L, 2010, CURR ONCOL REP, V12, P319, DOI 10.1007/s11912-010-0119-y; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Getz G, 2007, SCIENCE, V317, DOI 10.1126/science.1138764; Ghai R, 2011, P NATL ACAD SCI USA, V108, P7763, DOI 10.1073/pnas.1017110108; Gnirke A, 2009, NAT BIOTECHNOL, V27, P182, DOI 10.1038/nbt.1523; Greenman C, 2006, GENETICS, V173, P2187, DOI 10.1534/genetics.105.044677; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Nikolaev SI, 2012, NAT GENET, V44, P133, DOI 10.1038/ng.1026; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Scott KL, 2011, CANCER CELL, V20, P92, DOI 10.1016/j.ccr.2011.05.025; Stark MS, 2012, NAT GENET, V44, P165, DOI 10.1038/ng.1041; Stefansson B, 2008, BIOCHEMISTRY-US, V47, P1442, DOI 10.1021/bi7022877; Stefansson B, 2007, CELL CYCLE, V6, P1386, DOI 10.4161/cc.6.11.4276; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Wei XM, 2011, NAT GENET, V43, P442, DOI 10.1038/ng.810; Zaidi MR, 2011, NATURE, V469, P548, DOI 10.1038/nature09666; Zeng K, 2010, J CELL BIOL, V191, P1315, DOI 10.1083/jcb.201008106	53	1758	1792	3	219	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 20	2012	150	2					251	263		10.1016/j.cell.2012.06.024	http://dx.doi.org/10.1016/j.cell.2012.06.024			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817889	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000306595700006
J	Burks, AW; Jones, SM; Wood, RA; Fleischer, DM; Sicherer, SH; Lindblad, RW; Stablein, D; Henning, AK; Vickery, BP; Liu, AH; Scurlock, AM; Shreffler, WG; Plaut, M; Sampson, HA				Burks, A. Wesley; Jones, Stacie M.; Wood, Robert A.; Fleischer, David M.; Sicherer, Scott H.; Lindblad, Robert W.; Stablein, Donald; Henning, Alice K.; Vickery, Brian P.; Liu, Andrew H.; Scurlock, Amy M.; Shreffler, Wayne G.; Plaut, Marshall; Sampson, Hugh A.		Consortium Food Allergy Res CoFAR	Oral Immunotherapy for Treatment of Egg Allergy in Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOOD ALLERGY; NONANAPHYLACTIC CHILDREN; TOLERANCE INDUCTION; PEANUT ALLERGY; DOUBLE-BLIND; DESENSITIZATION; MECHANISMS; EFFICACY; IMPACT	BACKGROUND For egg allergy, dietary avoidance is the only currently approved treatment. We evaluated oral immunotherapy using egg-white powder for the treatment of children with egg allergy. METHODS In this double-blind, randomized, placebo-controlled study, 55 children, 5 to 11 years of age, with egg allergy received oral immunotherapy (40 children) or placebo (15). Initial dose-escalation, build-up, and maintenance phases were followed by an oral food challenge with egg-white powder at 10 months and at 22 months. Children who successfully passed the challenge at 22 months discontinued oral immunotherapy and avoided all egg consumption for 4 to 6 weeks. At 24 months, these children underwent an oral food challenge with egg-white powder and a cooked egg to test for sustained unresponsiveness. Children who passed this challenge at 24 months were placed on a diet with ad libitum egg consumption and were evaluated for continuation of sustained unresponsiveness at 30 months and 36 months. RESULTS After 10 months of therapy, none of the children who received placebo and 55% of those who received oral immunotherapy passed the oral food challenge and were considered to be desensitized; after 22 months, 75% of children in the oral-immunotherapy group were desensitized. In the oral-immunotherapy group, 28% (11 of 40 children) passed the oral food challenge at 24 months and were considered to have sustained unresponsiveness. At 30 months and 36 months, all children who had passed the oral food challenge at 24 months were consuming egg. Of the immune markers measured, small wheal diameters on skin-prick testing and increases in egg-specific IgG4 antibody levels were associated with passing the oral food challenge at 24 months. CONCLUSIONS These results show that oral immunotherapy can desensitize a high proportion of children with egg allergy and induce sustained unresponsiveness in a clinically significant subset. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT00461097.)	[Burks, A. Wesley; Vickery, Brian P.] Univ N Carolina, Dept Pediat, Med Ctr, Chapel Hill, NC 27599 USA; [Jones, Stacie M.; Scurlock, Amy M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.; Scurlock, Amy M.] Arkansas Childrens Hosp, Little Rock, AR 72202 USA; [Wood, Robert A.] Johns Hopkins Univ, Med Ctr, Dept Pediat, Baltimore, MD 21218 USA; [Fleischer, David M.; Liu, Andrew H.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Sicherer, Scott H.; Henning, Alice K.] Mt Sinai Sch Med, Dept Pediat, New York, NY USA; [Lindblad, Robert W.; Stablein, Donald; Henning, Alice K.] EMMES, Rockville, MD USA; [Plaut, Marshall] NIH, Bethesda, MD 20892 USA; [Shreffler, Wayne G.] Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; National Jewish Health; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; Harvard University; Harvard Medical School; Massachusetts General Hospital	Burks, AW (corresponding author), Univ N Carolina, Dept Pediat, Med Ctr, 260 MacNider Bldg,Campus Box 7220, Chapel Hill, NC 27599 USA.	wburks@email.unc.edu		Vickery, Brian/0000-0002-7243-5543; Shreffler, Wayne/0000-0001-6465-137X	National Institute of Allergy and Infectious Diseases (NIAID) [U19AI066738, U01AI066560]; National Institutes of Health-National Center for Research Resources and Clinical Research Centers [RR-024128, RR-025005, RR-025780, RR-029887, RR-029884]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024128, UL1RR029884, UL1RR025005, UL1RR029887, UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI066560, U19AI066738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health-National Center for Research Resources and Clinical Research Centers; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID) (U19AI066738 and U01AI066560) and the National Institutes of Health-National Center for Research Resources Clinical Translational Science Awards and Clinical Research Centers (RR-024128, to Duke University Medical Center; RR-025005, to Johns Hopkins School of Medicine; RR-025780, to National Jewish Health; RR-029887, to Mount Sinai School of Medicine; and RR-029884, to the University of Arkansas for Medical Sciences).	Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Akdis M, 2009, CURR OPIN IMMUNOL, V21, P700, DOI 10.1016/j.coi.2009.07.012; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, p83e1; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415, DOI 10.1016/S1081-1206(10)60908-8; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Brown HM, 2007, ANN ALLERG ASTHMA IM, V98, P203, DOI 10.1016/S1081-1206(10)60701-6; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Burks AW, 2008, J ALLERGY CLIN IMMUN, V121, P270, DOI 10.1016/j.jaci.2007.07.066; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Frew AJ, 2010, J ALLERGY CLIN IMMUN, V125, pS306, DOI 10.1016/j.jaci.2009.10.064; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nowak-Wegrzyn A, 2011, J ALLERGY CLIN IMMUN, V127, P558, DOI 10.1016/j.jaci.2010.12.1098; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Patriarca G, 2003, ALIMENT PHARM THER, V17, P459, DOI 10.1046/j.1365-2036.2003.01468.x; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042; Wanich N, 2009, J ALLERGY CLIN IMMUN, V123	38	498	510	6	68	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2012	367	3					233	243		10.1056/NEJMoa1200435	http://dx.doi.org/10.1056/NEJMoa1200435			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	22808958	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000306522900007
J	Noorani, A; Vuylsteke, A; Lewis, C; Parameshwar, J; Catarino, P				Noorani, Alia; Vuylsteke, Alain; Lewis, Clive; Parameshwar, Jayan; Catarino, Pedro			A moribund athlete	LANCET			English	Editorial Material									[Noorani, Alia; Lewis, Clive; Parameshwar, Jayan; Catarino, Pedro] Papworth Hosp, Dept Cardiothorac Transplantat, Papworth Everard, Cambs, England; [Vuylsteke, Alain] Papworth Hosp, Dept Anaesthesia & Intens Care, Papworth Everard, Cambs, England	Papworth Hospital; Papworth Hospital	Noorani, A (corresponding author), Papworth Hosp, Dept Cardiothorac Surg, Papworth Everard, Cambs, England.	alianoorani@gmail.com	Vuylsteke, Alain/AAF-2108-2020					Agarwal G, 2011, SURGERY, V150, P1202, DOI 10.1016/j.surg.2011.09.001; Chao A, 2008, ANAESTHESIA, V63, P86, DOI 10.1111/j.1365-2044.2007.05251.x; Hung M, 2012, JICS, V13, P2; Westaby S, 2012, NAT REV CARDIOL, V9, P195, DOI 10.1038/nrcardio.2011.205; Westaby S, 2009, NAT REV CARDIOL, V6, P482, DOI 10.1038/nrcardio.2009.58	5	10	10	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 7	2012	380	9836					74	74		10.1016/S0140-6736(12)60910-6	http://dx.doi.org/10.1016/S0140-6736(12)60910-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970GK	22770460				2022-12-28	WOS:000306115900037
J	Martin, A				Martin, Adrian			The Seasonal Smorgasbord of the Seas	SCIENCE			English	Editorial Material							PHYTOPLANKTON BLOOMS; COMPETITION; PLANKTON; CHAOS		Natl Oceanog Ctr, Southampton SO14 3ZH, Hants, England	NERC National Oceanography Centre	Martin, A (corresponding author), Natl Oceanog Ctr, Southampton SO14 3ZH, Hants, England.	adrian.martin@noc.ac.uk			Natural Environment Research Council [noc010009, noc010005] Funding Source: researchfish; NERC [noc010009, noc010005] Funding Source: UKRI	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Barton AD, 2010, SCIENCE, V327, P1509, DOI 10.1126/science.1184961; Behrenfeld MJ, 2010, ECOLOGY, V91, P977, DOI 10.1890/09-1207.1; Beninca E, 2008, NATURE, V451, P822, DOI 10.1038/nature06512; Boccaletti G, 2007, J PHYS OCEANOGR, V37, P2228, DOI 10.1175/JPO3101.1; HARDIN G, 1960, SCIENCE, V131, P1292, DOI 10.1126/science.131.3409.1292; Huisman J, 1999, NATURE, V402, P407, DOI 10.1038/46540; HUTCHINSON G, 1961, AM NAT, V95, P137, DOI 10.1086/282171; Mahadevan A, 2012, SCIENCE, V337, P54, DOI 10.1126/science.1218740; Perruche C, 2011, J MAR RES, V69, P105, DOI 10.1357/002224011798147606; SOMMER U, 1985, LIMNOL OCEANOGR, V30, P335, DOI 10.4319/lo.1985.30.2.0335; Sverdrup H.U., 1953, J CONSEILCONSEIL PER, V18, P287, DOI [10.1093/icesjms/18.3.287, DOI 10.1093/ICESJMS/18.3.287]; Taylor JR, 2011, LIMNOL OCEANOGR, V56, P2293, DOI 10.4319/lo.2011.56.6.2293; Teeling H, 2012, SCIENCE, V336, P608, DOI 10.1126/science.1218344	13	6	6	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2012	337	6090					46	47		10.1126/science.1223881	http://dx.doi.org/10.1126/science.1223881			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767919	Green Published			2022-12-28	WOS:000306053100038
J	Eyssallenne, AP				Eyssallenne, Antonia P.			How Far Do You Go? Intensive Care in a Resource-Poor Setting	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Eyssallenne, Antonia P.] Hosp Bernard Mevs Project Medishare, Port Au Prince, Haiti; [Eyssallenne, Antonia P.] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA	University of Miami	Eyssallenne, AP (corresponding author), Hosp Bernard Mevs Project Medishare, Port Au Prince, Haiti.							Lamas D, 2012, NEW ENGL J MED, V366, P199, DOI 10.1056/NEJMp1113622; Pollack IF, 2011, J NEUROSURG-PEDIATR, V8, P135, DOI 10.3171/2011.5.PEDS1178; Quill T, 1996, MIDWIFE DYING PROCES	3	6	6	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					8	9		10.1056/NEJMp1201108	http://dx.doi.org/10.1056/NEJMp1201108			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	968KJ	22762313				2022-12-28	WOS:000305979400017
J	Verhoest, G; Rohou, T; Gerard, F; Huet, R; Bensalah, K				Verhoest, Gregory; Rohou, Tanguy; Gerard, Francois; Huet, Romain; Bensalah, Karim			An explosive urinary tract infection	LANCET			English	Editorial Material									[Verhoest, Gregory; Huet, Romain; Bensalah, Karim] Rennes Univ Hosp, Dept Urol, F-35033 Rennes, France; [Rohou, Tanguy] Rennes Univ Hosp, Dept Radiol, F-35033 Rennes, France; [Gerard, Francois] Rennes Univ Hosp, Dept Vasc Surg, F-35033 Rennes, France	CHU Rennes; Universite de Rennes; CHU Rennes; Universite de Rennes; CHU Rennes; Universite de Rennes	Verhoest, G (corresponding author), Rennes Univ Hosp, Dept Urol, Henri Le Guillou St, F-35033 Rennes, France.	gregory.verhoest@chu-rennes.fr	Bensalah, Karim/ABD-7954-2020						0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 20	2012	380	9851					1418	1418		10.1016/S0140-6736(12)60402-4	http://dx.doi.org/10.1016/S0140-6736(12)60402-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	025NM	22748704				2022-12-28	WOS:000310196500031
J	Wu, CH; Fallini, C; Ticozzi, N; Keagle, PJ; Sapp, PC; Piotrowska, K; Lowe, P; Koppers, M; McKenna-Yasek, D; Baron, DM; Kost, JE; Gonzalez-Perez, P; Fox, AD; Adams, J; Taroni, F; Tiloca, C; Leclerc, AL; Chafe, SC; Mangroo, D; Moore, MJ; Zitzewitz, JA; Xu, ZS; van den Berg, LH; Glass, JD; Siciliano, G; Cirulli, ET; Goldstein, DB; Salachas, F; Meininger, V; Rossoll, W; Ratti, A; Gellera, C; Bosco, DA; Bassell, GJ; Silani, V; Drory, VE; Brown, RH; Landers, JE				Wu, Chi-Hong; Fallini, Claudia; Ticozzi, Nicola; Keagle, Pamela J.; Sapp, Peter C.; Piotrowska, Katarzyna; Lowe, Patrick; Koppers, Max; McKenna-Yasek, Diane; Baron, Desiree M.; Kost, Jason E.; Gonzalez-Perez, Paloma; Fox, Andrew D.; Adams, Jenni; Taroni, Franco; Tiloca, Cinzia; Leclerc, Ashley Lyn; Chafe, Shawn C.; Mangroo, Dev; Moore, Melissa J.; Zitzewitz, Jill A.; Xu, Zuo-Shang; van den Berg, Leonard H.; Glass, Jonathan D.; Siciliano, Gabriele; Cirulli, Elizabeth T.; Goldstein, David B.; Salachas, Francois; Meininger, Vincent; Rossoll, Wilfried; Ratti, Antonia; Gellera, Cinzia; Bosco, Daryl A.; Bassell, Gary J.; Silani, Vincenzo; Drory, Vivian E.; Brown, Robert H., Jr.; Landers, John E.			Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis	NATURE			English	Article							HEXANUCLEOTIDE REPEAT; SPASTIC PARAPLEGIA; NEURITE OUTGROWTH; MUTANT SOD1; PROTEIN; ACTIN; ALS; C9ORF72; EXPANSION; INCREASE	Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disorder resulting from motor neuron death. Approximately 10% of cases are familial (FALS), typically with a dominant inheritance mode. Despite numerous advances in recent years(1-9), nearly 50% of FALS cases have unknown genetic aetiology. Here we show that mutations within the profilin 1 (PFN1) gene can cause FALS. PFN1 is crucial for the conversion of monomeric (G)-actin to filamentous (F)-actin. Exome sequencing of two large ALS families showed different mutations within the PFN1 gene. Further sequence analysis identified 4 mutations in 7 out of 274 FALS cases. Cells expressing PFN1 mutants contain ubiquitinated, insoluble aggregates that in many cases contain the ALS-associated protein TDP-43. PFN1 mutants also display decreased bound actin levels and can inhibit axon outgrowth. Furthermore, primary motor neurons expressing mutant PFN1 display smaller growth cones with a reduced F/G-actin ratio. These observations further document that cytoskeletal pathway alterations contribute to ALS pathogenesis.	[Wu, Chi-Hong; Keagle, Pamela J.; Sapp, Peter C.; Piotrowska, Katarzyna; Lowe, Patrick; McKenna-Yasek, Diane; Baron, Desiree M.; Kost, Jason E.; Gonzalez-Perez, Paloma; Fox, Andrew D.; Adams, Jenni; Leclerc, Ashley Lyn; Bosco, Daryl A.; Brown, Robert H., Jr.; Landers, John E.] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01605 USA; [Fallini, Claudia; Rossoll, Wilfried; Bassell, Gary J.] Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; [Ticozzi, Nicola; Tiloca, Cinzia; Ratti, Antonia; Silani, Vincenzo] IRCCS Ist Auxol Italiano, Dept Neurol, I-20149 Milan, Italy; [Ticozzi, Nicola; Tiloca, Cinzia; Ratti, Antonia; Silani, Vincenzo] IRCCS Ist Auxol Italiano, Neurosci Lab, I-20149 Milan, Italy; [Sapp, Peter C.] MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Koppers, Max; van den Berg, Leonard H.] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurol, NL-3584 CX Utrecht, Netherlands; [Taroni, Franco; Gellera, Cinzia] Fdn IRCCS Ist Neurol Carlo Besta, Unit Genet Neurodegenerat & Metab Dis, I-20133 Milan, Italy; [Tiloca, Cinzia] Univ Milan, Dept Sci & Biomed Technol, Doctoral Sch Mol Med, I-20122 Milan, Italy; [Chafe, Shawn C.; Mangroo, Dev] Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada; [Moore, Melissa J.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA; [Zitzewitz, Jill A.; Xu, Zuo-Shang] Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA; [Glass, Jonathan D.; Bassell, Gary J.] Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Dept Neurol, Atlanta, GA 30322 USA; [Siciliano, Gabriele] Univ Pisa, Dept Neurosci, I-56126 Pisa, Italy; [Cirulli, Elizabeth T.; Goldstein, David B.] Duke Univ, Sch Med, Ctr Human Genome Variat, Durham, NC 27708 USA; [Salachas, Francois; Meininger, Vincent] UPMC, Hop La Pitie Salpetriere, APHP, Ctr Referent Malad Rares, F-75013 Paris, France; [Ratti, Antonia; Silani, Vincenzo] Univ Milan, Dino Ferrari Ctr, Dipartimento Fisiopatol Medicochirurg & Trapianti, I-20122 Milan, Italy; [Drory, Vivian E.] Tel Aviv Sourasky Med Ctr, Dept Neurol, IL-64239 Tel Aviv, Israel	University of Massachusetts System; University of Massachusetts Worcester; Emory University; IRCCS Istituto Auxologico Italiano; IRCCS Istituto Auxologico Italiano; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Utrecht University; Utrecht University Medical Center; IRCCS Istituto Neurologico Besta; University of Milan; University of Guelph; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Emory University; University of Pisa; Duke University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Milan; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Landers, JE (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01605 USA.	john.landers@umassmed.edu	Goldstein, David/AAY-8125-2020; Fallini, Claudia/AAZ-1244-2020; Taroni, Franco/N-3879-2013; Gellera, Cinzia/J-7887-2016; Resource Center, NINDS Human Genetics/AGF-2474-2022; Silani, Vincenzo/P-4421-2017; Sander-Effron, Samuel/AAX-2231-2020; Ticozzi, Nicola/K-8094-2016	Fallini, Claudia/0000-0001-8329-3467; Taroni, Franco/0000-0002-2420-5233; Gellera, Cinzia/0000-0002-3582-665X; Silani, Vincenzo/0000-0002-7698-3854; Ticozzi, Nicola/0000-0001-5963-7426; Koppers, Max/0000-0002-7751-1082; Cirulli Rogers, Liz/0000-0001-7808-2809; Rossoll, Wilfried/0000-0002-9622-541X; Landers, John/0000-0001-8084-5043	ALS Therapy Alliance; Project ALS; P2ALS; Angel Fund; Pierre L. de Bourgknecht ALS Research Foundation; Al-Athel ALS Research Foundation; ALS Family Charitable Foundation; National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) [1R01NS065847, 1R01NS050557, RC2-NS070-342]; Muscular Dystrophy Association [MDA173851]; Ministry of Health; SMA Europe fellowship; Massachusetts Institute of Technology; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050557, RC2NS070342, R01NS065847, U01NS052225] Funding Source: NIH RePORTER	ALS Therapy Alliance; Project ALS; P2ALS; Angel Fund; Pierre L. de Bourgknecht ALS Research Foundation; Al-Athel ALS Research Foundation; ALS Family Charitable Foundation; National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Muscular Dystrophy Association(Muscular Dystrophy Association); Ministry of Health; SMA Europe fellowship; Massachusetts Institute of Technology; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Support was provided by the ALS Therapy Alliance, Project ALS, P2ALS, the Angel Fund, the Pierre L. de Bourgknecht ALS Research Foundation, the Al-Athel ALS Research Foundation, the ALS Family Charitable Foundation and a Francesco Caleffi donation (N.T. and V.S.). Grant support was provided by the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) (1R01NS065847 (J.E.L.), 1R01NS050557 (R.H.B.), and RC2-NS070-342 (R.H.B.)), Muscular Dystrophy Association (MDA173851 (W.R.)) and AriSLA co-financed with support of '5x1000'-Healthcare research of the Ministry of Health (EXOMEFALS (N.T., C.G., V.S. and J.E.L.)). Support was provided by an SMA Europe fellowship to C.F. P.C.S. was supported through the auspices of H. R. Horvitz (Massachusetts Institute of Technology), an investigator of the Howard Hughes Medical Institute. We thank the laboratory of S. Doxsey, the UMass Medical School Digital Light Microscopy Core, the UMass Medical School Deep Sequencing Core, the Emory University Neuropathology Core, and M. Gearing and D. Cooper for their assistance.	Al-Chalabi A, 1999, HUM MOL GENET, V8, P157, DOI 10.1093/hmg/8.2.157; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Bosco DA, 2010, NAT NEUROSCI, V13, P1396, DOI 10.1038/nn.2660; Braun A, 2002, GENE, V283, P219, DOI 10.1016/S0378-1119(01)00855-1; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; Deng HX, 2011, NATURE, V477, P211, DOI 10.1038/nature10353; Duan WS, 2011, BRAIN RES, V1397, P1, DOI 10.1016/j.brainres.2011.05.006; Fallini C, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-17; Fujii R, 2005, CURR BIOL, V15, P587, DOI 10.1016/j.cub.2005.01.058; Giesemann T, 1999, J BIOL CHEM, V274, P37908, DOI 10.1074/jbc.274.53.37908; Gijselinck I, 2012, LANCET NEUROL, V11, P54, DOI 10.1016/S1474-4422(11)70261-7; Gros-Louis F, 2004, J BIOL CHEM, V279, P45951, DOI 10.1074/jbc.M408139200; Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514; Hazan J, 1999, NAT GENET, V23, P296, DOI 10.1038/15472; Johnson JO, 2010, NEURON, V68, P857, DOI 10.1016/j.neuron.2010.11.036; Kabashi E, 2008, NAT GENET, V40, P572, DOI 10.1038/ng.132; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Kwiatkowski TJ, 2009, SCIENCE, V323, P1205, DOI 10.1126/science.1166066; Landers JE, 2009, P NATL ACAD SCI USA, V106, P9004, DOI 10.1073/pnas.0812937106; Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336; Li RQ, 2009, GENOME RES, V19, P1124, DOI 10.1101/gr.088013.108; Meijering E, 2004, CYTOM PART A, V58A, P167, DOI 10.1002/cyto.a.20022; Mersiyanova IV, 2000, AM J HUM GENET, V67, P37, DOI 10.1086/302962; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; Perrot R, 2009, BRAIN RES BULL, V80, P282, DOI 10.1016/j.brainresbull.2009.06.004; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Reid E, 2002, AM J HUM GENET, V71, P1189, DOI 10.1086/344210; Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Shao JY, 2008, MOL CELL BIOL, V28, P5196, DOI 10.1128/MCB.00079-08; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Takeuchi H, 2002, BRAIN RES, V949, P11, DOI 10.1016/S0006-8993(02)02568-4; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; Vance C, 2009, SCIENCE, V323, P1208, DOI 10.1126/science.1165942; Wills Z, 1999, NEURON, V22, P291, DOI 10.1016/S0896-6273(00)81090-9; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967	39	403	414	4	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 23	2012	488	7412					499	+		10.1038/nature11280	http://dx.doi.org/10.1038/nature11280			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	992FS	22801503	Green Accepted			2022-12-28	WOS:000307761600034
J	Coustham, V; Li, PJ; Strange, A; Lister, C; Song, J; Dean, C				Coustham, Vincent; Li, Peijin; Strange, Amy; Lister, Clare; Song, Jie; Dean, Caroline			Quantitative Modulation of Polycomb Silencing Underlies Natural Variation in Vernalization	SCIENCE			English	Article							FLOWERING-LOCUS-C; NONCODING RNA; ARABIDOPSIS; FLC; REPRESSION; PROTEIN	Arabidopsis thaliana accessions have adapted to growth in a wide range of climates. Variation in flowering and alignment of vernalization response with winter length are central to this adaptation. Vernalization involves the epigenetic silencing of the floral repressor FLC via a conserved Polycomb (PRC2) mechanism involving trimethylation of Lys(27) on histone H3 (H3K27me3). We found that variation for response to winter length maps to cis polymorphism within FLC. A rare combination of four polymorphisms localized around the nucleation region of a PHD-Polycomb complex determines a need for longer cold. Chromatin immunoprecipitation experiments indicate that these polymorphisms influence the accumulation of H3K27me3 in Arabidopsis accession Lov-1, both at the nucleation site and over the gene body. Quantitative modulation of chromatin silencing through cis variation may be a general mechanism contributing to evolutionary change.	[Coustham, Vincent; Li, Peijin; Strange, Amy; Lister, Clare; Song, Jie; Dean, Caroline] John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dean, C (corresponding author), John Innes Ctr Plant Sci Res, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.	caroline.dean@jic.ac.uk	Li, Peijin/D-5764-2016; Coustham, Vincent/C-1836-2014; Coustham, Vincent/GON-4976-2022; Li, Peijin/AAT-6978-2021	Coustham, Vincent/0000-0002-5399-2723; Coustham, Vincent/0000-0002-5399-2723; Li, Peijin/0000-0003-1579-7553; Dean, Caroline/0000-0002-6555-3525	European Community; UK Biotechnology and Biological Sciences Research Council (BBSRC); European Research Council; BBSRC [BBS/E/J/000CA369, BB/E009662/1, BBS/E/J/000CA355, BBS/E/J/000CA344] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/J/000CA369, BBS/E/J/000CA344, BBS/E/J/000CA355, BB/E009662/1] Funding Source: researchfish	European Community(European Commission); UK Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); European Research Council(European Research Council (ERC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We thank all members of the Dean and Howard groups for discussions, and D. Filiault (Gregor Mendel Institute, Vienna) for help with analysis of the SNPs in the worldwide A. thaliana accessions. Supported by a Marie Curie Intra-European Fellowship within the 7th European Community Framework Programme (V. C.), a UK Biotechnology and Biological Sciences Research Council (BBSRC) Core Strategic Grant to the John Innes Centre, and a European Research Council Advanced Investigator grant (C.D.).	Angel A, 2011, NATURE, V476, P105, DOI 10.1038/nature10241; Carroll SB, 2008, CELL, V134, P25, DOI 10.1016/j.cell.2008.06.030; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; De Lucia F, 2008, P NATL ACAD SCI USA, V105, P16831, DOI 10.1073/pnas.0808687105; Gendall AR, 2001, CELL, V107, P525, DOI 10.1016/S0092-8674(01)00573-6; Greb T, 2007, CURR BIOL, V17, P73, DOI 10.1016/j.cub.2006.11.052; Gruber AR, 2008, NUCLEIC ACIDS RES, V36, pW70, DOI 10.1093/nar/gkn188; Hayden EJ, 2011, NATURE, V474, P92, DOI 10.1038/nature10083; Heo JB, 2011, SCIENCE, V331, P76, DOI 10.1126/science.1197349; Hoffmann MH, 2002, J BIOGEOGR, V29, P125, DOI 10.1046/j.1365-2699.2002.00647.x; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Nordborg M, 2005, PLOS BIOL, V3, P1289, DOI 10.1371/journal.pbio.0030196; Sheldon CC, 2002, PLANT CELL, V14, P2527, DOI 10.1105/tpc.004564; Shindo C, 2005, PLANT PHYSIOL, V138, P1163, DOI 10.1104/pp.105.061309; Shindo C, 2006, GENE DEV, V20, P3079, DOI 10.1101/gad.405306; Strange A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019949; Suzuki M, 2007, PLANT PHYSIOL, V143, P902, DOI 10.1104/pp.106.092320; Swiezewski S, 2009, NATURE, V462, P799, DOI 10.1038/nature08618; Weigel D, 2012, PLANT PHYSIOL, V158, P2, DOI 10.1104/pp.111.189845; Wittkopp PJ, 2004, NATURE, V430, P85, DOI 10.1038/nature02698; Zhang XY, 2007, PLOS BIOL, V5, P1026, DOI 10.1371/journal.pbio.0050129	21	109	115	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 3	2012	337	6094					584	587		10.1126/science.1221881	http://dx.doi.org/10.1126/science.1221881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982PU	22798408	Green Submitted			2022-12-28	WOS:000307058700046
J	Butler, JP; Loring, SH; Patz, S; Tsuda, A; Yablonskiy, DA; Mentzer, SJ				Butler, James P.; Loring, Stephen H.; Patz, Samuel; Tsuda, Akira; Yablonskiy, Dmitriy A.; Mentzer, Steven J.			Evidence for Adult Lung Growth in Humans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPUTED-TOMOGRAPHY; PNEUMONECTOMY; MICROSTRUCTURE; RESECTION; CHILDREN	A 33-year-old woman underwent a right-sided pneumonectomy in 1995 for treatment of a lung adenocarcinoma. As expected, there was an abrupt decrease in her vital capacity, but unexpectedly, it increased during the subsequent 15 years. Serial computed tomographic (CT) scans showed progressive enlargement of the remaining left lung and an increase in tissue density. Magnetic resonance imaging (MRI) with the use of hyperpolarized helium-3 gas showed overall acinar-airway dimensions that were consistent with an increase in the alveolar number rather than the enlargement of existing alveoli, but the alveoli in the growing lung were shallower than in normal lungs. This study provides evidence that new lung growth can occur in an adult human.	[Mentzer, Steven J.] Brigham & Womens Hosp, Div Thorac Surg, Dept Surg, Boston, MA 02115 USA; [Butler, James P.; Patz, Samuel] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; [Butler, James P.] Brigham & Womens Hosp, Div Sleep Disorders, Boston, MA 02115 USA; [Butler, James P.; Loring, Stephen H.; Tsuda, Akira] Harvard Univ, Sch Med, Boston, MA USA; [Butler, James P.; Tsuda, Akira] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Loring, Stephen H.] Beth Israel Deaconess Med Ctr, Dept Anesthesia & Crit Care, Boston, MA 02215 USA; [Yablonskiy, Dmitriy A.] Washington Univ, Dept Radiol, St Louis, MO USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Washington University (WUSTL)	Mentzer, SJ (corresponding author), Brigham & Womens Hosp, Div Thorac Surg, Dept Surg, 75 Francis St,Rm 259, Boston, MA 02115 USA.	smentzer@partners.org	Patz, Samuel/I-2879-2012; Yablonskiy, Dmitriy/N-7252-2017	Patz, Samuel/0000-0002-4500-1918; Yablonskiy, Dmitriy/0000-0003-2898-8797	National Institutes of Health [R01 HL094567, R01 HL096471, R01 HL070037, R01 HL054885, R01 HL52586]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096471, R01HL054885, R01HL094567, R01HL070037, R01HL052586] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported in part by grants from the National Institutes of Health (R01 HL094567, R01 HL096471, R01 HL070037, R01 HL054885, and R01 HL52586).	Bremer JL, 1936, J THORAC SURG, V6, P336; Brody JS, 1986, HDB PHYSL, P355; COXSON HO, 1995, J APPL PHYSIOL, V79, P1525, DOI 10.1152/jappl.1995.79.5.1525; de Jong PA, 2006, EUR RESPIR J, V27, P261, DOI 10.1183/09031936.06.00070805; de Jong PA, 2003, EUR RESPIR J, V22, P235, DOI 10.1183/09031936.03.00089702; Fujimoto T, 2002, THORAC CARDIOV SURG, V50, P292, DOI 10.1055/s-2002-34579; GAENSLER EA, 1951, J THORAC SURG, V22, P1; Hajari AJ, 2012, J APPL PHYSIOL, V112, P937, DOI 10.1152/japplphysiol.00768.2011; HSIA CCW, 1994, J CLIN INVEST, V94, P405, DOI 10.1172/JCI117337; Hsia CCW, 2004, AM J RESP CRIT CARE, V170, P319, DOI 10.1164/rccm.200209-1062ST; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; Kopec SE, 1998, CHEST, V114, P1158, DOI 10.1378/chest.114.4.1158; LAROS CD, 1987, J THORAC CARDIOV SUR, V93, P570; O'Donnell CR, 2010, CHEST, V137, P1108, DOI 10.1378/chest.09-1504; Osmanagic E, 2010, J APPL PHYSIOL, V109, P1592, DOI 10.1152/japplphysiol.00736.2010; PETERS RM, 1964, ANN SURG, V159, P652, DOI 10.1097/00000658-196405000-00002; STILES QR, 1969, J THORAC CARDIOV SUR, V58, P394, DOI 10.1016/S0022-5223(19)42588-9; Yablonskiy DA, 2009, J APPL PHYSIOL, V107, P1258, DOI 10.1152/japplphysiol.00386.2009; Yilmaz C, 2011, J APPL PHYSIOL, V111, P1150, DOI 10.1152/japplphysiol.00527.2011	19	168	174	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2012	367	3					244	247		10.1056/NEJMoa1203983	http://dx.doi.org/10.1056/NEJMoa1203983			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	22808959	Green Published, Green Accepted			2022-12-28	WOS:000306522900008
J	Kah, TA; Annuar, FH				Kah, Tan Aik; Annuar, Faridah Hanom			Retinoblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Kah, Tan Aik] Univ Malaysia Sarawak, Kota Samarahan, Malaysia; [Annuar, Faridah Hanom] Univ Kebangsaan Malaysia, Med Ctr, Kuala Lumpur, Malaysia	University of Malaysia Sarawak; Universiti Kebangsaan Malaysia	Kah, TA (corresponding author), Univ Malaysia Sarawak, Kota Samarahan, Malaysia.	portwinestain@hotmail.com							0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2012	367	3					258	258		10.1056/NEJMicm1112964	http://dx.doi.org/10.1056/NEJMicm1112964			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	22808961				2022-12-28	WOS:000306522900010
J	Montagner, M; Enzo, E; Forcato, M; Zanconato, F; Parenti, A; Rampazzo, E; Basso, G; Leo, G; Rosato, A; Bicciato, S; Cordenonsi, M; Piccolo, S				Montagner, Marco; Enzo, Elena; Forcato, Mattia; Zanconato, Francesca; Parenti, Anna; Rampazzo, Elena; Basso, Giuseppe; Leo, Genesio; Rosato, Antonio; Bicciato, Silvio; Cordenonsi, Michelangelo; Piccolo, Stefano			SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors	NATURE			English	Article							P53; EXPRESSION; HIF-1-ALPHA; PROTEASOME; PATHWAY; COMPLEX; PROTEIN; GROWTH; P63	The molecular determinants of malignant cell behaviours in breast cancer remain only partially understood(1). Here we show that SHARP1 (also known as BHLHE41 or DEC2) is a crucial regulator of the invasive and metastatic phenotype in triple-negative breast cancer (TNBC), one of the most aggressive types of breast cancer. SHARP1 is regulated by the p63 metastasis suppressor and inhibits TNBC aggressiveness through inhibition of hypoxia-inducible factor 1 alpha (HIF-1 alpha) and HIF-2 alpha (HIFs). SHARP1 opposes HIF-dependent TNBC cell migration in vitro, and invasive or metastatic behaviours in vivo. SHARP1 is required, and sufficient, to limit expression of HIF-target genes. In primary TNBC, endogenous SHARP1 levels are inversely correlated with those of HIF targets. Mechanistically, SHARP1 binds to HIFs and promotes HIF proteasomal degradation by serving as the HIF-presenting factor to the proteasome. This process is independent of pVHL (von Hippel-Lindau tumour suppressor), hypoxia and the ubiquitination machinery. SHARP1 therefore determines the intrinsic instability of HIF proteins to act in parallel to, and cooperate with, oxygen levels. This work sheds light on the mechanisms and pathways by which TNBC acquires invasiveness and metastatic propensity.	[Montagner, Marco; Enzo, Elena; Zanconato, Francesca; Cordenonsi, Michelangelo; Piccolo, Stefano] Univ Padua, Sch Med, Dept Med Biotechnol, I-35131 Padua, Italy; [Forcato, Mattia; Bicciato, Silvio] Univ Modena & Reggio Emilia, Dept Biomed Sci, Ctr Genome Res, I-41100 Modena, Italy; [Parenti, Anna] Univ Padua, Sect Pathol, Dept Med Diagnost Sci & Special Therapies, I-35126 Padua, Italy; [Rampazzo, Elena; Basso, Giuseppe] Univ Padua, Dept Pediat, I-35128 Padua, Italy; [Leo, Genesio] Hosp San Bassiano, Div Anat Pathol, I-36061 Bassano Del Grappa, Italy; [Rosato, Antonio] Dept Surg Oncol & Gastroenterol, I-35126 Padua, Italy; [Rosato, Antonio] Ist Oncol Veneto IRCCS, I-35126 Padua, Italy	University of Padua; Universita di Modena e Reggio Emilia; University of Padua; University of Padua; ULSS 7 Pedemontana; Ospedale San Bassiano; IRCCS Istituto Oncologico Veneto (IOV)	Piccolo, S (corresponding author), Univ Padua, Sch Med, Dept Med Biotechnol, Viale Colombo 3, I-35131 Padua, Italy.	piccolo@bio.unipd.it	Cordenonsi, Michelangelo/K-7692-2016; Bicciato, Silvio/C-9825-2009; Rosato, Antonio/E-8626-2010; Montagner, Marco/AAY-3236-2020; Forcato, Mattia/B-7733-2015; BICCIATO, Silvio/J-4466-2019; 高, 雨莉/HGU-8187-2022	Cordenonsi, Michelangelo/0000-0002-8253-5724; Bicciato, Silvio/0000-0002-1944-7078; Rosato, Antonio/0000-0002-5263-8386; Montagner, Marco/0000-0003-3080-2138; Forcato, Mattia/0000-0002-7383-6576; BICCIATO, Silvio/0000-0002-1944-7078; PICCOLO, STEFANO/0000-0002-2037-0004; BASSO, GIUSEPPE/0000-0002-2634-9302; Enzo, Elena/0000-0001-9768-6368	FIRC (Federazione Italiana Ricerca Cancro); Cariparo PhD fellowship; AIRC (Italian Association for Cancer Research); Italian Welfare Ministry; AIRC (Associazione Italiana per la Ricerca sul Cancro); Fondazione Citta della Speranza; MIUR (Ministero dell'Istruzione dell'Universita e della Ricerca Italia); PRIN grants; AIRC; HSFP; University of Padua; IIT Excellence grant; CNR-Miur Epigenetics Flagship project; Comitato Promotore Telethon	FIRC (Federazione Italiana Ricerca Cancro)(Fondazione AIRC per la ricerca sul cancro); Cariparo PhD fellowship(Fondazione Cariparo); AIRC (Italian Association for Cancer Research)(Fondazione AIRC per la ricerca sul cancro); Italian Welfare Ministry; AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); Fondazione Citta della Speranza; MIUR (Ministero dell'Istruzione dell'Universita e della Ricerca Italia); PRIN grants; AIRC(Fondazione AIRC per la ricerca sul cancro); HSFP; University of Padua; IIT Excellence grant; CNR-Miur Epigenetics Flagship project; Comitato Promotore Telethon(Fondazione Telethon)	We thank O. Wessely, G. Del Sal, C. Oakman and A. Di Leo for comments; and W. Kaelin, C. Borner, S. Libutti, Y. Maeda and Y. Kato for gifts of reagents. M.M. is a recipient of a FIRC (Federazione Italiana Ricerca Cancro) fellowship. We are in debt to E. Tagliafico and the Modena Affimetrix platform team for help with microarrays. E.E. is a recipient of a Cariparo PhD fellowship. M.M. was a recipient of an AIRC (Italian Association for Cancer Research) fellowship. This work is supported by a Young Italian Researchers grant of the Italian Welfare Ministry and an AIRC (Associazione Italiana per la Ricerca sul Cancro) MFAGgrant to M.C.; a Fondazione Citta della Speranza Grant, and MIUR (Ministero dell'Istruzione dell'Universita e della Ricerca Italia) and PRIN grants to G.B; and an AIRC Principal Investigator grant, an AIRC Special Program Molecular Clinical Oncology '5 per mille' grant, an HSFP grant, a University of Padua Strategic grant, an IIT Excellence grant, a CNR-Miur Epigenetics Flagship project, and a Comitato Promotore Telethon grant to S.P.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234; Elias AD, 2010, AM J CLIN ONCOL-CANC, V33, P637, DOI 10.1097/COC.0b013e3181b8afcf; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Gordan JD, 2007, CURR OPIN GENET DEV, V17, P71, DOI 10.1016/j.gde.2006.12.006; Helczynska K, 2008, CANCER RES, V68, P9212, DOI 10.1158/0008-5472.CAN-08-1135; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kong XG, 2007, J BIOL CHEM, V282, P15498, DOI 10.1074/jbc.M700704200; Lu X, 2010, CANCER RES, V70, P3905, DOI 10.1158/0008-5472.CAN-09-3739; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Sato F, 2008, GENES CELLS, V13, P131, DOI 10.1111/j.1365-2443.2007.01153.x; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Zhang HZ, 2011, APPL COMPUT HARMON A, V31, P1, DOI 10.1016/j.acha.2010.09.007	24	175	184	3	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 19	2012	487	7407					380	384		10.1038/nature11207	http://dx.doi.org/10.1038/nature11207			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JB	22801492				2022-12-28	WOS:000306506500046
J	Pronovost, PJ; Weisfeldt, ML				Pronovost, Peter J.; Weisfeldt, Myron L.			Science-Based Training in Patient Safety and Quality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							BLOOD-STREAM INFECTIONS; HEALTH-CARE; MEDICAL-EDUCATION; MARFANS-SYNDROME; UNITED-STATES; AORTIC-ROOT; IMPROVEMENT; HOSPITALS; INTERVENTION; PROGRAM		Johns Hopkins Univ, Sch Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD USA; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Pronovost, PJ (corresponding author), 1909 Thames St,2nd Floor, Baltimore, MD 21231 USA.	ppronovo@jhmi.edu						Auerbach AD, 2007, NEW ENGL J MED, V357, P608, DOI 10.1056/NEJMsb070738; Benning A, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d195; Berenholtz SM, 2010, JT COMM J QUAL PATIE, V36, P468, DOI 10.1016/S1553-7250(10)36069-7; Brooke BS, 2008, NEW ENGL J MED, V358, P2787, DOI 10.1056/NEJMoa0706585; Davidoff F, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3152; DeMets DL, 2011, JAMA-J AM MED ASSOC, V305, P713, DOI 10.1001/jama.2011.175; DePalo VA, 2010, QUAL SAF HEALTH CARE, V19, P555, DOI 10.1136/qshc.2009.038265; Dixon-Woods M, 2011, MILBANK Q, V89, P167, DOI 10.1111/j.1468-0009.2011.00625.x; Gosfield AG, 2005, HEALTH AFFAIR, V24, P1560, DOI 10.1377/hlthaff.24.6.1560; Gott VL, 1999, NEW ENGL J MED, V340, P1307, DOI 10.1056/NEJM199904293401702; Gurses AP, 2012, BMJ QUAL SAF, V21, P347, DOI 10.1136/bmjqs-2011-000421; Institute of Medicine, 2003, HLTH PROFESSIONS ED; Kirch DG, 2010, HEALTH AFFAIR, V29, P1600, DOI 10.1377/hlthaff.2010.0776; Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205; Leape L, 2009, QUAL SAF HEALTH CARE, V18, P424, DOI 10.1136/qshc.2009.036954; Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507; Lin DM, 2012, AM J MED QUAL, V27, P124, DOI 10.1177/1062860611414299; Lipitz-Snyderman A, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d219; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Miller MR, 2010, PEDIATRICS, V125, P206, DOI 10.1542/peds.2009-1382; Needham DM, 2009, INT J QUAL HEALTH C, V21, P145, DOI 10.1093/intqhc/mzp005; Newman-Toker DE, 2009, JAMA-J AM MED ASSOC, V301, P1060, DOI 10.1001/jama.2009.249; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Pronovost PJ, 2011, BRIT MED J, V342, DOI 10.1136/bmj.c6646; Pronovost PJ, 2011, CLIN INFECT DIS, V52, P507, DOI 10.1093/cid/ciq172; Pronovost PJ, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c309; Sisko AM, 2010, HEALTH AFFAIR, V29, P1933, DOI 10.1377/hlthaff.2010.0788; Srinivasan A., 2011, Morbidity and Mortality Weekly Report, V60, P243; Thompson DA, 2008, AM J MED QUAL, V23, P271, DOI 10.1177/1062860608317763; US Department of Health and Human Services, 2008, SURG GEN CALL ACT PR; Wachter RM, 2010, HEALTH AFFAIR, V29, P165, DOI 10.1377/hlthaff.2009.0785; Wachter RM, 2009, NEW ENGL J MED, V361, P1401, DOI 10.1056/NEJMsb0903885; Waters HR, 2011, AM J MED QUAL, V26, P333, DOI 10.1177/1062860611410685	33	7	7	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2					141	+		10.7326/0003-4819-157-2-201207170-00457	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00457			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	992ON	22786821				2022-12-28	WOS:000307787900021
J	Cagno, CK; Gordon, PR				Cagno, Colleen K.; Gordon, Paul R.			Neonatal Circumcision	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CANCER							Gordon, Paul/0000-0002-3366-1054				Alanis MC, 2004, OBSTET GYNECOL SURV, V59, P379, DOI 10.1097/00006254-200405000-00026; Baskin LS, 1996, PEDIATR EMERG CARE, V12, P62, DOI 10.1097/00006565-199602000-00018; Brady-Fryer B, 2009, COCHRANE DB SYST REV; Castellsague X, 2002, NEW ENGL J MED, V346, P1105, DOI 10.1056/NEJMoa011688; Lannon CM, 1999, PEDIATRICS, V103, P686; Nayir A, 2002, PEDIATR NEPHROL, V17, P307, DOI 10.1007/s00467-002-0835-0; Nayir A, 2001, PEDIATR NEPHROL, V16, P1129, DOI 10.1007/s004670100044; Schoen EJ, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.3.e36; Steadman Barbara, 2006, Urol Nurs, V26, P181	9	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2								10.1056/NEJMvcm0810449	http://dx.doi.org/10.1056/NEJMvcm0810449			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972IO	22784142				2022-12-28	WOS:000306270800001
J	Dietz, WH; Scanlon, KS				Dietz, William H.; Scanlon, Kelley S.			Eliminating the Use of Partially Hydrogenated Oil in Food Production and Preparation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TRANS-FATTY-ACIDS; POPULATION		[Dietz, William H.; Scanlon, Kelley S.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Scanlon, KS (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, 4770 Buford Hwy NE, Atlanta, GA 30341 USA.	kscanlon@cdc.gov						Doell D, 2012, FOOD ADDIT CONTAM A, V29, P861, DOI 10.1080/19440049.2012.664570; Institute of Medicine Food and Nutrition Board, 2002, DIET REF INT EN CARB; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; Mozaffarian D, 2009, EUR J CLIN NUTR, V63, pS22, DOI 10.1038/sj.ejcn.1602976; Mozaffarian D, 2009, EUR J CLIN NUTR, V63, pS5, DOI 10.1038/sj.ejcn.1602973; Mozaffarian D, 2010, NEW ENGL J MED, V362, P2037, DOI 10.1056/NEJMc1001841; Ratnayake WMN, 2009, J AOAC INT, V92, P1258; US Department of Agriculture and US Department of Health and Human Services, 2010, DIET GUID AM 2010; Vesper HW, 2012, JAMA-J AM MED ASSOC, V307, P562, DOI 10.1001/jama.2012.112; [No title captured]	10	19	19	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2012	308	2					143	144		10.1001/jama.2012.7379	http://dx.doi.org/10.1001/jama.2012.7379			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971QS	22782414				2022-12-28	WOS:000306219500026
J	Newman, MF; Ferguson, TB; White, JA; Ambrosio, G; Koglin, J; Nussmeier, NA; Pearl, RG; Pitt, B; Wechsler, AS; Weisel, RD; Reece, TL; Lira, A; Harrington, RA				Newman, Mark F.; Ferguson, T. Bruce; White, Jennifer A.; Ambrosio, Giuseppe; Koglin, Joerg; Nussmeier, Nancy A.; Pearl, Ronald G.; Pitt, Bertram; Wechsler, Andrew S.; Weisel, Richard D.; Reece, Tammy L.; Lira, Armando; Harrington, Robert A.		RED-CABG Steering Comm & Investiga	Effect of Adenosine-Regulating Agent Acadesine on Morbidity and Mortality Associated With Coronary Artery Bypass Grafting The RED-CABG Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVATED PROTEIN-KINASE; QUALITY-OF-LIFE; AICA RIBOSIDE; OPERATIVE MORTALITY; CARDIAC-SURGERY; CLINICAL-TRIAL; RISK; DEATH; REVASCULARIZATION; VALIDATION	Context Ischemia/reperfusion injury remains an important cause of morbidity and mortality after coronary artery bypass graft (CABG) surgery. In a meta-analysis of randomized controlled trials, perioperative and postoperative infusion of acadesine, a first-in-class adenosine-regulating agent, was associated with a reduction in early cardiac death, myocardial infarction, and combined adverse cardiac outcomes in participants undergoing on-pump CABG surgery. Objective To assess the efficacy and safety of acadesine administered in the perioperative period in reducing all-cause mortality, nonfatal stroke, and severe left ventricular dysfunction (SLVD) through 28 days. Design, Setting, and Participants The Reduction in Cardiovascular Events by Acadesine in Patients Undergoing CABG (RED-CABG) trial, a randomized, double-blind, placebo-controlled, parallel-group evaluation of intermediate-to high-risk patients (median age, 66 years) undergoing nonemergency, on-pump CABG surgery at 300 sites in 7 countries. Enrollment occurred from May 6, 2009, to July 30, 2010. Interventions Eligible participants were randomized 1: 1 to receive acadesine (0.1 mg/kg per minute for 7 hours) or placebo (both also added to cardioplegic solutions) beginning just before anesthesia induction. Main Outcome Measure Composite of all-cause mortality, nonfatal stroke, or need for mechanical support for SLVD during and following CABG surgery through postoperative day 28. Results Because results of a prespecified futility analysis indicated a very low likelihood of a statistically significant efficacious outcome, the trial was stopped after 3080 of the originally projected 7500 study participants were randomized. The primary outcome occurred in 75 of 1493 participants (5.0%) in the placebo group and 76 of 1493 (5.1%) in the acadesine group (odds ratio, 1.01 [95% CI, 0.73-1.41]). There were no differences in key secondary end points measured. Conclusion In this population of intermediate-to high-risk patients undergoing CABG surgery, acadesine did not reduce the composite of all-cause mortality, nonfatal stroke, or SLVD.	[Newman, Mark F.; White, Jennifer A.; Reece, Tammy L.; Harrington, Robert A.] Duke Univ, Med Ctr, Dept Anesthesiol, Duke Clin Res Inst, Durham, NC 27710 USA; [Ferguson, T. Bruce] E Carolinas Heart Inst, Dept Cardiovasc Sci, Greenville, NC USA; [Ambrosio, Giuseppe] Univ Perugia, Sch Med, I-06100 Perugia, Italy; [Koglin, Joerg; Lira, Armando] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA; [Nussmeier, Nancy A.] SUNY Upstate Med Univ, Syracuse, NY USA; [Pearl, Ronald G.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Pitt, Bertram] Univ Michigan, Sch Med, Ann Arbor, MI USA; [Wechsler, Andrew S.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA; [Weisel, Richard D.] Univ Hlth Network, Toronto, ON, Canada	Duke University; University of Perugia; Merck & Company; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Stanford University; University of Michigan System; University of Michigan; Drexel University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Newman, MF (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Duke Clin Res Inst, Box 3094, Durham, NC 27710 USA.	newman005@mc.duke.edu	Ambrosio, Giuseppe/C-6596-2013	Ambrosio, Giuseppe/0000-0002-9677-980X; LIVI, Ugolino/0000-0003-1394-736X	Schering-Plough/Merck; Novadaq Technologies; Schering-Plough/Merck through the Duke Clinical Research Institute; Novartis; Bayer; Takeda; AstraZeneca; Lily; BMS; Relypsa; BG Medicine; Amorcyte; Aurascence; Ardelyx; Cytopherx; Medtronic; Forrest Laboratories; Merck; Schering-Plough	Schering-Plough/Merck(Merck & CompanySchering Plough Corporation); Novadaq Technologies; Schering-Plough/Merck through the Duke Clinical Research Institute; Novartis(Novartis); Bayer(Bayer AG); Takeda(Takeda Pharmaceutical Company Ltd); AstraZeneca(AstraZeneca); Lily; BMS(Bristol-Myers Squibb); Relypsa; BG Medicine; Amorcyte; Aurascence; Ardelyx; Cytopherx; Medtronic(Medtronic); Forrest Laboratories; Merck(Merck & Company); Schering-Plough(Merck & CompanySchering Plough Corporation)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Newman reported receiving grant support and honoraria from Schering-Plough/Merck for activities related to the RED-CABG study and this article (all funds paid to the Duke Clinical Research Institute). Dr Ferguson reported receiving honoraria for study committee activities and support for travel to study meetings from Schering-Plough/Merck and receiving a pending grant from Novadaq Technologies (paid to his institution). Dr Ambrosio reported receiving payments from Schering-Plough/Merck for travel to study meetings. Dr Koglin reported holding stock in Merck. Dr Nussmeier reported receiving consulting fees/honoraria from Schering-Plough/Merck (disbursed through the Duke Clinical Research Institute) and receiving support from Schering-Plough/Merck for travel to study-related meetings. Dr Pearl reported receiving consulting fees and honoraria from Schering-Plough/Merck (disbursed through the Duke Clinical Research Institute) for participating on the RED-CABG executive committee. Dr Pitt reported receiving honoraria for study committee activities and support for travel to study meetings from Schering-Plough/Merck; receiving payment for consultancies from Novartis, Bayer, Takeda, AstraZeneca, Lily, BMS, Relypsa, BG Medicine, Amorcyte, Aurascence, Ardelyx, and Cytopherx; receiving grants from Novartis, Medtronic, and Forrest Laboratories; and holding stock in Relypsa, BG Medicine, and Aurascence. Dr Weschler reported receiving consulting fees or honoraria from Schering-Plough/Merck (disbursed through the Duke Clinical Research Institute) and receiving support from Schering-Plough/Merck for travel to study-related meetings. Dr Weisel reported receiving financial support for board membership (executive committee) from Schering-Plough/Merck. Dr Harrington reported receiving grant support and honoraria from Schering-Plough/Merck for activities related to the RED-CABG study and this article; serving on a Merck advisory board and receiving grant funding for several other clinical trials supported by Merck (all such funds paid to the Duke Clinical Research Institute); and receiving direct payments from Merck for consulting activities; a full listing of disclosure information for Dr Harrington is available at https://dcri.org/about-us/conflict-of-interest. No other authors reported disclosures.; The RED-CABG study was funded by Schering-Plough (subsequently Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey).	Alexander JH, 2008, JAMA-J AM MED ASSOC, V299, P1777, DOI 10.1001/jama.299.15.joc80027; Chan ESL, 2002, ARTHRITIS RES, V4, P266, DOI 10.1186/ar419; Clark RE, 1996, ANN THORAC SURG, V61, P21, DOI 10.1016/0003-4975(95)00734-2; Cohen DJ, 2011, NEW ENGL J MED, V364, P1016, DOI 10.1056/NEJMoa1001508; Davierwala PM, 2003, J THORAC CARDIOV SUR, V126, P1335, DOI 10.1016/S0022-5223(03)00936-X; DelRizzo DF, 1996, J CARDIAC SURG, V11, P18; Eagle Kim A, 2004, Circulation, V110, pe340; EDWARDS FH, 1994, ANN THORAC SURG, V57, P27, DOI 10.1016/0003-4975(94)90360-3; EDWARDS FH, 1994, ANN THORAC SURG, V57, P12, DOI 10.1016/0003-4975(94)90358-1; Ferguson TB, 2002, ANN THORAC SURG, V73, P480, DOI 10.1016/S0003-4975(01)03339-2; Gadalla AE, 2004, J NEUROCHEM, V88, P1272, DOI 10.1046/j.1471-4159.2003.02253.x; Grady KL, 2011, ANN THORAC SURG, V91, P777, DOI 10.1016/j.athoracsur.2010.11.015; GRUBER HE, 1989, CIRCULATION, V80, P1400, DOI 10.1161/01.CIR.80.5.1400; Guigas B, 2009, IUBMB LIFE, V61, P18, DOI 10.1002/iub.135; Guru V, 2008, CIRCULATION, V117, P2969, DOI 10.1161/CIRCULATIONAHA.107.722249; Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304; HE GW, 1994, J THORAC CARDIOV SUR, V108, P73; Iglesias MA, 2004, DIABETES, V53, P1649, DOI 10.2337/diabetes.53.7.1649; Ikonomidis JS, 1997, AM J PHYSIOL-HEART C, V272, pH1220, DOI 10.1152/ajpheart.1997.272.3.H1220; Jones RH, 1996, J AM COLL CARDIOL, V28, P1478, DOI 10.1016/S0735-1097(96)00359-2; Magovern JA, 1996, J AM COLL CARDIOL, V28, P1147, DOI 10.1016/S0735-1097(96)00310-5; Mangano DT, 1997, JAMA-J AM MED ASSOC, V277, P325, DOI 10.1001/jama.277.4.325; Mangano DT, 2002, NEW ENGL J MED, V347, P1309, DOI 10.1056/NEJMoa020798; Mentzer RM, 1999, ANN SURG, V229, P643, DOI 10.1097/00000658-199905000-00006; Mentzer RM, 2008, ANN THORAC SURG, V85, P1261, DOI 10.1016/j.athoracsur.2007.10.054; O'Connor GT, 1998, ANN THORAC SURG, V66, P1323, DOI 10.1016/S0003-4975(98)00762-0; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Reznick RM, 2007, CELL METAB, V5, P151, DOI 10.1016/j.cmet.2007.01.008; Schweikert B, 2006, HEART, V92, P62, DOI 10.1136/hrt.2004.052787; Shahian DM, 2009, ANN THORAC SURG, V88, pS2, DOI 10.1016/j.athoracsur.2009.05.053; Tardif JC, 2007, J THORAC CARDIOV SUR, V133, P1604, DOI 10.1016/j.jtcvs.2007.01.049; The Society of Thoracic Surgeons, STS NAT DAT; TU JV, 1995, CIRCULATION, V91, P677, DOI 10.1161/01.CIR.91.3.677; Verrier ED, 2004, JAMA-J AM MED ASSOC, V291, P2319, DOI 10.1001/jama.291.19.2319	34	39	41	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2012	308	2					157	164		10.1001/jama.2012.7633	http://dx.doi.org/10.1001/jama.2012.7633			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971QS	22782417				2022-12-28	WOS:000306219500029
J	Cooper, C				Cooper, Chris			The art of medicine Drug cheating at the Olympics: who, what, and why?	LANCET			English	Editorial Material							SPORT		Univ Essex, Sch Biol Sci, Ctr Sports & Exercise Sci, Colchester CO4 3SQ, Essex, England	University of Essex	Cooper, C (corresponding author), Univ Essex, Sch Biol Sci, Ctr Sports & Exercise Sci, Colchester CO4 3SQ, Essex, England.	ccooper@essex.ac.uk	Cooper, Chris/AAK-9729-2020	Cooper, Chris/0000-0003-0381-3990	Engineering and Physical Sciences Research Council [EP/F057709/1] Funding Source: researchfish; EPSRC [EP/F057709/1] Funding Source: UKRI	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; Cooper C., 2012, RUN SWIM THROW CHEAT; Franke WW, 1997, CLIN CHEM, V43, P1262; Lundby C, 2012, BRIT J PHARMACOL, V165, P1306, DOI 10.1111/j.1476-5381.2011.01822.x; Savulescu J, 2004, BRIT J SPORT MED, V38, P666, DOI 10.1136/bjsm.2003.005249; Striegel H, 2010, DRUG ALCOHOL DEPEN, V106, P230, DOI 10.1016/j.drugalcdep.2009.07.026; VANHELDER WP, 1991, CAN J SPORT SCI, V16, P248	7	2	2	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 7	2012	380	9836					21	22		10.1016/S0140-6736(12)61114-3	http://dx.doi.org/10.1016/S0140-6736(12)61114-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970GK	22779089				2022-12-28	WOS:000306115900015
J	Pradhan, D; Berger, K				Pradhan, Deepak; Berger, Kenneth			Dynamic Extrathoracic Airway Obstruction	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Pradhan, Deepak; Berger, Kenneth] NYU, Sch Med, New York, NY 10012 USA	New York University	Pradhan, D (corresponding author), NYU, Sch Med, New York, NY 10012 USA.	deepak.pradhan@nyumc.org		Berger, Kenneth/0000-0003-4879-6071; Pradhan, Deepak/0000-0002-5693-0157					0	3	3	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					E2	E2		10.1056/NEJMicm1010669	http://dx.doi.org/10.1056/NEJMicm1010669			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968KJ	22762344				2022-12-28	WOS:000305979400008
J	Roesner, S; Aggarwal, VK				Roesner, Stefan; Aggarwal, Varinder K.			ORGANIC CHEMISTRY Reactions at the end of a tether	NATURE			English	Editorial Material							ASYMMETRIC ALLYLBORATION; HOMOALLYLIC ALCOHOLS; CHIRAL SYNTHESIS; ORGANOBORANES; ALDEHYDES; REAGENT		[Roesner, Stefan; Aggarwal, Varinder K.] Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England	University of Bristol	Roesner, S (corresponding author), Univ Bristol, Sch Chem, Cantocks Close, Bristol BS8 1TS, Avon, England.	v.aggarwal@bristol.ac.uk	Roesner, Stefan/AAI-7729-2021; Aggarwal, Varinder/AAG-8504-2019	Roesner, Stefan/0000-0003-2143-4708; Aggarwal, Varinder/0000-0003-0344-6430	Engineering and Physical Sciences Research Council [EP/D501725/1, EP/E052185/1] Funding Source: researchfish; EPSRC [EP/E052185/1] Funding Source: UKRI	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		BROWN HC, 1990, J AM CHEM SOC, V112, P2389, DOI 10.1021/ja00162a047; BROWN HC, 1983, J AM CHEM SOC, V105, P2092, DOI 10.1021/ja00345a085; Chalifoux WA, 2012, NATURE, V487, P86, DOI 10.1038/nature11189; Harrison TJ, 2011, J AM CHEM SOC, V133, P7308, DOI 10.1021/ja201467z; JADHAV PK, 1986, J ORG CHEM, V51, P432, DOI 10.1021/jo00354a003; Kim H, 2011, J AM CHEM SOC, V133, P6517, DOI 10.1021/ja200712f; Kubota K, 2003, ANGEW CHEM INT EDIT, V42, P946, DOI 10.1002/anie.200390252	7	1	1	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 5	2012	487	7405					48	49		10.1038/nature11381	http://dx.doi.org/10.1038/nature11381			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968LM	22763453				2022-12-28	WOS:000305982900046
J	Lund, EM; Vaughn-Jensen, JE				Lund, Emily M.; Vaughn-Jensen, Jessica E.			Victimisation of children with disabilities	LANCET			English	Editorial Material							INTERPERSONAL VIOLENCE; SPECIAL-EDUCATION; ADULTS; PREVALENCE		[Lund, Emily M.; Vaughn-Jensen, Jessica E.] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Lund, EM (corresponding author), Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA.	emily.m.lund@gmail.com						Hughes K, 2012, LANCET, V379, P1621, DOI 10.1016/S0140-6736(11)61851-5; Hughes RB, 2011, REHABIL PSYCHOL, V56, P302, DOI 10.1037/a0025620; Jones L, 2012, LANCET; Lund EM, 2011, TRAUMA VIOLENCE ABUS, V12, P171, DOI 10.1177/1524838011416377; Petersilia JR, 2001, CRIM JUSTICE BEHAV, V28, P655, DOI 10.1177/009385480102800601; Rose CA, 2011, REM SPEC EDUC, V32, P114, DOI 10.1177/0741932510361247; Rose CA, 2009, EDUC PSYCHOL-UK, V29, P761, DOI 10.1080/01443410903254864; Sobsey D., 1991, SEX DISABIL, V9, P243, DOI [10.1007/BF01102395, DOI 10.1007/BF01102395]; Son E, 2012, CHILD YOUTH SERV REV, V34, P1540, DOI 10.1016/j.childyouth.2012.04.014	9	7	7	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 8	2012	380	9845					867	869		10.1016/S0140-6736(12)61071-X	http://dx.doi.org/10.1016/S0140-6736(12)61071-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	002QL	22795510				2022-12-28	WOS:000308547300008
J	Sasaki, M; Knobbe, CB; Munger, JC; Lind, EF; Brenner, D; Brustle, A; Harris, IS; Holmes, R; Wakeham, A; Haight, J; You-Ten, A; Li, WY; Schalm, S; Su, SM; Virtanen, C; Reifenberger, G; Ohashi, PS; Barber, DL; Figueroa, ME; Melnick, A; Zuniga-Pflucker, JC; Mak, TW				Sasaki, Masato; Knobbe, Christiane B.; Munger, Joshua C.; Lind, Evan F.; Brenner, Dirk; Bruestle, Anne; Harris, Isaac S.; Holmes, Roxanne; Wakeham, Andrew; Haight, Jillian; You-Ten, Annick; Li, Wanda Y.; Schalm, Stefanie; Su, Shinsan M.; Virtanen, Carl; Reifenberger, Guido; Ohashi, Pamela S.; Barber, Dwayne L.; Figueroa, Maria E.; Melnick, Ari; Zuniga-Pfluecker, Juan-Carlos; Mak, Tak W.			IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics	NATURE			English	Article							ACUTE MYELOID-LEUKEMIA; FALSE DISCOVERY RATE; STEM-CELLS; ONCOMETABOLITE 2-HYDROXYGLUTARATE; IDH2 MUTATIONS; DIFFERENTIATION; GENOME; NOTCH; MICE	Mutations in the IDH1 and IDH2 genes encoding isocitrate dehydrogenases are frequently found in human glioblastomas(1) and cytogenetically normal acute myeloid leukaemias (AML)(2). These alterations are gain-of-function mutations in that they drive the synthesis of the 'oncometabolite' R-2-hydroxyglutarate (2HG)(3). It remains unclear how IDH1 and IDH2 mutations modify myeloid cell development and promote leukaemogenesis. Here we report the characterization of conditional knock-in (KI) mice in which the most common IDH1 mutation, IDH1(R132H), is inserted into the endogenous murine Idh1 locus and is expressed in all haematopoietic cells (Vav-KI mice) or specifically in cells of the myeloid lineage (LysM-KI mice). These mutants show increased numbers of early haematopoietic progenitors and develop splenomegaly and anaemia with extramedullary haematopoiesis, suggesting a dysfunctional bone marrow niche. Furthermore, LysM-KI cells have hypermethylated histones and changes to DNA methylation similar to those observed in human IDH1- or IDH2-mutant AML. To our knowledge, our study is the first to describe the generation and characterization of conditional IDH1(R132H)-KI mice, and also the first report to demonstrate the induction of a leukaemic DNA methylation signature in a mouse model. Our report thus sheds light on the mechanistic links between IDH1 mutation and human AML.	[Sasaki, Masato; Knobbe, Christiane B.; Lind, Evan F.; Brenner, Dirk; Bruestle, Anne; Harris, Isaac S.; Wakeham, Andrew; Haight, Jillian; You-Ten, Annick; Li, Wanda Y.; Ohashi, Pamela S.; Mak, Tak W.] Univ Hlth Network, Ontario Canc Inst, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada; [Knobbe, Christiane B.; Reifenberger, Guido] Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany; [Munger, Joshua C.] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA; [Harris, Isaac S.; Barber, Dwayne L.; Mak, Tak W.] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; [Holmes, Roxanne; Zuniga-Pfluecker, Juan-Carlos] Univ Toronto, Sunnybrook Res Inst, Dept Immunol, Toronto, ON M4N 3M5, Canada; [Virtanen, Carl] Univ Hlth Network, Microarray Ctr, Toronto, ON M5S 1A8, Canada; [Figueroa, Maria E.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Melnick, Ari] Cornell Univ, Weill Cornell Med Coll, New York, NY 10021 USA; [Schalm, Stefanie; Su, Shinsan M.] Agios Pharmaceut Inc, Cambridge, MA 02139 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Heinrich Heine University Dusseldorf; University of Rochester; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Michigan System; University of Michigan; Cornell University; Agios Pharmaceuticals	Mak, TW (corresponding author), Univ Hlth Network, Ontario Canc Inst, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada.	tmak@uhnres.utoronto.ca	Reifenberger, Guido/AAE-3599-2019; Knobbe-Thomsen, Christiane B/D-3116-2019; Knobbe-Thomsen, Christiane/J-4963-2014; Zuniga-Pflucker, Juan C/H-1295-2012; Munger, Joshua/ABA-6395-2020; Melnick, Ari/AAA-5763-2020; Figueroa, Maria/AAE-8662-2019	Knobbe-Thomsen, Christiane/0000-0003-1231-0076; Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178; Bruestle, Anne/0000-0002-3842-5683; Munger, Joshua/0000-0001-5379-9440; Brenner, Dirk/0000-0001-8979-1045; Barber, Dwayne/0000-0001-5528-8150; Figueroa, Maria Eugenia/0000-0003-4887-4981; Ohashi, Pamela S./0000-0003-2915-9317; Lind, Evan/0000-0001-7026-2012; Harris, Isaac/0000-0002-6855-2763	Feodor-Lynen Postdoctoral Research Fellowship from the Alexander-von-Humboldt-Foundation, Germany; German Research Foundation (DFG); National Institute of Health [NIH R01AI081773]; Damon Runyon Cancer Research Foundation [DRR-09-10]; Leukemia & Lymphoma Society; Doris Duke Clinical Scientist Development Award; LLS SCOR grant [7132-08]; Burroughs Wellcome Clinical Translational Scientist Award; Starr Cancer Consortium [I4-A442]; Canada Research Chair in Developmental Immunology; Canadian Institutes of Health Research (CIHR); Ontario Ministry of Health and Long Term Care; Terry Fox Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI081773, R56AI081773] Funding Source: NIH RePORTER	Feodor-Lynen Postdoctoral Research Fellowship from the Alexander-von-Humboldt-Foundation, Germany; German Research Foundation (DFG)(German Research Foundation (DFG)); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation; Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); Doris Duke Clinical Scientist Development Award(Doris Duke Charitable Foundation (DDCF)); LLS SCOR grant; Burroughs Wellcome Clinical Translational Scientist Award; Starr Cancer Consortium; Canada Research Chair in Developmental Immunology(Canada Research Chairs); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario); Terry Fox Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank the Animal Research Colony (ARC) at the Ontario Cancer Institute for mouse care; I. Ng, A. Shahinian, J. Sylvester and S. McCracken for administrative and organizational expertise; M. Bailey and J. Tsao for technical assistance; F. Tong and R. Nayyar for assistance with flow cytometric analysis and sorting; the Weill Cornell Medical College (WCMC) Epigenomics Core Facility for technical help and expertise; G. Melino, D. Green, M. Minden, H. Chang and P. Lang for helpful discussions; J. Thomsen for figure layout and M. Saunders for scientific editing. C. B. K. and D. B. were supported in part by a Feodor-Lynen Postdoctoral Research Fellowship from the Alexander-von-Humboldt-Foundation, Germany. D. B. and A. B. were supported in part by a Fellowship from the German Research Foundation (DFG). J. C. M. is supported by a National Institute of Health grant (NIH R01AI081773) and is a Damon Runyon-Rachleff Innovation Awardee supported by the Damon Runyon Cancer Research Foundation (DRR-09-10). P.S.O. holds a Canada Research Chair in Autoimmunity and Tumor Immunity. M. E. F. is supported by the Leukemia & Lymphoma Society Special Fellow Award and a Doris Duke Clinical Scientist Development Award. A. M. is supported by an LLS SCOR grant (7132-08), a Burroughs Wellcome Clinical Translational Scientist Award and a Starr Cancer Consortium grant (I4-A442). J.-C.Z.-P. is supported by a Canada Research Chair in Developmental Immunology. This work was supported by grants from the Canadian Institutes of Health Research (CIHR) and the Ontario Ministry of Health and Long Term Care to T. W. M., and a program grant from the Terry Fox Foundation to P.S.O., J.-C.Z.-P. and T. W. M. Please note that the views expressed do not necessarily reflect those of the OMOHLTC.	Akalin A., PLOS GENET IN PRESS; Bajad SU, 2006, J CHROMATOGR A, V1125, P76, DOI 10.1016/j.chroma.2006.05.019; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Callens C, 2010, J EXP MED, V207, P731, DOI 10.1084/jem.20091488; Campbell C, 2008, CURR OPIN HEMATOL, V15, P319, DOI 10.1097/MOH.0b013e328303b9df; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; de Boer J, 2003, EUR J IMMUNOL, V33, P314, DOI 10.1002/immu.200310005; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Eliasson P, 2010, J CELL PHYSIOL, V222, P17, DOI 10.1002/jcp.21908; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Fujita PA, 2011, NUCLEIC ACIDS RES, V39, pD876, DOI 10.1093/nar/gkq963; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; Heidel FH, 2011, INT J HEMATOL, V94, P109, DOI 10.1007/s12185-011-0901-0; Holmes R, 2009, COLD SPRING HARB PRO, V2009; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Klinakis A, 2011, NATURE, V473, P230, DOI 10.1038/nature09999; Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901; Munger J, 2008, NAT BIOTECHNOL, V26, P1179, DOI 10.1038/nbt.1500; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Patel KP, 2011, AM J CLIN PATHOL, V135, P35, DOI 10.1309/AJCPD7NR2RMNQDVF; Patnaik MM, 2012, LEUKEMIA, V26, P101, DOI 10.1038/leu.2011.298; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Soderberg SS, 2009, ANN NY ACAD SCI, V1176, P55, DOI 10.1111/j.1749-6632.2009.04569.x; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Ye M, 2003, IMMUNITY, V19, P689, DOI 10.1016/S1074-7613(03)00299-1; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	34	381	395	1	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 30	2012	488	7413					656	+		10.1038/nature11323	http://dx.doi.org/10.1038/nature11323			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	996NC	22763442	Green Accepted			2022-12-28	WOS:000308095100056
J	Schuster-Bockler, B; Lehner, B				Schuster-Boeckler, Benjamin; Lehner, Ben			Chromatin organization is a major influence on regional mutation rates in human cancer cells	NATURE			English	Article							HUMAN GENOME; SOMATIC MUTATIONS; MAMMALIAN GENOME; MAP; RECOMBINATION; METHYLATIONS; LEUKEMIA; REPAIR	Cancer genome sequencing provides the first direct information on how mutation rates vary across the human genome in somatic cells(1-7). Testing diverse genetic and epigenetic features, here we show that mutation rates in cancer genomes are strikingly related to chromatin organization. Indeed, at the megabase scale, a single feature-levels of the heterochromatin-associated histone modification H3K9me3-can account for more than 40% of mutation-rate variation, and a combination of features can account for more than 55%. The strong association between mutation rates and chromatin organization is upheld in samples from different tissues and for different mutation types. This suggests that the arrangement of the genome into heterochromatin- and euchromatin-like domains is a dominant influence on regional mutation-rate variation in human somatic cells.	[Schuster-Boeckler, Benjamin; Lehner, Ben] CRG, EMBL CRG Syst Biol Unit, Barcelona 08003, Spain; [Schuster-Boeckler, Benjamin; Lehner, Ben] UPF, Barcelona 08003, Spain; [Schuster-Boeckler, Benjamin] Pear Comp LLP, London W5 1SH, England; [Lehner, Ben] Passeig Lluis Co 23, ICREA, Barcelona 08010, Spain	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; ICREA	Lehner, B (corresponding author), CRG, EMBL CRG Syst Biol Unit, Barcelona 08003, Spain.	ben.lehner@crg.es	Lehner, Ben/ABH-6562-2020; Lehner, Ben/L-3413-2014; Schuster-Böckler, Benjamin/H-8339-2019	Lehner, Ben/0000-0002-8817-1124; Lehner, Ben/0000-0002-8817-1124; Schuster-Böckler, Benjamin/0000-0002-8892-5133	European Research Council (ERC); European Union [277899 4DCellFate]; ERASysBioPLUS; Ministerio de Ciencia e Innovacion (MICINN) [BFU2008-00365, BFU2011-26206]; Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR); European Molecular Biology Organization (EMBO); EMBL-CRG Systems Biology Program; Juan de la Cierva postdoctoral fellowship; ICREA Funding Source: Custom	European Research Council (ERC)(European Research Council (ERC)European Commission); European Union(European Commission); ERASysBioPLUS; Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR)(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); European Molecular Biology Organization (EMBO)(European Molecular Biology Organization (EMBO)); EMBL-CRG Systems Biology Program; Juan de la Cierva postdoctoral fellowship(Instituto de Salud Carlos III); ICREA(ICREA)	This work was funded by an European Research Council (ERC) Starting Grant, European Union Framework 7 project 277899 4DCellFate, ERASysBioPLUS, Ministerio de Ciencia e Innovacion (MICINN) grants BFU2008-00365 and BFU2011-26206, Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), the European Molecular Biology Organization (EMBO) Young Investigator Program, the EMBL-CRG Systems Biology Program and a Juan de la Cierva postdoctoral fellowship to B.S-B. We thank T. Vavouri and T. Warnecke for comments on the manuscript, and R.S. Hansen for assistance with analysing replication timing data.	[Anonymous], 2010, NATURE, V467, P1061, DOI DOI 10.1038/NATURE09534; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; COOPER DN, 1989, HUM GENET, V83, P181, DOI 10.1007/BF00286715; Dreszer TR, 2012, NUCLEIC ACIDS RES, V40, pD918, DOI 10.1093/nar/gkr1055; Ellegren H, 2003, CURR OPIN GENET DEV, V13, P562, DOI 10.1016/j.gde.2003.10.008; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Gossmann TI, 2011, GENETICS, V189, P1389, DOI 10.1534/genetics.111.132654; Hansen RS, 2010, P NATL ACAD SCI USA, V107, P139, DOI 10.1073/pnas.0912402107; Hodgkinson A, 2012, HUM MUTAT, V33, P136, DOI 10.1002/humu.21616; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004; Lercher MJ, 2002, TRENDS GENET, V18, P337, DOI 10.1016/S0168-9525(02)02669-0; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369; Lindblad-Toh K, 2011, NATURE, V478, P476, DOI 10.1038/nature10530; Misteli T, 2007, CELL, V128, P787, DOI 10.1016/j.cell.2007.01.028; Paten B, 2008, GENOME RES, V18, P1814, DOI 10.1101/gr.076554.108; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Prendergast JGD, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-72; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022; Stamatoyannopoulos JA, 2009, NAT GENET, V41, P393, DOI 10.1038/ng.363; Vavouri T, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002036; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Wheeler DL, 2007, NUCLEIC ACIDS RES, V35, pD5, DOI 10.1093/nar/gkl1031; WOLFE KH, 1989, NATURE, V337, P283, DOI 10.1038/337283a0; Zhang Y, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-537	30	407	414	0	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 23	2012	488	7412					504	+		10.1038/nature11273	http://dx.doi.org/10.1038/nature11273			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	992FS	22820252				2022-12-28	WOS:000307761600035
J	Gallwitz, B; Rosenstock, J; Rauch, T; Bhattacharya, S; Patel, S; von Eynatten, M; Dugi, KA; Woerle, HJ				Gallwitz, Baptist; Rosenstock, Julio; Rauch, Thomas; Bhattacharya, Sudipta; Patel, Sanjay; von Eynatten, Maximilian; Dugi, Klaus A.; Woerle, Hans-Juergen			2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial	LANCET			English	Article							ALL-CAUSE MORTALITY; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; GLUCOSE CONTROL; ADD-ON; MELLITUS; METAANALYSIS; RISK; COMPLICATIONS; SULFONYLUREA	Background Addition of a sulphonylurea to metformin improves glycaemic control in type 2 diabetes, but is associated with hypoglycaemia and weight gain. We aimed to compare a dipeptidyl peptidase-4 inhibitor (linagliptin) against a commonly used sulphonylurea (glimepiride). Methods In this 2-year, parallel-group, non-inferiority double-blind trial, outpatients with type 2 diabetes and glycated haemoglobin A(1c) (HbA(1c)) 6.5-10.0% on stable metformin alone or with one additional oral antidiabetic drug (washed out during screening) were randomly assigned (1: 1) by computer-generated random sequence via a voice or web response system to linagliptin (5 mg) or glimepiride (1-4 mg) orally once daily. Study investigators and participants were masked to treatment assignment. The primary endpoint was change in HbA(1c) from baseline to week 104. Analyses included all patients randomly assigned to treatment groups who received at least one dose of treatment, had a baseline HbA(1c) measurement, and had at least one on-treatment HbA(1c) measurement. This trial is registered at ClinicalTrials.gov, number NCT00622284. Findings 777 patients were randomly assigned to linagliptin and 775 to glimepiride; 764 and 755 were included in analysis of the primary endpoint. Reductions in adjusted mean HbA(1c) (baseline 7.69% [SE 0.03] in both groups) were similar in the linagliptin (-0.16% [SE 0.03]) and glimepiride groups (-0.36% [0.03]; difference 0.20%, 97.5% CI 0.09-0.30), meeting the predefined non-inferiority criterion of 0.35%. Fewer participants had hypoglycaemia (58 [7%] of 776 vs 280 [36%] of 775 patients, p<0.0001) or severe hypoglycaemia (1 [<1%] vs 12 [2%]) with linagliptin compared with glimepiride. Linagliptin was associated with significantly fewer cardiovascular events (12 vs 26 patients; relative risk 0.46, 95% CI 0.23-0.91, p=0.0213). Interpretation The results of this long-term randomised active-controlled trial advance the clinical evidence and comparative effectiveness bases for treatment options available to patients with type 2 diabetes mellitus. The findings could improve decision making for clinical treatment when metformin alone is insufficient.	[Gallwitz, Baptist] Univ Klinikum Tubingen, Dept Med 4, Tubingen, Germany; [Rosenstock, Julio] Dallas Diabet & Endocrine Ctr Med City, Dallas, TX USA; [Rauch, Thomas; von Eynatten, Maximilian; Dugi, Klaus A.; Woerle, Hans-Juergen] Boehringer Ingelheim KG, D-6507 Ingelheim, Germany; [Bhattacharya, Sudipta] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany; [Patel, Sanjay] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Diabetes & Endocrine Center; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim	Gallwitz, B (corresponding author), Univ Klinikum, Med Klin 4, D-72076 Tubingen, Baden Wurttembe, Germany.	baptist.gallwitz@med.uni-tuebingen.de	Gallwitz, Baptist/AAQ-2051-2020; Woerle, Hans/ABE-1013-2021	Gallwitz, Baptist/0000-0002-8880-6409; HASSANIN, HANA/0000-0002-1492-3653; Bhattacharya, Sudipta/0000-0002-2155-9773	Pfizer; Roche; Sanofi; Novo Nordisk; Eli Lilly; MannKind; GlaxoSmithKline; Takeda; Daiichi Sankyo; Johnson Johnson; Novartis; Boehringer Ingelheim; Lexicon; Merck; Bristol-Myers Squibb; Forest; AstraZeneca; Amylin	Pfizer(Pfizer); Roche(Roche Holding); Sanofi; Novo Nordisk(Novo Nordisk); Eli Lilly(Eli Lilly); MannKind; GlaxoSmithKline(GlaxoSmithKline); Takeda(Takeda Pharmaceutical Company Ltd); Daiichi Sankyo(Daiichi Sankyo Company Limited); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Novartis(Novartis); Boehringer Ingelheim(Boehringer Ingelheim); Lexicon; Merck(Merck & Company); Bristol-Myers Squibb(Bristol-Myers Squibb); Forest; AstraZeneca(AstraZeneca); Amylin	BG is a member of advisory boards for AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Merck, Roche, Sanofi, and Takeda and has also received honoraria from these companies for giving lectures. JR has served on scientific advisory boards and received honorarium or consulting fees from Pfizer, Roche, Sanofi, Novo Nordisk, Eli Lilly, MannKind, GlaxoSmithKline, Takeda, Daiichi Sankyo, Johnson & Johnson, Novartis, Boehringer Ingelheim, and Lexicon. He has also received grants or research support from Merck, Pfizer, Sanofi, Novo Nordisk, Roche, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Takeda, Novartis, AstraZeneca, Amylin, Johnson & Johnson, Daiichi Sankyo, MannKind, Lexicon, and Boehringer Ingelheim.	Abbatecola AM, 2009, DRUG AGING, V26, P53, DOI 10.2165/11534660-000000000-00000; Amiel SA, 2008, DIABETIC MED, V25, P245, DOI 10.1111/j.1464-5491.2007.02341.x; Basevi V, 2011, DIABETES CARE, V34, P1887, DOI 10.2337/dc11-s011; Belsey J, 2008, DIABETES OBES METAB, V10, P1, DOI 10.1111/j.1463-1326.2008.00884.x; Childs BP, 2005, DIABETES CARE, V28, P1245; Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X; Del Prato S, 2011, DIABETES OBES METAB, V13, P258, DOI 10.1111/j.1463-1326.2010.01350.x; Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431; Fadini GP, 2011, VASC PHARMACOL, V55, P10, DOI 10.1016/j.vph.2011.05.001; Frederich R, 2010, POSTGRAD MED, V122, P16, DOI 10.3810/pgm.2010.05.2138; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Goke B, 2010, INT J CLIN PRACT, V64, P1619, DOI 10.1111/j.1742-1241.2010.02510.x; Heller SR, 2007, DIABETOLOGIA, V50, P1140, DOI 10.1007/s00125-007-0599-y; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Inzucchi SE, 2012, DIABETES CARE, V35, P1364, DOI 10.2337/dc12-0413; Johansen OE, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-3; Matthews DR, 2010, DIABETES OBES METAB, V12, P780, DOI 10.1111/j.1463-1326.2010.01233.x; Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987; Pollack MF, 2010, DIABETES RES CLIN PR, V87, P204, DOI 10.1016/j.diabres.2009.11.023; Rao AD, 2008, DIABETES CARE, V31, P1672, DOI 10.2337/dc08-0167; Rodbard HW, 2009, ENDOCR PRACT, V15, P540, DOI 10.4158/EP.15.6.540; Schweizer A, 2010, DIABETES OBES METAB, V12, P485, DOI 10.1111/j.1463-1326.2010.01215.x; Seck T, 2010, INT J CLIN PRACT, V64, P562, DOI 10.1111/j.1742-1241.2010.02353.x; Smyth S, 2006, NAT MED, V12, P75, DOI 10.1038/nm0106-75; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Taskinen MR, 2011, DIABETES OBES METAB, V13, P65, DOI 10.1111/j.1463-1326.2010.01326.x; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Tzoulaki I, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4731; Williams-Herman D, 2010, BMC ENDOCR DISORD, V10, DOI 10.1186/1472-6823-10-7	30	269	300	0	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 4	2012	380	9840					475	483		10.1016/S0140-6736(12)60691-6	http://dx.doi.org/10.1016/S0140-6736(12)60691-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983GY	22748821				2022-12-28	WOS:000307109000028
J	Scheen, AJ; Paquot, N				Scheen, Andre J.; Paquot, Nicolas			Gliptin versus a sulphonylurea as add-on to metformin	LANCET			English	Editorial Material							TYPE-2; EFFICACY; VILDAGLIPTIN; MANAGEMENT; GLIPIZIDE; 52-WEEK; SAFETY; 2-YEAR		[Scheen, Andre J.] Univ Liege, Div Diabet Nutr & Metab Disorders, B-4000 Liege, Belgium; CHU Sart Tilman, Clin Pharmacol Unit, Dept Med, B-4000 Liege, Belgium	University of Liege; University of Liege	Scheen, AJ (corresponding author), Univ Liege, Div Diabet Nutr & Metab Disorders, B-4000 Liege, Belgium.	andre.scheen@chu.ulg.ac.be						Arechavaleta R, 2011, DIABETES OBES METAB, V13, P160, DOI 10.1111/j.1463-1326.2010.01334.x; Elashoff M, 2011, GASTROENTEROLOGY, V141, P150, DOI 10.1053/j.gastro.2011.02.018; Filozof C, 2010, DIABETIC MED, V27, P318, DOI 10.1111/j.1464-5491.2010.02938.x; Gallwitz B, 2012, LANCET, V380, P475, DOI 10.1016/S0140-6736(12)60691-6; Goke B, 2010, INT J CLIN PRACT, V64, P1619, DOI 10.1111/j.1742-1241.2010.02510.x; Goossen K, 2012, DIABETES OBES METAB, V14, P1061, DOI 10.1111/j.1463-1326.2012.01610.x; Inzucchi SE, 2012, DIABETOLOGIA, V55, P1577, DOI 10.1007/s00125-012-2534-0; Matthews DR, 2010, DIABETES OBES METAB, V12, P780, DOI 10.1111/j.1463-1326.2010.01233.x; Scheen AJ, 2012, DIABETES METAB, V38, P89, DOI 10.1016/j.diabet.2011.11.001; Scheen AJ, 2008, LANCET, V372, P1197, DOI 10.1016/S0140-6736(08)61207-6; Scheen AJ, 2012, EXPERT OPIN PHARMACO, V13, P81, DOI 10.1517/14656566.2012.642866; Scheen AJ, 2010, LANCET, V375, P1410, DOI 10.1016/S0140-6736(10)60399-6; Seck T, 2010, INT J CLIN PRACT, V64, P562, DOI 10.1111/j.1742-1241.2010.02353.x; Ussher JR, 2012, ENDOCR REV, V33, P187, DOI 10.1210/er.2011-1052	14	21	21	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 4	2012	380	9840					450	452		10.1016/S0140-6736(12)60859-9	http://dx.doi.org/10.1016/S0140-6736(12)60859-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	983GY	22748818				2022-12-28	WOS:000307109000005
J	Pugh, TJ; Weeraratne, SD; Archer, TC; Krummel, DAP; Auclair, D; Bochicchio, J; Carneiro, MO; Carter, SL; Cibulskis, K; Erlich, RL; Greulich, H; Lawrence, MS; Lennon, NJ; McKenna, A; Meldrim, J; Ramos, AH; Ross, MG; Russ, C; Shefler, E; Sivachenko, A; Sogoloff, B; Stojanov, P; Tamayo, P; Mesirov, JP; Amani, V; Teider, N; Sengupta, S; Francois, JP; Northcott, PA; Taylor, MD; Yu, FR; Crabtree, GR; Kautzman, AG; Gabriel, SB; Getz, G; Jager, N; Jones, DTW; Lichter, P; Pfister, SM; Roberts, TM; Meyerson, M; Pomeroy, SL; Cho, YJ				Pugh, Trevor J.; Weeraratne, Shyamal Dilhan; Archer, Tenley C.; Krummel, Daniel A. Pomeranz; Auclair, Daniel; Bochicchio, James; Carneiro, Mauricio O.; Carter, Scott L.; Cibulskis, Kristian; Erlich, Rachel L.; Greulich, Heidi; Lawrence, Michael S.; Lennon, Niall J.; McKenna, Aaron; Meldrim, James; Ramos, Alex H.; Ross, Michael G.; Russ, Carsten; Shefler, Erica; Sivachenko, Andrey; Sogoloff, Brian; Stojanov, Petar; Tamayo, Pablo; Mesirov, Jill P.; Amani, Vladimir; Teider, Natalia; Sengupta, Soma; Francois, Jessica Pierre; Northcott, Paul A.; Taylor, Michael D.; Yu, Furong; Crabtree, Gerald R.; Kautzman, Amanda G.; Gabriel, Stacey B.; Getz, Gad; Jaeger, Natalie; Jones, David T. W.; Lichter, Peter; Pfister, Stefan M.; Roberts, Thomas M.; Meyerson, Matthew; Pomeroy, Scott L.; Cho, Yoon-Jae			Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations	NATURE			English	Article							STRUCTURAL BASIS; CHILDHOOD; LANDSCAPE; COMPLEX; GENES	Medulloblastomas are themost commonmalignant brain tumours in children(1). Identifying and understanding the genetic events that drive these tumours is critical for the development of more effective diagnostic, prognostic and therapeutic strategies. Recently, our group and others described distinct molecular subtypes ofmedulloblastoma on the basis of transcriptional and copy number profiles(2-5). Here we use whole-exome hybrid capture and deep sequencing to identify somatic mutations across the coding regions of 92 primary medulloblastoma/normal pairs. Overall, medulloblastomas have low mutation rates consistent with other paediatric tumours, with a median of 0.35 non-silent mutations per megabase. We identified twelve genes mutated at statistically significant frequencies, including previously known mutated genes in medulloblastoma such as CTNNB1, PTCH1, MLL2, SMARCA4 andTP53. Recurrent somatic mutations were newly identified in an RNA helicase gene, DDX3X, often concurrent with CTNNB1 mutations, and in the nuclear co-repressor (N-CoR) complex genes GPS2, BCOR and LDB1. We show that mutant DDX3X potentiates transactivation of a TCF promoter and enhances cell viability in combination with mutant, but not wild-type, beta-catenin. Together, our study reveals the alteration ofWNT, hedgehog, histone methyltransferase and now N-CoR pathways across medulloblastomas and within specific subtypes of this disease, and nominates theRNA helicase DDX3X as a component of pathogenic b-catenin signalling in medulloblastoma.	[Pugh, Trevor J.; Auclair, Daniel; Bochicchio, James; Carneiro, Mauricio O.; Carter, Scott L.; Cibulskis, Kristian; Erlich, Rachel L.; Greulich, Heidi; Lawrence, Michael S.; Lennon, Niall J.; McKenna, Aaron; Meldrim, James; Ramos, Alex H.; Ross, Michael G.; Russ, Carsten; Shefler, Erica; Sivachenko, Andrey; Sogoloff, Brian; Stojanov, Petar; Tamayo, Pablo; Mesirov, Jill P.; Gabriel, Stacey B.; Getz, Gad; Meyerson, Matthew; Pomeroy, Scott L.; Cho, Yoon-Jae] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Pugh, Trevor J.; Greulich, Heidi; Ramos, Alex H.; Roberts, Thomas M.; Meyerson, Matthew] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Pugh, Trevor J.; Greulich, Heidi; Ramos, Alex H.; Roberts, Thomas M.; Meyerson, Matthew] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Dept Med Oncol, Boston, MA 02115 USA; [Pugh, Trevor J.; Weeraratne, Shyamal Dilhan; Archer, Tenley C.; Greulich, Heidi; Ramos, Alex H.; Amani, Vladimir; Teider, Natalia; Sengupta, Soma; Francois, Jessica Pierre; Roberts, Thomas M.; Meyerson, Matthew; Pomeroy, Scott L.; Cho, Yoon-Jae] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Weeraratne, Shyamal Dilhan; Archer, Tenley C.; Amani, Vladimir; Teider, Natalia; Sengupta, Soma; Francois, Jessica Pierre; Pomeroy, Scott L.; Cho, Yoon-Jae] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Krummel, Daniel A. Pomeranz] Brandeis Univ, Waltham, MA 02453 USA; [Northcott, Paul A.; Taylor, Michael D.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Yu, Furong; Crabtree, Gerald R.; Kautzman, Amanda G.; Cho, Yoon-Jae] Stanford Univ, Sch Med, Dept Neurol, Stanford, CA 94305 USA; [Yu, Furong; Crabtree, Gerald R.; Kautzman, Amanda G.; Cho, Yoon-Jae] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Crabtree, Gerald R.] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Jaeger, Natalie; Jones, David T. W.; Lichter, Peter; Pfister, Stefan M.] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Meyerson, Matthew] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Brandeis University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Helmholtz Association; German Cancer Research Center (DKFZ); Harvard University; Brigham & Women's Hospital	Cho, YJ (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.	matthew_meyerson@dfci.harvard.edu; scott.pomeroy@childrens.harvard.edu; yjcho1@stanford.edu	Lawrence, Michael/AAC-8202-2020; Jones, David T. W./Z-1963-2019; Meyerson, Matthew L/E-7123-2012; Stojanov, Petar/GQI-4462-2022; Pfister, Stefan M/F-6860-2013; Mesirov, Jill/AGF-7626-2022; Jones, David TW/G-9588-2013; Northcott, Paul A/N-4022-2018; Pugh, Trevor/Y-2535-2019; Cibulskis, Kristian/AAC-7380-2019	Stojanov, Petar/0000-0001-7815-776X; Pfister, Stefan M/0000-0002-5447-5322; Jones, David TW/0000-0002-2036-5141; Northcott, Paul A/0000-0002-1220-5252; Pugh, Trevor/0000-0002-8073-5888; Taylor, Michael/0000-0001-7009-3466; Sengupta, Soma/0000-0003-4577-1397; Cibulskis, Kristian/0000-0003-1343-1582; Archer, Tenley/0000-0003-2723-4192; Meyerson, Matthew/0000-0002-9133-8108; Crabtree, Robert/0000-0002-6639-8707; Jaeger, Natalie/0000-0002-9589-7580	NIH [NHGRI U54HG003067, R01CA109467, R01CA105607, P30 HD18655, R01 CA030002, CA050661, R01 NS046789, R01 CA154480, R25NS070682, R01CA148699]; St. Baldrick's Foundation Scholar Award; Beirne Faculty Scholar endowment and Center for Children's Brain Tumors at Stanford University; German Cancer Aid [109252]; BMBF ICGC-PedBrain project; HHMI; Pediatric Brain Tumor Foundation; Canadian Institutes of Health Research Fellowship; Hospital for Sick Children; Mullarkey Research Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA148699, P01CA050661, R01CA030002, R01CA105607, R01CA109467, R01CA154480] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R25NS070682, R01NS046789] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St. Baldrick's Foundation Scholar Award; Beirne Faculty Scholar endowment and Center for Children's Brain Tumors at Stanford University; German Cancer Aid(Deutsche Krebshilfe); BMBF ICGC-PedBrain project; HHMI(Howard Hughes Medical Institute); Pediatric Brain Tumor Foundation; Canadian Institutes of Health Research Fellowship(Canadian Institutes of Health Research (CIHR)); Hospital for Sick Children(University of Toronto); Mullarkey Research Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH grants NHGRI U54HG003067 to E. S. Lander (E. S., D. A., S. B. G., G. G., M. M.); R01CA109467(S. L. P., J.P.M.); R01CA105607 (H. G., T. M. R., M. M., S. L. P.); P30 HD18655 (S. L. P.); R01 CA030002 and CA050661 (T. M. R.); R01 NS046789 (G. R. C.); R01 CA154480 (P. T.); R25NS070682 (S. S.) and R01CA148699 (M. D. T.); St. Baldrick's Foundation Scholar Award and the Beirne Faculty Scholar endowment and Center for Children's Brain Tumors at Stanford University (Y.-J.C.); German Cancer Aid (109252) and the BMBF ICGC-PedBrain project (N.J., D.T.W.J., P. L., S. M. P.); HHMI (G. R. C.); the Pediatric Brain Tumor Foundation (M. D. T.); Canadian Institutes of Health Research Fellowship (T.J.P.); Restracomp funding from the Hospital for Sick Children (P.A.N.); and the Mullarkey Research Fund (S. L. P.). We thank Children's Oncology Group and the Cooperative Human Tissue Network for providing tumour samples, the staff of the Broad Institute Biological Samples, Genome Sequencing and Genetic Analysis Platforms for their assistance in genomic processing of samples and generating the sequencing data used in this analysis, K. Keho and M. Brown at Pacific Biosciences for technical support with sample barcoding methods, and L. Gaffney of Broad Institute Communications for assistance with figure layout and design.	Baek SH, 2003, P NATL ACAD SCI USA, V100, P3245, DOI 10.1073/pnas.0330217100; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Central Brain Tumor Registry of the United States, 2011, STAT REP PRIM BRAIN; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Garbelli A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019810; Genome Reference Consortium, 2012, HUM GEN OV; Getz G, 2007, SCIENCE, V317, DOI 10.1126/science.1138764; Grossmann V, 2011, BLOOD, V118, P6153, DOI 10.1182/blood-2011-07-365320; Hogbom M, 2007, J MOL BIOL, V372, P150, DOI 10.1016/j.jmb.2007.06.050; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Ming JE, 2002, HUM GENET, V110, P297, DOI 10.1007/s00439-002-0695-5; Oberoi J, 2011, NAT STRUCT MOL BIOL, V18, P177, DOI 10.1038/nsmb.1983; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Ramos A, 2012, ONCOTATOR; Remke M, 2011, J CLIN ONCOL, V29, P2717, DOI 10.1200/JCO.2011.34.9373; Ren J, 2009, CELL RES, V19, P271, DOI 10.1038/cr.2009.6; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Satow R, 2006, DEV CELL, V11, P763, DOI 10.1016/j.devcel.2006.10.001; Sengoku T, 2006, CELL, V125, P287, DOI 10.1016/j.cell.2006.01.054; Smoll NR, 2012, CANCER-AM CANCER SOC, V118, P1313, DOI 10.1002/cncr.26387; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733	29	541	554	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 2	2012	488	7409					106	110		10.1038/nature11329	http://dx.doi.org/10.1038/nature11329			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981ZE	22820256	Green Accepted, Green Submitted			2022-12-28	WOS:000307010700042
J	Malta, DC; da Silva, JB				Malta, Deborah Carvalho; da Silva, Jarbas Barbosa			Policies to promote physical activity in Brazil	LANCET			English	Editorial Material									[Malta, Deborah Carvalho; da Silva, Jarbas Barbosa] Minist Saude Brasil, Secretaria Vigilancia Saude, BR-70070600 Brasilia, DF, Brazil; [Malta, Deborah Carvalho] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil	Universidade Federal de Minas Gerais	Malta, DC (corresponding author), Minist Saude Brasil, Secretaria Vigilancia Saude, BR-70070600 Brasilia, DF, Brazil.	dcmalta@uol.com.br	Malta, Deborah Carvalho/L-2491-2019; Malta, Deborah C/H-7880-2012; Malta, Deborah Carvalho/GNM-8218-2022	Malta, Deborah Carvalho/0000-0002-8214-5734; Malta, Deborah C/0000-0002-8214-5734; Malta, Deborah Carvalho/0000-0002-8214-5734				[Anonymous], UN GEN ASS 66 SESS P; Brasil Ministerio da Saude, 2011, STRAT ACT PLAN TACKL; Brasil Ministerio da Saude, 2011, VIG BRAS 2011 VIG FA; Hallal Pedro C, 2011, Rev. bras. epidemiol., V14, P53, DOI 10.1590/S1415-790X2011000500006; Malta DC, 2011, EPIDEMIOL SERV SAUDE, V20, P425, DOI 10.5123/S1679-49742011000400002; Malta DC, 2009, EPIDEMIOL SERV SAUDE, V18, P7; Ministerio do Planejamento Orcamento e Gestao (BR); Instituto Brasileiro de Geografia e Estatistica, 2010, PESQ ORC FAM 2008 20; Organization WH, 2016, GLOBAL STATUS REPORT; Reis RS, 2010, J PHYS ACT HEALTH, V7, pS137, DOI 10.1123/jpah.7.s2.s137; Schmidt MI, 2011, LANCET, V377, P1949, DOI 10.1016/S0140-6736(11)60135-9; Simoes EJ, 2009, AM J PUBLIC HEALTH, V99, P68, DOI 10.2105/AJPH.2008.141978; Welch JR, 2009, HUM ECOL, V37, P13, DOI 10.1007/s10745-009-9216-7	12	70	82	2	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2012	380	9838					195	196		10.1016/S0140-6736(12)61041-1	http://dx.doi.org/10.1016/S0140-6736(12)61041-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976TV	22818935				2022-12-28	WOS:000306609200008
J	Bhatt, DM; Pandya-Jones, A; Tong, AJ; Barozzi, I; Lissner, MM; Natoli, G; Black, DL; Smale, ST				Bhatt, Dev M.; Pandya-Jones, Amy; Tong, Ann-Jay; Barozzi, Iros; Lissner, Michelle M.; Natoli, Gioacchino; Black, Douglas L.; Smale, Stephen T.			Transcript Dynamics of Proinflammatory Genes Revealed by Sequence Analysis of Subcellular RNA Fractions	CELL			English	Article							MESSENGER-RNA; POLYMERASE-II; INFLAMMATORY RESPONSE; MAMMALIAN-CELLS; SEQ; EXPRESSION; ELONGATION; INDUCTION; MEDIATORS; MOLECULES	Macrophages respond to inflammatory stimuli by modulating the expression of hundreds of genes in a defined temporal cascade, with diverse transcriptional and posttranscriptional mechanisms contributing to the regulatory network. We examined proinflammatory gene regulation in activated macrophages by performing RNA-seq with fractionated chromatin-associated, nucleoplasmic, and cytoplasmic transcripts. This methodological approach allowed us to separate the synthesis of nascent transcripts from transcript processing and the accumulation of mature mRNAs. In addition to documenting the subcellular locations of coding and noncoding transcripts, the results provide a high-resolution view of the relationship between defined promoter and chromatin properties and the temporal regulation of diverse classes of coexpressed genes. The data also reveal a striking accumulation of full-length yet incompletely spliced transcripts in the chromatin fraction, suggesting that splicing often occurs after transcription has been completed, with transcripts retained on the chromatin until fully spliced.	[Bhatt, Dev M.; Pandya-Jones, Amy; Tong, Ann-Jay; Lissner, Michelle M.; Black, Douglas L.; Smale, Stephen T.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Pandya-Jones, Amy; Black, Douglas L.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; [Tong, Ann-Jay; Black, Douglas L.; Smale, Stephen T.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; [Barozzi, Iros; Natoli, Gioacchino] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; IRCCS European Institute of Oncology (IEO)	Black, DL (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.	dougb@microbio.ucla.edu; smale@mednet.ucla.edu	Natoli, gioacchino/ABB-8679-2020; Barozzi, Iros/GLQ-8907-2022; Natoli, gioacchino/J-2100-2018	Barozzi, Iros/0000-0003-0690-3473; Natoli, Gioacchino/0000-0003-0711-2411; Bhatt, Dev/0000-0003-3616-3701; Pandya-Jones, Amy/0000-0001-5519-4613	UCLA; NIH [R01GM086372, R01CA127279]; Broad Stem Cell Research Center at UCLA; NATIONAL CANCER INSTITUTE [R01CA127279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086372, R01GM049662] Funding Source: NIH RePORTER	UCLA(University of California System); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Broad Stem Cell Research Center at UCLA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Christopher Glass for sharing results prior to their publication; Alexander Hoffmann, Steve Horvath, Justin Langerman, Steve Ley, Chia-Ho Lin, and Matteo Pellegrini for helpful discussions; and Owen Witte for invaluable support. This work was supported by a UCLA Dissertation-Year Fellowship (to A.P.-J.), by NIH grants R01GM086372 and R01CA127279 (to S.T.S.), and by the Broad Stem Cell Research Center at UCLA. D.L.B. is an Investigator of the Howard Hughes Medical Institute.	Adelman K, 2009, P NATL ACAD SCI USA, V106, P18207, DOI 10.1073/pnas.0910177106; Amit I, 2009, SCIENCE, V326, P257, DOI 10.1126/science.1179050; Brody Y, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000573; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chen Q, 2011, MOL BIOL CELL, V22, P2646, DOI 10.1091/mbc.E11-03-0239; Churchman LS, 2011, NATURE, V469, P368, DOI 10.1038/nature09652; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271; Dye MJ, 2006, MOL CELL, V21, P849, DOI 10.1016/j.molcel.2006.01.032; Escoubet-Lozach L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002401; Fowler T, 2011, MOL CELL, V44, P348, DOI 10.1016/j.molcel.2011.09.014; Friedel CC, 2009, MOL BIOSYST, V5, P1271, DOI 10.1039/b911233b; Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86; Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042; Hao SL, 2009, NAT IMMUNOL, V10, P281, DOI 10.1038/ni.1699; Hargreaves DC, 2009, CELL, V138, P129, DOI 10.1016/j.cell.2009.05.047; Huang M, 2002, NAT CELL BIOL, V4, P774, DOI 10.1038/ncb855; Khodor YL, 2011, GENE DEV, V25, P2502, DOI 10.1101/gad.178962.111; Levin JZ, 2010, NAT METHODS, V7, P709, DOI [10.1038/NMETH.1491, 10.1038/nmeth.1491]; Litvak V, 2009, NAT IMMUNOL, V10, P437, DOI 10.1038/ni.1721; Liu H, 2002, MOL CELL BIOL, V22, P6471, DOI 10.1128/MCB.22.18.6471-6479.2002; Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108; Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Nechaev S, 2011, BBA-GENE REGUL MECH, V1809, P34, DOI 10.1016/j.bbagrm.2010.11.001; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; Pandya-Jones A, 2009, RNA, V15, P1896, DOI 10.1261/rna.1714509; Pawlicki JM, 2008, J CELL BIOL, V182, P61, DOI 10.1083/jcb.200803111; Perales R, 2009, MOL CELL, V36, P178, DOI 10.1016/j.molcel.2009.09.018; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Rabani M, 2011, NAT BIOTECHNOL, V29, P436, DOI 10.1038/nbt.1861; Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Ramsey SA, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000021; Schmid M, 2010, WIRES RNA, V1, P474, DOI 10.1002/wrna.24; Singh J, 2009, NAT STRUCT MOL BIOL, V16, P1128, DOI 10.1038/nsmb.1666; Smale ST, 2010, CELL, V140, P833, DOI 10.1016/j.cell.2010.01.037; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Vaidya SA, 2003, CURR OPIN IMMUNOL, V15, P402, DOI 10.1016/S0952-7915(03)00070-0; Vargas DY, 2011, CELL, V147, P1054, DOI 10.1016/j.cell.2011.10.024; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; Zambelli F, 2009, NUCLEIC ACIDS RES, V37, pW247, DOI 10.1093/nar/gkp464	43	319	323	0	29	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 20	2012	150	2					279	290		10.1016/j.cell.2012.05.043	http://dx.doi.org/10.1016/j.cell.2012.05.043			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817891	Green Accepted, Bronze			2022-12-28	WOS:000306595700008
J	Sugimura, R; He, XC; Venkatraman, A; Arai, F; Box, A; Semerad, C; Haug, JS; Peng, L; Zhong, XB; Suda, T; Li, LH				Sugimura, Ryohichi; He, Xi C.; Venkatraman, Aparna; Arai, Fumio; Box, Andrew; Semerad, Craig; Haug, Jeffrey S.; Peng, Lai; Zhong, Xiao-bo; Suda, Toshio; Li, Linheng			Noncanonical Wnt Signaling Maintains Hematopoietic Stem Cells in the Niche	CELL			English	Article							7-PASS TRANSMEMBRANE CADHERIN; BONE-MARROW; SELF-RENEWAL; ENDOTHELIAL-CELLS; PROGENITOR CELLS; PROTEIN; QUIESCENCE; EXPRESSION; IDENTIFICATION; MAINTENANCE	Wnt signaling is involved in self-renewal and maintenance of hematopoietic stem cells (HSCs); however, the particular role of noncanonical Wnt signaling in regulating HSCs in vivo is largely unknown. Here, we show Flamingo (Fmi) and Frizzled (Fz) 8, members of noncanonical Wnt signaling, both express in and functionally maintain quiescent long-term HSCs. Fmi regulates Fz8 distribution at the interface between HSCs and N-cadherin(+) osteoblasts (N-cad(+)OBs that enrich osteoprogenitors) in the niche. We further found that N-cad(+)OBs predominantly express noncanonical Wnt ligands and inhibitors of canonical Wnt signaling under homeostasis. Under stress, noncanonical Wnt signaling is attenuated and canonical Wnt signaling is enhanced in activation of HSCs. Mechanistically, noncanonical Wnt signaling mediated by Fz8 suppresses the Ca2+-NFAT- IFN gamma pathway, directly or indirectly through the CDC42-CK1 alpha complex and also antagonizes canonical Wnt signaling in HSCs. Taken together, our findings demonstrate that noncanonical Wnt signaling maintains quiescent long-term HSCs through Fmi and Fz8 interaction in the niche.	[Sugimura, Ryohichi; He, Xi C.; Venkatraman, Aparna; Box, Andrew; Semerad, Craig; Haug, Jeffrey S.; Li, Linheng] Stowers Inst Med Res, Kansas City, MO 64110 USA; [Venkatraman, Aparna] Christian Med Coll & Hosp, Ctr Stem Cell Res, Vellore 632002, Tamil Nadu, India; [Arai, Fumio; Suda, Toshio] Keio Univ, Sch Med, Dept Cell Differentiat, Shinjuku Ku, Tokyo 1608582, Japan; [Peng, Lai; Zhong, Xiao-bo] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA; [Li, Linheng] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA	Stowers Institute for Medical Research; Christian Medical College & Hospital (CMCH) Vellore; Keio University; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Li, LH (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	lil@stowers.org	Suda, Toshio/H-6761-2013; Sugimura, Rio/AAR-7280-2020; Arai, Fumio/J-5241-2013	Suda, Toshio/0000-0001-7540-1771; Sugimura, Rio/0000-0001-5701-3628; Arai, Fumio/0000-0003-1936-4907; Li, Linheng/0000-0001-9963-430X	SIMR; NIH, National Institute of General Medical Science [GM087376]; Department of Biotechnology, Government of India; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087376] Funding Source: NIH RePORTER	SIMR; NIH, National Institute of General Medical Science(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Paulson and H. Li for RNA-sequencing analysis, and Dr. H. Nakauchi for training in sorted HSC immunostaining. We appreciate Drs. G. Enikolopov, D. Rowe, V. Bautch, E. Fuchs, F. Costantini, and T. Xie for providing these mouse lines respectively: Nestin-GFP, Col2.3-GFP, CD31-ESCs, TOP-GAL, Axin2-d2EGFP, and pSicoR-EF1 alpha. We are grateful to J. Perry and other Li lab members for scientific discussion and critical reading of the manuscript; to M. Hembree, K. Westpfahl, D. Dukes, and B. Lewis for technical support; and to K. Tannen for manuscript editing and proofreading. We thank Y. Takahashi, J. Zhang, X. He, and K. Li for the art and graphic work. This work was funded by SIMR. X.-b.Z. is supported by NIH, National Institute of General Medical Science (Grant GM087376). A.V. is the recipient of an overseas research associateship from the Department of Biotechnology, Government of India. R.S. is a PhD student registered with the Open University.	Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Baldridge MT, 2010, NATURE, V465, P793, DOI 10.1038/nature09135; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; Butler JM, 2010, CELL STEM CELL, V6, P251, DOI 10.1016/j.stem.2010.02.001; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Challen GA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002357; Clements WK, 2011, NATURE, V474, P220, DOI 10.1038/nature10107; Dejmek J, 2006, MOL CELL BIOL, V26, P6024, DOI 10.1128/MCB.02354-05; Devenport D, 2008, NAT CELL BIOL, V10, P1257, DOI 10.1038/ncb1784; Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783; Dominici M, 2009, BLOOD, V114, P2333, DOI 10.1182/blood-2008-10-183459; Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815; Fleming HE, 2008, CELL STEM CELL, V2, P274, DOI 10.1016/j.stem.2008.01.003; Fujisaki J, 2011, NATURE, V474, P216, DOI 10.1038/nature10160; Grassinger J, 2010, BLOOD, V116, P3185, DOI 10.1182/blood-2009-12-260703; Gregory MA, 2010, CANCER CELL, V18, P74, DOI 10.1016/j.ccr.2010.04.025; Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007; Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806; Haug JS, 2008, CELL STEM CELL, V2, P367, DOI 10.1016/j.stem.2008.01.017; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Heinonen KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019279; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Huang T, 2011, J BIOL CHEM, V286, P37399, DOI 10.1074/jbc.M111.251165; Jeong M, 2009, J IMMUNOL, V183, P2495, DOI 10.4049/jimmunol.0804221; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Kiel MJ, 2009, CELL STEM CELL, V4, P170, DOI 10.1016/j.stem.2008.10.005; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kimura H, 2006, J CELL SCI, V119, P1118, DOI 10.1242/jcs.02832; Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; Louis I, 2008, IMMUNITY, V29, P57, DOI 10.1016/j.immuni.2008.04.023; Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Lymperi S, 2008, BLOOD, V111, P1173, DOI 10.1182/blood-2007-03-082800; Lymperi S, 2011, BLOOD, V117, P1540, DOI 10.1182/blood-2010-05-282855; Mahmood A, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/735420; Malhotra S, 2009, CELL STEM CELL, V4, P27, DOI 10.1016/j.stem.2008.12.004; Mendez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Miharada K, 2011, CELL STEM CELL, V9, P330, DOI 10.1016/j.stem.2011.07.016; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; MINTA A, 1989, J BIOL CHEM, V264, P8171; Monticelli S, 2002, EUR J IMMUNOL, V32, P2971, DOI 10.1002/1521-4141(2002010)32:10<2971::AID-IMMU2971>3.0.CO;2-G; MOON RT, 1993, DEVELOPMENT, V119, P97; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nemeth MJ, 2007, P NATL ACAD SCI USA, V104, P15436, DOI 10.1073/pnas.0704747104; Nemeth MJ, 2009, STEM CELLS, V27, P1109, DOI 10.1002/stem.32; Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017; Panakova D, 2010, NATURE, V466, P874, DOI 10.1038/nature09249; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Schaniel C, 2011, BLOOD, V118, P2420, DOI 10.1182/blood-2010-09-305664; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood-2003-11-4011; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Xie YC, 2009, NATURE, V457, P97, DOI 10.1038/nature07639; Yamazaki S, 2011, CELL, V147, P1146, DOI 10.1016/j.cell.2011.09.053; Yang LP, 2005, BLOOD, V105, P2717, DOI 10.1182/blood-2004-06-2159; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Zemlickova E, 2004, BIOCHEM BIOPH RES CO, V316, P39, DOI 10.1016/j.bbrc.2004.02.014; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhou LB, 2008, SCIENCE, V320, P946, DOI 10.1126/science.1155244; Zou P, 2011, CELL STEM CELL, V9, P247, DOI 10.1016/j.stem.2011.07.003	73	194	200	0	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 20	2012	150	2					351	365		10.1016/j.cell.2012.05.041	http://dx.doi.org/10.1016/j.cell.2012.05.041			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817897	Green Accepted, Bronze			2022-12-28	WOS:000306595700014
J	Van Braeckel, D; Temmerman, M; Roelens, K; Degomme, O				Van Braeckel, Dirk; Temmerman, Marleen; Roelens, Kristien; Degomme, Olivier			Slowing population growth for wellbeing and development	LANCET			English	Editorial Material									[Van Braeckel, Dirk; Temmerman, Marleen; Roelens, Kristien; Degomme, Olivier] Univ Ghent, Int Ctr Reprod Hlth, B-9000 Ghent, Belgium	Ghent University	Temmerman, M (corresponding author), Univ Ghent, Int Ctr Reprod Hlth, B-9000 Ghent, Belgium.	marleen.temmerman@ugent.be						Global Footprint Network, 2010, RES NAT FOOTPR ACC 2; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Kitzes J, 2008, PHILOS T R SOC B, V363, P467, DOI 10.1098/rstb.2007.2164; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Singh S, 2009, ADDING IT COSTS BENE; Temmerman M, CALL FAMILY PLANNING	6	5	5	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2012	380	9837					84	85		10.1016/S0140-6736(12)60902-7	http://dx.doi.org/10.1016/S0140-6736(12)60902-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784542				2022-12-28	WOS:000306359100009
J	De Wals, P; Deceuninck, G; Toth, E; Boulianne, N; Brunet, D; Boucher, RM; Landry, M; De Serres, G				De Wals, Philippe; Deceuninck, Genevieve; Toth, Eveline; Boulianne, Nicole; Brunet, Denis; Boucher, Renee-Myriam; Landry, Monique; De Serres, Gaston			Risk of Guillain-Barre Syndrome Following H1N1 Influenza Vaccination in Quebec	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED CASE SERIES; A H1N1; ADJUVANTED VACCINE; SAFETY	Context In fall 2009 in Quebec, Canada, an immunization campaign was launched against the 2009 influenza A(H1N1) pandemic strain, mostly using an AS03 adjuvant vaccine. By the end of the year, 57% of the 7.8 million residents had been vaccinated. Objective To assess the risk of Guillain-Barre syndrome (GBS) following pandemic influenza vaccine administration. Design Population-based cohort study with follow-up over the 6-month period October 2009 through March 2010. The investigation was ordered by the chief medical officer of health in accordance with the Quebec Public Health Act. Setting All acute care hospitals and neurology clinics in Quebec. Population Suspected and confirmed GBS cases reported by physicians, mostly neurologists, during active surveillance or identified in the provincial hospital summary discharge database. Medical records were reviewed and cases classified according to Brighton Collaboration definitions (categorized as level 1, 2, or 3, corresponding to criteria of decreasing certainty in diagnosis). Immunization status was verified and denominators were estimated from the provincial immunization registry (4.4 million vaccinated) and census data (total target population aged >= 6 months, 7.8 million), with a total of 3 623 046 person-years of observation. Main Outcome Measures Relative and attributable risks were calculated using a Poisson model and the self-controlled case-series method. Results Over a 6-month period, 83 confirmed GBS cases were identified, including 71 Brighton level 1 through 3 cases. Twenty-five confirmed cases had been vaccinated against 2009 influenza A(H1N1) 8 or fewer weeks before disease onset, with most (19/25) vaccinated 4 or fewer weeks before onset. In the Poisson model, the age-and sex-adjusted relative risk was 1.80 (95% CI, 1.12-2.87) for all confirmed cases during the 8-week postvaccination period and was 2.75 (95% CI, 1.63-4.62) during the 4-week postvaccination period. Using the self-controlled case-series method, relative risk estimates during the 4-week postvaccination period were 3.02 (95% CI, 1.64-5.56) for all confirmed cases (n=42) and 2.33 (95% CI, 1.19-4.57) for Brighton level 1 through 3 cases (n=36). The number of GBS cases attributable to vaccination was approximately 2 per 1 million doses. There was no indication of an excess risk in persons younger than 50 years. Conclusions In Quebec, the 2009 influenza A(H1N1) vaccine was associated with a small but significant risk of GBS. It is likely that the benefits of immunization outweigh the risks. JAMA. 2012;308(2):175-181	[De Wals, Philippe] Univ Laval, Dept Med Sociale & Prevent, CRIUCPQ, Quebec City, PQ G1V 4G5, Canada; [Deceuninck, Genevieve] Quebec Univ Hosp, Publ Hlth Res Unit, Quebec City, PQ, Canada; [Boucher, Renee-Myriam] Quebec Univ Hosp, Dept Pediat Neurol, Quebec City, PQ, Canada; [Boulianne, Nicole; De Serres, Gaston] Quebec Natl Publ Hlth Inst, Quebec City, PQ, Canada; [Brunet, Denis] Hop Enfants Jesus, Dept Neurol, Quebec City, PQ, Canada; [Toth, Eveline; Landry, Monique] Quebec Minist Hlth & Social Serv, Montreal, PQ, Canada	Laval University; Institut national de sante publique du Quebec (INSPQ); Laval University	De Wals, P (corresponding author), Univ Laval, Dept Med Sociale & Prevent, CRIUCPQ, 2725 Chemin Ste Foy, Quebec City, PQ G1V 4G5, Canada.	Philippe.De.Wals@ssss.gouv.qc.ca			GlaxoSmithKline; Novartis; Sanofi Pasteur; Merck; Pfizer; Ministere de la Sante et des Services sociaux du Quebec; Public Health Agency of Canada-Canadian Institutes for Health Research Influenza Research Network	GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Sanofi Pasteur; Merck(Merck & Company); Pfizer(Pfizer); Ministere de la Sante et des Services sociaux du Quebec; Public Health Agency of Canada-Canadian Institutes for Health Research Influenza Research Network(Canadian Institutes of Health Research (CIHR))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr De Wals reports receiving research grants, honoraria, and reimbursements of travel expenses from vaccine manufacturers including GlaxoSmithKline, Novartis, Sanofi Pasteur, Merck, and Pfizer. Ms Boulianne reports receiving research grants from Sanofi Pasteur and GlaxoSmithKline. Dr De Serres reports receiving research grants from Sanofi Pasteur and GlaxoSmithKline. No other disclosures were reported.; This study was funded by the Ministere de la Sante et des Services sociaux du Quebec and by the Public Health Agency of Canada-Canadian Institutes for Health Research Influenza Research Network.	Agence de la Sante et des Services sociaux du Saguenay-Lac-Saint-Jean, 2010, BIL CAMP VACC INFL P; Andrews N, 2011, VACCINE, V29, P7878, DOI 10.1016/j.vaccine.2011.08.069; Bardage C, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5956; Dieleman J, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3908; Direction de la Protection de la Sante publique, 2011, BIL DIR GEN SANT PUB; Douville-Fradet M, 2010, BIL EP PAND INFL AH1; Grimaldi-Bensouda L, 2011, AM J EPIDEMIOL, V174, P326, DOI 10.1093/aje/kwr072; Haber P, 2009, DRUG SAFETY, V32, P309, DOI 10.2165/00002018-200932040-00005; Hahn AF, 1998, LANCET, V352, P635, DOI 10.1016/S0140-6736(97)12308-X; Institute of Medicine, 2003, IMM SAF REV INFL VAC; LANGMUIR AD, 1984, AM J EPIDEMIOL, V119, P841, DOI 10.1093/oxfordjournals.aje.a113809; Lehmann HC, 2010, LANCET INFECT DIS, V10, P643, DOI 10.1016/S1473-3099(10)70140-7; McGrogan A, 2009, NEUROEPIDEMIOLOGY, V32, P150, DOI 10.1159/000184748; Ministere de la Sante et des Services sociaux, 2010, FLASH INFLUENZA, V14, P1; Nachamkin I, 2008, J INFECT DIS, V198, P226, DOI 10.1086/589624; Rothman K., 1998, MODERN EPIDEMIOLOGY; Sejvar JJ, 2011, VACCINE, V29, P599, DOI 10.1016/j.vaccine.2010.06.003; Skowronski DM, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7297; Stratton K.R., 2012, ADVERSE EFFECTS VACC; Tokars JI, 2012, PHARMACOEPIDEM DR S, V21, P546, DOI 10.1002/pds.3220; Van Buynder PG, 2010, INFLUENZA OTHER RESP, V4, P171, DOI 10.1111/j.1750-2659.2010.00146.x; Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302; Wu JA, 2010, NEW ENGL J MED, V363, P2416, DOI 10.1056/NEJMoa1006736	23	63	63	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2012	308	2					175	181		10.1001/jama.2012.7342	http://dx.doi.org/10.1001/jama.2012.7342			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971QS	22782419				2022-12-28	WOS:000306219500031
J	Wu, P; Takai, H; de Lange, T				Wu, Peng; Takai, Hiroyuki; de Lange, Titia			Telomeric 3 ' Overhangs Derive from Resection by Exo1 and Apollo and Fill-In by POT1b-Associated CST	CELL			English	Article							DNA-POLYMERASE-ALPHA; SINGLE-STRANDED-DNA; HUMAN-CHROMOSOMES; DAMAGE RESPONSE; CHECKPOINT ACTIVATION; PROTECTS TELOMERES; REPLICATION FORK; POT1 PROTEINS; S-PHASE; TRF2	A 3' overhang is critical for the protection and maintenance of mammalian telomeres, but its synthesis must be regulated to avoid excessive resection of the 5' end, which could cause telomere shortening. How this balance is achieved in mammals has not been resolved. Here, we determine the mechanism for 3' overhang synthesis in mouse cells by evaluating changes in telomeric overhangs throughout the cell cycle and at leading-and lagging-end telomeres. Apollo, a nuclease bound to the shelterin subunit TRF2, initiates formation of the 3' overhang at leading-, but not lagging-end telomeres. Hyperresection by Apollo is blocked at both ends by the shelterin protein POT1b. Exo1 extensively resects both telomere ends, generating transient long 3' overhangs in S/G2. CST/AAF, a DNA pol alpha.primase accessory factor, binds POT1b and shortens the extended overhangs produced by Exo1, likely through fill-in synthesis. 3' overhang formation is thus a multistep, shelterin-controlled process, ensuring functional telomeric overhangs at chromosome ends.	[Wu, Peng; Takai, Hiroyuki; de Lange, Titia] Rockefeller Univ, Lab Cell Biol & Genet, New York, NY 10065 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, Lab Cell Biol & Genet, 1230 York Ave, New York, NY 10065 USA.	delange@mail.rockefeller.edu	Takai, Helio/C-3301-2012; Takai, Hiroyuki/B-8352-2011; de Lange, Titia/B-8263-2011	Takai, Helio/0000-0001-9253-8307; de Lange, Titia/0000-0002-9267-367X; Wu, Peng/0000-0001-6565-0002	NIA/NIH Ruth L. Kirschstein NRSA Individual Fellowship [F30AG034744]; NIH MSTP [GM07739]; Breast Cancer Research Foundation; NIH [CA076027]; NATIONAL CANCER INSTITUTE [R01CA076027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F30AG034744] Funding Source: NIH RePORTER	NIA/NIH Ruth L. Kirschstein NRSA Individual Fellowship; NIH MSTP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We are thankful to W. Wright, J. Shay, Y. Zhao, and T. Chow at UTSW in Dallas for teaching one of us (P.W.) how to separate leading-and lagging-end telomeres. We thank D. White for expert mouse husbandry and the RU Flow Cytometry Resource Center for help with FACS sorting. De Lange lab members are thanked for advice. P.W. was supported by the NIA/NIH Ruth L. Kirschstein NRSA Individual Fellowship F30AG034744 and NIH MSTP grant GM07739 to the Weill Cornell/RU/MSKCC Tri-Institutional MD-PhD Program. H.T. was supported by a grant from the Breast Cancer Research Foundation. TdL is an American Cancer Society Research Professor. This work was supported by a grant from the NIH (CA076027).	Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Attwooll CL, 2009, MOL CELL BIOL, V29, P5540, DOI 10.1128/MCB.00479-09; Bae JB, 2008, ONCOGENE, V27, P5045, DOI 10.1038/onc.2008.139; Bertuch AA, 2006, CURR OPIN CELL BIOL, V18, P247, DOI 10.1016/j.ceb.2006.04.005; Casteel DE, 2009, J BIOL CHEM, V284, P5807, DOI 10.1074/jbc.M807593200; Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; Chai WH, 2006, MOL CELL, V21, P427, DOI 10.1016/j.molcel.2005.12.004; Chen Y, 2008, SCIENCE, V319, P1092, DOI 10.1126/science.1151804; Dai XY, 2010, EMBO J, V29, P2788, DOI 10.1038/emboj.2010.156; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Deng YB, 2009, NATURE, V460, P914, DOI 10.1038/nature08196; Dimitrova N, 2009, MOL CELL BIOL, V29, P5552, DOI 10.1128/MCB.00476-09; Gao H, 2007, NAT STRUCT MOL BIOL, V14, P208, DOI 10.1038/nsmb1205; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOULIAN M, 1990, J BIOL CHEM, V265, P13221; Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108; Grossi S, 2004, GENE DEV, V18, P992, DOI 10.1101/gad.300004; Guo X, 2007, EMBO J, V26, P4709, DOI 10.1038/sj.emboj.7601893; He H, 2009, MOL CELL BIOL, V29, P229, DOI 10.1128/MCB.01400-08; Hockemeyer D, 2005, EMBO J, V24, P2667, DOI 10.1038/sj.emboj.7600733; Hockemeyer D, 2008, GENE DEV, V22, P1773, DOI 10.1101/gad.1679208; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Huffman KE, 2000, J BIOL CHEM, V275, P19719, DOI 10.1074/jbc.M002843200; Lam YC, 2010, EMBO J, V29, P2230, DOI 10.1038/emboj.2010.58; Lenain C, 2006, CURR BIOL, V16, P1303, DOI 10.1016/j.cub.2006.05.021; Longhese MP, 2010, EMBO J, V29, P2864, DOI 10.1038/emboj.2010.165; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Mimitou EP, 2008, NATURE, V455, P770, DOI 10.1038/nature07312; Miyake Y, 2009, MOL CELL, V36, P193, DOI 10.1016/j.molcel.2009.08.009; Ohki R, 2004, NUCLEIC ACIDS RES, V32, P1627, DOI 10.1093/nar/gkh309; Palm W, 2009, MOL CELL BIOL, V29, P471, DOI 10.1128/MCB.01352-08; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Price CM, 2010, CELL CYCLE, V9, P3157, DOI 10.4161/cc.9.16.12547; Qi HY, 2000, GENE DEV, V14, P1777; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Schaetzlein S, 2007, CELL, V130, P863, DOI 10.1016/j.cell.2007.08.029; Sfeir AJ, 2005, MOL CELL, V18, P131, DOI 10.1016/j.molcel.2005.02.035; Surovtseva YV, 2009, MOL CELL, V36, P207, DOI 10.1016/j.molcel.2009.09.017; van Overbeek M, 2006, CURR BIOL, V16, P1295, DOI 10.1016/j.cub.2006.05.022; Wan M, 2009, J BIOL CHEM, V284, P26725, DOI 10.1074/jbc.M109.021105; Wu L, 2006, CELL, V126, P49, DOI 10.1016/j.cell.2006.05.037; Wu P, 2010, MOL CELL, V39, P606, DOI 10.1016/j.molcel.2010.06.031; Zhu Z, 2008, CELL, V134, P981, DOI 10.1016/j.cell.2008.08.037	44	207	211	0	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 6	2012	150	1					39	52		10.1016/j.cell.2012.05.026	http://dx.doi.org/10.1016/j.cell.2012.05.026			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22748632	Bronze, Green Accepted			2022-12-28	WOS:000306115000005
J	Nijman, RG; Thompson, M; van Veen, M; Perera, R; Moll, HA; Oostenbrink, R				Nijman, R. G.; Thompson, M.; van Veen, M.; Perera, R.; Moll, H. A.; Oostenbrink, R.			Derivation and validation of age and temperature specific reference values and centile charts to predict lower respiratory tract infection in children with fever: prospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-RATE; REFERENCE RANGES; BODY-TEMPERATURE; PNEUMONIA; TACHYPNEA; STANDARDS; INFANTS	Objectives To develop reference values and centile charts for respiratory rate based on age and body temperature, and to determine how well these reference values can predict the presence of lower respiratory tract infections (LRTI) in children with fever. Design Prospective observational study. Participants Febrile children aged at least 1 month to just under 16 years (derivation population, n=1555; validation population, n=671) selected from patients attending paediatric emergency departments or assessment units in hospitals. Setting One hospital in the Netherlands in 2006 and 2008 (derivation population); one hospital in the Netherlands in 2003-05 and one hospital in the United Kingdom in 2005-06 (validation population). Intervention We used the derivation population to produce respiratory rate centile charts, and calculated 50th, 75th, 90th, and 97th centiles of respiratory rate at a specific body temperature. Multivariable regression analysis explored associations between respiratory rate, age, and temperature; results were validated in the validation population by calculating diagnostic performance measures, z scores, and corresponding centiles of children with diagnoses of pneumonic LRTI (as confirmed by chest radiograph), non-pneumonic LRTI, and non-LRTI. Main outcome measure Age, respiratory rate (breaths/min) and body temperature (degrees C), presence of LRTI. Results Respiratory rate increased overall by 2.2 breaths/min per 1 degrees C rise (standard error 0.2) after accounting for age and temperature in the model. We observed no interactions between age, temperature, and respiratory rates. Age and temperature dependent cut-off values at the 97th centile were more useful for ruling in LRTI (specificity 0.94 (95% confidence interval 0.92 to 0.96), positive likelihood ratio 3.66 (2.34 to 5.73)) than existing respiratory rate thresholds such as Advanced Pediatrics Life Support values (0.53 (0.48 to 0.57), 1.59 (1.41 to 1.80)). However, centile cut-offs could not discriminate between pneumonic LRTI and non-pneumonic LRTI. Conclusions Age specific and temperature dependent centile charts describe new reference values for respiratory rate in children with fever. Cut-off values at the 97th centile were more useful in detecting the presence of LRTI than existing respiratory rate thresholds.	[Nijman, R. G.; van Veen, M.; Moll, H. A.; Oostenbrink, R.] Erasmus MC Sophia Childrens Hosp, Dept Gen Paediat, NL-3015 GJ Rotterdam, Netherlands; [Thompson, M.; Perera, R.] Univ Oxford, Dept Primary Care Hlth Sci, Oxford, England	Erasmus University Rotterdam; Erasmus MC; University of Oxford	Oostenbrink, R (corresponding author), Erasmus MC Sophia Childrens Hosp, Dept Gen Paediat, NL-3015 GJ Rotterdam, Netherlands.	r.oostenbrink@erasmusmc.nl		Nijman, Ruud Gerard/0000-0001-9671-8161; Perera, Rafael/0000-0003-2418-2091	Europe Container Terminals BV; European Society of Pediatric Infectious Diseases; National Institute for Health Research (NIHR) programme grant (MaDOx); MaDOx; NIHR [RP-PG-0407-10347]	Europe Container Terminals BV; European Society of Pediatric Infectious Diseases; National Institute for Health Research (NIHR) programme grant (MaDOx)(National Institute for Health Research (NIHR)); MaDOx; NIHR(National Institute for Health Research (NIHR))	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; RN is supported by ZonMW, a Dutch organisation for health research and development, and Erasmus MC Doelmatigheid; RO is supported by an unrestricted grant of Europe Container Terminals BV and by a fellowship grant of the European Society of Pediatric Infectious Diseases in 2010; MT is supported by a National Institute for Health Research (NIHR) programme grant (MaDOx), and the MaDOx programme presents independent research commissioned by NIHR under its Programme Grant for Applied Research funding stream (RP-PG-0407-10347).	[Anonymous], 2006, R LANG ENV STAT COMP; Bouwhuis C B, 2001, Ned Tijdschr Geneeskd, V145, P1847; Brent AJ, 2011, ARCH DIS CHILD, V96, P368, DOI 10.1136/adc.2010.183129; CAMPBELL H, 1989, LANCET, V1, P297, DOI 10.1016/S0140-6736(89)91308-1; CAMPBELL H, 1992, ARCH DIS CHILD, V67, P664, DOI 10.1136/adc.67.5.664; Cole TJ, 2009, STAT MED, V28, P880, DOI 10.1002/sim.3504; COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005; Craig JC, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1594; Davies P, 2009, EMERG MED J, V26, P641, DOI 10.1136/emj.2008.061598; DAVIGNON A, 1980, PEDIATR CARDIOL, V1, P123, DOI 10.1007/BF02083144; Fleming S, 2011, LANCET, V377, P1011, DOI 10.1016/S0140-6736(10)62226-X; GADOMSKI AM, 1994, J CLIN EPIDEMIOL, V47, P1043, DOI 10.1016/0895-4356(94)90120-1; Hanna CM, 2004, ANN EMERG MED, V43, P699, DOI 10.1016/j.annemergmed.2003.10.002; HOOKER E A, 1989, Journal of Emergency Medicine, V7, P129, DOI 10.1016/0736-4679(89)90257-6; Iliff A, 1952, CHILD DEV, V23, pA237; Lovett PB, 2005, ANN EMERG MED, V45, P68, DOI 10.1016/j.annemergmed.2004.06.016; Lynch T, 2004, PEDIATRICS, V113, pE186, DOI 10.1542/peds.113.3.e186; Lynch T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011989; Margolis P, 1998, JAMA-J AM MED ASSOC, V279, P308, DOI 10.1001/jama.279.4.308; MARKS MK, 1993, ARCH DIS CHILD, V69, P569, DOI 10.1136/adc.69.5.569; MENG XL, 1992, PSYCHOL BULL, V111, P172, DOI 10.1037/0033-2909.111.1.172; MORLEY CJ, 1990, ARCH DIS CHILD, V65, P834, DOI 10.1136/adc.65.8.834; Neuman MI, 2011, PEDIATRICS, V128, P246, DOI 10.1542/peds.2010-3367; ODEMPSEY TJD, 1993, ARCH DIS CHILD, V68, P492, DOI 10.1136/adc.68.4.492; Oostenbrink RTM, 2010, COMMUNICATION; Reitsma JB, 2009, J CLIN EPIDEMIOL, V62, P797, DOI 10.1016/j.jclinepi.2009.02.005; Roukema J, 2008, J AM MED INFORM ASSN, V15, P107, DOI 10.1197/jamia.M2164; RUSCONI F, 1994, PEDIATRICS, V94, P350; Shah S, 2010, PEDIATR INFECT DIS J, V29, P406, DOI 10.1097/INF.0b013e3181cb45a7; SIMOES EAF, 1991, ARCH DIS CHILD, V66, P1199, DOI 10.1136/adc.66.10.1199; TAYLOR JA, 1995, ARCH PEDIAT ADOL MED, V149, P283, DOI 10.1001/archpedi.1995.02170150063011; Thompson M, 2009, ARCH DIS CHILD, V94, P888, DOI 10.1136/adc.2009.159095; Thompson M, 2009, ARCH DIS CHILD, V94, P361, DOI 10.1136/adc.2008.145011; Turner N., 2006, ADV PAEDIAT LIFE SUP; Van den Bruel A, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3082; Van den Bruel A, 2010, LANCET, V375, P834, DOI 10.1016/S0140-6736(09)62000-6; van Veen M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1501; Virtanen A, 1998, CLIN CHEM, V44, P2353; VOORS AW, 1982, AM J EPIDEMIOL, V116, P276, DOI 10.1093/oxfordjournals.aje.a113412; Wallis LA, 2005, ARCH DIS CHILD, V90, P1117, DOI 10.1136/adc.2004.068718; World Health 0rganization, 1995, MAN AC RESP INF CHIL	41	34	35	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	2012	344								e4224	10.1136/bmj.e4224	http://dx.doi.org/10.1136/bmj.e4224			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972KA	22761088	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000306274800001
J	Lee, YJ; Morrison, BM; Li, Y; Lengacher, S; Farah, MH; Hoffman, PN; Liu, YT; Tsingalia, A; Jin, L; Zhang, PW; Pellerin, L; Magistretti, PJ; Rothstein, JD				Lee, Youngjin; Morrison, Brett M.; Li, Yun; Lengacher, Sylvain; Farah, Mohamed H.; Hoffman, Paul N.; Liu, Yiting; Tsingalia, Akivaga; Jin, Lin; Zhang, Ping-Wu; Pellerin, Luc; Magistretti, Pierre J.; Rothstein, Jeffrey D.			Oligodendroglia metabolically support axons and contribute to neurodegeneration	NATURE			English	Article							MONOCARBOXYLATE TRANSPORTER MCT1; AMYOTROPHIC-LATERAL-SCLEROSIS; CENTRAL-NERVOUS-SYSTEM; MOUSE-BRAIN; IN-VIVO; NEURONAL-ACTIVITY; GLUTAMATE UPTAKE; TRANSGENIC MICE; ADULT BRAIN; SPINAL-CORD	Oligodendroglia support axon survival and function through mechanisms independent of myelination, and their dysfunction leads to axon degeneration in several diseases. The cause of this degeneration has not been determined, but lack of energy metabolites such as glucose or lactate has been proposed. Lactate is transported exclusively by monocarboxylate transporters, and changes to these transporters alter lactate production and use. Here we show that the most abundant lactate transporter in the central nervous system, monocarboxylate transporter 1 (MCT1, also known as SLC16A1), is highly enriched within oligodendroglia and that disruption of this transporter produces axon damage and neuron loss in animal and cell culture models. In addition, this same transporter is reduced in patients with, and in mouse models of, amyotrophic lateral sclerosis, suggesting a role for oligodendroglial MCT1 in pathogenesis. The role of oligodendroglia in axon function and neuron survival has been elusive; this study defines a new fundamental mechanism by which oligodendroglia support neurons and axons.	[Lee, Youngjin; Morrison, Brett M.; Li, Yun; Farah, Mohamed H.; Hoffman, Paul N.; Liu, Yiting; Tsingalia, Akivaga; Jin, Lin; Zhang, Ping-Wu; Rothstein, Jeffrey D.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA; [Lengacher, Sylvain; Magistretti, Pierre J.] Ecole Polytech Fed Lausanne, Brain Mind Inst, Sch Life Sci, Stn 19, CH-1015 Lausanne, Switzerland; [Pellerin, Luc] Univ Lausanne, Dept Physiol, CH-1005 Lausanne, Switzerland; [Rothstein, Jeffrey D.] Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA; [Rothstein, Jeffrey D.] Johns Hopkins Univ, Brain Sci Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; Johns Hopkins University; Johns Hopkins University	Rothstein, JD (corresponding author), Johns Hopkins Univ, Dept Neurol, 855 N Wolfe St,Rangos 248, Baltimore, MD 21205 USA.	jrothstein@jhmi.edu	Lengacher, Sylvain/C-2591-2009; Pellerin, Luc/A-8912-2017; Lee, Youngjin/K-8909-2012; rothstein, jeffrey d/C-9470-2013	Lengacher, Sylvain/0000-0003-2190-9654; Pellerin, Luc/0000-0002-1016-1970; Morrison, Brett/0000-0001-5404-3899; LEE, Youngjin/0000-0002-5942-6204; Magistretti, Pierre Julius/0000-0002-6678-320X	National Institutes of Health [P50AG05146, PO1NS16375]; Muscular Dystrophy Association; Packard Center for ALS; Human Frontier Science Program [RG118/1998-B]; Swiss Fonds National de Recherche Scientifique [31003A-125063]; Swiss National Science Foundation (FNRS) [3100AO-108336/1]; Biaggi Foundation; Puccini Foundation;  [NIH-NS33958];  [P2ALS]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016375, R01NS033958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); Packard Center for ALS; Human Frontier Science Program(Human Frontier Science Program); Swiss Fonds National de Recherche Scientifique; Swiss National Science Foundation (FNRS)(Swiss National Science Foundation (SNSF)); Biaggi Foundation; Puccini Foundation; ; ; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank C. Coccia, S. Vidensky, I. Shats, L. Chakravarti, Y. Ayukawa and L. Mamedova for technical support, E. Potter for oligodendrocyte cultures, C. Cooke for electron microscopy, and S. Kang and D. Bergles for providing MOBP-eGFP BAC and CNP BacTrap mice, CASPR and Nav1.6 antibodies. Autopsy specimens were provided by the Johns Hopkins ALS Tissue Bank and the Johns Hopkins University Brain Resource Center supported by National Institutes of Health grants P50AG05146 and PO1NS16375. Support was provided by the Muscular Dystrophy Association (B. M. M. and Yo.L.), NIH-NS33958 (J.D.R.), P2ALS (J.D.R.), Packard Center for ALS (J. D. R.), Human Frontier Science Program-RG118/1998-B (L. P.), Swiss Fonds National de Recherche Scientifique-31003A-125063 (L. P.), Swiss National Science Foundation (FNRS)-3100AO-108336/1 (P. J. M.), Biaggi and Puccini Foundations (P. J. M). We dedicate this manuscript to J. W. Griffin, who passed away while this manuscript was under revision, and are grateful for his contributions to this manuscript and mentorship to many of the authors on this paper.	Benarroch EE, 2009, NEUROLOGY, V72, P1779, DOI 10.1212/WNL.0b013e3181a6b123; Bergersen L, 2002, NEUROCHEM RES, V27, P89, DOI 10.1023/A:1014806723147; Berthet C, 2009, J CEREBR BLOOD F MET, V29, P1780, DOI 10.1038/jcbfm.2009.97; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; Buntinx M, 2003, J NEUROCYTOL, V32, P25, DOI 10.1023/A:1027324230923; Chiry O, 2006, BRAIN RES, V1070, P65, DOI 10.1016/j.brainres.2005.11.064; Doerflinger NH, 2003, GENESIS, V35, P63, DOI 10.1002/gene.10154; Doyle JP, 2008, CELL, V135, P749, DOI 10.1016/j.cell.2008.10.029; Edgar JM, 2009, GLIA, V57, P1815, DOI 10.1002/glia.20893; Funfschilling U, 2012, NATURE, V485, P517, DOI 10.1038/nature11007; Garbern JY, 2002, BRAIN, V125, P551, DOI 10.1093/brain/awf043; Gerhart DZ, 1997, AM J PHYSIOL-ENDOC M, V273, pE207, DOI 10.1152/ajpendo.1997.273.1.E207; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hanu R, 2000, AM J PHYSIOL-CELL PH, V278, pC921, DOI 10.1152/ajpcell.2000.278.5.C921; HEYER EJ, 1982, BRAIN RES, V232, P41, DOI 10.1016/0006-8993(82)90609-6; Kang SH, 2010, NEURON, V68, P668, DOI 10.1016/j.neuron.2010.09.009; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Koehler-Stec EM, 1998, AM J PHYSIOL-ENDOC M, V275, pE516, DOI 10.1152/ajpendo.1998.275.3.E516; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Maekawa F, 2008, J NEUROCHEM, V107, P789, DOI 10.1111/j.1471-4159.2008.05650.x; MAYER ML, 1984, J PHYSIOL-LONDON, V354, P29, DOI 10.1113/jphysiol.1984.sp015360; McIver SR, 2005, J NEUROSCI RES, V82, P397, DOI 10.1002/jnr.20626; Morrison BM, 2000, EXP NEUROL, V165, P207, DOI 10.1006/exnr.2000.7457; Murray CM, 2005, NAT CHEM BIOL, V1, P371, DOI 10.1038/nchembio744; Pellerin L, 2005, J NEUROSCI RES, V79, P55, DOI 10.1002/jnr.20307; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Pellerin L, 1998, P NATL ACAD SCI USA, V95, P3990, DOI 10.1073/pnas.95.7.3990; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pierre K, 2000, NEUROSCIENCE, V100, P617, DOI 10.1016/S0306-4522(00)00294-3; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Regan MR, 2007, J NEUROSCI, V27, P6607, DOI 10.1523/JNEUROSCI.0790-07.2007; Rinholm JE, 2011, J NEUROSCI, V31, P538, DOI 10.1523/JNEUROSCI.3516-10.2011; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; Sanchez-Abarca LI, 2001, GLIA, V36, P321, DOI 10.1002/glia.1119; SASAKI S, 1992, J NEUROL SCI, V110, P114, DOI 10.1016/0022-510X(92)90017-F; Seilhean D, 2009, ACTA NEUROPATHOL, V118, P561, DOI 10.1007/s00401-009-0545-9; Suh SW, 2007, J PHARMACOL EXP THER, V321, P45, DOI 10.1124/jpet.106.115550; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Tekkok SB, 2005, J NEUROSCI RES, V81, P644, DOI 10.1002/jnr.20573; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; WALZ W, 1988, NEUROSCI LETT, V86, P296, DOI 10.1016/0304-3940(88)90499-5; Yamanaka K, 2008, NAT NEUROSCI, V11, P251, DOI 10.1038/nn2047; Yang YJ, 2011, GLIA, V59, P200, DOI 10.1002/glia.21089; Yang YJ, 2010, GLIA, V58, P277, DOI 10.1002/glia.20922; You F, 2007, J CELL BIOCHEM, V100, P256, DOI 10.1002/jcb.21082; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3	48	992	1023	6	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 26	2012	487	7408					443	U1502		10.1038/nature11314	http://dx.doi.org/10.1038/nature11314			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979KD	22801498	Green Accepted			2022-12-28	WOS:000306815300030
J	Subramanian, S; Tawakol, A; Burdo, TH; Abbara, S; Wei, J; Vijayakumar, J; Corsini, E; Abdelbaky, A; Zanni, MV; Hoffmann, U; Williams, KC; Lo, J; Grinspoon, SK				Subramanian, Sharath; Tawakol, Ahmed; Burdo, Tricia H.; Abbara, Suhny; Wei, Jeffrey; Vijayakumar, Jayanthi; Corsini, Erin; Abdelbaky, Amr; Zanni, Markella V.; Hoffmann, Udo; Williams, Kenneth C.; Lo, Janet; Grinspoon, Steven K.			Arterial Inflammation in Patients With HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATHEROSCLEROTIC PLAQUE INFLAMMATION; ACTIVATED MACROPHAGES; SOLUBLE CD163; RISK; CALCIUM; POPULATION; EVENTS; MARKER	Context Cardiovascular disease is increased in patients with human immunodeficiency virus (HIV), but the specific mechanisms are unknown. Objective To assess arterial wall inflammation in HIV, using (18)fluorine-2-deoxy-D-glucose positron emission tomography (F-18-FDG-PET), in relationship to traditional and nontraditional risk markers, including soluble CD163 (sCD163), a marker of monocyte and macrophage activation. Design, Setting, and Participants A cross-sectional study of 81 participants investigated between November 2009 and July 2011 at the Massachusetts General Hospital. Twenty-seven participants with HIV without known cardiac disease underwent cardiac 18F-FDG-PET for assessment of arterial wall inflammation and coronary computed tomography scanning for coronary artery calcium. The HIV group was compared with 2 separate non-HIV control groups. One control group (n=27) was matched to the HIV group for age, sex, and Framingham risk score (FRS) and had no known atherosclerotic disease (non-HIV FRS-matched controls). The second control group (n=27) was matched on sex and selected based on the presence of known atherosclerotic disease (non-HIV atherosclerotic controls). Main Outcome Measure Arterial inflammation was prospectively determined as the ratio of FDG uptake in the arterial wall of the ascending aorta to venous background as the target-to-background ratio (TBR). Results Participants with HIV demonstrated well-controlled HIV disease (mean [SD] CD4 cell count, 641 [288] cells/mu L; median [interquartile range] HIV-RNA level, <48 [<48 to <48] copies/mL). All were receiving antiretroviral therapy (mean [SD] duration, 12.3 [4.3] years). The mean FRS was low in both HIV and non-HIV FRS-matched control participants (6.4; 95% CI, 4.8-8.0 vs 6.6; 95% CI, 4.9-8.2; P=.87). Arterial inflammation in the aorta (aortic TBR) was higher in the HIV group vs the non-HIV FRS-matched control group (2.23; 95% CI, 2.07-2.40 vs 1.89; 95% CI, 1.80-1.97; P < .001), but was similar compared with the non-HIV atherosclerotic control group (2.23; 95% CI, 2.07-2.40 vs 2.13; 95% CI, 2.03-2.23; P=.29). Aortic TBR remained significantly higher in the HIV group vs the non-HIV FRS-matched control group after adjusting for traditional cardiovascular risk factors (P=.002) and in stratified analyses among participants with undetectable viral load, zero calcium, FRS of less than 10, a low-density lipoprotein cholesterol level of less than 100 mg/dL (<2.59 mmol/L), no statin use, and no smoking (all P <= .01). Aortic TBR was associated with sCD163 level (P=.04) but not with C-reactive protein (P=.65) or D-dimer (P=.08) among patients with HIV. Conclusion Participants infected with HIV vs noninfected control participants with similar cardiac risk factors had signs of increased arterial inflammation, which was associated with a circulating marker of monocyte and macrophage activation. JAMA. 2012;308(4):379-386 www.jama.com	[Zanni, Markella V.; Lo, Janet; Grinspoon, Steven K.] Massachusetts Gen Hosp, Program Nutr Metab, Boston, MA 02114 USA; [Zanni, Markella V.; Lo, Janet; Grinspoon, Steven K.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Subramanian, Sharath; Tawakol, Ahmed; Abbara, Suhny; Vijayakumar, Jayanthi; Corsini, Erin; Abdelbaky, Amr; Hoffmann, Udo] Massachusetts Gen Hosp, Dept Imaging, Boston, MA 02114 USA; [Subramanian, Sharath; Tawakol, Ahmed; Abbara, Suhny; Vijayakumar, Jayanthi; Corsini, Erin; Abdelbaky, Amr; Hoffmann, Udo] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA; [Tawakol, Ahmed] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA; [Burdo, Tricia H.; Williams, Kenneth C.] Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Boston College	Grinspoon, SK (corresponding author), Massachusetts Gen Hosp, Program Nutr Metab, 5 Longfellow Pl,Room 207, Boston, MA 02114 USA.	sgrinspoon@partners.org	Abbara, Suhny/C-3692-2014; Zanni, Markella/U-9108-2017; Corsini, Erin/AAG-6248-2020	Zanni, Markella/0000-0002-4711-3956; Bayley, Erin/0000-0003-4715-0244; Abbara, Suhny/0000-0003-2552-7362	National Institutes of Health [R01 HL 095123, K23 HL092792, NS37654, NS40237, K24 DK064545]; General Clinical Research Center [M01 RR01066-25S1]; Merck Co; GlaxoSmithKline; Genetech/Roche; Vascular Biogenics Ltd; Bristol-Myers Squibb; Bracco and Becton; Dickinson and Company; Elsevier and Amirsys; Siemens Healthcare; GE Healthcare; Bracco Diagnostics; American College of Radiology Imaging Network; National Institutes of Health; Amgen; Theratechnologies; Ferrer; sanofi-aventis; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL092792, R01HL095123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561, K24DK064545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040237, R01NS037654] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Merck Co(Merck & Company); GlaxoSmithKline(GlaxoSmithKline); Genetech/Roche(Roche Holding); Vascular Biogenics Ltd; Bristol-Myers Squibb(Bristol-Myers Squibb); Bracco and Becton; Dickinson and Company; Elsevier and Amirsys; Siemens Healthcare(Siemens AG); GE Healthcare(General ElectricGE Healthcare); Bracco Diagnostics; American College of Radiology Imaging Network(General Electric); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Amgen(Amgen); Theratechnologies; Ferrer; sanofi-aventis(Sanofi-Aventis); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Tawakol reported consulting for Roche, Bristol-Myers Squibb, and Novartis, and receiving grant support from Merck & Co, GlaxoSmithKline, Genetech/Roche, Vascular Biogenics Ltd, and Bristol-Myers Squibb, all unrelated to the manuscript. Dr Abbara reported consulting for Perceptive Informatics and Partners Imaging, receiving grant support from Bracco and Becton, Dickinson and Company, and receiving royalties from Elsevier and Amirsys, all unrelated to the manuscript. Dr Hoffmann reported receiving research support from Siemens Healthcare, GE Healthcare, Bracco Diagnostics, the American College of Radiology Imaging Network, and National Institutes of Health, all unrelated to the manuscript. Dr Grinspoon reported receiving research support from Amgen, Bristol-Myers Squibb, and Theratechnologies; consulting for Aileron, Theratechnologies, Alize Pharmaceuticals, Hoffmann-La Roche, and Serono; and receiving lecture fees from Ferrer and sanofi-aventis, all unrelated to the manuscript. No other authors reported any disclosures.; This work was supported by grant R01 HL 095123 from the National Institutes of Health (Dr Grinspoon). Relevant grants supporting investigators from the National Institutes of Health were K23 HL092792 (Dr Lo), NS37654 and NS40237 (Dr Williams), and K24 DK064545 (Dr Grinspoon). The General Clinical Research Center grant is M01 RR01066-25S1.	Alsheikh-Ali AA, 2010, ANN INTERN MED, V153, P387, DOI 10.7326/0003-4819-153-6-201009210-00272; Aristoteli LP, 2006, ATHEROSCLEROSIS, V184, P342, DOI 10.1016/j.atherosclerosis.2005.05.004; Aziz K, 2008, CIRCULATION, V117, P2061, DOI 10.1161/CIRCULATIONAHA.106.652313; Blaha MJ, 2011, LANCET, V378, P684, DOI 10.1016/S0140-6736(11)60784-8; Burdo TH, 2011, J INFECT DIS, V204, P1227, DOI 10.1093/infdis/jir520; Calmy A, 2009, AIDS, V23, P929, DOI 10.1097/QAD.0b013e32832995fa; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Einstein AJ, 2010, J AM COLL CARDIOL, V56, P1914, DOI 10.1016/j.jacc.2010.05.057; Fabriek BO, 2005, IMMUNOBIOLOGY, V210, P153, DOI 10.1016/j.imbio.2005.05.010; Fayad ZA, 2011, LANCET, V378, P1547, DOI 10.1016/S0140-6736(11)61383-4; Figueroa A, 2011, AM HEART ASS SCI SES; Fitch KV, 2010, JAIDS-J ACQ IMM DEF, V55, P495, DOI 10.1097/QAI.0b013e3181edab0b; Garedew A, 2010, CELL DEATH DIFFER, V17, P1540, DOI 10.1038/cdd.2010.27; Graebe M, 2009, EUR J VASC ENDOVASC, V37, P714, DOI 10.1016/j.ejvs.2008.11.018; KUBOTA R, 1994, J NUCL MED, V35, P104; Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203; Moreno JA, 2009, ATHEROSCLEROSIS, V207, P103, DOI 10.1016/j.atherosclerosis.2009.04.033; Paulmier B, 2008, J NUCL CARDIOL, V15, P209, DOI 10.1016/j.nuclcard.2007.10.009; Pedersen SF, 2010, NUCL MED COMMUN, V31, P423, DOI 10.1097/MNM.0b013e32833767e0; Rasmussen LD, 2011, AIDS, V25, P1637, DOI 10.1097/QAD.0b013e3283493fb0; Ratcliffe NR, 2001, IMMUNOL LETT, V77, P169, DOI 10.1016/S0165-2478(01)00217-6; Rogers IS, 2010, JACC-CARDIOVASC IMAG, V3, P388, DOI 10.1016/j.jcmg.2010.01.004; Rominger A, 2009, J NUCL MED, V50, P1611, DOI 10.2967/jnumed.109.065151; Rudd JHF, 2007, J AM COLL CARDIOL, V50, P892, DOI 10.1016/j.jacc.2007.05.024; Rudd JHF, 2002, CIRCULATION, V105, P2708, DOI 10.1161/01.CIR.0000020548.60110.76; Tawakol A, 2006, J AM COLL CARDIOL, V48, P1818, DOI 10.1016/j.jacc.2006.05.076; Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190; Yearley JH, 2007, AIDS RES HUM RETROV, V23, P515, DOI 10.1089/aid.2006.0211	28	341	344	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					379	386		10.1001/jama.2012.6698	http://dx.doi.org/10.1001/jama.2012.6698			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820791	Green Accepted, Bronze			2022-12-28	WOS:000306685500026
J	Bernstein, R				Bernstein, Rachel			Science for Sale: Academic Meets Industry	CELL			English	Editorial Material																			0	2	2	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 20	2012	150	2					239	240		10.1016/j.cell.2012.07.002	http://dx.doi.org/10.1016/j.cell.2012.07.002			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817884	Bronze			2022-12-28	WOS:000306595700001
J	Lynch, S; Ford, N; van Cutsem, G; Bygrave, H; Janssens, B; Decroo, T; Andrieux-Meyer, I; Roberts, T; Balkan, S; Casas, E; Ferreyra, C; Bemelmans, M; Cohn, J; Kahn, P; Goemaere, E				Lynch, Sharonann; Ford, Nathan; van Cutsem, Gilles; Bygrave, Helen; Janssens, Bart; Decroo, Tom; Andrieux-Meyer, Isabelle; Roberts, Teri; Balkan, Suna; Casas, Esther; Ferreyra, Cecilia; Bemelmans, Marielle; Cohn, Jen; Kahn, Patricia; Goemaere, Eric			Getting HIV Treatment to the Most People	SCIENCE			English	Editorial Material							ANTIRETROVIRAL THERAPY; AFRICA; RESISTANCE; HIV/AIDS; DRIVEN		[Kahn, Patricia] MSF Access Campaign, New York, NY 10001 USA; [Lynch, Sharonann] MSF Access Campaign, New York, NY 10001 USA; [Ford, Nathan] MSF, London EC1N 8QX, England; [van Cutsem, Gilles] MSF, ZA-1100 Cape Town, South Africa; [Bygrave, Helen; Goemaere, Eric] MSF, S Africa Med Unit, ZA-2017 Johannesburg, South Africa; [Janssens, Bart; Bemelmans, Marielle] MSF, B-1090 Brussels, Belgium; [Decroo, Tom] MSF, Tete, Mozambique; [Andrieux-Meyer, Isabelle; Roberts, Teri] MSF Access Campaign, CH-1211 Geneva 21, Switzerland; [Balkan, Suna] MSF, F-75011 Paris, France; [Casas, Esther] MSF, NL-1018 DD Amsterdam, Netherlands; [Ferreyra, Cecilia] MSF, Barcelona 08001, Spain; [Cohn, Jen] MSF Access Campaign, Nairobi 00200, Kenya	Doctors Without Borders; Doctors Without Borders; Doctors Without Borders; Doctors Without Borders; Doctors Without Borders; Doctors Without Borders; Doctors Without Borders; Doctors Without Borders; Doctors Without Borders; Doctors Without Borders; Doctors Without Borders; Doctors Without Borders	Kahn, P (corresponding author), MSF Access Campaign, New York, NY 10001 USA.	patricia.kahn@newyork.msf.org	Decroo, Tom/AAV-7208-2020; Van Cutsem, Gilles/ABB-1171-2021; Kahn, Patricia/AAC-3361-2020	Decroo, Tom/0000-0002-1205-1484; Van Cutsem, Gilles/0000-0002-8972-4480; Kahn, Patricia/0000-0002-3491-2839	M�decins Sans Fronti�res [OCA_pilot_00_Bygrave] Funding Source: researchfish	M�decins Sans Fronti�res		[Anonymous], 2012, UN GEN ASS 66 SESS 2; Bermudez Jorge, 2010, Open AIDS J, V4, P37, DOI 10.2174/1874613601004020037; Bygrave H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013198; Calmy A, 2007, CLIN INFECT DIS, V44, P128, DOI 10.1086/510073; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cohen R, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-23; Decroo T, 2011, JAIDS-J ACQ IMM DEF, V56, pE39, DOI 10.1097/QAI.0b013e3182055138; Fatti G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012888; Hamers R. L., 2012, AIDS, P1; Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9; Keiser O, 2011, AIDS, V25, P1761, DOI 10.1097/QAD.0b013e328349822f; Kuwenyi K., 6 IAS C HIV PATH TRE; Matambo T., 2012, MSF UK SCI DAY 25 MA; Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438; MSF, 2010, NO TIM QUIT HIV AIDS; Mugyenyi P, 2010, LANCET, V375, P123, DOI 10.1016/S0140-6736(09)62067-5; MURTAGH M, 2012, HIV AIDS DIAGNOSTIC; Rosen S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001056; Sanne I, 2010, LANCET, V376, P33, DOI 10.1016/S0140-6736(10)60894-X; Schwartlander B, 2011, LANCET, V377, P2031, DOI 10.1016/S0140-6736(11)60702-2; Sigaloff KCE, 2011, JAIDS-J ACQ IMM DEF, V58, P23, DOI 10.1097/QAI.0b013e318227fc34; van Zyl GU, 2011, CLIN INFECT DIS, V52, P264, DOI 10.1093/cid/ciq084; Ventelou B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034101; WHO/UNICEF, 2011, JOINT POS PAP PROV M, P1; World Health Organization, 2003, SCAL ANT THER RES LI	25	19	19	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 20	2012	337	6092					298	300		10.1126/science.1225702	http://dx.doi.org/10.1126/science.1225702			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	975WQ	22798404				2022-12-28	WOS:000306542600035
J	Brawley, OW				Brawley, Otis W.			Prostate Cancer Screening: What We Know, Don't Know, and Believe	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Brawley, Otis W.] Amer Canc Soc, Atlanta, GA 30329 USA	American Cancer Society	Brawley, OW (corresponding author), 250 Williams St, Atlanta, GA 30303 USA.	otis.brawley@cancer.org						Abrahamsson PA, 2009, EUR UROL, V56, P270, DOI 10.1016/j.eururo.2009.05.024; American Urological Association, 2012, AUA SPEAKS OUT USPST; Carroll P, 2009, PROSTATE SPECIFIC AN; Chou R, 2011, ANN INTERN MED, V155, P762, DOI 10.7326/0003-4819-155-11-201112060-00375; Hoffman RM, 2009, ARCH INTERN MED, V169, P1611, DOI 10.1001/archinternmed.2009.262; Kaswick JA, 2004, UROLOGY, V64, P189, DOI 10.1016/j.urology.2004.02.034; Lin K., 2011, AHRQ PUBLICATION; Moyer VA, 2012, ANN INTERN MED, V157, P120, DOI 10.7326/0003-4819-157-2-201207170-00459; NCCN Clinical Practice Guidelines in Oncology, 2012, NCCN CLIN PRACT GUID; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sinclair U, 1994, I CANDIDATE GOVERNOR, V109; Smith RA, 2011, CA-CANCER J CLIN, V61, P8, DOI 10.3322/caac.20096; Welch HG, 2010, J NATL CANCER I, V102, P605, DOI 10.1093/jnci/djq099	13	19	20	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2					135	+		10.7326/0003-4819-157-2-201207170-00460	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00460			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801675				2022-12-28	WOS:000307787900018
J	Schaefer, M; Sarkar, R; Knop, V; Effenberger, S; Friebe, A; Heinze, L; Spengler, U; Schlaepfer, T; Reimer, J; Buggisch, P; Ockenga, J; Link, R; Rentrop, M; Weidenbach, H; Fromm, G; Lieb, K; Baumert, TF; Heinz, A; Discher, T; Neumann, K; Zeuzem, S; Berg, T				Schaefer, Martin; Sarkar, Rahul; Knop, Viola; Effenberger, Susanne; Friebe, Astrid; Heinze, Loni; Spengler, Ulrich; Schlaepfer, Thomas; Reimer, Jens; Buggisch, Peter; Ockenga, Johann; Link, Ralph; Rentrop, Michael; Weidenbach, Hans; Fromm, Gwendolyn; Lieb, Klaus; Baumert, Thomas F.; Heinz, Andreas; Discher, Thomas; Neumann, Konrad; Zeuzem, Stefan; Berg, Thomas			Escitalopram for the Prevention of Peginterferon-alpha 2a-Associated Depression in Hepatitis C Virus-Infected Patients Without Previous Psychiatric Disease A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							INTERFERON-INDUCED DEPRESSION; PLACEBO-CONTROLLED TRIAL; GENOTYPE 1 INFECTION; DOUBLE-BLIND; MAJOR DEPRESSION; HCV INFECTION; ALPHA THERAPY; DSM-IV; RIBAVIRIN; RISK	Background: Depression is a major complication during treatment of chronic hepatitis C virus (HCV) infection with interferon-alpha (IFN-alpha). It is unclear whether antidepressants can prevent IFN-induced depression in patients without psychiatric risk factors. Objective: To examine whether preemptive antidepressant treatment with escitalopram can decrease the incidence or severity of depression associated with pegylated IFN-alpha in HCV-infected patients without a history of psychiatric disorders. Design: Randomized, multicenter, double-blind, prospective, placebo-controlled, parallel-group trial. (ClinicalTrials.gov registration number: NCT00136318) Setting: 10 university and 11 academic hospitals in Germany. Patients: 181 HCV-infected patients with no history of psychiatric disorders enrolled between August 2004 and December 2008. Intervention: Escitalopram, 10 mg/d (n = 90), or placebo (n = 91) administered 2 weeks before and for 24 to 48 weeks during antiviral therapy. Measurements: The primary end point was the incidence of depression, defined as a Montgomery-Asberg Depression Rating Scale (MADRS) score of 13 or higher. Secondary end points were time to depression, incidence of major depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, quality of life, sustained virologic response, tolerability, and safety. Results: 32% (95% CI, 21% to 43%) of the patients in the escitalopram group developed a MADRS score of 13 or higher compared with 59% (CI, 48% to 69%) in the placebo group (absolute difference, 27 percentage points [CI, 12 to 42 percentage points]; P < 0.001). Major depression was diagnosed in 8% of the patients in the escitalopram group and 19% in the placebo group (absolute risk difference, 11 percentage points [CI, 5 to 15 percentage points]; P = 0.031). Tolerability and safety parameters did not differ between the groups. In the escitalopram group, 56% (CI, 46% to 66%) of patients achieved a sustained virologic response compared with 46% (CI, 37% to 57%) in the placebo group (P = 0.21). Limitations: Results might not be generalizable to patients with previous psychiatric disease. Some patients withdrew or developed temporary elevated MADRS scores after randomization but before the study medication was started. Conclusion: Prophylactic antidepressant treatment with escitalopram was effective in reducing the incidence and severity of IFN-associated depression in HCV-infected patients without previous psychiatric disease.	[Schaefer, Martin] Kliniken Essen Mitte, Dept Psychiat Psychotherapy & Addict Med, D-45136 Essen, Germany; Charite, Campus Charite Mitte, D-13353 Berlin, Germany; Asklepios Westklinikum Hamburg, Hamburg, Germany; Univ Med Berlin, Charite, Campus Virchow Klinikum, Berlin, Germany; Goethe Univ Frankfurt, Med Klin 1, Frankfurt, Germany; Ruhr Univ Bochum, LWL Klin, Bochum, Germany; Univ Klinikum Bonn, Bonn, Germany; Univ Hamburg, Ctr Interdisciplinary Addict Res, Hamburg, Germany; Asklepios Clin, Inst Interdisciplinary Med, Hamburg, Germany; St Josephsklin, Offenburg, Germany; Klinikum Bremen Mitte, Med Klin 2, Bremen, Germany; Tech Univ Munich, Munich, Germany; Klinikum Mittelbaden, Baden Baden, Germany; Univ Giessen Klinikum, Marburg, Germany; Univ Med Mainz, Mainz, Germany; Med Univ Klin Freiburg, Freiburg, Germany; Charite, Inst Biometry & Clin Epidemiol, D-13353 Berlin, Germany; Univ Klinikum Leipzig, Clin & Policlin Gastroenterol & Rheumatol, Sect Hepatol, Leipzig, Germany	Kliniken Essen-Mitte; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Goethe University Frankfurt; Ruhr University Bochum; University of Bonn; University of Hamburg; Klinikum Bremen-Mitte; University of Hamburg; University Medical Center Hamburg-Eppendorf; Technical University of Munich; University Hospital of Giessen & Marburg; Johannes Gutenberg University of Mainz; University of Freiburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Leipzig University	Schaefer, M (corresponding author), Kliniken Essen Mitte, Dept Psychiat Psychotherapy & Addict Med, Henricistr 92, D-45136 Essen, Germany.	m.schaefer@kliniken-essen-mitte.de	Baumert, Thomas/ABF-4718-2020; Heinz, Andreas/ABB-7736-2020; Zeuzem, Stefan/AAE-7435-2019	Baumert, Thomas/0000-0002-8864-2168; Heinz, Andreas/0000-0001-5405-9065; Schlaepfer, Thomas/0000-0003-0612-9692; Berg, Thomas/0000-0003-0003-6241	Roche Pharma, Grenzach-Whylen, Germany; Lundbeck, Hamburg, Germany; German Network of Competence on Viral Hepatitis; Roche Pharma; Lundbeck	Roche Pharma, Grenzach-Whylen, Germany; Lundbeck, Hamburg, Germany; German Network of Competence on Viral Hepatitis; Roche Pharma; Lundbeck(Lundbeck Corporation)	The trial was supported in part by Roche Pharma, Grenzach-Whylen, Germany; Lundbeck, Hamburg, Germany (placebo medication and financial support); and the German Network of Competence on Viral Hepatitis.; Primary Funding Source: Roche Pharma and Lundbeck.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Bacon BR, 2011, NEW ENGL J MED, V364, P1207, DOI 10.1056/NEJMoa1009482; Capuron L, 2002, NEUROPSYCHOPHARMACOL, V26, P643, DOI 10.1016/S0893-133X(01)00407-9; Capuron L, 2011, PHARMACOL THERAPEUT, V130, P226, DOI 10.1016/j.pharmthera.2011.01.014; de Knegt RJ, 2011, ALIMENT PHARM THER, V34, P1306, DOI 10.1111/j.1365-2036.2011.04867.x; Diez-Quevedo C, 2011, J CLIN PSYCHIAT, V72, P522, DOI 10.4088/JCP.09m05282blu; First M.B., 2014, STRUCTURED CLIN INTE; Gleason OC, 2007, DIGEST DIS SCI, V52, P2557, DOI 10.1007/s10620-006-9729-5; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Kraus MR, 2008, GUT, V57, P531, DOI 10.1136/gut.2007.131607; Kraus MR, 2005, J VIRAL HEPATITIS, V12, P96, DOI 10.1111/j.1365-2893.2005.00554.x; Leutscher PDC, 2010, HEPATOLOGY, V52, P430, DOI 10.1002/hep.23699; Lux V, 2010, PSYCHOL MED, V40, P1691, DOI 10.1017/S0033291709992066; Mann JJ, 2005, NEW ENGL J MED, V353, P1819, DOI 10.1056/NEJMra050730; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Morasco BJ, 2010, PSYCHOSOMATICS, V51, P401, DOI 10.1176/appi.psy.51.5.401; Muller MJ, 2003, J AFFECT DISORDERS, V77, P255, DOI 10.1016/S0165-0327(02)00120-9; Nelson DR, 2011, LIVER INT, V31, P53, DOI 10.1111/j.1478-3231.2010.02391.x; Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494; Raison CL, 2007, ALIMENT PHARM THER, V25, P1163, DOI 10.1111/j.1365-2036.2007.03316.x; Raison CL, 2005, J CLIN PSYCHIAT, V66, P41, DOI 10.4088/JCP.v66n0106; Reichenberg A, 2005, AIDS, V19, pS174, DOI 10.1097/01.aids.0000192087.64432.ae; Schafer A, 2007, INT J METH PSYCH RES, V16, P186, DOI 10.1002/mpr.229; Schaefer M, 2005, J HEPATOL, V42, P793, DOI 10.1016/j.jhep.2005.01.020; Schaefer M, 2003, HEPATOLOGY, V37, P443, DOI 10.1053/jhep.2003.50031; Schaefer M, 2002, PROG NEURO-PSYCHOPH, V26, P731, DOI 10.1016/S0278-5846(01)00324-4; Schaefer M, 2007, HEPATOLOGY, V46, P991, DOI 10.1002/hep.21791; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sockalingam S, 2011, J VIRAL HEPATITIS, V18, P153, DOI 10.1111/j.1365-2893.2010.01393.x; Sockalingam S, 2010, J CLIN GASTROENTEROL, V44, P38, DOI 10.1097/MCG.0b013e3181b314ea; Ware J., 2001, SF 36 PHYS MENTAL HL, P1994; Younossi Z, 2007, HEPATOLOGY, V45, P806, DOI 10.1002/hep.21565; Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086; Zimmerman M, 2004, INT CLIN PSYCHOPHARM, V19, P215, DOI 10.1097/01.yic.0000130232.57629.46	34	56	60	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2					94	+		10.7326/0003-4819-157-2-201207170-00006	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801672				2022-12-28	WOS:000307787900015
J	Cottingham, J; Germain, A; Hunt, P				Cottingham, Jane; Germain, Adrienne; Hunt, Paul			Use of human rights to meet the unmet need for family planning	LANCET			English	Article							QUALITY-OF-CARE; HIV; INTERVENTIONS; HEALTH	In this report, we describe how human rights can help to shape laws, policies, programmes, and projects in relation to contraceptive information and services. Applying a human rights perspective and recognising the International Conference on Population and Development and Millennium Development Goal commitments to universal access to reproductive health including family planning, we support measurement of unmet need for family planning that encompasses more groups than has been the case until recently. We outline how human rights can be used to identify, reduce, and eliminate barriers to accessing contraception; the ways in which human rights can enhance laws and policies; and governments' legal obligations in relation to contraceptive information and services. We underline the crucial importance of accountability of states and identify some of the priorities for making family planning available that are mandated by human rights.	[Germain, Adrienne] Int Womens Hlth Coalit, New York, NY USA; [Hunt, Paul] Univ Essex, Dept Law, Human Rights Ctr, Colchester CO4 3SQ, Essex, England	University of Essex	Cottingham, J (corresponding author), 2 Rue Jacques Grosselin, CH-1227 Geneva, Switzerland.	cottinghamjc@gmail.com						African Union, 2006, MAP PLAN ACT OP CONT; Alves JED, 2009, DEMOGRAPHIC TRANSFOR, P297; [Anonymous], 2010, UN SPEC RAPP RIGHT S; [Anonymous], 2004, ECN4200449 UN; [Anonymous], 2010, DAILY INDEPENDE 1124; [Anonymous], 2011, WHO MOD LIST ESS MED; [Anonymous], 2009, IRIN PLUSNEWS   0625; Arends-Kuenning M, 2007, J BIOSOC SCI, V39, P1, DOI 10.1017/S0021932005001045; Backman G, 2008, LANCET, V372, P2047, DOI 10.1016/S0140-6736(08)61781-X; Bland A, 2010, INDEPENDENT LON 0417; BRUCE J, 1990, STUD FAMILY PLANN, V21, P61, DOI 10.2307/1966669; Center for Reproductive Rights, RE ACC EM CONTR COL; Center for Reproductive Rights, 2010, DEGN DEN VIOL RIGHTS; Center for Reproductive Rights Federation of Women Lawyers-Kenya (FIDA), 2007, FAIL DEL VIOL WOM HU; Center for Reproductive Rights UNFPA, 2010, BRIEF PAP RIGHT CONT; Cottingham J, 2010, B WORLD HEALTH ORGAN, V88, P551, DOI 10.2471/BLT.09.063412; Curtis S, 2011, INT PERSPECT SEX R H, V37, P58, DOI 10.1363/3705811; Dhanraj Deepa, 1991, SOMETHING WAR; EnGendeRights, 2009, ADV REPR RIGHTS US I; Gathura G, 2009, DAILY NATION    0927; Greenhalgh S, 2009, GOVERNING CHINAS POP; Grover A, 2011, A66254 UN; Guttmacher Institute IPPF, 2010, FACTS SEX REPR HLTH; Hunt P, 2010, AHRC140ADD2 UN; IPPF, 2003, CHART SEX REPR RIGHT; Kirby D, 2002, J SEX RES, V39, P27, DOI 10.1080/00224490209552116; Koenig M. A., 2003, IMPACT QUALITY CARE; Lazarus JV, 2010, CROAT MED J, V51, P74, DOI 10.3325/cmj.2010.51.74; Lichuma W, 2010, ROLE NATL HUMAN RIGH; Maria Mamerita Mestanza Chavez Peru, 2003, INTERAMERICAN COMMIS; Michielsen K, 2010, AIDS, V24, P1193, DOI 10.1097/QAD.0b013e3283384791; Ministers of Health and Education in Latin America and the Caribbean, 2008, 1 M MIN HLTH ED STOP; Munoz V, 2010, A65162 UN; Oringanje C, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005215.pub2; PATH WHO UNFPA, 2006, INT LIST ESS MED REP; Paulina del Carmen Ramirez Jacinto Mexico, 2007, 2107 PAUL CARM RAM J; Potts H, 2008, ACCOUNTABILITY RIGHT; RamaRao S, 2003, INT FAM PLAN PERSPEC, V29, P76, DOI 10.2307/3181061; Robin L, 2004, J ADOLESCENT HEALTH, V34, P3, DOI 10.1016/S1054-139X(03)00244-1; Sanogo Diouratie, 2003, Afr J Reprod Health, V7, P57, DOI 10.2307/3583214; Santelli J, 2006, J ADOLESCENT HEALTH, V38, P83, DOI 10.1016/j.jadohealth.2005.06.002; Santelli J, 2012, CURRENT ISSUES CONTR; Schmidt B, 1998, POLITICAL ENV; Serour GI, 2006, INT J GYNECOL OBSTET, V92, P333, DOI 10.1016/j.ijgo.2005.12.020; Silva-de-Alwis R, 2008, CHILD MARR LAW; Singh S, 2009, ADDING IT COSTS BENE; UN, 2000, GEN COMM 14 RIGHT HI; UN, 1989, CONV RIGHTS CHILD; UN Commission on Information and Accountability for Women's and Children's Health, 2011, KEEP PROM MEAS RES; UN Committee on Economic, 2000, GEN COMM 14 RIGHT HI; UN Committee on Economic Social and Cultural Rights (CESCR), 1990, GEN COMM 3 NAT STAT; UN Committee on the Elimination of Discrimination against Women, 2007, CEDAWCSCGCO1 UN, P33; UN Committee on the Elimination of Discrimination against Women, 2007, CEDAWCSURCO3 UN, P31; UN Committee on the Elimination of Discrimination against Women, 2008, CEDAWCMMRCO3 UN; UN Committee on the Elimination of Discrimination against Women, 2006, CEDAWCMKDCO3 UN; UN Committee on the Elimination of Discrimination against Women, 2007, CEDAWCAZECO3 UN, P25; UN Committee on the Elimination of Discrimination against Women, 1999, GEN REC 24 WOM HLTH; UN Committee on the Elimination of Discrimination against Women, 2007, CEDAWCKAZCO2 UN, P25; UN Committee on the Elimination of Discrimination against Women, 1994, GEN REC 21 EQ MARR F; UN Committee on the Elimination of Discrimination against Women, 2006, CEDAWCCHICO4 UN, P19; UN Committee on the Elimination of Discrimination against Women, 2008, CEDAWCSVNCO4 UN, P35; UN Committee on the Rights of the Child, 2003, CRCGC20034 U COMM RI; UN Committee on the Rights of the Child, 2003, CRCGC20031 UN COMM R, P15; UN Office of the High Commissioner for Human Rights, 2004, HUM RIGHT POV RED CO, P22; UN Office of the High Commissioner for Human Rights, 2006, PRINC GUID HUM RIGHT; UN Office of the High Commissioner for Human Rights and WHO, 2008, HUM RIGHT POV RED ST; UNESCO, 2009, ED2009WS36 UNESCO; United Nations, 1966, INT CONV EC SOC CULT; United Nations Population Fund, 1994, PROGR ACT AD INT C P; United Nations (UN), 1979, CONV EL ALL FORMS DI; Westeson J, 2010, SEXUAL HLTH HUMAN RI; WHO, 2010, WOR HEALT REP, P1; WHO, 2002, MAK DEC CONTR INTR G; WHO, 2011, UN ACC REPR HLTH ACC; WHO, 2008, EL FEM GEN MUT INT; World Health Organization, 2008, WHY IS GIV SPEC ATT; World Health Organization, 2003, SAF AB TECHN POL GUI	77	38	38	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2012	380	9837					172	180		10.1016/S0140-6736(12)60732-6	http://dx.doi.org/10.1016/S0140-6736(12)60732-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784536				2022-12-28	WOS:000306359100045
J	Chatterton, H; Younger, T; Fischer, A; Khunti, K				Chatterton, Hilary; Younger, Tricia; Fischer, Alastair; Khunti, Kamlesh		Programme Dev Grp	Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Younger, Tricia; Fischer, Alastair] Natl Inst Hlth & Clin Excellence, London WC1V 6NA, England; [Chatterton, Hilary] Natl Inst Hlth & Clin Excellence, Manchester, Lancs, England; [Khunti, Kamlesh] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England	National Institute for Health & Care Excellence; National Institute for Health & Care Excellence; University of Leicester	Younger, T (corresponding author), Natl Inst Hlth & Clin Excellence, London WC1V 6NA, England.	tricia.younger@nice.org.uk	/ABC-9527-2021	Khunti, Kamlesh/0000-0003-2343-7099	Department of Health [PDA/02/06/031] Funding Source: Medline; National Institute for Health Research [PDA/02/06/031] Funding Source: researchfish	Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR))		[Anonymous], 2009, METH DEV NICE PUBL H; Department of Health, 2009, PUTT PREV 1 NHS HLTH; Diabetes UK, 2012, DIAB UK 2012 KEY STA; John WG, 2012, USE HAEMOGLOBIN A1C; *NAT I HLTH CLIN E, 2008, CG66 NAT I HLTH CLIN; National Institute for Health and Clinical Excellence, 2003, TA60 NAT I HLTH CLIN; National Institute for Health and Clinical Excellence, 2009, CG87 NAT I HLTH CLIN; National Institute for Health and Clinical Excellence, 2011, PHG35 NAT I HLTH CLI; National Institute for Health and Clinical Excellence, 2006, CG43 NAT I HLTH CLIN; National Institute for Health and Clinical Excellence, 2009, NICE PUBL HLTH GUID; National Institute for Health and Clinical Excellence, 2012, PHG38 NAT I HLTH CLI, V38; Santaguida PL, 2005, EVIDENCE REPORTS TEC; Webb DR, 2011, DIABETES RES CLIN PR, V91, P280, DOI 10.1016/j.diabres.2010.11.021; World Health Organization, 2006, DEF DIAGN DIAB MELL; World Health Organization, 2011, US GLYC HAEM HBA1C D	15	68	68	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 12	2012	345								e4624	10.1136/bmj.e4624	http://dx.doi.org/10.1136/bmj.e4624			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NW	22791792				2022-12-28	WOS:000306519000004
J	Drife, JO				Drife, James Owen			A golden age	BRITISH MEDICAL JOURNAL			English	Editorial Material												J.O.Drife@leeds.ac.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 11	2012	345								e4620	10.1136/bmj.e4620	http://dx.doi.org/10.1136/bmj.e4620			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NU	22786937				2022-12-28	WOS:000306518800005
J	Hofmann, J; Krug, M; Ortegel, N; Gerard, L; Weber, M; Rosenfeld, W; Weinfurter, H				Hofmann, Julian; Krug, Michael; Ortegel, Norbert; Gerard, Lea; Weber, Markus; Rosenfeld, Wenjamin; Weinfurter, Harald			Heralded Entanglement Between Widely Separated Atoms	SCIENCE			English	Article							QUANTUM COMMUNICATION; INTERFERENCE; PHOTONS	Entanglement is the essential feature of quantum mechanics. Notably, observers of two or more entangled particles will find correlations in their measurement results that cannot be explained by classical statistics. To make it a useful resource, particularly for scalable long-distance quantum communication, the heralded generation of entanglement between distant massive quantum systems is necessary. We report on the creation and analysis of heralded entanglement between spins of two single rubidium-87 atoms trapped independently 20 meters apart. Our results illustrate the viability of an integral resource for quantum information science, as well as for fundamental tests of quantum mechanics.	[Hofmann, Julian; Krug, Michael; Ortegel, Norbert; Gerard, Lea; Weber, Markus; Rosenfeld, Wenjamin; Weinfurter, Harald] Univ Munich, Fak Phys, D-80799 Munich, Germany; [Rosenfeld, Wenjamin; Weinfurter, Harald] Max Planck Inst Quantum Opt, D-85748 Garching, Germany	University of Munich; Max Planck Society	Weber, M (corresponding author), Univ Munich, Fak Phys, D-80799 Munich, Germany.	markusweber@lmu.de; w.r@lmu.de	Weinfurter, Harald/F-8225-2015	Weinfurter, Harald/0000-0001-6882-3909; Rosenfeld, Wenjamin/0000-0002-2525-4467	European Union Project Q-Essence; Bundesministerium fur Bildung und Forschung Project QuORep; Elite Network of Bavaria through the excellence program Quantum Computing, Control and Communication	European Union Project Q-Essence; Bundesministerium fur Bildung und Forschung Project QuORep; Elite Network of Bavaria through the excellence program Quantum Computing, Control and Communication	We thank A. Deeg, C. Jakob, and C. Kurtsiefer for help during the early stages of the experiment. This work was supported by the European Union Project Q-Essence and the Bundesministerium fur Bildung und Forschung Project QuORep. J. H. acknowledges support by Elite Network of Bavaria through the excellence program Quantum Computing, Control and Communication.	Acin A, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.230501; BRAUNSTEIN SL, 1995, PHYS REV A, V51, pR1727, DOI 10.1103/PhysRevA.51.R1727; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Chou CW, 2007, SCIENCE, V316, P1316, DOI 10.1126/science.1140300; CLAUSER JF, 1978, REP PROG PHYS, V41, P1881, DOI 10.1088/0034-4885/41/12/002; Henkel F, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.253001; HONG CK, 1987, PHYS REV LETT, V59, P2044, DOI 10.1103/PhysRevLett.59.2044; Isenhower L, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.010503; Julsgaard B, 2001, NATURE, V413, P400, DOI 10.1038/35096524; Kuhr S, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.213002; Lee KC, 2011, SCIENCE, V334, P1253, DOI 10.1126/science.1211914; Matsukevich DN, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.150404; Matsukevich DN, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.030405; Mattle K, 1996, PHYS REV LETT, V76, P4656, DOI 10.1103/PhysRevLett.76.4656; Moehring DL, 2007, NATURE, V449, P68, DOI 10.1038/nature06118; Ritter S, 2012, NATURE, V484, P195, DOI 10.1038/nature11023; Rosenfeld W, 2011, OPT SPECTROSC+, V111, P535, DOI 10.1134/S0030400X11110233; Rosenfeld W, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.260403; Rosenfeld W, 2011, PHYS REV A, V84, DOI 10.1103/PhysRevA.84.022343; Rosenfeld W, 2009, ADV SCI LETT, V2, P469, DOI 10.1166/asl.2009.1059; Schlosser N, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.023005; Schrader D, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.150501; Simon C, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.110405; Specht HP, 2011, NATURE, V473, P190, DOI 10.1038/nature09997; vanEnk SJ, 1997, PHYS REV LETT, V78, P4293, DOI 10.1103/PhysRevLett.78.4293; Vewinger F, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.213001; Volz J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.030404; Weber M, 2006, PHYS REV A, V73, DOI 10.1103/PhysRevA.73.043406; WEINFURTER H, 1994, EUROPHYS LETT, V25, P559, DOI 10.1209/0295-5075/25/8/001; Wilk T, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.010502; Yuan ZS, 2008, NATURE, V454, P1098, DOI 10.1038/nature07241; ZUKOWSKI M, 1993, PHYS REV LETT, V71, P4287, DOI 10.1103/PhysRevLett.71.4287	33	284	286	4	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2012	337	6090					72	75		10.1126/science.1221856	http://dx.doi.org/10.1126/science.1221856			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767924				2022-12-28	WOS:000306053100045
J	Inuzuka, H; Gao, DM; Finley, LWS; Yang, W; Wan, LX; Fukushima, H; Chin, YR; Zhai, B; Shaik, S; Lau, AW; Wang, ZW; Gygi, SP; Nakayama, K; Teruya-Feldstein, J; Toker, A; Haigis, MC; Pandolfi, PP; Wei, WY				Inuzuka, Hiroyuki; Gao, Daming; Finley, Lydia W. S.; Yang, Wen; Wan, Lixin; Fukushima, Hidefumi; Chin, Y. Rebecca; Zhai, Bo; Shaik, Shavali; Lau, Alan W.; Wang, Zhiwei; Gygi, Steven P.; Nakayama, Keiko; Teruya-Feldstein, Julie; Toker, Alex; Haigis, Marcia C.; Pandolfi, Pier Paolo; Wei, Wenyi			Acetylation-Dependent Regulation of Skp2 Function	CELL			English	Article							CELL-CYCLE PROGRESSION; HUMAN BREAST-CANCER; BOX PROTEINS SKP2; UBIQUITIN LIGASE; E-CADHERIN; CYTOPLASMIC LOCALIZATION; FORKHEAD TRANSCRIPTION; HISTONE H3; INHIBITOR P27(KIP1); PROSTATE-CANCER	Aberrant Skp2 signaling has been implicated as a driving event in tumorigenesis. Although the underlying molecular mechanisms remain elusive, cytoplasmic Skp2 correlates with more aggressive forms of breast and prostate cancers. Here, we report that Skp2 is acetylated by p300 at K68 and K71, which is a process that can be antagonized by the SIRT3 deacetylase. Inactivation of SIRT3 leads to elevated Skp2 acetylation, which leads to increased Skp2 stability through impairment of the Cdh1-mediated proteolysis pathway. As a result, Skp2 oncogenic function is increased, whereby cells expressing an acetylation-mimetic mutant display enhanced cellular proliferation and tumorigenesis in vivo. Moreover, acetylation of Skp2 in the nuclear localization signal (NLS) promotes its cytoplasmic retention, and cytoplasmic Skp2 enhances cellular migration through ubiquitination and destruction of E-cadherin. Thus, our study identifies an acetylation-dependent regulatory mechanism governing Skp2 oncogenic function and provides insight into how cytoplasmic Skp2 controls cellular migration.	[Inuzuka, Hiroyuki; Gao, Daming; Wan, Lixin; Fukushima, Hidefumi; Chin, Y. Rebecca; Shaik, Shavali; Lau, Alan W.; Wang, Zhiwei; Toker, Alex; Pandolfi, Pier Paolo; Wei, Wenyi] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; [Finley, Lydia W. S.; Yang, Wen; Zhai, Bo; Gygi, Steven P.; Haigis, Marcia C.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; [Finley, Lydia W. S.; Yang, Wen; Haigis, Marcia C.] Harvard Univ, Sch Med, Paul F Glenn Labs Biol Mech Aging, Boston, MA 02215 USA; [Pandolfi, Pier Paolo] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Nakayama, Keiko] Tohoku Univ, Grad Sch Med, Div Dev Genet, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Teruya-Feldstein, Julie] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10065 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Tohoku University; Memorial Sloan Kettering Cancer Center	Wei, WY (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.	wwei2@bidmc.harvard.edu	Wan, Lixin/F-2124-2011; 高, 雨莉/HGU-8187-2022	CHIN, Yuet Ming Rebecca/0000-0001-8976-3466; Gao, Daming/0000-0003-4374-1055; Pandolfi, Pier Paolo/0000-0002-5352-5295; Wang, Zhiwei/0000-0002-6465-7779	Susan G. Komen Breast Cancer Foundation [0706963]; Department of Defense [PC080377]; National Institutes of Health [GM089763, GM094777, CA122099, AG041218]; NATIONAL CANCER INSTITUTE [R01CA122099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM094777, R01GM089763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG041218] Funding Source: NIH RePORTER	Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Lewis Cantley, Pengda Liu, and Qing Zhang for critical reading of the manuscript; Christoph Geisen, Yasuyujki Fujita, and Hui-Kuan Lin for providing reagents; and members of the Wei, Haigis, Pandolfi, and Toker labs for useful discussions. W.W. is an MLSC New Investigator and an American Cancer Society Research Scholar (W.W., RSG-12-096). This work was supported in part by the Susan G. Komen Breast Cancer Foundation (Y.R.C., 0706963), the Department of Defense Prostate Cancer Research Program (W.W., PC080377), and by grants from the National Institutes of Health (W.W., GM089763, GM094777; A.T., CA122099; H.I., AG041218).	Agarwal A, 2008, BLOOD, V112, P1960, DOI 10.1182/blood-2007-09-113860; Balasubramanyam K, 2004, J BIOL CHEM, V279, P33716, DOI 10.1074/jbc.M402839200; Bao JJ, 2010, J CELL BIOCHEM, V110, P238, DOI 10.1002/jcb.22531; Barbash O, 2008, CANCER CELL, V14, P68, DOI 10.1016/j.ccr.2008.05.017; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bell EL, 2011, ONCOGENE, V30, P2986, DOI 10.1038/onc.2011.37; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cooper HM, 2008, BIOCHEM J, V411, P279, DOI 10.1042/BJ20071624; di Bari MG, 2006, EMBO REP, V7, P727, DOI 10.1038/sj.embor.7400700; Dietschy T, 2009, J CELL SCI, V122, P1258, DOI 10.1242/jcs.037747; Dowen SE, 2003, INT J CANCER, V105, P326, DOI 10.1002/ijc.11066; Drobnjak M, 2003, CLIN CANCER RES, V9, P2613; Dupre-Crochet S, 2007, MOL CELL BIOL, V27, P3804, DOI 10.1128/MCB.01590-06; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Giehl K, 2008, FRONT BIOSCI-LANDMRK, V13, P3975, DOI 10.2741/2985; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005; Jing EX, 2011, P NATL ACAD SCI USA, V108, P14608, DOI 10.1073/pnas.1111308108; Karanam B, 2007, BIOCHEMISTRY-US, V46, P8207, DOI 10.1021/bi7000054; Kemper JK, 2009, CELL METAB, V10, P392, DOI 10.1016/j.cmet.2009.09.009; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kitagawa M, 2008, MOL CELL, V29, P217, DOI 10.1016/j.molcel.2007.11.036; Li JQ, 2004, INT J ONCOL, V25, P87; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lim MS, 2002, BLOOD, V100, P2950, DOI 10.1182/blood.V100.8.2950; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Perrot V, 2005, MOL ENDOCRINOL, V19, P2283, DOI 10.1210/me.2004-0292; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; Radke S, 2005, ONCOGENE, V24, P3448, DOI 10.1038/sj.onc.1208328; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Shim EH, 2003, CANCER RES, V63, P1583; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Sun LC, 2007, ACTA BIOCH BIOPH SIN, V39, P999, DOI 10.1111/j.1745-7270.2007.00361.x; Tang X, 2007, CELL, V129, P1165, DOI 10.1016/j.cell.2007.04.042; Tang XL, 2007, CELL, V131, P93, DOI 10.1016/j.cell.2007.07.034; Traub F, 2006, BREAST CANCER RES TR, V99, P185, DOI 10.1007/s10549-006-9202-3; Turnell AS, 2005, NATURE, V438, P690, DOI 10.1038/nature04151; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-7; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Yang YJ, 2011, GENE, V488, P46, DOI 10.1016/j.gene.2011.07.029; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang H, 2010, CELL CYCLE, V9, P868; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	69	153	162	4	53	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 6	2012	150	1					179	193		10.1016/j.cell.2012.05.038	http://dx.doi.org/10.1016/j.cell.2012.05.038			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770219	Green Accepted, Bronze			2022-12-28	WOS:000306115000016
J	O'Grady, NP; Murray, PR; Ames, N				O'Grady, Naomi P.; Murray, Patrick R.; Ames, Nancy			Preventing Ventilator-Associated Pneumonia Does the Evidence Support the Practice?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; SUBGLOTTIC SECRETIONS; CONTINUOUS ASPIRATION; ENDOTRACHEAL-TUBE; SELECTIVE DECONTAMINATION; BACTERIAL-COLONIZATION; NOSOCOMIAL PNEUMONIA; CONTROLLED-TRIAL; DIGESTIVE-TRACT; POSITION	Ventilator-associated pneumonia (VAP) is among the most common infections in patients requiring endotracheal tubes with mechanical ventilation. Ventilator-associated pneumonia is associated with increased hospital costs, a greater number of days in the intensive care unit, longer duration of mechanical ventilation, and higher mortality. Despite widely accepted recommendations for interventions designed to reduce rates of VAP, few studies have assessed the ability of these interventions to improve patient outcomes. As the understanding of VAP advances and new technologies to reduce VAP become available, studies should directly assess patient outcomes before the health care community implements specific prevention approaches in clinical practice. JAMA. 2012; 307(23):2534-2539 www.jama.com	[O'Grady, Naomi P.] NIH, Crit Care Med Dept, Ctr Clin, Bethesda, MD 20892 USA; [Murray, Patrick R.] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA; [Ames, Nancy] NIH, Dept Nursing & Patient Care Serv, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	O'Grady, NP (corresponding author), NIH, Crit Care Med Dept, Ctr Clin, Bldg 10 Room 2C142,10 Ctr Dr,MSC 1662, Bethesda, MD 20892 USA.	nogrady@mail.cc.nih.gov			Intramural NIH HHS [Z99 CL999999] Funding Source: Medline; CLINICAL CENTER [ZIACL001149] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CLINICAL CENTER		Agbaht K, 2007, CRIT CARE MED, V35, P2064, DOI 10.1097/01.CCM.0000277042.31524.66; Aly H, 2008, PEDIATRICS, V122, P770, DOI 10.1542/peds.2007-1826; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Bahrani-Mougeot FK, 2007, J CLIN MICROBIOL, V45, P1588, DOI 10.1128/JCM.01963-06; Bekaert M, 2011, AM J RESP CRIT CARE, V184, P1133, DOI 10.1164/rccm.201105-0867OC; Berra L, 2003, Minerva Anestesiol, V69, P342; Berra L, 2011, MINERVA ANESTESIOL, V77, P323; Berra L, 2012, CRIT CARE MED, V40, P119, DOI 10.1097/CCM.0b013e31822e9fe3; Berriel-Cass D, 2006, JT COMM J QUAL PATIE, V32, P612, DOI 10.1016/S1553-7250(06)32079-X; Bouza E, 2008, CHEST, V134, P938, DOI 10.1378/chest.08-0103; Chan Ee Yuee, 2007, Evid Based Nurs, V10, P19, DOI 10.1136/ebn.10.1.19; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Chastre J, 1998, AM J RESP CRIT CARE, V157, P1165, DOI 10.1164/ajrccm.157.4.9708057; Chlebicki MN, 2007, CRIT CARE MED, V35, P595, DOI 10.1097/01.CCM.0000253395.70708.AC; Coffin SE, 2008, INFECT CONT HOSP EP, V29, pS31, DOI 10.1086/591062; Cook D, 1998, JAMA-J AM MED ASSOC, V279, P781, DOI 10.1001/jama.279.10.781; Costerton W, 2003, J CLIN INVEST, V112, P1466, DOI 10.1172/JCI200320365; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; Dodek P, 2004, ANN INTERN MED, V141, P305, DOI 10.7326/0003-4819-141-4-200408170-00011; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; DUMOULIN GC, 1982, LANCET, V1, P242; Edwards JR, 2009, AM J INFECT CONTROL, V37, P783, DOI 10.1016/j.ajic.2009.10.001; Eggimann P, 2003, INTENS CARE MED, V29, P2086, DOI 10.1007/s00134-003-1991-9; Flanagan JL, 2007, J CLIN MICROBIOL, V45, P1954, DOI 10.1128/JCM.02187-06; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Heo SM, 2008, CLIN INFECT DIS, V47, P1562, DOI 10.1086/593193; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; INGLIS TJJ, 1989, J CLIN MICROBIOL, V27, P2014, DOI 10.1128/JCM.27.9.2014-2018.1989; Institute for Healthcare Improvement, IMPL IHI VENT BUNDL; Kollef MH, 2008, JAMA-J AM MED ASSOC, V300, P805, DOI 10.1001/jama.300.7.805; Kollef MH, 1999, CHEST, V116, P1339, DOI 10.1378/chest.116.5.1339; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; Kolobow T, 2005, ANESTHESIOLOGY, V102, P1063, DOI 10.1097/00000542-200505000-00028; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Labeau SO, 2011, LANCET INFECT DIS, V11, P845, DOI 10.1016/S1473-3099(11)70127-X; Liberati A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000022.pub3; Luna CM, 2006, EUR RESPIR J, V27, P158, DOI 10.1183/09031936.06.00049105; Mager DL, 2003, J CLIN PERIODONTOL, V30, P644, DOI 10.1034/j.1600-051X.2003.00376.x; Mauri T, 2010, RESP CARE, V55, P294; Nathens AB, 1999, ARCH SURG-CHICAGO, V134, P170, DOI 10.1001/archsurg.134.2.170; Niel-Weise BS, 2011, CRIT CARE, V15, DOI 10.1186/cc10135; Nolan T, 2006, JAMA-J AM MED ASSOC, V295, P1168, DOI 10.1001/jama.295.10.1168; Oostdijk EAN, 2010, AM J RESP CRIT CARE, V181, P452, DOI 10.1164/rccm.200908-1210OC; Panigada M, 2003, CRIT CARE MED, V31, P729, DOI 10.1097/01.CCM.0000049943.01252.E5; Park David R, 2005, Respir Care, V50, P742; Rea-Neto A, 2008, CRIT CARE, V12, DOI 10.1186/cc6877; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Schuster SC, 2008, NAT METHODS, V5, P16, DOI [10.1038/nmeth1156, 10.1038/NMETH1156]; Unahalekhaka A, 2007, JT COMM J QUAL PATIE, V33, P387, DOI 10.1016/S1553-7250(07)33044-4; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004; van Nieuwenhoven CA, 2006, CRIT CARE MED, V34, P396, DOI 10.1097/01.CCM.0000198529.76602.5E; Warren DK, 2003, CRIT CARE MED, V31, P1312, DOI 10.1097/01.CCM.0000063087.93157.06	53	49	57	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2012	307	23					2534	2539		10.1001/jama.2012.6445	http://dx.doi.org/10.1001/jama.2012.6445			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	960MB	22797453	Green Accepted			2022-12-28	WOS:000305391400030
J	Stevens, GA; Finucane, MM; Paciorek, CJ; Flaxman, SR; White, RA; Donner, AJ; Ezzati, M				Stevens, Gretchen A.; Finucane, Mariel M.; Paciorek, Christopher J.; Flaxman, Seth R.; White, Richard A.; Donner, Abigail J.; Ezzati, Majid		Nutr Impact Model Study Grp Child	Trends in mild, moderate, and severe stunting and underweight, and progress towards MDG 1 in 141 developing countries: a systematic analysis of population representative data	LANCET			English	Article							CHILD UNDERNUTRITION; MALNUTRITION; GROWTH; HEALTH; MORTALITY; INTERVENTIONS; IMPACT; CASH	Background There is little information on country trends in the complete distributions of children's anthropometric status, which are needed to assess all levels of mild to severe undernutrition. We aimed to estimate trends in the distributions of children's anthropometric status and assess progress towards the Millennium Development Goal 1 (MDG 1) target of halving the prevalence of weight-for-age Z score (WAZ) below -2 between 1990 and 2015 or reaching a prevalence of 2.3% or lower. Methods We collated population-representative data on height-for-age Z score (HAZ) and WAZ calculated with the 2006 WHO child growth standards. Our data sources were health and nutrition surveys, summary statistics from the WHO Global Database on Child Growth and Malnutrition, and summary statistics from reports of other national and international agencies. We used a Bayesian hierarchical mixture model to estimate Z-score distributions. We quantified the uncertainty of our estimates, assessed their validity, compared their performance to alternative models, and assessed sensitivity to key modelling choices. Findings In developing countries, mean HAZ improved from -1.86 (95% uncertainty interval -2.01 to -1.72) in 1985 to -1.16 (-1.29 to -1.04) in 2011; mean WAZ improved from -1.31 (-1.41 to -1.20) to -0.84 (-0.93 to -0.74). Over this period, prevalences of moderate-and-severe stunting declined from 47.2% (44.0 to 50.3) to 29.9% (27.1 to 32.9) and underweight from 30.1% (26.7 to 33.3) to 19.4% (16.5 to 22.2). The largest absolute improvements were in Asia and the largest relative reductions in prevalence in southern and tropical Latin America. Anthropometric status worsened in sub-Saharan Africa until the late 1990s and improved thereafter. In 2011, 314 (296 to 331) million children younger than 5 years were mildly, moderately, or severely stunted and 258 (240 to 274) million were mildly, moderately, or severely underweight. Developing countries as a whole have less than a 5% chance of meeting the MDG 1 target; but 61 of these 141 countries have a 50-100% chance. Interpretation Macroeconomic shocks, structural adjustment, and trade policy reforms in the 1980s and 1990s might have been responsible for worsening child nutritional status in sub-Saharan Africa. Further progress in the improvement of children's growth and nutrition needs equitable economic growth and investment in pro-poor food and primary care programmes, especially relevant in the context of the global economic crisis.	[Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, Ctr Environm & Hlth,MRC HPA, London W2 1PG, England; [Stevens, Gretchen A.] WHO, Dept Hlth Stat & Informat Syst, CH-1211 Geneva, Switzerland; [Finucane, Mariel M.; Donner, Abigail J.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [White, Richard A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Paciorek, Christopher J.] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA; [Flaxman, Seth R.] Carnegie Mellon Univ, Sch Comp Sci, Pittsburgh, PA 15213 USA; [Flaxman, Seth R.] Carnegie Mellon Univ, Heinz Coll, Pittsburgh, PA 15213 USA	Imperial College London; World Health Organization; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California Berkeley; Carnegie Mellon University; Carnegie Mellon University	Ezzati, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, Ctr Environm & Hlth,MRC HPA, Med Fac Bldg,Norfolk Pl, London W2 1PG, England.	majid.ezzati@imperial.ac.uk	Castetbon, Katia/F-2686-2017	Monterrubio, Eric/0000-0003-1417-9243; White, Richard Aubrey/0000-0002-6747-1726	Bill & Melinda Gates Foundation; UK Medical Research Council; MRC [MR/K005901/1] Funding Source: UKRI; Medical Research Council [MR/K005901/1, G0801056B] Funding Source: researchfish	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The Bill & Melinda Gates Foundation and the UK Medical Research Council.	ANAND S, 1993, J ECON PERSPECT, V7, P133, DOI 10.1257/jep.7.1.133; [Anonymous], 2011, MILL DEV GOALS REP; [Anonymous], [No title captured]; Bhutta ZA, 2008, LANCET, V371, P417, DOI 10.1016/S0140-6736(07)61693-6; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; Bryce J, 2008, LANCET, V371, P510, DOI 10.1016/S0140-6736(07)61694-8; Danaei G, 2011, LANCET, V377, P568, DOI 10.1016/S0140-6736(10)62036-3; de Onis M, 2000, B WORLD HEALTH ORGAN, V78, P1222; de Onis M, 2004, JAMA-J AM MED ASSOC, V291, P2600, DOI 10.1001/jama.291.21.2600; de Onis M, 2003, INT J EPIDEMIOL, V32, P518, DOI 10.1093/ije/dyg099; de Onis M, 2012, PUBLIC HEALTH NUTR, V15, P142, DOI 10.1017/S1368980011001315; Dunson D.B., 2010, BAYESIAN NONPARAMETR, P223; Fernald LCH, 2008, LANCET, V371, P828, DOI 10.1016/S0140-6736(08)60382-7; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; Fruhwirth-Schnatter S., 2006, FINITE MIXTURE MARKO; Gakidou E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3; Haddad L, 2003, WORLD BANK ECON REV, V17, P107, DOI 10.1093/wber/lhg012; Lagarde M, 2007, JAMA-J AM MED ASSOC, V298, P1900, DOI 10.1001/jama.298.16.1900; Lutter CK, 2011, PEDIATRICS, V128, pE1418, DOI 10.1542/peds.2011-1392; Monteiro CA, 2009, REV SAUDE PUBL, V43, P35, DOI 10.1590/S0034-89102009000100005; Myerson R, 2011, GLOBAL HLTH METRICS; PELLETIER DL, 1995, B WORLD HEALTH ORGAN, V73, P443; Pongou R, 2006, INT J EPIDEMIOL, V35, P648, DOI 10.1093/ije/dyl016; Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9; RAVALLION M, 1990, ECON DEV CULT CHANGE, V38, P489, DOI 10.1086/451812; Rivera JA, 2004, JAMA-J AM MED ASSOC, V291, P2563, DOI 10.1001/jama.291.21.2563; Rodriguez A, 2009, BIOSTATISTICS, V10, P155, DOI 10.1093/biostatistics/kxn024; Sanchez PA, 2005, LANCET, V365, P442, DOI 10.1016/S0140-6736(05)17834-9; Scrimshaw Nevin S., 1997, American Journal of Clinical Nutrition, V66, p464S; Smith LC, 2002, ECON DEV CULT CHANGE, V51, P55, DOI 10.1086/345313; Subramanyam MA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000424; Sundberg S, 2009, CAB REV PERSPECTIVES, V4, P92; Svedberg P, 2006, INT J EPIDEMIOL, V35, P1336, DOI 10.1093/ije/dyl157; Tentoni S, 2004, BJOG-INT J OBSTET GY, V111, P31, DOI 10.1046/j.1471-0528.2003.00006.x; UNICEF, 1990, STRAT IMPR NUTR CHIL; United Nations Statistics Division, 2004, IND MON MILL DEV GOA; Victora CG, 2010, PEDIATRICS, V125, pE473, DOI 10.1542/peds.2009-1519; Von Braun J., 2008, ACCELERATING PROGR R; World Bank, 2008, INT TRADE CLIMATE CH; World Health Organization, 2006, WHO CHILD GROWTH STA	40	225	233	0	58	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 1	2012	380	9844					824	834		10.1016/S0140-6736(12)60647-3	http://dx.doi.org/10.1016/S0140-6736(12)60647-3			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	000OP	22770478	Green Published			2022-12-28	WOS:000308396300031
J	Tsai, PT; Hull, C; Chu, YX; Greene-Colozzi, E; Sadowski, AR; Leech, JM; Steinberg, J; Crawley, JN; Regehr, WG; Sahin, M				Tsai, Peter T.; Hull, Court; Chu, YunXiang; Greene-Colozzi, Emily; Sadowski, Abbey R.; Leech, Jarrett M.; Steinberg, Jason; Crawley, Jacqueline N.; Regehr, Wade G.; Sahin, Mustafa			Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice	NATURE			English	Article							TUBEROUS SCLEROSIS COMPLEX; MOUSE MODEL; ULTRASONIC VOCALIZATIONS; BRAIN; CHILDREN; MTORC1	Autism spectrum disorders (ASDs) are highly prevalent neurodevelopmental disorders(1), but the underlying pathogenesis remains poorly understood. Recent studies have implicated the cerebellum in these disorders, with post-mortem studies in ASD patients showing cerebellar Purkinje cell (PC) loss(2,3), and isolated cerebellar injury has been associated with a higher incidence of ASDs(4). However, the extent of cerebellar contribution to the pathogenesis of ASDs remains unclear. Tuberous sclerosis complex (TSC) is a genetic disorder with high rates of comorbid ASDs(5) that result from mutation of either TSC1 or TSC2, whose protein products dimerize and negatively regulate mammalian target of rapamycin (mTOR) signalling. TSC is an intriguing model to investigate the cerebellar contribution to the underlying pathogenesis of ASDs, as recent studies in TSC patients demonstrate cerebellar pathology(6) and correlate cerebellar pathology with increased ASD symptomatology(7,8). Functional imaging also shows that TSC patients with ASDs display hypermetabolism in deep cerebellar structures, compared to TSC patients without ASDs(9). However, the roles of Tsc1 and the sequelae of Tsc1 dysfunction in the cerebellum have not been investigated so far. Here we show that both heterozygous and homozygous loss of Tsc1 in mouse cerebellar PCs results in autistic-like behaviours, including abnormal social interaction, repetitive behaviour and vocalizations, in addition to decreased PC excitability. Treatment of mutant mice with the mTOR inhibitor, rapamycin, prevented the pathological and behavioural deficits. These findings demonstrate new roles for Tsc1 in PC function and define a molecular basis for a cerebellar contribution to cognitive disorders such as autism.	[Tsai, Peter T.; Greene-Colozzi, Emily; Sadowski, Abbey R.; Leech, Jarrett M.; Steinberg, Jason; Sahin, Mustafa] Harvard Univ, Sch Med, Boston Childrens Hosp, FM Kirby Neurobiol Ctr,Dept Neurol, Boston, MA 02115 USA; [Hull, Court; Chu, YunXiang; Regehr, Wade G.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; [Crawley, Jacqueline N.] NIMH, Lab Behav Neurosci, Intramural Res Program, Bethesda, MD 20892 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Sahin, M (corresponding author), Harvard Univ, Sch Med, Boston Childrens Hosp, FM Kirby Neurobiol Ctr,Dept Neurol, Boston, MA 02115 USA.	peter.tsai@childrens.harvard.edu; mustafa.sahin@childrens.harvard.edu	SAHIN, MUSTAFA/I-8653-2019	SAHIN, MUSTAFA/0000-0001-7044-2953; tsai, peter/0000-0002-0729-9688; Hull, Court/0000-0002-0360-8367	Developmental Neurology Training grant [T32 NS007473]; American Academy of Neurology; Nancy Lurie Marks Family Foundation; National Institutes of Health (NIH) [R01 NS58956]; John Merck Scholars Fund; Autism Speaks; Boston Children's Hospital Translational Research Program; Manton Center for Orphan Disease Research; Boston Children's Hospital Intellectual and Developmental Disabilities Research Center [P30 HD18655]; Intramural Research Program, National Institute of Mental Health; NIH [R01NS032405]; Simons Foundation [SFARI 232304]; Howard Hughes Medical Institute Medical Research Fellowship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH020017, ZIAMH002179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K12NS079414, T32NS007473, R01NS032405, R01NS058956] Funding Source: NIH RePORTER	Developmental Neurology Training grant; American Academy of Neurology; Nancy Lurie Marks Family Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); John Merck Scholars Fund; Autism Speaks; Boston Children's Hospital Translational Research Program; Manton Center for Orphan Disease Research; Boston Children's Hospital Intellectual and Developmental Disabilities Research Center; Intramural Research Program, National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Simons Foundation; Howard Hughes Medical Institute Medical Research Fellowship(Howard Hughes Medical Institute); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank G. Corfas, M. Fagiolini, P. Rosenberg, S. Goldman and the Neurodevelopmental Behavioral Core of Boston Children's Hospital for assistance with behavioural experiments. We are grateful to C. Walsh, L. Benowitz and members of the Sahin laboratory for critical reading of the manuscript, and to M. Gregas for advice regarding statistical analysis. P. T. T. received support from the Developmental Neurology Training grant (T32 NS007473), American Academy of Neurology, and the Nancy Lurie Marks Family Foundation. This work and M. S. are supported in part by the National Institutes of Health (NIH; grant R01 NS58956), the John Merck Scholars Fund, Autism Speaks, the Nancy Lurie Marks Family Foundation, Boston Children's Hospital Translational Research Program, Manton Center for Orphan Disease Research and Boston Children's Hospital Intellectual and Developmental Disabilities Research Center (grant P30 HD18655). J.N.C. is supported by the Intramural Research Program, National Institute of Mental Health. W. G. R. is supported by the NIH (grant R01NS032405) and the Simons Foundation (grant SFARI 232304). Y.X.C. is supported by the Howard Hughes Medical Institute Medical Research Fellowship.	Amaral DG, 2008, TRENDS NEUROSCI, V31, P137, DOI 10.1016/j.tins.2007.12.005; Asano E, 2001, NEUROLOGY, V57, P1269, DOI 10.1212/WNL.57.7.1269; Barski JJ, 2000, GENESIS, V28, P93, DOI 10.1002/1526-968X(200011/12)28:3/4<93::AID-GENE10>3.3.CO;2-N; Bateup HS, 2011, J NEUROSCI, V31, P8862, DOI 10.1523/JNEUROSCI.1617-11.2011; Bauman ML, 2005, INT J DEV NEUROSCI, V23, P183, DOI 10.1016/j.ijdevneu.2004.09.006; Bednar I, 2002, MOL CELL NEUROSCI, V20, P354, DOI 10.1006/mcne.2002.1112; Buitrago MM, 2004, NEUROBIOL LEARN MEM, V81, P211, DOI 10.1016/j.nlm.2004.01.001; Choi YJ, 2008, GENE DEV, V22, P2485, DOI 10.1101/gad.1685008; De Zeeuw CI, 2011, NAT REV NEUROSCI, V12, P327, DOI 10.1038/nrn3011; Di Nardo A, 2009, J NEUROSCI, V29, P5926, DOI 10.1523/JNEUROSCI.0778-09.2009; Eluvathingal TJ, 2006, J CHILD NEUROL, V21, P846, DOI 10.1177/08830738060210100301; Ertan G, 2010, J NEURORADIOLOGY, V37, P231, DOI 10.1016/j.neurad.2009.12.006; Holmes A, 2001, BEHAV NEUROSCI, V115, P1129, DOI 10.1037//0735-7044.115.5.1129; Hull C, 2012, NEURON, V73, P149, DOI 10.1016/j.neuron.2011.10.030; Insel TR, 2004, ANNU REV NEUROSCI, V27, P697, DOI 10.1146/annurev.neuro.27.070203.144148; Jeste SS, 2008, J CHILD NEUROL, V23, P520, DOI 10.1177/0883073807309788; Kurejova M, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-18; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Limperopoulos C, 2007, PEDIATRICS, V120, P584, DOI 10.1542/peds.2007-1041; Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008; Meikle L, 2007, J NEUROSCI, V27, P5546, DOI 10.1523/JNEUROSCI.5540-06.2007; Muller RA, 2007, MENT RETARD DEV D R, V13, P85, DOI 10.1002/mrdd.20141; Nie D, 2010, NAT NEUROSCI, V13, P163, DOI 10.1038/nn.2477; Reith RM, 2011, NEUROBIOL DIS, V43, P113, DOI 10.1016/j.nbd.2011.02.014; Rice Catherine, 2009, Morbidity and Mortality Weekly Report, V58, P1; Ryu YH, 1999, EUR J NUCL MED, V26, P253, DOI 10.1007/s002590050385; Sajdel-Sulkowska EM, 2009, CEREBELLUM, V8, P366, DOI 10.1007/s12311-009-0105-9; Scattoni ML, 2009, NEUROSCI BIOBEHAV R, V33, P508, DOI 10.1016/j.neubiorev.2008.08.003; Schmahmann JD, 2004, J NEUROPSYCH CLIN N, V16, P367, DOI 10.1176/appi.neuropsych.16.3.367; Silverman JL, 2011, BRAIN RES, V1380, P120, DOI 10.1016/j.brainres.2010.09.026; Steinlin M, 2008, CEREBELLUM, V7, P607, DOI 10.1007/s12311-008-0083-3; Tavazoie SF, 2005, NAT NEUROSCI, V8, P1727, DOI 10.1038/nn1566; Tsai P, 2011, CURR OPIN NEUROL, V24, P106, DOI 10.1097/WCO.0b013e32834451c4; Weber AM, 2000, J AUTISM DEV DISORD, V30, P511, DOI 10.1023/A:1005679108529; Yang Mu, 2011, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0826s56; Yang Mu, 2009, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0824s48; Young DM, 2010, P NATL ACAD SCI USA, V107, P11074, DOI 10.1073/pnas.1005620107; Zhou J, 2009, J NEUROSCI, V29, P1773, DOI 10.1523/JNEUROSCI.5685-08.2009	38	541	553	3	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 30	2012	488	7413					647	+		10.1038/nature11310	http://dx.doi.org/10.1038/nature11310			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	996NC	22763451	Green Submitted, Green Accepted			2022-12-28	WOS:000308095100054
J	Pitsiladis, Y; Beis, L				Pitsiladis, Yannis; Beis, Lukas			To drink or not to drink to drink recommendations: the evidence	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							EXERCISE; RUNNERS		[Pitsiladis, Yannis; Beis, Lukas] Univ Glasgow, Coll Med Vet & Life Sci, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Pitsiladis, Y (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland.	Yannis.Pitsiladis@glasgow.ac.uk		Pitsiladis, Yannis/0000-0001-6210-2449				Beis LY, 2012, CLIN J SPORT MED, V22, P254, DOI 10.1097/JSM.0b013e31824a55d7; Cheuvront SN, 2001, SPORTS MED, V31, P743, DOI 10.2165/00007256-200131100-00004; Convertino VA, 1996, MED SCI SPORT EXER, V28, pR1, DOI 10.1097/00005768-199610000-00045; Fudge BW, 2006, BRIT J NUTR, V95, P59, DOI 10.1079/BJN20051608; Fudge BW, 2006, E AFRICAN RUNNING CR, P63; Galloway SDR, 1997, MED SCI SPORT EXER, V29, P1240, DOI 10.1097/00005768-199709000-00018; Goulet EDB, 2011, BRIT J SPORT MED, V45, P1149, DOI 10.1136/bjsm.2010.077966; Montain SJ, 2006, BRIT J SPORT MED, V40, P98, DOI 10.1136/bjsm.2005.018481; Noakes TD, 2007, J SPORT SCI, V25, P781, DOI 10.1080/02640410600875036; Noakes T D, 1993, Exerc Sport Sci Rev, V21, P297; Sawka MN, 2007, MED SCI SPORT EXER, V39, P377, DOI 10.1249/mss.0b013e31802ca597; Zouhal H, 2011, BRIT J SPORT MED, V45, P1101, DOI 10.1136/bjsm.2010.074641	12	0	0	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 19	2012	345								e4868	10.1136/bmj.e4868	http://dx.doi.org/10.1136/bmj.e4868			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978MA	22810390				2022-12-28	WOS:000306744300013
J	Williams, D; Craft, N				Williams, David; Craft, Naomi			Pre-eclampsia	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HYPERTENSIVE DISORDERS; GUIDELINES; MANAGEMENT; PREGNANCY; RISK		[Williams, David] Univ Coll London Hosp, London WC1E 6AU, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Williams, D (corresponding author), Univ Coll London Hosp, London WC1E 6AU, England.	d.j.williams@ucl.ac.uk	Williams, David/AFW-0581-2022	Williams, David/0000-0002-8186-9124				Bellamy L, 2007, BMJ-BRIT MED J, V335, P974, DOI 10.1136/bmj.39335.385301.BE; Burns H, 2011, BJOG-INT J OBSTET GY, V118, P5, DOI 10.1111/j.1471-0528.2010.02847.x; Cavkaytar S, 2007, ACTA OBSTET GYN SCAN, V86, P648, DOI 10.1080/00016340601185384; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; Duley L, 2009, SEMIN PERINATOL, V33, P130, DOI 10.1053/j.semperi.2009.02.010; FERRAZZANI S, 1994, AM J OBSTET GYNECOL, V171, P506, DOI 10.1016/0002-9378(94)90290-9; Hernandez-Diaz S, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2255; Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9; Koopmans CM, 2009, LANCET, V374, P979, DOI 10.1016/S0140-6736(09)60736-4; Lowe SA, 2009, AUST NZ J OBSTET GYN, V49, P242, DOI 10.1111/j.1479-828X.2009.01003.x; Milne F, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3129; Ray JG, 2001, EARLY HUM DEV, V64, P129, DOI 10.1016/S0378-3782(01)00181-5; Roberge S, 2012, AM J PERINATOL; Roberts D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub2; Saudan P, 1998, BRIT J OBSTET GYNAEC, V105, P1177, DOI 10.1111/j.1471-0528.1998.tb09971.x; Sibai BM, 2012, AM J OBSTET GYNECOL, V206, P470, DOI 10.1016/j.ajog.2011.09.002; Steegers EAP, 2010, LANCET, V376, P631, DOI 10.1016/S0140-6736(10)60279-6; Tuffnell DJ, 2005, BJOG-INT J OBSTET GY, V112, P875, DOI 10.1111/j.1471-0528.2005.00565.x; Visintin C, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c2207	19	14	14	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 19	2012	345								e4437	10.1136/bmj.e4437	http://dx.doi.org/10.1136/bmj.e4437			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978MA	22815427				2022-12-28	WOS:000306744300002
J	Nakamura, T; Zhao, Y; Yamagata, Y; Hua, YJ; Yang, W				Nakamura, Teruya; Zhao, Ye; Yamagata, Yuriko; Hua, Yue-Jin; Yang, Wei			Watching DNA polymerase eta make a phosphodiester bond	NATURE			English	Article							CRYSTAL-STRUCTURES; 2-METAL-ION MECHANISM; TERNARY COMPLEXES; TRANSITION-STATE; STRUCTURAL BASIS; ACTIVE-SITE; SUBSTRATE; FIDELITY; METAL; BINDING	DNA synthesis has been extensively studied, but the chemical reaction itself has not been visualized. Here we follow the course of phosphodiester bond formation using time-resolved X-ray crystallography. Native human DNA polymerase eta, DNA and dATP were co-crystallized at pH 6.0 without Mg2+. The polymerization reaction was initiated by exposing crystals to 1 mM Mg2+ at pH 7.0, and stopped by freezing at desired time points for structural analysis. The substrates and two Mg2+ ions are aligned within 40 s, but the bond formation is not evident until 80 s. From 80 to 300 s structures show a mixture of decreasing substrate and increasing product of the nucleotidyl-transfer reaction. Transient electron densities indicate that deprotonation and an accompanying C2'-endo to C3'-endo conversion of the nucleophile 3'-OH are rate limiting. A third Mg2+ ion, which arrives with the new bond and stabilizes the intermediate state, may be an unappreciated feature of the two-metal-ion mechanism.	[Nakamura, Teruya; Zhao, Ye; Yang, Wei] NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; [Nakamura, Teruya; Yamagata, Yuriko] Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan; [Zhao, Ye; Hua, Yue-Jin] Zhejiang Univ, Inst Nucl Agr Sci, Hangzhou 310029, Zhejiang, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Kumamoto University; Zhejiang University	Yang, W (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	wei.yang@nih.gov	Zhao, Ye/I-2936-2014; Yang, Wei/ABB-4785-2020; Yang, Wei/D-4926-2011	Zhao, Ye/0000-0002-5455-2586; Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195; Nakamura, Teruya/0000-0003-2013-3057	National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; Japan Society for the Promotion of Science; Kumamoto University; Kumayaku Alumni Research Fund; Chinese Ministry of Education; National Natural Science Foundation of China; Ministry of Education, Culture, Sports, Science, and Technology of Japan; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK036146] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [24113719] Funding Source: KAKEN	National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Kumamoto University; Kumayaku Alumni Research Fund; Chinese Ministry of Education(Ministry of Education, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank D. Leahy, M. Gellert and R. Craigie for editing the manuscript. The research was supported by the intramural research program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (W.Y., T.N. and Y.Z.); the Japan Society for the Promotion of Science Institutional Program for Young Researcher Overseas visits, Kumamoto University, and the Kumayaku Alumni Research Fund (T.N.); Chinese Ministry of Education scholarship (Y.Z.); National Natural Science Foundation of China (Y.-J.H.); and Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Y.Y.).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Batra VK, 2006, STRUCTURE, V14, P757, DOI 10.1016/j.str.2006.01.011; Berman AJ, 2007, EMBO J, V26, P3494, DOI 10.1038/sj.emboj.7601780; Biertumpfel C, 2010, NATURE, V465, P1044, DOI 10.1038/nature09196; BRODY RS, 1981, BIOCHEMISTRY-US, V20, P1245, DOI 10.1021/bi00508a030; Castro C, 2007, P NATL ACAD SCI USA, V104, P4267, DOI 10.1073/pnas.0608952104; Cavanaugh NA, 2010, J BIOL CHEM, V285, P24457, DOI 10.1074/jbc.M110.132407; Choi JY, 2005, J MOL BIOL, V352, P72, DOI 10.1016/j.jmb.2005.06.079; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; Cramer J, 2005, J BIOL CHEM, V280, P40552, DOI 10.1074/jbc.M504481200; DING XC, 1994, BIOCHEMISTRY-US, V33, P9285, DOI 10.1021/bi00197a032; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Evans RJ, 2008, P NATL ACAD SCI USA, V105, P20695, DOI 10.1073/pnas.0809989106; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Garcia-Diaz M, 2007, DNA REPAIR, V6, P1333, DOI 10.1016/j.dnarep.2007.03.005; Garcin ED, 2008, NAT STRUCT MOL BIOL, V15, P515, DOI 10.1038/nsmb.1414; Graham DL, 2002, CHEM BIOL, V9, P375, DOI 10.1016/S1074-5521(02)00112-6; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Johnson KA, 2008, J BIOL CHEM, V283, P26297, DOI 10.1074/jbc.R800034200; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; Le Du MH, 2002, J MOL BIOL, V316, P941, DOI 10.1006/jmbi.2001.5384; Lee JY, 2006, CELL, V127, P1349, DOI 10.1016/j.cell.2006.10.049; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Murray JB, 2000, MOL CELL, V5, P279, DOI 10.1016/S1097-2765(00)80423-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; Romier C, 1998, PROTEINS, V32, P414, DOI 10.1002/(SICI)1097-0134(19980901)32:4<414::AID-PROT2>3.3.CO;2-5; Rothwell PJ, 2005, ADV PROTEIN CHEM, V71, P401, DOI 10.1016/S0065-3233(04)71011-6; Rothwell PJ, 2005, MOL CELL, V19, P345, DOI 10.1016/j.molcel.2005.06.032; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; Shah AM, 2001, J BIOL CHEM, V276, P10824, DOI 10.1074/jbc.M008680200; Shan SO, 1999, P NATL ACAD SCI USA, V96, P12299, DOI 10.1073/pnas.96.22.12299; Showalter AK, 2002, BIOCHEMISTRY-US, V41, P10571, DOI 10.1021/bi026021i; Stahley MR, 2005, SCIENCE, V309, P1587, DOI 10.1126/science.1114994; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Wang F, 2009, CELL, V139, P1279, DOI 10.1016/j.cell.2009.11.043; Wang LH, 2007, J AM CHEM SOC, V129, P4731, DOI 10.1021/ja068821c; Wang LH, 2009, J MOL BIOL, V389, P787, DOI 10.1016/j.jmb.2009.04.029; Warshel A, 2006, CHEM REV, V106, P3210, DOI 10.1021/cr0503106; Yang W, 2006, MOL CELL, V22, P5, DOI 10.1016/j.molcel.2006.03.013; Yang W, 2007, P NATL ACAD SCI USA, V104, P15591, DOI 10.1073/pnas.0704219104; Yang W, 2011, Q REV BIOPHYS, V44, P1, DOI 10.1017/S0033583510000181; Zakharova E, 2004, BIOCHEMISTRY-US, V43, P6587, DOI 10.1021/bi049615p; Zhang H, 2007, NUCLEIC ACIDS RES, V35, P6052, DOI 10.1093/nar/gkm587; Zhao Y, 2012, P NATL ACAD SCI USA, V109, P7269, DOI 10.1073/pnas.1202681109	55	189	189	2	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2012	487	7406					196	U77		10.1038/nature11181	http://dx.doi.org/10.1038/nature11181			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972LP	22785315	Green Accepted			2022-12-28	WOS:000306278900031
J	Khunti, K; Davies, M				Khunti, Kamlesh; Davies, Melanie			Should we screen for type 2 diabetes: Yes	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							INTENSIVE GLUCOSE CONTROL		[Khunti, Kamlesh] Univ Leicester, Dept Hlth Sci, Leicester Diabet Ctr, Leicester LE5 4PW, Leics, England; [Davies, Melanie] Univ Leicester, Dept Cardiovasc Sci, Leicester LE5 4PW, Leics, England	University of Leicester; University of Leicester	Khunti, K (corresponding author), Univ Leicester, Dept Hlth Sci, Leicester Diabet Ctr, Leicester LE5 4PW, Leics, England.	kk22@le.ac.uk	/ABC-9527-2021	Davies, Melanie/0000-0002-9987-9371; Khunti, Kamlesh/0000-0003-2343-7099				Duckworth WC, 2011, J DIABETES COMPLICAT, V25, P355, DOI 10.1016/j.jdiacomp.2011.10.003; Eborall H, BJGP IN PRESS; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Gillies CL, 2008, BMJ-BRIT MED J, V336, P1180, DOI 10.1136/bmj.39545.585289.25; Gillies CL, 2007, BMJ-BRIT MED J, V334, P299, DOI 10.1136/bmj.39063.689375.55; Goyder E, 2008, FAM PRACT, V25, P370, DOI 10.1093/fampra/cmn054; Griffin SJ, 2011, LANCET, V378, P156, DOI 10.1016/S0140-6736(11)60698-3; Holman N, 2011, DIABETIC MED, V28, P575, DOI 10.1111/j.1464-5491.2010.03216.x; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Kahn R, 2010, LANCET, V375, P1365, DOI 10.1016/S0140-6736(09)62162-0; National Institute for Health and Care Excellence, 2012, PREV TYP 2 DIAB RISK; Skinner TC, 2005, DIABETIC MED, V22, P1497, DOI 10.1111/j.1464-5491.2005.01680.x; Wareham NJ, 2001, BMJ-BRIT MED J, V322, P986, DOI 10.1136/bmj.322.7292.986; Waugh N, 2007, HEALTH TECHNOL ASSES, V11, P1; World Health Organization, 2011, US GLYC HAEM HBA1C D	15	10	10	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 9	2012	345								e4514	10.1136/bmj.e4514	http://dx.doi.org/10.1136/bmj.e4514			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NR	22777029				2022-12-28	WOS:000306518500004
J	Andre, P; Ward-Thompson, D; Greaves, J				Andre, Philippe; Ward-Thompson, Derek; Greaves, Jane			Interferometric Identification of a Pre-Brown Dwarf	SCIENCE			English	Article							INITIAL MASS FUNCTION; PRESTELLAR CORES; MOLECULAR CLOUDS; STAR-FORMATION; STELLAR CORES; MAIN CLOUD; OPHIUCHUS; FRAGMENTATION; PROTOSTARS; DISCOVERY	It is not known whether brown dwarfs [stellar-like objects with masses less than the hydrogen-burning limit, 0.075 solar mass (M.)] are formed in the same way as solar-type stars or by some other process. Here we report the clear-cut identification of a self-gravitating condensation of gas and dust with a mass in the brown-dwarf regime, made through millimeter interferometric observations. The level of thermal millimeter continuum emission detected from this object indicates a mass similar to 0.02 to 0.03 M-circle dot, whereas the small radius, <460 astronomical units, and narrow spectral lines imply a dynamical mass of 0.015 to 0.02 M-circle dot. The identification of such a pre-brown dwarf core supports models according to which brown dwarfs are formed in the same manner as hydrogen-burning stars.	[Andre, Philippe] Univ Paris Diderot, Ctr Etud Saclay, Lab Astrophys Instrumentat & Modelisat AIM, CEA,DSM,CNRS, F-91191 Gif Sur Yvette, France; [Ward-Thompson, Derek] Univ Cent Lancashire, Jeremiah Horrocks Inst, Preston PR1 2HE, Lancs, England; [Greaves, Jane] Univ St Andrews, Sch Phys & Astron, SUPA, St Andrews KY16 9SS, Fife, Scotland	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; University of Central Lancashire; University of St Andrews	Andre, P (corresponding author), Univ Paris Diderot, Ctr Etud Saclay, Lab Astrophys Instrumentat & Modelisat AIM, CEA,DSM,CNRS, F-91191 Gif Sur Yvette, France.	philippe.andre@cea.fr	Naselsky, Pavel D/M-4799-2014	Naselsky, Pavel D/0000-0002-8891-0273; Ward-Thompson, Derek/0000-0003-1140-2761	Institut National des Sciences de l'Univers/CNRS (France); Max-Planck-Gesellschaft (Germany); Instituto Geografico Nacional (Spain); Science and Technology Facilities Council [ST/G001987/1, ST/J001651/1] Funding Source: researchfish; STFC [ST/G001987/1, ST/J001651/1] Funding Source: UKRI	Institut National des Sciences de l'Univers/CNRS (France)(Centre National de la Recherche Scientifique (CNRS)); Max-Planck-Gesellschaft (Germany)(Max Planck Society); Instituto Geografico Nacional (Spain); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	This work is based on observations carried out with the IRAM PdBI. IRAM is supported by Institut National des Sciences de l'Univers/CNRS (France), the Max-Planck-Gesellschaft (Germany), and the Instituto Geografico Nacional (Spain). It was stimulated by discussions held in the context of the European Marie Curie Research Training Network "Constellation" (MRTN-CT2006-035890). We are grateful to the IRAM Director, who awarded us one track of Director's Discretionary Time on the PdBI to confirm the detection of Oph B-11 in the 3.2-mm continuum. We thank F. Gueth and R. Neri for their help and expert advice concerning the interferometric data reduction for this project and M. Pound for useful comments on Oph B-11. The interferometric data used in this paper are archived at IRAM and available upon request from either IRAM or the corresponding author.	Allen L., 2007, PROTOSTARS PLANETS 5, V951, P361; Alves JF, 2001, NATURE, V409, P159, DOI 10.1038/35051509; Andre P, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014666; Basu S, 2012, ASTROPHYS J, V750, DOI 10.1088/0004-637X/750/1/30; Bate MR, 2002, MON NOT R ASTRON SOC, V332, pL65, DOI 10.1046/j.1365-8711.2002.05539.x; BERTOLDI F, 1992, ASTROPHYS J, V395, P140, DOI 10.1086/171638; BOSS AP, 1995, ASTROPHYS J, V439, pL55, DOI 10.1086/187743; Chabrier G, 2000, ANNU REV ASTRON ASTR, V38, P337, DOI 10.1146/annurev.astro.38.1.337; Enoch ML, 2010, ASTROPHYS J LETT, V722, pL33, DOI 10.1088/2041-8205/722/1/L33; Greaves JS, 2003, MON NOT R ASTRON SOC, V346, P441, DOI 10.1046/j.1365-2966.2003.07100.x; Hennebelle P, 2008, ASTROPHYS J, V684, P395, DOI 10.1086/589916; Kirk JM, 2005, MON NOT R ASTRON SOC, V360, P1506, DOI 10.1111/j.1365-2966.2005.09145.x; Kroupa P, 2001, MON NOT R ASTRON SOC, V322, P231, DOI 10.1046/j.1365-8711.2001.04022.x; LARSON RB, 1985, MON NOT R ASTRON SOC, V214, P379, DOI 10.1093/mnras/214.3.379; Liseau R, 1999, ASTRON ASTROPHYS, V344, P342; Loinard L, 2008, ASTROPHYS J LETT, V675, pL29, DOI 10.1086/529548; LOREN RB, 1990, ASTROPHYS J, V365, P269, DOI 10.1086/169480; Luhman K. L., 2007, PROTOSTARS PLANETS, VV, P443; Mamajek EE, 2008, ASTRON NACHR, V329, P10, DOI 10.1002/asna.200710827; Moraux E, 2003, ASTRON ASTROPHYS, V400, P891, DOI 10.1051/0004-6361:20021903; Motte F, 1998, ASTRON ASTROPHYS, V336, P150; NAKAJIMA T, 1995, NATURE, V378, P463, DOI 10.1038/378463a0; Padoan P, 2002, ASTROPHYS J, V576, P870, DOI 10.1086/341790; Padoan P, 2004, ASTROPHYS J, V617, P559, DOI 10.1086/345413; POUND MW, 1995, ASTROPHYS J, V444, P270, DOI 10.1086/175602; REBOLO R, 1995, NATURE, V377, P129, DOI 10.1038/377129a0; Reipurth B, 2001, ASTRON J, V122, P432, DOI 10.1086/321121; Stamatellos D, 2007, MON NOT R ASTRON SOC, V379, P1390, DOI 10.1111/j.1365-2966.2007.11999.x; Thies I, 2010, ASTROPHYS J, V717, P577, DOI 10.1088/0004-637X/717/1/577; Ward-Thompson D., 2007, PROTOSTARS PLANETS, P33; Whitworth AP, 2004, ASTRON ASTROPHYS, V427, P299, DOI 10.1051/0004-6361:20041131	32	54	54	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2012	337	6090					69	72		10.1126/science.1222602	http://dx.doi.org/10.1126/science.1222602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767923	Green Submitted			2022-12-28	WOS:000306053100044
J	Wood, B				Wood, Bernard			Phillip Vallentine Tobias (1925-2012) OBITUARY	NATURE			English	Biographical-Item									George Washington Univ, Washington, DC 20052 USA	George Washington University	Wood, B (corresponding author), George Washington Univ, Washington, DC 20052 USA.	bernardawood@gmail.com						TOBIAS PV, PUBLICATION LIST	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 5	2012	487	7405					40	40		10.1038/487040a	http://dx.doi.org/10.1038/487040a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968LM	22763546	Bronze			2022-12-28	WOS:000305982900040
J	Papp, K; Cather, JC; Rosoph, L; Sofen, H; Langley, RG; Matheson, RT; Hu, CC; Day, RM				Papp, Kim; Cather, Jennifer C.; Rosoph, Les; Sofen, Howard; Langley, Richard G.; Matheson, Robert T.; Hu, ChiaChi; Day, Robert M.			Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial	LANCET			English	Article							PHOSPHODIESTERASE-4; SAFETY; THERAPY	Background Apremilast, a small-molecule inhibitor of phosphodiesterase 4, works intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and doses of 20 mg twice daily have shown efficacy in the treatment of moderate to severe plaque psoriasis in a 12-week phase 2 study. We assessed the clinical efficacy and safety of different doses of apremilast in the treatment of patients with moderate to severe plaque psoriasis. Methods In this phase 2b, multicentre, randomised, placebo-controlled, dose-ranging study, patients (aged >= 18 years) with moderate to severe psoriasis were randomly assigned (in a 1: 1: 1: 1 ratio) to receive oral placebo or apremilast 10, 20, or 30 mg twice daily at 35 US and Canadian sites between Sept 24, 2008, and Oct 21, 2009. At week 16, patients in the placebo group were assigned apremilast 20 or 30 mg twice daily until week 24. Randomisation was generated with a permuted-block randomisation list via interactive voice response system. For the first 16 weeks, treatment assignment was concealed from both investigators and participants. During weeks 16-24, investigators and participants all knew that treatment was active, but the dose was concealed. The primary endpoint was the proportion of patients achieving at least 75% reduction from baseline psoriasis area and severity index (PASI-75) at week 16. Analyses were by intention to treat; missing values were imputed by last-observation-carried-forward. This trial is registered with ClinicalTrials.gov, number NCT00773734. Findings 89 patients were randomly assigned apremilast 10 mg, 87 apremilast 20 mg, and 88 apremilast 30 mg twice daily; 88 were assigned placebo. At week 16, PASI-75 was achieved in five patients (6%) assigned placebo, ten (11%) assigned apremilast 10 mg, 25 (29%) assigned 20 mg, and 36 (41%) assigned 30 mg. Apremilast 10 mg did not differ significantly from placebo in achievement of the endpoint (odds ratio 2.10; 95% CI 0.69-6.42); for both apremilast 20 mg (6.69; 2.43-18.5; p<0.0001) and apremilast 30 mg (11.5; 4.24-31.2; p<0.0001), the differences from placebo were significant. Most adverse events (96%) were mild or moderate; at least 5% of patients had nausea, upper respiratory tract infection, diarrhoea, nasopharyngitis, headache, arthralgia (placebo), gastroenteritis, or dyspepsia. Eight serious adverse events occurred (three each, placebo and apremilast 20 mg; two, apremilast 30 mg); none were judged to be related to apremilast. Apremilast had no apparent effect on the results of haematological, urinalysis, immunological or inflammation, serum chemistry, or electrocardiographic tests. Interpretation Apremilast, given orally at 20 or 30 mg twice daily, seems to be efficacious, safe, and tolerable for patients with moderate to severe plaque psoriasis. Our results support continuing, longer-term studies.	[Papp, Kim] Prob Med Res, Waterloo, ON N2J 1C4, Canada; [Cather, Jennifer C.] Modern Res Associates, Dallas, TX USA; [Rosoph, Les] N Bay Dermatol Ctr, N Bay, ON, Canada; [Sofen, Howard] Dermatol Res Associates, Los Angeles, CA USA; [Langley, Richard G.] Dalhousie Univ, Halifax, NS, Canada; [Matheson, Robert T.] Oregon Med Res Ctr, Portland, OR USA; [Hu, ChiaChi; Day, Robert M.] Celgene Corp, Summit, NJ USA	Dalhousie University; Bristol-Myers Squibb; Celgene Corporation	Papp, K (corresponding author), Prob Med Res, Waterloo, ON N2J 1C4, Canada.	kapapp@probitymedical.com	Sofen, Howard/AAD-1321-2021	Sofen, Howard/0000-0001-7789-6915; Papp, Kim A./0000-0001-9557-3642	Celgene Corporation, Summit, NJ, USA; Celgene Corporation	Celgene Corporation, Summit, NJ, USA(Bristol-Myers SquibbCelgene Corporation); Celgene Corporation(Bristol-Myers SquibbCelgene Corporation)	This study was supported by Celgene Corporation, Summit, NJ, USA. We thank Claire Barcellona, Marlene Kachnowski, Dale McElveen, Patricia Rohane, and Randall Stevens for their contributions to the overall study. The authors received editorial support in the preparation of this report from Jennifer Schwinn and Jane Moore of Peloton Advantage, funded by Celgene Corporation. The authors, however, directed and are fully responsible for all content and editorial decisions for this report.	[Anonymous], 2011, ENBR; [Anonymous], 2009, RHEUM; Brunasso AMG, 2011, ACTA DERM-VENEREOL, V91, P44, DOI 10.2340/00015555-0959; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Gottlieb AB, 2008, CURR MED RES OPIN, V24, P1529, DOI [10.1185/030079908X301866, 10.1185/030079908X301866 ]; Heystek HC, 2003, INT IMMUNOL, V15, P827, DOI 10.1093/intimm/dxg079; Hoffmann M, 2011, J INVEST DERMATOL, V131, pS89; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Kini SP, 2011, ARCH DERMATOL, V147, P1153, DOI 10.1001/archdermatol.2011.178; McCann FE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3041; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Nissel J, 2011, ANN C EUR LEAG RHEUM; Papp K, 2008, J AM ACAD DERMATOL, V58, pAB3; Peter D, 2007, J IMMUNOL, V178, P4820, DOI 10.4049/jimmunol.178.8.4820; Ravindran V, 2008, ANN RHEUM DIS, V67, P855, DOI 10.1136/ard.2007.072652; Reich K, 2005, LANCET, V366, P1367, DOI 10.1016/S0140-6736(05)67566-6; Richards HL, 2006, J EUR ACAD DERMATOL, V20, P370, DOI 10.1111/j.1468-3083.2006.01565.x; Saurat JH, 2010, DERMATOLOGY, V220, P128, DOI 10.1159/000275198; Schafer PH, 2010, BRIT J PHARMACOL, V159, P842, DOI 10.1111/j.1476-5381.2009.00559.x; Schett G, 2009, ARTHRITIS RHEUM-US, V60, P1203, DOI 10.1002/art.24592; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Tenor H, 2002, BRIT J PHARMACOL, V135, P609, DOI 10.1038/sj.bjp.0704480; Tyring S, 2007, ARCH DERMATOL, V143, P719, DOI 10.1001/archderm.143.6.719; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Wu A, 2011, J INVEST DERMATOL, V131, pS86; Wu A, 2010, ANN M AM COLL CLIN P; Wu A, 2006, ANN M AM COLL CLIN P	28	177	188	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 25	2012	380	9843					738	746		10.1016/S0140-6736(12)60642-4	http://dx.doi.org/10.1016/S0140-6736(12)60642-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995IK	22748702				2022-12-28	WOS:000308001300031
J	Alon, A; Grossman, I; Gat, Y; Kodali, VK; DiMaio, F; Mehlman, T; Haran, G; Baker, D; Thorpe, C; Fass, D				Alon, Assaf; Grossman, Iris; Gat, Yair; Kodali, Vamsi K.; DiMaio, Frank; Mehlman, Tevie; Haran, Gilad; Baker, David; Thorpe, Colin; Fass, Deborah			The dynamic disulphide relay of quiescin sulphydryl oxidase	NATURE			English	Article							K EPOXIDE REDUCTASE; PROTEIN-STRUCTURE; FAMILY; QSOX; ER	Protein stability, assembly, localization and regulation often depend on the formation of disulphide crosslinks between cysteine side chains. Enzymes known as sulphydryl oxidases catalysede novo disulphide formation and initiate intra-and intermolecular dithiol/disulphide relays to deliver the disulphides to substrate proteins(1,2). Quiescin sulphydryl oxidase (QSOX) is a unique, multi-domain disulphide catalyst that is localized primarily to the Golgi apparatus and secreted fluids(3) and has attracted attention owing to its overproduction in tumours(4,5). In addition to its physiological importance, QSOX is a mechanistically intriguing enzyme, encompassing functions typically carried out by a series of proteins in other disulphide-formation pathways. How disulphides are relayed through the multiple redox-active sites of QSOX and whether there is a functional benefit to concatenating these sites on a single polypeptide are open questions. Here we present the first crystal structure of an intact QSOX enzyme, derived from a trypanosome parasite. Notably, sequential sites in the disulphide relay were found more than 40 angstrom apart in this structure, too far for direct disulphide transfer. To resolve this puzzle, we trapped and crystallized an intermediate in the disulphide hand-off, which showed a 165 degrees domain rotation relative to the original structure, bringing the two active sites within disulphide-bonding distance. The comparable structure of a mammalian QSOX enzyme, also presented here, shows further biochemical features that facilitate disulphide transfer in metazoan orthologues. Finally, we quantified the contribution of concatenation to QSOX activity, providing general lessons for the understanding of multi-domain enzymes and the design of new catalytic relays.	[Alon, Assaf; Grossman, Iris; Gat, Yair; Fass, Deborah] Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; [Kodali, Vamsi K.; Thorpe, Colin] Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; [DiMaio, Frank; Baker, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA; [Mehlman, Tevie] Weizmann Inst Sci, Dept Biol Res Support, IL-76100 Rehovot, Israel; [Haran, Gilad] Weizmann Inst Sci, Dept Chem Phys, IL-76100 Rehovot, Israel	Weizmann Institute of Science; University of Delaware; University of Washington; University of Washington Seattle; Weizmann Institute of Science; Weizmann Institute of Science	Fass, D (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	deborah.fass@weizmann.ac.il	Baker, David/K-8941-2012; HARAN, GILAD/K-1489-2012; Kodali, Vamsi/A-8530-2010	Baker, David/0000-0001-7896-6217; Alon, Assaf/0000-0001-8102-5290; Kodali, Vamsi/0000-0001-8941-9761	Israel Science Foundation; Kimmelman Center for Macromolecular Assemblies; National Institutes of Health (NIH) [GM26643]; NIH [P41 RR001081]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026643] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); Kimmelman Center for Macromolecular Assemblies; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	S. Rogotner and O. Dym helped in growing the TbQSOX<INF>C</INF> crystals. We thank T. Ilani and A. Horovitz for reading of the manuscript and N. Nelson and his research group for help with X-ray data collection. A. Moseri assisted with high-performance liquid chromatography. This study was funded by the Israel Science Foundation. D. F. and A. A. acknowledge the Kimmelman Center for Macromolecular Assemblies for additional support. C. T. and V. K. K. acknowledge National Institutes of Health (NIH) grant GM26643. The molecular movie was produced using the University of California San Francisco Chimera package from the Resource for Biocomputing, Visualization and Informatics (supported by NIH grant P41 RR001081).	Afonine P. V., 2005, CCP4 NEWSLETT; Alon A, 2010, FEBS LETT, V584, P1521, DOI 10.1016/j.febslet.2010.03.001; Antwi K, 2009, J PROTEOME RES, V8, P4722, DOI 10.1021/pr900414f; Apperizeller-Herzog C, 2008, BBA-MOL CELL RES, V1783, P535, DOI 10.1016/j.bbamcr.2007.11.010; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; DiMaio F, 2011, NATURE, V473, P540, DOI 10.1038/nature09964; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Eswar Narayanan, 2008, V426, P145, DOI 10.1007/978-1-60327-058-8_8; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Fass D, 2008, BBA-MOL CELL RES, V1783, P557, DOI 10.1016/j.bbamcr.2007.11.009; Goodstadt L, 2004, TRENDS BIOCHEM SCI, V29, P289, DOI 10.1016/j.tibs.2004.04.004; Gross E, 2006, P NATL ACAD SCI USA, V103, P299, DOI 10.1073/pnas.0506448103; Heckler EJ, 2008, BIOCHEMISTRY-US, V47, P4955, DOI 10.1021/bi702522q; Inaba K, 2006, P NATL ACAD SCI USA, V103, P287, DOI 10.1073/pnas.0507570103; Jaje J, 2007, BIOCHEMISTRY-US, V46, P13031, DOI 10.1021/bi7016975; Kodali VK, 2010, ANTIOXID REDOX SIGN, V13, P1217, DOI 10.1089/ars.2010.3098; Kodali VK, 2010, BIOCHEMISTRY-US, V49, P2075, DOI 10.1021/bi902222s; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Levitt M, 2009, P NATL ACAD SCI USA, V106, P11079, DOI 10.1073/pnas.0905029106; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mitra P, 2010, FEBS LETT, V584, P1163, DOI 10.1016/j.febslet.2010.02.021; OSTROWSKI MC, 1980, BIOCHEMISTRY-US, V19, P2639, DOI 10.1021/bi00553a016; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Raje S, 2003, BIOCHEMISTRY-US, V42, P4560, DOI 10.1021/bi030003z; Riemer J, 2009, SCIENCE, V324, P1284, DOI 10.1126/science.1170653; Schulman S, 2010, P NATL ACAD SCI USA, V107, P15027, DOI 10.1073/pnas.1009972107; Song H, 2009, ONCOGENE, V28, P3307, DOI 10.1038/onc.2009.181; Tordai H, 2005, FEBS J, V272, P5064, DOI 10.1111/j.1742-4658.2005.04917.x; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Walter TS, 2006, STRUCTURE, V14, P1617, DOI 10.1016/j.str.2006.09.005; Xu H, 2008, J PROTEOME RES, V7, P138, DOI 10.1021/pr070363z; Zanata SM, 2005, REDOX REP, V10, P319, DOI 10.1179/135100005X83699	34	60	65	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 16	2012	488	7411					414	+		10.1038/nature11267	http://dx.doi.org/10.1038/nature11267			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988OS	22801504	Green Accepted			2022-12-28	WOS:000307501000049
J	Sundd, P; Gutierrez, E; Koltsova, EK; Kuwano, Y; Fukuda, S; Pospieszalska, MK; Groisman, A; Ley, K				Sundd, Prithu; Gutierrez, Edgar; Koltsova, Ekaterina K.; Kuwano, Yoshihiro; Fukuda, Satoru; Pospieszalska, Maria K.; Groisman, Alex; Ley, Klaus			'Slings' enable neutrophil rolling at high shear	NATURE			English	Article							SELECTIN GLYCOPROTEIN LIGAND-1; INTERCELLULAR-ADHESION MOLECULE-1; SLOW VISCOUS MOTION; P-SELECTIN; IN-VIVO; PHYSIOLOGICAL FLOW; SPHERE PARALLEL; PLANE WALL; MICE; TETHERS	Most leukocytes can roll along the walls of venules at lowshear stress (1 dyn cm(-2)), but neutrophils have the ability to roll at tenfold higher shear stress in microvessels in vivo(1,2). The mechanisms involved in this shear-resistant rolling are known to involve cell flattening(3) and pulling of long membrane tethers at the rear(4-6). Here we show that these long tethers do not retract as postulated(6,7), but instead persist and appear as 'slings' at the front of rolling cells. We demonstrate slings in a model of acute inflammationin vivo and on P-selectin in vitro, where P-selectin-glycoprotein-ligand-1 (PSGL-1) is found in discrete sticky patches whereas LFA-1 is expressed over the entire length on slings. As neutrophils roll forward, slings wrap around the rolling cells and undergo a step-wise peeling from the P-selectin substrate enabled by the failure of PSGL-1 patches under hydrodynamic forces. The 'step-wise peeling of slings' is distinct from the 'pulling of tethers' reported previously(4-6,8). Each sling effectively lays out a cell-autonomous adhesive substrate in front of neutrophils rolling at high shear stress during inflammation.	[Sundd, Prithu; Koltsova, Ekaterina K.; Kuwano, Yoshihiro; Pospieszalska, Maria K.; Ley, Klaus] La Jolla Inst Allergy & Immunol, Div Inflammat Biol, La Jolla, CA 92037 USA; [Gutierrez, Edgar; Groisman, Alex] Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA; [Kuwano, Yoshihiro] Univ Tokyo, Dept Dermatol, Tokyo 1138655, Japan; [Fukuda, Satoru] Univ Tokyo, Lab Electron Microscopy, Tokyo 1138655, Japan	La Jolla Institute for Immunology; University of California System; University of California San Diego; University of Tokyo; University of Tokyo	Ley, K (corresponding author), La Jolla Inst Allergy & Immunol, Div Inflammat Biol, La Jolla, CA 92037 USA.	klaus@liai.org	Sawant, Kirti V/H-3778-2013; Groisman, Alexander/AAU-7843-2021		American Heart Association [11SDG7340005, 10POST4160142-01]; NIH [EB 02185]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002185] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	The authors thank A. Zychlinsky for comments and reading the manuscript. This study was supported by the NCRP-Scientist Development Grant 11SDG7340005 from the American Heart Association (P. S.), WSA postdoctoral fellowship 10POST4160142-01 from American Heart Association (E. K. K.) and NIH EB 02185 (K.L.).	Atarashi K, 2005, J IMMUNOL, V174, P1424, DOI 10.4049/jimmunol.174.3.1424; Brochard-Wyart F, 2006, P NATL ACAD SCI USA, V103, P7660, DOI 10.1073/pnas.0602012103; Damiano ER, 1996, CIRC RES, V79, P1122, DOI 10.1161/01.RES.79.6.1122; Ding ZM, 1999, J IMMUNOL, V163, P5029; Doyle EL, 2011, BLOOD, V118, P4265, DOI 10.1182/blood-2010-11-321489; Faust N, 2000, BLOOD, V96, P719; FIRRELL JC, 1989, AM J PHYSIOL, V256, pH1667, DOI 10.1152/ajpheart.1989.256.6.H1667; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P637, DOI 10.1016/0009-2509(67)80047-2; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; HATTORI R, 1989, J BIOL CHEM, V264, P7768; Hocde SA, 2009, BIOPHYS J, V97, P379, DOI 10.1016/j.bpj.2009.04.035; Huang MT, 2006, BLOOD, V107, P4721, DOI 10.1182/blood-2005-11-4683; Krasik EF, 2004, BIOPHYS J, V87, P2919, DOI 10.1529/biophysj.104.039693; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; Kuwano Y, 2010, BLOOD, V116, P617, DOI 10.1182/blood-2010-01-266122; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Marshall BT, 2003, NATURE, V423, P190, DOI 10.1038/nature01605; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Pendl GG, 2002, BLOOD, V99, P946, DOI 10.1182/blood.V99.3.946; Pospieszalska MK, 2011, BIOPHYS J, V100, P1697, DOI 10.1016/j.bpj.2011.02.038; Pospieszalska MK, 2009, CURR TOP MEMBR, V64, P221, DOI 10.1016/S1063-5823(09)64008-4; Pospieszalska M, 2009, MICROCIRCULATION, V16, P115, DOI 10.1080/10739680802462792; Ramachandran V, 2004, P NATL ACAD SCI USA, V101, P13519, DOI 10.1073/pnas.0403608101; SCHMIDSCHONBEIN GW, 1990, CELL BIOPHYS, V17, P107, DOI 10.1007/BF02990492; Schmidtke DW, 2000, J CELL BIOL, V149, P719, DOI 10.1083/jcb.149.3.719; Shao JY, 2009, CURR TOP MEMBR, V64, P25, DOI 10.1016/S1063-5823(09)64002-3; Sperandio M, 2001, BLOOD, V97, P3812, DOI 10.1182/blood.V97.12.3812; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Sundd P, 2011, BIORHEOLOGY, V48, P1, DOI 10.3233/BIR-2011-0579; Sundd P, 2011, MICROCIRCULATION, V18, P361, DOI 10.1111/j.1549-8719.2011.00090.x; Sundd P, 2010, NAT METHODS, V7, P821, DOI [10.1038/NMETH.1508, 10.1038/nmeth.1508]; Tojo Akihiro, 2004, Medical Electron Microscopy, V37, P236, DOI 10.1007/s00795-004-0263-2; Waugh RE, 2009, CURR TOP MEMBR, V64, P3, DOI 10.1016/S1063-5823(09)64001-1; Wilcox R. R., 1987, NEW STAT PROCEDURES; Woodfin A, 2011, NAT IMMUNOL, V12, P761, DOI 10.1038/ni.2062; Xia LJ, 2002, J CLIN INVEST, V109, P939; Xu H, 1996, J IMMUNOL, V156, P4909; Zarbock A, 2007, IMMUNITY, V26, P773, DOI 10.1016/j.immuni.2007.04.011	39	128	128	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 16	2012	488	7411					399	+		10.1038/nature11248	http://dx.doi.org/10.1038/nature11248			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988OS	22763437	Green Accepted			2022-12-28	WOS:000307501000046
J	Atasoy, D; Betley, JN; Su, HH; Sternson, SM				Atasoy, Deniz; Betley, J. Nicholas; Su, Helen H.; Sternson, Scott M.			Deconstruction of a neural circuit for hunger	NATURE			English	Article							HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; NEUROPEPTIDE-Y; PARABRACHIAL NUCLEUS; OXYTOCIN NEURONS; NPY/AGRP NEURONS; ARCUATE NUCLEUS; ENERGY-BALANCE; AGRP NEURONS; PROTEIN AGRP; RELEASE	Hunger is a complex behavioural state that elicits intense food seeking and consumption. These behaviours are rapidly recapitulated by activation of starvation-sensitive AGRP neurons, which present an entry point for reverse-engineering neural circuits for hunger. Here we mapped synaptic interactions of AGRP neurons with multiple cell populations in mice and probed the contribution of these distinct circuits to feeding behaviour using optogenetic and pharmacogenetic techniques. An inhibitory circuit with paraventricular hypothalamus (PVH) neurons substantially accounted for acute AGRP neuron-evoked eating, whereas two other prominent circuits were insufficient. Within the PVH, we found that AGRP neurons target and inhibit oxytocin neurons, a small population that is selectively lost in Prader-Willi syndrome, a condition involving insatiable hunger. By developing strategies for evaluating molecularly defined circuits, we show that AGRP neuron suppression of oxytocin neurons is critical for evoked feeding. These experiments reveal a new neural circuit that regulates hunger state and pathways associated with overeating disorders.	[Atasoy, Deniz; Betley, J. Nicholas; Su, Helen H.; Sternson, Scott M.] Howard Hughes Med Inst, Ashburn, VA 20147 USA	Howard Hughes Medical Institute	Sternson, SM (corresponding author), Howard Hughes Med Inst, Janelia Farm Res Campus,19700 Helix Dr, Ashburn, VA 20147 USA.	sternsons@janelia.hhmi.org	Atasoy, Deniz/AAR-7917-2020; Atasoy, Deniz/B-3414-2018	Atasoy, Deniz/0000-0002-3325-8820; Sternson, Scott/0000-0002-0835-444X	Howard Hughes Medical Institute	Howard Hughes Medical Institute(Howard Hughes Medical Institute)	This research was funded by the Howard Hughes Medical Institute. We thank J. Cox, A. Wardlaw, K. Morris for mouse breeding, genotyping, and viral injection support; S. Michael and A. Hu for histology support; M. Ramirez and B. Zemelman for rAAV production; H. Gainer for discussions about the oxytocin promoter; and E. Boyden for technical assistance.	Andrews ZB, 2008, NATURE, V454, P846, DOI 10.1038/nature07181; Aponte Y, 2011, NAT NEUROSCI, V14, P351, DOI 10.1038/nn.2739; Aravanis AM, 2007, J NEURAL ENG, V4, pS143, DOI 10.1088/1741-2560/4/3/S02; ARLETTI R, 1990, PHYSIOL BEHAV, V48, P825, DOI 10.1016/0031-9384(90)90234-U; Armbruster BN, 2007, P NATL ACAD SCI USA, V104, P5163, DOI 10.1073/pnas.0700293104; Atasoy D, 2008, J NEUROSCI, V28, P7025, DOI 10.1523/JNEUROSCI.1954-08.2008; AVERY L, 1992, TRENDS GENET, V8, P312, DOI 10.1016/0168-9525(92)90263-4; Balthasar N, 2005, CELL, V123, P493, DOI 10.1016/j.cell.2005.08.035; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Baskin DG, 2010, ENDOCRINOLOGY, V151, P4207, DOI 10.1210/en.2010-0295; Best AR, 2009, NEURON, V62, P555, DOI 10.1016/j.neuron.2009.04.018; Biag J, 2012, J COMP NEUROL, V520, P6, DOI 10.1002/cne.22698; Blevins JE, 2003, BRAIN RES, V993, P30, DOI 10.1016/j.brainres.2003.08.036; Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525; Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043; Cannon W.B., 1939, WISDOM BODY, DOI [10.1097/00000441-193907000-00031, DOI 10.1097/00000441-193907000-00031]; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; Collins SR, 2007, NATURE, V446, P806, DOI 10.1038/nature05649; Cowley MA, 2003, NEURON, V37, P649, DOI 10.1016/S0896-6273(03)00063-1; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Dicken MS, 2012, J NEUROSCI, V32, P4042, DOI 10.1523/JNEUROSCI.6032-11.2012; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fields RL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032085; Gropp E, 2005, NAT NEUROSCI, V8, P1289, DOI 10.1038/nn1548; Hefft S, 2005, NAT NEUROSCI, V8, P1319, DOI 10.1038/nn1542; Higgs S, 1996, EUR J PHARMACOL, V313, P1, DOI 10.1016/0014-2999(96)00446-3; HODOS W, 1961, SCIENCE, V134, P943, DOI 10.1126/science.134.3483.943; Holder JL, 2000, HUM MOL GENET, V9, P101; Kaelin CB, 2004, ENDOCRINOLOGY, V145, P5798, DOI 10.1210/en.2004-0956; KELLY J, 1979, PHYSIOL BEHAV, V23, P1123, DOI 10.1016/0031-9384(79)90306-8; Knobloch HS, 2012, NEURON, V73, P553, DOI 10.1016/j.neuron.2011.11.030; Krashes MJ, 2011, J CLIN INVEST, V121, P1424, DOI 10.1172/JCI46229; Kublaoui BM, 2008, MOL ENDOCRINOL, V22, P1723, DOI 10.1210/me.2008-0067; LEIBOWITZ SF, 1981, PHYSIOL BEHAV, V27, P1031, DOI 10.1016/0031-9384(81)90366-8; Luquet S, 2005, SCIENCE, V310, P683, DOI 10.1126/science.1115524; Magnus CJ, 2011, SCIENCE, V333, P1292, DOI 10.1126/science.1206606; Peng HC, 2010, BIOINFORMATICS, V26, pi38, DOI 10.1093/bioinformatics/btq212; Petreanu L, 2007, NAT NEUROSCI, V10, P663, DOI 10.1038/nn1891; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; SWAAB DF, 1995, J CLIN ENDOCR METAB, V80, P573, DOI 10.1210/jc.80.2.573; SWANSON LW, 1983, ANNU REV NEUROSCI, V6, P269, DOI 10.1146/annurev.ne.06.030183.001413; SWANSON LW, 1980, BRAIN RES, V198, P190, DOI 10.1016/0006-8993(80)90354-6; Tong QC, 2008, NAT NEUROSCI, V11, P998, DOI 10.1038/nn.2167; Traurig M, 2009, DIABETES, V58, P1682, DOI 10.2337/db09-0028; Wieland HA, 1998, BRIT J PHARMACOL, V125, P549, DOI 10.1038/sj.bjp.0702084; Wu Q, 2012, NATURE, V483, P594, DOI 10.1038/nature10899; Wu Q, 2009, CELL, V137, P1225, DOI 10.1016/j.cell.2009.04.022; Xi D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036453; Yang YL, 2011, CELL, V146, P991, DOI 10.1016/j.cell.2011.07.039; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506; Young WS, 1999, J NEUROENDOCRINOL, V11, P935; Zhang G, 2011, NEURON, V69, P523, DOI 10.1016/j.neuron.2010.12.036; Zhang M, 2003, BEHAV NEUROSCI, V117, P202, DOI 10.1037/0735-7044.117.2.202	53	584	598	3	166	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 9	2012	488	7410					172	+		10.1038/nature11270	http://dx.doi.org/10.1038/nature11270			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	985LE	22801496	Green Accepted			2022-12-28	WOS:000307267000025
J	Schuur, JD; Venkatesh, AK				Schuur, Jeremiah D.; Venkatesh, Arjun K.			The Growing Role of Emergency Departments in Hospital Admissions	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Schuur, Jeremiah D.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Venkatesh, Arjun K.] Massachusetts Gen Hosp, Brigham & Womens Hosp, Harvard Affiliated Emergency Med Residency Progra, Boston, MA 02114 USA; [Schuur, Jeremiah D.; Venkatesh, Arjun K.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School	Schuur, JD (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA.							Asplin BR, 2005, JAMA-J AM MED ASSOC, V294, P1248, DOI 10.1001/jama.294.10.1248; BEAL AC, 2007, CLOSING DIVIDE MED H; Newton MF, 2008, JAMA-J AM MED ASSOC, V300, P1914, DOI 10.1001/jama.300.16.1914; Pitts SR, 2010, HEALTH AFFAIR, V29, P1620, DOI 10.1377/hlthaff.2009.1026; Tang N, 2010, JAMA-J AM MED ASSOC, V304, P664, DOI 10.1001/jama.2010.1112	5	253	254	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2012	367	5					391	393		10.1056/NEJMp1204431	http://dx.doi.org/10.1056/NEJMp1204431			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981VZ	22784039				2022-12-28	WOS:000307001900002
J	Millett, GA; Peterson, JL; Flores, SA; Hart, TA; Jeffries, WL; Wilson, PA; Rourke, SB; Heilig, CM; Elford, J; Fenton, KA; Remis, RS				Millett, Gregorio A.; Peterson, John L.; Flores, Stephen A.; Hart, Trevor A.; Jeffries, William L.; Wilson, Patrick A.; Rourke, Sean B.; Heilig, Charles M.; Elford, Jonathan; Fenton, Kevin A.; Remis, Robert S.			Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis	LANCET			English	Article							UNITED-STATES; ANTIRETROVIRAL THERAPY; PREVALENCE; BEHAVIORS; ABUSE; AGE; MSM	Background We did a meta-analysis to assess factors associated with disparities in HIV infection in black men who have sex with men (MSM) in Canada, the UK, and the USA. Methods We searched Embase, Medline, Google Scholar, and online conference proceedings from Jan 1, 1981, to Dec 31, 2011, for racial comparative studies with quantitative outcomes associated with HIV risk or HIV infection. Key words and Medical Subject Headings (US National Library of Medicine) relevant to race were cross-referenced with citations pertinent to homosexuality in Canada, the UK, and the USA. Data were aggregated across studies for every outcome of interest to estimate overall effect sizes, which were converted into summary ORs for 106 148 black MSM relative to 581 577 other MSM. Findings We analysed seven studies from Canada, 13 from the UK, and 174 from the USA. In every country, black MSM were as likely to engage similarly in serodiscordant unprotected sex as other MSM. Black MSM in Canada and the USA were less likely than other MSM to have a history of substance use (odds ratio, OR, 0.53, 95% CI 0.38-0.75, for Canada and 0.67, 0.50-0.92, for the USA). Black MSM in the UK (1.86, 1.58-2.18) and the USA (3.00, 2.06-4.40) were more likely to be HIV positive than were other MSM, but HIV-positive black MSM in each country were less likely (22% in the UK and 60% in the USA) to initiate combination antiretroviral therapy (cART) than other HIV-positive MSM. US HIV-positive black MSM were also less likely to have health insurance, have a high CD4 count, adhere to cART, or be virally suppressed than were other US HIV-positive MSM. Notably, despite a two-fold greater odds of having any structural barrier that increases HIV risk (eg, unemployment, low income, previous incarceration, or less education) compared with other US MSM, US black MSM were more likely to report any preventive behaviour against HIV infection (1.39, 1.23-1.57). For outcomes associated with HIV infection, disparities were greatest for US black MSM versus other MSM for structural barriers, sex partner demographics (eg, age, race), and HIV care outcomes, whereas disparities were least for sexual risk outcomes. Interpretation Similar racial disparities in HIV and sexually transmitted infections and cART initiation are seen in MSM in the UK and the USA. Elimination of disparities in HIV infection in black MSM cannot be accomplished without addressing structural barriers or differences in HIV clinical care access and outcomes.	[Millett, Gregorio A.; Flores, Stephen A.; Jeffries, William L.; Heilig, Charles M.; Fenton, Kevin A.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Washington, DC 20201 USA; [Peterson, John L.] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA; [Hart, Trevor A.; Remis, Robert S.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada; [Hart, Trevor A.] Univ Toronto, Dala Lana Sch Publ Hlth, Toronto, ON, Canada; [Wilson, Patrick A.] Columbia Univ, Dept Sociomed Sci, New York, NY USA; [Rourke, Sean B.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Remis, Robert S.] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; [Elford, Jonathan] City Univ London, Dept Publ Hlth, London EC1V 0HB, England	Centers for Disease Control & Prevention - USA; University System of Georgia; Georgia State University; Toronto Metropolitan University; University of Toronto; Columbia University; University of Toronto; University of Toronto; City University London	Millett, GA (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, E St SW,MS-06, Washington, DC 20201 USA.	gmillett@cdc.gov	Heilig, Charles M/C-2753-2008	Heilig, Charles M/0000-0003-1075-1310; Hart, Trevor/0000-0001-5107-7452				Aral SO, 2008, LANCET, V372, P337, DOI 10.1016/S0140-6736(08)61118-6; Bingham TA, 2003, AIDS EDUC PREV, V15, P39, DOI 10.1521/aeap.15.1.5.39.23613; BINSON D, 1995, J SEX RES, V32, P245, DOI 10.1080/00224499509551795; Blair JM, 2002, JAIDS-J ACQ IMM DEF, V31, P339, DOI 10.1097/00126334-200211010-00011; Carlos JA, 2010, AIDS EDUC PREV, V22, P430, DOI 10.1521/aeap.2010.22.5.430; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068; Hall HI, 2007, AM J PUBLIC HEALTH, V97, P1060, DOI 10.2105/AJPH.2006.087551; Hedges LV, 1998, PSYCHOL METHODS, V3, P486, DOI 10.1037/1082-989X.3.4.486; LINN LS, 1989, ARCH INTERN MED, V149, P2685, DOI 10.1001/archinte.149.12.2685; Lyons A, 2012, SEX TRANSM INFECT, V88, P252, DOI 10.1136/sextrans-2011-050253; MacKellar DA, 2006, AIDS, V20, P1637, DOI 10.1097/01.aids.0000238410.67700.d1; Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d; Millett GA, 2007, AIDS, V21, P2083, DOI 10.1097/QAD.0b013e3282e9a64b; Millett GA, 2006, AM J PUBLIC HEALTH, V96, P1007, DOI 10.2105/AJPH.2005.066720; Mimiaga MJ, 2009, JAIDS-J ACQ IMM DEF, V51, P340, DOI 10.1097/QAI.0b013e3181a24b38; Phillips GH, 2012, AIDS BEHAV; Prejean J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017502; Sethi G, 2012, JAIDS-J ACQ IMM DEF, V59, P523, DOI 10.1097/QAI.0b013e318245c9ca; The Canadian Medical Protective Association, 2008, TREAT NONR CAN; Viner RM, 2012, LANCET, V379, P1641, DOI 10.1016/S0140-6736(12)60149-4; Welles SL, 2009, AM J PUBLIC HEALTH, V99, P1079, DOI 10.2105/AJPH.2007.133280	22	501	507	1	67	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 28	2012	380	9839					341	348		10.1016/S0140-6736(12)60899-X	http://dx.doi.org/10.1016/S0140-6736(12)60899-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819656				2022-12-28	WOS:000306842800031
J	Sullivan, PS; Carballo-Dieguez, A; Coates, T; Goodreau, SM; McGowan, I; Sanders, EJ; Smith, A; Goswami, P; Sanchez, J				Sullivan, Patrick S.; Carballo-Dieguez, Alex; Coates, Thomas; Goodreau, Steven M.; McGowan, Ian; Sanders, Eduard J.; Smith, Adrian; Goswami, Prabuddhagopal; Sanchez, Jorge			Successes and challenges of HIV prevention in men who have sex with men	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED INFECTIONS; ANTIRETROVIRAL THERAPY; HIGH-RISK; BEHAVIORAL SURVEILLANCE; PREEXPOSURE PROPHYLAXIS; UNITED-STATES; DOUBLE-BLIND; VIRAL LOAD; ANAL SEX	Men who have sex with men (MSM) have been substantially affected by HIV epidemics worldwide. Epidemics in MSM are re-emerging in many high-income countries and gaining greater recognition in many low-income and middle-income countries. Better HIV prevention strategies are urgently needed. Our review of HIV prevention strategies for MSM identified several important themes. At the beginning of the epidemic, stand-alone behavioural interventions mostly aimed to reduce unprotected anal intercourse, which, although somewhat efficacious, did not reduce HIV transmission. Biomedical prevention strategies reduce the incidence of HIV infection. Delivery of barrier and biomedical interventions with coordinated behavioural and structural strategies could optimise the effectiveness of prevention. Modelling suggests that, with sufficient coverage, available interventions are sufficient to avert at least a quarter of new HIV infections in MSM in diverse countries. Scale-up of HIV prevention programmes for MSM is difficult because of homophobia and bias, suboptimum access to HIV testing and care, and financial constraints.	[Sullivan, Patrick S.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; [Carballo-Dieguez, Alex] Columbia Univ, HIV Ctr Clin & Behav Studies, New York, NY USA; [Coates, Thomas] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Goodreau, Steven M.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA; [McGowan, Ian] Univ Pittsburgh, Pittsburgh, PA USA; [Sanders, Eduard J.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya; [Sanders, Eduard J.; Smith, Adrian] Univ Oxford, Oxford, England; [Goswami, Prabuddhagopal] FHI 360, New Delhi, India; [Sanchez, Jorge] Asociac Civil Impacta Salud & Educ IMPACTA, Lima, Peru	Emory University; Rollins School Public Health; Columbia University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Oxford	Sullivan, PS (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.	patrick.sullivan@emory.edu	Goodreau, Steven/P-2366-2017; M, Ian/AAP-1032-2021; M, i/HCI-9242-2022	M, Ian/0000-0002-6470-8476; Smith, Adrian/0000-0003-0036-1490; Goswami, Prabuddhagopal/0000-0001-5676-7436; Sullivan, Patrick Sean/0000-0002-7728-0587; Goodreau, Steven/0000-0003-1009-5763	National Institutes of Health [NIMH: R01-MH85600, NIMHHD: RC1- MD004370, NIAID: R01-AI094575, NICHD: R01-HD067111]; Emory Center for AIDS Research [P30-AI050409]; SMG by Prevention Umbrella for MSM in the Americas (National Institute of Allergy and Infectious Diseases) [R01-AI083060]; American Foundation for AIDS Research; International AIDS Vaccine Initiative; Avahan, the Indian initiative of the Bill & Melinda Gates Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD042828, R01HD068395, R01HD067111] Funding Source: NIH RePORTER; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [RC1MD004370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083060, R01AI094575, P30AI050409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH085600, P30MH043520] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Emory Center for AIDS Research; SMG by Prevention Umbrella for MSM in the Americas (National Institute of Allergy and Infectious Diseases); American Foundation for AIDS Research; International AIDS Vaccine Initiative; Avahan, the Indian initiative of the Bill & Melinda Gates Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank Jeb Jones and Adam Vaughan for their assistance with preparation of figure 1 and the appendix, Wayne Johnson for his assistance with calculation of effect sizes for published studies, the PUMA research team (principal investigator Susan Buchbinder), and Sharoda Dasgupta and Kathryn Risher for their assistance with developing input parameters for the modelling. PSS was supported by the National Institutes of Health (NIMH: R01-MH85600; NIMHHD: RC1- MD004370; NIAID: R01-AI094575; NICHD: R01-HD067111) and the Emory Center for AIDS Research (P30-AI050409), SMG by Prevention Umbrella for MSM in the Americas (National Institute of Allergy and Infectious Diseases, R01-AI083060) and the American Foundation for AIDS Research, EJS by the International AIDS Vaccine Initiative, and PG by Avahan, the Indian initiative of the Bill & Melinda Gates Foundation.	Adam PCG, 2009, JAIDS-J ACQ IMM DEF, V52, pS143, DOI 10.1097/QAI.0b013e3181baf111; Anton P, 2011, 18 C RETR OPP INF BO, p34LB; Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca; Barnighausen T, 2011, LANCET INFECT DIS, V11, P942, DOI 10.1016/S1473-3099(11)70181-5; Baeten JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001888; Baral S, PUBLIC HLTH IN PRESS; Baral S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004997; Bekker L. G., 2012, Southern African Journal of HIV Medicine, V13, P40; Beyrer C, 2012, LANCET; Beyrer C, 2007, CLIN INFECT DIS, V44, P981, DOI 10.1086/512371; Beyrer C, 2010, SEX TRANSM INFECT, V86, P323, DOI 10.1136/sti.2009.040162; Brown EL, 2006, AM J EPIDEMIOL, V164, P733, DOI 10.1093/aje/kwj270; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Butler LM, 2009, JAIDS-J ACQ IMM DEF, V50, P162, DOI 10.1097/QAI.0b013e31819388a9; Carballo-Dieguez A, 2007, SEX TRANSM DIS, V34, P224, DOI 10.1097/01.olq.0000233715.59239.83; Carballo-Dieguez A, 2007, AIDS BEHAV, V11, P271, DOI 10.1007/s10461-006-9128-0; Celum C, 2010, NEW ENGL J MED, V362, P427, DOI 10.1056/NEJMoa0904849; Celum C, 2008, LANCET, V371, P2109, DOI 10.1016/S0140-6736(08)60920-4; Centers for Disease Control, 1981, MMWR-MORBID MORTAL W, V30, P250; Centers for Disease Control and Prevention, 2009 COMP HIV PREV I; Charania MR, 2011, AIDS BEHAV, V15, P1283, DOI 10.1007/s10461-010-9812-y; Chin-Hong PV, 2009, AIDS, V23, P1135, DOI 10.1097/QAD.0b013e32832b4449; Coates TJ, 2008, LANCET, V372, P669, DOI 10.1016/S0140-6736(08)60886-7; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cranage M, 2008, PLOS MED, V5, P1238, DOI 10.1371/journal.pmed.0050157; Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068; Degenhardt L, 2010, LANCET, V376, P285, DOI 10.1016/S0140-6736(10)60742-8; Dieffenbach CW, 2011, ANN INTERN MED, V154, P766, DOI 10.7326/0003-4819-154-11-201106070-00345; Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2; Eshleman SH, 2011, J INFECT DIS, V204, P1918, DOI 10.1093/infdis/jir651; Excler JL, 2011, AIDS RES HUM RETROV, V27, P669, DOI [10.1089/aid.2010.0206, 10.1089/AID.2010.0206]; Fay H, 2011, AIDS BEHAV, V15, P1088, DOI 10.1007/s10461-010-9861-2; Fisher M, 2010, AIDS, V24, P1739, DOI 10.1097/QAD.0b013e32833ac9e6; Gallagher KM, 2007, PUBLIC HEALTH REP, V122, P32, DOI 10.1177/00333549071220S106; Geibel S, 2008, SEX TRANSM DIS, V35, P746, DOI 10.1097/OLQ.0b013e318170589d; Gorbach PM, 2012, SEX TRANSM DIS, V39, P59, DOI 10.1097/OLQ.0b013e318235502b; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Hall HI, 2008, JAMA-J AM MED ASSOC, V300, P520, DOI 10.1001/jama.300.5.520; Jaffe HW, 2007, JAMA-J AM MED ASSOC, V298, P2412, DOI 10.1001/jama.298.20.2412; Johnson WD, 2005, AIDS EDUC PREV, V17, P568, DOI 10.1521/aeap.2005.17.6.568; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Kippax S, 2003, SOC SCI MED, V57, P1, DOI 10.1016/S0277-9536(02)00303-9; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Koblin B, 2004, LANCET, V364, P41, DOI 10.1016/S0140-6736(04)16588-4; Koenig LJ, 2008, HEALTH PSYCHOL, V27, P159, DOI 10.1037/0278-6133.27.2.159; Kurth Ann E, 2011, Curr HIV/AIDS Rep, V8, P62, DOI 10.1007/s11904-010-0063-3; Lane T, 2011, AIDS BEHAV, V15, P626, DOI 10.1007/s10461-009-9598-y; Law MG, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-10; Li DL, 2010, AIDS PATIENT CARE ST, V24, P595, DOI 10.1089/apc.2010.0083; MacQueen KM, 2005, AM J PREV MED, V28, P491, DOI 10.1016/j.amepre.2005.02.020; Mansergh G, PLOS MED IN PRESS; Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79; McGowan I, 2012, 19 C RETR OPP INF SE, p34LB; McGowan I, 2011, AIDS BEHAV, V15, pS66, DOI 10.1007/s10461-011-9899-9; McGowan I, 2010, CURR OPIN INFECT DIS, V23, P26, DOI 10.1097/QCO.0b013e328334fe70; Menza TW, 2009, SEX TRANSM DIS, V36, P547, DOI 10.1097/OLQ.0b013e3181a9cc41; *NAT CTR HIV EP CL, 2006, HIV AIDS VIR HEP SEX; Noar SA, 2009, AIDS, V23, P107, DOI 10.1097/QAD.0b013e32831c5500; Padian NS, 2008, LANCET, V372, P585, DOI 10.1016/S0140-6736(08)60885-5; Padian NS, 2011, JAIDS-J ACQ IMM DEF, V58, pE23, DOI 10.1097/QAI.0b013e318227af37; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Politch JA, 2012, AIDS, V26, P1535, DOI 10.1097/QAD.0b013e328353b11b; Powers KA, 2011, LANCET, V378, P256, DOI 10.1016/S0140-6736(11)60842-8; Renzi C, 2003, AIDS, V17, P727, DOI 10.1097/00002030-200303280-00011; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Russo J, 2010, SAFETY ANTIHIV ACTIV, P347; Sanchez Travis, 2006, Morbidity and Mortality Weekly Report, V55, P1; Sanders E, 2011, 18 C RETR OPP INF CR, P1042; Sanders EJ, 2007, AIDS, V21, P2513, DOI 10.1097/QAD.0b013e3282f2704a; Schmidt AJ, EUROPEAN MSM INTERNE; Shoptaw S, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-214; Silverman BG, 1997, SEX TRANSM DIS, V24, P11, DOI 10.1097/00007435-199701000-00004; Smith A., 2010, Morbidity and Mortality Weekly Report, V59, P1201; Smith AD, 2009, LANCET, V374, P416, DOI 10.1016/S0140-6736(09)61118-1; Smith D, AFRICA CALLING MOBIL; Stone E, 1999, J ACQ IMMUN DEF SYND, V20, P495, DOI 10.1097/00042560-199904150-00013; UNDP, DEV COMPR PACK SERV; van Griensven F, 2010, AIDS, V24, pS30, DOI 10.1097/01.aids.0000390087.22565.b4; van Griensven F, 2009, CURR OPIN HIV AIDS, V4, P300, DOI 10.1097/COH.0b013e32832c3bb3; Verma R, 2010, SEX TRANSM INFECT, V86, pI76, DOI 10.1136/sti.2009.039115; Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306, DOI 10.1093/oxfordjournals.aje.a010003; Wade AS, 2005, AIDS, V19, P2133, DOI 10.1097/01.aids.0000194128.97640.07; Wall Kristin M, 2010, J Int Assoc Physicians AIDS Care (Chic), V9, P284, DOI 10.1177/1545109710379051; Weber J, 2010, AIDS, V24, pS27, DOI 10.1097/01.aids.0000390705.73759.2c; Weller SC, 2009, COCHRANE DB SYST REV, V2002; Whitlock EP, 2004, ANN INTERN MED, V140, P557, DOI 10.7326/0003-4819-140-7-200404060-00017; Wilton L, 2009, AIDS BEHAV, V13, P532, DOI 10.1007/s10461-009-9529-y; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P1470, DOI 10.1001/jama.1987.03390110046011; World Health Organization, GUID PREV TREATM HIV; Yamey G, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001049	92	286	294	1	56	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 28	2012	380	9839					388	399		10.1016/S0140-6736(12)60955-6	http://dx.doi.org/10.1016/S0140-6736(12)60955-6			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819659	Green Accepted			2022-12-28	WOS:000306842800037
J	Yu, M; Ting, DT; Stott, SL; Wittner, BS; Ozsolak, F; Paul, S; Ciciliano, JC; Smas, ME; Winokur, D; Gilman, AJ; Ulman, MJ; Xega, K; Contino, G; Alagesan, B; Brannigan, BW; Milos, PM; Ryan, DP; Sequist, LV; Bardeesy, N; Ramaswamy, S; Toner, M; Maheswaran, S; Haber, DA				Yu, Min; Ting, David T.; Stott, Shannon L.; Wittner, Ben S.; Ozsolak, Fatih; Paul, Suchismita; Ciciliano, Jordan C.; Smas, Malgorzata E.; Winokur, Daniel; Gilman, Anna J.; Ulman, Matthew J.; Xega, Kristina; Contino, Gianmarco; Alagesan, Brinda; Brannigan, Brian W.; Milos, Patrice M.; Ryan, David P.; Sequist, Lecia V.; Bardeesy, Nabeel; Ramaswamy, Sridhar; Toner, Mehmet; Maheswaran, Shyamala; Haber, Daniel A.			RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis	NATURE			English	Article							STEM-CELL; TRANSCRIPTOME; PATHWAY	Circulating tumour cells (CTCs) shed into blood from primary cancers include putative precursors that initiate distal metastases(1). Although these cells are extraordinarily rare, they may identify cellular pathways contributing to the blood-borne dissemination of cancer. Here, we adapted a microfluidic device(2) for efficient capture of CTCs from an endogenous mouse pancreatic cancer model(3) and subjected CTCs to single-molecule RNA sequencing(4), identifying Wnt2 as a candidate gene enriched in CTCs. Expression of WNT2 in pancreatic cancer cells suppresses anoikis, enhances anchorage-independent sphere formation, and increases metastatic propensity in vivo. This effect is correlated with fibronectin upregulation and suppressed by inhibition of MAP3K7 (also known as TAK1) kinase. In humans, formation of non-adherent tumour spheres by pancreatic cancer cells is associated with upregulation of multiple WNT genes, and pancreatic CTCs revealed enrichment for WNT signalling in 5 out of 11 cases. Thus, molecular analysis of CTCs may identify candidate therapeutic targets to prevent the distal spread of cancer.	[Yu, Min; Ting, David T.; Stott, Shannon L.; Wittner, Ben S.; Paul, Suchismita; Ciciliano, Jordan C.; Smas, Malgorzata E.; Winokur, Daniel; Gilman, Anna J.; Ulman, Matthew J.; Xega, Kristina; Contino, Gianmarco; Alagesan, Brinda; Brannigan, Brian W.; Ryan, David P.; Sequist, Lecia V.; Bardeesy, Nabeel; Ramaswamy, Sridhar; Toner, Mehmet; Maheswaran, Shyamala; Haber, Daniel A.] Massachusetts Gen Hosp, Ctr Canc, Ctr Engn Med, Boston, MA 02114 USA; [Yu, Min; Ting, David T.; Stott, Shannon L.; Wittner, Ben S.; Paul, Suchismita; Ciciliano, Jordan C.; Smas, Malgorzata E.; Winokur, Daniel; Gilman, Anna J.; Ulman, Matthew J.; Xega, Kristina; Contino, Gianmarco; Alagesan, Brinda; Brannigan, Brian W.; Ryan, David P.; Sequist, Lecia V.; Bardeesy, Nabeel; Ramaswamy, Sridhar; Toner, Mehmet; Maheswaran, Shyamala; Haber, Daniel A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; [Yu, Min; Ting, David T.; Stott, Shannon L.; Wittner, Ben S.; Paul, Suchismita; Ciciliano, Jordan C.; Smas, Malgorzata E.; Winokur, Daniel; Gilman, Anna J.; Ulman, Matthew J.; Xega, Kristina; Contino, Gianmarco; Alagesan, Brinda; Brannigan, Brian W.; Ryan, David P.; Sequist, Lecia V.; Bardeesy, Nabeel; Ramaswamy, Sridhar; Toner, Mehmet; Maheswaran, Shyamala; Haber, Daniel A.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02114 USA; [Yu, Min; Haber, Daniel A.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; [Ozsolak, Fatih; Milos, Patrice M.] Helicos BioSci Corp, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Ctr Engn Med, Boston, MA 02114 USA.	maheswaran@helix.mgh.harvard.edu; haber@helix.mgh.harvard.edu	Stott, Shannon L./AAC-5311-2019; Ting, David/F-4389-2017	Ting, David/0000-0002-3261-2322; Contino, Gianmarco/0000-0001-5874-0405; Yu, Min/0000-0002-3969-8720	Stand Up To Cancer; Howard Hughes Medical Institute; NIBIB [5R01EB008047]; NIH [CA129933]; Pancreatic Cancer Action Network - AACR Fellowship; Warshaw Institute for Pancreatic Cancer Research; K12 Paul Calabresi Award for Clinical Oncology Clinical Research Career Development Program NIH [5K12CA87723-09]; NATIONAL CANCER INSTITUTE [R01CA129933, K12CA087723, P01CA117969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [U01EB012493, R01EB008047] Funding Source: NIH RePORTER	Stand Up To Cancer; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIBIB(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pancreatic Cancer Action Network - AACR Fellowship; Warshaw Institute for Pancreatic Cancer Research; K12 Paul Calabresi Award for Clinical Oncology Clinical Research Career Development Program NIH; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank C. Koris and the MGH clinical research coordinators for help with clinical studies, J. Gentry for computer informatics support, L. Libby for mouse studies, J. Walsh for microscopy expertise, Z. Nakamura for technical support, D. Jones for sequencing, and M. Rivera and S. Akhavanfard for RNA-ISH. This work was supported by Stand Up To Cancer (D. A. H., M. T., S. M.), Howard Hughes Medical Institute (D. A. H.), NIBIB Quantum Grant 5R01EB008047 (M. T.), NIH CA129933 (D. A. H.), Pancreatic Cancer Action Network - AACR Fellowship (D. T. T.), the Warshaw Institute for Pancreatic Cancer Research (D. T. T.), and the K12 Paul Calabresi Award for Clinical Oncology Clinical Research Career Development Program NIH 5K12CA87723-09 (D.T.T.).	Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bowers J, 2009, NAT METHODS, V6, P593, DOI 10.1038/nmeth.1354; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Lipson D, 2009, NAT BIOTECHNOL, V27, P652, DOI 10.1038/nbt.1551; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ozsolak F, 2010, NAT METHODS, V7, P619, DOI [10.1038/NMETH.1480, 10.1038/nmeth.1480]; Ozsolak F, 2010, GENOME RES, V20, P519, DOI 10.1101/gr.102129.109; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Stott SL, 2010, P NATL ACAD SCI USA, V107, P18392, DOI 10.1073/pnas.1012539107; Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801; Wang LK, 2010, BIOINFORMATICS, V26, P136, DOI 10.1093/bioinformatics/btp612; Yu M, 2011, J CELL BIOL, V192, P373, DOI 10.1083/jcb.201010021	14	373	396	5	177	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 26	2012	487	7408					510	U130		10.1038/nature11217	http://dx.doi.org/10.1038/nature11217			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979KD	22763454	Green Accepted, Green Submitted			2022-12-28	WOS:000306815300044
J	Chisty, A				Chisty, Alia			Forever Young	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Chisty, A (corresponding author), Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA.	alia.chisty@ucsfmedctr.org							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					351	352		10.1001/jama.2012.8883	http://dx.doi.org/10.1001/jama.2012.8883			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820787				2022-12-28	WOS:000306685500022
J	Das, P; Horton, R				Das, Pamela; Horton, Richard			Rethinking our approach to physical activity	LANCET			English	Editorial Material									[Das, Pamela; Horton, Richard] The Lancet, London NW1 7BY, England		Das, P (corresponding author), The Lancet, London NW1 7BY, England.							Beaglehole R, 2011, LANCET, V377, P1438, DOI 10.1016/S0140-6736(11)60393-0; Lee IM, 2012, LANCET; Organization WH, 2009, GLOB HLTH RISKS MORT; World Health Organization, 2011, GLOB HLTH OBS DAT RE	4	123	124	1	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 21	2012	380	9838					189	190		10.1016/S0140-6736(12)61024-1	http://dx.doi.org/10.1016/S0140-6736(12)61024-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976TV	22818931				2022-12-28	WOS:000306609200004
J	Carey, R; Harber, M				Carey, Renata; Harber, Mark			Kidney dialysis-the need for humanity	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Harber, Mark] Royal Free Hosp, London NW3 2QG, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Harber, M (corresponding author), Royal Free Hosp, Pond St, London NW3 2QG, England.	mark.harber@nhs.net							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 19	2012	345								e4492	10.1136/bmj.e4492	http://dx.doi.org/10.1136/bmj.e4492			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978MA	22815428	Bronze			2022-12-28	WOS:000306744300003
J	Canning, D; Schultz, TP				Canning, David; Schultz, T. Paul			The economic consequences of reproductive health and family planning	LANCET			English	Article							POPULATION; GROWTH; FERTILITY; IMPACT; DISEASE; ERADICATION; COMPONENTS; CHILDHOOD; NUTRITION; MORTALITY	We consider the evidence for the effect of access to reproductive health services on the achievement of Millennium Development Goals 1, 2, and 3, which aim to eradicate extreme poverty and hunger, achieve universal primary education, and promote gender equality and empower women. At the household level, controlled trials in Matlab, Bangladesh, and Navrongo, Ghana, have shown that increasing access to family planning services reduces fertility and improves birth spacing. In the Matlab study, findings from long-term follow-up showed that women's earnings, assets, and body-mass indexes, and children's schooling and body-mass indexes, substantially improved in areas with improved access to family planning services compared with outcomes in control areas. At the macroeconomic level, reductions in fertility enhance economic growth as a result of reduced youth dependency and an increased number of women participating in paid labour.	[Canning, David] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Schultz, T. Paul] Yale Univ, Dept Econ, New Haven, CT 06520 USA	Harvard University; Harvard T.H. Chan School of Public Health; Yale University	Canning, D (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, 665 Huntington Ave, Boston, MA 02115 USA.	dcanning@hsph.harvard.edu	Canning, David/A-1917-2008	Canning, David/0000-0003-4041-1229	William and Flora Hewlett Foundation	William and Flora Hewlett Foundation	This Series paper is a revised version of a paper prepared for the Working Group Meeting on Population, Family Planning and Achievement of the Millennium Development Goals, Chapel Hill, Dec 1-3, 2010. The authors thank the participants in that meeting for their comments. DC and TPS both received funding support for related research from the William and Flora Hewlett Foundation.	Acemoglu D, 2007, J POLIT ECON, V115, P925, DOI 10.1086/529000; Akachi Y, 2007, ANN HUM BIOL, V34, P397, DOI 10.1080/03014460701452868; Akachi Y, 2010, ECON HUM BIOL, V8, P273, DOI 10.1016/j.ehb.2010.05.015; Ashraf Q, 2008, NATL BUREAU EC REASE; Ashraf QH, 2011, NATL BUREAU EC REASE; Bailey MJ, 2006, Q J ECON, V121, P289; Barker DJP, 1992, FETAL INFANT ORIGINS; Becker G., 1974, EC FAMILY MARRIAGE C, P81, DOI DOI 10.1086/260166; Becker G., 1991, TREATISE FAMILY ENLA; Bleakley H, 2007, Q J ECON, V122, P73, DOI 10.1162/qjec.121.1.73; Bleakley H, 2003, J EUR ECON ASSOC, V1, P376, DOI 10.1162/154247603322391017; Bleakley H, 2010, AM ECON J-APPL ECON, V2, P1, DOI 10.1257/app.2.2.1; Bloom DE, 2010, EUR J POPUL, V26, P141, DOI 10.1007/s10680-009-9182-1; Bloom DE, 2010, J COMP ECON, V38, P17, DOI 10.1016/j.jce.2009.11.002; Bloom DE, 2009, J ECON GROWTH, V14, P79, DOI 10.1007/s10887-009-9039-9; Bloom David E., 2003, ECON SOC REV, V34, P229; Bloom DE, 2004, WORLD DEV, V32, P1, DOI 10.1016/j.worlddev.2003.07.002; BLOOM DE, 1988, J POLICY MODEL, V10, P57, DOI 10.1016/0161-8938(88)90035-X; Bloom DE, 2000, POPUL DEV REV, V26, P257; Cleland J, 2012, LANCET; Debpuur C, 2002, STUD FAMILY PLANN, V33, P141, DOI 10.1111/j.1728-4465.2002.00141.x; Desai J, 2011, DEMOGRAPHY, V48, P749, DOI 10.1007/s13524-011-0029-0; Duflo E, 2008, HBK ECON, V9, P3895, DOI 10.1016/S1573-4471(07)04061-2; Dyson T, 2010, POPULATION DEV DEMOG; Frankenberg E, 2005, POP STUD-J DEMOG, V59, P5, DOI 10.1080/0032472052000332674; Galor O, 2000, AM ECON REV, V90, P806, DOI 10.1257/aer.90.4.806; Goldin C., 1995, INVESTMENT WOMENS HU, P61; Hoddinott J, 2008, LANCET, V371, P411, DOI 10.1016/S0140-6736(08)60205-6; Joshi S, 2012, 6551 IZA; Joshi S., 2007, 951 YAL U EC GROWTH; Jukes MCH, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010019; Kalemli-Ozcan S, 2003, J DEV ECON, V70, P103, DOI 10.1016/S0304-3878(02)00089-5; Kelley AC, 2005, J POPUL ECON, V18, P275, DOI 10.1007/s00148-005-0222-9; Kelley AC, 1995, DEMOGRAPHY, V32, P543, DOI 10.2307/2061674; Menken J, 2003, POPUL DEV REV, V29, P405, DOI 10.1111/j.1728-4457.2003.00405.x; Miguel E, 2004, ECONOMETRICA, V72, P159, DOI 10.1111/j.1468-0262.2004.00481.x; Miller G, 2010, ECON J, V120, P709, DOI 10.1111/j.1468-0297.2009.02306.x; National Research Council, 1986, POPULATION GROWTH EC; O'Neill BC, 2010, P NATL ACAD SCI USA, V107, P17521, DOI 10.1073/pnas.1004581107; Pence BW, 2007, SCAND J PUBLIC HEALT, V35, P599, DOI 10.1080/14034940701349225; Phillips JF, 2009, POP ASS AM ANN M DET; PRITCHETT LH, 1994, POPUL DEV REV, V20, P1, DOI 10.2307/2137629; PSACHAROPOULOS G, 1994, WORLD DEV, V22, P1325, DOI 10.1016/0305-750X(94)90007-8; Radhakrishnan Uma., 2010, CESWP1028 US CENS BU; Schultz TP, 2005, HEALTH AND ECONOMIC GROWTH: FINDINGS AND POLICY IMPLICATIONS, P257; Schultz TP, 2008, HBK ECON, V9, P3249, DOI 10.1016/S1573-4471(07)04052-1; Schultz TP, 2009, WORLD BANK ECON REV, V23, P427, DOI 10.1093/wber/lhp015; Schultz T. Paul, 1992, FAMILY PLANNING PROG, P78; SCHULTZ TP, 1990, ECON DEV CULT CHANGE, V38, P457, DOI 10.1086/451811; Schultz TP., 1997, HDB POPULATION FAM A, VVol. 1, P349; Schultz TP, 2009, POP ASS AM ANN M DET; Speidel JJ, 2009, PHILOS T R SOC B, V364, P3049, DOI 10.1098/rstb.2009.0162; Thomas D, 2006, CALIFORNIA CTR POPUL; Thomas D, 2001, WORLD BANK ECON REV, V10, P189; Todd PE, 2008, HBK ECON, V9, P3847, DOI 10.1016/S1573-4471(07)04060-0; UN Department of Economic and Social Affairs, 2010, UN WORLD POP PROSP 2; Weil DN, 2007, Q J ECON, V122, P1265, DOI 10.1162/qjec.122.3.1265; YOUNG A, 1995, Q J ECON, V110, P641, DOI 10.2307/2946695	58	172	175	3	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2012	380	9837					165	171		10.1016/S0140-6736(12)60827-7	http://dx.doi.org/10.1016/S0140-6736(12)60827-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784535				2022-12-28	WOS:000306359100044
J	Gottschling, DE				Gottschling, Daniel E.			Fragile Delivery to the Genome	SCIENCE			English	Editorial Material							IRON-SULFUR CLUSTERS; ENDONUCLEASE-III; DNA-DAMAGE; MUTANTS; ENZYMES; PROTEIN		Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Gottschling, DE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.	dgottsch@fhcrc.org						CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; Gari K, 2012, SCIENCE, V337, P243, DOI 10.1126/science.1219664; Imlay JA, 2008, ANNU REV BIOCHEM, V77, P755, DOI 10.1146/annurev.biochem.77.061606.161055; Netz DJA, 2012, NAT CHEM BIOL, V8, P125, DOI 10.1038/nchembio.721; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; PRAKASH L, 1977, GENETICS, V86, P33; Romano CA, 2011, BIOCHEMISTRY-US, V50, P6133, DOI 10.1021/bi2003179; Rouault TA, 2012, DIS MODEL MECH, V5, P155, DOI 10.1242/dmm.009019; Rudolf J, 2006, MOL CELL, V23, P801, DOI 10.1016/j.molcel.2006.07.019; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sheftel A, 2010, TRENDS ENDOCRIN MET, V21, P302, DOI 10.1016/j.tem.2009.12.006; Stehling O, 2012, SCIENCE, V337, P195, DOI 10.1126/science.1219723; Veatch JR, 2009, CELL, V137, P1247, DOI 10.1016/j.cell.2009.04.014; White MF, 2012, CURR OPIN STRUC BIOL, V22, P94, DOI 10.1016/j.sbi.2011.11.004; Wu YL, 2012, NUCLEIC ACIDS RES, V40, P4247, DOI 10.1093/nar/gks039	15	4	4	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2012	337	6091					160	161		10.1126/science.1225852	http://dx.doi.org/10.1126/science.1225852			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798587				2022-12-28	WOS:000306323500029
J	Lim, BK; Huang, KW; Grueter, BA; Rothwell, PE; Malenka, RC				Lim, Byung Kook; Huang, Kee Wui; Grueter, Brad A.; Rothwell, Patrick E.; Malenka, Robert C.			Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens	NATURE			English	Article							LONG-TERM DEPRESSION; CONDITIONED PLACE PREFERENCE; DISTINCT ROLES; RECEPTOR; EXPRESSION; NEURONS; PLASTICITY; PATHWAYS; CIRCUIT; REWARD	Chronic stress is a strong diathesis for depression in humans and is used to generate animal models of depression. It commonly leads to several major symptoms of depression, including dysregulated feeding behaviour, anhedonia and behavioural despair. Although hypotheses defining the neural pathophysiology of depression have been proposed, the critical synaptic adaptations in key brain circuits that mediate stress-induced depressive symptoms remain poorly understood. Here we show that chronic stress in mice decreases the strength of excitatory synapses on D1 dopamine receptor-expressing nucleus accumbens medium spiny neurons owing to activation of the melanocortin 4 receptor. Stress-elicited increases in behavioural measurements of anhedonia, but not increases in measurements of behavioural despair, are prevented by blocking these melanocortin 4 receptor-mediated synaptic changes in vivo. These results establish that stress-elicited anhedonia requires a neuropeptide-triggered, cell-type-specific synaptic adaptation in the nucleus accumbens and that distinct circuit adaptations mediate other major symptoms of stress-elicited depression.	[Lim, Byung Kook; Huang, Kee Wui; Grueter, Brad A.; Rothwell, Patrick E.; Malenka, Robert C.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Nancy Pritzker Lab, Stanford, CA 94305 USA	Stanford University	Malenka, RC (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Nancy Pritzker Lab, 265 Campus Dr, Stanford, CA 94305 USA.	malenka@stanford.edu		Rothwell, Patrick/0000-0003-0514-2510; Lim, Byungkook/0000-0002-3766-5415; Grueter, Brad/0000-0002-4224-3866	Davis Foundation Postdoctoral Fellowship in Eating Disorders Research; National Institutes of Health; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH096491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA008227] Funding Source: NIH RePORTER	Davis Foundation Postdoctoral Fellowship in Eating Disorders Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank J. Kauer, D. Lyons and members of the Malenka laboratory for comments. The rabies virus complementary DNA plasmid and viral component-expressing plasmids were gifts from K. Conzelmann and I. Wickersham. BAC transgenic mice were provided by N. Calakos. BHK-B19G cells were a gift from E. Callaway. The AAVs used in this study were produced by the Stanford Neuroscience Gene Vector and Virus Core. The AAV-DJ helper plasmid was a gift from M. Kay. B. K. L. is supported by a Davis Foundation Postdoctoral Fellowship in Eating Disorders Research. We acknowledge funding from the National Institutes of Health (R.C.M.).	Atasoy D, 2008, J NEUROSCI, V28, P7025, DOI 10.1523/JNEUROSCI.1954-08.2008; Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569; Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014; Bos JL, 2006, TRENDS BIOCHEM SCI, V31, P680, DOI 10.1016/j.tibs.2006.10.002; Brebner K, 2005, SCIENCE, V310, P1340, DOI 10.1126/science.1116894; BROG JS, 1993, J COMP NEUROL, V338, P255, DOI 10.1002/cne.903380209; Chaki S, 2005, PEPTIDES, V26, P1952, DOI 10.1016/j.peptides.2004.11.029; Chaki S, 2003, EUR J PHARMACOL, V474, P95, DOI 10.1016/S0014-2999(03)02033-8; Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455; Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995; Covington HE, 2010, J NEUROSCI, V30, P16082, DOI 10.1523/JNEUROSCI.1731-10.2010; Cunningham CL, 2006, NAT PROTOC, V1, P1662, DOI 10.1038/nprot.2006.279; Durieux PF, 2009, NAT NEUROSCI, V12, P393, DOI 10.1038/nn.2286; Ferguson SM, 2011, NAT NEUROSCI, V14, P22, DOI 10.1038/nn.2703; Gao Q, 2007, ANNU REV NEUROSCI, V30, P367, DOI 10.1146/annurev.neuro.30.051606.094324; Gong SC, 2007, J NEUROSCI, V27, P9817, DOI 10.1523/JNEUROSCI.2707-07.2007; Grimm D, 2008, J VIROL, V82, P5887, DOI 10.1128/JVI.00254-08; Grueter BA, 2010, NAT NEUROSCI, V13, P1519, DOI 10.1038/nn.2685; Heusner CL, 2005, J NEUROSCI, V25, P6651, DOI 10.1523/JNEUROSCI.1474-05.2005; Hikida T, 2010, NEURON, V66, P896, DOI 10.1016/j.neuron.2010.05.011; Hsu R, 2005, EUR J NEUROSCI, V21, P2233, DOI 10.1111/j.1460-9568.2005.04038.x; Isaac JTR, 2007, NEURON, V54, P859, DOI 10.1016/j.neuron.2007.06.001; Kasanetz F, 2010, SCIENCE, V328, P1709, DOI 10.1126/science.1187801; Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234; Kelley AE, 2002, J NEUROSCI, V22, P3306; Kreitzer AC, 2008, NEURON, V60, P543, DOI 10.1016/j.neuron.2008.11.005; Lee SH, 2002, NEURON, V36, P661, DOI 10.1016/S0896-6273(02)01024-3; Li B, 2011, NATURE, V470, P535, DOI 10.1038/nature09742; Liu J, 2007, ENDOCRINOLOGY, V148, P5531, DOI 10.1210/en.2007-0745; Lobo MK, 2010, SCIENCE, V330, P385, DOI 10.1126/science.1188472; Mebatsion T, 1996, CELL, V84, P941, DOI 10.1016/S0092-8674(00)81072-7; Morton GJ, 2006, NATURE, V443, P289, DOI 10.1038/nature05026; Nestler EJ, 2006, BIOL PSYCHIAT, V59, P1151, DOI 10.1016/j.biopsych.2005.09.018; Nestler EJ, 2010, NAT NEUROSCI, V13, P1161, DOI 10.1038/nn.2647; Pascoli V, 2012, NATURE, V481, P71, DOI 10.1038/nature10709; Porsolt R. D., 2001, CURR PROTOC NEUROSCI, V14, p10A1; Shepherd JD, 2007, ANNU REV CELL DEV BI, V23, P613, DOI 10.1146/annurev.cellbio.23.090506.123516; Shuen JA, 2008, J NEUROSCI, V28, P2681, DOI 10.1523/JNEUROSCI.5492-07.2008; Thomas MJ, 2001, NAT NEUROSCI, V4, P1217, DOI 10.1038/nn757; Tsai HC, 2009, SCIENCE, V324, P1080, DOI 10.1126/science.1168878; Volkow ND, 2011, TRENDS COGN SCI, V15, P37, DOI 10.1016/j.tics.2010.11.001; Wickersham IR, 2007, NAT METHODS, V4, P47, DOI 10.1038/NMETH999; Wickersham IR, 2010, NAT PROTOC, V5, P595, DOI 10.1038/nprot.2009.248; Wolfart J, 2001, J NEUROSCI, V21, P3443, DOI 10.1523/JNEUROSCI.21-10-03443.2001; Woolfrey KM, 2009, NAT NEUROSCI, V12, P1275, DOI 10.1038/nn.2386; Yang YK, 2011, EUR J PHARMACOL, V660, P125, DOI 10.1016/j.ejphar.2010.12.020	46	240	247	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2012	487	7406					183	U64		10.1038/nature11160	http://dx.doi.org/10.1038/nature11160			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972LP	22785313	Green Accepted			2022-12-28	WOS:000306278900029
J	Basu, S				Basu, Shantanu			Brown-Dwarf Origins	SCIENCE			English	Editorial Material							INITIAL MASS FUNCTION; STARS; DISCOVERY		Western Univ, Dept Phys & Astron, London, ON N6A 3K7, Canada	Western University (University of Western Ontario)	Basu, S (corresponding author), Western Univ, Dept Phys & Astron, London, ON N6A 3K7, Canada.	basu@uwo.ca	Basu, Shantanu/AAW-7167-2021	Basu, Shantanu/0000-0003-0855-350X				Andre P, 2012, SCIENCE, V337, P69, DOI 10.1126/science.1222602; Bachiller R, 1999, NATO ADV SCI I C-MAT, V540, P227; Basu S, 2012, ASTROPHYS J, V750, DOI 10.1088/0004-637X/750/1/30; Bejar VJS, 2011, ASTROPHYS J, V743, DOI 10.1088/0004-637X/743/1/64; Cruz KL, 2007, ASTRON J, V133, P439, DOI 10.1086/510132; HAYASHI C, 1963, PROG THEOR PHYS, V30, P460, DOI 10.1143/PTP.30.460; Hennebelle P, 2008, ASTROPHYS J, V684, P395, DOI 10.1086/589916; KUMAR SS, 1963, ASTROPHYS J, V137, P1121, DOI 10.1086/147589; Luhman K. L., 2007, PROTOSTARS PLANETS, VV, P443; Metchev SA, 2008, ASTROPHYS J, V676, P1281, DOI 10.1086/524721; NAKAJIMA T, 1995, NATURE, V378, P463, DOI 10.1038/378463a0; Padoan P, 2002, ASTROPHYS J, V576, P870, DOI 10.1086/341790; REBOLO R, 1995, NATURE, V377, P129, DOI 10.1038/377129a0; Reipurth B, 2001, ASTRON J, V122, P432, DOI 10.1086/321121; Scholz A, 2012, ASTROPHYS J, V744, DOI 10.1088/0004-637X/744/1/6	15	2	2	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2012	337	6090					43	44		10.1126/science.1224342	http://dx.doi.org/10.1126/science.1224342			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767918				2022-12-28	WOS:000306053100036
J	Raymond, B; West, SA; Griffin, AS; Bonsall, MB				Raymond, Ben; West, Stuart A.; Griffin, Ashleigh S.; Bonsall, Michael B.			The Dynamics of Cooperative Bacterial Virulence in the Field	SCIENCE			English	Article							SOCIAL EVOLUTION; POPULATIONS; CONFLICT; COMPETITION; PARASITES; AMEBA; HOST	Laboratory experiments have shown that the fitness of microorganisms can depend on cooperation between cells. Although this insight has revolutionized our understanding of microbial life, results from artificial microcosms have not been validated in complex natural populations. We investigated the sociality of essential virulence factors (crystal toxins) in the pathogen Bacillus thuringiensis using diamondback moth larvae (Plutella xylostella) as hosts. We show that toxin production is cooperative, and in a manipulative field experiment, we observed persistent high relatedness and frequency-and density-dependent selection, which favor stable cooperation. Conditions favoring social virulence can therefore persist in the face of natural population processes, and social interactions (rapid cheat invasion) may account for the rarity of natural disease outbreaks caused by B. thuringiensis.	[Raymond, Ben] Royal Holloway Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England; [West, Stuart A.; Griffin, Ashleigh S.; Bonsall, Michael B.] Univ Oxford, Dept Zool, Oxford OX1 3PS, England; [Bonsall, Michael B.] St Peters Coll, Oxford OX1 2DL, England	University of London; Royal Holloway University London; University of Oxford; University of Oxford	Raymond, B (corresponding author), Royal Holloway Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England.	ben.raymond@rhul.ac.uk	Griffin, Ashleigh/C-6244-2014; West, Stuart A/M-3608-2014; Raymond, Ben/F-5872-2011	Griffin, Ashleigh/0000-0001-7674-9825; West, Stuart A/0000-0003-2152-3153; Bonsall, Michael/0000-0003-0250-0423	Natural Environment Research Fellowship award; Biotechnology and Biological Sciences Research Council [BBC 5127021]; European Research Council; Royal Society; Biotechnology and Biological Sciences Research Council [BB/C512702/1] Funding Source: researchfish; Natural Environment Research Council [NE/E012671/2] Funding Source: researchfish; NERC [NE/E012671/2] Funding Source: UKRI	Natural Environment Research Fellowship award; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); European Research Council(European Research Council (ERC)European Commission); Royal Society(Royal Society of London); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	Raw field data are available in the supplementary materials. This work was supported by a Natural Environment Research Fellowship award (to B.R.), the Biotechnology and Biological Sciences Research Council (grant no. BBC 5127021), the European Research Council, and the Royal Society. The authors declare no conflicts of interest.	AGAISSE H, 1995, J BACTERIOL, V177, P6027, DOI 10.1128/jb.177.21.6027-6032.1995; Brockhurst MA, 2006, CURR BIOL, V16, P2030, DOI 10.1016/j.cub.2006.08.068; Brown SP, 1999, P ROY SOC B-BIOL SCI, V266, P1899, DOI 10.1098/rspb.1999.0864; Brown SP, 2002, TRENDS MICROBIOL, V10, P401, DOI 10.1016/S0966-842X(02)02413-7; Buckling A, 2008, HEREDITY, V100, P484, DOI 10.1038/sj.hdy.6801093; Collier FA, 2005, FEMS MICROBIOL ECOL, V54, P417, DOI 10.1016/j.femsec.2005.05.005; Diggle SP, 2007, NATURE, V450, P411, DOI 10.1038/nature06279; Frank, 1998, FDN SOCIAL EVOLUTION; Frank SA, 1996, Q REV BIOL, V71, P37, DOI 10.1086/419267; Gilbert OM, 2007, P NATL ACAD SCI USA, V104, P8913, DOI 10.1073/pnas.0702723104; Griffin AS, 2004, NATURE, V430, P1024, DOI 10.1038/nature02744; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Kohler T, 2009, P NATL ACAD SCI USA, V106, P6339, DOI 10.1073/pnas.0811741106; MacLean RC, 2006, NATURE, V441, P498, DOI 10.1038/nature04624; MYERS JH, 1988, ADV ECOL RES, V18, P179; Porcar M, 2000, J APPL MICROBIOL, V89, P309, DOI 10.1046/j.1365-2672.2000.01115.x; Prescott L. M., 2002, MICROBIOLOGY, P5; Raymond B, 2008, J INVERTEBR PATHOL, V98, P307, DOI 10.1016/j.jip.2008.01.005; Raymond B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000905; Raymond B, 2010, TRENDS MICROBIOL, V18, P189, DOI 10.1016/j.tim.2010.02.006; Reidl J, 2002, FEMS MICROBIOL REV, V26, P125, DOI 10.1111/j.1574-6976.2002.tb00605.x; Ross-Gillespie A, 2007, AM NAT, V170, P331, DOI 10.1086/519860; Rumbaugh KP, 2009, CURR BIOL, V19, P341, DOI 10.1016/j.cub.2009.01.050; Sachs JL, 2004, Q REV BIOL, V79, P135, DOI 10.1086/383541; Sandoz KM, 2007, P NATL ACAD SCI USA, V104, P15876, DOI 10.1073/pnas.0705653104; Soberon M, 2007, SCIENCE, V318, P1640, DOI 10.1126/science.1146453; Strassmann JE, 2000, NATURE, V408, P965, DOI 10.1038/35050087; West SA, 2003, P ROY SOC B-BIOL SCI, V270, P37, DOI 10.1098/rspb.2002.2209; West SA, 2006, NAT REV MICROBIOL, V4, P597, DOI 10.1038/nrmicro1461	29	83	83	0	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2012	337	6090					85	88		10.1126/science.1218196	http://dx.doi.org/10.1126/science.1218196			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767928				2022-12-28	WOS:000306053100049
J	Ali, SN; Tan, T; Meeran, K; Wynne, K				Ali, S. N.; Tan, T.; Meeran, K.; Wynne, K.			CASE REPORT A man with anxiety, confusion, and red eyes	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							MILK-ALKALI SYNDROME; VERSION		[Ali, S. N.; Tan, T.; Meeran, K.; Wynne, K.] Univ London Imperial Coll Sci Technol & Med, Imperial Ctr Endocrinol, London W12 0NN, England	Imperial College London	Wynne, K (corresponding author), Univ London Imperial Coll Sci Technol & Med, Imperial Ctr Endocrinol, London W12 0NN, England.	k.wynne@imperial.ac.uk	Wynne, Katie/P-9465-2019; Tan, Tricia/ABD-5502-2020; Tan, Tricia M.M./C-7140-2011	Wynne, Katie/0000-0002-7980-3337; Tan, Tricia M.M./0000-0001-5873-3432				Beall DP, 2006, AM J MED SCI, V331, P233, DOI 10.1097/00000441-200605000-00001; BEALL DP, 1995, MEDICINE, V74, P89, DOI 10.1097/00005792-199503000-00004; BERLYNE GM, 1967, LANCET, V1, P4; Cope CL, 1936, CLIN SCI, V2, P287; GANOTE CE, 1975, ARCH PATHOL, V99, P650; Grubb Mandy, 2009, Cases J, V2, P8198, DOI 10.1186/1757-1626-0002-0000008198; Kaklamanos M, 2007, BMJ-BRIT MED J, V335, P397, DOI 10.1136/bmj.39247.754676.BE; Medarov BI, 2009, MAYO CLIN PROC, V84, P261, DOI 10.1016/S0025-6196(11)61144-0; Muldowney WP, 1996, AM J KIDNEY DIS, V27, P270, DOI 10.1016/S0272-6386(96)90552-1; ORWOLL ES, 1982, ANN INTERN MED, V97, P242, DOI 10.7326/0003-4819-97-2-242; Patel AM, 2010, J AM SOC NEPHROL, V21, P1440, DOI 10.1681/ASN.2010030255; Picolos Michalis K, 2005, Endocr Pract, V11, P272; Picolos MK, 2005, CLIN ENDOCRINOL, V63, P566, DOI 10.1111/j.1365-2265.2005.02383.x; Silverberg SJ, 2008, PRIMER METABOLIC BON, P302	14	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 5	2012	344								e4443	10.1136/bmj.e4443	http://dx.doi.org/10.1136/bmj.e4443			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972KH	22767615				2022-12-28	WOS:000306275500012
J	Bischoff-Ferrari, HA; Willett, WC; Orav, EJ; Lips, P; Meunier, PJ; Lyons, RA; Flicker, L; Wark, J; Jackson, RD; Cauley, JA; Meyer, HE; Pfeifer, M; Sanders, KM; Stahelin, HB; Theiler, R; Dawson-Hughes, B				Bischoff-Ferrari, Heike A.; Willett, Walter C.; Orav, Endel J.; Lips, Paul; Meunier, Pierre J.; Lyons, Ronan A.; Flicker, Leon; Wark, John; Jackson, Rebecca D.; Cauley, Jane A.; Meyer, Haakon E.; Pfeifer, Michael; Sanders, Kerrie M.; Stahelin, Hannes B.; Theiler, Robert; Dawson-Hughes, Bess			A Pooled Analysis of Vitamin D Dose Requirements for Fracture Prevention	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							D SUPPLEMENTATION; HIP FRACTURE; DOUBLE-BLIND; SECONDARY HYPERPARATHYROIDISM; CALCIUM SUPPLEMENTATION; OLDER-PEOPLE; RISK; WOMEN; MEN; FALLS	BACKGROUND The results of meta-analyses examining the relationship between vitamin D supplementation and fracture reduction have been inconsistent. METHODS We pooled participant-level data from 11 double-blind, randomized, controlled trials of oral vitamin D supplementation (daily, weekly, or every 4 months), with or without calcium, as compared with placebo or calcium alone in persons 65 years of age or older. Primary end points were the incidence of hip and any nonvertebral fractures according to Cox regression analyses, with adjustment for age group, sex, type of dwelling, and study. Our primary aim was to compare data from quartiles of actual intake of vitamin D (including each individual participant's adherence to the treatment and supplement use outside the study protocol) in the treatment groups of all trials with data from the control groups. RESULTS We included 31,022 persons (mean age, 76 years; 91% women) with 1111 incident hip fractures and 3770 nonvertebral fractures. Participants who were randomly assigned to receive vitamin D, as compared with those assigned to control groups, had a nonsignificant 10% reduction in the risk of hip fracture (hazard ratio, 0.90; 95% confidence interval [CI], 0.80 to 1.01) and a 7% reduction in the risk of nonvertebral fracture (hazard ratio, 0.93; 95% CI, 0.87 to 0.99). By quartiles of actual intake, reduction in the risk of fracture was shown only at the highest intake level (median, 800 IU daily; range, 792 to 2000), with a 30% reduction in the risk of hip fracture (hazard ratio, 0.70; 95% CI, 0.58 to 0.86) and a 14% reduction in the risk of any nonvertebral fracture (hazard ratio, 0.86; 95% CI, 0.76 to 0.96). Benefits at the highest level of vitamin D intake were fairly consistent across subgroups defined by age group, type of dwelling, baseline 25-hydroxyvitamin D level, and additional calcium intake. CONCLUSIONS High-dose vitamin D supplementation (>= 800 IU daily) was somewhat favorable in the prevention of hip fracture and any nonvertebral fracture in persons 65 years of age or older. (Funded by the Swiss National Foundations and others.)	[Bischoff-Ferrari, Heike A.] Univ Zurich Hosp, Ctr Aging & Mobil, CH-8091 Zurich, Switzerland; [Bischoff-Ferrari, Heike A.] Univ Zurich, Ctr Aging & Mobil, CH-8006 Zurich, Switzerland; [Bischoff-Ferrari, Heike A.] Waid City Hosp, Zurich, Switzerland; [Bischoff-Ferrari, Heike A.] Univ Zurich Hosp, Dept Rheumatol, CH-8091 Zurich, Switzerland; [Theiler, Robert] City Hosp Triemli, Dept Rheumatol, Zurich, Switzerland; [Stahelin, Hannes B.] Univ Basel Hosp, Dept Geriatr, CH-4031 Basel, Switzerland; [Willett, Walter C.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Dept Nutr, Boston, MA 02111 USA; [Orav, Endel J.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Dept Biostat, Boston, MA 02111 USA; [Dawson-Hughes, Bess] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Harvard Sch Publ Hlth, Boston, MA 02111 USA; [Dawson-Hughes, Bess] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Bone Metab Lab, Boston, MA 02111 USA; [Lips, Paul] Vrije Univ Amsterdam, Med Ctr, Dept Internal Med & Endocrinol, Amsterdam, Netherlands; [Lips, Paul] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Meunier, Pierre J.] Claude Bernard Univ Lyon, Lyon, France; [Lyons, Ronan A.] Swansea Univ, Dept Publ Hlth, Swansea, W Glam, Wales; [Flicker, Leon] Univ Western Australia, Western Australian Ctr Hlth & Ageing, Crawley, Australia; [Wark, John] Univ Melbourne, Royal Melbourne Hosp, Bone & Mineral Serv, Dept Med, Melbourne, Vic 3050, Australia; [Sanders, Kerrie M.] Univ Melbourne, Dept Clin & Biomed Sci, Barwon Hlth, Melbourne, Vic, Australia; [Jackson, Rebecca D.] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; [Jackson, Rebecca D.] Ohio State Univ, Dept Endocrinol, Columbus, OH 43210 USA; [Jackson, Rebecca D.] Ohio State Univ, Dept Diabet, Columbus, OH 43210 USA; [Jackson, Rebecca D.] Ohio State Univ, Dept Metab, Columbus, OH 43210 USA; [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Meyer, Haakon E.] Univ Oslo, Oslo, Norway; [Meyer, Haakon E.] Norwegian Inst Publ Hlth, Oslo, Norway; [Pfeifer, Michael] Inst Clin Osteol & German Osteol Fdn, Bad Pyrmont, Germany	University of Zurich; University Zurich Hospital; University of Zurich; University of Zurich; University Zurich Hospital; Triemli Hospital; University of Basel; Tufts University; United States Department of Agriculture (USDA); Tufts University; United States Department of Agriculture (USDA); Harvard University; Harvard T.H. Chan School of Public Health; Tufts University; United States Department of Agriculture (USDA); Tufts University; United States Department of Agriculture (USDA); Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Swansea University; University of Western Australia; Royal Melbourne Hospital; University of Melbourne; University of Melbourne; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Oslo; Norwegian Institute of Public Health (NIPH)	Bischoff-Ferrari, HA (corresponding author), Univ Zurich Hosp, Ctr Aging & Mobil, Gloriastr 25, CH-8091 Zurich, Switzerland.		Lyons, Ronan/G-7741-2012; Meyer, Haakon E./AAH-9333-2019; Sanders, Kerrie/E-9033-2015; Flicker, Leon/AAE-1530-2022	Lyons, Ronan/0000-0001-5225-000X; Sanders, Kerrie/0000-0002-2718-6592; Flicker, Leon/0000-0002-3650-0475; Bischoff-Ferrari, Heike/0000-0002-4554-658X; Meyer, Haakon E/0000-0002-3262-8260; Cauley, Jane A/0000-0003-0752-4408	Swiss National Foundations [PP00B-114864]; European Commission [DO-HEALTH-278588]; DSM Nutritional Products	Swiss National Foundations(Swiss National Science Foundation (SNSF)); European Commission(European CommissionEuropean Commission Joint Research Centre); DSM Nutritional Products	Supported by a professorship grant (PP00B-114864) from the Swiss National Foundations, a grant (DO-HEALTH-278588) from the European Commission Framework 7 Program, and DSM Nutritional Products.	Abrahamsen B, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5463; Avenell A, 2009, COCHRANE DB SYST REV, V2; Bischoff-Ferrari HA, 2007, AM J CLIN NUTR, V86, P1780; Bischoff-Ferrari HA, 2010, ARCH INTERN MED, V170, P813, DOI 10.1001/archinternmed.2010.67; Bischoff-Ferrari HA, 2009, J BONE MINER RES, V24, P935, DOI [10.1359/JBMR.081242, 10.1359/jbmr.081242]; Bischoff-Ferrari HA, 2009, ARCH INTERN MED, V169, P551, DOI 10.1001/archinternmed.2008.600; Boonen S, 2007, J CLIN ENDOCR METAB, V92, P1415, DOI 10.1210/jc.2006-1404; Chapuy MC, 2002, OSTEOPOROSIS INT, V13, P257, DOI 10.1007/s001980200023; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Cranney Ann, 2007, Evid Rep Technol Assess (Full Rep), P1; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Flicker L, 2005, J AM GERIATR SOC, V53, P1881, DOI 10.1111/j.1532-5415.2005.00468.x; Grant AM, 2005, LANCET, V365, P1621, DOI 10.1016/S0140-6736(05)63013-9; Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148; Jackson RD, 2006, NEW ENGL J MED, V354, P1102; Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218; Liang K Y, 1995, Lifetime Data Anal, V1, P403; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; Lyons RA, 2007, OSTEOPOROSIS INT, V18, P811, DOI 10.1007/s00198-006-0309-5; Melton LJ, 1999, OSTEOPOROSIS INT, V9, P29, DOI 10.1007/s001980050113; Meyer HE, 2002, J BONE MINER RES, V17, P709, DOI 10.1359/jbmr.2002.17.4.709; Pfeifer M, 2009, OSTEOPOROSIS INT, V20, P315, DOI 10.1007/s00198-008-0662-7; Pfeifer M, 2000, J BONE MINER RES, V15, P1113, DOI 10.1359/jbmr.2000.15.6.1113; Pfeifer M, 2001, J BONE MINER RES, V16, p[1735, 1935]; Ross AC, 2011, J AM DIET ASSOC, V111, P524, DOI 10.1016/j.jada.2011.01.004; Sanders KM, 2010, JAMA-J AM MED ASSOC, V303, P2357, DOI 10.1001/jama.2010.783; Sanders KM, 2010, JAMA-J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594; Smith H, 2007, RHEUMATOLOGY, V46, P1852, DOI 10.1093/rheumatology/kem240; Steingrimsdottir L, 2005, JAMA-J AM MED ASSOC, V294, P2336, DOI 10.1001/jama.294.18.2336; Trivedi DP, 2003, BMJ-BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469	30	520	537	0	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					40	49		10.1056/NEJMoa1109617	http://dx.doi.org/10.1056/NEJMoa1109617			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968KJ	22762317	Green Published			2022-12-28	WOS:000305979400004
J	Huang, CC; Shih, SL				Huang, Chun-Chao; Shih, Shin-Lin			Steeple Sign of Croup	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Huang, Chun-Chao] Mackay Mem Hosp, Taipei, Taiwan; [Shih, Shin-Lin] Taipei Med Univ, Taipei, Taiwan	Mackay Memorial Hospital; Taipei Medical University	Huang, CC (corresponding author), Mackay Mem Hosp, Taipei, Taiwan.	hcc.5306@ms1.mmh.org.tw							0	1	1	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					66	66		10.1056/NEJMicm1113937	http://dx.doi.org/10.1056/NEJMicm1113937			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968KJ	22762320				2022-12-28	WOS:000305979400007
J	Moerchen, M				Moerchen, Margaret			ASTRONOMY Warm dust makes a fast getaway	NATURE			English	Editorial Material							DEBRIS DISKS; STARS; MISSION		[Moerchen, Margaret] Leiden Observ, NL-2333 CA Leiden, Netherlands; [Moerchen, Margaret] European So Observ, Santiago 19, Chile	Leiden University; Leiden University - Excl LUMC; European Southern Observatory	Moerchen, M (corresponding author), Leiden Observ, NL-2333 CA Leiden, Netherlands.	mmoerche@eso.org		Moerchen, Margaret/0000-0003-2743-0943				AUMANN HH, 1984, ASTROPHYS J, V278, pL23, DOI 10.1086/184214; Hog E, 2000, ASTRON ASTROPHYS, V355, pL27; Ishihara D, 2010, ASTRON ASTROPHYS, V514, DOI 10.1051/0004-6361/200913811; Kenyon SJ, 2008, ASTROPHYS J SUPPL S, V179, P451, DOI 10.1086/591794; Lisse CM, 2009, ASTROPHYS J, V701, P2019, DOI 10.1088/0004-637X/701/2/2019; Melis C, 2012, NATURE, V487, P74, DOI 10.1038/nature11210; NEUGEBAUER G, 1984, ASTROPHYS J, V278, pL1, DOI 10.1086/184209; Telesco CM, 1998, P SOC PHOTO-OPT INS, V3354, P534, DOI 10.1117/12.317279; Wright EL, 2010, ASTRON J, V140, P1868, DOI 10.1088/0004-6256/140/6/1868; Wyatt MC, 2007, ASTROPHYS J, V658, P569, DOI 10.1086/510999; Wyatt MC, 2008, ANNU REV ASTRON ASTR, V46, P339, DOI 10.1146/annurev.astro.45.051806.110525	11	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 5	2012	487	7405					45	46		10.1038/487045a	http://dx.doi.org/10.1038/487045a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968LM	22763550				2022-12-28	WOS:000305982900043
J	Bright, TJ; Wong, A; Dhurjati, R; Bristow, E; Bastian, L; Coeytaux, RR; Samsa, G; Hasselblad, V; Williams, JW; Musty, MD; Wing, L; Kendrick, AS; Sanders, GD; Lobach, D				Bright, Tiffani J.; Wong, Anthony; Dhurjati, Ravi; Bristow, Erin; Bastian, Lori; Coeytaux, Remy R.; Samsa, Gregory; Hasselblad, Vic; Williams, John W.; Musty, Michael D.; Wing, Liz; Kendrick, Amy S.; Sanders, Gillian D.; Lobach, David			Effect of Clinical Decision-Support Systems A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED-CONTROLLED-TRIAL; ELECTRONIC MEDICAL-RECORD; PHYSICIAN ORDER ENTRY; PROMOTING SCREENING MAMMOGRAPHY; HEALTH INFORMATION-TECHNOLOGY; LABORATORY MONITORING ALERTS; PRIMARY-CARE PHYSICIANS; INNER-CITY SETTINGS; QUALITY-OF-CARE; COMPUTERIZED REMINDERS	Background: Despite increasing emphasis on the role of clinical decision-support systems (CDSSs) for improving care and reducing costs, evidence to support widespread use is lacking. Purpose: To evaluate the effect of CDSSs on clinical outcomes, health care processes, workload and efficiency, patient satisfaction, cost, and provider use and implementation. Data Sources: MEDLINE, CINAHL, PsycINFO, and Web of Science through January 2011. Study Selection: Investigators independently screened reports to identify randomized trials published in English of electronic CDSSs that were implemented in clinical settings; used by providers to aid decision making at the point of care; and reported clinical, health care process, workload, relationship-centered, economic, or provider use outcomes. Data Extraction: Investigators extracted data about study design, participant characteristics, interventions, outcomes, and quality. Data Synthesis: 148 randomized, controlled trials were included. A total of 128 (86%) assessed health care process measures, 29 (20%) assessed clinical outcomes, and 22 (15%) measured costs. Both commercially and locally developed CDSSs improved health care process measures related to performing preventive services (n = 25; odds ratio [OR], 1.42 [95% CI, 1.27 to 1.58]), ordering clinical studies (n = 20; OR, 1.72 [CI, 1.47 to 2.00]), and prescribing therapies (n = 46; OR, 1.57 [CI, 1.35 to 1.82]). Few studies measured potential unintended consequences or adverse effects. Limitations: Studies were heterogeneous in interventions, populations, settings, and outcomes. Publication bias and selective reporting cannot be excluded. Conclusion: Both commercially and locally developed CDSSs are effective at improving health care process measures across diverse settings, but evidence for clinical, economic, workload, and efficiency outcomes remains sparse. This review expands knowledge in the field by demonstrating the benefits of CDSSs outside of experienced academic centers.	Duke Univ, Sch Med, Duke Evidence Based Practice Ctr, Duke Clin Res Inst, Durham, NC USA; Univ Utah, Sch Med, Salt Lake City, UT USA	Duke University; Utah System of Higher Education; University of Utah	Sanders, GD (corresponding author), Evidence Based Practice Ctr, Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.	gillian.sanders@duke.edu	Williams, John/AAM-4572-2020	Williams, John/0000-0002-5267-5558; Kendrick, Amy/0000-0001-8769-1702; Dhurjati, Ravi/0000-0002-0674-4065	Agency for Healthcare Research and Quality; Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services [290-2007-10066-I]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Agency for Healthcare Research and Quality.; This project was funded under contract 290-2007-10066-I from the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.	Agency for Healthcare Research and Quality, 2011, METH GUID EFF COMP E; Alper BS, 2005, ANN FAM MED, V3, P507, DOI 10.1370/afm.370; Ansari M, 2003, CIRCULATION, V107, P2799, DOI 10.1161/01.CIR.0000070952.08969.5B; Apkon M, 2005, ARCH INTERN MED, V165, P2388, DOI 10.1001/archinte.165.20.2388; Atkins D, 2011, J CLIN EPIDEMIOL, V64, P1198, DOI 10.1016/j.jclinepi.2010.11.021; Bates DW, 1999, AM J MED, V106, P144, DOI 10.1016/S0002-9343(98)00410-0; Bell LM, 2010, PEDIATRICS, V125, pE770, DOI 10.1542/peds.2009-1385; Bertoni AG, 2009, ARCH INTERN MED, V169, P678, DOI 10.1001/archinternmed.2009.44; BIRD JA, 1990, MED CARE, V28, P1005, DOI 10.1097/00005650-199011000-00003; Bosworth HB, 2009, AM HEART J, V157, P450, DOI 10.1016/j.ahj.2008.11.003; Bosworth HB, 2005, CONTEMP CLIN TRIALS, V26, P155, DOI 10.1016/j.cct.2004.12.006; Bourgeois FC, 2010, CLIN PEDIATR, V49, P976, DOI 10.1177/0009922810373649; Brier ME, 2010, CLIN J AM SOC NEPHRO, V5, P814, DOI 10.2215/CJN.07181009; Bryan Cathy, 2008, Inform Prim Care, V16, P79; Buntin MB, 2011, HEALTH AFFAIR, V30, P464, DOI 10.1377/hlthaff.2011.0178; BURACK RC, 1994, MED CARE, V32, P609, DOI 10.1097/00005650-199406000-00006; Burack RC, 2003, PREV MED, V36, P547, DOI 10.1016/S0091-7435(02)00062-2; Burack RC, 1998, CANCER, V82, P2391, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2391::AID-CNCR13>3.0.CO;2-K; Burack RC, 1997, MED CARE, V35, P921, DOI 10.1097/00005650-199709000-00005; Cannon DS, 2000, J AM MED INFORM ASSN, V7, P196, DOI 10.1136/jamia.2000.0070196; Cavalcanti AB, 2009, J CRIT CARE, V24, P371, DOI 10.1016/j.jcrc.2009.05.005; CHAMBERS CV, 1989, J FAM PRACTICE, V29, P273; Chaudhry B, 2006, ANN INTERN MED, V144, P742, DOI 10.7326/0003-4819-144-10-200605160-00125; Christakis DA, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.2.e15; Cleveringa FGW, 2010, DIABETES CARE, V33, P258, DOI 10.2337/dc09-1232; Cleveringa FGW, 2008, DIABETES CARE, V31, P2273, DOI 10.2337/dc08-0312; Co JPT, 2010, PEDIATRICS, V126, P239, DOI 10.1542/peds.2009-0710; Cobos A, 2005, DIS MANAG HEALTH OUT, V13, P421, DOI 10.2165/00115677-200513060-00007; Davis Robert L, 2007, PLoS Clin Trials, V2, pe25, DOI 10.1371/journal.pctr.0020025; Del Fiol G, 2008, J AM MED INFORM ASSN, V15, P752, DOI 10.1197/jamia.M2725; Demakis JG, 2000, JAMA-J AM MED ASSOC, V284, P1411, DOI 10.1001/jama.284.11.1411; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dexter PR, 2001, NEW ENGL J MED, V345, P965, DOI 10.1056/NEJMsa010181; Dexter PR, 2004, JAMA-J AM MED ASSOC, V292, P2366, DOI 10.1001/jama.292.19.2366; Downs M, 2006, BRIT MED J, V332, P692, DOI 10.1136/bmj.332.7543.692; Dykes PC, 2010, JAMA-J AM MED ASSOC, V304, P1912, DOI 10.1001/jama.2010.1567; Eccles M, 2002, BMJ-BRIT MED J, V325, P941, DOI 10.1136/bmj.325.7370.941; Emery J, 2007, BRIT J CANCER, V97, P486, DOI 10.1038/sj.bjc.6603897; Etchells E, 2010, QUAL SAF HEALTH CARE, V19, P99, DOI 10.1136/qshc.2008.028407; Feldstein A, 2006, J AM GERIATR SOC, V54, P450, DOI 10.1111/j.1532-5415.2005.00618.x; Feldstein AC, 2006, ARCH INTERN MED, V166, P1848, DOI 10.1001/archinte.166.17.1848; Field TS, 2009, J AM MED INFORM ASSN, V16, P480, DOI 10.1197/jamia.M2981; FIHN SD, 1994, J GEN INTERN MED, V9, P131, DOI 10.1007/BF02600026; Fiks AG, 2009, PEDIATRICS, V124, P159, DOI 10.1542/peds.2008-2823; Filippi A, 2003, DIABETES CARE, V26, P1497, DOI 10.2337/diacare.26.5.1497; Fitzmaurice DA, 2000, ARCH INTERN MED, V160, P2343, DOI 10.1001/archinte.160.15.2343; Flanagan JR, 1999, J AM MED INFORM ASSN, P755; Flottorp S, 2002, BMJ-BRIT MED J, V325, P367, DOI 10.1136/bmj.325.7360.367; FORDHAM D, 1990, M D COMPUT, V7, P289; Fortuna RJ, 2009, J GEN INTERN MED, V24, P897, DOI 10.1007/s11606-009-1013-x; Frame P S, 1994, Arch Fam Med, V3, P581, DOI 10.1001/archfami.3.7.581; Frank Oliver, 2004, Aust Fam Physician, V33, P87; Fretheim A, 2006, PLOS MED, V3, P792, DOI 10.1371/journal.pmed.0030216; Fretheim A, 2006, PLOS MED, V3, P783, DOI 10.1371/journal.pmed.0030134; Garg AX, 2005, JAMA-J AM MED ASSOC, V293, P1223, DOI 10.1001/jama.293.10.1223; Gill JM, 2009, POPUL HEALTH MANAG, V12, P221, DOI 10.1089/pop.2009.0003; Gilutz H, 2009, ISR MED ASSOC J, V11, P23; Goud R, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1440; Graumlich JF, 2009, J HOSP MED, V4, P356, DOI [10.1002/jhm.469, 10.1002/jhm.565]; Greiver M, 2005, CAN FAM PHYSICIAN, V51, P382; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; Gurwitz JH, 2008, J AM GERIATR SOC, V56, P2225, DOI 10.1111/j.1532-5415.2008.02004.x; Hamilton Emily, 2004, J Healthc Qual, V26, P37; Harpole LH, 1997, J AM MED INFORM ASSN, V4, P511, DOI 10.1136/jamia.1997.0040511; Heidenreich PA, 2007, CIRCULATION, V115, P2829, DOI 10.1161/CIRCULATIONAHA.106.684753; Hetlevik I, 2000, INT J TECHNOL ASSESS, V16, P210, DOI 10.1017/S0266462300161185; Hetlevik I, 1999, SCAND J PRIM HEALTH, V17, P35; Hetlevik Irene, 1998, Blood Pressure, V7, P270; Hicks LS, 2008, J GEN INTERN MED, V23, P429, DOI 10.1007/s11606-007-0403-1; Hobbs FDR, 1996, FAM PRACT, V13, P133, DOI 10.1093/fampra/13.2.133; Holbrook A, 2009, CAN MED ASSOC J, V181, P37, DOI 10.1503/cmaj.081272; Holt TA, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-11; Holt TA, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X483904; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Judge J, 2006, J AM MED INFORM ASSN, V13, P385, DOI 10.1197/jamia.M1945; Kaushal R, 2003, ARCH INTERN MED, V163, P1409, DOI 10.1001/archinte.163.12.1409; Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F; Kenealy T, 2005, J GEN INTERN MED, V20, P916, DOI 10.1111/j.1525-1497.2005.0197.x; Khan Shamima, 2010, Health Outcomes Res Med, V1, pe61; Kline JA, 2009, ANN EMERG MED, V53, P727, DOI 10.1016/j.annemergmed.2008.09.034; Krall MA, 2004, ST HEAL T, V107, P135; Kucher N, 2005, NEW ENGL J MED, V352, P969, DOI 10.1056/NEJMoa041533; Kuperman GJ, 1999, J AM MED INFORM ASSN, V6, P512, DOI 10.1136/jamia.1999.0060512; Lee NJ, 2009, ADV NURS SCI, V32, P211, DOI 10.1097/ANS.0b013e3181b0d6bf; Lees KR, 2003, QJM-INT J MED, V96, P143, DOI 10.1093/qjmed/hcg019; Linder JA, 2009, ARCH INTERN MED, V169, P781, DOI 10.1001/archinternmed.2009.53; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; Lo HG, 2009, J AM MED INFORM ASSN, V16, P66, DOI 10.1197/jamia.M2687; LOBACH DF, 1994, J AM MED INFORM ASSN, P787; Locatelli F, 2009, J NEPHROL, V22, P662; MacLean CD, 2009, J GEN INTERN MED, V24, P1303, DOI 10.1007/s11606-009-1147-x; Manotti C, 2001, HAEMATOLOGICA, V86, P1060; Marco F, 2003, PATHOPHYSIOL HAEMO T, V33, P59, DOI 10.1159/000073847; Martens JD, 2007, INT J MED INFORM, V76, pS403, DOI 10.1016/j.ijmedinf.2007.04.005; Martens JD, 2006, STUD HEALTH TECHNOL, V124, P617; Matheny ME, 2008, J AM MED INFORM ASSN, V15, P424, DOI 10.1197/jamia.M2602; Maviglia SM, 2006, J AM MED INFORM ASSN, V13, P67, DOI 10.1197/jamia.M1861; McCowan C, 2001, MED INFORM INTERNET, V26, P191, DOI 10.1080/14639230110067890; MCDONALD CJ, 1992, M D COMPUT, V9, P304; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDOWELL I, 1989, J FAM PRACTICE, V28, P420; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; MCDOWELL I, 1986, CAN MED ASSOC J, V135, P991; McGregor JC, 2006, J AM MED INFORM ASSN, V13, P378, DOI 10.1197/jamia.M2049; McLaughlin D, 2010, CLIN PEDIATR, V49, P355, DOI 10.1177/0009922809339844; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; Montgomery AA, 2000, BRIT MED J, V320, P686, DOI 10.1136/bmj.320.7236.686; Murray MD, 2004, PHARMACOTHERAPY, V24, P324, DOI 10.1592/phco.24.4.324.33173; ORNSTEIN SM, 1991, J FAM PRACTICE, V32, P82; Osheroff J. A., 2005, IMPROVING OUTCOMES C; Overhage JM, 1997, J AM MED INFORM ASSN, V4, P364, DOI 10.1136/jamia.1997.0040364; Overhage JM, 1996, ARCH INTERN MED, V156, P1551, DOI 10.1001/archinte.156.14.1551; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Palen TE, 2006, AM J MANAG CARE, V12, P389; Palen TE, 2010, AM J MANAG CARE, V16, pE267; Paul M, 2006, J ANTIMICROB CHEMOTH, V58, P1238, DOI 10.1093/jac/dkl372; Peterson JF, 2007, STUD HEALTH TECHNOL, V129, P1037; Peterson KA, 2008, DIABETES CARE, V31, P2238, DOI 10.2337/dc08-2034; Phillips LS, 2005, DIABETES CARE, V28, P2352, DOI 10.2337/diacare.28.10.2352; Player Marty S, 2010, Qual Prim Care, V18, P223; Price Morgan, 2005, Can Fam Physician, V51, P1506; Raebel MA, 2006, PHARMACOTHERAPY, V26, P619, DOI 10.1592/phco.26.5.619; Raebel MA, 2005, ARCH INTERN MED, V165, P2395, DOI 10.1001/archinte.165.20.2395; Raebel MA, 2007, J AM GERIATR SOC, V55, P977, DOI 10.1111/j.1532-5415.2007.01202.x; Reeve JF, 2008, BRIT J CLIN PHARMACO, V65, P377, DOI 10.1111/j.1365-2125.2007.03012.x; Rollman BL, 2001, ARCH INTERN MED, V161, P189, DOI 10.1001/archinte.161.2.189; Rood E, 2005, J AM MED INFORM ASSN, V12, P172, DOI 10.1197/jamia.M1598; ROSSER WW, 1992, CAN MED ASSOC J, V146, P911; ROSSER WW, 1991, CAN MED ASSOC J, V145, P807; Rossi RA, 1997, J GEN INTERN MED, V12, P672, DOI 10.1046/j.1525-1497.1997.07140.x; Rothschild JM, 2007, TRANSFUSION, V47, P228, DOI 10.1111/j.1537-2995.2007.01093.x; Roukema J, 2008, J AM MED INFORM ASSN, V15, P107, DOI 10.1197/jamia.M2164; Roumie CL, 2006, ANN INTERN MED, V145, P165, DOI 10.7326/0003-4819-145-3-200608010-00004; Roy PM, 2009, ANN INTERN MED, V151, P677, DOI 10.7326/0003-4819-151-10-200911170-00003; Samore MH, 2005, JAMA-J AM MED ASSOC, V294, P2305, DOI 10.1001/jama.294.18.2305; Schriefer SP, 2009, FAM MED, V41, P502; Sequist TD, 2005, J AM MED INFORM ASSN, V12, P431, DOI 10.1197/jamia.M1788; Sequist TD, 2009, ARCH INTERN MED, V169, P364, DOI 10.1001/archinternmed.2008.564; Shojania KG, 2010, CAN MED ASSOC J, V182, pE216, DOI 10.1503/cmaj.090578; Shojania KG, 1998, J AM MED INFORM ASSN, V5, P554, DOI 10.1136/jamia.1998.0050554; Simon SR, 2006, J AM GERIATR SOC, V54, P963, DOI 10.1111/j.1532-5415.2006.00734.x; Sintchenko V, 2007, MED INFORM INTERNET, V32, P225, DOI 10.1080/14639230701447701; Smith DH, 2009, AM J MANAG CARE, V15, P281; Smith SA, 2008, MAYO CLIN PROC, V83, P747, DOI 10.4065/83.7.747; Stiell IG, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4146; Strom BL, 2010, ARCH INTERN MED, V170, P1578, DOI 10.1001/archinternmed.2010.324; Strom BL, 2010, J AM MED INFORM ASSN, V17, P411, DOI 10.1136/jamia.2009.000695; Subramanian U, 2004, AM J MED, V116, P375, DOI 10.1016/j.amjmed.2003.11.021; Sundaram V, 2009, INT J STD AIDS, V20, P527, DOI 10.1258/ijsa.2008.008423; Tamblyn R, 2003, CAN MED ASSOC J, V169, P549; Tamblyn R, 2008, J AM MED INFORM ASSN, V15, P430, DOI 10.1197/jamia.M2606; Tamblyn R, 2010, MED DECIS MAKING, V30, P176, DOI 10.1177/0272989X09342752; Taylor V, 1999, J GEN INTERN MED, V14, P104, DOI 10.1046/j.1525-1497.1999.00295.x; Terrell KM, 2010, ANN EMERG MED, V56, P623, DOI 10.1016/j.annemergmed.2010.03.025; Terrell KM, 2009, J AM GERIATR SOC, V57, P1388, DOI 10.1111/j.1532-5415.2009.02352.x; Tierney WM, 2005, HEALTH SERV RES, V40, P477, DOI 10.1111/j.1475-6773.2005.0t369.x; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; Tierney WM, 2003, J GEN INTERN MED, V18, P967, DOI 10.1111/j.1525-1497.2003.30635.x; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; Unrod M, 2007, J GEN INTERN MED, V22, P478, DOI 10.1007/s11606-006-0069-0; Vadher B, 1997, BMJ-BRIT MED J, V314, P1252, DOI 10.1136/bmj.314.7089.1252; Vadher BD, 1997, CLIN LAB HAEMATOL, V19, P203; van Wijk MAM, 2001, ANN INTERN MED, V134, P274, DOI 10.7326/0003-4819-134-4-200102200-00010; van Wyk JT, 2008, CIRCULATION, V117, P371, DOI 10.1161/CIRCULATIONAHA.107.697201; VISSERS MC, 1995, COMPUT METH PROG BIO, V48, P53, DOI 10.1016/0169-2607(95)01660-L; Vissers MC, 1996, COMPUT METH PROG BIO, V49, P177, DOI 10.1016/0169-2607(95)01714-3; Walker J, 2010, SEX TRANSM DIS, V37, P445, DOI 10.1097/OLQ.0b013e3181cfcb4c; WHITE KS, 1984, J AM COLL CARDIOL, V4, P571, DOI 10.1016/S0735-1097(84)80104-7; Wilson BJ, 2006, FAM PRACT, V23, P537, DOI 10.1093/fampra/cml026; Zanetti G, 2003, INFECT CONT HOSP EP, V24, P13, DOI 10.1086/502109; Ziemer DC, 2006, ARCH INTERN MED, V166, P507, DOI 10.1001/archinte.166.5.507	173	615	629	3	148	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2012	157	1					29	U77		10.7326/0003-4819-157-1-201207030-00450	http://dx.doi.org/10.7326/0003-4819-157-1-201207030-00450			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	992NS	22751758				2022-12-28	WOS:000307784900004
J	Doherty, RB				Doherty, Robert B.			The Supreme Court and the Affordable Care Act: Milestone or Detour on the Road to Universal Coverage?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Doherty, Robert B.] Amer Coll Physicians, Philadelphia, PA USA	American College of Physicians	Doherty, RB (corresponding author), Amer Coll Physicians, 25 Massachusetts Ave NW, Washington, DC 20001 USA.							Berwick DM, 2012, WASHINGTON POST; Berwick DM, 2011, NEW ENGL J MED, V365, P1753, DOI 10.1056/NEJMp1111671; Bronson DL, 2012, EVERY AM WILL BENEFI; Clement S, 2012, WASHINGTON POST 0628; Denniston Lyle, 2012, SCOTUSBLOG      0628; Gawande A, 2012, NEW YORKER DAIL 0628; Harvey H, 2012, UPDATED ESTIMATES IN; Iglehart JK, 2012, NEW ENGL J MED, V366, P2144, DOI 10.1056/NEJMp1205537; Ness D, 2012, HEALTHAFFAIRS   0621; Pear R., 2012, NY TIMES; Rosenbaum S, 2012, HEALTHAFFAIRS   0628	11	1	1	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 16	2012	157	8					577	+		10.7326/0003-4819-157-7-201210020-00509	http://dx.doi.org/10.7326/0003-4819-157-7-201210020-00509			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021SP	22777567				2022-12-28	WOS:000309906000020
J	Johnson, JN; Ackerman, MJ				Johnson, Jonathan N.; Ackerman, Michael J.			Competitive Sports Participation in Athletes With Congenital Long QT Syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							RISK-FACTORS; CHILDREN		[Johnson, Jonathan N.] Mayo Clin, Div Pediat Cardiol, Rochester, MN 55905 USA; [Ackerman, Michael J.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Johnson, JN (corresponding author), Mayo Clin, Div Pediat Cardiol, Rochester, MN 55905 USA.	ackerman.michael@mayo.edu						Ackerman MJ, 2004, NAT MED, V10, P463, DOI 10.1038/nm0504-463; Goldenberg I, 2008, CIRCULATION, V117, P2184, DOI 10.1161/CIRCULATIONAHA.107.701243; Liu JF, 2011, J AM COLL CARDIOL, V57, P941, DOI 10.1016/j.jacc.2010.10.025; Mitchell JH, 2005, J AM COLL CARDIOL, V45, P1364, DOI 10.1016/j.jacc.2005.02.015; Pelliccia A, 2005, EUR HEART J, V26, P1422, DOI 10.1093/eurheartj/ehi325; Zipes DP, 2005, J AM COLL CARDIOL, V45, P1354, DOI 10.1016/j.jacc.2005.02.014	6	58	59	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 22	2012	308	8					764	765		10.1001/jama.2012.9334	http://dx.doi.org/10.1001/jama.2012.9334			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	991ML	22820673	Bronze			2022-12-28	WOS:000307705300014
J	Basler, M; Mekalanos, JJ				Basler, M.; Mekalanos, J. J.			Type 6 Secretion Dynamics Within and Between Bacterial Cells	SCIENCE			English	Article									[Basler, M.; Mekalanos, J. J.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Mekalanos, JJ (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, 200 Longwood Ave, Boston, MA 02115 USA.	john_mekalanos@hms.harvard.edu	Basler, Marek/A-3559-2012	Basler, Marek/0000-0001-5414-2088	National Institute of Allergy and Infectious Disease [AI-018045, AI-26289]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018045, R01AI018045, R01AI026289, R37AI018045] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank T. G. Bernhardt and N. T. Peters for suggestions on the use of fluorescence microscopy resources and B. Ho and K. Roberts for helpful discussions. This work was supported by National Institute of Allergy and Infectious Disease grants AI-018045 and AI-26289 to J.J.M.	Basler M, 2012, NATURE, V483, P182, DOI 10.1038/nature10846; Bonemann G, 2009, EMBO J, V28, P315, DOI 10.1038/emboj.2008.269; Leiman PG, 2009, P NATL ACAD SCI USA, V106, P4154, DOI 10.1073/pnas.0813360106; Pietrosiuk A, 2011, J BIOL CHEM, V286, P30010, DOI 10.1074/jbc.M111.253377; Pukatzki S, 2006, P NATL ACAD SCI USA, V103, P1528, DOI 10.1073/pnas.0510322103; Russell AB, 2011, NATURE, V475, P343, DOI 10.1038/nature10244; Silverman JM, 2011, MOL MICROBIOL, V82, P1277, DOI 10.1111/j.1365-2958.2011.07889.x	8	165	168	2	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 17	2012	337	6096					815	815		10.1126/science.1222901	http://dx.doi.org/10.1126/science.1222901			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	989BQ	22767897	Green Accepted			2022-12-28	WOS:000307535600035
J	Reich, D; Patterson, N; Campbell, D; Tandon, A; Mazieres, S; Ray, N; Parra, MV; Rojas, W; Duque, C; Mesa, N; Garcia, LF; Triana, O; Blair, S; Maestre, A; Dib, JC; Bravi, CM; Bailliet, G; Corach, D; Hunemeier, T; Bortolini, MC; Salzano, FM; Petzl-Erler, ML; Acuna-Alonzo, V; Aguilar-Salinas, C; Canizales-Quinteros, S; Tusie-Luna, T; Riba, L; Rodriguez-Cruz, M; Lopez-Alarcon, M; Coral-Vazquez, R; Canto-Cetina, T; Silva-Zolezzi, I; Fernandez-Lopez, JC; Contreras, AV; Jimenez-Sanchez, G; Gomez-Vazquez, MJ; Molina, J; Carracedo, A; Salas, A; Gallo, C; Poletti, G; Witonsky, DB; Alkorta-Aranburu, G; Sukernik, RI; Osipova, L; Fedorova, SA; Vasquez, R; Villena, M; Moreau, C; Barrantes, R; Pauls, D; Excoffier, L; Bedoya, G; Rothhammer, F; Dugoujon, JM; Larrouy, G; Klitz, W; Labuda, D; Kidd, J; Kidd, K; Di Rienzo, A; Freimer, NB; Price, AL; Ruiz-Linares, A				Reich, David; Patterson, Nick; Campbell, Desmond; Tandon, Arti; Mazieres, Stephane; Ray, Nicolas; Parra, Maria V.; Rojas, Winston; Duque, Constanza; Mesa, Natalia; Garcia, Luis F.; Triana, Omar; Blair, Silvia; Maestre, Amanda; Dib, Juan C.; Bravi, Claudio M.; Bailliet, Graciela; Corach, Daniel; Huenemeier, Tabita; Bortolini, Maria Catira; Salzano, Francisco M.; Petzl-Erler, Maria Luiza; Acuna-Alonzo, Victor; Aguilar-Salinas, Carlos; Canizales-Quinteros, Samuel; Tusie-Luna, Teresa; Riba, Laura; Rodriguez-Cruz, Maricela; Lopez-Alarcon, Mardia; Coral-Vazquez, Ramon; Canto-Cetina, Thelma; Silva-Zolezzi, Irma; Fernandez-Lopez, Juan Carlos; Contreras, Alejandra V.; Jimenez-Sanchez, Gerardo; Gomez-Vazquez, Maria Jose; Molina, Julio; Carracedo, Angel; Salas, Antonio; Gallo, Carla; Poletti, Giovanni; Witonsky, David B.; Alkorta-Aranburu, Gorka; Sukernik, Rem I.; Osipova, Ludmila; Fedorova, Sardana A.; Vasquez, Rene; Villena, Mercedes; Moreau, Claudia; Barrantes, Ramiro; Pauls, David; Excoffier, Laurent; Bedoya, Gabriel; Rothhammer, Francisco; Dugoujon, Jean-Michel; Larrouy, Georges; Klitz, William; Labuda, Damian; Kidd, Judith; Kidd, Kenneth; Di Rienzo, Anna; Freimer, Nelson B.; Price, Alkes L.; Ruiz-Linares, Andres			Reconstructing Native American population history	NATURE			English	Article							COLONIZATION; SETTLEMENT; DISPERSAL; DIVERSITY; PATTERNS; ORIGIN; MODEL; ASIA	The peopling of the Americas has been the subject of extensive genetic, archaeological and linguistic research; however, central questions remain unresolved(1-5). One contentious issue is whether the settlement occurred by means of a single(6-8) migration or multiple streams of migration from Siberia(9-15). The pattern of dispersals within the Americas is also poorly understood. To address these questions at a higher resolution than was previously possible, we assembled data from 52 Native American and 17 Siberian groups genotyped at 364,470 single nucleotide polymorphisms. Here we show that Native Americans descend from at least three streams of Asian gene flow. Most descend entirely from a single ancestral population that we call `First American'. However, speakers of Eskimo-Aleut languages from the Arctic inherit almost half their ancestry from a second stream of Asian gene flow, and the Na-Dene-speaking Chipewyan from Canada inherit roughly one-tenth of their ancestry from a third stream. We show that the initial peopling followed a southward expansion facilitated by the coast, with sequential population splits and little gene flow after divergence, especially in South America. A major exception is in Chibchan speakers on both sides of the Panama isthmus, who have ancestry from both North and South America.	[Reich, David; Tandon, Arti] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Reich, David; Patterson, Nick; Tandon, Arti; Price, Alkes L.] Broad Inst Harvard, Cambridge, MA 02142 USA; [Reich, David; Patterson, Nick; Tandon, Arti] MIT, Cambridge, MA 02142 USA; [Campbell, Desmond; Mazieres, Stephane; Parra, Maria V.; Rojas, Winston; Duque, Constanza; Mesa, Natalia; Bravi, Claudio M.; Huenemeier, Tabita; Ruiz-Linares, Andres] UCL, Dept Genet Evolut & Environm, London WC1E 6BT, England; Univ Hong Kong, Dept Psychiat, Pokfulam, Hong Kong, Peoples R China; [Campbell, Desmond] Univ Hong Kong, Ctr Genom Sci, Pokfulam, Hong Kong, Peoples R China; [Mazieres, Stephane] Aix Marseille Univ, CNRS, EFS, ADES,UMR7268, F-13344 Marseille, France; [Ray, Nicolas] Univ Geneva, Inst Environm Sci, CH-1227 Geneva, Switzerland; [Ray, Nicolas] Univ Geneva, Forel Inst, CH-1227 Geneva, Switzerland; [Parra, Maria V.; Rojas, Winston; Duque, Constanza; Mesa, Natalia; Garcia, Luis F.; Triana, Omar; Blair, Silvia; Maestre, Amanda; Bedoya, Gabriel] Univ Antioquia, Medellin, Colombia; [Dib, Juan C.] Fdn Salud Trop, Santa Marta, Colombia; [Bravi, Claudio M.; Bailliet, Graciela] Consejo Nacl Invest Cient & Tecn, CICPCA, CCT La Plata, Inst Multidisciplinario Biol Celular, RA-1900 La Plata, Argentina; [Corach, Daniel] Univ Buenos Aires, Serv Huellas Digitales Genet, RA-1053 Buenos Aires, DF, Argentina; [Corach, Daniel] Univ Buenos Aires, CONICET, RA-1053 Buenos Aires, DF, Argentina; [Huenemeier, Tabita; Bortolini, Maria Catira; Salzano, Francisco M.] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Genet, BR-91501970 Porto Alegre, RS, Brazil; [Petzl-Erler, Maria Luiza] Univ Fed Parana, Dept Genet, BR-81531980 Curitiba, Parana, Brazil; [Acuna-Alonzo, Victor] Natl Inst Anthropol & Hist, Mexico City 06100, DF, Mexico; [Aguilar-Salinas, Carlos] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Endocrinol & Metab, Mexico City 14100, DF, Mexico; [Canizales-Quinteros, Samuel; Tusie-Luna, Teresa; Riba, Laura] Univ Nacl Autonoma Mexico, Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Unidad Biol Mol & Med Genom, Mexico City 14100, DF, Mexico; [Canizales-Quinteros, Samuel] Univ Nacl Autonoma Mexico, Fac Quim, Dept Biol, Mexico City 04510, DF, Mexico; [Rodriguez-Cruz, Maricela; Lopez-Alarcon, Mardia] Hosp Pediat Mexico City, Inst Mexicano Seguro Social, CMNSXXI, Unidad Invest Med Nutr, Mexico City 06720, DF, Mexico; [Coral-Vazquez, Ramon] Inst Politecn Nacl, Escuela Super Med, Secc Posgrado, Mexico City 11340, DF, Mexico; [Canto-Cetina, Thelma] Ctr Invest Reg, Dept Salud Reprod & Genet, Lab Biol Reproducc, Merida 97000, Mexico; [Silva-Zolezzi, Irma; Fernandez-Lopez, Juan Carlos; Contreras, Alejandra V.; Jimenez-Sanchez, Gerardo] Inst Nacl Med Genom, Mexico City 14610, DF, Mexico; [Gomez-Vazquez, Maria Jose] Univ Autonoma Nuevo Leon, San Nicolas De Los Garza 66451, Nuevo Leon, Mexico; [Molina, Julio] Ctr Invest Biomed Guatemala, Guatemala City, Guatemala; [Carracedo, Angel; Salas, Antonio] Univ Santiago de Compostela, Fdn Med Xenom SERGAS, Inst Ciencias Forenses, Santiago De Compostela, Spain; [Gallo, Carla; Poletti, Giovanni] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Labs Invest & Desarrollo, Lima 15102, Peru; [Witonsky, David B.; Alkorta-Aranburu, Gorka; Di Rienzo, Anna] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Sukernik, Rem I.] Russian Acad Sci, Siberian Branch, Inst Mol & Cellular Biol, Lab Human Mol Genet, Novosibirsk 630090, Russia; [Osipova, Ludmila] Russian Acad Sci, Siberian Branch, Inst Cytol & Genet, Novosibirsk 630090, Russia; [Fedorova, Sardana A.] Yakut Res Ctr Complex Med Problems, Dept Mol Genet, Sakha 677010, Yakutia, Russia; [Fedorova, Sardana A.] NE Fed Univ, Sakha 677010, Yakutia, Russia; [Vasquez, Rene; Villena, Mercedes] Univ Autonoma Tomas Frias, Inst Boliviano Biol Altura, Potosi, Bolivia; [Moreau, Claudia; Labuda, Damian] Univ Montreal, Dept Pediat, Ctr Rech, CHU St Justine, Montreal, PQ H3T 1C5, Canada; [Barrantes, Ramiro] Univ Costa Rica, Escuela Biol, San Jose, Costa Rica; [Pauls, David] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; [Excoffier, Laurent] Univ Bern, Inst Ecol & Evolut, Computat & Mol Populat Genet Lab, CH-3012 Bern, Switzerland; [Excoffier, Laurent] Swiss Inst Bioinformat, CH-1015 Lausanne, Switzerland; [Rothhammer, Francisco] Univ Chile, Fac Med, Programa Genet Humana ICBM, Inst Alta Invest ,Univ Tarapaca, Arica 1001236, Chile; [Rothhammer, Francisco] Ctr Invest Hombre El Desierto, Arica 1001236, Chile; [Dugoujon, Jean-Michel; Larrouy, Georges] Univ Toulouse 3, CNRS, UMR 5288, F-31000 Toulouse, France; [Klitz, William] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Kidd, Judith; Kidd, Kenneth] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; [Freimer, Nelson B.] Univ Calif Los Angeles, Ctr Neurobehav Genet, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA; [Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); University of London; University College London; University of Hong Kong; University of Hong Kong; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Universite Bordeaux-Montaigne; UDICE-French Research Universities; Aix-Marseille Universite; University of Geneva; University of Geneva; Universidad de Antioquia; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of La Plata; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Universidade Federal do Rio Grande do Sul; Universidade Federal do Parana; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Instituto Mexicano del Seguro Social; Instituto Politecnico Nacional - Mexico; Instituto Nacional de Medicina Genomica; Universidad Autonoma de Nuevo Leon; Universidade de Santiago de Compostela; Universidad Peruana Cayetano Heredia; University of Chicago; Russian Academy of Sciences; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; North-Eastern Federal University in Yakutsk; Universidad Mayor de San Andres; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universidad Costa Rica; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Bern; Swiss Institute of Bioinformatics; Universidad de Chile; Universidad de Tarapaca; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of California System; University of California Berkeley; Yale University; University of California System; University of California Los Angeles; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Reich, D (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	reich@genetics.med.harvard.edu; a.ruizlin@ucl.ac.uk	Mazières, Stéphane/R-2061-2019; RODRIGUEZ-CRUZ, MARICELA/C-2445-2018; Ruiz-Linares, Andres/AAR-1104-2021; Gallo, Carla/Q-4296-2019; Acuna Alonzo, Victor/E-2312-2013; Ray, Nicolas/C-8988-2009; Carracedo, Angel/D-4257-2012; Ray, Nicolas/AFG-2968-2022; Sukernik, Rem I/N-6990-2015; Mazieres, Stephane/G-1702-2010; Alarcon, Mardia Lopez/AAD-8373-2019; Fernandez, Juan Carlos/C-4976-2013; Salinas, Carlos A Aguilar/AAL-4491-2020; Fedorova, Sardana/K-5445-2017; Osipova, Ludmila P/O-6480-2014; Excoffier, Laurent/D-3498-2013; Petzl-Erler, Maria Luiza/H-8221-2012; Salas, Antonio/E-3977-2012; Hünemeier, Tábita/F-4181-2011; Salas, Antonio/U-2029-2019; Salzano, Francisco M/L-7916-2015; Contreras, Alejandra Virginia/E-7815-2013	Ruiz-Linares, Andres/0000-0001-8372-1011; Acuna Alonzo, Victor/0000-0003-2205-7625; Ray, Nicolas/0000-0002-4696-5313; Carracedo, Angel/0000-0003-1085-8986; Ray, Nicolas/0000-0002-4696-5313; Mazieres, Stephane/0000-0003-1266-4659; Alarcon, Mardia Lopez/0000-0001-8017-4390; Fernandez, Juan Carlos/0000-0003-3680-4193; Osipova, Ludmila P/0000-0001-7602-1156; Excoffier, Laurent/0000-0002-7507-6494; Petzl-Erler, Maria Luiza/0000-0002-0345-5276; Salas, Antonio/0000-0002-2336-702X; Salas, Antonio/0000-0002-2336-702X; Gallo, Carla/0000-0001-8348-0473; Campbell, Desmond/0000-0003-1085-714X; Contreras, Alejandra Virginia/0000-0003-3653-5958; Canto, Thelma/0000-0002-5952-375X; Corach, Daniel/0000-0002-0662-7424; Fedorova, Sardana/0000-0002-6952-3868; Rojas Montoya, Winston/0000-0002-7654-3998; Coral, Ramon/0000-0001-6126-2002; Hunemeier, Tabita/0000-0002-3156-2079; Blair Trujillo, silvia/0000-0002-9030-6585; Triana, Omar/0000-0001-8031-0225; Parra-Marin, Maria Victoria/0000-0002-8475-471X; Jaramillo Garcia, Luis Fernando/0000-0003-2909-9318; Di Rienzo, Anna/0000-0002-8982-9098	National Institutes of Health [NS043538, NS037484, MH075007, GM079558, GM079558-S1, GM057672, HG006399]; Biotechnology and Biological Sciences Research Council [BB/1021213/1]; National Science Foundation HOMINID [BCS-1032255]; Canadian Institutes of Health Research grant; Universidad de Antioquia CODI grant; Fondo de Investigacion Sanitaria grant [PS 09/2368]; Ministerio de Ciencia e Innovacion [SAF2011-26983]; Wenner-Gren Foundation [ICRG-65]; Russian Foundation for Basic Research [06-04-048182, 02-06-80524a]; Siberian Branch Russian Academy of Sciences field grant; Centre National de la Recherche Scientifique Programme Interdisciplinaire de Recherche Amazonie grant; Harvard Medical School; Harvard School of Public Health; BBSRC [BB/I021213/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/I021213/1] Funding Source: researchfish; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG006399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057672, R01GM079558, R01GM100233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH075007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043538, R01NS037484] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); National Science Foundation HOMINID; Canadian Institutes of Health Research grant(Canadian Institutes of Health Research (CIHR)); Universidad de Antioquia CODI grant; Fondo de Investigacion Sanitaria grant; Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Wenner-Gren Foundation; Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Siberian Branch Russian Academy of Sciences field grant; Centre National de la Recherche Scientifique Programme Interdisciplinaire de Recherche Amazonie grant; Harvard Medical School; Harvard School of Public Health; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank the volunteers who provided the samples that made this study possible. We thank E. D. Ruiz for assistance in the collection involving the Mixtec, Zapotec and Mixe; and P. Herrera for assistance in the collection involving the Quechua; A. Carnevale, M. Crawford, M. Metspalu, F. C. Nielsen, X. Soberon, R. Villems and E. Willerslev for facilitating sharing of data from Mexican, Siberian and Arctic populations; C. Stevens and A. Crenshaw for assistance with genotyping; and P. Bellwood, D. Bolnick, K. Bryc, J. Diamond, T. Dillehay, R. Gonzalez-Jose, M. Hammer, J. Hill, B. Kemp, S. LeBlanc, D. Meltzer, P. Moorjani, A. Moreno-Estrada, B. Pakendorf, J. Pickrell, M. Ruhlen, D. G. Smith, M. Stoneking, N. Tuross and A. Williams for critiques and discussions. Support was provided by National Institutes of Health grants NS043538 (A. R.-L.), NS037484 and MH075007 (N. B. F.), GM079558 (A. D.), GM079558-S1 (A. D.), GM057672 (K. K. K. and J. R. K.), and HG006399 (D. R., N. P. & A. L. P); by a Biotechnology and Biological Sciences Research Council grant BB/1021213/1; by a National Science Foundation HOMINID grant BCS-1032255 (D. R. and N. P.); by a Canadian Institutes of Health Research grant (D. L.); by a Universidad de Antioquia CODI grant (G. B.); by a Fondo de Investigacion Sanitaria grant PS 09/2368 (A. C.); by a Ministerio de Ciencia e Innovacion grant SAF2011-26983 (A. S.); by a Wenner-Gren Foundation grant ICRG-65 (A. D. and R. S.); by Russian Foundation for Basic Research grants 06-04-048182 (R. S.) and 02-06-80524a (L.O.); by a Siberian Branch Russian Academy of Sciences field grant (L.O.); by a Centre National de la Recherche Scientifique Programme Interdisciplinaire de Recherche Amazonie grant (J.-M.D.); and by startup funds from Harvard Medical School (D. R.) and the Harvard School of Public Health (A.L.P.).	Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Balter M, 2012, SCIENCE, V335, P158, DOI 10.1126/science.335.6065.158; Bortolini MC, 2003, AM J HUM GENET, V73, P524, DOI 10.1086/377588; Brown MD, 1998, AM J HUM GENET, V63, P1852, DOI 10.1086/302155; Browning SR, 2007, AM J HUM GENET, V81, P1084, DOI 10.1086/521987; Bryc K, 2010, P NATL ACAD SCI USA, V107, P8954, DOI 10.1073/pnas.0914618107; Campbell Lyle, 1997, AM INDIAN LANGUAGES; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Cooke R, 2005, J ARCHAEOL RES, V13, P129, DOI 10.1007/s10804-005-2486-4; de Azevedo S, 2011, AM J PHYS ANTHROPOL, V146, P539, DOI 10.1002/ajpa.21564; Dillehay TD, 2009, P NATL ACAD SCI USA, V106, P971, DOI 10.1073/pnas.0808424106; Fagundes NJR, 2008, AM J HUM GENET, V82, P583, DOI 10.1016/j.ajhg.2007.11.013; Goebel T, 2008, SCIENCE, V319, P1497, DOI 10.1126/science.1153569; Greenberg J. H, 1987, LANGUAGE AM; GREENBERG JH, 1986, CURR ANTHROPOL, V27, P477, DOI 10.1086/203472; Karafet TM, 1999, AM J HUM GENET, V64, P817, DOI 10.1086/302282; Kitchen A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001596; Lell JT, 2002, AM J HUM GENET, V70, P192, DOI 10.1086/338457; Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282; Meltzer D. J., 2009, 1 PEOPLES NEW WORLD; O'Rourke DH, 2010, CURR BIOL, V20, pR202, DOI 10.1016/j.cub.2009.11.051; Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190; Perego UA, 2009, CURR BIOL, V19, P1, DOI 10.1016/j.cub.2008.11.058; Price AL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000519; Rasmussen M, 2010, NATURE, V463, P757, DOI 10.1038/nature08835; Ray N, 2005, MOL ECOL NOTES, V5, P177, DOI 10.1111/j.1471-8286.2004.00843.x; Ray N, 2010, MOL BIOL EVOL, V27, P337, DOI 10.1093/molbev/msp238; Reich D, 2009, NATURE, V461, P489, DOI 10.1038/nature08365; Ruhlen M, 1991, GUIDE WORLDS LANGUAG; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schroeder KB, 2007, BIOL LETTERS, V3, P218, DOI 10.1098/rsbl.2006.0609; Tamm E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000829; Volodko NV, 2008, AM J HUM GENET, V82, P1084, DOI 10.1016/j.ajhg.2008.03.019; Wall JD, 2011, MOL BIOL EVOL, V28, P2231, DOI 10.1093/molbev/msr049; Wang S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000037; Wang S, 2007, PLOS GENET, V3, P2049, DOI 10.1371/journal.pgen.0030185; Yang NN, 2010, ANN HUM GENET, V74, P525, DOI 10.1111/j.1469-1809.2010.00608.x	37	458	476	3	234	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 16	2012	488	7411					370	+		10.1038/nature11258	http://dx.doi.org/10.1038/nature11258			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	988OS	22801491	Green Submitted, Green Published, Green Accepted			2022-12-28	WOS:000307501000040
J	Tzeng, SR; Kalodimos, CG				Tzeng, Shiou-Ru; Kalodimos, Charalampos G.			Protein activity regulation by conformational entropy	NATURE			English	Article							CATABOLITE ACTIVATOR PROTEIN; MOLECULAR RECOGNITION; DYNAMIC ACTIVATION; ESCHERICHIA-COLI; RECEPTOR PROTEIN; NMR-SPECTROSCOPY; ORDER PARAMETERS; LIGAND-BINDING; FREE-ENERGY; RELAXATION	How the interplay between protein structure and internal dynamics regulates protein function is poorly understood. Often, ligand binding, post-translational modifications and mutations modify protein activity in a manner that is not possible to rationalize solely on the basis of structural data(1). It is likely that changes in the internal motions of proteins have a major role in regulating protein activity(2-7), but the nature of their contributions remains elusive, especially in quantitative terms. Here we show that changes in conformational entropy can determine whether protein-ligand interactions will occur, even among protein complexes with identical binding interfaces. We have used NMR spectroscopy to determine the changes in structure and internal dynamics that are elicited by the binding of DNA to several variants of the catabolite activator protein (CAP) that differentially populate the inactive and active DNA-binding domain states. We found that the CAP variants have markedly different affinities for DNA, despite the CAP-DNA-binding interfaces being essentially identical in the various complexes. Combined with thermodynamic data, the results show that conformational entropy changes can inhibit the binding of CAP variants that are structurally poised for optimal DNA binding or can stimulate the binding activity of CAP variants that only transiently populate the DNA-binding-domain active state. Collectively, the data show how changes in fast internal dynamics (conformational entropy) and slow internal dynamics (energetically excited conformational states) can regulate binding activity in a way that cannot be predicted on the basis of the protein's ground-state structure.	[Tzeng, Shiou-Ru; Kalodimos, Charalampos G.] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Kalodimos, CG (corresponding author), Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA.	babis@rutgers.edu	Kalodimos, Charalampos/Q-9846-2018	Kalodimos, Charalampos/0000-0001-6354-2796; TZENG, SHIOU-RU/0000-0002-7180-0190	National Science Foundation (NSF) [MCB1121896]; Div Of Molecular and Cellular Bioscience [1121896] Funding Source: National Science Foundation	National Science Foundation (NSF)(National Science Foundation (NSF)); Div Of Molecular and Cellular Bioscience(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	We are grateful to L. Kay for providing the methyl relaxation pulse sequences, D. Korzhnev for his help with the relaxation dispersion data analysis, and S. Kim and M.-T. Pai for their help with protein preparation and NMR experiments. This work was supported by National Science Foundation (NSF) grant MCB1121896 to C.G.K.	AKKE M, 1993, J AM CHEM SOC, V115, P9832, DOI 10.1021/ja00074a073; Akke M, 2012, BIOCHEM SOC T, V40, P419, DOI 10.1042/BST20110750; Baldwin AJ, 2009, NAT CHEM BIOL, V5, P808, DOI 10.1038/nchembio.238; Boehr DD, 2009, NAT CHEM BIOL, V5, P789, DOI 10.1038/nchembio.232; Bosshard HR, 2001, NEWS PHYSIOL SCI, V16, P171; Bouvignies G, 2011, NATURE, V477, P111, DOI 10.1038/nature10349; CHERVENAK MC, 1994, J AM CHEM SOC, V116, P10533, DOI 10.1021/ja00102a021; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; Frederick KK, 2007, NATURE, V448, P325, DOI 10.1038/nature05959; Gekko K, 2004, BIOCHEMISTRY-US, V43, P3844, DOI 10.1021/bi036271e; Henzler-Wildman K, 2007, NATURE, V450, P964, DOI 10.1038/nature06522; Ishima R, 2000, NAT STRUCT BIOL, V7, P740, DOI 10.1038/78963; Lawson CL, 2004, CURR OPIN STRUC BIOL, V14, P10, DOI 10.1016/j.sbi.2004.01.012; Li PL, 2008, NAT STRUCT MOL BIOL, V15, P613, DOI 10.1038/nsmb.1428; Li ZG, 1996, PROTEIN SCI, V5, P2647, DOI 10.1002/pro.5560051228; Marlow MS, 2010, NAT CHEM BIOL, V6, P352, DOI 10.1038/nchembio.347; Mobley DL, 2009, STRUCTURE, V17, P489, DOI 10.1016/j.str.2009.02.010; Olsson TSG, 2011, PROTEIN SCI, V20, P1607, DOI 10.1002/pro.692; Palmer AG, 2005, METHOD ENZYMOL, V394, P430, DOI 10.1016/S0076-6879(05)94018-4; Petit CM, 2009, P NATL ACAD SCI USA, V106, P18249, DOI 10.1073/pnas.0904492106; Popovych N, 2006, NAT STRUCT MOL BIOL, V13, P831, DOI 10.1038/nsmb1132; Popovych N, 2009, P NATL ACAD SCI USA, V106, P6927, DOI 10.1073/pnas.0900595106; Sapienza PJ, 2010, CURR OPIN PHARMACOL, V10, P723, DOI 10.1016/j.coph.2010.09.006; Tzeng SR, 2011, CURR OPIN STRUC BIOL, V21, P62, DOI 10.1016/j.sbi.2010.10.007; Tzeng SR, 2009, NATURE, V462, P368, DOI 10.1038/nature08560; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; Wand AJ, 2001, NAT STRUCT BIOL, V8, P926, DOI 10.1038/nsb1101-926; Yang DW, 1996, J MOL BIOL, V263, P369, DOI 10.1006/jmbi.1996.0581; Yao XL, 2008, NAT CHEM BIOL, V4, P491, DOI 10.1038/nchembio.99; Youn H, 2008, J BACTERIOL, V190, P4532, DOI 10.1128/JB.00074-08	30	359	360	9	283	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 9	2012	488	7410					236	240		10.1038/nature11271	http://dx.doi.org/10.1038/nature11271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	985LE	22801505				2022-12-28	WOS:000307267000039
J	Lyons, JA; Aragao, D; Slattery, O; Pisliakov, AV; Soulimane, T; Caffrey, M				Lyons, Joseph A.; Aragao, David; Slattery, Orla; Pisliakov, Andrei V.; Soulimane, Tewfik; Caffrey, Martin			Structural insights into electron transfer in caa(3)-type cytochrome oxidase	NATURE			English	Article							CRYSTALLIZING MEMBRANE-PROTEINS; C-OXIDASE; THERMUS-THERMOPHILUS; PARACOCCUS-DENITRIFICANS; NUCLEOTIDE-SEQUENCE; MOLECULAR-DYNAMICS; FORCE-FIELD; SUBUNIT; COMPLEX; SITE	Cytochrome c oxidase is a member of the haem copper oxidase superfamily (HCO)(1). HCOs function as the terminal enzymes in the respiratory chain of mitochondria and aerobic prokaryotes, coupling molecular oxygen reduction to transmembrane proton pumping. Integral to the enzyme's function is the transfer of electrons from cytochrome c to the oxidase via a transient association of the two proteins. Electron entry and exit are proposed to occur from the same site on cytochrome c(2-4). Here we report the crystal structure of the caa(3)-type cytochrome oxidase from Thermus thermophilus, which has a covalently tethered cytochrome c domain. Crystals were grown in a bicontinuous mesophase using a synthetic short-chain monoacylglycerol as the hosting lipid. From the electron density map, at 2.36 angstrom resolution, a novel integral membrane subunit and a native glycoglycerophospholipid embedded in the complex were identified. Contrary to previous electron transfer mechanisms observed for soluble cytochrome c, the structure reveals the architecture of the electron transfer complex for the fused cupredoxin/cytochrome c domain, which implicates different sites on cytochrome c for electron entry and exit. Support for an alternative to the classical proton gate characteristic of this HCO class is presented.	[Lyons, Joseph A.; Slattery, Orla; Soulimane, Tewfik] Univ Limerick, Dept Chem & Environm Sci, Limerick, Ireland; [Lyons, Joseph A.; Aragao, David; Caffrey, Martin] Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland; [Aragao, David] Australian Synchrotron, Clayton, Vic 3168, Australia; [Pisliakov, Andrei V.] RIKEN Adv Sci Inst, Theoret Biochem Lab, Wako, Saitama 3510198, Japan; [Soulimane, Tewfik] Univ Limerick, Mat & Surface Sci Inst, Limerick, Ireland; [Caffrey, Martin] Trinity Coll Dublin, Sch Med, Dublin, Ireland	University of Limerick; Trinity College Dublin; RIKEN; University of Limerick; Trinity College Dublin	Soulimane, T (corresponding author), Univ Limerick, Dept Chem & Environm Sci, Limerick, Ireland.	tewfik.soulimane@ul.ie; martin.caffrey@tcd.ie	Aragao, David/A-1695-2012; Aragao, David/AAV-5514-2021; Pisliakov, Andrei/C-7007-2012; Lyons, Joseph/AAA-2528-2020	Aragao, David/0000-0002-6551-4657; Aragao, David/0000-0002-6551-4657; Pisliakov, Andrei/0000-0003-1536-0589; Caffrey, Martin/0000-0002-2931-4551; Lyons, Joseph/0000-0003-0218-4862	Science Foundation Ireland [07/IN.1/B1836, BICF685]; National Institutes of Health [GM75915, P50GM073210, U54GM094599]; FP7 COST [CM0902]; Marie Curie Actions [PIEF-GA-2009-235612]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM094599, P50GM073210, R01GM061070, R01GM075915] Funding Source: NIH RePORTER	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FP7 COST; Marie Curie Actions(European Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge support from Science Foundation Ireland Grants 07/IN.1/B1836 (M. C.) and BICF685 (T. S.), the National Institutes of Health Grants GM75915, P50GM073210, U54GM094599 (M. C.), and FP7 COST CM0902 (M. C.) and Marie Curie Actions PIEF-GA-2009-235612 (D. A.). We thank D. Hart, J. Lee and T. Smyth for help with 7.7 MAG synthesis, M. Dewor for amino acid sequencing, C. Soares for discussions regarding surface potential calculations, and G. Winter for help with data reduction from multiple crystals. The assistance and support of beamline scientists at the Advanced Photon Source (23-ID), Diamond Light Source (I24) and Swiss Light Source (PX1) are gratefully acknowledged.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Backgren C, 2000, BIOCHEMISTRY-US, V39, P7863, DOI 10.1021/bi000806b; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASHFORD D, 1992, J MOL BIOL, V224, P473, DOI 10.1016/0022-2836(92)91009-E; Bond CS, 2009, ACTA CRYSTALLOGR D, V65, P510, DOI 10.1107/S0907444909007835; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buse G, 1999, PROTEIN SCI, V8, P985, DOI 10.1110/ps.8.5.985; Caffrey M, 2009, CURR TOP MEMBR, V63, P83, DOI 10.1016/S1063-5823(09)63004-0; Caffrey M, 2009, NAT PROTOC, V4, P706, DOI 10.1038/nprot.2009.31; Caffrey M, 2009, ANNU REV BIOPHYS, V38, P29, DOI 10.1146/annurev.biophys.050708.133655; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Cherezov V, 2004, ACTA CRYSTALLOGR D, V60, P1795, DOI 10.1107/S0907444904019109; Cherezov V, 2009, J R SOC INTERFACE, V6, pS587, DOI 10.1098/rsif.2009.0142.focus; Drosou V, 2002, EUR J BIOCHEM, V269, P2980, DOI 10.1046/j.1432-1033.2002.02979.x; Drosou V, 2002, BIOCHEMISTRY-US, V41, P10629, DOI 10.1021/bi020094k; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; FEE JA, 1980, P NATL ACAD SCI-BIOL, V77, P147, DOI 10.1073/pnas.77.1.147; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Fischetti RF, 2009, J SYNCHROTRON RADIAT, V16, P217, DOI 10.1107/S0909049508040612; Ho BK, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-49; Hofer N, 2011, CRYST GROWTH DES, V11, P1182, DOI 10.1021/cg101384p; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Klauda JB, 2010, J PHYS CHEM B, V114, P7830, DOI 10.1021/jp101759q; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; Li DF, 2011, CRYST GROWTH DES, V11, P530, DOI 10.1021/cg101378s; Lomize AL, 2006, PROTEIN SCI, V15, P1318, DOI 10.1110/ps.062126106; LUBBEN M, 1994, J BIOL CHEM, V269, P21473; Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Maneg O, 2004, BBA-BIOENERGETICS, V1655, P274, DOI 10.1016/j.bbabio.2003.10.010; Maneg O, 2003, J BIOL CHEM, V278, P46734, DOI 10.1074/jbc.M307594200; MATHER MW, 1991, J BIOL CHEM, V266, P5025; MATHER MW, 1993, J BIOL CHEM, V268, P5395; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Misquitta LV, 2004, STRUCTURE, V12, P2113, DOI 10.1016/j.str.2004.09.020; Muresanu L, 2006, J BIOL CHEM, V281, P14503, DOI 10.1074/jbc.M601108200; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; Pereira MM, 2008, BBA-BIOENERGETICS, V1777, P929, DOI 10.1016/j.bbabio.2008.05.441; Pereira MM, 2001, BBA-BIOENERGETICS, V1505, P185, DOI 10.1016/S0005-2728(01)00169-4; Pereira MM, 2006, FEBS LETT, V580, P1350, DOI 10.1016/j.febslet.2006.01.055; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Roberts VA, 1999, J BIOL CHEM, V274, P38051, DOI 10.1074/jbc.274.53.38051; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Santana M, 2001, J BACTERIOL, V183, P687, DOI 10.1128/JB.183.2.687-699.2001; Soares CM, 2004, J BIOL INORG CHEM, V9, P124, DOI 10.1007/s00775-003-0509-9; Soulimane T, 2000, PROTEIN SCI, V9, P2068, DOI 10.1110/ps.9.11.2068; Soulimane T., 2003, MEMBRANE PROTEIN PUR, P229; Srinivasan V, 2005, J MOL BIOL, V345, P1047, DOI 10.1016/j.jmb.2004.10.069; STEFFENS GCM, 1987, EUR J BIOCHEM, V164, P295, DOI 10.1111/j.1432-1033.1987.tb11057.x; Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367; Wienk H, 2003, BIOCHEMISTRY-US, V42, P6005, DOI 10.1021/bi027198f; Winter G, 2010, J APPL CRYSTALLOGR, V43, P186, DOI 10.1107/S0021889809045701; Witt H, 1998, J BIOL CHEM, V273, P5132, DOI 10.1074/jbc.273.9.5132; Zhang L, 1996, PROTEINS, V24, P433, DOI 10.1002/(SICI)1097-0134(199604)24:4<433::AID-PROT3>3.0.CO;2-F	58	98	99	2	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 26	2012	487	7408					514	518		10.1038/nature11182	http://dx.doi.org/10.1038/nature11182			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979KD	22763450	Green Accepted			2022-12-28	WOS:000306815300045
J	Fauci, AS; Folkers, GK				Fauci, Anthony S.; Folkers, Gregory K.			Toward an AIDS-Free Generation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HIV PREVENTION		[Fauci, Anthony S.; Folkers, Gregory K.] NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fauci, AS (corresponding author), NIAID, NIH, 31 Ctr Dr,Bldg 31,Room 7A-03,MSC 2520, Bethesda, MD 20892 USA.	afauci@niaid.nih.gov						Celum C, 2012, CURR OPIN INFECT DIS, V25, P51, DOI 10.1097/QCO.0b013e32834ef5ef; Chun TW, 2012, AIDS, V26, P1261, DOI 10.1097/QAD.0b013e328353f3f1; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Granich R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030216; Gray R, 2012, AIDS, V26, P609, DOI 10.1097/QAD.0b013e3283504a3f; Johnston MI, 2011, NEW ENGL J MED, V365, P873, DOI 10.1056/NEJMp1107621; WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E	7	63	63	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					343	344		10.1001/jama.2012.8142	http://dx.doi.org/10.1001/jama.2012.8142			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820783	Bronze			2022-12-28	WOS:000306685500018
J	Das, P				Das, Pamela			Ken Powell: running the distance for physical activity	LANCET			English	Biographical-Item																		POWELL K, PUBLICATION LIST	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 21	2012	380	9838					209	209		10.1016/S0140-6736(12)61204-5	http://dx.doi.org/10.1016/S0140-6736(12)61204-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976TV	22817965				2022-12-28	WOS:000306609200016
J	Westhorpe, FG; Straight, AF				Westhorpe, Frederick G.; Straight, Aaron F.			The Split Personality of CENP-A Nucleosomes	CELL			English	Editorial Material							CENTROMERIC NUCLEOSOME; YEAST		[Westhorpe, Frederick G.; Straight, Aaron F.] Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Straight, AF (corresponding author), Stanford Univ, Dept Biochem, Stanford, CA 94305 USA.	astraigh@stanford.edu		Westhorpe, Fred/0000-0002-1401-1996; Straight, Aaron/0000-0001-5885-7881	NIGMS NIH HHS [R01 GM074728] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074728] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Black B, 2011, CELL, V144, P471, DOI 10.1016/j.cell.2011.02.002; Bui M, 2012, CELL, V150, P317, DOI 10.1016/j.cell.2012.05.035; Coffman VC, 2011, J CELL BIOL, V195, P563, DOI 10.1083/jcb.201106078; Foltz DR, 2006, NAT CELL BIOL, V8, P458, DOI 10.1038/ncb1397; Furuyama S, 2007, P NATL ACAD SCI USA, V104, P14706, DOI 10.1073/pnas.0706985104; Henikoff S., 2012, CHROMOSOMA; Lawrimore J, 2011, J CELL BIOL, V195, P573, DOI 10.1083/jcb.201106036; Lochmann B, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002739; Maddox PS, 2012, CURR OPIN GENET DEV, V22, P139, DOI 10.1016/j.gde.2011.11.005; Mizuguchi G, 2007, CELL, V129, P1153, DOI 10.1016/j.cell.2007.04.026; Shivaraju M, 2012, CELL, V150, P304, DOI 10.1016/j.cell.2012.05.034	11	2	2	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 20	2012	150	2					245	247		10.1016/j.cell.2012.07.003	http://dx.doi.org/10.1016/j.cell.2012.07.003			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817887	Green Accepted, Bronze			2022-12-28	WOS:000306595700004
J	Lyons, PA; Rayner, TF; Trivedi, S; Holle, JU; Watts, RA; Jayne, DRW; Baslund, B; Brenchley, P; Bruchfeld, A; Chaudhry, AN; Tervaert, JWC; Deloukas, P; Feighery, C; Gross, WL; Guillevin, L; Gunnarsson, I; Harper, L; Hruskova, Z; Little, MA; Martorana, D; Neumann, T; Ohlsson, S; Padmanabhan, S; Pusey, CD; Salama, AD; Sanders, JSF; Savage, CO; Segelmark, M; Stegeman, CA; Tesar, V; Vaglio, A; Wieczorek, S; Wilde, B; Zwerina, J; Rees, AJ; Clayton, DG; Smith, KGC				Lyons, Paul A.; Rayner, Tim F.; Trivedi, Sapna; Holle, Julia U.; Watts, Richard A.; Jayne, David R. W.; Baslund, Bo; Brenchley, Paul; Bruchfeld, Annette; Chaudhry, Afzal N.; Tervaert, Jan Willem Cohen; Deloukas, Panos; Feighery, Conleth; Gross, Wolfgang L.; Guillevin, Loic; Gunnarsson, Iva; Harper, Lorraine; Hruskova, Zdenka; Little, Mark A.; Martorana, Davide; Neumann, Thomas; Ohlsson, Sophie; Padmanabhan, Sandosh; Pusey, Charles D.; Salama, Alan D.; Sanders, Jan-Stephan F.; Savage, Caroline O.; Segelmark, Mrten; Stegeman, Coen A.; Tesar, Vladimir; Vaglio, Augusto; Wieczorek, Stefan; Wilde, Benjamin; Zwerina, Jochen; Rees, Andrew J.; Clayton, David G.; Smith, Kenneth G. C.			Genetically Distinct Subsets within ANCA-Associated Vasculitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; ANTIBODY-ASSOCIATED VASCULITIS; GENOME-WIDE ASSOCIATION; SMALL-VESSEL VASCULITIS; WEGENERS-GRANULOMATOSIS; SYSTEMIC VASCULITIS; PATHOGENESIS; PROTEINASE-3; NEUTROPHILS; DISEASE	BACKGROUND Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a severe condition encompassing two major syndromes: granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) and microscopic polyangiitis. Its cause is unknown, and there is debate about whether it is a single disease entity and what role ANCA plays in its pathogenesis. We investigated its genetic basis. METHODS A genomewide association study was performed in a discovery cohort of 1233 U. K. patients with ANCA-associated vasculitis and 5884 controls and was replicated in 1454 Northern European case patients and 1666 controls. Quality control, population stratification, and statistical analyses were performed according to standard criteria. RESULTS We found both major-histocompatibility-complex (MHC) and non-MHC associations with ANCA-associated vasculitis and also that granulomatosis with polyangiitis and microscopic polyangiitis were genetically distinct. The strongest genetic associations were with the antigenic specificity of ANCA, not with the clinical syndrome. Anti-proteinase 3 ANCA was associated with HLA-DP and the genes encoding alpha(1)-antitrypsin (SERPINA1) and proteinase 3 (PRTN3) (P = 6.2x10(-89), P = 5.6x10(-12), and P = 2.6x10(-7), respectively). Anti-myeloperoxidase ANCA was associated with HLA-DQ (P = 2.1x10(-8)). CONCLUSIONS This study confirms that the pathogenesis of ANCA-associated vasculitis has a genetic component, shows genetic distinctions between granulomatosis with polyangiitis and microscopic polyangiitis that are associated with ANCA specificity, and suggests that the response against the autoantigen proteinase 3 is a central pathogenic feature of proteinase 3 ANCA-associated vasculitis. These data provide preliminary support for the concept that proteinase 3 ANCA-associated vasculitis and myeloperoxidase ANCA-associated vasculitis are distinct autoimmune syndromes. (Funded by the British Heart Foundation and others.)	[Lyons, Paul A.; Rayner, Tim F.; Trivedi, Sapna; Clayton, David G.; Smith, Kenneth G. C.] Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 0XY, England; [Lyons, Paul A.; Rayner, Tim F.; Trivedi, Sapna; Jayne, David R. W.; Chaudhry, Afzal N.; Smith, Kenneth G. C.] Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; [Clayton, David G.] Addenbrookes Hosp, Dept Med Genet, Cambridge, England; [Trivedi, Sapna; Jayne, David R. W.; Chaudhry, Afzal N.; Smith, Kenneth G. C.] Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Cambridge, England; [Deloukas, Panos] Wellcome Trust Sanger Inst, Cambridge, England; [Watts, Richard A.] Ipswich Hosp Natl Hlth Serv Trust, Dept Rheumatol, Ipswich, Suffolk, England; [Watts, Richard A.] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England; [Brenchley, Paul] Univ Manchester, Sch Biomed, Manchester, Lancs, England; [Savage, Caroline O.] GlaxoSmithKline, Stevenage, Herts, England; [Harper, Lorraine; Stegeman, Coen A.] Univ Birmingham, Sch Immun & Infect, Birmingham, W Midlands, England; [Little, Mark A.; Salama, Alan D.] UCL, Ctr Nephrol, Royal Free Hosp, London, England; [Padmanabhan, Sandosh] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Pusey, Charles D.; Salama, Alan D.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Renal Sect, London, England; [Holle, Julia U.; Gross, Wolfgang L.] Univ Hosp Schleswig Holstein, Dept Rheumatol, Lubeck, Germany; [Holle, Julia U.; Gross, Wolfgang L.] Klinikum Bad Bramstedt, Dept Rheumatol & Immunol, Bad Bramstedt, Germany; [Wieczorek, Stefan] Ruhr Univ Bochum, Dept Human Genet, Bochum, Germany; [Neumann, Thomas] Univ Hosp, Dept Internal Med 3, Jena, Germany; [Zwerina, Jochen] Univ Erlangen Nurnberg, Dept Internal Med 3, D-91054 Erlangen, Germany; [Baslund, Bo] Copenhagen Univ Hosp, Dept Rheumatol, Rigshospitalet, Copenhagen, Denmark; [Bruchfeld, Annette] Karolinska Univ Hosp, Dept Clin Sci Intervent & Technol, Div Renal Med, Stockholm, Sweden; [Gunnarsson, Iva] Karolinska Univ Hosp, Dept Med, Rheumatol Unit, Stockholm, Sweden; [Ohlsson, Sophie; Segelmark, Mrten] Karolinska Inst, Stockholm, Sweden; [Ohlsson, Sophie; Segelmark, Mrten] Lund Univ, Dept Clin Sci, Lund, Sweden; [Segelmark, Mrten] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Tervaert, Jan Willem Cohen; Wilde, Benjamin] Maastricht Univ, Med Ctr, Cardiovasc Res Inst, Div Clin & Expt Immunol,Dept Internal Med, Maastricht, Netherlands; [Sanders, Jan-Stephan F.; Stegeman, Coen A.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, NL-9700 AB Groningen, Netherlands; [Feighery, Conleth] Trinity Coll Dublin, Dept Immunol, Dublin, Ireland; [Feighery, Conleth] St James Hosp, Dublin, Ireland; [Guillevin, Loic] Univ Paris, Hop Cochin, F-75252 Paris, France; [Hruskova, Zdenka; Tesar, Vladimir] Charles Univ Prague, Dept Nephrol, Prague, Czech Republic; [Hruskova, Zdenka; Tesar, Vladimir] Gen Univ Hosp, Prague, Czech Republic; [Martorana, Davide] Univ Hosp, Mol Genet Unit, Parma, Italy; [Vaglio, Augusto] Univ Hosp, Nephrol Unit, Parma, Italy; [Zwerina, Jochen] Med Univ Vienna, Hanusch Hosp Wiener Gebietskrankenkasse, Ludwig Boltzmann Inst Osteol, Vienna, Austria; [Zwerina, Jochen] Med Univ Vienna, Hanusch Hosp, Allgemeine Unfallversicherungsanstalt, Trauma Ctr Meidling, Vienna, Austria; [Rees, Andrew J.] Med Univ Vienna, Clin Inst Pathol, Vienna, Austria	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Wellcome Trust Sanger Institute; Ipswich Hospital NHS Trust; Ipswich Hospital; University of East Anglia; University of Manchester; GlaxoSmithKline; University of Birmingham; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Glasgow; Imperial College London; University of Kiel; Schleswig Holstein University Hospital; Ruhr University Bochum; Friedrich Schiller University of Jena; University of Erlangen Nuremberg; University of Copenhagen; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Lund University; Linkoping University; Maastricht University; University of Groningen; Trinity College Dublin; Trinity College Dublin; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Charles University Prague; General University Hospital Prague; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Parma; University Hospital of Parma; University of Parma; University Hospital of Parma; Ludwig Boltzmann Institute; Medical University of Vienna; WGKK - Hanusch Hospital; Medical University of Vienna; WGKK - Hanusch Hospital; Medical University of Vienna	Smith, KGC (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Box 139,Hills Rd, Cambridge CB2 0XY, England.	kgcs2@cam.ac.uk	Wieczorek, Stefan/F-7721-2014; tervaert, jan willem cohen/AAB-1111-2019; Vaglio, Augusto/AHE-8117-2022; Ohlsson, Sophie/W-9495-2019; Little, Mark/E-7072-2014; Sanders, Jan-Stephan/ABC-6782-2021; Wilde, Benjamin/H-9986-2012; Tesar, Vladimir/O-2312-2017; Holle, Julia/G-6138-2012; Deloukas, Panos/B-2922-2013; Little, Mark/O-2161-2019; Gross, Wolfgang Ludwig WG/C-8733-2011; Padmanabhan, Sandosh/S-3963-2016; Neumann, Thomas/F-2116-2016; Martorana, Davide/K-6374-2016; Hrušková, Zdenka/O-2079-2017	Vaglio, Augusto/0000-0002-3814-9172; Ohlsson, Sophie/0000-0002-5253-1650; Little, Mark/0000-0001-6003-397X; Wilde, Benjamin/0000-0002-5115-6799; Tesar, Vladimir/0000-0001-6982-0689; Deloukas, Panos/0000-0001-9251-070X; Little, Mark/0000-0001-6003-397X; Neumann, Thomas/0000-0001-6810-6889; Martorana, Davide/0000-0002-7572-7031; Hrušková, Zdenka/0000-0002-2658-365X; Segelmark, Marten/0000-0002-1221-0772; Bruchfeld, Annette/0000-0002-9752-9941; Rayner, Tim/0000-0002-6992-5592; Jayne, David/0000-0002-1712-0637; Stegeman, Coen/0000-0002-0224-0927; Sanders, Jan-Stephan/0000-0002-0904-3969; Padmanabhan, Sandosh/0000-0003-3869-5808; Smith, Kenneth/0000-0003-3829-4326; harper, lorraine/0000-0003-1343-9234; Brenchley, Paul/0000-0003-1290-9919	British Heart Foundation [SP/09/001/27117]; Wellcome Trust [083650/Z/07/Z]; National Institute of Health Research Biomedical Research Centres of Cambridge, Imperial College, and Manchester; Medical Research Council; Kidney Research UK; West Anglia Comprehensive Local Research Network; Norfolk and Suffolk Comprehensive Local Research Network; German Research Foundation [KFO170]; European Union [CP-FP 261382]; MRC [G0400929] Funding Source: UKRI; Medical Research Council [G0400929] Funding Source: researchfish	British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome Trust); National Institute of Health Research Biomedical Research Centres of Cambridge, Imperial College, and Manchester; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Kidney Research UK(Kidney Research UK (KRUK)); West Anglia Comprehensive Local Research Network; Norfolk and Suffolk Comprehensive Local Research Network; German Research Foundation(German Research Foundation (DFG)); European Union(European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by grants from the British Heart Foundation (SP/09/001/27117, to Dr. Smith); the Wellcome Trust (083650/Z/07/Z, to Dr. Smith); the National Institute of Health Research Biomedical Research Centres of Cambridge, Imperial College, and Manchester; the Medical Research Council and Kidney Research UK (to Drs. Rees and Pusey); the West Anglia Comprehensive Local Research Network (to Drs. Smith and Jayne); the Norfolk and Suffolk Comprehensive Local Research Network (to Dr. Watts); and the German Research Foundation (KFO170, to Drs. Holle and Wieczorek); and by a contract from the European Union FP7 Infectious Triggers of Chronic Autoimmunity Consortium (CP-FP 261382, to Drs. Smith, Lyons, and Rees).	Borgmann S, 2001, CLIN IMMUNOL, V98, P244, DOI 10.1006/clim.2000.4962; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Chen M, 2010, NAT REV RHEUMATOL, V6, P653, DOI 10.1038/nrrheum.2010.158; Ciavatta DJ, 2010, J CLIN INVEST, V120, P3209, DOI 10.1172/JCI40034; Cooper JD, 2008, NAT GENET, V40, P1399, DOI 10.1038/ng.249; Cortes A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3204; Cotsapas C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002254; ESNAULT VLM, 1993, KIDNEY INT, V43, P1329, DOI 10.1038/ki.1993.186; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; Falk RJ, 2011, ARTHRITIS RHEUM-US, V63, P863, DOI 10.1002/art.30286; Finkielman JD, 2007, ANN INTERN MED, V147, P611, DOI 10.7326/0003-4819-147-9-200711060-00005; Flossmann O, 2011, ANN RHEUM DIS, V70, P488, DOI 10.1136/ard.2010.137778; Gencik M, 2000, KIDNEY INT, V58, P2473, DOI 10.1046/j.1523-1755.2000.00430.x; Hagen EC, 1998, KIDNEY INT, V53, P743, DOI 10.1046/j.1523-1755.1998.00807.x; Hoffman GS, 2005, ANN INTERN MED, V143, P683, DOI 10.7326/0003-4819-143-9-200511010-00012; Hogan SL, 2006, ANN INTERN MED, V144, P377, DOI 10.7326/0003-4819-144-5-200603070-00019; Jagiello P, 2004, HUM GENET, V114, P468, DOI 10.1007/s00439-004-1092-z; Jayne D, 2003, NEW ENGL J MED, V349, P36, DOI 10.1056/NEJMoa020286; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Jones RB, 2010, NEW ENGL J MED, V363, P211, DOI 10.1056/NEJMoa0909169; Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959; Knight A, 2008, ARTHRITIS RHEUM-US, V58, P302, DOI 10.1002/art.23157; Lane SE, 2005, QJM-INT J MED, V98, P97, DOI 10.1093/qjmed/hci015; Linder R, 2011, J RHEUMATOL, V38, P1039, DOI 10.3899/jrheum.100814; Little MA, 2011, CLIN EXP IMMUNOL, V164, P124; Monach PA, 2010, CURR OPIN RHEUMATOL, V22, P157, DOI 10.1097/BOR.0b013e32833654a8; Mukhtyar C, 2008, ANN RHEUM DIS, V67, P1004, DOI 10.1136/ard.2007.071936; Radford DJ, 2000, ARTHRITIS RHEUM, V43, P1337, DOI 10.1002/1529-0131(200006)43:6<1337::AID-ANR16>3.0.CO;2-M; Rarok AA, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000028642.26222.00; Sable-Fourtassou G, 2005, ANN INTERN MED, V143, P632, DOI 10.7326/0003-4819-143-9-200511010-00006; Savage COS, 2011, CLIN EXP IMMUNOL, V164, P23, DOI 10.1111/j.1365-2249.2011.04362.x; Stanescu HC, 2011, NEW ENGL J MED, V364, P616, DOI 10.1056/NEJMoa1009742; Stegeman CA, 2002, NEPHROL DIAL TRANSPL, V17, P2077, DOI 10.1093/ndt/17.12.2077; Stone JH, 2010, NEW ENGL J MED, V363, P221, DOI 10.1056/NEJMoa0909905; Suppiah R, 2011, ARTHRIT CARE RES, V63, P588, DOI 10.1002/acr.20433; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Watts R, 2007, ANN RHEUM DIS, V66, P222, DOI 10.1136/ard.2006.054593; Wieczorek S, 2010, CURR OPIN RHEUMATOL, V22, P8, DOI 10.1097/BOR.0b013e3283331151; Willcocks LC, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2928; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918	40	609	639	5	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2012	367	3					214	223		10.1056/NEJMoa1108735	http://dx.doi.org/10.1056/NEJMoa1108735			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	22808956	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000306522900005
J	Crane, BR				Crane, Brian R.			Nature's Intricate Clockwork	SCIENCE			English	Editorial Material							CIRCADIAN CLOCKS; PROTEIN; PHOTOADAPTATION; NEUROSPORA; DOMAINS; PERIOD; DIMER		Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14850 USA	Cornell University	Crane, BR (corresponding author), Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14850 USA.	bc69@cornell.edu						Albrecht U, 2012, NEURON, V74, P246, DOI 10.1016/j.neuron.2012.04.006; Atchley WR, 2005, P NATL ACAD SCI USA, V102, P6401, DOI 10.1073/pnas.0408964102; Chen CH, 2010, P NATL ACAD SCI USA, V107, P16715, DOI 10.1073/pnas.1011190107; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Grimaldi B, 2009, INT J BIOCHEM CELL B, V41, P81, DOI 10.1016/j.biocel.2008.08.035; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Huang NA, 2012, SCIENCE, V337, P189, DOI 10.1126/science.1222804; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King HA, 2011, J MOL BIOL, V413, P561, DOI 10.1016/j.jmb.2011.08.048; Lowrey PL, 2011, ADV GENET, V74, P175, DOI 10.1016/B978-0-12-387690-4.00006-4; Malzahn E, 2010, CELL, V142, P762, DOI 10.1016/j.cell.2010.08.010; Scheuermann TH, 2007, METHOD ENZYMOL, V435, P3, DOI 10.1016/S0076-6879(07)35001-5; Yildiz O, 2005, MOL CELL, V17, P69, DOI 10.1016/j.molcel.2004.11.022; Zoltowski BD, 2008, BIOCHEMISTRY-US, V47, P7012, DOI 10.1021/bi8007017	15	4	4	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2012	337	6091					165	166		10.1126/science.1224611	http://dx.doi.org/10.1126/science.1224611			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798591				2022-12-28	WOS:000306323500033
J	Liu, W; Chun, E; Thompson, AA; Chubukov, P; Xu, F; Katritch, V; Han, GW; Roth, CB; Heitman, LH; IJzerman, AP; Cherezov, V; Stevens, RC				Liu, Wei; Chun, Eugene; Thompson, Aaron A.; Chubukov, Pavel; Xu, Fei; Katritch, Vsevolod; Han, Gye Won; Roth, Christopher B.; Heitman, Laura H.; IJzerman, Adriaan P.; Cherezov, Vadim; Stevens, Raymond C.			Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions	SCIENCE			English	Article							ADENOSINE A(2A) RECEPTOR; CRYSTAL-STRUCTURE; OPIOID RECEPTOR; MODULATION; RHODOPSIN; COMPLEX; AMILORIDE; RESIDUES; SITE	Pharmacological responses of G protein-coupled receptors (GPCRs) can be fine-tuned by allosteric modulators. Structural studies of such effects have been limited due to the medium resolution of GPCR structures. We reengineered the human A(2A) adenosine receptor by replacing its third intracellular loop with apocytochrome b(562)RIL and solved the structure at 1.8 angstrom resolution. The high-resolution structure allowed us to identify 57 ordered water molecules inside the receptor comprising three major clusters. The central cluster harbors a putative sodium ion bound to the highly conserved aspartate residue Asp(2.50). Additionally, two cholesterols stabilize the conformation of helix VI, and one of 23 ordered lipids intercalates inside the ligand-binding pocket. These high-resolution details shed light on the potential role of structured water molecules, sodium ions, and lipids/cholesterol in GPCR stabilization and function.	[Liu, Wei; Chun, Eugene; Thompson, Aaron A.; Chubukov, Pavel; Xu, Fei; Katritch, Vsevolod; Han, Gye Won; Cherezov, Vadim; Stevens, Raymond C.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Roth, Christopher B.] Receptos, San Diego, CA 92121 USA; [Heitman, Laura H.; IJzerman, Adriaan P.] Leiden Amsterdam Ctr Drug Res, Div Med Chem, NL-2300 RA Leiden, Netherlands	Scripps Research Institute; Leiden University; Leiden University - Excl LUMC	Cherezov, V (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	vcherezo@scripps.edu; stevens@scripps.edu	Han, Gye Won/GLQ-8724-2022; IJzerman, Ad/ABG-1353-2020; Cherezov, Vadim/L-9812-2013; Han, Gye Won/GLT-1531-2022; Katritch, Vsevolod/Q-8357-2016; Katritch, Vsevolod/Y-2721-2019; Stevens, Raymond/K-7272-2015; Han, Gye Won/GLQ-8673-2022; Heitman, Laura/H-9019-2017	Han, Gye Won/0000-0003-4107-835X; IJzerman, Ad/0000-0002-1182-2259; Cherezov, Vadim/0000-0002-5265-3914; Katritch, Vsevolod/0000-0003-3883-4505; Stevens, Raymond/0000-0002-4522-8725; Heitman, Laura/0000-0002-1381-8464; Thompson, Aaron/0000-0003-4314-4242	NIH Common Fund in Structural Biology grant [P50 GM073197]; NIH/National Institute of General Medical Sciences (NIGMS) PSI: Biology grant [U54 GM094618]; NIGMS [R01 GM089857, Y1-GM-1104]; Dutch Research Council Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) TOP grant [714.011.001]; NWO Veni grant [11188]; National Cancer Institute [Y1-CO-1020]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM073197, U54GM094618, R01GM089857] Funding Source: NIH RePORTER	NIH Common Fund in Structural Biology grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Institute of General Medical Sciences (NIGMS) PSI: Biology grant; NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Dutch Research Council Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) TOP grant; NWO Veni grant; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH Common Fund in Structural Biology grant P50 GM073197 for technology development, NIH/National Institute of General Medical Sciences (NIGMS) PSI: Biology grant U54 GM094618 for biological studies and structure production, NIGMS grant R01 GM089857 to V. C., a Dutch Research Council Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) TOP grant (714.011.001: "The crystal structure of the adenosine A<INF>2A</INF> receptor: The follow-up") to A. P. I., and an NWO Veni grant (11188) to L. H. H. We thank J. Velasquez for help on molecular biology; T. Trinh, K. Allin, and M. Chu for help on baculovirus expression; T. Mulder-Krieger and H. de Vries for their technical expertise in the biochemical characterization, G. van Westen for his educated comments on the crystal structure; M. Mileni for reviewing the final structure; J. P. Changeux for discussions on GPCR allostery and the potential for allosteric stabilizers; K. Kadyshevskaya for assistance with figure preparation; A. Walker for assistance with manuscript preparation; J. Smith, R. Fischetti, and N. Sanishvili for assistance in development and use of the minibeam and beamtime at GM/CA-CAT beamline 23-ID at the Advanced Photon Source, which is supported by National Cancer Institute grant Y1-CO-1020 and NIGMS grant Y1-GM-1104. Coordinates and the structure factors have been deposited in the Protein Data Bank under the accession code (4EIY). R. C. S. is a founder and on the Board of Directors of Receptos, a GPCR structure-based drug discovery company. R. C. S., C. B. R., A. A. T., W. L., F. X., E. C., and V. K. are inventors on a patent applied for jointly by The Scripps Research Institute and Receptos on the use of fusion proteins to crystallize GPCRs.	Angel TE, 2009, P NATL ACAD SCI USA, V106, P8555, DOI 10.1073/pnas.0903545106; Barbhaiya H, 1996, MOL PHARMACOL, V50, P1635; Burger K, 2000, CELL MOL LIFE SCI, V57, P1577, DOI 10.1007/PL00000643; Canals M, 2011, TRENDS BIOCHEM SCI, V36, P663, DOI 10.1016/j.tibs.2011.08.005; Changeux JP, 2012, ANNU REV BIOPHYS, V41, P103, DOI 10.1146/annurev-biophys-050511-102222; Chun E, 2012, STRUCTURE, V20, P967, DOI 10.1016/j.str.2012.04.010; Dore AS, 2011, STRUCTURE, V19, P1283, DOI 10.1016/j.str.2011.06.014; Gao ZG, 2003, MOL PHARMACOL, V63, P1021, DOI 10.1124/mol.63.5.1021; Gao ZG, 2000, BIOCHEM PHARMACOL, V60, P669, DOI 10.1016/S0006-2952(00)00360-9; Goblyos A, 2011, BBA-BIOMEMBRANES, V1808, P1309, DOI 10.1016/j.bbamem.2010.06.013; Granier S, 2012, NATURE, V485, P400, DOI 10.1038/nature11111; Haga K, 2012, NATURE, V482, P547, DOI 10.1038/nature10753; Hanson MA, 2012, SCIENCE, V335, P851, DOI [10.1126/science.1244693, 10.1126/science.1215904]; Harding MM, 2002, ACTA CRYSTALLOGR D, V58, P872, DOI 10.1107/S0907444902003712; Ho BK, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-49; HOWARD MJ, 1987, MOL PHARMACOL, V32, P53; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; Katritch V, 2012, TRENDS PHARMACOL SCI, V33, P17, DOI 10.1016/j.tips.2011.09.003; Katritch V, 2011, NEUROPHARMACOLOGY, V60, P108, DOI 10.1016/j.neuropharm.2010.07.009; Kenakin TP, 2012, BRIT J PHARMACOL, V165, P1659, DOI 10.1111/j.1476-5381.2011.01749.x; Kruse AC, 2012, NATURE, V482, P552, DOI 10.1038/nature10867; Lebon G, 2011, NATURE, V474, P521, DOI 10.1038/nature10136; Magnani F, 2008, P NATL ACAD SCI USA, V105, P10744, DOI 10.1073/pnas.0804396105; Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954; NUNNARI JM, 1987, J BIOL CHEM, V262, P12387; Nygaard R, 2009, TRENDS PHARMACOL SCI, V30, P249, DOI 10.1016/j.tips.2009.02.006; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Parker MS, 2008, AMINO ACIDS, V35, P1, DOI 10.1007/s00726-008-0637-6; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Selent J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000884; Thompson AA, 2012, NATURE, V485, P395, DOI 10.1038/nature11085; Vroling B, 2011, NUCLEIC ACIDS RES, V39, pD309, DOI 10.1093/nar/gkq1009; Wu HX, 2012, NATURE, V485, P327, DOI 10.1038/nature10939; Xu F, 2011, SCIENCE, V332, P322, DOI 10.1126/science.1202793; Zhorov BS, 1998, J BIOMOL STRUCT DYN, V15, P631, DOI 10.1080/07391102.1998.10508980	35	877	896	7	195	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2012	337	6091					232	236		10.1126/science.1219218	http://dx.doi.org/10.1126/science.1219218			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798613	Green Accepted			2022-12-28	WOS:000306323500058
J	Munoz, J; Ali, H				Munoz, Javier; Ali, Haythem			A Pain in the Neck Cerebellar hemangioblastoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Munoz, Javier; Ali, Haythem] Henry Ford Hosp, Dept Hematol Oncol, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	Munoz, J (corresponding author), Henry Ford Hosp, Dept Hematol Oncol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	javier.munoz@me.com						Hanse MCJ, 2007, J NEURO-ONCOL, V82, P163, DOI 10.1007/s11060-006-9321-z; Hilliard AA, 2004, NEW ENGL J MED, V350, P599, DOI 10.1056/NEJMcps031794; National Comprehensive Cancer Network, SMALL CELL LUNG CANC; NEUMANN HPH, 1989, J NEUROSURG, V70, P24, DOI 10.3171/jns.1989.70.1.0024; Wagner H Jr, 1997, Chest Surg Clin N Am, V7, P151	5	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2012	308	2					182	183		10.1001/jama.2012.4295	http://dx.doi.org/10.1001/jama.2012.4295			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971QS	22782420				2022-12-28	WOS:000306219500032
J	Krautler, NJ; Kana, V; Kranich, J; Tian, YH; Perera, D; Lemm, D; Schwarz, P; Armulik, A; Browning, JL; Tallquist, M; Buch, T; Oliveira-Martins, JB; Zhu, CH; Hermann, M; Wagner, U; Brink, R; Heikenwalder, M; Aguzzi, A				Krautler, Nike Julia; Kana, Veronika; Kranich, Jan; Tian, Yinghua; Perera, Dushan; Lemm, Doreen; Schwarz, Petra; Armulik, Annika; Browning, Jeffrey L.; Tallquist, Michelle; Buch, Thorsten; Oliveira-Martins, Jose B.; Zhu, Caihong; Hermann, Mario; Wagner, Ulrich; Brink, Robert; Heikenwalder, Mathias; Aguzzi, Adriano			Follicular Dendritic Cells Emerge from Ubiquitous Perivascular Precursors	CELL			English	Article							TUMOR-NECROSIS-FACTOR; LYMPHOTOXIN-BETA-RECEPTOR; LYMPH-NODE; B-CELL; T-CELL; ABNORMAL-DEVELOPMENT; APOPTOTIC CELLS; IMMUNE-RESPONSE; RETICULAR CELLS; MICE DEFICIENT	The differentiation of follicular dendritic cells (FDC) is essential to the remarkable microanatomic plasticity of lymphoid follicles. Here we show that FDC arise from ubiquitous perivascular precursors (preFDC) expressing platelet-derived growth factor receptor beta (PDGFR beta). PDGFR beta-Cre-driven reporter gene recombination resulted inFDClabeling, whereas conditional ablation of PDGFR beta(+)-derived cells abolished FDC, indicating that FDC originate from PDGFR beta(+) cells. Lymphotoxin-alpha-overexpressing prion protein (PrP)(+) kidneys developed PrP+ FDC after transplantation into PrP- mice, confirming that preFDC exist outside lymphoid organs. Adipose tissue-derived PDGFR beta(+) stromal-vascular cells responded to FDC maturation factors and, when transplanted into lymphotoxin b receptor (LT beta R)(-) kidney capsules, differentiated into Mfge8(+)CD21/35(+) Fc gamma RII beta+PrP+FDC capable of trapping immune complexes and recruiting B cells. Spleens of lymphocyte-deficient mice contained perivascular PDGFRb + FDC precursors whose expansion required both lymphoid tissue inducer (LTi) cells and lymphotoxin. The ubiquity of preFDC and their strategic location at blood vessels may explain the de novo generation of organized lymphoid tissue at sites of lymphocytic inflammation.	[Krautler, Nike Julia; Kana, Veronika; Kranich, Jan; Perera, Dushan; Lemm, Doreen; Schwarz, Petra; Armulik, Annika; Oliveira-Martins, Jose B.; Zhu, Caihong; Hermann, Mario; Heikenwalder, Mathias; Aguzzi, Adriano] Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; [Tian, Yinghua] Univ Zurich Hosp, Div Visceral & Transplant Surg, CH-8091 Zurich, Switzerland; [Krautler, Nike Julia; Brink, Robert] Garvan Inst Med Res, Sydney, NSW 2010, Australia; [Browning, Jeffrey L.] Biogen Idec Inc, Immunobiol, Cambridge Ctr 124, Cambridge, MA 02142 USA; [Tallquist, Michelle] UT SW Med Ctr Dallas, Dallas, TX 75390 USA; [Buch, Thorsten] Univ Zurich, Inst Expt Immunol, CH-8057 Zurich, Switzerland; [Hermann, Mario] Univ Zurich, Inst Lab Anim Sci, CH-8057 Zurich, Switzerland; [Wagner, Ulrich] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Garvan Institute of Medical Research; Biogen; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Zurich; University of Zurich; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland.	adriano.aguzzi@usz.ch	Buch, Thorsten/P-1659-2019; Brink, Robert/B-7910-2010; Heikenwalder, Mathias/AAA-2269-2020; Tallquist, Michelle/AAU-5277-2021; Aguzzi, Adriano/A-3351-2008	Buch, Thorsten/0000-0002-2236-9074; Brink, Robert/0000-0002-9586-3655; Tallquist, Michelle/0000-0002-1383-144X; Kana, Veronika/0000-0002-9362-3156; Browning, Jeffrey/0000-0001-9168-5233; Keller, Annika/0000-0003-1466-3633; Kranich, Jan/0000-0002-9928-4132; Aguzzi, Adriano/0000-0002-0344-6708	European Union (PRIORITY and LUPAS); Swiss National Foundation (SNF); Stammbach Foundation; Novartis Research Foundation; European Research Council; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL100401, R01HL074257] Funding Source: NIH RePORTER	European Union (PRIORITY and LUPAS); Swiss National Foundation (SNF)(Swiss National Science Foundation (SNSF)); Stammbach Foundation; Novartis Research Foundation; European Research Council(European Research Council (ERC)European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank S. Nagata, M. Kopf, and R. Adams for generously providing Mfge8<SUP>-/-</SUP>, Cd21/35<SUP>-/-</SUP> and Pdgfrb-Cre mice. S. Luther, H. Zeilhofer, S. Uhlig, T. Suter for materials and reagents. D. Junghans, I. Fischer, M. Nuvolone, T. Chtanova, H. Takizawa, T. Phan, and R. Salomon for discussions. R. Moos, M. Delic, A. Wethmar, N. Wey, S. Behnke, A. Fitsche, S. Walters, K. Webster, N. Zammit and J.M. Mateos (Center for Microscopy and Image Analysis, University of Zurich) for technical assistance, and R. Krautler for editing. A. Aguzzi is supported by grants of the European Union (PRIORITY and LUPAS), the Swiss National Foundation (SNF) (one individual award and one Sinergia award with T. Buch and P. Pelczar), the Stammbach Foundation, and the Novartis Research Foundation. A. Aguzzi also holds an Advanced Investigator Grant of the European Research Council. N. Krautler and A. Armulik are supported by the SNF.	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302; Aloisi F, 2006, NAT REV IMMUNOL, V6, P205, DOI 10.1038/nri1786; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Balogh P, 2001, CELL IMMUNOL, V214, P45, DOI 10.1006/cimm.2001.1874; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; Bofill M, 2000, J PATHOL, V191, P217; Buch T, 2005, NAT METHODS, V2, P419, DOI 10.1038/NMETH762; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Cupedo T, 2004, J IMMUNOL, V173, P4889, DOI 10.4049/jimmunol.173.8.4889; Cyster JG, 2000, IMMUNOL REV, V176, P181; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Drayton DL, 2006, NAT IMMUNOL, V7, P344, DOI 10.1038/ni1330; Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; Finke D, 2002, IMMUNITY, V17, P363, DOI 10.1016/S1074-7613(02)00395-3; Foo SS, 2006, CELL, V124, P161, DOI 10.1016/j.cell.2005.10.034; FORCE WR, 1995, J IMMUNOL, V155, P5280; Fu YX, 1998, J EXP MED, V187, P1009, DOI 10.1084/jem.187.7.1009; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521; Goldman JP, 1998, BRIT J HAEMATOL, V103, P335, DOI 10.1046/j.1365-2141.1998.00980.x; Gretz JE, 1997, IMMUNOL REV, V156, P11, DOI 10.1111/j.1600-065X.1997.tb00955.x; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Huber C, 2005, J IMMUNOL, V174, P5526, DOI 10.4049/jimmunol.174.9.5526; HUMPHREY JH, 1984, EUR J IMMUNOL, V14, P859, DOI 10.1002/eji.1830140916; IMAZEKI N, 1992, IMMUNOLOGY, V76, P508; KAMPERDIJK EWA, 1978, CELL TISSUE RES, V192, P1; Kapasi ZF, 1998, J IMMUNOL, V160, P1078; KAPASI ZF, 1993, ADV EXP MED BIOL, V329, P383; Katakai T, 2008, J IMMUNOL, V181, P6189, DOI 10.4049/jimmunol.181.9.6189; Kim MY, 2008, IMMUNOLOGY, V124, P166, DOI 10.1111/j.1365-2567.2007.02750.x; Kim MY, 2006, J IMMUNOL, V177, P3074, DOI 10.4049/jimmunol.177.5.3074; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; Kranich J, 2008, J EXP MED, V205, P1293, DOI 10.1084/jem.20071019; Lee IY, 2003, BIOCHEM BIOPH RES CO, V304, P701, DOI 10.1016/S0006-291X(03)00649-1; LeHir M, 1996, J INFLAMM, V47, P76; LeHir M, 1996, J EXP MED, V183, P2367, DOI 10.1084/jem.183.5.2367; Link A, 2007, NAT IMMUNOL, V8, P1255, DOI 10.1038/ni1513; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Ludewig B, 1998, J EXP MED, V188, P1493, DOI 10.1084/jem.188.8.1493; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; Mebius RE, 2003, NAT REV IMMUNOL, V3, P292, DOI 10.1038/nri1054; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Motegi S, 2011, ARTERIOSCL THROM VAS, V31, P2653, DOI 10.1161/ATVBAHA.111.233619; Motegi S, 2011, ARTERIOSCL THROM VAS, V31, P2024, DOI 10.1161/ATVBAHA.111.232587; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Ngo VN, 2001, J EXP MED, V194, P1649, DOI 10.1084/jem.194.11.1649; Pasparakis M, 2000, CELL IMMUNOL, V201, P33, DOI 10.1006/cimm.2000.1636; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Phan TG, 2007, NAT IMMUNOL, V8, P992, DOI 10.1038/ni1494; PICARELLA DE, 1992, P NATL ACAD SCI USA, V89, P10036, DOI 10.1073/pnas.89.21.10036; Rennert PD, 1998, IMMUNITY, V9, P71, DOI 10.1016/S1074-7613(00)80589-0; Strick-Marchand H, 2008, J IMMUNOL, V181, P2764, DOI 10.4049/jimmunol.181.4.2764; Suematsu S, 2004, NAT BIOTECHNOL, V22, P1539, DOI 10.1038/nbt1039; Takatori H, 2009, J EXP MED, V206, P35, DOI 10.1084/jem.20072713; Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232; TEW JG, 1982, J RETICULOENDOTH SOC, V31, P371; Tian YH, 2010, J SURG RES, V163, pE91, DOI 10.1016/j.jss.2010.04.019; Tumanov AV, 2004, J IMMUNOL, V173, P86, DOI 10.4049/jimmunol.173.1.86; WARE CF, 1992, J IMMUNOL, V149, P3881; Wilke G, 2010, EUR J IMMUNOL, V40, P2165, DOI 10.1002/eji.200940202; YOSHIDA T, 1989, ARCH HISTOL CYTOL, V52, P327, DOI 10.1679/aohc.52.327; Zhang N, 2003, J IMMUNOL, V171, P1667, DOI 10.4049/jimmunol.171.4.1667	69	257	259	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 6	2012	150	1					194	206		10.1016/j.cell.2012.05.032	http://dx.doi.org/10.1016/j.cell.2012.05.032			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770220	Bronze, Green Accepted			2022-12-28	WOS:000306115000017
J	Mallett, S; Halligan, S; Thompson, M; Collins, GS; Altman, DG				Mallett, Susan; Halligan, Steve; Thompson, Matthew; Collins, Gary S.; Altman, Douglas G.			Interpreting diagnostic accuracy studies for patient care	BRITISH MEDICAL JOURNAL			English	Article							DECISION CURVE ANALYSIS; STATISTICS-IN-MEDICINE; PENCINA,M.J. ET-AL.; ROC CURVE; PREDICTIVE ABILITY; AREA; MARKER; TESTS; RECLASSIFICATION; SYSTEMS	A diagnostic test accuracy study provides evidence on how well a test correctly identifies or rules out disease and informs subsequent decisions about treatment for clinicians, their patients, and healthcare providers. The authors highlight several different ways in which data from diagnostic test accuracy studies can be presented and interpreted, and discuss their advantages and disadvantages.	[Mallett, Susan; Thompson, Matthew] Univ Oxford, Dept Primary Care Hlth Sci, Oxford Ctr Monitoring & Diag, Oxford OX2 6GG, England; [Halligan, Steve] UCL, Ctr Med Imaging, London NW1 2BU, England; [Collins, Gary S.; Altman, Douglas G.] Univ Oxford, Ctr Stat Med, Oxford OX2 6UD, England	University of Oxford; University of London; University College London; University of Oxford	Mallett, S (corresponding author), Univ Oxford, Dept Primary Care Hlth Sci, Oxford Ctr Monitoring & Diag, Oxford OX2 6GG, England.	susan.mallett@phc.ox.ac.uk	Collins, Gary Stephen/A-2258-2014; Mallett, Sue/GPS-9933-2022; Halligan, Steve/C-5875-2009	Collins, Gary Stephen/0000-0002-2772-2316; Halligan, Steve/0000-0003-0632-5108; Mallett, Sue/0000-0002-0596-8200	UK Department of Health via a National Institute for Health Research (NIHR) [RP-PG-0407-10338]; Cancer Research UK programme [C5529]; NIHR Comprehensive Biomedical Research Centre; National Institute for Health Research [RP-PG-0407-10338] Funding Source: researchfish	UK Department of Health via a National Institute for Health Research (NIHR); Cancer Research UK programme(Cancer Research UK); NIHR Comprehensive Biomedical Research Centre; National Institute for Health Research(National Institute for Health Research (NIHR))	This work was funded by UK Department of Health via a National Institute for Health Research (NIHR) programme grant (RP-PG-0407-10338) and Cancer Research UK programme grant (C5529). A proportion of this work was undertaken at UCLH/UCL, which receives a proportion of funding from the NIHR Comprehensive Biomedical Research Centre funding scheme. The views expressed in this publication are those of the authors and not necessarily those of the UK Department of Health.	Adams NM, 1999, PATTERN RECOGN, V32, P1139, DOI 10.1016/S0031-3203(98)00154-X; Baker SG, 2003, J NATL CANCER I, V95, P511, DOI 10.1093/jnci/95.7.511; Bandos AI, 2005, ACAD RADIOL, V12, P1293, DOI 10.1016/j.acra.2005.05.028; DENEEF P, 1993, MED DECIS MAKING, V13, P126, DOI 10.1177/0272989X9301300206; DOrsi C.J., 2003, BI RADS MAMMOGRAPHY; Gallas BD, 2012, ACAD RADIOL, V19, P463, DOI 10.1016/j.acra.2011.12.016; Gigerenzer G., 2007, PSYCHOL SCI PUBL INT, V8, P53, DOI [10.1111/j.1539-6053.2008.00033.x, DOI 10.1111/J.1539-6053.2008.00033.X]; Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X; Greenland S, 2008, STAT MED, V27, P199, DOI 10.1002/sim.2995; HAGLUND C, 1994, BRIT J CANCER, V70, P487, DOI 10.1038/bjc.1994.332; Hand DJ, 2010, STAT MED, V29, P1502, DOI 10.1002/sim.3859; Hand DJ, 2009, MACH LEARN, V77, P103, DOI 10.1007/s10994-009-5119-5; HILDEN J, 1991, MED DECIS MAKING, V11, P95, DOI 10.1177/0272989X9101100204; Leisenring W, 2000, BIOMETRICS, V56, P345, DOI 10.1111/j.0006-341X.2000.00345.x; LUSTED LB, 1971, NEW ENGL J MED, V284, P416, DOI 10.1056/NEJM197102252840805; Moons KGM, 1997, MED DECIS MAKING, V17, P447, DOI 10.1177/0272989X9701700410; NIEDERAU C, 1992, PANCREAS, V7, P66, DOI 10.1097/00006676-199201000-00011; Peirce C S, 1884, Science, V4, P453, DOI 10.1126/science.ns-4.93.453-a; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Pepe MS, 2008, STAT MED, V27, P173, DOI 10.1002/sim.2991; Schwartz LM, 2000, WESTERN J MED, V173, P307, DOI 10.1136/ewjm.173.5.307; Speigelhalter D, 2011, UNDERSTANDING UNCERT; THOMPSON ML, 1989, STAT MED, V8, P1277, DOI 10.1002/sim.4780081011; Vergouwe Yvonne, 2002, Semin Urol Oncol, V20, P96, DOI 10.1053/suro.2002.32521; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Vickers AJ, 2008, BMC MED INFORM DECIS, V8, DOI 10.1186/1472-6947-8-53; Wagner RE, 2004, MED DECIS MAKING, V24, P561, DOI 10.1177/0272989X04271043; Wagner RF, 2002, ACAD RADIOL, V9, P1264, DOI 10.1016/S1076-6332(03)80560-3; Wagner RF, 2007, ACAD RADIOL, V14, P723, DOI 10.1016/j.acra.2007.03.001; Walter SD, 2005, STAT MED, V24, P2025, DOI 10.1002/sim.2103; WIEAND S, 1989, BIOMETRIKA, V76, P585, DOI 10.1093/biomet/76.3.585	31	145	147	1	28	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 2	2012	344								e3999	10.1136/bmj.e3999	http://dx.doi.org/10.1136/bmj.e3999			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972JV	22750423	Bronze			2022-12-28	WOS:000306274300006
J	Gurbel, PA; Nolin, TD; Tantry, US				Gurbel, Paul A.; Nolin, Thomas D.; Tantry, Udaya S.			Clopidogrel Efficacy and Cigarette Smoking Status	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Gurbel, Paul A.] Sinai Hosp Baltimore, Sinai Ctr Thrombosis Res, Cardiac Catheterizat Lab, Baltimore, MD 21215 USA; [Nolin, Thomas D.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA; [Nolin, Thomas D.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA	Sinai Center Thrombosis Research; Sinai Hospital of Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gurbel, PA (corresponding author), Sinai Hosp Baltimore, Sinai Ctr Thrombosis Res, Cardiac Catheterizat Lab, 2401 W Belvedere Ave, Baltimore, MD 21215 USA.	pgurbel@lifebridgehealth.org	Nolin, Thomas/AAB-7311-2020	Nolin, Thomas/0000-0003-4339-1382				Berger JS, 2009, CIRCULATION, V120, P2337, DOI 10.1161/CIRCULATIONAHA.109.866533; Bliden KP, 2008, J AM COLL CARDIOL, V52, P531, DOI 10.1016/j.jacc.2008.04.045; Desai NR, 2009, J AM COLL CARDIOL, V53, P1273, DOI 10.1016/j.jacc.2008.12.044; Ferreiro JL, 2012, J AM COLL CARDIOL, V59, pA62; Mehta SR, 2010, LANCET, V376, P1233, DOI 10.1016/S0140-6736(10)61088-4; Salek FS, 2010, PHARMACOTHERAPY, V30, p154e; SARAFF KY, 2006, J AM COLL CARDIOL, V47, pB36	7	47	48	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2012	307	23					2495	2496		10.1001/jama.2012.5930	http://dx.doi.org/10.1001/jama.2012.5930			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	960MB	22797448				2022-12-28	WOS:000305391400024
J	Koppikar, P; Bhagwat, N; Kilpivaara, O; Manshouri, T; Adli, M; Hricik, T; Liu, F; Saunders, LM; Mullally, A; Abdel-Wahab, O; Leung, L; Weinstein, A; Marubayashi, S; Goel, A; Gonen, M; Estrov, Z; Ebert, BL; Chiosis, G; Nimer, SD; Bernstein, BE; Verstovsek, S; Levine, RL				Koppikar, Priya; Bhagwat, Neha; Kilpivaara, Outi; Manshouri, Taghi; Adli, Mazhar; Hricik, Todd; Liu, Fan; Saunders, Lindsay M.; Mullally, Ann; Abdel-Wahab, Omar; Leung, Laura; Weinstein, Abby; Marubayashi, Sachie; Goel, Aviva; Goenen, Mithat; Estrov, Zeev; Ebert, Benjamin L.; Chiosis, Gabriela; Nimer, Stephen D.; Bernstein, Bradley E.; Verstovsek, Srdan; Levine, Ross L.			Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy	NATURE			English	Article							TYROSINE KINASE; LUNG ADENOCARCINOMAS; RESISTANCE; MUTATION; GEFITINIB; CANCER; EFFICACY; IDENTIFICATION; SAFETY	The identification of somatic activating mutations in JAK2 (refs 1-4) and in the thrombopoietin receptor gene (MPL)(5) in most patients with myeloproliferative neoplasm (MPN) led to the clinical development of JAK2 kinase inhibitors(6,7). JAK2 inhibitor therapy improves MPN-associated splenomegaly and systemic symptoms but does not significantly decrease or eliminate the MPN clone in most patients with MPN. We therefore sought to characterize mechanisms by which MPN cells persist despite chronic inhibition of JAK2. Here we show that JAK2 inhibitor persistence is associated with reactivation of JAK-STAT signalling and with heterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 in trans by other JAK kinases. Further, this phenomenon is reversible: JAK2 inhibitor withdrawal is associated with resensitization to JAK2 kinase inhibitors and with reversible changes in JAK2 expression. We saw increased JAK2 heterodimerization and sustained JAK2 activation in cell lines, in murine models and in patients treated with JAK2 inhibitors. RNA interference and pharmacological studies show that JAK2-inhibitor-persistent cells remain dependent on JAK2 protein expression. Consequently, therapies that result in JAK2 degradation retain efficacy in persistent cells and may provide additional benefit to patients with JAK2-dependent malignancies treated with JAK2 inhibitors.	[Koppikar, Priya; Bhagwat, Neha; Kilpivaara, Outi; Hricik, Todd; Saunders, Lindsay M.; Abdel-Wahab, Omar; Leung, Laura; Weinstein, Abby; Marubayashi, Sachie; Goel, Aviva; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Bhagwat, Neha; Saunders, Lindsay M.] Mem Sloan Kettering Canc Ctr, Gerstner Sloan Kettering Grad Sch Biomed Sci, New York, NY 10065 USA; [Manshouri, Taghi; Estrov, Zeev; Verstovsek, Srdan] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Adli, Mazhar; Bernstein, Bradley E.] Massachusetts Gen Hosp, Dept Pathol, Howard Hughes Med Inst, Boston, MA 02114 USA; [Adli, Mazhar; Bernstein, Bradley E.] MIT, Broad Inst Harvard, Boston, MA 02114 USA; [Mullally, Ann; Ebert, Benjamin L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol,Dept Med, Boston, MA 02115 USA; [Abdel-Wahab, Omar; Nimer, Stephen D.; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10065 USA; [Goenen, Mithat] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Levine, RL (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.	leviner@mskcc.org	Gonen, Mithat/E-4826-2012; levine, ross/AAE-7658-2019	Gonen, Mithat/0000-0001-8683-8477; Beckmann, Aviva/0000-0001-6099-6135; Verstovsek, MD, PhD, Professor of Medicine, Srdan/0000-0002-6912-8569; Abdel-Wahab, Omar/0000-0002-3907-6171; Beckmann, Aviva/0000-0002-5739-5512	National Cancer Institute [1R01CA151949-01]; Leukemia and Lymphoma Society; Myeloproliferative Neoplasms Foundation; Starr Cancer Consortium; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA151949] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Myeloproliferative Neoplasms Foundation; Starr Cancer Consortium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank C. Sawyers, J. Licht, P. Poulikakos and N. Rosen for advice and suggestions; P. Bhatt for his help in the saturation mutagenesis screen; T. Taldone for synthesis of PU-H71; L. Staudt and T. Look for shRNA constructs against JAK2 and TYK2, respectively; and T. Radimerski and P. Manley for providing BBT-594. We are grateful to the Genomics Core Laboratories at Memorial Sloan-Kettering Cancer Center and the Geoffrey Beene Core for their assistance with 454 sequencing. This work was supported in part by National Cancer Institute grant 1R01CA151949-01 to R. L. L., by a grant from the Leukemia and Lymphoma Society to R. L. L. and by a grant from the Myeloproliferative Neoplasms Foundation and the Starr Cancer Consortium to R. L. L., B. E. B. and B. L. E. B. E. B. is a Howard Hughes Medical Institute Early Career Scientist.	Andraos R, 2012, CANCER DISCOV, V2, P512, DOI 10.1158/2159-8290.CD-11-0324; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guerini V, 2008, LEUKEMIA, V22, P740, DOI 10.1038/sj.leu.2405049; He HZ, 2006, J MED CHEM, V49, P381, DOI 10.1021/jm0508078; Ihle JN, 2007, CURR OPIN GENET DEV, V17, P8, DOI 10.1016/j.gde.2006.12.009; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Koppikar P, 2010, BLOOD, V115, P2919, DOI 10.1182/blood-2009-04-218842; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Marubayashi S, 2010, J CLIN INVEST, V120, P3578, DOI 10.1172/JCI42442; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mullighan CG, 2009, P NATL ACAD SCI USA, V106, P9414, DOI 10.1073/pnas.0811761106; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pardanani A, 2011, J CLIN ONCOL, V29, P789, DOI 10.1200/JCO.2010.32.8021; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Rider L, 2007, J BIOL CHEM, V282, P30985, DOI 10.1074/jbc.M701794200; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028; Wang YC, 2009, BLOOD, V114, P5024, DOI 10.1182/blood-2009-05-222133; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200	32	254	260	8	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 6	2012	489	7414					155	U222		10.1038/nature11303	http://dx.doi.org/10.1038/nature11303			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	999WW	22820254	Green Submitted, Green Accepted			2022-12-28	WOS:000308347000054
J	Anand, PK; Malireddi, RKS; Lukens, JR; Vogel, P; Bertin, J; Lamkanfi, M; Kanneganti, TD				Anand, Paras K.; Malireddi, R. K. Subbarao; Lukens, John R.; Vogel, Peter; Bertin, John; Lamkanfi, Mohamed; Kanneganti, Thirumala-Devi			NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens	NATURE			English	Article							LISTERIA-MONOCYTOGENES; INFLAMMASOME; SALMONELLA; CASPASE-1; INFECTION; ACTIVATION; RECEPTORS; KINASE; ROLES	Members of the intracellular nucleotide-binding and oligomerization domain (NOD)-like receptor (NLR) family contribute to immune responses through activation of nuclear factor-kappa B (NF-kappa B), type I interferon and inflammasome signalling(1). Mice lacking the NLR family member NLRP6 were recently shown to be susceptible to colitis and colorectal tumorigenesis(2-4), but the role of NLRP6 in microbial infections and the nature of the inflammatory signalling pathways regulated by NLRP6 remain unclear. Here we show that Nlrp6-deficient mice are highly resistant to infection with the bacterial pathogens Listeria monocytogenes, Salmonella typhimurium and Escherichia coli. Infected Nlrp6-deficient mice had increased numbers of monocytes and neutrophils in circulation, and NLRP6 signalling in both haematopoietic and radioresistant cells contributed to increased susceptibility. Nlrp6 deficiency enhanced activation of mitogen-activated protein kinase (MAPK) and the canonical NF-kappa B pathway after Toll-like receptor ligation, but not cytosolic NOD1/2 ligation, in vitro. Consequently, infected Nlrp6-deficient cells produced increased levels of NF-kappa B-and MAPK-dependent cytokines and chemokines. Thus, our results reveal NLRP6 as a negative regulator of inflammatory signalling, and demonstrate a role for this NLR in impeding clearance of both Gram-positive and -negative bacterial pathogens.	[Anand, Paras K.; Malireddi, R. K. Subbarao; Lukens, John R.; Kanneganti, Thirumala-Devi] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; [Vogel, Peter] St Jude Childrens Res Hosp, Anim Resources Ctr, Memphis, TN 38105 USA; [Vogel, Peter] St Jude Childrens Res Hosp, Vet Pathol Core, Memphis, TN 38105 USA; [Bertin, John] GlaxoSmithKline, Immunoinflammat TA, Pattern Recognit Receptor DPU, Collegeville, PA 19426 USA; [Lamkanfi, Mohamed] Univ Ghent, Dept Biochem, B-9000 Ghent, Belgium; [Lamkanfi, Mohamed] VIB, Dept Med Prot Res, B-9000 Ghent, Belgium	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; GlaxoSmithKline; Ghent University; Flanders Institute for Biotechnology (VIB)	Kanneganti, TD (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA.	thirumala-devi.kanneganti@stjude.org	Kanneganti, Thirumala-Devi/M-9435-2018; Kanneganti, Thirumala-Devi/Y-2503-2019; Malireddi, RKSubbarao/C-5804-2013; Vogel, Peter/N-2490-2018	Kanneganti, Thirumala-Devi/0000-0002-6395-6443; Kanneganti, Thirumala-Devi/0000-0002-6395-6443; Malireddi, RKSubbarao/0000-0001-8855-9447; Vogel, Peter/0000-0002-7535-0545; Anand, Paras/0000-0003-2503-3653; Lukens, John/0000-0002-6795-0866	European Union [256432]; European Research Council [281600]; Fund for Scientific Research Flanders [G030212N, 1.2.201.10.N.00, 1.5.122.11.N.00]; National Institute of Health [AR056296, AI101935]; American Lebanese Syrian Associated Charities (ALSAC); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI101935, R37AI101935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056296] Funding Source: NIH RePORTER	European Union(European Commission); European Research Council(European Research Council (ERC)European Commission); Fund for Scientific Research Flanders(FWO); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese Syrian Associated Charities (ALSAC)(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank A. Coyle, E. Grant and R. Flavell for the supply of mutant mice. M. L. is supported by grants from the European Union Framework Program 7 (Marie-Curie Grant 256432), European Research Council (grant 281600) and the Fund for Scientific Research Flanders (G030212N, 1.2.201.10.N.00 and 1.5.122.11.N.00). This work was supported by National Institute of Health Grants (AR056296 and AI101935), and the American Lebanese Syrian Associated Charities (ALSAC) to T.-D.K.	Anand PK, 2011, J BIOL CHEM, V286, P42981, DOI 10.1074/jbc.M111.310599; Broz P, 2010, J EXP MED, V207, P1745, DOI 10.1084/jem.20100257; CDC (Centers for Disease Control & Prevention), CDC EST FOODB ILLN U; Chen GY, 2011, J IMMUNOL, V186, P7187, DOI 10.4049/jimmunol.1100412; Corr SC, 2009, CELL MICROBIOL, V11, P703, DOI 10.1111/j.1462-5822.2009.01294.x; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Franchi L, 2006, NAT IMMUNOL, V7, P576, DOI 10.1038/ni1346; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Henao-Mejia J, 2012, NATURE, V482, P179, DOI 10.1038/nature10809; Hybiske K, 2008, NAT REV MICROBIOL, V6, P99, DOI 10.1038/nrmicro1821; Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002; Kanneganti TD, 2010, NAT REV IMMUNOL, V10, P688, DOI 10.1038/nri2851; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Lara-Tejero M, 2006, J EXP MED, V203, P1407, DOI 10.1084/jem.20060206; Meixenberger K, 2010, J IMMUNOL, V184, P922, DOI 10.4049/jimmunol.0901346; Normand S, 2011, P NATL ACAD SCI USA, V108, P9601, DOI 10.1073/pnas.1100981108; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; Scallan E, 2011, EMERG INFECT DIS, V17, P7, DOI 10.3201/eid1701.P11101; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; STEVENSON MM, 1981, J IMMUNOL, V127, P402; van Ooij C, 2011, NAT REV MICROBIOL, V9, P481, DOI 10.1038/nrmicro2599; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003	25	270	287	2	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 16	2012	488	7411					389	+		10.1038/nature11250	http://dx.doi.org/10.1038/nature11250			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988OS	22763455	Green Accepted			2022-12-28	WOS:000307501000044
J	Afdhal, NH				Afdhal, Nezam H.			Management of Nonalcoholic Fatty Liver Disease A 60-Year-Old Man With Probable Nonalcoholic Fatty Liver Disease: Weight Reduction, Liver Biopsy, or Both?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; ATTENUATION PARAMETER CAP; TERM-FOLLOW-UP; VITAMIN-E; NATURAL-HISTORY; URSODEOXYCHOLIC ACID; INSULIN-RESISTANCE; BARIATRIC SURGERY; SCORING SYSTEM	Nonalcoholic fatty liver disease (NAFLD) is one of the most common hepatic disorders in the United States, but uncertainty remains as to the optimal way to manage it. Using the case of Mr T, a 60-year-old man with obesity, diabetes mellitus, and increased serum transaminase levels, an evidence-based approach to diagnosis and treatment is discussed. Diagnosis of NAFLD is based on patient clinical profile and risk factors for metabolic syndrome, the exclusion of other liver diseases, radiologic imaging and sometimes biopsy. At this point in Mr T's disease, the most important step is differentiation between simple steatosis and nonalcoholic steatohepatitis (NASH). Simple steatosis has a benign natural history, but NASH is progressive and may lead to cirrhosis, liver failure, and liver cancer. An evidence-based approach to treatment is limited by lack of large randomized trials, particularly of combinations of therapies, but weight loss, exercise, and medical therapies targeted at the mechanism of liver injury in NASH are recommended. Improved noninvasive diagnostic tests, a clearer understanding of the natural history of NAFLD, and large, well-designed clinical trials are needed. JAMA. 2012;308(6):608-616	[Afdhal, Nezam H.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Afdhal, Nezam H.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Afdhal, NH (corresponding author), Beth Israel Deaconess Med Ctr, 110 Francis St,Lowry 4th Floor, Boston, MA 02215 USA.	nafdhal@bidmc.harvard.edu		Afdhal, Nezam/0000-0002-7342-6593	Conatus; Echosens; Gilead; GlaxoSmithKline; Idenix; Isis; Novartis; Quest; Pharmasett; Schering-Plough/Merck; Vertex	Conatus; Echosens; Gilead(Gilead Sciences); GlaxoSmithKline(GlaxoSmithKline); Idenix; Isis; Novartis(Novartis); Quest; Pharmasett; Schering-Plough/Merck(Merck & CompanySchering Plough Corporation); Vertex(Vertex Pharmaceuticals)	The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Afdhal reports receiving research support from Conatus, Echosens, Gilead, GlaxoSmithKline, Idenix, Isis, Novartis, Quest, Pharmasett, Schering-Plough/Merck, and Vertex; serving as consultant/advisory board member for Biogen, Biolex, Boehringer Ingelheim, Echosens, Fibrogen, GlaxoSmithKline, Human Genome Sciences, Idera Pharmaceuticals, Isis, Ligand, Novartis, Schering-Plough/Merck, Springbank, and Vertex; holding stock/stock options in Medgenics and Springbank; and reimbursement for other expenses from Merck.	Adams LA, 2005, GASTROENTEROLOGY, V129, P113, DOI 10.1053/j.gastro.2005.04.014; Adams LA, 2005, J HEPATOL, V42, P132, DOI 10.1016/j.jhep.2004.09.012; Aithal GP, 2008, GASTROENTEROLOGY, V135, P1176, DOI 10.1053/j.gastro.2008.06.047; ANDERSEN T, 1991, J HEPATOL, V12, P224, DOI 10.1016/0168-8278(91)90942-5; Angulo P, 1999, HEPATOLOGY, V30, P1356, DOI 10.1002/hep.510300604; Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496; Argo CK, 2009, J HEPATOL, V51, P371, DOI 10.1016/j.jhep.2009.03.019; Belfort R, 2006, NEW ENGL J MED, V355, P2297, DOI 10.1056/NEJMoa060326; Bhala N, 2011, HEPATOLOGY, V54, P1208, DOI 10.1002/hep.24491; Brunt EM, 2009, HEPATOLOGY, V49, P809, DOI 10.1002/hep.22724; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x; Bugianesi E, 2005, AM J GASTROENTEROL, V100, P1082, DOI 10.1111/j.1572-0241.2005.41583.x; Campos GM, 2008, HEPATOLOGY, V47, P1916, DOI 10.1002/hep.22241; Chalasani N, 2004, GASTROENTEROLOGY, V126, P1287, DOI 10.1053/j.gastro.2004.02.015; Chalasani N, 2012, J HEPATOL, V55, P2005; Chavaez-Tapia NC, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007340.pub2; de Ledinghen V, 2006, J HEPATOL, V45, P592, DOI 10.1016/j.jhep.2006.05.008; de Ledinghen V, 2012, LIVER INT, V32, P911, DOI 10.1111/j.1478-3231.2012.02820.x; de Ledinghen V, 2012, J HEPATOL, V56, P833, DOI 10.1016/j.jhep.2011.10.017; Dixon JB, 2001, GASTROENTEROLOGY, V121, P91, DOI 10.1053/gast.2001.25540; Dufour JF, 2006, CLIN GASTROENTEROL H, V4, P1537, DOI 10.1016/j.cgh.2006.09.025; Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327; Feldstein AE, 2009, HEPATOLOGY, V50, P1072, DOI 10.1002/hep.23050; Furuya CK, 2007, J GASTROEN HEPATOL, V22, P510, DOI 10.1111/j.1440-1746.2007.04833.x; George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Harrison SA, 2009, HEPATOLOGY, V49, P80, DOI 10.1002/hep.22575; Johnson NA, 2009, HEPATOLOGY, V50, P1105, DOI 10.1002/hep.23129; Klein S, 2006, GASTROENTEROLOGY, V130, P1564, DOI 10.1053/j.gastro.2006.01.042; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706; Laurin J, 1996, HEPATOLOGY, V23, P1464; Lavine JE, 2011, JAMA-J AM MED ASSOC, V305, P1659, DOI 10.1001/jama.2011.520; Lewis JH, 2007, HEPATOLOGY, V46, P1453, DOI 10.1002/hep.21848; Lindor KD, 2004, HEPATOLOGY, V39, P770, DOI 10.1002/hep.20092; Machado M, 2006, J HEPATOL, V45, P600, DOI 10.1016/j.jhep.2006.06.013; Malik R, 2009, J GASTROEN HEPATOL, V24, P564, DOI 10.1111/j.1440-1746.2008.05731.x; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5; Marchesini G, 2001, LANCET, V358, P893, DOI 10.1016/S0140-6736(01)06042-1; Mathurin P, 2009, GASTROENTEROLOGY, V137, P532, DOI 10.1053/j.gastro.2009.04.052; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; Mofrad P, 2003, HEPATOLOGY, V37, P1286, DOI 10.1053/jhep.2003.50229; Musso G, 2011, ANN MED, V43, P617, DOI 10.3109/07853890.2010.518623; Myers RP, 2012, LIVER INT, V32, P902, DOI 10.1111/j.1478-3231.2012.02781.x; Nettschwander-Tetri BA, 2010, HEPATOLOGY, V52, P913, DOI 10.1002/hep.23784; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V38, P1008, DOI 10.1053/jhep.2003.50420; Ong JP, 2008, J HEPATOL, V49, P608, DOI 10.1016/j.jhep.2008.06.018; Parker HM, 2012, J HEPATOL, V56, P944, DOI 10.1016/j.jhep.2011.08.018; Petersen KF, 2005, DIABETES, V54, P603, DOI 10.2337/diabetes.54.3.603; POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114; Pratt DS, 2000, NEW ENGL J MED, V342, P1266, DOI 10.1056/NEJM200004273421707; Promrat K, 2010, HEPATOLOGY, V51, P121, DOI 10.1002/hep.23276; Rafiq N, 2009, CLIN GASTROENTEROL H, V7, P234, DOI 10.1016/j.cgh.2008.11.005; Ratziu V, 2008, GASTROENTEROLOGY, V135, P100, DOI 10.1053/j.gastro.2008.03.078; Rosenberg WMC, 2004, GASTROENTEROLOGY, V127, P1704, DOI 10.1053/j.gastro.2004.08.052; Sanyal AJ, 2006, HEPATOLOGY, V43, P682, DOI 10.1002/hep.21103; Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256; Sanyal AJ, 2010, NEW ENGL J MED, V362, P1675, DOI 10.1056/NEJMoa0907929; Sheth SG, 1997, ANN INTERN MED, V126, P137, DOI 10.7326/0003-4819-126-2-199701150-00008; Soderberg C, 2010, HEPATOLOGY, V51, P595, DOI 10.1002/hep.23314; Uygun A, 2004, ALIMENT PHARM THER, V19, P537, DOI 10.1111/j.1365-2036.2004.01888.x; Valenti L, 2010, GASTROENTEROLOGY, V138, P905, DOI 10.1053/j.gastro.2009.11.013; VANNESS MM, 1989, ANN INTERN MED, V111, P473, DOI 10.7326/0003-4819-111-6-473; Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x; Weston SR, 2005, HEPATOLOGY, V41, P372, DOI 10.1002/hep.20554; Williams CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/j.gastro.2010.09.038; Zelber-Sagi S, 2006, CLIN GASTROENTEROL H, V4, P639, DOI 10.1016/j.cgh.2006.02.004	68	21	21	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 8	2012	308	6					608	616		10.1001/jama.2012.8402	http://dx.doi.org/10.1001/jama.2012.8402			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984YA	22760235				2022-12-28	WOS:000307228400028
J	Thigpen, MC; Kebaabetswe, PM; Paxton, LA; Smith, DK; Rose, CE; Segolodi, TM; Henderson, FL; Pathak, SR; Soud, FA; Chillag, KL; Mutanhaurwa, R; Chirwa, LI; Kasonde, M; Abebe, D; Buliva, E; Gvetadze, RJ; Johnson, S; Sukalac, T; Thomas, VT; Hart, C; Johnson, JA; Malotte, CK; Hendrix, CW; Brooks, JT				Thigpen, Michael C.; Kebaabetswe, Poloko M.; Paxton, Lynn A.; Smith, Dawn K.; Rose, Charles E.; Segolodi, Tebogo M.; Henderson, Faith L.; Pathak, Sonal R.; Soud, Fatma A.; Chillag, Kata L.; Mutanhaurwa, Rodreck; Chirwa, Lovemore Ian; Kasonde, Michael; Abebe, Daniel; Buliva, Evans; Gvetadze, Roman J.; Johnson, Sandra; Sukalac, Thom; Thomas, Vasavi T.; Hart, Clyde; Johnson, Jeffrey A.; Malotte, C. Kevin; Hendrix, Craig W.; Brooks, John T.		TDF2 Study Grp	Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TENOFOVIR DISOPROXIL FUMARATE; PREVENTION; EMTRICITABINE; INFECTION; TRIALS	Background Preexposure prophylaxis with antiretroviral agents has been shown to reduce the transmission of human immunodeficiency virus (HIV) among men who have sex with men; however, the efficacy among heterosexuals is uncertain. Methods We randomly assigned HIV-seronegative men and women to receive either tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or matching placebo once daily. Monthly study visits were scheduled, and participants received a comprehensive package of prevention services, including HIV testing, counseling on adherence to medication, management of sexually transmitted infections, monitoring for adverse events, and individualized counseling on risk reduction; bone mineral density testing was performed semiannually in a subgroup of participants. Results A total of 1219 men and women underwent randomization (45.7% women) and were followed for 1563 person-years (median, 1.1 years; maximum, 3.7 years). Because of low retention and logistic limitations, we concluded the study early and followed enrolled participants through an orderly study closure rather than expanding enrollment. The TDF-FTC group had higher rates of nausea (18.5% vs. 7.1%, P<0.001), vomiting (11.3% vs. 7.1%, P = 0.008), and dizziness (15.1% vs. 11.0%, P = 0.03) than the placebo group, but the rates of serious adverse events were similar (P = 0.90). Participants who received TDF-FTC, as compared with those who received placebo, had a significant decline in bone mineral density. K65R, M184V, and A62V resistance mutations developed in 1 participant in the TDF-FTC group who had had an unrecognized acute HIV infection at enrollment. In a modified intention-to-treat analysis that included the 33 participants who became infected during the study (9 in the TDF-FTC group and 24 in the placebo group; 1.2 and 3.1 infections per 100 person-years, respectively), the efficacy of TDF-FTC was 62.2% (95% confidence interval, 21.5 to 83.4; P = 0.03). Conclusions Daily TDF-FTC prophylaxis prevented HIV infection in sexually active heterosexual adults. The long-term safety of daily TDF-FTC prophylaxis, including the effect on bone mineral density, remains unknown. (Funded by the Centers for Disease Control and Prevention and the National Institutes of Health; TDF2 ClinicalTrials.gov number, NCT00448669.)	[Thigpen, Michael C.; Paxton, Lynn A.; Smith, Dawn K.; Rose, Charles E.; Henderson, Faith L.; Chillag, Kata L.; Gvetadze, Roman J.; Sukalac, Thom; Thomas, Vasavi T.; Hart, Clyde; Johnson, Jeffrey A.; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA; [Pathak, Sonal R.] Northrop Grumman, Atlanta, GA USA; [Kebaabetswe, Poloko M.; Segolodi, Tebogo M.; Soud, Fatma A.; Mutanhaurwa, Rodreck; Chirwa, Lovemore Ian; Kasonde, Michael; Abebe, Daniel; Buliva, Evans; Johnson, Sandra] CDC Botswana, HIV Prevent Res Unit, Gaborone, Botswana; [Malotte, C. Kevin] Calif State Univ Long Beach, Long Beach, CA 90840 USA; [Hendrix, Craig W.] Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Pharmacol, Baltimore, MD 21205 USA	Centers for Disease Control & Prevention - USA; California State University System; California State University Long Beach; Johns Hopkins University	Thigpen, MC (corresponding author), 3150 Rampart Rd, Ft Collins, CO 80521 USA.	mthigpen@cdc.gov	Trajman, Anete/C-7679-2016; Hendrix, Craig W/G-4182-2014; Mermin, Jonathan/J-9847-2012	Trajman, Anete/0000-0002-4000-4984; Hendrix, Craig W/0000-0002-5696-8665; Kilmarx, Peter/0000-0001-6464-3345	Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention; Division of AIDS, National Institutes of Health; Roche Diagnostics; Gilean Sciences; FOGARTY INTERNATIONAL CENTER [D43TW001036] Funding Source: NIH RePORTER	Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Division of AIDS, National Institutes of Health; Roche Diagnostics; Gilean Sciences; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	Supported by the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, and the Division of AIDS, National Institutes of Health.; Dr. Hart reports receiving royalties from Roche Diagnostics; the agreement with Roche pays the Centers for Disease Control and Prevention and project investigators annually for the rights to use a molecular clone in the test kits. Dr. Hendrix reports receiving grant support from Gilean Sciences. No other potential conflict of interest relevant to this article was reported.	[Anonymous], 2011, 6 IAS C HIV PATH TRE; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Botswana Central Statistics Office, 2009, BOTSW AIDS IMP SURV; Buliva E, 2009, 5 IAS C HIV PATH TRE; Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016; Djomand G, 2008, JAIDS-J ACQ IMM DEF, V48, P82, DOI 10.1097/QAI.0b013e31817236ab; Donnell D, 2012, 19 C RETR OPP INF SE; FHI 360, FEM PREP PROJ; Garcia-Lerma JG, 2008, PLOS MED, V5, P291, DOI 10.1371/journal.pmed.0050028; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Karim QA, 2011, SCIENCE, V333, P524; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Li JF, 2011, J INFECT DIS, V203, P798, DOI 10.1093/infdis/jiq126; Liu AY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023688; McComsey GA, 2011, J INFECT DIS, V203, P1791, DOI 10.1093/infdis/jir188; Microbicide Trials Network, 2011, MTN STAT DEC DISC US; Padian NS, 2008, LANCET, V372, P585, DOI 10.1016/S0140-6736(08)60885-5; Peterson Leigh, 2007, PLoS Clin Trials, V2, pe27, DOI 10.1371/journal.pctr.0020027; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614	19	1382	1415	1	87	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2012	367	5					423	434		10.1056/NEJMoa1110711	http://dx.doi.org/10.1056/NEJMoa1110711			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981VZ	22784038				2022-12-28	WOS:000307001900007
J	Mateen, FJ; Mills, EJ				Mateen, Farrah J.; Mills, Edward J.			Aging and HIV-Related Cognitive Loss	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SUB-SAHARAN AFRICA; NEUROCOGNITIVE IMPAIRMENT; PREVALENCE		[Mateen, Farrah J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21231 USA; [Mateen, Farrah J.] Johns Hopkins Univ, Johns Hopkins Hosp, Dept Neurol, Baltimore, MD 21231 USA; [Mills, Edward J.] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; University of Ottawa	Mateen, FJ (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St,Room E8527, Baltimore, MD 21231 USA.	fmateen@jhsph.edu		Mateen, Farrah/0000-0002-4293-8115				Centers for Disease Control and Prevention, HIV SURV REP, V21; Cysique LA, 2011, SEX HEALTH, V8, P541, DOI 10.1071/SH11003; Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1; Negin J, 2010, B WORLD HEALTH ORGAN, V88, P847, DOI 10.2471/BLT.10.076349; Robertson KR, 2007, AIDS, V21, P1915, DOI 10.1097/QAD.0b013e32828e4e27; Simioni S, 2010, AIDS, V24, P1243, DOI 10.1097/QAD.0b013e3283354a7b; Smurzynski M, 2011, AIDS, V25, P357, DOI 10.1097/QAD.0b013e32834171f8; Valcour V, 2011, CLIN INFECT DIS, V53, P836, DOI 10.1093/cid/cir524; Walensky RP, 2009, ANN INTERN MED, V151, P157, DOI 10.7326/0003-4819-151-3-200908040-00138; Wong MH, 2007, NEUROLOGY, V68, P350, DOI 10.1212/01.wnl.0000252811.48891.6d	10	18	18	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					349	350		10.1001/jama.2012.8538	http://dx.doi.org/10.1001/jama.2012.8538			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820786				2022-12-28	WOS:000306685500021
J	Flamand, M; Duchaine, TF				Flamand, Mathieu; Duchaine, Thomas F.			SnapShot: Endogenous RNA Pathways	CELL			English	Editorial Material							C-ELEGANS; INTERFERENCE; SIRNAS; PIRNAS		[Flamand, Mathieu; Duchaine, Thomas F.] McGill Univ, Goodman Canc Res Ctr, Dept Biochem, Montreal, PQ H3A 1A3, Canada	McGill University	Flamand, M (corresponding author), McGill Univ, Goodman Canc Res Ctr, Dept Biochem, Montreal, PQ H3A 1A3, Canada.		Flamand, Mathieu/R-6102-2019; Duchaine, Thomas/U-2399-2019	Duchaine, Thomas/0000-0002-3454-1839				Brodersen P, 2006, TRENDS GENET, V22, P268, DOI 10.1016/j.tig.2006.03.003; Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504; Lee HC, 2012, CELL, V150, P78, DOI 10.1016/j.cell.2012.06.016; Lee SR, 2007, NAT STRUCT MOL BIOL, V14, P604, DOI 10.1038/nsmb1262; Li LD, 2011, METHODS MOL BIOL, V764, P169, DOI 10.1007/978-1-61779-188-8_11; Martienssen RA, 2005, TRENDS GENET, V21, P450, DOI 10.1016/j.tig.2005.06.005; Pak J, 2007, SCIENCE, V315, P241, DOI 10.1126/science.1132839; Sijen T, 2007, SCIENCE, V315, P244, DOI 10.1126/science.1136699; Tushir JS, 2009, CELL, V139, P830, DOI 10.1016/j.cell.2009.10.042; Yigit E, 2006, CELL, V127, P747, DOI 10.1016/j.cell.2006.09.033	10	2	3	0	12	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 20	2012	150	2							442.e1	10.1016/j.cell.2012.07.006	http://dx.doi.org/10.1016/j.cell.2012.07.006			1	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817902	Bronze			2022-12-28	WOS:000306595700021
J	Law, DR; Shapley, AE; Steidel, CC; Reddy, NA; Christensen, CR; Erb, DK				Law, David R.; Shapley, Alice E.; Steidel, Charles C.; Reddy, Naveen A.; Christensen, Charlotte R.; Erb, Dawn K.			High velocity dispersion in a rare grand-design spiral galaxy at redshift z=2.18	NATURE			English	Article							STAR-FORMING GALAXIES; ULTRA DEEP FIELD; SIMILAR-TO 2; ADAPTIVE OPTICS; SINS SURVEY; SPECTROSCOPY; EVOLUTION; DISKS; KINEMATICS; SIMULATIONS	Although grand-design spiral galaxies are relatively common in the local Universe, only one has been spectroscopically confirmed(1) to lie at redshift z > 2 (HDFX 28; z = 2.011); and it may prove to be a major merger that simply resembles a spiral in projection. The rarity of spirals has been explained as a result of disks being dynamically 'hot' at z > 2 (refs 2-5), which may instead favour the formation of commonly observed clumpy structures(6-10). Alternatively, current instrumentation may simply not be sensitive enough to detect spiral structures comparable to those in the modern Universe(11). At z < 2, the velocity dispersion of disks decreases(12), and spiral galaxies are more numerous by z approximate to 1 (refs 7, 13-15). Here we report observations of the grand-design spiral galaxy Q2343-BX442 at z = 2.18. Spectroscopy of ionized gas shows that the disk is dynamically hot, implying an uncertain origin for the spiral structure. The kinematics of the galaxy are consistent with a thick disk undergoing a minor merger, which can drive the formation of short-lived spiral structure(16-18). A duty cycle of <100 Myr for such tidally induced spiral structure in a hot massive disk is consistent with its rarity.	[Law, David R.] Univ Toronto, Dunlap Inst Astron & Astrophys, Toronto, ON M5S 3H4, Canada; [Shapley, Alice E.] Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA; [Steidel, Charles C.] CALTECH, Pasadena, CA 91125 USA; [Reddy, Naveen A.] Univ Calif Riverside, Dept Phys & Astron, Riverside, CA 92521 USA; [Christensen, Charlotte R.] Steward Observ, Tucson, AZ 85721 USA; [Erb, Dawn K.] Univ Wisconsin, Dept Phys, Milwaukee, WI 53211 USA	University of Toronto; University of California System; University of California Los Angeles; California Institute of Technology; University of California System; University of California Riverside; University of Wisconsin System; University of Wisconsin Milwaukee	Law, DR (corresponding author), Univ Toronto, Dunlap Inst Astron & Astrophys, 50 St George St, Toronto, ON M5S 3H4, Canada.	drlaw@di.utoronto.ca		Steidel, Charles/0000-0002-4834-7260; Law, David/0000-0002-9402-186X	Space Telescope Science Institute [GO-11694]; NASA [NAS 5-26555]; David and Lucile Packard Foundation; US National Science Foundation [AST-1009452]; Direct For Mathematical & Physical Scien [0908805] Funding Source: National Science Foundation	Space Telescope Science Institute(Space Telescope Science Institute); NASA(National Aeronautics & Space Administration (NASA)); David and Lucile Packard Foundation(The David & Lucile Packard Foundation); US National Science Foundation(National Science Foundation (NSF)); Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	D.R.L and C.C.S have been supported by grant GO-11694 from the Space Telescope Science Institute, which is operated by the Association of Universities for Research in Astronomy, Inc., for NASA, under contract NAS 5-26555. A.E.S acknowledges support from the David and Lucile Packard Foundation. C.R.C acknowledges support from the US National Science Foundation through grant AST-1009452. D.R.L appreciates discussions with J. Taylor, R. Abraham, J. Dubinski, F. Governato and A. Brooks, and thanks M. Peeples for help in obtaining the Keck/OSIRIS data.	Abraham RG, 2001, SCIENCE, V293, P1273, DOI 10.1126/science.1060855; Bigiel F, 2008, ASTRON J, V136, P2846, DOI 10.1088/0004-6256/136/6/2846; Bottema R, 2003, MON NOT R ASTRON SOC, V344, P358, DOI 10.1046/j.1365-8711.2003.06613.x; Bournaud F, 2009, ASTROPHYS J LETT, V694, pL158, DOI 10.1088/0004-637X/694/2/L158; Conselice CJ, 2011, MON NOT R ASTRON SOC, V417, P2770, DOI 10.1111/j.1365-2966.2011.19442.x; Conselice CJ, 2005, ASTROPHYS J, V620, P564, DOI 10.1086/426102; Dawson S, 2003, ASTRON J, V125, P1236, DOI 10.1086/367792; Dobbs CL, 2010, MON NOT R ASTRON SOC, V403, P625, DOI 10.1111/j.1365-2966.2009.16161.x; Dubinski J, 2008, ASTR SOC P, V396, P321; Elmegreen BG, 2006, ASTROPHYS J, V650, P644, DOI 10.1086/507578; Elmegreen BG, 2009, ASTROPHYS J, V692, P12, DOI 10.1088/0004-637X/692/1/12; Elmegreen DM, 2007, ASTROPHYS J, V658, P763, DOI 10.1086/511667; Elmegreen DM, 2005, ASTROPHYS J, V631, P85, DOI 10.1086/432502; Genzel R, 2008, ASTROPHYS J, V687, P59, DOI 10.1086/591840; Genzel R, 2006, NATURE, V442, P786, DOI 10.1038/nature05052; Genzel R, 2011, ASTROPHYS J, V733, DOI 10.1088/0004-637X/733/2/101; Kennicutt RC, 1998, ASTROPHYS J, V498, P541, DOI 10.1086/305588; Kriek M, 2009, ASTROPHYS J LETT, V705, pL71, DOI 10.1088/0004-637X/705/1/L71; Labbe I, 2003, ASTROPHYS J, V591, pL95, DOI 10.1086/377149; Law DR, 2007, ASTROPHYS J, V669, P929, DOI 10.1086/521786; Law DR, 2007, ASTROPHYS J, V656, P1, DOI 10.1086/510357; Law DR, 2012, ASTROPHYS J, V745, DOI 10.1088/0004-637X/745/1/85; Law DR, 2009, ASTROPHYS J, V697, P2057, DOI 10.1088/0004-637X/697/2/2057; Martig M, 2010, ASTROPHYS J LETT, V714, pL275, DOI 10.1088/2041-8205/714/2/L275; Purcell CW, 2011, NATURE, V477, P301, DOI 10.1038/nature10417; Schreiber NMF, 2011, ASTROPHYS J, V731, DOI 10.1088/0004-637X/731/1/65; Schreiber NMF, 2009, ASTROPHYS J, V706, P1364, DOI 10.1088/0004-637X/706/2/1364; Toomre A., 1981, STRUCTURE EVOLUTION, P111; Wadsley JW, 2004, NEW ASTRON, V9, P137, DOI 10.1016/j.newast.2003.08.004; Wright SA, 2009, ASTROPHYS J, V699, P421, DOI 10.1088/0004-637X/699/1/421	30	55	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 19	2012	487	7407					338	340		10.1038/nature11256	http://dx.doi.org/10.1038/nature11256			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JB	22810697	Green Submitted			2022-12-28	WOS:000306506500036
J	Noakes, T; Spedding, M				Noakes, Timothy; Spedding, Michael			Run for your life	NATURE			English	Editorial Material							EVOLUTION		[Noakes, Timothy] Univ Cape Town, ZA-7701 Rondebosch, South Africa	University of Cape Town	Noakes, T (corresponding author), Univ Cape Town, ZA-7701 Rondebosch, South Africa.	timothy.noakes@uct.ac.za; spedves2@orange.fr	Spedding, Michael/AAE-7342-2019; Noakes, Timothy D./E-7253-2011; Noakes, Tim/AAD-3162-2020	Spedding, Michael/0000-0002-1248-8221; Noakes, Timothy D./0000-0001-7244-2375; Noakes, Tim/0000-0001-7244-2375				Agid Y, 2007, NAT REV DRUG DISCOV, V6, P189, DOI 10.1038/nrd2217; Bramble DM, 2004, NATURE, V432, P345, DOI 10.1038/nature03052; Chalder M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2758; Hill KR, 2011, SCIENCE, V331, P1286, DOI 10.1126/science.1199071; Konopka G, 2010, NEURON, V68, P231, DOI 10.1016/j.neuron.2010.10.012; Markham A, 2012, EUR J NEUROSCI, V35, P366, DOI 10.1111/j.1460-9568.2011.07965.x; Mattson MP, 2012, AGEING RES REV, V11, P347, DOI 10.1016/j.arr.2012.01.007; Noakes T., 2012, WATERLOGGED SERIOUS; Noble EE, 2011, AM J PHYSIOL-REG I, V300, pR1053, DOI 10.1152/ajpregu.00776.2010; Qi HS, 2009, NEUROPHARMACOLOGY, V56, P37, DOI 10.1016/j.neuropharm.2008.06.068	10	43	44	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 19	2012	487	7407					295	296		10.1038/487295a	http://dx.doi.org/10.1038/487295a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	975JB	22810678	Bronze			2022-12-28	WOS:000306506500016
J	Smetacek, V; Klaas, C; Strass, VH; Assmy, P; Montresor, M; Cisewski, B; Savoye, N; Webb, A; d'Ovidio, F; Arrieta, JM; Bathmann, U; Bellerby, R; Berg, GM; Croot, P; Gonzalez, S; Henjes, J; Herndl, GJ; Hoffmann, LJ; Leach, H; Losch, M; Mills, MM; Neill, C; Peeken, I; Rottgers, R; Sachs, O; Sauter, E; Schmidt, MM; Schwarz, J; Terbruggen, A; Wolf-Gladrow, D				Smetacek, Victor; Klaas, Christine; Strass, Volker H.; Assmy, Philipp; Montresor, Marina; Cisewski, Boris; Savoye, Nicolas; Webb, Adrian; d'Ovidio, Francesco; Arrieta, Jesus M.; Bathmann, Ulrich; Bellerby, Richard; Berg, Gry Mine; Croot, Peter; Gonzalez, Santiago; Henjes, Joachim; Herndl, Gerhard J.; Hoffmann, Linn J.; Leach, Harry; Losch, Martin; Mills, Matthew M.; Neill, Craig; Peeken, Ilka; Roettgers, Ruediger; Sachs, Oliver; Sauter, Eberhard; Schmidt, Maike M.; Schwarz, Jill; Terbrueggen, Anja; Wolf-Gladrow, Dieter			Deep carbon export from a Southern Ocean iron-fertilized diatom bloom	NATURE			English	Article							ATMOSPHERIC CO2; SEA-FLOOR; CYCLES; MODEL	Fertilization of the ocean by adding iron compounds has induced diatom-dominated phytoplankton blooms accompanied by considerable carbon dioxide drawdown in the ocean surface layer. However, because the fate of bloom biomass could not be adequately resolved in these experiments, the timescales of carbon sequestration from the atmosphere are uncertain. Here we report the results of a five-week experiment carried out in the closed core of a vertically coherent, mesoscale eddy of the Antarctic Circumpolar Current, during which we tracked sinking particles from the surface to the deep-sea floor. A large diatom bloom peaked in the fourth week after fertilization. This was followed by mass mortality of several diatom species that formed rapidly sinking, mucilaginous aggregates of entangled cells and chains. Taken together, multiple lines of evidence-although each with important uncertainties-lead us to conclude that at least half the bloom biomass sank far below a depth of 1,000 metres and that a substantial portion is likely to have reached the sea floor. Thus, iron-fertilized diatom blooms may sequester carbon for timescales of centuries in ocean bottom water and for longer in the sediments.	[Smetacek, Victor; Klaas, Christine; Strass, Volker H.; Assmy, Philipp; Cisewski, Boris; Bathmann, Ulrich; Henjes, Joachim; Losch, Martin; Peeken, Ilka; Sachs, Oliver; Sauter, Eberhard; Schwarz, Jill; Terbrueggen, Anja; Wolf-Gladrow, Dieter] Alfred Wegener Inst Polar & Marine Res, D-27570 Bremerhaven, Germany; [Smetacek, Victor] Natl Inst Oceanog, Panaji 403004, Goa, India; [Assmy, Philipp] Norwegian Polar Res Inst, Fram Ctr, N-9296 Tromso, Norway; [Montresor, Marina] Stn Zool Anton Dohrn, I-80121 Naples, Italy; [Cisewski, Boris] Johann Heinrich von Thunen Inst, Inst Sea Fisheries, D-22767 Hamburg, Germany; [Savoye, Nicolas] Vrije Univ Brussel, Dept Analyt & Environm Chem, B-1050 Brussels, Belgium; [Savoye, Nicolas] Univ Bordeaux, CNRS, EPOC, UMR 5805,Stn Marine Arcachon, F-33120 Arcachon, France; [Webb, Adrian] Univ Cape Town, Dept Oceanog, ZA-7701 Cape Town, South Africa; [d'Ovidio, Francesco] CNRS UPMC IRD MNHN, LOCEAN IPSL, F-75252 Paris, France; [Arrieta, Jesus M.; Gonzalez, Santiago; Herndl, Gerhard J.] Royal Netherlands Inst Sea Res, Dept Biol Oceanog, NL-1790 AB Den Burg, Netherlands; [Arrieta, Jesus M.] CSIC UIB, Inst Mediterraneo Estudios Avanzados, Dept Global Change Res, Esporles 07190, Mallorca, Spain; [Bathmann, Ulrich] Leibniz Inst Balt Sea Res Warnemunde, D-18119 Rostock, Germany; [Bellerby, Richard; Neill, Craig] Univ Bergen, Bjerknes Ctr Climate Res, N-5007 Bergen, Norway; [Bellerby, Richard] Norwegian Inst Water Res, N-5006 Bergen, Norway; [Berg, Gry Mine; Mills, Matthew M.] Stanford Univ, Dept Environm Earth Syst Sci, Stanford, CA 94305 USA; [Croot, Peter; Hoffmann, Linn J.] Helmholtz Ctr Ocean Res Kiel, D-24105 Kiel, Germany; [Croot, Peter] Natl Univ Ireland, Sch Nat Sci, Galway, Ireland; [Henjes, Joachim] Phytolut GmbH, D-28759 Bremen, Germany; [Herndl, Gerhard J.] Univ Vienna, Dept Marine Biol, A-1090 Vienna, Austria; [Leach, Harry] Univ Liverpool, Sch Environm Sci, Liverpool L69 3GP, Merseyside, England; [Neill, Craig] Commonwealth Sci & Ind Res Org, Wealth Oceans Flagship, Hobart, Tas 7000, Australia; [Peeken, Ilka] Univ Bremen, MARUM Ctr Marine Environm Sci, D-28359 Bremen, Germany; [Roettgers, Ruediger] Helmholtz Zentrum Geesthacht, Ctr Mat & Coastal Res, Inst Coastal Res, D-21502 Geesthacht, Germany; [Sachs, Oliver] Eberhard & Partner AG, CH-5000 Aarau, Switzerland; [Schmidt, Maike M.] Univ Bremen, Ctr Biomol Interact Bremen, FB 2, D-28359 Bremen, Germany; [Schwarz, Jill] Univ Plymouth, Sch Marine Sci & Engn, Plymouth PL4 8AA, Devon, England	Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Institute of Oceanography (NIO); Norwegian Polar Institute; Stazione Zoologica Anton Dohrn di Napoli; Johann Heinrich von Thunen Institute; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite de Bordeaux; University of Cape Town; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Sorbonne Universite; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ); Consejo Superior de Investigaciones Cientificas (CSIC); Universitat de les Illes Balears; University of Barcelona; Leibniz Institut fur Ostseeforschung Warnemunde; Bjerknes Centre for Climate Research; University of Bergen; Norwegian Institute for Water Research (NIVA); Stanford University; Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; Ollscoil na Gaillimhe-University of Galway; University of Vienna; University of Liverpool; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Bremen; Helmholtz Association; Helmholtz-Zentrum Geesthacht - Zentrum fur Material- und Kustenforschung; University of Bremen; University of Plymouth	Smetacek, V (corresponding author), Alfred Wegener Inst Polar & Marine Res, Handelshafen 12, D-27570 Bremerhaven, Germany.	victor.smetacek@awi.de; christine.klaas@awi.de	Bellerby, Richard/ABD-6590-2021; Croot, Peter L/C-8460-2009; Hoffmann, Linn/I-6042-2012; Cisewski, Boris/GWV-4320-2022; Herndl, Gerhard J./B-1513-2013; Hoffmann, Linn/J-3761-2019; Losch, Martin/S-5896-2016; d'Ovidio, Francesco/ABA-8461-2021; Herndl, Gerhard J./S-3011-2019; Arrieta, Jesus M/B-1226-2008; Croot, Peter/U-5296-2019	Bellerby, Richard/0000-0003-3598-4006; Croot, Peter L/0000-0003-1396-0601; Hoffmann, Linn/0000-0001-9175-6097; Cisewski, Boris/0000-0002-1130-6107; Herndl, Gerhard J./0000-0002-2223-2852; Hoffmann, Linn/0000-0003-0242-4686; Losch, Martin/0000-0002-3824-5244; Herndl, Gerhard J./0000-0002-2223-2852; Arrieta, Jesus M/0000-0002-0190-6950; Wolf-Gladrow, Dieter/0000-0001-9531-8668; Strass, Volker/0000-0002-7539-1400; Montresor, Marina/0000-0002-2475-1787; Klaas, Christine/0000-0002-6679-8970; Sauter, Eberhard/0000-0001-7954-952X; Peeken, Ilka/0000-0003-1531-1664; Henjes, Joachim/0000-0002-6688-8802; d'Ovidio, Francesco/0000-0002-9664-7778	Cnes	Cnes(Centre National D'etudes Spatiales)	We thank C. Balt, K. Loquay, S. Mkatshwa, H. Prandke, H. Rohr, M. Thomas and I. Voge for help on board. We are also grateful to U. Struck for POC and PON analyses. The altimeter products were produced by Ssalto/Duacs and distributed by Aviso with support from Cnes. We thank the captain and crew of RV Polarstern (cruise ANT XXI/3) for support throughout the cruise.	Abelmann A, 2006, PALEOCEANOGRAPHY, V21, DOI 10.1029/2005PA001199; Anderson RF, 2009, SCIENCE, V323, P1443, DOI 10.1126/science.1167441; Beaulieu SE, 2002, OCEANOGR MAR BIOL, V40, P171; Bishop JKB, 2004, SCIENCE, V304, P417, DOI 10.1126/science.1087717; Blain S, 2007, NATURE, V446, P1070, DOI 10.1038/nature05700; Boyd PW, 2007, SCIENCE, V315, P612, DOI 10.1126/science.1131669; Cassar N, 2007, SCIENCE, V317, P1067, DOI 10.1126/science.1144602; Chelton DB, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030812; Cisewski B, 2008, J GEOPHYS RES-OCEANS, V113, DOI 10.1029/2007JC004372; Coale KH, 2004, SCIENCE, V304, P408, DOI 10.1126/science.1089778; d'Ovidio F, 2009, DEEP-SEA RES PT I, V56, P15, DOI 10.1016/j.dsr.2008.07.014; de Baar HJW, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002601; Hamme RC, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL044629; Hibbert A, 2009, J MAR RES, V67, P1, DOI 10.1357/002224009788597935; JACKSON GA, 1990, DEEP-SEA RES, V37, P1197, DOI 10.1016/0198-0149(90)90038-W; Jacquet SHM, 2008, GLOBAL BIOGEOCHEM CY, V22, DOI 10.1029/2006GB002902; Kohfeld KE, 2005, SCIENCE, V308, P74, DOI 10.1126/science.11053 75; Lampitt RS, 2001, PROG OCEANOGR, V50, P27, DOI 10.1016/S0079-6611(01)00047-7; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; Paytan A, 2007, CHEM REV, V107, P563, DOI 10.1021/cr0503613; Pollard RT, 2009, NATURE, V457, P577, DOI 10.1038/nature07716; RIEBESELL U, 1992, DEEP-SEA RES, V39, P1085, DOI 10.1016/0198-0149(92)90058-2; Sigman DM, 2010, NATURE, V466, P47, DOI 10.1038/nature09149; The Royal Society, 2009, 1009 RS	24	267	273	8	449	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 19	2012	487	7407					313	319		10.1038/nature11229	http://dx.doi.org/10.1038/nature11229			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JB	22810695				2022-12-28	WOS:000306506500032
J	Smith, A; Jones, G				Smith, Adam; Jones, Greg			Miracle pills and fireproof trainers: user endorsement in social media	BRITISH MEDICAL JOURNAL			English	Editorial Material												adam@adamesmith.co.uk	Smith, Adam/GPS-8322-2022					Advertising Standards Authority, 2011, ASA ADJ ION BAL; ASA, NONC ONL ADV ION BAL; ASA, ADV COD; Ionic Balance, WHY ION BAL; Merrell, PHOTOS MERRELL; PacificHealth Laboratories, END EXC NAT TRAIN SU; Sweney M, 2012, NIKE BECOMES 1 UK CO; YouTube, WAT WAT SUCKS GAT BE	8	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 19	2012	345								e4682	10.1136/bmj.e4682	http://dx.doi.org/10.1136/bmj.e4682			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978MA	22810385				2022-12-28	WOS:000306744300007
J	Wilt, TJ; Brawer, MK; Jones, KM; Barry, MJ; Aronson, WJ; Fox, S; Gingrich, JR; Wei, JT; Gilhooly, P; Grob, DM; Nsouli, I; Iyer, P; Cartagena, R; Snider, G; Roehrborn, C; Sharifi, R; Blank, W; Pandya, P; Andriole, GL; Culkin, D; Wheeler, T				Wilt, Timothy J.; Brawer, Michael K.; Jones, Karen M.; Barry, Michael J.; Aronson, William J.; Fox, Steven; Gingrich, Jeffrey R.; Wei, John T.; Gilhooly, Patricia; Grob, B. Mayer; Nsouli, Imad; Iyer, Padmini; Cartagena, Ruben; Snider, Glenn; Roehrborn, Claus; Sharifi, Roohollah; Blank, William; Pandya, Parikshit; Andriole, Gerald L.; Culkin, Daniel; Wheeler, Thomas		Prostate Cancer Intervention Versu	Radical Prostatectomy versus Observation for Localized Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE SURGICAL MARGINS; QUALITY-OF-LIFE; RANDOMIZED-TRIAL; PROGNOSTIC-SIGNIFICANCE; ACTIVE SURVEILLANCE; MEN; SPECIMENS; OUTCOMES; TRENDS; MANAGEMENT	BACKGROUND The effectiveness of surgery versus observation for men with localized prostate cancer detected by means of prostate-specific antigen (PSA) testing is not known. METHODS From November 1994 through January 2002, we randomly assigned 731 men with localized prostate cancer (mean age, 67 years; median PSA value, 7.8 ng per milliliter) to radical prostatectomy or observation and followed them through January 2010. The primary outcome was all-cause mortality; the secondary outcome was prostate-cancer mortality. RESULTS During the median follow-up of 10.0 years, 171 of 364 men (47.0%) assigned to radical prostatectomy died, as compared with 183 of 367 (49.9%) assigned to observation (hazard ratio, 0.88; 95% confidence interval [CI], 0.71 to 1.08; P = 0.22; absolute risk reduction, 2.9 percentage points). Among men assigned to radical prostatectomy, 21 (5.8%) died from prostate cancer or treatment, as compared with 31 men (8.4%) assigned to observation (hazard ratio, 0.63; 95% CI, 0.36 to 1.09; P = 0.09; absolute risk reduction, 2.6 percentage points). The effect of treatment on all-cause and prostate-cancer mortality did not differ according to age, race, coexisting conditions, self-reported performance status, or histologic features of the tumor. Radical prostatectomy was associated with reduced all-cause mortality among men with a PSA value greater than 10 ng per milliliter (P = 0.04 for interaction) and possibly among those with intermediate-risk or high-risk tumors (P = 0.07 for interaction). Adverse events within 30 days after surgery occurred in 21.4% of men, including one death. CONCLUSIONS Among men with localized prostate cancer detected during the early era of PSA testing, radical prostatectomy did not significantly reduce all-cause or prostate-cancer mortality, as compared with observation, through at least 12 years of follow-up. Absolute differences were less than 3 percentage points. (Funded by the Department of Veterans Affairs Cooperative Studies Program and others; PIVOT ClinicalTrials.gov number, NCT00007644.)	[Wilt, Timothy J.] Univ Minnesota, Ctr Chron Dis Out comes Res, Minneapolis Vet Affairs VA, Hlth Care Syst, Minneapolis, MN 55455 USA; [Wilt, Timothy J.] Univ Minnesota, Sch Med, Sect Gen Med, Minneapolis, MN 55455 USA; [Brawer, Michael K.] Urol IDEA, Seattle, WA USA; [Jones, Karen M.] Coordinating Ctr, VA Cooperat Studies Program, Perry Point, MD USA; [Fox, Steven] Agcy Healthcare Res & Qual, Rockville, MD USA; [Barry, Michael J.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA; [Aronson, William J.] Greater Angeles Healthcare Syst, VA Med Ctr, Los Angeles, CA USA; [Iyer, Padmini] VA Med Ctr, Long Beach, CA USA; [Grob, B. Mayer] Richmond VA Med Ctr, Richmond, VA USA; [Gingrich, Jeffrey R.] Univ Pittsburgh, Dept Urol, Pittsburgh, PA USA; [Gingrich, Jeffrey R.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA; [Wei, John T.] Univ Michigan, Ann Arbor, MI 48109 USA; [Gilhooly, Patricia] VA New Jer sey Hlth Care Syst, E Orange, NJ USA; [Nsouli, Imad] VA Med Ctr Syracuse, Syracuse, NY USA; [Blank, William] Brooklyn VA Med Ctr, Brooklyn, NY USA; [Cartagena, Ruben] VA Western New York Hlth Syst, Buffalo, NY USA; [Snider, Glenn] Louis Johnson VA Med Ctr, Clarksburg, WV USA; [Roehrborn, Claus] Univ Texas Dallas, SW Med Ctr, Dept Urol, Dallas, TX USA; [Pandya, Parikshit] Temple VA Med Ctr, Temple, TX USA; [Wheeler, Thomas] Baylor Coll Med, Houston, TX 77030 USA; [Sharifi, Roohollah] Jesse Brown VA Med Ctr, Chicago, IL USA; [Andriole, Gerald L.] Washington Univ, St Louis, MO USA; [Culkin, Daniel] Univ Oklahoma, Norman, OK 73019 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Agency for Healthcare Research & Quality; Harvard University; Massachusetts General Hospital; Hunter Holmes McGuire Veterinary Affairs Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; University of Michigan System; University of Michigan; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Washington University (WUSTL); University of Oklahoma System; University of Oklahoma - Norman	Wilt, TJ (corresponding author), Univ Minnesota, Ctr Chron Dis Out comes Res, Minneapolis Vet Affairs VA, Hlth Care Syst, Minneapolis, MN 55455 USA.	tim.wilt@va.gov	Wei, John T/E-8967-2012; Wilt, Timothy J/R-5572-2017	Gingrich, Jeffrey/0000-0002-4516-2893	Department of Veterans Affairs; National Cancer Institute; Agency for Healthcare Research and Quality; Sanofi-Aventis; Amgen; Augmenix; Bayer; Bristol-Myers Squibb; Cambridge Endo; Caris; GlaxoSmithKline; Janssen Biotech; Myriad Genetics; Steba Biotech; Ortho Clinical Diagnostics; Viking Medical; Envisioneering Medical; Johnson Johnson; Medivation; Wilex; NATIONAL CANCER INSTITUTE [P50CA092131] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Sanofi-Aventis(Sanofi-Aventis); Amgen(Amgen); Augmenix; Bayer(Bayer AG); Bristol-Myers Squibb(Bristol-Myers Squibb); Cambridge Endo; Caris; GlaxoSmithKline(GlaxoSmithKline); Janssen Biotech(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Myriad Genetics; Steba Biotech; Ortho Clinical Diagnostics; Viking Medical; Envisioneering Medical; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Medivation; Wilex; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the Department of Veterans Affairs Cooperative Studies Program, the National Cancer Institute, and the Agency for Healthcare Research and Quality.; Dr. Barry reports being employed by and serving as a board member of the Foundation for Informed Medical Decision Making, which receives royalties from Health Dialog. Dr. Wei reports serving on the board for Envisioneering, receiving consulting fees and grant support from Sanofi-Aventis, providing expert testimony for Genprobe concerning prostate-cancer detection, and serving as proctor for benign prostatic hyperplasia laser surgery for American Medical Systems. Dr. Andriole reports receiving consulting fees, payment for the development of presentations, and payment for travel, accommodation, and meeting expenses from Amgen; consulting fees, stock options, and payment for travel, accommodation, and meeting expenses from Augmenix; consulting fees and payment for travel, accommodation, and meeting expenses from Bayer; consulting fees and payment for travel, accommodation, and meeting expenses from Bristol-Myers Squibb; consulting fees, stock options, and payment for travel, accommodation, and meeting expenses from Cambridge Endo; consulting fees and payment for travel, accommodation, and meeting expenses from Caris; consulting fees and payment for travel, accommodation, and meeting expenses from GlaxoSmithKline; consulting fees and payment for travel, accommodation, and meeting expenses from Janssen Biotech; consulting fees and payment for travel, accommodation, and meeting expenses from Myriad Genetics; consulting fees and payment for travel, accommodation, and meeting expenses from Steba Biotech; consulting fees and payment for travel, accommodation, and meeting expenses from Ortho Clinical Diagnostics; consulting fees and stock options from Viking Medical; stock options from Envisioneering Medical; and grant support to his institution from Johnson & Johnson, Medivation, and Wilex; and being a member of an independent data monitoring committee for Amarex. Dr. Wheeler reports serving as a board member of Medscape; receiving consulting fees from GlaxoSmithKline; providing expert testimony for various law firms regarding medical malpractice, product liability, and toxic tort; receiving royalties from Metabolon; and receiving stock options from Digipath. No other potential conflict of interest relevant to this article was reported.	Albertsen PC, 2005, J NATL CANCER I, V97, P1248, DOI 10.1093/jnci/dji248; Allison P. D, 1995, SURVIVAL ANAL USING; Andriole GL, 2012, J NATL CANCER I, V104, P125, DOI 10.1093/jnci/djr500; [Anonymous], 1997, AJCC CANC STAGING MA; Bill-Axelson A, 2008, J NATL CANCER I, V100, P1144, DOI 10.1093/jnci/djn255; Bill-Axelson A, 2011, NEW ENGL J MED, V364, P1708, DOI 10.1056/NEJMoa1011967; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cooperberg MR, 2007, J UROLOGY, V178, pS14, DOI 10.1016/j.juro.2007.03.135; Cooperberg MR, 2010, J CLIN ONCOL, V28, P1117, DOI 10.1200/JCO.2009.26.0133; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; Djulbegovic M, 2011, BMJ-BRIT MED J, V341, pc4543, DOI DOI 10.1136/BMJ.C4543; Donovan J, 2002, BMJ-BRIT MED J, V325, P766, DOI 10.1136/bmj.325.7367.766; Dubben HH, 2009, LANCET ONCOL, V10, P294, DOI 10.1016/S1470-2045(09)70066-X; Eastham JA, 2003, J UROLOGY, V170, P2292, DOI 10.1097/01.ju.0000091100.83725.51; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; Fransson P, 2001, CANCER-AM CANCER SOC, V92, P3111, DOI 10.1002/1097-0142(20011215)92:12<3111::AID-CNCR10160>3.0.CO;2-E; Ganz PA, 2012, ANN INTERN MED, V156, P591, DOI [10.7326/0003-4819-156-8-201204170-00401, 10.7326/0003-4819-156-8-201204170-00010]; Ghani KR, 2005, EUR UROL, V47, P196, DOI 10.1016/j.eururo.2004.07.029; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Hayes JH, 2011, JAMA-J AM MED ASSOC, V305, P1862, DOI 10.1001/jama.2011.587; Iversen P, 1995, Scand J Urol Nephrol Suppl, V172, P65; Johansson E, 2011, LANCET ONCOL, V12, P891, DOI 10.1016/S1470-2045(11)70162-0; Lu-Yao GL, 2009, JAMA-J AM MED ASSOC, V302, P1202, DOI 10.1001/jama.2009.1348; National Cancer Institute, 2007, SEER CANC STAT REV 1; Newschaffer CJ, 2000, JNCI-J NATL CANCER I, V92, P613, DOI 10.1093/jnci/92.8.613; Obek C, 1999, UROLOGY, V54, P682, DOI 10.1016/S0090-4295(99)00204-6; OHORI M, 1995, J UROLOGY, V154, P1818, DOI 10.1016/S0022-5347(01)66792-2; Rosario DJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d7894; Sanda MG, 2008, NEW ENGL J MED, V358, P1250, DOI 10.1056/NEJMoa074311; Schellhammer P, 1997, UROLOGY, V49, P27, DOI 10.1016/S0090-4295(99)80321-5; Schroder F, 2012, BJU INT, V366, p[981, 1582]; Shao YH, 2009, JNCI-J NATL CANCER I, V101, P1280, DOI 10.1093/jnci/djp262; Stamey TA, 2002, J UROLOGY, V167, P103, DOI 10.1016/S0022-5347(05)65392-X; Swindle P, 2005, J UROLOGY, V174, P903, DOI 10.1097/01.ju.0000169475.00949.78; Thompson I, 2007, GUIDELINE MANAGEMENT; Thompson IM, 2010, JAMA-J AM MED ASSOC, V304, P2411, DOI 10.1001/jama.2010.1761; Vis AN, 2006, EUR UROL, V50, P258, DOI 10.1016/j.eururo.2005.11.030; Welch HG, 2009, J NATL CANCER I, V101, P1325, DOI 10.1093/jnci/djp278; Widmark A, 2011, 53 ANN ASTRO M MIAM; Wilt T, 2008, COMP EFFECTIVENESS T; Wilt TJ, 2008, ANN INTERN MED, V148, P888, DOI 10.7326/0003-4819-148-11-200806030-00023; Wilt TJ, 2008, ANN INTERN MED, V148, P435, DOI 10.7326/0003-4819-148-6-200803180-00209; Wilt TJ, 2009, CONTEMP CLIN TRIALS, V30, P81, DOI 10.1016/j.cct.2008.08.002	43	1370	1391	2	103	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2012	367	3					203	213		10.1056/NEJMoa1113162	http://dx.doi.org/10.1056/NEJMoa1113162			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	22808955	Green Accepted			2022-12-28	WOS:000306522900004
J	Lipsitz, LA				Lipsitz, Lewis A.			Understanding Health Care as a Complex System The Foundation for Unintended Consequences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GUIDELINES		[Lipsitz, Lewis A.] Hebrew SeniorLife, Inst Aging Res, Beth Israel Deaconess Med Ctr, Boston, MA 02131 USA; [Lipsitz, Lewis A.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Hebrew SeniorLife; Harvard University; Harvard Medical School	Lipsitz, LA (corresponding author), Hebrew SeniorLife, Inst Aging Res, Beth Israel Deaconess Med Ctr, 1200 Ctr St, Boston, MA 02131 USA.	lipsitz@hsl.harvard.edu			NATIONAL INSTITUTE ON AGING [R37AG025037] Funding Source: NIH RePORTER; NIA NIH HHS [T32 AG023480, R37 AG025037] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Gawande Atul, 2009, New Yorker, P34; Jha AK, 2012, NEW ENGL J MED, V366, P1606, DOI 10.1056/NEJMsa1112351; Nelson L, 2012, CBO PUBLICATION; Plsek P, 2001, CROSSING QUALITY CHA, P13; Shackelton RJ, 2009, J EVAL CLIN PRACT, V15, P1035, DOI 10.1111/j.1365-2753.2009.01201.x; Sturmberg JP, 2012, J EVAL CLIN PRACT, V18, P202, DOI 10.1111/j.1365-2753.2011.01792.x	7	148	150	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2012	308	3					243	244		10.1001/jama.2012.7551	http://dx.doi.org/10.1001/jama.2012.7551			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975AC	22797640	Green Accepted			2022-12-28	WOS:000306477900023
J	Lauer, MS				Lauer, Michael S.			Lemons for Obesity	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							UNCERTAINTY		[Lauer, Michael S.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lauer, MS (corresponding author), 6701 Rockledge Dr,Room 8128, Bethesda, MD 20892 USA.	lauerm@nhlbi.nih.gov	Lauer, Michael S/L-9656-2013	Lauer, Michael S/0000-0002-9217-8177				AKERLOF GA, 1970, Q J ECON, V84, P488, DOI 10.2307/1879431; Gigerenzer G., 2007, PSYCHOL SCI PUBL INT, V8, P53, DOI [10.1111/j.1539-6053.2008.00033.x, DOI 10.1111/J.1539-6053.2008.00033.X]; Lauer Michael S, 2009, Cleve Clin J Med, V76 Suppl 2, pS18, DOI 10.3949/ccjm.76.s2.04; Moyer VA, 2012, ANN INTERN MED, V156, P392, DOI 10.7326/0003-4819-156-5-201203060-00015; Roan S, 2012, LOS ANGELES TIMES; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; Vivus, 2012, VI 0521 QNEX ADV COM; Wegwarth O, 2012, ANN INTERN MED, V156, P340, DOI 10.7326/0003-4819-156-5-201203060-00005	9	4	4	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2					139	+		10.7326/0003-4819-157-2-201207170-00438	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00438			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801677				2022-12-28	WOS:000307787900020
J	Gregoire, LJ; Payne, AJ; Valdes, PJ				Gregoire, Lauren J.; Payne, Antony J.; Valdes, Paul J.			Deglacial rapid sea level rises caused by ice-sheet saddle collapses	NATURE			English	Article							MELTWATER PULSE 1A; CLIMATE-CHANGE; LAKE AGASSIZ; COLD EVENT; MODEL; RECONSTRUCTIONS; DRAINAGE; TRIGGER; AGES	The last deglaciation (21 to 7 thousand years ago) was punctuated by several abrupt meltwater pulses, which sometimes caused noticeable climate change(1,2). Around 14 thousand years ago, meltwater pulse 1A (MWP-1A), the largest of these events, produced a sea level rise of 14-18 metres over 350 years(3). Although this enormous surge of water certainly originated from retreating ice sheets, there is no consensus on the geographical source or underlying physical mechanisms governing the rapid sea level rise(4-6). Here we present an ice-sheet modelling simulation in which the separation of the Laurentide and Cordilleran ice sheets in North America produces a meltwater pulse corresponding to MWP-1A. Another meltwater pulse is produced when the Labrador and Baffin ice domes around Hudson Bay separate, which could be associated with the '8,200-year' event, the most pronounced abrupt climate event of the past nine thousand years(7). For both modelled pulses, the saddle between the two ice domes becomes subject to surface melting because of a general surface lowering caused by climate warming. The melting then rapidly accelerates as the saddle between the two domes gets lower, producing nine metres of sea level rise over 500 years. This mechanism of an ice 'saddle collapse' probably explains MWP-1A and the 8,200-year event and sheds light on the consequences of these events on climate.	[Gregoire, Lauren J.; Payne, Antony J.; Valdes, Paul J.] Univ Bristol, Sch Geog Sci, Bristol BS8 1SS, Avon, England	University of Bristol	Gregoire, LJ (corresponding author), Univ Bristol, Sch Geog Sci, Univ Rd, Bristol BS8 1SS, Avon, England.	lauren.gregoire@bristol.ac.uk	payne, antony/A-8916-2008; Gregoire, Lauren J/A-7005-2011; Valdes, Paul/T-2004-2019; Valdes, Paul/C-4129-2013	payne, antony/0000-0001-8825-8425; Gregoire, Lauren J/0000-0003-0258-7282; Valdes, Paul/0000-0002-1902-3283; 	Marie Curie Research Training Network NICE [MRTN-CT-2006-036127]; NERC QUEST [NE/D001846/1]; ORMEN [NE/C509558/1]; Natural Environment Research Council [NE/D001846/1] Funding Source: researchfish; Directorate For Geosciences [1023724] Funding Source: National Science Foundation; NERC [NE/D001846/1] Funding Source: UKRI	Marie Curie Research Training Network NICE(European Commission); NERC QUEST(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); ORMEN; Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work was supported by the Marie Curie Research Training Network NICE (MRTN-CT-2006-036127) and the NERC QUEST (NE/D001846/1) and ORMEN (NE/C509558/1) projects. Glimmer was developed within the NERC National Centre for Earth Observation. We thank R. Kahana for providing part of the input climate data and for comments on the manuscript. We also thank members of the BRIDGE group, the NICE network and PALSEA, a PAGES/INQUA/WUN network, for discussions and suggestions. The numerical simulations were carried out using the computational facilities of the BRIDGE group and those of the Advanced Computing Research Centre, University of Bristol (http://www.bris.ac.uk/acrc/).	Abe-Ouchi A, 2007, CLIM PAST, V3, P423, DOI 10.5194/cp-3-423-2007; Aharon P, 2006, EARTH PLANET SC LETT, V241, P260, DOI 10.1016/j.epsl.2005.10.034; Amante C., 2009, ETOPO1 1 ARC MINUTE; Andersen KK, 2004, NATURE, V431, P147, DOI 10.1038/nature02805; Barber DC, 1999, NATURE, V400, P344, DOI 10.1038/22504; BARD E, 1990, NATURE, V346, P456, DOI 10.1038/346456a0; BERGER A, 1992, EARTH PLANET SC LETT, V111, P369, DOI 10.1016/0012-821X(92)90190-7; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; Carlson AE, 2009, QUATERNARY SCI REV, V28, P1625, DOI 10.1016/j.quascirev.2009.02.011; Charbit S, 2007, CLIM PAST, V3, P15, DOI 10.5194/cp-3-15-2007; Clark PU, 2001, SCIENCE, V293, P283, DOI 10.1126/science.1062517; Clark PU, 2002, SCIENCE, V295, P2438; Davies MH, 2011, PALEOCEANOGRAPHY, V26, DOI 10.1029/2010PA002051; Deschamps P, 2012, NATURE, V483, P559, DOI 10.1038/nature10902; Dyke AS, 2004, DEV QUA SCI, V2, P373, DOI 10.1016/S1571-0866(04)80209-4; Fulton RJ, 2004, DEV QUA SCI, V2, P39, DOI 10.1016/S1571-0866(04)80184-2; Ganopolski A, 2010, CLIM PAST, V6, P229, DOI 10.5194/cp-6-229-2010; Gregoire L, 2010, THESIS U BRISTOL; Hanebuth T, 2000, SCIENCE, V288, P1033, DOI 10.1126/science.288.5468.1033; Laske G., 1997, EOS T AM GEOPHYSICAL, V78, pF483; Le Meur E., 1996, ANN GLACIOL, V23, P309, DOI [10.3189/S0260305500013586, DOI 10.3189/S0260305500013586, DOI 10.013/EPIC.12717]; Li YX, 2012, EARTH PLANET SC LETT, V315, P41, DOI 10.1016/j.epsl.2011.05.034; Marshall SJ, 2002, QUATERNARY SCI REV, V21, P175, DOI 10.1016/S0277-3791(01)00089-0; Menviel L, 2011, QUATERNARY SCI REV, V30, P1155, DOI 10.1016/j.quascirev.2011.02.005; Munyikwa K, 2011, QUAT GEOCHRONOL, V6, P407, DOI 10.1016/j.quageo.2011.03.010; Murton JB, 2010, NATURE, V464, P740, DOI 10.1038/nature08954; PAYNE A, 1990, EARTH SURF PROCESSES, V15, P625, DOI 10.1002/esp.3290150705; Peltier WR, 2006, QUATERNARY SCI REV, V25, P3322, DOI 10.1016/j.quascirev.2006.04.010; Peltier WR, 2004, ANNU REV EARTH PL SC, V32, P111, DOI 10.1146/annurev.earth.32.082503.144359; REEH N, 1991, POLARFORSCHUNG, V0059; Rohling EJ, 2005, NATURE, V434, P975, DOI 10.1038/nature03421; Rutt IC, 2009, J GEOPHYS RES-EARTH, V114, DOI 10.1029/2008JF001015; Smith RS, 2008, GEOSCI MODEL DEV, V1, P53, DOI 10.5194/gmd-1-53-2008; Spahni R, 2005, SCIENCE, V310, P1317, DOI 10.1126/science.1120132; Stanford JD, 2011, GLOBAL PLANET CHANGE, V79, P193, DOI 10.1016/j.gloplacha.2010.11.002; Stanford JD, 2006, PALEOCEANOGRAPHY, V21, DOI 10.1029/2006PA001340; Tarasov L, 2006, QUATERNARY SCI REV, V25, P659, DOI 10.1016/j.quascirev.2005.12.006; Tarasov L, 2012, EARTH PLANET SC LETT, V315, P30, DOI 10.1016/j.epsl.2011.09.010; Teller JT, 2002, QUATERNARY SCI REV, V21, P879, DOI 10.1016/S0277-3791(01)00145-7; Thornalley DJR, 2010, PALEOCEANOGRAPHY, V25, DOI 10.1029/2009PA001772; Weaver AJ, 2003, SCIENCE, V299, P1709, DOI 10.1126/science.1081002; WEERTMAN J, 1961, J GEOPHYS RES, V66, P3783, DOI 10.1029/JZ066i011p03783; Zweck C, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005489	43	143	144	1	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2012	487	7406					219	U1506		10.1038/nature11257	http://dx.doi.org/10.1038/nature11257			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972LP	22785319	Green Submitted, Green Accepted			2022-12-28	WOS:000306278900036
J	Peters, BA; Kermani, BG; Sparks, AB; Alferov, O; Hong, P; Alexeev, A; Jiang, Y; Dahl, F; Tang, YT; Haas, J; Robasky, K; Zaranek, AW; Lee, JH; Ball, MP; Peterson, JE; Perazich, H; Yeung, G; Liu, J; Chen, LS; Kennemer, MI; Pothuraju, K; Konvicka, K; Tsoupko-Sitnikov, M; Pant, KP; Ebert, JC; Nilsen, GB; Baccash, J; Halpern, AL; Church, GM; Drmanac, R				Peters, Brock A.; Kermani, Bahram G.; Sparks, Andrew B.; Alferov, Oleg; Hong, Peter; Alexeev, Andrei; Jiang, Yuan; Dahl, Fredrik; Tang, Y. Tom; Haas, Juergen; Robasky, Kimberly; Zaranek, Alexander Wait; Lee, Je-Hyuk; Ball, Madeleine Price; Peterson, Joseph E.; Perazich, Helena; Yeung, George; Liu, Jia; Chen, Linsu; Kennemer, Michael I.; Pothuraju, Kaliprasad; Konvicka, Karel; Tsoupko-Sitnikov, Mike; Pant, Krishna P.; Ebert, Jessica C.; Nilsen, Geoffrey B.; Baccash, Jonathan; Halpern, Aaron L.; Church, George M.; Drmanac, Radoje			Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells	NATURE			English	Article							OPEN-ACCESS DATABASE; JASPAR	Recent advances in whole-genome sequencing have brought the vision of personal genomics and genomic medicine closer to reality. However, current methods lack clinical accuracy and the ability to describe the context (haplotypes) in which genome variants co-occur in a cost-effective manner. Here we describe a low-cost DNA sequencing and haplotyping process, long fragment read (LFR) technology, which is similar to sequencing long single DNA molecules without cloning or separation of metaphase chromosomes. In this study, ten LFR libraries were made using only similar to 100 picograms of human DNA per sample. Up to 97% of the heterozygous single nucleotide variants were assembled into long haplotype contigs. Removal of false positive single nucleotide variants not phased by multiple LFR haplotypes resulted in a final genome error rate of 1 in 10 megabases. Cost-effective and accurate genome sequencing and haplotyping from 10-20 human cells, as demonstrated here, will enable comprehensive genetic studies and diverse clinical applications.	[Peters, Brock A.; Kermani, Bahram G.; Sparks, Andrew B.; Alferov, Oleg; Hong, Peter; Alexeev, Andrei; Jiang, Yuan; Dahl, Fredrik; Tang, Y. Tom; Haas, Juergen; Peterson, Joseph E.; Perazich, Helena; Yeung, George; Liu, Jia; Chen, Linsu; Kennemer, Michael I.; Pothuraju, Kaliprasad; Konvicka, Karel; Tsoupko-Sitnikov, Mike; Pant, Krishna P.; Ebert, Jessica C.; Nilsen, Geoffrey B.; Baccash, Jonathan; Halpern, Aaron L.; Drmanac, Radoje] Complete Genom Inc, Mountain View, CA 94043 USA; [Robasky, Kimberly; Zaranek, Alexander Wait; Lee, Je-Hyuk; Ball, Madeleine Price; Church, George M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Robasky, Kimberly] Boston Univ, Program Bioinformat, Boston, MA 02215 USA; [Lee, Je-Hyuk] Harvard Univ, Sch Med, Wyss Inst Biologically Inspired Engn, Cambridge, MA 02115 USA	Harvard University; Harvard Medical School; Boston University; Harvard University	Peters, BA (corresponding author), Complete Genom Inc, 2071 Stierlin Court, Mountain View, CA 94043 USA.	bpeters@completegenomics.com; rdrmanac@completegenomics.com	Nilsen, Geoffrey/AAY-8095-2021	church, george/0000-0001-6232-9969; Peters, Brock/0000-0002-5137-3902; Zaranek, Alexander (Sasha) Wait/0000-0002-0415-9655; Robasky, Kimberly/0000-0002-0090-8698; Ball, Mad/0000-0003-0544-5925	US Department of Commerce; National Institute of Standards and Technology [70NANB7H7027]; National Institutes of Health [P50HG005550]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG005550] Funding Source: NIH RePORTER	US Department of Commerce; National Institute of Standards and Technology(National Institute of Standards & Technology (NIST) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We would like to acknowledge the continuing contributions and support of all Complete Genomics employees, in particular M. McElwain, D. Bailey, D. Kruse and J. Turcotte for their help with preparing the manuscript. We also wish to thank W. Chao for his help with Figures 1 and 2. Some of this work was supported by the US Department of Commerce, National Institute of Standards and Technology, Advanced Technology Program, Cooperative Agreement Number 70NANB7H7027 and National Institutes of Health grant P50HG005550. We would like to thank J. Chen for managing the NIST grant.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Ahn SM, 2009, GENOME RES, V19, P1622, DOI 10.1101/gr.092197.109; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; [Anonymous], 2010, Nature, V467, P1026, DOI 10.1038/4671026a; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Browning SR, 2011, NAT REV GENET, V12, P703, DOI 10.1038/nrg3054; Bryne JC, 2008, NUCLEIC ACIDS RES, V36, pD102, DOI 10.1093/nar/gkm955; Carnevali P, 2012, J COMPUT BIOL, V19, P279, DOI 10.1089/cmb.2011.0201; Conrad DF, 2011, NAT GENET, V43, P712, DOI 10.1038/ng.862; Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499; Drmanac R., 2006, US patent, Patent No. [7,901 891, 7901891]; Drmanac R, 2010, SCIENCE, V327, P78, DOI 10.1126/science.1181498; Duitama J, 2012, NUCLEIC ACIDS RES, V40, P2041, DOI 10.1093/nar/gkr1042; Fan HC, 2011, NAT BIOTECHNOL, V29, P51, DOI 10.1038/nbt.1739; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Kermani B. G., 2010, US patent, Patent No. [PCT/US2010/023083, 2010023083]; Kim JI, 2009, NATURE, V460, P1011, DOI 10.1038/nature08211; Kitzman JO, 2011, NAT BIOTECHNOL, V29, P59, DOI 10.1038/nbt.1740; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Levy S, 2007, PLOS BIOL, V5, P2113, DOI 10.1371/journal.pbio.0050254; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Lohmueller KE, 2008, NATURE, V451, P994, DOI 10.1038/nature06611; Ma L, 2010, NAT METHODS, V7, P299, DOI [10.1038/NMETH.1443, 10.1038/nmeth.1443]; MacArthur DG, 2012, SCIENCE, V335, P823, DOI 10.1126/science.1215040; McKernan KJ, 2009, GENOME RES, V19, P1527, DOI 10.1101/gr.091868.109; Pushkarev D, 2009, NAT BIOTECHNOL, V27, P847, DOI 10.1038/nbt.1561; Roach JC, 2011, AM J HUM GENET, V89, P382, DOI 10.1016/j.ajhg.2011.07.023; Rothberg JM, 2011, NATURE, V475, P348, DOI 10.1038/nature10242; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Suk EK, 2011, GENOME RES, V21, P1672, DOI 10.1101/gr.125047.111; Tewhey R, 2011, NAT REV GENET, V12, P215, DOI 10.1038/nrg2950; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang J, 2008, NATURE, V456, P60, DOI 10.1038/nature07484; Wheeler DA, 2008, NATURE, V452, P872, DOI 10.1038/nature06884; Yang H, 2011, P NATL ACAD SCI USA, V108, P12, DOI 10.1073/pnas.1016725108; Zhang K, 2006, NAT GENET, V38, P382, DOI 10.1038/ng1741	37	163	253	2	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2012	487	7406					190	195		10.1038/nature11236	http://dx.doi.org/10.1038/nature11236			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972LP	22785314	hybrid, Green Accepted, Green Submitted			2022-12-28	WOS:000306278900030
J	Srivastava, R; Aslam, M; Kalluri, SR; Schirmer, L; Buck, D; Tackenberg, B; Rothhammer, V; Chan, A; Gold, R; Berthele, A; Bennett, JL; Korn, T; Hemmer, B				Srivastava, Rajneesh; Aslam, Muhammad; Kalluri, Sudhakar Reddy; Schirmer, Lucas; Buck, Dorothea; Tackenberg, Bjoern; Rothhammer, Veit; Chan, Andrew; Gold, Ralf; Berthele, Achim; Bennett, Jeffrey L.; Korn, Thomas; Hemmer, Bernhard			Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECTIFYING K+ CHANNEL; NEUROMYELITIS-OPTICA; SENSORINEURAL DEAFNESS; HETEROGENEITY; EXPRESSION; MUTATIONS; LESIONS; KCNJ10; IDENTIFICATION; DEMYELINATION	BACKGROUND Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. Many findings suggest that the disease has an autoimmune pathogenesis; the target of the immune response is not yet known. METHODS We screened serum IgG from persons with multiple sclerosis to identify antibodies that are capable of binding to brain tissue and observed specific binding of IgG to glial cells in a subgroup of patients. Using a proteomic approach focusing on membrane proteins, we identified the ATP-sensitive inward rectifying potassium channel KIR4.1 as the target of the IgG antibodies. We used a multifaceted validation strategy to confirm KIR4.1 as a target of the autoantibody response in multiple sclerosis and to show its potential pathogenicity in vivo. RESULTS Serum levels of antibodies to KIR4.1 were higher in persons with multiple sclerosis than in persons with other neurologic diseases and healthy donors (P<0.001 for both comparisons). We replicated this finding in two independent groups of persons with multiple sclerosis or other neurologic diseases (P<0.001 for both comparisons). Analysis of the combined data sets indicated the presence of serum antibodies to KIR4.1 in 186 of 397 persons with multiple sclerosis (46.9%), in 3 of 329 persons with other neurologic diseases (0.9%), and in none of the 59 healthy donors. These antibodies bound to the first extracellular loop of KIR4.1. Injection of KIR4.1 serum IgG into the cisternae magnae of mice led to a profound loss of KIR4.1 expression, altered expression of glial fibrillary acidic protein in astrocytes, and activation of the complement cascade at sites of KIR4.1 expression in the cerebellum. CONCLUSIONS KIR4.1 is a target of the autoantibody response in a subgroup of persons with multiple sclerosis. (Funded by the German Ministry for Education and Research and Deutsche Forschungsgemeinschaft.)	[Srivastava, Rajneesh; Aslam, Muhammad; Kalluri, Sudhakar Reddy; Schirmer, Lucas; Buck, Dorothea; Rothhammer, Veit; Berthele, Achim; Korn, Thomas; Hemmer, Bernhard] Tech Univ Munich, Dept Neurol, Klinikum Rechts Isar, D-81675 Munich, Germany; [Tackenberg, Bjoern] Univ Marburg, Dept Neurol, Marburg, Germany; [Chan, Andrew; Gold, Ralf] Ruhr Univ Bochum, Dept Neurol, Bochum, Germany; [Bennett, Jeffrey L.] Univ Colorado, Dept Neurol, Denver, CO 80202 USA; [Bennett, Jeffrey L.] Univ Colorado, Dept Ophthalmol, Denver, CO 80202 USA	Technical University of Munich; Philipps University Marburg; Ruhr University Bochum; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver	Hemmer, B (corresponding author), Tech Univ Munich, Dept Neurol, Klinikum Rechts Isar, Ismaningerstr 22, D-81675 Munich, Germany.	hemmer@lrz.tu-muenchen.de	Kalluri, Sudhakar Reddy/C-6928-2013; Hemmer, Bernhard/GPX-8451-2022; Korn, Thomas/AAE-6960-2019; Hemmer, Bernhard/AAT-8388-2021	Hemmer, Bernhard/0000-0001-5985-6784; Korn, Thomas/0000-0002-3633-0955; Schirmer, Lucas/0000-0001-7142-4116; Chan, Andrew/0000-0003-3434-7283	German Competence Network Multiple Sclerosis through the German Ministry for Education and Research (Control-MS) [01GI0917]; Deutsche Forschungsgemeinschaft (DFG) [He2386/7-1]; Gemeinnutzige Hertie-Stiftung; German Academic Exchange Service; National Multiple Sclerosis Society [RG4320]; Guthy-Jackson Charitable Foundation; German Ministry for Education and Research; NATIONAL EYE INSTITUTE [R01EY022936] Funding Source: NIH RePORTER	German Competence Network Multiple Sclerosis through the German Ministry for Education and Research (Control-MS); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Gemeinnutzige Hertie-Stiftung; German Academic Exchange Service(Deutscher Akademischer Austausch Dienst (DAAD)); National Multiple Sclerosis Society(National Multiple Sclerosis Society); Guthy-Jackson Charitable Foundation; German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Supported by grants from the German Competence Network Multiple Sclerosis through the German Ministry for Education and Research (Control-MS, 01GI0917) and from the Deutsche Forschungsgemeinschaft (DFG) (He2386/7-1). Dr. Korn is supported by grants from the DFG and the Gemeinnutzige Hertie-Stiftung; Dr. Aslam, by grants from the German Academic Exchange Service; and Dr. Bennett, by grants from the National Multiple Sclerosis Society (RG4320) and the Guthy-Jackson Charitable Foundation.; Funded by the German Ministry for Education and Research and Deutsche Forschungsgemeinschaft	Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Archelos JJ, 1998, ANN NEUROL, V43, P15, DOI 10.1002/ana.410430107; Ascherio A, 2007, ANN NEUROL, V61, P288, DOI 10.1002/ana.21117; Bennett JL, 2009, ANN NEUROL, V66, P617, DOI 10.1002/ana.21802; Berger T, 2007, J NEUROL SCI, V259, P21, DOI 10.1016/j.jns.2006.05.070; Berglund L, 2008, MOL CELL PROTEOMICS, V7, P2019, DOI 10.1074/mcp.R800013-MCP200; Bockenhauer D, 2009, NEW ENGL J MED, V360, P1960, DOI 10.1056/NEJMoa0810276; Bradl M, 2009, ANN NEUROL, V66, P630, DOI 10.1002/ana.21837; Breij ECW, 2008, ANN NEUROL, V63, P16, DOI 10.1002/ana.21311; Cepok S, 2005, J CLIN INVEST, V115, P1352, DOI 10.1172/JCI200523661; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Cortese I, 1996, P NATL ACAD SCI USA, V93, P11063, DOI 10.1073/pnas.93.20.11063; Derfuss T, 2010, J MOL MED, V88, P753, DOI 10.1007/s00109-010-0632-3; Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Higashi K, 2001, AM J PHYSIOL-CELL PH, V281, pC922, DOI 10.1152/ajpcell.2001.281.3.C922; Keegan M, 2005, LANCET, V366, P579, DOI 10.1016/S0140-6736(05)67102-4; Klein M, 2003, ANN NEUROL, V54, P451, DOI 10.1002/ana.10684; Kucheryavykh YV, 2007, GLIA, V55, P274, DOI 10.1002/glia.20455; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; McFarland HF, 2007, NAT IMMUNOL, V8, P913, DOI 10.1038/ni1507; Meinl E, 2006, ANN NEUROL, V59, P880, DOI 10.1002/ana.20890; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Neusch C, 2001, J NEUROSCI, V21, P5429, DOI 10.1523/JNEUROSCI.21-15-05429.2001; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; Poopalasundaram S, 2000, GLIA, V30, P362, DOI 10.1002/(SICI)1098-1136(200006)30:4<362::AID-GLIA50>3.0.CO;2-4; Quintana FJ, 2008, P NATL ACAD SCI USA, V105, P18889, DOI 10.1073/pnas.0806310105; Roemer SF, 2007, BRAIN, V130, P1194, DOI 10.1093/brain/awl371; Saadoun S, 2010, BRAIN, V133, P349, DOI 10.1093/brain/awp309; Sala-Rabanal M, 2010, J BIOL CHEM, V285, P36040, DOI 10.1074/jbc.M110.163170; Scholl UI, 2009, P NATL ACAD SCI USA, V106, P5842, DOI 10.1073/pnas.0901749106; Seifert G, 2009, J NEUROSCI, V29, P7474, DOI 10.1523/JNEUROSCI.3790-08.2009; Sharma R, 2010, ACTA NEUROPATHOL, V120, P223, DOI 10.1007/s00401-010-0704-z; Somers V, 2008, J IMMUNOL, V180, P3957, DOI 10.4049/jimmunol.180.6.3957; Storch MK, 1998, ANN NEUROL, V43, P465, DOI 10.1002/ana.410430409; Tang XF, 2010, BIOCHEM BIOPH RES CO, V399, P537, DOI 10.1016/j.bbrc.2010.07.105; Tang XF, 2009, GLIA, V57, P1706, DOI 10.1002/glia.20882; Uccelli A, 2005, TRENDS IMMUNOL, V26, P254, DOI 10.1016/j.it.2005.02.009	40	254	262	4	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2					115	123		10.1056/NEJMoa1110740	http://dx.doi.org/10.1056/NEJMoa1110740			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972IO	22784115	Green Accepted			2022-12-28	WOS:000306270800008
J	Caldeira, D; Alarcao, J; Vaz-Carneiro, A; Costa, J				Caldeira, Daniel; Alarcao, Joana; Vaz-Carneiro, Antonio; Costa, Joao			Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; ACUTE MYOCARDIAL-INFARCTION; ACE-INHIBITORS; ELDERLY-PATIENTS; INSERTION/DELETION POLYMORPHISM; ASPIRATION PNEUMONIA; HEART-FAILURE; CARDIOVASCULAR EVENTS; RANDOMIZED-TRIAL; CYTOKINE LEVELS	Objective To systematically review longitudinal studies evaluating use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and risk of pneumonia. Design Systematic review and meta-analysis. Data sources Medline through PubMed, Web of Science with conference proceedings (inception to June 2011), and US Food and Drug Administration website (June 2011). Systematic reviews and references of retrieved articles were also searched. Study selection Two reviewers independently selected randomised controlled trials and cohort and case-control studies evaluating the use of ACE inhibitors or ARBs and risk of pneumonia and retrieved characteristics of the studies and data estimates. Data synthesis The primary outcome was incidence of pneumonia and the secondary outcome was pneumonia related mortality. Subgroup analyses were carried according to baseline morbidities (stroke, heart failure, and chronic kidney disease) and patients' characteristics (Asian and non-Asian). Pooled estimates of odds ratios and 95% confidence intervals were derived by random effects meta-analysis. Adjusted frequentist indirect comparisons between ACE inhibitors and ARBs were estimated and combined with direct evidence whenever available. Heterogeneity was assessed using the I-2 test. Results 37 eligible studies were included. ACE inhibitors were associated with a significantly reduced risk of pneumonia compared with control treatment (19 studies: odds ratio 0.66, 95% confidence interval 0.55 to 0.80; I-2 = 79%) and ARBs (combined direct and indirect odds ratio estimate 0.69, 0.56 to 0.85). In patients with stroke, the risk of pneumonia was also lower in those treated with ACE inhibitors compared with control treatment (odds ratio 0.46, 0.34 to 0.62) and ARBs (0.42, 0.22 to 0.80). ACE inhibitors were associated with a significantly reduced risk of pneumonia among Asian patients (0.43, 0.34 to 0.54) compared with non-Asian patients (0.82, 0.67 to 1.00; P<0.001). Compared with control treatments, both ACE inhibitors (seven studies: odds ratio 0.73, 0.58 to 0.92; I-2 = 51%) and ARBs (one randomised controlled trial: 0.63, 0.40 to 1.00) were associated with a decrease in pneumonia related mortality, without differences between interventions. Conclusions The best evidence available points towards a putative protective role of ACE inhibitors but not ARBs in risk of pneumonia. Patient populations that may benefit most are those with previous stroke and Asian patients. ACE inhibitors were also associated with a decrease in pneumonia related mortality, but the data lacked strength.	[Caldeira, Daniel; Costa, Joao] Univ Lisbon, Fac Med, Lab Clin Pharmacol & Therapeut, P-1649028 Lisbon, Portugal; [Alarcao, Joana; Vaz-Carneiro, Antonio; Costa, Joao] Univ Lisbon, Fac Med, Ctr Evidence Based Med, P-1649028 Lisbon, Portugal; [Vaz-Carneiro, Antonio; Costa, Joao] Univ Lisbon, Fac Med, Cochrane Coordinating Ctr Portugal, P-1649028 Lisbon, Portugal	Universidade de Lisboa; Universidade de Lisboa; Universidade de Lisboa	Costa, J (corresponding author), Univ Lisbon, Fac Med, Lab Clin Pharmacol & Therapeut, P-1649028 Lisbon, Portugal.	jncosta@fm.ul.pt	Caldeira, Daniel/AAJ-7974-2020; Vaz-Carneiro, António/L-8026-2013; Costa, João/GRR-7688-2022; , CINTESIS/C-6631-2014	Caldeira, Daniel/0000-0002-2520-5673; Vaz-Carneiro, António/0000-0002-2783-0544; Costa, João/0000-0002-5831-4921; , CINTESIS/0000-0001-7248-2086				Almirall J, 1999, EUR RESPIR J, V13, P349, DOI 10.1183/09031936.99.13234999; [Anonymous], 2010, CIRCULATION, Vxx, pe348; Antunes G, 2002, EUR RESPIR J, V20, P990, DOI 10.1183/09031936.02.00295102; Arai T, 2000, AM J HYPERTENS, V13, P1050, DOI 10.1016/S0895-7061(00)00301-0; Arai T, 2000, CHEST, V117, P1819, DOI 10.1378/chest.117.6.1819; Arai T, 2005, NEUROLOGY, V64, P573, DOI 10.1212/01.WNL.0000150897.14961.0F; Arai T, 1998, LANCET, V352, P1937, DOI 10.1016/S0140-6736(05)60437-0; Arai T, 2001, CHEST, V119, P660, DOI 10.1378/chest.119.2.660; Asperen RMWV, 2008, EUR RESPIR J, V31, P363, DOI 10.1183/09031936.00060207; Brown NJ, 1998, J CARDIOVASC PHARM, V32, P373, DOI 10.1097/00005344-199809000-00006; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Buitrago-Lopez A, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4488; Carter Patrice, 2010, BMJ, V341, pc4229, DOI 10.1136/bmj.c4229; Chalmers JD, 2008, AM J MED, V121, P1002, DOI 10.1016/j.amjmed.2008.06.030; Corrales-Medina VF, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001048; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Deeks J, 2001, SYSTEMATIC REV HLTH, P313, DOI [DOI 10.1002/9780470693926.CH15, DOI 10.1002/9780470693926.CH16]; Deeks JJ, 2002, STAT MED, V21, P1575, DOI 10.1002/sim.1188; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dickstein K, 2002, LANCET, V360, P752, DOI 10.1016/S0140-6736(02)09895-1; Dicpinigaitis PV, 2006, CHEST, V129, p169S, DOI 10.1378/chest.129.1_suppl.169S; El Solh AA, 2004, J AM GERIATR SOC, V52, P2010, DOI 10.1111/j.1532-5415.2004.52556.x; El Solh Ali A, 2007, Am J Geriatr Pharmacother, V5, P352, DOI 10.1016/j.amjopharm.2007.12.005; Eom CS, 2011, CAN MED ASSOC J, V183, P310, DOI 10.1503/cmaj.092129; Etminan M, 2006, PHARMACOTHERAPY, V26, P479, DOI 10.1592/phco.26.4.479; File TM, 2003, LANCET, V362, P1991, DOI 10.1016/S0140-6736(03)15021-0; Fox AJ, 1996, NAT MED, V2, P814, DOI 10.1038/nm0796-814; Fung HB, 2010, AM J GERIATR PHARMAC, V8, P47, DOI 10.1016/j.amjopharm.2010.01.003; Glenny AM, 2005, HEALTH TECHNOL ASSES, V9, P1; Gullestad L, 1999, J AM COLL CARDIOL, V34, P2061, DOI 10.1016/S0735-1097(99)00495-7; Harada J, 2006, J AM GERIATR SOC, V54, P175, DOI 10.1111/j.1532-5415.2005.00575_8.x; Higgins J., 2022, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9781119536604; Hilker R, 2003, STROKE, V34, P975, DOI 10.1161/01.STR.0000063373.70993.CD; Hou FF, 2006, NEW ENGL J MED, V354, P131, DOI 10.1056/NEJMoa053107; Hu Z, 2010, J INT MED RES, V38, P415, DOI 10.1177/147323001003800204; Kanda A, 2004, J AM GERIATR SOC, V52, P846, DOI 10.1111/j.1532-5415.2004.52230_5.x; Kasanuki H, 2009, EUR HEART J, V30, P1203, DOI 10.1093/eurheartj/ehp101; Katzan IL, 2003, NEUROLOGY, V60, P620, DOI 10.1212/01.WNL.0000046586.38284.60; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; Kranzhofer R, 1999, ARTERIOSCL THROM VAS, V19, P1623, DOI 10.1161/01.ATV.19.7.1623; Lee Hsuei-Chen, 2008, Acta Neurol Taiwan, V17, P17; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lim WS, 2009, THORAX, V64, P1, DOI 10.1136/thx.2009.121434; Majumdar SR, 2006, BMJ-BRIT MED J, V333, P999, DOI 10.1136/BMJ.38992.565972.7C; Marciniak C, 2009, AM J PHYS MED REHAB, V88, P30, DOI 10.1097/PHM.0b013e3181909b73; Metersky ML, 2000, ARCH INTERN MED, V160, P3385, DOI 10.1001/archinte.160.22.3385; MORICE AH, 1987, LANCET, V2, P1116; Mortensen EM, 2008, EUR RESPIR J, V31, P611, DOI 10.1183/09031936.00162006; Mortensen EM, 2002, ARCH INTERN MED, V162, P1059, DOI 10.1001/archinte.162.9.1059; Mortensen Eric M, 2005, BMC Pulm Med, V5, P12, DOI 10.1186/1471-2466-5-12; Mukamal KJ, 2010, J HYPERTENS, V28, P401, DOI 10.1097/HJH.0b013e3283330948; Myles PR, 2009, PHARMACOEPIDEM DR S, V18, P697, DOI 10.1002/pds.1769; Nakagawa T, 1997, ARCH INTERN MED, V157, P321, DOI 10.1001/archinte.157.3.321; Nakagawa T, 2000, J INTERN MED, V247, P255, DOI 10.1046/j.1365-2796.2000.00599.x; Nakayama K, 1998, CHEST, V113, P1425, DOI 10.1378/chest.113.5.1425; Ohkubo T, 2004, AM J RESP CRIT CARE, V169, P1041, DOI 10.1164/rccm.200309-1219OC; Okaishi K, 1999, AM J HYPERTENS, V12, P778, DOI 10.1016/S0895-7061(99)00035-7; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; PONTOPPIDAN H, 1960, JAMA-J AM MED ASSOC, V174, P2209, DOI 10.1001/jama.1960.03030180029007; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; Rafailidis PI, 2008, EUR J CLIN PHARMACOL, V64, P565, DOI 10.1007/s00228-008-0467-9; Ramirez J, 2008, CLIN INFECT DIS, V47, P182, DOI 10.1086/589246; Roth EJ, 2001, STROKE, V32, P523, DOI 10.1161/01.STR.32.2.523; Ruggenenti P, 1997, LANCET, V349, P1857; Sagnella GA, 1999, J HYPERTENS, V17, P657, DOI 10.1097/00004872-199917050-00009; Samokhvalov AV, 2010, EPIDEMIOL INFECT, V138, P1789, DOI 10.1017/S0950268810000774; Schrader J, 2005, STROKE, V36, P1218, DOI 10.1161/01.STR.0000166048.35740.a9; Sekizawa K, 1998, LANCET, V352, P1069, DOI 10.1016/S0140-6736(05)60114-6; SEKIZAWA K, 1990, LANCET, V335, P1228, DOI 10.1016/0140-6736(90)92758-A; Siempos II, 2008, J ANTIMICROB CHEMOTH, V62, P661, DOI 10.1093/jac/dkn283; Smeeth L, 1999, BMJ-BRIT MED J, V318, P1548, DOI 10.1136/bmj.318.7197.1548; Song F, 2008, J CLIN EPIDEMIOL, V61, P455, DOI 10.1016/j.jclinepi.2007.06.006; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Takahashi T, 2005, AM J HYPERTENS, V18, P1353, DOI 10.1016/j.amjhyper.2005.04.020; Teramoto S, 1999, LANCET, V353, P843, DOI 10.1016/S0140-6736(05)76506-5; Teramoto S, 2007, EUR RESPIR J, V29, P218, DOI 10.1183/09031936.00115106; Tleyjeh IM, 2009, ARCH INTERN MED, V169, P1658, DOI 10.1001/archinternmed.2009.286; Tomaki M, 1996, THORAX, V51, P199, DOI 10.1136/thx.51.2.199; van de Garde EMW, 2006, EUR RESPIR J, V27, P1217, DOI 10.1183/09031936.06.00110005; van de Garde EMW, 2008, CHEST, V133, P220, DOI 10.1378/chest.07-1400; van de Garde EMW, 2007, J HYPERTENS, V25, P235, DOI 10.1097/HJH.0b013e328010520a; Vermeij FH, 2009, CEREBROVASC DIS, V27, P465, DOI 10.1159/000210093; Vinogradova Y, 2009, BRIT J GEN PRACT, V59, P742, DOI 10.3399/bjgp09X472629; von Elm E, 2007, EPIDEMIOLOGY, V18, P800, DOI 10.1097/EDE.0b013e3181577654; Walter U, 2007, J NEUROL, V254, P1323, DOI 10.1007/s00415-007-0520-0; Weber M, 1997, CLIN THER, V19, P604, DOI 10.1016/S0149-2918(97)80086-0; WIDIMSKY J, 1995, EUR J CLIN PHARMACOL, V49, P95, DOI 10.1007/BF00192366; Willenheimer R, 2002, INT J CARDIOL, V85, P261, DOI 10.1016/S0167-5273(02)00154-7; Wong WCW, 2008, EMERG THEMES EPIDEMI, V5, DOI 10.1186/1742-7622-5-23; Yusuf S, 2008, LANCET, V372, P1174, DOI 10.1016/S0140-6736(08)61242-8; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Yusuf S, 2008, NEW ENGL J MED, V359, P1225, DOI 10.1056/NEJMoa0804593; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317	97	153	160	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 11	2012	345								e4260	10.1136/bmj.e4260	http://dx.doi.org/10.1136/bmj.e4260			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975NU	22786934	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000306518800001
J	Holmes, D				Holmes, David			Profile Karim Khan: good sport	LANCET			English	Biographical-Item																			0	3	3	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 7	2012	380	9836					20	20		10.1016/S0140-6736(12)61113-1	http://dx.doi.org/10.1016/S0140-6736(12)61113-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970GK	22770447				2022-12-28	WOS:000306115900014
J	Di Angelantonio, E; Gao, P; Pennells, L; Kaptoge, S; Caslake, M; Thompson, A; Butterworth, AS; Sarwar, N; Wormser, D; Saleheen, D; Ballantyne, CM; Psaty, BM; Sundstrom, J; Ridker, PM; Nagel, D; Gillum, RF; Ford, I; Ducimetiere, P; Kiechl, S; Dullaart, RPF; Assmann, G; D'Agostino, RB; Dagenais, GR; Cooper, JA; Kromhout, D; Onat, A; Tipping, RW; Gomez-de-la-Camara, A; Rosengren, A; Sutherland, SE; Gallacher, J; Fowkes, FGR; Casiglia, E; Hofman, A; Salomaa, V; Barrett-Connor, E; Clarke, R; Brunner, E; Jukema, JW; Simons, LA; Sandhu, M; Wareham, NJ; Khaw, KT; Kauhanen, J; Salonen, JT; Howard, WJ; Nordestgaard, BG; Wood, AM; Thompson, SG; Boekholdt, SM; Sattar, N; Packard, C; Gudnason, V; Danesh, J				Di Angelantonio, Emanuele; Gao, Pei; Pennells, Lisa; Kaptoge, Stephen; Caslake, Muriel; Thompson, Alexander; Butterworth, Adam S.; Sarwar, Nadeem; Wormser, David; Saleheen, Danish; Ballantyne, Christie M.; Psaty, Bruce M.; Sundstrom, Johan; Ridker, Paul M.; Nagel, Dorothea; Gillum, Richard F.; Ford, Ian; Ducimetiere, Pierre; Kiechl, Stefan; Dullaart, Robin P. F.; Assmann, Gerd; D'Agostino, Ralph B.; Dagenais, Gilles R.; Cooper, Jackie A.; Kromhout, Daan; Onat, Altan; Tipping, Robert W.; Gomez-de-la-Camara, Agustin; Rosengren, Annika; Sutherland, Susan E.; Gallacher, John; Fowkes, F. Gerry R.; Casiglia, Edoardo; Hofman, Albert; Salomaa, Veikko; Barrett-Connor, Elizabeth; Clarke, Robert; Brunner, Eric; Jukema, J. Wouter; Simons, Leon A.; Sandhu, Manjinder; Wareham, Nicholas J.; Khaw, Kay-Tee; Kauhanen, Jussi; Salonen, Jukka T.; Howard, William J.; Nordestgaard, Borge G.; Wood, Angela M.; Thompson, Simon G.; Boekholdt, S. Matthijs; Sattar, Naveed; Packard, Chris; Gudnason, Vilmundur; Danesh, John		Emerging Risk Factors Collaboratio	Lipid-Related Markers and Cardiovascular Disease Prediction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-HDL CHOLESTEROL; APOLIPOPROTEIN-B; MYOCARDIAL-INFARCTION; LDL CHOLESTEROL; A-I; RISK; LIPOPROTEINS; GUIDELINES; METAANALYSIS; ASSOCIATION	Context The value of assessing various emerging lipid-related markers for prediction of first cardiovascular events is debated. Objective To determine whether adding information on apolipoprotein B and apolipoprotein A-I, lipoprotein(a), or lipoprotein-associated phospholipase A(2) to total cholesterol and high-density lipoprotein cholesterol (HDL-C) improves cardiovascular disease (CVD) risk prediction. Design, Setting, and Participants Individual records were available for 165 544 participants without baseline CVD in 37 prospective cohorts (calendar years of recruitment: 1968-2007) with up to 15 126 incident fatal or nonfatal CVD outcomes (10 132 CHD and 4994 stroke outcomes) during a median follow-up of 10.4 years (interquartile range, 7.6-14 years). Main Outcome Measures Discrimination of CVD outcomes and reclassification of participants across predicted 10-year risk categories of low (<10%), intermediate (10%-<20%), and high (>= 20%) risk. Results The addition of information on various lipid-related markers to total cholesterol, HDL-C, and other conventional risk factors yielded improvement in the model's discrimination: C-index change, 0.0006 (95% CI, 0.0002-0.0009) for the combination of apolipoprotein B and A-I; 0.0016 (95% CI, 0.0009-0.0023) for lipoprotein(a); and 0.0018 (95% CI, 0.0010-0.0026) for lipoprotein-associated phospholipase A(2) mass. Net reclassification improvements were less than 1% with the addition of each of these markers to risk scores containing conventional risk factors. We estimated that for 100 000 adults aged 40 years or older, 15 436 would be initially classified at intermediate risk using conventional risk factors alone. Additional testing with a combination of apolipoprotein B and A-I would reclassify 1.1%; lipoprotein(a), 4.1%; and lipoprotein-associated phospholipase A(2) mass, 2.7% of people to a 20% or higher predicted CVD risk category and, therefore, in need of statin treatment under Adult Treatment Panel III guidelines. Conclusion In a study of individuals without known CVD, the addition of information on the combination of apolipoprotein B and A-I, lipoprotein(a), or lipoprotein-associated phospholipase A(2) mass to risk scores containing total cholesterol and HDL-C led to slight improvement in CVD prediction. JAMA. 2012; 307(23):2499-2506 www.jama.com	[Di Angelantonio, Emanuele; Gao, Pei; Pennells, Lisa; Kaptoge, Stephen; Thompson, Alexander; Butterworth, Adam S.; Sarwar, Nadeem; Wormser, David; Saleheen, Danish; Wareham, Nicholas J.; Khaw, Kay-Tee; Thompson, Simon G.; Danesh, John] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England; [Caslake, Muriel] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Ballantyne, Christie M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Ballantyne, Christie M.] Univ Washington, Dept Med, Seattle, WA USA; [Ballantyne, Christie M.] Univ Washington, Dept Epidemiol, Seattle, WA USA; [Ballantyne, Christie M.] Univ Washington, Dept Hlth Serv, Seattle, WA USA; [Sundstrom, Johan] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden; [Ridker, Paul M.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA; [Nagel, Dorothea] LMU, Klinikum Univ Munchen, Munich, Germany; [Gillum, Richard F.] Ctr Dis Control & Prevent, Washington, DC USA; [Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland; [Ducimetiere, Pierre] INSERM, F-75654 Paris 13, France; [Kiechl, Stefan] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; [Kiechl, Stefan] Univ Ulm, Dept Internal Med Cardiol 2, Med Ctr, Ulm, Germany; [Dullaart, Robin P. F.] Univ Groningen, Univ Groningen Hosp, Univ Med Ctr Groningen, Groningen, Netherlands; [D'Agostino, Ralph B.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA; [Dagenais, Gilles R.] Inst Univ Cardiol & Pneumolo Quebec, Dept Med, Quebec City, PQ, Canada; [Cooper, Jackie A.] UCL, Ctr Cardiovasc Genet, London WC1E 6BT, England; [Kromhout, Daan] Wageningen Univ, Div Human Nutr, Wageningen, Netherlands; [Onat, Altan] Istanbul Univ, Inst Expt Med Res, Istanbul, Turkey; [Tipping, Robert W.] Merck Res Labs, Philadelphia, PA USA; [Gomez-de-la-Camara, Agustin] Hosp 12 Octubre, Unidad Invest, E-28041 Madrid, Spain; [Rosengren, Annika] Univ Gothenburg, Dept Med, Sahlgrenska Acad, Gothenburg, Sweden; [Sutherland, Susan E.] Med Univ S Carolina, Charleston, SC USA; [Gallacher, John] Cardiff Univ, Dept Epidemiol, Cardiff, S Glam, Wales; [Fowkes, F. Gerry R.] Univ Edinburgh, Wolfson Unit, Edinburgh, Midlothian, Scotland; [Casiglia, Edoardo] Univ Pavia, Dept Clin & Expt Med, Padua, Italy; [Hofman, Albert] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [Salomaa, Veikko] Natl Inst Hlth & Welf, Dept Epidemiol, Helsinki, Finland; [Barrett-Connor, Elizabeth] Univ Calif San Diego, San Diego, CA 92103 USA; [Brunner, Eric] Univ Oxford, Clin Trials Serv Unit, Oxford, England; [Brunner, Eric] UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; [Jukema, J. Wouter] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands; [Simons, Leon A.] Univ New S Wales, Lipid Res Dept, Darlinghurst, NSW, Australia; [Kauhanen, Jussi] Univ Eastern Finland, Kuopio, Finland; [Salonen, Jukka T.] Metab Analyt Serv Inc, Helsinki, Finland; [Howard, William J.] Washington Hosp Ctr, Hlth Res Inst, Washington, DC 20010 USA; [Nordestgaard, Borge G.] Univ Copenhagen, Dept Clin Biochem, Copenhagen, Denmark; [Sattar, Naveed] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Packard, Chris] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Cambridge; University of Glasgow; Baylor College of Medicine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Uppsala University; Harvard University; Brigham & Women's Hospital; University of Munich; Centers for Disease Control & Prevention - USA; University of Glasgow; Institut National de la Sante et de la Recherche Medicale (Inserm); Medical University of Innsbruck; Ulm University; University of Groningen; Boston University; University of London; University College London; Wageningen University & Research; Istanbul University; Merck & Company; Hospital Universitario 12 de Octubre; University of Gothenburg; Medical University of South Carolina; Cardiff University; University of Edinburgh; University of Pavia; Erasmus University Rotterdam; Erasmus MC; Finland National Institute for Health & Welfare; University of California System; University of California San Diego; University of Oxford; University of London; University College London; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of New South Wales Sydney; University of Eastern Finland; MedStar Washington Hospital Center; University of Copenhagen; University of Amsterdam; Academic Medical Center Amsterdam; University of Glasgow	Danesh, J (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England.	erfc@medschl.cam.ac.uk	DiAngelantonio, Emanuele/ABE-6852-2020; Marmot, M G/Y-3920-2019; Cushman, Mary/K-1157-2019; Kauhanen, Jussi/ABC-4064-2021; Nordestgaard, Borge Gronne/ABF-1310-2020; Rubio, Miguel Angel/GRJ-0134-2022; Sundstrom, Johan/R-2139-2019; de la Camara, Agustin Gomez/S-7123-2018; Bakker, Stephan J. L./J-4023-2015; Jukema, J. Wouter/ABD-6503-2021; Gao, Pei/AAF-3065-2019; Gao, Pei/R-4794-2018; Boekholdt, Matthijs S.M./G-7562-2014; Brunner, Eric/H-2114-2011; Gudnason, Vilmundur/AAE-7126-2019; Khaw, Kay-Tee/AAZ-3209-2021; Kromhout, Daan/A-8566-2014; Gudnason, Vilmundur/K-6885-2015; Ford, Ian/ABE-6145-2020; Sundström, Johan/A-6286-2009; Wood, Angela/GZA-5762-2022; Ballantyne, Christie/A-6599-2008; Benn, Marianne/O-4164-2019; Meisinger, Christine/B-5358-2014; Lamarche, Benoit/ABA-4785-2021	Marmot, M G/0000-0002-2431-6419; Cushman, Mary/0000-0002-7871-6143; Rubio, Miguel Angel/0000-0002-0495-6240; Sundstrom, Johan/0000-0003-2247-8454; Bakker, Stephan J. L./0000-0003-3356-6791; Jukema, J. Wouter/0000-0002-3246-8359; Gao, Pei/0000-0001-8649-1290; Gao, Pei/0000-0001-8649-1290; Brunner, Eric/0000-0002-0595-4474; Gudnason, Vilmundur/0000-0001-5696-0084; Gudnason, Vilmundur/0000-0001-5696-0084; Sundström, Johan/0000-0003-2247-8454; Wood, Angela/0000-0002-7937-304X; Benn, Marianne/0000-0002-1701-595X; Lamarche, Benoit/0000-0002-4443-5378; Sutherland, Susan/0000-0001-7184-8920; Nordestgaard, Borge/0000-0002-1954-7220; Ballantyne, Christie/0000-0002-6432-1730; Koenig, Wolfgang/0000-0002-2064-9603; Pennells, Lisa Anne/0000-0002-8594-3061; Casiglia, Edoardo/0000-0002-0003-3289; Willeit, Peter/0000-0002-1866-7159; Boekholdt, Matthijs/0000-0002-0861-0765; Frikke-Schmidt, Ruth/0000-0003-4084-5027; Di Angelantonio, Emanuele/0000-0001-8776-6719; Kivimaki, Mika/0000-0002-4699-5627; Gomez de la Camara, Agustin/0000-0001-6827-6319; Price, Jackie/0000-0003-3251-3970; Venkatasubramanian, Siddharth/0000-0002-5860-0768; Butterworth, Adam/0000-0002-6915-9015; Amouyel, Philippe/0000-0001-9088-234X	British Heart Foundation; European Union; Lead-up Medical Network; Merck Sharp and Dohme; John Wiley Son; Elsevier (France); Medical Research Council; UK National Institute of Health Research; Cambridge Biomedical Research Centre; Roche; GlaxoSmithKline; National Institute of Health; Wellcome Trust; Abbott; Amarin; AstraZeneca; Bristol-Myers Squibb; Gentech; Kowa; Merck; Novartis; Sanofi-Synthelabo; Takeda; National Institutes of Health; American Diabetes Association; American Heart Association; Adnexus; Amylin; Esperion; Genetech; Idera Pharma, Kowa; Omthera; Pfizer; Resverlogix; Medtronic; Vascular Bio-genics; ISIS Inc; Genzyme; Else Kroner Fresenius Foundation; Vifor Company; Federal Ministry of Education and Research; Boehringer Ingelheim; Cerenis; BioInvet; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes Health Research; Heart and Stroke of Canada; Netherlands Prevention Foundation; Swedish Research Council; Swedish Heart and Lung Foundation; BUPA Foundation; Denka; diaDexus; European Research Council; Evelyn Trust; Fogarty International Centre; UK Biobank; MRC [MC_U105260792, G0601284, G0902037, G0501792, G0701619, G0701863, MC_U137686857] Funding Source: UKRI; British Heart Foundation [RG/08/014/24067, RG/07/008/23674, RG/08/013/25942] Funding Source: researchfish; Medical Research Council [G19/35, G8802774, G0701619, G1000143, G0100222, MC_U137686857, G0902037, MC_U106179471, G0501792, G0601284, G0401527, G0701863, MC_U105260792] Funding Source: researchfish; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000062] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085083, U01HL080295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023629] Funding Source: NIH RePORTER	British Heart Foundation(British Heart Foundation); European Union(European Commission); Lead-up Medical Network; Merck Sharp and Dohme(Merck & Company); John Wiley Son; Elsevier (France); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK National Institute of Health Research(National Institute for Health Research (NIHR)); Cambridge Biomedical Research Centre(General Electric); Roche(Roche Holding); GlaxoSmithKline(GlaxoSmithKline); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome Trust); Abbott(Abbott Laboratories); Amarin; AstraZeneca(AstraZeneca); Bristol-Myers Squibb(Bristol-Myers Squibb); Gentech; Kowa; Merck(Merck & Company); Novartis(Novartis); Sanofi-Synthelabo; Takeda(Takeda Pharmaceutical Company Ltd); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); American Heart Association(American Heart Association); Adnexus; Amylin; Esperion; Genetech; Idera Pharma, Kowa; Omthera; Pfizer(Pfizer); Resverlogix; Medtronic(Medtronic); Vascular Bio-genics; ISIS Inc; Genzyme(Sanofi-AventisGenzyme Corporation); Else Kroner Fresenius Foundation; Vifor Company; Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Boehringer Ingelheim(Boehringer Ingelheim); Cerenis; BioInvet; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Canadian Institutes Health Research(Canadian Institutes of Health Research (CIHR)); Heart and Stroke of Canada; Netherlands Prevention Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); BUPA Foundation; Denka; diaDexus; European Research Council(European Research Council (ERC)European Commission); Evelyn Trust; Fogarty International Centre(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); UK Biobank; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Di Angelantonio reported that he has received research funding from the British Heart Foundation and European Union; compensation for consultancy and lecturers from Lead-up Medical Network, Merck Sharp and Dohme, and John Wiley & Sons; support for travel or accommodations from Pfizer; and royalties from Elsevier (France). Dr Gao reported that she has received research funding from the British Heart Foundation and the Medical Research Council. Dr Pennells reported that she has received research funding from the Medical Research Council. Dr Kaptoge reported that he has received research funding from British Heart Foundation, Medical Research Council, UK National Institute of Health Research, and Cambridge Biomedical Research Centre. Dr Caslake reported that she has received research funding from Roche and Merck Sharp and Dohme and support for travel and accommodations from Randox Laboratories and Denka Seiken. Dr A. Thompson reported that he has received research funding from the British Heart Foundation and Medical Research Council; has been an employee of Roche Products Ltd since September 2011; and has received compensation from GlaxoSmithKline for giving lectures. Dr Sarwar reported that he has been an employee of Pfizer Inc since April 2011. Dr Wormser reported that he has received research funding from the British Heart Foundation and Medical Research Council. Dr Saleheen reported that he has received research funding from the National Institute of Health and Wellcome Trust. Dr Ballantyne reported that she has received research funding from Abbott, Amarin, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Gentech, Kowa, Merck, Novartis, Roche, Sanofi-Synthelabo, Takeda, National Institutes of Health, American Diabetes Association, and American Heart Association and compensation for consultancy and for lectures from Abbott, Adnexus, Amarin, Amylin, AstraZeneca, Bristol-Myers Squibb, Esperion, Genetech, GlaxoSmithKline, Idera Pharma, Kowa, Merck, Novartis, Omthera, Pfizer, Resverlogix, Roche, Sanofi-Synthelabo, and Takeda. Dr Psaty reported that he serves on a data safety and monitoring board for a clinical trial of a device funded by the manufacturer Zoll LieCor and on the Steering Committee for the Yale Open-Data Project funded by Medtronic. Dr Ridker reported that he is listed as a coinventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Seimens; received research funding from AstraZeneca and Novartis; and compensation for consultancy from Merck, Vascular Bio-genics, ISIS Inc, and Genzyme. Dr Kiechl reported that he has received research funding from the Fonds zur Forderung der wissenschaftlichen Forschung. Dr Koenig reported that he has received research funding from the Else Kroner Fresenius Foundation, Vifor Company, European Union, Federal Ministry of Education and Research and Boehringer Ingelheim; and compensation for consultancy and lecturers from Roche, Cerenis, Anthera, BioInvet, Novartis, AstraZeneca, Merck Sharp and Dohme, Roche, and Boehringer Ingelheim. Dr Assmann reported that he has received compensation for consultancy and lecturers from Merck Sharp and Dohme, and Residual Risk Reduction Initiative and has served on board for the Residual Risk Reduction Initiative.; Dr Dagenais reported that he has received research funding from the National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, Canadian Institutes Health Research, and Heart and Stroke of Canada and compensation for expert testimony and lecturers from Abbott and Boehringer Ingelheim. Dr Kromhout reported that he has received research funding from the Netherlands Prevention Foundation. Mr Tipping reported that he is an employee of Merck. Dr Rosengren reported that she has received research funding from the Swedish Research Council and Swedish Heart and Lung Foundation. Dr Barrett-Connor reported that she has received research funding from the National Institutes of Health. Dr Clarke reported that he has received research funding from the British Heart Foundation. Dr Brunner reported that he has received research funding from the Medical Research Council and British Heart Foundation. Dr Jukema reported that he has received research funding from the European Union. Dr Sandhu reported that he has received research funding from the British Heart Foundation. Dr Wareham reported that he has received research funding from the Medical Research Council. Dr Khaw reported that she has received research funding from the UK Medical Research Council and Cancer Research. Dr Howard reported that he has received compensation for consultancy and lecturers from Merck, Abbott, and GlaxoSmithKline. Dr S. G. Thompson reported that he has received research funding from the British Heart Foundation. Dr Sattar reported that he has received research funding from Pfizer and has served on the advisory board for Niaspan for Merck Sharp and Dohme. Dr Packard reported that he has received compensation for consultancy and lecturers from AstraZeneca, Roche, and Merck Sharp and Dohme. Dr Danesh reported that he has received research funding from the British Heart Foundation, BUPA Foundation, Cambridge Biomedical Research Centre, Denka, diaDexus, European Union, European Research Council, Evelyn Trust, Fogarty International Centre, GlaxoSmithKline, Medical Research Council, Merck Sharp and Dohme, National Heart, Lung, and Blood Institute, National Institute of Neurological Disorders and Stroke, National Institute for Health Research, Novartis, Pfizer, Roche, Wellcome Trust, and UK Biobank and has served on advisory boards for Merck, Pfizer, and Novartis. All other members of the writing committee declare that they have no conflicts of interest.	[Anonymous], 2007, EUR J EPIDEMIOL, V22, P839, DOI 10.1007/s10654-007-9165-7; Arsenault BJ, 2011, NAT REV CARDIOL, V8, P197, DOI 10.1038/nrcardio.2010.223; Arsenault BJ, 2009, J AM COLL CARDIOL, V55, P35, DOI 10.1016/j.jacc.2009.07.057; Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Boekholdt SM, 2012, JAMA-J AM MED ASSOC, V307, P1302, DOI 10.1001/jama.2012.366; Brunzell JD, 2008, DIABETES CARE, V31, P811, DOI 10.2337/dc08-9018; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; ClinicalTrials. gov, TREATM HDL RED INC V; Contois JH, 2009, CLIN CHEM, V55, P407, DOI 10.1373/clinchem.2008.118356; D'Agostino RB, 2008, CIRCULATION, V117, P743, DOI 10.1161/CIRCULATIONAHA.107.699579; Danesh J, 2009, STAT MED, V28, P389, DOI 10.1002/sim.3378; Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619; Erqou S, 2009, JAMA-J AM MED ASSOC, V302, P412, DOI 10.1001/jama.2009.1063; Genest J, 2009, CAN J CARDIOL, V25, P567, DOI 10.1016/S0828-282X(09)70715-9; Greenland P, 2010, J AM COLL CARDIOL, V56, pE50, DOI 10.1016/j.jacc.2010.09.001; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Kamstrup PR, 2009, JAMA-J AM MED ASSOC, V301, P2331, DOI 10.1001/jama.2009.801; Maningat P, 2011, NEW ENGL J MED, V365, P2250, DOI 10.1056/NEJMp1112023; McQueen MJ, 2008, LANCET, V372, P224, DOI 10.1016/S0140-6736(08)61076-4; Myers GL, 2009, CLIN CHEM, V55, P378, DOI 10.1373/clinchem.2008.115899; Nordestgaard BG, 2010, EUR HEART J, V31, P2844, DOI 10.1093/eurheartj/ehq386; Parish S, 2012, CIRCULATION, V125, P2469, DOI 10.1161/CIRCULATIONAHA.111.073684; Parish S, 2009, EUR HEART J, V30, P2137, DOI 10.1093/eurheartj/ehp221; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Perk Joep, 2012, Atherosclerosis, V223, P1, DOI [10.1016/j.atherosclerosis.2012.05.007, 10.1007/s12529-012-9242-5, 10.1093/eurheartj/ehs092]; Reiner Z, 2011, EUR HEART J, V32, P1769, DOI [10.1093/eurheartj/ehr158, 10.1016/j.atherosclerosis.2011.06.012]; Ridker PM, 2005, JAMA-J AM MED ASSOC, V294, P326, DOI 10.1001/jama.294.3.326; Sniderman AD, 2011, CIRC-CARDIOVASC QUAL, V4, P337, DOI 10.1161/CIRCOUTCOMES.110.959247; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Thompson A, 2010, LANCET, V375, P1536, DOI 10.1016/S0140-6736(10)60319-4; Walldius G, 2001, LANCET, V358, P2026, DOI 10.1016/S0140-6736(01)07098-2; White H, 2010, AM HEART J, V160, P655, DOI 10.1016/j.ahj.2010.07.006	32	330	342	0	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2012	307	23					2499	2506		10.1001/jama.2012.6571	http://dx.doi.org/10.1001/jama.2012.6571			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	960MB	22797450	Green Accepted			2022-12-28	WOS:000305391400026
J	Chen, LY; Redon, S; Lingner, J				Chen, Liuh-Yow; Redon, Sophie; Lingner, Joachim			The human CST complex is a terminator of telomerase activity	NATURE			English	Article							DNA-POLYMERASE-ALPHA; SINGLE-STRANDED-DNA; CHROMOSOME ENDS; REPLICATION; PROTECTION; EXTENSION; INTERACTS; PROTEIN; CELLS; PROCESSIVITY	The lengths of human telomeres, which protect chromosome ends from degradation and end fusions(1,2), are crucial determinants of cell lifespan(3). During embryogenesis and in cancer, the telomerase enzyme counteracts telomeric DNA shortening. As shown in cancer cells, human telomerase binds the shelterin component TPP1 at telomeres(4,5) during the S phase of the cell cycle, and adds similar to 60 nucleotides in a single round of extension(6), after which telomerase is turned off by unknown mechanisms. Here we show that the human CST (CTC1, STN1 and TEN1) complex, previously implicated in telomere protection and DNA metabolism(7-11), inhibits telomerase activity through primer sequestration and physical interaction with the protection of telomeres 1 (POT1)-TPP1 telomerase processivity factor(12,13). CST competes with POT1-TPP1 for telomeric DNA, and CST-telomeric-DNA binding increases during late S/G2 phase only on telomerase action, coinciding with telomerase shut-off. Depletion of CST allows excessive telomerase activity, promoting telomere elongation. We propose that through binding of the telomerase-extended telomere, CST limits telomerase action at individual telomeres to approximately one binding and extension event per cell cycle. Our findings define the sequence of events that occur to first enable and then terminate telomerase-mediated telomere elongation.	[Chen, Liuh-Yow; Redon, Sophie; Lingner, Joachim] Ecole Polytech Fed Lausanne, Frontiers Genet Natl Ctr Competence Res, Sch Life Sci, Swiss Inst Expt Canc Res ISREC,Stn 19, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research	Lingner, J (corresponding author), Ecole Polytech Fed Lausanne, Frontiers Genet Natl Ctr Competence Res, Sch Life Sci, Swiss Inst Expt Canc Res ISREC,Stn 19, CH-1015 Lausanne, Switzerland.	joachim.lingner@epfl.ch	Chen, Liuh-Yow/AAA-3963-2021	Chen, Liuh-Yow/0000-0002-9857-068X; Lingner, Joachim/0000-0002-2853-5803	Swiss National Science Foundation; European Research Council [232812]; Swiss Cancer League; EPFL	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Research Council(European Research Council (ERC)European Commission); Swiss Cancer League; EPFL	We thank P. Reichenbach, K. Ong and S. Feuerhahn for technical help, the PCF-EPFL core facility for protein expression and J. Cooper for discussion. Research in the laboratory of J.L. was supported by the Swiss National Science Foundation, a European Research Council advanced investigator grant (grant agreement no. 232812), the Swiss Cancer League and EPFL.	Abreu E, 2010, MOL CELL BIOL, V30, P2971, DOI 10.1128/MCB.00240-10; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Casteel DE, 2009, J BIOL CHEM, V284, P5807, DOI 10.1074/jbc.M807593200; Cristofari G, 2006, EMBO J, V25, P565, DOI 10.1038/sj.emboj.7600952; Cristofari G, 2007, NAT METHODS, V4, P851, DOI 10.1038/NMETH1099; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; de Lange T, 2009, SCIENCE, V326, P948, DOI 10.1126/science.1170633; Gao H, 2007, NAT STRUCT MOL BIOL, V14, P208, DOI 10.1038/nsmb1205; Grossi S, 2004, GENE DEV, V18, P992, DOI 10.1101/gad.300004; Gu PL, 2012, EMBO J, V31, P2309, DOI 10.1038/emboj.2012.96; Jain D, 2010, ANNU REV GENET, V44, P243, DOI 10.1146/annurev-genet-102108-134841; Latrick CM, 2010, EMBO J, V29, P924, DOI 10.1038/emboj.2009.409; Martin V, 2007, P NATL ACAD SCI USA, V104, P14038, DOI 10.1073/pnas.0705497104; Miyake Y, 2009, MOL CELL, V36, P193, DOI 10.1016/j.molcel.2009.08.009; Nakaoka H, 2012, J BIOL CHEM, V287, P619, DOI 10.1074/jbc.M111.263723; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Qi HY, 2000, GENE DEV, V14, P1777; Surovtseva YV, 2009, MOL CELL, V36, P207, DOI 10.1016/j.molcel.2009.09.017; Wang F, 2007, NATURE, V445, P506, DOI 10.1038/nature05454; Xin HW, 2007, NATURE, V445, P559, DOI 10.1038/nature05469; Zhao Y, 2011, MOL CELL, V42, P297, DOI 10.1016/j.molcel.2011.03.020; Zhao Y, 2009, CELL, V138, P463, DOI 10.1016/j.cell.2009.05.026	22	216	222	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 23	2012	488	7412					540	+		10.1038/nature11269	http://dx.doi.org/10.1038/nature11269			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	992FS	22763445				2022-12-28	WOS:000307761600043
J	Smith, CD				Smith, Cynthia D.		Alliance Acad Internal Med	Teaching High-Value, Cost-Conscious Care to Residents: The Alliance for Academic Internal Medicine-American College of Physicians Curriculum	ANNALS OF INTERNAL MEDICINE			English	Article							REGIONAL-VARIATIONS; SATISFACTION; APPROPRIATE; OUTCOMES; QUALITY	Health care expenditures are projected to reach nearly 20% of the U.S. gross domestic product by 2020. Up to $765 billion of this spending has been identified as potentially avoidable; many of the avoidable costs have been attributed to unnecessary services. Postgraduate trainees have historically received little specific training in the stewardship of health care resources and minimal feedback on resource utilization and its effect on the cost of care. This article describes a new curriculum that was developed collaboratively by the Alliance for Academic Internal Medicine and the American College of Physicians to address this training gap. The curriculum introduces a simple, stepwise framework for delivering high-value care and focuses on teaching trainees to incorporate high-value, cost-conscious care principles into their clinical practice. It consists of ten 1-hour, case-based, interactive sessions designed to be flexibly incorporated into the existing conference structure of a residency training program.	Amer Coll Physicians, Philadelphia, PA 19106 USA	American College of Physicians	Smith, CD (corresponding author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	dsmith@acponline.org		Dine, Constance/0000-0001-5894-0861	AAIM; ACP; ABIM Foundation	AAIM; ACP; ABIM Foundation	Special thanks to the AAIM, ACP, and ABIM Foundation for their support and vision and to the following persons for reviewing the curriculum: Patrick C. Alguire, MD, Senior Vice President, American College of Physicians; Steven E. Weinberger, MD, Chief Executive Officer, American College of Physicians; Vineet Arora, MD, MA, Associate Professor of Medicine, Assistant Dean for Scholarship and Discovery, Pritzker School of Medicine and Associate Program Director, Internal Medicine Residency Program, University of Chicago; P. Preston Reynolds, MD, PhD, Professor, General Medicine, Geriatrics and Palliative Care, University of Virginia School of Medicine; and Edward B. Warren, Manager, Education and Career Development, American College of Physicians.	[Anonymous], 1983, 9825 HR 1; Asch DA, 2009, JAMA-J AM MED ASSOC, V302, P1277, DOI 10.1001/jama.2009.1356; Dine C Jessica, 2010, J Grad Med Educ, V2, P175, DOI 10.4300/JGME-D-10-00021.1; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Gould BE, 2004, FAM MED, V36, pS57; Institute of Medicine, 2010, HEALTHC IMP LOW COST; Office of the Actuary National Health Statistics Group, 2012, NAT HLTH EXP DAT PRO; Owens DK, 2011, ANN INTERN MED, V154, P174, DOI 10.7326/0003-4819-154-3-201102010-00007; Pangaro L., 2010, ACP TEACHING MED SER; Qaseem A, 2012, ANN INTERN MED, V156, P147, DOI 10.7326/0003-4819-156-2-201201170-00011; Weinberger SE, 2011, ACAD MED, V86, P1352, DOI 10.1097/ACM.0b013e3182308db7; Weinberger SE, 2011, ANN INTERN MED, V155, P386, DOI 10.7326/0003-4819-155-6-201109200-00007	13	75	77	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 21	2012	157	4					284	+		10.7326/0003-4819-157-4-201208210-00496	http://dx.doi.org/10.7326/0003-4819-157-4-201208210-00496			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992XG	22777503				2022-12-28	WOS:000307813200018
J	Scimia, MC; Hurtado, C; Ray, S; Metzler, S; Wei, K; Wang, JM; Woods, CE; Purcell, NH; Catalucci, D; Akasaka, T; Bueno, OF; Vlasuk, GP; Kaliman, P; Bodmer, R; Smith, LH; Ashley, E; Mercola, M; Brown, JH; Ruiz-Lozano, P				Scimia, Maria Cecilia; Hurtado, Cecilia; Ray, Saugata; Metzler, Scott; Wei, Ke; Wang, Jianming; Woods, Chris E.; Purcell, Nicole H.; Catalucci, Daniele; Akasaka, Takeshi; Bueno, Orlando F.; Vlasuk, George P.; Kaliman, Perla; Bodmer, Rolf; Smith, Layton H.; Ashley, Euan; Mercola, Mark; Brown, Joan Heller; Ruiz-Lozano, Pilar			APJ acts as a dual receptor in cardiac hypertrophy	NATURE			English	Article							IN-VIVO; GENE-EXPRESSION; ANGIOTENSIN-II; APELIN; STRETCH; PROTEIN; CONTRACTILITY; MYOCYTES; CARDIOMYOCYTES; INVOLVEMENT	Cardiac hypertrophy is initiated as an adaptive response to sustained overload but progresses pathologically as heart failure ensues(1). Here we report that genetic loss of APJ, a G-protein-coupled receptor, confers resistance to chronic pressure overload by markedly reducing myocardial hypertrophy and heart failure. In contrast, mice lacking apelin (the endogenous APJ ligand) remain sensitive, suggesting an apelin-independent function of APJ. Freshly isolated APJ-null cardiomyocytes exhibit an attenuated response to stretch, indicating that APJ is a mechanosensor. Activation of APJ by stretch increases cardiomyocyte cell size and induces molecular markers of hypertrophy. Whereas apelin stimulates APJ to activate G alpha(i) and elicits a protective response, stretch signals in an APJ-dependent, G-protein-independent fashion to induce hypertrophy. Stretch-mediated hypertrophy is prevented by knockdown of beta-arrestins or by pharmacological doses of apelin acting through G alpha(i). Taken together, our data indicate that APJ is a bifunctional receptor for both mechanical stretch and the endogenous peptide apelin. By sensing the balance between these stimuli, APJ occupies a pivotal point linking sustained overload to cardiomyocyte hypertrophy.	[Scimia, Maria Cecilia; Hurtado, Cecilia; Ray, Saugata; Wei, Ke; Wang, Jianming; Akasaka, Takeshi; Bodmer, Rolf; Smith, Layton H.; Mercola, Mark; Ruiz-Lozano, Pilar] Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA; [Metzler, Scott; Ruiz-Lozano, Pilar] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; [Woods, Chris E.; Ashley, Euan] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Purcell, Nicole H.; Brown, Joan Heller] Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA; [Catalucci, Daniele] CNR, Biomed & Genet Res Inst, I-20138 Milan, Italy; [Catalucci, Daniele] Humanitas Clin & Res Ctr, I-20089 Milan, Italy; [Bueno, Orlando F.; Vlasuk, George P.] Wyeth Pharmaceut, Madison, NJ USA; [Kaliman, Perla] Inst Biomed Res August Pi & Sunyer IDIBAPS, E-08036 Barcelona, Spain	Sanford Burnham Prebys Medical Discovery Institute; Stanford University; Stanford University; University of California System; University of California San Diego; Consiglio Nazionale delle Ricerche (CNR); Pfizer; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Ruiz-Lozano, P (corresponding author), Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA.	prlozano@stanford.edu	Catalucci, Daniele/AAA-6056-2022; Catalucci, Daniele/B-6745-2015; Ray, Saugata/E-3160-2012	Catalucci, Daniele/0000-0001-7041-6114; Catalucci, Daniele/0000-0001-7041-6114; Smith, Layton/0000-0003-2621-9740	Wyeth Sponsored Research Agreement; National Institutes of Health (NIH) [R01HL086879, R37HL059502, R01HL083463, R01HL054732, NS05422, RO1HL28143, P01 HL085577]; Sanford Children's Center; Ellison Medical Foundation; Muscular Dystrophy association; Florida Department of Health [06-NIR-09]; California Institute for Regenerative Medicine; Italian Ministry of Research and Education; Italian Society of Cardiology (SIC and Sanofi-Aventis Foundation); American Heart Association Postdoctoral Award; Ministerio de Ciencia e Innovacion (MICINN) Spain [SAF2010-15050]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054732, R01HL028143, R37HL059502, R01HL086879, R01HL083463, P01HL085577, R37HL028143] Funding Source: NIH RePORTER	Wyeth Sponsored Research Agreement; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sanford Children's Center; Ellison Medical Foundation(Lawrence Ellison Foundation); Muscular Dystrophy association(Muscular Dystrophy Association); Florida Department of Health; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); Italian Ministry of Research and Education(Ministry of Education, Universities and Research (MIUR)); Italian Society of Cardiology (SIC and Sanofi-Aventis Foundation); American Heart Association Postdoctoral Award(American Heart Association); Ministerio de Ciencia e Innovacion (MICINN) Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We are thankful to N. Ling, S. Zhao and F. Abdel-Wahhab for technical assistance; E. Sergienko for help optimizing arrestin assay; E. Adamson for reading the manuscript; and M. Querol for graphics design. This work was supported by Wyeth Sponsored Research Agreement and National Institutes of Health (NIH) grant R01HL086879 to P. R. L.; NIH grants R37HL059502 and R01HL083463 and the Sanford Children's Center to M. M.; NIH grant R01HL054732, grants from the Ellison Medical Foundation and the Muscular Dystrophy association to R. B., NIH grant (NS05422) and Florida Department of Health grant 06-NIR-09 to L. H. S., and NIH grants RO1HL28143, P01 HL085577 to J.H.B. M. C. S. has received support from the California Institute for Regenerative Medicine (clinical fellow), the Italian Ministry of Research and Education and the Italian Society of Cardiology (SIC and Sanofi-Aventis Foundation). C. H. holds an American Heart Association Postdoctoral Award, S. R. is a Sanford Children's Health Research Center fellow. P. K. is supported by SAF2010-15050 Ministerio de Ciencia e Innovacion (MICINN) Spain.	Ashley EA, 2005, CARDIOVASC RES, V65, P73, DOI 10.1016/j.cardiores.2004.08.018; Bollensdorff C, 2011, PFLUG ARCH EUR J PHY, V462, P39, DOI 10.1007/s00424-011-0964-z; Charo DN, 2009, AM J PHYSIOL-HEART C, V297, pH1904, DOI 10.1152/ajpheart.00686.2009; Chun HJ, 2008, J CLIN INVEST, V118, P3343, DOI 10.1172/JCI34871; Civelli O, 2005, TRENDS PHARMACOL SCI, V26, P15, DOI 10.1016/j.tips.2004.11.005; Frank D, 2008, HYPERTENSION, V51, P309, DOI 10.1161/HYPERTENSIONAHA.107.098046; Iribe G, 2009, CIRC RES, V104, P787, DOI 10.1161/CIRCRESAHA.108.193334; Jia YX, 2006, REGUL PEPTIDES, V133, P147, DOI 10.1016/j.regpep.2005.09.033; KNOWLTON KU, 1995, J CLIN INVEST, V96, P1311, DOI 10.1172/JCI118166; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; Kuba K, 2007, CIRC RES, V101, pE32, DOI 10.1161/CIRCRESAHA.107.158659; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Magga J, 1997, CIRCULATION, V96, P3053, DOI 10.1161/01.CIR.96.9.3053; Masri B, 2006, J BIOL CHEM, V281, P18317, DOI 10.1074/jbc.M600606200; Means CK, 2008, J BIOL CHEM, V283, P11954, DOI 10.1074/jbc.M707422200; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Rapacciuolo A, 2001, ACTA PHYSIOL SCAND, V173, P51, DOI 10.1046/j.1365-201X.2001.00884.x; ROCKMAN HA, 1994, P NATL ACAD SCI USA, V91, P2694, DOI 10.1073/pnas.91.7.2694; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Scott IC, 2007, DEV CELL, V12, P403, DOI 10.1016/j.devcel.2007.01.012; Siddiquee K, 2011, J HYPERTENS, V29, P724, DOI 10.1097/HJH.0b013e32834347de; Szokodi I, 2002, CIRC RES, V91, P434, DOI 10.1161/01.RES.0000033522.37861.69; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137	27	177	189	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 16	2012	488	7411					394	398		10.1038/nature11263	http://dx.doi.org/10.1038/nature11263			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988OS	22810587	Green Accepted, Green Submitted			2022-12-28	WOS:000307501000045
J	Saab, AS; Neumeyer, A; Jahn, HM; Cupido, A; Simek, AAM; Boele, HJ; Scheller, A; Le Meur, K; Gotz, M; Monyer, H; Sprengel, R; Rubio, ME; Deitmer, JW; De Zeeuw, CI; Kirchhoff, F				Saab, Aiman S.; Neumeyer, Alexander; Jahn, Hannah M.; Cupido, Alexander; Simek, Antonia A. M.; Boele, Henk-Jan; Scheller, Anja; Le Meur, Karim; Goetz, Magdalena; Monyer, Hannah; Sprengel, Rolf; Rubio, Maria E.; Deitmer, Joachim W.; De Zeeuw, Chris I.; Kirchhoff, Frank			Bergmann Glial AMPA Receptors Are Required for Fine Motor Coordination	SCIENCE			English	Article							KAINATE RECEPTORS; PLASTICITY; CEREBELLUM; CELLS; COMMUNICATION	The impact of glial neurotransmitter receptors in vivo is still elusive. In the cerebellum, Bergmann glial (BG) cells express alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors (AMPARs) composed exclusively of GluA1 and/or GluA4 subunits. With the use of conditional gene inactivation, we found that the majority of cerebellar GluA1/A4-type AMPARs are expressed in BG cells. In young mice, deletion of BG AMPARs resulted in retraction of glial appendages from Purkinje cell (PC) synapses, increased amplitude and duration of evoked PC currents, and a delayed formation of glutamatergic synapses. In adult mice, AMPAR inactivation also caused retraction of glial processes. The physiological and structural changes were accompanied by behavioral impairments in fine motor coordination. Thus, BG AMPARs are essential to optimize synaptic integration and cerebellar output function throughout life.	[Simek, Antonia A. M.; Boele, Henk-Jan; De Zeeuw, Chris I.] Erasmus MC, Dept Neurosci, Rotterdam, Netherlands; [Saab, Aiman S.; Jahn, Hannah M.; Cupido, Alexander; Scheller, Anja; Le Meur, Karim; Kirchhoff, Frank] Univ Saarland, Dept Mol Physiol, D-6650 Homburg, Germany; [Saab, Aiman S.; Jahn, Hannah M.; Scheller, Anja; Kirchhoff, Frank] Max Planck Inst Expt Med, Dept Neurogenet, D-3400 Gottingen, Germany; [Neumeyer, Alexander; Deitmer, Joachim W.] Tech Univ Kaiserslautern, Fachbereich Biol, Kaiserslautern, Germany; [Goetz, Magdalena] Univ Munich, Dept Physiol, D-8000 Munich, Germany; [Goetz, Magdalena] Helmholtz Ctr Munich, Inst Stem Cell Res, Neuherberg, Germany; [Monyer, Hannah] Heidelberg Univ, German Canc Res Ctr, Dept Clin Neurobiol, Heidelberg, Germany; [Monyer, Hannah] Heidelberg Univ, Fac Med, Heidelberg, Germany; [Sprengel, Rolf] Max Planck Inst Med Res, Dept Mol Neurobiol, Heidelberg, Germany; [Rubio, Maria E.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [De Zeeuw, Chris I.] Royal Netherlands Acad Arts & Sci KNAW, Netherlands Inst Neurosci, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Saarland University; Max Planck Society; University of Kaiserslautern; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Max Planck Society; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	De Zeeuw, CI (corresponding author), Erasmus MC, Dept Neurosci, Rotterdam, Netherlands.	c.dezeeuw@erasmusmc.nl; frank.kirchhoff@uks.eu	Boele, Henk-Jan/AAI-7261-2021; Kirchhoff, Frank/B-9335-2008; Scheller, Anja/B-8577-2018; Boele, Henk-Jan/AAK-3836-2021	Boele, Henk-Jan/0000-0001-8449-4391; Kirchhoff, Frank/0000-0002-2324-2761; Scheller, Anja/0000-0001-8955-2634; Saab, Aiman S./0000-0003-3886-8369	Max-Planck Society (INSERM-AMIGO); Deutsche Forschungsgemeinschaft (DFG)-Research Center Molecular Physiology of the Brain; DFG-SPP [1172]; DFG-Transregio [TRR43]; European Union (EU) [FP7-202167 NeuroGLIA, FP7-ITN-237956 EdU-Glia]; Research Initiative in Membrane Biology University of Kaiserslautern; Dutch Organization for Medical Sciences; Life Sciences; Fund for Economic Structure Reinforcement (NeuroBasic); Prinses Beatrix Fonds; EU ERCadvanced, CEREBNET program; EU C7 program;  [DFG-SFB870];  [DFG-SFB894];  [R01-DC006881]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006881] Funding Source: NIH RePORTER	Max-Planck Society (INSERM-AMIGO); Deutsche Forschungsgemeinschaft (DFG)-Research Center Molecular Physiology of the Brain(German Research Foundation (DFG)); DFG-SPP(German Research Foundation (DFG)); DFG-Transregio(German Research Foundation (DFG)); European Union (EU)(CGIAREuropean Commission); Research Initiative in Membrane Biology University of Kaiserslautern; Dutch Organization for Medical Sciences; Life Sciences(European Commission); Fund for Economic Structure Reinforcement (NeuroBasic); Prinses Beatrix Fonds; EU ERCadvanced, CEREBNET program; EU C7 program; ; ; ; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank K.-A. Nave for continuous support, S. Rudolph and P. G. Hirrlinger for early contributions, T. Ruhwedel and F. Rhode for technical assistance, and D. Rhode and C. Casper for animal husbandry. This work was supported by the Max-Planck Society (INSERM-AMIGO, F. K.); Deutsche Forschungsgemeinschaft (DFG)-Research Center Molecular Physiology of the Brain (F. K.); DFG-SPP 1172 (F. K. and J.W.D.); DFG-SFB870 (M. G.); DFG-SFB894 (F. K.); DFG-Transregio TRR43 (F. K.); European Union (EU)-FP7-202167 NeuroGLIA (F. K.) and FP7-ITN-237956 EdU-Glia (F. K.); R01-DC006881 (M. E. R.); the Research Initiative in Membrane Biology University of Kaiserslautern (J.W.D.); the Dutch Organization for Medical Sciences (C.I.D.Z.); Life Sciences (C.I.D.Z.); Fund for Economic Structure Reinforcement (NeuroBasic; C.I.D.Z.); Prinses Beatrix Fonds (C.I.D.Z.); and the EU ERCadvanced, CEREBNET, and C7 programs (C.I.D.Z.).	BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; De Zeeuw CI, 2011, NAT REV NEUROSCI, V12, P327, DOI 10.1038/nrn3011; Fuchs EC, 2007, NEURON, V53, P591, DOI 10.1016/j.neuron.2007.01.031; Grosche J, 1999, NAT NEUROSCI, V2, P139, DOI 10.1038/5692; Hirai H, 2005, NAT NEUROSCI, V8, P1534, DOI 10.1038/nn1576; Koekkoek SKE, 2003, SCIENCE, V301, P1736, DOI 10.1126/science.1088383; Lavialle M, 2011, P NATL ACAD SCI USA, V108, P12915, DOI 10.1073/pnas.1100957108; Lino M, 2001, SCIENCE, V292, P926, DOI 10.1126/science.1058827; Matsui K, 2005, J NEUROSCI, V25, P7538, DOI 10.1523/JNEUROSCI.1927-05.2005; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; Mori T, 2006, GLIA, V54, P21, DOI 10.1002/glia.20350; MULLER T, 1992, SCIENCE, V256, P1563, DOI 10.1126/science.1317969; Perea G, 2009, TRENDS NEUROSCI, V32, P421, DOI 10.1016/j.tins.2009.05.001; Person AL, 2012, NATURE, V481, P502, DOI 10.1038/nature10732; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Van Der Giessen RS, 2008, NEURON, V58, P599, DOI 10.1016/j.neuron.2008.03.016; Verkhratsky A, 2007, J ANAT, V210, P651, DOI 10.1111/j.1469-7580.2007.00734.x; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805	20	126	127	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 10	2012	337	6095					749	753		10.1126/science.1221140	http://dx.doi.org/10.1126/science.1221140			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986PE	22767895				2022-12-28	WOS:000307354500059
J	Jonsson, T; Atwal, JK; Steinberg, S; Snaedal, J; Jonsson, PV; Bjornsson, S; Stefansson, H; Sulem, P; Gudbjartsson, D; Maloney, J; Hoyte, K; Gustafson, A; Liu, YC; Lu, YM; Bhangale, T; Graham, RR; Huttenlocher, J; Bjornsdottir, G; Andreassen, OA; Jonsson, EG; Palotie, A; Behrens, TW; Magnusson, OT; Kong, A; Thorsteinsdottir, U; Watts, RJ; Stefansson, K				Jonsson, Thorlakur; Atwal, Jasvinder K.; Steinberg, Stacy; Snaedal, Jon; Jonsson, Palmi V.; Bjornsson, Sigurbjorn; Stefansson, Hreinn; Sulem, Patrick; Gudbjartsson, Daniel; Maloney, Janice; Hoyte, Kwame; Gustafson, Amy; Liu, Yichin; Lu, Yanmei; Bhangale, Tushar; Graham, Robert R.; Huttenlocher, Johanna; Bjornsdottir, Gyda; Andreassen, Ole A.; Jonsson, Erik G.; Palotie, Aarno; Behrens, Timothy W.; Magnusson, Olafur T.; Kong, Augustine; Thorsteinsdottir, Unnur; Watts, Ryan J.; Stefansson, Kari			A mutation in APP protects against Alzheimer's disease and age-related cognitive decline	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; IDENTIFICATION; PURIFICATION; PREVALENCE; IMPUTATION; DEMENTIA; CLEAVAGE; GENE; BACE	The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer's disease(1-4). The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-beta precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease. This substitution is adjacent to the aspartyl protease beta-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the beta-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.	[Jonsson, Thorlakur; Steinberg, Stacy; Stefansson, Hreinn; Sulem, Patrick; Gudbjartsson, Daniel; Huttenlocher, Johanna; Bjornsdottir, Gyda; Magnusson, Olafur T.; Kong, Augustine; Thorsteinsdottir, Unnur; Stefansson, Kari] deCODE Genet, IS-101 Reykjavik, Iceland; [Atwal, Jasvinder K.; Maloney, Janice; Hoyte, Kwame; Gustafson, Amy; Liu, Yichin; Lu, Yanmei; Bhangale, Tushar; Graham, Robert R.; Behrens, Timothy W.; Watts, Ryan J.] Genentech Inc, San Francisco, CA 94080 USA; [Snaedal, Jon; Jonsson, Palmi V.; Bjornsson, Sigurbjorn] Landspitali Univ Hosp, Dept Geriatr, IS-101 Reykjavik, Iceland; [Huttenlocher, Johanna] Inst Human Genet, Dept Med Genet, D-72026 Tubingen, Germany; [Andreassen, Ole A.] Univ Oslo, Ulleval Univ Hosp, Dept Psychiat, N-0407 Oslo, Norway; [Andreassen, Ole A.] Univ Oslo, Inst Psychiat, N-0407 Oslo, Norway; [Jonsson, Erik G.] Karolinska Hosp & Inst, HUBIN Project, Dept Clin Neurosci, SE-17176 Stockholm, Sweden; [Palotie, Aarno] Univ Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; [Jonsson, Palmi V.; Thorsteinsdottir, Unnur; Stefansson, Kari] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland	Roche Holding; Genentech; Landspitali National University Hospital; Eberhard Karls University of Tubingen; University of Oslo; University of Oslo; Karolinska Institutet; Karolinska University Hospital; University of Helsinki; University of Iceland	Stefansson, K (corresponding author), deCODE Genet, Sturlugata 8, IS-101 Reykjavik, Iceland.	kstefans@decode.is	Andreassen, Ole A./AAY-7531-2020; Stefansson, Kari/AAE-7187-2019	Stefansson, Hreinn/0000-0002-9331-6666; Gudbjartsson, Daniel/0000-0002-5222-9857; Andreassen, Ole A./0000-0002-4461-3568; Bjornsdottir, Gyda/0000-0002-8100-0306; Palotie, Aarno/0000-0002-2527-5874; Jonsson, Erik/0000-0001-8368-6332; Kong, Augustine/0000-0001-8193-5438	Lung GO Sequencing Project [HL-102923]; WHI Sequencing Project [HL-102924]; Broad GO Sequencing Project [HL-102925]; Seattle GO Sequencing Project [HL-102926]; Heart GO Sequencing Project [HL-103010]	Lung GO Sequencing Project; WHI Sequencing Project; Broad GO Sequencing Project; Seattle GO Sequencing Project; Heart GO Sequencing Project	We would like to thank the NHLBI GO Exome Sequencing Project and its ongoing studies, which produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010).	CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cruchaga C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031039; Cruts M, 2012, ALZHEIMERS DIS FRONT; Di Fede G, 2009, SCIENCE, V323, P1473, DOI 10.1126/science.1168979; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Giaccone G, 2010, ACTA NEUROPATHOL, V120, P803, DOI 10.1007/s00401-010-0747-1; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Hardy J, 2010, APP MUTATIONS TABLE; Holm H, 2011, NAT GENET, V43, P316, DOI 10.1038/ng.781; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kong A, 2008, NAT GENET, V40, P1068, DOI 10.1038/ng.216; Kong A, 2010, NATURE, V467, P1099, DOI 10.1038/nature09525; Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; NHLBI Exome Sequencing Project (ESP), 2012, EX VAR SERV; PEACOCK ML, 1993, NEUROLOGY, V43, P1254, DOI 10.1212/WNL.43.6.1254; Plassman BL, 2007, NEUROEPIDEMIOLOGY, V29, P125, DOI 10.1159/000109998; Qiu Chengxuan, 2009, Dialogues Clin Neurosci, V11, P111; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI [10.1038/nrneurol.2011.2, 10.1101/cshperspect.a006239]; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; Sulem P, 2011, NAT GENET, V43, P1127, DOI 10.1038/ng.972; Tomasselli AG, 2003, J NEUROCHEM, V84, P1006, DOI 10.1046/j.1471-4159.2003.01597.x; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhang YW, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-3	28	1142	1195	8	319	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 2	2012	488	7409					96	99		10.1038/nature11283	http://dx.doi.org/10.1038/nature11283			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981ZE	22801501				2022-12-28	WOS:000307010700040
J	Wilson, TR; Fridlyand, J; Yan, YB; Penuel, E; Burton, L; Chan, E; Peng, J; Lin, E; Wang, YL; Sosman, J; Ribas, A; Li, J; Moffat, J; Sutherlin, DP; Koeppen, H; Merchant, M; Neve, R; Settleman, J				Wilson, Timothy R.; Fridlyand, Jane; Yan, Yibing; Penuel, Elicia; Burton, Luciana; Chan, Emily; Peng, Jing; Lin, Eva; Wang, Yulei; Sosman, Jeff; Ribas, Antoni; Li, Jiang; Moffat, John; Sutherlin, Daniel P.; Koeppen, Hartmut; Merchant, Mark; Neve, Richard; Settleman, Jeff			Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors	NATURE			English	Article							RECEPTOR TYROSINE KINASES; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; MET AMPLIFICATION; TUMOR-CELLS; SENSITIVITY; SURVIVAL; THERAPY; HETEROGENEITY; ACTIVATION	Mutationally activated kinases define a clinically validated class of targets for cancer drug therapy(1). However, the efficacy of kinase inhibitors in patients whose tumours harbour such alleles is invariably limited by innate or acquired drug resistance(2,3). The identification of resistance mechanisms has revealed a recurrent theme-the engagement of survival signals redundant to those transduced by the targeted kinase(4). Cancer cells typically express multiple receptor tyrosine kinases (RTKs) that mediate signals that converge on common critical downstream cell-survival effectors-most notably, phosphatidylinositol-3-OH kinase (PI(3)K) and mitogen-activated protein kinase (MAPK)(5). Consequently, an increase in RTK-ligand levels, through autocrine tumour-cell production, paracrine contribution from tumour stroma(6) or systemic production, could confer resistance to inhibitors of an oncogenic kinase with a similar signalling output. Here, using a panel of kinase-'addicted' human cancer cell lines, we found that most cells can be rescued from drug sensitivity by simply exposing them to one or more RTK ligands. Among the findings with clinical implications was the observation that hepatocyte growth factor(HGF) confers resistance to the BRAF inhibitor PLX4032 (vemurafenib) in BRAF-mutant melanoma cells. These observations highlight the extensive redundancy of RTK-transduced signalling in cancer cells and the potentially broad role of widely expressed RTK ligands in innate and acquired resistance to drugs targeting oncogenic kinases.	[Wilson, Timothy R.; Chan, Emily; Peng, Jing; Lin, Eva; Merchant, Mark; Neve, Richard; Settleman, Jeff] Genentech Inc, Res Oncol, San Francisco, CA 94080 USA; [Fridlyand, Jane] Genentech Inc, Biostatast, San Francisco, CA 94080 USA; [Yan, Yibing; Penuel, Elicia; Burton, Luciana; Wang, Yulei] Genentech Inc, Dev Sci, San Francisco, CA 94080 USA; [Sosman, Jeff] Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Nashville, TN 37232 USA; [Ribas, Antoni] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Li, Jiang] Roche Nutley, Med Dev Biometr Biostat, Nutley, NJ 07110 USA; [Moffat, John] Genentech Inc, Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA; [Sutherlin, Daniel P.] Genentech Inc, Discovery Chem, San Francisco, CA 94080 USA; [Koeppen, Hartmut] Genentech Inc, Res Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Vanderbilt University; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Settleman, J (corresponding author), Genentech Inc, Res Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	settleman.jeffrey@gene.com	Wilson, Timothy R/F-8210-2012	Wang, Yulei/0000-0002-9057-9786; Merchant, Mark/0000-0003-0690-8581	NCI NIH HHS [K24 CA097588] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K24CA097588] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Calbo J, 2011, CANCER CELL, V19, P244, DOI 10.1016/j.ccr.2010.12.021; Catenacci DVT, 2011, CANCER DISCOV, V1, P573, DOI 10.1158/2159-8290.CD-11-0175; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Engelman JA, 2008, CURR OPIN GENET DEV, V18, P73, DOI 10.1016/j.gde.2008.01.004; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Garrett JT, 2011, CANCER BIOL THER, V11, P793, DOI 10.4161/cbt.11.9.15045; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Liang K, 2010, CANCER CELL, V18, P423, DOI 10.1016/j.ccr.2010.10.025; Liederer BM, 2011, XENOBIOTICA, V41, P327, DOI 10.3109/00498254.2010.542500; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; McDermott U, 2007, P NATL ACAD SCI USA, V104, P19936, DOI 10.1073/pnas.0707498104; McDermott U, 2010, CANCER RES, V70, P1625, DOI 10.1158/0008-5472.CAN-09-3620; Moritz A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000998; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Straussman R., 2012, NATURE; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Wilson TR, 2011, CANCER CELL, V20, P158, DOI 10.1016/j.ccr.2011.07.011; Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957; Zhang W, 2011, CANCER BIOL THER, V11, P150, DOI 10.4161/cbt.11.2.14623	29	879	920	5	123	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 26	2012	487	7408					505	U1652		10.1038/nature11249	http://dx.doi.org/10.1038/nature11249			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979KD	22763448	Green Accepted			2022-12-28	WOS:000306815300043
J	Steinbrook, R				Steinbrook, Robert			HIV/AIDS in 1990 and 2012 From San Francisco to Washington, DC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University	Steinbrook, R (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,I-456 SHM,POB 208008, New Haven, CT 06520 USA.	rsteinbrook@attglobal.net						[Anonymous], 1981, MORBIDITY MORTALITY, V30, P250; Centers for Disease Control and Prevention (CDC), 2012, FACT SHEET HIV US GL; Emanuel EJ, 2012, JAMA-J AM MED ASSOC, V307, P2097, DOI 10.1001/jama.2012.4989; Joint United Nations Programme on HIV/AIDS (UNAIDS), HIV REL RESTR ENTR S; Steinbrook R., 1990, LOS ANGELES TIMES, pA1; Steinbrook R, 2007, NEW ENGL J MED, V357, P2653, DOI 10.1056/NEJMp0708117; Torian Lucia, 2011, Morbidity and Mortality Weekly Report, V60, P689; UNAIDS, 2011, 10 TARG 2011 UN GEN; Wachter RM., 1991, FRAGILE COALITION; World Health Organization, 2011, GLOB HIV AIDS RESP P	10	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					345	346		10.1001/jama.2012.7855	http://dx.doi.org/10.1001/jama.2012.7855			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820784				2022-12-28	WOS:000306685500019
J	Hallal, PC; Bauman, AE; Heath, GW; Kohl, HW; Lee, IM; Pratt, M				Hallal, Pedro C.; Bauman, Adrian E.; Heath, Gregory W.; Kohl, Harold W., III; Lee, I-Min; Pratt, Michael			Physical activity: more of the same is not enough	LANCET			English	Editorial Material							HEALTH		[Hallal, Pedro C.] Univ Fed Pelotas, BR-96030002 Pelotas, Brazil; [Bauman, Adrian E.] Univ Sydney, Sch Publ Hlth, Prevent Res Collaborat, Sydney, NSW 2006, Australia; [Heath, Gregory W.] Univ Tennessee, Coll Med, Chattanooga, TN USA; [Kohl, Harold W., III] Univ Texas Hlth Sci Ctr, Houston Sch Publ Hlth, Austin, TX USA; [Kohl, Harold W., III] Univ Texas Austin, Dept Kinesiol & Hlth Educ, Austin, TX 78712 USA; [Lee, I-Min] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA USA; [Pratt, Michael] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA	Universidade Federal de Pelotas; University of Sydney; University of Tennessee System; University of Tennessee Health Science Center; University of Texas System; University of Texas Austin; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Centers for Disease Control & Prevention - USA	Hallal, PC (corresponding author), Univ Fed Pelotas, BR-96030002 Pelotas, Brazil.	prchallal@terra.com.br	Lee, I-Min/ABD-5409-2021; Heath, Gregory Wayne/AAE-2464-2020; Hallal, Pedro C/A-3249-2011	Heath, Gregory Wayne/0000-0003-2864-5225; Hallal, Pedro C/0000-0003-1470-6461				Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; International Olympic Committee, 2006, 2006 HAV SPORT ALL D; MORRIS JN, 1953, LANCET, V265, P1053; Mountjoy M, 2011, BRIT J SPORT MED, V45, P839, DOI 10.1136/bjsports-2011-090228; Physical Activity Guidelines Advisory Committee, 2008, PHYS ACT GUID ADV CO; UN, 2011, 2011 HIGH LEV M PREV; Wen CP, 2011, LANCET, V378, P1244, DOI 10.1016/S0140-6736(11)60749-6; WHO, 2010, GLOB REC PHYS ACT HL, V1st, P15; WHO, 2011, PHYS IN GLOB PUBL HL	9	108	113	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2012	380	9838					190	191		10.1016/S0140-6736(12)61027-7	http://dx.doi.org/10.1016/S0140-6736(12)61027-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976TV	22818932				2022-12-28	WOS:000306609200005
J	Pratt, M; Sarmiento, OL; Montes, F; Ogilvie, D; Marcus, BH; Perez, LG; Brownson, RC				Pratt, Michael; Sarmiento, Olga L.; Montes, Felipe; Ogilvie, David; Marcus, Bess H.; Perez, Lilian G.; Brownson, Ross C.		Lancet Phys Activity Series Workin	The implications of megatrends in information and communication technology and transportation for changes in global physical activity	LANCET			English	Article							WEB-BASED INTERVENTION; PUBLIC-HEALTH; ACTIVITY BEHAVIOR; PROMOTE WALKING; INTERNET; TRANSIT; EQUITY; CAR; DETERMINANTS; PREVENTION	Physical inactivity accounts for more than 3 million deaths per year, most from non-communicable diseases in low-income and middle-income countries. We used reviews of physical activity interventions and a simulation model to examine how megatrends in information and communication technology and transportation directly and indirectly affect levels of physical activity across countries of low, middle, and high income. The model suggested that the direct and potentiating effects of information and communication technology, especially mobile phones, are nearly equal in magnitude to the mean effects of planned physical activity interventions. The greatest potential to increase population physical activity might thus be in creation of synergistic policies in sectors outside health including communication and transportation. However, there remains a glaring mismatch between where studies on physical activity interventions are undertaken and where the potential lies in low-income and middle-income countries for population-level effects that will truly affect global health.	[Pratt, Michael; Perez, Lilian G.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; [Pratt, Michael; Sarmiento, Olga L.] Univ Los Andes, Sch Med, CEIBA Complex Syst Res Ctr, Bogota, Colombia; [Montes, Felipe] Univ Los Andes, CEIBA Complex Syst Res Ctr, Dept Ind Engn, Bogota, Colombia; [Ogilvie, David] Inst Publ Hlth, MRC Epidemiol Unit, Cambridge, England; [Ogilvie, David] Inst Publ Hlth, UKCRC Ctr Diet & Act Res, Cambridge, England; [Marcus, Bess H.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; [Brownson, Ross C.] Washington Univ, Prevent Res Ctr St Louis, Brown Sch, St Louis, MO USA; [Brownson, Ross C.] Washington Univ, Sch Med, Div Publ Hlth Sci, St Louis, MO USA	Centers for Disease Control & Prevention - USA; CEIBA; Universidad de los Andes (Colombia); CEIBA; Universidad de los Andes (Colombia); University of Cambridge; University of Cambridge; University of California System; University of California San Diego; Washington University (WUSTL); Washington University (WUSTL)	Pratt, M (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.	mpratt@cdc.gov	Montes, Felipe/AAV-3051-2020; Kahlmeier, Sonja/B-8141-2014; Sarmiento, Olga L/AAS-4165-2020; lobelo, felipe/B-9148-2013; Reis, Rodrigo/F-7447-2012; Martin, Brian W/H-3241-2012; Lambert, Estelle/ABF-1268-2020; Parra, Diana/D-7633-2013; Katzmarzyk, Peter/N-1974-2017; Loos, Ruth/Q-2862-2016; Wells, Jonathan/A-4604-2009; Owen, Neville/K-5986-2012; Sallis, James F/D-3001-2014	Montes, Felipe/0000-0002-9923-4004; Kahlmeier, Sonja/0000-0001-6905-9244; Sarmiento, Olga L/0000-0002-9190-3568; Reis, Rodrigo/0000-0002-9872-9865; Lambert, Estelle/0000-0003-4315-9153; Parra, Diana/0000-0002-9797-6231; Guthold, Regina/0000-0003-3073-6468; Goenka, Shifalika/0000-0001-6993-2883; Katzmarzyk, Peter/0000-0002-9280-6022; Loos, Ruth/0000-0002-8532-5087; Wells, Jonathan/0000-0003-0411-8025; Owen, Neville/0000-0003-2784-4820; Ogilvie, David/0000-0002-0270-4672; Sallis, James F/0000-0003-2555-9452	Coca Cola Company; International Union for Health Promotion and Education; Centre for Diet and Activity Research; UKCRC Public Health Research Centre of Excellence; British Heart Foundation; Economic and Social Research Council; Medical Research Council; National Institute for Health Research; Wellcome Trust; UK Clinical Research Collaboration; Center for Interdisciplinary Studies in Basic and Applied Complexity; CeiBA (Bogota, Colombia) [519 2010]; CDC Prevention Research Center's programme [U48/DP001903]; ESRC [ES/G007462/1] Funding Source: UKRI; MRC [MC_U106188470, MC_U106179474] Funding Source: UKRI; Economic and Social Research Council [ES/G007462/1] Funding Source: researchfish; Medical Research Council [MC_U106188470, MC_U106179474] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P50CA095815] Funding Source: NIH RePORTER; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [U48DP000060, U48DP001903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK092950] Funding Source: NIH RePORTER	Coca Cola Company; International Union for Health Promotion and Education; Centre for Diet and Activity Research; UKCRC Public Health Research Centre of Excellence; British Heart Foundation(British Heart Foundation); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome Trust); UK Clinical Research Collaboration; Center for Interdisciplinary Studies in Basic and Applied Complexity; CeiBA (Bogota, Colombia); CDC Prevention Research Center's programme(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention (CDC). We thank Andres Medaglia Gonzalez and Roberto Zarama for their mentoring support and Carlos Grijalba, Carlos Pedraza, and Andrea Ramirez for their contributions to the systematic search (Universidad de los Andes, Bogota, Colombia), and Britta Larsen (University of California San Diego, San Diego, CA, USA) and Madalena Soares (CDC) for their assistance with the report; several organisations that have provided grant support to one or more of the authors and their research teams: the Coca Cola Company (unrestricted training grant to the CDC Foundation in support of the work of MP, LGP, and Madalena Soares); the International Union for Health Promotion and Education (partial support of in-person writing meetings in Atlanta, GA, USA, and Rio de Janeiro, Brazil); the Centre for Diet and Activity Research, a UKCRC Public Health Research Centre of Excellence funded by the British Heart Foundation, Economic and Social Research Council, Medical Research Council, National Institute for Health Research, and the Wellcome Trust under the auspices of the UK Clinical Research Collaboration (support of DO); the Center for Interdisciplinary Studies in Basic and Applied Complexity, CeiBA (Bogota, Colombia; Colciencias grant 519 2010, support of FM); and the CDC Prevention Research Center's programme contract U48/DP001903 (Applying Evidence-Physical Activity Recommendations in Brazil) for support of RCB.	Acemoglu D, 2006, AM POLIT SCI REV, V100, P115, DOI 10.1017/S0003055406062046; Acemoglu D, 2000, AM ECON REV, V90, P126, DOI 10.1257/aer.90.2.126; Acemoglu D, 2010, WHY NATIONS FAIL; Adams J, 1999, PROJ ENV SUST TRANSP; Anderson-Bill ES, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1614; Bauman A, 2008, OBES REV, V9, P119, DOI 10.1111/j.1467-789X.2007.00452.x; Bell AC, 2002, OBES RES, V10, P277, DOI 10.1038/oby.2002.38; Besser LM, 2005, AM J PREV MED, V29, P273, DOI 10.1016/j.amepre.2005.06.010; Brand C, 2008, ENERG POLICY, V36, P224, DOI 10.1016/j.enpol.2007.08.016; Braveman P, 2003, J EPIDEMIOL COMMUN H, V57, P254, DOI 10.1136/jech.57.4.254; Brownson R. C., 2011, EVIDENCE BASED PUBLI; Brownson RC, 2009, ANNU REV PUBL HEALTH, V30, P175, DOI 10.1146/annurev.publhealth.031308.100134; Buis LR, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-331; Cervero R, 2009, INT J SUSTAIN TRANSP, V3, P203, DOI 10.1080/15568310802178314; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Conn VS, 2011, AM J PUBLIC HEALTH, V101, P751, DOI 10.2105/AJPH.2010.194381; Craig P, 2012, J EPIDEMIOL COMMUN H, V66, P1182, DOI 10.1136/jech-2011-200375; Cuijpers P, 2005, EUR J PUBLIC HEALTH, V15, P166, DOI 10.1093/eurpub/cki124; De Hartog J, 2010, ENV HLTH PERSPECT, V118, P8; *DEP TRANSP, 2006, TRANSP STAT B NAT TR; Dora C, 1999, BRIT MED J, V318, P1686, DOI 10.1136/bmj.318.7199.1686; Ellaway A., 2003, TRANSP RES F, V6, P217, DOI DOI 10.1016/S1369-8478(03)00027-5; Ferney SL, 2009, PREV MED, V48, P144, DOI 10.1016/j.ypmed.2008.10.022; Fjeldsoe BS, 2009, MED SCI SPORT EXER, V41, P1020, DOI 10.1249/MSS.0b013e31819461c2; Fox Susannah, 2011, SOCIAL LIFE HLTH INF; Garcia R, 2009, PREV MED, V49, P330, DOI 10.1016/j.ypmed.2009.07.016; Gastner MT, 2004, P NATL ACAD SCI USA, V101, P7499, DOI 10.1073/pnas.0400280101; Global Mobile Statistics, 2011, GLOBAL MOBILE STAT; Gomez LF, 2010, J PHYS ACT HEALTH, V7, pS196, DOI 10.1123/jpah.7.s2.s196; Goodman A, 2012, SOC SCI MED, V74, P1929, DOI 10.1016/j.socscimed.2012.01.042; Gordon-Larsen P, 2006, PEDIATRICS, V117, P417, DOI 10.1542/peds.2005-0058; Green LW, 2009, ANNU REV PUBL HEALTH, V30, P151, DOI 10.1146/annurev.publhealth.031308.100049; Green LW, 2006, EVAL HEALTH PROF, V29, P126, DOI 10.1177/0163278705284445; Grim M, 2011, AM J HEALTH PROMOT, V25, P227, DOI 10.4278/ajhp.081216-ARB-307; Heath GW, 2012, LANCET; Hoehner CM, 2008, AM J PREV MED, V34, P224, DOI 10.1016/j.amepre.2007.11.016; Illich I, 1974, IND TRAFFIC ENERGY E; Irvine AB, 2011, AM J HEALTH PROMOT, V25, P199, DOI 10.4278/ajhp.04121736; Kalba K., 2008, GLOBAL ADOPTION DIFF; Kaplan WA, 2006, GLOBALIZATION HEALTH, V2, DOI 10.1186/1744-8603-2-9; Kelders SM, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1624; Keniston Kenneth., 2003, 4 DIGITAL DIVIDES; Kling R., 1998, TECHNOLOGICAL SOCIAL; Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6; Lopez Russell P, 2006, Environ Health, V5, P25, DOI 10.1186/1476-069X-5-25; MacDonald JM, 2010, AM J PREV MED, V39, P105, DOI 10.1016/j.amepre.2010.03.016; Main C, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-178; Marcus BH, 2007, ARCH INTERN MED, V167, P944, DOI 10.1001/archinte.167.9.944; Marmot M, 2008, LANCET, V372, P1661, DOI 10.1016/S0140-6736(08)61690-6; Marshall AL, 2003, AM J PREV MED, V25, P88, DOI 10.1016/S0749-3797(03)00111-9; Massoudi BL, 2010, J BIOMED INFORM, V43, pS41, DOI 10.1016/j.jbi.2010.07.012; McCarthy M., 1999, SOCIAL DETERMINANTS; Milner HV, 2006, COMP POLIT STUD, V39, P176, DOI 10.1177/0010414005282983; Miranda JJ, 2008, TROP MED INT HEALTH, V13, P1225, DOI 10.1111/j.1365-3156.2008.02116.x; Montes F, 2012, J URBAN HEALTH, V89, P153, DOI 10.1007/s11524-011-9628-8; Norman GJ, 2007, AM J PREV MED, V33, P336, DOI 10.1016/j.amepre.2007.05.007; Ogilvie D, 2005, J EPIDEMIOL COMMUN H, V59, P886, DOI 10.1136/jech.2005.034199; Ogilvie D, 2007, BMJ-BRIT MED J, V334, P1204, DOI 10.1136/bmj.39198.722720.BE; Ogilvie D, 2011, AM J PUBLIC HEALTH, V101, P473, DOI 10.2105/AJPH.2010.198002; Ogilvie D, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-703; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; Organization WH, 2009, GLOB HLTH RISKS MORT; Parente S., 2002, BARRIERS RICHES; Petticrew M, 2005, PUBLIC HEALTH, V119, P751, DOI 10.1016/j.puhe.2004.11.008; Plotnikoff RC, 2010, AM J HEALTH PROMOT, V24, P255, DOI 10.4278/ajhp.08032830; Porta M, 2008, DICT EPIDEMIOLOGY; Pressler A, 2010, PREV MED, V51, P234, DOI 10.1016/j.ypmed.2010.07.008; Pucher J, 2007, TRANSPORT REV, V27, P379, DOI 10.1080/01441640601089988; Pucher J, 2010, PREV MED, V50, pS106, DOI 10.1016/j.ypmed.2009.07.028; Rabl A, 2012, TRANSPORT POLICY, V19, P121, DOI 10.1016/j.tranpol.2011.09.008; Rhodes RE, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-37; Rice RE, 2003, TELECOMMUN POLICY, V27, P597, DOI 10.1016/S0308-5961(03)00068-5; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Rychetnik L, 2004, J EPIDEMIOL COMMUN H, V58, P538, DOI 10.1136/jech.2003.011585; Sallis JE, 2006, ANNU REV PUBL HEALTH, V27, P297, DOI 10.1146/annurev.publhealth.27.021405.102100; Sallis JF, 2004, TRANSPORT RES A-POL, V38, P249, DOI 10.1016/j.tra.2003.11.003; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; Sonkin B, 2006, J ROY SOC MED, V99, P402, DOI 10.1258/jrsm.99.8.402; Steele Rebekah, 2007, J Phys Act Health, V4, P245; Taylor Wendell C, 2007, J Phys Act Health, V4 Suppl 1, pS50; Transport, 2010, TRANSP SOC TRENDS; van den Berg MH, 2007, J MED INTERNET RES, V9, DOI 10.2196/jmir.9.3.e26; Vandelanotte C, 2007, AM J PREV MED, V33, P54, DOI 10.1016/j.amepre.2007.02.041; Villanueva K, 2008, PREV MED, V47, P338, DOI 10.1016/j.ypmed.2008.03.005; Vital Wave Consulting, 2009, MHEALTH DEV OPP MOB; Wanner M, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1179; Wener RE, 2007, ENVIRON BEHAV, V39, P62, DOI 10.1177/0013916506295571; WHO, 2009, 2008 2012 ACT PLAN G; WHO, 2010, GLOB REC PHYS ACT HL, V1st, P15; Woodcock J, 2009, LANCET, V374, P1930, DOI 10.1016/S0140-6736(09)61714-1; World Bank, 2011, WORLD DEVELOPMENT REPORT 2011: CONFLICT, SECURITY AND DEVELOPMENT, P1, DOI 10.1596/978-0-8213-8439-8; World Health Organization, 2004, GLOB STRAT DIET PHYS; World Health Organization (WHO), 2011, POL DECL HIGH LEV M; Yach D, 2004, JAMA-J AM MED ASSOC, V291, P2616, DOI 10.1001/jama.291.21.2616; Yang L, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5293; Zarama R, CICLOVIAS CICL UNPUB; Zaza S, 2005, GUIDE COMMUNITY PREV	97	173	179	1	77	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2012	380	9838					282	293		10.1016/S0140-6736(12)60736-3	http://dx.doi.org/10.1016/S0140-6736(12)60736-3			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976TV	22818940	Green Submitted, Green Published, Green Accepted			2022-12-28	WOS:000306609200037
J	Wang, JB; Fan, HC; Behr, B; Quake, SR				Wang, Jianbin; Fan, H. Christina; Behr, Barry; Quake, Stephen R.			Genome-wide Single-Cell Analysis of Recombination Activity and De Novo Mutation Rates in Human Sperm	CELL			English	Article							HOT-SPOTS; GENE; EVOLUTION; PATTERNS; CROSSOVERS; HOTSPOTS; REGIONS; PRDM9	Meiotic recombination and de novo mutation are the two main contributions toward gamete genome diversity, and many questions remain about how an individual human's genome is edited by these two processes. Here, we describe a high-throughput method for single-cell whole-genome analysis that was used to measure the genomic diversity in one individual's gamete genomes. A microfluidic system was used for highly parallel sample processing and to minimize nonspecific amplification. High-density genotyping results from 91 single cells were used to create a personal recombination map, which was consistent with population-wide data at low resolution but revealed significant differences from pedigree data at higher resolution. We used the data to test for meiotic drive and found evidence for gene conversion. High-throughput sequencing on 31 single cells was used to measure the frequency of large-scale genome instability, and deeper sequencing of eight single cells revealed de novo mutation rates with distinct characteristics.	[Wang, Jianbin; Fan, H. Christina; Quake, Stephen R.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Behr, Barry] Stanford Univ, Dept Obstet, Stanford, CA 94305 USA; [Behr, Barry] Stanford Univ, Dept Gynecol, Stanford, CA 94305 USA; [Quake, Stephen R.] Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; [Quake, Stephen R.] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Quake, SR (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.	quake@stanford.edu	t, lf/AAJ-4924-2020; Wang, Jianbin/G-7533-2015	Wang, Jianbin/0000-0001-6725-7925	CCNE-T; NCI-NIH [U54CA151459]; Chinese Scholarship Council; Siebel Foundation; NATIONAL CANCER INSTITUTE [U54CA151459] Funding Source: NIH RePORTER	CCNE-T; NCI-NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Chinese Scholarship Council(China Scholarship Council); Siebel Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Jessica Melin and the Stanford Microfluidic Foundry for fabrication of the microfluidic devices. We thank Janice Gebhardt and the Stanford IVF Laboratory for semen sample processing. We thank Norma Neff, Gary Mantalas, and Ben Passarelli for assistance in sequencing experiments and data processing. We also thank Jad Kanbar for help with PCR experiments. The project was supported by CCNE-T, a grant funded by NCI-NIH (grant number U54CA151459). J.W. was supported by a scholarship from the Chinese Scholarship Council. H.C.F was supported by a scholarship from the Siebel Foundation.	Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Ashley EA, 2010, LANCET, V375, P1525, DOI 10.1016/S0140-6736(10)60452-7; Baudat F, 2010, SCIENCE, V327, P836, DOI 10.1126/science.1183439; Blainey PC, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1074; Cheung VG, 2007, AM J HUM GENET, V80, P526, DOI 10.1086/512131; Conrad DF, 2011, NAT GENET, V43, P712, DOI 10.1038/ng.862; Coop G, 2008, SCIENCE, V319, P1395, DOI 10.1126/science.1151851; Crow JF, 2000, NAT REV GENET, V1, P40, DOI 10.1038/35049558; Fan HC, 2011, NAT BIOTECHNOL, V29, P51, DOI 10.1038/nbt.1739; Gay J, 2007, GENETICS, V177, P881, DOI 10.1534/genetics.107.078907; Hou Y, 2012, CELL, V148, P873, DOI 10.1016/j.cell.2012.02.028; Jeffreys AJ, 2005, NAT GENET, V37, P601, DOI 10.1038/ng1565; Kong A, 2008, SCIENCE, V319, P1398, DOI 10.1126/science.1152422; Kong A, 2010, NATURE, V467, P1099, DOI 10.1038/nature09525; Levy S, 2007, PLOS BIOL, V5, P2113, DOI 10.1371/journal.pbio.0050254; Li J, 2012, PLOS GENET, V8, P201, DOI [10.1371/journal.pgen.1002692, 10.1371/journal.pgen.1002630]; Luetjens CM, 2002, HUM REPROD, V17, P1826, DOI 10.1093/humrep/17.7.1826; Macklon NS, 2002, HUM REPROD UPDATE, V8, P333, DOI 10.1093/humupd/8.4.333; Makova KD, 2002, NATURE, V416, P624, DOI 10.1038/416624a; Mancera E, 2008, NATURE, V454, P479, DOI 10.1038/nature07135; Marcy Y, 2007, PLOS GENET, V3, P1702, DOI 10.1371/journal.pgen.0030155; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Myers S, 2005, SCIENCE, V310, P321, DOI 10.1126/science.1117196; Myers S, 2008, NAT GENET, V40, P1124, DOI 10.1038/ng.213; Myers S, 2010, SCIENCE, V327, P876, DOI 10.1126/science.1182363; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Pushkarev D, 2009, NAT BIOTECHNOL, V27, P847, DOI 10.1038/nbt.1561; Quelin C, 2009, EUR J MED GENET, V52, P41, DOI 10.1016/j.ejmg.2008.10.002; Sun F, 2004, AM J HUM GENET, V74, P521, DOI 10.1086/382138; Tiemann-Boege I, 2006, PLOS GENET, V2, P682, DOI 10.1371/journal.pgen.0020070; Wang JYJ, 2006, CANCER CELL, V9, P417, DOI 10.1016/j.ccr.2006.05.013; Webb AJ, 2008, P NATL ACAD SCI USA, V105, P10471, DOI 10.1073/pnas.0804933105; Wheeler DA, 2008, NATURE, V452, P872, DOI 10.1038/nature06884; WILLIAMS C, 1993, HUM MOL GENET, V2, P445, DOI 10.1093/hmg/2.4.445; Wong CC, 2010, NAT BIOTECHNOL, V28, P1115, DOI 10.1038/nbt.1686; Woyke T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026161; Xu X, 2012, CELL, V148, P886, DOI 10.1016/j.cell.2012.02.025; Zollner S, 2004, AM J HUM GENET, V74, P62, DOI 10.1086/381131	38	362	395	3	128	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 20	2012	150	2					402	412		10.1016/j.cell.2012.06.030	http://dx.doi.org/10.1016/j.cell.2012.06.030			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817899	Bronze, Green Accepted			2022-12-28	WOS:000306595700018
J	Noakes, TD				Noakes, T. D.			Commentary: role of hydration in health and exercise	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ULTRAMARATHON RUNNERS; POSTURAL HYPOTENSION; HYPONATREMIA; MANAGEMENT; TRIAL		[Noakes, T. D.] Univ Cape Town, Dept Human Biol, ZA-7700 Newlands, South Africa; [Noakes, T. D.] Sports Sci Inst S Africa, ZA-7700 Newlands, South Africa	University of Cape Town	Noakes, TD (corresponding author), Univ Cape Town, Dept Human Biol, ZA-7700 Newlands, South Africa.	Timothy.noakes@uct.ac.za	Noakes, Timothy D./E-7253-2011; Noakes, Tim/AAD-3162-2020	Noakes, Timothy D./0000-0001-7244-2375; Noakes, Tim/0000-0001-7244-2375				Anley C, 2011, BRIT J SPORT MED, V45, P1113, DOI 10.1136/bjsm.2010.071951; Cuthill JA, 2009, EMERG MED J, V26, P906, DOI 10.1136/emj.2008.065524; Goulet EDB, 2011, BRIT J SPORT MED, V45, P1149, DOI 10.1136/bjsm.2010.077966; Hew-Butler T, 2005, CLIN J SPORT MED, V15, P206, DOI 10.1097/01.jsm.0000174702.23983.41; Hew-Butler T, 2008, CLIN J SPORT MED, V18, P350, DOI 10.1097/JSM.0b013e3181802c6d; HOLTZHAUSEN LM, 1994, MED SCI SPORT EXER, V26, P1095; HOLTZHAUSEN LM, 1995, MED SCI SPORT EXER, V27, P1595; IRVING RA, 1991, J APPL PHYSIOL, V70, P342, DOI 10.1152/jappl.1991.70.1.342; McGarvey J, 2010, BRIT J SPORT MED, V44, P716, DOI 10.1136/bjsm.2008.053249; Noakes T., 2012, WATERLOGGED SERIOUS; Noakes TD, 2005, P NATL ACAD SCI USA, V102, P18550, DOI 10.1073/pnas.0509096102; Rae DE, 2008, MED SCI SPORT EXER, V40, P1193, DOI 10.1249/MSS.0b013e31816a7155	12	6	6	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 19	2012	345								e4171	10.1136/bmj.e4171	http://dx.doi.org/10.1136/bmj.e4171			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978MA	22810384				2022-12-28	WOS:000306744300001
J	Cleland, J; Conde-Agudelo, A; Peterson, H; Ross, J; Tsui, A				Cleland, John; Conde-Agudelo, Agustin; Peterson, Herbert; Ross, John; Tsui, Amy			Contraception and health	LANCET			English	Article							SHORT INTERPREGNANCY INTERVAL; INTRAUTERINE-DEVICE USE; MATERNAL MORTALITY; PERINATAL OUTCOMES; NUTRITIONAL-STATUS; RISK; BIRTH; INFANT; CHILD; DISEASE	Increasing contraceptive use in developing countries has cut the number of maternal deaths by 40% over the past 20 years, merely by reducing the number of unintended pregnancies. By preventing high-risk pregnancies, especially in women of high parities, and those that would have ended in unsafe abortion, increased contraceptive use has reduced the maternal mortality ratio-the risk of maternal death per 100 000 livebirths-by about 26% in little more than a decade. A further 30% of maternal deaths could be avoided by fulfilment of unmet need for contraception. The benefits of modern contraceptives to women's health, including non-contraceptive benefits of specific methods, outweigh the risks. Contraception can also improve perinatal outcomes and child survival, mainly by lengthening interpregnancy intervals. In developing countries, the risk of prematurity and low birthweight doubles when conception occurs within 6 months of a previous birth, and children born within 2 years of an elder sibling are 60% more likely to die in infancy than are those born more than 2 years after their sibling.	[Cleland, John] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; [Conde-Agudelo, Agustin] Eunice Kennedy Shriver Natl Inst Hlth & Human Dev, Perinatol Res Branch, Hutzel Womens Hosp, NIH, Bethesda, MD USA; [Conde-Agudelo, Agustin] Eunice Kennedy Shriver Natl Inst Hlth & Human Dev, Perinatol Res Branch, Hutzel Womens Hosp, NIH, Detroit, MI USA; [Peterson, Herbert] Univ N Carolina, Dept Maternal & Child Hlth, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Peterson, Herbert] Univ N Carolina, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC USA; [Ross, John] Futures Grp Inc, Washington, DC USA; [Tsui, Amy] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA	University of London; London School of Hygiene & Tropical Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Cleland, J (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	john.cleland@lshtm.ac.uk	Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016	Bill and Melinda Gates Institute	Bill and Melinda Gates Institute	We thank Anyeli Rosas-Bermudez for assistance with the section on perinatal health. AT's participation was supported by funding from the Bill and Melinda Gates Institute to the Johns Hopkins Bloomberg School of Public Health.	Adam I, 2009, J MATERN-FETAL NEO M, V22, P1068, DOI 10.3109/14767050903009222; Ahmed S., 2012, LANCET; Ali MM, 2010, STUD FAMILY PLANN, V41, P129, DOI 10.1111/j.1728-4465.2010.00234.x; Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5; ATRASH HK, 1990, OBSTET GYNECOL, V76, P1055; Auger N, 2008, BMC PREGNANCY CHILDB, V8, P7, DOI DOI 10.1186/1471-2393-8-7; Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; Beining RM, 2008, ANN EPIDEMIOL, V18, P492, DOI 10.1016/j.annepidem.2007.11.011; Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1; BHATIA JC, 1993, STUD FAMILY PLANN, V24, P310, DOI 10.2307/2939224; Bouvier-Colle MH, 2001, ACTA OBSTET GYN SCAN, V80, P113; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Canning D, 2011, ASS MATERNAL HLTH IN; Castellsague X, 2011, LANCET ONCOL, V12, P1023, DOI 10.1016/S1470-2045(11)70223-6; Cecatti JG, 2008, MATERN CHILD HLTH J, V12, P275, DOI 10.1007/s10995-007-0219-y; Cibula D, 2010, HUM REPROD UPDATE, V16, P631, DOI 10.1093/humupd/dmq022; Collumbien M., 2004, COMP QUANTIFICATION, P1255; Conde-Agudelo A, 2000, BRIT MED J, V321, P1255, DOI 10.1136/bmj.321.7271.1255; Conde-Agudelo A, 2006, JAMA-J AM MED ASSOC, V295, P1809, DOI 10.1001/jama.295.15.1809; Conde-Agudelo A, 2007, AM J OBSTET GYNECOL, V196, P297, DOI 10.1016/j.ajog.2006.05.055; Curtis KM, 2009, AIDS, V23, pS55, DOI 10.1097/01.aids.0000363778.58203.b6; Darroch Jacqueline E., 2011, ESTIMATING UNINTENDE; DeFranco EA, 2007, AM J OBSTET GYNECOL, V197, p264e1; Dewey KG, 2007, MATERN CHILD NUTR, V3, P151, DOI 10.1111/j.1740-8709.2007.00092.x; FARLEY TMM, 1992, LANCET, V339, P785, DOI 10.1016/0140-6736(92)91904-M; Fikree FF, 1997, ACTA OBSTET GYN SCAN, V76, P637, DOI 10.3109/00016349709024603; FORTNEY JA, 1987, STUD FAMILY PLANN, V18, P109, DOI 10.2307/1966702; FRANKS AL, 1990, AM J OBSTET GYNECOL, V163, P1120, DOI 10.1016/0002-9378(90)90668-W; Garenne M, 1997, Afr J Reprod Health, V1, P14, DOI 10.2307/3583271; Glasier AF, 2003, CONTRACEPTION, V67, P1, DOI 10.1016/S0010-7824(02)00474-2; Goldie SJ, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000264; Grisaru-Granovsky S, 2009, CONTRACEPTION, V80, P512, DOI 10.1016/j.contraception.2009.06.006; Heffron R, 2012, LANCET INFECT DIS, V12, P19, DOI 10.1016/S1473-3099(11)70247-X; HOBCRAFT J, 1983, POPUL INDEX, V49, P585, DOI 10.2307/2737284; Hobcraft J, 1987, INT C BETT HLTH WOM; HOBCRAFT JN, 1985, POP STUD-J DEMOG, V39, P363, DOI 10.1080/0032472031000141576; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Jain AK, 2011, STUD FAMILY PLANN, V42, P247, DOI 10.1111/j.1728-4465.2011.00288.x; KOENIG MA, 1988, STUD FAMILY PLANN, V19, P69, DOI 10.2307/1966492; KOST K, 1991, FAM PLANN PERSPECT, V23, P54, DOI 10.2307/2135450; Magadi M, 2001, J BIOSOC SCI, V33, P375, DOI 10.1017/S0021932001003753; Mahy M, 2003, DEMOGRAPHIC HLTH SUR, V4; Marchbanks PA, 2002, NEW ENGL J MED, V346, P2025, DOI 10.1056/NEJMoa013202; MHANGO C, 1986, STUD FAMILY PLANN, V17, P243, DOI 10.2307/1966974; Nabukera SK, 2008, J OBSTET GYNAECOL RE, V34, P941, DOI 10.1111/j.1447-0756.2008.00808.x; *NAT I POP RES TRA, 2003, BANGL MAT HLTH SERV; Peterson HB, 2008, OBSTET GYNECOL, V111, P189, DOI 10.1097/01.AOG.0000298621.98372.62; Petitti DB, 2003, NEW ENGL J MED, V349, P1443, DOI 10.1056/NEJMcp030751; Rodrigues T, 2008, EUR J OBSTET GYN R B, V136, P184, DOI 10.1016/j.ejogrb.2007.03.014; Ross JA, 2012, MATERN CHILD HLTH J, V16, P456, DOI 10.1007/s10995-011-0777-x; Rutstein SO, 2005, INT J GYNECOL OBSTET, V89, pS7, DOI 10.1016/j.ijgo.2004.11.012; Rutstein SO, 2005, EFFECT BIRTH SPACING; Rutstein SO, 2008, 41 MACR INT DEM HLTH; Sedgh G, 2007, LANCET, V370, P1338, DOI 10.1016/S0140-6736(07)61575-X; Shah I, 2011, INT J GYNECOL OBSTET, V115, P1338; Singh S, 2009, ADDING IT COSTS BENE; Singh S, 2010, STUD FAMILY PLANN, V41, P241, DOI 10.1111/j.1728-4465.2010.00250.x; Smits LJM, 2001, LANCET, V358, P2074, DOI 10.1016/S0140-6736(01)07105-7; Stringer EM, 2009, AIDS, V23, P1377, DOI 10.1097/QAD.0b013e32832cbca8; TRUSSELL J, 1984, STUD FAMILY PLANN, V15, P267, DOI 10.2307/1966071; TUNCER RA, 1995, ACTA OBSTET GYN SCAN, V74, P604, DOI 10.3109/00016349509013470; Ujah IAO, 2003, AFR J REPROD HEALTH, V9, P27; UN Department for Economic and Social Information Analysis Population Division, 1994, HLTH RAT FAM PLANN T; Vessey M, 2010, CONTRACEPTION, V82, P221, DOI 10.1016/j.contraception.2010.04.006; Wee DW, 2010, AM J EPIDEMIOL, V172, P855, DOI 10.1093/aje/kwq207; WHO, 2005, Wkly Epidemiol Rec, V80, P302; Williams EK, 2008, J TROP PEDIATRICS, V54, P321, DOI 10.1093/tropej/fmn027; WINIKOFF B, 1987, STUD FAMILY PLANN, V18, P128, DOI 10.2307/1966808; World Health Organization, 2007, WHORHR071; World Health Organization, HORM CONTR HIV TECHN; World Health Organization, 2013, UNS AB GLOB REG EST; World Health Organization UNICEF UNFPA The World Bank, 2010, TRENDS MAT MOR 1990; Yerushalmy J, 1940, PUBLIC HEALTH REP, V55, P1195, DOI 10.2307/4583352; Zhu BP, 1999, NEW ENGL J MED, V340, P589, DOI 10.1056/NEJM199902253400801	74	355	359	2	67	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2012	380	9837					149	156		10.1016/S0140-6736(12)60609-6	http://dx.doi.org/10.1016/S0140-6736(12)60609-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784533				2022-12-28	WOS:000306359100042
J	Gilmore, K; Gebreyesus, TA				Gilmore, Kate; Gebreyesus, Tedros Adhanom			What will it take to eliminate preventable maternal deaths?	LANCET			English	Editorial Material									[Gilmore, Kate] UN Populat Fund, New York, NY 10158 USA; [Gebreyesus, Tedros Adhanom] Minist Hlth, Addis Ababa, Ethiopia	United Nations Population Fund	Gilmore, K (corresponding author), UN Populat Fund, New York, NY 10158 USA.	gilmore@unfpa.org						Ahmed S., 2012, LANCET; Ayad M, 2009, DHS FURTHER ANAL REP, V67; Danel I, 2011, B WORLD HEALTH ORGAN, V89, P779, DOI 10.2471/BLT.11.097220; Ethiopia Central Statistical Agency ICF International, 2012, ETH 2011 DEM HLTH SU; Godal T, 2012, LANCET, V379, P2025, DOI 10.1016/S0140-6736(12)60863-0; Singh S, 2012, ADDING IT COSTS BENE; UN Economic and Social Council, 2012, 46 SESS EL MAT MORT; World Health Organization UNFPA UNICEF Averting Maternal Death and Disability (AMDD), 2009, AV MAT DEATH DIS AMD; World Health Organization (WHO), 2012, TRENDS MAT MORT 1990	9	11	13	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2012	380	9837					87	88		10.1016/S0140-6736(12)60982-9	http://dx.doi.org/10.1016/S0140-6736(12)60982-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784544				2022-12-28	WOS:000306359100011
J	O'Neill, BC; Liddle, B; Jiang, LW; Smith, KR; Pachauri, S; Dalton, M; Fuchs, R				O'Neill, Brian C.; Liddle, Brant; Jiang, Leiwen; Smith, Kirk R.; Pachauri, Shonali; Dalton, Michael; Fuchs, Regina			Demographic change and carbon dioxide emissions	LANCET			English	Article							POPULATION-GROWTH; CO2 EMISSIONS; CLIMATE-CHANGE; ENVIRONMENTAL-IMPACT; ENERGY USE; STIRPAT; URBANIZATION; COUNTRIES; AFFLUENCE; DYNAMICS	Relations between demographic change and emissions of the major greenhouse gas carbon dioxide (CO2) have been studied from different perspectives, but most projections of future emissions only partly take demographic influences into account. We review two types of evidence for how CO2 emissions from the use of fossil fuels are affected by demographic factors such as population growth or decline, ageing, urbanisation, and changes in household size. First, empirical analyses of historical trends tend to show that CO2 emissions from energy use respond almost proportionately to changes in population size and that ageing and urbanisation have less than proportional but statistically significant effects. Second, scenario analyses show that alternative population growth paths could have substantial effects on global emissions of CO2 several decades from now, and that ageing and urbanisation can have important effects in particular world regions. These results imply that policies that slow population growth would probably also have climate-related benefits.	[O'Neill, Brian C.; Jiang, Leiwen] Natl Ctr Atmospher Res, Boulder, CO 80305 USA; [Liddle, Brant] Victoria Univ, Melbourne, Vic 8001, Australia; [Smith, Kirk R.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Pachauri, Shonali; Fuchs, Regina] Int Inst Appl Syst Anal, A-2361 Laxenburg, Austria; [Dalton, Michael] NOAA, Alaska Fisheries Sci Ctr, Seattle, WA USA	National Center Atmospheric Research (NCAR) - USA; Victoria University; University of California System; University of California Berkeley; International Institute for Applied Systems Analysis (IIASA); National Oceanic Atmospheric Admin (NOAA) - USA	O'Neill, BC (corresponding author), Natl Ctr Atmospher Res, POB 3000, Boulder, CO 80305 USA.	boneill@ucar.edu	Pachauri, Shonali/AAR-7383-2020; O'Neill, Brian C./E-6531-2013; Liddle, Brantley/K-9542-2014	O'Neill, Brian C./0000-0001-7505-8897; Liddle, Brantley/0000-0003-3199-0214; jiang, leiwen/0000-0002-2073-6440; Pachauri, Shonali/0000-0001-8138-3178				Birdsall N., 1992, ANOTHER LOOK POPULAT, P1020; BONGAARTS J, 1992, POPUL DEV REV, V18, P299, DOI 10.2307/1973681; Bryant L, 2009, B WORLD HEALTH ORGAN, V87, P852, DOI 10.2471/BLT.08.062562; Campbell M, 2007, SCIENCE, V315, P1501, DOI 10.1126/science.1140057; Chertow MR., 2000, J IND ECOL, V4, P13, DOI [DOI 10.1162/10881980052541927, 10.1162/10881980052541927]; Cohen JE, 2010, P AM PHILOS SOC, V154, P158; Cole MA, 2004, POPUL ENVIRON, V26, P5, DOI 10.1023/B:POEN.0000039950.85422.eb; COMMONER B, 1971, ENVIRONMENT, V13, P2, DOI 10.1080/00139157.1971.9930577; Cramer JC, 1998, DEMOGRAPHY, V35, P45, DOI 10.2307/3004026; Cramer JC, 2000, POPUL ENVIRON, V21, P315, DOI 10.1007/BF02436134; Dalton M, 2008, ENERG ECON, V30, P642, DOI 10.1016/j.eneco.2006.07.002; de Sherbinin A, 2007, ANNU REV ENV RESOUR, V32, P345, DOI 10.1146/annurev.energy.32.041306.100243; Denman KL, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P499; Dietz T, 1997, P NATL ACAD SCI USA, V94, P175, DOI 10.1073/pnas.94.1.175; EHRLICH PR, 1971, SCIENCE, V171, P1212, DOI 10.1126/science.171.3977.1212; Engelman R., 2010, 183 WORLDW I; Fan Y, 2006, ENVIRON IMPACT ASSES, V26, P377, DOI 10.1016/j.eiar.2005.11.007; Fisher B., 2007, CLIMATE CHANGE 2007; Forster P, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P129; Gaffin SR, 1997, POPUL ENVIRON, V18, P389, DOI 10.1007/BF02208514; JIANG Leiwen, 2009, IR09026 IIASA; Jorgenson AK, 2010, POPUL ENVIRON, V32, P27, DOI 10.1007/s11111-010-0117-x; Krey V, 2012, ENERG ECON, V34, pS272, DOI 10.1016/j.eneco.2012.04.013; Liddle B, 2004, POPUL ENVIRON, V26, P23, DOI 10.1023/B:POEN.0000039951.37276.f3; Liddle B, 2010, POPUL ENVIRON, V31, P317, DOI 10.1007/s11111-010-0101-5; Liddle B, 2011, DEMOGR RES, V24, P749, DOI 10.4054/DemRes.2011.24.30; Lutz W, 2011, SCIENCE, V333, P587, DOI 10.1126/science.1206964; MacKellar FL, 1995, POPUL DEV REV, V21, P849, DOI 10.2307/2137777; Martinez-Zarzoso I, 2007, ENVIRON RESOUR ECON, V38, P497, DOI 10.1007/s10640-007-9096-5; Martinez-Zarzoso I, 2011, ECOL ECON, V70, P1344, DOI 10.1016/j.ecolecon.2011.02.009; Menz T, 2012, ENERG ECON, V34, P842, DOI 10.1016/j.eneco.2011.07.016; Moreland Scott., 2010, WORLD POPULATION PRO; Murtaugh PA, 2009, GLOBAL ENVIRON CHANG, V19, P14, DOI 10.1016/j.gloenvcha.2008.10.007; Nakicenovic N., 2000, SPECIAL REPORT EMISS; NRC, 1999, NAT NUMB EXP NAT EC, P262, DOI [10.17226/6374, DOI 10.17226/6374]; O'Neill BC, 2000, CLIMATIC CHANGE, V47, P283, DOI 10.1023/A:1005627509071; O'Neill BC., 2001, POPULATION CLIMATE C; O'Neill BC, 2010, P NATL ACAD SCI USA, V107, P17521, DOI 10.1073/pnas.1004581107; O'Neill BC, 2002, POPUL DEV REV, V28, P53; Poumanyvong P, 2010, ECOL ECON, V70, P434, DOI 10.1016/j.ecolecon.2010.09.029; Prskawetz A., 2004, VIENNA YB POPULATION, V2, P175, DOI DOI 10.1553/P0PULATI0NYEARB00K2004S175; Rosa EA, 2004, AMBIO, V33, P509, DOI 10.1639/0044-7447(2004)033[0509:TTADOE]2.0.CO;2; Shi AQ, 2003, ECOL ECON, V44, P29, DOI 10.1016/S0921-8009(02)00223-9; Stephenson J, 2010, J PUBLIC HEALTH-UK, V32, P150, DOI 10.1093/pubmed/fdq038; UN, 2004, WORLD POP 2300; Wheeler D., 2010, 229 CGD; York R, 2003, ECOL ECON, V46, P351, DOI 10.1016/S0921-8009(03)00188-5; York R, 2002, SOC SCI QUART, V83, P18, DOI 10.1111/1540-6237.00068	49	115	119	7	124	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2012	380	9837					157	164		10.1016/S0140-6736(12)60958-1	http://dx.doi.org/10.1016/S0140-6736(12)60958-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784534				2022-12-28	WOS:000306359100043
J	Rozati, H; Jaffer, ZN; Al-Hadithy, N				Rozati, Hamoun; Jaffer, Zahra N.; Al-Hadithy, Nawfal			A young man with wrist pain	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ACUTE SCAPHOID FRACTURES; FOLLOW-UP; NONOPERATIVE TREATMENT; RADIOGRAPHY; METAANALYSIS; SIGNS		[Rozati, Hamoun; Jaffer, Zahra N.; Al-Hadithy, Nawfal] Lister Hosp, Stevenage SG1 4AB, Herts, England	Lister Hospital	Rozati, H (corresponding author), Lister Hosp, Stevenage SG1 4AB, Herts, England.	h.rozati@nhs.net						Bernard SA, 2010, J ORTHOP TRAUMA, V24, P448, DOI 10.1097/BOT.0b013e3181c3e865; Bucholz RW, 2010, FRACTURES ADULTS; DIAS JJ, 1988, J BONE JOINT SURG BR, V70, P299, DOI 10.1302/0301-620X.70B2.3346310; Doornberg JN, 2011, J TRAUMA, V71, P1073, DOI 10.1097/TA.0b013e318222f485; Duckworth AD, 2011, J TRAUMA; Gaebler C, 1996, J TRAUMA, V41, P73, DOI 10.1097/00005373-199607000-00011; Gaebler C, 2009, FRACTURES ADULTS, V1; Low G, 2005, CLIN RADIOL, V60, P1106, DOI 10.1016/j.crad.2005.07.001; McNally EG, 2000, EUR RADIOL, V10, P1926, DOI 10.1007/s003300000530; Parvizi J, 1998, J HAND SURG-BRIT EUR, V23B, P324, DOI 10.1016/S0266-7681(98)80050-8; Pincus S, 2009, WEST J EMERG MED, V10, P227; Rettig ME, 2001, J HAND SURG-AM, V26A, P271, DOI 10.1053/jhsu.2001.21524; Rhemrev SJ, 2009, INJURY, V40, P638, DOI 10.1016/j.injury.2008.10.028; Ribak S, 2010, INT ORTHOP, V34, P683, DOI 10.1007/s00264-009-0862-6; Ring D, 2000, J Am Acad Orthop Surg, V8, P225; Saeden B, 2001, J BONE JOINT SURG BR, V83B, P230, DOI 10.1302/0301-620X.83B2.11197; Slutsky DJ, 2010, SCAPHOID; Suh Nina, 2010, Hand (N Y), V5, P345, DOI 10.1007/s11552-010-9276-6; Temple CLF, 2005, J HAND SURG-AM, V30A, P534, DOI 10.1016/j.jhsa.2005.01.001; Yin ZG, 2007, CLIN ORTHOP RELAT R, P142, DOI 10.1097/BLO.0b013e31803d359a; Yin ZG, 2010, CLIN ORTHOP RELAT R, V468, P723, DOI 10.1007/s11999-009-1081-6	21	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	2012	345								e4466	10.1136/bmj.e4466	http://dx.doi.org/10.1136/bmj.e4466			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975NX	22797846				2022-12-28	WOS:000306519100004
J	Boyer, EW				Boyer, Edward W.			DRUG THERAPY Management of Opioid Analgesic Overdose	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INTRAVENOUS NALOXONE; PULMONARY-EDEMA; UNITED-STATES; SEPTIC SHOCK; CHILDREN; MORPHINE; DEATHS; DISPOSITION; METHADONE; PHARMACOKINETICS		Univ Massachusetts, Med Ctr, Dept Emergency Med, Div Med Toxicol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Boyer, EW (corresponding author), Univ Massachusetts, Med Ctr, Dept Emergency Med, Div Med Toxicol, 55 Lake Ave N, Worcester, MA 01655 USA.	edward.boyer@childrens.harvard.edu	Boyer, Edward/AAF-3609-2020		NIDA NIH HHS [R01 DA018572, R21 DA022677, R21 DA014929] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014929, R01DA018572, R21DA022677] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alam A, 2012, ARCH INTERN MED, V172, P425, DOI 10.1001/archinternmed.2011.1827; ALBERTO G, 1989, ANN EMERG MED, V18, P889, DOI 10.1016/S0196-0644(89)80220-3; ALLEN L, 1982, J CLIN PHARMACOL, V22, pS1; American Association of Poison Control Centers, NAT POIS DAT SYST 20; [Anonymous], 2003, POISINDEX SYST INTR; Bailey JE, 2009, ANN EMERG MED, V53, P419, DOI 10.1016/j.annemergmed.2008.07.015; Baumann A, 2007, ACTA ANAESTH SCAND, V51, P447, DOI 10.1111/j.1399-6576.2007.01276.x; BERKOWITZ B A, 1976, Clinical Pharmacokinetics, V1, P219, DOI 10.2165/00003088-197601030-00004; Bond GR, 2012, J PEDIATR-US, V160, P265, DOI 10.1016/j.jpeds.2011.07.042; Boyer EW, 2010, AM J ADDICTION, V19, P89, DOI 10.1111/j.1521-0391.2009.00002.x; Boyer EW, 2003, CLIN CHEM, V49, P353, DOI 10.1373/49.3.353; Chau DL, 2008, CLIN INTERV AGING, V3, P273, DOI 10.2147/CIA.S1847; Christenson J, 2000, ACAD EMERG MED, V7, P1110, DOI 10.1111/j.1553-2712.2000.tb01260.x; Chyka P. A., 1997, CLIN TOXICOL, V35, P721; Clark Richard F., 1995, Journal of Emergency Medicine, V13, P797, DOI 10.1016/0736-4679(95)02002-0; Clarke SFJ, 2005, EMERG MED J, V22, P612, DOI 10.1136/emj.2003.009613; Department of Justice Drug Enforcement Administration, AUT REP CONS ORD SYS; EHRMAN R, 1992, PSYCHOPHARMACOLOGY, V108, P218, DOI 10.1007/BF02245311; ETCHES RC, 1994, CAN J ANAESTH, V41, P125, DOI 10.1007/BF03009805; EVANS JM, 1974, BRIT MED J, V2, P589, DOI 10.1136/bmj.2.5919.589; FISHMAN J, 1973, J PHARMACOL EXP THER, V187, P575; GABOW PA, 1982, MEDICINE, V61, P141, DOI 10.1097/00005792-198205000-00002; GAL TJ, 1982, ANESTHESIOLOGY, V57, P367, DOI 10.1097/00000542-198211000-00004; Geib AJ, 2006, PEDIATRICS, V118, P1746, DOI 10.1542/peds.2006-0948; GOLDFRANK L, 1986, ANN EMERG MED, V15, P566, DOI 10.1016/S0196-0644(86)80994-5; GREENBLATT DJ, 1982, NEW ENGL J MED, V306, P1081; GROEGER JS, 1983, CRIT CARE MED, V11, P650, DOI 10.1097/00003246-198308000-00013; Gutstein HB, 2006, GOODMAN GILMANS PHAR, P547; Hayes BD, 2008, PEDIATRICS, V121, pE782, DOI 10.1542/peds.2007-1774; Heard KJ, 2008, NEW ENGL J MED, V359, P285, DOI 10.1056/NEJMct0708278; Hendra TJ, 1996, BRIT MED J, V313, P481; HOFFMAN JR, 1991, ANN EMERG MED, V20, P246, DOI 10.1016/S0196-0644(05)80933-3; HOFFMAN RS, 1995, JAMA-J AM MED ASSOC, V274, P562, DOI 10.1001/jama.274.7.562; HOLDSWORTH MT, 1994, GERONTOLOGY, V40, P32; Juurlink DN, 2007, HADDAD WINCHESTERS C, P81, DOI [10.1016/B978-0-7216-0693-4.50009-8, DOI 10.1016/B978-0-7216-0693-4.50009-8]; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; Katz N, 2008, PAIN MED, V9, P587, DOI 10.1111/j.1526-4637.2008.00471.x; Katz NP, 2003, ANESTH ANALG, V97, P1097, DOI 10.1213/01.ANE.0000080159.83342.B5; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Khandelwal N, 2011, HEPATOLOGY, V53, P567, DOI 10.1002/hep.24060; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Moon JM, 2011, J EMERG MED, V40, P37, DOI 10.1016/j.jemermed.2007.10.075; National Comprehensive Cancer Network, 2011, CLIN PRACT GUID ONC; Nelsen JL, 2010, WORLD J EMERG MED, V1, P75; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; O'Malley GF, 1999, ANN EMERG MED, V34, P279, DOI 10.1016/S0196-0644(99)70249-0; Okie S, 2011, NEW ENGL J MED, V364, P290; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; OLINGER CP, 1990, STROKE, V21, P721, DOI 10.1161/01.STR.21.5.721; OLKKOLA KT, 1995, PAEDIATR ANAESTH, V5, P303, DOI 10.1111/j.1460-9592.1995.tb00311.x; Opioid analgesic risk evaluation and mitigation strategies (REMS), 2010, OP AN RISK EV MIT ST; Osler W., 1880, MONTREAL GEN HOSP RE, V1, P291; Osterhoudt KC, 2002, ACAD EMERG MED, V9, P962, DOI 10.1197/aemj.9.9.962; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Paulozzi LJ, 2011, J CLIN PSYCHIAT, V72, P589, DOI 10.4088/JCP.10com06560; Pedapati EV, 2011, PEDIATR CRIT CARE ME, V12, pE102, DOI 10.1097/PCC.0b013e3181f3a118; PETERS WP, 1981, LANCET, V1, P529; POND SM, 1984, CLIN PHARMACOKINET, V9, P1, DOI 10.2165/00003088-198409010-00001; Prosser JM, 2010, J MED TOXICOL, V6, P443, DOI 10.1007/s13181-010-0092-8; RIGG JRA, 1978, BRIT J ANAESTH, V50, P759, DOI 10.1093/bja/50.8.759; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Selbst SM, 2008, PEDIATR EMERG CARE, V24, P700, DOI 10.1097/PEC.0b013e318188fbf4; Shaw L, 2001, CLIN TOXICOLOGICAL L; SMIALEK JE, 1977, JAMA-J AM MED ASSOC, V238, P2516, DOI 10.1001/jama.238.23.2516; Smith SW, 2008, ANN PHARMACOTHER, V42, P1333, DOI 10.1345/aph.1K680; Sporer KA, 2001, CHEST, V120, P1628, DOI 10.1378/chest.120.5.1628; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Talaie H, 2009, J MED TOXICOL, V5, P63, DOI 10.1007/BF03161089; TENENBEIN M, 1984, J PEDIATR-US, V105, P645, DOI 10.1016/S0022-3476(84)80440-0; Toblin RL, 2010, J CLIN PSYCHIAT, V71, P491, DOI 10.4088/JCP.09m05567blu; Tsui BCH, 2004, ANESTH ANALG, V98, P434, DOI 10.1213/01.ANE.0000095152.81728.DC; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; Whistler JL, 2012, DRUG ALCOHOL DEPEN, V121, P189, DOI 10.1016/j.drugalcdep.2011.10.031; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x; Zacny JP, 2005, DRUG ALCOHOL DEPEN, V80, P273, DOI 10.1016/j.drugalcdep.2005.05.007	78	325	332	6	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2					146	155		10.1056/NEJMra1202561	http://dx.doi.org/10.1056/NEJMra1202561			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972IO	22784117	Green Accepted			2022-12-28	WOS:000306270800011
J	Fahy, T				Fahy, Tom			Do cases like that of Anders Breivik show that fanaticism is a form of madness? No	BRITISH MEDICAL JOURNAL			English	Editorial Material									Inst Psychiat, London SE5 8AF, England	University of London; King's College London	Fahy, T (corresponding author), Inst Psychiat, London SE5 8AF, England.	thomas.fahy@kcl.ac.uk						Post JM, 2009, PSYCHIATRY, V72, P13, DOI 10.1521/psyc.2009.72.1.13	1	3	3	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 11	2012	345								e4647	10.1136/bmj.e4647	http://dx.doi.org/10.1136/bmj.e4647			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NU	22786939				2022-12-28	WOS:000306518800006
J	Rulli, T; Emanuel, EJ; Wendler, D				Rulli, Tina; Emanuel, Ezekiel J.; Wendler, David			The Moral Duty to Buy Health Insurance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Rulli, Tina; Wendler, David] NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA; [Emanuel, Ezekiel J.] Univ Penn, Off Vice Provost, Philadelphia, PA 19104 USA; [Emanuel, Ezekiel J.] Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of Pennsylvania; University of Pennsylvania	Wendler, D (corresponding author), NIH, Dept Bioeth, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.	dwendler@nih.gov						Fairchild AL, 2006, HEALTH AFFAIR, V25, P958, DOI 10.1377/hlthaff.25.4.958; Hadley J, 2008, HEALTH AFFAIR, V27, pW399, DOI 10.1377/hlthaff.27.5.w399; Health Care Fees, APP PRIC; Kaiser Commission on Key Facts, 2009, MED UN 5 BAS FACTS U; Mariner WK, 2011, NEW ENGL J MED, V364, P201, DOI 10.1056/NEJMp1014367; US Agency for Healthcare Research and Quality, WELC H CUPNET HEALTH	6	4	4	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2012	308	2					137	138		10.1001/jama.2012.5648	http://dx.doi.org/10.1001/jama.2012.5648			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	971QS	22782412	Green Published			2022-12-28	WOS:000306219500023
J	Asencio, C; Davidson, IF; Santarella-Mellwig, R; Thi, BNLH; Mall, M; Wallenfang, MR; Mattaj, IW; Gorjanacz, M				Asencio, Claudio; Davidson, Iain F.; Santarella-Mellwig, Rachel; Thi Bach Nga Ly-Hartig; Mall, Moritz; Wallenfang, Matthew R.; Mattaj, Iain W.; Gorjanacz, Matyas			Coordination of Kinase and Phosphatase Activities by Lem4 Enables Nuclear Envelope Reassembly during Mitosis	CELL			English	Article							TO-AUTOINTEGRATION FACTOR; CAENORHABDITIS-ELEGANS; MITOTIC EXIT; MEMBRANE PROTEIN; HUMAN-CELLS; C. ELEGANS; BAF; EMERIN; INSIGHTS; EMBRYOS	Mitosis in metazoa requires nuclear envelope (NE) disassembly and reassembly. NE disassembly is driven by multiple phosphorylation events. Mitotic phosphorylation of the protein BAF reduces its affinity for chromatin and the LEM family of inner nuclear membrane proteins; loss of this BAF-mediated chromatin-NE link contributes to NE disassembly. BAF must reassociate with chromatin and LEM proteins at mitotic exit to reform the NE; however, how its dephosphorylation is regulated is unknown. Here, we show that the C. elegans protein LEM-4L and its human ortholog Lem4 (also called ANKLE2) are both required for BAF dephosphorylation. They act in part by inhibiting BAF's mitotic kinase, VRK-1, in vivo and in vitro. In addition, Lem4/LEM-4L interacts with PP2A and is required for it to dephosphorylate BAF during mitotic exit. By coordinating VRK-1- and PP2A-mediated signaling on BAF, Lem4/LEM-4L controls postmitotic NE formation in a function conserved from worms to humans.	[Asencio, Claudio; Davidson, Iain F.; Santarella-Mellwig, Rachel; Thi Bach Nga Ly-Hartig; Mall, Moritz; Mattaj, Iain W.; Gorjanacz, Matyas] European Mol Biol Lab, D-69117 Heidelberg, Germany; [Wallenfang, Matthew R.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	European Molecular Biology Laboratory (EMBL); Johns Hopkins University	Mattaj, IW (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	mattaj@embl.org	Mall, Moritz/AAA-3558-2019	Mall, Moritz/0000-0002-1278-2594; Mattaj, Iain/0000-0002-5537-8284	NIH	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Tokuko Haraguchi for GFP-BAF plasmid; Toby Gibson, Norman Davey, and Damien Devos for bioinformatics assistance; Ulrike Bauer and Victoria McParland for technical assistance; Stefan Leicht for help with 2D gels; and members of the Advanced Light Microscopy Facility (EMBL Heidelberg) for microscopy help. We thank Jan Ellenberg, Peter Lenart, Maja Kohn, Geraldine Seydoux, Boris Bryk, and the Mattaj lab for comments on the manuscript. The NIH-funded Caenorhabditis Genetic Center provided some C. elegans strains. I.F.D. was an EMBO Long-Term Fellow, C.A. a Spanish Ministry of Science and Innovation Fellow, and M.G. a Human Frontier Science Program Organization Fellow.	Askjaer P, 2002, MOL BIOL CELL, V13, P4355, DOI 10.1091/mbc.E02-06-0346; Bollen M, 2009, TRENDS CELL BIOL, V19, P531, DOI 10.1016/j.tcb.2009.06.005; Breitkreutz A, 2010, SCIENCE, V328, P1043, DOI 10.1126/science.1176495; Browne GJ, 2007, BIOCHEM J, V402, P187, DOI 10.1042/BJ20060600; Burke B, 2002, NAT REV MOL CELL BIO, V3, P487, DOI 10.1038/nrm860; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Dauer WT, 2009, DEV CELL, V17, P626, DOI 10.1016/j.devcel.2009.10.016; Fernandez AG, 2006, CURR BIOL, V16, P1757, DOI 10.1016/j.cub.2006.07.071; Franz C, 2005, EMBO J, V24, P3519, DOI 10.1038/sj.emboj.7600825; Galy V, 2003, MOL BIOL CELL, V14, P5104, DOI 10.1091/mbc.E03-04-0237; Galy V, 2006, CURR BIOL, V16, P1748, DOI 10.1016/j.cub.2006.06.067; Glatter T, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.75; Golden A, 2000, J CELL BIOL, V151, P1469, DOI 10.1083/jcb.151.7.1469; Gorjanacz M, 2007, EMBO J, V26, P132, DOI 10.1038/sj.emboj.7601470; Guttinger S, 2009, NAT REV MOL CELL BIO, V10, P178, DOI 10.1038/nrm2641; Haraguchi T, 2001, J CELL SCI, V114, P4575; Haraguchi T, 2008, J CELL SCI, V121, P2540, DOI 10.1242/jcs.033597; Hetzer MW, 2005, ANNU REV CELL DEV BI, V21, P347, DOI 10.1146/annurev.cellbio.21.090704.151152; Kang TH, 2007, MOL CELL BIOL, V27, P8533, DOI 10.1128/MCB.00018-07; Kitagawa D, 2011, DEV CELL, V20, P550, DOI 10.1016/j.devcel.2011.02.005; Klerkx EPF, 2009, DEV BIOL, V335, P12, DOI 10.1016/j.ydbio.2009.08.007; Lancaster OM, 2007, J CELL BIOL, V179, P817, DOI 10.1083/jcb.200706067; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Margalit A, 2005, P NATL ACAD SCI USA, V102, P3290, DOI 10.1073/pnas.0408364102; Margalit A, 2007, TRENDS CELL BIOL, V17, P202, DOI 10.1016/j.tcb.2007.02.004; Neumann B, 2006, NAT METHODS, V3, P385, DOI 10.1038/NMETH876; Nichols RJ, 2006, MOL BIOL CELL, V17, P2451, DOI 10.1091/mbc.E05-12-1179; Schmitz MHA, 2010, NAT CELL BIOL, V12, P886, DOI 10.1038/ncb2092; Shimi T, 2004, J STRUCT BIOL, V147, P31, DOI 10.1016/j.jsb.2003.11.013; Song MH, 2011, DEV CELL, V20, P563, DOI 10.1016/j.devcel.2011.03.007; Stefansson B, 2008, BIOCHEMISTRY-US, V47, P1442, DOI 10.1021/bi7022877; Ulbert S, 2006, FEBS LETT, V580, P6435, DOI 10.1016/j.febslet.2006.10.060; Vagnarelli P, 2011, DEV CELL, V21, P328, DOI 10.1016/j.devcel.2011.06.020; Wagner N, 2007, INT REV CYTOL, V261, P1, DOI 10.1016/S0074-7696(07)61001-8; Wurzenberger C, 2011, NAT REV MOL CELL BIO, V12, P469, DOI 10.1038/nrm3149	35	105	128	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 6	2012	150	1					122	135		10.1016/j.cell.2012.04.043	http://dx.doi.org/10.1016/j.cell.2012.04.043			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770216	Bronze			2022-12-28	WOS:000306115000012
J	Capra, EJ; Perchuk, BS; Skerker, JM; Laub, MT				Capra, Emily J.; Perchuk, Barrett S.; Skerker, Jeffrey M.; Laub, Michael T.			Adaptive Mutations that Prevent Crosstalk Enable the Expansion of Paralogous Signaling Protein Families	CELL			English	Article							ESCHERICHIA-COLI K-12; TRANSDUCTION PATHWAYS; 2-COMPONENT; SYSTEMS; SPECIFICITY; IDENTIFICATION; EVOLUTION	Orthologous proteins often harbor numerous substitutions, but whether these differences result from neutral or adaptive processes is usually unclear. To tackle this challenge, we examined the divergent evolution of a model bacterial signaling pathway comprising the kinase PhoR and its cognate substrate PhoB. We show that the specificity-determining residues of these proteins are typically under purifying selection but have, in alpha-proteobacteria, undergone a burst of diversification followed by extended stasis. By reversing mutations that accumulated in an alpha-proteobacterial PhoR, we demonstrate that these substitutions were adaptive, enabling PhoR to avoid crosstalk with a paralogous pathway that arose specifically in alpha-proteobacteria. Our findings demonstrate that duplication and the subsequent need to avoid crosstalk strongly influence signaling protein evolution. These results provide a concrete example of how system-wide insulation can be achieved postduplication through a surprisingly limited number of mutations. Our work may help explain the apparent ease with which paralogous protein families expanded in all organisms.	[Capra, Emily J.; Perchuk, Barrett S.; Laub, Michael T.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Laub, Michael T.] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Skerker, Jeffrey M.] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of California System; University of California Berkeley	Laub, MT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	laub@mit.edu		Laub, Michael/0000-0002-8288-7607	NSF [0821391]	NSF(National Science Foundation (NSF))	We thank O. Ashenberg for help with bioinformatics, Y.E. Chen for help with strain construction, and A. Podgornaia, A. Keating, O. Ashenberg, and K. Foster for helpful comments on the manuscript. Sequence analyses were performed on a computer cluster supported by NSF grant 0821391. M.T.L. is an Early Career Scientist of the Howard Hughes Medical Institute. This work was supported by an NSF graduate fellowship to E.J.C. and an NSF CAREER award to M.T.L.	Alm E, 2006, PLOS COMPUT BIOL, V2, P1329, DOI 10.1371/journal.pcbi.0020143; Bell CH, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000306; Capra EJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001220; Casino P, 2009, CELL, V139, P325, DOI 10.1016/j.cell.2009.08.032; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Dean AM, 2007, NAT REV GENET, V8, P675, DOI 10.1038/nrg2160; ELY B, 1991, METHOD ENZYMOL, V204, P372; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Gora KG, 2010, MOL CELL, V39, P455, DOI 10.1016/j.molcel.2010.06.024; Grimshaw CE, 1998, BIOCHEMISTRY-US, V37, P1365, DOI 10.1021/bi971917m; Hou TJ, 2009, MOL CELL PROTEOMICS, V8, P639, DOI 10.1074/mcp.M800450-MCP200; Laub MT, 2007, ANNU REV GENET, V41, P121, DOI 10.1146/annurev.genet.41.042007.170548; Liu BA, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002105; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; Noriega CE, 2010, MOL MICROBIOL, V75, P394, DOI 10.1111/j.1365-2958.2009.06987.x; Ohno S., 1970, EVOLUTION GENE DUPLI; Pires-daSilva A, 2003, NAT REV GENET, V4, P39, DOI 10.1038/nrg977; Siryaporn A, 2008, MOL MICROBIOL, V70, P494, DOI 10.1111/j.1365-2958.2008.06426.x; Skerker JM, 2008, CELL, V133, P1043, DOI 10.1016/j.cell.2008.04.040; Skerker JM, 2005, PLOS BIOL, V3, P1770, DOI 10.1371/journal.pbio.0030334; Stiffler MA, 2007, SCIENCE, V317, P364, DOI 10.1126/science.1144592; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Tonikian R, 2008, PLOS BIOL, V6, P2043, DOI 10.1371/journal.pbio.0060239; Huynh TN, 2011, MOL MICROBIOL, V82, P275, DOI 10.1111/j.1365-2958.2011.07829.x; WANNER BL, 1987, J BACTERIOL, V169, P5569, DOI 10.1128/jb.169.12.5569-5574.1987; Weigt M, 2009, P NATL ACAD SCI USA, V106, P67, DOI 10.1073/pnas.0805923106; Wistrand M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-99; Yamamoto K, 2005, J BIOL CHEM, V280, P1448, DOI 10.1074/jbc.M410104200; Yang ZH, 2000, TRENDS ECOL EVOL, V15, P496, DOI 10.1016/S0169-5347(00)01994-7; Zarrinpar A, 2003, NATURE, V426, P676, DOI 10.1038/nature02178	31	79	81	1	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 6	2012	150	1					222	232		10.1016/j.cell.2012.05.033	http://dx.doi.org/10.1016/j.cell.2012.05.033			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770222	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000306115000019
J	Greenman, CD				Greenman, Chris D.			Haploinsufficient Gene Selection in Cancer	SCIENCE			English	Editorial Material							GENOME; SIGNATURES; MUTATION		[Greenman, Chris D.] Univ E Anglia, Dept Comp, Norwich NR4 7TJ, Norfolk, England; [Greenman, Chris D.] Genome Anal Ctr, Norwich NR4 7UH, Norfolk, England	University of East Anglia; The Genome Analysis Centre (TGAC)	Greenman, CD (corresponding author), Univ E Anglia, Dept Comp, Norwich Res Pk, Norwich NR4 7TJ, Norfolk, England.	c.greenman@uea.ac.uk						Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; NOWELL PC, 1960, SCIENCE, V132, P1497; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Solimini NL, 2012, SCIENCE, V337, P104, DOI 10.1126/science.1219580; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xue W, 2012, P NATL ACAD SCI USA, V109, P8212, DOI 10.1073/pnas.1206062109	14	9	9	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2012	337	6090					47	48		10.1126/science.1224806	http://dx.doi.org/10.1126/science.1224806			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767920				2022-12-28	WOS:000306053100039
J	Saczynski, JS; Marcantonio, ER; Quach, L; Fong, TG; Gross, A; Inouye, SK; Jones, RN				Saczynski, Jane S.; Marcantonio, Edward R.; Quach, Lien; Fong, Tamara G.; Gross, Alden; Inouye, Sharon K.; Jones, Richard N.			Cognitive Trajectories after Postoperative Delirium	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY-BYPASS; CONFUSION ASSESSMENT METHOD; MINI-MENTAL STATE; PREDICTION RULE; CARDIAC-SURGERY; HIP FRACTURE; DECLINE; OUTCOMES; DYSFUNCTION; IMPAIRMENT	BACKGROUND Delirium is common after cardiac surgery and may be associated with long-term changes in cognitive function. We examined postoperative delirium and the cognitive trajectory during the first year after cardiac surgery. METHODS We enrolled 225 patients 60 years of age or older who were planning to undergo coronary-artery bypass grafting or valve replacement. Patients were assessed preoperatively, daily during hospitalization beginning on postoperative day 2, and at 1, 6, and 12 months after surgery. Cognitive function was assessed with the use of the Mini-Mental State Examination (MMSE; score range, 0 to 30, with lower scores indicating poorer performance). Delirium was diagnosed with the use of the Confusion Assessment Method. We examined performance on the MMSE in the first year after surgery, controlling for demographic characteristics, coexisting conditions, hospital, and surgery type. RESULTS The 103 participants (46%) in whom delirium developed postoperatively had lower preoperative mean MMSE scores than those in whom delirium did not develop (25.8 vs. 26.9, P<0.001). In adjusted models, those with delirium had a larger drop in cognitive function (as measured by the MMSE score) 2 days after surgery than did those without delirium (7.7 points vs. 2.1, P<0.001) and had significantly lower postoperative cognitive function than those without delirium, both at 1 month (mean MMSE score, 24.1 vs. 27.4; P<0.001) and at 1 year (25.2 vs. 27.2, P<0.001) after surgery. With adjustment for baseline differences, the between-group difference in mean MMSE scores was significant 30 days after surgery (P<0.001) but not at 6 or 12 months (P=0.056 for both). A higher percentage of patients with delirium than those without delirium had not returned to their preoperative baseline level at 6 months (40% vs. 24%, P=0.01), but the difference was not significant at 12 months (31% vs. 20%, P=0.055). CONCLUSIONS Delirium is associated with a significant decline in cognitive ability during the first year after cardiac surgery, with a trajectory characterized by an initial decline and prolonged impairment. (Funded by the Harvard Older Americans Independence Center and others.)	[Saczynski, Jane S.] Univ Massachusetts, Sch Med, Dept Med, Div Geriatr Med, Worcester, MA 01605 USA; [Saczynski, Jane S.] Univ Massachusetts, Sch Med, Meyers Primary Care Inst, Worcester, MA 01605 USA; [Marcantonio, Edward R.; Quach, Lien; Fong, Tamara G.; Gross, Alden; Inouye, Sharon K.; Jones, Richard N.] Hebrew SeniorLife, Aging Brain Ctr, Inst Aging Res, Boston, MA USA; [Marcantonio, Edward R.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; [Marcantonio, Edward R.; Gross, Alden; Inouye, Sharon K.; Jones, Richard N.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA; [Fong, Tamara G.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Marcantonio, Edward R.; Fong, Tamara G.; Inouye, Sharon K.; Jones, Richard N.] Harvard Univ, Sch Med, Boston, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Hebrew SeniorLife; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Saczynski, JS (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Geriatr Med, 377 Plantat St,Suite 315, Worcester, MA 01605 USA.	jane.saczynski@umassmed.edu	Inouye, Sharon/R-7216-2019; Marcantonio, Edward R/U-3929-2017; Pesudovs, Konrad/T-9403-2019; Jones, Richard Norman/J-3488-2013	Marcantonio, Edward R/0000-0002-2911-4250; Pesudovs, Konrad/0000-0002-6322-9369; Jones, Richard Norman/0000-0002-1049-218X	Harvard Older Americans Independence Center [P60AG008812]; National Institute on Aging [K01AG33643, R01AG030618, P01AG031720]; National Heart, Lung, and Blood Institute [U01HL105268]; National Institutes of Health (NIH) Mid-Career Investigator Award [K24AG035075]; NIH [T32 AG023480]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K24AG035075, R01AG030618, P60AG008812, P01AG031720, K01AG033643, T32AG023480] Funding Source: NIH RePORTER	Harvard Older Americans Independence Center; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health (NIH) Mid-Career Investigator Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by grants from the Harvard Older Americans Independence Center (P60AG008812), the National Institute on Aging (K01AG33643, to Dr. Saczynski), the National Heart, Lung, and Blood Institute (U01HL105268, to Dr. Saczynski), and the National Institute on Aging (R01AG030618, to Dr. Marcantonio, and P01AG031720, to Dr. Inouye), and by a National Institutes of Health (NIH) Mid-Career Investigator Award (K24AG035075, to Dr. Marcantonio) and an NIH Translational Research in Aging fellowship (T32 AG023480, to Dr. Gross). No potential conflict of interest relevant to this article was reported.	Albert M S, 1992, J Geriatr Psychiatry Neurol, V5, P14; Andrew MJ, 2001, J CARDIOTHOR VASC AN, V15, P9, DOI 10.1053/jcan.2001.20210; [Anonymous], 2004, NATL I ALCOHOL A WIN, P3; ANTHONY JC, 1982, PSYCHOL MED, V12, P397, DOI 10.1017/S0033291700046730; Blom G., 1958, STAT ESTIMATES TRANS; Bryson GL, 2011, CAN J ANESTH, V58, P246, DOI 10.1007/s12630-010-9446-6; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Collison T, 2006, ARCH SURG-CHICAGO, V141, P1214, DOI 10.1001/archsurg.141.12.1214; Cook DJ, 2007, ANN THORAC SURG, V83, P1389, DOI 10.1016/j.athoracsur.2006.11.089; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Fearn SJ, 2001, J THORAC CARDIOV SUR, V121, P1150, DOI 10.1067/mtc.2001.114099; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fong TG, 2009, NAT REV NEUROL, V5, P210, DOI 10.1038/nrneurol.2009.24; Franco K, 2001, PSYCHOSOMATICS, V42, P68, DOI 10.1176/appi.psy.42.1.68; Furlaneto ME, 2007, CLINICS, V62, P545, DOI 10.1590/S1807-59322007000500003; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Goto T, 2001, ANN THORAC SURG, V72, P137, DOI 10.1016/S0003-4975(01)02676-5; Gottesman RF, 2010, ANN NEUROL, V67, P338, DOI 10.1002/ana.21899; Gruber-Baldini AL, 2003, J AM GERIATR SOC, V51, P1227, DOI 10.1046/j.1532-5415.2003.51406.x; Ho PM, 2004, ANN THORAC SURG, V77, P597, DOI 10.1016/S0003-4975(03)01358-4; Hudetz JA, 2009, PSYCHOL REP, V105, P921, DOI 10.2466/PR0.105.3.921-932; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Jackson JC, 2004, NEUROPSYCHOL REV, V14, P87, DOI 10.1023/B:NERV.0000028080.39602.17; Kat MG, 2008, DEMENT GERIATR COGN, V26, P1, DOI 10.1159/000140611; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; Knipp SC, 2008, ANN THORAC SURG, V85, P872, DOI 10.1016/j.athoracsur.2007.10.083; Koster S, 2009, ANN THORAC SURG, V87, P1469, DOI 10.1016/j.athoracsur.2009.02.080; Loponen P, 2008, SCAND CARDIOVASC J, V42, P337, DOI 10.1080/14017430801939217; Maldonado JR, 2009, PSYCHOSOMATICS, V50, P206, DOI 10.1176/appi.psy.50.3.206; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; Marcantonio ER, 2001, J AM GERIATR SOC, V49, P516, DOI 10.1046/j.1532-5415.2001.49108.x; McKhann GM, 1997, LANCET, V349, P1282, DOI 10.1016/S0140-6736(96)09466-4; McKhann GM, 1997, ANN THORAC SURG, V63, P510; Mullges W, 2000, CRIT CARE MED, V28, P1808, DOI 10.1097/00003246-200006000-00020; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; Raymond PD, 2006, EUR J CARDIO-THORAC, V29, P82, DOI 10.1016/j.ejcts.2005.10.016; Rudolph JL, 2010, ACTA ANAESTH SCAND, V54, P663, DOI 10.1111/j.1399-6576.2010.02236.x; Rudolph JL, 2010, J AM GERIATR SOC, V58, P643, DOI 10.1111/j.1532-5415.2010.02762.x; Rudolph JL, 2009, CIRCULATION, V119, P229, DOI 10.1161/CIRCULATIONAHA.108.795260; Sands LP, 2003, J GERONTOL A-BIOL, V58, P37; Selnes AA, 2006, NEUROL CLIN, V24, P133, DOI 10.1016/j.ncl.2005.10.001; Selnes OA, 2003, ANN THORAC SURG, V75, P1377, DOI 10.1016/S0003-4975(03)00021-3; Selnes OA, 2012, NEW ENGL J MED, V366, P250, DOI 10.1056/NEJMra1100109; Simon SE, 2006, J AM MED DIR ASSOC, V7, P412, DOI 10.1016/j.jamda.2006.02.006; Singer J.D., 2003, APPL LONGITUDINAL DA; Sockalingam S, 2005, J CARDIAC SURG, V20, P560, DOI 10.1111/j.1540-8191.2005.00134.x; Stanley TO, 2002, ANESTH ANALG, V94, P290, DOI 10.1097/00000539-200202000-00011; Tagarakis Georgios I, 2007, Am J Alzheimers Dis Other Demen, V22, P223, DOI 10.1177/1533317507299415; Wei LA, 2008, J AM GERIATR SOC, V56, P823, DOI 10.1111/j.1532-5415.2008.01674.x; Wong CL, 2010, JAMA-J AM MED ASSOC, V304, P779, DOI 10.1001/jama.2010.1182	52	653	680	7	86	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					30	39		10.1056/NEJMoa1112923	http://dx.doi.org/10.1056/NEJMoa1112923			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968KJ	22762316	Green Accepted, Green Published			2022-12-28	WOS:000305979400003
J	Brewer, C				Brewer, Colin			Exclusive! Journalist admits to getting it wrong	BRITISH MEDICAL JOURNAL			English	Editorial Material									Stapleford Ctr, London, England		Brewer, C (corresponding author), Stapleford Ctr, London, England.	brewerismo@gmail.com							0	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 4	2012	344								e4559	10.1136/bmj.e4559	http://dx.doi.org/10.1136/bmj.e4559			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972KE	22763572				2022-12-28	WOS:000306275200011
J	Baeten, JM; Donnell, D; Ndase, P; Mugo, NR; Campbell, JD; Wangisi, J; Tappero, JW; Bukusi, EA; Cohen, CR; Katabira, E; Ronald, A; Tumwesigye, E; Were, E; Fife, KH; Kiarie, J; Farquhar, C; John-Stewart, G; Kakia, A; Odoyo, J; Mucunguzi, A; Nakku-Joloba, E; Twesigye, R; Ngure, K; Apaka, C; Tamooh, H; Gabona, F; Mujugira, A; Panteleeff, D; Thomas, KK; Kidoguchi, L; Krows, M; Revall, J; Morrison, S; Haugen, H; Emmanuel-Ogier, M; Ondrejcek, L; Coombs, RW; Frenkel, L; Hendrix, C; Bumpus, NN; Bangsberg, D; Haberer, JE; Stevens, WS; Lingappa, JR; Celum, C				Baeten, J. M.; Donnell, D.; Ndase, P.; Mugo, N. R.; Campbell, J. D.; Wangisi, J.; Tappero, J. W.; Bukusi, E. A.; Cohen, C. R.; Katabira, E.; Ronald, A.; Tumwesigye, E.; Were, E.; Fife, K. H.; Kiarie, J.; Farquhar, C.; John-Stewart, G.; Kakia, A.; Odoyo, J.; Mucunguzi, A.; Nakku-Joloba, E.; Twesigye, R.; Ngure, K.; Apaka, C.; Tamooh, H.; Gabona, F.; Mujugira, A.; Panteleeff, D.; Thomas, K. K.; Kidoguchi, L.; Krows, M.; Revall, J.; Morrison, S.; Haugen, H.; Emmanuel-Ogier, M.; Ondrejcek, L.; Coombs, R. W.; Frenkel, L.; Hendrix, C.; Bumpus, N. N.; Bangsberg, D.; Haberer, J. E.; Stevens, W. S.; Lingappa, J. R.; Celum, C.		Partners PrEP Study Team	Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUB-SAHARAN AFRICA; PREEXPOSURE PROPHYLAXIS; INTERMITTENT PROPHYLAXIS; SEXUAL TRANSMISSION; VIRAL LOAD; THERAPY; INFECTION; ADHERENCE; MACAQUES; COUPLES	Background Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations. Methods We conducted a randomized trial of oral antiretroviral therapy for use as preexposure prophylaxis among HIV-1-serodiscordant heterosexual couples from Kenya and Uganda. The HIV-1-seronegative partner in each couple was randomly assigned to one of three study regimens - once-daily tenofovir (TDF), combination tenofovir-emtricitabine (TDF-FTC), or matching placebo - and followed monthly for up to 36 months. At enrollment, the HIV-1-seropositive partners were not eligible for antiretroviral therapy, according to national guidelines. All couples received standard HIV-1 treatment and prevention services. Results We enrolled 4758 couples, of whom 4747 were followed: 1584 randomly assigned to TDF, 1579 to TDF-FTC, and 1584 to placebo. For 62% of the couples followed, the HIV-1-seronegative partner was male. Among HIV-1-seropositive participants, the median CD4 count was 495 cells per cubic millimeter (interquartile range, 375 to 662). A total of 82 HIV-1 infections occurred in seronegative participants during the study, 17 in the TDF group (incidence, 0.65 per 100 person-years), 13 in the TDF-FTC group (incidence, 0.50 per 100 person-years), and 52 in the placebo group (incidence, 1.99 per 100 person-years), indicating a relative reduction of 67% in the incidence of HIV-1 with TDF (95% confidence interval [CI], 44 to 81; P<0.001) and of 75% with TDF-FTC (95% CI, 55 to 87; P<0.001). Protective effects of TDF-FTC and TDF alone against HIV-1 were not significantly different (P = 0.23), and both study medications significantly reduced the HIV-1 incidence among both men and women. The rate of serious adverse events was similar across the study groups. Eight participants receiving active treatment were found to have been infected with HIV-1 at baseline, and among these eight, antiretroviral resistance developed in two during the study. Conclusions Oral TDF and TDF-FTC both protect against HIV-1 infection in heterosexual men and women. (Funded by the Bill and Melinda Gates Foundation; Partners PrEP ClinicalTrials.gov number, NCT00557245.)	[Baeten, J. M.] Univ Washington, Dept Global Hlth, Int Clin Res Ctr, Seattle, WA 98104 USA; [Baeten, J. M.; Farquhar, C.; John-Stewart, G.; Coombs, R. W.; Lingappa, J. R.; Celum, C.] Univ Washington, Dept Med, Seattle, WA 98104 USA; [Baeten, J. M.; Farquhar, C.; John-Stewart, G.; Celum, C.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA; [Coombs, R. W.; Frenkel, L.] Univ Washington, Dept Lab Med, Seattle, WA 98104 USA; [Frenkel, L.; Lingappa, J. R.] Univ Washington, Dept Pediat, Seattle, WA 98104 USA; [Donnell, D.] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, Seattle, WA 98104 USA; [Ondrejcek, L.] DF Net Res, Seattle, WA USA; [Frenkel, L.] Seattle Childrens Hosp Res Inst, Seattle, WA USA; [Mugo, N. R.; Bukusi, E. A.; Kiarie, J.; Ngure, K.; Tamooh, H.] Univ Nairobi, Dept Obstet & Gynecol, Nairobi, Kenya; [Mugo, N. R.; Bukusi, E. A.; Kiarie, J.; Ngure, K.; Tamooh, H.] Kenyatta Natl Hosp, Nairobi, Kenya; [Bukusi, E. A.; Odoyo, J.] Kenya Govt Med Res Ctr, Ctr Microbiol Res, Nairobi, Kenya; [Were, E.; Apaka, C.] Moi Univ, Dept Reprod Hlth, Eldoret, Kenya; [Campbell, J. D.] Ctr Dis Control & Prevent, Entebbe, Uganda; [Wangisi, J.; Kakia, A.; Mucunguzi, A.] Makerere Univ, AIDS Support Org, Kampala, Uganda; [Katabira, E.; Ronald, A.; Nakku-Joloba, E.; Gabona, F.] Makerere Univ, Infect Dis Inst, Kampala, Uganda; [Tumwesigye, E.; Twesigye, R.] Kabwohe Clin Res Ctr, Kabwohe, Uganda; [Tappero, J. W.] Ctr Dis Control & Prevent, Atlanta, GA USA; [Bukusi, E. A.; Cohen, C. R.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA; [Ronald, A.] Univ Manitoba, Dept Med, Winnipeg, MB, Canada; [Fife, K. H.] Indiana Univ, Dept Med, Indianapolis, IN USA; [Hendrix, C.; Bumpus, N. N.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA; [Bangsberg, D.; Haberer, J. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Bangsberg, D.; Haberer, J. E.] Harvard Univ, Sch Med, Boston, MA USA; [Stevens, W. S.] Univ Witwatersrand, Dept Mol Med & Hematol, Johannesburg, South Africa; [Stevens, W. S.] Wits Hlth Consortium, Contract Lab Serv, Johannesburg, South Africa	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Seattle Children's Hospital; University of Nairobi; Kenyatta National Hospital; Kenya Medical Research Institute; Moi University; Makerere University; Makerere University; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco; University of Manitoba; Indiana University System; Indiana University-Purdue University Indianapolis; Johns Hopkins University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Witwatersrand; University of Witwatersrand	Baeten, JM (corresponding author), Univ Washington, Dept Global Hlth, Int Clin Res Ctr, Box 359927,325 9th Ave, Seattle, WA 98104 USA.	jbaeten@uw.edu	Haberer, Jessica/AAH-7976-2019; John-Stewart, Grace/U-3351-2019; Lingappa, Jairam/N-7760-2017; Hendrix, Craig W/G-4182-2014; John-Stewart, Grace/L-3650-2019; Trajman, Anete/C-7679-2016	Haberer, Jessica/0000-0001-5845-3190; Hendrix, Craig W/0000-0002-5696-8665; Trajman, Anete/0000-0002-4000-4984; Ronald, Allan/0000-0002-5746-3490; Joloba, Moses/0000-0002-0334-9983; Were, Edwin/0000-0002-4783-0795; Donnell, Deborah/0000-0002-0587-7480; John-Stewart, Grace/0000-0002-4301-1573; kiarie, james/0000-0003-4180-7858; Frenkel, Lisa M/0000-0001-9566-8959; Ondondo, Raphael/0000-0001-5922-7208; Mujugira, Andrew/0000-0001-6646-6733; Thomas, Katherine K/0000-0002-7024-468X; Rono, Bernard/0000-0001-6553-8491	Bill and Melinda Gates Foundation [47674]; NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH087228] Funding Source: NIH RePORTER	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Supported by a research grant (ID #47674) from the Bill and Melinda Gates Foundation.	[Anonymous], 2011, OR TOP PREP TRIALS T; [Anonymous], 2011, NIH MOD VOICE HIV PR; Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca; Celum C, 2010, NEW ENGL J MED, V362, P427, DOI 10.1056/NEJMoa0904849; Cohen MS, 2007, ANN INTERN MED, V146, P591, DOI 10.7326/0003-4819-146-8-200704170-00010; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cooper RD, 2010, CLIN INFECT DIS, V51, P496, DOI 10.1086/655681; Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2; Dunkle KL, 2008, LANCET, V371, P2183, DOI 10.1016/S0140-6736(08)60953-8; Eyawo O, 2010, LANCET INFECT DIS, V10, P770, DOI 10.1016/S1473-3099(10)70189-4; Garcia-Lerma JG, 2008, PLOS MED, V5, P291, DOI 10.1371/journal.pmed.0050028; Garcia-Lerma JG, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000391; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Grant RM, 2010, CLIN INFECT DIS, V50, pS96, DOI 10.1086/651479; Haberer J, 2011, 18 C RETR OPP INF BO; Hallett TB, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001123; Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9; Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107; Karim QA, 2011, SCIENCE, V333, P524; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Karim SSA, 2011, LANCET, V378, pE23, DOI 10.1016/S0140-6736(11)61136-7; Karim SSA, 2011, LANCET, V378, P279, DOI 10.1016/S0140-6736(11)60878-7; Kumwenda NI, 2008, NEW ENGL J MED, V359, P119, DOI 10.1056/NEJMoa0801941; Laeyendecker O, 2004, J CLIN MICROBIOL, V42, P1794, DOI 10.1128/JCM.42.4.1794-1796.2004; Lampe MA, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2011.02.026; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Matthews LT, 2010, AIDS, V24, P1975, DOI 10.1097/QAD.0b013e32833bedeb; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; Mugo NR, 2011, AIDS, V25, P1887, DOI 10.1097/QAD.0b013e32834a9338; Mujugira A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025828; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Padian NS, 2011, LANCET, V378, P269, DOI 10.1016/S0140-6736(11)60877-5; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rehle TM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011094; Roland ME, 2005, CLIN INFECT DIS, V41, P1507, DOI 10.1086/497268; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; Vernazza PL, 2011, AIDS, V25, P2005, DOI 10.1097/QAD.0b013e32834a36d0; Ware NC, 2012, JAIDS-J ACQ IMM DEF, V59, P463, DOI 10.1097/QAI.0b013e31824a060b	40	2136	2180	4	175	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2012	367	5					399	410		10.1056/NEJMoa1108524	http://dx.doi.org/10.1056/NEJMoa1108524			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981VZ	22784037	Green Accepted			2022-12-28	WOS:000307001900005
J	Killen, J; Harrington, M; Fauci, AS				Killen, Jack; Harrington, Mark; Fauci, Anthony S.			MSM, AIDS research activism, and HAART	LANCET			English	Editorial Material									[Killen, Jack] NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA; [Harrington, Mark] Treatment Act Grp, New York, NY USA; [Fauci, Anthony S.] NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Killen, J (corresponding author), NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA.	jack.killen@nih.gov						Ad-hoc coalition of AIDS and health organisations, 1990, HIV AIDS BIOM RES PR; *CDCP, 1981, MMWR-MORBID MORTAL W, V30, P305; DELANEY M, 1989, J INFECT DIS, V159, P416, DOI 10.1093/infdis/159.3.416; Epstein S., 1996, IMPURE SCI; Food and Drug Administration, EXP ACC EXP APPR NEW; Geffen N., 2010, DEBUNKING DELUSIONS; Goldberg R, C CALL PWAS SAT HIGH; Jennings V, 1990, WASH POST, pB1; Killen John Y., 2008, OXFORD TXB CLIN RES, P97; Nunn Amy, 2009, POLITICS HIST AIDS T; Pozalski I, 1981, MMWR-MORBID MORTAL W, V30, P1; WACHTER RM, 1992, NEW ENGL J MED, V326, P128, DOI 10.1056/NEJM199201093260209	12	11	11	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 28	2012	380	9839					314	316		10.1016/S0140-6736(12)60635-7	http://dx.doi.org/10.1016/S0140-6736(12)60635-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819655				2022-12-28	WOS:000306842800007
J	Sampat, BN; Shadlen, KC; Amin, TM				Sampat, Bhaven N.; Shadlen, Kenneth C.; Amin, Tahir M.			Challenges to India's Pharmaceutical Patent Laws	SCIENCE			English	Editorial Material							LIFE		[Sampat, Bhaven N.] Columbia Univ, New York, NY 10032 USA; [Shadlen, Kenneth C.] London Sch Econ, London WC2A 2AE, England; [Amin, Tahir M.] Initiat Med Access & Knowledge, New York, NY 10016 USA; [Amin, Tahir M.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02115 USA	Columbia University; University of London; London School Economics & Political Science; Harvard University; Harvard Medical School	Sampat, BN (corresponding author), Columbia Univ, New York, NY 10032 USA.	bns3@columbia.edu		Shadlen, Kenneth/0000-0003-4010-4835				Basheer S., PATENT OPPOSITIONS I; Basheer Shamnad, 2008, SCRIPTED, V5, P232; Correa C.M., 2007, GUIDELINES EXAMINATI; Eisenberg Rebecca S., 2008, LEWIS CLARK L REV, V12, P375; Furrow ME, 2008, FOOD DRUG LAW J, V63, P275; Grogan K., 2012, PHARMATIMES     0224; Hemphill CS, 2012, J HEALTH ECON, V31, P327, DOI 10.1016/j.jhealeco.2012.01.004; Hemphill CS, 2011, J EMPIR LEGAL STUD, V8, P613, DOI 10.1111/j.1740-1461.2011.01235.x; Jaffe A. B., 2006, INNOVATION ITS DISCO; Kapczynski A, 2009, CALIF LAW REV, V97, P1571; Novartis, GLIV PAT CAS IND FAC; Office of the U.S, 2012, SPEC 301 REP 2010 20; ParagraphFour.com, GLEEV IM TABL; Pharmaceutical Research and Manufacturers of America, 2010, SPEC 301 SUBM; Pray L., 2008, NAT ED, V1, P565; U.S.- India Business Council, 2009, VAL INCR PHARM INN B; UNAIDS, 2011, DOHA 10 TRIPS FLEX A	17	13	13	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 27	2012	337	6093					414	415		10.1126/science.1224892	http://dx.doi.org/10.1126/science.1224892			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	979FS	22767892				2022-12-28	WOS:000306802300024
J	Pishdad, GR; Pishdad, R; Pishdad, P				Pishdad, Gholam R.; Pishdad, Reza; Pishdad, Parisa			A dual hyperthyroidism	LANCET			English	Editorial Material							PAPILLARY THYROID-CARCINOMA; RADIOACTIVE IODINE; NODULE		[Pishdad, Gholam R.] Shiraz Univ Med Sci, Namazi Hosp, Endocrine & Metab Res Ctr, Shiraz, Iran; [Pishdad, Reza] Shiraz Univ Med Sci, Namazi Hosp, Dept Internal Med, Shiraz, Iran; [Pishdad, Parisa] Shiraz Univ Med Sci, Namazi Hosp, Dept Radiol, Shiraz, Iran	Shiraz University of Medical Science; Shiraz University of Medical Science; Shiraz University of Medical Science	Pishdad, GR (corresponding author), Shiraz Univ, Med Ctr, Namazi Hosp, Endocrine & Metab Res Ctr, POB 71365-577, Shiraz, Iran.	pishdadg@sums.ac.ir	Pishdad, Parisa/V-1924-2017	Pishdad, Parisa/0000-0002-8134-7182				Bitton R N, 2001, Endocr Pract, V7, P106; Cirillo RL, 1998, CLIN NUCL MED, V23, P345, DOI 10.1097/00003072-199806000-00001; OZAKI O, 1994, WORLD J SURG, V18, P518, DOI 10.1007/BF00353753; Tfayli HM, 2010, THYROID, V20, P1029, DOI 10.1089/thy.2010.0144; Uludag M, 2008, HORM-INT J ENDOCRINO, V7, P175, DOI 10.1007/BF03401510	5	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 21	2012	380	9838					306	306		10.1016/S0140-6736(12)60523-6	http://dx.doi.org/10.1016/S0140-6736(12)60523-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976TV	22817976				2022-12-28	WOS:000306609200039
J	Avorn, J				Avorn, Jerry			Two Centuries of Assessing Drug Risks	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LITIGATION		[Avorn, Jerry] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Avorn, Jerry] Harvard Univ, Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Avorn, J (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Graham DY, 2011, AM J MED SCI, V342, P356, DOI 10.1097/MAJ.0b013e3182113658; Harris G., 2006, NY TIMES; Holmes OW, 1919, BARTLETTS FAMILIAR Q; Kesselheim AS, 2007, JAMA-J AM MED ASSOC, V297, P308, DOI 10.1001/jama.297.3.308; Madigan D, 2012, AM HEART J, V164, P186, DOI 10.1016/j.ahj.2012.05.002	5	24	25	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2012	367	3					193	197		10.1056/NEJMp1206652	http://dx.doi.org/10.1056/NEJMp1206652			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975PI	22808954				2022-12-28	WOS:000306522900001
J	O'Halloran, T; Bell, RJ; Robinson, PJ; Davis, SR				O'Halloran, Tessa; Bell, Robin J.; Robinson, Penelope J.; Davis, Susan R.			Urinary Incontinence in Young Nulligravid Women A Cross-sectional Analysis	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; SEEKING BEHAVIOR; PREVALENCE; QUESTIONNAIRE; COHORT; RISK; AGE	Background: Although pregnancy is a risk factor for urinary incontinence (UI), the extent of UI in nulligravid women has not been reported. Objective: To investigate the rate of UI in a sample of young nulligravid women and its potential risk factors and effect on quality of life. Design: Cross-sectional, self-administered questionnaire-based study. Setting: University campuses and medical and allied health clinics. Participants: Nulligravid Australian women aged 16 to 30 years. Measurements: The Questionnaire for Urinary Incontinence Diagnosis, the Psychological General Well-Being Index (PGWBI), the King's Health Questionnaire, and the International Physical Activity Questionnaire-Short Form. Demographic variables and potential risk factors were also documented. Results: 1018 of 1620 questionnaires (63%) were returned, and 1002 provided analyzable data. The mean age of participants was 22.5 years (SD, 3.2). The rate of any UI was 12.6% (95% CI, 10.5% to 14.7%). Incontinence was slightly more common in students than in nonstudents (13.2% [CI, 11.0% to 15.8%] vs. 10.6% [CI, 6.7% to 14.6%]). Rates of UI varied according to sexual activity and use of combined oral contraceptives (COCs), with highest rates reported by students who were ever sexually active and not using COCs (21.5% [CI, 16.7% to 27.3%]). Women with UI reported significantly lower overall well-being than women without UI and had worse PGWBI scores related to anxiety, depression, positive well-being, and self-control. Limitation: A convenience sample of healthy, well-educated women was recruited, and response rates and participant characteristics varied by setting. Conclusion: In a sample of young nulligravid women, UI was associated with ever being sexually active and no COC use, as well as lower psychological well-being. Further research is needed to assess the prevalence and risk factors for UI in nulligravid women.	[O'Halloran, Tessa; Bell, Robin J.; Robinson, Penelope J.; Davis, Susan R.] Monash Univ, Sch Publ Hlth, Womens Hlth Res Program, Melbourne, Vic 3004, Australia	Monash University	Davis, SR (corresponding author), Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, 99 Commercial Rd, Melbourne, Vic 3004, Australia.	susan.davis@monash.edu	Davis, Susan D/GZL-2361-2022; Bell, Robin J/H-6750-2014; Davis, Susan R/A-3111-2009	Bell, Robin J/0000-0003-1935-7627; Davis, Susan R/0000-0002-2955-0415	Australian National Health and Medical Research Council [490939]; Victorian Cancer Agency Public Health Research Fellowship	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Victorian Cancer Agency Public Health Research Fellowship	By grant 490939 from the Australian National Health and Medical Research Council (Dr. Davis) and a Victorian Cancer Agency Public Health Research Fellowship (Dr. Bell).	Bell RJ, 2010, SUPPORT CARE CANCER, V18, P921, DOI 10.1007/s00520-009-0726-z; Booth M, 2000, RES Q EXERCISE SPORT, V71, pS114; Botlero R, 2008, INT J UROL, V15, P230, DOI 10.1111/j.1442-2042.2007.01976.x; Botlero R, 2010, MENOPAUSE, V17, P332, DOI 10.1097/gme.0b013e3181ba571a; Botlero R, 2009, MATURITAS, V62, P134, DOI 10.1016/j.maturitas.2008.12.017; Bradley CS, 2005, AM J OBSTET GYNECOL, V192, P66, DOI 10.1016/j.ajog.2004.07.037; Brown SJ, 2010, INT UROGYNECOL J, V21, P193, DOI 10.1007/s00192-009-1011-x; Brown WJ, 2001, J SCI MED SPORT, V4, P373, DOI 10.1016/S1440-2440(01)80046-3; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Dupuy H.J., 1984, ASSESSMENT QUALITY L, P170; Hagglund D, 1999, FAM PRACT, V16, P506, DOI 10.1093/fampra/16.5.506; Hagglund D, 2007, J CLIN NURS, V16, P1946, DOI 10.1111/j.1365-2702.2007.01787.x; Hagglund D, 2007, SCAND J CARING SCI, V21, P305, DOI 10.1111/j.1471-6712.2007.00481.x; Iliadou A, 2009, FERTIL STERIL, V92, P428, DOI 10.1016/j.fertnstert.2008.07.002; Kelleher CJ, 1997, BRIT J OBSTET GYNAEC, V104, P1374, DOI 10.1111/j.1471-0528.1997.tb11006.x; MacLennan AH, 2000, BRIT J OBSTET GYNAEC, V107, P1460, DOI 10.1111/j.1471-0528.2000.tb11669.x; NEMIR A, 1954, AM J OBSTET GYNECOL, V68, P1166; NYGAARD IE, 1994, OBSTET GYNECOL, V84, P183; Shaw C, 2001, J CLIN NURS, V10, P15, DOI 10.1046/j.1365-2702.2001.00443.x; Siracusano S, 2003, EUR J OBSTET GYN R B, V107, P201, DOI 10.1016/S0301-2115(02)00407-4; Townsend MK, 2009, J UROLOGY, V181, P2170, DOI 10.1016/j.juro.2009.01.040; WOLIN LH, 1969, J UROLOGY, V101, P545, DOI 10.1016/S0022-5347(17)62378-4	22	35	35	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2					87	+		10.7326/0003-4819-157-2-201207170-00005	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	992ON	22801671				2022-12-28	WOS:000307787900014
J	Al Rabeeah, A; Memish, ZA; Zumla, A; Shafi, S; McCloskey, B; Moolla, A; Barbeschi, M; Heymann, D; Horton, R				Al Rabeeah, Abdullah; Memish, Ziad A.; Zumla, Alimuddin; Shafi, Shuja; McCloskey, Brian; Moolla, Ahmad; Barbeschi, Maurizio; Heymann, David; Horton, Richard			Mass gatherings medicine and global health security	LANCET			English	Editorial Material									[Al Rabeeah, Abdullah; Memish, Ziad A.] Minist Hlth, Riyadh 11176, Saudi Arabia; [Memish, Ziad A.] Alfaisal Univ, Riyadh, Saudi Arabia; [Zumla, Alimuddin] UCL, Div Infect & Immun, London, England; [Shafi, Shuja] Muslim Council Britain, London, England; [McCloskey, Brian] Hlth Protect Agcy, WHO Collaborating Ctr Mass Gatherings, London, England; [Moolla, Ahmad] Univ London Imperial Coll Sci Technol & Med, London, England; [Barbeschi, Maurizio] World Hlth Org, Geneva, Switzerland; [Heymann, David] Chatham House, London, England; [Heymann, David] London Sch Hyg & Trop Med, London WC1, England; [Horton, Richard] The Lancet, London NW1 7BY, England	Ministry of Health - Saudi Arabia; Alfaisal University; University of London; University College London; Health Protection Agency; Imperial College London; World Health Organization; University of London; London School of Hygiene & Tropical Medicine	Memish, ZA (corresponding author), Minist Hlth, Riyadh 11176, Saudi Arabia.	zmemish@yahoo.com	ZUMLA, Alimuddin/ABA-8208-2020; Memish, Ziad Ahmed/AEJ-9424-2022	ZUMLA, Alimuddin/0000-0002-5111-5735; Memish, Ziad Ahmed/0000-0002-5099-0714; Shafi, Shuja/0000-0002-4659-8365				Abubakar I, 2012, LANCET INFECT DIS, V12, P66, DOI 10.1016/S1473-3099(11)70246-8; Memish ZA, 2012, LANCET INFECT DIS, V12, P56, DOI 10.1016/S1473-3099(11)70337-1; Memish ZA, 2012, LANCET INFECT DIS, V12, P10, DOI 10.1016/S1473-3099(11)70319-X; Ministry of Health Kingdom of Saudi Arabia, 2012, WHO GEN ASS EMBR SAU; Steffen R, 2012, LANCET INFECT DIS, V12, P142, DOI 10.1016/S1473-3099(11)70293-6; Tam JS, 2012, LANCET INFECT DIS, V12, P231, DOI 10.1016/S1473-3099(11)70353-X; WHO, 2012, EX BOARD 130 SESS JA; WHO, 2012, 65 WORLD HLTH ASS EX; World Health Organization, 2011, GLOB MASS GATH IMPL	9	18	18	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 7	2012	380	9836					3	4						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970GK	22770444				2022-12-28	WOS:000306115900004
J	Dawson, MA; Kouzarides, T				Dawson, Mark A.; Kouzarides, Tony			Cancer Epigenetics: From Mechanism to Therapy	CELL			English	Review							HISTONE DEACETYLASE INHIBITORS; IDENTIFIES FREQUENT MUTATION; METHYLTRANSFERASE GENE EZH2; CHROMATIN REMODELING GENES; ACUTE MYELOID-LEUKEMIA; SOMATIC MUTATIONS; DNA METHYLATION; INACTIVATING MUTATIONS; MOLECULAR-MECHANISMS; GENOME	The epigenetic regulation of DNA-templated processes has been intensely studied over the last 15 years. DNA methylation, histone modification, nucleosome remodeling, and RNA-mediated targeting regulate many biological processes that are fundamental to the genesis of cancer. Here, we present the basic principles behind these epigenetic pathways and highlight the evidence suggesting that their misregulation can culminate in cancer. This information, along with the promising clinical and preclinical results seen with epigenetic drugs against chromatin regulators, signifies that it is time to embrace the central role of epigenetics in cancer.	[Dawson, Mark A.; Kouzarides, Tony] Univ Cambridge, Gurdon Inst, Cambridge CB2 1QN, England; [Dawson, Mark A.; Kouzarides, Tony] Univ Cambridge, Dept Pathol, Cambridge CB2 1QN, England; [Dawson, Mark A.] Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 0XY, England; [Dawson, Mark A.] Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 0XY, England	University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QN, England.	t.kouzarides@gurdon.cam.ac.uk	Dawson, Mark A/B-9317-2017	Dawson, Mark A/0000-0002-5464-5029; Kouzarides, Tony/0000-0002-8918-4162	Wellcome-Beit Intermediate Clinical Fellowship; Cancer Research UK (CRUK)	Wellcome-Beit Intermediate Clinical Fellowship; Cancer Research UK (CRUK)(Cancer Research UK)	The scope of this review and its space limitations have unfortunately meant that we have not been able to separately cite many of the original publications that have contributed substantially to the field. We sincerely apologize to the authors of these publications. We would like to thank Drs. Andy Bannister and Brian Huntly for valued input and critical appraisal of the manuscript. We would also like to thank Dr. Peter Campbell for sharing data from the International Cancer Genome Consortium and Prof. Gerald Crabtree for helpful discussions. Mark Dawson is supported by a Wellcome-Beit Intermediate Clinical Fellowship, and the Kouzarides lab is funded by a program grant from Cancer Research UK (CRUK).	ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Allis CD, 2007, EPIGENETICS; Amaral PP, 2008, SCIENCE, V319, P1787, DOI 10.1126/science.1155472; Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Baek SH, 2011, MOL CELL, V42, P274, DOI 10.1016/j.molcel.2011.03.022; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Chung CW, 2011, J BIOMOL SCREEN, V16, P1170, DOI 10.1177/1087057111421372; Cimmino L, 2011, CELL STEM CELL, V9, P193, DOI 10.1016/j.stem.2011.08.007; Cole PA, 2008, NAT CHEM BIOL, V4, P590, DOI 10.1038/nchembio.111; Coles AH, 2009, J CELL PHYSIOL, V218, P45, DOI 10.1002/jcp.21583; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Dawson M.A., 2011, ENCY MOL CELL BIOL M; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; de Wit E, 2012, GENE DEV, V26, P11, DOI 10.1101/gad.179804.111; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dialynas GK, 2008, MUTAT RES-FUND MOL M, V647, P13, DOI 10.1016/j.mrfmmm.2008.09.007; Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636; Federico M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/475641; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gore SD, 2011, HEMATOL-AM SOC HEMAT, P550, DOI 10.1182/asheducation-2011.1.550; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732; Langemeijer SMC, 2009, NAT GENET, V41, P838, DOI 10.1038/ng.391; Lee JS, 2010, CELL, V142, P682, DOI 10.1016/j.cell.2010.08.011; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Li DQ, 2012, CANCER RES, V72, P387, DOI 10.1158/0008-5472.CAN-11-2345; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lorsbach RB, 2003, LEUKEMIA, V17, P637, DOI 10.1038/sj.leu.2402834; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Rando OJ, 2009, ANNU REV BIOCHEM, V78, P245, DOI 10.1146/annurev.biochem.78.071107.134639; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Rui LX, 2010, CANCER CELL, V18, P590, DOI 10.1016/j.ccr.2010.11.013; Ruthenburg AJ, 2011, CELL, V145, P692, DOI 10.1016/j.cell.2011.03.053; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Segal E, 2009, NAT REV GENET, V10, P443, DOI 10.1038/nrg2591; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Stunnenberg HG, 2011, BIOESSAYS, V33, P547, DOI 10.1002/bies.201100044; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tan MJ, 2011, CELL, V146, P1015, DOI 10.1016/j.cell.2011.08.008; Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang GG, 2007, TRENDS MOL MED, V13, P373, DOI 10.1016/j.molmed.2007.07.004; Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036; Wang J, 2005, EMBO J, V24, P368, DOI 10.1038/sj.emboj.7600521; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102; Wu H, 2011, GENE DEV, V25, P2436, DOI 10.1101/gad.179184.111; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang X, 2012, CANCER GENE THER, V19, P153, DOI 10.1038/cgt.2011.85; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	116	1937	2038	38	668	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 6	2012	150	1					12	27		10.1016/j.cell.2012.06.013	http://dx.doi.org/10.1016/j.cell.2012.06.013			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770212	Bronze			2022-12-28	WOS:000306115000003
J	Inker, LA; Schmid, CH; Tighiouart, H; Eckfeldt, JH; Feldman, HI; Greene, T; Kusek, JW; Manzi, J; Van Lente, F; Zhang, YL; Coresh, J; Levey, AS				Inker, Lesley A.; Schmid, Christopher H.; Tighiouart, Hocine; Eckfeldt, John H.; Feldman, Harold I.; Greene, Tom; Kusek, John W.; Manzi, Jane; Van Lente, Frederick; Zhang, Yaping Lucy; Coresh, Josef; Levey, Andrew S.		CKD-EPI Investigators	Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC KIDNEY-DISEASE; RISK POPULATION COHORTS; COLLABORATIVE METAANALYSIS; HIGHER ALBUMINURIA; ESTIMATING GFR; RENAL-DISEASE; ALL-CAUSE; MORTALITY; EQUATIONS; ASSOCIATION	BACKGROUND Estimates of glomerular filtration rate (GFR) that are based on serum creatinine are routinely used; however, they are imprecise, potentially leading to the overdiagnosis of chronic kidney disease. Cystatin C is an alternative filtration marker for estimating GFR. METHODS Using cross-sectional analyses, we developed estimating equations based on cystatin C alone and in combination with creatinine in diverse populations totaling 5352 participants from 13 studies. These equations were then validated in 1119 participants from 5 different studies in which GFR had been measured. Cystatin and creatinine assays were traceable to primary reference materials. RESULTS Mean measured GFRs were 68 and 70 ml per minute per 1.73 m(2) of body-surface area in the development and validation data sets, respectively. In the validation data set, the creatinine-cystatin C equation performed better than equations that used creatinine or cystatin C alone. Bias was similar among the three equations, with a median difference between measured and estimated GFR of 3.9 ml per minute per 1.73 m(2) with the combined equation, as compared with 3.7 and 3.4 ml per minute per 1.73 m(2) with the creatinine equation and the cystatin C equation (P = 0.07 and P = 0.05), respectively. Precision was improved with the combined equation (inter-quartile range of the difference, 13.4 vs. 15.4 and 16.4 ml per minute per 1.73 m(2), respectively [P = 0.001 and P<0.001]), and the results were more accurate (percentage of estimates that were >30% of measured GFR, 8.5 vs. 12.8 and 14.1, respectively [P<0.001 for both comparisons]). In participants whose estimated GFR based on creatinine was 45 to 74 ml per minute per 1.73 m(2), the combined equation improved the classification of measured GFR as either less than 60 ml per minute per 1.73 m(2) or greater than or equal to 60 ml per minute per 1.73 m(2) (net reclassification index, 19.4% [P<0.001]) and correctly reclassified 16.9% of those with an estimated GFR of 45 to 59 ml per minute per 1.73 m(2) as having a GFR of 60 ml or higher per minute per 1.73 m(2). CONCLUSIONS The combined creatinine-cystatin C equation performed better than equations based on either of these markers alone and may be useful as a confirmatory test for chronic kidney disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases.)	[Inker, Lesley A.] Tufts Med Ctr, Div Nephrol, Boston, MA 02111 USA; [Eckfeldt, John H.] Univ Minnesota, Minneapolis, MN USA; [Feldman, Harold I.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Greene, Tom] Univ Utah, Salt Lake City, UT USA; [Kusek, John W.] NIH, Bethesda, MD 20892 USA; [Manzi, Jane; Coresh, Josef] Johns Hopkins Univ, Baltimore, MD USA; [Van Lente, Frederick] Cleveland Clin Fdn, Cleveland, OH 44195 USA	Tufts Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; Johns Hopkins University; Cleveland Clinic Foundation	Inker, LA (corresponding author), Tufts Med Ctr, Div Nephrol, 800 Washington St,Box 391, Boston, MA 02111 USA.	linker@tuftsmedicalcenter.org	Schmid, Christopher H./J-2398-2014; Bakoush, Omran/B-9395-2009; Froissart, Marc/L-7493-2014	Schmid, Christopher H./0000-0002-0855-5313; Bakoush, Omran/0000-0003-1447-9836; Froissart, Marc/0000-0002-4010-3173; rossing, peter/0000-0002-1531-4294; Greene, Tom/0000-0002-3706-7570	National Institute of Diabetes and Digestive and Kidney Diseases [UO1 DK 053869, UO1 DK 067651, UO1 DK 35073]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK067651, U01DK053869, U01DK035073] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants (UO1 DK 053869, UO1 DK 067651, and UO1 DK 35073) from the National Institute of Diabetes and Digestive and Kidney Diseases.	Astor BC, 2011, KIDNEY INT, V79, P1331, DOI 10.1038/ki.2010.550; Blirup-Jensen S, 2008, SCAND J CLIN LAB INV, V68, P67, DOI 10.1080/00365510802150067; College of American Pathologists, 2011, CURR STAT REP EST GL; Efron B., 1994, MONOGRAPHS STAT APPL; Gansevoort RT, 2011, KIDNEY INT, V80, P93, DOI 10.1038/ki.2010.531; Grubb A, 2010, CLIN CHEM LAB MED, V48, P1619, DOI 10.1515/CCLM.2010.318; Inker LA, 2011, AM J KIDNEY DIS, V58, P682, DOI 10.1053/j.ajkd.2011.05.019; Kwong YT, 2010, AM J KIDNEY DIS, V56, P39, DOI 10.1053/j.ajkd.2010.02.347; Levey AS, 2011, ANN INTERN MED, V155, P408, DOI 10.7326/0003-4819-155-6-201109200-00024; Levey AS, 2007, CLIN CHEM, V53, P766, DOI 10.1373/clinchem.2006.077180; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140-6736(10)60674-5; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Peralta CA, 2011, JAMA-J AM MED ASSOC, V305, P1545, DOI 10.1001/jama.2011.468; Peralta CA, 2011, J AM SOC NEPHROL, V22, P147, DOI 10.1681/ASN.2010050483; Rule AD, 2006, KIDNEY INT, V69, P399, DOI 10.1038/sj.ki.5000073; Shlipak MG, 2005, NEW ENGL J MED, V352, P2049, DOI 10.1056/NEJMoa043161; Stevens LA, 2008, AM J KIDNEY DIS, V51, P395, DOI 10.1053/j.ajkd.2007.11.018; Stevens LA, 2006, NEW ENGL J MED, V354, P2473, DOI 10.1056/NEJMra054415; Stevens LA, 2010, CURR OPIN NEPHROL HY, V19, P298, DOI 10.1097/MNH.0b013e32833893e2; Stevens LA, 2008, J NEPHROL, V21, P797; Stevens LA, 2009, KIDNEY INT, V75, P652, DOI 10.1038/ki.2008.638; Tangri N, 2011, KIDNEY INT, V79, P471, DOI 10.1038/ki.2010.431; van der Velde M, 2011, KIDNEY INT, V79, P1341, DOI 10.1038/ki.2010.536; Vinge E, 1999, SCAND J CLIN LAB INV, V59, P587, DOI 10.1080/00365519950185076	25	2398	2480	4	111	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					20	29		10.1056/NEJMoa1114248	http://dx.doi.org/10.1056/NEJMoa1114248			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968KJ	22762315	Green Accepted			2022-12-28	WOS:000305979400002
J	Merola, JF; Ghoroghchian, PP; Samuels, MA; Levy, BD; Loscalzo, J				Merola, Joseph F.; Ghoroghchian, Paiman Peter; Samuels, Martin A.; Levy, Bruce D.; Loscalzo, Joseph			At a Loss	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BARIATRIC SURGERY; DEFICIENCIES	A 31-year-old woman who had been unable to eat or drink for the preceding week was admitted to the hospital. For the preceding 8 months she had had nausea, vomiting, and abdominal discomfort and several episodes of crampy epigastric pain with vomiting and intermittent chills and sweats, but no documented fevers. She also had loose, pale stools occasionally, but these episodes did not represent a notable change from her baseline. Gradually increasing fatigue, loss of appetite, and a recent weight loss of several kilograms were also reported. The patient's medical history included hypertension, obesity, and migraine headaches. She had undergone Roux-en-Y gastric bypass 5 years before presentation and subsequently lost approximately 45 kg (100 lb). Her weight had been stable for the past few years; her body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) was 33. She had undergone laparoscopic cholecystectomy 10 years before presentation. Her only medication was nifedipine, and she took a multivitamin on occasion.	[Merola, Joseph F.; Ghoroghchian, Paiman Peter; Levy, Bruce D.; Loscalzo, Joseph] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Samuels, Martin A.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; [Samuels, Martin A.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Levy, BD (corresponding author), Brigham & Womens Hosp, Dept Med, Harvard Inst Med Bldg,HIM855,77 Ave Louis Pasteur, Boston, MA 02115 USA.	blevy@partners.org	Loscalzo, Joseph/ABD-8980-2021	Merola, Joseph/0000-0001-6514-4353	Lighthouse Learning	Lighthouse Learning	Dr. Samuels reports receiving salary support and payment for educational presentations from Lighthouse Learning and royalties from Oakstone Publishing, McGraw-Hill, and Elsevier. No other potential conflict of interest relevant to this article was reported.	Day E, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858, DOI 10.1002/14651858.CD004033.PUB2]; DeMaria EJ, 2007, NEW ENGL J MED, V356, P2176, DOI 10.1056/NEJMct067019; Frank P, 2010, GASTROENTEROL CLIN N, V39, P135, DOI 10.1016/j.gtc.2009.12.011; Furtado Luis Carlos do Rego, 2010, Br J Nurs, V19, P428; Korsakoff S., 1889, REV PHILOSOPHIQUE FR, V20, P501; Korsakoff SS, 1887, WERNICKE KORSAKOFF S; Kumar N, 2003, ARCH NEUROL-CHICAGO, V60, P1782, DOI 10.1001/archneur.60.12.1782; Kumar N, 2010, NEUROL CLIN, V28, P107, DOI 10.1016/j.ncl.2009.09.006; Shankar P, 2010, NUTRITION, V26, P1031, DOI 10.1016/j.nut.2009.12.003; Thomson AD, 2003, ALCOHOL ALCOHOLISM, V38, P291, DOI 10.1093/alcalc/agg094; Thomson AD, 2002, ALCOHOL ALCOHOLISM, V37, P513, DOI 10.1093/alcalc/37.6.513; VICTOR M, 1955, NEUROLOGY, V5, P394, DOI 10.1212/WNL.5.6.394; Victor M, 1971, Contemp Neurol Ser, V7, P1; Wernicke C, 1881, LEHRBUCH GEHIRNKRANK, P229	14	9	9	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					67	73		10.1056/NEJMcps1111668	http://dx.doi.org/10.1056/NEJMcps1111668			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968KJ	22762321				2022-12-28	WOS:000305979400009
J	Schoeninger, MJ				Schoeninger, Margaret J.			PALAEOANTHROPOLOGY The ancestral dinner table	NATURE			English	Editorial Material							HOMININS; SAVANNAS; AFRICA											Cerling TE, 1992, PALAEOGEOGR PALAEOCL, V97, P241, DOI 10.1016/0031-0182(92)90211-M; Codron D, 2006, AM J PHYS ANTHROPOL, V129, P204, DOI 10.1002/ajpa.20253; Darwin C., 1871, DESCENT MAN SELECTIO; Gould S.J, 1983, HENS TEETH HORSES TO, P355; Henry AG, 2012, NATURE, V487, P90, DOI 10.1038/nature11185; Moore J., 1992, TOPICS PRIMATOLOGY, P99; Pickering R, 2011, SCIENCE, V333, P1421, DOI 10.1126/science.1203697; Schoeninger MJ, 1999, AM J PRIMATOL, V49, P297, DOI 10.1002/(SICI)1098-2345(199912)49:4<297::AID-AJP2>3.0.CO;2-N; Sponheimer M, 2005, J HUM EVOL, V48, P301, DOI 10.1016/j.jhevol.2004.11.008; White TD, 2009, SCIENCE, V326, P75, DOI 10.1126/science.1175802; Wood B, 2011, EVOL ANTHROPOL, V20, P264, DOI 10.1002/evan.20335	11	4	4	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2012	487	7405					42	43		10.1038/487042a	http://dx.doi.org/10.1038/487042a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	968LM	22763547				2022-12-28	WOS:000305982900041
J	Kim, SC; Gostin, LO; Cole, TB				Kim, Susan C.; Gostin, Lawrence O.; Cole, Thomas B.			Child Abuse Reporting Rethinking Child Protection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Kim, Susan C.; Gostin, Lawrence O.] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						Administration for Children and Families US Department of Health and Human Services, US DEP HLTH HUM SERV; [Anonymous], NY TIMES; Chappell B, PENN STATE ABUSE SCA; Fenster J, 2012, NEW HAVEN REGIS 0125; John Jay College of Criminal Justice, 2004, NAT SCOP SEX AB MIN; Rebocho MF, 2012, J INTERPERS VIOLENCE	6	10	13	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2012	308	1					37	38		10.1001/jama.2012.6414	http://dx.doi.org/10.1001/jama.2012.6414			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971DD	22760287				2022-12-28	WOS:000306183000019
J	Zhang, J; Xie, FL; Delzell, E; Chen, L; Winthrop, KL; Lewis, JD; Saag, KG; Baddley, JW; Curtis, JR				Zhang, Jie; Xie, Fenglong; Delzell, Elizabeth; Chen, Lang; Winthrop, Kevin L.; Lewis, James D.; Saag, Kenneth G.; Baddley, John W.; Curtis, Jeffrey R.			Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RHEUMATOID-ARTHRITIS; UNITED-STATES; VARICELLA; RECOMMENDATIONS; CHILDREN; SAFETY; RATES	Context Based on limited data, the live attenuated herpes zoster (HZ) vaccine is contraindicated in patients taking anti-tumor necrosis factor (anti-TNF) therapies or other biologics commonly used to treat immune-mediated diseases. The safety and effectiveness of the vaccine are unclear for these patients. Objective To examine the association between HZ vaccination and HZ incidence within and beyond 42 days after vaccination in patients with selected immune-mediated diseases and in relation to biologics and other therapies used to treat these conditions. Design, Setting, and Patients Retrospective cohort study of 463 541 Medicare beneficiaries 60 years and older with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease using Medicare claims data from January 1, 2006, through December 31, 2009. Main Outcome Measures Herpes zoster incidence rate within 42 days after vaccination (a safety concern) and beyond 42 days; hazard ratios estimated using Cox proportional hazards models for HZ comparing vaccinated vs unvaccinated patients. Results Median duration of follow-up was 2.0 years (interquartile range, 0.8-3.0); 4.0% of patients received HZ vaccine. The overall crude HZ incidence rate was 7.8 cases per 1000 person-years (95% CI, 3.7-16.5) within 42 days after vaccination. The rate among the unvaccinated was 11.6 cases per 1000 person-years (95% CI, 11.4-11.9). Among 633 patients exposed to biologics at the time of vaccination or within the subsequent 42 days, no case of HZ or varicella occurred. After multivariable adjustment, HZ vaccination was associated with a hazard ratio of 0.61 (95% CI, 0.52-0.71) for HZ risk after 42 days. Conclusions Receipt of HZ vaccine was not associated with a short-term increase in HZ incidence among Medicare beneficiaries with selected immune-mediated diseases, including those exposed to biologics. The vaccine was associated with a lower HZ incidence over a median of 2 years of follow-up. JAMA. 2012; 308(1):43-49 www.jama.com	[Zhang, Jie; Delzell, Elizabeth; Curtis, Jeffrey R.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA; [Xie, Fenglong; Chen, Lang; Saag, Kenneth G.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; [Baddley, John W.] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL 35294 USA; [Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Dept Med, Div Infect Dis, Portland, OR 97201 USA; [Lewis, James D.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Oregon Health & Science University; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham	Curtis, JR (corresponding author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, FOT 805D,510 20th St S, Birmingham, AL 35294 USA.	jcurtis@uab.edu			Amgen; Pfizer; UCB; Abbott; Centocor; Takeda; Shire; Merck; Genentech/Roche; BMS; Agency for Healthcare Research and Quality (AHRQ) [R01 HS018517, T32HS013852]; National Institutes of Health [AR 053351]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS018517, T32HS013852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR053351] Funding Source: NIH RePORTER	Amgen(Amgen); Pfizer(Pfizer); UCB(UCB Pharma SA); Abbott(Abbott Laboratories); Centocor; Takeda(Takeda Pharmaceutical Company Ltd); Shire; Merck(Merck & Company); Genentech/Roche(Roche HoldingGenentech); BMS(Bristol-Myers Squibb); Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Dr Zhang reported having received research support from Amgen. Dr Delzell reported having received research support from Amgen. Dr Winthrop reported having received consulting fees from Pfizer, Amgen, UCB, and Abbott and grants from Pfizer. Dr Lewis reported having received research grants from Centocor, Takeda, and Shire and having served as a consultant for Amgen, Abbott, Pfizer, and Millennium Pharmaceuticals. Dr Saag is the chair of the American College of Rheumatology Quality of Care Committee and reported having received consulting fees from Merck. Dr Baddley reported having received consulting fees from Abbott and Merck. Dr Curtis reported having received research grants and consulting fees from Amgen, UCB, Abbott, Genentech/Roche, Centocor, BMS, and Merck. No other disclosures were reported.; This project was supported by the Agency for Healthcare Research and Quality (AHRQ) (R01 HS018517). Dr Zhang received support from the AHRQ (T32HS013852), and Dr Curtis received support from the National Institutes of Health (AR 053351).	Baker CJ, 2011, ANN INTERN MED, V154, P168, DOI 10.7326/0003-4819-154-3-201102010-00006; DONAHUE JG, 1995, ARCH INTERN MED, V155, P1605, DOI 10.1001/archinte.155.15.1605; Gershon AA, 2009, PEDIATR INFECT DIS J, V28, P653, DOI 10.1097/INF.0b013e3181998f06; Gupta G, 2006, CLIN GASTROENTEROL H, V4, P1483, DOI 10.1016/j.cgh.2006.09.019; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; Harpaz Rafael, 2007, Morbidity and Mortality Weekly Report, V57, P1; Insinga RP, 2005, J GEN INTERN MED, V20, P748, DOI 10.1111/j.1525-1497.2005.0150.x; Kilgore Paul E., 2003, Journal of Medical Virology, V70, pS111, DOI 10.1002/jmv.10364; Marehbian J, 2009, AM J GASTROENTEROL, V104, P2524, DOI 10.1038/ajg.2009.322; Marin Mona, 2007, Morbidity and Mortality Weekly Report, V56, P1; Mueller NH, 2008, NEUROL CLIN, V26, P675, DOI 10.1016/j.ncl.2008.03.011; Nelson KE, 2004, INFECT DIS EPIDEMIOL; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Scheinberg M, 2010, ARTHRIT CARE RES, V62, P896, DOI 10.1002/acr.20045; Schmader KE, 2012, CLIN INFECT DIS, V54, P922, DOI 10.1093/cid/cir970; Singh JA, 2012, ARTHRIT CARE RES, V64, P625, DOI 10.1002/acr.21641; Smitten AL, 2007, ARTHRIT RHEUM-ARTHR, V57, P1431, DOI 10.1002/art.23112; Son M, 2010, J INFECT DIS, V201, P1806, DOI 10.1086/652798; Strangfeld A, 2009, JAMA-J AM MED ASSOC, V301, P737, DOI 10.1001/jama.2009.146; Tseng HF, 2011, JAMA-J AM MED ASSOC, V305, P160, DOI 10.1001/jama.2010.1983; Wolfe F, 2006, RHEUMATOLOGY, V45, P1370, DOI 10.1093/rheumatology/kel328; Yawn BP, 2011, AM J EPIDEMIOL, V174, P1054, DOI 10.1093/aje/kwr206; Zhang J, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3497	23	201	208	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2012	308	1					43	49		10.1001/jama.2012.7304	http://dx.doi.org/10.1001/jama.2012.7304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971DD	22760290	Green Accepted, Bronze			2022-12-28	WOS:000306183000022
J	Gregory, AP; Dendrou, CA; Attfield, KE; Haghikia, A; Xifara, DK; Butter, F; Poschmann, G; Kaur, G; Lambert, L; Leach, OA; Promel, S; Punwani, D; Felce, JH; Davis, SJ; Gold, R; Nielsen, FC; Siegel, RM; Mann, M; Bell, JI; McVean, G; Fugger, L				Gregory, Adam P.; Dendrou, Calliope A.; Attfield, Kathrine E.; Haghikia, Aiden; Xifara, Dionysia K.; Butter, Falk; Poschmann, Gereon; Kaur, Gurman; Lambert, Lydia; Leach, Oliver A.; Proemel, Simone; Punwani, Divya; Felce, James H.; Davis, Simon J.; Gold, Ralf; Nielsen, Finn C.; Siegel, Richard M.; Mann, Matthias; Bell, John I.; McVean, Gil; Fugger, Lars			TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; GENOME-WIDE ASSOCIATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RESONANCE ENERGY-TRANSFER; SUSCEPTIBILITY LOCI; DISEASE SUSCEPTIBILITY; METAANALYSIS; DEMYELINATION; INHIBITION; MECHANISMS	Although there has been much success in identifying genetic variants associated with common diseases using genome-wide association studies (GWAS)(1), it has been difficult to demonstrate which variants are causal and what role they have in disease. Moreover, the modest contribution that these variants make to disease risk has raised questions regarding their medical relevance(2). Here we have investigated a single nucleotide polymorphism (SNP) in the TNFRSF1A gene, that encodes tumour necrosis factor receptor 1 (TNFR1), which was discovered through GWAS to be associated with multiple sclerosis (MS)(3,4), but not with other autoimmune conditions such as rheumatoid arthritis(5), psoriasis(6) and Crohn's disease(7). By analysing MS GWAS(3,4) data in conjunction with the 1000 Genomes Project data(8) we provide genetic evidence that strongly implicates this SNP, rs1800693, as the causal variant in the TNFRSF1A region. We further substantiate this through functional studies showing that the MS risk allele directs expression of a novel, soluble form of TNFR1 that can block TNF. Importantly, TNF-blocking drugs can promote onset or exacerbation of MS9-11, but they have proven highly efficacious in the treatment of autoimmune diseases for which there is no association with rs1800693. This indicates that the clinical experience with these drugs parallels the disease association of rs1800693, and that the MS-associated TNFR1 variant mimics the effect of TNF-blocking drugs. Hence, our study demonstrates that clinical practice can be informed by comparing GWAS across common autoimmune diseases and by investigating the functional consequences of the disease-associated genetic variation.	[Gregory, Adam P.; Kaur, Gurman; Punwani, Divya; Felce, James H.; Davis, Simon J.; Fugger, Lars] Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, MRC Human Immunol Unit, Oxford OX3 9DS, England; [Dendrou, Calliope A.; Attfield, Kathrine E.; Haghikia, Aiden; Lambert, Lydia; Leach, Oliver A.; Proemel, Simone; Fugger, Lars] Univ Oxford, John Radcliffe Hosp, Div Clin Neurol, Nuffield Dept Clin Neurosci, Oxford OX3 9DS, England; [Haghikia, Aiden; Gold, Ralf] Ruhr Univ Bochum, St Josef Hosp Bochum, Dept Neurol, D-44791 Bochum, Germany; [Xifara, Dionysia K.; McVean, Gil] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; [Butter, Falk; Mann, Matthias] Max Planck Inst Biochem, Dept Prote & Signal Transduct, D-82152 Martinsried, Germany; [Poschmann, Gereon] Univ Dusseldorf, Biol Med Forschungszentrum, Mol Prote Lab, D-40225 Dusseldorf, Germany; [Nielsen, Finn C.] Univ Copenhagen, Rigshosp, Ctr Genom Med, DK-2100 Copenhagen O, Denmark; [Siegel, Richard M.] NIAMSD, Immunoregulat Sect, Autoimmun Branch, NIH, Bethesda, MD 20892 USA; [Bell, John I.] Univ Oxford, Oxford OX3 7DG, England; [Fugger, Lars] Skejby Sygehus, Aarhus Univ Hosp, Inst Clin, DK-8200 Aarhus N, Denmark	University of Oxford; University of Oxford; Ruhr University Bochum; University of Oxford; Wellcome Centre for Human Genetics; Max Planck Society; Heinrich Heine University Dusseldorf; Rigshospitalet; University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Oxford; Aarhus University	Fugger, L (corresponding author), Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, MRC Human Immunol Unit, Oxford OX3 9DS, England.	lars.fugger@imm.ox.ac.uk	Mann, Matthias/A-3454-2013; Nielsen, Finn Cilius/AAA-4926-2020	Mann, Matthias/0000-0003-1292-4799; Butter, Falk/0000-0002-7197-7279; McVean, Gil/0000-0002-5012-4162; Kaur, Gurman/0000-0001-7722-3956; Promel, Simone/0000-0001-7800-7323; Attfield, Kathrine/0000-0003-3387-521X; Dendrou, Calliope/0000-0003-1179-4021; Felce, James/0000-0001-5531-9244	UK Medical Research Council (MRC); European Union [FP7/2007-2013]; Naomi Bramson Trust; Wellcome Trust [090532/Z/09/Z, 086084/Z/08/Z]; MRC; Deutsche Forschungsgemeinschaft; Christopher Welch Scholarship; MS Society; Dorothy Hodgkin Postgraduate Award; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041175] Funding Source: NIH RePORTER; MRC [MC_UU_12010/4, MC_UU_12010/3] Funding Source: UKRI; Medical Research Council [MC_UU_12010/3, MC_UU_12010/4, G1000800i] Funding Source: researchfish; Rosetrees Trust [M210] Funding Source: researchfish	UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); Naomi Bramson Trust; Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Christopher Welch Scholarship; MS Society; Dorothy Hodgkin Postgraduate Award; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Rosetrees Trust(Rosetrees Trust)	We thank the volunteers who donated blood samples, the IMSGC and WTCCC2 for data access, A. Auton for help with association analysis data preparation, G. R. Screaton for providing TNFR1 constructs, and A. Vincent and N. Willcox for critical reading of the manuscript. Work in the authors' laboratories is supported by the UK Medical Research Council (MRC), the European Union through grant FP7/2007-2013 (SYBILLA), the Naomi Bramson Trust (L.F.), and the Wellcome Trust (090532/Z/09/Z and 086084/Z/08/Z; G.M.). A.P.G., A.H., L.L., O.A.L. and D.P. are supported by an MRC studentship, the Deutsche Forschungsgemeinschaft, a Christopher Welch Scholarship, funding from the MRC and the MS Society, and a Dorothy Hodgkin Postgraduate Award, respectively.	Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Arnason BGW, 1999, NEUROLOGY, V53, P457, DOI 10.1212/wnl.53.3.457; BAKER D, 1994, EUR J IMMUNOL, V24, P2040, DOI 10.1002/eji.1830240916; Bosch X, 2011, NAT REV NEUROL, V7, P165, DOI 10.1038/nrneurol.2011.1; Brambilla R, 2011, BRAIN, V134, P2736, DOI 10.1093/brain/awr199; Chan FKM, 2001, CYTOMETRY, V44, P361, DOI 10.1002/1097-0320(20010801)44:4<361::AID-CYTO1128>3.0.CO;2-3; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; De Jager PL, 2009, NAT GENET, V41, P776, DOI 10.1038/ng.401; Evans DM, 2011, NAT GENET, V43, P761, DOI 10.1038/ng.873; Feldmann M, 2005, NATURE, V435, P612, DOI 10.1038/nature03727; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Goldstein DB, 2009, NEW ENGL J MED, V360, P1696, DOI 10.1056/NEJMp0806284; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; James JR, 2006, NAT METHODS, V3, P1001, DOI 10.1038/nmeth978; Kimberley FC, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2197; Lander ES, 2011, NATURE, V470, P187, DOI 10.1038/nature09792; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088; Mells GF, 2011, NAT GENET, V43, P329, DOI 10.1038/ng.789; Probert L, 2000, BRAIN, V123, P2005, DOI 10.1093/brain/123.10.2005; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Schutze S, 2008, NAT REV MOL CELL BIO, V9, P655, DOI 10.1038/nrm2430; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582; Strange A, 2010, NAT GENET, V42, P985, DOI 10.1038/ng.694; Taoufik E, 2011, BRAIN, V134, P2722, DOI 10.1093/brain/awr203; vanOosten BW, 1996, NEUROLOGY, V47, P1531, DOI 10.1212/WNL.47.6.1531	30	255	262	0	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 23	2012	488	7412					508	+		10.1038/nature11307	http://dx.doi.org/10.1038/nature11307			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	992FS	22801493	Green Accepted			2022-12-28	WOS:000307761600036
J	Mansour, AA; Gafni, O; Weinberger, L; Zviran, A; Ayyash, M; Rais, Y; Krupalnik, V; Zerbib, M; Amann-Zalcenstein, D; Maza, I; Geula, S; Viukov, S; Holtzman, L; Pribluda, A; Canaani, E; Horn-Saban, S; Amit, I; Novershtern, N; Hanna, JH				Mansour, Abed AlFatah; Gafni, Ohad; Weinberger, Leehee; Zviran, Asaf; Ayyash, Muneef; Rais, Yoach; Krupalnik, Vladislav; Zerbib, Mirie; Amann-Zalcenstein, Daniela; Maza, Itay; Geula, Shay; Viukov, Sergey; Holtzman, Liad; Pribluda, Ariel; Canaani, Eli; Horn-Saban, Shirley; Amit, Ido; Novershtern, Noa; Hanna, Jacob H.			The H3K27 demethylase Utx regulates somatic and germ cell epigenetic reprogramming	NATURE			English	Article							EMBRYONIC STEM-CELLS; PLURIPOTENT GROUND-STATE; MOUSE; GENOME; JMJD3; DYNAMICS; NETWORK; NANOG; MODEL	Induced pluripotent stem cells (iPSCs) can be derived from somatic cells by ectopic expression of different transcription factors, classically Oct4 (also known as Pou5f1), Sox2, Klf4 and Myc (abbreviated as OSKM)(1). This process is accompanied by genome-wide epigenetic changes(2-5), but how these chromatin modifications are biochemically determined requires further investigation. Here we show in mice and humans that the histone H3 methylated Lys 27(H3K27) demethylase Utx(6-9) (also known as Kdm6a) regulates the efficient induction, rather than maintenance, of pluripotency. Murine embryonic stem cells lacking Utx can execute lineage commitment and contribute to adult chimaeric animals; however, somatic cells lacking Utx fail to robustly reprogram back to the ground state of pluripotency. Utx directly partners with OSK reprogramming factors and uses its histone demethylase catalytic activity to facilitate iPSC formation. Genomic analysis indicates that Utx depletion results in aberrant dynamics of H3K27me3 repressive chromatin demethylation in somatic cells undergoing reprogramming. The latter directly hampers the derepression of potent pluripotency promoting gene modules (including Sall1, Sall4 and Utf1), which can cooperatively substitute for exogenous OSK supplementation in iPSC formation. Remarkably, Utx safeguards the timely execution of H3K27me3 demethylation observed in embryonic day 10.5-11 primordial germcells (PGCs)(10), and Utx-deficientPGCs show cell-autonomous aberrant epigenetic reprogramming dynamics during their embryonic maturation in vivo. Subsequently, this disrupts PGC development by embryonic day 12.5, and leads to diminished germline transmission in mouse chimaeras generated from Utx-knockout pluripotent cells. Thus, we identify Utx as a novel mediator with distinct functions during the re-establishment of pluripotency and germ cell development. Furthermore, our findings highlight the principle that molecular regulators mediating loss of repressive chromatin during in vivo germ cell reprogramming can be co-opted during in vitro reprogramming towards ground state pluripotency.	[Mansour, Abed AlFatah; Gafni, Ohad; Weinberger, Leehee; Zviran, Asaf; Rais, Yoach; Krupalnik, Vladislav; Zerbib, Mirie; Maza, Itay; Geula, Shay; Viukov, Sergey; Holtzman, Liad; Pribluda, Ariel; Novershtern, Noa; Hanna, Jacob H.] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; [Ayyash, Muneef] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; [Amann-Zalcenstein, Daniela; Amit, Ido] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; [Amann-Zalcenstein, Daniela; Horn-Saban, Shirley] Weizmann Inst Sci, Dept Biol Serv, Genom Unit, IL-76100 Rehovot, Israel; [Canaani, Eli] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science	Hanna, JH (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	noa.novershtern@weizmann.ac.il; jacob.hanna@weizmann.ac.il	Hanna, Jacob/K-1339-2012; Geula, Shay Yosef/Z-3789-2019	Hanna, Jacob/0000-0003-2042-9974; Geula, Shay Yosef/0000-0001-8111-4410; Mansour, Abed AlFatah/0000-0001-9025-6998; Novershtern, Noa/0000-0002-2244-6877	ERC starting investigator grant [StG-2011-281906]; Israel Science Foundation Regular and Bikura research grants; ICRF Foundation; Fritz Thyssen Stiftung; Alon Foundation; E. A. and R. Drake, and the Leona M. and Harry B. Helmsley Charitable Trust; Weizmann Dean fellowship awards	ERC starting investigator grant; Israel Science Foundation Regular and Bikura research grants; ICRF Foundation; Fritz Thyssen Stiftung; Alon Foundation; E. A. and R. Drake, and the Leona M. and Harry B. Helmsley Charitable Trust; Weizmann Dean fellowship awards	J.H.H. is supported by a generous gift from Ilana and Pascal Mantoux, The Sir Charles Clore Research Prize, an ERC starting investigator grant (StG-2011-281906), the Israel Science Foundation Regular and Bikura research grants, the ICRF Foundation, Fritz Thyssen Stiftung, the Alon Foundation scholar award, a grant from E. A. and R. Drake, and the Leona M. and Harry B. Helmsley Charitable Trust. N.N. and A. P. are supported by Weizmann Dean fellowship awards. We thank A. Smith, H. Niwa and M. Saitou for reagents. We thank the Weizmann Institute management for providing critical financial and infrastructural support.	Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brons IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019; Guo G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018189; Hajkova P, 2008, NATURE, V452, P877, DOI 10.1038/nature06714; Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592; Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787; Hayashi K, 2011, CELL, V146, P519, DOI 10.1016/j.cell.2011.06.052; He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545; Hemberger M, 2009, NAT REV MOL CELL BIO, V10, P526, DOI 10.1038/nrm2727; Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Koche RP, 2011, CELL STEM CELL, V8, P96, DOI 10.1016/j.stem.2010.12.001; Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee S, 2012, DEV CELL, V22, P25, DOI 10.1016/j.devcel.2011.11.009; Leitch HG, 2010, DEVELOPMENT, V137, P2279, DOI 10.1242/dev.050427; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Sen GL, 2008, GENE DEV, V22, P1865, DOI 10.1101/gad.1673508; Silva J, 2009, CELL, V138, P722, DOI 10.1016/j.cell.2009.07.039; Singhal N, 2010, CELL, V141, P943, DOI 10.1016/j.cell.2010.04.037; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Stadtfeld M, 2008, CELL STEM CELL, V2, P230, DOI 10.1016/j.stem.2008.02.001; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004	35	267	282	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 16	2012	488	7411					409	+		10.1038/nature11272	http://dx.doi.org/10.1038/nature11272			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988OS	22801502				2022-12-28	WOS:000307501000048
J	Limketkai, BN; Mehta, SH; Sutcliffe, CG; Higgins, YM; Torbenson, MS; Brinkley, SC; Moore, RD; Thomas, DL; Sulkowski, MS				Limketkai, Berkeley N.; Mehta, Shruti H.; Sutcliffe, Catherine G.; Higgins, Yvonne M.; Torbenson, Michael S.; Brinkley, Sherilyn C.; Moore, Richard D.; Thomas, David L.; Sulkowski, Mark S.			Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPATITIS-C-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; SIMPLE NONINVASIVE INDEX; TRANSIENT ELASTOGRAPHY; SIGNIFICANT FIBROSIS; INFECTED PATIENTS; GENOTYPE 1; HIV; PROGRESSION	Context Human immunodeficiency virus (HIV) accelerates hepatitis C virus (HCV) disease progression; however, the effect of liver disease stage and antiviral therapy on the risk of clinical outcomes is incompletely understood. Objective To determine the incidence of end-stage liver disease (ESLD), hepatocellular carcinoma (HCC), or death according to baseline hepatic fibrosis and antiviral treatment for HIV/HCV coinfected individuals. Design, Setting, and Participants Prospective cohort of 638 coinfected adults (80% black, 66% men) receiving care at the Johns Hopkins HIV clinic and receiving a liver biopsy and who were prospectively monitored for clinical events between July 1993 and August 2011 (median follow-up, 5.82 years; interquartile range, 3.42-8.85 years). Histological specimens were scored for hepatic fibrosis stage according to the METAVIR scoring system. Main Outcome Measure Incidence of composite outcome of ESLD, HCC, or death. Results Patients experienced a graded increased risk in incidence of clinical outcomes based on baseline hepatic fibrosis stage (classification range, F0-F4): F0, 23.63 (95% CI, 16.80-33.24); F1, 36.33 (95% CI, 28.03-47.10); F2, 53.40 (95% CI, 33.65-84.76); F3, 56.14 (95% CI, 31.09-101.38); and F4, 79.43 (95% CI, 55.86-112.95) per 1000 person-years (P < .001). In multivariable negative binomial regression, fibrosis stages F2 through F4 and antiretroviral therapy were independently associated with composite ESLD, HCC, or all-cause mortality after adjustment for demographic characteristics, injection drug use, and CD4 cell count. Compared with F0, the incidence rate ratio (RR) for F2 was 2.31 (95% CI, 1.23-4.34; P = .009); F3, 3.18 (95% CI, 1.47-6.88; P = .003); and F4, 3.57 (95% CI, 2.06-6.19; P < .001). Human immunodeficiency virus treatment was associated with fewer clinical events (incidence RR, 0.27; 95% CI, 0.19-0.38; P < .001). For the 226 patients who underwent HCV treatment, the incidence of clinical events did not significantly differ between treatment nonresponders and untreated patients (incidence RR, 1.27; 95% CI, 0.86-1.86; P = .23). In contrast, no events were observed in the 51 patients with sustained virologic response (n = 36) and relapse (n = 15), including 19 with significant fibrosis. Conclusion In this cohort of patients with HIV/HCV coinfection, hepatic fibrosis stage was independently associated with a composite outcome of ESLD, HCC, or death.	[Limketkai, Berkeley N.; Higgins, Yvonne M.; Torbenson, Michael S.; Brinkley, Sherilyn C.; Moore, Richard D.; Thomas, David L.; Sulkowski, Mark S.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Mehta, Shruti H.; Sutcliffe, Catherine G.; Moore, Richard D.; Thomas, David L.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Sulkowski, MS (corresponding author), 1830 Bldg,Room 445,1800 Orleans St, Baltimore, MD 21287 USA.	msulkowski@jhmi.edu		Sutcliffe, Catherine/0000-0001-8512-8326	Bristol-Myers Squibb; Columbia University; International Cancer Control Association; Merck; Vertex Pharmaceuticals; Roche/Genentech; Gilead Sciences; Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals; Gilead; Janssen; Vertex; National Institute on Drug Abuse (NIDA) [K24DA00432, K24DA034621, R01DA11602, R01DA16065, R37DA13806, P30DA13868]; National Institute on Alcohol Abuse and Alcoholism (NIAAA) [R01AA016893]; National Institute of Allergy and Infectious Diseases (NIAID) [P30AI094189]; National Center for Research Resources (NCRR), components of the National Institutes of Health (NIH) [UL1RR025005]; NIH Roadmap for Medical Research; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069918, P30AI094189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA015032, R01AA016893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA013868, K24DA000432, K24DA034621, R01DA016065, R01DA011602, R37DA013806] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); Columbia University; International Cancer Control Association; Merck(Merck & Company); Vertex Pharmaceuticals(Vertex Pharmaceuticals); Roche/Genentech(Roche HoldingGenentech); Gilead Sciences(Gilead Sciences); Abbott Laboratories(Abbott Laboratories); Boehringer Ingelheim Pharmaceuticals(Boehringer Ingelheim); Gilead(Gilead Sciences); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Vertex(Vertex Pharmaceuticals); National Institute on Drug Abuse (NIDA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Institute on Alcohol Abuse and Alcoholism (NIAAA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources (NCRR), components of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Limketkai reported receiving a grant from Bristol-Myers Squibb. Dr Mehta reported receiving consulting fees from Columbia University. Dr Sutcliffe reported receiving payment for conference planning from the International Cancer Control Association. Ms Brinkley reported receiving consulting fees from Merck and Vertex Pharmaceuticals and payment for lectures from Merck, Vertex Pharmaceuticals, and Roche/Genentech. Dr Thomas reported receiving consulting fees from Merck and grants to Johns Hopkins University from Merck and Gilead Sciences. Dr Sulkowski reported receiving consulting fees and research grants to Johns Hopkins University from Abbott Laboratories, Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Gilead, Janssen, Merck, Roche/Genentech, and Vertex. Ms Higgins, Dr Torbenson, and Dr Moore reported no conflicts of interest.; Financial support for this study came from grants K24DA00432, K24DA034621, R01DA11602, R01DA16065, R37DA13806, and P30DA13868 from the National Institute on Drug Abuse (NIDA), R01AA016893 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), P30AI094189 from the National Institute of Allergy and Infectious Diseases (NIAID), and UL1RR025005 from the National Center for Research Resources (NCRR), components of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research.	Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706; Chen TY, 2009, CLIN INFECT DIS, V49, P1605, DOI 10.1086/644771; de Ledinghen V, 2006, JAIDS-J ACQ IMM DEF, V41, P175; Ghany MG, 2009, HEPATOLOGY, V49, P1335, DOI 10.1002/hep.22759; Graham CS, 2001, CLIN INFECT DIS, V33, P562, DOI 10.1086/321909; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Kirk GD, 2009, CLIN INFECT DIS, V48, P963, DOI 10.1086/597350; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Linas BP, 2011, J VIRAL HEPATITIS, V18, P506, DOI 10.1111/j.1365-2893.2010.01325.x; Lok AS, 2012, NEW ENGL J MED, V366, P216, DOI 10.1056/NEJMoa1104430; Mehta SH, 2005, HEPATOLOGY, V41, P123, DOI 10.1002/hep.20541; Mehta SH, 2008, J COMMUN HEALTH, V33, P126, DOI 10.1007/s10900-007-9083-3; Mehta SH, 2006, AIDS, V20, P2361, DOI 10.1097/QAD.0b013e32801086da; Melita SH, 2009, J HEPATOL, V50, P36, DOI 10.1016/j.jhep.2008.07.039; Morgan TR, 2010, HEPATOLOGY, V52, P833, DOI 10.1002/hep.23744; Myers RP, 2003, AIDS, V17, P721, DOI 10.1097/00002030-200303280-00010; Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG HIV 1; Pineda JA, 2007, HEPATOLOGY, V46, P622, DOI 10.1002/hep.21757; Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494; Qurishi N, 2003, LANCET, V362, P1708, DOI 10.1016/S0140-6736(03)14844-1; Regev A, 2002, AM J GASTROENTEROL, V97, P2614, DOI 10.1111/j.1572-0241.2002.06038.x; Rockstroh JK, 2008, HIV MED, V9, P82, DOI 10.1111/j.1468-1293.2007.00535.x; Rodriguez-Torres M, 2009, 60 ANN M AM ASS STUD; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Sherman KE, 2002, CLIN INFECT DIS, V34, P831, DOI 10.1086/339042; Soriano V, 2007, AIDS, V21, P1073, DOI 10.1097/QAD.0b013e3281084e4d; Sterling RK, 2006, HEPATOLOGY, V43, P1317, DOI 10.1002/hep.21178; Subramanian A, 2010, GASTROENTEROLOGY, V138, P159, DOI 10.1053/j.gastro.2009.09.053; Sulkowski MS, 2007, AIDS, V21, P2209, DOI 10.1097/QAD.0b013e3282f10de9; Sulkowski MS, 2002, JAMA-J AM MED ASSOC, V288, P199, DOI 10.1001/jama.288.2.199; Thein HH, 2008, AIDS, V22, P1979, DOI 10.1097/QAD.0b013e32830e6d51; Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346; Wise M, 2010, PUBLIC HEALTH REP, V125, P414, DOI 10.1177/003335491012500310	35	166	172	2	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					370	378		10.1001/jama.2012.7844	http://dx.doi.org/10.1001/jama.2012.7844			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820790	Green Accepted, Bronze			2022-12-28	WOS:000306685500025
J	Borumandi, F; Gaggl, A				Borumandi, Farzad; Gaggl, Alexander			Traumatic Abducens Nerve Palsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Borumandi, Farzad; Gaggl, Alexander] Paracelsus Med Univ, Salzburg, Austria	Paracelsus Private Medical University	Borumandi, F (corresponding author), Paracelsus Med Univ, Salzburg, Austria.	f.borumandi@web.de							0	0	0	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2012	367	3					E5	E5		10.1056/NEJMicm1114545	http://dx.doi.org/10.1056/NEJMicm1114545			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	22808984				2022-12-28	WOS:000306522900011
J	Nelson, HD; Walker, M; Zakher, B; Mitchell, J				Nelson, Heidi D.; Walker, Miranda; Zakher, Bernadette; Mitchell, Jennifer			Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations	ANNALS OF INTERNAL MEDICINE			English	Review							ESTROGEN PLUS PROGESTIN; CONJUGATED EQUINE ESTROGENS; INITIATIVE RANDOMIZED-TRIAL; DOSE TRANSDERMAL ESTRADIOL; CORONARY-HEART-DISEASE; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; HEALTHY POSTMENOPAUSAL WOMEN; MILD COGNITIVE IMPAIRMENT; BREAST-CANCER INCIDENCE	Background: Menopausal hormone therapy to prevent chronic conditions is currently not recommended because of its adverse effects. Purpose: To update evidence about the effectiveness of hormone therapy in reducing risk for chronic conditions and adverse effects, and to examine whether outcomes vary among women in different subgroups. Data Sources: MEDLINE (January 2002 to November 2011), Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (through the 3rd quarter of 2011), Scopus, and reference lists. Study Selection: Randomized, placebo-controlled trials of menopausal hormone therapy published in English since 2002 that assessed primary prevention of chronic conditions. Data Extraction: Investigators extracted data on participants, study design, analysis, follow-up, and results; 2 investigators independently rated study quality by using established criteria. Data Synthesis: 9 fair-quality trials met the inclusion criteria. The Women's Health Initiative reported most of the results, had 11 years of follow-up, and had data most applicable to postmenopausal women in the United States. It showed that estrogen plus progestin therapy reduced fractures (46 fewer per 10 000 woman-years) and increased invasive breast cancer (8 more per 10 000 woman-years), stroke (9 more per 10 000 woman-years), deep venous thrombosis (12 more per 10 000 woman-years), pulmonary embolism (9 more per 10 000 woman-years), lung cancer death (5 more per 10 000 woman-years), gallbladder disease (20 more per 10 000 woman-years), dementia (22 more per 10 000 woman-years), and urinary incontinence (872 more per 10 000 woman-years). Estrogen-only therapy reduced fractures (56 fewer per 10 000 woman-years), invasive breast cancer (8 fewer per 10 000 woman-years), and death (2 fewer per 10 000 woman-years) and increased stroke (11 more per 10 000 woman-years), deep venous thrombosis (7 more per 10 000 woman-years), gallbladder disease (33 more per 10 000 woman-years), and urinary incontinence (1271 more per 10 000 woman-years). Outcomes did not consistently differ by age or comorbid conditions. Limitation: Limitations of the trials included low adherence, high attrition, inadequate power to detect risks for some outcomes, and evaluation of few regimens. Conclusion: Estrogen plus progestin and estrogen alone decreased risk for fractures but increased risk for stroke, thromboembolic events, gallbladder disease, and urinary incontinence. Estrogen plus progestin increased risk for breast cancer and probable dementia, whereas estrogen alone decreased risk for breast cancer.	[Nelson, Heidi D.] Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Mailcode BICC, Portland, OR 97239 USA; Providence Hlth & Serv, Providence Canc Ctr, Portland, OR USA	Oregon Health & Science University	Nelson, HD (corresponding author), Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Mailcode BICC, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	nelsonh@ohsu.edu			AHRQ [HHSA-290-2007-10057-I-EPC3]; Agency for Healthcare Research and Quality	AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	By contract HHSA-290-2007-10057-I-EPC3, task order 3, from the AHRQ.; Primary Funding Source: Agency for Healthcare Research and Quality.	American Academy of Family Physicians, 2005, HORM REPL THER; American College of Obstetricians and Gynecologists Women's Health Care Physicians, 2004, Obstet Gynecol, V103, P203; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2012, LANCET ONCOL, V13, P476, DOI 10.1016/S1470-2045(12)70075-X; Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; [Anonymous], 2012, MENOPAUSE, V19, P257, DOI 10.1097/gme.0b013e31824b970a; Berg AO, 2002, ANN INTERN MED, V137, P834, DOI 10.7326/0003-4819-137-10-200211190-00013; Bonds DE, 2006, DIABETOLOGIA, V49, P459, DOI 10.1007/s00125-005-0096-0; Brunner RL, 2005, ARCH INTERN MED, V165, P1976, DOI 10.1001/archinte.165.17.1976; Canadian Task Force on Preventive Health Care, 2004, HORM REPL THER PRIM; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; Cherry N, 2002, LANCET, V360, P2001; Chlebowski RT, 2010, JAMA-J AM MED ASSOC, V304, P1684, DOI 10.1001/jama.2010.1500; Chlebowski RT, 2010, JNCI-J NATL CANCER I, V102, P1413, DOI 10.1093/jnci/djq285; Chlebowski RT, 2009, LANCET, V374, P1243, DOI 10.1016/S0140-6736(09)61526-9; Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Cirillo DJ, 2005, JAMA-J AM MED ASSOC, V293, P330, DOI 10.1001/jama.293.3.330; Culhane NS, 2003, J FAM PRACTICE, V52, P754; Curb JD, 2006, ARCH INTERN MED, V166, P772, DOI 10.1001/archinte.166.7.772; Cushman M, 2004, JAMA-J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Espeland MA, 2010, J AM GERIATR SOC, V58, P1263, DOI 10.1111/j.1532-5415.2010.02953.x; Ettinger B, 2004, OBSTET GYNECOL, V104, P443, DOI 10.1097/01.AOG.0000137833.43248.79; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Grady D, 2002, AM J MED, V113, P543, DOI 10.1016/S0002-9343(02)01270-6; Gramling R, 2009, EPIDEMIOLOGY, V20, P752, DOI 10.1097/EDE.0b013e3181a71279; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Heiss G, 2008, JAMA-J AM MED ASSOC, V299, P1036, DOI 10.1001/jama.299.9.1036; Hendrix SL, 2005, JAMA-J AM MED ASSOC, V293, P935, DOI 10.1001/jama.293.8.935; Hendrix SL, 2006, CIRCULATION, V113, P2425, DOI 10.1161/CIRCULATIONAHA.105.594077; Hendrix Susan L, 2003, J Am Osteopath Assoc, V103, pS3; Hsia J, 2004, CIRCULATION, V109, P620, DOI 10.1161/01.CIR.0000115309.63979.92; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Johnson MS, 2005, ANN INTERN MED, V142, P855, DOI 10.7326/0003-4819-142-10-200505170-00011; Johnson SR, 2005, OBSTET GYNECOL, V105, P779, DOI 10.1097/01.AOG.0000157116.23249.52; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Margolis KL, 2004, DIABETOLOGIA, V47, P1175, DOI 10.1007/s00125-004-1448-x; Mosca, 2011, CIRCULATION, V123, pE624, DOI 10.1161/CIR.0b013e318222b330; Nelson H.D., 2012, MENOPAUSAL HORMONE T; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Resnick SM, 2006, J CLIN ENDOCR METAB, V91, P1802, DOI 10.1210/jc.2005-2097; Resnick SM, 2009, J CLIN ENDOCR METAB, V94, P4152, DOI 10.1210/jc.2009-1340; Ritenbaugh C, 2008, CANCER EPIDEM BIOMAR, V17, P2609, DOI 10.1158/1055-9965.EPI-08-0385; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Steinauer JE, 2005, OBSTET GYNECOL, V106, P940, DOI 10.1097/01.AOG.0000180394.08406.15; Tierney MC, 2009, PSYCHONEUROENDOCRINO, V34, P1065, DOI 10.1016/j.psyneuen.2009.02.009; Toh S, 2010, ANN INTERN MED, V152, P211, DOI 10.7326/0003-4819-152-4-201002160-00005; U.S. Food and Drug Administration, 2010, ESTR ESTR PROG THER; Vickers Madge R, 2007, BMC Womens Health, V7, P2, DOI 10.1186/1472-6874-7-2; Waetjen LE, 2005, OBSTET GYNECOL, V106, P946, DOI 10.1097/01.AOG.0000182576.48290.6d; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Yaffe K, 2006, ARCH NEUROL-CHICAGO, V63, P945, DOI 10.1001/archneur.63.7.945	64	94	98	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2					104	+		10.7326/0003-4819-157-2-201207170-00466	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00466			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22786830				2022-12-28	WOS:000307787900016
J	Ropper, AH				Ropper, Allan H.			Two Centuries of Neurology and Psychiatry in the Journal	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; DEEP-BRAIN STIMULATION; ACTIVATED FACTOR-VII; CONTROLLED-TRIAL; ANTIPSYCHOTIC-DRUGS; DOUBLE-BLIND; THERAPY; DISEASE; HYPOTHERMIA; NATALIZUMAB		[Ropper, Allan H.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; [Ropper, Allan H.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Ropper, AH (corresponding author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.	aropper@partners.org						ADAMS RD, 1965, NEW ENGL J MED, V273, P117, DOI 10.1056/NEJM196507152730301; ALFREY AC, 1976, NEW ENGL J MED, V294, P184, DOI 10.1056/NEJM197601222940402; ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; AMARENCO P, 1994, NEW ENGL J MED, V331, P1474, DOI 10.1056/NEJM199412013312202; Aminoff MJ, 1993, BOSTON MED SURG J; Beard GM., 1869, BOSTON MED SURG J, V3, P217, DOI [10.1056/nejm186904290801301, 10.1056/NEJM186904290801301, DOI 10.1056/NEJM186904290801301]; BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BOCKMAN JM, 1985, NEW ENGL J MED, V312, P73, DOI 10.1056/NEJM198501103120202; BORNSTEIN MB, 1987, NEW ENGL J MED, V317, P408, DOI 10.1056/NEJM198708133170703; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Briggs LV, 1905, BOSTON MED SURG J, V152, P0001; Brown-Sequard E, 1856, BOSTON MED SURG J, V55, P457; Brown-Sequard E, 1856, BOSTON MED SURG J, V56, P155; Brown-Sequard E, 1856, BOSTON MED SURG J, V56, P433; Brown-Sequard E, 1856, BOSTON MED SURG J, V55, P377; Brown-Sequard E, 1856, BOSTON MED SURG J, V56, P174; Brown-Sequard E, 1856, BOSTON MED SURG J, V56, P338; Brown-Sequard E, 1856, BOSTON MED SURG J, V56, P216; Brown-Sequard E, 1856, BOSTON MED SURG J, V55, P337; Brown-Sequard E, 1856, BOSTON MED SURG J, V56, P54; Brown-Sequard E, 1856, BOSTON MED SURG J, V56, P112; Brown-Sequard E, 1872, BOSTON MED SURG J, V87, P261; Brown-Sequard E, 1856, BOSTON MED SURG J, V57, P255; Brown-Sequard E, 1856, BOSTON MED SURG J, V55, P421; Brown-Sequard E, 1856, BOSTON MED SURG J, V56, P271; Brown-Sequard E, 1852, BOSTON MED SURG J, V47, P334; Brown-Sequard E, 1856, BOSTON MED SURG J, V56, P473; Castleman B, 1968, NEUROLOGIC CLINICOPA; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; COOPER IS, 1964, NEW ENGL J MED, V270, P967, DOI 10.1056/NEJM196405072701901; COTZIAS GC, 1967, NEW ENGL J MED, V276, P374, DOI 10.1056/NEJM196702162760703; COTZIAS GC, 1969, NEW ENGL J MED, V280, P337, DOI 10.1056/NEJM196902132800701; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; DENNYBROWN DE, 1952, NEW ENGL J MED, V246, P839, DOI 10.1056/NEJM195205292462201; Deuschl G, 2006, NEW ENGL J MED, V355, P1289; Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; EISENBERG L, 1986, BRIT J PSYCHIAT, V148, P497, DOI 10.1192/bjp.148.5.497; FERRARI MD, 1991, NEW ENGL J MED, V325, P316; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; Fothergill LD, 1938, NEW ENGL J MED, V219, P411, DOI 10.1056/NEJM193809222191201; Garcia HH, 2004, NEW ENGL J MED, V350, P249, DOI 10.1056/NEJMoa031294; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hommel M, 1996, NEW ENGL J MED, V335, P145; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; JANNETTA PJ, 1984, NEW ENGL J MED, V310, P1700, DOI 10.1056/NEJM198406283102604; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KJELLBERG RN, 1983, NEW ENGL J MED, V309, P269, DOI 10.1056/NEJM198308043090503; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Kupsch A, 2006, NEW ENGL J MED, V355, P1978, DOI 10.1056/NEJMoa063618; Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847; LANGSTON JW, 1983, NEW ENGL J MED, V309, P310; LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lieberman JA, 2010, NEW ENGL J MED, V363, P1092; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Lovett RW, 1888, BOSTON MED SURG J, V118, P641; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; LUDWIG AO, 1948, NEW ENGL J MED, V238, P175, DOI 10.1056/NEJM194802052380602; Mallet L, 2009, NEW ENGL J MED, V361, P1027; Mallet L, 2008, NEW ENGL J MED, V359, P2121, DOI 10.1056/NEJMoa0708514; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mason BH, 1916, BOSTON MED SURG J, V174, P5, DOI 10.1056/NEJM191601061740103; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Mixter W.J., 1934, NEW ENGL J MED, V211, P210, DOI [10.1056/NEJM193408022110506, DOI 10.1056/NEJM193408022110506]; Mixter WJ, 1940, NEW ENGL J MED, V223, P523, DOI 10.1056/NEJM194010032231401; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Myburgh J, 2007, NEW ENGL J MED, V357, P874; PALMER RS, 1948, NEW ENGL J MED, V239, P322, DOI 10.1056/NEJM194808262390902; PETITO CK, 1985, NEW ENGL J MED, V312, P874, DOI 10.1056/NEJM198504043121402; Peul WC, 2007, NEW ENGL J MED, V356, P2245, DOI 10.1056/NEJMoa064039; REIVICH M, 1961, NEW ENGL J MED, V265, P878, DOI 10.1056/NEJM196111022651804; RICHARDSON E, 1961, NEW ENGL J MED, V265, P815, DOI 10.1056/NEJM196110262651701; ROBINS E, 1952, NEW ENGL J MED, V246, P677, DOI 10.1056/NEJM195205012461801; Romano J, 1940, NEW ENGL J MED, V223, P708, DOI 10.1056/NEJM194010312231804; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; Schneider LS, 2006, NEW ENGL J MED, V355, P1525, DOI 10.1056/NEJMoa061240; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240; SIDDIQUE T, 1991, NEW ENGL J MED, V324, P1381, DOI 10.1056/NEJM199105163242001; SIDDIQUE T, 1991, NEW ENGL J MED, V325, P524; SIDDIQUE T, 1991, NEW ENGL J MED, V325, P71; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; SUNDT TM, 1978, NEW ENGL J MED, V299, P116, DOI 10.1056/NEJM197807202990303; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Trivedi MH, 2006, NEW ENGL J MED, V354, P1243, DOI 10.1056/NEJMoa052964; Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972; Vidailhet M, 2005, NEW ENGL J MED, V352, P459, DOI 10.1056/NEJMoa042187; VIETS HR, 1962, NEW ENGL J MED, V266, P23, DOI 10.1056/NEJM196201042660107; WARRELL DA, 1982, NEW ENGL J MED, V306, P313, DOI 10.1056/NEJM198202113060601; Warren JC, 1814, BOSTON MED SURG J, V3, P40; Wenning W, 2009, NEW ENGL J MED, V361, P1075, DOI 10.1056/NEJMoa0810257; WHITLEY RJ, 1977, NEW ENGL J MED, V297, P289, DOI 10.1056/NEJM197708112970601; Williams D, 1938, NEW ENGL J MED, V218, P998, DOI 10.1056/NEJM193806162182402; Willoughby RE, 2005, NEW ENGL J MED, V352, P2508, DOI 10.1056/NEJMoa050382; YOUNG E, 1967, NEW ENGL J MED, V276, P665, DOI 10.1056/NEJM196703232761204; ZERVAS NT, 1972, NEW ENGL J MED, V286, P1075, DOI 10.1056/NEJM197205182862003	112	3	5	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					58	65		10.1056/NEJMra1104781	http://dx.doi.org/10.1056/NEJMra1104781			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968KJ	22762319	Bronze			2022-12-28	WOS:000305979400006
J	Alphonse, VD; Kemper, AR; Strom, BT; Beeman, SM; Duma, SM				Alphonse, Vanessa D.; Kemper, Andrew R.; Strom, Brock T., III; Beeman, Stephanie M.; Duma, Stefan M.			Mechanisms of Eye Injuries From Fireworks	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Alphonse, Vanessa D.; Kemper, Andrew R.; Strom, Brock T., III; Beeman, Stephanie M.; Duma, Stefan M.] Wake Forest Univ, Virginia Tech, Ctr Injury Biomech, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University; Wake Forest University	Alphonse, VD (corresponding author), Wake Forest Univ, Virginia Tech, Ctr Injury Biomech, Blacksburg, VA 24061 USA.	vda@vt.edu	Kemper, Andrew/B-4353-2012; Duma, Stefan/A-8368-2012	Kemper, Andrew/0000-0002-5177-1820; 				*CDCP, 2004, MMWR-MORBID MORTAL W, V53, P562; Duma S, FINAL REPORT EYE INJ; Duma SM, 2012, CURR EYE RES, V37, P43, DOI 10.3109/02713683.2011.601841; Kennedy Eric A, 2004, Annu Proc Assoc Adv Automot Med, V48, P165; Smith GA, 1996, PEDIATRICS, V98, P1; US Consumer Product Safety Commission, 1991, NAT EL INJ SURV SYST	6	12	12	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2012	308	1					33	34		10.1001/jama.2012.6964	http://dx.doi.org/10.1001/jama.2012.6964			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971DD	22760285				2022-12-28	WOS:000306183000017
J	Reynolds, EE; Trivedi, NS				Reynolds, Eileen E.; Trivedi, Neha S.			Update: A 47-Year-Old Woman With an Indwelling Intravenous Catheter and Sepsis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MANAGEMENT							Trivedi, Neha/0000-0003-1006-1408				Angus DC, 2011, JAMA-J AM MED ASSOC, V305, P1469, DOI 10.1001/jama.2011.438; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41	2	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2012	308	1					82	82		10.1001/jama.2012.6665	http://dx.doi.org/10.1001/jama.2012.6665			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971DD	22760292	Green Accepted			2022-12-28	WOS:000306183000027
J	Moyer, VA				Moyer, Virginia A.		US Preventive Serv Task Force	Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; SUN PROTECTION BEHAVIORS; EXPERT-SYSTEMS; PRIMARY-CARE; INTERVENTION; ADOLESCENTS; POPULATION; RADIATION; SMOKING	Description: Update of the 2003 U.S. Preventive Services Task Force (USPSTF) recommendation statement on counseling to prevent skin cancer. Methods: The USPSTF performed a targeted literature search for new evidence that counseling patients about sun protection reduces intermediate outcomes (such as sunburn) or skin cancer. Other key questions addressed the link between counseling and behavior change, the link between behavior change and incidence of skin cancer, and the adverse effects of counseling or sun-protective behavior changes. Recommendations: The USPSTF recommends counseling children, adolescents, and young adults aged 10 to 24 years who have fair skin about minimizing their exposure to ultraviolet radiation to reduce risk for skin cancer (B recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of counseling adults older than 24 years about minimizing risks to prevent skin cancer (I statement).	[Moyer, Virginia A.; US Preventive Serv Task Force] US Prevent Serv Task Force, Rockville, MD USA		Moyer, VA (corresponding author), US Prevent Serv Task Force, Rockville, MD USA.							ACS, 2011, CANC FACTS FIG 2011; American Academy of Family Physicians, 2011, CLIN PREV SERV SKIN; American Congress of Obstetricians and Gynecologists, 2011, GUID AD HLTH CAR; Balk SJ, 2011, PEDIATRICS, V127, P588, DOI 10.1542/peds.2010-3501; Community Preventive Services Task Force, 2011, PREV SKIN CANC ED PO; Crane LA, 2006, PREV MED, V42, P162, DOI 10.1016/j.ypmed.2005.11.007; El Ghissassi F, 2009, LANCET ONCOL, V10, P751, DOI 10.1016/S1470-2045(09)70213-X; Geller AC, 2006, CANCER-AM CANCER SOC, V107, P806, DOI 10.1002/cncr.22050; Glanz K, 2010, AM J PUBLIC HEALTH, V100, P735, DOI 10.2105/AJPH.2008.155705; Green AC, 2011, J CLIN ONCOL, V29, P257, DOI 10.1200/JCO.2010.28.7078; Hillhouse J, 2008, CANCER-AM CANCER SOC, V113, P3257, DOI 10.1002/cncr.23922; Howlader N, 2011, SEER CANC STAT REV 1; Lin J.S., 2011, AHRQ PUBLICATION; Lin JS, 2011, ANN INTERN MED, V154, P190, DOI 10.7326/0003-4819-154-3-201102010-00009; Mahler HIM, 2007, HEALTH PSYCHOL, V26, P350, DOI 10.1037/0278-6133.26.3.350; Milne E, 2007, AM J PUBLIC HEALTH, V97, P306, DOI 10.2105/AJPH.2005.080499; Norman GJ, 2007, ARCH PEDIAT ADOL MED, V161, P146, DOI 10.1001/archpedi.161.2.146; Patrick K, 2006, ARCH PEDIAT ADOL MED, V160, P128, DOI 10.1001/archpedi.160.2.128; Prochaska JO, 2005, PREV MED, V41, P406, DOI 10.1016/j.ypmed.2004.09.050; Prochaska JO, 2004, HEALTH PSYCHOL, V23, P503, DOI 10.1037/0278-6133.23.5.503; Stapleton J, 2010, J BEHAV MED, V33, P181, DOI 10.1007/s10865-009-9246-z; Turrisi R, 2008, ARCH DERMATOL, V144, P1521, DOI 10.1001/archderm.144.11.1521; *US PREV SERV TASK, 2003, COUNS PREV SKIN CANC; van der Pols JC, 2006, CANCER EPIDEM BIOMAR, V15, P2546, DOI 10.1158/1055-9965.EPI-06-0352	24	66	67	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2012	157	1					59	U103		10.7326/0003-4819-157-1-201207030-00442	http://dx.doi.org/10.7326/0003-4819-157-1-201207030-00442			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	992NS	22751761				2022-12-28	WOS:000307784900006
J	Perkins, GD; Kimani, PK; Bullock, I; Clutton-Brock, T; Davies, RP; Gale, M; Lam, J; Lockey, A; Stallard, N				Perkins, Gavin D.; Kimani, Peter K.; Bullock, Ian; Clutton-Brock, Tom; Davies, Robin P.; Gale, Mike; Lam, Jenny; Lockey, Andrew; Stallard, Nigel		Elect Adv Life Support Collaborato	Improving the Efficiency of Advanced Life Support Training A Randomized, Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							PERSONAL RESUSCITATION MANNEQUIN; CARDIAC-ARREST; CORE COMPETENCES; CARE; EDUCATION; SIMULATION; SKILLS; GUIDELINES; STATEMENT; CONSENSUS	Background: Each year, more than 1.5 million health care professionals receive advanced life support (ALS) training. Objective: To determine whether a blended approach to ALS training that includes electronic learning (e-learning) produces outcomes similar to those of conventional, instructor-led ALS training. Design: Open-label, noninferiority, randomized trial. Randomization, stratified by site, was generated by Sealed Envelope (Sealed Envelope, London, United Kingdom). (International Standardized Randomized Controlled Trial Number Register: ISCRTN86380392) Setting: 31 ALS centers in the United Kingdom and Australia. Participants: 3732 health care professionals recruited between December 2008 and October 2010. Intervention: A 1-day course supplemented with e-learning versus a conventional 2-day course. Measurements: The primary outcome was performance in a cardiac arrest simulation test at the end of the course. Secondary outcomes comprised knowledge- and skill-based assessments, repeated assessment after remediation training, and resource use. Results: 440 of the 1843 participants randomly assigned to the blended course and 444 of the 1889 participants randomly assigned to conventional training did not attend the courses. Performance in the cardiac arrest simulation test after course attendance was lower in the electronic advanced life support (e-ALS) group compared with the conventional advanced life support (c-ALS) group; 1033 persons (74.5%) in the e-ALS group and 1146 persons (80.2%) in the c-ALS group passed (mean difference, -5.7% [95% CI, -8.8% to -2.7%]). Knowledge- and skill-based assessments were similar between groups, as was the final pass rate after remedial teaching, which was 94.2% in the e-ALS group and 96.7% in the c-ALS group (mean difference, -2.6% [CI, -4.1% to 1.2%]). Faculty, catering, and facility costs were $438 per participant for electronic ALS training and $935 for conventional ALS training. Limitations: Many professionals (24%) did not attend the courses. The effect on patient outcomes was not evaluated. Conclusion: Compared with conventional ALS training, an approach that included e-learning led to a slightly lower pass rate for cardiac arrest simulation tests, similar scores on a knowledge test, and reduced costs.	[Perkins, Gavin D.] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England; Heart England NHS Fdn Trust, Birmingham, W Midlands, England; Royal Coll Physicians, Natl Clin Guideline Ctr, London, England; Resuscitat Council, London, England; Univ Birmingham, Med Sch Birmingham, Birmingham B15 2TT, W Midlands, England; Calderdale Royal Hosp, Salterhebble, Halifax, England; Australian Resuscitat Council, Melbourne, Vic, Australia	University of Warwick; Heart of England NHS Foundation Trust; Royal College of Physicians; University of Birmingham	Perkins, GD (corresponding author), Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.	g.d.perkins@warwick.ac.uk	Morley, Peter/G-5280-2017; Perkins, Gavin/E-7613-2010	Morley, Peter/0000-0003-2653-090X; Lockey, Andrew/0000-0002-3900-6317; Kimani, Peter/0000-0001-8200-3173; Williams, Daryl/0000-0002-6987-5804; Perkins, Gavin/0000-0003-3027-7548; Davies, Robin/0000-0003-1773-7642; Stallard, Nigel/0000-0001-7781-1512	National Institute of Health Research; Resuscitation Council (UK); National Institute of Health Research Clinician Scientist Award	National Institute of Health Research(National Institute for Health Research (NIHR)); Resuscitation Council (UK); National Institute of Health Research Clinician Scientist Award	National Institute of Health Research and Resuscitation Council (UK).; The study was funded with a grant from the Resuscitation Council (UK). Dr. Perkins was supported by a National Institute of Health Research Clinician Scientist Award.	Barrett H, 2006, INTENS CARE MED, V32, P1371, DOI 10.1007/s00134-006-0215-5; Bjorshol CA, 2009, RESUSCITATION, V80, P898, DOI 10.1016/j.resuscitation.2009.06.009; Cook DA, 2008, JAMA-J AM MED ASSOC, V300, P1181, DOI 10.1001/jama.300.10.1181; Cook DA, 2010, MED EDUC, V44, P765, DOI 10.1111/j.1365-2923.2010.03723.x; Cooper S, 1999, RESUSCITATION, V42, P27, DOI 10.1016/S0300-9572(99)00080-5; Curtis L., UNIT COSTS HLTH SOCI; de Vries W, 2007, RESUSCITATION, V75, P491, DOI 10.1016/j.resuscitation.2007.05.014; Delasobera BE, 2010, RESUSCITATION, V81, P217, DOI 10.1016/j.resuscitation.2009.10.013; Finn J, 2010, RESUSCITATION, V81, P790, DOI 10.1016/j.resuscitation.2010.05.010; Flin R, 2010, BRIT J ANAESTH, V105, P38, DOI 10.1093/bja/aeq134; Gagnon Marie-Pierre, 2007, Inform Prim Care, V15, P83; Graubard BI, 1999, BIOMETRICS, V55, P652, DOI 10.1111/j.0006-341X.1999.00652.x; Hawkes N, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2333; Isbye DL, 2006, RESUSCITATION, V69, P435, DOI 10.1016/j.resuscitation.2005.10.027; Jensen ML, 2009, RESUSCITATION, V80, P903, DOI 10.1016/j.resuscitation.2009.06.005; Kamin C, 2006, ACAD MED, V81, P632, DOI 10.1097/01.ACM.0000232413.43142.8b; LaVange LM, 2001, STAT MED, V20, P2609, DOI 10.1002/sim.732; Moretti MA, 2007, RESUSCITATION, V72, P458, DOI 10.1016/j.resuscitation.2006.06.039; Moule P, 2010, J ADV NURS, V66, P2785, DOI 10.1111/j.1365-2648.2010.05453.x; Napier F, 2009, RESUSCITATION, V80, P1034, DOI 10.1016/j.resuscitation.2009.04.043; O'Dowd A, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b5330; Perkins Gavin, 2002, BMJ, V325, pS81; Perkins GD, 2007, RESUSCITATION, V75, P484, DOI 10.1016/j.resuscitation.2007.05.020; Perkins GD, 2007, RESUSCITATION, V73, P202, DOI 10.1016/j.resuscitation.2007.01.005; Perkins GD, 2010, RESUSCITATION, V81, P877, DOI 10.1016/j.resuscitation.2010.03.019; Perkins GD, 2005, INTENS CARE MED, V31, P1627, DOI 10.1007/s00134-005-2837-4; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Sandars J., 2010, BMJ-BRIT MED J, V341, pc5214; SCHNEIDER T, 1995, RESUSCITATION, V29, P129, DOI 10.1016/0300-9572(94)00833-2; Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32; Smith CM, 2007, INTENS CARE MED, V33, P901, DOI 10.1007/s00134-007-0564-8; Soar J, 2010, RESUSCITATION, V81, pE288, DOI 10.1016/j.resuscitation.2010.08.030; Soar J, 2010, RESUSCITATION, V81, P1434, DOI 10.1016/j.resuscitation.2010.08.014; Spearpoint KG, 2009, RESUSCITATION, V80, P638, DOI 10.1016/j.resuscitation.2009.03.002; Yeung JH, 2012, CRIT CARE M IN PRESS, V40; Yeung J, 2011, RESUSCITATION, V82, P657, DOI 10.1016/j.resuscitation.2011.02.035	36	63	66	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2012	157	1					19	28		10.7326/0003-4819-157-1-201207030-00005	http://dx.doi.org/10.7326/0003-4819-157-1-201207030-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992NS	22751757				2022-12-28	WOS:000307784900003
J	Radecki, RP				Radecki, Ryan P.			Dabigatran: Uncharted Waters and Potential Harms	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ATRIAL-FIBRILLATION; WARFARIN; THERAPY; RIVAROXABAN; ETEXILATE; APIXABAN; REVERSAL; RISK		Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Radecki, RP (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med, 6431 Fannin St,JJL 450, Houston, TX 77030 USA.	Ryan.P.Radecki@uth.tmc.edu		Radecki, Ryan/0000-0001-8590-6618				Alexander JH, 2011, NEW ENGL J MED, V365, P699, DOI 10.1056/NEJMoa1105819; [Anonymous], 2011, BOEHR BEST TOD DURCH; Naranjo IC, 2011, CEREBROVASC DIS, V32, P614, DOI 10.1159/000334578; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Cotton BA, 2011, NEW ENGL J MED, V365, P2039, DOI 10.1056/NEJMc1111095; Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017; Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747; Freeman JV, 2011, ANN INTERN MED, V154, P1, DOI 10.7326/0003-4819-154-1-201101040-00289; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Legrand M, 2011, ARCH INTERN MED, V171, P1285, DOI 10.1001/archinternmed.2011.314; Liesenfeld KH, 2011, J THROMB HAEMOST, V9, P2168, DOI 10.1111/j.1538-7836.2011.04498.x; Mega JL, 2012, NEW ENGL J MED, V366, P9, DOI 10.1056/NEJMoa1112277; Moore TJ, 2012, SIGNALS DABIGATRAN M; Moore TJ, 2011, SIGNALS 2 NEWLY APPR; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Uchino K, 2012, ARCH INTERN MED, V172, P397, DOI 10.1001/archinternmed.2011.1666; US Food and Drug Administration, 2011, FDA DRUG SAF COMM SA; van Ryn J, 2010, THROMB HAEMOSTASIS, V103, P1116, DOI 10.1160/TH09-11-0758; Zhou W, 2011, STROKE, V42, P3594, DOI 10.1161/STROKEAHA.111.624650	19	22	22	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2012	157	1					66	U107		10.7326/0003-4819-157-1-201207030-00467	http://dx.doi.org/10.7326/0003-4819-157-1-201207030-00467			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992NS	22751762				2022-12-28	WOS:000307784900007
J	Bhaumik, S				Bhaumik, Soumyadeep			India's attempt to reform medical councils sparks protest	LANCET			English	Editorial Material														Bhaumik, Soumyadeep/0000-0001-9579-4453					0	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 30	2012	379	9835					2414	2414		10.1016/S0140-6736(12)61049-6	http://dx.doi.org/10.1016/S0140-6736(12)61049-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	967NV	22764372				2022-12-28	WOS:000305915900010
J	Maseide, PH				Maseide, Per Helge			The battle about Breivik's mind	LANCET			English	Editorial Material																			0	6	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 30	2012	379	9835					2413	2413		10.1016/S0140-6736(12)61048-4	http://dx.doi.org/10.1016/S0140-6736(12)61048-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	967NV	22764371				2022-12-28	WOS:000305915900009
J	Watts, G				Watts, Geoff			Andrew Fielding Huxley Obituary	LANCET			English	Biographical-Item																		HUXLEY AF, PUBLICATION LIST	1	0	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 30	2012	379	9835					2422	2422		10.1016/S0140-6736(12)61056-3	http://dx.doi.org/10.1016/S0140-6736(12)61056-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	967NV	22764376				2022-12-28	WOS:000305915900015
J	Gostin, LO				Gostin, Lawrence O.			The Supreme Court's Historic Ruling on the Affordable Care Act Economic Sustainability and Universal Coverage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							REFORM		Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Gostin, Lawrence/0000-0001-5286-4044				Connors EE, 2010, JAMA-J AM MED ASSOC, V303, P2521, DOI 10.1001/jama.2010.856; Gostin LO, 2012, JAMA-J AM MED ASSOC, V307, P369, DOI 10.1001/jama.2012.16; Holan G, COST UNCOMPENSATED C	3	18	18	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 8	2012	308	6					571	572		10.1001/jama.2012.9061	http://dx.doi.org/10.1001/jama.2012.9061			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984YA	22772470				2022-12-28	WOS:000307228400020
J	Straussman, R; Morikawa, T; Shee, K; Barzily-Rokni, M; Qian, ZR; Du, JY; Davis, A; Mongare, MM; Gould, J; Frederick, DT; Cooper, ZA; Chapman, PB; Solit, DB; Ribas, A; Lo, RS; Flaherty, KT; Ogino, S; Wargo, JA; Golub, TR				Straussman, Ravid; Morikawa, Teppei; Shee, Kevin; Barzily-Rokni, Michal; Qian, Zhi Rong; Du, Jinyan; Davis, Ashli; Mongare, Margaret M.; Gould, Joshua; Frederick, Dennie T.; Cooper, Zachary A.; Chapman, Paul B.; Solit, David B.; Ribas, Antoni; Lo, Roger S.; Flaherty, Keith T.; Ogino, Shuji; Wargo, Jennifer A.; Golub, Todd R.			Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion	NATURE			English	Article							C-MET; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; V600E MUTATION; GROWTH-FACTOR; COLON-CANCER; MELANOMA; BRAF; VEMURAFENIB; OVEREXPRESSION	Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour micro-environment confers innate resistance to therapy. Here we developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs. We found that stroma-mediated resistance is common, particularly to targeted agents. We characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance(1-4). Proteomic analysis showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signalling pathways, and immediate resistance to RAF inhibition. Immunohistochemistry experiments confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment. Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma. A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines. More generally, this study indicates that the systematic dissection of interactions between tumours and their micro-environment can uncover important mechanisms underlying drug resistance.	[Straussman, Ravid; Shee, Kevin; Barzily-Rokni, Michal; Du, Jinyan; Davis, Ashli; Mongare, Margaret M.; Gould, Joshua; Golub, Todd R.] Eli & Edythe L Broad Inst, Cambridge, MA 02142 USA; [Morikawa, Teppei; Qian, Zhi Rong; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Frederick, Dennie T.; Cooper, Zachary A.; Flaherty, Keith T.; Wargo, Jennifer A.] Massachusetts Gen Hosp, Div Surg Oncol Med Oncol & Dermatol, Boston, MA 02114 USA; [Chapman, Paul B.; Solit, David B.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Solit, David B.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Ribas, Antoni] Univ Calif Los Angeles, Div Hematol & Oncol, Dept Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Ribas, Antoni; Lo, Roger S.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Lo, Roger S.] Univ Calif Los Angeles, Div Dermatol, Dept Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Ogino, Shuji; Golub, Todd R.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Golub, Todd R.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Golub, Todd R.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute	Golub, TR (corresponding author), Eli & Edythe L Broad Inst, 7 Cambridge Ctr, Cambridge, MA 02142 USA.	golub@broadinstitute.org	Hunt, David M/K-6024-2012; Solit, David B./AAC-5309-2019; Shee, Kevin/V-6803-2019	Hunt, David M/0000-0002-9264-3948; Shee, Kevin/0000-0001-5378-7650; Qian, Zhi rong/0000-0003-1633-4120; Cooper, Zachary/0000-0003-1059-0940; Ogino, Shuji/0000-0002-3909-2323	Howard Hughes Medical Institute; National Cancer Institute [P50CA093683, U54CA112962]; Melanoma Research Alliance Team Science Award; NATIONAL CANCER INSTITUTE [U54CA112962, UM1CA186709, P50CA093683, R01CA166480] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Melanoma Research Alliance Team Science Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all members of the Golub laboratory for discussions. We thank C. M. Johannessen, I. Rabinowitch, N. Shoresh and A. Goren for critical reading of the manuscript, and L. Gaffney for expert assistance with the graphics. This work was supported by the Howard Hughes Medical Institute, National Cancer Institute grants P50CA093683 and U54CA112962 (T. R. G.) and a Melanoma Research Alliance Team Science Award.	Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Jiang CC, 2011, CLIN CANCER RES, V17, P721, DOI 10.1158/1078-0432.CCR-10-2225; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kammula US, 2007, CANCER LETT, V248, P219, DOI 10.1016/j.canlet.2006.07.007; Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609; Lee YJ, 2011, ANN DERMATOL, V23, P33, DOI 10.5021/ad.2011.23.1.33; LIU C, 1992, ONCOGENE, V7, P181; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Puri N, 2007, CLIN CANCER RES, V13, P2246, DOI 10.1158/1078-0432.CCR-06-0776; Shao YP, 2010, CANCER RES, V70, P6670, DOI 10.1158/0008-5472.CAN-09-4471; Shekhar MPV, 2007, AM J PATHOL, V170, P1546, DOI 10.2353/ajpath.2007.061004; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wang HS, 2011, CANCER RES, V71, P5535, DOI 10.1158/0008-5472.CAN-10-4351; Wang W, 2009, CLIN CANCER RES, V15, P6630, DOI 10.1158/1078-0432.CCR-09-1001; Williams RT, 2006, P NATL ACAD SCI USA, V103, P6688, DOI 10.1073/pnas.0602030103; Wilson TR, 2012, NATURE	30	1302	1353	7	313	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 26	2012	487	7408					500	U118		10.1038/nature11183	http://dx.doi.org/10.1038/nature11183			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979KD	22763439	Green Accepted, Green Submitted			2022-12-28	WOS:000306815300042
J	Fan, HC; Gu, W; Wang, JB; Blumenfeld, YJ; El-Sayed, YY; Quake, SR				Fan, H. Christina; Gu, Wei; Wang, Jianbin; Blumenfeld, Yair J.; El-Sayed, Yasser Y.; Quake, Stephen R.			Non-invasive prenatal measurement of the fetal genome	NATURE			English	Article							MATERNAL PLASMA; DNA; ANEUPLOIDY	The vast majority of prenatal genetic testing requires invasive sampling. However, this poses a risk to the fetus, so one must make a decision that weighs the desire for genetic information against the risk of an adverse outcome due to hazards of the testing process. These issues are not required to be coupled, and it would be desirable to discover genetic information about the fetus without incurring a health risk. Here we demonstrate that it is possible to non-invasively sequence the entire prenatal genome. Our results show that molecular counting of parental haplotypes in maternal plasma by shotgun sequencing of maternal plasma DNA allows the inherited fetal genome to be deciphered non-invasively. We also applied the counting principle directly to each allele in the fetal exome by performing exome capture on maternal plasma DNA before shotgun sequencing. This approach enables non-invasive exome screening of clinically relevant and deleterious alleles that were paternally inherited or had arisen as de novo germline mutations, and complements the haplotype counting approach to provide a comprehensive view of the fetal genome. Non-invasive determination of the fetal genome may ultimately facilitate the diagnosis of all inherited and de novo genetic disease.	[Fan, H. Christina; Gu, Wei; Wang, Jianbin; Quake, Stephen R.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Blumenfeld, Yair J.; El-Sayed, Yasser Y.] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, Stanford, CA 94305 USA; [Quake, Stephen R.] Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; [Quake, Stephen R.] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Quake, SR (corresponding author), Stanford Univ, Dept Bioengn, Clark Ctr Rm E300,318 Campus Dr, Stanford, CA 94305 USA.	quake@stanford.edu	Blumenfeld, Yair/P-9396-2019; Wang, Jianbin/G-7533-2015	Blumenfeld, Yair/0000-0002-9440-8175; Wang, Jianbin/0000-0001-6725-7925; Gu, Wei/0000-0002-2480-6645	NATIONAL CANCER INSTITUTE [U54CA151459] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD000251] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Bellis MA, 2005, J EPIDEMIOL COMMUN H, V59, P749, DOI 10.1136/jech.2005.036517; Bianchi DW, 2012, OBSTET GYNECOL, V119, P890, DOI 10.1097/AOG.0b013e31824fb482; Bodurtha J, 2012, NEW ENGL J MED, V366, P64, DOI 10.1056/NEJMra1105043; BURKI E, 1948, OPHTHALMOLOGICA, V115, P241; Chiu Rossa W K, 2011, BMJ, V342, pc7401, DOI 10.1136/bmj.c7401; Clark MJ, 2011, NAT BIOTECHNOL, V29, P908, DOI 10.1038/nbt.1975; Ehrich M, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.12.060; Fan H. C., 2010, PREPRINT; Fan HC, 2008, P NATL ACAD SCI USA, V105, P16266, DOI 10.1073/pnas.0808319105; Fan HC, 2011, NAT BIOTECHNOL, V29, P51, DOI 10.1038/nbt.1739; Kinde I, 2011, P NATL ACAD SCI USA, V108, P9530, DOI 10.1073/pnas.1105422108; Lo YMD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001720; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; MACINTYRE S, 1991, LANCET, V338, P869, DOI 10.1016/0140-6736(91)91513-T; Marchini J, 2006, AM J HUM GENET, V78, P437, DOI 10.1086/500808; Palomaki GE, 2012, GENET MED, V14, P296, DOI 10.1038/gim.2011.73; Palomaki GE, 2011, GENET MED, V13, P913, DOI 10.1097/GIM.0b013e3182368a0e; Sehnert AJ, 2011, CLIN CHEM, V57, P1042, DOI 10.1373/clinchem.2011.165910; White RA, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-116	20	268	360	1	97	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 19	2012	487	7407					320	+		10.1038/nature11251	http://dx.doi.org/10.1038/nature11251			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JB	22763444	Green Accepted			2022-12-28	WOS:000306506500033
J	Ezeh, AC; Bongaarts, J; Mberu, B				Ezeh, Alex C.; Bongaarts, John; Mberu, Blessing			Global population trends and policy options	LANCET			English	Article							FERTILITY; PREFERENCES; TRANSITION; COUNTRIES; IMPACT	Rapid population growth is a threat to wellbeing in the poorest countries, whereas very low fertility increasingly threatens the future welfare of many developed countries. The mapping of global trends in population growth from 2005-10 shows four distinct patterns. Most of the poorest countries, especially in sub-Saharan Africa, are characterised by rapid growth of more than 2% per year. Moderate annual growth of 1-2% is concentrated in large countries, such as India and Indonesia, and across north Africa and western Latin America. Whereas most advanced-economy countries and large middle-income countries, such as China and Brazil, are characterised by low or no growth (0-1% per year), most of eastern Europe, Japan, and a few western European countries are characterised by population decline. Countries with rapid growth face adverse social, economic, and environmental pressures, whereas those with low or negative growth face rapid population ageing, unsustainable burdens on public pensions and health-care systems, and slow economic growth. Countries with rapid growth should consider the implementation of voluntary family planning programmes as their main policy option to reduce the high unmet need for contraception, unwanted pregnancies, and probirth reproductive norms. In countries with low or negative growth, policies to address ageing and very low fertility are still evolving. Further research into the potential effect of demographic policies on other social systems, social groups, and fertility decisions and trends is therefore recommended.	[Ezeh, Alex C.; Mberu, Blessing] African Populat & Hlth Res Ctr, Nairobi, Kenya; [Bongaarts, John] Populat Council, New York, NY 10021 USA	African Population & Health Research Centre; Population Council	Ezeh, AC (corresponding author), African Populat & Hlth Res Ctr, POB 10787,00100 GPO, Nairobi, Kenya.	aezeh@aphrc.org	Ezeh, Alex/AAN-8646-2020	Ezeh, Alex/0000-0002-1309-4697				Alexandratos N, 2005, POPUL DEV REV, V31, P237, DOI 10.1111/j.1728-4457.2005.00064.x; [Anonymous], 1994, DETERMINANTS REPROD; Azmat G, 2008, IUSSP SEM FERT PUBL; Birdsall N., 2001, POPULATION MATTERS; Bloom D., 2003, DEMOGRAPHIC DIVIDEND; Boccuzzo G., 2008, IMPACT BONUS BIRTH R, V6, P125, DOI 10.1553/populationyearbook2008s125; Bongaarts J., 2011, SAIS REV INT AFFAIRS, V31, P35; Bongaarts J, 2001, INT PERSPECT SEX R H, V37, P209; Caldwell JC., 2002, J POPUL RES, V19, P1, DOI [DOI 10.1007/BF03031966, 10.1007/BF03031966]; CLELAND J, 1987, POP STUD-J DEMOG, V41, P5, DOI 10.1080/0032472031000142516; Cleland J, 2006, LANCET, V368, P1810, DOI 10.1016/S0140-6736(06)69480-4; Demeny P, 2011, POPUL DEV REV, V37, P249, DOI 10.1111/j.1728-4457.2011.00386.x; EASTERLIN R. A., 1978, HIST STUDIES CHANGIN; EASTERLIN RA, 1975, STUD FAMILY PLANN, V6, P54, DOI 10.2307/1964934; Freedman R, 1997, STUD FAMILY PLANN, V28, P1, DOI 10.2307/2137966; Gauthier AH, 2007, POPUL RES POLICY REV, V26, P323, DOI 10.1007/s11113-007-9033-x; ICDDR B, 1994, 73 ICDDR B PUBL HLTH; ICDDR B, 2001, 88 ICDDR B PUBL HLTH; KOENIG MA, 1987, STUD FAMILY PLANN, V18, P117, DOI 10.2307/1966807; McDonald P, 2006, POPUL DEV REV, V32, P485, DOI 10.1111/j.1728-4457.2006.00134.x; Perra MS, 2008, IUSSP SEM FERT PUBL; PRITCHETT LH, 1994, POPUL DEV REV, V20, P1, DOI 10.2307/2137629; SIMMONS R, 1988, STUD FAMILY PLANN, V19, P29, DOI 10.2307/1966737; Singh S, 2009, ADDING IT COSTS BENE; Skeldon R, 2009, INT MIGR, V47, P3, DOI 10.1111/j.1468-2435.2008.00484.x; Teitelbaum M, GLOBAL PROBLEMS POPU; UNAIDS, 2010, GLOB REP UNAIDS REP; United Nations, 2011, WORLD POP PROSP 2010; United Nations, 2009, WORLD POP PROSP 2008; United Nations Department of Economic and Social Affairs Population Division, 2011, WORLD CONTR US 2010	30	118	122	6	121	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2012	380	9837					142	148		10.1016/S0140-6736(12)60696-5	http://dx.doi.org/10.1016/S0140-6736(12)60696-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784532				2022-12-28	WOS:000306359100041
J	Webborn, N; Van de Vliet, P				Webborn, Nick; Van de Vliet, Peter			Paralympic medicine	LANCET			English	Article							SPINAL-CORD-INJURY; BASKETBALL PLAYERS; BOTULINUM TOXIN; CEREBRAL-PALSY; SPORT; WHEELCHAIR; GAMES; PERFORMANCE; RESPONSES; EXERCISE	Paralympic medicine describes the health-care issues of those 4500 or so athletes who gather every 4 years to compete in 20 sports at the Summer Paralympic Games and in five sports at the Winter Paralympic Games. Paralympic athletes compete within six impairment groups: amputation or limb deficiencies, cerebral palsy, spinal cord-related disability, visual impairment, intellectual impairment, or a range of physically impairing disorders that do not fall into the other classification categories, known as les autres. The variety of impairments, many of which are severe, fluctuating, or progressive disorders (and are sometimes rare), makes maintenance of health in thousands of Paralympians while they undertake elite competition an unusual demand on health-care resources. The increased physical fitness of athletes with disabilities has important implications for cardiovascular risk reduction in a population for whom the prevalence of risk factors can be high.	[Webborn, Nick] Univ Brighton, Chelsea Sch Sport, Ctr Sport Res, Eastbourne BN20 7SR, E Sussex, England; [Webborn, Nick] British Paralymp Assoc, London, England; [Van de Vliet, Peter] Int Paralymp Comm, Int Paralymp Comm Med & Sci Dept, Bonn, Germany; [Van de Vliet, Peter] Univ Manitoba, Fac Kinesiol & Recreat Management, Hlth Leisure & Human Performance Res Inst, Winnipeg, MB, Canada	University of Brighton; University of Manitoba	Webborn, N (corresponding author), Univ Brighton, Chelsea Sch Sport, Ctr Sport Res, Eastbourne BN20 7SR, E Sussex, England.	nickwebborn@sportswise.org.uk	Jansevanrensburg, Christa/F-7848-2017	Jansevanrensburg, Christa/0000-0003-1058-6992; Webborn, Nick/0000-0003-3636-5557				American Association of Intellectual and Developmental Disabilities, DEF INT DIS; Autti-Ramo I, 2001, EUR J NEUROL, V8, P136, DOI 10.1046/j.1468-1331.2001.00046.x; Bernardi M, 2011, IOC WORLD C PREV INJ; Bernardi M, 2010, J SPORTS MED PHYS FI, V50, P29; Bernardi M, 2010, MED SCI SPORT EXER, V42, P1200, DOI 10.1249/MSS.0b013e3181c67d82; Bhambhani Y, 2010, DISABIL REHABIL, V32, P2172, DOI 10.3109/09638288.2010.505678; Burkett B, 2003, PROSTHET ORTHOT INT, V27, P36; Burkett B, 2001, PROSTHET ORTHOT INT, V25, P210, DOI 10.1080/03093640108726604; Burkett B, 2012, CLIN J SPORT MED, V22, P46, DOI 10.1097/JSM.0b013e31824200a4; Burkett B, 2010, BRIT J SPORT MED, V44, P533, DOI 10.1136/bjsm.2009.068957; Burkett B, 2010, BRIT J SPORT MED, V44, P215, DOI 10.1136/bjsm.2009.067249; Burnham RW., 1994, CLIN J SPORT MED, V4, P1; Camporesi S, 2008, J MED ETHICS, V34, P639, DOI 10.1136/jme.2008.026674; dos Santos LHC, 2011, PEDIATR NEUROL, V44, P357, DOI 10.1016/j.pediatrneurol.2010.12.001; CURTIS KA, 1985, PARAPLEGIA, V23, P170, DOI 10.1038/sc.1985.29; Curtis KA, 1999, J ORTHOP SPORT PHYS, V29, P225, DOI 10.2519/jospt.1999.29.4.225; Enock KE, 2008, PUBLIC HEALTH, V122, P1229, DOI 10.1016/j.puhe.2008.04.016; Fernhall Bo, 2008, J Health Hum Serv Adm, V30, P468; FERRARA MS, 1990, PARAPLEGIA, V28, P335, DOI 10.1038/sc.1990.44; Filho JAO, 2006, BRIT J SPORT MED, V40, P918, DOI 10.1136/bjsm.2006.029421; GASS GC, 1984, MED SCI SPORT EXER, V16, P355; HOFFMAN MD, 1986, SPORTS MED, V3, P312, DOI 10.2165/00007256-198603050-00002; Hopman MTE, 1998, INT J SPORTS MED, V19, P98, DOI 10.1055/s-2007-971889; International Paralympic Committee, MED COD; International Paralympic Committee, SPORT SPEC CLASS; International Paralympic Committee, 2011, IPC HDB; Khan SA, 2011, CLIN THER, V33, P168, DOI 10.1016/j.clinthera.2011.03.002; Krassioukov A, 2012, CLIN J SPORT MED, V22, P39, DOI 10.1097/JSM.0b013e3182420699; Lippi G, 2008, BRIT J SPORT MED, V42, P160, DOI 10.1136/bjsm.2008.046730; Mah CD, 2011, SLEEP, V34, P943, DOI 10.5665/SLEEP.1132; SAWKA MN, 1980, J APPL PHYSIOL, V49, P784, DOI 10.1152/jappl.1980.49.5.784; Stevens SL, 2008, J SPINAL CORD MED, V31, P373, DOI 10.1080/10790268.2008.11760739; STOTTS KM, 1986, ARCH PHYS MED REHAB, V67, P109, DOI 10.1016/0003-9993(86)90116-4; Taunton J, 2012, CLIN J SPORT MED, V22, P10, DOI 10.1097/JSM.0b013e318242ec68; The International Paralympic Committee, SANCT ATHL; Tweedy SM, 2011, BRIT J SPORT MED, V45, P259, DOI 10.1136/bjsm.2009.065060; Tweedy SM, 2002, ADAPT PHYS ACT Q, V19, P220, DOI 10.1123/apaq.19.2.220; Van De Vliet P, 2012, FIMS SPORTS MED MANU; Vanlandewijck YC, 2011, SPORTS MED; Webborn ADJ, 1999, BRIT J SPORT MED, V33, P74; Webborn ADJ, 1999, BRIT J SPORT MED, V33, P138, DOI 10.1136/bjsm.33.2.138; Webborn ADJ, 1996, BR J THER REHABIL, V3, P429; Webborn ADJ, 2009, EPIDEMIOLOGY INJURY, P437; Webborn ADJ, 2005, ABS SPORTS EXERCISE, P76; Webborn N, 2006, MED SCI SPORT EXER, V38, P811, DOI 10.1249/01.mss.0000218120.05244.da; Webborn N, 2005, J APPL PHYSIOL, V98, P2101, DOI 10.1152/japplphysiol.00784.2004; Webborn N, 2010, BRIT J SPORT MED, V44, P455, DOI 10.1136/bjsm.2007.043687; Webborn N., 2006, CLIN SPORTS MED; Webborn N., 2008, EXERCISE PHYSL SPECI, P309; Webborn N, 2012, BRIT J SPORT MED, V46, P193, DOI 10.1136/bjsports-2011-090417; Webborn N, 2012, CLIN J SPORT MED, V22, P3, DOI 10.1097/JSM.0b013e318243309f	51	62	65	0	38	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 7	2012	380	9836					65	71		10.1016/S0140-6736(12)60831-9	http://dx.doi.org/10.1016/S0140-6736(12)60831-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	970GK	22770458				2022-12-28	WOS:000306115900035
J	Casals, F; Bertranpetit, J				Casals, Ferran; Bertranpetit, Jaume			Human Genetic Variation, Shared and Private	SCIENCE			English	Editorial Material							VARIANTS; EXCESS; SPECTRUM		[Casals, Ferran; Bertranpetit, Jaume] Univ Pompeu Fabra, IBE Inst Evolutionary Biol UPF CSIC, Barcelona, Catalonia, Spain	Pompeu Fabra University	Casals, F (corresponding author), Univ Pompeu Fabra, IBE Inst Evolutionary Biol UPF CSIC, Barcelona, Catalonia, Spain.	jaume.bertranpetit@upf.edu	Bertranpetit, Jaume/F-8550-2012; Casals, Ferran/H-4347-2015	Bertranpetit, Jaume/0000-0003-0100-0590; Casals, Ferran/0000-0002-8941-0369				Asimit J, 2010, ANNU REV GENET, V44, P293, DOI 10.1146/annurev-genet-102209-163421; Barbujani G, 1997, P NATL ACAD SCI USA, V94, P4516, DOI 10.1073/pnas.94.9.4516; Coventry A, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1130; Gibson G, 2012, NAT REV GENET, V13, P135, DOI 10.1038/nrg3118; Gravel S, 2011, P NATL ACAD SCI USA, V108, P11983, DOI 10.1073/pnas.1019276108; Keinan A, 2012, SCIENCE, V336, P740, DOI 10.1126/science.1217283; Li YR, 2010, NAT GENET, V42, P969, DOI 10.1038/ng.680; Lynch M, 2010, P NATL ACAD SCI USA, V107, P961, DOI 10.1073/pnas.0912629107; MacArthur DG, 2012, SCIENCE, V335, P823, DOI 10.1126/science.1215040; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Marth GT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r84; Mathieson I, 2012, NAT GENET, V44, P243, DOI 10.1038/ng.1074; Nelson MR, 2012, SCIENCE, V337, P100, DOI 10.1126/science.1217876; Tennessen JA, 2012, SCIENCE, V337, P64, DOI 10.1126/science.1219240; Visscher PM, 2012, AM J HUM GENET, V90, P7, DOI 10.1016/j.ajhg.2011.11.029	15	26	26	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2012	337	6090					39	40		10.1126/science.1224528	http://dx.doi.org/10.1126/science.1224528			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	969KC	22767915				2022-12-28	WOS:000306053100033
J	Strunk, BS; Novak, MN; Young, CL; Karbstein, K				Strunk, Bethany S.; Novak, Megan N.; Young, Crystal L.; Karbstein, Katrin			A Translation-Like Cycle Is a Quality Control Checkpoint for Maturing 40S Ribosome Subunits	CELL			English	Article							MESSENGER-RNA DECAY; SACCHAROMYCES-CEREVISIAE; INITIATION; BIOGENESIS; MATURATION; COMPLEX; PROTEINS; SITE	Assembly factors (AFs) prevent premature translation initiation on small (40S) ribosomal subunit assembly intermediates by blocking ligand binding. However, it is unclear how AFs are displaced from maturing 40S ribosomes, if or how maturing subunits are assessed for fidelity, and what prevents premature translation initiation once AFs dissociate. Here we show that maturation involves a translation-like cycle whereby the translation factor eIF5B, a GTPase, promotes joining of large (60S) subunits with pre-40S subunits to give 80S-like complexes, which are subsequently disassembled by the termination factor Rli1, an ATPase. The AFs Tsr1 and Rio2 block the mRNA channel and initiator tRNA binding site, and therefore 80S-like ribosomes lack mRNA or initiator tRNA. After Tsr1 and Rio2 dissociate from 80S-like complexes Rli1-directed displacement of 60S subunits allows for translation initiation. This cycle thus provides a functional test of 60S subunit binding and the GTPase site before ribosomes enter the translating pool.	[Strunk, Bethany S.; Novak, Megan N.; Young, Crystal L.; Karbstein, Katrin] Scripps Res Inst, Dept Canc Biol, Jupiter, FL 33458 USA; [Novak, Megan N.] Furman Univ, Dept Chem, Greenville, SC 29613 USA; [Young, Crystal L.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	Scripps Research Institute; University of Michigan System; University of Michigan	Karbstein, K (corresponding author), Scripps Res Inst, Dept Canc Biol, Jupiter, FL 33458 USA.	kkarbst@scripps.edu		Young-Erdos, Crystal/0000-0003-2323-8372; Strunk, Bethany/0000-0003-2337-4614; Karbstein, Katrin/0000-0002-4034-1331	National Science Foundation; Kellogg School of Science and Technology; National Institutes of Health [R01-GM086451]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086451] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); Kellogg School of Science and Technology; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Hinnebusch and T. Dever for providing antibodies and plasmids and J. Hershey, C. Fraser, K. Nettles, and J. Cleveland for critical review of the manuscript. We also thank M. Chalmer and C. Steckler for carrying out mass spectrometry experiments. B.S.S. was partially supported by a National Science Foundation predoctoral fellowship. M.N.N. was supported by a Summer Undergraduate Research Fellows (SURF) fellowship from the Kellogg School of Science and Technology. This work is funded by grant R01-GM086451 from the National Institutes of Health.	Acker MG, 2009, J MOL BIOL, V385, P491, DOI 10.1016/j.jmb.2008.10.029; Arava Y, 2003, P NATL ACAD SCI USA, V100, P3889, DOI 10.1073/pnas.0635171100; Baudin-Baillieu A, 2009, NUCLEIC ACIDS RES, V37, P7665, DOI 10.1093/nar/gkp816; Becker T, 2012, NATURE, V482, P501, DOI 10.1038/nature10829; Becker T, 2011, NAT STRUCT MOL BIOL, V18, P715, DOI 10.1038/nsmb.2057; Bhattacharya A, 2010, MOL CELL BIOL, V30, P5562, DOI 10.1128/MCB.00618-10; Bussiere C, 2012, J CELL BIOL, V197, P747, DOI 10.1083/jcb.201112131; Cole SE, 2009, MOL CELL, V34, P440, DOI 10.1016/j.molcel.2009.04.017; Ferreira-Cerca S, 2005, MOL CELL, V20, P263, DOI 10.1016/j.molcel.2005.09.005; Filbin ME, 2009, CURR OPIN STRUC BIOL, V19, P267, DOI 10.1016/j.sbi.2009.03.005; Granneman S, 2005, MOL CELL BIOL, V25, P10352, DOI 10.1128/MCB.25.23.10352-10364.2005; Jakovljevic J, 2004, MOL CELL, V14, P331, DOI 10.1016/S1097-2765(04)00215-1; Karbstein K, 2011, CURR OPIN CHEM BIOL, V15, P657, DOI 10.1016/j.cbpa.2011.07.023; Khoshnevis S, 2010, EMBO REP, V11, P214, DOI 10.1038/embor.2009.272; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; Kos M, 2010, MOL CELL, V37, P809, DOI 10.1016/j.molcel.2010.02.024; Lamanna AC, 2011, J MOL BIOL, V405, P3, DOI 10.1016/j.jmb.2010.09.064; Lamanna AC, 2009, P NATL ACAD SCI USA, V106, P14259, DOI 10.1073/pnas.0905403106; Li ZH, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000213; Liang XH, 2007, MOL CELL, V28, P965, DOI 10.1016/j.molcel.2007.10.012; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Passmore LA, 2007, MOL CELL, V26, P41, DOI 10.1016/j.molcel.2007.03.018; Pertschy B, 2009, J BIOL CHEM, V284, P35079, DOI 10.1074/jbc.M109.040774; Pisareva VP, 2011, EMBO J, V30, P1804, DOI 10.1038/emboj.2011.93; Rabl J, 2011, SCIENCE, V331, P730, DOI 10.1126/science.1198308; Shin BS, 2011, NAT STRUCT MOL BIOL, V18, P1227, DOI 10.1038/nsmb.2133; Shoemaker CJ, 2011, P NATL ACAD SCI USA, V108, pE1392, DOI 10.1073/pnas.1113956108; Soudet J, 2010, EMBO J, V29, P80, DOI 10.1038/emboj.2009.307; Strunk BS, 2011, SCIENCE, V333, P1449, DOI 10.1126/science.1208245; Strunk BS, 2009, RNA, V15, P2083, DOI 10.1261/rna.1792109; Valasek L, 2007, METHOD ENZYMOL, V429, P163, DOI 10.1016/S0076-6879(07)29008-1; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540	33	185	185	0	22	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 6	2012	150	1					111	121		10.1016/j.cell.2012.04.044	http://dx.doi.org/10.1016/j.cell.2012.04.044			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770215	Bronze, Green Accepted			2022-12-28	WOS:000306115000011
J	Valente, TW				Valente, Thomas W.			Network Interventions	SCIENCE			English	Review							SOCIAL-NETWORK; HIV PREVENTION; HEALTH-CARE; DIFFUSION; COMPETITION; ASSIGNMENT; CONTAGION; BEHAVIOR; PROGRAM; EXAMPLE	The term "network interventions" describes the process of using social network data to accelerate behavior change or improve organizational performance. In this Review, four strategies for network interventions are described, each of which has multiple tactical alternatives. Many of these tactics can incorporate different mathematical algorithms. Consequently, researchers have many intervention choices at their disposal. Selecting the appropriate network intervention depends on the availability and character of network data, perceived characteristics of the behavior, its existing prevalence, and the social context of the program.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Inst Prevent Res, Los Angeles, CA 90034 USA	University of Southern California	Valente, TW (corresponding author), Univ So Calif, Keck Sch Med, Dept Prevent Med, Inst Prevent Res, Los Angeles, CA 90034 USA.	tvalente@usc.edu			NIH (National Institute on Alcohol Abuse and Alcoholism) [1RC1AA019239-01]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [RC1AA019239] Funding Source: NIH RePORTER	NIH (National Institute on Alcohol Abuse and Alcoholism)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported by NIH grant number 1RC1AA019239-01 (from the National Institute on Alcohol Abuse and Alcoholism). I thank A. Heckert for help with Fig. 2 and R. Davis, L. Koehly, W. Loges, P. Matous, J. Okamoto, and three anonymous reviewers for comments on earlier drafts.	[Anonymous], [No title captured]; Aral S, 2011, ENG SOCIAL CONTAGION; Aral S, 2011, MANAGE SCI, V57, P1623, DOI 10.1287/mnsc.1110.1421; Aral S, 2009, P NATL ACAD SCI USA, V106, P21544, DOI 10.1073/pnas.0908800106; BECKER MH, 1970, AM SOCIOL REV, V35, P267, DOI 10.2307/2093205; Bondonio D, 1998, SOC NETWORKS, V20, P301, DOI 10.1016/S0378-8733(98)00007-0; Borgatti S, 2005, KEYPLAYER PROGRAM; Borgatti S. P., 2006, Computational & Mathematical Organization Theory, V12, P21, DOI 10.1007/s10588-006-7084-x; Borgatti S. P., 2005, UCINET 6 WINDOWS SOF; Borgatti SP, 1999, SOC NETWORKS, V21, P375; Boulos MNK, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-24; Buller D, 2000, HEALTH EDUC BEHAV, V27, P232, DOI 10.1177/109019810002700209; Burt R.S., 2005, BROKERAGE CLOSURE IN; Centola D, 2010, SCIENCE, V329, P1194, DOI 10.1126/science.1185231; Christakis NA, 2007, NEW ENGL J MED, V357, P370, DOI 10.1056/NEJMsa066082; Coleman J. S., 1966, MED INNOVATION DIFFU; Cross R, 2002, CALIF MANAGE REV, V44, P25, DOI 10.2307/41166121; Cross R., 2006, HIDDEN POWER SOCIAL; Doreian P., 1997, EVOLUTION SOCIAL NET; Everett MG, 2010, SOC NETWORKS, V32, P339, DOI 10.1016/j.socnet.2010.06.004; FREEMAN LC, 1979, SOC NETWORKS, V1, P215, DOI 10.1016/0378-8733(78)90021-7; Girvan M, 2002, P NATL ACAD SCI USA, V99, P7821, DOI 10.1073/pnas.122653799; Gould RV., 1989, SOCIOL METHODOL, V19, P89, DOI DOI 10.2307/270949; Heckathorn DD, 1997, SOC PROBL, V44, P174, DOI 10.1525/sp.1997.44.2.03x0221m; Hlebec V., 2002, FIELD METHOD, V14, P288, DOI DOI 10.1177/15222X014003003; Hovland CI, 1951, PUBLIC OPIN QUART, V15, P635, DOI 10.1086/266350; KATZ ML, 1985, AM ECON REV, V75, P424; Kelly J. A., 2006, BMJ-BRIT MED J, V333, P1953; Koschutzki D., 2005, NETWORK ANAL METHODO; Latkin CA, 1996, AM J COMMUN PSYCHOL, V24, P341, DOI 10.1007/BF02512026; Latkin CA, 2009, SOC SCI MED, V68, P740, DOI 10.1016/j.socscimed.2008.11.019; Lin Z, 2006, ORGAN SCI, V17, P598, DOI 10.1287/orsc.1060.0210; Manski Charles F., 1995, IDENTIFICATION PROBL; MARKUS ML, 1987, COMMUN RES, V14, P491, DOI 10.1177/009365087014005003; Medley A, 2009, AIDS EDUC PREV, V21, P181, DOI 10.1521/aeap.2009.21.3.181; Meltzer D, 2010, SOC SCI MED, V71, P1119, DOI 10.1016/j.socscimed.2010.05.012; Monge P. R., 2003, THEORIES COMMUNICATI, DOI 10.1093/oso/9780195160369.001.0001; Newman MEJ, 2004, PHYS REV E, V69, DOI [10.1103/PhysRevE.69.026113, 10.1103/PhysRevE.70.056131]; Newman MEJ., 2006, STRUCTURE DYNAMICS N; Nickerson DW, 2008, AM POLIT SCI REV, V102, P49, DOI 10.1017/S0003055408080039; Palmore J. A., 1967, SOCIOLOGICAL CONTRIB, P272; Rice R. E., 2001, INTERNET HLTH COMMUN; Roberts N., 2011, J SOCIAL STRUCTURE, V12; Robins G.L., 2005, MODELS METHODS SOCIA, P192; Robins G, 2007, SOC NETWORKS, V29, P173, DOI 10.1016/j.socnet.2006.08.002; Rogers E.M., 2003, DIFFUSION INNOVATION, V5th; Rosen E., 2009, ANATOMY BUZZ REVISTE; Sacerdote B, 2001, Q J ECON, V116, P681, DOI 10.1162/00335530151144131; Simoni JM, 2011, AIDS BEHAV, V15, P376, DOI 10.1007/s10461-010-9836-3; Snijders TA, 2005, MODELS LONGITUDINAL, P215; Snijders TAB, 2010, SOC NETWORKS, V32, P44, DOI 10.1016/j.socnet.2009.02.004; Starkey F, 2009, HEALTH EDUC RES, V24, P977, DOI 10.1093/her/cyp045; Thomas JC, 1998, AM J PUBLIC HEALTH, V88, P1252; Valente T, 1995, NETWORK MODELS DIFFU; Valente TW, 2007, HEALTH EDUC BEHAV, V34, P881, DOI 10.1177/1090198106297855; Valente TW, 2007, ADDICTION, V102, P1804, DOI 10.1111/j.1360-0443.2007.01992.x; Valente TW, 2010, SOC NETWORKS, V32, P212, DOI 10.1016/j.socnet.2010.03.003; Valente TW, 2008, EVAL PROGRAM PLANN, V31, P392, DOI 10.1016/j.evalprogplan.2008.06.002; Valente TW, 2003, AM J PUBLIC HEALTH, V93, P1837, DOI 10.2105/AJPH.93.11.1837; Valente TW, 1996, SOC NETWORKS, V18, P69, DOI 10.1016/0378-8733(95)00256-1; Valente TW, 1999, ANN AM ACAD POLIT SS, V566, P55, DOI 10.1177/0002716299566001005; Valente TW, 2010, SOCIAL NETWORKS HLTH, DOI DOI 10.1093/ACPROF:OSO/9780195301014.001.0001/ACPROF-9780195301014; Wasserman, 1994, SOCIAL NETWORK ANAL, DOI DOI 10.1017/CBO9780511815478; Wasserman S., MODELS METHODS SOCIA, P8, DOI DOI 10.1017/CBO9780511811395.002; Watts D. J, 1999, SMALL WORLDS DYNAMIC; Wenger E., 2002, CULTIVATING COMMUNIT; WHITE HC, 1981, AM J SOCIOL, V87, P517, DOI 10.1086/227495	67	738	750	4	204	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2012	337	6090					49	53		10.1126/science.1217330	http://dx.doi.org/10.1126/science.1217330			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	969KC	22767921				2022-12-28	WOS:000306053100040
J	Gibson, DR				Gibson, David R.			Decisions at the brink	NATURE			English	Editorial Material									Princeton Univ, Princeton, NJ 08544 USA	Princeton University	Gibson, DR (corresponding author), Princeton Univ, Princeton, NJ 08544 USA.	drgibson@princeton.edu						Dobbs M., 2008, ONE MINUTE MIDNIGHT; Fursenko Aleksandr, 1997, KHRUSHCHEV CASTRO KE; Kennedy R., 1969, 13 DAYS MEMOIR CUBAN; May Ernest, 1997, KENNEDY TAPES; Stern SM., 2003, AVERTING FINAL FAILU	5	2	2	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 5	2012	487	7405					27	29		10.1038/487027a	http://dx.doi.org/10.1038/487027a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	968LM	22763533	Bronze			2022-12-28	WOS:000305982900015
J	Sogaard, R; Laustsen, J; Lindholt, JS				Sogaard, Rikke; Laustsen, Jesper; Lindholt, Jes S.			Cost effectiveness of abdominal aortic aneurysm screening and rescreening in men in a modern context: evaluation of a hypothetical cohort using a decision analytical model	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; GROWTH-RATES; REPAIR; MANAGEMENT; RUPTURE; MORTALITY; RISK	Objective To assess the cost effectiveness of different screening strategies for abdominal aortic aneurysm in men, from the perspective of a national health service. Setting Screening units at regional hospitals. Participants Hypothetical cohort of 65 year old men from the general population. Main outcome measures Costs ( pound in 2010) and effect on health outcomes (quality adjusted life years (QALYs)). Results Screening seems to be highly cost effective compared with not screening. The model estimated a 92% probability that some form of screening would be cost effective at a threshold of 20 pound 000 ((sic)24 790; $31 460). If men with an aortic diameter of 25-29 mm at the initial screening were rescreened once after five years, 452 men per 100 000 initially screened would benefit from early detection, whereas lifetime rescreening every five years would detect 794 men per 100 000. We estimated the associated incremental cost effectiveness ratios for rescreening once and lifetime rescreening to be 10 pound 013 and 29 pound 680 per QALY, respectively. The individual probability of being the most cost effective strategy was higher for each rescreening strategy than for the screening once strategy (in view of the 20 pound 000 threshold). Conclusions This study confirms the cost effectiveness of screening versus no screening and lends further support to considerations of rescreening men at least once for abdominal aortic aneurysm.	[Sogaard, Rikke] Univ So Denmark, Ctr Appl Hlth Serv Res & Technol Assessment CAST, Inst Publ Hlth, DK-5000 Odense, Denmark; [Laustsen, Jesper] Aarhus Univ Hosp, Dept Cardiothorac & Vasc Surg, DK-8000 Aarhus, Denmark; [Lindholt, Jes S.] Viborg Hosp, Vasc Res Unit, Viborg, Denmark; [Lindholt, Jes S.] Odense Univ Hosp, Dept Cardiothorac & Vasc Surg, DK-5000 Odense, Denmark	University of Southern Denmark; Aarhus University; Aarhus University; University of Southern Denmark; Odense University Hospital	Sogaard, R (corresponding author), Univ So Denmark, Ctr Appl Hlth Serv Res & Technol Assessment CAST, Inst Publ Hlth, DK-5000 Odense, Denmark.	ris@cast.sdu.dk	Lindholt, Jes/J-2907-2014	Lindholt, Jes/0000-0001-9536-4488; Sogaard, Rikke/0000-0003-3557-8550	Health Research Fund of Central Denmark Region; Research Fund of Viborg Hospital; 7th European Framework Programme [Health-2007-2.4.2-2, 200647]	Health Research Fund of Central Denmark Region; Research Fund of Viborg Hospital; 7th European Framework Programme(European Commission)	The Health Research Fund of Central Denmark Region and the Research Fund of Viborg Hospital funded the work. The sponsors had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.; All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: support from the Health Research Fund of Central Denmark Region and the Research Fund of Viborg Hospital; JSL was sponsored by the 7th European Framework Programme (Health-2007-2.4.2-2; project title "Fighting aneurysmal disease"; grant agreement no 200647); no other relationships or activities that could appear to have influenced the submitted work.	Ades AE, 2004, MED DECIS MAKING, V24, P207, DOI 10.1177/0272989X04263162; Ashton HA, 2002, LANCET, V360, P1531, DOI 10.1016/S0140-6736(02)11522-4; Brown PM, 2003, J VASC SURG, V37, P280, DOI 10.1067/mva.2003.119; Brownsword R, 2010, J MED ETHICS, V36, P827, DOI 10.1136/jme.2010.035519; CMO and Public Health Directorate, 2010, SCOTT ABD AORT AN SC; Grondal N, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-67; Henriksson M, 2005, BRIT J SURG, V92, P976, DOI 10.1002/bjs.5122; Kent KC, 2010, NEW ENGL J MED, V362, P1930, DOI 10.1056/NEJMe1004299; Kim LG, 2007, J MED SCREEN, V14, P46, DOI 10.1258/096914107780154477; Lederle FA, 2002, JAMA-J AM MED ASSOC, V287, P2968, DOI 10.1001/jama.287.22.2968; Levin David C, 2007, J Am Coll Radiol, V4, P125, DOI 10.1016/j.jacr.2006.08.010; Lindholt JS, 2011, BRIT J SURG, V98, P619, DOI 10.1002/bjs.7464; Lindholt JS, 2010, BRIT J SURG, V97, P826, DOI 10.1002/bjs.7001; Lindholt Jes S, 2010, Ugeskr Laeger, V172, P2206; Lindholt JS, 2000, EUR J VASC ENDOVASC, V20, P79, DOI 10.1053/ejvs.1999.1087; Lindholt JS, 2005, BMJ-BRIT MED J, V330, P750, DOI 10.1136/bmj.38369.620162.82; Metcalfe D, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1384; Moll FL, 2011, EUR J VASC ENDOVASC, V41, pS1, DOI 10.1016/j.ejvs.2010.09.011; Montreuil B, 2008, CAN J SURG, V51, P23; NHS, 2011, ABD AORT AN SCREEN P; Powell JT, 2011, BRIT J SURG, V98, P609, DOI 10.1002/bjs.7465; Scott RAP, 2005, J MED SCREEN, V12, P57, DOI 10.1258/0969141053908339; Silverstein Marc D, 2005, Proc (Bayl Univ Med Cent), V18, P345; Sogaard R, 2011, MODELLING COST EFFEC; Sogaard R, 2012, J HEALTH SERV RES PO, V17, P44, DOI 10.1258/jhsrp.2011.010133; Sorensen J, 2009, SCAND J PUBLIC HEALT, V37, P467, DOI 10.1177/1403494809105286; Spronk S, 2011, BRIT J SURG, V98, P1546, DOI 10.1002/bjs.7620; Sweeting MJ, 2010, MAKING PREDICTIONS C; Tambyraja AL, 2004, EUR J VASC ENDOVASC, V28, P229, DOI 10.1016/j.ejvs.2004.03.024; Thompson SG, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b2307; Vammen S, 2001, INT J ANG, V10, P246; Vardulaki KA, 1998, BRIT J SURG, V85, P1674; Walley T, 2005, BRIT J CLIN PHARMACO, V60, P543, DOI 10.1111/j.1365-2125.2005.02478.x; Wanhainen A, 2005, J VASC SURG, V41, P741, DOI 10.1016/j.jvs.2005.01.055; Wilson JMG, 1968, PRINCIPLES PRACTICE	35	48	49	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 5	2012	344								e4276	10.1136/bmj.e4276	http://dx.doi.org/10.1136/bmj.e4276			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972KH	22767630	Green Published, hybrid			2022-12-28	WOS:000306275500001
J	Walter, FM; Morris, HC; Humphrys, E; Hall, PN; Prevost, AT; Burrows, N; Bradshaw, L; Wilson, ECF; Norris, P; Walls, J; Johnson, M; Kinmonth, AL; Winthrop, JDE				Walter, Fiona M.; Morris, Helen C.; Humphrys, Elka; Hall, Per N.; Prevost, A. Toby; Burrows, Nigel; Bradshaw, Lucy; Wilson, Edward C. F.; Norris, Paul; Walls, Joe; Johnson, Margaret; Kinmonth, Ann Louise; Winthrop, Jon D. Emery			Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SPECTROPHOTOMETRIC INTRACUTANEOUS ANALYSIS; CUTANEOUS MALIGNANT-MELANOMA; SKIN-CANCER; 7-POINT CHECKLIST; DERMOSCOPY; PHYSICIANS; DERMATOLOGISTS; INTERVENTIONS; ACCURACY; INTERVAL	Objectives To assess whether adding a novel computerised diagnostic tool, the MoleMate system (SIAscopy with primary care scoring algorithm), to current best practice results in more appropriate referrals of suspicious pigmented lesions to secondary care, and to assess its impact on clinicians and patients. Design Randomised controlled trial. Setting 15 general practices in eastern England. Participants 1297 adults with pigmented skin lesions not immediately diagnosed as benign. Interventions Patients were assessed by trained primary care clinicians using best practice (clinical history, naked eye examination, seven point checklist) either alone (control group) or with the MoleMate system (intervention group). Main outcome measures Appropriateness of referral, defined as the proportion of referred lesions that were biopsied or monitored. Secondary outcomes related to the clinicians (diagnostic performance, confidence, learning effects) and patients (satisfaction, anxiety). Economic evaluation, diagnostic performance of the seven point checklist, and five year follow-up of melanoma incidence were also secondary outcomes and will be reported later. Results 1297 participants with 1580 lesions were randomised: 643 participants with 788 lesions to the intervention group and 654 participants with 792 lesions to the control group. The appropriateness of referral did not differ significantly between the intervention or control groups: 56.8% (130/229) v 64.5% (111/172); difference -8.1% (95% confidence interval -18.0% to 1.8%). The proportion of benign lesions appropriately managed in primary care did not differ (intervention 99.6% v control 99.2%, P=0.46), neither did the percentage agreement with an expert decision to biopsy or monitor (intervention 98.5% v control 95.7%, P=0.26). The percentage agreement with expert assessment that the lesion was benign was significantly lower with MoleMate (intervention 84.4% v control 90.6%, P<0.001), and a higher proportion of lesions were referred (intervention 29.8% v control 22.4%, P=0.001). Thirty six histologically confirmed melanomas were diagnosed: 18/18 were appropriately referred in the intervention group and 17/18 in the control group. Clinicians in both groups were confident, and there was no evidence of learning effects, and therefore contamination, between groups. Patients in the intervention group ranked their consultations higher for thoroughness and reassuring care, although anxiety scores were similar between the groups. Conclusions We found no evidence that the MoleMate system improved appropriateness of referral. The systematic application of best practice guidelines alone was more accurate than the MoleMate system, and both performed better than reports of current practice. Therefore the systematic application of best practice guidelines (including the seven point checklist) should be the paradigm for management of suspicious skin lesions in primary care.	[Walter, Fiona M.; Morris, Helen C.; Prevost, A. Toby; Kinmonth, Ann Louise; Winthrop, Jon D. Emery] Univ Cambridge, Dept Publ Hlth & Primary Care, Primary Care Unit, Cambridge CB2 0SR, England; [Humphrys, Elka] Canc Res UK, London, England; [Humphrys, Elka] UCL Canc Trials Ctr, London, England; [Hall, Per N.; Burrows, Nigel; Norris, Paul] Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England; [Prevost, A. Toby] Kings Coll London, Dept Primary Care & Publ Hlth Sci, London WC2R 2LS, England; [Bradshaw, Lucy] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England; [Wilson, Edward C. F.] Univ E Anglia, Fac Hlth, Hlth Econ Grp, Norwich NR4 7TJ, Norfolk, England; [Walls, Joe] Norfolk & Norwich Univ Hosp NHS Trust, Norwich, Norfolk, England; [Walter, Fiona M.; Winthrop, Jon D. Emery] Univ Western Australia, Sch Primary Aboriginal & Rural Hlth Care, Crawley, WA, Australia	University of Cambridge; Cancer Research UK; University of London; University College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; King's College London; University of Nottingham; University of East Anglia; Norfolk & Norwich University Hospitals NHS Foundation Trust; University of Western Australia	Walter, FM (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Primary Care Unit, Cambridge CB2 0SR, England.	fmw22@medschl.cam.ac.uk	Walter, Fiona/F-3054-2014; Walter, Fiona/GYR-1347-2022; Wilson, Ed/P-4310-2019	Wilson, Ed/0000-0002-8369-1577; Prevost, A. Toby/0000-0003-1723-0796; Walter, Fiona/0000-0002-7191-6476; Humphrys, Elka/0000-0002-6127-0157	National Institute for Health Research (NIHR) School for Primary Care Research; Department of Health; NHS Cambridgeshire; East of England Primary Care Research Network; MRC [G0200391] Funding Source: UKRI; Medical Research Council [G0200391] Funding Source: researchfish; National Institute for Health Research [CL-2006-14-003] Funding Source: researchfish	National Institute for Health Research (NIHR) School for Primary Care Research(National Institute for Health Research (NIHR)); Department of Health; NHS Cambridgeshire; East of England Primary Care Research Network; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by the National Institute for Health Research (NIHR) School for Primary Care Research. The views expressed in this paper are those of the authors and not necessarily those of the Department of Health. ALK is an NIHR senior investigator. Service support costs were obtained from the Department of Health with the support of NHS Cambridgeshire and the East of England Primary Care Research Network.	All-Party Parliamentary Group on Skin, 2003, REP ENQ TREATM MAN P; Altamura D, 2008, ARCH DERMATOL, V144, P502, DOI 10.1001/archderm.144.4.502; Argenziano G, 2006, J CLIN ONCOL, V24, P1877, DOI 10.1200/JCO.2005.05.0864; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Chen SC, 2001, ARCH DERMATOL, V137, P1627; Chen SC, 2006, J GEN INTERN MED, V21, P678, DOI 10.1111/j.1525-1497.2006.00462.x; Emery J, 2007, BRIT J CANCER, V97, P486, DOI 10.1038/sj.bjc.6603897; Emery JD, 2010, BMC DERMATOL, V10, DOI 10.1186/1471-5945-10-9; Ferrante di Ruffano L, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e686; Foster N, 2012, BRIT J GEN PRACT, V62, P10, DOI 10.3399/bjgp12X616238; Gerbert B, 2002, J CANCER EDUC, V17, P7; Glud M, 2009, MELANOMA RES, V19, P176, DOI 10.1097/CMR.0b013e328322fe5f; Goulart JM, 2011, J GEN INTERN MED, V26, P1027, DOI 10.1007/s11606-011-1692-y; Govindan K, 2007, J PLAST RECONSTR AES, V60, P639, DOI 10.1016/j.bjps.2006.10.003; Grol R, 2000, BRIT J GEN PRACT, V50, P882; Haniffa MA, 2007, BRIT J DERMATOL, V156, P1350, DOI 10.1111/j.1365-2133.2007.07932.x; HEALSMITH MF, 1994, BRIT J DERMATOL, V130, P48, DOI 10.1111/j.1365-2133.1994.tb06881.x; Jiwa M., 2010, BRIT MED J, V341, P1172; Lens MB, 2004, BRIT J DERMATOL, V150, P179, DOI 10.1111/j.1365-2133.2004.05708.x; Lerman C, 1997, J CONSULT CLIN PSYCH, V65, P414, DOI 10.1037/0022-006X.65.3.414; MACKIE RM, 1991, CLIN EXP DERMATOL, V16, P151, DOI 10.1111/j.1365-2230.1991.tb00329.x; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Menzies SW, 2009, BRIT J DERMATOL, V161, P1270, DOI 10.1111/j.1365-2133.2009.09374.x; Moncrieff M, 2002, BRIT J DERMATOL, V146, P448, DOI 10.1046/j.1365-2133.2002.04569.x; Murchie Peter, 2007, Eur J Gen Pract, V13, P151, DOI 10.1080/13814780701627354; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; NHS Scotland, 2021, SCOTT REF GUID SUSP; Patel JK, 2008, EUR J DERMATOL, V18, P617, DOI 10.1684/ejd.2008.0508; Pockney P, 2009, BRIT J CANCER, V100, P24, DOI 10.1038/sj.bjc.6604810; Vedsted P, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X588484; Vestergaard ME, 2008, BRIT J DERMATOL, V159, P669, DOI 10.1111/j.1365-2133.2008.08713.x; Walter FM, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-36; Wood Annabel, 2008, Inform Prim Care, V16, P41; Youl PH, 2007, MED J AUSTRALIA, V187, P215, DOI 10.5694/j.1326-5377.2007.tb01202.x	34	48	50	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 4	2012	344								e4110	10.1136/bmj.e4110	http://dx.doi.org/10.1136/bmj.e4110			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972KE	22763392	Green Published			2022-12-28	WOS:000306275200001
J	Richard, T; Brohee, D; Van Meerhaeghe, A; Vanhaeverbeek, M				Richard, Thibault; Brohee, Dany; Van Meerhaeghe, Alain; Vanhaeverbeek, Michel			Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus	ANNALS OF INTERNAL MEDICINE			English	Letter							GLYCEMIC CONTROL		[Richard, Thibault; Brohee, Dany; Van Meerhaeghe, Alain; Vanhaeverbeek, Michel] Hop Vesale, CHU Charleroi, B-6110 Montignies le Tilleul, Belgium		Richard, T (corresponding author), Hop Vesale, CHU Charleroi, B-6110 Montignies le Tilleul, Belgium.							Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Hemmingsen B, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6898; Montori VM, 2009, ANN INTERN MED, V150, P803, DOI 10.7326/0003-4819-150-11-200906020-00008; Qaseem A, 2012, ANN INTERN MED, V156, P218, DOI 10.7326/0003-4819-156-3-201202070-00011; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2012	157	1					76	76		10.7326/0003-4819-157-1-201207030-00018	http://dx.doi.org/10.7326/0003-4819-157-1-201207030-00018			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992NS	22751769				2022-12-28	WOS:000307784900012
J	Holt, E				Holt, Ed			Uzbekistan accused of forced sterilisation campaign	LANCET			English	Editorial Material																			0	6	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 30	2012	379	9835					2415	2415		10.1016/S0140-6736(12)61050-2	http://dx.doi.org/10.1016/S0140-6736(12)61050-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	967NV	22764373				2022-12-28	WOS:000305915900011
J	Rathinam, VAK; Vanaja, SK; Waggoner, L; Sokolovska, A; Becker, C; Stuart, LM; Leong, JM; Fitzgerald, KA				Rathinam, Vijay A. K.; Vanaja, Sivapriya Kailasan; Waggoner, Lisa; Sokolovska, Anna; Becker, Christine; Stuart, Lynda M.; Leong, John M.; Fitzgerald, Katherine A.			TRIF Licenses Caspase-11-Dependent NLRP3 Inflammasome Activation by Gram-Negative Bacteria	CELL			English	Article							NF-KAPPA-B; CASPASE-1 ACTIVATION; GENE-EXPRESSION; CELL-DEATH; ASC; APOPTOSIS; RECEPTOR; TRAM; INTERLEUKIN-1-BETA; RECOGNITION	Systemic infections with Gram-negative bacteria are characterized by high mortality rates due to the "sepsis syndrome," a widespread and uncontrolled inflammatory response. Though it is well recognized that the immune response during Gram-negative bacterial infection is initiated after the recognition of endotoxin by Toll-like receptor 4, the molecular mechanisms underlying the detrimental inflammatory response during Gram-negative bacteremia remain poorly defined. Here, we identify a TRIF pathway that licenses NLRP3 inflammasome activation by all Gram-negative bacteria. By engaging TRIF, Gram-negative bacteria activate caspase-11. TRIF activates caspase-11 via type I IFN signaling, an event that is both necessary and sufficient for caspase-11 induction and autoactivation. Caspase-11 subsequently synergizes with the assembled NLRP3 inflammasome to regulate caspase-1 activation and leads to caspase-1-independent cell death. These events occur specifically during infection with Gram-negative, but not Gram-positive, bacteria. The identification of TRIF as a regulator of caspase-11 underscores the importance of TLRs as master regulators of inflammasomes during Gram-negative bacterial infection.	[Rathinam, Vijay A. K.; Vanaja, Sivapriya Kailasan; Waggoner, Lisa; Fitzgerald, Katherine A.] Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA; [Vanaja, Sivapriya Kailasan; Leong, John M.] Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; [Sokolovska, Anna; Becker, Christine; Stuart, Lynda M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA	University of Massachusetts System; University of Massachusetts Worcester; Tufts University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Fitzgerald, KA (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA.	kate.fitzgerald@umassmed.edu	Fitzgerald, Katherine/ABE-6317-2020; Rathinam, Vijay/ABE-7544-2020	Rathinam, Vijay/0000-0002-8009-3977; Fitzgerald, Kate/0000-0003-3175-609X	NIH [AI083713, AI046454, AI079198]; NERCE [NIH/NIAID U54 AI057159]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079198, R01AI083713, R01AI046454, U54AI057159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NERCE; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Anna Cerny for animal husbandry and genotyping; Sanjay Ram, Douglas Golenbock, Rahul Gupta, Victor Boyartchuk, Brian Akerley, Sandy Wong, Beth McCormick, and Stephen Lory for bacterial strains; Christine Biron and Delia Demers for Stat-1<SUP>-/-</SUP> femurs; Karen Mossman and Derek Cummings for Irf9<SUP>-/-</SUP> femurs; Vishva Dixit and Nobuhiko Kayagaki for caspase-11<SUP>-/-</SUP> mice and additional reagents; Bill Kaiser for caspase-8<SUP>-/-</SUP>Rip3<SUP>-/-</SUP> and caspase-8<SUP>+/-</SUP>Rip3<SUP>-/-</SUP> femurs; Jakob von Moltke and Russell Vance for immortalized BMDMs; Egil Lien, Douglas Golenbock, and Ann Rothstein for critical reading of the manuscript; and all members of the Fitzgerald lab for helpful discussions. This work is supported by NIH grants AI083713 (to K. A. F.), AI046454 (to J.M.L.), and AI079198 (to L. M. S.) and NERCE Post-Doctoral Fellowship Awards NIH/NIAID U54 AI057159 to V. A. K. R and S.K.V.	Costa A, 2012, J IMMUNOL, V188, P1953, DOI 10.4049/jimmunol.1102543; Cusson-Hermance N, 2005, J BIOL CHEM, V280, P36560, DOI 10.1074/jbc.M506831200; Duncan JA, 2009, J IMMUNOL, V182, P6460, DOI 10.4049/jimmunol.0802696; Fang RD, 2011, J IMMUNOL, V187, P4890, DOI 10.4049/jimmunol.1100381; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Franchi L, 2007, J BIOL CHEM, V282, P18810, DOI 10.1074/jbc.M610762200; Franchi L, 2012, NAT IMMUNOL, V13, P325, DOI 10.1038/ni.2231; Gonzalez-Navajas JM, 2012, NAT REV IMMUNOL, V12, P125, DOI 10.1038/nri3133; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Han KJ, 2004, J BIOL CHEM, V279, P15652, DOI 10.1074/jbc.M311629200; Ip WKE, 2010, J IMMUNOL, V184, P7071, DOI 10.4049/jimmunol.1000110; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Kagan JC, 2008, NAT IMMUNOL, V9, P361, DOI 10.1038/ni1569; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Kaiser WJ, 2005, J IMMUNOL, V174, P4942, DOI 10.4049/jimmunol.174.8.4942; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Miao EA, 2006, NAT IMMUNOL, V7, P569, DOI 10.1038/ni1344; Miao EA, 2010, P NATL ACAD SCI USA, V107, P3076, DOI 10.1073/pnas.0913087107; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; Rathinam VAK, 2011, CURR OPIN VIROL, V1, P455, DOI 10.1016/j.coviro.2011.11.004; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; Rathinam VAK, 2010, NAT IMMUNOL, V11, P395, DOI 10.1038/ni.1864; Rathinam VAK, 2008, MICROBES INFECT, V10, P1316, DOI 10.1016/j.micinf.2008.07.030; Roberts ZJ, 2007, J EXP MED, V204, P1559, DOI 10.1084/jem.20061845; Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383; Sander LE, 2011, NATURE, V474, P385, DOI 10.1038/nature10072; Sauer JD, 2011, INFECT IMMUN, V79, P688, DOI 10.1128/IAI.00999-10; Schauvliege R, 2002, J BIOL CHEM, V277, P41624, DOI 10.1074/jbc.M207852200; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Sutterwala FS, 2007, J EXP MED, V204, P3235, DOI 10.1084/jem.20071239; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Weber A, 2010, CELL DEATH DIFFER, V17, P942, DOI 10.1038/cdd.2009.190; Willingham SB, 2007, CELL HOST MICROBE, V2, P147, DOI 10.1016/j.chom.2007.07.009; Willingham SB, 2009, J IMMUNOL, V183, P2008, DOI 10.4049/jimmunol.0900138; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yen JH, 2009, BLOOD, V114, P1344, DOI 10.1182/blood-2008-12-196592; Zhang ZQ, 2011, IMMUNITY, V34, P866, DOI 10.1016/j.immuni.2011.03.027; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	46	506	517	2	58	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 3	2012	150	3					606	619		10.1016/j.cell.2012.07.007	http://dx.doi.org/10.1016/j.cell.2012.07.007			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	985WO	22819539	Green Accepted, Bronze			2022-12-28	WOS:000307301400018
J	Cohen, D				Cohen, Deborah			The truth about sports drinks	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							EXERCISE; PERFORMANCE; HEALTH		BMJ, London WC1H 9JR, England		Cohen, D (corresponding author), BMJ, London WC1H 9JR, England.	dcohen@bmj.com						ACSM-(American College of Sport Medicine), 2007, MED SCI SPORTS EXERC, V39, P377; Almond CSD, 2005, NEW ENGL J MED, V352, P1550, DOI 10.1056/NEJMoa043901; American Academy of Pediatrics Policy Statement-Climatic heat stress and exercising children and adolescents, 2011, PEDIATRICS, V128, pe741; American College of Sports Medicine, 1993, ROUNDT EX FLUID REPL; Anderson SJ, 2000, PEDIATRICS, V106, P158; [Anonymous], SYMPT DEH; [Anonymous], 2000, ERROR HYPERLINK REFE; [Anonymous], 2005, URINE TESTS HELP AUS; [Anonymous], 2005, MARKETING WEEK  1006; [Anonymous], EX ASS HYP WHOS RISK; [Anonymous], NUTR TIPS FLUIDS; [Anonymous], HYP; [Anonymous], WAT IS NOT EN; British Soft Drinks Association, 2011, POP DEM; Cade Robert, 2007, TIMES; Coca-Cola, HYDR TIPS; Convertino VA, 1996, MED SCI SPORT EXER, V28, pR1, DOI 10.1097/00005768-199610000-00045; Diabetes UK, TRAINING EVENTS COMP; Eleftheriou-Smith L-M, 2011, MARKETING; Expert Group on Hydration, DRINK SCH; Jeukendrup Asker, ASK JEUK; Goulet EDB, 2011, BRIT J SPORT MED, V45, P1149, DOI 10.1136/bjsm.2010.077966; Harris J.L., 2011, SUGARY DRINK FACTS; Heneghan C, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001702; Heneghan C, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e4797; Heneghan C, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4848; Institute of Medicine Food and Nutrition Board, DIET REF INT WAT POT; International Markets Bureau, 2010, OV GLOB SPORTS NUTR; Kays J, 2003, EXPLORE, V8; Kenny WL, 2004, NATA NEWS        JUN; Kleinman M, 2003, MARKETING; Marshall SW, 2010, BRIT J SPORT MED, V44, P8, DOI 10.1136/bjsm.2009.068171; Maughan R, 2001, SPORTS DRINKS BASIC; Maughan R J, 1993, Br J Sports Med, V27, P34; Mayo Clinic, DEH; McCartney M, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4280; Moynihan R, 2002, BRIT MED J, V324, P886, DOI 10.1136/bmj.324.7342.886; Murray B, 2008, PREVENTING DEHYDRATI; Natural Hydration Council, 2012, NEW RES SHOWS NAT IN; Noakes TD, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4171; Nutrition Working Group of the International Olympic Committee, 2010, NUTR ATHL; Pears E, 2012, PR WEEK         0131; Robert Wood Johnson Foundation, 2012, CONS SPORTS DRINKS C; Rogers D, 2003, MARKETING; Rosner MH, 2007, CLIN J AM SOC NEPHRO, V2, P151, DOI 10.2215/CJN.02730806; Thompson M, 2012, BMJ             0617, V345, pe4573; Virgin Active Health Clubs, OUR PARTN	47	41	41	1	47	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 19	2012	345								e4737	10.1136/bmj.e4737	http://dx.doi.org/10.1136/bmj.e4737			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978MA	22810386				2022-12-28	WOS:000306744300009
J	Budenholzer, B				Budenholzer, Brian			HPV-16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia >= grade 3 in young women	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Budenholzer, Brian] E Carolina Univ, Brody Sch Med, Greenville, NC USA	University of North Carolina; East Carolina University	Budenholzer, B (corresponding author), E Carolina Univ, Brody Sch Med, Greenville, NC USA.								0	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2							JC2-7	10.7326/0003-4819-157-2-201207170-02007	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-02007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801705				2022-12-28	WOS:000307787900006
J	Bartram, J; Elliott, M; Chuang, P				Bartram, Jamie; Elliott, Mark; Chuang, Patty			Getting wet, clean, and healthy: why households matter	LANCET			English	Editorial Material									[Bartram, Jamie; Elliott, Mark; Chuang, Patty] Univ N Carolina, Water Inst, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Bartram, J (corresponding author), Univ N Carolina, Water Inst, Chapel Hill, NC 27599 USA.	jbartram@email.unc.edu	Elliott, Mark/D-5947-2013; Elliott, Mark/N-1574-2019	Elliott, Mark/0000-0002-7835-0612; Elliott, Mark/0000-0002-7835-0612; Bartram, Jamie/0000-0002-6542-6315				Bartram J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000367; Bongaarts J, 2001, POP STUD-J DEMOG, V55, P263, DOI 10.1080/00324720127697; Hutton G, 2007, J WATER HEALTH, V5, P481, DOI 10.2166/wh.2007.009; Ironmonger, 1999, J POPULATION RES, V16, P65, DOI DOI 10.1007/BF03029455; Jennings VE, 2004, WORKING PAPERS SERIE, V914; Potts M, 2007, LANCET, V369, P354, DOI 10.1016/S0140-6736(07)60158-5; UN-HABITAT, 2005, GLOBAL REPORT HUMAN; UNICEF, 2012, PROGR DRINK WAT SAN; United Nations Population Division, WORLD POP PROSP 2010	9	8	8	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2012	380	9837					85	86		10.1016/S0140-6736(12)60903-9	http://dx.doi.org/10.1016/S0140-6736(12)60903-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784543				2022-12-28	WOS:000306359100010
J	Landrey, A				Landrey, Alison			Learning to Talk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Colorado, Internal Med Residency Program, Denver, CO 80202 USA	University of Colorado System; University of Colorado Denver	Landrey, A (corresponding author), Univ Colorado, Internal Med Residency Program, Denver, CO 80202 USA.	alison.landrey@gmail.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2012	308	2					145	146		10.1001/jama.2012.7435	http://dx.doi.org/10.1001/jama.2012.7435			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971QS	22782415				2022-12-28	WOS:000306219500027
J	Merkhofer, EC; Johnson, TL				Merkhofer, Evan C.; Johnson, Tracy L.			U1 snRNA Rewrites the "Script"	CELL			English	Editorial Material							MESSENGER-RNA POLYADENYLATION; POLY(A) POLYMERASE	Expression of eukaryotic mRNAs requires the collaboration of a host of RNA processing factors acting upon the transcript. Berg et al. describe how a pre-mRNA splicing factor modulates the activity of the polyadenylation machinery to regulate mRNA length, with important implications for isoform expression in activated neuronal and immune cells.	[Merkhofer, Evan C.; Johnson, Tracy L.] Univ Calif San Diego, Mol Biol Sect, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Johnson, TL (corresponding author), Univ Calif San Diego, Mol Biol Sect, Div Biol Sci, La Jolla, CA 92093 USA.	johnsont@ucsd.edu			NIGMS NIH HHS [R01 GM085474] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085474] Funding Source: NIH RePORTER; Div Of Molecular and Cellular Bioscience [1051921] Funding Source: National Science Foundation	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Div Of Molecular and Cellular Bioscience(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))		Baserga S., 1993, RNA WORLD, P359; Berg MG, 2012, CELL, V150, P53, DOI 10.1016/j.cell.2012.05.029; Brody Y, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000573; Gunderson FQ, 2011, P NATL ACAD SCI USA, V108, P2004, DOI 10.1073/pnas.1011982108; Gunderson SI, 1998, MOL CELL, V1, P255, DOI 10.1016/S1097-2765(00)80026-X; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; Kaida D, 2010, NATURE, V468, P664, DOI 10.1038/nature09479; Kwek KY, 2002, NAT STRUCT BIOL, V9, P800, DOI 10.1038/nsb862; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; Weill L, 2012, NAT STRUCT MOL BIOL, V19, P577, DOI 10.1038/nsmb.2311	10	6	7	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 6	2012	150	1					9	11		10.1016/j.cell.2012.06.017	http://dx.doi.org/10.1016/j.cell.2012.06.017			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770211	Bronze, Green Accepted			2022-12-28	WOS:000306115000002
J	Chalifoux, WA; Reznik, SK; Leighton, JL				Chalifoux, Wesley A.; Reznik, Samuel K.; Leighton, James L.			Direct and highly regioselective and enantioselective allylation of beta-diketones	NATURE			English	Article							ASYMMETRIC ALLYLBORATION; ALDEHYDE CROTYLATION; KETONES; REARRANGEMENTS; ACETOPHENONES; CONFORMATIONS; MACROLIDE; SILICON	The enantioselective allylation of ketones is a problem of fundamental importance in asymmetric reaction design, especially given that only a very small number of methods can generate tertiary carbinols. Despite the vast amount of attention that synthetic chemists have given to this problem(1-8), success has generally been limited to just a few simple ketone types. A method for the selective allylation of functionally complex ketones would greatly increase the utility of ketone allylation methods in the chemical synthesis of important targets. Here we describe the operationally simple, direct, regioselective and enantioselective allylation of beta-diketones. The strong tendency of beta-diketones to act as nucleophilic species was overcome by using their enol form to provide the necessary Bronsted-acid activation. This reaction significantly expands the pool of enantiomerically enriched and functionally complex tertiary carbinols that may be easily accessed. It also overturns more than a century of received wisdom regarding the reactivity of beta-diketones.	[Chalifoux, Wesley A.; Reznik, Samuel K.; Leighton, James L.] Columbia Univ, Dept Chem, New York, NY 10027 USA	Columbia University	Leighton, JL (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.	leighton@chem.columbia.edu		Chalifoux, Wesley/0000-0002-6849-6829	National Institute of General Medical Sciences [GM58133]; Natural Sciences and Engineering Research Council of Canada; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058133] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a grant from the National Institute of General Medical Sciences (GM58133). W. A. C. was supported by a Natural Sciences and Engineering Research Council of Canada Postdoctoral Fellowship. We thank the US National Science Foundation (CRIF-0840451) for acquisition of a 400 MHz NMR spectrometer. We thank our colleagues G. Parkin and W. Sattler for an X-ray structure analysis (see the Supplementary Information), and the US National Science Foundation (CHE-0619638) for acquisition of an X-ray diffractometer.	Barnett DS, 2009, ANGEW CHEM INT EDIT, V48, P8679, DOI 10.1002/anie.200904715; Burns NZ, 2006, ANGEW CHEM INT EDIT, V45, P3811, DOI 10.1002/anie.200600910; Canales E, 2005, J AM CHEM SOC, V127, P11572, DOI 10.1021/ja053865r; CHENG CL, 1973, J CHEM SOC PERK T 2, P1461, DOI 10.1039/p29730001461; Deng D., 1994, CHINESE CHEM LETT, V5, P173; FUSETANI N, 1993, J AM CHEM SOC, V115, P3977, DOI 10.1021/ja00063a017; Gaich T, 2010, J ORG CHEM, V75, P4657, DOI 10.1021/jo1006812; Hackman BM, 2004, ORG LETT, V6, P4375, DOI 10.1021/ol0480731; Kim H, 2011, J AM CHEM SOC, V133, P6517, DOI 10.1021/ja200712f; KIRA M, 1995, CHEM LETT, P281, DOI 10.1246/cl.1995.281; KOBAYASHI M, 1993, TETRAHEDRON LETT, V34, P2795, DOI 10.1016/S0040-4039(00)73564-7; Kulhanek J, 2004, J PHYS ORG CHEM, V17, P686, DOI 10.1002/poc.750; Leighton JL, 2010, ALDRICHIM ACTA, V43, P3; Marton D, 1997, J ORGANOMET CHEM, V540, P77, DOI 10.1016/S0022-328X(97)00083-1; MCCLARIN JA, 1980, J ORGANOMET CHEM, V188, P129, DOI 10.1016/S0022-328X(00)82808-9; Miller JJ, 2007, J AM CHEM SOC, V129, P2752, DOI 10.1021/ja068915m; MIRARCHI D, 1984, J MOL STRUCT, V118, P303, DOI 10.1016/0022-2860(84)87226-9; Nakamura M, 1998, J AM CHEM SOC, V120, P5846, DOI 10.1021/ja9804262; PETTIT GR, 1993, J ORG CHEM, V58, P1302, DOI 10.1021/jo00058a004; PINNAVAIA TJ, 1974, J AM CHEM SOC, V96, P3012, DOI 10.1021/ja00816a068; PINNAVAIA TJ, 1970, J AM CHEM SOC, V92, P4544, DOI 10.1021/ja00718a011; Ramachandran PV, 2004, TETRAHEDRON LETT, V45, P2603, DOI 10.1016/j.tetlet.2004.01.146; REICH HJ, 1973, J AM CHEM SOC, V95, P3418, DOI 10.1021/ja00791a077; Robak MT, 2010, CHEM REV, V110, P3600, DOI 10.1021/cr900382t; SEEMAN JI, 1983, CHEM REV, V83, P83, DOI 10.1021/cr00054a001; Shi SL, 2010, J AM CHEM SOC, V132, P6638, DOI 10.1021/ja101948s; Spletstoser JT, 2008, ORG LETT, V10, P5593, DOI 10.1021/ol802489w; Wadamoto M, 2005, J AM CHEM SOC, V127, P14556, DOI 10.1021/ja0553351; Waltz KM, 2002, ANGEW CHEM INT EDIT, V41, P3697, DOI 10.1002/1521-3773(20021004)41:19<3697::AID-ANIE3697>3.0.CO;2-U; Wu TR, 2004, ORG LETT, V6, P2701, DOI 10.1021/ol0490882	30	30	30	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 5	2012	487	7405					86	89		10.1038/nature11189	http://dx.doi.org/10.1038/nature11189			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968LM	22763452	Green Accepted			2022-12-28	WOS:000305982900055
J	Lipson, AB				Lipson, Alisa B.			How I Ended Up Watching Myself	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									BC Childrens Hosp, Dept Pediat, Vancouver, BC, Canada	BC Childrens Hospital; University of British Columbia	Lipson, AB (corresponding author), BC Childrens Hosp, Dept Pediat, Vancouver, BC, Canada.	ablipson@cw.bc.ca							0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2012	308	1					41	42		10.1001/jama.2012.7433	http://dx.doi.org/10.1001/jama.2012.7433			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971DD	22760289				2022-12-28	WOS:000306183000021
J	Shui, JW; Larange, A; Kim, G; Vela, JL; Zahner, S; Cheroutre, H; Kronenberg, M				Shui, Jr-Wen; Larange, Alexandre; Kim, Gisen; Vela, Jose Luis; Zahner, Sonja; Cheroutre, Hilde; Kronenberg, Mitchell			HVEM signalling at mucosal barriers provides host defence against pathogenic bacteria	NATURE			English	Article							NF-KAPPA-B; HERPESVIRUS ENTRY MEDIATOR; CITROBACTER-RODENTIUM; PROTECTS MICE; NK CELLS; RECEPTOR; IL-22; INNATE; EXPRESSION; INFECTION	The herpes virus entry mediator (HVEM), a member of the tumour-necrosis factor receptor family, has diverse functions, augmenting or inhibiting the immune response(1). HVEM was recently reported as a colitis risk locus in patients(2), and in a mouse model of colitis we demonstrated an anti-inflammatory role for HVEM3, but its mechanism of action in the mucosal immune system was unknown. Here we report an important role for epithelial HVEM in innate mucosal defence against pathogenic bacteria. HVEM enhances immune responses by NF-kappa B-inducing kinase-dependent Stat3 activation, which promotes the epithelial expression of genes important for immunity. During intestinal Citrobacter rodentium infection(4-6), a mouse model for enteropathogenic Escherichia coli infection, Hvem(-/-) mice showed decreased Stat3 activation, impaired responses in the colon, higher bacterial burdens and increased mortality. We identified the immunoglobulin superfamily molecule CD160 (refs 7 and 8), expressed predominantly by innate-like intraepithelial lymphocytes, as the ligand engaging epithelial HVEM for host protection. Likewise, in pulmonary Streptococcus pneumoniae infection(9), HVEM is also required for host defence. Our results pinpoint HVEM as an important orchestrator of mucosal immunity, integrating signals from innate lymphocytes to induce optimal epithelial Stat3 activation, which indicates that targeting HVEM with agonists could improve host defence.	[Shui, Jr-Wen; Larange, Alexandre; Kim, Gisen; Vela, Jose Luis; Zahner, Sonja; Cheroutre, Hilde; Kronenberg, Mitchell] La Jolla Inst Allergy & Immunol, Div Dev Immunol, La Jolla, CA 92037 USA	La Jolla Institute for Immunology	Kronenberg, M (corresponding author), La Jolla Inst Allergy & Immunol, Div Dev Immunol, 9420 Athena Circle, La Jolla, CA 92037 USA.	mitch@liai.org	Shui, Jr-Wen/Q-2617-2018; Kronenberg, Mitchell/AAT-6078-2021	Shui, Jr-Wen/0000-0002-5243-3727; 	National Institutes of Health [RO1-AI061516, PO1 DK46763, F32-DK082249, F32-AI083029]; La Jolla Institute for Allergy and Immunology; Center for Infectious Disease [LIAI-JAN-2011-CID]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061516, R01AI064584, F32AI083029, R01AI050265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK046763, F32DK082249] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); La Jolla Institute for Allergy and Immunology; Center for Infectious Disease; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the National Institutes of Health (RO1-AI061516 to M. K.; PO1 DK46763 to M. K.; F32-DK082249 to J.-W.S.; F32-AI083029 to J.L.V.), La Jolla Institute for Allergy and Immunology and the Center for Infectious Disease (LIAI-JAN-2011-CID to J.-W.S.). We thank W. Quyang for providing Reg3 gamma-Ig fusion protein, and O. Turovskaya for performing histology staining and pathological scoring. We also thank C. Benedict for providing NIK<SUP>aly/aly</SUP> mice, K. Pfeffer for providing Hvem<SUP>-/-</SUP> and Light<SUP>-/-</SUP> mice and K. Murphy for Btla<SUP>-/-</SUP> mice. This is manuscript number 1347 from the La Jolla Institute for Allergy and Immunology.	Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Anumanthan A, 1998, J IMMUNOL, V161, P2780; Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316; Brand S, 2006, AM J PHYSIOL-GASTR L, V290, pG827, DOI 10.1152/ajpgi.00513.2005; Cheung TC, 2009, P NATL ACAD SCI USA, V106, P6244, DOI 10.1073/pnas.0902115106; Gelebart P, 2011, TRANSL ONCOL, V4, P9, DOI 10.1593/tlo.10172; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Jin W, 2009, BLOOD, V113, P6603, DOI 10.1182/blood-2008-12-192914; Lebeis SL, 2009, INFECT IMMUN, V77, P604, DOI 10.1128/IAI.00907-08; LeBlanc PM, 2008, CELL HOST MICROBE, V3, P146, DOI 10.1016/j.chom.2008.02.004; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Ma CX, 2006, CELL MICROBIOL, V8, P1669, DOI 10.1111/j.1462-5822.2006.00741.x; Maeda M, 2005, J IMMUNOL, V175, P4426, DOI 10.4049/jimmunol.175.7.4426; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Mizgerd JP, 2008, AM J PHYSIOL-LUNG C, V294, pL387, DOI 10.1152/ajplung.00330.2007; Mundy R, 2005, CELL MICROBIOL, V7, P1697, DOI 10.1111/j.1462-5822.2005.00625.x; Murphy TL, 2010, ANNU REV IMMUNOL, V28, P389, DOI 10.1146/annurev-immunol-030409-101202; Nakamatsu M, 2007, MICROBES INFECT, V9, P364, DOI 10.1016/j.micinf.2006.12.003; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Quinton LJ, 2008, AM J RESP CELL MOL, V38, P699, DOI 10.1165/rcmb.2007-0365OC; Quinton LJ, 2007, J IMMUNOL, V178, P1896, DOI 10.4049/jimmunol.178.3.1896; Quinton LJ, 2011, CELL TISSUE RES, V343, P153, DOI 10.1007/s00441-010-1044-y; Rooney IA, 2000, J BIOL CHEM, V275, P14307, DOI 10.1074/jbc.275.19.14307; Schaer C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018495; Steinberg MW, 2008, J EXP MED, V205, P1463, DOI 10.1084/jem.20071160; Sugimoto K, 2008, J CLIN INVEST, V118, P534, DOI [10.1172/JC133194, 10.1172/JCI33194]; Tachiiri A, 2003, GENES IMMUN, V4, P153, DOI 10.1038/sj.gene.6363934; Torchinsky MB, 2009, NATURE, V458, P78, DOI 10.1038/nature07781; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2010, SEMIN IMMUNOPATHOL, V32, P17, DOI 10.1007/s00281-009-0188-x; Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003; Zenewicz LA, 2008, IMMUNITY, V29, P947, DOI 10.1016/j.immuni.2008.11.003; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720	33	94	99	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 9	2012	488	7410					222	+		10.1038/nature11242	http://dx.doi.org/10.1038/nature11242			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	985LE	22801499	Green Accepted			2022-12-28	WOS:000307267000036
J	Beyrer, C; Baral, SD; van Griensven, F; Goodreau, SM; Chariyalertsak, S; Wirtz, AL; Brookmeyer, R				Beyrer, Chris; Baral, Stefan D.; van Griensven, Frits; Goodreau, Steven M.; Chariyalertsak, Suwat; Wirtz, Andrea L.; Brookmeyer, Ron			Global epidemiology of HIV infection in men who have sex with men	LANCET			English	Article							HIGH-RISK; MOLECULAR EPIDEMIOLOGY; LOW-INCOME; CIRCUMCISION STATUS; RECOMBINANT FORMS; ANAL INTERCOURSE; IDENTIFIED MEN; SAN-FRANCISCO; BISEXUAL MEN; POSITIVE GAY	Epidemics of HIV in men who have sex with men (MSM) continue to expand in most countries. We sought to understand the epidemiological drivers of the global epidemic in MSM and why it continues unabated. We did a comprehensive review of available data for HIV prevalence, incidence, risk factors, and the molecular epidemiology of HIV in MSM from 2007 to 2011, and modelled the dynamics of HIV transmission with an agent-based simulation. Our findings show that the high probability of transmission per act through receptive anal intercourse has a central role in explaining the disproportionate disease burden in MSM. HIV can be transmitted through large MSM networks at great speed. Molecular epidemiological data show substantial clustering of HIV infections in MSM networks, and higher rates of dual-variant and multiple-variant HIV infection in MSM than in heterosexual people in the same populations. Prevention strategies that lower biological transmission and acquisition risks, such as approaches based on antiretrovirals, off er promise for controlling the expanding epidemic in MSM, but their potential effectiveness is limited by structural factors that contribute to low health-seeking behaviours in populations of MSM in many parts of the world.	[Beyrer, Chris] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Ctr Publ Hlth & Human Rights, Baltimore, MD 21205 USA; [van Griensven, Frits] Univ Calif San Francisco, Inst Global Hlth, San Francisco, CA 94143 USA; [Goodreau, Steven M.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA; [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand; [Chariyalertsak, Suwat] Chiang Mai Univ, Fac Med, Dept Community Med, Chiang Mai 50000, Thailand; [Brookmeyer, Ron] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; Chiang Mai University; Chiang Mai University; University of California System; University of California Los Angeles	Beyrer, C (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Ctr Publ Hlth & Human Rights, 615 N Wolfe St E 7152, Baltimore, MD 21205 USA.	cbeyrer@jhsph.edu	Baral, Stefan/D-2930-2013; Goodreau, Steven/P-2366-2017; Baral, Stefan/AAG-4818-2020; van Griensven, Frits/G-4719-2013	Baral, Stefan/0000-0002-5482-2419; van Griensven, Frits/0000-0002-0971-2843; Goodreau, Steven/0000-0003-1009-5763	amfAR the Foundation for AIDS Research; Bill & Melinda Gates Foundation; Johns Hopkins Center for AIDS Research (NIAID) [1P30AI094189-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD042828, R01HD068395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083060, P30AI094189] Funding Source: NIH RePORTER	amfAR the Foundation for AIDS Research; Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); Johns Hopkins Center for AIDS Research (NIAID); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This report was supported by grants to the Center for Public Health and Human Rights at Johns Hopkins from amfAR the Foundation for AIDS Research and from the Bill & Melinda Gates Foundation. The Johns Hopkins Center for AIDS Research (NIAID, 1P30AI094189-01A1) provided partial support to CB. We thank Marco Ambrosio, Shirina Kakayeva, Madeleine Schlefer, and Darrin Adams for the data extraction from the comprehensive searches for this report. We also thank Susan Buchbinder and colleagues for assistance with the modelling, which was based on work done for their Prevention Umbrella for MSM in the Americas (PUMA; NIAID, R01-AI083060).	[Anonymous], NAT HIV AIDS STRAT U; Arroyo MA, 2010, AIDS RES HUM RETROV, V26, P5, DOI 10.1089/aid.2009.0150; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Baggaley RF, 2010, INT J EPIDEMIOL, V39, P1048, DOI 10.1093/ije/dyq057; Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2; Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339; Baral S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-766; Baral S, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-36; Beyrer C, 2011, DIR DEV, P1, DOI 10.1596/978-0-8213-8726-9; Beyrer C, 2010, SEX TRANSM INFECT, V86, P323, DOI 10.1136/sti.2009.040162; Beyrer C, 2010, EPIDEMIOL REV, V32, P137, DOI 10.1093/epirev/mxq011; Beyrer C, 2010, CLIN INFECT DIS, V50, pS108, DOI 10.1086/651481; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Caceres CF, 2008, AIDS BEHAV, V12, P544, DOI 10.1007/s10461-007-9348-y; Carballo-Dieguez A, 2004, J HOMOSEXUAL, V47, P1, DOI 10.1300/J082v47n01_01; Cassels S, 2008, JAIDS-J ACQ IMM DEF, V47, pS34, DOI 10.1097/QAI.0b013e3181605da3; Centers for Disease Control (CDC), 1981, MMWR Morb Mortal Wkly Rep, V30, P409; Centers for Disease Control (CDC), 1981, MMWR Morb Mortal Wkly Rep, V30, P305; Centers for Disease Control (CDC), 1981, MMWR Morb Mortal Wkly Rep, V30, P250; Charlebois ED, 2011, CLIN INFECT DIS, V52, P1046, DOI 10.1093/cid/cir085; Chin-Hong PV, 2009, AIDS, V23, P1135, DOI 10.1097/QAD.0b013e32832b4449; Choi KH, 2004, SEX TRANSM DIS, V31, P475, DOI 10.1097/01.olq.0000135988.19969.62; Choi KH, 2004, AIDS EDUC PREV, V16, P19, DOI 10.1521/aeap.16.1.19.27721; Colfax G, 2010, LANCET, V376, P458, DOI 10.1016/S0140-6736(10)60753-2; Crepaz N, 2009, AIDS, V23, P1617, DOI 10.1097/QAD.0b013e32832effae; Crosby R, 2007, SEX TRANSM DIS, V34, P744, DOI 10.1097/OLQ.0b013e31804f81de; Davaalkham J, 2011, AIDS RES HUM RETROV, V27, P1073, DOI [10.1089/aid.2010.0196, 10.1089/AID.2010.0196]; DOLL LS, 1992, J SEX RES, V29, P1, DOI 10.1080/00224499209551630; Elford J, 2007, SEX TRANSM DIS, V34, P93, DOI 10.1097/01.olq.0000223247.68174.f9; Evans AR, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-69; Faugier J, 1997, J ADV NURS, V26, P790, DOI 10.1046/j.1365-2648.1997.00371.x; Fay H, 2011, AIDS BEHAV, V15, P1088, DOI 10.1007/s10461-010-9861-2; Freeman P, 2011, ARCH PEDIAT ADOL MED, V165, P736, DOI 10.1001/archpediatrics.2011.118; German D, 2011, JAIDS-J ACQ IMM DEF, V57, P77, DOI 10.1097/QAI.0b013e318211b41e; GONSIOREK JC, 1995, SUICIDE LIFE-THREAT, V25, P40, DOI 10.1111/j.1943-278X.1995.tb00489.x; Goodreau SM, 2007, SEX TRANSM INFECT, V83, P458, DOI 10.1136/sti.2007.025627; Gorbach Pamina M, 2011, J Acquir Immune Defic Syndr, V56, P176, DOI 10.1097/QAI.0b013e3181ff9750; Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4; Grulich AE, 2010, INT J EPIDEMIOL, V39, P1064, DOI 10.1093/ije/dyq101; Guo Y, 2011, AIDS CARE, V23, P1400, DOI 10.1080/09540121.2011.565029; Halkitis PN, 2005, AIDS, V19, pS27, DOI 10.1097/01.aids.0000167349.23374.a3; Heckathorn DD, 2002, SOC PROBL, V49, P11, DOI 10.1525/sp.2002.49.1.11; Heckathorn DD, 1997, SOC PROBL, V44, P174, DOI 10.1525/sp.1997.44.2.03x0221m; Hughes GJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000590; Johnson WD, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001230.pub2; Johnston LG, 2009, AIDS CARE, V21, P1195, DOI 10.1080/09540120902729973; Kaltsidis H, 2011, J IMMUNOL METHODS, V370, P43, DOI 10.1016/j.jim.2011.05.007; Kao CF, 2011, AIDS RES HUM RETROV, V27, P745, DOI 10.1089/aid.2010.0244; Kelly JA, 2002, AIDS CARE, V14, P63, DOI 10.1080/09540120220097946; Kelly JA, 2001, AIDS EDUC PREV, V13, P175, DOI 10.1521/aeap.13.2.175.19734; Kelly JA, 2010, AIDS EDUC PREV, V22, P483, DOI 10.1521/aeap.2010.22.6.483; Koblin BA, 2006, AIDS, V20, P731, DOI 10.1097/01.aids.0000216374.61442.55; Konda KA, 2008, AIDS BEHAV, V12, P483, DOI 10.1007/s10461-007-9221-z; Kouyos RD, 2010, J INFECT DIS, V201, P1488, DOI 10.1086/651951; Lane T, 2011, AIDS BEHAV, V15, P626, DOI 10.1007/s10461-009-9598-y; Le Vu S, 2010, LANCET INFECT DIS, V10, P682, DOI 10.1016/S1473-3099(10)70167-5; Lee CC, 2009, HIV MED, V10, P370, DOI 10.1111/j.1468-1293.2009.00698.x; Leoz M, 2011, AIDS, V25, P1371, DOI 10.1097/QAD.0b013e328347c060; Lewis F, 2008, PLOS MED, V5, P392, DOI 10.1371/journal.pmed.0050050; Li H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000890; Lieb S, 2007, JAIDS-J ACQ IMM DEF, V46, P485, DOI 10.1097/QAI.0b013e3181594c4d; Luan RS, 2005, EUR J EPIDEMIOL, V20, P581, DOI 10.1007/s10654-005-4305-4; Magnus M, 2010, AIDS PATIENT CARE ST, V24, P615, DOI 10.1089/apc.2010.0111; Malekinejad M, 2011, DRUG ALCOHOL DEPEN, V118, P83, DOI 10.1016/j.drugalcdep.2011.03.002; Marcus U, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-181; Mayer KH, 2012, LANCET; McAllister SM, 2008, INT J STD AIDS, V19, P752, DOI 10.1258/ijsa.2008.008153; McFarland W, 2011, AIDS CARE, V23, P261, DOI 10.1080/09540121.2010.507748; McGarrigle CA, 2006, SEX TRANSM INFECT, V82, pIII78, DOI 10.1136/sti.2006.020339; Middelkoop K, 2011, 6 IAS C HIV PATH TRE; Millett GA, 2012, LANCET; Millett GA, 2008, JAMA-J AM MED ASSOC, V300, P1674, DOI 10.1001/jama.300.14.1674; Millett GA, 2007, JAIDS-J ACQ IMM DEF, V46, P643, DOI 10.1097/QAI.0b013e31815b834d; Millett GA, 2007, AIDS, V21, P2083, DOI 10.1097/QAD.0b013e3282e9a64b; Millett GA, 2006, AM J PUBLIC HEALTH, V96, P1007, DOI 10.2105/AJPH.2005.066720; Mumtaz G, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000444; Mumtaz G, 2011, SEX TRANSM INFECT, V87, P101, DOI 10.1136/sti.2010.043711; Oster AM, 2011, AIDS, V25, P1103, DOI 10.1097/QAD.0b013e3283471efa; Paz-Bailey G, 2004, SEX TRANSM DIS, V31, P581, DOI 10.1097/01.olq.0000140009.28121.0f; Peinado J, 2007, J SEX RES, V44, P233, DOI 10.1080/00224490701443676; Poteat T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028760; Rosenberg ES, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-189; Sanders EJ, 2007, AIDS, V21, P2513, DOI 10.1097/QAD.0b013e3282f2704a; Sanders EJ, 2011, 18 C RETR OPP INF BO; Semaan S., 2010, METHODOLOGICAL INNOV, V5, P60, DOI DOI 10.4256/MIO.2010.0019; Shepard C. W., 2009, Morbidity and Mortality Weekly Report, V58, P1296; Smith A., 2010, Morbidity and Mortality Weekly Report, V59, P1201; Smith AMA, 2004, SEX TRANSM INFECT, V80, P455, DOI 10.1136/sti.2004.010355; Smith DM, 2005, J INFECT DIS, V192, P438, DOI 10.1086/431682; Sullivan PS, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1797; Sullivan PS, 2009, ANN EPIDEMIOL, V19, P423, DOI 10.1016/j.annepidem.2009.03.004; Sullivan PS, 2012, LANCET; Templeton D. J., 2007, 4 IAS C HIV PATH TRE, P22; Templeton DJ, 2009, AIDS, V23, P2347, DOI 10.1097/QAD.0b013e32833202b8; UNAIDS, 2010, REP GLOB AIDS EP 201; UNAIDS, DAT AN; Urbanus AT, 2009, AIDS, V23, pF1, DOI 10.1097/QAD.0b013e32832e5631; Uuskula A, 2010, J URBAN HEALTH, V87, P304, DOI 10.1007/s11524-009-9427-7; van Griensven F., 2006, Morbidity and Mortality Weekly Report, V55, P844; van Griensven F., 2009, J ACQ IMMUN DEF SYND, V53, P234, DOI [DOI 10.1097/QAI.0B013E3181C2FC86, 10.1097/QAI.0b013e3181c2fc86]; van Griensven F, 2009, CURR OPIN HIV AIDS, V4, P300, DOI 10.1097/COH.0b013e32832c3bb3; Vermund SH, 2008, JAMA-J AM MED ASSOC, V300, P1698, DOI 10.1001/jama.300.14.1698; Wang WH, 2008, AIDS RES HUM RETROV, V24, P1245, DOI 10.1089/aid.2008.0095; WHO, HIV AIDS DAT STAT; Zhang XX, 2007, AIDS, V21, pS53, DOI 10.1097/01.aids.0000304697.39637.4c	105	1037	1082	6	175	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 28	2012	380	9839					367	377		10.1016/S0140-6736(12)60821-6	http://dx.doi.org/10.1016/S0140-6736(12)60821-6			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819660	Green Accepted			2022-12-28	WOS:000306842800035
J	Pichlmair, A; Kandasamy, K; Alvisi, G; Mulhern, O; Sacco, R; Habjan, M; Binder, M; Stefanovic, A; Eberle, CA; Goncalves, A; Burckstummer, T; Muller, AC; Fauster, A; Holze, C; Lindsten, K; Goodbourn, S; Kochs, G; Weber, F; Bartenschlager, R; Bowie, AG; Bennett, KL; Colinge, J; Superti-Furga, G				Pichlmair, Andreas; Kandasamy, Kumaran; Alvisi, Gualtiero; Mulhern, Orla; Sacco, Roberto; Habjan, Matthias; Binder, Marco; Stefanovic, Adrijana; Eberle, Carol-Ann; Goncalves, Adriana; Buerckstuemmer, Tilmann; Mueller, Andre C.; Fauster, Astrid; Holze, Cathleen; Lindsten, Kristina; Goodbourn, Stephen; Kochs, Georg; Weber, Friedemann; Bartenschlager, Ralf; Bowie, Andrew G.; Bennett, Keiryn L.; Colinge, Jacques; Superti-Furga, Giulio			Viral immune modulators perturb the human molecular network by common and unique strategies	NATURE			English	Article							PROTEIN; EXPRESSION; EVASION; INNATE; ACTIVATION; RESPONSES; PATHWAYS; REVEALS; SYSTEMS; SCREEN	Viruses must enter host cells to replicate, assemble and propagate. Because of the restricted size of their genomes, viruses have had to evolve efficient ways of exploiting host cell processes to promote their own life cycles and also to escape host immune defence mechanisms(1,2). Many viral open reading frames (viORFs) with immune-modulating functions essential for productive viral growth have been identified across a range of viral classes(3,4). However, there has been no comprehensive study to identify the host factors with which these viORFs interact for a global perspective of viral perturbation strategies(5-11). Here we show that different viral perturbation patterns of the host molecular defence network can be deduced from a mass-spectrometry-based host-factor survey in a defined human cellular system by using 70 innate immune-modulating viORFs from 30 viral species. The 579 host proteins targeted by the viORFs mapped to an unexpectedly large number of signalling pathways and cellular processes, suggesting yet unknown mechanisms of antiviral immunity. We further experimentally verified the targets heterogeneous nuclear ribonucleoprotein U, phosphatidylinositol-3-OH kinase, the WNK (with-no-lysine) kinase family and USP19 (ubiquitin-specific peptidase 19) as vulnerable nodes in the host cellular defence system. Evaluation of the impact of viral immune modulators on the host molecular network revealed perturbation strategies used by individual viruses and by viral classes. Our data are also valuable for the design of broad and specific antiviral therapies.	[Pichlmair, Andreas; Kandasamy, Kumaran; Sacco, Roberto; Stefanovic, Adrijana; Eberle, Carol-Ann; Goncalves, Adriana; Buerckstuemmer, Tilmann; Mueller, Andre C.; Fauster, Astrid; Bennett, Keiryn L.; Colinge, Jacques; Superti-Furga, Giulio] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1090 Vienna, Austria; [Pichlmair, Andreas; Habjan, Matthias; Holze, Cathleen] Max Planck Inst Biochem, Innate Immun Lab, D-82152 Martinsried, Germany; [Alvisi, Gualtiero; Binder, Marco; Bartenschlager, Ralf] Heidelberg Univ, Dept Infect Dis, D-69120 Heidelberg, Germany; [Mulhern, Orla; Bowie, Andrew G.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Dublin 2, Ireland; [Habjan, Matthias; Kochs, Georg; Weber, Friedemann] Univ Freiburg, Dept Virol, D-79104 Freiburg, Germany; [Lindsten, Kristina] Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; [Goodbourn, Stephen] Univ London, Div Basic Med Sci, London SW17 0RE, England; [Weber, Friedemann] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, D-79108 Freiburg, Germany; [Weber, Friedemann] Univ Marburg, Inst Virol, D-35043 Marburg, Germany	Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Max Planck Society; Ruprecht Karls University Heidelberg; Trinity College Dublin; University of Freiburg; Karolinska Institutet; University of London; University of Freiburg; Philipps University Marburg	Superti-Furga, G (corresponding author), Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1090 Vienna, Austria.	gsuperti@cemm.oeaw.ac.at	Colinge, Jacques/Z-2613-2019; Kandasamy, Richard Kumaran/C-8981-2009; Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015; Weber, Friedemann/AAB-3425-2019; Colinge, Jacques/D-1578-2017; Binder, Marco/E-9717-2011; Bartenschlager, Ralf/L-2582-2015	Colinge, Jacques/0000-0003-2466-4824; Kandasamy, Richard Kumaran/0000-0002-0894-1222; Superti-Furga, Giulio/0000-0002-0570-1768; Colinge, Jacques/0000-0003-2466-4824; Binder, Marco/0000-0002-5805-6109; Mueller, Andre/0000-0002-0608-8176; Habjan, Matthias/0000-0002-3623-4496; Bennett, Keiryn L./0000-0001-9356-7708; Goodbourn, Stephen/0000-0002-4530-1179; Bartenschlager, Ralf/0000-0001-5601-9307; Stefanovic, Adrijana/0000-0002-5497-8843; Fauster, Astrid/0000-0003-4608-5604; Alvisi, Gualtiero/0000-0002-8177-3616; Buerckstuemmer, Tilmann/0000-0002-5961-0829; Burckstummer, Tilmann/0000-0001-5681-8045; Bowie, Andrew/0000-0001-5316-4373; Weber, Friedemann/0000-0001-9737-337X	Austrian Academy of Sciences; i-FIVE European Research Council; European Molecular Biology Organization [ATLF 463-2008]; Science Foundation Ireland [07/IN1/B934]; Deutsche Forschungsgemeinschaft [We2616/5-2, SFB593/B13, Ko1579/5-1, FOR1202]; German Ministry for Education and Research (Suszeptibilitat bei Infektionen) [01KI 0786]; Austrian Ministry of Science and Research (GEN-AU/BIN)	Austrian Academy of Sciences; i-FIVE European Research Council; European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Ministry for Education and Research (Suszeptibilitat bei Infektionen); Austrian Ministry of Science and Research (GEN-AU/BIN)	We thank C. Basler, A. Bergthaler, K.-K. Conzelmann, A. Garcia-Sastre, M. Hardy, W. Kaiser, E. Muhlberger, R. Randall, B. Roizman, N. Ruggli, B. Sherry and T. Wolf for providing viral ORF cDNAs; P. Jordan for providing WNK expression constructs; S. Nakagawa for Flag-hnRNP-U; M. Sophie-Hiet for GFP-NS5A; M. Zayas for the pFK-Jc1-NS5A-HAexpression plasmid; E. Rudashevskaya, A. Stukalov, F. Breitwieser and M. Trippler for support; H. Pickersgill and T. Brummelkamp for critically reading the manuscript; C. Baumann for discussions; and M. Vidal for discussions and for sharing unpublished information. The work was funded by the Austrian Academy of Sciences, an i-FIVE European Research Council grant to G.S.-F., a European Molecular Biology Organization long-term fellowship to A. P. (ATLF 463-2008), Science Foundation Ireland grant 07/IN1/B934 to O.M. and A. G. B., Deutsche Forschungsgemeinschaft grants We2616/5-2 and SFB593/B13 to F. W., Ko1579/5-1 to G. K., and FOR1202, TP1 to R. B., and the German Ministry for Education and Research (Suszeptibilitat bei Infektionen: HCV; TP1, 01KI 0786) to R. B. J.C. is funded by the Austrian Ministry of Science and Research (GEN-AU/BIN).	Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Appel N, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000035; Arima N, 2001, J BIOL CHEM, V276, P12675, DOI 10.1074/jbc.M008329200; Bowie AG, 2008, NAT REV IMMUNOL, V8, P911, DOI 10.1038/nri2436; Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725; Burckstummer T, 2006, NAT METHODS, V3, P1013, DOI 10.1038/nmeth968; Burkard TR, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-17; Cravatt BF, 2007, NATURE, V450, P991, DOI 10.1038/nature06525; Dittmann J, 2008, J VIROL, V82, P3624, DOI 10.1128/JVI.01753-07; Finlay BB, 2006, CELL, V124, P767, DOI 10.1016/j.cell.2006.01.034; Glatter T, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.75; Goff SP, 2007, NAT REV MICROBIOL, V5, P253, DOI 10.1038/nrmicro1541; Habjan M, 2008, J GEN VIROL, V89, P2157, DOI 10.1099/vir.0.2008/002097-0; Hasegawa Y, 2010, DEV CELL, V19, P469, DOI 10.1016/j.devcel.2010.08.006; Hassink GC, 2009, EMBO REP, V10, P755, DOI 10.1038/embor.2009.69; Haura EB, 2011, J PROTEOME RES, V10, P182, DOI 10.1021/pr100863f; Jager S, 2012, NATURE, V481, P365, DOI 10.1038/nature10719; Karlas A, 2010, NATURE, V463, P818, DOI 10.1038/nature08760; Keating SE, 2007, J BIOL CHEM, V282, P33435, DOI 10.1074/jbc.M705266200; Kislinger T, 2006, CELL, V125, P173, DOI 10.1016/j.cell.2006.01.044; Konig R, 2010, NATURE, V463, P813, DOI 10.1038/nature08699; Krishnan MN, 2008, NATURE, V455, P242, DOI 10.1038/nature07207; Li ST, 2011, IMMUNITY, V35, P426, DOI 10.1016/j.immuni.2011.06.014; Lu Y, 2009, MOL CELL BIOL, V29, P547, DOI 10.1128/MCB.00329-08; Lynn DJ, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.55; Moniz S, 2010, CELL MOL LIFE SCI, V67, P1265, DOI 10.1007/s00018-010-0261-6; Pichlmair A, 2011, NAT IMMUNOL, V12, P624, DOI 10.1038/ni.2048; Pietschmann T, 2006, P NATL ACAD SCI USA, V103, P7408, DOI 10.1073/pnas.0504877103; Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0; Reiss S, 2011, CELL HOST MICROBE, V9, P32, DOI 10.1016/j.chom.2010.12.002; Rodriguez JJ, 2003, J VIROL, V77, P11842, DOI 10.1128/JVI.77.21.11842-11845.2003; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Schmolke M, 2010, CELL MICROBIOL, V12, P873, DOI 10.1111/j.1462-5822.2010.01475.x; Schroder M, 2008, EMBO J, V27, P2147, DOI 10.1038/emboj.2008.143; Shapira SD, 2009, CELL, V139, P1255, DOI 10.1016/j.cell.2009.12.018; Uetz P, 2006, SCIENCE, V311, P239, DOI 10.1126/science.1116804; Valente ST, 2006, MOL CELL, V23, P597, DOI 10.1016/j.molcel.2006.07.021; Watanabe T, 2010, CELL HOST MICROBE, V7, P427, DOI 10.1016/j.chom.2010.05.008; Zybailov B, 2006, J PROTEOME RES, V5, P2339, DOI 10.1021/pr060161n	39	180	185	4	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 26	2012	487	7408					486	U101		10.1038/nature11289	http://dx.doi.org/10.1038/nature11289			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979KD	22810585	Green Published			2022-12-28	WOS:000306815300039
J	Wu, J; Bostrom, P; Sparks, LM; Ye, L; Choi, JH; Giang, AH; Khandekar, M; Virtanen, KA; Nuutila, P; Schaart, G; Huang, KX; Tu, H; Lichtenbelt, WDV; Hoeks, J; Enerback, S; Schrauwen, P; Spiegelman, BM				Wu, Jun; Bostrom, Pontus; Sparks, Lauren M.; Ye, Li; Choi, Jang Hyun; Giang, An-Hoa; Khandekar, Melin; Virtanen, Kirsi A.; Nuutila, Pirjo; Schaart, Gert; Huang, Kexin; Tu, Hua; Lichtenbelt, Wouter D. van Marken; Hoeks, Joris; Enerbaeck, Sven; Schrauwen, Patrick; Spiegelman, Bruce M.			Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human	CELL			English	Article							BROWN ADIPOSE-TISSUE; WHITE FAT; TRANSCRIPTIONAL CONTROL; SKELETAL-MUSCLE; IN-VIVO; IDENTIFICATION; PROGENITORS; ACTIVATION; INDUCTION; OBESITY	Brown fat generates heat via the mitochondrial uncoupling protein UCP1, defending against hypothermia and obesity. Recent data suggest that there are two distinct types of brown fat: classical brown fat derived from a myf-5 cellular lineage and UCP1-positive cells that emerge in white fat from a non-myf-5 lineage. Here, we report the isolation of "beige" cells from murine white fat depots. Beige cells resemble white fat cells in having extremely low basal expression of UCP1, but, like classical brown fat, they respond to cyclic AMP stimulation with high UCP1 expression and respiration rates. Beige cells have a gene expression pattern distinct from either white or brown fat and are preferentially sensitive to the polypeptide hormone irisin. Finally, we provide evidence that previously identified brown fat deposits in adult humans are composed of beige adipocytes. These data provide a foundation for studying this mammalian cell type with therapeutic potential.	[Wu, Jun; Bostrom, Pontus; Ye, Li; Choi, Jang Hyun; Giang, An-Hoa; Khandekar, Melin; Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA; [Wu, Jun; Bostrom, Pontus; Ye, Li; Choi, Jang Hyun; Giang, An-Hoa; Khandekar, Melin; Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; [Sparks, Lauren M.; Lichtenbelt, Wouter D. van Marken; Hoeks, Joris; Schrauwen, Patrick] Maastricht Univ Med Ctr, NUTRIM Sch Nutr Toxicol & Metab, Dept Human Biol, NL-6229 ER Maastricht, Netherlands; [Schaart, Gert] Maastricht Univ Med Ctr, NUTRIM Sch Nutr Toxicol & Metab, Dept Human Movement Sci, NL-6229 ER Maastricht, Netherlands; [Enerbaeck, Sven] Gothenburg Univ, Inst Biomed, S-40530 Gothenburg, Sweden; [Virtanen, Kirsi A.; Nuutila, Pirjo] Univ Turku, Turku PET Ctr, FI-20521 Turku, Finland; [Huang, Kexin; Tu, Hua] Lakepharma Inc, Belmont, CA 94002 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); University of Gothenburg; University of Turku	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.	bruce_spiegelman@dfci.harvard.edu	Nuutila, Pirjo/J-2087-2012; Choi, Jang Hyun/B-3055-2012	schrauwen, patrick/0000-0002-0973-847X; Hoeks, Joris/0000-0002-0265-0870; Nuutila, Pirjo/0000-0001-9597-338X; Sparks, Lauren/0000-0002-9257-5666; Schaart, Gert/0000-0003-4259-9528	NIH [DK31405, DK90861]; JPB Foundation; Netherlands Organization for Scientific Research; American Heart Association [09POST2010078]; American Heart Association (National Center) [12SDG8070003]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031405, RC4DK090861, K01DK094824, R37DK031405] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); JPB Foundation; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); American Heart Association(American Heart Association); American Heart Association (National Center)(American Heart Association); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Y. Wang (Center for Cancer Computational Biology at Dana-Farber Cancer Institute) for assistance with affymetrix gene chip analysis, S. White (Beth Israel Deaconess Medical Center Histology Core) for cryosectioning, and A. Korde for technical help. We are grateful to Drs. P. Seale, R. Gupta, P. Cohen, S. Kleiner, and J. Lo for useful discussions. B.M.S. is supported by NIH grants DK31405 and DK90861 and by a grant from the JPB Foundation. P.S. is supported by a VICI research grant for innovative research from the Netherlands Organization for Scientific Research. J.W. was supported in part by a postdoctoral fellowship from the American Heart Association (Founders Affiliate, 09POST2010078) and by a Scientist Developmental Grant from the American Heart Association (National Center, 12SDG8070003). J.W. and B.M.S. conceived and designed the experiments. J.W., P.B., L.M.S., L.Y., J.H.C., A.G., M.K., G.S., and J.H. performed experiments. All authors analyzed the data. P.N., W.D.M.L., and S.E. provided reagents and samples, and J.W. and B.M.S. wrote the manuscript. B.M.S. and S.E. are shareholders and consultants to Ember Therapeutics, which has licensed the rights to irisin from the DFCI.	Billon N, 2012, STEM CELL REV REP, V8, P55, DOI 10.1007/s12015-011-9242-x; Bordicchia M, 2012, J CLIN INVEST, V122, P1022, DOI 10.1172/JCI59701; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Cinti S, 2002, J ENDOCRINOL INVEST, V25, P823, DOI 10.1007/BF03344046; Collins S, 2004, MOL ENDOCRINOL, V18, P2123, DOI 10.1210/me.2004-0193; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; Coulter AA, 2003, PHYSIOL GENOMICS, V14, P139, DOI 10.1152/physiolgenomics.00057.2003; COUSIN B, 1992, J CELL SCI, V103, P931; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; Fisher FM, 2012, GENE DEV, V26, P271, DOI 10.1101/gad.177857.111; Gesta S, 2006, P NATL ACAD SCI USA, V103, P6676, DOI 10.1073/pnas.0601752103; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Gupta RK, 2010, NATURE, V464, P619, DOI 10.1038/nature08816; Himms-Hagen J, 2000, AM J PHYSIOL-CELL PH, V279, pC670, DOI 10.1152/ajpcell.2000.279.3.C670; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; Ishibashi J, 2010, SCIENCE, V328, P1113, DOI 10.1126/science.1190816; Joe AWB, 2010, NAT CELL BIOL, V12, P153, DOI 10.1038/ncb2015; Joe AWB, 2009, STEM CELLS, V27, P2563, DOI 10.1002/stem.190; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; Lee YH, 2012, CELL METAB, V15, P480, DOI 10.1016/j.cmet.2012.03.009; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; Mirbolooki MR, 2011, EJNMMI RES, V1, DOI 10.1186/2191-219X-1-30; Orava J, 2011, CELL METAB, V14, P272, DOI 10.1016/j.cmet.2011.06.012; Ouellet V, 2012, J CLIN INVEST, V122, P545, DOI 10.1172/JCI60433; Petrovic N, 2010, J BIOL CHEM, V285, P7153, DOI 10.1074/jbc.M109.053942; Rodeheffer MS, 2008, CELL, V135, P240, DOI 10.1016/j.cell.2008.09.036; Schulz TJ, 2011, P NATL ACAD SCI USA, V108, P143, DOI 10.1073/pnas.1010929108; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Seale P, 2007, CELL METAB, V6, P38, DOI 10.1016/j.cmet.2007.06.001; Seale P, 2011, J CLIN INVEST, V121, P96, DOI 10.1172/JCI44271; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Uezumi A, 2010, NAT CELL BIOL, V12, P143, DOI 10.1038/ncb2014; Vegiopoulos A, 2010, SCIENCE, V328, P1158, DOI 10.1126/science.1186034; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; von Heydebreck A, 2001, Bioinformatics, V17 Suppl 1, pS107; Whittle AJ, 2011, TRENDS MOL MED, V17, P405, DOI 10.1016/j.molmed.2011.04.001; Xue BZ, 2007, J LIPID RES, V48, P41, DOI 10.1194/jlr.M600287-JLR200; Xue BZ, 2005, MOL CELL BIOL, V25, P8311, DOI 10.1128/MCB.25.18.8311-8322.2005; YOUNG P, 1984, FEBS LETT, V167, P10, DOI 10.1016/0014-5793(84)80822-4	39	2223	2346	19	377	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 20	2012	150	2					366	376		10.1016/j.cell.2012.05.016	http://dx.doi.org/10.1016/j.cell.2012.05.016			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22796012	Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000306595700015
J	Thompson, M; Heneghan, C; Cohen, D				Thompson, Matthew; Heneghan, Carl; Cohen, Deborah			How valid is the European Food Safety Authority's assessment of sports drinks?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Thompson, Matthew; Heneghan, Carl] Univ Oxford, Dept Primary Care Hlth Sci, Oxford OX2 6GG, England; [Cohen, Deborah] BMJ, London WC1H 9JR, England	University of Oxford	Thompson, M (corresponding author), Univ Oxford, Dept Primary Care Hlth Sci, Oxford OX2 6GG, England.	matthew.thompson@phc.ox.ac.uk						Agostoni C, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2211; [Anonymous], 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2481; EFSA, MEMB PAN DIET PROD N; Egger M, 1985, SYSTEMATIC REV HLTH; Heneghan C, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e4797; James Lind Library, 2007, UP TO DAT SYST REV R; Scientific Committee on Food, 2001, REP SCI COMM FOOD CO	7	5	5	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 19	2012	345								e4753	10.1136/bmj.e4753	http://dx.doi.org/10.1136/bmj.e4753			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978MA	22810387				2022-12-28	WOS:000306744300010
J	Wearn, OR; Reuman, DC; Ewers, RM				Wearn, Oliver R.; Reuman, Daniel C.; Ewers, Robert M.			Extinction Debt and Windows of Conservation Opportunity in the Brazilian Amazon	SCIENCE			English	Article							DEFORESTATION; LOSSES; FUTURE; AREA	Predicting when future species extinctions will occur is necessary for directing conservation investments but has proved difficult. We developed a new method for predicting extinctions over time, accounting for the timing and magnitude of habitat loss. We applied this to the Brazilian Amazon, predicting that local extinctions of forest-dependent vertebrate species have thus far been minimal ( 1% of species by 2008), with more than 80% of extinctions expected to be incurred from historical habitat loss still to come. Realistic deforestation scenarios suggest that local regions will lose an average of nine vertebrate species and have a further 16 committed to extinction by 2050. There is a window of opportunity to dilute the legacy of historical deforestation by concentrating conservation efforts in areas with greatest debt.	[Wearn, Oliver R.; Reuman, Daniel C.; Ewers, Robert M.] Univ London Imperial Coll Sci Technol & Med, Ascot SL5 7PY, Berks, England; [Wearn, Oliver R.] Zool Soc London, Inst Zool, London NW1 4RY, England; [Reuman, Daniel C.] Rockefeller Univ, New York, NY 10065 USA	Imperial College London; Zoological Society of London; Rockefeller University	Ewers, RM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Silwood Pk, Ascot SL5 7PY, Berks, England.	r.ewers@imperial.ac.uk		Wearn, Oliver/0000-0001-8258-3534	UK Natural Environment Research Council; European Research Council; NERC [NE/I011889/1] Funding Source: UKRI; Natural Environment Research Council [NE/I011889/1] Funding Source: researchfish	UK Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); European Research Council(European Research Council (ERC)European Commission); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	R. Bernard provided GIS assistance, and T. Gardner, J. Barlow, and A. Lees commented on the manuscript and provided data. The UK Natural Environment Research Council supported O.R.W. and D. C. R. and the European Research Council supported R. M. E. during this work. Data were obtained from online sources (10, 18, 26).	Achard F, 2002, SCIENCE, V297, P999, DOI 10.1126/science.1070656; Bird JP, 2012, DIVERS DISTRIB, V18, P273, DOI 10.1111/j.1472-4642.2011.00843.x; Brooks T, 1996, NATURE, V380, P115, DOI 10.1038/380115a0; Brooks TM, 1999, CONSERV BIOL, V13, P1140, DOI 10.1046/j.1523-1739.1999.98341.x; Ceballos G, 2002, SCIENCE, V296, P904, DOI 10.1126/science.1069349; DIAMOND JM, 1972, P NATL ACAD SCI USA, V69, P3199, DOI 10.1073/pnas.69.11.3199; Drakare S, 2006, ECOL LETT, V9, P215, DOI 10.1111/j.1461-0248.2005.00848.x; Feeley KJ, 2009, P NATL ACAD SCI USA, V106, P12382, DOI 10.1073/pnas.0900698106; Ferraz G, 2007, SCIENCE, V315, P238, DOI 10.1126/science.1133097; Grelle CEV, 2005, ORYX, V39, P347, DOI 10.1017/S0030605305000700; Hayashi S., 2011, MATO GROSSO SAD ALER; Hubbell SP, 2008, P NATL ACAD SCI USA, V105, P11498, DOI 10.1073/pnas.0801915105; *INPE, 2009, PROJ PRODES MON FLOR; Laurance WF, 2001, SCIENCE, V291, P438, DOI 10.1126/science.291.5503.438; MAC ARTHUR ROBERT H., 1967; Metzger JP, 2010, SCIENCE, V329, P276, DOI 10.1126/science.329.5989.276-b; Mittermeier RA, 2003, P NATL ACAD SCI USA, V100, P10309, DOI 10.1073/pnas.1732458100; Nepstad D, 2009, SCIENCE, V326, P1350, DOI 10.1126/science.1182108; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; PIMM SL, 1995, P NATL ACAD SCI USA, V92, P9343, DOI 10.1073/pnas.92.20.9343; Ridgely R. S, 2007, DIGITAL DISTRIBUTION; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; Soares BS, 2006, NATURE, V440, P520, DOI 10.1038/nature04389; TILMAN D, 1994, NATURE, V371, P65, DOI 10.1038/371065a0; World Conservation Union, 2008, 2008 IUCN RED LIST T	25	153	154	4	223	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2012	337	6091					228	232		10.1126/science.1219013	http://dx.doi.org/10.1126/science.1219013			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798612				2022-12-28	WOS:000306323500057
J	Narvaez-Moreno, B; Rodriguez, JJP				Narvaez-Moreno, Basilio; Pereyra Rodriguez, Jose Juan			Yellow Urticaria	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Narvaez-Moreno, Basilio; Pereyra Rodriguez, Jose Juan] Univ Hosp Virgen del Rocio, Seville, Spain	Virgen del Rocio University Hospital	Narvaez-Moreno, B (corresponding author), Univ Hosp Virgen del Rocio, Seville, Spain.	basilioaedv@gmail.com	IBIS, DERMATOLOGIA/H-7489-2016; Pereyra-Rodríguez, José-Juan/AAZ-6295-2020	Pereyra-Rodríguez, José-Juan/0000-0001-6843-5877					0	5	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2								10.1056/NEJMicm1112161	http://dx.doi.org/10.1056/NEJMicm1112161			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972IO	22784143				2022-12-28	WOS:000306270800002
J	Goyder, E; Irwig, L; Payne, N				Goyder, Elizabeth; Irwig, Les; Payne, Nick			Should we screen for type 2 diabetes? No	BRITISH MEDICAL JOURNAL			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; COST-EFFECTIVENESS ANALYSIS; PHYSICAL-ACTIVITY; RISK; METAANALYSIS; PEOPLE; ADULTS		[Goyder, Elizabeth; Payne, Nick] Univ Sheffield, ScHARR, Sheffield S1 4DA, S Yorkshire, England; [Irwig, Les] Univ Sydney, Screening & Test Evaluat Program, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia	University of Sheffield; University of Sydney	Goyder, E (corresponding author), Univ Sheffield, ScHARR, Sheffield S1 4DA, S Yorkshire, England.	e.goyder@sheffield.ac.uk						Capewell S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000320; Department of Health, 2008, IMP ASS PUTT PREV 1; Egger G, 1997, BRIT MED J, V315, P477, DOI 10.1136/bmj.315.7106.477; Gaziano TA, 2005, CIRCULATION, V112, P3569, DOI 10.1161/CIRCULATIONAHA.105.535922; Gillies CL, 2008, BMJ-BRIT MED J, V336, P1180, DOI 10.1136/bmj.39545.585289.25; Gillies CL, 2007, BMJ-BRIT MED J, V334, P299, DOI 10.1136/bmj.39063.689375.55; Haines A, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1018; International Obesity Task Force, 2011, OB PREV WORLDW; NHS Camden, SERV SPEC NHS HLTH C; NHS West Sussex, 2011, LOC ENH SERV; Noble D, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d7163; Nocon M, 2008, EUR J CARDIOV PREV R, V15, P239, DOI 10.1097/HJR.0b013e3282f55e09; Paddison CAM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4535; Price HC, 2011, DIABETIC MED, V28, P363, DOI 10.1111/j.1464-5491.2010.03212.x; Swinburn Boyd A, 2008, Aust New Zealand Health Policy, V5, P12, DOI 10.1186/1743-8462-5-12; Teychenne M, 2008, PREV MED, V46, P397, DOI 10.1016/j.ypmed.2008.01.009; Wald NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018742; Wise Jacqui, 2012, BMJ, V344, pe2296, DOI 10.1136/bmj.e2296	18	3	3	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 9	2012	345								e4516	10.1136/bmj.e4516	http://dx.doi.org/10.1136/bmj.e4516			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NR	22777030				2022-12-28	WOS:000306518500005
J	Lu, CP; Polak, L; Rocha, AS; Pasolli, HA; Chen, SC; Sharma, N; Blanpain, C; Fuchs, E				Lu, Catherine P.; Polak, Lisa; Rocha, Ana Sofia; Pasolli, H. Amalia; Chen, Shann-Ching; Sharma, Neha; Blanpain, Cedric; Fuchs, Elaine			Identification of Stem Cell Populations in Sweat Glands and Ducts Reveals Roles in Homeostasis and Wound Repair	CELL			English	Article							FUNCTIONAL MAMMARY-GLAND; SKIN; EXPRESSION; CHANNEL; NICHE; FATE; MICE	Sweat glands are abundant in the body and essential for thermoregulation. Like mammary glands, they originate from epidermal progenitors. However, they display few signs of cellular turnover, and whether they have stem cells and tissue-regenerative capacity remains largely unexplored. Using lineage tracing, we here identify in sweat ducts multipotent progenitors that transition to unipotency after developing the sweat gland. In characterizing four adult stem cell populations of glandular skin, we show that they display distinct regenerative capabilities and remain unipotent when healing epidermal, myoepithelial-specific, and lumenal-specific injuries. We devise purification schemes and isolate and transcriptionally profile progenitors. Exploiting molecular differences between sweat and mammary glands, we show that only some progenitors regain multipotency to produce de novo ductal and glandular structures, but that these can retain their identity even within certain foreign microenvironments. Our findings provide insight into glandular stem cells and a framework for the further study of sweat gland biology.	[Fuchs, Elaine] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA; [Lu, Catherine P.; Polak, Lisa; Pasolli, H. Amalia; Fuchs, Elaine] Rockefeller Univ, Lab Mammalian Cell Biol & Dev, New York, NY 10065 USA; [Rocha, Ana Sofia; Sharma, Neha; Blanpain, Cedric] Univ Libre Brussels, IRIBHM, B-1050 Brussels, Belgium; [Chen, Shann-Ching] St Jude Childrens Hosp, Dept Pathol, Memphis, TN 38105 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Universite Libre de Bruxelles; St Jude Children's Research Hospital	Fuchs, E (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA.	fuchslb@rockefeller.edu	Fuchs, Elaine/G-1565-2016; Blanpain, Cedric/ABD-8392-2021	Lu, Catherine/0000-0003-4593-327X; Pasolli, Hilda Amalia/0000-0003-3899-3530; Sharma, Neha/0000-0002-8062-1661	Stem Cell Research Foundation; Starr Foundation; NIH [R01-AR050452]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR060654, K01AR066073, R01AR050452] Funding Source: NIH RePORTER	Stem Cell Research Foundation; Starr Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank D. Chu for sparking interest in sweat glands in the Fuchs lab. We thank Y.-C. Hsu, X. Wu, and B. Keyes for intellectual input and helpful suggestions. We thank Rockefeller's Comparative Bioscience Center (AAALAC accredited) for care and breeding of mice in accordance with National Institutes of Health (NIH) guidelines; Bioimaging Center (A. North, director) for advice on image acquisition; and Flow Cytometry facility (S. Mazel, director) for FACS sorting. E.F. is an Investigator of The Howard Hughes Medical Institute. C.P.L. is a Ruth Kirschstein Postdoctoral Fellow (NIH 5F32AR060654-02). This work was supported initially by pilot grants from Stem Cell Research and Starr Foundations (E.F.) and more recently by NIH R01-AR050452 (E.F.).	BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Biedermann T, 2010, J INVEST DERMATOL, V130, P1996, DOI 10.1038/jid.2010.83; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; BLECHER SR, 1986, J INVEST DERMATOL, V87, P720, DOI 10.1111/1523-1747.ep12456718; Booth BW, 2008, P NATL ACAD SCI USA, V105, P14891, DOI 10.1073/pnas.0803214105; Boulanger CA, 2007, P NATL ACAD SCI USA, V104, P3871, DOI 10.1073/pnas.0611637104; Cui CY, 2012, P NATL ACAD SCI USA, V109, P1199, DOI 10.1073/pnas.1117213109; Ferraris C, 2000, DEVELOPMENT, V127, P5487; Jensen UB, 2008, J CELL SCI, V121, P609, DOI 10.1242/jcs.025502; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Krahl D, 2010, J CUTAN PATHOL, V37, P350, DOI 10.1111/j.1600-0560.2009.01369.x; Kunisada M, 2009, HUM MOL GENET, V18, P1769, DOI 10.1093/hmg/ddp089; Langbein L, 2005, J INVEST DERMATOL, V125, P428, DOI 10.1111/j.0022-202X.2005.23860.x; Lobitz Jr. W.C., 1956, J INVEST DERMATOL, V26, P259; LOBITZ WC, 1956, J INVEST DERMATOL, V26, P247, DOI 10.1038/jid.1956.37; LOBITZ WC, 1954, J INVEST DERMATOL, V23, P329, DOI 10.1038/jid.1954.116; LOBITZ WC, 1961, ANNU REV MED, V12, P289, DOI 10.1146/annurev.me.12.020161.001445; Miller SJ, 1998, J INVEST DERMATOL, V110, P13, DOI 10.1046/j.1523-1747.1998.00087.x; MOLL I, 1992, J INVEST DERMATOL, V98, P777, DOI 10.1111/1523-1747.ep12499950; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Mustonen T, 2004, DEVELOPMENT, V131, P4907, DOI 10.1242/dev.01377; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Sato F, 2000, J HISTOCHEM CYTOCHEM, V48, P345, DOI 10.1177/002215540004800304; SATO K, 1973, J CLIN INVEST, V52, P2166, DOI 10.1172/JCI107401; Sato K., 1993, DERMATOLOGY GEN MED, P221; Schon M, 1999, J CELL SCI, V112, P1925; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Song YL, 2002, J PHYSIOL-LONDON, V541, P561, DOI 10.1113/jphysiol.2001.020180; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551	33	204	216	1	35	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 6	2012	150	1					136	150		10.1016/j.cell.2012.04.045	http://dx.doi.org/10.1016/j.cell.2012.04.045			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770217	Green Accepted, Bronze			2022-12-28	WOS:000306115000013
J	Mahadevan, A; D'Asaro, E; Lee, C; Perry, MJ				Mahadevan, Amala; D'Asaro, Eric; Lee, Craig; Perry, Mary Jane			Eddy-Driven Stratification Initiates North Atlantic Spring Phytoplankton Blooms	SCIENCE			English	Article							MIXED-LAYER EDDIES; PARAMETERIZATION; CONVECTION; ONSET; VARIABILITY; EXPORT; SINK; FLUX; SEA	Springtime phytoplankton blooms photosynthetically fix carbon and export it from the surface ocean at globally important rates. These blooms are triggered by increased light exposure of the phytoplankton due to both seasonal light increase and the development of a near-surface vertical density gradient (stratification) that inhibits vertical mixing of the phytoplankton. Classically and in current climate models, that stratification is ascribed to a springtime warming of the sea surface. Here, using observations from the subpolar North Atlantic and a three-dimensional biophysical model, we show that the initial stratification and resulting bloom are instead caused by eddy-driven slumping of the basin-scale north-south density gradient, resulting in a patchy bloom beginning 20 to 30 days earlier than would occur by warming.	[D'Asaro, Eric; Lee, Craig] Univ Washington, Appl Phys Lab, Seattle, WA 98105 USA; [Mahadevan, Amala] Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; [Perry, Mary Jane] Univ Maine, Darling Marine Ctr, Walpole, ME 04573 USA	University of Washington; University of Washington Seattle; Woods Hole Oceanographic Institution; University of Maine System; University of Maine Orono	D'Asaro, E (corresponding author), Univ Washington, Appl Phys Lab, Seattle, WA 98105 USA.	dasaro@apl.washington.edu			NSF [OCE-0628107, OCE-0628379, OCE-0928617, OPP-0901407]; ONR [N000141210101]; NASA [NNX-08AL92G, NNX-12AD47G, NNX08AW97G]; Directorate For Geosciences [0928617] Funding Source: National Science Foundation; Division Of Ocean Sciences [0928138] Funding Source: National Science Foundation; Division Of Polar Programs [0901650] Funding Source: National Science Foundation	NSF(National Science Foundation (NSF)); ONR(Office of Naval Research); NASA(National Aeronautics & Space Administration (NASA)); Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); Division Of Ocean Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); Division Of Polar Programs(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	We thank the NSF (grants OCE-0628107, OCE-0628379, OCE-0928617, and OPP-0901407), ONR (grant N000141210101), and NASA (grants NNX-08AL92G, NNX-12AD47G, and NNX08AW97G) for financial support. We also thank K. Gudmundsson, H. Valdimarsson, K. Fennel, I. Cetinic, M. Alkire, B. Sackmann, E. Kallin, N. Briggs, E. Rehm, A. Gray, J. Gobat, G, Shilling, A. Huxtable, M. Ohmart, and the captains and crews of R/V Bjarni Saemundsson and R/V Knorr for their efforts in gathering and analyzing the data. Data from NAB08 are publicly available at the Biological and Chemical Oceanography Data Management Office: http://osprey.bcodmo.org/project.cfm?flag=view&id=102&sortby=project. Argo float data were collected and made freely available by the International Argo Program (IAP) and the national programs that contribute to the IAP.	Alkire MB, 2012, DEEP-SEA RES PT I, V64, P157, DOI 10.1016/j.dsr.2012.01.012; Backhaus JO, 2003, MAR ECOL PROG SER, V251, P1, DOI 10.3354/meps251001; Bagniewski W., 2010, BIOGEOSCIENCES, V7, P1; Behrenfeld MJ, 2010, ECOLOGY, V91, P977, DOI 10.1890/09-1207.1; Boccaletti G, 2007, J PHYS OCEANOGR, V37, P2228, DOI 10.1175/JPO3101.1; Bracco A, 2000, P ROY SOC B-BIOL SCI, V267, P1795, DOI 10.1098/rspb.2000.1212; D'Asaro EA, 2003, J ATMOS OCEAN TECH, V20, P896, DOI 10.1175/1520-0426(2003)020<0896:POALF>2.0.CO;2; D'Asaro E, 2011, SCIENCE, V332, P318, DOI 10.1126/science.1201515; FALKOWSKI PG, 1994, PHOTOSYNTH RES, V39, P235, DOI 10.1007/BF00014586; Fennel K., 2011, EOS, V92, P465, DOI DOI 10.1029/2011E0500002; Fox-Kemper B, 2011, OCEAN MODEL, V39, P61, DOI 10.1016/j.ocemod.2010.09.002; Fox-Kemper B, 2008, J PHYS OCEANOGR, V38, P1145, DOI 10.1175/2007JPO3792.1; Fox-Kemper B, 2008, J PHYS OCEANOGR, V38, P1166, DOI 10.1175/2007JPO3788.1; Frajka-Williams E, 2009, DEEP-SEA RES PT I, V56, P2144, DOI 10.1016/j.dsr.2009.07.008; Grist JP, 2003, J CLIMATE, V16, P3274, DOI 10.1175/1520-0442(2003)016<3274:IAAOTS>2.0.CO;2; Harcourt RR, 2010, J ATMOS OCEAN TECH, V27, P1918, DOI 10.1175/2010JTECHO731.1; Henson SA, 2006, DEEP-SEA RES PT I, V53, P1601, DOI 10.1016/j.dsr.2006.07.009; Holte J, 2009, J ATMOS OCEAN TECH, V26, P1920, DOI 10.1175/2009JTECHO543.1; Levy M, 1998, J MARINE SYST, V16, P7, DOI 10.1016/S0924-7963(97)00097-3; Levy M, 1999, DEEP-SEA RES PT I, V46, P1137, DOI 10.1016/S0967-0637(98)00105-8; Mahadevan A, 1996, J PHYS OCEANOGR, V26, P1881, DOI 10.1175/1520-0485(1996)026<1881:ANMOMP>2.0.CO;2; Mahadevan A, 2010, J GEOPHYS RES-OCEANS, V115, DOI 10.1029/2008JC005203; Martin P, 2011, DEEP-SEA RES PT I, V58, P338, DOI 10.1016/j.dsr.2011.01.006; Okamoto S, 2010, DEEP-SEA RES PT II, V57, P1608, DOI 10.1016/j.dsr2.2010.03.005; Rudnick DL, 1999, SCIENCE, V283, P526, DOI 10.1126/science.283.5401.526; Sabine CL, 2004, SCIENCE, V305, P367, DOI 10.1126/science.1097403; Siegel DA, 2002, SCIENCE, V296, P730, DOI 10.1126/science.1069174; STONE PH, 1970, J ATMOS SCI, V27, P721, DOI 10.1175/1520-0469(1970)027<0721:ONGBSP>2.0.CO;2; Sverdrup H.U., 1953, J CONSEILCONSEIL PER, V18, P287, DOI [10.1093/icesjms/18.3.287, DOI 10.1093/ICESJMS/18.3.287]; TANDON A, 1994, J PHYS OCEANOGR, V24, P1419, DOI 10.1175/1520-0485(1994)024<1419:MLRDTA>2.0.CO;2; Taylor JR, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL049312; Taylor JR, 2011, LIMNOL OCEANOGR, V56, P2293, DOI 10.4319/lo.2011.56.6.2293; Thomas LN, 2005, J PHYS OCEANOGR, V35, P1086, DOI 10.1175/JPO2737.1; Waniek JJ, 2003, J MARINE SYST, V39, P57, DOI 10.1016/S0924-7963(02)00248-8; WATSON AJ, 1991, NATURE, V350, P50, DOI 10.1038/350050a0	35	310	315	9	179	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2012	337	6090					54	58		10.1126/science.1218740	http://dx.doi.org/10.1126/science.1218740			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767922				2022-12-28	WOS:000306053100041
J	Olnes, MJ; Scheinberg, P; Calvo, KR; Desmond, R; Tang, Y; Dumitriu, B; Parikh, AR; Soto, S; Biancotto, A; Feng, XM; Lozier, J; Wu, CO; Young, NS; Dunbar, CE				Olnes, Matthew J.; Scheinberg, Phillip; Calvo, Katherine R.; Desmond, Ronan; Tang, Yong; Dumitriu, Bogdan; Parikh, Ankur R.; Soto, Susan; Biancotto, Angelique; Feng, Xingmin; Lozier, Jay; Wu, Colin O.; Young, Neal S.; Dunbar, Cynthia E.			Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RABBIT ANTITHYMOCYTE GLOBULIN; IMMUNOSUPPRESSIVE THERAPY; C-MPL; MARROW-TRANSPLANTATION; STIMULATING FACTOR; MICE LACKING; BONE-MARROW; STEM-CELLS; THROMBOPOIETIN; SURVIVAL	BACKGROUND Severe aplastic anemia, which is characterized by immune-mediated bone marrow hypoplasia and pancytopenia, can be treated effectively with immunosuppressive therapy or allogeneic transplantation. One third of patients have disease that is refractory to immunosuppression, with persistent, severe cytopenia and a profound deficit in hematopoietic stem cells and progenitor cells. Thrombopoietin may increase the number of hematopoietic stem cells and progenitor cells. METHODS We conducted a phase 2 study involving patients with aplastic anemia that was refractory to immunosuppression to determine whether the oral thrombopoietin mimetic eltrombopag (Promacta) can improve blood counts. Twenty-five patients received eltrombopag at a dose of 50 mg, which could be increased, as needed, to a maximum dose of 150 mg daily, for a total of 12 weeks. Primary end points were clinically significant changes in blood counts or transfusion independence. Patients with a response continued to receive eltrombopag. RESULTS Eleven of 25 patients (44%) had a hematologic response in at least one lineage at 12 weeks, with minimal toxic effects. Nine patients no longer needed platelet transfusions (median increase in platelet count, 44,000 per cubic millimeter). Six patients had improved hemoglobin levels (median increase, 4.4 g per deciliter); 3 of them were previously dependent on red-cell transfusions and no longer needed transfusions. Nine patients had increased neutrophil counts (median increase, 1350 per cubic millimeter). Serial bone marrow biopsies showed normalization of trilineage hematopoiesis in patients who had a response, without increased fibrosis. Monitoring of immune function revealed no consistent changes. CONCLUSIONS Treatment with eltrombopag was associated with multilineage clinical responses in some patients with refractory severe aplastic anemia. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT00922883.)	[Olnes, Matthew J.; Scheinberg, Phillip; Desmond, Ronan; Tang, Yong; Dumitriu, Bogdan; Parikh, Ankur R.; Soto, Susan; Feng, Xingmin; Young, Neal S.; Dunbar, Cynthia E.] NHLBI, Hematol Branch, Natl Inst Hlth, Bethesda, MD 20892 USA; [Wu, Colin O.] NHLBI, Off Biostat Res, Natl Inst Hlth, Bethesda, MD 20892 USA; [Calvo, Katherine R.; Lozier, Jay] NHLBI, Hematol Sect, Dept Lab Med, Mark O Hatfield Clin Res Ctr,Natl Inst Hlth, Bethesda, MD 20892 USA; [Biancotto, Angelique] Trans NIH Ctr Human Immunol Autoimmun & Inflammat, Natl Inst Hlth, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA	Dunbar, CE (corresponding author), NHLBI, Hematol Branch, Natl Inst Hlth, Bldg 10 CRC 4E 5132, Bethesda, MD 20892 USA.	dunbarc@nhlbi.nih.gov	biancotto, angelique/C-4632-2011; Calvo, Katherine/A-8109-2009; Scheinberg, Phillip/H-5251-2012	biancotto, angelique/0000-0003-2271-009X; Scheinberg, Phillip/0000-0002-9047-4538; Dunbar, Cynthia/0000-0002-7645-838X; Calvo, Katherine/0000-0002-0771-4191	National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002315, ZIAHL006063] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL090025, ZIACL080014] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CLINICAL CENTER	Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT00922883.	Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Bussel JB, 2007, NEW ENGL J MED, V357, P2237, DOI 10.1056/NEJMoa073275; Calado RT, 2012, LEUKEMIA, V26, P700, DOI 10.1038/leu.2011.272; Di Bona E, 1999, BRIT J HAEMATOL, V107, P330, DOI 10.1046/j.1365-2141.1999.01693.x; Emmons RVB, 1996, BLOOD, V87, P4068, DOI 10.1182/blood.V87.10.4068.bloodjournal87104068; Erickson-Miller CL, 2009, STEM CELLS, V27, P424, DOI 10.1634/stemcells.2008-0366; Feng XM, 2011, HAEMATOL-HEMATOL J, V96, P602, DOI 10.3324/haematol.2010.030536; Geddis AE, 2011, PEDIATR BLOOD CANCER, V57, P199, DOI 10.1002/pbc.22927; Geller N.L., 2003, ADV CLIN TRIAL BIOST, P41; Gurion R, 2009, HAEMATOL-HEMATOL J, V94, P712, DOI 10.3324/haematol.2008.002170; Kaushansky K, 2008, BLOOD, V111, P981, DOI 10.1182/blood-2007-05-088500; Kimura S, 1998, P NATL ACAD SCI USA, V95, P1195, DOI 10.1073/pnas.95.3.1195; Kuter DJ, 2009, BLOOD, V114, P3748, DOI 10.1182/blood-2009-05-224766; Kuter DJ, 2009, ANNU REV MED, V60, P193, DOI 10.1146/annurev.med.60.042307.181154; Maciejewski JP, 1996, BLOOD, V88, P1983, DOI 10.1182/blood.V88.6.1983.bloodjournal8861983; MANOHARAN A, 1979, BRIT J HAEMATOL, V43, P185, DOI 10.1111/j.1365-2141.1979.tb03740.x; Qian H, 2007, CELL STEM CELL, V1, P671, DOI 10.1016/j.stem.2007.10.008; Rosenfeld S, 2003, JAMA-J AM MED ASSOC, V289, P1130, DOI 10.1001/jama.289.9.1130; Scheinberg P, 2011, NEW ENGL J MED, V365, P430, DOI 10.1056/NEJMoa1103975; Scheinberg P, 2010, JAMA-J AM MED ASSOC, V304, P1901, DOI 10.1001/jama.2010.1564; Scheinberg P, 2010, JAMA-J AM MED ASSOC, V304, P1358, DOI 10.1001/jama.2010.1376; Scheinberg P, 2009, BRIT J HAEMATOL, V144, P206, DOI 10.1111/j.1365-2141.2008.07450.x; SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9; Socie G, 2000, SEMIN HEMATOL, V37, P91; Socie G, 2007, BLOOD, V109, P2794, DOI 10.1182/blood-2006-07-034272; Valdez JM, 2011, CLIN INFECT DIS, V52, P726, DOI 10.1093/cid/ciq245; Viollier R, 2005, ANN HEMATOL, V84, P47, DOI 10.1007/s00277-004-0930-3; Young NS, 2006, BLOOD, V108, P2509, DOI 10.1182/blood-2006-03-010777; ZEIGLER FC, 1994, BLOOD, V84, P4045, DOI 10.1182/blood.V84.12.4045.bloodjournal84124045	29	318	347	4	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					11	19		10.1056/NEJMoa1200931	http://dx.doi.org/10.1056/NEJMoa1200931			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968KJ	22762314	Green Accepted			2022-12-28	WOS:000305979400001
J	Farrell, C; McConaghy, P				Farrell, Conor; McConaghy, Paul			Perioperative management of patients taking treatment for chronic pain	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; GABAPENTIN; FENTANYL; DRUG		[Farrell, Conor] Ulster Hosp, Anaesthet & Chron Pain Dept, Belfast BT16 1RH, Antrim, North Ireland; [McConaghy, Paul] Craigavon Area Hosp, Portadown BT63 5QQ, North Ireland		Farrell, C (corresponding author), Ulster Hosp, Anaesthet & Chron Pain Dept, Belfast BT16 1RH, Antrim, North Ireland.	farrell_conor@hotmail.com			NAPP pharmaceuticals; Pfizer; Medtronic; St Jude Medical; Grunenthal	NAPP pharmaceuticals; Pfizer(Pfizer); Medtronic(Medtronic); St Jude Medical(St. Jude Medical); Grunenthal(HAL Allergy Group)	Both authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; PF has received honorariums for presentations at regional meetings and been funded for travel to and attendance at meetings by NAPP pharmaceuticals, Pfizer, Medtronic, St Jude Medical, and Grunenthal; there are no other relationships or activities that could appear to have influenced the submitted work.	[Anonymous], 2010, EQUALITY EXCELLENCE; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Attal N, 2010, EUR J NEUROL, V17, P1113, DOI 10.1111/j.1468-1331.2010.02999.x; Barrueto F, 2002, J TOXICOL-CLIN TOXIC, V40, P925, DOI 10.1081/CLT-120016965; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Brill S, 2006, CURR OPIN ANESTHESIO, V19, P325, DOI 10.1097/01.aco.0000192813.38236.99; British Pain Society, 2009, SPIN CORD STIM MAN P; Electronic Medicines Compendium, 2010, SUMM PROD CHAR; Electronic Medicines Compendium, 2011, SUMM PROD CHAR; European Medical Alliance, POST PAIN MAN GOOD C; Grider JS, 2008, ANESTH ANALG, V107, P1393, DOI 10.1213/ane.0b013e318181b818; Hadi I, 2006, CAN J ANAESTH, V53, P1190, DOI 10.1007/BF03021580; HENRY DA, 1977, BMJ-BRIT MED J, V1, P83, DOI 10.1136/bmj.1.6053.83-a; Ho KY, 2006, PAIN, V126, P91, DOI 10.1016/j.pain.2006.06.018; Joint Formulary Committee, 2017, BRIT NATL FORMULARY, V80th; Jones D, 2005, ANAESTH INTENS CARE, V33, P181, DOI 10.1177/0310057X0503300205; Kalkman CJ, 2003, PAIN, V105, P415, DOI 10.1016/S0304-3959(03)00252-5; Kehlet H, 1999, SURG CLIN N AM, V79, P431, DOI 10.1016/S0039-6109(05)70390-X; Kong VKF, 2007, BRIT J ANAESTH, V99, P775, DOI 10.1093/bja/aem316; Kopf A, 2005, HOSP PHARM EUROPE, P21; Kudoh A, 2002, CAN J ANAESTH, V49, P132, DOI 10.1007/BF03020484; Lewis N, 2005, CONTIN ED ANAESTH S, V5; Lewis NL, 2005, BJA EDUC, V5, P127, DOI 10.1093/bjaceaccp/mki034; Margetts L, 2007, BJA EDUC, V7, P171, DOI 10.1093/bjaceaccp/mkm033; Mehta V, 2006, ANAESTHESIA, V61, P269, DOI 10.1111/j.1365-2044.2005.04503.x; Mercadante S, 2004, J PAIN, V5, P2, DOI 10.1016/j.jpain.2003.09.007; Perks A, 2009, J NEUROSURG ANESTH, V21, P127, DOI 10.1097/ANA.0b013e31819a6ca3; Rang ST, 2008, CAN J ANAESTH, V55, P521, DOI 10.1007/BF03016672; Richebe P, 2009, CAN J ANAESTH, V56, P969, DOI 10.1007/s12630-009-9202-y; Ruggera PS, 2003, PHYS MED BIOL, V48, P2919, DOI 10.1088/0031-9155/48/17/312; Ryder SA, 2005, BJA EDUC, V5, P18, DOI 10.1093/bjaceaccp/mki003; society TBp,, 2008, INTRATHECAL DRUG DEL; Stannard C., 2010, OPIOIDS PERSISTENT P; Taylor N, 1996, SOC SCI MED, V43, P1137, DOI 10.1016/0277-9536(96)00056-1; THOMAS V, 1995, BRIT J ANAESTH, V74, P271, DOI 10.1093/bja/74.3.271; Weinrieb Robert M, 2005, Expert Opin Drug Saf, V4, P337, DOI 10.1517/14740338.4.2.337	36	14	15	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	2012	344								e4148	10.1136/bmj.e4148	http://dx.doi.org/10.1136/bmj.e4148			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972KA	22761087				2022-12-28	WOS:000306274800009
J	Onwuteaka-Philipsen, BD; Brinkman-Stoppelenburg, A; Penning, C; de Jong-Krul, GJF; van Delden, JJM; van der Heide, A				Onwuteaka-Philipsen, Bregje D.; Brinkman-Stoppelenburg, Arianne; Penning, Corine; de Jong-Krul, Gwen J. F.; van Delden, Johannes J. M.; van der Heide, Agnes			Trends in end-of-life practices before and after the enactment of the euthanasia law in the Netherlands from 1990 to 2010: a repeated cross-sectional survey	LANCET			English	Article							6 EUROPEAN COUNTRIES; PALLIATIVE CARE; ASSISTED SUICIDE; HASTENED DEATH; DECISIONS; SEDATIVES; OPIOIDS; CANCER; SURVIVAL; BELGIUM	Background In 2002, the euthanasia act came into effect in the Netherlands, which was followed by a slight decrease in the euthanasia frequency. We assessed frequency and characteristics of euthanasia, physician-assisted suicide, and other end-of-life practices in 2010, and assessed trends since 1990. Methods In 1990, 1995, 2001, 2005, and 2010 we did nationwide studies of a stratified sample from the death registry of Statistics Netherlands, to which all deaths and causes were reported. We mailed questionnaires to physicians attending these deaths (2010: n=8496 deaths). All cases were weighted to adjust for the stratification procedure and for differences in response rates in relation to the age, sex, marital status, region of residence, and cause and place of death. Findings In 2010, of all deaths in the Netherlands, 2.8% (95% CI 2.5-3.2; 475 of 6861) were the result of euthanasia. This rate is higher than the 1.7% (1.5-1.8; 294 of 9965) in 2005, but comparable with those in 2001 and 1995. Distribution of sex, age, and diagnosis was stable between 1990 and 2010. In 2010, 77% (3136 of 4050) of all cases of euthanasia or physician-assisted suicide were reported to a review committee (80% [1933 of 2425] in 2005). Ending of life without an explicit patient request in 2010 occurred less often (0.2%; 95% CI 0.1-0.3; 13 of 6861) than in 2005, 2001, 1995, and 1990 (0.8%; 0.6-1.1; 45 of 5197). Continuous deep sedation until death occurred more frequently in 2010 (12.3% [11.6-13.1; 789 of 6861]) than in 2005 (8.2% [7.8-8.6; 521 of 9965]). Of all deaths in 2010, 0.4% (0.3-0.6; 18 of 6861) were the result of the patient's decision to stop eating and drinking to end life; in half of these cases the patient had made a euthanasia request that was not granted. Interpretation Our study provides insight in consequences of regulating euthanasia and physician-assisted suicide within the broader context of end-of-life practices. In the Netherlands the euthanasia law resulted in a relatively transparent practice. Although translating these results to other countries is not straightforward, they can inform the debate on legalisation of assisted dying in other countries.	[Onwuteaka-Philipsen, Bregje D.] Vrije Univ Amsterdam, Med Ctr, Dept Publ & Occupat Hlth, NL-1081 BT Amsterdam, Netherlands; [Onwuteaka-Philipsen, Bregje D.] Vrije Univ Amsterdam, Med Ctr, VUmc Expertise Ctr Palliat Care, EMGO Inst Hlth & Care Res, NL-1081 BT Amsterdam, Netherlands; [Brinkman-Stoppelenburg, Arianne; van der Heide, Agnes] Univ Med Ctr Rotterdam, Dept Publ Hlth, Erasmus MC, Rotterdam, Netherlands; [Penning, Corine; de Jong-Krul, Gwen J. F.] Stat Netherlands, The Hague, Netherlands; [van Delden, Johannes J. M.] Univ Med Ctr Utrecht, Julius Ctr, Utrecht, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center	Onwuteaka-Philipsen, BD (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Publ & Occupat Hlth, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	b.philipsen@vumc.nl		Stoppelenburg, Arianne/0000-0001-6377-1599	Netherlands Organization for Research and Development (ZonMw)	Netherlands Organization for Research and Development (ZonMw)	The Netherlands Organization for Research and Development (ZonMw).	Bilsen J, 2009, NEW ENGL J MED, V361, P1119, DOI 10.1056/NEJMc0904292; Bosshard G, 2008, J MED ETHICS, V34, P28, DOI 10.1136/jme.2006.018911; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; Chabot BE, 2009, SOC SCI MED, V68, P1745, DOI 10.1016/j.socscimed.2009.03.005; Delbeke E, 2011, EUR J HEALTH LAW, V18, P149, DOI 10.1163/157180911X565191; Deliens L, 2003, LANCET, V362, P1239, DOI 10.1016/S0140-6736(03)14520-5; den Hartogh G, 2003, MED CONTACT, V58, P1063; Dyer C, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6779; Ferrand E, 2011, LANCET, V377, P467, DOI 10.1016/S0140-6736(11)60160-8; Finlay I, 2006, PALLIATIVE MED, V20, P115, DOI 10.1191/0269216306pm1119xx; Fleming JI, 1992, BIOETHICS RES NOTES, V4, P1; Good PD, 2005, INTERN MED J, V35, P512, DOI 10.1111/j.1445-5994.2005.00888.x; Gordijn B, 2004, HEALTH CARE ANAL, V12, P195, DOI 10.1023/B:HCAN.0000044926.05523.ef; Levene IR, 2010, CAN MED ASSOC J, V182, P1330, DOI 10.1503/cmaj.110-2092; Morita T, 2001, J PAIN SYMPTOM MANAG, V21, P282, DOI 10.1016/S0885-3924(01)00258-5; Onwuteaka-Philipsen BD, 2003, LANCET, V362, P395, DOI 10.1016/S0140-6736(03)14029-9; Pereira J, 2011, CURR ONCOL, V18, pE38; Regional Review Committees Euthanasia, 2011, ANN REP 2010; Rodin G, 2007, J PAIN SYMPTOM MANAG, V33, P661, DOI 10.1016/j.jpainsymman.2006.09.034; Seale C, 2009, PALLIATIVE MED, V23, P198, DOI 10.1177/0269216308102042; Sykes N, 2003, LANCET ONCOL, V4, P312, DOI 10.1016/S1470-2045(03)01079-9; TENHAVE HAMJ, 1992, HASTINGS CENT REP, V22, P34, DOI 10.2307/3562563; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; van der Heide A, 2007, NEW ENGL J MED, V356, P1957, DOI 10.1056/NEJMsa071143; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; van der Steen JT, 2009, J PALLIAT MED, V12, P789, DOI 10.1089/jpm.2009.0049; vanderWal G, 1996, NEW ENGL J MED, V335, P1706	28	190	193	1	76	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 8	2012	380	9845					908	915		10.1016/S0140-6736(12)61034-4	http://dx.doi.org/10.1016/S0140-6736(12)61034-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	002QL	22789501				2022-12-28	WOS:000308547300033
J	Koblin, BA; Tieu, HV; Frye, V				Koblin, Beryl A.; Tieu, Hong-Van; Frye, Victoria			Disparities in HIV/AIDS in black men who have sex with men	LANCET			English	Editorial Material							RACIAL DISPARITIES; HEALTH		[Koblin, Beryl A.; Tieu, Hong-Van] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Infect Dis Prevent, New York, NY 10065 USA; [Frye, Victoria] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Social & Behav Sci, New York, NY 10065 USA	New York Blood Center; New York Blood Center	Koblin, BA (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Infect Dis Prevent, New York, NY 10065 USA.	bkoblin@nybloodcenter.org		Frye, Victoria/0000-0003-3239-7201	NATIONAL INSTITUTE ON DRUG ABUSE [K01DA031035] Funding Source: NIH RePORTER; NIDA NIH HHS [K01 DA031035] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 2012, NY TIMES        0330; Baker Bruce D., 2010, ED POLICY ANAL ARCH, V18, P1, DOI DOI 10.14507/EPAA.V18N9.2010; Bruce D, 2011, HEALTH EDUC BEHAV, V38, P367, DOI 10.1177/1090198110375911; CRYSTAL S, 1995, HEALTH SERV RES, V30, P593; Department of Labor, 2012, AFR AM LAB FORC REC; Frye V, 2006, J URBAN HEALTH, V83, P308, DOI 10.1007/s11524-006-9033-x; Howell K, 2008, REV LAW SOC CHANGE, V33, P271; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; Mechanic D, 2005, HEALTH AFFAIR, V24, P335, DOI 10.1377/hlthaff.24.2.335; Millett GA, 2012, LANCET; New York Civil Liberties Union, 2012, NYPD STOP FRISK ACT; Prejean J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017502; Tieu HV, 2010, J URBAN HEALTH, V87, P113, DOI 10.1007/s11524-009-9416-x; Torian LV, 2002, SEX TRANSM DIS, V29, P73, DOI 10.1097/00007435-200202000-00002	14	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 28	2012	380	9839					316	318		10.1016/S0140-6736(12)61075-7	http://dx.doi.org/10.1016/S0140-6736(12)61075-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819657				2022-12-28	WOS:000306842800008
J	Rompolas, P; Deschene, ER; Zito, G; Gonzalez, DG; Saotome, I; Haberman, AM; Greco, V				Rompolas, Panteleimon; Deschene, Elizabeth R.; Zito, Giovanni; Gonzalez, David G.; Saotome, Ichiko; Haberman, Ann M.; Greco, Valentina			Live imaging of stem cell and progeny behaviour in physiological hair-follicle regeneration	NATURE			English	Article							NICHE; SKIN; MORPHOGENESIS; ACTIVATION; INDUCTION; GROWTH; CYCLE	Tissue development and regeneration depend on cell-cell interactions and signals that target stem cells and their immediate progeny(1). However, the cellular behaviours that lead to a properly regenerated tissue are not well understood. Using a new, non-invasive, intravital two-photon imaging approach we study physiological hair-follicle regeneration over time in live mice. By these means we have monitored the behaviour of epithelial stem cells and their progeny(2-4) during physiological hair regeneration and addressed how the mesenchyme(5) influences their behaviour. Consistent with earlier studies(6), stem cells are quiescent during the initial stages of hair regeneration, whereas the progeny are more actively dividing. Moreover, stem cell progeny divisions are spatially organized within follicles. In addition to cell divisions, coordinated cell movements of the progeny allow the rapid expansion of the hair follicle. Finally, we show the requirement of the mesenchyme for hair regeneration through targeted cell ablation and long-term tracking of live hair follicles. Thus, we have established an in vivo approach that has led to the direct observation of cellular mechanisms of growth regulation within the hair follicle and that has enabled us to precisely investigate functional requirements of hair-follicle components during the process of physiological regeneration.	[Rompolas, Panteleimon; Deschene, Elizabeth R.; Zito, Giovanni; Saotome, Ichiko; Greco, Valentina] Yale Univ, Sch Med, Yale Canc Ctr, Dept Genet,Dept Dermatol,Yale Stem Cell Ctr, New Haven, CT 06510 USA; [Gonzalez, David G.; Haberman, Ann M.] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA	Yale University; Yale University	Greco, V (corresponding author), Yale Univ, Sch Med, Yale Canc Ctr, Dept Genet,Dept Dermatol,Yale Stem Cell Ctr, 333 Cedar St, New Haven, CT 06510 USA.	valentina.greco@yale.edu	, Zito/O-3836-2019; Zito, Giovanni/AAC-3639-2022	, Zito/0000-0002-0482-6729; Rompolas, Panteleimon/0000-0001-9135-7651	James Hudson Brown-Alexander Brown Coxe postdoctoral fellowship; National Institute of General Medical Sciences, US National Institutes of Health, Public Health Service; American Skin Association; American Cancer Society; Yale Rheumatologic Disease Research Core Center [NIH P30AR053495]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR053495, R01AR063663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007223] Funding Source: NIH RePORTER	James Hudson Brown-Alexander Brown Coxe postdoctoral fellowship; National Institute of General Medical Sciences, US National Institutes of Health, Public Health Service; American Skin Association; American Cancer Society(American Cancer Society); Yale Rheumatologic Disease Research Core Center; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to A. Horwich, V. Reinke and A. Giraldez for critical discussion of the work. We thank S. King for feedback on the manuscript, and E. Fuchs for the K14H2BGFP, Lef1RFP and pTREH2BGFP mice and A. Glick for the K5tta mice. P. R. is supported by the James Hudson Brown-Alexander Brown Coxe postdoctoral fellowship. G.Z. is a New York Stem Cell Foundation-Druckenmiller Fellow. E. D. is supported by the Cell and Molecular Biology Training Grant of the National Institute of General Medical Sciences, US National Institutes of Health, Public Health Service. This work was supported in part by the American Skin Association, the American Cancer Society and the Yale Rheumatologic Disease Research Core Center grant NIH P30AR053495.	COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941; Fuchs E, 2009, CELL, V137, P811, DOI 10.1016/j.cell.2009.05.002; Greco V, 2010, DEVELOPMENT, V137, P1585, DOI 10.1242/dev.041103; Greco V, 2009, CELL STEM CELL, V4, P155, DOI 10.1016/j.stem.2008.12.009; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; Lo Celso C, 2009, NATURE, V457, P92, DOI 10.1038/nature07434; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; Petersson M, 2011, EMBO J, V30, P3004, DOI 10.1038/emboj.2011.199; Plikus MV, 2008, NATURE, V451, P340, DOI 10.1038/nature06457; Ra H, 2011, J INVEST DERMATOL, V131, P1061, DOI 10.1038/jid.2010.401; Rendl M, 2005, PLOS BIOL, V3, P1910, DOI 10.1371/journal.pbio.0030331; RUBIN L, 1972, DEV BIOL, V28, P94, DOI 10.1016/0012-1606(72)90129-7; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Uchugonova A, 2011, CELL CYCLE, V10, P2017, DOI 10.4161/cc.10.12.15895; Waghmare SK, 2008, EMBO J, V27, P1309, DOI 10.1038/emboj.2008.72; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; Watt FM, 2009, EMBO MOL MED, V1, P260, DOI 10.1002/emmm.200900033; Xie YC, 2009, NATURE, V457, P97, DOI 10.1038/nature07639; Zhang YV, 2009, CELL STEM CELL, V5, P267, DOI 10.1016/j.stem.2009.06.004	22	240	244	5	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 26	2012	487	7408					496	U1600		10.1038/nature11218	http://dx.doi.org/10.1038/nature11218			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979KD	22763436	Green Accepted, Green Published			2022-12-28	WOS:000306815300041
J	Thompson, MA; Aberg, JA; Hoy, JF; Telenti, A; Benson, C; Cahn, P; Eron, JJ; Gunthard, HF; Hammer, SM; Reiss, P; Richman, DD; Rizzardini, G; Thomas, DL; Jacobsen, DM; Volberding, PA				Thompson, Melanie A.; Aberg, Judith A.; Hoy, Jennifer F.; Telenti, Amalio; Benson, Constance; Cahn, Pedro; Eron, Joseph J., Jr.; Guenthard, Huldrych F.; Hammer, Scott M.; Reiss, Peter; Richman, Douglas D.; Rizzardini, Giuliano; Thomas, David L.; Jacobsen, Donna M.; Volberding, Paul A.			Antiretroviral Treatment of Adult HIV Infection 2012 Recommendations of the International Antiviral Society-USA Panel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							TWICE-DAILY RALTEGRAVIR; CHRONIC KIDNEY-DISEASE; LOW-LEVEL VIREMIA; MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; DOUBLE-BLIND; HEPATITIS-C; VIRUS-INFECTION; PHARMACOKINETIC INTERACTIONS; ABACAVIR-LAMIVUDINE		[Thompson, Melanie A.] AIDS Res Consortium Atlanta, Atlanta, GA 30308 USA; [Aberg, Judith A.] NYU, Sch Med, New York, NY USA; [Hammer, Scott M.] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Hoy, Jennifer F.] Monash Univ, Melbourne, Vic 3004, Australia; [Hoy, Jennifer F.] Alfred Hosp, Melbourne, Vic, Australia; [Telenti, Amalio] Univ Lausanne Hosp, Lausanne, Switzerland; [Benson, Constance; Richman, Douglas D.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; [Richman, Douglas D.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Cahn, Pedro] Univ Buenos Aires, Sch Med, Hosp Juan Fernandez, Buenos Aires, DF, Argentina; [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina; [Eron, Joseph J., Jr.] Univ N Carolina, Chapel Hill, NC USA; [Guenthard, Huldrych F.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Reiss, Peter] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Rizzardini, Giuliano] Osped Luigi Sacco Milano, Milan, Italy; [Thomas, David L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Jacobsen, Donna M.] Int Antiviral Soc USA, San Francisco, CA USA; [Volberding, Paul A.] Univ Calif San Francisco, San Francisco, CA 94143 USA	New York University; Columbia University; Monash University; Florey Institute of Neuroscience & Mental Health; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of Buenos Aires; University of North Carolina; University of North Carolina Chapel Hill; University of Zurich; University Zurich Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Milan; Luigi Sacco Hospital; Johns Hopkins University; University of California System; University of California San Francisco	Thompson, MA (corresponding author), AIDS Res Consortium Atlanta, 131 Ponce de Leon Ave NE,Ste 130, Atlanta, GA 30308 USA.	drmt@mindspring.com	Telenti, Amalio/AAY-1674-2021; gunthard, huldrych f/F-1724-2011; Hoy, Jennifer/AAK-7968-2020	gunthard, huldrych f/0000-0002-1142-6723; Hoy, Jennifer/0000-0002-6948-7086	Boehringer-Ingelheim (BI); Cepheid; GeoVax; Gilead; GlaxoSmithKline (GSK); Kaketsuken; Kowa Research Institute; Merck Research Laboratories; Myriad; Peregrine; Pfizer; Progenics; Roche Molecular Systems; Theratechnologies; Tibotec; Tobira; Viiv Healthcare; MSD; BMS; Abbott; GSK; Janssen-Cilag; Merck; Janssen; IAS-USA; Health Resources and Services Administration (HRSA); National Resource Center of the AIDS Education and Treatment Centers (via funding from HRSA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI050410] Funding Source: NIH RePORTER	Boehringer-Ingelheim (BI)(Boehringer Ingelheim); Cepheid; GeoVax; Gilead(Gilead Sciences); GlaxoSmithKline (GSK)(GlaxoSmithKline); Kaketsuken; Kowa Research Institute; Merck Research Laboratories(Merck & Company); Myriad; Peregrine; Pfizer(Pfizer); Progenics; Roche Molecular Systems; Theratechnologies; Tibotec; Tobira; Viiv Healthcare; MSD; BMS(Bristol-Myers Squibb); Abbott(Abbott Laboratories); GSK(GlaxoSmithKline); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck(Merck & Company); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); IAS-USA; Health Resources and Services Administration (HRSA)(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); National Resource Center of the AIDS Education and Treatment Centers (via funding from HRSA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	All authors have completed and submitted the ICMJE form for Disclosure of Potential Conflicts of Interest). Disclosure information represents the previous 3 years (updated June 14, 2012). Dr Thompson's institution, AIDS Research Consortium of Atlanta, has received research grants from Boehringer-Ingelheim (BI), Cepheid, GeoVax, Gilead, GlaxoSmithKline (GSK), Kaketsuken, Kowa Research Institute, Merck Research Laboratories, Myriad, Panacos (now Myriad), Peregrine, Pfizer, Pharmasset (now Gilead), Progenics, Roche Molecular Systems, Theratechnologies, Tibotec, Tobira, and Viiv Healthcare. She has served as a clinical trial design consultant for Kowa Research Institute and GeoVax. She also has served on data and safety monitoring boards for GSK/ViiV Healthcare and Tibotec. She participated in 1 scientific advisory consultation on PrEP for Gilead. Her spouse is a former employee of Inhibitex. Dr Aberg has been a scientific advisor to Merck, Tibotec, and ViiV Healthcare. She will receive clinical research support awarded to New York University School of Medicine from Kowa Research Institute in 2012. Dr Hoy has served on the advisory boards for Gilead, ViiV Healthcare, Janssen Cilag, and Merck, Sharp & Dohme (MSD). Her institution has received research support from MSD and Gilead and honoraria for speaking or chairing engagements from Gilead and Janssen Cilag. Her spouse has been a medical advisor/consultant for Roche, MSD, Gilead, Bristol-Myers Squibb (BMS), and Janssen Cilag. He has been a paid speaker and has received conference sponsorship from MSD and BMS. Dr Telenti's institution has received honoraria from his serving on data and safety monitoring boards for GSK and consulting for Merck. His institution has received research funds from Gilead. Dr Benson's spouse has served as a consultant to 3-V Biologicals, Gilead, Inhibitex, Johnson & Johnson Services, Laboratory Corp of America, Merck, Santaris Pharma, and Tobira. He has stock options for Achillion. Dr Cahn has served on advisory boards for Avexa, Gilead, GSK, Merck, Pfizer, and Tibotec. He has served an investigator for Abbott, Avexa, BI, Gilead, GSK, Merck, Pfizer, Pharmasset, Roche, and Tibotec and his institution has received honoraria for speaking or chairing engagements from Abbott, BMS, GSK, Merck, Pfizer, and Tibotec. Dr Eron has received research grants to University of North Carolina from BMS, GSK/Viiv Healthcare, Merck, TaiMed Biologics, and Tobira. He has served as an ad hoc consultant to Avexa, Argos, BMS, Chimerix, Gilead, GSK/Viiv Healthcare, Inhibitex, Merck, Myriad, Pfizer, Tibotec, Tobira, and Virco Laboratories. He is a data and safety monitoring board member for Vertex. Dr Gunthard has served as a medical adviser and/or consultant for Abbott, BI, BMS, Gilead, GSK, Janssen-Cilag, Pfizer, Tibotec, and ViiV Healthcare. He has received unrestricted research and educational grants to his institution from Abbott, BMS, Gilead, GSK, Janssen-Cilag, MSD, Pfizer, and Tibotec. Dr Hammer has served as a scientific advisor to Merck, Progenics, and MedImmune and as a member of data monitoring committees for BMS-sponsored clinical trials. Dr Reiss has served as a scientific advisor to BMS, Gilead, Grupo Ferrer, GSK, Janssen, Merck, and Viiv Healthcare. He has served on data and safety monitoring boards and end-point adjudication committees for Janssen and his institution has received honoraria for speaking engagements at scientific conferences from BMS, Gilead, and GSK. He has received research support from Gilead, ViiV Healthcare, Merck, Janssen, BMS, Abbott, and BI.; Dr Richman has been a consultant to Biota, BMS, Chimerix, Gen-Probe, Gilead, Johnson & Johnson, Merck, Monogram Biosciences, and Tobira. He has been the recipient of research grants or contracts from Merck. He has been a stock options holder of Chemerix. Dr Rizzardini has served as a consultant to BMS and on advisory boards of Janssen-Cilag and Gilead Science. His institition has received research support from Gilead, ViiV Healthcare, and Merck. Dr Thomas has received grants and research support from Gilead and Merck and served as a consultant to Merck. Dr Volberding has served on scientific advisory boards for BMS and data and safety monitoring boards for Gilead. No other disclosures were reported.; This work is supported and funded by the IAS-USA, a mission-based, nonmembership, 501(c)(3) not-for-profit organization. The IAS-USA appointed panel members to develop the guidelines and provide staff support. In the last 5 years, IAS-USA has received commercial support (grants) for selected continuing medical education (CME) activities that are pooled (ie, no single company supports any single effort) from Abbott, BI, BMS, Gilead Sciences, GSK, Janssen, Merck, Pfizer, Roche, Tibotec, Vertex, and ViiV Healthcare. The designation of selected CME activities refers to the IAS-USA structure of only accepting commercial support if there are enough companies with competing products to meet the criteria for independence and only on types of programs that are appropriate for support by commercial sources (eg, guidelines are not supported by industry grants). The IAS-USA also receives support from the Health Resources and Services Administration (HRSA) and the National Resource Center of the AIDS Education and Treatment Centers (via funding from HRSA). No private sector or government funding was used to support the effort. Panel members are not compensated for participation in the effort.	Abdool Karim S, 2011, 18 C RETR OPP INF FE; Abrams D, 2009, NEW ENGL J MED, V361, P1548, DOI 10.1056/NEJMoa0903175; [Anonymous], 2011, 6 IAS C HIV PATH TRE; [Anonymous], 2011, 6 IAS C HIV PATH TRE; Bardeguez AD, 2008, JAIDS-J ACQ IMM DEF, V48, P408, DOI 10.1097/QAI.0b013e31817bbe80; Bedimo R, 2012, AIDS, V26, P825, DOI 10.1097/QAD.0b013e32835192ae; Bedimo RJ, 2011, CLIN INFECT DIS, V53, P84, DOI 10.1093/cid/cir269; Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911; Boulanger C, 2009, CLIN INFECT DIS, V49, P1305, DOI 10.1086/606056; Boulle A, 2008, JAMA-J AM MED ASSOC, V300, P530, DOI 10.1001/jama.300.5.530; Brainard DM, 2011, J CLIN PHARMACOL, V51, P943, DOI 10.1177/0091270010375959; Brenner BG, 2011, J INFECT DIS, V204, P1115, DOI 10.1093/infdis/jir468; Byakwaga H, 2011, J INFECT DIS, V204, P1532, DOI 10.1093/infdis/jir559; Cahn P, 2011, AIDS, V25, P929, DOI 10.1097/QAD.0b013e328345ee95; Cain LE, 2011, ANN INTERN MED, V154, P509, DOI 10.7326/0003-4819-154-8-201104190-00001; Canducci F, 2011, J INFECT DIS, V204, P1811, DOI 10.1093/infdis/jir636; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Centers for Disease Control and Prevention (CDC), SEX TRANSM DIS SURV; Choi AI, 2011, AIDS, V25, P1289, DOI 10.1097/QAD.0b013e328347fa16; Clifford DB, 2009, HIV CLIN TRIALS, V10, P343, DOI 10.1310/hct1006-343; Cohen CJ, 2011, LANCET, V378, P229, DOI 10.1016/S0140-6736(11)60983-5; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; d'Arminio Monforte A, 2012, 19 C RETR OPP INF; Daar ES, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-7-201104050-00316; Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068; De Lazzari E, 2008, HIV MED, V9, P221, DOI 10.1111/j.1468-1293.2008.00552.x; Dieterich D, 2012, 19 C RETR OPP INF MA; Doyle T, 2012, CLIN INFECT DIS, V54, P724, DOI 10.1093/cid/cir936; Doyle T, 2012, CURR OPIN INFECT DIS, V25, P17, DOI 10.1097/QCO.0b013e32834ef5d9; Elion R, 2011, AIDS, V25, P1881, DOI 10.1097/QAD.0b013e32834b4d48; Eron JJ, 2011, LANCET INFECT DIS, V11, P895, DOI 10.1016/S1473-3099(11)70286-9; Eron JJ, 2010, LANCET, V375, P396, DOI 10.1016/S0140-6736(09)62041-9; Ford MA, 2012, MONITORING HIV CARE; Frentz D, 2012, AIDS REV, V14, P17; Friedland G, 2006, J ANTIMICROB CHEMOTH, V58, P1299, DOI 10.1093/jac/dkl399; Fulco PP, 2010, ANN PHARMACOTHER, V44, P377, DOI 10.1345/aph.1M370; Funk MJ, 2011, ARCH INTERN MED, V171, P1560, DOI 10.1001/archinternmed.2011.401; Gathe J, 2011, ANTIVIR THER, V16, P759, DOI 10.3851/IMP1803; Geng EH, 2011, CLIN INFECT DIS, V53, P1008, DOI 10.1093/cid/cir608; German P, 2012, 51 INT C ANT AG CHEM; Gianella S, 2011, ANTIVIR THER, V16, P535, DOI 10.3851/IMP1776; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Grijsen ML, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001196; Gupta SK, 2005, CLIN INFECT DIS, V40, P1559, DOI 10.1086/430257; Gutmann C, 2010, AIDS, V24, P2347, DOI 10.1097/QAD.0b013e32833db9a1; Hansen ABE, 2012, AIDS, V26, P285, DOI 10.1097/QAD.0b013e32834ed8a7; Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626; Hatano H, 2011, J INFECT DIS, V203, P960, DOI 10.1093/infdis/jiq138; Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607; Ho JE, 2012, AIDS, V26, P1115, DOI 10.1097/QAD.0b013e328352ce54; Hogan CM, 2012, J INFECT DIS, V205, P87, DOI 10.1093/infdis/jir699; Hollingsworth TD, 2008, J INFECT DIS, V198, P687, DOI 10.1086/590501; Holodniy M, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0025792, 10.1371/journal.pone.0014764]; Hughes JP, 2012, J INFECT DIS, V205, P358, DOI 10.1093/infdis/jir747; Islam FM, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-234; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Jenny-Avital ER, 2009, CLIN INFECT DIS, V48, P1471, DOI 10.1086/598336; Jereb John A., 2011, Morbidity and Mortality Weekly Report, V60, P1650; Joint United Nations Programme on HIV/AIDS, PROGR REP SUMM 2011; Karim SSA, 2011, NEW ENGL J MED, V365, P1492, DOI 10.1056/NEJMoa1014181; Katlama C, 2010, AIDS, V24, P2365, DOI 10.1097/QAD.0b013e32833dec20; Kenedi CA, 2011, AIDS BEHAV, V15, P1803, DOI 10.1007/s10461-011-9939-5; Krentz HB, 2012, ANTIVIR THER; Lambers FAE, 2011, AIDS, V25, pF21, DOI 10.1097/QAD.0b013e32834bac44; Lang S, 2010, ARCH INTERN MED, V170, P1228, DOI 10.1001/archinternmed.2010.197; Lee NM, 2011, GASTROENTEROL CLIN N, V40, P309, DOI 10.1016/j.gtc.2011.03.009; Lescure FX, 2012, NEPHROL DIAL TRANSPL, V27, P2349, DOI 10.1093/ndt/gfr676; Llibre JM, 2011, AIDS, V25, P1683, DOI 10.1097/QAD.0b013e3283499cd9; Lopez-Cortes LF, 2002, CLIN PHARMACOKINET, V41, P681, DOI 10.2165/00003088-200241090-00004; Madruga JV, 2007, LANCET, V370, P49, DOI 10.1016/S0140-6736(07)61049-6; Maggiolo F, 2012, JAIDS-J ACQ IMM DEF, V60, P473, DOI 10.1097/QAI.0b013e3182567a57; Makadzange AT, 2010, CLIN INFECT DIS, V50, P1532, DOI 10.1086/652652; Maman D, 2012, AIDS, V26, P1393, DOI 10.1097/QAD.0b013e328352d054; Martinez E, 2010, AIDS, V24, P1697, DOI 10.1097/QAD.0b013e32833a608a; Marzolini C, 2011, J ANTIMICROB CHEMOTH, V66, P2107, DOI 10.1093/jac/dkr248; Mathis S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022003; Matthews GV, 2011, AIDS, V25, P1727, DOI 10.1097/QAD.0b013e328349bbf3; McComsey GA, 2011, J INFECT DIS, V203, P1791, DOI 10.1093/infdis/jir188; McMahon MA, 2007, NEW ENGL J MED, V356, P2614, DOI 10.1056/NEJMoa067710; Microbicide Trials Network, VOICE STUDY VAGINAL; Mills A, 2011, 51 INT C ANT AG CHEM; Mocroft A, 2010, AIDS, V24, P1667, DOI 10.1097/QAD.0b013e328339fe53; Molina JM, 2012, LANCET INFECT DIS, V12, P27, DOI 10.1016/S1473-3099(11)70249-3; Molina JM, 2011, LANCET, V378, P238, DOI 10.1016/S0140-6736(11)60936-7; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; Naiker S, 2011, 18 C RETR OPP INF FE; National Institute of Allergy and Infectious Diseases, 2012, HIV TREATM STUD PAT; Nikolopoulos GK, 2009, CLIN INFECT DIS, V48, P1763, DOI 10.1086/599110; Parienti JJ, 2009, CLIN INFECT DIS, V48, P484, DOI 10.1086/596482; Politch JA, 2012, AIDS, V26, P1535, DOI 10.1097/QAD.0b013e328353b11b; Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494; Powers KA, 2011, LANCET, V378, P256, DOI 10.1016/S0140-6736(11)60842-8; Qurishi N, 2003, LANCET, V362, P1708, DOI 10.1016/S0140-6736(03)14844-1; Rasmussen TA, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-267; Ribaudo HJ, 2006, ANTIVIR THER, V11, P751; Ribaudo HJ, 2011, CLIN INFECT DIS, V52, P929, DOI 10.1093/cid/ciq244; Rieder P, 2010, AIDS, V24, P1177, DOI 10.1097/QAD.0b013e328338e4de; Rusconi S, 2012, J INT AIDS SOC S4, V13, P044; Sangsari S, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-22; Sax PE, 2012, LANCET, V379, P2439, DOI 10.1016/S0140-6736(12)60917-9; Sax PE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031591; Sayana S, 2011, JAIDS-J ACQ IMM DEF, V56, pE97, DOI 10.1097/QAI.0b013e31820472e8; Scherrer AU, 2011, CLIN INFECT DIS, V53, P1143, DOI 10.1093/cid/cir669; Scherrer AU, 2011, JAIDS-J ACQ IMM DEF, V57, P24, DOI 10.1097/QAI.0b013e318211925e; Scherzer R, 2012, AIDS, V26, P867, DOI 10.1097/QAD.0b013e328351f68f; Schouten JT, 2010, CLIN INFECT DIS, V50, P787, DOI 10.1086/650539; Seaberg EC, 2010, STROKE, V41, P2163, DOI 10.1161/STROKEAHA.110.583856; Seden K, 2011, CURR OPIN HIV AIDS, V6, P514, DOI 10.1097/COH.0b013e32834b54dc; Sekar V, 2011, J CLIN PHARMACOL, V51, P271, DOI 10.1177/0091270010365558; Silverberg MJ, 2011, CANCER EPIDEM BIOMAR, V20, P2551, DOI 10.1158/1055-9965.EPI-11-0777; Smith D. K., 2011, Morbidity and Mortality Weekly Report, V60, P65; Smith KY, 2009, AIDS, V23, P1547, DOI 10.1097/QAD.0b013e32832cbcc2; Soliman EZ, 2011, AIDS, V25, P367, DOI 10.1097/QAD.0b013e328341dcc0; Stellbrink HJ, 2010, CLIN INFECT DIS, V51, P963, DOI 10.1086/656417; Sulkowski M, 2012, 19 C RETR OPP INF MA; Sulkowski MS, 2007, AIDS, V21, P2209, DOI 10.1097/QAD.0b013e3282f10de9; Taiwo B, 2011, J INFECT DIS, V204, P515, DOI 10.1093/infdis/jir353; The Antiretroviral Pregnancy Registry, 2012, ANT PREGN REG INT RE; The White House Office of the Press Secretary, FACT SHEET BEG END A; Thio CL, 2010, ANTIVIR THER, V15, P487, DOI 10.3851/IMP1553; Thompson MA, 2012, ANN INTERN MED, V156, P817, DOI 10.7326/0003-4819-156-11-201206050-00419; Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004; Torok ME, 2011, CLIN INFECT DIS, V52, P1374, DOI 10.1093/cid/cir230; Trottier B, 2010, HIV CLIN TRIALS, V11, P175, DOI 10.1310/hct1104-175; US Food and Drug Administration, 2011, FDA DRUG SAF COMM SA; Valantin MA, 2010, J ANTIMICROB CHEMOTH, V65, P556, DOI 10.1093/jac/dkp462; Van Damme L, 2012, 19 C RETR OPP INF MA; van Lelyveld SFL, 2012, AIDS, V26, P465, DOI 10.1097/QAD.0b013e32834f32f8; Vandekerckhove LPR, 2011, LANCET INFECT DIS, V11, P394, DOI 10.1016/S1473-3099(10)70319-4; Vispo E, 2010, HIV CLIN TRIALS, V11, P197, DOI 10.1310/hct1104-197; von Wyl V, 2012, CLIN INFECT DIS, V54, P131, DOI 10.1093/cid/cir728; von Wyl V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027463; Vrouenraets SME, 2011, HIV MED, V12, P620, DOI 10.1111/j.1468-1293.2011.00941.x; Wandeler G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027903; Wearne N, 2012, NEPHROL DIAL TRANSPL, V27, P4109, DOI 10.1093/ndt/gfr702; Wilby KJ, 2012, ANN HEPATOL, V11, P179, DOI 10.1016/S1665-2681(19)31022-1; Wilkin TJ, 2010, HIV CLIN TRIALS, V11, P351, DOI 10.1310/hct1106-351; Wittkop L, 2011, LANCET INFECT DIS, V11, P363, DOI 10.1016/S1473-3099(11)70032-9; Worm SW, 2010, J INFECT DIS, V201, P318, DOI 10.1086/649897; Yin MT, 2012, J CLIN ENDOCR METAB, V97, P554, DOI 10.1210/jc.2011-2197; Young J, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001194; Young J, 2012, AIDS, V26, P567, DOI 10.1097/QAD.0b013e32834f337c; Zeng M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002437; Zhang J, 2011, J ANTIMICROB CHEMOTH, V66, P2075, DOI 10.1093/jac/dkr266; Zolopa AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005575	145	661	668	0	85	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					387	402		10.1001/jama.2012.7961	http://dx.doi.org/10.1001/jama.2012.7961			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820792				2022-12-28	WOS:000306685500027
J	Heath, GW; Parra, DC; Sarmiento, OL; Andersen, LB; Owen, N; Goenka, S; Montes, F; Brownson, RC				Heath, Gregory W.; Parra, Diana C.; Sarmiento, Olga L.; Andersen, Lars Bo; Owen, Neville; Goenka, Shifalika; Montes, Felipe; Brownson, Ross C.		Lancet Phys Activity Series Workin	Evidence-based intervention in physical activity: lessons from around the world	LANCET			English	Article							MASS-MEDIA CAMPAIGNS; PUBLIC-HEALTH; CARDIORESPIRATORY FITNESS; COST-EFFECTIVENESS; IMPROVING HEALTH; LIFE-STYLE; EXERCISE; SCHOOL; METAANALYSIS; POLICIES	Promotion of physical activity is a priority for health agencies. We searched for reviews of physical activity interventions, published between 2000 and 2011, and identified effective, promising, or emerging interventions from around the world. The informational approaches of community-wide and mass media campaigns, and short physical activity messages targeting key community sites are recommended. Behavioural and social approaches are effective, introducing social support for physical activity within communities and worksites, and school-based strategies that encompass physical education, classroom activities, after-school sports, and active transport. Recommended environmental and policy approaches include creation and improvement of access to places for physical activity with informational outreach activities, community-scale and street-scale urban design and land use, active transport policy and practices, and community-wide policies and planning. Thus, many approaches lead to acceptable increases in physical activity among people of various ages, and from different social groups, countries, and communities.	[Heath, Gregory W.] Univ Tennessee, Coll Med, Chattanooga, TN USA; [Parra, Diana C.; Brownson, Ross C.] Washington Univ, Brown Sch Social Work, Prevent Res Ctr St Louis, St Louis, MO USA; [Parra, Diana C.; Brownson, Ross C.] Washington Univ, Sch Med, Div Publ Hlth Sci, St Louis, MO USA; [Sarmiento, Olga L.] Univ Los Andes, Sch Med, CEIBA Complex Syst Res Ctr, Bogota, Colombia; [Montes, Felipe] Univ Los Andes, CEIBA Complex Syst Res Ctr, Dept Ind Engn, Bogota, Colombia; [Andersen, Lars Bo] Univ So Denmark, Ctr Res Childhood Hlth, Inst Sports Sci & Clin Biomech, Odense, Denmark; [Andersen, Lars Bo] Norwegian Sch Sport Sci, Dept Sports Med, Oslo, Norway; [Owen, Neville] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia; [Owen, Neville] Univ Queensland, Sch Populat Hlth, Canc Prevent Res Ctr, Brisbane, Qld, Australia; [Goenka, Shifalika] Publ Hlth Fdn India, Indian Inst Publ Hlth, Delhi, India	University of Tennessee System; University of Tennessee Health Science Center; Washington University (WUSTL); Washington University (WUSTL); CEIBA; Universidad de los Andes (Colombia); CEIBA; Universidad de los Andes (Colombia); University of Southern Denmark; Norwegian School of Sport Sciences; Baker Heart and Diabetes Institute; University of Queensland; Public Health Foundation of India	Heath, GW (corresponding author), 928 Oak St, Chattanooga, TN 37403 USA.	gregory-heath@utc.edu	Montes, Felipe/AAV-3051-2020; Heath, Gregory Wayne/AAE-2464-2020; Kahlmeier, Sonja/B-8141-2014; Parra, Diana C/B-7761-2015; Lambert, Estelle/ABF-1268-2020; Reis, Rodrigo/F-7447-2012; Parra, Diana C/D-7633-2013; lobelo, felipe/B-9148-2013; Owen, Neville/K-5986-2012; Martin, Brian W/H-3241-2012; Sarmiento, Olga L/AAS-4165-2020; Wells, Jonathan/A-4604-2009; Loos, Ruth/Q-2862-2016; Sallis, James F/D-3001-2014; Katzmarzyk, Peter/N-1974-2017	Montes, Felipe/0000-0002-9923-4004; Heath, Gregory Wayne/0000-0003-2864-5225; Kahlmeier, Sonja/0000-0001-6905-9244; Parra, Diana C/0000-0002-9797-6231; Lambert, Estelle/0000-0003-4315-9153; Reis, Rodrigo/0000-0002-9872-9865; Parra, Diana C/0000-0002-9797-6231; Owen, Neville/0000-0003-2784-4820; Sarmiento, Olga L/0000-0002-9190-3568; Wells, Jonathan/0000-0003-0411-8025; Loos, Ruth/0000-0002-8532-5087; Goenka, Shifalika/0000-0001-6993-2883; Sallis, James F/0000-0003-2555-9452; Guthold, Regina/0000-0003-3073-6468; Katzmarzyk, Peter/0000-0002-9280-6022	MRC [MC_U106188470] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [P50CA095815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK092950] Funding Source: NIH RePORTER; Medical Research Council [MC_U106188470] Funding Source: Medline; NCI NIH HHS [P50 CA095815] Funding Source: Medline; NIDDK NIH HHS [P30 DK092950] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alves Roseane Victor, 2004, Rev Bras Med Esporte, V10, P31, DOI 10.1590/S1517-86922004000100003; [Anonymous], 1988, FUT PUBL HLTH; [Anonymous], 2010, TOR CHART PHYS ACT G; Atkin AJ, 2011, INT J BEHAV MED, V18, P176, DOI 10.1007/s12529-010-9111-z; Baker PRA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008366.pub2; Bauman A.E., 2012, LANCET; Bauman A, 2008, AM J PREV MED, V34, pS249, DOI 10.1016/j.amepre.2008.03.015; Bauman A, 2006, EVAL PROGRAM PLANN, V29, P312, DOI 10.1016/j.evalprogplan.2005.12.004; Beaulieu J, 2002, PUBLIC HEALTH REP, V117, P28, DOI 10.1093/phr/117.1.28; Beets MW, 2009, AM J PREV MED, V36, P527, DOI 10.1016/j.amepre.2009.01.033; Berkowitz JM, 2008, AM J PREV MED, V34, pS257, DOI 10.1016/j.amepre.2008.03.005; Brennan L, 2011, ANNU REV PUBL HEALTH, V32, P199, DOI 10.1146/annurev-publhealth-031210-101206; Brown DR, 2001, PUBLIC HEALTH REP, V116, P197, DOI 10.1093/phr/116.3.197; Brownson RC, 2007, AM J PREV MED, V3, P500; Brownson RC, 2010, J PHYS ACT HEALTH, V7, pS242, DOI 10.1123/jpah.7.s2.s242; Brownson RC, 2009, ANNU REV PUBL HEALTH, V30, P175, DOI 10.1146/annurev.publhealth.031308.100134; Cargo M, 2008, ANNU REV PUBL HEALTH, V29, P325, DOI 10.1146/annurev.publhealth.29.091307.083824; Chief medical officers of England Scotland Wales and Northern Island, 2011, START ACT STAY ACT R; Cohen DA, 2012, HEALTH PLACE, V18, P39, DOI 10.1016/j.healthplace.2011.09.008; Conn VS, 2011, AM J PUBLIC HEALTH, V101, P751, DOI 10.2105/AJPH.2010.194381; Conn VS, 2009, AM J PREV MED, V37, P330, DOI 10.1016/j.amepre.2009.06.008; Conn VS, 2002, ANN BEHAV MED, V24, P190, DOI 10.1207/S15324796ABM2403_04; de Nazelle A, 2011, ENVIRON INT, V37, P766, DOI 10.1016/j.envint.2011.02.003; del Castillo AD, 2011, TRANSL BEHAV MED, V1, P350, DOI 10.1007/s13142-011-0038-y; Dunn AL, 1999, JAMA-J AM MED ASSOC, V281, P327, DOI 10.1001/jama.281.4.327; Eden KB, 2002, ANN INTERN MED, V137, P208, DOI 10.7326/0003-4819-137-3-200208060-00015; European Union Sport and Health Working Group, 2008, EUR UN PHYS ACT GUID; Ferreira M., 2005, Revista Brasileira de Medicina do Esporte, V11, P172, DOI 10.1590/S1517-86922005000300004; Franks Adele L, 2005, Prev Chronic Dis, V2, pA26; Gourlan MJ, 2011, OBES REV, V12, pE633, DOI 10.1111/j.1467-789X.2011.00874.x; Haskell W, 2007, CIRCULATION, V116, P1, DOI DOI 10.1161/CIRCULATIONAHA.107.183534; Heath Gregory W, 2006, J Phys Act Health, V3, pS55, DOI 10.1123/jpah.3.s1.s55; Heath GW, 2009, J PHYS ACT HEALTH, V6, pS159, DOI 10.1123/jpah.6.s2.s159; Hoehner CM, 2008, AM J PREV MED, V34, P224, DOI 10.1016/j.amepre.2007.11.016; Israel B.A., 2005, METHODS COMMUNITY BA, VVol. 3, P3; Jeffery RW, 1998, J CONSULT CLIN PSYCH, V66, P777, DOI 10.1037/0022-006X.66.5.777; Jenkins A, 2009, AM J HEALTH PROMOT, V24, P102, DOI 10.4278/ajhp.0801158; Kahlmeier S, 2010, J PHYS ACT HEALTH, V7, pS120, DOI 10.1123/jpah.7.s1.s120; Kahn EB, 2002, AM J PREV MED, V22, P73, DOI 10.1016/S0749-3797(02)00434-8; Kahn EB, 2005, GUIDE COMMUNITY PREV, P80; Kang M, 2009, RES Q EXERCISE SPORT, V80, P131, DOI 10.1080/02701367.2009.10599546; Kohl HW, 2012, LANCET; Koplan JP, 2005, B WORLD HEALTH ORGAN, V83, P154; Krebs P, 2010, PREV MED, V51, P214, DOI 10.1016/j.ypmed.2010.06.004; Kriemler S, 2011, BRIT J SPORT MED, V45, P923, DOI 10.1136/bjsports-2011-090186; KRISKA AM, 1986, MED SCI SPORT EXER, V18, P557; Lee IM, 2012, LANCET; Lin JS, 2010, BEHAV COUNSELING PRO; LINENGER JM, 1991, AM J PREV MED, V7, P298, DOI 10.1016/S0749-3797(18)30903-6; LOMBARD DN, 1995, HEALTH PSYCHOL, V14, P164, DOI 10.1037/0278-6133.14.2.164; Martins C, 2000, REV BRASILEIRA CIENC, V12, P14; Matsudo Sandra Mahecha, 2006, Promot Educ, V13, P133; Matsudo SM, 2006, PROMOT ED, V13, P158; Matsudo VKR, 2010, MED SCI SPORT EXER, V42, P2231, DOI 10.1249/MSS.0b013e3181e1fe8e; Michie S, 2009, HEALTH PSYCHOL, V28, P690, DOI 10.1037/a0016136; Montes F, 2012, J URBAN HEALTH, V89, P153, DOI 10.1007/s11524-011-9628-8; National Institute for Health and Clinical Excellence, 2008, PROM CREAT BUILT NAT; Nocon M, 2010, SCAND J PUBLIC HEALT, V38, P633, DOI 10.1177/1403494810375865; OWEN N, 1995, AM J PUBLIC HEALTH, V85, P244, DOI 10.2105/AJPH.85.2.244; Pain BM, 2001, REV ATIVIDADE FISICA, V6, P50; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Patrick K, 2009, J PHYS ACT HEALTH, V6, pS211, DOI 10.1123/jpah.6.s2.s211; Pavey TG, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6462; Pearce N, 1996, AM J PUBLIC HEALTH, V86, P678, DOI 10.2105/AJPH.86.5.678; Physical Activity Guidelines Advisory Committee, 2008, PHYS ACT GUID ADV CO; POWELL KE, 1985, PUBLIC HEALTH REP, V100, P118; Pratt M, 2012, LANCET; Reger B, 2002, PREV MED, V35, P285, DOI 10.1006/pmed.2002.1074; Reis RS, 2010, J PHYS ACT HEALTH, V7, pS137, DOI 10.1123/jpah.7.s2.s137; Resaland GK, 2011, SCAND J MED SCI SPOR, V21, P302, DOI 10.1111/j.1600-0838.2009.01028.x; Ribeiro IC, 2010, GLOB HEALTH PROMOT, V17, P5, DOI 10.1177/1757975910365231; Roussos ST, 2000, ANNU REV PUBL HEALTH, V21, P369, DOI 10.1146/annurev.publhealth.21.1.369; Roux L, 2008, AM J PREV MED, V35, P578, DOI 10.1016/j.amepre.2008.06.040; Sallis J.F., 2008, HLTH BEHAV HLTH ED, V4th edition, P465; Sallis JE, 2006, ANNU REV PUBL HEALTH, V27, P297, DOI 10.1146/annurev.publhealth.27.021405.102100; Sallis JF, 2002, AM J PREV MED, V22, P208, DOI 10.1016/S0749-3797(01)00435-4; Sarmiento O, 2010, J PHYS ACT HEALTH, V7, pS163, DOI 10.1123/jpah.7.s2.s163; Saude Md, 2011, SAUDE BRASIL 2010 AN; Sevick MA, 2000, AM J PREV MED, V19, P1, DOI 10.1016/S0749-3797(00)00154-9; Simoes EJ, 2009, AM J PUBLIC HEALTH, V99, P68, DOI 10.2105/AJPH.2008.141978; Soler RE, 2010, AM J PREV MED, V38, pS292, DOI 10.1016/j.amepre.2009.10.028; Summerbell CD, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001871.pub4, 10.1002/14651858.CD001871.pub2]; Trost SG, 2002, MED SCI SPORT EXER, V34, P1996, DOI 10.1097/00005768-200212000-00020; van Sluijs EMF, 2005, AM J PUBLIC HEALTH, V95, P1825, DOI 10.2105/AJPH.2004.044537; van Sluijs EMF, 2007, BMJ-BRIT MED J, V335, P703, DOI 10.1136/bmj.39320.843947.BE; Vandelanotte C, 2007, AM J PREV MED, V33, P54, DOI 10.1016/j.amepre.2007.02.041; Wang GJ, 2004, AM J PUBLIC HEALTH, V94, P549, DOI 10.2105/AJPH.94.4.549; Webb OJ, 2011, J PHYS ACT HEALTH, V8, P558, DOI 10.1123/jpah.8.4.558; WHO, 2010, GLOB REC PHYS ACT HL, V1st, P15; Williams SL, 2011, HEALTH EDUC RES, V26, P308, DOI 10.1093/her/cyr005; Woodcock J, 2009, LANCET, V374, P1930, DOI 10.1016/S0140-6736(09)61714-1; World Health Organization, 2007, GUID POP BAS APPR IN; Yildirim M, 2011, INT J PEDIATR OBES, V6, pE46, DOI 10.3109/17477166.2011.566440; Young DR, 1996, AM J EPIDEMIOL, V144, P264	94	677	697	38	414	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2012	380	9838					272	281		10.1016/S0140-6736(12)60816-2	http://dx.doi.org/10.1016/S0140-6736(12)60816-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976TV	22818939	Green Submitted, Green Accepted, Green Published			2022-12-28	WOS:000306609200036
J	Sen, RJ; Fugmann, SD				Sen, Ranjan; Fugmann, Sebastian D.			Transcription, Splicing, and Release: Are We There Yet?	CELL			English	Editorial Material									[Sen, Ranjan; Fugmann, Sebastian D.] NIA, Lab Mol Biol & Immunol, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sen, RJ (corresponding author), NIA, Lab Mol Biol & Immunol, 251 Bayview Blvd, Baltimore, MD 21224 USA.	ranjan.sen@nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE ON AGING [ZIAAG000387, ZIAAG000383] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bhatt DM, 2012, CELL, V150, P279, DOI 10.1016/j.cell.2012.05.043; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Hargreaves DC, 2009, CELL, V138, P129, DOI 10.1016/j.cell.2009.05.047; Khodor YL, 2011, GENE DEV, V25, P2502, DOI 10.1101/gad.178962.111; Pandya-Jones A, 2009, RNA, V15, P1896, DOI 10.1261/rna.1714509; Rabani M, 2011, NAT BIOTECHNOL, V29, P436, DOI 10.1038/nbt.1861; Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020; Singh J, 2009, NAT STRUCT MOL BIOL, V16, P1128, DOI 10.1038/nsmb.1666	8	2	2	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 20	2012	150	2					241	243		10.1016/j.cell.2012.07.004	http://dx.doi.org/10.1016/j.cell.2012.07.004			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817885	Bronze			2022-12-28	WOS:000306595700002
J	Lobue, PA; Castro, KG				Lobue, Philip A.; Castro, Kenneth G.			Is It Time to Replace the Tuberculin Skin Test With a Blood Test?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GAMMA RELEASE ASSAYS; COST-EFFECTIVENESS; GOLD		[Lobue, Philip A.; Castro, Kenneth G.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Lobue, PA (corresponding author), Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd,Mail Stop E-10, Atlanta, GA 30333 USA.	plobue@cdc.gov	Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354	Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		[Anonymous], 2000, MMWR Recomm Rep, V49, P1; Belknap R, 2010, AM J RESP CRIT CARE, V181; Costa JT, 2011, INT ARCH OCC ENV HEA, V84, P461, DOI 10.1007/s00420-010-0571-x; de Perio MA, 2009, ARCH INTERN MED, V169, P179, DOI 10.1001/archinternmed.2008.524; Gandra S, 2010, INFECT CONT HOSP EP, V31, P1279, DOI 10.1086/657336; Hill AN, 2012, EPIDEMIOL INFECT, V11, P1; Marra F, 2008, INT J TUBERC LUNG D, V12, P1414; Mazurek Gerald H., 2010, Morbidity and Mortality Weekly Report, V59, P1; Pai M, 2008, ANN INTERN MED, V149, P177, DOI 10.7326/0003-4819-149-3-200808050-00241; Rangaka MX, 2012, LANCET INFECT DIS, V12, P45, DOI 10.1016/S1473-3099(11)70210-9	10	19	20	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2012	308	3					241	242		10.1001/jama.2012.7511	http://dx.doi.org/10.1001/jama.2012.7511			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975AC	22797639	Green Accepted			2022-12-28	WOS:000306477900022
J	Habumuremyi, PD; Zenawi, M				Habumuremyi, Pierre Damien; Zenawi, Meles			Making family planning a national development priority	LANCET			English	Editorial Material									[Habumuremyi, Pierre Damien] Govt Rwanda, Off Prime Minister, Kigali, Rwanda; [Zenawi, Meles] Govt Ethiopia, Off Prime Minister Fed Democrat Republ Ethiopia, Addis Ababa, Ethiopia		Habumuremyi, PD (corresponding author), Govt Rwanda, Off Prime Minister, Kigali, Rwanda.							Bloom DE, 2006, FINANC DEV, V43, P8; Bruce J., 2010, PIVOTAL MOMENT POPUL, P260; Central Statistical Agency [Ethiopia] ICF International, 2012, ETH DEM HLTH SURV 20; Cleland J, 2012, LANCET; Guzman J.M., 2009, POPULATION DYNAMICS; Hillebrand E, 2008, WORLD DEV, V36, P727, DOI 10.1016/j.worlddev.2007.05.013; Joshi S., 2007, FAMILY PLANNING INVE; National Institute of Statistics of Rwanda Ministry of Health of Rwanda and ICF International, 2012, RWAND DEM HLTH SURV; Razzaque A, 2005, INT J GYNECOL OBSTET, V89, pS41, DOI 10.1016/j.ijgo.2005.01.003; Singh S, 2012, ADDING IT COSTS BENE; UN-Habitat, 2011, STAT WORLDS CIT 2010; United Nations, 2011, MILL DEV GOALS REP 2; World Health Organization (WHO), 2012, TRENDS MAT MORT 1990	13	22	22	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2012	380	9837					78	80		10.1016/S0140-6736(12)60904-0	http://dx.doi.org/10.1016/S0140-6736(12)60904-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784539				2022-12-28	WOS:000306359100006
J	Jenkins, DL; Davis, LG; Stafford, TW; Campos, PF; Hockett, B; Jones, GT; Cummings, LS; Yost, C; Connolly, TJ; Yohe, RM; Gibbons, SC; Raghavan, M; Rasmussen, M; Paijmans, JLA; Hofreiter, M; Kemp, BM; Barta, JL; Monroe, C; Gilbert, MTP; Willerslev, E				Jenkins, Dennis L.; Davis, Loren G.; Stafford, Thomas W., Jr.; Campos, Paula F.; Hockett, Bryan; Jones, George T.; Cummings, Linda Scott; Yost, Chad; Connolly, Thomas J.; Yohe, Robert M., II; Gibbons, Summer C.; Raghavan, Maanasa; Rasmussen, Morten; Paijmans, Johanna L. A.; Hofreiter, Michael; Kemp, Brian M.; Barta, Jodi Lynn; Monroe, Cara; Gilbert, M. Thomas P.; Willerslev, Eske			Clovis Age Western Stemmed Projectile Points and Human Coprolites at the Paisley Caves	SCIENCE			English	Article							NORTH-AMERICA; TECHNOLOGIES; SITE; DNA; USA	The Paisley Caves in Oregon record the oldest directly dated human remains (DNA) in the Western Hemisphere. More than 100 high-precision radiocarbon dates show that deposits containing artifacts and coprolites ranging in age from 12,450 to 2295 C-14 years ago are well stratified. Western Stemmed projectile points were recovered in deposits dated to 11,070 to 11,340 C-14 years ago, a time contemporaneous with or preceding the Clovis technology. There is no evidence of diagnostic Clovis technology at the site. These two distinct technologies were parallel developments, not the product of a unilinear technological evolution. "Blind testing" analysis of coprolites by an independent laboratory confirms the presence of human DNA in specimens of pre-Clovis age. The colonization of the Americas involved multiple technologically divergent, and possibly genetically divergent, founding groups.	[Jenkins, Dennis L.; Connolly, Thomas J.] Univ Oregon, Museum Nat & Cultural Hist, Eugene, OR 97403 USA; [Davis, Loren G.] Oregon State Univ, Dept Anthropol, Corvallis, OR 97331 USA; [Stafford, Thomas W., Jr.; Campos, Paula F.; Raghavan, Maanasa; Rasmussen, Morten; Gilbert, M. Thomas P.; Willerslev, Eske] Univ Copenhagen, Ctr GeoGenet, DK-1350 Copenhagen, Denmark; [Stafford, Thomas W., Jr.] Stafford Res Labs Inc, Lafayette, CO 80026 USA; [Campos, Paula F.] Univ Coimbra, Museu Ciencia, P-3000272 Coimbra, Portugal; [Hockett, Bryan] Nevada State Off, Bur Land Management, Reno, NV 89502 USA; [Jones, George T.] Hamilton Coll, Dept Anthropol, Clinton, NY 13323 USA; [Cummings, Linda Scott] PaleoRes Inst, Golden, CO 80401 USA; [Yohe, Robert M., II; Gibbons, Summer C.] Calif State Univ, Anthropol Program, Bakersfield, CA 93311 USA; [Paijmans, Johanna L. A.; Hofreiter, Michael] Univ York, Dept Biol, York Y010 5DD, N Yorkshire, England; [Kemp, Brian M.; Barta, Jodi Lynn; Monroe, Cara] Washington State Univ, Dept Anthropol, Pullman, WA 99164 USA; [Kemp, Brian M.; Barta, Jodi Lynn; Monroe, Cara] Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA; [Barta, Jodi Lynn] Madonna Univ, Dept Biol & Hlth Sci, Livonia, MI 48150 USA; [Monroe, Cara] Univ Calif Santa Barbara, Dept Anthropol, Santa Barbara, CA 93106 USA	University of Oregon; Oregon State University; University of Copenhagen; Universidade de Coimbra; Hamilton College; California State University System; California State University Bakersfield; University of York - UK; Washington State University; Washington State University; University of California System; University of California Santa Barbara	Jenkins, DL (corresponding author), Univ Oregon, Museum Nat & Cultural Hist, Eugene, OR 97403 USA.	djenkins@uoregon.edu; ewillerslev@snm.ku.dk	Willerslev, Eske/AAA-5686-2019; Campos, Paula/ABF-9898-2021; Willerslev, Eske/A-9619-2011; Gilbert, Marcus TP/A-8936-2013; Yost, Chad L./J-7156-2019; Campos, Paula F/B-1634-2010; Hofreiter, Michael/A-3996-2017	Willerslev, Eske/0000-0002-7081-6748; Gilbert, Marcus TP/0000-0002-5805-7195; Yost, Chad L./0000-0002-8867-7854; Campos, Paula F/0000-0003-1285-4671; Hofreiter, Michael/0000-0003-0441-4705; Raghavan, Maanasa/0000-0003-1997-0739; Paijmans, Johanna L.A./0000-0002-1938-7052	NSF [0924606]; Danish National Research Foundation; U.S. Bureau of Land Management; archaeological field school, University of Oregon; Museum of Natural and Cultural History, University of Oregon; Keystone Archaeological Research Fund, Oregon State University; Bernice Peltier Huber Charitable Trust; Great Basin Paleoindian Research Unit of the University of Nevada, Reno; Playa Fellowship Residency grants; D. Dana, A. Hurley, S. Kohntopp, R. Engle, Origer Associates Inc.	NSF(National Science Foundation (NSF)); Danish National Research Foundation(Danmarks Grundforskningsfond); U.S. Bureau of Land Management; archaeological field school, University of Oregon; Museum of Natural and Cultural History, University of Oregon; Keystone Archaeological Research Fund, Oregon State University; Bernice Peltier Huber Charitable Trust; Great Basin Paleoindian Research Unit of the University of Nevada, Reno; Playa Fellowship Residency grants; D. Dana, A. Hurley, S. Kohntopp, R. Engle, Origer Associates Inc.	Support for the Paisley Caves Project was provided by NSF grant 0924606; the Danish National Research Foundation; the U.S. Bureau of Land Management; the archaeological field school and the Museum of Natural and Cultural History, University of Oregon; the Keystone Archaeological Research Fund, Oregon State University; the Bernice Peltier Huber Charitable Trust; the Great Basin Paleoindian Research Unit of the University of Nevada, Reno; Playa Fellowship Residency grants; and D. Dana, A. Hurley, S. Kohntopp, R. Engle, Origer Associates Inc., and other private contributors. P. Bauman and Enertek Solutions provided high-tech lighting in the caves in 2011. D. Kennett and B. J. Culletan contributed ultrafiltration and XAD AMS radiocarbon dating of three paleontological and two cordage samples. M. Rondeau analyzed all of the lithic debitage and tools from reliable contexts at the site, verifying Jones' analysis. E. Carlson illustrated the projectile points. T. Goebel, D. Grayson, D. Madsen, and an anonymous individual reviewed drafts of the manuscript. G. McDonald, E. Scott, and E. Davis identified paleontological specimens and consulted us about taxonomy. Paisley Caves archaeological materials are stored at the University of Oregon under accession nos. 1294, 1374, 1704, 1829, 1830, 1895, 1896, and 1961. The 16S rRNA sequences have been deposited in GenBank under accession nos. JQ734469 to JQ734473.	Adovasio J. M., 2004, ENTERING AM NE ASIA; [Anonymous], 2010, INT MONOGRAPHS PREHI; BACON CR, 1983, J VOLCANOL GEOTH RES, V18, P57, DOI 10.1016/0377-0273(83)90004-5; Beck C., 2012, M MARGINS PREHISTORI; Beck C, 2010, AM ANTIQUITY, V75, P81, DOI 10.7183/0002-7316.75.1.81; Bonnichsen R., 2005, ICE AGE PEOPLES N AM; Bryan A., 2005, ICE AGE PEOPLES N AM, P249; Bryan A.L., 1979, NEVADA STATE MUSEUM, V17, P162; Davis L. G., 2012, M MARGINS PREHISTORI; Davis LG, 2004, GEOARCHAEOLOGY, V19, P685, DOI 10.1002/gea.20020; Dillehay TD, 2008, SCIENCE, V320, P784, DOI 10.1126/science.1156533; Erlandson JM, 2011, SCIENCE, V331, P1181, DOI 10.1126/science.1201477; Gilbert MTP, 2009, SCIENCE, V325, P148, DOI 10.1126/science.1168457; Gilbert MTP, 2008, SCIENCE, V320, P786, DOI 10.1126/science.1154116; Goebel Ted., 2007, BAR INT SERIES, P147; Graf K., 2007, PALEOINDIAN PALEOARC; Haile J, 2007, MOL BIOL EVOL, V24, P982, DOI 10.1093/molbev/msm016; Haile J, 2009, P NATL ACAD SCI USA, V106, P22352, DOI 10.1073/pnas.0912510106; Haynes G., 2009, PALEOANTHROPOLOGY, V271, P2009; Haynes G., 2002, EARLY SETTLEMENT N A; Ikawa-Smith F., 2004, ENTERING AM NE ASIA; Jenkins D. L., 2007, PALEOINDIAN PALEOARC; Kelly RL, 2003, QUATERN INT, V109, P133, DOI 10.1016/S1040-6182(02)00209-4; Lepper Bradley T., 2004, NEW PERSPECTIVES 1 A; Meltzer D. J., 2009, 1 PEOPLES NEW WORLD; Poinar H, 2009, SCIENCE, V325, DOI [10.1126/science.1167531, 10.1126/science.1168182]; Waters M.R., 2011, CLOVIS LITHIC TECHNO; Waters MR, 2007, SCIENCE, V315, P1122, DOI 10.1126/science.1137166; Waters MR, 2011, SCIENCE, V334, P351, DOI 10.1126/science.1207663; WILLIAMS JM, 1988, ACCOUNTS CHEM RES, V21, P1, DOI 10.1021/ar00145a001	30	143	146	2	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2012	337	6091					223	+		10.1126/science.1218443	http://dx.doi.org/10.1126/science.1218443			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798611				2022-12-28	WOS:000306323500056
J	Braxton, JM				Braxton, John M.			Make mentorship matter	NATURE			English	Editorial Material									Vanderbilt Univ, Nashville, TN 37203 USA	Vanderbilt University	Braxton, JM (corresponding author), Vanderbilt Univ, Nashville, TN 37203 USA.	john.braxton@vanderbilt.edu							0	3	3	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2012	487	7406					165	166		10.1038/487165a	http://dx.doi.org/10.1038/487165a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	972LP	22785296	Bronze			2022-12-28	WOS:000306278900014
J	Prokopetz, JJZ; Lehmann, LS				Prokopetz, Julian J. Z.; Lehmann, Lisa Soleymani			Redefining Physicians' Role in Assisted Dying	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Prokopetz, Julian J. Z.] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA; [Lehmann, Lisa Soleymani] Brigham & Womens Hosp, Ctr Bioeth, Boston, MA 02115 USA; [Lehmann, Lisa Soleymani] Harvard Univ, Div Med Eth, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Prokopetz, JJZ (corresponding author), Brigham & Womens Hosp, Dept Orthoped Surg, 75 Francis St, Boston, MA 02115 USA.							Curlin FA, 2008, AM J HOSP PALLIAT ME, V25, P112, DOI 10.1177/1049909107310141; Ganzini L, 2009, J PAIN SYMPTOM MANAG, V38, P807, DOI 10.1016/j.jpainsymman.2009.04.026; Lindsay RA, 2009, AM J BIOETHICS, V9, P19, DOI 10.1080/15265160802654137; Smith KA, 2011, J PALLIAT MED, V14, P445, DOI 10.1089/jpm.2010.0425	4	19	21	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2					97	99		10.1056/NEJMp1205283	http://dx.doi.org/10.1056/NEJMp1205283			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972IO	22784111				2022-12-28	WOS:000306270800003
J	Jiang, YW; Jo, AY; Graff, JM				Jiang, Yuwei; Jo, A-Young; Graff, Jonathan M.			SnapShot: Adipocyte Life Cycle	CELL			English	Editorial Material							ADIPOSE-TISSUE; CELLS; WHITE; VASCULATURE; DYNAMICS		[Jiang, Yuwei; Jo, A-Young; Graff, Jonathan M.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Jiang, YW (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK064261, R01DK064261, R01DK088220] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK064261, R01 DK088220, R56 DK064261] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Gupta RK, 2012, CELL METAB, V15, P230, DOI 10.1016/j.cmet.2012.01.010; Hausman D B, 2001, Obes Rev, V2, P239, DOI 10.1046/j.1467-789X.2001.00042.x; Tran KV, 2012, CELL METAB, V15, P222, DOI 10.1016/j.cmet.2012.01.008; Rigamonti A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017637; Rodeheffer MS, 2008, CELL, V135, P240, DOI 10.1016/j.cell.2008.09.036; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232; Tang W, 2011, CELL METAB, V14, P116, DOI 10.1016/j.cmet.2011.05.012	10	19	20	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 6	2012	150	1					234	+		10.1016/j.cell.2012.06.022	http://dx.doi.org/10.1016/j.cell.2012.06.022			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770223	Bronze			2022-12-28	WOS:000306115000021
J	Melis, C; Zuckerman, B; Rhee, JH; Song, I; Murphy, SJ; Bessell, MS				Melis, Carl; Zuckerman, B.; Rhee, Joseph H.; Song, Inseok; Murphy, Simon J.; Bessell, Michael S.			Rapid disappearance of a warm, dusty circumstellar disk	NATURE			English	Article							PLANET; SPECTROGRAPH; COLLISIONS; SYSTEM; STARS; ORBIT; SPEX	Stars form with gaseous and dusty circumstellar envelopes, which rapidly settle into disks that eventually give rise to planetary systems. Understanding the process by which these disks evolve is paramount in developing an accurate theory of planet formation that can account for the variety of planetary systems discovered so far. The formation of Earth-like planets through collisional accumulation of rocky objects within a disk has mainly been explored in theoretical and computational work in which post-collision ejecta evolution typically is ignored(1-3), although recent work has considered the fate of such material(4). Here we report observations of a young, Sun-like star (TYC 8241 2652 1) where infrared flux from post-collisional ejecta has decreased drastically, by a factor of about 30, over a period of less than two years. The star seems to have gone from hosting substantial quantities of dusty ejecta, in a region analogous to where the rocky planets orbit in the Solar System, to retaining at most a meagre amount of cooler dust. Such a phase of rapid ejecta evolution has not been previously predicted or observed, and no currently available physical model satisfactorily explains the observations.	[Melis, Carl] Univ Calif San Diego, Ctr Astrophys & Space Sci, San Diego, CA 92093 USA; [Zuckerman, B.] Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA; [Rhee, Joseph H.] Calif State Polytech Univ Pomona, Dept Phys & Astron, Pomona, CA 91768 USA; [Song, Inseok] Univ Georgia, Dept Phys & Astron, Athens, GA 30602 USA; [Murphy, Simon J.; Bessell, Michael S.] Australian Natl Univ, Coll Math & Phys Sci, Res Sch Astron & Astrophys, Weston, ACT 2611, Australia	University of California System; University of California San Diego; University of California System; University of California Los Angeles; California State University System; California State Polytechnic University Pomona; University System of Georgia; University of Georgia; Australian National University	Melis, C (corresponding author), Univ Calif San Diego, Ctr Astrophys & Space Sci, San Diego, CA 92093 USA.	cmelis@ucsd.edu	Song, Inseok/GSI-5721-2022	Song, Inseok/0000-0002-5815-7372; Murphy, Simon/0000-0002-5648-3107; Bessell, Michael/0000-0001-7801-1410; Murphy, Simon/0000-0003-4932-7699	LLNL Minigrant; US National Science Foundation; NASA; University of Georgia; Direct For Mathematical & Physical Scien [1003318] Funding Source: National Science Foundation	LLNL Minigrant; US National Science Foundation(National Science Foundation (NSF)); NASA(National Aeronautics & Space Administration (NASA)); University of Georgia; Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	We thank J. Kastner for advice regarding X-ray data and M. Jura for suggesting the runaway accretion model. This work was based on observations obtained at the Gemini Observatory and makes use of data products from the Two Micron All Sky Survey and information from the SIMBAD and VizieR databases. C. M. acknowledges support from a LLNL Minigrant to UCLA and from the US National Science Foundation. This work was supported in part by NASA grants to UCLA and the University of Georgia.	Akeson RL, 2007, ASTROPHYS J, V670, P1240, DOI 10.1086/522579; Asphaug E, 2006, NATURE, V439, P155, DOI 10.1038/nature04311; Boley AC, 2012, ASTROPHYS J LETT, V750, DOI 10.1088/2041-8205/750/1/L21; Currie T, 2011, ASTROPHYS J, V734, DOI 10.1088/0004-637X/734/2/115; Cushing MC, 2004, PUBL ASTRON SOC PAC, V116, P362, DOI 10.1086/382907; Grigorieva A, 2007, ASTRON ASTROPHYS, V461, P537, DOI 10.1051/0004-6361:20065210; Hauschildt PH, 1999, ASTROPHYS J, V512, P377, DOI 10.1086/306745; Hog E, 2000, ASTRON ASTROPHYS, V355, pL27; Ishihara D, 2010, ASTRON ASTROPHYS, V514, DOI 10.1051/0004-6361/200913811; Jura M, 2003, ASTROPHYS J, V584, pL91, DOI 10.1086/374036; Kenyon SJ, 2006, ASTRON J, V131, P1837, DOI 10.1086/499807; Lisse CM, 2009, ASTROPHYS J, V701, P2019, DOI 10.1088/0004-637X/701/2/2019; Melis C, 2010, ASTROPHYS J LETT, V717, pL57, DOI 10.1088/2041-8205/717/1/L57; Metzger BD, 2012, MON NOT R ASTRON SOC, V423, P505, DOI 10.1111/j.1365-2966.2012.20895.x; Mouillet D, 1997, MON NOT R ASTRON SOC, V292, P896, DOI 10.1093/mnras/292.4.896; Padgett DL, 1996, ASTROPHYS J, V471, P847, DOI 10.1086/178012; Poglitsch A, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014535; Rayner JT, 2003, PUBL ASTRON SOC PAC, V115, P362, DOI 10.1086/367745; Rhee JH, 2008, ASTROPHYS J, V675, P777, DOI 10.1086/524935; Stewart ST, 2012, ASTROPHYS J, V751, DOI 10.1088/0004-637X/751/1/32; Telesco CM, 1998, P SOC PHOTO-OPT INS, V3354, P534, DOI 10.1117/12.317279; Vacca WD, 2003, PUBL ASTRON SOC PAC, V115, P389, DOI 10.1086/346193; WETHERILL GW, 1990, ANNU REV EARTH PL SC, V18, P205, DOI 10.1146/annurev.ea.18.050190.001225; White RJ, 2003, ASTROPHYS J, V582, P1109, DOI 10.1086/344673; Wright EL, 2010, ASTRON J, V140, P1868, DOI 10.1088/0004-6256/140/6/1868; Zuckerman B, 2012, ASTROPHYS J, V752, DOI 10.1088/0004-637X/752/1/58; Zuckerman B, 2001, ANNU REV ASTRON ASTR, V39, P549, DOI 10.1146/annurev.astro.39.1.549	28	56	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2012	487	7405					74	76		10.1038/nature11210	http://dx.doi.org/10.1038/nature11210			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968LM	22763553	Green Submitted			2022-12-28	WOS:000305982900052
J	Pezzulo, AA; Tang, XX; Hoegger, MJ; Abou Alaiwa, MH; Ramachandran, S; Moninger, TO; Karp, PH; Wohlford-Lenane, CL; Haagsman, HP; van Eijk, M; Banfi, B; Horswill, AR; Stoltz, DA; McCray, PB; Welsh, MJ; Zabner, J				Pezzulo, Alejandro A.; Tang, Xiao Xiao; Hoegger, Mark J.; Abou Alaiwa, Mahmoud H.; Ramachandran, Shyam; Moninger, Thomas O.; Karp, Phillip H.; Wohlford-Lenane, Christine L.; Haagsman, Henk P.; van Eijk, Martin; Banfi, Botond; Horswill, Alexander R.; Stoltz, David A.; McCray, Paul B., Jr.; Welsh, Michael J.; Zabner, Joseph			Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung	NATURE			English	Article							ANTIMICROBIAL PEPTIDES; ANTIBACTERIAL ACTIVITY; BICARBONATE SECRETION; ION COMPOSITION; EPITHELIA; LIQUID; CONDUCTANCE; ABSORPTION; TRANSPORT; MODEL	Cystic fibrosis (CF) is a life-shortening disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene(1). Although bacterial lung infection and the resulting inflammation cause most of the morbidity and mortality, how the loss of CFTR function first disrupts airway host defence has remained uncertain(2-6). To investigate the abnormalities that impair elimination when a bacterium lands on the pristine surface of a newborn CF airway, we interrogated the viability of individual bacteria immobilized on solid grids and placed onto the airway surface. As a model, we studied CF pigs, which spontaneously develop hallmark features of CF lung disease(7,8). At birth, their lungs lack infection and inflammation, but have a reduced ability to eradicate bacteria(8). Here we show that in newborn wild-type pigs, the thin layer of airway surface liquid (ASL) rapidly kills bacteria in vivo, when removed from the lung and in primary epithelial cultures. Lack of CFTR reduces bacterial killing. We found that the ASL pH was more acidic in CF pigs, and reducing pH inhibited the antimicrobial activity of ASL. Reducing ASL pH diminished bacterial killing in wild-type pigs, and, conversely, increasing ASL pH rescued killing in CF pigs. These results directly link the initial host defence defect to the loss of CFTR, an anion channel that facilitates HCO3- transport(9-13). Without CFTR, airway epithelial HCO3- secretion is defective, the ASL pH falls and inhibits antimicrobial function, and thereby impairs the killing of bacteria that enter the newborn lung. These findings suggest that increasing ASL pH might prevent the initial infection in patients with CF, and that assaying bacterial killing could report on the benefit of therapeutic interventions.	[Pezzulo, Alejandro A.; Tang, Xiao Xiao; Hoegger, Mark J.; Abou Alaiwa, Mahmoud H.; Karp, Phillip H.; Banfi, Botond; Stoltz, David A.; Welsh, Michael J.; Zabner, Joseph] Univ Iowa, Dept Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Tang, Xiao Xiao; Karp, Phillip H.; Welsh, Michael J.] Univ Iowa, Howard Hughes Med Inst, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Ramachandran, Shyam; Wohlford-Lenane, Christine L.; McCray, Paul B., Jr.] Univ Iowa, Dept Pediat, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Moninger, Thomas O.] Univ Iowa, Cent Electron Microscopy Facil, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Haagsman, Henk P.; van Eijk, Martin] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, NL-3584 CL Utrecht, Netherlands; [Horswill, Alexander R.] Univ Iowa, Dept Microbiol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Welsh, Michael J.] Univ Iowa, Dept Mol Physiol & Biophys, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA	University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; Utrecht University; University of Iowa; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Dept Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA.	michael-welsh@uiowa.edu; joseph-zabner@uiowa.edu	Hoegger, Mark/K-7926-2019; Haagsman, Henk P/F-8919-2010	Banfi, Botond/0000-0001-9273-1318; Abou Alaiwa, Mahmoud/0000-0003-4525-0217; Stoltz, David/0000-0003-0893-9015; Welsh, Michael/0000-0002-1646-6206; McCray, Paul/0000-0002-4067-577X; Pezzulo, Alejandro/0000-0001-7544-5109; Zabner, Joseph/0000-0002-9606-1339	National Institutes of Health (NIH) [HL51670, HL091842, HL102288]; Cystic Fibrosis Foundation; Gilead Sciences Research Scholars Program in Cystic Fibrosis; Human Frontier Science Program [RGP001612009-C];  [AI076671]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051670, U01HL102288, P01HL091842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI076671, R01AI078921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); Gilead Sciences Research Scholars Program in Cystic Fibrosis; Human Frontier Science Program(Human Frontier Science Program); ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J. Bartlett, X. Chamling, J.-H. Chen, L. Durairaj, N. Gansemer, E. Hornick, P. Hughes, P. Ludwig, T. Mayhew, K. Mohn, L. Ostedgaard, M. Rector, L. Reznikov, L. Schneider, A. Shelton, T. Starner, P. Tan, A. Tucker, A. Walimbe and T. Yahr for assistance and/or discussion. This work was supported by the National Institutes of Health (NIH; HL51670, HL091842, HL102288) and the Cystic Fibrosis Foundation. D. A. S. was supported by AI076671 and Gilead Sciences Research Scholars Program in Cystic Fibrosis. H. P. H. was supported by Program Grant (RGP001612009-C) of the Human Frontier Science Program. M. J. W. is a Howard Hughes Medical Institute investigator.	Blossfeld S, 2007, PLANT CELL ENVIRON, V30, P176, DOI 10.1111/j.1365-3040.2006.01616.x; Chen JH, 2010, CELL, V143, P911, DOI 10.1016/j.cell.2010.11.029; Coakley RD, 2003, P NATL ACAD SCI USA, V100, P16083, DOI 10.1073/pnas.2634339100; Cole AM, 2000, J MICROBIOL METH, V41, P135, DOI 10.1016/S0167-7012(00)00140-8; Do TQ, 2008, J IMMUNOL, V181, P4177, DOI 10.4049/jimmunol.181.6.4177; Fantner GE, 2010, NAT NANOTECHNOL, V5, P280, DOI [10.1038/NNANO.2010.29, 10.1038/nnano.2010.29]; Fischer H, 2006, J MEMBRANE BIOL, V211, P139, DOI 10.1007/s00232-006-0861-0; Foundation C. F., 2010, CYST FIBR FDN PAT RE; Ganz T, 2004, J LEUKOCYTE BIOL, V75, P34, DOI 10.1189/jlb.0403150; Garnett JP, 2011, J BIOL CHEM, V286, P41069, DOI 10.1074/jbc.M111.266734; Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Grubb BR, 1999, PHYSIOL REV, V79, P193; Guggino WB, 1999, CELL, V96, P607, DOI 10.1016/S0092-8674(00)80570-X; Karp Philip H, 2002, Methods Mol Biol, V188, P115; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; Laubel DM, 2006, CURR TOP MICROBIOL, V306, P153; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Machen TE, 2006, AM J PHYSIOL-CELL PH, V291, pC218, DOI 10.1152/ajpcell.00605.2005; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; Quinton PM, 2010, AM J PHYSIOL-CELL PH, V299, pC1222, DOI 10.1152/ajpcell.00362.2010; Rogers CS, 2008, SCIENCE, V321, P1837, DOI 10.1126/science.1163600; Rogers CS, 2008, J CLIN INVEST, V118, P1571, DOI 10.1172/JCI34773; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; Shuba YM, 2008, CELL CALCIUM, V44, P220, DOI 10.1016/j.ceca.2007.12.003; Singer M, 2004, NAT MED, V10, P193, DOI 10.1038/nm983; Singh PK, 2000, AM J PHYSIOL-LUNG C, V279, pL799, DOI 10.1152/ajplung.2000.279.5.L799; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; SMITH JJ, 1992, J CLIN INVEST, V89, P1148, DOI 10.1172/JCI115696; Smith TC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004258; Song YL, 2006, AM J PHYSIOL-CELL PH, V290, pC741, DOI 10.1152/ajpcell.00379.2005; Stoltz DA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000928; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Travis SM, 1999, AM J RESP CELL MOL, V20, P872, DOI 10.1165/ajrcmb.20.5.3572; van Eijk M, 2003, J IMMUNOL, V171, P1431, DOI 10.4049/jimmunol.171.3.1431; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; Wine Jeffrey J, 2004, Proc Am Thorac Soc, V1, P47, DOI 10.1513/pats.2306015; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1	41	569	581	3	143	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2012	487	7405					109	+		10.1038/nature11130	http://dx.doi.org/10.1038/nature11130			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968LM	22763554	Green Accepted			2022-12-28	WOS:000305982900060
J	Tavare, A				Tavare, Aniket			Where are we with transparency over performance of doctors and institutions?	BRITISH MEDICAL JOURNAL			English	Editorial Material							COLORECTAL SURGERY; QUALITY		BMJ, London WC1H 9JR, England		Tavare, A (corresponding author), BMJ, London WC1H 9JR, England.	ATavare@bmj.com						[Anonymous], 2011, FOSTER INTELLIGENCE, P5; Black N, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2066; Bridgewater B, 2010, 4 EACTS ADULT CARDIA; Bridgewater B, 2011, MAINTAINING PATIENTS; Burns EM, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4836; Burns EM, J PUBLIC HLTH, V34, P138; Department of Health, 2012, POW INF PUTT ALL US; Diabetes UK, 2012, STAT NAT 2012; Gleave R, 2012, GUARDIAN        0404; Hall C, 2002, TELEGRAPH       0118; Hawkes N, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2153; Kennedy SI, 2001, 5207 DH; Keogh BE, 1998, BMJ-BRIT MED J, V316, P1759, DOI 10.1136/bmj.316.7147.1759; Keogh BE, 2008, PRESIDENTIAL ADDRESS; King's Fund, 2011, IMPR QUAL CAR GEN PR; King's Fund, 2010, GETT MEAS QUAL OPP C; LANSLEY A, 2010, COMMUNICATION   0608; NHS, 2011, ATL VAR 2011; O'Dowd A, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3988; Renal Association UK, 2010, 13 REN ASS UK; Scott N, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5947; Society of Cardiothoracic Surgeons, HEART SURG UK	22	17	17	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 3	2012	344								e4464	10.1136/bmj.e4464	http://dx.doi.org/10.1136/bmj.e4464			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972KA	22761095				2022-12-28	WOS:000306274800023
J	Korin, N; Kanapathipillai, M; Matthews, BD; Crescente, M; Brill, A; Mammoto, T; Ghosh, K; Jurek, S; Bencherif, SA; Bhatta, D; Coskun, AU; Feldman, CL; Wagner, DD; Ingber, DE				Korin, Netanel; Kanapathipillai, Mathumai; Matthews, Benjamin D.; Crescente, Marilena; Brill, Alexander; Mammoto, Tadanori; Ghosh, Kaustabh; Jurek, Samuel; Bencherif, Sidi A.; Bhatta, Deen; Coskun, Ahmet U.; Feldman, Charles L.; Wagner, Denisa D.; Ingber, Donald E.			Shear-Activated Nanotherapeutics for Drug Targeting to Obstructed Blood Vessels	SCIENCE			English	Article							VON-WILLEBRAND-FACTOR; PLATELET-AGGREGATION; WALL SHEAR; NANOPARTICLES; FIBRINOLYSIS; STABILITY; ADHESION; PLGA; MICE	Obstruction of critical blood vessels due to thrombosis or embolism is a leading cause of death worldwide. Here, we describe a biomimetic strategy that uses high shear stress caused by vascular narrowing as a targeting mechanism-in the same way platelets do-to deliver drugs to obstructed blood vessels. Microscale aggregates of nanoparticles were fabricated to break up into nanoscale components when exposed to abnormally high fluid shear stress. When coated with tissue plasminogen activator and administered intravenously in mice, these shear-activated nanotherapeutics induce rapid clot dissolution in a mesenteric injury model, restore normal flow dynamics, and increase survival in an otherwise fatal mouse pulmonary embolism model. This biophysical strategy for drug targeting, which lowers required doses and minimizes side effects while maximizing drug efficacy, offers a potential new approach for treatment of life-threatening diseases that result from acute vascular occlusion.	[Korin, Netanel; Kanapathipillai, Mathumai; Bencherif, Sidi A.; Ingber, Donald E.] Harvard Univ, Wyss Inst Biologically Inspired Engn, Boston, MA 02115 USA; [Matthews, Benjamin D.; Mammoto, Tadanori; Ghosh, Kaustabh; Jurek, Samuel; Ingber, Donald E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program,Dept Pathol, Boston, MA 02115 USA; [Matthews, Benjamin D.; Mammoto, Tadanori; Ghosh, Kaustabh; Jurek, Samuel; Ingber, Donald E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Surg, Boston, MA 02115 USA; [Matthews, Benjamin D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Med, Boston, MA 02115 USA; [Crescente, Marilena; Brill, Alexander; Wagner, Denisa D.] Childrens Hosp Boston, Program Cellular & Mol Med, Immune Dis Inst, Boston, MA 02115 USA; [Crescente, Marilena; Brill, Alexander; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Bencherif, Sidi A.; Bhatta, Deen; Ingber, Donald E.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Coskun, Ahmet U.] Northeastern Univ, Boston, MA 02115 USA; [Feldman, Charles L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School; Harvard University; Northeastern University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ingber, DE (corresponding author), Harvard Univ, Wyss Inst Biologically Inspired Engn, Boston, MA 02115 USA.	don.ingber@wyss.harvard.edu	Ingber, Donald E/AAC-5894-2019; Brill, Alexander/L-7587-2018	Brill, Alexander/0000-0002-4558-0390; Korin, Netanel/0000-0001-7244-889X; BENCHERIF, SIDI/0000-0002-7704-5608; Crescente, Marilena/0000-0003-3164-512X	U.S. Department of Defense [BC074986]; Novartis Pharmaceuticals; Boston Scientific; Wyss Institute for Biologically Inspired Engineering at Harvard University; Wyss Technology Development Fellowship	U.S. Department of Defense(United States Department of Defense); Novartis Pharmaceuticals(Novartis); Boston Scientific(Boston Scientific); Wyss Institute for Biologically Inspired Engineering at Harvard University; Wyss Technology Development Fellowship	We thank D. Huh, K. Roberts, and R. F. Valentini for helpful comments and K. Johnson and D. Stanton for help with the graphics. This work was supported by a U.S. Department of Defense Breast Cancer Innovator award BC074986 (to D. E. I.), grants from Novartis Pharmaceuticals and Boston Scientific (to C. L. F. and A. U. C.), and the Wyss Institute for Biologically Inspired Engineering at Harvard University. N.K. is a recipient of a Wyss Technology Development Fellowship. Harvard University and the authors (D. E. I., N.K., M.K.) have filed two patents related to this work: (i) Shear-Activated Nanotherapeutics for Drug Targeting (patent application pending) and (ii) Shear Controlled Release for Stenotic Lesions and Thrombolytic Therapies (patent application pending WO 2012/074588).	Bark DL, 2010, J BIOMECH, V43, P2970, DOI 10.1016/j.jbiomech.2010.07.011; Bergmeier W, 2006, P NATL ACAD SCI USA, V103, P16900, DOI 10.1073/pnas.0608207103; Chauhan AK, 2006, J EXP MED, V203, P767, DOI 10.1084/jem.20051732; Danielyan K, 2008, CIRCULATION, V118, P1442, DOI 10.1161/CIRCULATIONAHA.107.750257; Di Marco M, 2010, INT J NANOMED, V5, P37; Frenette PS, 1998, BLOOD, V91, P1318, DOI 10.1182/blood.V91.4.1318; Ganguly K, 2006, J PHARMACOL EXP THER, V316, P1130, DOI 10.1124/jpet.105.093450; Goto S, 1999, CIRCULATION, V99, P608, DOI 10.1161/01.CIR.99.5.608; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; Ingall TJ, 2004, STROKE, V35, P2418, DOI 10.1161/01.STR.0000140891.70547.56; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; Murciano JC, 2003, NAT BIOTECHNOL, V21, P891, DOI 10.1038/nbt846; Murciano JC, 2002, AM J PHYSIOL-LUNG C, V282, pL529, DOI 10.1152/ajplung.00112.2001; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nesbitt WS, 2009, NAT MED, V15, P665, DOI 10.1038/nm.1955; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; Rana S, 2010, CURR OPIN CHEM BIOL, V14, P828, DOI 10.1016/j.cbpa.2010.10.001; Ruggeri ZM, 2006, BLOOD, V108, P1903, DOI 10.1182/blood-2006-04-011551; Santander-Ortega MJ, 2007, COLLOID SURFACE A, V296, P132, DOI 10.1016/j.colsurfa.2006.09.036; Santander-Ortega MJ, 2006, J COLLOID INTERF SCI, V302, P522, DOI 10.1016/j.jcis.2006.07.031; SIEGEL JM, 1994, J BIOMECH ENG-T ASME, V116, P446, DOI 10.1115/1.2895795; Straub JA, 2007, INT J PHARM, V328, P35, DOI 10.1016/j.ijpharm.2006.07.052; STRONY J, 1993, AM J PHYSIOL, V265, pH1787; Wechsler LR, 2011, NEW ENGL J MED, V364, P2138, DOI 10.1056/NEJMct1007370; Wootton DM, 1999, ANNU REV BIOMED ENG, V1, P299, DOI 10.1146/annurev.bioeng.1.1.299	25	344	362	15	373	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 10	2012	337	6095					738	742		10.1126/science.1217815	http://dx.doi.org/10.1126/science.1217815			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986PE	22767894				2022-12-28	WOS:000307354500056
J	D'Hont, A; Denoeud, F; Aury, JM; Baurens, FC; Carreel, F; Garsmeur, O; Noel, B; Bocs, S; Droc, G; Rouard, M; Da Silva, C; Jabbari, K; Cardi, C; Poulain, J; Souquet, M; Labadie, K; Jourda, C; Lengelle, J; Rodier-Goud, M; Alberti, A; Bernard, M; Correa, M; Ayyampalayam, S; Mckain, MR; Leebens-Mack, J; Burgess, D; Freeling, M; Mbeguie-A-Mbeguie, D; Chabannes, M; Wicker, T; Panaud, O; Barbosa, J; Hribova, E; Heslop-Harrison, P; Habas, R; Rivallan, R; Francois, P; Poiron, C; Kilian, A; Burthia, D; Jenny, C; Bakry, F; Brown, S; Guignon, V; Kema, G; Dita, M; Waalwijk, C; Joseph, S; Dievart, A; Jaillon, O; Leclercq, J; Argout, X; Lyons, E; Almeida, A; Jeridi, M; Dolezel, J; Roux, N; Risterucci, AM; Weissenbach, J; Ruiz, M; Glaszmann, JC; Quetier, F; Yahiaoui, N; Wincker, P				D'Hont, Angelique; Denoeud, France; Aury, Jean-Marc; Baurens, Franc-Christophe; Carreel, Francoise; Garsmeur, Olivier; Noel, Benjamin; Bocs, Stephanie; Droc, Gaetan; Rouard, Mathieu; Da Silva, Corinne; Jabbari, Kamel; Cardi, Celine; Poulain, Julie; Souquet, Marlene; Labadie, Karine; Jourda, Cyril; Lengelle, Juliette; Rodier-Goud, Marguerite; Alberti, Adriana; Bernard, Maria; Correa, Margot; Ayyampalayam, Saravanaraj; Mckain, Michael R.; Leebens-Mack, Jim; Burgess, Diane; Freeling, Mike; Mbeguie-A-Mbeguie, Didier; Chabannes, Matthieu; Wicker, Thomas; Panaud, Olivier; Barbosa, Jose; Hribova, Eva; Heslop-Harrison, Pat; Habas, Remy; Rivallan, Ronan; Francois, Philippe; Poiron, Claire; Kilian, Andrzej; Burthia, Dheema; Jenny, Christophe; Bakry, Frederic; Brown, Spencer; Guignon, Valentin; Kema, Gert; Dita, Miguel; Waalwijk, Cees; Joseph, Steeve; Dievart, Anne; Jaillon, Olivier; Leclercq, Julie; Argout, Xavier; Lyons, Eric; Almeida, Ana; Jeridi, Mouna; Dolezel, Jaroslav; Roux, Nicolas; Risterucci, Ange-Marie; Weissenbach, Jean; Ruiz, Manuel; Glaszmann, Jean-Christophe; Quetier, Francis; Yahiaoui, Nabila; Wincker, Patrick			The banana (Musa acuminata) genome and the evolution of monocotyledonous plants	NATURE			English	Article							DIFFERENTIAL EXPRESSION; DNA-SEQUENCES; GENE; DIVERSIFICATION; IDENTIFICATION; RESOURCE; RICE; POLYPLOIDY; ALIGNMENT; BALANCE	Bananas (Musa spp.), including dessert and cooking types, are giant perennial monocotyledonous herbs of the order Zingiberales, a sister group to the well-studied Poales, which include cereals. Bananas are vital for food security in many tropical and subtropical countries and the most popular fruit in industrialized countries(1). The Musa domestication process started some 7,000 years ago in Southeast Asia. It involved hybridizations between diverse species and subspecies, fostered by human migrations(2), and selection of diploid and triploid seedless, parthenocarpic hybrids thereafter widely dispersed by vegetative propagation. Half of the current production relies on somaclones derived from a single triploid genotype (Cavendish)(1). Pests and diseases have gradually become adapted, representing an imminent danger for global banana production(3,4). Here we describe the draft sequence of the 523-megabase genome of a Musa acuminata doubled-haploid genotype, providing a crucial stepping-stone for genetic improvement of banana. We detected three rounds of whole-genome duplications in the Musa lineage, independently of those previously described in the Poales lineage and the one we detected in the Arecales lineage. This first monocotyledon high-continuity whole-genome sequence reported outside Poales represents an essential bridge for comparative genome analysis in plants. As such, it clarifies commelinid-monocotyledon phylogenetic relationships, reveals Poaceae-specific features and has led to the discovery of conserved noncoding sequences predating monocotyledon-eudicotyledon divergence.	[D'Hont, Angelique; Baurens, Franc-Christophe; Carreel, Francoise; Garsmeur, Olivier; Bocs, Stephanie; Droc, Gaetan; Cardi, Celine; Souquet, Marlene; Jourda, Cyril; Lengelle, Juliette; Rodier-Goud, Marguerite; Rivallan, Ronan; Francois, Philippe; Poiron, Claire; Burthia, Dheema; Jenny, Christophe; Bakry, Frederic; Guignon, Valentin; Joseph, Steeve; Dievart, Anne; Leclercq, Julie; Argout, Xavier; Jeridi, Mouna; Risterucci, Ange-Marie; Ruiz, Manuel; Glaszmann, Jean-Christophe; Yahiaoui, Nabila] Ctr Cooperat Int Rech Agron Dev CIRAD, UMR AGAP, F-34398 Montpellier, France; [Denoeud, France; Aury, Jean-Marc; Noel, Benjamin; Da Silva, Corinne; Jabbari, Kamel; Poulain, Julie; Labadie, Karine; Alberti, Adriana; Bernard, Maria; Correa, Margot; Jaillon, Olivier; Weissenbach, Jean; Wincker, Patrick] CEA, IG, F-91057 Evry, France; [Denoeud, France; Jabbari, Kamel; Jaillon, Olivier; Weissenbach, Jean; Wincker, Patrick] CNRS, UMR 8030, Evry, France; [Denoeud, France; Jabbari, Kamel; Jaillon, Olivier; Weissenbach, Jean; Wincker, Patrick] Univ Evry, UMR 8030, Evry, France; [Carreel, Francoise; Chabannes, Matthieu; Habas, Remy] CIRAD, UMR BGPI, F-34398 Montpellier, France; [Rouard, Mathieu; Guignon, Valentin; Roux, Nicolas] Biovers Int, F-34397 Montpellier 5, France; [Ayyampalayam, Saravanaraj; Mckain, Michael R.; Leebens-Mack, Jim] Univ Georgia, Dept Plant Biol, Athens, GA 30602 USA; [Burgess, Diane; Freeling, Mike; Almeida, Ana] Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; [Mbeguie-A-Mbeguie, Didier] CIRAD, UMR QUALISUD Stn Neufchateau, F-97130 Capesterre Belle Eau, France; [Wicker, Thomas] Univ Zurich, Inst Plant Biol, CH-8008 Zurich, Switzerland; [Panaud, Olivier; Barbosa, Jose] UMR 5096 CNRS UPVD, Lab Genome & Dev Plantes, F-66000 Perpignan, France; [Hribova, Eva] Ctr Reg Hana Biotechnol & Agr Res, Inst Expt Bot, CZ-77200 Olomouc, Czech Republic; [Heslop-Harrison, Pat] Univ Leicester, Dept Biol, Leicester LE1 7RH, Leics, England; [Kilian, Andrzej] Divers Arrays Technol, Yarralumla, ACT 2600, Australia; [Brown, Spencer] CNRS, UPR 2355, Inst Sci Vegetal, F-91198 Gif Sur Yvette, France; [Brown, Spencer] FRC3115, F-91198 Gif Sur Yvette, France; [Guignon, Valentin; Kema, Gert; Waalwijk, Cees] Univ Wageningen, Plant Res Int, NL-6700 AA Wageningen, Netherlands; [Lyons, Eric] Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA; [Quetier, Francis] Univ Evry Val dEssonne, Dept Biol, Evry, France; [Dita, Miguel] Brazilian Agr Res Corp EMBRAPA, Embrapa Cassava & Fruits, BR-44380000 Salvador, BA, Brazil	CIRAD; Universite de Montpellier; CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA; CIRAD; Alliance; Bioversity International; University System of Georgia; University of Georgia; University of California System; University of California Berkeley; CIRAD; University of Zurich; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite Perpignan Via Domitia; Czech Academy of Sciences; Institute of Experimental Botany of the Czech Academy of Sciences; University of Leicester; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Wageningen University & Research; University of Arizona; UDICE-French Research Universities; Universite Paris Saclay; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA)	D'Hont, A (corresponding author), Ctr Cooperat Int Rech Agron Dev CIRAD, UMR AGAP, F-34398 Montpellier, France.	angelique.d'hont@cirad.fr; pwincker@genoscope.cns.fr	DHONT, Angélique/AAL-8074-2021; Aury, Jean-Marc/N-1621-2019; Leclercq, Julie/B-2147-2012; Chabannes, Matthieu/AAR-7769-2021; Jaillon, Olivier/GRY-6287-2022; MBEGUIE-A-MBEGUIE, Didier/C-8641-2009; Alberti, Adriana/AAZ-2013-2021; Rouard, Mathieu/H-5035-2017; Waalwijk, Cees/X-9439-2019; Labadie, Karine/AAG-7355-2022; Labadie, Karine/AFL-7408-2022; Wicker, Thomas/Z-1978-2019; Heslop-Harrison, JS/C-9207-2009; Dolezel, Jaroslav/B-7716-2008; hribova, eva/F-7291-2014; Leebens-Mack, James/AAF-6770-2019; BROWN, Spencer/B-6878-2014; Rodriguez, Miguel Angel Dita/O-6120-2014; BAURENS, Franc-Christophe/ABC-7226-2021; Gaetan, DROC/AAH-2616-2021; BAKRY, Frédéric/I-4857-2012; Poiron, Claire/M-7895-2015; Alberti, Adriana/E-7142-2017; Heslop-Harrison, J.S./M-9826-2019; Roux, Nicolas/ABG-4156-2020; Quetier, Francis/J-7923-2017	Aury, Jean-Marc/0000-0003-1718-3010; Alberti, Adriana/0000-0003-3372-9423; Rouard, Mathieu/0000-0003-0284-1885; Waalwijk, Cees/0000-0001-5367-2108; Labadie, Karine/0000-0001-7467-8509; Labadie, Karine/0000-0001-7467-8509; Heslop-Harrison, JS/0000-0002-3105-2167; Dolezel, Jaroslav/0000-0002-6263-0492; Leebens-Mack, James/0000-0003-4811-2231; Rodriguez, Miguel Angel Dita/0000-0002-0496-4267; BAURENS, Franc-Christophe/0000-0002-5219-8771; Gaetan, DROC/0000-0003-1849-1269; Poiron, Claire/0000-0002-3995-1343; Alberti, Adriana/0000-0003-3372-9423; Heslop-Harrison, J.S./0000-0002-3105-2167; Argout, Xavier/0000-0002-0100-5511; Hribova, Eva/0000-0002-6868-4344; Jaillon, Olivier/0000-0002-7237-9596; Kema, Gerrit HJ/0000-0002-2732-6911; Noel, Benjamin/0000-0002-5830-3253; Quetier, Francis/0000-0003-4388-9287; Jenny, Christophe/0000-0001-6165-6888; Guignon, Valentin/0000-0003-0903-6811; Ruiz, Manuel/0000-0001-8153-276X; Dievart, Anne/0000-0001-9460-4638; Poulain, Julie/0000-0002-8744-3116; DA SILVA, Corinne/0000-0002-7618-7831; , Thomas/0000-0002-6777-7135; Denoeud, France/0000-0001-8819-7634; Jourda, Cyril/0000-0002-7799-3501; Leclercq, Julie/0000-0001-8110-3762; Kilian, Andrzej/0000-0002-2730-7462; Chabannes, Matthieu/0000-0001-5754-5982	French National Research Agency; Commissariat a l'Energie Atomique; Centre de cooperation Internationale en Recherche Agronomique pour le Developpement; Direct For Biological Sciences [0830009] Funding Source: National Science Foundation; Division Of Environmental Biology [0841988] Funding Source: National Science Foundation; Division Of Integrative Organismal Systems [0922742] Funding Source: National Science Foundation; Div Of Molecular and Cellular Bioscience [0820821] Funding Source: National Science Foundation	French National Research Agency(French National Research Agency (ANR)); Commissariat a l'Energie Atomique(French Atomic Energy Commission); Centre de cooperation Internationale en Recherche Agronomique pour le Developpement; Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO)); Division Of Environmental Biology(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO)); Division Of Integrative Organismal Systems(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO)); Div Of Molecular and Cellular Bioscience(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	This work was mainly supported by French National Research Agency, Commissariat a l'Energie Atomique and Centre de cooperation Internationale en Recherche Agronomique pour le Developpement. The Generation Challenge program supported DArT genotyping, and Stichting Het Groene Woudt part of BAC-end sequencing. We thank M. Teixeira Souza for authorizing early access to BAC-End sequences, L. Baudouin and T. Hardcastle for their help with the Bayseq analysis, O. Inizan, T. Flutre and F. Choulet for their help in transposable-element mapping. We thank the SouthGreen Bioinformatics Platform (http://southgreen.cirad.fr) for providing us with computational resources. We thank D. Manley for his help with the English in this paper.	Al-Dous EK, 2011, NAT BIOTECHNOL, V29, P521, DOI 10.1038/nbt.1860; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Argout X, 2011, NAT GENET, V43, P101, DOI 10.1038/ng.736; Aury JM, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-603; Bairoch A, 2005, NUCLEIC ACIDS RES, V33, pD154, DOI 10.1093/nar/gki070; Bakry F, 2008, FRUITS, V63, P45, DOI 10.1051/fruits:2007044; Birchler JA, 2005, TRENDS GENET, V21, P219, DOI 10.1016/j.tig.2005.02.010; Birney E, 2004, GENOME RES, V14, P988, DOI 10.1101/gr.1865504; Carels N, 2000, GENETICS, V154, P1819; Cuperus JT, 2011, PLANT CELL, V23, P431, DOI 10.1105/tpc.110.082784; D'Hont A, 2000, THEOR APPL GENET, V100, P177, DOI 10.1007/s001220050024; de Bellaire LD, 2010, FRUITS, V65, P327, DOI 10.1051/fruits/2010034; Denoeud F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r175; Dita MA, 2010, PLANT PATHOL, V59, P348, DOI 10.1111/j.1365-3059.2009.02221.x; Fils-Lycaon B, 2011, SCI HORTIC-AMSTERDAM, V129, P197, DOI 10.1016/j.scienta.2011.03.029; Flutre T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016526; Freeling M, 2009, CURR OPIN PLANT BIOL, V12, P126, DOI 10.1016/j.pbi.2009.01.005; Gayral P, 2009, J MOL EVOL, V69, P65, DOI 10.1007/s00239-009-9253-2; Givnish TJ, 2010, ANN MO BOT GARD, V97, P584, DOI 10.3417/2010023; Glemet E, 1997, COMPUT APPL BIOSCI, V13, P137; Hardcastle TJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-422; Howe KL, 2002, GENOME RES, V12, P1418, DOI 10.1101/gr.149502; Iskra-Caruana ML, 2010, MOL PLANT MICROBE IN, V23, P1394, DOI 10.1094/MPMI-05-10-0107; Jeridi M, 2011, ANN BOT-LONDON, V108, P975, DOI 10.1093/aob/mcr207; Jiao YN, 2011, NATURE, V473, P97, DOI 10.1038/nature09916; Katoh K, 2009, METHODS MOL BIOL, V537, P39, DOI 10.1007/978-1-59745-251-9_3; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Korf I, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-59; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lescot M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-58; Lescot T., 2011, FRUITROP, V189, P58; Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503; Lyons E, 2008, PLANT J, V53, P661, DOI 10.1111/j.1365-313X.2007.03326.x; Ma JX, 2004, GENOME RES, V14, P860, DOI 10.1101/gr.1466204; Magallon S, 2009, AM J BOT, V96, P349, DOI 10.3732/ajb.0800060; MARIE D, 1993, BIOL CELL, V78, P41, DOI 10.1016/0248-4900(93)90113-S; Mott R, 1997, COMPUT APPL BIOSCI, V13, P477; Ouyang S, 2007, NUCLEIC ACIDS RES, V35, pD883, DOI 10.1093/nar/gkl976; Parra G, 2000, GENOME RES, V10, P511, DOI 10.1101/gr.10.4.511; Paterson AH, 2004, CURR OPIN BIOTECH, V15, P120, DOI 10.1016/j.copbio.2004.03.001; Paterson AH, 2009, NATURE, V457, P551, DOI 10.1038/nature07723; Perrier X, 2011, P NATL ACAD SCI USA, V108, P11311, DOI 10.1073/pnas.1102001108; Piffanelli P, 2008, FRUITS, V63, P375, DOI 10.1051/fruits:2008037; Poland JA, 2011, P NATL ACAD SCI USA, V108, P6893, DOI 10.1073/pnas.1010894108; Raboin LM, 2005, MOL BREEDING, V16, P333, DOI 10.1007/s11032-005-2452-7; Rouard M, 2011, NUCLEIC ACIDS RES, V39, pD1095, DOI 10.1093/nar/gkq811; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; Salse J, 2008, PLANT CELL, V20, P11, DOI 10.1105/tpc.107.056309; Schnable JC, 2011, P NATL ACAD SCI USA, V108, P4069, DOI 10.1073/pnas.1101368108; Simmonds N. W., 1962, EVOLUTION BANANAS, P101; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Suyama M, 2006, NUCLEIC ACIDS RES, V34, pW609, DOI 10.1093/nar/gkl315; Tang HB, 2010, P NATL ACAD SCI USA, V107, P472, DOI 10.1073/pnas.0908007107; Van de Peer Y, 2009, TRENDS PLANT SCI, V14, P680, DOI 10.1016/j.tplants.2009.09.001; Veitia RA, 2008, TRENDS GENET, V24, P390, DOI 10.1016/j.tig.2008.05.005; Wall PK, 2008, NUCLEIC ACIDS RES, V36, pD970, DOI 10.1093/nar/gkm972; Woodhouse MR, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000409; Woolfe A, 2005, PLOS BIOL, V3, P116, DOI 10.1371/journal.pbio.0030007; Yang ZH, 2007, MOL BIOL EVOL, V24, P1586, DOI 10.1093/molbev/msm088	61	704	733	17	362	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 9	2012	488	7410					213	+		10.1038/nature11241	http://dx.doi.org/10.1038/nature11241			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	985LE	22801500	hybrid			2022-12-28	WOS:000307267000034
J	Millett, GA; Jeffries, WL; Peterson, JL; Malebranche, DJ; Lane, T; Flores, SA; Fenton, KA; Wilson, PA; Steiner, R; Heilig, CM				Millett, Gregorio A.; Jeffries, William L.; Peterson, John L.; Malebranche, David J.; Lane, Tim; Flores, Stephen A.; Fenton, Kevin A.; Wilson, Patrick A.; Steiner, Riley; Heilig, Charles M.			Common roots: a contextual review of HIV epidemics in black men who have sex with men across the African diaspora	LANCET			English	Article							SEXUALLY-TRANSMITTED INFECTIONS; CONSPIRACY BELIEFS; AMERICAN MEN; PARTNER CHARACTERISTICS; ANTIRETROVIRAL THERAPY; CIRCUMCISION STATUS; FOOD INSECURITY; RISK BEHAVIORS; UNITED-STATES; HUMAN-RIGHTS	Pooled estimates from across the African diaspora show that black men who have sex with men (MSM) are 15 times more likely to be HIV positive compared with general populations and 8.5 times more likely compared with black populations. Disparities in the prevalence of HIV infection are greater in African and Caribbean countries that criminalise homosexual activity than in those that do not criminalise such behaviour. With the exception of US and African epidemiological studies, most studies of black MSM mainly focus on outcomes associated with HIV behavioural risk rather than on prevalence, incidence, or undiagnosed infection. Nevertheless, black MSM across the African diaspora share common experiences such as discrimination, cultural norms valuing masculinity, concerns about confidentiality during HIV testing or treatment, low access to HIV drugs, threats of violence or incarceration, and few targeted HIV prevention resources.	[Millett, Gregorio A.; Jeffries, William L.; Flores, Stephen A.; Fenton, Kevin A.; Steiner, Riley; Heilig, Charles M.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Washington, DC 20201 USA; [Peterson, John L.] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA; [Malebranche, David J.] Emory Univ, Dept Med, Atlanta, GA 30322 USA; [Lane, Tim] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA; [Wilson, Patrick A.] Columbia Univ, Dept Sociomed Sci, New York, NY USA	Centers for Disease Control & Prevention - USA; University System of Georgia; Georgia State University; Emory University; University of California System; University of California San Francisco; Columbia University	Millett, GA (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 395 E St, Washington, DC 20201 USA.	gmillett@CDC.gov	Heilig, Charles M/C-2753-2008	Heilig, Charles M/0000-0003-1075-1310				Adebajo S, 2008, INT AIDS C MEX CIT M; African and Black Diaspora Global Network on HIV and AIDS, HIV AIDS IMP AFR BLA; Agence-France Presse, ZIMB MP DET CALL MUG; Angus Reid Public Opinion, JAM REJ BAS RIGHTS H; [Anonymous], BBC NEWS; [Anonymous], GAMBIA NEWS; Baillargeon J, 2009, JAMA-J AM MED ASSOC, V301, P848, DOI 10.1001/jama.2009.202; Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339; Baral S, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-36; Baral S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004997; BARTHOLOMEW C, 1987, JAMA-J AM MED ASSOC, V257, P2604, DOI 10.1001/jama.257.19.2604; Beyrer C, EPIDEMIOLOGY HIV MSM; Beyrer C, 2012, LANCET; Bingham TA, 2003, AIDS EDUC PREV, V15, P39, DOI 10.1521/aeap.15.1.5.39.23613; Bogart LM, 2011, AIDS BEHAV, V15, P1180, DOI 10.1007/s10461-010-9796-7; Bogart LM, 2010, JAIDS-J ACQ IMM DEF, V53, P648, DOI 10.1097/QAI.0b013e3181c57dbc; Bosu WK, 2009, MODES TRANSMISSION W; Brown I, HIV DRUG AVAILABLE O; Cambiano V, 2010, AIDS, V24, P1153, DOI 10.1097/QAD.0b013e32833847af; Canning P, AFRICA WILL MASSIVE; Centers for Disease Control and Prevention, FUND ALL DISTR PROGR; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Doerner R, 2010, INT AIDS C VIENN AUS; Elford J, ETHNICITY SEXUALITY; Elford J, USE SEXUAL HLTH SERV; Etiebet M, 2011, C RETR OPP INF SEATT, P1104; Federal Bureau of Investigation, 2010, UN CRIM REP HAT CRIM; Figueroa JP, 2008, W INDIAN MED J, V57, P562; Fisher J, NIGERIAN LEADERS UNI; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Foundation for AIDS Research and Johns Hopkins Bloomberg School of Public Health, ACH AIDS FREE GEN GA; Fox J, 2010, AIDS, V24, P2397, DOI 10.1097/QAD.0b013e32833cbb5b; Fuqua V, 2012, AIDS BEHAV, V16, P256, DOI 10.1007/s10461-011-9918-x; Geibel S, 2008, SEX TRANSM DIS, V35, P746, DOI 10.1097/OLQ.0b013e318170589d; Glick SN, 2010, JAIDS-J ACQ IMM DEF, V55, P516, DOI 10.1097/QAI.0b013e3181f275e0; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Gunter M, 2011, INT AIDS C VIENN AUS; Hall HI, 2007, AM J PUBLIC HEALTH, V97, P1060, DOI 10.2105/AJPH.2006.087551; Hall HI, 2009, JAIDS-J ACQ IMM DEF, V51, pS13, DOI 10.1097/QAI.0b013e3181a2639e; Harper GW, 2013, AIDS BEHAV, V17, P213, DOI 10.1007/s10461-011-0071-3; He WJ, 2008, CELL HOST MICROBE, V4, P52, DOI 10.1016/j.chom.2008.06.002; Henry E, 2010, SEX TRANSM INFECT, V86, P136, DOI 10.1136/sti.2009.036939; Hickson F, 2009, TESTING TARGETS FIND; Hightow-Weidman LB, 2011, J ADOLESCENT HEALTH, V48, P94, DOI 10.1016/j.jadohealth.2010.05.011; Horswell C, HOUSTON FAMILY LAYS; Human Rights Watch, CRIM ID RIGHTS AB CA; Human Rights Watch, HAT DEATH HOM VIOL J; Husbands W, 2008, MABWANA HLTH COMMUNI; Hutchinson AB, 2007, JAIDS-J ACQ IMM DEF, V45, P603, DOI 10.1097/QAI.0b013e3181151262; Ibrahim F, 2008, HIV MED, V9, P616, DOI 10.1111/j.1468-1293.2008.00605.x; International Gay and Lesbian Human Rights Commission Serovie, IMP EARTHQ REL REC P; Jeffries WL, 2013, AIDS BEHAV, V17, P1442, DOI 10.1007/s10461-012-0189-y; Johnson CA, MAP HIV AIDS PROGRAM; Joseph J, RSDU PILOT SERIES; Kelley C, 2012, C RETR OPP INF SEATT, P567; Knox J, 2011, INT J STD AIDS, V22, P709, DOI 10.1258/ijsa.2011.010350; Krentz HB, 2004, HIV MED, V5, P93, DOI 10.1111/j.1468-1293.2004.00193.x; Lane T, 2011, AIDS BEHAV, V15, P626, DOI 10.1007/s10461-009-9598-y; Larmarange J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013189; Lauby JL, 2012, AIDS BEHAV, V16, P508, DOI 10.1007/s10461-011-0002-3; Lewis GB, 2003, PUBLIC OPIN QUART, V67, P59, DOI 10.1086/346009; Malebranche DJ, 2009, MEN MASC, V12, P90, DOI 10.1177/1097184X07309504; Malebranche DJ, 2004, J NATL MED ASSOC, V96, P97; Marmor M, 2001, J ACQ IMMUN DEF SYND, V27, P472, DOI 10.1097/00126334-200108150-00009; Maulsby C, 2012, AIDS BEHAV, V16, P543, DOI 10.1007/s10461-011-0046-4; McKeown E, 2010, CULT HEALTH SEX, V12, P843, DOI 10.1080/13691058.2010.499963; Merrigan M, 2011, SEX TRANSM INFECT, V87, P65, DOI 10.1136/sti.2008.034991; Millett G, 2005, J NATL MED ASSOC, V97, p52S; Millett GA, 2007, HIV AIDS PREVENTION; Millett GA, 2012, LANCET; Millett GA, 2008, JAMA-J AM MED ASSOC, V300, P1674, DOI 10.1001/jama.300.14.1674; Millett GA, 2007, JAIDS-J ACQ IMM DEF, V46, P643, DOI 10.1097/QAI.0b013e31815b834d; Millett GA, 2007, AIDS, V21, P2083, DOI 10.1097/QAD.0b013e3282e9a64b; Mmali J, UGANDA FEAR GAY DEAT; MOREAU A, 2007, IMPLEMENTING STI HIV; Moutinho Laura, 2006, Rev. Estud. Fem., V14, P103; Murray DAB, 2000, AM ANTHROPOL, V102, P261, DOI 10.1525/aa.2000.102.2.261; Muula AS, 2007, CROAT MED J, V48, P398; Myers T, 2001, HIV RES NEEDS ASSESS; National Aids Trust, HIV BLACK CAR COMM U; National Gay and Lesbian Task Force, SAY LOUD IM BLACK IM; Ndiaye O, 2011, 6 IAS C HIV PATH TRE; Onyango-Ouma W, 2005, UNDERSTANDING HIV ST; Oster AM, 2011, AIDS, V25, P2157, DOI 10.1097/QAD.0b013e32834bfde9; Oster AM, 2011, AM J PUBLIC HEALTH, V101, P137, DOI 10.2105/AJPH.2009.185850; Ottoson D, STATE SPONSORED HOMO; Paparini S, 2008, AIDS CARE, V20, P601, DOI 10.1080/09540120701867040; Parker R., 1998, Critical Public Health, V8, P329, DOI 10.1080/09581599808402919; Peterson JL, 2009, AM J PUBLIC HEALTH, V99, P976, DOI 10.2105/AJPH.2008.143214; Petroll AE, 2011, SEX TRANSM DIS, V38, P63, DOI 10.1097/OLQ.0b013e3181ebd50f; Petrovski S, 2011, AIDS, V25, P513, DOI 10.1097/QAD.0b013e328343817b; Pierce SJ, 2007, J PUBLIC HEALTH MAN, pS72; Pinho O, DESEJO PODER RACISMO; Population Council, OV EP ADDR HIV PREV; Poteat T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028760; Prejean J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017502; Price MA, 2012, JAIDS-J ACQ IMM DEF, V59, P185, DOI 10.1097/QAI.0b013e31823d8693; Prost A, 2008, AIDS BEHAV, V12, P170, DOI 10.1007/s10461-007-9237-4; Public Health Agency Canada, PEOPL COUNTR HIV END; Raymond HF, 2009, AIDS BEHAV, V13, P630, DOI 10.1007/s10461-009-9574-6; Rispel LC, 2011, J PUBLIC HEALTH POL, V32, pS137, DOI 10.1057/jphp.2011.29; Robinson BE, 2013, ARCH SEX BEHAV, V42, P267, DOI 10.1007/s10508-011-9891-5; Rosenberg NA, 2010, NAT REV GENET, V11, P356, DOI 10.1038/nrg2760; Rubin MS, 2010, AM J PUBLIC HEALTH, V100, P1053, DOI 10.2105/AJPH.2009.170241; Rutledge SE, 2009, SOCIOL HEALTH ILL, V31, P17, DOI 10.1111/j.1467-9566.2008.01133.x; Sanders EJ, 2007, AIDS, V21, P2513, DOI 10.1097/QAD.0b013e3282f2704a; Sanders EJ, 2010, SEX TRANSM INFECT, V86, P440, DOI 10.1136/sti.2010.043224; Sandfort TGM, 2008, SEX TRANSM INFECT, V84, P425, DOI 10.1136/sti.2008.031500; Severson K, WEIGHING RACE HATE M; Smith A., 2010, Morbidity and Mortality Weekly Report, V59, P1201; Smith AD, 2009, LANCET, V374, P416, DOI 10.1016/S0140-6736(09)61118-1; Sylla J, BIG UPDATE SEXUAL HL; Tabet SR, 1996, AIDS, V10, P201, DOI 10.1097/00002030-199602000-00011; Tieu HV, 2010, J URBAN HEALTH, V87, P113, DOI 10.1007/s11524-009-9416-x; Tovanabutra S, 2010, AIDS RES HUM RETROV, V26, P123, DOI 10.1089/aid.2009.0115; Traore C, DEBUNKING MYTHS FOCU; Tun W, 2012, AIDS CARE, V24, P459, DOI 10.1080/09540121.2011.617412; Uganda Ministry of Health, 2010, CRAN SURV REP HIGH R; UNAIDS, STAT HIV CAR; UNAIDS, UN ACC CAR MUST INCL; USAID, MEN WHO HAV SEX MEN; Wade AS, 2005, AIDS, V19, P2133, DOI 10.1097/01.aids.0000194128.97640.07; Walker K, 2011, INT J EPIDEMIOL, V40, P1358, DOI 10.1093/ije/dyr125; Weatherburn P, 2008, MULTIPLE CHANCES FIN; Weiser SD, 2012, AIDS, V26, P67, DOI 10.1097/QAD.0b013e32834cad37; Weiser SD, 2009, J GEN INTERN MED, V24, P14, DOI 10.1007/s11606-008-0824-5; Westergaard RP, 2011, CLIN INFECT DIS, V53, P725, DOI 10.1093/cid/cir491; Wheeler DP, 2005, AIDS EDUC PREV, V17, P102, DOI 10.1521/aeap.17.2.102.58693; Willis KA, ROLE JAMAICA RED CRO; Wiysonge CS, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007496.pub2; Zulu K, 2006, INT AIDS C TOR CAN A	131	79	79	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 28	2012	380	9839					411	423		10.1016/S0140-6736(12)60722-3	http://dx.doi.org/10.1016/S0140-6736(12)60722-3			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819654				2022-12-28	WOS:000306842800039
J	Semugoma, P; Nemande, S; Baral, SD				Semugoma, Paul; Nemande, Steave; Baral, Stefan D.			The irony of homophobia in Africa	LANCET			English	Editorial Material									[Baral, Stefan D.] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Key Populat Ctr Publ Hlth & Human Rights, Baltimore, MD 21205 USA; [Semugoma, Paul] African Men Sexual Hlth & Rights, Johannesburg, South Africa; [Nemande, Steave] Integrat Clin, Douala, Cameroon	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Baral, SD (corresponding author), Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Key Populat Ctr Publ Hlth & Human Rights, Baltimore, MD 21205 USA.	sbaral@jhsph.edu	Baral, Stefan/D-2930-2013; Baral, Stefan/AAG-4818-2020	Baral, Stefan/0000-0002-5482-2419				amfAR Foundation for AIDS Research Johns Hopkins Bloomberg School of Public Health, 2011, ACH AIDS FREE GEN GA; amfAR International AIDS Vaccine Initiative Johns Hopkins University-Center for Public Health and Human Rights United Nations Development Program, 2011, RESP PROT FULF BEST; Andrew M, 2011, DEMOCRATIC REPUBLIC; [Anonymous], 2009, VOICE AM        1102; [Anonymous], 2012, MASK UGANDAS PRESIDE; Behen P, 2011, COMMUNICATION   0308; Beyrer C, 2011, DIR DEV, P1, DOI 10.1596/978-0-8213-8726-9; Beyrer C, 2012, LANCET; Carter M., 2007, PEPFAR MONEY BEING U; Fadera H, 2012, GAMBIA NO ROOM GAYS; Haberlandt Michael, 1998, BOY WIVES FEMALE HUS, P63; International Gay and Lesbian Human Rights Commission, 2011, AFR CIV SOC COND MAL; International Lesbian Gay Bisexual Trans and Intersex Association, 2012, STAT SPONS HOM WORLD; Kajubi P, 2008, AIDS BEHAV, V12, P492, DOI 10.1007/s10461-007-9323-7; Kaoma K, 2011, EXPOSING TRAFFICKING; Kenya National AIDS and STI Control Programme, 2012, MOST AT RISK POP UNV; Poteat T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028760; Trapence G, 2012, LANCET	18	30	30	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 28	2012	380	9839					312	314		10.1016/S0140-6736(12)60901-5	http://dx.doi.org/10.1016/S0140-6736(12)60901-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819661				2022-12-28	WOS:000306842800006
J	Dix, MM; Simon, GM; Wang, C; Okerberg, E; Patricelli, MP; Cravatt, BF				Dix, Melissa M.; Simon, Gabriel M.; Wang, Chu; Okerberg, Eric; Patricelli, Matthew P.; Cravatt, Benjamin F.			Functional Interplay between Caspase Cleavage and Phosphorylation Sculpts the Apoptotic Proteome	CELL			English	Article							CATALYTIC SUBUNIT; KINASE; IDENTIFICATION; ACTIVATION; SUBSTRATE; SUSCEPTIBILITY; STAUROSPORINE; SPECIFICITY; TARGET; DEATH	Caspase proteases are principal mediators of apoptosis, where they cleave hundreds of proteins. Phosphorylation also plays an important role in apoptosis, although the extent to which proteolytic and phosphorylation pathways crosstalk during programmed cell death remains poorly understood. Using a quantitative proteomic platform that integrates phosphorylation sites into the topographical maps of proteins, we identify a cohort of over 500 apoptosis-specific phosphorylation events and show that they are enriched on cleaved proteins and clustered around sites of caspase proteolysis. We find that caspase cleavage can expose new sites for phosphorylation, and, conversely, that phosphorylation at the +3 position of cleavage sites can directly promote substrate proteolysis by caspase-8. This study provides a global portrait of the apoptotic phosphoproteome, revealing heretofore unrecognized forms of functional crosstalk between phosphorylation and caspase proteolytic pathways that lead to enhanced rates of protein cleavage and the unveiling of new sites for phosphorylation.	[Dix, Melissa M.; Simon, Gabriel M.; Wang, Chu; Cravatt, Benjamin F.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Dix, Melissa M.; Simon, Gabriel M.; Wang, Chu; Cravatt, Benjamin F.] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA; [Okerberg, Eric; Patricelli, Matthew P.] ActivX Biosci, La Jolla, CA 92307 USA	Scripps Research Institute; Scripps Research Institute; Kyorin Pharmaceutical Co Ltd	Cravatt, BF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cravatt@scripps.edu	Wang, Chu/AAE-8759-2021; wang, chu/GYJ-2191-2022; Wang, Chu/C-4442-2015	Wang, Chu/0000-0002-6925-1268; Wang, Chu/0000-0002-6925-1268	NIH [CA087660]; California Breast Cancer Foundation; ARCS Foundation; Koshland Graduate Fellowship in Enzyme Biochemistry; Skaggs Institute for Chemical Biology; Activx Biosciences; NATIONAL CANCER INSTITUTE [R01CA087660, R37CA087660] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Breast Cancer Foundation; ARCS Foundation; Koshland Graduate Fellowship in Enzyme Biochemistry; Skaggs Institute for Chemical Biology; Activx Biosciences; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH (CA087660), a Predoctoral Fellowship from the California Breast Cancer Foundation (M.M.D.), the ARCS Foundation (M.M.D.), a Koshland Graduate Fellowship in Enzyme Biochemistry (G.M.S.), and the Skaggs Institute for Chemical Biology. We are grateful to Brian Grabiner and David Sabatini for their generous gift of lentiviral vectors. This work was supported in part by a grant from Activx Biosciences.	Agard NJ, 2012, P NATL ACAD SCI USA, V109, P1913, DOI 10.1073/pnas.1117158109; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; ALLALUNISTURNER MJ, 1995, CANCER RES, V55, P5200; Arntzen MO, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.010447; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blanchard H, 2000, J MOL BIOL, V302, P9, DOI 10.1006/jmbi.2000.4041; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Chakravarthy BR, 1999, J NEUROCHEM, V72, P933, DOI 10.1046/j.1471-4159.1999.0720933.x; Chen GG, 2005, J CELL PHYSIOL, V203, P127, DOI 10.1002/jcp.20230; Chen GG, 2005, APOPTOSIS, V10, P185, DOI 10.1007/s10495-005-6073-8; Chereau D, 2003, BIOCHEMISTRY-US, V42, P4151, DOI 10.1021/bi020593l; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Crawford ED, 2011, ANNU REV BIOCHEM, V80, P1055, DOI 10.1146/annurev-biochem-061809-121639; Dix MM, 2008, CELL, V134, P679, DOI 10.1016/j.cell.2008.06.038; Duncan JS, 2010, BBA-PROTEINS PROTEOM, V1804, P505, DOI 10.1016/j.bbapap.2009.11.001; Ekici OD, 2006, J MED CHEM, V49, P5728, DOI 10.1021/jm0601405; Esposti MD, 2003, J BIOL CHEM, V278, P15749, DOI 10.1074/jbc.M209208200; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Hehner SP, 1999, CELL DEATH DIFFER, V6, P833, DOI 10.1038/sj.cdd.4400559; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Janes KA, 2005, SCIENCE, V310, P1646, DOI 10.1126/science.1116598; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kurokawa M, 2009, CELL, V138, P838, DOI 10.1016/j.cell.2009.08.021; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; Mahrus S, 2008, CELL, V134, P866, DOI 10.1016/j.cell.2008.08.012; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Patricelli MP, 2011, CHEM BIOL, V18, P699, DOI 10.1016/j.chembiol.2011.04.011; Pearlman SM, 2011, CELL, V147, P934, DOI 10.1016/j.cell.2011.08.052; Rank KB, 2001, PROTEIN EXPRES PURIF, V22, P258, DOI 10.1006/prep.2001.1433; Schwartz D, 2005, NAT BIOTECHNOL, V23, P1391, DOI 10.1038/nbt1146; Short DM, 2007, PROTEOMICS, V7, P3085, DOI 10.1002/pmic.200600964; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stolzenberg I, 2000, CELL TISSUE RES, V301, P273, DOI 10.1007/s004410000239; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tozser J, 2003, BIOCHEM J, V372, P137, DOI 10.1042/BJ20021901; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Weerapana E, 2010, NATURE, V468, P790, DOI 10.1038/nature09472; Xu T, 2006, MOL CELL PROTEOMICS, V5, pS174	43	104	107	1	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 20	2012	150	2					426	440		10.1016/j.cell.2012.05.040	http://dx.doi.org/10.1016/j.cell.2012.05.040			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817901	Green Accepted, Bronze			2022-12-28	WOS:000306595700020
J	Duraffourd, C; De Vadder, F; Goncalves, D; Delaere, F; Penhoat, A; Brusset, B; Rajas, F; Chassard, D; Duchampt, A; Stefanutti, A; Gautier-Stein, A; Mithieux, G				Duraffourd, Celine; De Vadder, Filipe; Goncalves, Daisy; Delaere, Fabien; Penhoat, Armelle; Brusset, Bleuenn; Rajas, Fabienne; Chassard, Dominique; Duchampt, Adeline; Stefanutti, Anne; Gautier-Stein, Amandine; Mithieux, Gilles			Mu-Opioid Receptors and Dietary Protein Stimulate a Gut-Brain Neural Circuitry Limiting Food Intake	CELL			English	Article							GLUCAGON-LIKE PEPTIDE-1; RAT SMALL-INTESTINE; MESSENGER-RNA; EXPRESSION; GLUCONEOGENESIS; GENE; CHOLECYSTOKININ; MECHANISMS; NUCLEUS; SATIETY	Intestinal gluconeogenesis is involved in the control of food intake. We show that mu-opioid receptors (MORs) present in nerves in the portal vein walls respond to peptides to regulate a gut-brain neural circuit that controls intestinal gluconeogenesis and satiety. In vitro, peptides and protein digests behave as MOR antagonists in competition experiments. In vivo, they stimulate MOR-dependent induction of intestinal gluconeogenesis via activation of brain areas receiving inputs from gastrointestinal ascending nerves. MOR-knockout mice do not carry out intestinal gluconeogenesis in response to peptides and are insensitive to the satiety effect induced by protein-enriched diets. Portal infusions of MOR modulators have no effect on food intake in mice deficient for intestinal gluconeogenesis. Thus, the regulation of portal MORs by peptides triggering signals to and from the brain to induce intestinal gluconeogenesis are links in the satiety phenomenon associated with alimentary protein assimilation.	[Duraffourd, Celine; De Vadder, Filipe; Goncalves, Daisy; Delaere, Fabien; Penhoat, Armelle; Brusset, Bleuenn; Rajas, Fabienne; Chassard, Dominique; Duchampt, Adeline; Stefanutti, Anne; Gautier-Stein, Amandine; Mithieux, Gilles] INSERM, U855, F-69372 Lyon, France; [Duraffourd, Celine; De Vadder, Filipe; Goncalves, Daisy; Delaere, Fabien; Penhoat, Armelle; Brusset, Bleuenn; Rajas, Fabienne; Chassard, Dominique; Duchampt, Adeline; Stefanutti, Anne; Gautier-Stein, Amandine; Mithieux, Gilles] Univ Lyon, F-69008 Lyon, France; [Duraffourd, Celine; De Vadder, Filipe; Goncalves, Daisy; Delaere, Fabien; Penhoat, Armelle; Brusset, Bleuenn; Rajas, Fabienne; Chassard, Dominique; Duchampt, Adeline; Stefanutti, Anne; Gautier-Stein, Amandine; Mithieux, Gilles] Univ Lyon 1, F-69622 Villeurbanne, France; [Chassard, Dominique] HFME, Hosp Civils Lyon, F-69250 Bron, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon	Mithieux, G (corresponding author), INSERM, U855, F-69372 Lyon, France.	gilles.mithieux@inserm.fr	PENHOAT, ARMELLE/GMX-2754-2022; RAJAS, Fabienne/P-4091-2016; Penhoat, Armelle/M-1305-2018	PENHOAT, ARMELLE/0000-0003-3181-9564; RAJAS, Fabienne/0000-0002-9233-7633; Gautier-Stein, Amandine/0000-0002-6003-1891; De Vadder, Filipe/0000-0001-9195-5344; Gilles, Mithieux/0000-0003-3579-8529	INSERM; Centre National de la Recherche Scientifique; Institut National de la Recherche Agronomique; Universite Lyon 1; Ministere de la Recherche et de l'Enseignement Superieur; Ecole Normale Superieure de Lyon; Ecole Nationale du Genie Rural des Eaux et Forets; Agence Nationale de la Recherche [ANR1.14, ANR-07-PNRA-015]	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Recherche Agronomique; Universite Lyon 1; Ministere de la Recherche et de l'Enseignement Superieur; Ecole Normale Superieure de Lyon(Grant Agency of the Czech Republic); Ecole Nationale du Genie Rural des Eaux et Forets; Agence Nationale de la Recherche(French National Research Agency (ANR))	All protocols used in this work were performed according to the recommendations of our local animal ethics committee for animal experimentation, which gave its authorization. The staff members of the animal facility of the University Claude Bernard-Lyon 1 (ALECS) are acknowledged for precious help in housing rats and mice, including Aude Barataud for helpful discussions on the pharmacology of MOR. The authors thank INSERM for funding their work and the Centre National de la Recherche Scientifique (A.S., G.M., F.R.), the Institut National de la Recherche Agronomique (A.G.-S.), the Universite Lyon 1 (D.C.) and INSERM (A. P) for funding their positions. The authors also wish to thank the Ministere de la Recherche et de l'Enseignement Superieur (C.D., D.G.) the Ecole Normale Superieure de Lyon (B.B., F.D.V.), the Ecole Nationale du Genie Rural des Eaux et Forets (F.D.) for funding their positions as postgraduate or Ph.D students. A.D. was hired thanks to grants from the Agence Nationale de la Recherche (ANR1.14 [NutriSens project] and ANR-07-PNRA-015 [SensoFat project]). The authors declare that there are no conflicts of interest in relation to this work.	Berthoud HR, 2004, ANAT REC PART A, V280A, P827, DOI 10.1002/ar.a.20088; Bohm SK, 1997, BIOCHEM J, V322, P1; BOLL M, 1994, PFLUG ARCH EUR J PHY, V429, P146, DOI 10.1007/BF02584043; BOOTH DA, 1970, PHYSIOL BEHAV, V5, P1299, DOI 10.1016/0031-9384(70)90044-2; BULLITT E, 1990, J COMP NEUROL, V296, P517, DOI 10.1002/cne.902960402; Capasso A, 1997, FEBS LETT, V417, P141, DOI 10.1016/S0014-5793(97)01271-4; CHIBA H, 1989, J DAIRY RES, V56, P363, DOI 10.1017/S0022029900028818; Croset M, 2001, DIABETES, V50, P740, DOI 10.2337/diabetes.50.4.740; Daniel H, 2004, ANNU REV PHYSIOL, V66, P361, DOI 10.1146/annurev.physiol.66.032102.144149; Ding YQ, 1996, J COMP NEUROL, V367, P375; GEORGE SR, 1994, BIOCHEM BIOPH RES CO, V205, P1438, DOI 10.1006/bbrc.1994.2826; GIBBS J, 1976, AM J PHYSIOL, V230, P15, DOI 10.1152/ajplegacy.1976.230.1.15; Glass MJ, 1999, NEUROPEPTIDES, V33, P360, DOI 10.1054/npep.1999.0050; Greenwood-Van Meerveld B, 2004, NEUROGASTROENT MOTIL, V16, P46, DOI 10.1111/j.1743-3150.2004.00555.x; Hayes MT, 2011, OBES SURG, V21, P759, DOI 10.1007/s11695-011-0380-7; HEDNER T, 1987, SCAND J GASTROENTERO, V22, P27, DOI 10.3109/00365528709090997; Holzer P, 2009, REGUL PEPTIDES, V155, P11, DOI 10.1016/j.regpep.2009.03.012; Jean C, 2001, J NUTR, V131, P91, DOI 10.1093/jn/131.1.91; Kotz CM, 2000, AM J PHYSIOL-REG I, V278, pR499, DOI 10.1152/ajpregu.2000.278.2.R499; KREIL G, 1983, LIFE SCI, V33, P137, DOI 10.1016/0024-3205(83)90463-0; Lee VHL, 2000, EUR J PHARM SCI, V11, pS41, DOI 10.1016/S0928-0987(00)00163-9; LORENTZ M, 1988, BRAIN RES, V445, P157, DOI 10.1016/0006-8993(88)91086-4; Meisel H, 2000, BRIT J NUTR, V84, pS27; Mithieux G, 2004, AM J PHYSIOL-ENDOC M, V286, pE370, DOI 10.1152/ajpendo.00299.2003; Mithieux G, 2004, J BIOL CHEM, V279, P44231, DOI 10.1074/jbc.R400011200; Mithieux G, 2005, CELL METAB, V2, P321, DOI 10.1016/j.cmet.2005.09.010; Mithieux G, 2009, NUTRITION, V25, P881, DOI 10.1016/j.nut.2009.06.010; Moran TH, 2000, NUTRITION, V16, P858, DOI 10.1016/S0899-9007(00)00419-6; MORITOKI H, 1984, EUR J PHARMACOL, V100, P29, DOI 10.1016/0014-2999(84)90312-1; MORLEY JE, 1983, NEUROSCI BIOBEHAV R, V7, P281, DOI 10.1016/0149-7634(83)90020-9; Nielsen CU, 2003, CURR DRUG TARGETS, V4, P373, DOI 10.2174/1389450033491028; Pan YX, 2005, DNA CELL BIOL, V24, P736, DOI 10.1089/dna.2005.24.736; Pasternak DA, 2004, J NEUROCHEM, V91, P881, DOI 10.1111/j.1471-4159.2004.02767.x; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Penhoat A, 2011, PHYSIOL BEHAV, V105, P89, DOI 10.1016/j.physbeh.2011.03.012; Pillot B, 2009, ENDOCRINOLOGY, V150, P616, DOI 10.1210/en.2008-0601; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Rajas F, 2000, DIABETES, V49, P1165, DOI 10.2337/diabetes.49.7.1165; Reimer K, 2009, PHARMACOLOGY, V83, P10, DOI 10.1159/000165778; ROLLS BJ, 1988, PHYSIOL BEHAV, V43, P145, DOI 10.1016/0031-9384(88)90230-2; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; Schiller P., 2002, AM PEPTIDE S, V6, P229; Shin AC, 2010, NEUROSCIENCE, V170, P580, DOI 10.1016/j.neuroscience.2010.07.017; SHIOMI H, 1981, NEUROPHARMACOLOGY, V20, P633, DOI 10.1016/0028-3908(81)90109-X; Sternini C, 2000, NEUROSCIENCE, V98, P233, DOI 10.1016/S0306-4522(00)00118-4; Sternini C, 2004, NEUROGASTROENT MOTIL, V16, P3, DOI 10.1111/j.1743-3150.2004.00553.x; Sternini C, 2001, AM J PHYSIOL-GASTR L, V281, pG8, DOI 10.1152/ajpgi.2001.281.1.G8; Taylor DA, 2001, J PHARMACOL EXP THER, V297, P11; TESCHEMACHER H, 1986, J DAIRY RES, V53, P135, DOI 10.1017/S0022029900024730; Thaler JP, 2009, ENDOCRINOLOGY, V150, P2518, DOI 10.1210/en.2009-0367; Troy S, 2008, CELL METAB, V8, P201, DOI 10.1016/j.cmet.2008.08.008; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; Vahl TP, 2007, ENDOCRINOLOGY, V148, P4965, DOI 10.1210/en.2006-0153; WEST DB, 1984, AM J PHYSIOL, V246, pR776, DOI 10.1152/ajpregu.1984.246.5.R776; Will MJ, 2003, J NEUROSCI, V23, P2882; Yang JC, 2000, BRAIN RES, V870, P199, DOI 10.1016/S0006-8993(00)02369-6; Yeomans MR, 2002, NEUROSCI BIOBEHAV R, V26, P713, DOI 10.1016/S0149-7634(02)00041-6; Zhang JP, 2006, EUR J PHARMACOL, V545, P147, DOI 10.1016/j.ejphar.2006.06.069; Zheng HY, 2002, AM J PHYSIOL-REG I, V282, pR1773, DOI 10.1152/ajpregu.00019.2002; ZIOUDROU C, 1979, J BIOL CHEM, V254, P2446	60	72	77	4	38	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 20	2012	150	2					377	388		10.1016/j.cell.2012.05.039	http://dx.doi.org/10.1016/j.cell.2012.05.039			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22771138	Green Submitted, Bronze			2022-12-28	WOS:000306595700016
J	Freddolino, PL; Tavazoie, S				Freddolino, Peter L.; Tavazoie, Saeed			The Dawn of Virtual Cell Biology	CELL			English	Editorial Material									[Freddolino, Peter L.; Tavazoie, Saeed] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; [Freddolino, Peter L.; Tavazoie, Saeed] Columbia Univ, Initiat Syst Biol, New York, NY 10032 USA	Columbia University; Columbia University	Tavazoie, S (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 1150 St Nicholas Ave,Room 405A, New York, NY 10032 USA.	st2744@columbia.edu			NIAID NIH HHS [R01 AI077562] Funding Source: Medline; NIEHS NIH HHS [DP1 ES022578] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077562] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [DP1ES022578] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Castellanos M, 2004, P NATL ACAD SCI USA, V101, P6681, DOI 10.1073/pnas.0400962101; DORNENBURG JE, 2010, MBIO, V1; Feist AM, 2008, NAT BIOTECHNOL, V26, P659, DOI 10.1038/nbt1401; Gutenkunst RN, 2007, PLOS COMPUT BIOL, V3, P1871, DOI 10.1371/journal.pcbi.0030189; Karr J. R., 2012, CELL, V150; Khersonsky O, 2010, ANNU REV BIOCHEM, V79, P471, DOI 10.1146/annurev-biochem-030409-143718; Lee JM, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000086; Orth JD, 2010, NAT BIOTECHNOL, V28, P245, DOI 10.1038/nbt.1614; Roberts E, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002010	9	15	15	0	20	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 20	2012	150	2					248	250		10.1016/j.cell.2012.07.001	http://dx.doi.org/10.1016/j.cell.2012.07.001			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817888	Bronze, Green Accepted			2022-12-28	WOS:000306595700005
J	Menne, J; Nitschke, M; Stingele, R; Abu-Tair, M; Beneke, J; Bramstedt, J; Bremer, JP; Brunkhorst, R; Busch, V; Dengler, R; Deuschl, G; Fellermann, K; Fickenscher, H; Gerigk, C; Goettsche, A; Greeve, J; Hafer, C; Hagenmuller, F; Haller, H; Herget-Rosenthal, S; Hertenstein, B; Hofmann, C; Lang, M; Kielstein, JT; Klostermeier, UC; Knobloch, J; Kuehbacher, M; Kunzendorf, U; Lehnert, H; Manns, MP; Menne, TF; Meyer, TN; Michael, C; Munte, T; Neumann-Grutzeck, C; Nuernberger, J; Pavenstaedt, H; Ramazan, L; Renders, L; Repenthin, J; Ries, W; Rohr, A; Rump, LC; Samuelsson, O; Sayk, F; Schmidt, BMW; Schnatter, S; Schocklmann, H; Schreiber, S; von Seydewitz, CU; Steinhoff, J; Stracke, S; Suerbaum, S; van de Loo, A; Vischedyk, M; Weissenborn, K; Wellhoner, P; Wiesner, M; Zeissig, S; Buning, J; Schiffer, M; Kuehbacher, T				Menne, Jan; Nitschke, Martin; Stingele, Robert; Abu-Tair, Mariam; Beneke, Jan; Bramstedt, Joern; Bremer, Jan P.; Brunkhorst, Reinhard; Busch, Veit; Dengler, Reinhard; Deuschl, Guenther; Fellermann, Klaus; Fickenscher, Helmut; Gerigk, Christoph; Goettsche, Alexander; Greeve, Jobst; Hafer, Carsten; Hagenmueller, Friedrich; Haller, Hermann; Herget-Rosenthal, Stefan; Hertenstein, Bernd; Hofmann, Christina; Lang, Melanie; Kielstein, Jan T.; Klostermeier, Ulrich C.; Knobloch, Johannes; Kuehbacher, Markus; Kunzendorf, Ulrich; Lehnert, Hendrik; Manns, Michael P.; Menne, Tobias F.; Meyer, Tobias N.; Michael, Claus; Muente, Thomas; Neumann-Grutzeck, Christine; Nuernberger, Jens; Pavenstaedt, Hermann; Ramazan, Leyla; Renders, Lutz; Repenthin, Jonas; Ries, Wolfgang; Rohr, Axel; Rump, Lars Christian; Samuelsson, Ola; Sayk, Friedhelm; Schmidt, Bernhard M. W.; Schnatter, Sabine; Schoecklmann, Harald; Schreiber, Stefan; von Seydewitz, Cay U.; Steinhoff, Jurgen; Stracke, Sylvia; Suerbaum, Sebastian; van de Loo, Andreas; Vischedyk, Martin; Weissenborn, Karin; Wellhoener, Peter; Wiesner, Monika; Zeissig, Sebastian; Buening, Juergen; Schiffer, Mario; Kuehbacher, Tanja		EHEC-HUS Consortium	Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study	BRITISH MEDICAL JOURNAL			English	Article							SHIGA-TOXIN; O157-H7 INFECTIONS; GERMAN OUTBREAK; ECULIZUMAB; STRAIN; ANTIBIOTICS; SCOTLAND; DIARRHEA; ADULTS; DEATH	Objective To evaluate the effect of different treatment strategies on enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome. Design Multicentre retrospective case-control study. Setting 23 hospitals in northern Germany. Participants 298 adults with enterohaemorrhagic E coli induced haemolytic uraemic syndrome. Main outcome measures Dialysis, seizures, mechanical ventilation, abdominal surgery owing to perforation of the bowel or bowel necrosis, and death. Results 160 of the 298 patients (54%) temporarily required dialysis, with only three needing treatment long term. 37 patients (12%) had seizures, 54 (18%) required mechanical ventilation, and 12 (4%) died. No clear benefit was found from use of plasmapheresis or plasmapheresis with glucocorticoids. 67 of the patients were treated with eculizumab, a monoclonal antibody directed against the complement cascade. No short term benefit was detected that could be attributed to this treatment. 52 patients in one centre that used a strategy of aggressive treatment with combined antibiotics had fewer seizures (2% v 15%, P=0.03),fewer deaths (0% v 5%, p=0.029), required no abdominal surgery, and excreted E coli for a shorter duration. Conclusions Enterohaemorrhagic E coli induced haemolytic uraemic syndrome is a severe self limiting acute condition. Our findings question the benefit of eculizumab and of plasmapheresis with or without glucocorticoids. Patients with established haemolytic uraemic syndrome seemed to benefit from antibiotic treatment and this should be investigated in a controlled trial.	[Menne, Jan] Hannover Med Sch, Dept Hypertens & Nephrol, D-30625 Hannover, Germany; [Nitschke, Martin; Fellermann, Klaus; Hofmann, Christina; Knobloch, Johannes; Lehnert, Hendrik; Muente, Thomas; Sayk, Friedhelm; Steinhoff, Jurgen; Wellhoener, Peter; Buening, Juergen] Univ Hosp Schleswig Holstein, Lubeck, Germany; [Stingele, Robert; Deuschl, Guenther; Fickenscher, Helmut; Goettsche, Alexander; Klostermeier, Ulrich C.; Kunzendorf, Ulrich; Renders, Lutz; Rohr, Axel; Schoecklmann, Harald; Schreiber, Stefan; Zeissig, Sebastian; Kuehbacher, Tanja] Univ Hosp Schleswig Holstein, Kiel, Germany; [Abu-Tair, Mariam] Evangelic Hosp Gilead, Bielefeld, Germany; [Bramstedt, Joern] Bremerhaven Hosp Reinkenheide, Bremerhaven, Germany; [Bremer, Jan P.; Hagenmueller, Friedrich; Neumann-Grutzeck, Christine; von Seydewitz, Cay U.] Asklepios Hosp Hamburg Altona, Hamburg, Germany; [Brunkhorst, Reinhard] Hosp Hannover, Hannover, Germany; [Busch, Veit; Pavenstaedt, Hermann] Univ Hosp Munster, Munster, Germany; [Gerigk, Christoph; van de Loo, Andreas] Marienhosp Hamburg, Hamburg, Germany; [Greeve, Jobst; Vischedyk, Martin] St Vincenz Hosp, Paderborn, Germany; [Herget-Rosenthal, Stefan] Red Cross Hosp Bremen, Bremen, Germany; [Hertenstein, Bernd] Bremen Hosp Mitte, Bremen, Germany; [Lang, Melanie; Meyer, Tobias N.; Repenthin, Jonas] Asklepios Hosp Hamburg Barmbek, Hamburg, Germany; [Kuehbacher, Markus] Univ Hagen, Hagen, Germany; [Menne, Tobias F.] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Nuernberger, Jens] Helios Hosp Schwerin, Schwerin, Germany; [Ries, Wolfgang] Diakonissenkrankenhaus Flensburg, Flensburg, Germany; [Rump, Lars Christian] Univ Dusseldorf, D-40225 Dusseldorf, Germany; [Samuelsson, Ola] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Schnatter, Sabine] Ernst Bergmann Clin, Potsdam, Germany; [Stracke, Sylvia] Ernst Moritz Arndt Univ Greifswald, Ctr Clin, Greifswald, Germany; [Wiesner, Monika] Hosp Oldenburg, Oldenburg, Germany	Hannover Medical School; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; Asklepios Klinik Altona; University of Munster; St. Marien Hospital; Klinikum Bremen-Mitte; Fern University Hagen; Newcastle Freeman Hospital; Newcastle University - UK; Heinrich Heine University Dusseldorf; Sahlgrenska University Hospital; Klinikum Ernst von Bergmann; Ernst Moritz Arndt Universitat Greifswald; Klinikum Oldenburg	Menne, J (corresponding author), Hannover Med Sch, Dept Hypertens & Nephrol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	menne.jan@mh-hannover.de	Bremer, Phillip/AAE-7842-2020; Arlt, Alexander/G-7308-2019; Münte, Thomas/C-2077-2014; Schiffer, Mario/U-7050-2019; Knobloch, Johannes K./D-6456-2011; Fickenscher, Helmut/J-9655-2019; van de Loo, Fons AJ/A-3425-2014; Fussek, Sebastian/G-7989-2016; Kuehbacher, Tanja/H-4745-2012; Ott, Stephan J/G-1965-2010; Kielstein, Jan T./I-2956-2019; Deuschl, Gunther/A-7986-2010; Zeissig, Sebastian/B-6297-2012; Nitschke, Martin/ABA-9388-2021; Aden, Konrad/H-1477-2014; Stracke, Sylvia/ABB-8871-2020	Arlt, Alexander/0000-0002-6160-1059; Schiffer, Mario/0000-0002-8414-1470; Knobloch, Johannes K./0000-0002-2591-6387; Fickenscher, Helmut/0000-0003-0043-1153; van de Loo, Fons AJ/0000-0002-5851-099X; Kielstein, Jan T./0000-0001-8110-9064; Deuschl, Gunther/0000-0002-4176-9196; Zeissig, Sebastian/0000-0001-5124-0897; Nitschke, Martin/0000-0002-2716-7527; Aden, Konrad/0000-0003-3482-7316; 	Deutsche Forschungsgesellschaft excellence cluster "Inflammation at interfaces" [EXC 306]; Alexion Pharmaceuticals	Deutsche Forschungsgesellschaft excellence cluster "Inflammation at interfaces"(German Research Foundation (DFG)); Alexion Pharmaceuticals	This study received partial funding from the Deutsche Forschungsgesellschaft excellence cluster "Inflammation at interfaces" (recipient SS, No EXC 306).; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: doctors from the following 10 centers (Medical School Hannover, Hannover; University Hospital Schleswig Holstein, Lubeck; Evangelic Hospital Gilead, Bielefeld; Bremerhaven Hospital Reinkenheide, Bremerhaven; University Hospital Munster, Munster; Red Cross Hospital Bremen, Bremen; Bremen Hospital-Mitte, Bremen; Hospital Oldenburg, Oldenburg; Diakonissenkrankenhaus Flensburg; Asklepios Clinic Hamburg Barmbek, Hamburg) participated in a single arm multicentre trial, sponsored by Alexion Pharmaceuticals; no support from any organisation for the submitted work; and no other relationships or activities that could appear to have influenced the submitted work.	Bambauer R, 2011, THER APHER DIAL, V15, P10, DOI 10.1111/j.1744-9987.2010.00903.x; BELL BP, 1994, JAMA-J AM MED ASSOC, V272, P1349, DOI 10.1001/jama.272.17.1349; Bielaszewska M, 2012, ANTIMICROB AGENTS CH, V56, P3277, DOI 10.1128/AAC.06315-11; Bielaszewska M, 2011, LANCET INFECT DIS, V11, P671, DOI 10.1016/S1473-3099(11)70165-7; Chandler WL, 2002, NEW ENGL J MED, V346, P23, DOI 10.1056/NEJMoa011033; Colic E, 2011, LANCET, V378, P1089, DOI 10.1016/S0140-6736(11)61145-8; Cornick NA, 2002, J INFECT DIS, V186, P57, DOI 10.1086/341295; Denamur E, 2011, CLIN MICROBIOL INFEC, V17, P1124, DOI 10.1111/j.1469-0691.2011.03620.x; Ducker C, 2011, DEUT MED WOCHENSCHR, V136, P1770, DOI 10.1055/s-0031-1286099; Dundas S, 2001, CLIN INFECT DIS, V33, P923, DOI 10.1086/322598; Frank C, 2011, NEW ENGL J MED, V365, P1771, DOI 10.1056/NEJMoa1106483; German Society of Nephrology (DGfN), 2011, THER APH EHEC ASS HU; Greinacher A, 2011, LANCET, V378, P1166, DOI 10.1016/S0140-6736(11)61253-1; Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648; Kemper MJ, 2012, PEDIATR NEPHROL, V27, P161, DOI 10.1007/s00467-011-2067-7; Lapeyraque AL, 2011, NEW ENGL J MED, V364, P2561, DOI 10.1056/NEJMc1100859; Magnus T, 2012, BRAIN, V135, P1850, DOI 10.1093/brain/aws090; Mellmann A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022751; Nitschke M, 2012, JAMA-J AM MED ASSOC, V307, P1046, DOI 10.1001/jama.2012.264; Nurnberger J, 2009, NEW ENGL J MED, V360, P542, DOI 10.1056/NEJMc0808527; Pennington H, 2010, LANCET, V376, P1428, DOI 10.1016/S0140-6736(10)60963-4; Perez N, 1998, PEDIATR NEPHROL, V12, P101, DOI 10.1007/s004670050413; Rahal EA, 2011, INT J ANTIMICROB AG, V37, P135, DOI 10.1016/j.ijantimicag.2010.10.009; Rasko DA, 2011, NEW ENGL J MED, V365, P709, DOI 10.1056/NEJMoa1106920; Robert Koch Institut, 2011, ABSCHL DARST BEW EP; Rohde H, 2011, NEW ENGL J MED, V365, P718, DOI 10.1056/NEJMoa1107643; Ruggenenti P, 2011, LANCET, V378, P1057, DOI 10.1016/S0140-6736(11)61217-8; Scheiring J, 2010, EUR J PEDIATR, V169, P7, DOI 10.1007/s00431-009-1039-4; Stahl AL, 2011, BLOOD, V117, P5503, DOI 10.1182/blood-2010-09-309161; Szczepiorkowski ZM, 2010, J CLIN APHERESIS, V25, P83, DOI 10.1002/jca.20240; Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2; Thurman JM, 2009, CLIN J AM SOC NEPHRO, V4, P1920, DOI 10.2215/CJN.02730409; Wong CS, 2000, NEW ENGL J MED, V342, P1930, DOI 10.1056/NEJM200006293422601; Wood R, 2001, EPIDEMIOL INFECT, V127, P413, DOI 10.1017/S0950268801006136; Zhang XP, 2000, J INFECT DIS, V181, P664, DOI 10.1086/315239	35	188	195	0	24	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 19	2012	345								e4565	10.1136/bmj.e4565	http://dx.doi.org/10.1136/bmj.e4565			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	978MA	22815429	Green Published, hybrid			2022-12-28	WOS:000306744300005
J	Moritz, MA				Moritz, Max A.			Wildfires ignite debate on global warming	NATURE			English	Editorial Material									Univ Calif Berkeley, Environm Sci Policy & Management Dept, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Moritz, MA (corresponding author), Univ Calif Berkeley, Environm Sci Policy & Management Dept, Berkeley, CA 94720 USA.	mmoritz@berkeley.edu							0	8	8	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 19	2012	487	7407					273	273		10.1038/487273a	http://dx.doi.org/10.1038/487273a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	975JB	22810656	Bronze			2022-12-28	WOS:000306506500004
J	Burton, DR; Poignard, P; Stanfield, RL; Wilson, IA				Burton, Dennis R.; Poignard, Pascal; Stanfield, Robyn L.; Wilson, Ian A.			Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses	SCIENCE			English	Review							HEPATITIS-C VIRUS; HUMAN MONOCLONAL-ANTIBODIES; INFLUENZA-A VIRUSES; MEMORY B-CELLS; STRUCTURAL BASIS; RATIONAL DESIGN; ENVELOPE GLYCOPROTEIN; E2 GLYCOPROTEIN; HIV-1; EPITOPE	Certain human pathogens avoid elimination by our immune system by rapidly mutating the surface protein sites targeted by antibody responses, and consequently they tend to be problematic for vaccine development. The behavior described is prominent for a subset of viruses-the highly antigenically diverse viruses-which include HIV, influenza, and hepatitis C viruses. However, these viruses do harbor highly conserved exposed sites, usually associated with function, which can be targeted by broadly neutralizing antibodies. Until recently, not many such antibodies were known, but advances in the field have enabled increasing numbers to be identified. Molecular characterizations of the antibodies and, most importantly, of the sites of vulnerability that they recognize give hope for the discovery of new vaccines and drugs.	[Burton, Dennis R.; Poignard, Pascal] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Burton, Dennis R.; Poignard, Pascal] Scripps Res Inst, Int AIDS Vaccine Initiat IAVI Neutralizing Antibo, La Jolla, CA 92037 USA; [Burton, Dennis R.] Massachusetts Gen Hosp, MIT, Ragon Inst, Boston, MA 02129 USA; [Burton, Dennis R.] Harvard Univ, Boston, MA 02129 USA; [Stanfield, Robyn L.; Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, Dept Mol Biol, La Jolla, CA 92037 USA; [Stanfield, Robyn L.; Wilson, Ian A.] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA; [Poignard, Pascal] IAVI, New York, NY 10038 USA	Scripps Research Institute; International AIDS Vaccine Initiative; Scripps Research Institute; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Scripps Research Institute; International AIDS Vaccine Initiative; Scripps Research Institute; International AIDS Vaccine Initiative	Burton, DR (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.	burton@scripps.edu; wilson@scripps.edu	poignard, pascal/AAB-4613-2020; poignard, pascal/N-6678-2013; Cheng, Yushao/E-6256-2011; Stanfield, Robyn/AAH-3190-2019	Poignard, Pascal/0000-0002-0021-7192	NIH; IAVI; Ragon Institute; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI084817, P01AI082362] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); IAVI; Ragon Institute; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We acknowledge the financial support of the NIH, the IAVI, and the Ragon Institute. We thank C. Corbaci for help in preparation of the manuscript and all of our past and present laboratory members for their many contributions to our research efforts.	[Anonymous], PYMOL MOL GRAPH SYST; Azoitei ML, 2011, SCIENCE, V334, P373, DOI 10.1126/science.1209368; Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9339, DOI 10.1073/pnas.89.19.9339; Basler CF, 2008, ANTIVIR RES, V79, P166, DOI 10.1016/j.antiviral.2008.04.006; Bohne-Lang A, 2005, NUCLEIC ACIDS RES, V33, pW214, DOI 10.1093/nar/gki385; Bommakanti G, 2010, P NATL ACAD SCI USA, V107, P13701, DOI 10.1073/pnas.1007465107; Bonsignori M, 2011, J VIROL, V85, P9998, DOI 10.1128/JVI.05045-11; Broering TJ, 2009, J VIROL, V83, P12473, DOI 10.1128/JVI.01138-09; Bryson S, 2009, J VIROL, V83, P11862, DOI 10.1128/JVI.01604-09; BUCHACHER A, 1992, VACCINES 92 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P191; Burton DR, 2005, P NATL ACAD SCI USA, V102, P14943, DOI 10.1073/pnas.0505126102; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Cardoso RMF, 2007, J MOL BIOL, V365, P1533, DOI 10.1016/j.jmb.2006.10.088; CONLEY AJ, 1994, P NATL ACAD SCI USA, V91, P3348, DOI 10.1073/pnas.91.8.3348; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; Corti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008805; Diskin R, 2011, SCIENCE, V334, P1289, DOI 10.1126/science.1213782; Do Kwon Y, 2012, P NATL ACAD SCI USA, V109, P5663, DOI 10.1073/pnas.1112391109; Douek DC, 2006, CELL, V124, P677, DOI 10.1016/j.cell.2006.02.005; Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323; Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Eren R, 2006, J VIROL, V80, P2654, DOI 10.1128/JVI.80.6.2654-2664.2006; Fleishman SJ, 2011, SCIENCE, V332, P816, DOI 10.1126/science.1202617; Gerhard W, 2001, CURR TOP MICROBIOL, V260, P171; Giang E, 2012, P NATL ACAD SCI USA, V109, P6205, DOI 10.1073/pnas.1114927109; Graham-Rowe D, 2011, NATURE, V480, pS2, DOI 10.1038/480S2a; GRAVES PN, 1983, VIROLOGY, V126, P106, DOI 10.1016/0042-6822(83)90465-8; Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4; Hessell AJ, 2010, J VIROL, V84, P1302, DOI 10.1128/JVI.01272-09; Hessell AJ, 2009, NAT MED, V15, P951, DOI 10.1038/nm.1974; Hessell AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000433; Huber M, 2010, J VIROL, V84, P10700, DOI 10.1128/JVI.01111-10; Johansson DX, 2007, P NATL ACAD SCI USA, V104, P16269, DOI 10.1073/pnas.0705522104; Johnson PR, 2009, NAT MED, V15, P901, DOI 10.1038/nm.1967; Kashyap AK, 2008, P NATL ACAD SCI USA, V105, P5986, DOI 10.1073/pnas.0801367105; Keck ZY, 2008, J VIROL, V82, P6061, DOI 10.1128/JVI.02475-07; Kong L, 2012, P NATL ACAD SCI USA, V109, P9499, DOI 10.1073/pnas.1202924109; Krause JC, 2011, J IMMUNOL, V187, P3704, DOI 10.4049/jimmunol.1101823; Krause JC, 2011, J VIROL, V85, P10905, DOI 10.1128/JVI.00700-11; Law M, 2008, NAT MED, V14, P25, DOI 10.1038/nm1698; Li GM, 2012, P NATL ACAD SCI USA, V109, P9047, DOI 10.1073/pnas.1118979109; Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159; Mascola JR, 2010, ANNU REV IMMUNOL, V28, P413, DOI 10.1146/annurev-immunol-030409-101256; Mascola JR, 2003, CURR MOL MED, V3, P209, DOI 10.2174/1566524033479799; McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696; McLellan JS, 2011, J MOL BIOL, V409, P853, DOI 10.1016/j.jmb.2011.04.044; Meunier JC, 2008, J VIROL, V82, P966, DOI 10.1128/JVI.01872-07; Ohshima N, 2011, J VIROL, V85, P11048, DOI 10.1128/JVI.05397-11; OKUNO Y, 1993, J VIROL, V67, P2552, DOI 10.1128/JVI.67.5.2552-2558.1993; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Owsianka A, 2005, J VIROL, V79, P11095, DOI 10.1128/JVI.79.17.11095-11104.2005; Owsianka A, 2001, J GEN VIROL, V82, P1877, DOI 10.1099/0022-1317-82-8-1877; Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256; Sabo MC, 2011, J VIROL, V85, P7005, DOI 10.1128/JVI.00586-11; Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227; Schofield DJ, 2005, HEPATOLOGY, V42, P1055, DOI 10.1002/hep.20906; Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4; Stamatatos L, 2009, NAT MED, V15, P866, DOI 10.1038/nm.1949; Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Throsby M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003942; UNAIDS, 2011, GET ZER FAST SMART B; US Department of Health Human Services, 2011, COMB SIL EP VIR HEP; VUJCIC LK, 1995, AIDS RES HUM RETROV, V11, P783, DOI 10.1089/aid.1995.11.783; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746; Wei CJ, 2010, SCIENCE, V329, P1060, DOI 10.1126/science.1192517; Whittle JRR, 2011, P NATL ACAD SCI USA, V108, P14216, DOI 10.1073/pnas.1111497108; Wrammert J, 2011, J EXP MED, V208, P181, DOI 10.1084/jem.20101352; Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Xiao XD, 2009, BIOCHEM BIOPH RES CO, V390, P404, DOI 10.1016/j.bbrc.2009.09.029; Xu R, 2010, SCIENCE, V328, P357, DOI 10.1126/science.1186430; Yoshida R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000350; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819	79	329	343	2	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2012	337	6091					183	186		10.1126/science.1225416	http://dx.doi.org/10.1126/science.1225416			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798606	Green Accepted			2022-12-28	WOS:000306323500046
J	Dietrich, JP; Werner, N; Clowe, D; Finoguenov, A; Kitching, T; Miller, L; Simionescu, A				Dietrich, Joerg P.; Werner, Norbert; Clowe, Douglas; Finoguenov, Alexis; Kitching, Tom; Miller, Lance; Simionescu, Aurora			A filament of dark matter between two clusters of galaxies	NATURE			English	Article							HOT INTERGALACTIC MEDIUM; WEAK LENSING SURVEYS; X-RAY-ABSORPTION; COSMIC WEB; SHAPE MEASUREMENT; SCULPTOR WALL; SUPERCLUSTER; ABELL-222; UNIVERSE; BARYONS	It is a firm prediction of the concordance cold-dark-matter cosmological model that galaxy clusters occur at the intersection of large-scale structure filaments(1). The thread-like structure of this 'cosmic web' has been traced by galaxy redshift surveys for decades(2,3). More recently, the warm-hot intergalactic medium (a sparse plasma with temperatures of 10(5) kelvin to 10(7) kelvin) residing in low-redshift filaments has been observed in emission(4) and absorption(5,6). However, a reliable direct detection of the underlying dark-matter skeleton, which should contain more than half of all matter(7), has remained elusive, because earlier candidates for such detections(8-10) were either falsified(11,12) or suffered from low signal-to-noise ratios(8,10) and unphysical misalignments of dark and luminous matter(9,10). Here we report the detection of a dark-matter filament connecting the two main components of the Abell 222/223 supercluster system from its weak gravitational lensing signal, both in a non-parametric mass reconstruction and in parametric model fits. This filament is coincident with an overdensity of galaxies(10,13) and diffuse, soft-X-ray emission(4), and contributes a mass comparable to that of an additional galaxy cluster to the total mass of the supercluster. By combining this result with X-ray observations(4), we can place an upper limit of 0.09 on the hot gas fraction (the mass of X-ray-emitting gas divided by the total mass) in the filament.	[Dietrich, Joerg P.] Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA; [Dietrich, Joerg P.] Univ Michigan, Michigan Ctr Theoret Phys, Ann Arbor, MI 48109 USA; [Werner, Norbert; Simionescu, Aurora] Stanford Univ, Kavli Inst Particle Astrophys & Cosmol, Stanford, CA 94305 USA; [Clowe, Douglas] Ohio Univ, Dept Phys & Astron, Clippinger Lab 251B, Athens, OH 45701 USA; [Finoguenov, Alexis] Max Planck Inst Extraterr Phys, D-85748 Garching, Germany; [Kitching, Tom] Univ Edinburgh, Royal Observ, Inst Astron, Edinburgh EH9 3HJ, Midlothian, Scotland; [Miller, Lance] Univ Oxford, Dept Phys, Oxford OX1 3RH, England	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Stanford University; University System of Ohio; Ohio University; Max Planck Society; University of Edinburgh; University of Oxford	Dietrich, JP (corresponding author), Univ Michigan, Dept Phys, 450 Church St, Ann Arbor, MI 48109 USA.	jorgd@umich.edu	Werner, Norbert/G-2832-2019; Werner, Norbert/AAW-2434-2021	Werner, Norbert/0000-0003-0392-0120; Werner, Norbert/0000-0003-0392-0120; Simionescu, Aurora/0000-0002-9714-3862; Dietrich, Jorg/0000-0002-8134-9591	NSF [AST 0807304]; National Aeronautics and Space Administration [PF9-00070]; Science and Technology Facilities Council [ST/H002456/1] Funding Source: researchfish; STFC [ST/H002456/1] Funding Source: UKRI	NSF(National Science Foundation (NSF)); National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	J.P.D. was supported by NSF grant AST 0807304. A. S. acknowledges support from the National Aeronautics and Space Administration through Einstein Postdoctoral Fellowship Award Number PF9-00070.	Allen SW, 2008, MON NOT R ASTRON SOC, V383, P879, DOI 10.1111/j.1365-2966.2007.12610.x; Aragon-Calvo MA, 2010, MON NOT R ASTRON SOC, V408, P2163, DOI 10.1111/j.1365-2966.2010.17263.x; Bond JR, 1996, NATURE, V380, P603, DOI 10.1038/380603a0; Buote DA, 2009, ASTROPHYS J, V695, P1351, DOI 10.1088/0004-637X/695/2/1351; Colberg JM, 2005, MON NOT R ASTRON SOC, V359, P272, DOI 10.1111/j.1365-2966.2005.08897.x; Dave R, 2001, ASTROPHYS J, V552, P473, DOI 10.1086/320548; Dietrich JP, 2005, ASTRON ASTROPHYS, V440, P453, DOI 10.1051/0004-6361:20041523; Dietrich JP, 2002, ASTRON ASTROPHYS, V394, P395, DOI 10.1051/0004-6361:20021195; Dolag K, 2004, ASTRON ASTROPHYS, V416, P853, DOI 10.1051/0004-6361:20031757; Fang TT, 2010, ASTROPHYS J, V714, P1715, DOI 10.1088/0004-637X/714/2/1715; Gavazzi R, 2004, ASTRON ASTROPHYS, V422, P407, DOI 10.1051/0004-6361:20047109; GELLER MJ, 1989, SCIENCE, V246, P897, DOI 10.1126/science.246.4932.897; Gray ME, 2002, ASTROPHYS J, V568, P141, DOI 10.1086/338763; Heymans C, 2008, MON NOT R ASTRON SOC, V385, P1431, DOI 10.1111/j.1365-2966.2008.12919.x; Ilbert O, 2006, ASTRON ASTROPHYS, V457, P841, DOI 10.1051/0004-6361:20065138; JOEVEER M, 1978, MON NOT R ASTRON SOC, V185, P357, DOI 10.1093/mnras/185.2.357; KAHN FD, 1959, ASTROPHYS J, V130, P705, DOI 10.1086/146762; Kaiser N, 1998, PHOTOMETRIC WEAK LEN; KING IR, 1966, ASTRON J, V71, P64, DOI 10.1086/109857; Kitching TD, 2008, MON NOT R ASTRON SOC, V390, P149, DOI 10.1111/j.1365-2966.2008.13628.x; Mead JMG, 2010, MON NOT R ASTRON SOC, V401, P2257, DOI 10.1111/j.1365-2966.2009.15840.x; Miller L, 2007, MON NOT R ASTRON SOC, V382, P315, DOI 10.1111/j.1365-2966.2007.12363.x; Navarro JF, 1997, ASTROPHYS J, V490, P493, DOI 10.1086/304888; SANDAGE A, 1986, ASTROPHYS J, V307, P1, DOI 10.1086/164387; Simionescu A, 2011, SCIENCE, V331, P1576, DOI [10.1126/science.1200331, 10.1126/science.1195970]; Werner N, 2008, ASTRON ASTROPHYS, V482, pL29, DOI 10.1051/0004-6361:200809599	26	86	86	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2012	487	7406					202	204		10.1038/nature11224	http://dx.doi.org/10.1038/nature11224			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972LP	22763438	Green Submitted			2022-12-28	WOS:000306278900032
J	Rosenbaum, L; Lamas, D				Rosenbaum, Lisa; Lamas, Daniela			Cents and Sensitivity - Teaching Physicians to Think about Costs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE; RESPONSIBILITY											Brody H, 2012, NEW ENGL J MED, V366, P1949, DOI 10.1056/NEJMp1203365; Brody H, 2010, NEW ENGL J MED, V362, P283, DOI 10.1056/NEJMp0911423; Cooke M, 2010, NEW ENGL J MED, V362, P1253, DOI 10.1056/NEJMp0911502; Veatch R.M, 1991, PATIENT PHYS RELATIO; Weinberger SE, 2011, ANN INTERN MED, V155, P386, DOI 10.7326/0003-4819-155-6-201109200-00007	5	47	47	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2					99	101		10.1056/NEJMp1205634	http://dx.doi.org/10.1056/NEJMp1205634			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972IO	22784112				2022-12-28	WOS:000306270800004
J	Acharyya, S; Oskarsson, T; Vanharanta, S; Malladi, S; Kim, J; Morris, PG; Manova-Todorova, K; Leversha, M; Hogg, N; Seshan, VE; Norton, L; Brogi, E; Massague, J				Acharyya, Swarnali; Oskarsson, Thordur; Vanharanta, Sakari; Malladi, Srinivas; Kim, Juliet; Morris, Patrick G.; Manova-Todorova, Katia; Leversha, Margaret; Hogg, Nancy; Seshan, Venkatraman E.; Norton, Larry; Brogi, Edi; Massague, Joan			A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis	CELL			English	Article							BREAST-CANCER; SUPPRESSOR-CELLS; MYELOID CELLS; TUMOR; RESISTANCE; CHEMOKINE; THERAPY; GENES; CHEMOTHERAPY; INFLAMMATION	Metastasis and chemoresistance in cancer are linked phenomena, but the molecular basis for this link is unknown. We uncovered a network of paracrine signals between carcinoma, myeloid, and endothelial cells that drives both processes in breast cancer. Cancer cells that overexpress CXCL1 and 2 by transcriptional hyperactivation or 4q21 amplification are primed for survival in metastatic sites. CXCL1/2 attract CD11b(+)Gr1(+) myeloid cells into the tumor, which produce chemokines including S100A8/9 that enhance cancer cell survival. Although chemotherapeutic agents kill cancer cells, these treatments trigger a parallel stromal reaction leading to TNF-alpha production by endothelial and other stromal cells. TNF-alpha via NF-kB heightens the CXCL1/2 expression in cancer cells, thus amplifying the CXCL1/2-S100A8/9 loop and causing chemoresistance. CXCR2 blockers break this cycle, augmenting the efficacy of chemotherapy against breast tumors and particularly against metastasis. This network of endothelial-carcinoma-myeloid signaling interactions provides a mechanism linking chemoresistance and metastasis, with opportunities for intervention.	[Acharyya, Swarnali; Oskarsson, Thordur; Vanharanta, Sakari; Malladi, Srinivas; Kim, Juliet; Massague, Joan] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Morris, Patrick G.; Norton, Larry] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Manova-Todorova, Katia] Mem Sloan Kettering Canc Ctr, Mol Cytol Core Facil, New York, NY 10065 USA; [Leversha, Margaret] Mem Sloan Kettering Canc Ctr, Mol Cytogenet Core Facil, New York, NY 10065 USA; [Brogi, Edi] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Seshan, Venkatraman E.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA; [Hogg, Nancy] Canc Res UK London Res Inst, Leukocyte Adhes Lab, London WC2A 3PX, England; [Massague, Joan] Howard Hughes Med Inst, Chevy Chase, MD 21205 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cancer Research UK; Howard Hughes Medical Institute	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA.	massaguj@mskcc.org	Oskarsson, Thordur/HBP-9601-2022	Oskarsson, Thordur/0000-0002-0983-6969; Massague, Joan/0000-0001-9324-8408; Norton, Larry/0000-0003-3701-9250	NIH [CA94060, U54 CA163167]; Alan and Sandra Gerry Metastasis Research Initiative; Department of Defense; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA094060, R37CA034610, U54CA163167] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alan and Sandra Gerry Metastasis Research Initiative; Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank J. Joyce, J. Bromberg, E. Pamer, H. G. Wendel, I. Ferrero, Z. Granot, R. Downey and members of Massague laboratory for insightful discussions, J. Howard for her help with clinical cases, D. Macalinao, W. Shu, M. Akram, K. Chadalavada, T. Tong, M. Turkekul, A. Barlas, and E. de Stanchina for technical advice and support. This work was funded by NIH grants CA94060 and U54 CA163167 and the Alan and Sandra Gerry Metastasis Research Initiative. S.A. is supported by a Department of Defense Era of Hope postdoctoral fellowship. J. M. is an Investigator of the Howard Hughes Medical Institute.	Amiri KI, 2003, PROG NUCLEIC ACID RE, V74, P1, DOI 10.1016/S0079-6603(03)01009-2; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bieche I, 2007, ENDOCR-RELAT CANCER, V14, P1039, DOI 10.1677/erc.1.01301; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chapman RW, 2009, PHARMACOL THERAPEUT, V121, P55, DOI 10.1016/j.pharmthera.2008.10.005; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Ebos JML, 2009, CLIN CANCER RES, V15, P5020, DOI 10.1158/1078-0432.CCR-09-0095; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gebhardt C, 2006, BIOCHEM PHARMACOL, V72, P1622, DOI 10.1016/j.bcp.2006.05.017; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hobbs JAR, 2003, MOL CELL BIOL, V23, P2564, DOI 10.1128/MCB.23.7.2564-2576.2003; Hsieh HL, 2003, BIOCHEM BIOPH RES CO, V307, P375, DOI 10.1016/S0006-291X(03)01190-2; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Ijichi H, 2011, J CLIN INVEST, V121, P4106, DOI 10.1172/JCI42754; Jones SE, 2008, CLIN BREAST CANCER, V8, P224, DOI 10.3816/CBC.2008.n.025; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Montero AJ, 2012, BREAST CANCER RES TR, V132, P215, DOI 10.1007/s10549-011-1889-0; Morris PG, 2009, EXPERT OPIN PHARMACO, V10, P967, DOI [10.1517/14656560902834961 , 10.1517/14656560902834961]; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P739, DOI 10.1093/jnci/djh131; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Stewart TJ, 2007, J IMMUNOL, V179, P2851, DOI 10.4049/jimmunol.179.5.2851; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Weiss L, 2000, CANCER METAST REV, V19, P193, DOI 10.1023/A:1010646304844; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	44	711	755	1	126	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 6	2012	150	1					165	178		10.1016/j.cell.2012.04.042	http://dx.doi.org/10.1016/j.cell.2012.04.042			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770218	Bronze, Green Accepted			2022-12-28	WOS:000306115000015
J	Ch'ng, TH; Uzgil, B; Lin, P; Avliyakulov, NK; O'Dell, TJ; Martin, KC				Ch'ng, Toh Hean; Uzgil, Besim; Lin, Peter; Avliyakulov, Nuraly K.; O'Dell, Thomas J.; Martin, Kelsey C.			Activity-Dependent Transport of the Transcriptional Coactivator CRTC1 from Synapse to Nucleus	CELL			English	Article							ELEMENT-BINDING PROTEIN; LONG-TERM POTENTIATION; SENSITIVE COINCIDENCE DETECTOR; MEDIATED GENE-EXPRESSION; MEMORY STORAGE; CREB; PLASTICITY; HIPPOCAMPUS; ACTIVATION; RECEPTOR	Long-lasting changes in synaptic efficacy, such as those underlying long-term memory, require transcription. Activity-dependent transport of synaptically localized transcriptional regulators provides a direct means of coupling synaptic stimulation with changes in transcription. The CREB-regulated transcriptional coactivator (CRTC1), which is required for long-term hippocampal plasticity, binds CREB to potently promote transcription. We show that CRTC1 localizes to synapses in silenced hippocampal neurons but translocates to the nucleus in response to localized synaptic stimulation. Regulated nuclear translocation occurs only in excitatory neurons and requires calcium influx and calcineurin activation. CRTC1 is controlled in a dual fashion with activity regulating CRTC1 nuclear translocation and cAMP modulating its persistence in the nucleus. Neuronal activity triggers a complex change in CRTC1 phosphorylation, suggesting that CRTC1 may link specific types of stimuli to specific changes in gene expression. Together, our results indicate that synapse-to-nuclear transport of CRTC1 dynamically informs the nucleus about synaptic activity.	[Ch'ng, Toh Hean; Avliyakulov, Nuraly K.; Martin, Kelsey C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; [Uzgil, Besim] Univ Calif Los Angeles, David Geffen Sch Med, Interdept Program Neurosci, Los Angeles, CA 90095 USA; [Lin, Peter] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [O'Dell, Thomas J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; [Martin, Kelsey C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Martin, Kelsey C.] Univ Calif Los Angeles, David Geffen Sch Med, Integrated Ctr Learning & Memory, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Martin, KC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.	kcmartin@mednet.ucla.edu	Chng, Toh Hean/F-8753-2015	Ch'ng, Toh Hean/0000-0002-7170-1512	NARSAD; NIH [R01 MH077022, R01 MH609197]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH077022] Funding Source: NIH RePORTER	NARSAD(NARSAD); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank members of the Carew and K.C.M. lab for helpful discussions and C. Alberini, K. Olofsdotter-Otis, V. Ho, C. Houser, and L. Zipursky for critical reading of the manuscript. We thank M. Chin for advice on qPCR experiments, M. DeSalvo for processing tissue samples, M. Haykinson for advice on DIGE, and Z. Peng and C. Houser for immunohistochemistry of acute slices. The work was supported by a NARSAD Young Investigator Award (to T.H.C.), NIH R01 MH077022 (to K.C.M.), and R01 MH609197 (to T.J.O.).	Altarejos JY, 2008, NAT MED, V14, P1112, DOI 10.1038/nm.1866; Balschun D, 2003, J NEUROSCI, V23, P6304; Benito E, 2010, TRENDS NEUROSCI, V33, P230, DOI 10.1016/j.tins.2010.02.001; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Ch'ng TH, 2011, CURR OPIN NEUROBIOL, V21, P345, DOI 10.1016/j.conb.2011.01.011; Cohen S, 2008, ANNU REV CELL DEV BI, V24, P183, DOI 10.1146/annurev.cellbio.24.110707.175235; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Delgado JY, 2005, NEUROPHARMACOLOGY, V48, P936, DOI 10.1016/j.neuropharm.2005.01.008; Hoffman DA, 1998, J NEUROSCI, V18, P3521; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Jeffrey RA, 2009, J NEUROSCI, V29, P15613, DOI 10.1523/JNEUROSCI.3314-09.2009; Jeong H, 2012, NAT MED, V18, P159, DOI 10.1038/nm.2559; Jiang M, 2006, NAT PROTOC, V1, P695, DOI 10.1038/nprot.2006.86; Johnson HA, 2007, J NEUROSCI, V27, P5915, DOI 10.1523/JNEUROSCI.0447-07.2007; Jordan BA, 2009, TRENDS NEUROSCI, V32, P392, DOI 10.1016/j.tins.2009.04.001; Kandel ER, 2001, BIOSCIENCE REP, V21, P565, DOI 10.1023/A:1014775008533; Katoh Y, 2004, EUR J BIOCHEM, V271, P4307, DOI 10.1111/j.1432-1033.2004.04372.x; Katoh Y, 2006, FEBS J, V273, P2730, DOI 10.1111/j.1742-4658.2006.05291.x; Kauffman AL, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000372; Kopec CD, 2006, J NEUROSCI, V26, P2000, DOI 10.1523/JNEUROSCI.3918-05.2006; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Kovacs KA, 2007, P NATL ACAD SCI USA, V104, P4700, DOI 10.1073/pnas.0607524104; Liu Y, 2008, NATURE, V456, P269, DOI 10.1038/nature07349; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P245, DOI 10.1113/jphysiol.1986.sp016007; Mair W, 2011, NATURE, V470, P404, DOI 10.1038/nature09706; McGaugh JL, 2006, TRENDS COGN SCI, V10, P345, DOI 10.1016/j.tics.2006.06.001; Navakkode S, 2007, NEUROPHARMACOLOGY, V52, P1547, DOI 10.1016/j.neuropharm.2007.02.010; Neugebauer F, 2009, BRAIN RES, V1273, P29, DOI 10.1016/j.brainres.2009.03.055; O'Dell TJ, 2010, CELL SIGNAL, V22, P728, DOI 10.1016/j.cellsig.2009.12.004; Perazzona B, 2004, J NEUROSCI, V24, P8823, DOI 10.1523/JNEUROSCI.4542-03.2004; Ravnskjaer K, 2007, EMBO J, V26, P2880, DOI 10.1038/sj.emboj.7601715; Rossato JI, 2009, SCIENCE, V325, P1017, DOI 10.1126/science.1172545; Saha RN, 2011, NAT NEUROSCI, V14, P848, DOI 10.1038/nn.2839; Sasaki T, 2011, NEURON, V69, P106, DOI 10.1016/j.neuron.2010.12.004; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Thompson KR, 2004, NEURON, V44, P997, DOI 10.1016/j.neuron.2004.11.025; Turrigiano GG, 2008, CELL, V135, P422, DOI 10.1016/j.cell.2008.10.008; Watts AG, 2011, J NEUROENDOCRINOL, V23, P754, DOI 10.1111/j.1365-2826.2011.02178.x; Zhou Y, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000016	44	137	143	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 6	2012	150	1					207	221		10.1016/j.cell.2012.05.027	http://dx.doi.org/10.1016/j.cell.2012.05.027			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770221	Green Accepted, Bronze			2022-12-28	WOS:000306115000018
J	Bateman, RJ; Xiong, CJ; Benzinger, TLS; Fagan, AM; Goate, A; Fox, NC; Marcus, DS; Cairns, NJ; Xie, XY; Blazey, TM; Holtzman, DM; Santacruz, A; Buckles, V; Oliver, A; Moulder, K; Aisen, PS; Ghetti, B; Klunk, WE; McDade, E; Martins, RN; Masters, CL; Mayeux, R; Ringman, JM; Rossor, MN; Schofield, PR; Sperling, RA; Salloway, S; Morris, JC				Bateman, Randall J.; Xiong, Chengjie; Benzinger, Tammie L. S.; Fagan, Anne M.; Goate, Alison; Fox, Nick C.; Marcus, Daniel S.; Cairns, Nigel J.; Xie, Xianyun; Blazey, Tyler M.; Holtzman, David M.; Santacruz, Anna; Buckles, Virginia; Oliver, Angela; Moulder, Krista; Aisen, Paul S.; Ghetti, Bernardino; Klunk, William E.; McDade, Eric; Martins, Ralph N.; Masters, Colin L.; Mayeux, Richard; Ringman, John M.; Rossor, Martin N.; Schofield, Peter R.; Sperling, Reisa A.; Salloway, Stephen; Morris, John C.			Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRESENILIN-1 MUTATION; AMYLOID DEPOSITION; ATROPHY; CORTEX; BRAIN; ONSET; STATE; MRI	BACKGROUND The order and magnitude of pathologic processes in Alzheimer's disease are not well understood, partly because the disease develops over many years. Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to determine the sequence and magnitude of pathologic changes that culminate in symptomatic disease. METHODS In this prospective, longitudinal study, we analyzed data from 128 participants who underwent baseline clinical and cognitive assessments, brain imaging, and cerebrospinal fluid (CSF) and blood tests. We used the participant's age at baseline assessment and the parent's age at the onset of symptoms of Alzheimer's disease to calculate the estimated years from expected symptom onset (age of the participant minus parent's age at symptom onset). We conducted cross-sectional analyses of baseline data in relation to estimated years from expected symptom onset in order to determine the relative order and magnitude of pathophysiological changes. RESULTS Concentrations of amyloid-beta (A beta)(42) in the CSF appeared to decline 25 years before expected symptom onset. A beta deposition, as measured by positron-emission tomography with the use of Pittsburgh compound B, was detected 15 years before expected symptom onset. Increased concentrations of tau protein in the CSF and an increase in brain atrophy were detected 15 years before expected symptom onset. Cerebral hypometabolism and impaired episodic memory were observed 10 years before expected symptom onset. Global cognitive impairment, as measured by the Mini-Mental State Examination and the Clinical Dementia Rating scale, was detected 5 years before expected symptom onset, and patients met diagnostic criteria for dementia at an average of 3 years after expected symptom onset. CONCLUSIONS We found that autosomal dominant Alzheimer's disease was associated with a series of pathophysiological changes over decades in CSF biochemical markers of Alzheimer's disease, brain amyloid deposition, and brain metabolism as well as progressive cognitive impairment. Our results require confirmation with the use of longitudinal data and may not apply to patients with sporadic Alzheimer's disease. (Funded by the National Institute on Aging and others; DIAN ClinicalTrials.gov number, NCT00869817.)	[Bateman, Randall J.; Fagan, Anne M.; Holtzman, David M.; Santacruz, Anna; Buckles, Virginia; Oliver, Angela; Moulder, Krista; Morris, John C.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Xiong, Chengjie; Xie, Xianyun] Washington Univ, Sch Med, Dept Biostat, St Louis, MO USA; [Goate, Alison] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; [Benzinger, Tammie L. S.; Marcus, Daniel S.; Blazey, Tyler M.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Cairns, Nigel J.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Fox, Nick C.; Rossor, Martin N.] UCL, Inst Neurol, London WC1E 6BT, England; [Aisen, Paul S.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Ghetti, Bernardino] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA; [Klunk, William E.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Klunk, William E.; McDade, Eric] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Martins, Ralph N.] Edith Cowan Univ, Ctr Excellence Alzheimers Dis Res & Care, Joondalup, WA, Australia; [Masters, Colin L.] Univ Melbourne, Mental Hlth Res Inst, Melbourne, Vic, Australia; [Schofield, Peter R.] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia; [Mayeux, Richard] Columbia Univ Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; [Mayeux, Richard] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; [Ringman, John M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Sperling, Reisa A.] Massachusetts Gen Hosp, Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Boston, MA 02114 USA; [Sperling, Reisa A.] Massachusetts Gen Hosp, Brigham & Womens Hosp, Dept Neurol, Boston, MA 02114 USA; [Sperling, Reisa A.] Harvard Univ, Sch Med, Boston, MA USA; [Salloway, Stephen] Brown Univ, Warren Alpert Med Sch, Butler Hosp, Dept Neurol, Providence, RI 02912 USA; [Salloway, Stephen] Brown Univ, Warren Alpert Med Sch, Butler Hosp, Memory & Aging Program, Providence, RI 02912 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of London; University College London; University of California System; University of California San Diego; Indiana University System; Indiana University Bloomington; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Edith Cowan University; University of Melbourne; University of New South Wales Sydney; Columbia University; Columbia University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Brigham & Women's Hospital; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Massachusetts General Hospital; Harvard University; Harvard Medical School; Brown University; Butler Hospital Rhode Island; Brown University; Butler Hospital Rhode Island	Bateman, RJ (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	batemanr@wustl.edu	Rossor, Martin/C-1598-2008; Benzinger, Tammie/L-6104-2013; Mayeux, Richard/E-9788-2013; Cairns, Nigel/AAB-9713-2020; Fox, Nick C/B-1319-2009; Fox, Nick C/AAE-1849-2021; Schofield, Peter/C-9669-2011	Benzinger, Tammie/0000-0002-8114-0552; Mayeux, Richard/0000-0001-6519-9696; Cairns, Nigel/0000-0001-9858-3344; Fox, Nick C/0000-0002-6660-657X; Fox, Nick C/0000-0002-6660-657X; Goate, Alison/0000-0002-0576-2472; Klunk, William/0000-0001-5512-0251; Bateman, Randall/0000-0002-7729-1702; Rossor, Martin/0000-0001-8215-3120; Schofield, Peter/0000-0003-2967-9662; Martins, Ralph/0000-0002-4828-9363	National Institute on Aging; Medical Research Council [G0601846] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10123] Funding Source: researchfish; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448, UL1TR000124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS048056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U19AG032438, UF1AG032438, U19AG010483] Funding Source: NIH RePORTER; MRC [G0601846] Funding Source: UKRI	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funded by the National Institute on Aging and others; DIAN ClinicalTrials.gov number, NCT00869817.; Supported by the National Institute on Aging and a private nonprofit foundation (see disclosure at NEJM.org).	[Anonymous], 2011, SUMM OP IN AUTH VYND; [Anonymous], 2007, BAP PAT MILD MOD ALZ; [Anonymous], 2009, EFF LY2062430 PROGR; Bateman RJ, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt59; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Brookmeyer R, 2011, ALZHEIMERS DEMENT, V7, P61, DOI 10.1016/j.jalz.2010.11.007; Cruchaga C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031039; Fagan AM, 2007, ARCH NEUROL-CHICAGO, V64, P343, DOI 10.1001/archneur.64.3.noc60123; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gomez-Isla T, 1999, BRAIN, V122, P1709, DOI 10.1093/brain/122.9.1709; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hardy J, 2002, SCIENCE, V297, P2209; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Jack CR, 1997, NEUROLOGY, V49, P786, DOI 10.1212/WNL.49.3.786; Johnson SM, 2005, ACCOUNTS CHEM RES, V38, P911, DOI 10.1021/ar020073i; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Klunk WE, 2007, J NEUROSCI, V27, P6174, DOI 10.1523/JNEUROSCI.0730-07.2007; Lopera F, 1997, JAMA-J AM MED ASSOC, V277, P793, DOI 10.1001/jama.277.10.793; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Minoshima S, 1997, ANN NEUROL, V42, P85, DOI 10.1002/ana.410420114; Mintun MA, 2006, NEUROLOGY, V67, P446, DOI 10.1212/01.wnl.0000228230.26044.a4; Morris JC, 1997, NEUROLOGY, V48, P1508, DOI 10.1212/WNL.48.6.1508; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Mueller SG, 2005, NEUROIMAG CLIN N AM, V15, P869, DOI 10.1016/j.nic.2005.09.008; Perrin RJ, 2009, NATURE, V461, P916, DOI 10.1038/nature08538; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Price JL, 2001, ARCH NEUROL-CHICAGO, V58, P1395, DOI 10.1001/archneur.58.9.1395; Ridha BH, 2006, LANCET NEUROL, V5, P828, DOI 10.1016/S1474-4422(06)70550-6; Ringman JM, 2008, NEUROLOGY, V71, P85, DOI 10.1212/01.wnl.0000303973.71803.81; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Wechsler D., 1984, WMS R WECHSLER MEMOR; Wijsman EM, 2005, AM J MED GENET B, V132B, P14, DOI 10.1002/ajmg.b.30087; YAMAMOTO A, 1980, ATHEROSCLEROSIS, V35, P259, DOI 10.1016/0021-9150(80)90124-0	33	2242	2288	19	413	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 30	2012	367	9					795	804		10.1056/NEJMoa1202753	http://dx.doi.org/10.1056/NEJMoa1202753			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	996EN	22784036	Green Accepted, Green Published			2022-12-28	WOS:000308067400001
J	Angelo, K; Rancz, EA; Pimentel, D; Hundahl, C; Hannibal, J; Fleischmann, A; Pichler, B; Margrie, TW				Angelo, Kamilla; Rancz, Ede A.; Pimentel, Diogo; Hundahl, Christian; Hannibal, Jens; Fleischmann, Alexander; Pichler, Bruno; Margrie, Troy W.			A biophysical signature of network affiliation and sensory processing in mitral cells	NATURE			English	Article							HYPERPOLARIZATION-ACTIVATED CURRENT; PYRAMIDAL NEURONS; OLFACTORY-BULB; I-H; INTEGRATIVE PROPERTIES; ENTORHINAL CORTEX; DIVERSITY; CHANNELS; MOUSE; OSCILLATIONS	One defining characteristic of the mammalian brain is its neuronal diversity(1). For a given region, substructure, layer or even cell type, variability in neuronal morphology and connectivity persists(2-5). Although it is well known that such cellular properties vary considerably according to neuronal type, the substantial biophysical diversity of neurons of the same morphological class is typically averaged out and ignored. Here we show that the amplitude of hyperpolarization-evoked sag of membrane potential recorded in olfactory bulb mitral cells is an emergent, homotypic property of local networks and sensory information processing. Simultaneous whole-cell recordings from pairs of cells show that the amount of hyperpolarization-evoked sag potential and current (I-h)(6) is stereotypic for mitral cells belonging to the same glomerular circuit. This is corroborated by a mosaic, glomerulus-based pattern of expression of the HCN2 (hyperpolarization-activated cyclic nucleotidegated channel 2) subunit of the Ih channel. Furthermore, inter-glomerular differences in both membrane potential sag and HCN2 protein are diminished when sensory input to glomeruli is genetically and globally altered so that only one type of odorant receptor is universally expressed(7). Population diversity in this intrinsic property therefore reflects differential expression between local mitral cell networks processing distinct odour-related information.	[Angelo, Kamilla; Rancz, Ede A.; Pimentel, Diogo; Margrie, Troy W.] UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6BT, England; [Angelo, Kamilla; Hundahl, Christian] Univ Copenhagen, Fac Hlth Sci, Dept Neurosci & Pharmacol, DK-2200 Copenhagen N, Denmark; [Rancz, Ede A.; Pichler, Bruno; Margrie, Troy W.] MRC Natl Inst Med Res, Div Neurophysiol, London NW7 1AA, England; [Hundahl, Christian; Hannibal, Jens] Univ Copenhagen, Bispebjerg Hosp, Dept Clin Biochem, DK-2200 Copenhagen N, Denmark; [Fleischmann, Alexander] Coll France, Ctr Interdisciplinary Res Biol CIRB, F-75231 Paris 05, France	University of London; University College London; University of Copenhagen; MRC National Institute for Medical Research; University of Copenhagen; Bispebjerg Hospital; UDICE-French Research Universities; PSL Research University Paris; College de France	Margrie, TW (corresponding author), UCL, Dept Neurosci Physiol & Pharmacol, Gower St, London WC1E 6BT, England.	troy.margrie@nimr.mrc.ac.uk	Hundahl, Christian Ansgar/H-3938-2015; Rancz, Ede Attila/AAS-6867-2020; Hannibal, Jens/H-5482-2019	Hannibal, Jens/0000-0001-9416-0125; Rancz, Ede Attila/0000-0002-7951-1385	Sir Henry Wellcome Fellowship; Oticon Foundation; Danish Council for Independent Research; Lundbeckfondation; Gulbenkian PhD Programme; Fundacao para a Ciencia e Tecnologia; Wellcome Trust; Medical Research Council [MC_U1175975156]; MRC [MC_U117597156] Funding Source: UKRI; Medical Research Council [MC_U117597156] Funding Source: researchfish	Sir Henry Wellcome Fellowship; Oticon Foundation; Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Lundbeckfondation; Gulbenkian PhD Programme; Fundacao para a Ciencia e Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank M. Velez-Fort for comments on the manuscript. E. A. R. is a recipient of a Sir Henry Wellcome Fellowship. This project was supported by the Oticon Foundation, the Danish Council for Independent Research and the Lundbeckfondation (K. A.), the Gulbenkian PhD Programme and Fundacao para a Ciencia e Tecnologia (D. P.), The Wellcome Trust (T. W. M.) and Medical Research Council MC_U1175975156 (B. P. and T.W.M.).	Angelo K, 2011, SCI REP-UK, V1, DOI 10.1038/srep00050; Brochtrup A, 2011, CURR OPIN NEUROBIOL, V21, P85, DOI 10.1016/j.conb.2010.11.001; Brown SP, 2009, NATURE, V457, P1133, DOI 10.1038/nature07658; Cadetti L, 2001, NEUROREPORT, V12, P3117, DOI 10.1097/00001756-200110080-00027; Desai NS, 1999, NAT NEUROSCI, V2, P515, DOI 10.1038/9165; Dhawale AK, 2010, NAT NEUROSCI, V13, P1404, DOI 10.1038/nn.2673; Ermentrout GB, 2008, TRENDS NEUROSCI, V31, P428, DOI 10.1016/j.tins.2008.06.002; Fleischmann A, 2008, NEURON, V60, P1068, DOI 10.1016/j.neuron.2008.10.046; Garden DLF, 2008, NEURON, V60, P875, DOI 10.1016/j.neuron.2008.10.044; George MS, 2009, NAT NEUROSCI, V12, P577, DOI 10.1038/nn.2307; Giocomo LM, 2007, SCIENCE, V315, P1719, DOI 10.1126/science.1139207; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; Jinno S, 2007, J NEUROSCI, V27, P8790, DOI 10.1523/JNEUROSCI.1847-07.2007; Luthi A, 1998, NEURON, V20, P553, DOI 10.1016/S0896-6273(00)80994-0; Magee JC, 1998, J NEUROSCI, V18, P7613; Marder E, 2006, NAT REV NEUROSCI, V7, P563, DOI 10.1038/nrn1949; Migliore M, 2002, NAT REV NEUROSCI, V3, P362, DOI 10.1038/nrn810; Mombaerts P, 1996, CURR OPIN NEUROBIOL, V6, P481, DOI 10.1016/S0959-4388(96)80053-5; Nolan MF, 2007, J NEUROSCI, V27, P12440, DOI 10.1523/JNEUROSCI.2358-07.2007; Notomi T, 2004, J COMP NEUROL, V471, P241, DOI 10.1002/cne.11039; Padmanabhan K, 2010, NAT NEUROSCI, V13, P1276, DOI 10.1038/nn.2630; Pimentel DO, 2008, J PHYSIOL-LONDON, V586, P2107, DOI 10.1113/jphysiol.2007.149575; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Schoppa NE, 2001, NEURON, V31, P639, DOI 10.1016/S0896-6273(01)00389-0; Schulz DJ, 2006, NAT NEUROSCI, V9, P356, DOI 10.1038/nn1639; Tsiola A, 2003, J COMP NEUROL, V461, P415, DOI 10.1002/cne.10628; van Welie I, 2004, P NATL ACAD SCI USA, V101, P5123, DOI 10.1073/pnas.0307711101; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	30	57	57	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 16	2012	488	7411					375	378		10.1038/nature11291	http://dx.doi.org/10.1038/nature11291			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988OS	22820253	Green Accepted			2022-12-28	WOS:000307501000041
J	Denning, DP; Hatch, V; Horvitz, HR				Denning, Daniel P.; Hatch, Victoria; Horvitz, H. Robert			Programmed elimination of cells by caspase-independent cell extrusion in C. elegans	NATURE			English	Article							FUNCTIONAL GENOMIC ANALYSIS; DNA-DEGRADATION; DEATH; NEMATODE; MECHANISMS; ENGULFMENT; APOPTOSIS; KINASE; EPITHELIUM; PATHWAY	The elimination of unnecessary or defective cells from metazoans occurs during normal development and tissue homeostasis, as well as in response to infection or cellular damage(1). Although many cells are removed through caspase-mediated apoptosis followed by phagocytosis by engulfing cells(2), other mechanisms of cell elimination occur(3), including the extrusion of cells from epithelia through a poorly understood, possibly caspase-independent, process(4). Here we identify a mechanism of cell extrusion that is caspase independent and that can eliminate a subset of the Caenorhabditis elegans cells programmed to die during embryonic development. In wild-type animals, these cells die soon after their generation through caspase-mediated apoptosis. However, in mutants lacking all four C. elegans caspase genes, these cells are eliminated by being extruded from the developing embryo into the extra-embryonic space of the egg. The shed cells show apoptosis-like cytological and morphological characteristics, indicating that apoptosis can occur in the absence of caspases in C. elegans. We describe a kinase pathway required for cell extrusion involving PAR-4, STRD-1 and MOP-25.1/-25.2, the C. elegans homologues of the mammalian tumour-suppressor kinase LKB1 and its binding partners STRAD alpha and MO25 alpha. The AMPK-related kinase PIG-1, a possible target of the PAR-4-STRD-1-MOP-25 kinase complex, is also required for cell shedding. PIG-1 promotes shed-cell detachment by preventing the cell-surface expression of cell-adhesion molecules. Our findings reveal a mechanism for apoptotic cell elimination that is fundamentally distinct from that of canonical programmed cell death.	[Denning, Daniel P.; Hatch, Victoria; Horvitz, H. Robert] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Denning, Daniel P.; Hatch, Victoria; Horvitz, H. Robert] MIT, Dept Biol, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.	horvitz@mit.edu			National Institutes of Health National Center for Research Resources (NCRR); Damon Runyon Cancer Research Foundation; Charles A. King Trust	National Institutes of Health National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Damon Runyon Cancer Research Foundation; Charles A. King Trust	We thank Z. Zhou, T. Hirose and S. Nakano for reporter constructs; B. Castor, E. Murphy and R. Droste for determining DNA sequences; S. Dennis for screening of the deletion library; N. An for strain management; and, J. Yuan, S. Nakano, N. Paquin, C. Engert and A. Saffer for discussions. The Caenorhabditis Genetic Center, which is funded by the National Institutes of Health National Center for Research Resources (NCRR), provided many strains. S. Mitani provided grp-1(tm1956). D. P. D. was supported by post-doctoral fellowships from the Damon Runyon Cancer Research Foundation and from the Charles A. King Trust. H. R. H. is the David H. Koch Professor of Biology at the Massachusetts Institute of Technology and an Investigator at the Howard Hughes Medical Institute.	Abdus-Saboor I, 2011, DEVELOPMENT, V138, P3545, DOI 10.1242/dev.068148; Abraham MC, 2007, DEV CELL, V12, P73, DOI 10.1016/j.devcel.2006.11.012; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; BRENNER S, 1974, GENETICS, V77, P71; Buechner M, 2002, TRENDS CELL BIOL, V12, P479, DOI 10.1016/S0962-8924(02)02364-4; Coopersmith CM, 1999, AM J PHYSIOL-GASTR L, V276, pG677, DOI 10.1152/ajpgi.1999.276.3.G677; Cordes S, 2006, DEVELOPMENT, V133, P2747, DOI 10.1242/dev.02447; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Fuchs Y, 2011, CELL, V147, P742, DOI 10.1016/j.cell.2011.10.033; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hirose T, 2010, P NATL ACAD SCI USA, V107, P15479, DOI 10.1073/pnas.1010023107; Kinchen JM, 2008, NAT CELL BIOL, V10, P556, DOI 10.1038/ncb1718; Labouesse Michel, 2006, WormBook, P1; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Lu Q, 2008, DEVELOPMENT, V135, P1069, DOI 10.1242/dev.016063; Narbonne P, 2010, DEVELOPMENT, V137, P661, DOI 10.1242/dev.042044; Ou GS, 2010, SCIENCE, V330, P677, DOI 10.1126/science.1196112; Parrish JZ, 2003, MOL CELL, V11, P987, DOI 10.1016/S1097-2765(03)00095-9; Potten CS, 1998, PHILOS T R SOC B, V353, P821, DOI 10.1098/rstb.1998.0246; Potts MB, 2011, NAT REV CANCER, V11, P50, DOI 10.1038/nrc2984; Reddien PW, 2004, ANNU REV CELL DEV BI, V20, P193, DOI 10.1146/annurev.cellbio.20.022003.114619; Rosenblatt J, 2001, CURR BIOL, V11, P1847, DOI 10.1016/S0960-9822(01)00587-5; Rual JF, 2004, GENOME RES, V14, P2162, DOI 10.1101/gr.2505604; Schwartz HT, 2007, NAT PROTOC, V2, P705, DOI 10.1038/nprot.2007.93; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaham S, 1998, J BIOL CHEM, V273, P35109, DOI 10.1074/jbc.273.52.35109; Shaham S, 1999, GENETICS, V153, P1655; Singhvi A, 2011, CURR BIOL, V21, P948, DOI 10.1016/j.cub.2011.04.025; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Venegas V, 2007, MOL BIOL CELL, V18, P3180, DOI 10.1091/mbc.E07-02-0138; Watson AJM, 2009, ANN NY ACAD SCI, V1165, P135, DOI 10.1111/j.1749-6632.2009.04027.x; Wu YC, 2000, GENE DEV, V14, P536; Yuan JY, 2010, GENE DEV, V24, P2592, DOI 10.1101/gad.1984410; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377	38	50	62	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 9	2012	488	7410					226	+		10.1038/nature11240	http://dx.doi.org/10.1038/nature11240			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	985LE	22801495	Green Accepted, Green Submitted			2022-12-28	WOS:000307267000037
J	Guichard, P; Desfosses, A; Maheshwari, A; Hachet, V; Dietrich, C; Brune, A; Ishikawa, T; Sachse, C; Gonczy, P				Guichard, Paul; Desfosses, Ambroise; Maheshwari, Aditi; Hachet, Virginie; Dietrich, Carsten; Brune, Andreas; Ishikawa, Takashi; Sachse, Carsten; Goenczy, Pierre			Cartwheel Architecture of Trichonympha Basal Body	SCIENCE			English	Article							CENTRIOLES		[Guichard, Paul; Hachet, Virginie; Goenczy, Pierre] Swiss Fed Inst Technol EPFL, Swiss Inst Expt Canc Res ISREC, Sch Life Sci, Lausanne, Switzerland; [Desfosses, Ambroise; Sachse, Carsten] European Mol Biol Lab, Struct & Computat Biol Unit, Heidelberg, Germany; [Maheshwari, Aditi; Ishikawa, Takashi] Paul Scherrer Inst, Villigen, Switzerland; [Dietrich, Carsten; Brune, Andreas] Max Planck Inst Terr Microbiol, Dept Biogeochem, D-35043 Marburg, Germany	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; European Molecular Biology Laboratory (EMBL); Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Max Planck Society	Gonczy, P (corresponding author), Swiss Fed Inst Technol EPFL, Swiss Inst Expt Canc Res ISREC, Sch Life Sci, Lausanne, Switzerland.	pierre.gonczy@epfl.ch	Sachse, Carsten/AAY-9384-2020; Brune, Andreas/C-6944-2011; Ishikawa, Takashi/E-5023-2017; Guichard, Paul/AAL-8603-2020; Sachse, Carsten/H-2727-2012	Sachse, Carsten/0000-0002-1168-5143; Brune, Andreas/0000-0002-2667-4391; Ishikawa, Takashi/0000-0002-1976-7477; Guichard, Paul/0000-0002-0363-1049; Sachse, Carsten/0000-0002-1168-5143; Desfosses, Ambroise/0000-0002-6525-5042; HAMEL, VIRGINIE/0000-0001-5092-2343; Gonczy, Pierre/0000-0002-6305-6883	Swiss National Foundation [Sinergia CRSII3_125463, NF31003A-125131/1]; European Research Council [AdG 233335]	Swiss National Foundation(Swiss National Science Foundation (SNSF)); European Research Council(European Research Council (ERC)European Commission)	We thank M. Steinmetz, A.-M. Tassin, and Y. Hongoh for fruitful discussions and comments on the manuscript; J.-D. Rochaix and A. Shapiguzov for Chlamydomonas; and S. Rosset and G. Knott (BioEM core facility, EPFL) for help with EM. Supported by grants from the Swiss National Foundation (Sinergia CRSII3_125463 to P. G.; NF31003A-125131/1 to T. I.) and the European Research Council (AdG 233335 to P. G.). Additional data and information are in the supplementary materials.	Cottee MA, 2011, NAT CHEM BIOL, V7, P650, DOI 10.1038/nchembio.660; GIBBONS IR, 1960, J BIOPHYS BIOCHEM CY, V7, P697, DOI 10.1083/jcb.7.4.697; Gonczy P, 2012, NAT REV MOL CELL BIO, V13, P425, DOI 10.1038/nrm3373; Kitagawa D, 2011, CELL, V144, P364, DOI 10.1016/j.cell.2011.01.008; Li S, 2012, EMBO J, V31, P552, DOI 10.1038/emboj.2011.460; van Breugel M, 2011, SCIENCE, V331, P1196, DOI 10.1126/science.1199325	6	68	71	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 3	2012	337	6094					553	553		10.1126/science.1222789	http://dx.doi.org/10.1126/science.1222789			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982PU	22798403				2022-12-28	WOS:000307058700036
J	Das, P; Horton, R				Das, Pamela; Horton, Richard			The cultural challenge of HIV/AIDS	LANCET			English	Editorial Material									[Das, Pamela; Horton, Richard] The Lancet, London NW1 7BY, England		Das, P (corresponding author), The Lancet, London NW1 7BY, England.							Altman D, 2012, LANCET; Beyrer C, 2012, LANCET; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Mayer KH, 2012, LANCET; Millett GA, 2012, LANCET; Sullivan PS, 2012, LANCET; The International AIDS Society Scientific Working Group on HIV Cure, 2012, NAT REV IMM IN PRESS; Trapence G, 2012, LANCET; UNAIDS, 2010, GLOB REP UNAIDS REP; US Department of State, 2011, COMMUNICATION   0308	10	15	17	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 28	2012	380	9839					309	310		10.1016/S0140-6736(12)61074-5	http://dx.doi.org/10.1016/S0140-6736(12)61074-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819658				2022-12-28	WOS:000306842800004
J	Chiu, HY; Tsai, TF				Chiu, Hsien-Yi; Tsai, Tsen-Fang			A Crusted Plaque on the Right Nipple	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SYPHILIS; CHANCRE		[Tsai, Tsen-Fang] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University	Tsai, TF (corresponding author), Natl Taiwan Univ Hosp, Dept Dermatol, 7 Chung Shan S Rd, Taipei 100, Taiwan.	tftsai@yahoo.com		Chiu, Hsien-Yi/0000-0002-0493-9707; TSAI, TSEN-FANG/0000-0002-1498-1474				Dourmishev LA, 2005, CLIN DERMATOL, V23, P555, DOI 10.1016/j.clindermatol.2005.01.015; Flynn TR, 2010, NEW ENGL J MED, V362, P740, DOI 10.1056/NEJMcpc0910089; Lee JYY, 2006, J EUR ACAD DERMATOL, V20, P886, DOI 10.1111/j.1468-3083.2006.01560.x; Oh Y, 2008, INT J DERMATOL, V47, P978, DOI 10.1111/j.1365-4632.2008.03617.x; Sim JH, 2010, ARCH DERMATOL, V146, P81, DOI 10.1001/archdermatol.2009.335-a	5	11	13	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					403	404		10.1001/jama.2012.7538	http://dx.doi.org/10.1001/jama.2012.7538			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820793				2022-12-28	WOS:000306685500028
J	Beltrao, P; Albanese, V; Kenner, LR; Swaney, DL; Burlingame, A; Villen, J; Lim, WA; Fraser, JS; Frydman, J; Krogan, NJ				Beltrao, Pedro; Albanese, Veronique; Kenner, Lillian R.; Swaney, Danielle L.; Burlingame, Alma; Villen, Judit; Lim, Wendell A.; Fraser, James S.; Frydman, Judith; Krogan, Nevan J.			Systematic Functional Prioritization of Protein Posttranslational Modifications	CELL			English	Article							PHOSPHORYLATION; EVOLUTION; NETWORKS; LYSINE; IDENTIFICATION; COMPLEXES; SELECTION; REVEALS; SWITCH; SITES	Protein function is often regulated by posttranslational modifications (PTMs), and recent advances in mass spectrometry have resulted in an exponential increase in PTM identification. However, the functional significance of the vast majority of these modifications remains unknown. To address this problem, we compiled nearly 200,000 phosphorylation, acetylation, and ubiquitination sites from 11 eukaryotic species, including 2,500 newly identified ubiquitylation sites for Saccharomyces cerevisiae. We developed methods to prioritize the functional relevance of these PTMs by predicting those that likely participate in cross-regulatory events, regulate domain activity, or mediate protein-protein interactions. PTM conservation within domain families identifies regulatory "hot spots" that overlap with functionally important regions, a concept that we experimentally validated on the HSP70 domain family. Finally, our analysis of the evolution of PTM regulation highlights potential routes for neutral drift in regulatory interactions and suggests that only a fraction of modification sites are likely to have a significant biological role.	[Beltrao, Pedro; Kenner, Lillian R.; Lim, Wendell A.; Fraser, James S.; Krogan, Nevan J.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94107 USA; [Burlingame, Alma] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94107 USA; [Beltrao, Pedro; Kenner, Lillian R.; Burlingame, Alma; Lim, Wendell A.; Fraser, James S.; Krogan, Nevan J.] QB3, Calif Inst Quantitat Biosci, San Francisco, CA 94107 USA; [Albanese, Veronique; Frydman, Judith] Clark Ctr, Dept Biol, BioX Program, Stanford, CA 94305 USA; [Swaney, Danielle L.; Villen, Judit] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; [Lim, Wendell A.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA; [Krogan, Nevan J.] J David Gladstone Inst, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Beltrao, P (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94107 USA.	pedro.beltrao@ucsf.edu; krogan@cmp.ucsf.edu	Beltrao, Pedro/B-3342-2010	Beltrao, Pedro/0000-0002-2724-7703; Albanese, Veronique/0000-0002-5947-7415; Fraser, James/0000-0002-5080-2859; , judith/0000-0003-2302-6943; Kenner, Lukas/0000-0003-2184-1338; Villen, Judit/0000-0002-1005-1739	National Institutes of Health [AI090935, GM082250, GM084448, GM084279, GM081879, GM55040, GM062583, PN2 EY016546, GM56433, DP5 OD009180, RR01614]; Howard Hughes Medical Institute; Packard Foundation; Human Frontier Science Program; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [PN2EY016546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763, P01AI090935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062583, R01GM056433, R01GM084448, P50GM081879, R37GM056433, R01GM084279, R01GM055040, P50GM082250] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD009180] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Packard Foundation(The David & Lucile Packard Foundation); Human Frontier Science Program(Human Frontier Science Program); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Stephen Michnick and Peter Kaiser for strains and plasmids, Betty Craig for the ssa1-45 ts cells, and Stephanie Escusa and Jonathan Warner for reagents. This work was supported by grants from the National Institutes of Health (AI090935, GM082250, GM084448, GM084279, GM081879 [N.J.K.]); GM55040, GM062583, GM081879, PN2 EY016546 [W.A.L.]; GM56433 [J.F.]; DP5 OD009180 [J.S.F.]; and RR01614 [A.B.]), the Howard Hughes Medical Institute (W.A.L.), and the Packard Foundation (W.A.L.). P.B. is supported by the Human Frontier Science Program, J.S.F. is a QB3@UCSF Fellow, and N.J.K. is a Searle Scholar and a Keck Young Investigator.	Aghajan M, 2010, NAT BIOTECHNOL, V28, P738, DOI 10.1038/nbt.1645; Albanese V, 2006, CELL, V124, P75, DOI 10.1016/j.cell.2005.11.039; Ali MMU, 2006, NATURE, V440, P1013, DOI 10.1038/nature04716; Ba ANN, 2010, MOL BIOL EVOL, V27, P2027, DOI 10.1093/molbev/msq090; Beausoleil SA, 2006, NAT BIOTECHNOL, V24, P1285, DOI 10.1038/nbt1240; Beltrao P, 2007, PLOS COMPUT BIOL, V3, P258, DOI 10.1371/journal.pcbi.0030025; Beltrao P, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000134; Carroll SB, 2005, PLOS BIOL, V3, P1159, DOI 10.1371/journal.pbio.0030245; Choudhary C, 2010, NAT REV MOL CELL BIO, V11, P427, DOI 10.1038/nrm2900; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Ear PH, 2009, NAT METHODS, V6, P813, DOI [10.1038/NMETH.1389, 10.1038/nmeth.1389]; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Emanuele MJ, 2011, CELL, V147, P459, DOI 10.1016/j.cell.2011.09.019; Esteve PO, 2011, NAT STRUCT MOL BIOL, V18, P42, DOI 10.1038/nsmb.1939; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Holt LJ, 2009, SCIENCE, V325, P1682, DOI 10.1126/science.1172867; Horton LE, 2001, J BIOL CHEM, V276, P14426, DOI 10.1074/jbc.M100266200; Huber A, 2009, GENE DEV, V23, P1929, DOI 10.1101/gad.532109; Hunter T, 2007, MOL CELL, V28, P730, DOI 10.1016/j.molcel.2007.11.019; Jonkers W, 2009, EUKARYOT CELL, V8, P677, DOI 10.1128/EC.00386-08; Kaiser P, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-16; Kampinga HH, 2010, NAT REV MOL CELL BIO, V11, P579, DOI 10.1038/nrm2941; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Landry CR, 2009, TRENDS GENET, V25, P193, DOI 10.1016/j.tig.2009.03.003; Lavoie H, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000329; Li SY, 2010, BIOCOMPUT-PAC SYM, P337; Lienhard GE, 2008, TRENDS BIOCHEM SCI, V33, P351, DOI 10.1016/j.tibs.2008.05.004; Ludwig MZ, 2000, NATURE, V403, P564, DOI 10.1038/35000615; Michnick SW, 2010, METHOD ENZYMOL, V470, P335, DOI 10.1016/S0076-6879(10)70014-8; Moses AM, 2007, P NATL ACAD SCI USA, V104, P17713, DOI 10.1073/pnas.0700997104; Narayanan A, 2009, CURR OPIN STRUC BIOL, V19, P156, DOI 10.1016/j.sbi.2009.02.007; Neduva V, 2005, FEBS LETT, V579, P3342, DOI 10.1016/j.febslet.2005.04.005; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Paolinelli R, 2009, NAT STRUCT MOL BIOL, V16, P412, DOI 10.1038/nsmb.1583; Pereira-Leal JB, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r51; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Soroka J, 2012, MOL CELL, V45, P517, DOI 10.1016/j.molcel.2011.12.031; Soufi B, 2009, MOL BIOSYST, V5, P1337, DOI 10.1039/b902256b; Stark C, 2010, DATABASE-OXFORD, DOI 10.1093/database/bap026; Stein A, 2011, NUCLEIC ACIDS RES, V39, pD718, DOI 10.1093/nar/gkq962; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Tan CSH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000316; Tsong AE, 2006, NATURE, V443, P415, DOI 10.1038/nature05099; van Dam TJP, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000132; Wagner A, 2008, NAT REV GENET, V9, P965, DOI 10.1038/nrg2473; Wagner SA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.013284; Wandinger SK, 2006, EMBO J, V25, P367, DOI 10.1038/sj.emboj.7600930; Weinert BT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001902; Yang XJ, 2006, MOL CELL, V23, P779, DOI 10.1016/j.molcel.2006.08.009	51	286	290	2	94	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 20	2012	150	2					413	425		10.1016/j.cell.2012.05.036	http://dx.doi.org/10.1016/j.cell.2012.05.036			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817900	Green Accepted, Bronze			2022-12-28	WOS:000306595700019
J	Karr, JR; Sanghvi, JC; Macklin, DN; Gutschow, MV; Jacobs, JM; Bolival, B; Assad-Garcia, N; Glass, JI; Covert, MW				Karr, Jonathan R.; Sanghvi, Jayodita C.; Macklin, Derek N.; Gutschow, Miriam V.; Jacobs, Jared M.; Bolival, Benjamin; Assad-Garcia, Nacyra, Jr.; Glass, John I.; Covert, Markus W.			A Whole-Cell Computational Model Predicts Phenotype from Genotype	CELL			English	Article							GENOME-REDUCED BACTERIUM; ESCHERICHIA-COLI; RNA-POLYMERASE; MINIMAL CELL; MYCOPLASMA-GENITALIUM; REPLICATION; MOLECULE; PROTEIN; TIME; DEHYDROGENASE	Understanding how complex phenotypes arise from individual molecules and their interactions is a primary challenge in biology that computational approaches are poised to tackle. We report a whole-cell computational model of the life cycle of the human pathogen Mycoplasma genitalium that includes all of its molecular components and their interactions. An integrative approach to modeling that combines diverse mathematics enabled the simultaneous inclusion of fundamentally different cellular processes and experimental measurements. Our whole-cell model accounts for all annotated gene functions and was validated against a broad range of data. The model provides insights into many previously unobserved cellular behaviors, including in vivo rates of protein-DNA association and an inverse relationship between the durations of DNA replication initiation and replication. In addition, experimental analysis directed by model predictions identified previously undetected kinetic parameters and biological functions. We conclude that comprehensive whole-cell models can be used to facilitate biological discovery.	[Sanghvi, Jayodita C.; Macklin, Derek N.; Gutschow, Miriam V.; Jacobs, Jared M.; Bolival, Benjamin; Covert, Markus W.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Karr, Jonathan R.] Stanford Univ, Grad Program Biophys, Stanford, CA 94305 USA; [Assad-Garcia, Nacyra, Jr.; Glass, John I.] J Craig Venter Inst, Rockville, MD 20850 USA	Stanford University; Stanford University; J. Craig Venter Institute	Covert, MW (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.	mcovert@stanford.edu	Karr, Jonathan/D-1407-2013; Glass, John/A-6572-2015	Karr, Jonathan/0000-0002-2605-5080; Glass, John/0000-0002-3784-5301; Covert, Markus/0000-0002-5993-8912	NIH [1DP1OD006413]; Hellman Faculty Scholarship; NSF; Bio-X Graduate Student Fellowships; NDSEG; Stanford Graduate Student Fellowships; Benchmark Stanford Graduate Fellowship; U.S. Department of Energy [DE-FC02-02ER63453]; NATIONAL LIBRARY OF MEDICINE [DP1LM011510] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD006413] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hellman Faculty Scholarship; NSF(National Science Foundation (NSF)); Bio-X Graduate Student Fellowships; NDSEG; Stanford Graduate Student Fellowships; Benchmark Stanford Graduate Fellowship; U.S. Department of Energy(United States Department of Energy (DOE)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank R. Altman, S. Brenner, Z. Bryant, J. Ferrell, K. Huang, B. Palsson, S. Quake, L. Serrano, J. Swartz, E. Yus, and the Covert Lab for numerous enlightening discussions on bacterial physiology and computational modeling; T. Vora for critical reading of the manuscript; and M. O'Reilly and J. Maynard for graphical design assistance. This work was supported by an NIH Director's Pioneer Award (1DP1OD006413) and a Hellman Faculty Scholarship to M.W.C.; NSF and Bio-X Graduate Student Fellowships to J.C.S.; NDSEG, NSF, and Stanford Graduate Student Fellowships to J.R.K.; a Benchmark Stanford Graduate Fellowship to D.N.M.; and a U.S. Department of Energy Cooperative Agreement (DE-FC02-02ER63453) to the J. Craig Venter Institute.	Atlas JC, 2008, IET SYST BIOL, V2, P369, DOI 10.1049/iet-syb:20070079; Bennett BD, 2009, NAT CHEM BIOL, V5, P593, DOI 10.1038/nchembio.186; Bratton BP, 2011, J BACTERIOL, V193, P5138, DOI 10.1128/JB.00198-11; Brenner S, 2010, PHILOS T R SOC B, V365, P207, DOI 10.1098/rstb.2009.0221; Browning ST, 2004, BIOTECHNOL BIOENG, V88, P575, DOI 10.1002/bit.20223; Castellanos M, 2004, P NATL ACAD SCI USA, V101, P6681, DOI 10.1073/pnas.0400962101; Castellanos M, 2007, BIOTECHNOL BIOENG, V97, P397, DOI 10.1002/bit.21251; Chandrasekaran S, 2010, P NATL ACAD SCI USA, V107, P17845, DOI 10.1073/pnas.1005139107; Cordwell SJ, 1997, GENE, V195, P113, DOI 10.1016/S0378-1119(97)00063-2; Covert MW, 2008, BIOINFORMATICS, V24, P2044, DOI 10.1093/bioinformatics/btn352; Covert MW, 2004, NATURE, V429, P92, DOI 10.1038/nature02456; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; de Kok A, 1998, BBA-PROTEIN STRUCT M, V1385, P353, DOI 10.1016/S0167-4838(98)00079-X; Di Ventura B, 2006, NATURE, V443, P527, DOI 10.1038/nature05127; DOMACH MM, 1984, BIOTECHNOL BIOENG, V26, P1140, DOI 10.1002/bit.260260925; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Gibson DG, 2008, SCIENCE, V319, P1215, DOI 10.1126/science.1151721; Gibson DG, 2010, SCIENCE, V329, P52, DOI 10.1126/science.1190719; Glass JI, 2006, P NATL ACAD SCI USA, V103, P425, DOI 10.1073/pnas.0510013103; Guell M, 2009, SCIENCE, V326, P1268, DOI 10.1126/science.1176951; Harada Y, 1999, BIOPHYS J, V76, P709, DOI 10.1016/S0006-3495(99)77237-1; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Kuhner S, 2009, SCIENCE, V326, P1235, DOI 10.1126/science.1176343; Lartigue C, 2007, SCIENCE, V317, P632, DOI 10.1126/science.1144622; Lartigue C, 2009, SCIENCE, V325, P1693, DOI 10.1126/science.1173759; Morowitz H.J., 1992, BEGINNINGS CELLULAR; MOROWITZ HJ, 1962, J MOL BIOL, V4, P93, DOI 10.1016/S0022-2836(62)80041-2; Orth JD, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.65; Orth JD, 2010, NAT BIOTECHNOL, V28, P245, DOI 10.1038/nbt.1614; Pollack J. Dennis, 2002, OMICS A Journal of Integrative Biology, V6, P247, DOI 10.1089/15362310260256909; Pomerantz RT, 2010, SCIENCE, V327, P590, DOI 10.1126/science.1179595; RUSSELL JB, 1995, MICROBIOL REV, V59, P48, DOI 10.1128/MMBR.59.1.48-62.1995; SCHMIDT HL, 1986, EUR J BIOCHEM, V156, P149, DOI 10.1111/j.1432-1033.1986.tb09560.x; So LH, 2011, NAT GENET, V43, P554, DOI 10.1038/ng.821; Sundararaj S, 2004, NUCLEIC ACIDS RES, V32, pD293, DOI 10.1093/nar/gkh108; Suthers PF, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000285; Taniguchi Y, 2010, SCIENCE, V329, P533, DOI 10.1126/science.1188308; Thiele I, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000312; Tomita M, 1999, BIOINFORMATICS, V15, P72, DOI 10.1093/bioinformatics/15.1.72; Vora T, 2009, MOL CELL, V35, P247, DOI 10.1016/j.molcel.2009.06.035; Yu J, 2006, SCIENCE, V311, P1600, DOI 10.1126/science.1119623; Yus E, 2009, SCIENCE, V326, P1263, DOI 10.1126/science.1177263	42	781	799	4	222	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 20	2012	150	2					389	401		10.1016/j.cell.2012.05.044	http://dx.doi.org/10.1016/j.cell.2012.05.044			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817898	Green Accepted, Bronze			2022-12-28	WOS:000306595700017
J	Dutta, P; Courties, G; Wei, Y; Leuschner, F; Gorbatov, R; Robbins, CS; Iwamoto, Y; Thompson, B; Carlson, AL; Heidt, T; Majmudar, MD; Lasitschka, F; Etzrodt, M; Waterman, P; Waring, MT; Chicoine, AT; van der Laan, AM; Niessen, HWM; Piek, JJ; Rubin, BB; Butany, J; Stone, JR; Katus, HA; Murphy, SA; Morrow, DA; Sabatine, MS; Vinegoni, C; Moskowitz, MA; Pittet, MJ; Libby, P; Lin, CP; Swirski, FK; Weissleder, R; Nahrendorf, M				Dutta, Partha; Courties, Gabriel; Wei, Ying; Leuschner, Florian; Gorbatov, Rostic; Robbins, Clinton S.; Iwamoto, Yoshiko; Thompson, Brian; Carlson, Alicia L.; Heidt, Timo; Majmudar, Maulik D.; Lasitschka, Felix; Etzrodt, Martin; Waterman, Peter; Waring, Michael T.; Chicoine, Adam T.; van der Laan, Anja M.; Niessen, Hans W. M.; Piek, Jan J.; Rubin, Barry B.; Butany, Jagdish; Stone, James R.; Katus, Hugo A.; Murphy, Sabina A.; Morrow, David A.; Sabatine, Marc S.; Vinegoni, Claudio; Moskowitz, Michael A.; Pittet, Mikael J.; Libby, Peter; Lin, Charles P.; Swirski, Filip K.; Weissleder, Ralph; Nahrendorf, Matthias			Myocardial infarction accelerates atherosclerosis	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; ACUTE CORONARY SYNDROMES; MONOCYTE SUBSETS; PROGENITOR CELLS; ARTERY-DISEASE; BONE-MARROW; INFLAMMATION; PLAQUES; NICHE; IDENTIFICATION	During progression of atherosclerosis, myeloid cells destabilize lipid-rich plaques in the arterial wall and cause their rupture, thus triggering myocardial infarction and stroke. Survivors of acute coronary syndromes have a high risk of recurrent events for unknown reasons. Here we show that the systemic response to ischaemic injury aggravates chronic atherosclerosis. After myocardial infarction or stroke, Apoe(-/-) mice developed larger atherosclerotic lesions with a more advanced morphology. This disease acceleration persisted over many weeks and was associated with markedly increased monocyte recruitment. Seeking the source of surplus monocytes in plaques, we found that myocardial infarction liberated haematopoietic stem and progenitor cells from bone marrow niches via sympathetic nervous system signalling. The progenitors then seeded the spleen, yielding a sustained boost in monocyte production. These observations provide new mechanistic insight into atherogenesis and provide a novel therapeutic opportunity to mitigate disease progression.	[Dutta, Partha; Courties, Gabriel; Leuschner, Florian; Gorbatov, Rostic; Robbins, Clinton S.; Iwamoto, Yoshiko; Thompson, Brian; Carlson, Alicia L.; Heidt, Timo; Majmudar, Maulik D.; Etzrodt, Martin; Waterman, Peter; Stone, James R.; Vinegoni, Claudio; Pittet, Mikael J.; Lin, Charles P.; Swirski, Filip K.; Weissleder, Ralph; Nahrendorf, Matthias] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA; [Dutta, Partha; Courties, Gabriel; Leuschner, Florian; Gorbatov, Rostic; Robbins, Clinton S.; Iwamoto, Yoshiko; Thompson, Brian; Carlson, Alicia L.; Heidt, Timo; Majmudar, Maulik D.; Etzrodt, Martin; Waterman, Peter; Stone, James R.; Vinegoni, Claudio; Pittet, Mikael J.; Lin, Charles P.; Swirski, Filip K.; Weissleder, Ralph; Nahrendorf, Matthias] Harvard Univ, Sch Med, Boston, MA 02114 USA; [Wei, Ying; Moskowitz, Michael A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Stroke & Neurovasc Regulat Lab, Charlestown, MA 02129 USA; [Wei, Ying; Moskowitz, Michael A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Stroke & Neurovasc Regulat Lab, Charlestown, MA 02129 USA; [Leuschner, Florian; Katus, Hugo A.] Med Univ Hosp Heidelberg, Dept Cardiol, D-69120 Heidelberg, Germany; [Majmudar, Maulik D.; Libby, Peter] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; [Lasitschka, Felix] Univ Heidelberg Hosp, Inst Pathol, D-69120 Heidelberg, Germany; [Waring, Michael T.; Chicoine, Adam T.] MIT & Harvard Massachusetts Gen Hosp, Ragon Inst MGH, Charlestown, MA 02129 USA; [Waring, Michael T.; Chicoine, Adam T.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; [van der Laan, Anja M.; Piek, Jan J.] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; [Niessen, Hans W. M.] Vrije Univ Amsterdam Med Ctr, ICaR VU, Dept Pathol & Cardiac Surg, NL-1081 HV Amsterdam, Netherlands; [Rubin, Barry B.] Univ Toronto, Toronto Gen Hosp, Peter Munk Cardiac Ctr, Div Vasc Surg, Toronto, ON M5G 2C4, Canada; [Butany, Jagdish] Univ Toronto, Peter Munk Cardiac Ctr, Dept Pathol, Toronto, ON M5G 2C4, Canada; [Stone, James R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Murphy, Sabina A.; Morrow, David A.; Sabatine, Marc S.] Brigham & Womens Hosp, Div Cardiovasc, Dept Med, TIMI Study Grp, Boston, MA 02145 USA; [Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Ruprecht Karls University Heidelberg; Harvard University; Brigham & Women's Hospital; Ruprecht Karls University Heidelberg; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Howard Hughes Medical Institute; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Toronto; Peter Munk Cardiac Centre; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; Peter Munk Cardiac Centre; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Nahrendorf, M (corresponding author), Massachusetts Gen Hosp, Ctr Syst Biol, Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA.	rweissleder@mgh.harvard.edu; mnahrendorf@mgh.harvard.edu	Vinegoni, Claudio/A-9490-2012; Pittet, Mikael/ABD-6300-2021; Libby, Peter/AAY-6404-2021; Sabatine, Marc/AAJ-6751-2020; vinegoni, claudio/AGU-2461-2022; Wei, Yen/H-5329-2012; Etzrodt, Martin/P-3325-2015; Swirski, Filip/AAF-1340-2019	Vinegoni, Claudio/0000-0002-9818-3639; Libby, Peter/0000-0002-1502-502X; Sabatine, Marc/0000-0002-0691-3359; Etzrodt, Martin/0000-0003-1928-3904; Swirski, Filip/0000-0002-3163-9152; Robbins, Clinton/0000-0001-9848-1495; /0000-0003-0828-4143; Courties, Gabriel/0000-0002-0003-7407; Niessen, Hans/0000-0001-9404-9822; Butany, Jagdish/0000-0003-0549-7602	National Institute of Health [R01-HL096576, R01-HL095629, R01-EB006432, T32-CA79443, P50-CA086355]; Deutsche Forschungsgemeinschaft [SFB 938/Z2]; NATIONAL CANCER INSTITUTE [T32CA079443, P50CA086355] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL094301, R01HL096576, R01HL095612, R01HL095629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI084880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB006432] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank the CSB Mouse Imaging Program (J. Truelove, D. Jeon, J. Donahoe, B. Marinelli) and K. Naxerova for helpful discussions. This work was funded by grants from the National Institute of Health R01-HL096576, R01-HL095629 (M.N.); R01-EB006432, T32-CA79443, P50-CA086355 (R.W.). F.L. was funded in part by Deutsche Forschungsgemeinschaft SFB 938/Z2. Fig. 5e was produced using Servier Medical Art (http://www.servier.com).	Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Chen JQ, 2002, CIRCULATION, V105, P2766, DOI 10.1161/01.CIR.0000017860.20619.23; Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Goldstein JA, 2000, NEW ENGL J MED, V343, P915, DOI 10.1056/NEJM200009283431303; Hoffmann C, 2004, N-S ARCH PHARMACOL, V369, P151, DOI 10.1007/s00210-003-0860-y; Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; KRUSZEWSKA B, 1995, J IMMUNOL, V155, P4613; Leuschner F, 2012, J EXP MED, V209, P123, DOI 10.1084/jem.20111009; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146; Lo Celso C, 2011, J CELL SCI, V124, P3529, DOI 10.1242/jcs.074112; Lo Celso C, 2009, NATURE, V457, P92, DOI 10.1038/nature07434; Massa M, 2005, BLOOD, V105, P199, DOI 10.1182/blood-2004-05-1831; Mendez-Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685; Mendez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262; Milonas C, 2010, AM J CARDIOL, V105, P1229, DOI 10.1016/j.amjcard.2009.12.032; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Nahrendorf M, 2010, CIRCULATION, V121, P2437, DOI 10.1161/CIRCULATIONAHA.109.916346; Nahrendorf M, 2009, ARTERIOSCL THROM VAS, V29, P1444, DOI 10.1161/ATVBAHA.109.193086; Psaltis PJ, 2012, CIRCULATION, V125, P592, DOI 10.1161/CIRCULATIONAHA.111.059360; Randolph GJ, 2009, J THROMB HAEMOST, V7, P28, DOI 10.1111/j.1538-7836.2009.03423.x; Robbins CS, 2012, CIRCULATION, V125, P364, DOI 10.1161/CIRCULATIONAHA.111.061986; Sabatine MS, 2002, J AM COLL CARDIOL, V40, P1761, DOI 10.1016/S0735-1097(02)02484-1; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; ZIGMOND RE, 1977, P NATL ACAD SCI USA, V74, P3078, DOI 10.1073/pnas.74.7.3078	36	712	741	5	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 19	2012	487	7407					325	329		10.1038/nature11260	http://dx.doi.org/10.1038/nature11260			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JB	22763456	Green Submitted, Green Accepted			2022-12-28	WOS:000306506500034
J	Waldorff, FB; Buss, DV; Eckermann, A; Rasmussen, MLH; Keiding, N; Rishoj, S; Siersma, V; Sorensen, J; Sorensen, LV; Vogel, A; Waldemar, G				Waldorff, F. B.; Buss, D. V.; Eckermann, A.; Rasmussen, M. L. H.; Keiding, N.; Rishoj, S.; Siersma, V.; Sorensen, J.; Sorensen, L. V.; Vogel, A.; Waldemar, G.			Efficacy of psychosocial intervention in patients with mild Alzheimer's disease: the multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSTIC EVALUATION; BASE-LINE; DEMENTIA; CAREGIVERS; PEOPLE; MANAGEMENT; INVENTORY; DONEPEZIL; SYMPTOMS; CARERS	Objective To assess the efficacy at 12 months of an early psychosocial counselling and support programme for outpatients with mild Alzheimer's disease and their primary care givers. Design Multicentre, randomised, controlled, rater blinded trial. Setting Primary care and memory clinics in five Danish districts. Participants 330 outpatients with mild Alzheimer's disease and their 330 primary care givers. Interventions Participating dyads (patient and primary care giver) were randomised to control support during follow-up or to control support plus DAISY intervention (multifaceted and semi-tailored counselling, education, and support). Main outcome measures Primary outcomes at 12 months for patients were change from baseline in mini mental state examination (MMSE) score, Cornell depression scale score, and proxy rated European quality of life visual analogue scale (EQ-VAS) score. For care givers, outcomes were change from baseline in geriatric depression scale (GDS 30 items) score and EQ-VAS score. Results Because of multiple testing, statistical significance was set at an adjusted P limit of <0.0005. At 12 months there were no significant differences between the two allocation groups in changes from baseline in the primary and secondary outcomes. However, although non-significant with the adjusted P limit, a small difference was observed for one of the primary patient outcomes (Cornell depression scale score) in patients in favour of the DAISY intervention group before and after adjusting for attrition (P=0.0146 and P=0.0103 respectively). Conclusions The multifaceted, semi-tailored intervention with counselling, education, and support for patients with mild Alzheimer's disease and their care givers did not have any significant effect beyond that with well structured follow-up support at 12 months after adjustment for multiple comparisons. The small positive effect found in the unadjusted primary outcome addressing depressive symptoms in patients may call for further research focusing on patients with Alzheimer's disease and comorbid depression.	[Waldorff, F. B.; Buss, D. V.; Eckermann, A.; Rasmussen, M. L. H.; Rishoj, S.; Sorensen, L. V.; Vogel, A.; Waldemar, G.] Univ Copenhagen Hosp, Rigshosp, Dept Neurol, Memory Disorders Res Grp, DK-2100 Copenhagen, Denmark; [Waldorff, F. B.; Siersma, V.] Univ Copenhagen, Inst Publ Hlth, Dept Gen Practice, DK-1168 Copenhagen, Denmark; [Waldorff, F. B.; Siersma, V.] Univ Copenhagen, Inst Publ Hlth, Res Unit, DK-1168 Copenhagen, Denmark; [Keiding, N.] Univ Copenhagen, Inst Publ Hlth, Dept Biostat, DK-1168 Copenhagen, Denmark; [Sorensen, J.] Univ So Denmark, Ctr Appl Hlth Serv Res & Technol Assessment CAST, Odense, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Southern Denmark	Waldorff, FB (corresponding author), Univ Copenhagen Hosp, Rigshosp, Dept Neurol, Memory Disorders Res Grp, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.	fransw@sund.ku.dk	Waldorff, Frans Boch/P-7845-2015; Sorensen, Jan/AAN-3738-2020; Siersma, Volkert D/G-6867-2016; Waldorff, Frans Boch/J-3330-2012; Sørensen, Lisbeth/AAJ-1428-2020	Sorensen, Jan/0000-0003-0857-9267; Siersma, Volkert D/0000-0003-1941-2681; Vogel, Asmus/0000-0002-3401-1061; Waldorff, Frans Boch/0000-0002-7859-633X	National Board of Social Services at the Danish Ministry of Social Affairs; Danish Ministry of Health; Danish Health Foundation	National Board of Social Services at the Danish Ministry of Social Affairs; Danish Ministry of Health; Danish Health Foundation	The DAISY study was supported by the National Board of Social Services at the Danish Ministry of Social Affairs, the Danish Ministry of Health and the Danish Health Foundation. All researchers were independent from the funders, and the funders were not involved in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the article for publication.	Acton GJ, 2001, RES NURS HEALTH, V24, P349, DOI 10.1002/nur.1036; ALEXOPOULOS GS, 1988, BIOL PSYCHIAT, V23, P271, DOI 10.1016/0006-3223(88)90038-8; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BRODATY H, 1993, ARCH NEUROL-CHICAGO, V50, P643, DOI 10.1001/archneur.1993.00540060073021; Brodaty H, 2003, J AM GERIATR SOC, V51, P657, DOI 10.1034/j.1600-0579.2003.00210.x; Cooke DD, 2001, AGING MENT HEALTH, V5, P120; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dufouil C, 2004, STAT MED, V23, P2215, DOI 10.1002/sim.1821; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; Ishiyama FI, 1993, TRUMPETER, V10, P2; Jonsson L, 2006, ALZ DIS ASSOC DIS, V20, P49; Lavoie JP, 2005, AGING MENT HEALTH, V9, P25, DOI 10.1080/13607860412331323827; Livingston G, 2005, AM J PSYCHIAT, V162, P1996, DOI 10.1176/appi.ajp.162.11.1996; Logsdon R.G., 1999, J MENTAL HLTH AGING, V5, P21, DOI DOI 10.1037/T03352-000; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mebane-Sims I, 2009, ALZHEIMERS DEMENT, V5, P234, DOI 10.1016/j.jalz.2009.03.001; Mittelman MS, 2008, AM J GERIAT PSYCHIAT, V16, P893, DOI 10.1097/JGP.0b013e3181898095; Mittelman MS, 2004, AM J PSYCHIAT, V161, P850, DOI 10.1176/appi.ajp.161.5.850; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; Nelis S, 2007, COCHRANE DATABASE SY; Olazaran J, 2010, DEMENT GERIATR COGN, V30, P161, DOI 10.1159/000316119; Peavy VR, 1997, SOCIODYNAMIC COUNSEL; Phung TKT, 2009, DEMENT GERIATR COGN, V27, P534, DOI 10.1159/000223664; Pinquart M, 2006, INT PSYCHOGERIATR, V18, P577, DOI 10.1017/S1041610206003462; Pusey H, 2001, AGING MENT HEALTH, V5, P107, DOI 10.1080/13607860120038302; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Reynish E, 2007, NEUROEPIDEMIOLOGY, V29, P29, DOI 10.1159/000108915; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Schulz R, 2002, GERONTOLOGIST, V42, P589, DOI 10.1093/geront/42.5.589; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Seltzer B, 2004, ARCH NEUROL-CHICAGO, V61, P1852, DOI 10.1001/archneur.61.12.1852; Sorensen LV, 2008, AGING MENT HEALTH, V12, P444, DOI 10.1080/13607860802224342; Sorensen S, 2002, GERONTOLOGIST, V42, P356, DOI 10.1093/geront/42.3.356; Thompson CA, 2003, COCHRANE DATABASE SY; Thompson Carl A, 2007, BMC Geriatr, V7, P18, DOI 10.1186/1471-2318-7-18; Ulstein ID, 2007, DEMENT GERIATR COGN, V24, P469, DOI 10.1159/000110740; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Vogel A, 2006, INT J GERIATR PSYCH, V21, P1132, DOI 10.1002/gps.1619; Waldemar G, 2011, NEUROEPIDEMIOLOGY, V36, P52, DOI 10.1159/000322942; Waldemar G, 2007, INT J GERIATR PSYCH, V22, P47, DOI 10.1002/gps.1652; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Winblad B, 2001, NEUROLOGY, V57, P489, DOI 10.1212/WNL.57.3.489; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	46	76	77	0	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 17	2012	345								e4693	10.1136/bmj.e4693	http://dx.doi.org/10.1136/bmj.e4693			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978LQ	22807076	Green Published, hybrid			2022-12-28	WOS:000306742900002
J	Ahmed, S; Li, QF; Liu, L; Tsui, AO				Ahmed, Saifuddin; Li, Qingfeng; Liu, Li; Tsui, Amy O.			Maternal deaths averted by contraceptive use: an analysis of 172 countries	LANCET			English	Article							HEALTH-BENEFITS; MORTALITY; PREGNANCY; BANGLADESH; FERTILITY; INTERVALS; INFANT; MATLAB; CHILD	Background Family planning is one of the four pillars of the Safe Motherhood Initiative to reduce maternal death in developing countries. We aimed to estimate the effect of contraceptive use on maternal mortality and the expected reduction in maternal mortality if the unmet need for contraception were met, at country, regional, and world levels. Method We extracted relevant data from the Maternal Mortality Estimation Inter-Agency Group (MMEIG) database, the UN World Contraceptive Use 2010 database, and the UN World Population Prospects 2010 database, and applied a counterfactual modelling approach (model I), replicating the MMEIG (WHO) maternal mortality estimation method, to estimate maternal deaths averted by contraceptive use in 172 countries. We used a second model (model II) to make the same estimate for 167 countries and to estimate the effect of satisfying unmet need for contraception. We did sensitivity analyses and compared agreement between the models. Findings We estimate, using model I, that 342 203 women died of maternal causes in 2008, but that contraceptive use averted 272 040 (uncertainty interval 127 937-407 134) maternal deaths (44% reduction), so without contraceptive use, the number of maternal deaths would have been 1.8 times higher than the 2008 total. Satisfying unmet need for contraception could prevent another 104 000 maternal deaths per year (29% reduction). Interpretation Numbers of unwanted pregnancies and unmet contraceptive need are still high in many developing countries. We provide evidence that use of contraception is a substantial and effective primary prevention strategy to reduce maternal mortality in developing countries.	[Ahmed, Saifuddin; Li, Qingfeng; Tsui, Amy O.] Johns Hopkins Univ, Dept Populat Family & Reprod Hlth, Bloomberg Sch Publ Hlth, Bill & Melinda Gates Inst Populat & Reprod Hlth, Baltimore, MD 21205 USA; [Liu, Li] Johns Hopkins Univ, Dept Int Hlth, Bill & Melinda Gates Inst Populat & Reprod Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Bill & Melinda Gates Foundation; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Bill & Melinda Gates Foundation; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Ahmed, S (corresponding author), Johns Hopkins Univ, Dept Populat Family & Reprod Hlth, Bloomberg Sch Publ Hlth, Bill & Melinda Gates Inst Populat & Reprod Hlth, Baltimore, MD 21205 USA.	sahmed@jhsph.edu	liu, li/HGC-0900-2022; Li, Qingfeng/J-9520-2016	Li, Qingfeng/0000-0002-6390-6921	Bill and Melinda Gates Foundation	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	Bill and Melinda Gates Foundation.	AbouZahr C, 1999, B WORLD HEALTH ORGAN, V77, P767; [Anonymous], 1996, MOTH BAB PACK IMPL S; Berelson B., 1972, POPULATION COUNCIL A; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; DaVanzo J, 2007, BJOG-INT J OBSTET GY, V114, P1079, DOI 10.1111/j.1471-0528.2007.01338.x; DaVanzo J, 2008, POP STUD-J DEMOG, V62, P131, DOI 10.1080/00324720802022089; Dayal M, 2001, SEMIN REPROD MED, V19, P295, DOI 10.1055/s-2001-18637; Diamond-Smith N, 2011, INT PERSPECT SEX R H, V37, P155, DOI 10.1363/3715511; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; FORTNEY JA, 1987, STUD FAMILY PLANN, V18, P109, DOI 10.2307/1966702; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Jain AK, 2011, STUD FAMILY PLANN, V42, P247, DOI 10.1111/j.1728-4465.2011.00288.x; Jensen JT, 2000, OBSTET GYN CLIN N AM, V27, P705, DOI 10.1016/S0889-8545(05)70169-8; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Liu L, 2008, POP STUD-J DEMOG, V62, P191, DOI 10.1080/00324720801897796; Maguire K, 2011, AM J OBSTET GYNECOL, V205, pS4, DOI 10.1016/j.ajog.2011.06.056; O'Loughlin J, 1997, MED J AUSTRALIA, V167, P622, DOI 10.5694/j.1326-5377.1997.tb138915.x; ORY HW, 1982, FAM PLANN PERSPECT, V14, P182, DOI 10.2307/2134636; Potts M, 1990, Netw Res Triangle Park N C, V11, P2; Prata N, 2010, WOMENS HEALTH, V6, P311, DOI 10.2217/WHE.10.8; Prata N, 2010, HEALTH POLICY, V94, P1, DOI 10.1016/j.healthpol.2009.08.012; Ross, 2008, CONTRACEPTIVE USE AF; Ross JA, 2012, MATERN CHILD HLTH J, V16, P456, DOI 10.1007/s10995-011-0777-x; Seltzer JR., 2002, ORIGINS EVOLUTION FA; Singh S, 2009, ADDING IT COSTS BENE; Stata Corporation, 2009, STAT STAT SOFTW REL; Stover J, 2010, MATERN CHILD HLTH J, V14, P687, DOI 10.1007/s10995-009-0505-y; TRUSSELL J, 1984, STUD FAMILY PLANN, V15, P267, DOI 10.2307/1966071; UNICEF, PLAN ACT IMPL WORLD; United Nations, 2011, WORLD CONTR US 2010; United Nations Department of Economic and Social Affairs, WORLD POP PROSP 2010; WHO, 2010, TRENDS MAT MORT 1990; Wilmoth J., 2010, LEVELS TRENDS MATERN; WINIKOFF B, 1987, STUD FAMILY PLANN, V18, P128, DOI 10.2307/1966808; World Health Organization, 2013, UNS AB GLOB REG EST; World Health Organization (WHO); UNFPA; UNICEF; Columbia University. Mailman School of Public Health, 2009, MON EM OBST CAR HDB; Yeakey MP, 2009, STUD FAMILY PLANN, V40, P205, DOI 10.1111/j.1728-4465.2009.00203.x	37	389	393	0	33	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2012	380	9837					111	125		10.1016/S0140-6736(12)60478-4	http://dx.doi.org/10.1016/S0140-6736(12)60478-4			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784531				2022-12-28	WOS:000306359100038
J	Steinmetz, PRH; Kraus, JEM; Larroux, C; Hammel, JU; Amon-Hassenzahl, A; Houliston, E; Worheide, G; Nickel, M; Degnan, BM; Technau, U				Steinmetz, Patrick R. H.; Kraus, Johanna E. M.; Larroux, Claire; Hammel, Joerg U.; Amon-Hassenzahl, Annette; Houliston, Evelyn; Woerheide, Gert; Nickel, Michael; Degnan, Bernard M.; Technau, Ulrich			Independent evolution of striated muscles in cnidarians and bilaterians	NATURE			English	Article							MULTIPLE SEQUENCE ALIGNMENT; TETHYA-WILHELMA; SEA-ANEMONE; INVERTEBRATE MUSCLES; MOLECULAR EVOLUTION; GENOME REVEALS; EXPRESSION; PROTEIN; CHAIN; DEMOSPONGE	Striated muscles are present in bilaterian animals (for example, vertebrates, insects and annelids) and some non-bilaterian eumetazoans (that is, cnidarians and ctenophores). The considerable ultrastructural similarity of striated muscles between these animal groups is thought to reflect a common evolutionary origin(1,2). Here we show that a muscle protein core set, including a type II myosin heavy chain (MyHC) motor protein characteristic of striated muscles in vertebrates, was already present in unicellular organisms before the origin of multicellular animals. Furthermore, 'striated muscle' and 'non-muscle' myhc orthologues are expressed differentially in two sponges, compatible with a functional diversification before the origin of true muscles and the subsequent use of striated muscle MyHC in fast-contracting smooth and striated muscle. Cnidarians and ctenophores possess striated muscle myhc orthologues but lack crucial components of bilaterian striated muscles, such as genes that code for titin and the troponin complex, suggesting the convergent evolution of striated muscles. Consistently, jellyfish orthologues of a shared set of bilaterian Z-disc proteins are not associated with striated muscles, but are instead expressed elsewhere or ubiquitously. The independent evolution of eumetazoan striated muscles through the addition of new proteins to a pre-existing, ancestral contractile apparatus may serve as a model for the evolution of complex animal cell types.	[Steinmetz, Patrick R. H.; Kraus, Johanna E. M.; Technau, Ulrich] Univ Vienna, Dept Mol Evolut & Dev, Ctr Organismal Syst Biol, A-1090 Vienna, Austria; [Larroux, Claire; Degnan, Bernard M.] Univ Queensland, Sch Biol Sci, Ctr Marine Sci, Brisbane, Qld 4072, Australia; [Larroux, Claire; Woerheide, Gert] Univ Munich, Dept Earth & Environm Sci Palaeontol & Geobiol, D-80333 Munich, Germany; [Hammel, Joerg U.; Nickel, Michael] Univ Jena, Inst Spezielle Zool & Evolut biol, Phyletischem Museum, D-07743 Jena, Germany; [Amon-Hassenzahl, Annette] Tech Univ Darmstadt, Inst Zool, D-64287 Darmstadt, Germany; [Houliston, Evelyn] CNRS, Biol Dev UMR 7009, F-06230 Villefranche Sur Mer, France; [Houliston, Evelyn] Univ Paris 06, F-06230 Villefranche Sur Mer, France; [Woerheide, Gert; Nickel, Michael] Univ Munich, GeoBio Ctr, D-80333 Munich, Germany; [Woerheide, Gert] Bayer Staatssammlung Palaontol & Geol, D-80333 Munich, Germany	University of Vienna; University of Queensland; University of Munich; Friedrich Schiller University of Jena; Technical University of Darmstadt; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; University of Munich	Technau, U (corresponding author), Univ Vienna, Dept Mol Evolut & Dev, Ctr Organismal Syst Biol, Althanstr 14, A-1090 Vienna, Austria.	ulrich.technau@univie.ac.at	Nickel, Michael/D-1005-2010; Steinmetz, Patrick/AAD-4093-2022; Wörheide, Gert/C-1080-2008; Hammel, Jörg/D-6555-2011; Larroux, Claire/U-7981-2017	Nickel, Michael/0000-0003-2982-7805; Wörheide, Gert/0000-0002-6380-7421; Hammel, Jörg/0000-0002-6744-6811; Larroux, Claire/0000-0002-3503-4150; Technau, Ulrich/0000-0003-4472-8258; Houliston, Evelyn/0000-0001-9264-2585; Degnan, Bernard/0000-0001-7573-8518; Steinmetz, Patrick/0000-0002-3705-2774	Austrian Science Fund [P21108-B17]; ITN EVONET [215781]; Australian Research Council; Alexander von Humboldt Foundation; ANR; German Science Foundation [1174, Wo896/6]; Austrian Science Fund (FWF) [P 21108] Funding Source: researchfish	Austrian Science Fund(Austrian Science Fund (FWF)); ITN EVONET; Australian Research Council(Australian Research Council); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); ANR(French National Research Agency (ANR)); German Science Foundation(German Research Foundation (DFG)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	For access and use of publicly available, unpublished genome sequences, we thank the Origins of Multicellularity Sequencing Project, Broad Institute of Harvard and MIT (http://www.broadinstitute.org/), the Joint Genome Institute as well as A. Baxevanis and J. Ryan. We thank M. Adamska for providing Amphimedon total RNA, M. Kube for T. wilhelma transcriptome 454 sequencing, D. Fredman and T. Momose for the C. hemisphaerica and T. Nosenko for T. wilhelma transcriptome assemblies, H. Schmidt for advice on phylogeny, B. Weiss for technical assistance with T. wilhelma sections, Genoscope for C. hemisphaerica sequencing projects and the members of the Technau laboratory for discussion. The research was funded by fellowships of the Austrian Science Fund P21108-B17 and the ITN EVONET (project 215781) to U. T., the Australian Research Council to B. M. D., the Alexander von Humboldt Foundation to C. L., ANR grant DiploDevo to E. H. and the German Science Foundation through the Priority Program 1174 Deep Metazoan Phylogeny (project Wo896/6) to G.W.	Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; Adamska M, 2010, EVOL DEV, V12, P494, DOI 10.1111/j.1525-142X.2010.00435.x; Altekar G, 2004, BIOINFORMATICS, V20, P407, DOI 10.1093/bioinformatics/btg427; Ayme-Southgate AJ, 2008, J MOL EVOL, V67, P653, DOI 10.1007/s00239-008-9177-2; Banks JA, 2011, SCIENCE, V332, P960, DOI 10.1126/science.1203810; BOELSTERLI U, 1977, J MORPHOL, V154, P259, DOI 10.1002/jmor.1051540206; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Burton P. M., 2007, J EXP ZOOL PART B, V308B, P1; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Chapman D.M., 1974, P1; Chapman JA, 2010, NATURE, V464, P592, DOI 10.1038/nature08830; Chevalier S, 2006, DEV GENES EVOL, V216, P709, DOI 10.1007/s00427-006-0103-6; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Craig R, 2006, CURR OPIN STRUC BIOL, V16, P204, DOI 10.1016/j.sbi.2006.03.006; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Fernandez-Fueyo E, 2012, P NATL ACAD SCI USA, V109, P5458, DOI 10.1073/pnas.1119912109; Finn RD, 2010, NUCLEIC ACIDS RES, V38, pD211, DOI 10.1093/nar/gkp985; Frank D, 2006, J MOL MED, V84, P446, DOI 10.1007/s00109-005-0033-1; Fritz-Laylin LK, 2010, CELL, V140, P631, DOI 10.1016/j.cell.2010.01.032; Fritzenwanker JH, 2002, DEV GENES EVOL, V212, P99, DOI 10.1007/s00427-002-0214-7; Genikhovich G., 2009, COLD SPRING HARB PRO, V2009; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010; Hammel J. U., 2010, THESIS F SCHILLER U; Hammel JU, 2009, FRONT ZOOL, V6, DOI 10.1186/1742-9994-6-19; Hooper SL, 2008, PROG NEUROBIOL, V86, P72, DOI 10.1016/j.pneurobio.2008.06.004; Hooper SL, 2005, PHYSIOL REV, V85, P1001, DOI 10.1152/physrev.00019.2004; Hunter S, 2009, NUCLEIC ACIDS RES, V37, pD211, DOI 10.1093/nar/gkn785; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kenny PA, 1999, GENE, V232, P11, DOI 10.1016/S0378-1119(99)00122-5; King N, 2008, NATURE, V451, P783, DOI 10.1038/nature06617; Korn ED, 2000, P NATL ACAD SCI USA, V97, P12559, DOI 10.1073/pnas.230441597; Larroux C, 2006, EVOL DEV, V8, P150, DOI 10.1111/j.1525-142X.2006.00086.x; Larroux C., 2008, COLD SPRING HARB PRO, V2008; Leys SP, 2001, BIOL BULL-US, V201, P323, DOI 10.2307/1543611; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACKIE GO, 1988, ZOOMORPHOLOGY, V107, P319, DOI 10.1007/BF00312216; Martindale MQ, 2004, DEVELOPMENT, V131, P2463, DOI 10.1242/dev.01119; Merchant SS, 2007, SCIENCE, V318, P245, DOI 10.1126/science.1143609; Nickel M, 2004, J EXP BIOL, V207, P4515, DOI 10.1242/jeb.01289; Nickel M, 2006, ZOOMORPHOLOGY, V125, P209, DOI 10.1007/s00435-006-0021-1; Nickel M, 2011, J EXP BIOL, V214, P1692, DOI 10.1242/jeb.049148; Oota S, 1999, MOL BIOL EVOL, V16, P856, DOI 10.1093/oxfordjournals.molbev.a026170; Philippe H, 2009, CURR BIOL, V19, P706, DOI 10.1016/j.cub.2009.02.052; Putnam NH, 2008, NATURE, V453, P1064, DOI 10.1038/nature06967; Putnam NH, 2007, SCIENCE, V317, P86, DOI 10.1126/science.1139158; Renfer E, 2010, P NATL ACAD SCI USA, V107, P104, DOI 10.1073/pnas.0909148107; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Rui YN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001208; Ruiz-Trillo I, 2007, TRENDS GENET, V23, P113, DOI 10.1016/j.tig.2007.01.005; Ryan JF, 2010, EVODEVO, V1, DOI 10.1186/2041-9139-1-9; Sanger JM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.132pe37; Sara Michele, 2001, Stuttgarter Beitraege zur Naturkunde Serie A (Biologie), V631, P1; Schmidt-Rhaesa A, 2007, EVOLUTION ORGAN SYST; SCHUCHERT P, 1993, DIFFERENTIATION, V54, P11, DOI 10.1111/j.1432-0436.1993.tb00654.x; Seipel K, 2005, DEV BIOL, V282, P14, DOI 10.1016/j.ydbio.2005.03.032; Shinzato C, 2011, NATURE, V476, P320, DOI 10.1038/nature10249; Squire JM, 2005, ADV PROTEIN CHEM, V71, P17, DOI 10.1016/S0065-3233(04)71002-5; Srivastava M, 2008, NATURE, V454, P955, DOI 10.1038/nature07191; Srivastava M, 2010, NATURE, V466, P720, DOI 10.1038/nature09201; Sutter SB, 2004, DEV GENES EVOL, V214, P352, DOI 10.1007/s00427-004-0413-5; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Torruella G, 2012, MOL BIOL EVOL, V29, P531, DOI 10.1093/molbev/msr185; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; WEISSENFELS N, 1982, MICROSC ACTA, V85, P345; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724	67	157	159	1	109	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2012	487	7406					231	U1508		10.1038/nature11180	http://dx.doi.org/10.1038/nature11180			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972LP	22763458	Green Accepted			2022-12-28	WOS:000306278900039
J	Taylor, M				Taylor, Max			Do cases like that of Anders Breivik show that fanaticism is a form of madness? Yes	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ St Andrews, St Andrews KY16 9AX, Fife, Scotland	University of St Andrews	Taylor, M (corresponding author), Univ St Andrews, St Andrews KY16 9AX, Fife, Scotland.	mt40@st-andrews.ac.uk						Horgan J, 2005, CASS SER POLIT VIOLE, P1, DOI 10.4324/9780203496961; Horgan J, 2011, Jihadi Terrorism and the Radicalisation Challenge: European and American Experiences, 2nd Edition, P173; Post JM, 2010, ANN NY ACAD SCI, V1208, P15, DOI 10.1111/j.1749-6632.2010.05694.x; Taylor M., 1988, TERRORIST; Taylor Max, 1991, FANATICS BEHAV APPRO	5	4	4	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 11	2012	345								e4612	10.1136/bmj.e4612	http://dx.doi.org/10.1136/bmj.e4612			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NU	22786942				2022-12-28	WOS:000306518800004
J	Douglas, IJ; Evans, SJW; Hingorani, AD; Grosso, AM; Timmis, A; Hemingway, H; Smeeth, L				Douglas, Ian J.; Evans, Stephen J. W.; Hingorani, Aroon D.; Grosso, Anthony M.; Timmis, Adam; Hemingway, Harry; Smeeth, Liam			Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED CASE SERIES; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; CONCOMITANT USE; OMEPRAZOLE; OUTCOMES; IMPACT; RISK	Objective To measure the association between use of proton pump inhibitors and a range of harmful outcomes in patients using clopidogrel and aspirin. Design Observational cohort study and self controlled case series. Setting United Kingdom General Practice Research Database with linked data from the Myocardial Ischaemia National Audit Project (MINAP) and the Office for National Statistics (the cardiovascular disease research using linked bespoke studies and electronic records (CALIBER) collaboration) Population 24 471 patients receiving clopidogrel and aspirin. Main outcome measures The primary outcome was death or incident myocardial infarction. Secondary outcomes were death, incident myocardial infarction, vascular death, and non-vascular death. Comparisons were made between proton pump inhibitor use and non-use. Results Of the 24 471 patients prescribed clopidogrel and aspirin, 12 439 (50%) were also prescribed a proton pump inhibitor at some time during the study. Death or incident myocardial infarction occurred in 1419 (11%) patients while they were receiving a proton pump inhibitor compared with 1341 (8%) who were not receiving a proton pump inhibitor. In multivariate analysis, the hazard ratio for the association between proton pump inhibitor use and death or incident myocardial infarction was 1.37 (95% confidence interval 1.27 to 1.48). Comparable results were seen for secondary outcomes and with other 2C19 inhibitors and with non-2C19 inhibitors. With the self controlled case series design to remove the effect of differences between people, there was no association between proton pump inhibitor use and myocardial infarction, with a rate ratio of 0.75 (0.55 to 1.01). Similarly, with the self controlled case series there was no association with myocardial infarction for other 2C19 inhibitors/non-inhibitors. Conclusion The lack of a specific association and the discrepancy between findings of the analyses between and within people suggests that the interaction between proton pump inhibitors and clopidogrel is clinically unimportant.	[Douglas, Ian J.; Evans, Stephen J. W.; Smeeth, Liam] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England; [Hingorani, Aroon D.; Hemingway, Harry] UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; [Grosso, Anthony M.] Univ Coll London Hosp, Dept Pharm, London NW1 2PG, England; [Timmis, Adam] Barts & London Heart & Chest Ctr, Dept Cardiol, London E2 9JX, England	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	Douglas, IJ (corresponding author), London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.	ian.douglas@lshtm.ac.uk	Hemingway, Harry/C-1219-2009; Smeeth, Liam/X-5862-2018	Hemingway, Harry/0000-0003-2279-0624; Smeeth, Liam/0000-0002-9168-6022; Evans, Stephen/0000-0002-1474-2596; Hingorani, Aroon/0000-0001-8365-0081	Wellcome Trust [086091/Z/08/Z]; National Institute for Health Research [RP-PG-0407-10314]; Medical Research Council; Barts Cardiovascular Biomedical Research Unit; MRC [G0802403] Funding Source: UKRI; Medical Research Council [G0802403] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10090] Funding Source: researchfish	Wellcome Trust(Wellcome Trust); National Institute for Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Barts Cardiovascular Biomedical Research Unit; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	The CALIBER (cardiovascular disease research using linked bespoke studies and electronic records) study is funded by the Wellcome Trust (086091/Z/08/Z, P I Hemingway) and the National Institute for Health Research (RP-PG-0407-10314, P I Hemingway). The protocol for CALIBER is registered at Clinicaltrials.gov (NCT01231867).; IJD is funded by a Medical Research Council Methodology Fellowship and LS is funded by a Wellcome Trust Fellowship. AT acknowledges the support of Barts Cardiovascular Biomedical Research Unit funded by the National Institute for Health Research. The funders played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.	Aubert RE, 2008, CIRCULATION, V118, pS815; Bauer T, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4588; Bhatt DL, 2010, NEW ENGL J MED, V363, P1909, DOI 10.1056/NEJMoa1007964; Boggon R, 2011, EUR HEART J     0411; Dunn SP, 2008, CIRCULATION, V118, pS815; Gallagher AM, 2011, PHARMACOEPIDEM DR S, V20, pS230; Gilard M, 2008, J AM COLL CARDIOL, V51, P256, DOI 10.1016/j.jacc.2007.06.064; Herrett E, 2010, HEART, V96, P1264, DOI 10.1136/hrt.2009.192328; Ho PM, 2009, JAMA-J AM MED ASSOC, V301, P937, DOI 10.1001/jama.2009.261; Juurlink DN, 2009, CAN MED ASSOC J, V180, P713, DOI 10.1503/cmaj.082001; Lawson DH, 1998, QJM-MON J ASSOC PHYS, V91, P445, DOI 10.1093/qjmed/91.6.445; O'Donoghue ML, 2009, LANCET, V374, P989, DOI 10.1016/S0140-6736(09)61525-7; Office for National Statistics, 2000, KEY HLTH STAT GEN PR, P149; Ogu CC, 2000, BAYLOR U MED CTR P, V13, P421; Pezalla E, 2008, J AM COLL CARDIOL, V52, P1038, DOI 10.1016/j.jacc.2008.05.053; Pratt NL, 2010, DRUG AGING, V27, P885, DOI 10.2165/11584490-000000000-00000; Rassen JA, 2009, CIRCULATION, V120, P2322, DOI 10.1161/CIRCULATIONAHA.109.873497; Ray WA, 2010, ANN INTERN MED, V152, P337, DOI 10.7326/0003-4819-152-6-201003160-00003; Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227; Small DS, 2008, J CLIN PHARMACOL, V48, P475, DOI 10.1177/0091270008315310; The Clinical Practice research Datalink Group, 2012, GEN PRACT RES DAT; Valkhoff VE, 2011, ALIMENT PHARM THER, V33, P77, DOI 10.1111/j.1365-2036.2010.04485.x; Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302; Wright RS, 2011, J AM COLL CARDIOL, V57, P1920, DOI 10.1016/j.jacc.2011.02.009; Zairis MN, 2010, CAN J CARDIOL, V26, pE54, DOI 10.1016/S0828-282X(10)70008-8	25	57	58	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	2012	345								e4388	10.1136/bmj.e4388	http://dx.doi.org/10.1136/bmj.e4388			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975NT	22782731	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000306518700003
J	Gornall, J				Gornall, Jonathan			TELEHEALTH Does telemedicine deserve the green light?	BRITISH MEDICAL JOURNAL			English	Editorial Material												jgornall@mac.com						Blunt I., TRENDS EMERGENCY ADM; Car J, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4201; Chaudhry SI, 2010, NEW ENGL J MED, V363, P2301, DOI 10.1056/NEJMoa1010029; Department of Health, 2011, WHOL SYST DEM PROGR; Department of Health, 2012, CONC DEP HLTH TEL TE; Department of Health, 2011, YEAR NHS CHIEF EX AN; Goodwin N, 2012, WHERE NEXT TELEHEALT; Robinson S, 2012, GP              0425; Steventon A, 2012, IMPACT TELEHEALTH US; Steventon A, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3874; Todd R, 2012, E HLTH INSIDER  0307	11	11	11	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 10	2012	345								e4622	10.1136/bmj.e4622	http://dx.doi.org/10.1136/bmj.e4622			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NT	22782733				2022-12-28	WOS:000306518700007
J	Somvanshi, VS; Sloup, RE; Crawford, JM; Martin, AR; Heidt, AJ; Kim, KS; Clardy, J; Ciche, TA				Somvanshi, Vishal S.; Sloup, Rudolph E.; Crawford, Jason M.; Martin, Alexander R.; Heidt, Anthony J.; Kim, Kwi-suk; Clardy, Jon; Ciche, Todd A.			A Single Promoter Inversion Switches Photorhabdus Between Pathogenic and Mutualistic States	SCIENCE			English	Article							XENORHABDUS-LUMINESCENS; ESCHERICHIA-COLI; GENE-EXPRESSION; BACTERIA; EVOLUTION; HETERORHABDITIS; CLASSIFICATION; IDENTIFICATION; BIOSYNTHESIS; NEMATODES	Microbial populations stochastically generate variants with strikingly different properties, such as virulence or avirulence and antibiotic tolerance or sensitivity. Photorhabdus luminescens bacteria have a variable life history in which they alternate between pathogens to a wide variety of insects and mutualists to their specific host nematodes. Here, we show that the P. luminescens pathogenic variant (P form) switches to a smaller-cell variant (M form) to initiate mutualism in host nematode intestines. A stochastic promoter inversion causes the switch between the two distinct forms. M-form cells are much smaller (one-seventh the volume), slower growing, and less bioluminescent than P-form cells; they are also avirulent and produce fewer secondary metabolites. Observations of form switching by individual cells in nematodes revealed that the M form persisted in maternal nematode intestines, were the first cells to colonize infective juvenile (IJ) offspring, and then switched to P form in the IJ intestine, which armed these nematodes for the next cycle of insect infection.	[Somvanshi, Vishal S.; Sloup, Rudolph E.; Martin, Alexander R.; Heidt, Anthony J.; Kim, Kwi-suk; Ciche, Todd A.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; [Somvanshi, Vishal S.; Sloup, Rudolph E.; Martin, Alexander R.; Heidt, Anthony J.; Kim, Kwi-suk; Ciche, Todd A.] Michigan State Univ, Ctr Microbial Pathogenesis, E Lansing, MI 48824 USA; [Crawford, Jason M.; Clardy, Jon] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Michigan State University; Michigan State University; Harvard University; Harvard Medical School	Ciche, TA (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.	ciche@msu.edu	Somvanshi, Vishal Singh/AAD-6959-2021	Somvanshi, Vishal Singh/0000-0002-6835-963X; Ciche, Todd/0000-0002-1462-5269; Heidt, Anthony/0000-0003-1741-3621	Michigan State University Research for Excellence Fund Center for Microbial Pathogenesis; AgBioResearch; NIH [R01 GM086258, 1K99 GM097096-01]; Damon Runyon Cancer Research Foundation [DRG-2002-09]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R00GM097096, K99GM097096, R01GM086258] Funding Source: NIH RePORTER	Michigan State University Research for Excellence Fund Center for Microbial Pathogenesis; AgBioResearch; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank L. R. Kroos and L. R. Snyder for helpful discussions and comments on the manuscript and K. Lewis and J. Landgraf for technical assistance. This study was supported by Michigan State University Research for Excellence Fund Center for Microbial Pathogenesis, AgBioResearch, and startup funds (to T. A. C.) and by NIH (grant R01 GM086258 to J. C.). During the course of the work, J. M. C. was supported by a Damon Runyon Cancer Research Foundation fellowship (DRG-2002-09) and an NIH Pathway to Independence award (grant 1K99 GM097096-01 to J. M. C.). The microarray data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (GEO) (30) and are accessible through GEO Series accession no. GSE32088 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE32088).	Acar M, 2008, NAT GENET, V40, P471, DOI 10.1038/ng.110; AKHURST RJ, 1980, J GEN MICROBIOL, V121, P303; Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; Bintrim SB, 1998, J BACTERIOL, V180, P1261, DOI 10.1128/JB.180.5.1261-1269.1998; Bowen D, 1998, SCIENCE, V280, P2129, DOI 10.1126/science.280.5372.2129; Bowen DJ, 2003, MICROBIOL-SGM, V149, P1581, DOI 10.1099/mic.0.26171-0; Bowen DJ, 1998, APPL ENVIRON MICROB, V64, P3029; Chalabaev S, 2008, APPL ENVIRON MICROB, V74, P1717, DOI 10.1128/AEM.02589-07; Ciche TA, 2003, APPL ENVIRON MICROB, V69, P1890, DOI 10.1128/AEM.69.4.1890-1897.2003; Ciche TA, 2008, APPL ENVIRON MICROB, V74, P2275, DOI 10.1128/AEM.02646-07; Crawford JM, 2010, CURR BIOL, V20, P69, DOI 10.1016/j.cub.2009.10.059; Daborn PJ, 2002, P NATL ACAD SCI USA, V99, P10742, DOI 10.1073/pnas.102068099; Deng WY, 2004, P NATL ACAD SCI USA, V101, P3597, DOI 10.1073/pnas.0400326101; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eichler K, 1996, J BACTERIOL, V178, P1248, DOI 10.1128/jb.178.5.1248-1257.1996; Eleftherianos I, 2007, P NATL ACAD SCI USA, V104, P2419, DOI 10.1073/pnas.0610525104; HURLBERT RE, 1989, APPL ENVIRON MICROB, V55, P1136, DOI 10.1128/AEM.55.5.1136-1143.1989; Joyce SA, 2003, MOL MICROBIOL, V47, P1445, DOI 10.1046/j.1365-2958.2003.03389.x; Joyce SA, 2008, ANGEW CHEM INT EDIT, V47, P1942, DOI 10.1002/anie.200705148; Makarova KS, 2011, NAT REV MICROBIOL, V9, P467, DOI 10.1038/nrmicro2577; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Nuccio SP, 2007, MICROBIOL MOL BIOL R, V71, P551, DOI 10.1128/MMBR.00014-07; Proctor RA, 2006, NAT REV MICROBIOL, V4, P295, DOI 10.1038/nrmicro1384; RICHARDSON WH, 1988, APPL ENVIRON MICROB, V54, P1602, DOI 10.1128/AEM.54.6.1602-1605.1988; Somvanshi VS, 2010, MOL MICROBIOL, V77, P1021, DOI 10.1111/j.1365-2958.2010.07270.x; van der Woude MW, 2004, CLIN MICROBIOL REV, V17, P581, DOI 10.1128/CMR.17.3.581-611.2004; Waterfield NR, 2009, ANNU REV MICROBIOL, V63, P557, DOI 10.1146/annurev.micro.091208.073507; Williams JS, 2005, MICROBIOL-SGM, V151, P2543, DOI 10.1099/mic.0.28136-0; ZIEG J, 1978, CELL, V15, P237, DOI 10.1016/0092-8674(78)90098-3	30	73	73	5	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2012	337	6090					88	93		10.1126/science.1216641	http://dx.doi.org/10.1126/science.1216641			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767929	Green Accepted			2022-12-28	WOS:000306053100050
J	Toth, LT; Aronson, RB; Vollmer, SV; Hobbs, JW; Urrego, DH; Cheng, H; Enochs, IC; Combosch, DJ; van Woesik, R; Macintyre, IG				Toth, Lauren T.; Aronson, Richard B.; Vollmer, Steven V.; Hobbs, Jennifer W.; Urrego, Dunia H.; Cheng, Hai; Enochs, Ian C.; Combosch, David J.; van Woesik, Robert; Macintyre, Ian G.			ENSO Drove 2500-Year Collapse of Eastern Pacific Coral Reefs	SCIENCE			English	Article							NINO-SOUTHERN-OSCILLATION; EL-NINO; CLIMATE-CHANGE; TROPICAL PACIFIC; OCEAN ACIDIFICATION; HOLOCENE; RECORD; GROWTH; SEA; DISTURBANCES	Cores of coral reef frameworks along an upwelling gradient in Panama show that reef ecosystems in the tropical eastern Pacific collapsed for 2500 years, representing as much as 40% of their history, beginning about 4000 years ago. The principal cause of this millennial-scale hiatus in reef growth was increased variability of the El Nino-Southern Oscillation (ENSO) and its coupling with the Intertropical Convergence Zone. The hiatus was a Pacific-wide phenomenon with an underlying climatology similar to probable scenarios for the next century. Global climate change is probably driving eastern Pacific reefs toward another regional collapse.	[Toth, Lauren T.; Aronson, Richard B.; Hobbs, Jennifer W.; Urrego, Dunia H.; van Woesik, Robert] Florida Inst Technol, Dept Biol Sci, Melbourne, FL 32901 USA; [Aronson, Richard B.; Macintyre, Ian G.] Smithsonian Inst, Dept Paleobiol, Natl Museum Nat Hist, Washington, DC 20560 USA; [Vollmer, Steven V.; Combosch, David J.] Northeastern Univ, Ctr Marine Sci, Nahant, MA 01908 USA; [Urrego, Dunia H.] Univ Bordeaux 1, UMR CNRS EPOC 5805, F-33405 Talence, France; [Cheng, Hai] Xi An Jiao Tong Univ, Inst Global Environm Change, Xian 710049, Peoples R China; [Cheng, Hai] Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA; [Enochs, Ian C.] Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Cooperat Inst Marine & Atmospher Sci, Miami, FL 33149 USA; [Enochs, Ian C.] NOAA, Atlantic Oceanog & Meteorol Labs, Miami, FL 33149 USA	Florida Institute of Technology; Smithsonian Institution; Smithsonian National Museum of Natural History; Northeastern University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Xi'an Jiaotong University; University of Minnesota System; University of Minnesota Twin Cities; University of Miami; National Oceanic Atmospheric Admin (NOAA) - USA; Atlantic Oceanographic & Meteorological Laboratory (AOML)	Aronson, RB (corresponding author), Florida Inst Technol, Dept Biol Sci, 150 W Univ Blvd, Melbourne, FL 32901 USA.	raronson@fit.edu	Enochs, Ian/B-8051-2014; CHENG, HAI/H-3413-2017	Enochs, Ian/0000-0002-8867-0361; CHENG, HAI/0000-0002-5305-9458; Aronson, Richard/0000-0003-0383-3844; Toth, Lauren/0000-0002-2568-802X; Combosch, David/0000-0001-7004-7435; Urrego, Dunia H./0000-0001-7938-5529	Smithsonian Institution; NSF; Florida Institute of Technology	Smithsonian Institution(Smithsonian Institution); NSF(National Science Foundation (NSF)); Florida Institute of Technology	We thank M. Bush, A. Correa-Metrio, P. Glynn, H. Lessios, D. Manzello, W. Precht, and P. Reimer for advice and V. Brandtneris, L. Camilli, M. Dardeau, K. Hendrickson, A. Lam, A. Moesinger, R. Muthukrishnan, E. Ochoa, J. Reynolds, B. Valencia, and A. Velarde for assistance. Supported by the Smithsonian Institution, NSF, and the Florida Institute of Technology. This research was carried out under permits from the Republic of Panama. Data are available online in NOAA's Paleoclimatology database (www.ncdc.noaa.gov/paleo/).	[Anonymous], 1969, MEMORIAS S INT LAGUN; Baker AC, 2008, ESTUAR COAST SHELF S, V80, P435, DOI 10.1016/j.ecss.2008.09.003; Bellwood, 1988, P 6 INT COR REEF S A, P253; Cantin NE, 2010, SCIENCE, V329, P322, DOI 10.1126/science.1190182; Collins M, 2010, NAT GEOSCI, V3, P391, DOI 10.1038/NGEO868; Conroy JL, 2008, QUATERNARY SCI REV, V27, P1166, DOI 10.1016/j.quascirev.2008.02.015; Correge T, 2000, PALEOCEANOGRAPHY, V15, P465, DOI 10.1029/1999PA000409; CORTES J, 1994, CORAL REEFS, V13, P65, DOI 10.1007/BF00300763; De'ath G, 2009, SCIENCE, V323, P116, DOI 10.1126/science.1165283; Donders TH, 2008, QUATERNARY SCI REV, V27, P571, DOI 10.1016/j.quascirev.2007.11.010; Eakin CM, 1996, CORAL REEFS, V15, P109; Gagan MK, 2004, QUATERN INT, V118, P127, DOI 10.1016/S1040-6182(03)00134-4; GLYNN P, 1977, P 3 INT COR REEF S, P251; GLYNN PW, 1992, AM ZOOL, V32, P707; GLYNN PW, 1977, J MAR RES, V35, P567; Hamanaka N, 2012, GLOBAL PLANET CHANGE, V80-81, P21, DOI 10.1016/j.gloplacha.2011.10.004; Haug GH, 2001, SCIENCE, V293, P1304, DOI 10.1126/science.1059725; Hoegh-Guldberg O, 2007, SCIENCE, V318, P1737, DOI 10.1126/science.1152509; Kleypas JA, 1997, PALEOCEANOGRAPHY, V12, P533, DOI 10.1029/97PA01134; Lachniet MS, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004694; Lybolt M, 2011, FRONT ECOL ENVIRON, V9, P154, DOI 10.1890/090176; Manzello DP, 2008, P NATL ACAD SCI USA, V105, P10450, DOI 10.1073/pnas.0712167105; Martinez I, 2006, PALAEOGEOGR PALAEOCL, V234, P114, DOI 10.1016/j.palaeo.2005.10.022; Moy CM, 2002, NATURE, V420, P162, DOI 10.1038/nature01194; Pandolfi JM, 2011, SCIENCE, V333, P418, DOI 10.1126/science.1204794; Perry CT, 2010, GEOLOGY, V38, P119, DOI 10.1130/G30444.1; Rein B, 2007, QUATERN INT, V161, P56, DOI 10.1016/j.quaint.2006.10.023; Riedinger MA, 2002, J PALEOLIMNOL, V27, P1, DOI 10.1023/A:1013514408468; Sonnenholzner JI, 2009, MAR ECOL PROG SER, V375, P209, DOI 10.3354/meps07890; Thompson DM, 2009, P ROY SOC B-BIOL SCI, V276, P2893, DOI 10.1098/rspb.2009.0591; Toscano MA, 2003, CORAL REEFS, V22, P257, DOI 10.1007/s00338-003-0315-4; U.S. Geological Survey, 1998, 98779 US GEOL SURV, P98; Wood R., 1999, REEF EVOLUTION; Yan H, 2011, NAT GEOSCI, V4, P611, DOI 10.1038/ngeo1231	34	108	112	2	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2012	337	6090					81	84		10.1126/science.1221168	http://dx.doi.org/10.1126/science.1221168			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767927				2022-12-28	WOS:000306053100048
J	Wolke, M; Klinner, J; Kessler, H; Hemmerich, A				Wolke, Matthias; Klinner, Julian; Kessler, Hans; Hemmerich, Andreas			Cavity Cooling Below the Recoil Limit	SCIENCE			English	Article							ATOMS; OPTOMECHANICS; FREQUENCY; GAS	Conventional laser cooling relies on repeated electronic excitations by near-resonant light, which constrains its area of application to a selected number of atomic species prepared at moderate particle densities. Optical cavities with sufficiently large Purcell factors allow for laser cooling schemes, avoiding these limitations. Here, we report on an atom-cavity system, combining a Purcell factor above 40 with a cavity bandwidth below the recoil frequency associated with the kinetic energy transfer in a single photon scattering event. This lets us access a yet-unexplored regime of atom-cavity interactions, in which the atomic motion can be manipulated by targeted dissipation with sub-recoil resolution. We demonstrate cavity-induced heating of a Bose-Einstein condensate and subsequent cooling at particle densities and temperatures incompatible with conventional laser cooling.	[Wolke, Matthias; Klinner, Julian; Kessler, Hans; Hemmerich, Andreas] Univ Hamburg, Inst Laser Phys, D-22761 Hamburg, Germany	University of Hamburg	Hemmerich, A (corresponding author), Univ Hamburg, Inst Laser Phys, Luruper Chaussee 149, D-22761 Hamburg, Germany.	hemmerich@physnet.uni-hamburg.de	Keßler, Hans/ABE-1120-2021	Keßler, Hans/0000-0002-8501-6145	Deutsche Forschungsgemeinschaft [He2334/12-1, SFB 925, GrK 1355]; Excellence cluster "Frontiers in Quantum Photon Science"	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Excellence cluster "Frontiers in Quantum Photon Science"	This work was partially supported by Deutsche Forschungsgemeinschaft (He2334/12-1, SFB 925, GrK 1355) and the Excellence cluster "Frontiers in Quantum Photon Science." A. H. is grateful to E. Demler, L. Mathey, and C. Morais Smith for useful discussions.	Adams CS, 1997, PROG QUANT ELECTRON, V21, P1, DOI 10.1016/S0079-6727(96)00006-7; Baumann K, 2010, NATURE, V464, P1301, DOI 10.1038/nature09009; Beige A, 2005, NEW J PHYS, V7, DOI 10.1088/1367-2630/7/1/096; Black AT, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.203001; Bloch I, 2008, REV MOD PHYS, V80, P885, DOI 10.1103/RevModPhys.80.885; Brennecke F, 2008, SCIENCE, V322, P235, DOI 10.1126/science.1163218; Bux S, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.203601; Chan HW, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.063003; Diddams SA, 2004, SCIENCE, V306, P1318, DOI 10.1126/science.1102330; Domokos P, 2003, J OPT SOC AM B, V20, P1098, DOI 10.1364/JOSAB.20.001098; Horak P, 1997, PHYS REV LETT, V79, P4974, DOI 10.1103/PhysRevLett.79.4974; Horak P, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.033609; Kippenberg TJ, 2008, SCIENCE, V321, P1172, DOI 10.1126/science.1156032; Leibrandt DR, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.103001; Maunz P, 2004, NATURE, V428, P50, DOI 10.1038/nature02387; Metcalf HJ., 1999, LASER COOLING TRAPPI; Morigi G, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.073001; Murch KW, 2008, NAT PHYS, V4, P561, DOI 10.1038/nphys965; Nagorny B, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.031401; Nussmann S, 2005, NAT PHYS, V1, P122, DOI 10.1038/nphys120; PURCELL EM, 1946, PHYS REV, V69, P37, DOI 10.1103/PhysRev.69.37; Purdy TP, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.133602; Slama S, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.053603; Udem T, 2002, NATURE, V416, P233, DOI 10.1038/416233a; Vuletic V, 2000, PHYS REV LETT, V84, P3787, DOI 10.1103/PhysRevLett.84.3787	25	87	87	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2012	337	6090					75	78		10.1126/science.1219166	http://dx.doi.org/10.1126/science.1219166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767925				2022-12-28	WOS:000306053100046
J	Feinberg, J				Feinberg, Judith			Truvada PrEP: Why I Voted "Yes"	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL LOAD; TRANSMISSION		Univ Cincinnati, Med Ctr, Holmes Hosp Div, Cincinnati, OH 45267 USA	University of Cincinnati	Feinberg, J (corresponding author), Univ Cincinnati, Med Ctr, Holmes Hosp Div, POB 670405, Cincinnati, OH 45267 USA.	judith.feinberg@uc.edu						[Anonymous], 19 C RETR OPP INF SE; Baeten JM, 2012, NEW ENGL J MED; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Karim SSA, 2012, LANCET, V379, P2047, DOI 10.1016/S0140-6736(12)60786-7; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; US Department of Health and Human Services, 2012, GUID US ANT AG HIV 1	8	4	4	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 2	2012	157	7					521	523		10.7326/0003-4819-157-7-201210020-00513	http://dx.doi.org/10.7326/0003-4819-157-7-201210020-00513			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	016MQ	22820485				2022-12-28	WOS:000309523200008
J	Wei, P; Wong, WW; Park, JS; Corcoran, EE; Peisajovich, SG; Onuffer, JJ; Weiss, A; Lim, WA				Wei, Ping; Wong, Wilson W.; Park, Jason S.; Corcoran, Ethan E.; Peisajovich, Sergio G.; Onuffer, James J.; Weiss, Arthur; Lim, Wendell A.			Bacterial virulence proteins as tools to rewire kinase pathways in yeast and immune cells	NATURE			English	Article							NF-KAPPA-B; T-CELLS; PHOSPHOTHREONINE LYASE; TYROSINE-PHOSPHATASE; SYNTHETIC BIOLOGY; GENE-EXPRESSION; ADVERSE EVENT; ACTIVATION; YERSINIA; ADAPTATION	Bacterial pathogens have evolved specific effector proteins that, by interfacing with host kinase signalling pathways, provide a mechanism to evade immune responses during infection(1,2). Although these effectors contribute to pathogen virulence, we realized that they might also serve as valuable synthetic biology reagents for engineering cellular behaviour. Here we exploit two effector proteins, the Shigella flexneri OspF protein(3) and Yersinia pestis YopH protein(4), to rewire kinase-mediated responses systematically both in yeast and mammalian immune cells. Bacterial effector proteins can be directed to inhibit specific mitogen-activated protein kinase pathways selectively in yeast by artificially targeting them to pathway-specific complexes. Moreover, we show that unique properties of the effectors generate new pathway behaviours: OspF, which irreversibly inactivates mitogen-activated protein kinases(4), was used to construct a synthetic feedback circuit that shows novel frequency-dependent input filtering. Finally, we show that effectors can be used in T cells, either as feedback modulators to tune the T-cell response amplitude precisely, or as an inducible pause switch that can temporarily disable T-cell activation. These studies demonstrate how pathogens could provide a rich toolkit of parts to engineer cells for therapeutic or biotechnological applications.	[Wei, Ping; Wong, Wilson W.; Park, Jason S.; Peisajovich, Sergio G.; Onuffer, James J.; Lim, Wendell A.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Wei, Ping; Wong, Wilson W.; Park, Jason S.; Corcoran, Ethan E.; Peisajovich, Sergio G.; Weiss, Arthur; Lim, Wendell A.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA; [Wong, Wilson W.; Park, Jason S.; Corcoran, Ethan E.; Onuffer, James J.; Weiss, Arthur; Lim, Wendell A.] Univ Calif San Francisco, Cell Prop Lab, San Francisco, CA 94158 USA; [Corcoran, Ethan E.; Weiss, Arthur] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA.	lim@cmp.ucsf.edu		Wei, Ping/0000-0002-1275-7145	American Cancer Society fellowship [PF-09-137-01-TBE]; Li Foundation Fellowship; California Institute for Regenerative Medicine fellowship [TG2-01153]; National Institutes of Health [PN2EY016546, RO1GM055040, RO1GM062583, P50GM081879]; NSF Synthetic Biology and Engineering Research Center; Packard Foundation; Howard Hughes Medical Institute; NATIONAL EYE INSTITUTE [PN2EY016546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007618, R01GM055040, P50GM081879, R01GM062583] Funding Source: NIH RePORTER	American Cancer Society fellowship(American Cancer Society); Li Foundation Fellowship; California Institute for Regenerative Medicine fellowship; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF Synthetic Biology and Engineering Research Center; Packard Foundation(The David & Lucile Packard Foundation); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank K. Orth for the YopH plasmid; K. McNally and S. Neou for tissue culture support; H. El-Samad, C. Voigt, C. Tang and the Lim laboratory for discussions. We acknowledge the 2007 UCSF iGEM team (M. Chen, E. Chou, J. Huang, L. Jann, E. Meltzer, A. Ng and R. Ovadia) for their initial work on bacterial effectors in yeast. This work was supported by American Cancer Society fellowship PF-09-137-01-TBE (W.W.W), a Li Foundation Fellowship (P. W.), a California Institute for Regenerative Medicine fellowship (grant number TG2-01153) (J. S. P.), National Institutes of Health grants PN2EY016546, RO1GM055040, RO1GM062583 and P50GM081879 (W. A. L.), the NSF Synthetic Biology and Engineering Research Center (W. A. L.), the Packard Foundation (W. A. L.) and the Howard Hughes Medical Institute (A. W. and W.A.L.).	Arbibe L, 2007, NAT IMMUNOL, V8, P47, DOI 10.1038/ni1423; Bashor CJ, 2008, SCIENCE, V319, P1539, DOI 10.1126/science.1151153; Bonini C, 2007, MOL THER, V15, P1248, DOI 10.1038/sj.mt.6300190; Brandman O, 2008, SCIENCE, V322, P390, DOI 10.1126/science.1160617; Brentjens R, 2010, MOL THER, V18, P666, DOI 10.1038/mt.2010.31; Broberg CA, 2010, CURR OPIN MICROBIOL, V13, P34, DOI 10.1016/j.mib.2009.12.004; Cai L, 2008, NATURE, V455, P485, DOI 10.1038/nature07292; Ciceri F, 2009, LANCET ONCOL, V10, P489, DOI 10.1016/S1470-2045(09)70074-9; de Witte MA, 2008, J IMMUNOL, V180, P6365, DOI 10.4049/jimmunol.180.9.6365; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Gerke C, 2005, J EXP MED, V201, P361, DOI 10.1084/jem.20041120; Hersen P, 2008, P NATL ACAD SCI USA, V105, P7165, DOI 10.1073/pnas.0710770105; June CH, 2009, NAT REV IMMUNOL, V9, P704, DOI 10.1038/nri2635; Khalil AS, 2010, NAT REV GENET, V11, P367, DOI 10.1038/nrg2775; Kieback E, 2008, P NATL ACAD SCI USA, V105, P623, DOI 10.1073/pnas.0710198105; Kramer RW, 2007, PLOS PATHOG, V3, P179, DOI 10.1371/journal.ppat.0030021; Lee PJ, 2008, BIOTECHNIQUES, V44, P91, DOI 10.2144/000112673; Li HT, 2007, SCIENCE, V315, P1000, DOI 10.1126/science.1138960; Lin J, 2003, J CELL BIOL, V162, P673, DOI 10.1083/jcb.200303040; Mettetal JT, 2008, SCIENCE, V319, P482, DOI 10.1126/science.1151582; Morgan RA, 2010, CANCER J, V16, P336, DOI 10.1097/PPO.0b013e3181eb3879; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Muzzey D, 2009, CELL, V138, P160, DOI 10.1016/j.cell.2009.04.047; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Peisajovich SG, 2010, SCIENCE, V328, P368, DOI 10.1126/science.1182376; Pelet S, 2011, SCIENCE, V332, P732, DOI 10.1126/science.1198851; Purnick PEM, 2009, NAT REV MOL CELL BIO, V10, P410, DOI 10.1038/nrm2698; Ribet D, 2010, CELL, V143, P694, DOI 10.1016/j.cell.2010.11.019; Shaw AS, 2009, NAT REV IMMUNOL, V9, P47, DOI 10.1038/nri2473; Yao T, 1999, J EXP MED, V190, P1343, DOI 10.1084/jem.190.9.1343; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; Zhu YQ, 2007, MOL CELL, V28, P899, DOI 10.1016/j.molcel.2007.11.011	32	94	105	3	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 16	2012	488	7411					384	+		10.1038/nature11259	http://dx.doi.org/10.1038/nature11259			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988OS	22820255	Green Accepted, Green Submitted			2022-12-28	WOS:000307501000043
J	Lee, IM; Shiroma, EJ; Lobelo, F; Puska, P; Blair, SN; Katzmarzyk, PT				Lee, I-Min; Shiroma, Eric J.; Lobelo, Felipe; Puska, Pekka; Blair, Steven N.; Katzmarzyk, Peter T.		Lancet Phys Activity Series Workin	Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy	LANCET			English	Article							ALL-CAUSE MORTALITY; CORONARY-HEART-DISEASE; BREAST-CANCER; METAANALYSIS; RISK; SMOKING; POPULATION; INTENSITY; CHINA	Background Strong evidence shows that physical inactivity increases the risk of many adverse health conditions, including major non-communicable diseases such as coronary heart disease, type 2 diabetes, and breast and colon cancers, and shortens life expectancy. Because much of the world's population is inactive, this link presents a major public health issue. We aimed to quantify the effect of physical inactivity on these major non-communicable diseases by estimating how much disease could be averted if inactive people were to become active and to estimate gain in life expectancy at the population level. Methods For our analysis of burden of disease, we calculated population attributable fractions (PAFs) associated with physical inactivity using conservative assumptions for each of the major non-communicable diseases, by country, to estimate how much disease could be averted if physical inactivity were eliminated. We used life-table analysis to estimate gains in life expectancy of the population. Findings Worldwide, we estimate that physical inactivity causes 6% (ranging from 3.2% in southeast Asia to 7.8% in the eastern Mediterranean region) of the burden of disease from coronary heart disease, 7% (3.9-9.6) of type 2 diabetes, 10% (5.6-14.1) of breast cancer, and 10% (5.7-13.8) of colon cancer. Inactivity causes 9% (range 5.1-12.5) of premature mortality, or more than 5.3 million of the 57 million deaths that occurred worldwide in 2008. If inactivity were not eliminated, but decreased instead by 10% or 25%, more than 533 000 and more than 1.3 million deaths, respectively, could be averted every year. We estimated that elimination of physical inactivity would increase the life expectancy of the world's population by 0.68 (range 0.41-0.95) years. Interpretation Physical inactivity has a major health effect worldwide. Decrease in or removal of this unhealthy behaviour could improve health substantially.	[Lee, I-Min] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; [Shiroma, Eric J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Lobelo, Felipe] Ctr Dis Control & Prevent, Global Hlth Promot Off, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA; [Puska, Pekka] Natl Inst Hlth & Welf, Helsinki, Finland; [Blair, Steven N.] Univ S Carolina, Arnold Sch Publ Hlth, Dept Epidemiol Biostat, Columbia, SC 29208 USA; [Blair, Steven N.] Univ S Carolina, Arnold Sch Publ Hlth, Dept Exercise Sci, Columbia, SC 29208 USA; [Katzmarzyk, Peter T.] Pennington Biomed Res Ctr, Baton Rouge, LA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Centers for Disease Control & Prevention - USA; Finland National Institute for Health & Welfare; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Lee, IM (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA.	ilee@rics.bwh.harvard.edu	Reis, Rodrigo/F-7447-2012; Sarmiento, Olga L/AAS-4165-2020; Parra, Diana C/D-7633-2013; Shiroma, Eric/AAV-5487-2021; Kahlmeier, Sonja/B-8141-2014; Lambert, Estelle/ABF-1268-2020; Katzmarzyk, Peter T/N-1974-2017; lobelo, felipe/B-9148-2013; Martin, Brian W/H-3241-2012; Lobelo, R.L Felipe/AAB-2264-2021; Lee, I-Min/ABD-5409-2021; Owen, Neville/K-5986-2012; Wells, Jonathan/A-4604-2009; Loos, Ruth/Q-2862-2016; Sallis, James F/D-3001-2014	Reis, Rodrigo/0000-0002-9872-9865; Sarmiento, Olga L/0000-0002-9190-3568; Parra, Diana C/0000-0002-9797-6231; Shiroma, Eric/0000-0003-4920-2642; Kahlmeier, Sonja/0000-0001-6905-9244; Lambert, Estelle/0000-0003-4315-9153; Katzmarzyk, Peter T/0000-0002-9280-6022; Lobelo, R.L Felipe/0000-0003-4185-7193; Owen, Neville/0000-0003-2784-4820; Goenka, Shifalika/0000-0001-6993-2883; Wells, Jonathan/0000-0003-0411-8025; Loos, Ruth/0000-0002-8532-5087; Guthold, Regina/0000-0003-3073-6468; Sallis, James F/0000-0003-2555-9452	US National Institutes of Health [CA154647, HL007575]; Louisiana Public Facilities Authority Endowed Chair in Nutrition; MRC [MC_U106188470] Funding Source: UKRI; Medical Research Council [MC_U106188470] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA154647] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007575] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisiana Public Facilities Authority Endowed Chair in Nutrition; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention. I-ML was supported in part by grant CA154647 from the US National Institutes of Health. EJS was supported in part by grant HL007575 from the US National Institutes of Health. PTK was supported in part by the Louisiana Public Facilities Authority Endowed Chair in Nutrition. We thank Kenneth E Powell, Shane A Norris, and Beverly J Levine for reviewing a previous draft of the report and providing critical input. We thank several people for providing data to calculate the adjustment factor: David Batty, Kennet Harald, Duck-chul Lee, Charles E Matthews, Martin Shipley, Emmanuel Stamatakis, Xuemei Sui, and Nicholas J Wareham. We thank Jacob R Sattelmair and Kathleen Y Wolin for assisting with meta-analyses.	[Anonymous], 2011, LIF TABL WHO MEMB ST; Beaglehole R, 2011, LANCET, V378, P449, DOI 10.1016/S0140-6736(11)60879-9; Blair SN, 2010, ANN EPIDEMIOL, V20, P651, DOI 10.1016/j.annepidem.2010.06.001; Courneya KS, 2011, RECENT RESULTS CANC, V186, P1, DOI 10.1007/978-3-642-04231-7; Crimmins EM, 2011, EXPLAINING DIVERGENT LEVELS OF LONGEVITY IN HIGH-INCOME COUNTRIES, P1; Ezzati M, 2003, LANCET, V362, P847, DOI 10.1016/S0140-6736(03)14338-3; Ezzati M, 2004, COMP QUANTIFICATION; Franco OH, 2005, ARCH INTERN MED, V165, P2355, DOI 10.1001/archinte.165.20.2355; Gu DF, 2009, NEW ENGL J MED, V360, P150, DOI 10.1056/NEJMsa0802902; Jeon CY, 2007, DIABETES CARE, V30, P744, DOI 10.2337/dc06-1842; Kodama S, 2009, JAMA-J AM MED ASSOC, V301, P2024, DOI 10.1001/jama.2009.681; Lee I-M, 2009, EPIDEMIOLOGIC METHOD, P100; Lollgen H, 2009, INT J SPORTS MED, V30, P213, DOI 10.1055/s-0028-1128150; Monninkhof EM, 2007, EPIDEMIOLOGY, V18, P137, DOI 10.1097/01.ede.0000251167.75581.98; Olshansky SJ, 2005, NEW ENGL J MED, V352, P1138, DOI 10.1056/NEJMsr043743; Organization WH, 2016, GLOBAL STATUS REPORT; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; POWELL KE, 1994, MED SCI SPORT EXER, V26, P851; Rastogi T, 2004, INT J EPIDEMIOL, V33, P759, DOI 10.1093/ije/dyh042; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; ROOK A, 1954, Br Med J, V1, P773; Sattelmair J, 2011, CIRCULATION, V124, P789, DOI 10.1161/CIRCULATIONAHA.110.010710; Tian XB, 2011, J EPIDEMIOL, V21, P376, DOI 10.2188/jea.JE20110001; United States Department of Health and Human Services, 2008 PHYS ACT GUID A; Warburton DER, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-39; Wen CP, 2011, LANCET, V378, P1244, DOI 10.1016/S0140-6736(11)60749-6; WHO, 2010, GLOB REC PHYS ACT HL, V1st, P15; Wolin KY, 2009, BRIT J CANCER, V100, P611, DOI 10.1038/sj.bjc.6604917; World Health Organization, 2011, GLOB HLTH OBS DAT RE; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	30	4545	4728	32	686	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2012	380	9838					219	229		10.1016/S0140-6736(12)61031-9	http://dx.doi.org/10.1016/S0140-6736(12)61031-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976TV	22818936	Green Accepted, Green Published, Green Submitted			2022-12-28	WOS:000306609200031
J	Fried, MW; Navarro, VJ; Afdhal, N; Belle, SH; Wahed, AS; Hawke, RL; Doo, E; Meyers, CM; Reddy, KR				Fried, Michael W.; Navarro, Victor J.; Afdhal, Nezam; Belle, Steven H.; Wahed, Abdus S.; Hawke, Roy L.; Doo, Edward; Meyers, Catherine M.; Reddy, K. Rajender		Silymarin NASH & C Hepatitis SyNC	Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon Therapy A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM TREATMENT; VIRUS-INFECTION; METAANALYSIS; PHARMACOKINETICS; FLAVONOLIGNANS; SILIPIDE; PEGINTERFERON; SILIBININ; RIBAVIRIN; PRODUCT	Context The botanical product silymarin, an extract of milk thistle, is commonly used by patients to treat chronic liver disease, despite scant and conflicting evidence of its efficacy. Objective To determine the effect of silymarin on liver disease activity in patients with chronic hepatitis C virus (HCV) infection unsuccessfully treated with interferon-based therapy. Design, Setting, and Participants Multicenter, double-blind, placebo-controlled trial conducted at 4 medical centers in the United States. Participants included 154 persons with chronic HCV infection and serum alanine aminotransferase (ALT) levels of 65 U/L or greater who were previously unsuccessfully treated with interferon-based therapy. Enrollment began in May 2008 and was completed in May 2010, with the last follow-up visit completed in March 2011. Intervention Participants were randomly assigned to receive 420-mg silymarin, 700-mg silymarin, or matching placebo administered 3 times per day for 24 weeks. Main Outcome Measures The primary outcome measure was serum ALT level of 45 U/L or less (considered within the normal range) or less than 65 U/L, provided this was at least a 50% decline from baseline values. Secondary outcomes included changes in ALT levels, HCV RNA levels, and quality-of-life measures. Results After 24 weeks of treatment, only 2 participants in each treatment group(P >= .99) met the primary outcome measure (3.8% [95% CI, 0.5% to 13.2%] for placebo, 4.0% [95% CI, 0.5% to 13.7%] for 420-mg silymarin, and 3.8% [95% CI, 0.5% to 13.2%] for 700-mg silymarin). The mean decline in serum ALT activity at the end of treatment did not differ significantly (P=.75) across the 3 treatment groups (mean decline, -4.3 [95% CI, -17.3 to 8.7] U/L for placebo, -14.4 [95% CI, -41.6 to 12.7] U/L for 420-mg silymarin, -11.3 [95% CI, -27.9 to 5.4] U/L for 700-mg silymarin); there likewise were no significant differences in HCV RNA levels (mean change, 0.07 [95% CI, -0.05 to 0.18] log(10) IU/mL for placebo, -0.03[95% CI, -0.18 to 0.12] log(10) IU/mL for 420-mg silymarin, 0.04 [95% CI, -0.08 to 0.16] log(10) IU/mL for 700-mg silymarin; P=.54) or quality-of-life measures. The adverse event profile of silymarin was comparable with that of placebo. Conclusion Higher than customary doses of silymarin did not significantly reduce serum ALT levels more than placebo in participants with chronic HCV infection unsuccessfully treated with interferon-based therapy.	[Fried, Michael W.] Univ N Carolina, UNC Liver Ctr, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA; [Hawke, Roy L.] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27599 USA; [Navarro, Victor J.] Thomas Jefferson Univ, Div Gastroenterol & Hepatol, Philadelphia, PA 19107 USA; [Afdhal, Nezam] Beth Israel Deaconess Med Ctr, Ctr Liver, Boston, MA 02215 USA; [Belle, Steven H.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Belle, Steven H.; Wahed, Abdus S.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA; [Doo, Edward] NIDDKD, NIH, Bethesda, MD 20892 USA; [Meyers, Catherine M.] NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA; [Reddy, K. Rajender] Univ Penn, Div Gastroenterol & Hepatol, Philadelphia, PA 19104 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Jefferson University; Harvard University; Beth Israel Deaconess Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; University of Pennsylvania	Fried, MW (corresponding author), Univ N Carolina, UNC Liver Ctr, Div Gastroenterol & Hepatol, CB 7584,Room 8015 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.	mfried@med.unc.edu		Wahed, Abdus/0000-0001-6911-7221; Afdhal, Nezam/0000-0002-7342-6593	National Institutes of Health (NIH) National Center for Complementary and Alternative Medicine (NCCAM) [UO1 AT003571, UO1 AT003560, UO1 AT003573, UO1 AT003566, UO1 AT003574]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH Clinical & Translational Sciences Awards Division of Research Resources [UL1 RR024134, UL1 TR000083]; NIH [DK066144]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000083] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [U01AT003566, U01AT003573, U01AT003560, U01AT003574, U01AT003571] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK066144] Funding Source: NIH RePORTER	National Institutes of Health (NIH) National Center for Complementary and Alternative Medicine (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH Clinical & Translational Sciences Awards Division of Research Resources; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported with cooperative agreements from the National Institutes of Health (NIH) National Center for Complementary and Alternative Medicine (NCCAM) (UO1 AT003571, UO1 AT003560, UO1 AT003573, UO1 AT003566, and UO1 AT003574); with cofunding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); and with support from the NIH Clinical & Translational Sciences Awards Division of Research Resources (UL1 RR024134, UL1 TR000083). Dr Fried is also supported by an NIH Mid-Career Award (DK066144). The trial was conducted under an Investigational New Drug Application from the US Food and Drug Administration. Rottapharm vertical bar Madaus (Monza, Italy, and Cologne, Germany) donated the silymarin study medication and matching placebo. Abbott Molecular Inc (Des Plaines, Illinois) donated the Abbott RealTime HCV assays.	Abenavoli L, 2010, PHYTOTHER RES, V24, P1423, DOI 10.1002/ptr.3207; Ahmed-Belkacem A, 2010, GASTROENTEROLOGY, V138, P1112, DOI 10.1053/j.gastro.2009.11.053; Bonifaz V, 2009, LIVER INT, V29, P366, DOI 10.1111/j.1478-3231.2008.01833.x; Bonis PAL, 1997, HEPATOLOGY, V26, P1035, DOI 10.1053/jhep.1997.v26.pm0009328332; Carithers RL, 1997, HEPATOLOGY, V26, pS83, DOI 10.1002/hep.510260715; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; Conjeevaram HS, 2006, GASTROENTEROLOGY, V131, P470, DOI 10.1053/j.gastro.2006.06.008; Ferenci P, 2008, GASTROENTEROLOGY, V135, P1561, DOI 10.1053/j.gastro.2008.07.072; Freedman ND, 2011, ALIMENT PHARM THER, V33, P127, DOI 10.1111/j.1365-2036.2010.04503.x; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Ghany MG, 2009, HEPATOLOGY, V49, P1335, DOI 10.1002/hep.22759; Hawke RL, 2010, J CLIN PHARMACOL, V50, P434, DOI 10.1177/0091270009347475; Jacobs BP, 2002, AM J MED, V113, P506, DOI 10.1016/S0002-9343(02)01244-5; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Little R. J. A., 1987, STAT ANAL MISSING DA; Liu JP, 2003, AM J GASTROENTEROL, V98, P538, DOI 10.1111/j.1572-0241.2003.07298.x; Magdalan J, 2011, HUM EXP TOXICOL, V30, P38, DOI 10.1177/0960327110368418; Miranda SR, 2008, DRUG METAB DISPOS, V36, P2219, DOI 10.1124/dmd.108.021790; MORAZZONI P, 1993, EUR J DRUG METAB PH, V18, P289, DOI 10.1007/BF03188811; MORAZZONI P, 1992, EUR J DRUG METAB PH, V17, P39, DOI 10.1007/BF03189986; Morishima C, 2010, GASTROENTEROLOGY, V138, P671, DOI 10.1053/j.gastro.2009.09.021; Patel K, 2011, WORLD J GASTROENTERO, V17, P4581, DOI 10.3748/wjg.v17.i41.4581; Polyak SJ, 2007, GASTROENTEROLOGY, V132, P1925, DOI 10.1053/j.gastro.2007.02.038; Polyak SJ, 2010, P NATL ACAD SCI USA, V107, P5995, DOI 10.1073/pnas.0914009107; Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rambaldi A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003620.pub3; Reddy KR, 2012, CLIN TRIALS, V9, P102, DOI 10.1177/1740774511427064; Saller R, 2008, FORSCH KOMPLEMENTMED, V15, P9, DOI 10.1159/000113648; SCHANDALIK R, 1992, ARZNEIMITTEL-FORSCH, V42-2, P964; Seeff LB, 2008, HEPATOLOGY, V47, P605, DOI 10.1002/hep.22044; Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4; Shiffman ML, 1997, HEPATOLOGY, V26, P780, DOI 10.1002/hep.510260335; Verma S, 2007, CLIN GASTROENTEROL H, V5, P408, DOI 10.1016/j.cgh.2006.10.014; Wagoner J, 2010, HEPATOLOGY, V51, P1912, DOI 10.1002/hep.23587; Ware J., 2001, SF 36 PHYS MENTAL HL, P1994; Wen Z, 2008, DRUG METAB DISPOS, V36, P65, DOI 10.1124/dmd.107.017566; Younossi ZM, 1999, GUT, V45, P295, DOI 10.1136/gut.45.2.295	38	110	113	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2012	308	3					274	282		10.1001/jama.2012.8265	http://dx.doi.org/10.1001/jama.2012.8265			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975AC	22797645	Bronze, Green Accepted			2022-12-28	WOS:000306477900028
J	Chown, SL; Lee, JE; Hughes, KA; Barnes, J; Barrett, PJ; Bergstrom, DM; Convey, P; Cowan, DA; Crosbie, K; Dyer, G; Frenot, Y; Grant, SM; Herr, D; Kennicutt, MC; Lamers, M; Murray, A; Possingham, HP; Reid, K; Riddle, MJ; Ryan, PG; Sanson, L; Shaw, JD; Sparrow, MD; Summerhayes, C; Terauds, A; Wall, DH				Chown, S. L.; Lee, J. E.; Hughes, K. A.; Barnes, J.; Barrett, P. J.; Bergstrom, D. M.; Convey, P.; Cowan, D. A.; Crosbie, K.; Dyer, G.; Frenot, Y.; Grant, S. M.; Herr, D.; Kennicutt, M. C., II; Lamers, M.; Murray, A.; Possingham, H. P.; Reid, K.; Riddle, M. J.; Ryan, P. G.; Sanson, L.; Shaw, J. D.; Sparrow, M. D.; Summerhayes, C.; Terauds, A.; Wall, D. H.			Challenges to the Future Conservation of the Antarctic	SCIENCE			English	Editorial Material									[Chown, S. L.; Lee, J. E.] Univ Stellenbosch, ZA-7600 Stellenbosch, South Africa; [Chown, S. L.] Monash Univ, Clayton, Vic 3800, Australia; [Barrett, P. J.] Victoria Univ Wellington, Wellington, New Zealand; [Cowan, D. A.] Univ Western Cape, ZA-7535 Bellville, South Africa; [Frenot, Y.] Univ Rennes, CNRS, Unite Mixte Rech Ecobio, Rennes, France; [Kennicutt, M. C., II] Texas A&M Univ, College Stn, TX 77843 USA; [Lamers, M.] Wageningen Univ, Wageningen, Netherlands; [Possingham, H. P.; Shaw, J. D.] Univ Queensland, Brisbane, Qld 4072, Australia; [Ryan, P. G.] Univ Cape Town, ZA-7700 Rondebosch, South Africa; [Wall, D. H.] Colorado State Univ, Ft Collins, CO 80523 USA	Stellenbosch University; Monash University; Victoria University Wellington; University of the Western Cape; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Texas A&M University System; Texas A&M University College Station; Wageningen University & Research; University of Queensland; University of Cape Town; Colorado State University	Chown, SL (corresponding author), Univ Stellenbosch, ZA-7600 Stellenbosch, South Africa.	steven.chown@monash.edu	Chown, Steven L/H-3347-2011; Convey, Peter/AAV-5728-2020; Chown, Steven/ABD-7646-2021; Bergstrom, Dana/AAC-2837-2022; Cowan, Donald A/E-3991-2012; POSSINGHAM, HUGH/R-8310-2019; Wall, Diana H/F-5491-2011; Possingham, Hugh/B-1337-2008	Chown, Steven L/0000-0001-6069-5105; Convey, Peter/0000-0001-8497-9903; Bergstrom, Dana/0000-0001-8484-8954; Cowan, Donald A/0000-0001-8059-861X; POSSINGHAM, HUGH/0000-0001-7755-996X; Possingham, Hugh/0000-0001-7755-996X; Ryan, Peter/0000-0002-3356-2056; Frenot, Yves/0000-0003-2666-1272; Shaw, Justine/0000-0002-9603-2271; Lamers, Machiel/0000-0002-4189-3066	NERC [bas010013] Funding Source: UKRI; Natural Environment Research Council [bas010013] Funding Source: researchfish; Office of Polar Programs (OPP) [1115245] Funding Source: National Science Foundation	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Office of Polar Programs (OPP)(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))		[Anonymous], 2011, SCI DIPLOMACY ANTARC; Blight LK, 2010, SCIENCE, V330, P1316, DOI 10.1126/science.330.6009.1316; Chown SL, 2012, P NATL ACAD SCI USA, V109, P4938, DOI 10.1073/pnas.1119787109; Committee for Environmental Protection, 2011, NONN SPEC MAN; Dyer Gwynne, 2010, CLIMATE WARS FIGHT S; Joyner CC, 2011, SCIENCE DIPLOMACY: ANTARCTICA, SCIENCE, AND THE GOVERNANCE OF INTERNATIONAL SPACES, P97; McNeil BI, 2008, P NATL ACAD SCI USA, V105, P18860, DOI 10.1073/pnas.0806318105; Rignot E, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL046583; Ruoppolo V, 2013, POLAR REC, V49, P97, DOI 10.1017/S0032247411000763; Segan DB, 2011, ENVIRON MODELL SOFTW, V26, P1434, DOI 10.1016/j.envsoft.2011.08.002; Sutherland WJ, 2012, TRENDS ECOL EVOL, V27, P12, DOI 10.1016/j.tree.2011.10.011; Terauds A, 2012, DIVERS DISTRIB, V18, P726, DOI 10.1111/j.1472-4642.2012.00925.x; Tin T, 2009, ANTARCT SCI, V21, P3, DOI 10.1017/S0954102009001722; Vaughan NE, 2011, CLIMATIC CHANGE, V109, P745, DOI 10.1007/s10584-011-0027-7	14	117	120	0	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2012	337	6091					158	159		10.1126/science.1222821	http://dx.doi.org/10.1126/science.1222821			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798586	Green Submitted			2022-12-28	WOS:000306323500028
J	Dutton, A; Lambeck, K				Dutton, A.; Lambeck, K.			Ice Volume and Sea Level During the Last Interglacial	SCIENCE			English	Article							CORAL-REEFS; GREENLAND; RISE; CONSTRAINTS; DURATION; COLLAPSE; PERIOD; COAST; SHEET	During the last interglacial period, similar to 125,000 years ago, sea level was at least several meters higher than at present, with substantial variability observed for peak sea level at geographically diverse sites. Speculation that the West Antarctic ice sheet collapsed during the last interglacial period has drawn particular interest to understanding climate and ice-sheet dynamics during this time interval. We provide an internally consistent database of coral U-Th ages to assess last interglacial sea-level observations in the context of isostatic modeling and stratigraphic evidence. These data indicate that global (eustatic) sea level peaked 5.5 to 9 meters above present sea level, requiring smaller ice sheets in both Greenland and Antarctica relative to today and indicating strong sea-level sensitivity to small changes in radiative forcing.	[Dutton, A.; Lambeck, K.] Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; [Dutton, A.] Univ Florida, Dept Geol Sci, Gainesville, FL 32611 USA; [Lambeck, K.] Ecole Normale Super, Dept Geosci, F-75231 Paris, France	Australian National University; State University System of Florida; University of Florida; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Dutton, A (corresponding author), Australian Natl Univ, Res Sch Earth Sci, 1 Mills Rd, Canberra, ACT 0200, Australia.	adutton@ufl.edu	Dutton, Andrea/A-2506-2008	Dutton, Andrea/0000-0002-3836-119X	Past Global Changes/IMAGES (International Marine Past Global Change Study); Australian Research Council; Australian National University; Chaire Internationale de Recherche Blaise Pascal financee par l'Etat et la Region Ile-de-France; Division Of Earth Sciences [1023724] Funding Source: National Science Foundation	Past Global Changes/IMAGES (International Marine Past Global Change Study); Australian Research Council(Australian Research Council); Australian National University(Australian National University); Chaire Internationale de Recherche Blaise Pascal financee par l'Etat et la Region Ile-de-France; Division Of Earth Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	We acknowledge useful discussions with many of our colleagues, including T. Esat, E.-K. Potter, and members of the PALSEA (Paleo-Constraints on Sea Level Rise) working group funded by Past Global Changes/IMAGES (International Marine Past Global Change Study). We also extend our gratitude to many authors who provided additional information or data to supplement their U-Th measurements that appear in database S1. This project has been partially funded by the Australian Research Council and the Australian National University. K. L. was partly funded by the Chaire Internationale de Recherche Blaise Pascal financee par l'Etat et la Region Ile-de-France. Data compiled for this review are available in the supplementary materials and are archived online at the World Data Center for Paleoclimatology.	Bamber JL, 2009, SCIENCE, V324, P901, DOI 10.1126/science.1169335; Blanchon P, 2009, NATURE, V458, P881, DOI 10.1038/nature07933; CHEN JH, 1991, GEOL SOC AM BULL, V103, P82, DOI 10.1130/0016-7606(1991)103<0082:PCOTLI>2.3.CO;2; Clark PU, 2009, NATURE, V462, P856, DOI 10.1038/462856a; Colville EJ, 2011, SCIENCE, V333, P620, DOI 10.1126/science.1204673; Cuffey KM, 2000, NATURE, V404, P591, DOI 10.1038/35007053; Edwards RL, 2003, REV MINERAL GEOCHEM, V52, P363, DOI 10.2113/0520363; Engelhart SE, 2009, GEOLOGY, V37, P1115, DOI 10.1130/G30360A.1; FARRELL WE, 1976, GEOPHYS J ROY ASTR S, V46, P647, DOI 10.1111/j.1365-246X.1976.tb01252.x; Ferranti L, 2006, QUATERN INT, V145, P30, DOI 10.1016/j.quaint.2005.07.009; Hearty PJ, 2007, QUATERNARY SCI REV, V26, P2090, DOI 10.1016/j.quascirev.2007.06.019; Kopp RE, 2009, NATURE, V462, P863, DOI 10.1038/nature08686; LAMBECK K, 1992, NATURE, V357, P125, DOI 10.1038/357125a0; Lambeck K, 2012, EARTH PLANET SC LETT, V315, P4, DOI 10.1016/j.epsl.2011.08.026; Lhomme N, 2005, QUATERNARY SCI REV, V24, P173, DOI 10.1016/j.quascirev.2004.08.020; McKay NP, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL048280; Milne GA, 2008, QUATERNARY SCI REV, V27, P2292, DOI 10.1016/j.quascirev.2008.08.018; Otto-Bliesner BL, 2006, SCIENCE, V311, P1751, DOI 10.1126/science.1120808; Plaziat Jean-Claude, 2008, Carnets de Geologie, P1; Potter EK, 2004, EARTH PLANET SC LETT, V217, P171, DOI 10.1016/S0012-821X(03)00587-9; Raymo ME, 2012, NATURE, V483, P453, DOI 10.1038/nature10891; Siddall M., 2009, J QUATERNARY SCI, V25, P19; Stirling CH, 1998, EARTH PLANET SC LETT, V160, P745, DOI 10.1016/S0012-821X(98)00125-3; Stirling CH, 2009, EARTH PLANET SC LETT, V284, P269, DOI 10.1016/j.epsl.2009.04.045; Tarasov L, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001731; VEEH HH, 1966, J GEOPHYS RES, V71, P3379, DOI 10.1029/JZ071i014p03379	26	287	295	6	187	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2012	337	6091					216	219		10.1126/science.1205749	http://dx.doi.org/10.1126/science.1205749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798610				2022-12-28	WOS:000306323500054
J	Spence, D				Spence, Des			Women's magazines damage women's health	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						British Association of Aesthetic Plastic Surgeons, PLAST SURG UK	1	0	0	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 12	2012	345								e4680	10.1136/bmj.e4680	http://dx.doi.org/10.1136/bmj.e4680			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NW	22791776				2022-12-28	WOS:000306519000007
J	Volz, J; Rauschenbeutel, A				Volz, Juergen; Rauschenbeutel, Arno			Two Atoms Announce Their Long-Distance Relationship	SCIENCE			English	Editorial Material							QUANTUM COMMUNICATION		[Volz, Juergen; Rauschenbeutel, Arno] Vienna Univ Technol, Vienna Ctr Quantum Sci & Technol, Atominst, A-1020 Vienna, Austria	Technische Universitat Wien	Volz, J (corresponding author), Vienna Univ Technol, Vienna Ctr Quantum Sci & Technol, Atominst, Stadionallee 2, A-1020 Vienna, Austria.	jvolz@ati.ac.at; arno.rauschenbeutel@tuwien.ac.at	Volz, Jürgen/N-6457-2016; Rauschenbeutel, Arno/C-1472-2013	Volz, Jürgen/0000-0002-3174-2141; Rauschenbeutel, Arno/0000-0003-2467-4029				Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; CLAUSER JF, 1978, REP PROG PHYS, V41, P1881, DOI 10.1088/0034-4885/41/12/002; Gisin N, 2002, REV MOD PHYS, V74, P145, DOI 10.1103/RevModPhys.74.145; Hofmann J, 2012, SCIENCE, V337, P72, DOI 10.1126/science.1221856; Pan JW, 1998, PHYS REV LETT, V80, P3891, DOI 10.1103/PhysRevLett.80.3891; Schlosser N, 2001, NATURE, V411, P1024, DOI 10.1038/35082512; Shor PW, 1997, SIAM J COMPUT, V26, P1484, DOI [10.1137/S0097539795293172, 10.1137/S0036144598347011]; Ursin R, 2007, NAT PHYS, V3, P481, DOI 10.1038/nphys629	9	2	3	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2012	337	6090					40	41		10.1126/science.1224202	http://dx.doi.org/10.1126/science.1224202			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	969KC	22767916				2022-12-28	WOS:000306053100034
J	Turnbaugh, PJ				Turnbaugh, Peter J.			MICROBIOLOGY Fat, bile and gut microbes	NATURE			English	Editorial Material							SULFATE-REDUCING BACTERIA; BILOPHILA-WADSWORTHIA; DIETARY-FAT; ACID		Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA	Harvard University	Turnbaugh, PJ (corresponding author), Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA.	pturnbaugh@fas.harvard.edu		Turnbaugh, Peter/0000-0002-0888-2875				Baron EJ, 1997, ANAEROBE, V3, P83, DOI 10.1006/anae.1997.0075; Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009; Devkota S, 2012, NATURE, V487, P104, DOI 10.1038/nature11225; Laue H, 1997, APPL ENVIRON MICROB, V63, P2016, DOI 10.1128/AEM.63.5.2016-2021.1997; LINDSTEDT S, 1965, J CLIN INVEST, V44, P1754, DOI 10.1172/JCI105283; Loubinoux J, 2002, FEMS MICROBIOL ECOL, V40, P107, DOI 10.1111/j.1574-6941.2002.tb00942.x; Rowan FE, 2009, BRIT J SURG, V96, P151, DOI 10.1002/bjs.6454; Turnbaugh PJ, 2010, ACTA CRYSTALLOGR F, V66, P1261, DOI 10.1107/S1744309110029088; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; Walker AW, 2011, ISME J, V5, P220, DOI 10.1038/ISMEJ.2010.118	10	29	29	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2012	487	7405					47	48		10.1038/487047a	http://dx.doi.org/10.1038/487047a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968LM	22763552				2022-12-28	WOS:000305982900045
J	Carson, JL; Grossman, BJ; Kleinman, S; Tinmouth, AT; Marques, MB; Fung, MK; Holcomb, JB; Illoh, O; Kaplan, LJ; Katz, LM; Rao, SV; Roback, JD; Shander, A; Tobian, AAR; Weinstein, R; McLaughlin, LGS; Djulbegovic, B				Carson, Jeffrey L.; Grossman, Brenda J.; Kleinman, Steven; Tinmouth, Alan T.; Marques, Marisa B.; Fung, Mark K.; Holcomb, John B.; Illoh, Orieji; Kaplan, Lewis J.; Katz, Louis M.; Rao, Sunil V.; Roback, John D.; Shander, Aryeh; Tobian, Aaron A. R.; Weinstein, Robert; McLaughlin, Lisa Grace Swinton; Djulbegovic, Benjamin		Clinical Transfusion Med Comm AAB	Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; CRITICALLY-ILL; RESTRICTIVE TRANSFUSION; RESIDUAL RISK; ADULT TRAUMA; ANEMIA; HIP; REQUIREMENTS; MULTICENTER; STRATEGIES	Description: Although approximately 85 million units of red blood cells (RBCs) are transfused annually worldwide, transfusion practices vary widely. The AABB (formerly, the American Association of Blood Banks) developed this guideline to provide clinical recommendations about hemoglobin concentration thresholds and other clinical variables that trigger RBC transfusions in hemodynamically stable adults and children. Methods: These guidelines are based on a systematic review of randomized clinical trials evaluating transfusion thresholds. We performed a literature search from 1950 to February 2011 with no language restrictions. We examined the proportion of patients who received any RBC transfusion and the number of RBC units transfused to describe the effect of restrictive transfusion strategies on RBC use. To determine the clinical consequences of restrictive transfusion strategies, we examined overall mortality, nonfatal myocardial infarction, cardiac events, pulmonary edema, stroke, thromboembolism, renal failure, infection, hemorrhage, mental confusion, functional recovery, and length of hospital stay. Recommendation 1: The AABB recommends adhering to a restrictive transfusion strategy (7 to 8 g/dL) in hospitalized, stable patients (Grade: strong recommendation; high-quality evidence). Recommendation 2: The AABB suggests adhering to a restrictive strategy in hospitalized patients with preexisting cardiovascular disease and considering transfusion for patients with symptoms or a hemoglobin level of 8 g/dL or less (Grade: weak recommendation; moderate-quality evidence). Recommendation 3: The AABB cannot recommend for or against a liberal or restrictive transfusion threshold for hospitalized, hemodynamically stable patients with the acute coronary syndrome (Grade: uncertain recommendation; very low-quality evidence). Recommendation 4: The AABB suggests that transfusion decisions be influenced by symptoms as well as hemoglobin concentration (Grade: weak recommendation; low-quality evidence).	[Carson, Jeffrey L.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, New Brunswick, NJ 08903 USA; Washington Univ, Sch Med, St Louis, MO USA; AABB, Bethesda, MD USA; Johns Hopkins Univ, Sch Med, Bethesda, MD USA; Univ British Columbia, Victoria, BC, Canada; Ottawa Hosp, Res Inst, Ottawa, ON, Canada; Univ Alabama Birmingham, Birmingham, AL USA; Fletcher Allen Hlth Care, Burlington, VT USA; Univ Texas Houston, Med Ctr, Ctr Translat Injury Res, Houston, TX USA; Univ Texas Houston, Med Ctr, Dept Surg, Houston, TX USA; US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA; Yale Med Grp, New Haven, CT USA; Univ Iowa, Mississippi Valley Reg Blood Ctr, Davenport, IA USA; Univ Iowa, Carver Coll Med, Davenport, IA USA; Duke Univ, Sch Med, Durham, NC USA; Emory Univ, Sch Med, Atlanta, GA USA; Englewood Hosp & Med Ctr, Englewood, NJ USA; Univ Massachusetts, Sch Med, Worcester, MA USA; Amer Red Cross, Rockville, MD USA; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA; Res Inst, Tampa, FL USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Washington University (WUSTL); Johns Hopkins University; University of British Columbia; University of Ottawa; Ottawa Hospital Research Institute; University of Alabama System; University of Alabama Birmingham; University of Vermont Medical Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; US Food & Drug Administration (FDA); University of Iowa; University of Iowa; Duke University; Emory University; Englewood Hospital & Medical Center; University of Massachusetts System; University of Massachusetts Worcester; American Red Cross; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Carson, JL (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, 125 Paterson St, New Brunswick, NJ 08903 USA.	carson@umdnj.edu	Girelli, Domenico/B-1183-2008; Djulbegovic, Benjamin/I-3661-2012	Girelli, Domenico/0000-0001-9684-1899; Djulbegovic, Benjamin/0000-0003-0671-1447; Fung, Mark/0000-0001-6081-4151; holcomb, john/0000-0001-8312-9157; Grossman, Brenda/0000-0002-1500-8211; Marques, Marisa/0000-0002-6689-7856	AABB, Bethesda, Maryland	AABB, Bethesda, Maryland	Support for the development of this guideline was provided by the AABB, Bethesda, Maryland.	AABB, 2006, AABB POL CONFL INT C; ANDERSON HT, 1978, SURGERY, V84, P8; [Anonymous], 1994, Transfus Med, V4, P251; [Anonymous], ODDS BEING INV FAT A; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; [Australasian Society of Blood Transfusion National Health and Medical Research Council], 2001, CLIN PRACT GUID APPR; Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161; Bennett-Guerrero E, 2010, JAMA-J AM MED ASSOC, V304, P1568, DOI 10.1001/jama.2010.1406; Bierbaum BE, 1999, J BONE JOINT SURG AM, V81A, P2, DOI 10.2106/00004623-199901000-00002; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; Bracey AW, 1999, TRANSFUSION, V39, P1070, DOI 10.1046/j.1537-2995.1999.39101070.x; Bush RL, 1997, AM J SURG, V174, P143, DOI 10.1016/S0002-9610(97)00073-1; Carless PA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub2; Carson JL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub3; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; Carson JL, 1998, TRANSFUSION, V38, P522, DOI 10.1046/j.1537-2995.1998.38698326331.x; Colomo A, 2009, HEPATOLOGY, V50, p403A; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dzik WH, 2003, TRANSFUSION, V43, P1190, DOI 10.1046/j.1537-2995.2003.00523.x; Federowicz I, 1996, TRANSFUSION, V36, P21, DOI 10.1046/j.1537-2995.1996.36196190511.x; FISHER M R, 1956, Br J Clin Pract, V10, P770; FORTUNE JB, 1987, J TRAUMA, V27, P243, DOI 10.1097/00005373-198703000-00003; Foss NB, 2009, TRANSFUSION, V49, P227, DOI 10.1111/j.1537-2995.2008.01967.x; Grover M, 2006, VOX SANG, V90, P105, DOI 10.1111/j.1423-0410.2006.00730.x; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; HAGL S, 1977, BASIC RES CARDIOL, V72, P344, DOI 10.1007/BF02023594; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439, DOI 10.1001/jama.273.18.1439; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; HILL SR, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002042.PUB2; Holle RL., 2011, LIGHTNING FATALITIES; Hutton B, 2005, CAN J ANAESTH, V52, P581, DOI 10.1007/BF03015766; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; Kohn L, 2000, Jt Comm J Qual Improv, V26, P227; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Li GX, 2011, TRANSFUSION, V51, P338, DOI 10.1111/j.1537-2995.2010.02816.x; Linden JV, 1997, TRANSFUSION, V37, P243, DOI 10.1046/j.1537-2995.1997.37297203534.x; Linden JV, 2000, TRANSFUSION, V40, P1207, DOI 10.1046/j.1537-2995.2000.40101207.x; Lotke PA, 1999, J ARTHROPLASTY, V14, P647, DOI 10.1016/S0883-5403(99)90216-4; MacMahon S, 2001, LANCET, V357, P455, DOI 10.1016/S0140-6736(00)04017-4; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Middelburg RA, 2010, TRANSFUSION, V50, P1181, DOI 10.1111/j.1537-2995.2010.02675.x; Minino AM, 2011, DEATHS FINAL DATA 20; Murphy MF, 2001, BRIT J HAEMATOL, V113, P24; Napolitano LM, 2009, J TRAUMA, V67, P1439, DOI 10.1097/TA.0b013e3181ba7074; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; Popovsky M A, 1996, Immunohematology, V12, P87; So-Osman C, 2010, VOX SANG, V98, P56, DOI 10.1111/j.1423-0410.2009.01225.x; Stehling LC, 1996, ANESTHESIOLOGY, V84, P732; Takei T, 2009, JAIDS-J ACQ IMM DEF, V52, pS127, DOI 10.1097/QAI.0b013e3181baf0ac; Toy P, 2012, BLOOD, V119, P1757, DOI 10.1182/blood-2011-08-370932; U. Food D. Administration, 2011, FAT REP FDA FOLL BLO; U.S. Department of Health and Human Services, 2011, 2009 NAT BLOOD COLL; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Vuille-Lessard E, 2010, TRANSFUSION, V50, P2117, DOI 10.1111/j.1537-2995.2010.02697.x; Webert KE, 2008, TRANSFUSION, V48, P81, DOI 10.1111/j.1537-2995.2007.01485.x; WILKERSON DK, 1988, SURGERY, V103, P665; Zou SM, 2010, TRANSFUSION, V50, P1495, DOI 10.1111/j.1537-2995.2010.02622.x; Zou SM, 2009, TRANSFUSION, V49, P1609, DOI 10.1111/j.1537-2995.2009.02195.x; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	63	714	748	5	57	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2012	157	1					49	U95		10.7326/0003-4819-157-1-201206190-00429	http://dx.doi.org/10.7326/0003-4819-157-1-201206190-00429			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992NS	22751760				2022-12-28	WOS:000307784900005
J	Kamerow, D				Kamerow, Douglas			Direct primary care: a new system for general practice	BRITISH MEDICAL JOURNAL			English	Editorial Material												dkamerow@rti.org		Kamerow, Douglas/0000-0001-7000-9957				Agency for Health Care Policy and Research, 2011, AHRQ PUBL; Iglehart JK, 2012, NEW ENGL J MED, V366, P2144, DOI 10.1056/NEJMp1205537; Japsen B, 2012, NY TIMES        0521; Wu WN, 2010, HEALTH AFFAIR, V29, P959, DOI 10.1377/hlthaff.2010.0047	4	2	2	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 2	2012	344								e4482	10.1136/bmj.e4482	http://dx.doi.org/10.1136/bmj.e4482			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972JV	22750424				2022-12-28	WOS:000306274300004
J	Jones, L; Bellis, MA; Wood, S; Hughes, K; McCoy, E; Eckley, L; Bates, G; Mikton, C; Shakespeare, T; Officer, A				Jones, Lisa; Bellis, Mark A.; Wood, Sara; Hughes, Karen; McCoy, Ellie; Eckley, Lindsay; Bates, Geoff; Mikton, Christopher; Shakespeare, Tom; Officer, Alana			Prevalence and risk of violence against children with disabilities: a systematic review and meta-analysis of observational studies	LANCET			English	Article							PHYSICAL-DISABILITY; SEXUAL-ABUSE; HEARING-LOSS; HEALTH-CARE; VICTIMIZATION; MALTREATMENT; ADOLESCENTS; EXPOSURE; PUBLICATION; BEHAVIORS	Background Globally, at least 93 million children have moderate or severe disability. Children with disabilities are thought to have a substantially greater risk of being victims of violence than are their non-disabled peers. Establishment of reliable estimates of the scale of the problem is an essential first step in the development of effective prevention programmes. We therefore undertook a systematic review and meta-analysis to synthesise evidence for the prevalence and risk of violence against children with disabilities. Methods For this systematic review and meta-analysis, we searched 12 electronic databases to identify cross-sectional, case-control, or cohort studies reported between Jan 1, 1990, and Aug 17, 2010, with estimates of prevalence of violence against children (aged <= 18 years) with disabilities or their risk of being victims of violence compared with children without disabilities. Findings 17 studies were selected from 10 663 references. Reports of 16 studies provided data suitable for meta-analysis of prevalence and 11 for risk. Pooled prevalence estimates were 26.7% (95% CI 13.8-42.1) for combined violence measures, 20.4% (13.4-28.5) for physical violence, and 13.7% (9.2-18.9) for sexual violence. Odds ratios for pooled risk estimates were 3.68 (2.56-5.29) for combined violence measures, 3.56 (2.80-4.52) for physical violence, and 2.88 (2.24-3.69) for sexual violence. Huge heterogeneity was identified across most estimates (I-2>75%). Variations were not consistently explained with meta-regression analysis of the characteristics of the studies. Interpretation The results of this systematic review confirm that children with disabilities are more likely to be victims of violence than are their peers who are not disabled. However, the continued scarcity of robust evidence, due to a lack of well designed research studies, poor standards of measurement of disability and violence, and insufficient assessment of whether violence precedes the development of disability, leaves gaps in knowledge that need to be addressed.	[Jones, Lisa; Bellis, Mark A.; Wood, Sara; Hughes, Karen; McCoy, Ellie; Eckley, Lindsay; Bates, Geoff] Liverpool John Moores Univ, Ctr Publ Hlth, Liverpool L3 2ET, Merseyside, England; [Mikton, Christopher; Shakespeare, Tom; Officer, Alana] WHO, Dept Violence & Injury Prevent & Disabil, CH-1211 Geneva, Switzerland	Liverpool John Moores University; World Health Organization	Bellis, MA (corresponding author), Liverpool John Moores Univ, Ctr Publ Hlth, Liverpool L3 2ET, Merseyside, England.	m.a.bellis@ljmu.ac.uk	Jones, Lisa/C-2678-2013; Bellis, Mark A./HGA-2019-2022	Jones, Lisa/0000-0001-5136-5614; Hughes, Karen/0000-0001-8097-3395; Bates, Geoff/0000-0001-6932-2372	WHO Department of Violence and Injury Prevention and Disability	WHO Department of Violence and Injury Prevention and Disability	WHO Department of Violence and Injury Prevention and Disability.	Alriksson-Schmidt AI, 2010, J SCHOOL HEALTH, V80, P361, DOI 10.1111/j.1746-1561.2010.00514.x; Ammerman R. T., 1993, MALTREATMENT CHILDRE; AMMERMAN RT, 1994, J AM ACAD CHILD PSY, V33, P567, DOI 10.1097/00004583-199405000-00015; Balogh R, 2001, J INTELL DISABIL RES, V45, P194, DOI 10.1046/j.1365-2788.2001.00293.x; Becker KB, 2002, AM J ORTHOPSYCHIAT, V72, P83, DOI 10.1037//0002-9432.72.1.83; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BENEDICT MI, 1990, CHILD ABUSE NEGLECT, V14, P207, DOI 10.1016/0145-2134(90)90031-N; Blum RW, 2001, J ADOLESCENT HEALTH, V28, P481, DOI 10.1016/S1054-139X(01)00201-4; Brown J, 1998, CHILD ABUSE NEGLECT, V22, P1065, DOI 10.1016/S0145-2134(98)00087-8; Centre for Reviews and Dissemination, 2008, SYSTEMATIC REV CRDS; Cuevas CA, 2009, J INTERPERS VIOLENCE, V24, P636, DOI 10.1177/0886260508317197; Dawkins JL, 1996, DEV MED CHILD NEUROL, V38, P603, DOI 10.1111/j.1469-8749.1996.tb12125.x; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DuRant RH, 2000, J PEDIATR-US, V137, P707, DOI 10.1067/mpd.2000.109146; Ebeling Hanna, 2002, Int J Circumpolar Health, V61 Suppl 2, P51; Gilbert R, 2009, LANCET, V373, P68, DOI 10.1016/S0140-6736(08)61706-7; Govindshenoy M, 2007, CHILD CARE HLTH DEV, V33, P552, DOI 10.1111/j.1365-2214.2006.00693.x; Groce N, 2005, VIOL DIS CHILDR UN S; Hearn J, 2011, CHILD YOUTH SERV REV, V33, P715, DOI 10.1016/j.childyouth.2010.11.011; Hershkowitz I, 2007, AM J ORTHOPSYCHIAT, V77, P629, DOI 10.1037/0002-9432.77.4.629; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hughes K, 2012, LANCET, V379, P1621, DOI 10.1016/S0140-6736(11)61851-5; Jemta L, 2008, ACTA PAEDIATR, V97, P641, DOI 10.1111/j.1651-2227.2008.00757.x; Jones SE, 2008, J SCHOOL HEALTH, V78, P252, DOI 10.1111/j.1746-1561.2008.00297.x; Litrownik AJ, 2003, J FAM VIOLENCE, V18, P59, DOI 10.1023/A:1021405515323; MacMillan HL, 2009, LANCET, V373, P250, DOI 10.1016/S0140-6736(08)61708-0; Mandell DS, 2005, CHILD ABUSE NEGLECT, V29, P1359, DOI 10.1016/j.chiabu.2005.06.006; Miller D., 1993, BEHAV DISORDERS, V18, P129; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Piek JP, 2005, BRIT J EDUC PSYCHOL, V75, P453, DOI 10.1348/000709904X24573; Pinheiro P.S., 2006, WORLD REPORT VIOLENC; Reiter S, 2007, J INTELLECT DISABILI, V11, P371, DOI 10.1177/1744629507084602; Sidebotham P, 2003, CHILD ABUSE NEGLECT, V27, P337, DOI 10.1016/S0145-2134(03)00010-3; Spencer N, 2005, PEDIATRICS, V116, P609, DOI 10.1542/peds.2004-1882; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Straus MA, 2005, CHILD ABUSE NEGLECT, V29, P19, DOI 10.1016/j.chiabu.2004.08.005; Stuart A, 1994, KENDALLS ADV THEORY; Sullivan PM, 2009, CLIN CHILD FAM PSYCH, V12, P196, DOI 10.1007/s10567-009-0056-1; Sullivan PM, 2000, CHILD ABUSE NEGLECT, V24, P1257, DOI 10.1016/S0145-2134(00)00190-3; Sullivan PM., 2000, MENTAL HLTH DEAFNESS, P149; Suris JC, 1996, J ADOLESCENT HEALTH, V19, P124, DOI 10.1016/1054-139X(95)00282-W; Titus JC, 2008, J DEAF STUD DEAF EDU, V13, P336, DOI 10.1093/deafed/enm068; Titus JC, 2010, AM ANN DEAF, V155, P19, DOI 10.1353/aad.0.0127; Van Cleave J, 2006, PEDIATRICS, V118, pE1212, DOI 10.1542/peds.2005-3034; VERDUGO MA, 1995, CHILD ABUSE NEGLECT, V19, P205, DOI 10.1016/0145-2134(94)00117-D; Vizcarra MB, 2001, REV MED CHILE, V129, P1425; WHO, 2011, WORLD REPORT ON DISABILITY, P1; WHO, 2011, GLOB BURD DIS DIS IN; World Health Organization, 2002, WORLD REPORT VIOLENC	49	412	418	5	113	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 8	2012	380	9845					899	907		10.1016/S0140-6736(12)60692-8	http://dx.doi.org/10.1016/S0140-6736(12)60692-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	002QL	22795511				2022-12-28	WOS:000308547300032
J	Padmanabhan, K; Robles, MS; Westerling, T; Weitz, CJ				Padmanabhan, Kiran; Robles, Maria S.; Westerling, Thomas; Weitz, Charles J.			Feedback Regulation of Transcriptional Termination by the Mammalian Circadian Clock PERIOD Complex	SCIENCE			English	Article							NEGATIVE FEEDBACK; COMPONENTS; MECHANISM; PROTEINS; LIMB; REPRESSION; OSCILLATOR; NEUROSPORA; ALPHA	Eukaryotic circadian clocks are built on transcriptional feedback loops. In mammals, the PERIOD (PER) and CRYPTOCHROME (CRY) proteins accumulate, form a large nuclear complex (PER complex), and repress their own transcription. We found that mouse PER complexes included RNA helicases DDX5 and DHX9, active RNA polymerase II large subunit, Per and Cry pre-mRNAs, and SETX, a helicase that promotes transcriptional termination. During circadian negative feedback, RNA polymerase II accumulated near termination sites on Per and Cry genes but not on control genes. Recruitment of PER complexes to the elongating polymerase at Per and Cry termination sites inhibited SETX action, impeding RNA polymerase II release and thereby repressing transcriptional reinitiation. Circadian clock negative feedback thus includes direct control of transcriptional termination.	[Padmanabhan, Kiran; Robles, Maria S.; Weitz, Charles J.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; [Westerling, Thomas] Harvard Univ, Sch Med, Ctr Funct Canc Epigenet, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Weitz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	cweitz@hms.harvard.edu	Robles, Maria S/D-6307-2015; Robles, Maria/ABH-1497-2020; Padmanabhan, Kiran/N-2953-2013	Robles, Maria S/0000-0001-9149-8761; Robles, Maria/0000-0001-9149-8761; Westerling, Thomas/0000-0001-8537-6493; Padmanabhan, Kiran/0000-0001-7020-1682	G. Harold and Leila Y. Mathers Charitable Foundation; David Mahoney Fellowship; Edward R. and Anne G. Lefler Center fellowship	G. Harold and Leila Y. Mathers Charitable Foundation; David Mahoney Fellowship; Edward R. and Anne G. Lefler Center fellowship	We thank M. Liu for technical assistance and J. Gray and M. Greenberg (Harvard Medical School) for helpful comments. All data are tabulated in the paper and supplementary materials. This work was supported by the G. Harold and Leila Y. Mathers Charitable Foundation (C. J. W.), a David Mahoney Fellowship (K. P.), and an Edward R. and Anne G. Lefler Center fellowship (M.S.R.).	Brown SA, 2005, SCIENCE, V308, P693, DOI 10.1126/science.1107373; Calvo O, 2003, GENE DEV, V17, P1321, DOI 10.1101/gad.1093603; Chen RM, 2009, MOL CELL, V36, P417, DOI 10.1016/j.molcel.2009.10.012; Cheng P, 2005, GENE DEV, V19, P234, DOI 10.1101/gad.1266805; Das R, 2007, MOL CELL, V26, P867, DOI 10.1016/j.molcel.2007.05.036; Dunlap JC, 2006, CURR OPIN MICROBIOL, V9, P579, DOI 10.1016/j.mib.2006.10.008; Duong HA, 2011, SCIENCE, V332, P1436, DOI 10.1126/science.1196766; Fuller-Pace FV, 2006, NUCLEIC ACIDS RES, V34, P4206, DOI 10.1093/nar/gkl460; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Guo JH, 2009, CELL, V138, P1236, DOI 10.1016/j.cell.2009.06.043; Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Menet JS, 2010, GENE DEV, V24, P358, DOI 10.1101/gad.1883910; Perales R, 2009, MOL CELL, V36, P178, DOI 10.1016/j.molcel.2009.09.018; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Robles MS, 2010, SCIENCE, V327, P463, DOI 10.1126/science.1180067; Sato TK, 2006, NAT GENET, V38, P312, DOI 10.1038/ng1745; Shi YS, 2009, MOL CELL, V33, P365, DOI 10.1016/j.molcel.2008.12.028; Skourti-Stathaki K, 2011, MOL CELL, V42, P794, DOI 10.1016/j.molcel.2011.04.026; West S, 2009, MOL CELL, V33, P354, DOI 10.1016/j.molcel.2009.01.008	21	110	120	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 3	2012	337	6094					599	602		10.1126/science.1221592	http://dx.doi.org/10.1126/science.1221592			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982PU	22767893				2022-12-28	WOS:000307058700050
J	Holmes, D				Holmes, David			Alex Ezeh: bringing world-class research home	LANCET			English	Biographical-Item													Ezeh, Alex/AAN-8646-2020	Ezeh, Alex/0000-0002-1309-4697					0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2012	380	9837					101	101		10.1016/S0140-6736(12)61165-9	http://dx.doi.org/10.1016/S0140-6736(12)61165-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22794233				2022-12-28	WOS:000306359100022
J	Gobert, M; Lafaille, JJ				Gobert, Michael; Lafaille, Juan J.			Maternal-Fetal Immune Tolerance, Block by Block	CELL			English	Editorial Material							T-CELLS; PREECLAMPSIA; PREGNANCY; EVOLUTION; GENE	How difficult is to go from egg to implanted embryo? The evolution of placentation in eutherian mammals created enormous challenges, in particular to the maternal immune system, as the fetus expresses paternal antigens that are capable of triggering immune rejection. Samstein et al. reveal a role for inducible regulatory T cells in the enforcement of maternal-fetal immune tolerance.	[Gobert, Michael; Lafaille, Juan J.] NYU, Sch Med, Skirball Inst, Kimmel Ctr Biol & Med, New York, NY 10016 USA; [Lafaille, Juan J.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA	New York University; New York University	Lafaille, JJ (corresponding author), NYU, Sch Med, Skirball Inst, Kimmel Ctr Biol & Med, New York, NY 10016 USA.	juan.lafaille@med.nyu.edu			NIAID NIH HHS [R56 AI088553, R56 AI041647] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI088553, R56AI041647] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersen KG, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00113; Bilate AM, 2012, ANNU REV IMMUNOL, V30, P733, DOI 10.1146/annurev-immunol-020711-075043; Hirano M, 2011, ADV IMMUNOL, V109, P125, DOI 10.1016/B978-0-12-387664-5.00004-2; Lynch VJ, 2011, NAT GENET, V43, P1154, DOI 10.1038/ng.917; Nahmias AJ, 2011, ANN NY ACAD SCI, V1230, P25, DOI 10.1111/j.1749-6632.2011.06137.x; Redman CWG, 2010, AM J REPROD IMMUNOL, V63, P534, DOI 10.1111/j.1600-0897.2010.00831.x; Samstein RM, 2012, CELL, V150, P29, DOI 10.1016/j.cell.2012.05.031; Santner-Nanan B, 2009, J IMMUNOL, V183, P7023, DOI 10.4049/jimmunol.0901154; Wildman DE, 2011, PLACENTA, V32, pS142, DOI 10.1016/j.placenta.2011.01.005; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750	10	28	33	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 6	2012	150	1					7	9		10.1016/j.cell.2012.06.020	http://dx.doi.org/10.1016/j.cell.2012.06.020			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770210	Green Accepted, Bronze			2022-12-28	WOS:000306115000001
J	Hemmelgarn, BR; James, MT; Manns, BJ; O'Hare, AM; Muntner, P; Ravani, P; Quinn, RR; Turin, TC; Tan, Z; Tonelli, M				Hemmelgarn, Brenda R.; James, Matthew T.; Manns, Braden J.; O'Hare, Ann M.; Muntner, Paul; Ravani, Pietro; Quinn, Robert R.; Turin, Tanvir Chowdhury; Tan, Zhi; Tonelli, Marcello		Alberta Kidney Dis Network	Rates of Treated and Untreated Kidney Failure in Older vs Younger Adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY RISK; RENAL-DISEASE; DIALYSIS; OUTCOMES; PROTEINURIA; POPULATION; PREVALENCE; SYMPTOMS	Context Studies of kidney failure in older adults have focused on receipt of dialysis, which may underestimate the burden of disease if older people are less likely to receive treatment. Objective To determine the extent to which age is associated with the likelihood of treatment of kidney failure. Design, Setting, and Participants Community-based cohort study of 1 816 824 adults in Alberta, Canada, who had outpatient estimated glomerular filtration rate (eGFR) measured between May 1, 2002, and March 31, 2008, with a baseline eGFR of 15 mL/min/1.73 m(2) or higher and who did not require renal replacement therapy at baseline. Age was categorized as 18 to 44, 45 to 54, 55 to 64, 65 to 74, 75 to 84, and 85 or more years and eGFR as 90 or higher, 60 to 89, 45 to 59, 30 to 44, and 15 to 29 mL/min/1.73 m(2). Main Outcome Measures Adjusted rates of treated kidney failure (receipt of dialysis or kidney transplantation), untreated kidney failure (progression to eGFR <15 mL/min/1.73 m(2) without renal replacement therapy), and death. Results During a median follow-up of 4.4 years, 97 451 (5.36%) died, 3295 (0.18%) developed kidney failure that was treated and 3116 (0.17%) developed kidney failure that went untreated. Within each eGFR stratum the rate of treated kidney failure was higher in younger compared with older people. For example, in the lowest eGFR stratum (15-29 mL/min/1.73 m(2)), adjusted rates of treated kidney failure were more than 10-fold higher among the youngest (18-44 years) compared with the oldest (>= 85 years) groups (adjusted rate, 24.00 [95% CI, 14.78-38.97] vs 1.53 [95% CI, 0.59-3.99] per 1000 person-years, respectively; P < .001). Rates of untreated kidney failure were consistently higher at older ages. In the eGFR stratum of 15 to 29 mL/min/1.73 m(2), adjusted rates of untreated kidney failure were more than 5-fold higher among the oldest (>= 85 years), compared with the youngest (18-44 years) groups (adjusted rate, 19.95 [95% CI, 15.79-25.19] vs 3.53 [95% CI, 1.56-8.01] per 1000 person-years, respectively; P < .001). Rates of kidney failure overall (treated and untreated combined) demonstrated less variation across age groups; eg, the adjusted rate per 1000 person years for those with eGFR of 15-29 mL/min/1.73 m(2) was 36.45 (95% CI, 24.46-54.32) among participants aged 18 to 44 years and 20.19 (95% CI, 15.27-26.69) among those aged 85 years or older (P=.01). Conclusion In Alberta, Canada, rates of untreated kidney failure are significantly higher in older compared with younger individuals. JAMA. 2012; 307(23):2507-2515 www.jama.com	[Hemmelgarn, Brenda R.; James, Matthew T.; Manns, Braden J.; Ravani, Pietro; Quinn, Robert R.; Turin, Tanvir Chowdhury; Tan, Zhi] Univ Calgary, Dept Med, Calgary, AB, Canada; [Hemmelgarn, Brenda R.; James, Matthew T.; Manns, Braden J.; Ravani, Pietro] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Hemmelgarn, Brenda R.; James, Matthew T.; Manns, Braden J.; Ravani, Pietro; Quinn, Robert R.] Univ Calgary, Libin Cardiovasc Inst, Calgary, AB, Canada; [O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA USA; [Muntner, Paul] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, W Midlands, England; [Tonelli, Marcello] Univ Alberta, Dept Med, Edmonton, AB, Canada	University of Calgary; University of Calgary; Libin Cardiovascular Institute Of Alberta; University of Calgary; University of Washington; University of Washington Seattle; University of Alberta	Hemmelgarn, BR (corresponding author), Foothills Med Ctr, Div Nephrol, 1403 29th St NW, Calgary, AB T2N 2T9, Canada.	brenda.hemmelgarn@albertahealthservices.ca	Tonelli, Marcello/B-3028-2009; Turin, Tanvir C/L-7617-2016; Quinn, Robert R/E-7017-2011; Ravani, Pietro/J-3050-2015; Hemmelgarn, Brenda R./I-6894-2012; Manns, Braden J/I-8942-2012	Tonelli, Marcello/0000-0002-0846-3187; Turin, Tanvir C/0000-0002-7499-5050; Ravani, Pietro/0000-0001-6973-8570; 	Amgen; UpToDate; Canadian Institute of Health Research (CIHR); Alberta Innovates-Health Solutions (AI-HS); Roy and Vi Baay Chair in Kidney Research; Government of Canada Research Chair; Canadian Diabetes Association	Amgen(Amgen); UpToDate; Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Innovates-Health Solutions (AI-HS); Roy and Vi Baay Chair in Kidney Research; Government of Canada Research Chair; Canadian Diabetes Association	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr O'Hare reports receiving royalties from UpToDate. Dr Muntner reports consulting for and receiving salary support through a grant to his institution by Amgen. No other disclosures were reported.; This work was supported by the Canadian Institute of Health Research (CIHR) and by an interdisciplinary team grant from Alberta Innovates-Health Solutions (AI-HS). Drs Hemmelgarn, Manns, and Tonelli were supported by career salary awards from AI-HS. Dr Hemmelgarn was supported by the Roy and Vi Baay Chair in Kidney Research and Dr Tonelli was supported by a Government of Canada Research Chair. Dr Turin is supported by Fellowship Awards from CIHR and the Canadian Diabetes Association.	Bello A, 2012, AM J KIDNEY DIS, V59, P364, DOI 10.1053/j.ajkd.2011.09.006; Cassel CK, 2012, JAMA-J AM MED ASSOC, V307, P1801, DOI 10.1001/jama.2012.476; Clark WF, 2011, CAN MED ASSOC J, V183, P47, DOI 10.1503/cmaj.100349; Clement FM, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-25; Cooper BA, 2010, NEW ENGL J MED, V363, P609, DOI 10.1056/NEJMoa1000552; Dor Avi, 2007, Int J Health Care Finance Econ, V7, P73, DOI 10.1007/s10754-007-9024-9; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; Hall YN, 2010, CLIN J AM SOC NEPHRO, V5, P828, DOI 10.2215/CJN.09011209; Hemmelgarn BR, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-30; Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512; Jassal SV, 2007, CAN MED ASSOC J, V177, P1033, DOI 10.1503/cmaj.061765; Keith DS, 2004, ARCH INTERN MED, V164, P659, DOI 10.1001/archinte.164.6.659; Kurella M, 2007, ANN INTERN MED, V146, P177, DOI 10.7326/0003-4819-146-3-200702060-00006; Lamb EJ, 2009, ANN CLIN BIOCHEM, V46, P205, DOI 10.1258/acb.2009.009007; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140-6736(10)60674-5; Matsushita K, 2010, AM J KIDNEY DIS, V55, P648, DOI 10.1053/j.ajkd.2009.12.016; Murphy EL, 2009, NEPHRON CLIN PRACT, V111, pC74, DOI 10.1159/000183177; Murtagh FEM, 2007, J PALLIAT MED, V10, P1266, DOI 10.1089/jpm.2007.0017; O'Hare AM, 2007, J AM SOC NEPHROL, V18, P2758, DOI 10.1681/ASN.2007040422; O'Hare AM, 2006, J AM SOC NEPHROL, V17, P846, DOI 10.1681/ASN.2005090986; O'Hare AM, 2010, JAMA-J AM MED ASSOC, V304, P180, DOI 10.1001/jama.2010.924; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Quan HD, 2009, HYPERTENSION, V54, P1423, DOI 10.1161/HYPERTENSIONAHA.109.139279; Raymond NT, 2007, NEPHROL DIAL TRANSPL, V22, P3214, DOI 10.1093/ndt/gfm396; Roderick PJ, 2009, AM J KIDNEY DIS, V53, P950, DOI 10.1053/j.ajkd.2008.12.036; Rosansky S, 2011, CLIN J AM SOC NEPHRO, V6, P1222, DOI 10.2215/CJN.09301010; Sekkarie MA, 1998, AM J KIDNEY DIS, V31, P464, DOI 10.1053/ajkd.1998.v31.pm9506683; Statistics Canada, ETHN PORTR CAN HIGHL; *US REN DAT SYST, 2003, USRDS 2003 ANN DAT R	32	110	117	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2012	307	23					2507	2515		10.1001/jama.2012.6455	http://dx.doi.org/10.1001/jama.2012.6455			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	960MB	22797451	Bronze			2022-12-28	WOS:000305391400027
J	Tinetti, ME; Fried, TR; Boyd, CM				Tinetti, Mary E.; Fried, Terri R.; Boyd, Cynthia M.			Designing Health Care for the Most Common Chronic Condition-Multimorbidity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Tinetti, Mary E.; Fried, Terri R.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; [Tinetti, Mary E.] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA; [Fried, Terri R.] VA Connecticut Healthcare Syst, Clin Epidemiol Unit, New Haven, CT USA; [Boyd, Cynthia M.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Boyd, Cynthia M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Tinetti, ME (corresponding author), Yale Univ, Sch Med, Dept Med, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	mary.tinetti@yale.edu			NATIONAL INSTITUTE ON AGING [K23AG032910, R03AG035146, R01AG038528, P30AG021342, K24AG028443] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson G, 2010, CHRONIC CARE MAKING; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Boyd CM, GUIDING PRINCIPLES C; Fried TR, 2011, ARCH INTERN MED, V171, P75, DOI 10.1001/archinternmed.2010.318; National Quality Forum, MULT CHRON COND MCC; Piette JD, 2006, DIABETES CARE, V29, P725, DOI 10.2337/diacare.29.03.06.dc05-2078; RTI International, ACC CAR ORG 2012 PRO; Weiss CO, 2007, JAMA-J AM MED ASSOC, V298, P1160, DOI 10.1001/jama.298.10.1160-a	8	533	537	4	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2012	307	23					2493	2494		10.1001/jama.2012.5265	http://dx.doi.org/10.1001/jama.2012.5265			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	960MB	22797447	Green Accepted			2022-12-28	WOS:000305391400023
J	Altman, DG; Bland, JM				Altman, Douglas G.; Bland, J. Martin			How to obtain the P value from a confidence interval	BMJ-BRITISH MEDICAL JOURNAL			English	Article									[Altman, Douglas G.] Univ Oxford, Ctr Stat Med, Oxford OX2 6UD, England; [Bland, J. Martin] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England	University of Oxford; University of York - UK	Altman, DG (corresponding author), Univ Oxford, Ctr Stat Med, Oxford OX2 6UD, England.	doug.altman@csm.ox.ac.uk						Altman DG, 2011, BRIT MED J, V342, pd2090; Bland JM, 1996, BRIT MED J, V312, P700; LIN JT, 1989, APPL STAT-J ROY ST C, V38, P69; Mancia G, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1197; Taggart DP, 2001, LANCET, V358, P870, DOI 10.1016/S0140-6736(01)06069-X	5	293	293	2	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 8	2011	343								d2304	10.1136/bmj.d2304	http://dx.doi.org/10.1136/bmj.d2304			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V41KQ	22803193	Bronze, Green Submitted			2022-12-28	WOS:000209545500002
J	Beyrer, C; Sullivan, PS; Sanchez, J; Dowdy, D; Altman, D; Trapence, G; Collins, C; Katabira, E; Kazatchkine, M; Sidibe, M; Mayer, KH				Beyrer, Chris; Sullivan, Patrick S.; Sanchez, Jorge; Dowdy, David; Altman, Dennis; Trapence, Gift; Collins, Chris; Katabira, Elly; Kazatchkine, Michel; Sidibe, Michel; Mayer, Kenneth H.			A call to action for comprehensive HIV services for men who have sex with men	LANCET			English	Article							HEALTH OUTCOMES; UNITED-STATES; PREVENTION; INFECTION; POPULATIONS; EPIDEMIC; BLACK; RISK; MSM	Where surveillance has been done, it has shown that men (MSM) who have sex with men bear a disproportionate burden of HIV. Yet they continue to be excluded, sometimes systematically, from HIV services because of stigma, discrimination, and criminalisation. This situation must change if global control of the HIV epidemic is to be achieved. On both public health and human rights grounds, expansion of HIV prevention, treatment, and care to MSM is an urgent imperative. Effective combination prevention and treatment approaches are feasible, and culturally competent care can be developed, even in rights-challenged environments. Condom and lubricant access for MSM globally is highly cost effective. Antiretroviral-based prevention, and antiretroviral access for MSM globally, would also be cost effective, but would probably require substantial reductions in drug costs in high-income countries to be feasible. To address HIV in MSM will take continued research, political will, structural reform, community engagement, and strategic planning and programming, but it can and must be done.	[Beyrer, Chris] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, Dept Epidemiol, Baltimore, MD 21205 USA; [Sullivan, Patrick S.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Sanchez, Jorge] Asociac Civil Impacta Salud & Educ IMPACTA, Lima, Peru; [Altman, Dennis] La Trobe Univ, Fac Humanities & Social Sci, Melbourne, Vic, Australia; [Trapence, Gift] Ctr Dev People CEDEP, Lilongwe, Malawi; [Collins, Chris] amfAR, Washington, DC USA; [Katabira, Elly] Makerere Univ, Kampala, Uganda; [Katabira, Elly] Int AIDS Soc, Geneva, Switzerland; [Kazatchkine, Michel] Univ Paris 05, Paris, France; [Sidibe, Michel] UNAIDS, Geneva, Switzerland; [Mayer, Kenneth H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Fenway Hlth, Boston, MA 02215 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Emory University; Rollins School Public Health; La Trobe University; Makerere University; UDICE-French Research Universities; Universite Paris Cite; UNAIDS; Fenway Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Beyrer, C (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, Dept Epidemiol, Baltimore, MD 21205 USA.	cbeyrer@jhsph.edu		Altman, Dennis/0000-0001-7823-5326; Sullivan, Patrick Sean/0000-0002-7728-0587	amfAR, The Foundation for AIDS Research; Bill & Melinda Gates Foundation; Johns Hopkins Center for AIDS Research (NIAID) [1P30AI094189-01A1]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083060, P30AI094189] Funding Source: NIH RePORTER	amfAR, The Foundation for AIDS Research; Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); Johns Hopkins Center for AIDS Research (NIAID); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This paper and the special theme series which it summarises was supported by grants to the Center for Public Health and Human Rights at Johns Hopkins University from amfAR, The Foundation for AIDS Research and from the Bill & Melinda Gates Foundation. The Johns Hopkins Center for AIDS Research (NIAID, 1P30AI094189-01A1) provided partial support to CB. The authors would also like to thank Susan Buchbinder and colleagues for assistance with the modelling, which was based on work done for their Prevention Umbrella for MSM in the Americas, PUMA (NIAID, R01-AI083060.). We would like to thank His Grace Archbishop Emeritus Desmond Tutu for his contribution. For the text box on the Commission on HIV and the Law, the Commissioners wish to acknowledge the contribution of Mandeep Dhaliwal and Jeffrey O'Malley. Stefan D Baral of Johns Hopkins contributed to figure 3 and Andrea Wirtz, faculty member in the Department of Epidemiology at Johns Hopkins, contributed to figure 1. Emily Clouse, research coordinator for the Center for Public Health and Human Rights, has supported all of the authors in the organisation and management of this effort.	Adam PCG, 2009, JAIDS-J ACQ IMM DEF, V52, pS143, DOI 10.1097/QAI.0b013e3181baf111; Altman D, 2012, LANCET; Altman D, 2008, SOCIAL IDENTITIES, V14, P15; American Foundation for AIDS Research, 2012, ACH AIDS FREE GEN GA; Barroso Carmen, 2010, ROUTLEDGE HDB SEXUAL, P379; Beyrer C, 2011, DIR DEV, P1, DOI 10.1596/978-0-8213-8726-9; Beyrer C, 2012, LANCET; Beyrer C, 2010, CLIN INFECT DIS, V50, pS108, DOI 10.1086/651481; Bostwick WB, 2010, AM J PUBLIC HEALTH, V100, P468, DOI 10.2105/AJPH.2008.152942; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Csete J, 2010, J LAW MED ETHICS, V38, P816, DOI 10.1111/j.1748-720X.2010.00535.x; de la Dehesa R, 2012, CONTEMP POLIT, V18, P186, DOI 10.1080/13569775.2012.674336; Fay H, 2011, AIDS BEHAV, V15, P1088, DOI 10.1007/s10461-010-9861-2; Friedman MS, 2008, AIDS BEHAV, V12, P891, DOI 10.1007/s10461-007-9319-3; George C, 2012, CULT HEALTH SEX, V14, P549, DOI 10.1080/13691058.2012.674158; Global Commission on HIV and the Law, 2012, HIV LAW RISKS RIGHTS; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Hall HI, 2009, JAIDS-J ACQ IMM DEF, V51, pS13, DOI 10.1097/QAI.0b013e3181a2639e; Hatzenbuehler ML, 2011, ANN BEHAV MED, V42, P227, DOI 10.1007/s12160-011-9275-z; Helfer LR, 2002, COLUMBIA LAW REV, V102, P1832, DOI 10.2307/1123662; Herrick AL, 2011, AIDS BEHAV, V15, pS25, DOI 10.1007/s10461-011-9895-0; Jaffe HW, 2007, JAMA-J AM MED ASSOC, V298, P2412, DOI 10.1001/jama.298.20.2412; Jurgens R, 2010, LANCET, V376, P475, DOI 10.1016/S0140-6736(10)60830-6; Killen J, 2012, LANCET; Koppenhaver RT, 2011, JAIDS-J ACQ IMM DEF, V58, pE51, DOI 10.1097/QAI.0b013e31822b74fe; Lauby JL, 2012, AIDS BEHAV, V16, P508, DOI 10.1007/s10461-011-0002-3; Levy A, 2010, PHARMACOECONOMICS, V28, P35, DOI 10.2165/11587430-000000000-00000; Lewis NM, 2009, HEALTH PLACE, V15, P1029, DOI 10.1016/j.healthplace.2009.05.003; Mayer KH, 2012, LANCET; Millett GA, 2012, LANCET; PEPFAR, 2011, TECHN GUID COMB HIV; Stephenson R, 2011, AIDS BEHAV, V15, pS80, DOI 10.1007/s10461-011-9893-2; Sullivan P, 2011, WELBC05 6 INT AIDS S; Sullivan PS, 2012, LANCET; Trapence G, 2012, LANCET; US Department of State, 2011, US SECR STAT H RODHA; WHO, 2011, GLOB HLTH OBS WORLD; WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E; Wolitski R, 2007, UNEQUAL OPPORTUNITY; World Health Organization, 2011, PREVENTION TREATMENT; 1981, MMWR, V30, P305	41	178	181	0	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 28	2012	380	9839					424	438		10.1016/S0140-6736(12)61022-8	http://dx.doi.org/10.1016/S0140-6736(12)61022-8			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819663	Green Accepted			2022-12-28	WOS:000306842800040
J	Erb, TJ; Kiefer, P; Hattendorf, B; Gunther, D; Vorholt, JA				Erb, Tobias J.; Kiefer, Patrick; Hattendorf, Bodo; Guenther, Detlef; Vorholt, Julia A.			GFAJ-1 Is an Arsenate-Resistant, Phosphate-Dependent Organism	SCIENCE			English	Article							TRANSPORT	The bacterial isolate GFAJ-1 has been proposed to substitute arsenic for phosphorus to sustain growth. We have shown that GFAJ-1 is able to grow at low phosphate concentrations (1.7 mu M), even in the presence of high concentrations of arsenate (40 mM), but lacks the ability to grow in phosphorus-depleted (<0.3 mu M), arsenate-containing medium. High-resolution mass spectrometry analyses revealed that phosphorylated central metabolites and phosphorylated nucleic acids predominated. A few arsenylated compounds, including C6 sugar arsenates, were detected in extracts of GFAJ-1, when GFAJ-1 was incubated with arsenate, but further experiments showed they formed abiotically. Inductively coupled plasma mass spectrometry confirmed the presence of phosphorus in nucleic acid extracts, while arsenic could not be detected and was below 1 per mil relative to phosphorus. Taken together, we conclude that GFAJ-1 is an arsenate-resistant, but still a phosphate-dependent, bacterium.	[Erb, Tobias J.; Kiefer, Patrick; Vorholt, Julia A.] ETH, Inst Microbiol, CH-8093 Zurich, Switzerland; [Hattendorf, Bodo; Guenther, Detlef] ETH, Inorgan Chem Lab, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Erb, TJ (corresponding author), ETH, Inst Microbiol, Wolfgang Pauli Str 10, CH-8093 Zurich, Switzerland.	toerb@ethz.ch; vorholt@micro.biol.ethz.ch	Vorholt, Julia/K-3514-2016; Kiefer, Patrick/G-5138-2010; Erb, Tobias/J-5214-2013	Vorholt, Julia/0000-0002-6011-4910; Erb, Tobias/0000-0003-3685-0894; Hattendorf, Bodo/0000-0001-9991-2410	ETH Fellowship	ETH Fellowship	We thank R. Oremland and J. S. Blum for providing strain GFAJ-1, P. Christen and F. Ryffel for technical and experimental assistance, as well as an anonymous reviewer for valuable suggestions and comments on our manuscript. T.J.E. was supported through an ETH Fellowship.	ATKINSON DE, 1967, J BIOL CHEM, V242, P3239; Benner SA, 2011, SCIENCE, V332, DOI 10.1126/science.1201304; Borhani DW, 2011, SCIENCE, V332, DOI 10.1126/science.1201255; Canovas D, 2003, ENVIRON MICROBIOL, V5, P133, DOI 10.1046/j.1462-2920.2003.00386.x; Cotner JB, 2011, SCIENCE, V332, DOI 10.1126/science.1201943; Csabai I, 2011, SCIENCE, V332, DOI 10.1126/science.1201399; Foster PL, 2011, SCIENCE, V332, DOI 10.1126/science.1201551; Keseler IM, 2011, NUCLEIC ACIDS RES, V39, pD583, DOI 10.1093/nar/gkq1143; Kiefer P, 2011, ANAL CHEM, V83, P850, DOI 10.1021/ac102445r; LAGUNAS R, 1980, ARCH BIOCHEM BIOPHYS, V205, P67, DOI 10.1016/0003-9861(80)90084-3; Liebig J., 1855, GRUNDSATZE AGRIKULTU; MOORE SA, 1983, J BIOL CHEM, V258, P6266; Oehler S, 2011, SCIENCE, V332, DOI 10.1126/science.1201381; Redfield RJ, 2011, SCIENCE, V332, DOI [10.1126/science.1201304, 10.1126/science.1201482]; Schoepp-Cothenet B, 2011, SCIENCE, V332, DOI 10.1126/science.1201438; WILLSKY GR, 1980, J BACTERIOL, V144, P366, DOI 10.1128/JB.144.1.366-374.1980; WILLSKY GR, 1980, J BACTERIOL, V144, P356, DOI 10.1128/JB.144.1.356-365.1980; Wolfe-Simon F, 2011, SCIENCE, V332, P1163, DOI 10.1126/science.1197258	18	64	65	1	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 27	2012	337	6093					467	470		10.1126/science.1218455	http://dx.doi.org/10.1126/science.1218455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979FS	22773139				2022-12-28	WOS:000306802300043
J	Bauman, AE; Reis, RS; Sallis, JF; Wells, JC; Loos, RJF; Martin, BW				Bauman, Adrian E.; Reis, Rodrigo S.; Sallis, James F.; Wells, Jonathan C.; Loos, Ruth J. F.; Martin, Brian W.		Lancet Phys Activity Series Workin	Correlates of physical activity: why are some people physically active and others not?	LANCET			English	Article							ENERGY-EXPENDITURE; OLDER-ADULTS; BUILT ENVIRONMENT; LEISURE-TIME; NEIGHBORHOOD ENVIRONMENT; FAMILIAL AGGREGATION; AMBULATORY ACTIVITY; ACTIVITY BEHAVIOR; GENETIC-FACTORS; DEFICIENT MICE	Physical inactivity is an important contributor to non-communicable diseases in countries of high income, and increasingly so in those of low and middle income. Understanding why people are physically active or inactive contributes to evidence-based planning of public health interventions, because effective programmes will target factors known to cause inactivity. Research into correlates (factors associated with activity) or determinants (those with a causal relationship) has burgeoned in the past two decades, but has mostly focused on individual-level factors in high-income countries. It has shown that age, sex, health status, self-efficacy, and motivation are associated with physical activity. Ecological models take a broad view of health behaviour causation, with the social and physical environment included as contributors to physical inactivity, particularly those outside the health sector, such as urban planning, transportation systems, and parks and trails. New areas of determinants research have identified genetic factors contributing to the propensity to be physically active, and evolutionary factors and obesity that might predispose to inactivity, and have explored the longitudinal tracking of physical activity throughout life. An understanding of correlates and determinants, especially in countries of low and middle income, could reduce the effect of future epidemics of inactivity and contribute to effective global prevention of non-communicable diseases.	[Bauman, Adrian E.] Univ Sydney, Sch Publ Hlth, Prevent Res Collaborat, Sydney, NSW 2006, Australia; [Reis, Rodrigo S.] Pontificia Univ Catolica Parana, Sch Hlth & Biosci, Curitiba, Parana, Brazil; [Reis, Rodrigo S.] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil; [Sallis, James F.] Univ Calif San Diego, San Diego, CA 92103 USA; [Wells, Jonathan C.] UCL, UCL Inst Child Hlth, London, England; [Loos, Ruth J. F.] Addenbrookes Hosp, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England; [Loos, Ruth J. F.] Mt Sinai Sch Med, Genet Obes & Related Metab Traits Program, New York, NY USA; [Martin, Brian W.] Univ Zurich, Inst Social & Prevent Med, Phys Act & Hlth Unit, CH-8006 Zurich, Switzerland	University of Sydney; Pontificia Universidade Catolica do Parana; Universidade Federal do Parana; University of California System; University of California San Diego; University of London; University College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Icahn School of Medicine at Mount Sinai; University of Zurich	Bauman, AE (corresponding author), Univ Sydney, Sch Publ Hlth, Prevent Res Collaborat, Bldg K25, Sydney, NSW 2006, Australia.	adrian.bauman@sydney.edu.au	Martin, Brian W/H-3241-2012; Kahlmeier, Sonja/B-8141-2014; Loos, Ruth/GON-5877-2022; Sallis, James F/D-3001-2014; Sarmiento, Olga L/AAS-4165-2020; Lambert, Estelle/ABF-1268-2020; Loos, Ruth J F/Q-2862-2016; Fahimifar, Sepideh/M-5303-2019; Wells, Jonathan/A-4604-2009; Parra, Diana C/D-7633-2013; lobelo, felipe/B-9148-2013; Reis, Rodrigo/F-7447-2012; Lobelo, R.L Felipe/AAB-2264-2021; Katzmarzyk, Peter/N-1974-2017	Kahlmeier, Sonja/0000-0001-6905-9244; Sallis, James F/0000-0003-2555-9452; Sarmiento, Olga L/0000-0002-9190-3568; Lambert, Estelle/0000-0003-4315-9153; Loos, Ruth J F/0000-0002-8532-5087; Wells, Jonathan/0000-0003-0411-8025; Parra, Diana C/0000-0002-9797-6231; Reis, Rodrigo/0000-0002-9872-9865; Lobelo, R.L Felipe/0000-0003-4185-7193; Katzmarzyk, Peter/0000-0002-9280-6022; Guthold, Regina/0000-0003-3073-6468; Goenka, Shifalika/0000-0001-6993-2883	Medical Research Council [MC_U106179473, MC_U106188470] Funding Source: Medline; MRC [MC_U106188470, MC_U106179473] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aaltonen S, 2010, TWIN RES HUM GENET, V13, P475, DOI 10.1375/twin.13.5.475; Allender S, 2008, HEALTH PROMOT INT, V23, P160, DOI 10.1093/heapro/dan012; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; Bauman A, 2008, OBES REV, V9, P119, DOI 10.1111/j.1467-789X.2007.00452.x; Bauman A, 2011, J EPIDEMIOL COMMUN H, V65, P35, DOI 10.1136/jech.2008.086710; Bauman A, 2009, J PHYS ACT HEALTH, V6, pS196, DOI 10.1123/jpah.6.s2.s196; Bauman AE, 2002, AM J PREV MED, V23, P5, DOI 10.1016/S0749-3797(02)00469-5; Belansky ES, 2009, J PUBLIC HEALTH POL, V30, pS141, DOI 10.1057/jphp.2008.50; Bellew B, 2011, CURR CARDIOVASC RISK, V5, P340, DOI 10.1007/s12170-011-0180-6; Biddle SJH, 2005, J PHYS ACT HEALTH, V2, P423, DOI [DOI 10.1123/JPAH.2.4.423, 10.1123/jpah.2.4.423]; Black AE, 1996, EUR J CLIN NUTR, V50, P72; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; Brownson RC, 2001, AM J PUBLIC HEALTH, V91, P1995, DOI 10.2105/AJPH.91.12.1995; Bull FC, 2009, J PHYS ACT HEALTH, V6, P790, DOI 10.1123/jpah.6.6.790; Butler AA, 2001, NAT NEUROSCI, V4, P605, DOI 10.1038/88423; Cai GW, 2006, OBESITY, V14, P1596, DOI 10.1038/oby.2006.184; Carlson JA, 2012, PREV MED, V54, P68, DOI 10.1016/j.ypmed.2011.10.004; Carlsson S, 2006, MED SCI SPORT EXER, V38, P1396, DOI 10.1249/01.mss.0000228941.17034.c1; Van Cauwenberg J, 2011, HEALTH PLACE, V17, P458, DOI 10.1016/j.healthplace.2010.11.010; Church TS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019657; Cook I, 2008, INT J OBESITY, V32, P1327, DOI 10.1038/ijo.2008.26; Craggs C, 2011, AM J PREV MED, V40, P645, DOI 10.1016/j.amepre.2011.02.025; Cunningham GO, 2004, AM J HEALTH PROMOT, V18, P435, DOI 10.4278/0890-1171-18.6.435; Dans A, 2011, LANCET, V377, P680, DOI 10.1016/S0140-6736(10)61506-1; Daugbjerg SB, 2009, J PHYS ACT HEALTH, V6, P805, DOI 10.1123/jpah.6.6.805; de Geus E.J., 2011, GENETIC MOL ASPECTS, P294, DOI 10.1002/9781444327335.ch25; De Moor MHM, 2009, MED SCI SPORT EXER, V41, P1887, DOI 10.1249/MSS.0b013e3181a2f646; Ding D, 2011, AM J PREV MED, V41, P442, DOI 10.1016/j.amepre.2011.06.036; Dishman R.K., 1994, ADV EXERCISE ADHEREN; Dishman RK, 1997, MED SCI SPORT EXER, V29, P37, DOI 10.1097/00005768-199701000-00006; Dufour DL, 2008, AM J HUM BIOL, V20, P249, DOI 10.1002/ajhb.20764; Dumith SC, 2011, PREV MED, V53, P24, DOI 10.1016/j.ypmed.2011.02.017; Duncan Mitch J, 2005, Int J Behav Nutr Phys Act, V2, P11, DOI 10.1186/1479-5868-2-11; Edwardson CL, 2010, PSYCHOL SPORT EXERC, V11, P522, DOI 10.1016/j.psychsport.2010.05.001; Ekelund U, 2008, AM J CLIN NUTR, V88, P612, DOI 10.1093/ajcn/88.3.612; Epstein LH, 2000, REFRAMING HEALTH BEHAVIOR CHANGE WITH BEHAVIORAL ECONOMICS, P293; Eriksson M, 2006, BEHAV GENET, V36, P238, DOI 10.1007/s10519-005-9018-7; Erlichman J, 2001, ARE CURRENT PHYS ACT; FAO, 2004, REP HUM EN REQ; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Fisher A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010110; Fortier MD, 2001, MED SCI SPORT EXER, V33, P1905, DOI 10.1097/00005768-200111000-00016; Franco M, 2007, AM J EPIDEMIOL, V166, P1374, DOI 10.1093/aje/kwm226; Franks PW, 2005, AM J CLIN NUTR, V82, P901, DOI 10.1093/ajcn/82.4.901; Guthold R, 2011, AM J PREV MED, V41, P52, DOI 10.1016/j.amepre.2011.03.008; Hallal PC, 2012, LANCET, V380, P247, DOI 10.1016/S0140-6736(12)60646-1; Heath GW, 2012, LANCET, V380, P272, DOI 10.1016/S0140-6736(12)60816-2; Hinkley T, 2008, AM J PREV MED, V34, P435, DOI 10.1016/j.amepre.2008.02.001; Hou NQ, 2011, PREV MED, V52, P365, DOI 10.1016/j.ypmed.2011.02.007; Humpel N, 2002, AM J PREV MED, V22, P188, DOI 10.1016/S0749-3797(01)00426-3; Ingram DK, 2000, MED SCI SPORT EXER, V32, P1623; Joosen AMCP, 2005, AM J CLIN NUTR, V82, P1253, DOI 10.1093/ajcn/82.6.1253; Kaewthummanukul Thanee, 2006, AAOHN J, V54, P249; Kaprio J, 1981, Prog Clin Biol Res, V69 Pt C, P37; Kelder SH, 2009, J PUBLIC HEALTH POL, V30, pS221, DOI 10.1057/jphp.2008.64; Kelly MA, 1998, J NEUROSCI, V18, P3470; Kirk MA, 2011, AM J PREV MED, V40, P476, DOI 10.1016/j.amepre.2010.12.015; KLINGBERG F, 1993, NEUROREPORT, V4, P639, DOI 10.1097/00001756-199306000-00009; Koeneman MA, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-142; Kohl Harold W 3rd, 2012, Lancet, V380, P294, DOI 10.1016/S0140-6736(12)60898-8; Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LEONARD WR, 1992, AM J HUM BIOL, V4, P179, DOI 10.1002/ajhb.1310040204; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; Lewis BA, 2002, AM J PREV MED, V23, P26, DOI 10.1016/S0749-3797(02)00471-3; Licinio J, 2004, P NATL ACAD SCI USA, V101, P4531, DOI 10.1073/pnas.0308767101; Loos RJF, 2004, INT J OBESITY, V29, P420; Lubans DR, 2008, PREV MED, V47, P463, DOI 10.1016/j.ypmed.2008.07.011; Macniven R, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-41; Maia JAR, 2002, AM J PREV MED, V23, P87, DOI 10.1016/S0749-3797(02)00478-6; Malina RM, 2008, AM J HUM BIOL, V20, P373, DOI 10.1002/ajhb.20772; McCormack GR, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-125; Metcalf BS, 2011, ARCH DIS CHILD, V96, P942, DOI 10.1136/adc.2009.175927; Mitchell BD, 2003, ANN EPIDEMIOL, V13, P128, DOI 10.1016/S1047-2797(02)00255-7; Murphy Niamh M, 2007, J Phys Act Health, V4, P193; Ness AR, 2007, PLOS MED, V4, P476, DOI 10.1371/journal.pmed.0040097; Noakes TD, 2005, BRIT J SPORT MED, V39, P120, DOI 10.1136/bjsm.2003.010330; Owen N, 2004, AM J PREV MED, V27, P67, DOI 10.1016/j.amepre.2004.03.006; Panter JR, 2010, J PHYS ACT HEALTH, V7, P551, DOI 10.1123/jpah.7.4.551; Plonczynski Donna J, 2003, Medsurg Nurs, V12, P213; Pratt M, 2004, AM J PREV MED, V27, P136, DOI 10.1016/j.amepre.2004.06.015; Pratt M, 2012, LANCET, V380, P282, DOI 10.1016/S0140-6736(12)60736-3; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; Pucher J, 2008, TRANSPORT REV, V28, P495, DOI 10.1080/01441640701806612; Rhodes RE, 2006, BRIT J SPORT MED, V40, P958, DOI 10.1136/bjsm.2006.028860; Rhodes RE, 1999, SPORTS MED, V28, P397, DOI 10.2165/00007256-199928060-00003; Rhodes RE, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-37; Rodgers A, 2004, PLOS MED, V1, P44, DOI 10.1371/journal.pmed.0010027; Saelens BE, 2008, MED SCI SPORT EXER, V40, pS550, DOI 10.1249/MSS.0b013e31817c67a4; Saelens BE, 2012, MED SCI SPORT EXER, V44, P637, DOI 10.1249/MSS.0b013e318237fe18; Sallis JE, 2006, ANNU REV PUBL HEALTH, V27, P297, DOI 10.1146/annurev.publhealth.27.021405.102100; Sallis JF, 2000, MED SCI SPORT EXER, V32, P963, DOI 10.1097/00005768-200009000-00012; Sallis JF, 2000, ANN BEHAV MED, V22, P294, DOI 10.1007/BF02895665; Sallis JF, 2008, HLTH BEHAV HLTH ED T, V260, P465; Simonen RL, 2003, PHYSIOL BEHAV, V78, P751, DOI 10.1016/S0031-9384(03)00084-2; Simonen RL, 2003, MED SCI SPORT EXER, V35, P1355, DOI 10.1249/01.MSS.0000078937.22939.7E; Simonen RL, 2002, MED SCI SPORT EXER, V34, P1137, DOI 10.1097/00005768-200207000-00014; Ste Marie L, 2000, P NATL ACAD SCI USA, V97, P12339, DOI 10.1073/pnas.220409497; Stefan N, 2002, INT J OBESITY, V26, P1629, DOI 10.1038/sj.ijo.0802161; Telama R, 2009, OBESITY FACTS, V2, P187, DOI 10.1159/000222244; TOKUNAGA K, 1991, BRAIN RES BULL, V26, P393, DOI 10.1016/0361-9230(91)90012-9; Trichopoulos, 2010, TEACHING EPIDEMIOLOG, P25; Trost SG, 2002, MED SCI SPORT EXER, V34, P1996, DOI 10.1097/00005768-200212000-00020; Uijtdewilligen L, 2011, BRIT J SPORT MED, V45, P896, DOI 10.1136/bjsports-2011-090197; Van der Horst K, 2007, MED SCI SPORT EXER, V39, P1241, DOI 10.1249/mss.0b013e318059bf35; van Stralen MM, 2009, HEALTH PSYCHOL REV, V3, P147, DOI 10.1080/17437190903229462; Wendel-Vos W, 2007, OBES REV, V8, P425, DOI 10.1111/j.1467-789X.2007.00370.x; Westerterp KR, 2008, INT J OBESITY, V32, P1256, DOI 10.1038/ijo.2008.74; WHO, 2011, GLOB STAT REP NONC D; Wilks DC, 2011, OBES REV, V12, pe119, DOI 10.1111/j.1467-789X.2010.00775.x; World Health Organization, 2004, GLOB STRAT DIET PHYS; Yadav K, 2008, OBES REV, V9, P400, DOI 10.1111/j.1467-789X.2008.00505.x; Zhou QY, 1995, CELL, V83, P1197, DOI 10.1016/0092-8674(95)90145-0	113	2220	2291	49	757	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2012	380	9838					258	271		10.1016/S0140-6736(12)60735-1	http://dx.doi.org/10.1016/S0140-6736(12)60735-1			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976TV	22818938				2022-12-28	WOS:000306609200035
J	Wen, CP; Wu, XF				Wen, Chi Pang; Wu, Xifeng			Stressing harms of physical inactivity to promote exercise	LANCET			English	Editorial Material							LIFE EXPECTANCY; MORTALITY; COHORT; TAIWAN		[Wen, Chi Pang] Natl Hlth Res Inst, Zhunan, Taiwan; [Wen, Chi Pang] China Med Univ Hosp, Zhunan, Taiwan; [Wu, Xifeng] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Div Canc Prevent & Populat Sci, Houston, TX 77030 USA	National Health Research Institutes - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of Texas System; UTMD Anderson Cancer Center	Wen, CP (corresponding author), Natl Hlth Res Inst, Zhunan, Taiwan.	cwengood@nhri.org.tw						*CDCP, 1996, SURG GEN REP PHYS AC; Lee IM, 2012, LANCET; National Research Council. Committee on Physical Activity Land Use Institute of Medicine, 2005, DOES BUILT ENV INFL; Organization WH, 2009, GLOB HLTH RISKS MORT; Pimlott N, 2010, CAN FAM PHYSICIAN, V56, P407; Shavelle Robert M, 2008, J Insur Med, V40, P170; Wai JPM, 2008, ASIA PAC J CLIN NUTR, V17, P297; Walsh JME, 1999, AM J PREV MED, V16, P307, DOI 10.1016/S0749-3797(99)00021-5; Wen CP, 2012, LANCET, V379, P800, DOI 10.1016/S0140-6736(12)60342-0; Wen CP, 2011, LANCET, V378, P1244, DOI 10.1016/S0140-6736(11)60749-6; Wen CP, 2005, TOB CONTROL, V14, pI76, DOI 10.1136/tc.2004.007955; Woodcock J, 2011, INT J EPIDEMIOL, V40, P121, DOI 10.1093/ije/dyq104; World Health Organization, WHO FRAM CONV TOB CO; World Health Organization, 2008, WHO REP GLOB TOB EP; World Health Organization, UN HIGH LEV M NONC D	15	109	111	1	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 21	2012	380	9838					192	193		10.1016/S0140-6736(12)60954-4	http://dx.doi.org/10.1016/S0140-6736(12)60954-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976TV	22818933				2022-12-28	WOS:000306609200006
J	Heneghan, C; Gill, P; O'Neill, B; Lasserson, D; Thake, M; Thompson, M; Howick, J				Heneghan, Carl; Gill, Peter; O'Neill, Braden; Lasserson, Dan; Thake, Miriam; Thompson, Matthew; Howick, Jeremy			Mythbusting sports and exercise products	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CHAIN AMINO-ACID; BULL ENERGY DRINK; GRADUATED COMPRESSION STOCKINGS; INDUCED MUSCLE DAMAGE; CYCLING TIME-TRIAL; CARBOHYDRATE-PROTEIN SUPPLEMENTATION; REPEATED SPRINT PERFORMANCE; CHOCOLATE MILK CONSUMPTION; WELL-TRAINED MEN; ENDURANCE PERFORMANCE		[Heneghan, Carl; Gill, Peter; O'Neill, Braden; Lasserson, Dan; Thake, Miriam; Thompson, Matthew; Howick, Jeremy] Univ Oxford, Dept Primary Care Hlth Sci, Ctr Evidence Based Med, Oxford OX1 2ET, England	University of Oxford	Heneghan, C (corresponding author), Univ Oxford, Dept Primary Care Hlth Sci, Ctr Evidence Based Med, Oxford OX1 2ET, England.	carl.heneghan@phc.ox.ac.uk	Howick, Jeremy/ADP-7644-2022; Gill, Peter J./A-6021-2012	Gill, Peter J./0000-0002-6253-1312; Lasserson, Daniel/0000-0001-8274-5580				Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; Alford C, 2001, AMINO ACIDS, V21, P139, DOI 10.1007/s007260170021; Ali A, 2007, J SPORT SCI, V25, P413, DOI 10.1080/02640410600718376; Ali A, 2011, J STRENGTH COND RES, V25, P1385, DOI 10.1519/JSC.0b013e3181d6848e; Almond CSD, 2005, NEW ENGL J MED, V352, P1550, DOI 10.1056/NEJMoa043901; ARIEFF AI, 1976, MEDICINE, V55, P121, DOI 10.1097/00005792-197603000-00002; Armstrong LE, 1998, INT J SPORT NUTR, V8, P345, DOI 10.1123/ijsn.8.4.345; ARMSTRONG LE, 1994, INT J SPORT NUTR, V4, P265, DOI 10.1123/ijsn.4.3.265; Astorino TA, 2012, AMINO ACIDS, V42, P1803, DOI 10.1007/s00726-011-0900-8; Astorino TA, 2010, J STRENGTH COND RES, V24, P257, DOI 10.1519/JSC.0b013e3181c1f88a; Baum M, 2001, AMINO ACIDS, V20, P75, DOI 10.1007/s007260170067; Berardi JM, 2006, MED SCI SPORT EXER, V38, P1106, DOI 10.1249/01.mss.0000222826.49358.f3; Berardi JM, 2008, J INT SOC SPORT NUTR, V5, DOI 10.1186/1550-2783-5-24; Bernhardt T, 2005, J STRENGTH COND RES, V19, P292; BERRY MJ, 1987, AM J PHYS MED REHAB, V66, P121; Betts JA, 2005, INT J SPORT NUTR EXE, V15, P590, DOI 10.1123/ijsnem.15.6.590; Betts J, 2007, J SPORT SCI, V25, P1449, DOI 10.1080/02640410701213459; Betts JA, 2011, MED SCI SPORT EXER, V43, P1244, DOI 10.1249/MSS.0b013e31821b0dcc; Betts JA, 2010, SPORTS MED, V40, P941, DOI 10.2165/11536900-000000000-00000; Blomstrand E, 1997, ACTA PHYSIOL SCAND, V159, P41, DOI 10.1046/j.1365-201X.1997.547327000.x; Candow DG, 2009, J STRENGTH COND RES, V23, P1271, DOI 10.1519/JSC.0b013e3181a026c2; Chatard JC, 2004, EUR J APPL PHYSIOL, V93, P347, DOI 10.1007/s00421-004-1163-9; Cheuvront SN, 2010, AM J CLIN NUTR, V92, P565, DOI 10.3945/ajcn.2010.29490; Clarkson PM, 2002, AM J PHYS MED REHAB, V81, pS52, DOI [10.1097/00002060-200211001-00007, 10.1097/01.PHM.0000029772.45258.43]; Clauson KA, 2008, J AM PHARM ASSOC, V48, pE55, DOI 10.1331/JAPhA.2008.07055; Coburn JW, 2006, J STRENGTH COND RES, V20, P284; Cockburn E, 2010, APPL PHYSIOL NUTR ME, V35, P270, DOI 10.1139/H10-017; Cockburn E, 2008, APPL PHYSIOL NUTR ME, V33, P775, DOI 10.1139/H08-057; Conger SA, 2011, INT J SPORT NUTR EXE, V21, P71, DOI 10.1123/ijsnem.21.1.71; Crowe MJ, 2006, EUR J APPL PHYSIOL, V97, P664, DOI 10.1007/s00421-005-0036-1; Davies V, 2009, J STRENGTH COND RES, V23, P1786, DOI 10.1519/JSC.0b013e3181b42589; Davis JK, 2009, SPORTS MED, V39, P813, DOI 10.2165/11317770-000000000-00000; de Glanville KM, 2012, J STRENGTH COND RES, V26, P480, DOI 10.1519/JSC.0b013e318225ff61; De Lorenzo A, 2003, DIABETES NUTR METAB, V16, P291; Del Coso J, 2012, J INT SOC SPORT NUTR, V9, DOI 10.1186/1550-2783-9-21; Deldicque L, 2008, CURR OPIN CLIN NUTR, V11, P774, DOI 10.1097/MCO.0b013e3283139489; Doan BK, 2003, J SPORT SCI, V21, P601, DOI 10.1080/0264041031000101971; Doherty M, 2005, SCAND J MED SCI SPOR, V15, P69, DOI 10.1111/j.1600-0838.2005.00445.x; Doherty M, 2004, INT J SPORT NUTR EXE, V14, P626, DOI 10.1123/ijsnem.14.6.626; Duffield R, 2007, BRIT J SPORT MED, V41, P409, DOI 10.1136/bjsm.2006.033753; Duffield R, 2008, INT J SPORT PHYSIOL, V3, P454, DOI 10.1123/ijspp.3.4.454; Duffield R, 2010, J SCI MED SPORT, V13, P136, DOI 10.1016/j.jsams.2008.10.006; Duncan MJ, 2011, J STRENGTH COND 1124; Eberman LE, 2009, ATHL TRAIN SPORTS HL, V1, P267, DOI DOI 10.3928/19425864-20091020; FALLOWFIELD JL, 1995, INT J SPORT NUTR, V5, P285, DOI 10.1123/ijsn.5.4.285; Ferguson-Stegall L, 2011, J STRENGTH COND RES, V25, P1210, DOI 10.1519/JSC.0b013e318212db21; Fisone G, 2004, CELL MOL LIFE SCI, V61, P857, DOI 10.1007/s00018-003-3269-3; FLOYD JC, 1970, DIABETES, V19, P109, DOI 10.2337/diab.19.2.109; Forbes SC, 2007, INT J SPORT NUTR EXE, V17, P433, DOI 10.1123/ijsnem.17.5.433; French DN, 2008, MED SCI SPORT EXER, V40, P1297, DOI 10.1249/MSS.0b013e31816b10d5; Ganio MS, 2009, J STRENGTH COND RES, V23, P315, DOI 10.1519/JSC.0b013e31818b979a; GEISS KR, 1994, AMINO ACIDS, V7, P45, DOI 10.1007/BF00808445; Gill ND, 2006, BRIT J SPORT MED, V40, P260, DOI 10.1136/bjsm.2005.022483; Gilson SF, 2010, J INT SOC SPORT NUTR, V7, DOI 10.1186/1550-2783-7-19; Goulet EDB, 2007, INT J SPORT NUTR EXE, V17, P391, DOI 10.1123/ijsnem.17.4.391; Goulet EDB, 2011, BRIT J SPORT MED, V45, P1149, DOI 10.1136/bjsm.2010.077966; Graff L, 1983, HDB ROUTINE URINALYS, P2; Green MS, 2008, INT J SPORT NUTR EXE, V18, P1, DOI 10.1123/ijsnem.18.1.1; Greer BK, 2007, INT J SPORT NUTR EXE, V17, P595, DOI 10.1123/ijsnem.17.6.595; Greer BK, 2011, J STRENGTH COND RES, V25, P539, DOI 10.1519/JSC.0b013e3181bf443a; Gualano AB, 2011, J SPORT MED PHYS FIT, V51, P82; Guard A, 2005, INJURY PREV, V11, P33, DOI 10.1136/ip.2003.004044; Gwacham N, 2012, INT J SPORT NUTR EXE, V22, P109, DOI 10.1123/ijsnem.22.2.109; Harvey G, 2008, J SCI MED SPORT, V11, P600, DOI 10.1016/j.jsams.2007.05.012; Heneghan C, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001702; Higgins JP, 2010, MAYO CLIN PROC, V85, P1033, DOI 10.4065/mcp.2010.0381; Higgins T, 2009, J SCI MED SPORT, V12, P223, DOI 10.1016/j.jsams.2007.08.018; Houghton LA, 2009, J SCI MED SPORT, V12, P303, DOI 10.1016/j.jsams.2007.09.004; Hsu MC, 2011, CHINESE J PHYSIOL, V54, P71, DOI 10.4077/CJP.2011.AMK075; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; Ivy JL, 2009, INT J SPORT NUTR EXE, V19, P61, DOI 10.1123/ijsnem.19.1.61; Jakeman JR, 2010, J STRENGTH COND RES, V24, P3157, DOI 10.1519/JSC.0b013e3181e4f80c; Johnson AK, 1997, FRONT NEUROENDOCRIN, V18, P292, DOI 10.1006/frne.1997.0153; Karp JR, 2006, INT J SPORT NUTR EXE, V16, P78, DOI 10.1123/ijsnem.16.1.78; Kemmler W, 2009, J STRENGTH COND RES, V23, P101, DOI 10.1519/JSC.0b013e31818eaef3; Kerksick CM, 2006, J STRENGTH COND RES, V20, P643, DOI 10.1519/R-17695.1; Kipps C, 2011, BRIT J SPORT MED, V45, P14, DOI 10.1136/bjsm.2009.059535; Kovacs EMR, 1999, J SPORT MED PHYS FIT, V39, P47; Kraemer WJ, 2010, J STRENGTH COND RES, V24, P804, DOI 10.1519/JSC.0b013e3181d33025; KRAEMER WJ, 1996, J STRENGTH COND RES, V10, P180; Lew CH, 2010, INT J SPORT NUTR EXE, V20, P330, DOI 10.1123/ijsnem.20.4.330; Luden ND, 2007, INT J SPORT NUTR EXE, V17, P109, DOI 10.1123/ijsnem.17.1.109; Lunn WR, 2012, MED SCI SPORT EXER, V44, P682, DOI 10.1249/MSS.0b013e3182364162; Manz F, 2003, EUR J CLIN NUTR, V57, pS10, DOI 10.1038/sj.ejcn.1601896; Matsumoto K, 2009, J SPORT MED PHYS FIT, V49, P424; Matsumoto K, 2009, J NUTR SCI VITAMINOL, V55, P52, DOI 10.3177/jnsv.55.52; Maughan RJ, 2007, J SPORT SCI, V25, pS103, DOI 10.1080/02640410701607395; MAY ME, 1989, DIABETES METAB REV, V5, P227, DOI 10.1002/dmr.5610050303; Menetrier A, 2011, INT J SPORTS MED, V32, P864, DOI 10.1055/s-0031-1283181; Millard-Stafford M, 2005, INT J SPORT NUTR EXE, V15, P610, DOI 10.1123/ijsnem.15.6.610; Millward DJ, 2004, J SPORT SCI, V22, P143, DOI 10.1080/0264041031000140617; Nelson AR, 2012, MED SCI SPORT EXER, V44, P57, DOI 10.1249/MSS.0b013e3182290371; Nicholas CW, 1997, INT J SPORT NUTR, V7, P251, DOI 10.1123/ijsn.7.4.251; Nissen S, 1996, J APPL PHYSIOL, V81, P2095, DOI 10.1152/jappl.1996.81.5.2095; Noakes T., 2012, WATERLOGGED SERIOUS; Nutrition Working Group of the International Olympic Committee, NUTR ATHL; Orbeta RL, 2006, J ADOLESCENT HEALTH, V38, P451, DOI 10.1016/j.jadohealth.2005.05.014; Pitkanen HT, 2003, AMINO ACIDS, V25, P85, DOI 10.1007/s00726-002-0343-3; Pollock NW, 1997, MED SCI SPORTS EXERC, V29l, P261; Portier H, 2008, EUR J APPL PHYSIOL, V104, P787, DOI 10.1007/s00421-008-0832-5; Reissig CJ, 2009, DRUG ALCOHOL DEPEN, V99, P1, DOI 10.1016/j.drugalcdep.2008.08.001; Rimaud D, 2010, EUR J APPL PHYSIOL, V110, P425, DOI 10.1007/s00421-010-1503-x; ROBINSON TA, 1995, EUR J APPL PHYSIOL O, V71, P153, DOI 10.1007/BF00854973; Rodriguez NR, 2009, MED SCI SPORT EXER, V41, P709, DOI 10.1249/MSS.0b013e31890eb86; Rowlands DS, 2008, APPL PHYSIOL NUTR ME, V33, P39, DOI 10.1139/H07-136; Rowlands DS, 2007, INT J SPORT NUTR EXE, V17, P521, DOI 10.1123/ijsnem.17.6.521; Sawka MN, 2007, MED SCI SPORT EXER, V39, P377, DOI 10.1249/mss.0b013e31802ca597; Scanlan AT, 2008, INT J SPORT PHYSIOL, V3, P424, DOI 10.1123/ijspp.3.4.424; Seifert SM, 2011, PEDIATRICS, V127, P511, DOI 10.1542/peds.2009-3592; Shimomura Y, 2010, INT J SPORT NUTR EXE, V20, P236, DOI 10.1123/ijsnem.20.3.236; Shirreffs SM, 1996, MED SCI SPORT EXER, V28, P1260, DOI 10.1097/00005768-199610000-00009; Smith N, 2010, EVID-BASED COMPL ALT, V7, P279, DOI 10.1093/ecam/nem162; Spaccarotella KJ, 2011, J STRENGTH COND RES, V25, P3456, DOI 10.1519/JSC.0b013e3182163071; Sperlich B, 2010, J SPORT SCI, V28, P609, DOI 10.1080/02640410903582768; Stearns RL, 2010, J STRENGTH COND RES, V24, P2192, DOI 10.1519/JSC.0b013e3181ddfacf; Stock MS, 2010, J STRENGTH COND RES, V24, P2211, DOI 10.1519/JSC.0b013e3181dc3a10; Thomas K, 2009, APPL PHYSIOL NUTR ME, V34, P78, DOI 10.1139/H08-137; Thomson JS, 2011, APPL PHYSIOL NUTR ME, V36, P242, DOI [10.1139/h10-104, 10.1139/H10-104]; Tipton KD, 1999, AM J PHYSIOL-ENDOC M, V276, pE628, DOI 10.1152/ajpendo.1999.276.4.E628; VANHALL G, 1995, J PHYSIOL-LONDON, V486, P789, DOI 10.1113/jphysiol.1995.sp020854; Varela-Sanz A, 2011, J STRENGTH COND RES, V25, P2902, DOI 10.1519/JSC.0b013e31820f5049; VARNIER M, 1994, EUR J APPL PHYSIOL O, V69, P26, DOI 10.1007/BF00867923; Walker DK, 2011, MED SCI SPORT EXER, V43, P2249, DOI 10.1249/MSS.0b013e318223b037; Walker TB, 2010, INT J SPORT NUTR EXE, V20, P409, DOI 10.1123/ijsnem.20.5.409; WHO, 2012, WHO POS PAP OR REH S; Williams MB, 2003, J STRENGTH COND RES, V17, P12, DOI 10.1519/1533-4287(2003)017<0012:EORBOG>2.0.CO;2; Wojcik JR, 2001, INT J SPORT NUTR EXE, V11, P406, DOI 10.1123/ijsnem.11.4.406; Wolk BJ, 2012, CURR OPIN PEDIATR, V24, P243, DOI 10.1097/MOP.0b013e3283506827; ZAWADZKI KM, 1992, J APPL PHYSIOL, V72, P1854, DOI 10.1152/jappl.1992.72.5.1854	129	9	9	1	65	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 19	2012	345								e4848	10.1136/bmj.e4848	http://dx.doi.org/10.1136/bmj.e4848			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978MA	22810389				2022-12-28	WOS:000306744300012
J	Muzny, DM; Bainbridge, MN; Chang, K; Dinh, HH; Drummond, JA; Fowler, G; Kovar, CL; Lewis, LR; Morgan, MB; Newsham, IF; Reid, JG; Santibanez, J; Shinbrot, E; Trevino, LR; Wu, YQ; Wang, M; Gunaratne, P; Donehower, LA; Creighton, CJ; Wheeler, DA; Gibbs, RA; Lawrence, MS; Voet, D; Jing, R; Cibulskis, K; Sivachenko, A; Stojanov, P; McKenna, A; Lander, ES; Gabriel, S; Getz, G; Ding, L; Fulton, RS; Koboldt, DC; Wylie, T; Walker, J; Dooling, DJ; Fulton, L; Delehaunty, KD; Fronick, CC; Demeter, R; Mardis, ER; Wilson, RK; Chu, A; Chun, HJE; Mungall, AJ; Pleasance, E; Robertson, AG; Stoll, D; Balasundaram, M; Birol, I; Butterfield, YSN; Chuah, E; Coope, RJN; Dhalla, N; Guin, R; Hirst, C; Hirst, M; Holt, RA; Lee, D; Li, HI; Mayo, M; Moore, RA; Schein, JE; Slobodan, JR; Tam, A; Thiessen, N; Varhol, R; Zeng, T; Zhao, Y; Jones, SJM; Marra, MA; Bass, AJ; Ramos, AH; Saksena, G; Cherniack, AD; Schumacher, SE; Tabak, B; Carter, SL; Pho, NH; Nguyen, H; Onofrio, RC; Crenshaw, A; Ardlie, K; Beroukhim, R; Winckler, W; Getz, G; Meyerson, M; Protopopov, A; Zhang, J; Hadjipanayis, A; Lee, E; Xi, R; Yang, L; Ren, X; Zhang, H; Sathiamoorthy, N; Shukla, S; Chen, PC; Haseley, P; Xiao, Y; Lee, S; Seidman, J; Chin, L; Park, PJ; Kucherlapati, R; Auman, JT; Hoadley, KA; Du, Y; Wilkerson, MD; Shi, Y; Liquori, C; Meng, S; Li, L; Turman, YJ; Topal, MD; Tan, D; Waring, S; Buda, E; Walsh, J; Jones, CD; Mieczkowski, PA; Singh, D; Wu, J; Gulabani, A; Dolina, P; Bodenheimer, T; Hoyle, AP; Simons, JV; Soloway, M; Mose, LE; Jefferys, SR; Balu, S; O'Connor, BD; Prins, JF; Chiang, DY; Hayes, DN; Perou, CM; Hinoue, T; Weisenberger, DJ; Maglinte, DT; Pan, F; Berman, BP; Van den Berg, DJ; Shen, H; Jr, TT; Baylin, SB; Laird, PW; Getz, G; Noble, M; Voet, D; Saksena, G; Gehlenborg, N; DiCara, D; Zhang, J; Zhang, H; Wu, CJ; Liu, SY; Shukla, S; Lawrence, MS; Zhou, L; Sivachenko, A; Lin, P; Stojanov, P; Jing, R; Park, RW; Nazaire, MD; Robinson, J; Thorvaldsdottir, H; Mesirov, J; Park, PJ; Chin, L; Thorsson, V; Reynolds, SM; Bernard, B; Kreisberg, R; Lin, J; Iype, L; Bressler, R; Erkkila, T; Gundapuneni, M; Liu, Y; Norberg, A; Robinson, T; Da Yang; Zhang, W; Shmulevich, I; De Ronde, JJ; Schultz, N; Cerami, E; Ciriello, G; Goldberg, AP; Gross, B; Jacobsen, A; Gao, J; Kaczkowski, B; Sinha, R; Aksoy, BA; Antipin, Y; Reva, B; Shen, R; Taylor, BS; Chan, TA; Ladanyi, M; Sander, C; Akbani, R; Zhang, N; Broom, BM; Casasent, T; Unruh, A; Wakefield, C; Hamilton, SR; Cason, RC; Baggerly, KA; Weinstein, JN; Haussler, D; Benz, CC; Stuart, JM; Benz, SC; Sanborn, JZ; Vaske, CJ; Zhu, J; Szeto, C; Scott, GK; Yau, C; Ng, S; Goldstein, T; Ellrott, K; Collisson, E; Cozen, AE; Zerbino, D; Wilks, C; Craft, B; Spellman, P; Penny, R; Shelton, T; Hatfield, M; Morris, S; Yena, P; Shelton, C; Sherman, M; Paulauskis, J; Gastier-Foster, JM; Bowen, J; Ramirez, NC; Black, A; Pyatt, R; Wise, L; White, P; Bertagnolli, M; Brown, J; Chan, TA; Chu, GC; Czerwinski, C; Denstman, F; Dhir, R; Doerner, A; Fuchs, CS; Guillem, JG; Iacocca, M; Juhl, H; Kaufman, A; Kohl, B; Van Le, X; Mariano, MC; Medina, EN; Meyers, M; Nash, GM; Paty, PB; Petrelli, N; Rabeno, B; Richards, WG; Solit, D; Swanson, P; Temple, L; Tepper, JE; Thorp, R; Vakiani, E; Weiser, MR; Willis, JE; Witkin, G; Zeng, Z; Zinner, MJ; Zornig, C; Jensen, MA; Sfeir, R; Kahn, AB; Chu, AL; Kothiyal, P; Wang, Z; Snyder, EE; Pontius, J; Pihl, TD; Ayala, B; Backus, M; Walton, J; Whitmore, J; Baboud, J; Berton, DL; Nicholls, MC; Srinivasan, D; Raman, R; Girshik, S; Kigonya, PA; Alonso, S; Sanbhadti, RN; Barletta, SP; Greene, JM; Pot, DA; Shaw, KRM; Dillon, LAL; Buetow, K; Davidsen, T; Demchok, JA; Eley, G; Ferguson, M; Fielding, P; Schaefer, C; Sheth, M; Yang, L; Guyer, MS; Ozenberger, BA; Palchik, JD; Peterson, J; Sofia, HJ; Thomson, E				Muzny, Donna M.; Bainbridge, Matthew N.; Chang, Kyle; Dinh, Huyen H.; Drummond, Jennifer A.; Fowler, Gerald; Kovar, Christie L.; Lewis, Lora R.; Morgan, Margaret B.; Newsham, Irene F.; Reid, Jeffrey G.; Santibanez, Jireh; Shinbrot, Eve; Trevino, Lisa R.; Wu, Yuan-Qing; Wang, Min; Gunaratne, Preethi; Donehower, Lawrence A.; Creighton, Chad J.; Wheeler, David A.; Gibbs, Richard A.; Lawrence, Michael S.; Voet, Douglas; Jing, Rui; Cibulskis, Kristian; Sivachenko, Andrey; Stojanov, Petar; McKenna, Aaron; Lander, Eric S.; Gabriel, Stacey; Getz, Gad; Ding, Li; Fulton, Robert S.; Koboldt, Daniel C.; Wylie, Todd; Walker, Jason; Dooling, David J.; Fulton, Lucinda; Delehaunty, Kim D.; Fronick, Catrina C.; Demeter, Ryan; Mardis, Elaine R.; Wilson, Richard K.; Chu, Andy; Chun, Hye-Jung E.; Mungall, Andrew J.; Pleasance, Erin; Robertson, A. Gordon; Stoll, Dominik; Balasundaram, Miruna; Birol, Inanc; Butterfield, Yaron S. N.; Chuah, Eric; Coope, Robin J. N.; Dhalla, Noreen; Guin, Ranabir; Hirst, Carrie; Hirst, Martin; Holt, Robert A.; Lee, Darlene; Li, Haiyan I.; Mayo, Michael; Moore, Richard A.; Schein, Jacqueline E.; Slobodan, Jared R.; Tam, Angela; Thiessen, Nina; Varhol, Richard; Zeng, Thomas; Zhao, Yongjun; Jones, Steven J. M.; Marra, Marco A.; Bass, Adam J.; Ramos, Alex H.; Saksena, Gordon; Cherniack, Andrew D.; Schumacher, Stephen E.; Tabak, Barbara; Carter, Scott L.; Pho, Nam H.; Nguyen, Huy; Onofrio, Robert C.; Crenshaw, Andrew; Ardlie, Kristin; Beroukhim, Rameen; Winckler, Wendy; Getz, Gad; Meyerson, Matthew; Protopopov, Alexei; Zhang, Juinhua; Hadjipanayis, Angela; Lee, Eunjung; Xi, Ruibin; Yang, Lixing; Ren, Xiaojia; Zhang, Hailei; Sathiamoorthy, Narayanan; Shukla, Sachet; Chen, Peng-Chieh; Haseley, Psalm; Xiao, Yonghong; Lee, Semin; Seidman, Jonathan; Chin, Lynda; Park, Peter J.; Kucherlapati, Raju; Auman, J. Todd; Hoadley, Katherine A.; Du, Ying; Wilkerson, Matthew D.; Shi, Yan; Liquori, Christina; Meng, Shaowu; Li, Ling; Turman, Yidi J.; Topal, Michael D.; Tan, Donghui; Waring, Scot; Buda, Elizabeth; Walsh, Jesse; Jones, Corbin D.; Mieczkowski, Piotr A.; Singh, Darshan; Wu, Junyuan; Gulabani, Anisha; Dolina, Peter; Bodenheimer, Tom; Hoyle, Alan P.; Simons, Janae V.; Soloway, Matthew; Mose, Lisle E.; Jefferys, Stuart R.; Balu, Saianand; O'Connor, Brian D.; Prins, Jan F.; Chiang, Derek Y.; Hayes, D. Neil; Perou, Charles M.; Hinoue, Toshinori; Weisenberger, Daniel J.; Maglinte, Dennis T.; Pan, Fei; Berman, Benjamin P.; Van den Berg, David J.; Shen, Hui; Jr, Timothy Triche; Baylin, Stephen B.; Laird, Peter W.; Getz, Gad; Noble, Michael; Voet, Doug; Saksena, Gordon; Gehlenborg, Nils; DiCara, Daniel; Zhang, Juinhua; Zhang, Hailei; Wu, Chang-Jiun; Liu, Spring Yingchun; Shukla, Sachet; Lawrence, Michael S.; Zhou, Lihua; Sivachenko, Andrey; Lin, Pei; Stojanov, Petar; Jing, Rui; Park, Richard W.; Nazaire, Marc-Danie; Robinson, Jim; Thorvaldsdottir, Helga; Mesirov, Jill; Park, Peter J.; Chin, Lynda; Thorsson, Vesteinn; Reynolds, Sheila M.; Bernard, Brady; Kreisberg, Richard; Lin, Jake; Iype, Lisa; Bressler, Ryan; Erkkilae, Timo; Gundapuneni, Madhumati; Liu, Yuexin; Norberg, Adam; Robinson, Tom; Da Yang; Zhang, Wei; Shmulevich, Ilya; De Ronde, Jorma J.; Schultz, Nikolaus; Cerami, Ethan; Ciriello, Giovanni; Goldberg, Arthur P.; Gross, Benjamin; Jacobsen, Anders; Gao, Jianjiong; Kaczkowski, Bogumil; Sinha, Rileen; Aksoy, B. Arman; Antipin, Yevgeniy; Reva, Boris; Shen, Ronglai; Taylor, Barry S.; Chan, Timothy A.; Ladanyi, Marc; Sander, Chris; Akbani, Rehan; Zhang, Nianxiang; Broom, Bradley M.; Casasent, Tod; Unruh, Anna; Wakefield, Chris; Hamilton, Stanley R.; Cason, R. Craig; Baggerly, Keith A.; Weinstein, John N.; Haussler, David; Benz, Christopher C.; Stuart, Joshua M.; Benz, Stephen C.; Sanborn, J. Zachary; Vaske, Charles J.; Zhu, Jingchun; Szeto, Christopher; Scott, Gary K.; Yau, Christina; Ng, Sam; Goldstein, Ted; Ellrott, Kyle; Collisson, Eric; Cozen, Aaron E.; Zerbino, Daniel; Wilks, Christopher; Craft, Brian; Spellman, Paul; Penny, Robert; Shelton, Troy; Hatfield, Martha; Morris, Scott; Yena, Peggy; Shelton, Candace; Sherman, Mark; Paulauskis, Joseph; Gastier-Foster, Julie M.; Bowen, Jay; Ramirez, Nilsa C.; Black, Aaron; Pyatt, Robert; Wise, Lisa; White, Peter; Bertagnolli, Monica; Brown, Jen; Chan, Timothy A.; Chu, Gerald C.; Czerwinski, Christine; Denstman, Fred; Dhir, Rajiv; Doerner, Arnulf; Fuchs, Charles S.; Guillem, Jose G.; Iacocca, Mary; Juhl, Hartmut; Kaufman, Andrew; Kohl, Bernard, III; Van Le, Xuan; Mariano, Maria C.; Medina, Elizabeth N.; Meyers, Michael; Nash, Garrett M.; Paty, Phillip B.; Petrelli, Nicholas; Rabeno, Brenda; Richards, William G.; Solit, David; Swanson, Pat; Temple, Larissa; Tepper, Joel E.; Thorp, Richard; Vakiani, Efsevia; Weiser, Martin R.; Willis, Joseph E.; Witkin, Gary; Zeng, Zhaoshi; Zinner, Michael J.; Zornig, Carsten; Jensen, Mark A.; Sfeir, Robert; Kahn, Ari B.; Chu, Anna L.; Kothiyal, Prachi; Wang, Zhining; Snyder, Eric E.; Pontius, Joan; Pihl, Todd D.; Ayala, Brenda; Backus, Mark; Walton, Jessica; Whitmore, Jon; Baboud, Julien; Berton, Dominique L.; Nicholls, Matthew C.; Srinivasan, Deepak; Raman, Rohini; Girshik, Stanley; Kigonya, Peter A.; Alonso, Shelley; Sanbhadti, Rashmi N.; Barletta, Sean P.; Greene, John M.; Pot, David A.; Shaw, Kenna R. Mills; Dillon, Laura A. L.; Buetow, Ken; Davidsen, Tanja; Demchok, John A.; Eley, Greg; Ferguson, Martin; Fielding, Peter; Schaefer, Carl; Sheth, Margi; Yang, Liming; Guyer, Mark S.; Ozenberger, Bradley A.; Palchik, Jacqueline D.; Peterson, Jane; Sofia, Heidi J.; Thomson, Elizabeth			Comprehensive molecular characterization of human colon and rectal cancer	NATURE			English	Article							COLORECTAL-CANCER; INTESTINAL EPITHELIUM; SOMATIC MUTATIONS; HUMAN BREAST; WILMS-TUMOR; GENE; DIFFERENTIATION; ONCOGENE; CELLS; WTX	To characterize somatic alterations in colorectal carcinoma, we conducted a genome-scale analysis of 276 samples, analysing exome sequence, DNA copy number, promoter methylation and messenger RNA and microRNA expression. A subset of these samples (97) underwent low-depth-of-coverage whole-genome sequencing. In total, 16% of colorectal carcinomas were found to be hypermutated: three-quarters of these had the expected high microsatellite instability, usually with hypermethylation and MLH1 silencing, and one-quarter had somatic mismatch-repair gene and polymerase e (POLE) mutations. Excluding the hypermutated cancers, colon and rectum cancers were found to have considerably similar patterns of genomic alteration. Twenty-four genes were significantly mutated, and in addition to the expected APC, TP53, SMAD4, PIK3CA and KRAS mutations, we found frequent mutations in ARID1A, SOX9 and FAM123B. Recurrent copy-number alterations include potentially drug-targetable amplifications of ERBB2 and newly discovered amplification of IGF2. Recurrent chromosomal translocations include the fusion of NAV2 and WNT pathway member TCF7L1. Integrative analyses suggest new markers for aggressive colorectal carcinoma and an important role for MYC-directed transcriptional activation and repression.	[Hadjipanayis, Angela; Chen, Peng-Chieh; Seidman, Jonathan; Kucherlapati, Raju] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Donehower, Lawrence A.; Creighton, Chad J.; Sivachenko, Andrey] Baylor Coll Med, Human Genome Sequencing Ctr, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Gunaratne, Preethi] Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; [Lawrence, Michael S.; Voet, Douglas; Jing, Rui; Cibulskis, Kristian; Stojanov, Petar; McKenna, Aaron; Lander, Eric S.; Gabriel, Stacey; Getz, Gad; Bass, Adam J.; Ramos, Alex H.; Saksena, Gordon; Cherniack, Andrew D.; Schumacher, Stephen E.; Tabak, Barbara; Carter, Scott L.; Pho, Nam H.; Nguyen, Huy; Onofrio, Robert C.; Crenshaw, Andrew; Ardlie, Kristin; Beroukhim, Rameen; Winckler, Wendy; Meyerson, Matthew; Chin, Lynda; Noble, Michael; Voet, Doug; Gehlenborg, Nils; DiCara, Daniel; Zhang, Juinhua; Zhang, Hailei; Wu, Chang-Jiun; Liu, Spring Yingchun; Shukla, Sachet; Zhou, Lihua; Sivachenko, Andrey; Lin, Pei; Nazaire, Marc-Danie; Robinson, Jim; Thorvaldsdottir, Helga; Mesirov, Jill] MIT, Eli & Edythe L Broad Inst, Cambridge, MA 02142 USA; [Voet, Douglas; Jing, Rui; Cibulskis, Kristian; Stojanov, Petar; McKenna, Aaron; Lander, Eric S.; Gabriel, Stacey; Getz, Gad; Bass, Adam J.; Ramos, Alex H.; Saksena, Gordon; Cherniack, Andrew D.; Schumacher, Stephen E.; Tabak, Barbara; Carter, Scott L.; Pho, Nam H.; Nguyen, Huy; Onofrio, Robert C.; Crenshaw, Andrew; Ardlie, Kristin; Beroukhim, Rameen; Winckler, Wendy; Meyerson, Matthew; Chin, Lynda; Noble, Michael; Voet, Doug; Gehlenborg, Nils; DiCara, Daniel; Zhang, Juinhua; Zhang, Hailei; Wu, Chang-Jiun; Liu, Spring Yingchun; Shukla, Sachet; Zhou, Lihua; Sivachenko, Andrey; Lin, Pei; Nazaire, Marc-Danie; Robinson, Jim; Thorvaldsdottir, Helga; Mesirov, Jill] Harvard Univ, Cambridge, MA 02142 USA; [Lander, Eric S.] MIT, Dept Biol, Cambridge, MA 02142 USA; [Lander, Eric S.] Harvard Univ, Dept Syst Biol, Boston, MA 02115 USA; [Ding, Li; Fulton, Robert S.; Koboldt, Daniel C.; Wylie, Todd; Walker, Jason; Dooling, David J.; Fulton, Lucinda; Delehaunty, Kim D.; Fronick, Catrina C.; Demeter, Ryan; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Sch Med, Genome Inst, St Louis, MO 63108 USA; [Ding, Li; Dooling, David J.; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63108 USA; [Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63108 USA; [Chu, Andy; Chun, Hye-Jung E.; Mungall, Andrew J.; Pleasance, Erin; Robertson, A. Gordon; Stoll, Dominik; Balasundaram, Miruna; Birol, Inanc; Butterfield, Yaron S. N.; Chuah, Eric; Coope, Robin J. N.; Dhalla, Noreen; Guin, Ranabir; Hirst, Carrie; Hirst, Martin; Holt, Robert A.; Lee, Darlene; Li, Haiyan I.; Mayo, Michael; Moore, Richard A.; Schein, Jacqueline E.; Slobodan, Jared R.; Tam, Angela; Thiessen, Nina; Varhol, Richard; Zeng, Thomas; Zhao, Yongjun; Jones, Steven J. M.; Marra, Marco A.] BC Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada; [Meyerson, Matthew] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Protopopov, Alexei; Zhang, Juinhua; Ren, Xiaojia; Zhang, Hailei; Shukla, Sachet; Xiao, Yonghong; Chin, Lynda; Zhang, Juinhua; Zhang, Hailei; Wu, Chang-Jiun; Liu, Spring Yingchun; Shukla, Sachet] Dana Farber Canc Inst, Dept Med Oncol, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA; [Hadjipanayis, Angela; Lee, Eunjung; Chen, Peng-Chieh; Haseley, Psalm; Park, Peter J.; Kucherlapati, Raju] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA; [Lee, Eunjung; Xi, Ruibin; Yang, Lixing; Haseley, Psalm; Lee, Semin; Park, Peter J.; Gehlenborg, Nils; Park, Richard W.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA; [Sathiamoorthy, Narayanan; Park, Peter J.] Childrens Hosp, Informat Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Auman, J. Todd] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA; [Auman, J. Todd] Univ N Carolina, Inst Pharmacogenet & Individualized Therapy, Chapel Hill, NC 27599 USA; [Hoadley, Katherine A.; Mieczkowski, Piotr A.; Chiang, Derek Y.; Perou, Charles M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; [Hoadley, Katherine A.; Topal, Michael D.; Mose, Lisle E.; Jefferys, Stuart R.; Perou, Charles M.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Hoadley, Katherine A.; Du, Ying; Wilkerson, Matthew D.; Shi, Yan; Liquori, Christina; Meng, Shaowu; Li, Ling; Turman, Yidi J.; Topal, Michael D.; Waring, Scot; Buda, Elizabeth; Walsh, Jesse; Wu, Junyuan; Gulabani, Anisha; Dolina, Peter; Bodenheimer, Tom; Hoyle, Alan P.; Simons, Janae V.; Soloway, Matthew; Balu, Saianand; O'Connor, Brian D.; Chiang, Derek Y.; Hayes, D. Neil; Perou, Charles M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Tan, Donghui] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA; [Jones, Corbin D.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; [Singh, Darshan; Prins, Jan F.] Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27599 USA; [Hayes, D. Neil] Univ N Carolina, Dept Internal Med, Div Med Oncol, Chapel Hill, NC USA; [Hinoue, Toshinori; Weisenberger, Daniel J.; Maglinte, Dennis T.; Pan, Fei; Berman, Benjamin P.; Van den Berg, David J.; Shen, Hui; Jr, Timothy Triche; Laird, Peter W.] Univ So Calif, Epigenome Ctr, Los Angeles, CA 90089 USA; [Baylin, Stephen B.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Canc Biol, Baltimore, MD 21231 USA; [Thorsson, Vesteinn; Reynolds, Sheila M.; Bernard, Brady; Kreisberg, Richard; Lin, Jake; Iype, Lisa; Bressler, Ryan; Erkkilae, Timo; Gundapuneni, Madhumati; Norberg, Adam; Robinson, Tom; Shmulevich, Ilya] Inst Syst Biol, Seattle, WA 98109 USA; [Liu, Yuexin; Da Yang; Zhang, Wei; Hamilton, Stanley R.; Cason, R. Craig] Univ Texas MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA; [De Ronde, Jorma J.; Schultz, Nikolaus; Cerami, Ethan; Ciriello, Giovanni; Goldberg, Arthur P.; Gross, Benjamin; Jacobsen, Anders; Gao, Jianjiong; Kaczkowski, Bogumil; Sinha, Rileen; Antipin, Yevgeniy; Reva, Boris; Taylor, Barry S.; Sander, Chris] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10065 USA; [De Ronde, Jorma J.] Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands; [Shen, Ronglai] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA; [Ladanyi, Marc] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, Dept Pathol, New York, NY 10065 USA; [Akbani, Rehan; Zhang, Nianxiang; Broom, Bradley M.; Casasent, Tod; Unruh, Anna; Wakefield, Chris; Baggerly, Keith A.; Weinstein, John N.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Weinstein, John N.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Haussler, David; Stuart, Joshua M.; Benz, Stephen C.; Sanborn, J. Zachary; Vaske, Charles J.; Zhu, Jingchun; Szeto, Christopher; Ng, Sam; Goldstein, Ted; Ellrott, Kyle; Cozen, Aaron E.; Zerbino, Daniel; Wilks, Christopher; Craft, Brian] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA; [Haussler, David; Stuart, Joshua M.; Benz, Stephen C.; Sanborn, J. Zachary; Vaske, Charles J.; Zhu, Jingchun; Szeto, Christopher; Ng, Sam; Goldstein, Ted; Ellrott, Kyle; Cozen, Aaron E.; Zerbino, Daniel; Wilks, Christopher; Craft, Brian] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA; [Haussler, David] Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA; [Benz, Christopher C.; Scott, Gary K.; Yau, Christina] Buck Inst Age Res, Novato, CA 94945 USA; [Collisson, Eric] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA; [Spellman, Paul] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA; [Penny, Robert; Shelton, Troy; Hatfield, Martha; Morris, Scott; Yena, Peggy; Shelton, Candace; Sherman, Mark; Paulauskis, Joseph] Int Genom Consortium, Phoenix, AZ 85004 USA; [Gastier-Foster, Julie M.; Bowen, Jay; Ramirez, Nilsa C.; Black, Aaron; Pyatt, Robert; Wise, Lisa; White, Peter] Nationwide Childrens Hosp, Res Inst, Nationwide Childrens Hosp Biospecimen Core Resour, Columbus, OH 43205 USA; [Gastier-Foster, Julie M.; Ramirez, Nilsa C.; Pyatt, Robert; White, Peter] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43205 USA; [Gastier-Foster, Julie M.; White, Peter] Ohio State Univ, Dept Pediat, Coll Med, Columbus, OH 43205 USA; [Bertagnolli, Monica] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; [Brown, Jen; Czerwinski, Christine; Iacocca, Mary; Rabeno, Brenda; Swanson, Pat; Witkin, Gary] Christiana Care Hlth Syst, Dept Pathol, Newark, DE 19718 USA; [Chu, Gerald C.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Brookline, MA 02115 USA; [Denstman, Fred; Petrelli, Nicholas] Helen F Graham Canc Ctr Christiana Care, Dept Surg, Newark, DC 19718 USA; [Dhir, Rajiv] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; [Doerner, Arnulf] Krankenhaus Alten Eichen, Chirurg Klin, D-22527 Hamburg, Germany; [Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Brookline, MA 02115 USA; [Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Brookline, MA 02115 USA; [Guillem, Jose G.; Nash, Garrett M.; Paty, Phillip B.; Weiser, Martin R.; Zeng, Zhaoshi] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Juhl, Hartmut] Indivumed Inc, Kensington, MD 20895 USA; [Kohl, Bernard, III; Van Le, Xuan; Thorp, Richard] ILSbio LLC, Chestertown, MD 21620 USA; [Tepper, Joel E.] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; [Solit, David] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Willis, Joseph E.] Case Med Ctr, Dept Pathol, Cleveland, OH 44106 USA; [Zornig, Carsten] Israelit Krankenhaus, Chirurg Klin, D-22297 Hamburg, Germany; [Jensen, Mark A.; Sfeir, Robert; Kahn, Ari B.; Chu, Anna L.; Kothiyal, Prachi; Wang, Zhining; Snyder, Eric E.; Pontius, Joan; Pihl, Todd D.; Ayala, Brenda; Backus, Mark; Walton, Jessica; Whitmore, Jon; Baboud, Julien; Berton, Dominique L.; Nicholls, Matthew C.; Srinivasan, Deepak; Raman, Rohini; Girshik, Stanley; Kigonya, Peter A.; Alonso, Shelley; Sanbhadti, Rashmi N.; Barletta, Sean P.; Greene, John M.; Pot, David A.] SRA Int, Fairfax, VA 22033 USA; [Shaw, Kenna R. Mills; Dillon, Laura A. L.; Demchok, John A.; Fielding, Peter; Sheth, Margi; Yang, Liming] NCI, Canc Genome Atlas Program Off, NIH, Bethesda, MD 20892 USA; [Buetow, Ken; Davidsen, Tanja; Schaefer, Carl] NCI, Ctr Biomed Informat & Informat Technol CBIIT, NIH, Rockville, MD 20852 USA; [Eley, Greg] Scimentis LLC, Statham, GA 30666 USA; [Ferguson, Martin] MLF Consulting, Arlington, MA 02474 USA; [Guyer, Mark S.; Ozenberger, Bradley A.; Palchik, Jacqueline D.; Peterson, Jane; Sofia, Heidi J.; Thomson, Elizabeth] NHGRI, NIH, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; Baylor College of Medicine; University of Houston System; University of Houston; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); British Columbia Cancer Agency; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Southern California; Johns Hopkins University; Johns Hopkins Medicine; Institute for Systems Biology (ISB); University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Netherlands Cancer Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; Howard Hughes Medical Institute; University of California System; University of California Santa Cruz; Buck Institute for Research on Aging; University of California System; University of California San Francisco; Oregon Health & Science University; International Genomics Consortium; International Genomics Consortium; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Christiana Care Health System; Harvard University; Brigham & Women's Hospital; Christiana Care Health System; Helen F. Graham Cancer Center & Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Memorial Sloan Kettering Cancer Center; University of North Carolina; University of North Carolina Chapel Hill; Memorial Sloan Kettering Cancer Center; Case Western Reserve University; SRA International; International Genomics Consortium; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Center for Cancer Genomics (CCG); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Kucherlapati, R (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	rkucherlapati@partners.org	Vaske, Charles/D-6018-2013; Wheeler, David A/M-9740-2018; Mardis, Elaine/W-2202-2019; Weisenberger, Daniel/AAA-8314-2020; Kaczkowski, Bogumil/D-5336-2017; Chiang, Derek/L-6452-2019; Cibulskis, Kristian/AAC-7380-2019; BERMAN, BENJAMIN/AAT-3720-2021; Drummond, Jennifer/AAG-1654-2020; Jones, Steven J/C-3621-2009; Wilson, Richard K./AAF-4139-2019; Perou, Charles M/H-9934-2014; Lawrence, Michael/AAC-8202-2020; Stojanov, Petar/GQI-4462-2022; Hirst, Martin/B-7684-2016; Solit, David B./AAC-5309-2019; Lee, Semin/S-2629-2016; Shen, Hui/AAO-4387-2020; Reva, Boris/AAB-8932-2022; Ganesh, Dunna Sai/AGX-5170-2022; Yang, Lixing/A-7073-2013; Yang, Da/I-9054-2012; Chan, Timothy A/ABD-5850-2021; Ladanyi, Marc/AAG-8585-2019; Walker, Jason/A-9702-2013; Mesirov, Jill/AGF-7626-2022; Laird, Peter W/G-8683-2012; Shinbrot, Eve/V-2784-2019; Akbani, Rehan/AAG-1490-2019; Holt, Robert A/C-3303-2009; Kucherlapati, Raju/ABC-8807-2021; Reva, Boris A./B-6436-2014; White, Peter/E-4301-2011; Marra, Marco A/B-5987-2008; Cherniack, Andrew/AAC-5310-2019; Birol, Inanc/G-5440-2011; Meyerson, Matthew L/E-7123-2012; Auman, James/AAY-7748-2020; Schultz, Nikolaus/ABE-6347-2020; Schumacher, Steven/E-9821-2013; Schein, Jacquie E/G-3674-2015; Cherniack, Andrew D./AAY-8132-2020; Berman, Benjamin P/D-5942-2014; Gao, JianJiong/B-5673-2016; Mungall, Andrew J./U-7067-2018; Skanderup, Anders Jacobsen/K-1081-2013; Van Den Berg, David J/G-8598-2017	Vaske, Charles/0000-0001-8151-6612; Wheeler, David A/0000-0002-9056-6299; Weisenberger, Daniel/0000-0001-8303-2603; Kaczkowski, Bogumil/0000-0001-6554-5608; BERMAN, BENJAMIN/0000-0002-2099-9005; Drummond, Jennifer/0000-0002-2612-5958; Jones, Steven J/0000-0003-3394-2208; Wilson, Richard K./0000-0002-1992-1358; Perou, Charles M/0000-0001-9827-2247; Stojanov, Petar/0000-0001-7815-776X; Lee, Semin/0000-0002-9015-6046; Walker, Jason/0000-0001-7547-5789; Laird, Peter W/0000-0001-9117-3641; Shinbrot, Eve/0000-0002-8879-3150; Holt, Robert A/0000-0002-7259-1247; Reva, Boris A./0000-0002-8805-389X; White, Peter/0000-0002-5218-5903; Marra, Marco A/0000-0001-7146-7175; Birol, Inanc/0000-0003-0950-7839; Schumacher, Steven/0000-0002-6819-5647; Cherniack, Andrew D./0000-0003-0470-0111; Berman, Benjamin P/0000-0002-2099-9005; Gao, JianJiong/0000-0002-5739-1781; Mungall, Andrew J./0000-0002-0905-2742; Skanderup, Anders Jacobsen/0000-0001-6847-4980; Van Den Berg, David J/0000-0002-5404-5218; Cozen, Aaron/0000-0003-2409-0023; Stuart, Joshua/0000-0002-2171-565X; Park, Peter/0000-0001-9378-960X; Schultz, Nikolaus/0000-0002-0131-4904; Chang, Kyle/0000-0001-5295-9676; Pot, David/0000-0002-1480-9826; Benz, Stephen/0000-0002-4067-0602; Weinstein, John/0000-0001-9401-6908; Stoll, Dominik/0000-0003-0701-4301; O'Connor, Brian/0000-0002-7681-6415; Casasent, Anna/0000-0002-7857-179X; Bowen, Jay/0000-0001-6861-9043; Hoadley, Katherine/0000-0002-1216-477X; Meyerson, Matthew/0000-0002-9133-8108; Chen, Peng-Chieh ( Jessica )/0000-0002-2060-1765; Sinha, Rileen/0000-0001-5497-5055; Mieczkowski, Piotr/0000-0003-2418-0096; Zerbino, Daniel/0000-0001-5350-3056	National Institutes of Health [U24CA143799, U24CA143835, U24CA143840, U24CA143843, U24CA143845, U24CA143848, U24CA143858, U24CA143866, U24CA143867, U24CA143882, U24CA143883, U24CA144025, U54HG003067, U54HG003079, U54HG003273]; NATIONAL CANCER INSTITUTE [U24CA143858, U24CA143866, U24CA143843, U24CA143799, U24CA143840, U24CA126554, U24CA143883, P30CA016672, U24CA143835, U24CA144025, U24CA143882, P30CA016086, U24CA143845, U24CA143867, U24CA143848] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003079, U54HG003273, U54HG003067, R01HG006272] Funding Source: NIH RePORTER; Emerging Frontiers [0850237] Funding Source: National Science Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Emerging Frontiers(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	This work was supported by the following grants from the National Institutes of Health: U24CA143799, U24CA143835, U24CA143840, U24CA143843, U24CA143845, U24CA143848, U24CA143858, U24CA143866, U24CA143867, U24CA143882, U24CA143883, U24CA144025, U54HG003067, U54HG003079 and U54HG003273.	AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bass AJ, 2011, NAT GENET, V43, P964, DOI 10.1038/ng.936; Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Camps J, 2009, GENE CHROMOSOME CANC, V48, P1002, DOI 10.1002/gcc.20699; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/NMETH.1363, 10.1038/nmeth.1363]; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Ciriello G, 2012, GENOME RES, V22, P398, DOI 10.1101/gr.125567.111; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dooley AL, 2011, GENE DEV, V25, P1470, DOI 10.1101/gad.2046711; Ewan K, 2010, CANCER RES, V70, P5963, DOI 10.1158/0008-5472.CAN-10-1028; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57; Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110; House CD, 2010, CANCER RES, V70, P6957, DOI 10.1158/0008-5472.CAN-10-1169; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jones S, 2012, HUM MUTAT, V33, P100, DOI 10.1002/humu.21633; Jubb AM, 2011, GUT, V60, P1606, DOI 10.1136/gut.2010.231746; Liu ZH, 2005, MOL CANCER RES, V3, P21; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Minsky BD, 2011, SEMIN ONCOL, V38, P542, DOI 10.1053/j.seminoncol.2011.05.008; Mori-Akiyama Y, 2007, GASTROENTEROLOGY, V133, P539, DOI 10.1053/j.gastro.2007.05.020; Nagl NG, 2006, CANCER RES, V66, P1289, DOI 10.1158/0008-5472.CAN-05-3427; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Sack U, 2011, MOL BIOL CELL, V22, P3344, DOI 10.1091/mbc.E10-09-0739; Scheel SK, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-413; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Stange DE, 2010, GUT, V59, P1236, DOI 10.1136/gut.2009.195701; Topol LL, 2009, J BIOL CHEM, V284, P3323, DOI 10.1074/jbc.M808048200; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; VARLEY JM, 1987, ONCOGENE, V1, P423; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xi RB, 2011, P NATL ACAD SCI USA, V108, pE1128, DOI 10.1073/pnas.1110574108; YOKOTA J, 1986, LANCET, V1, P765	44	4793	4886	29	935	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 19	2012	487	7407					330	337		10.1038/nature11252	http://dx.doi.org/10.1038/nature11252			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JB	22810696	Green Published, hybrid, Green Submitted, Green Accepted			2022-12-28	WOS:000306506500035
J	Fonarow, GC; Pan, WQ; Saver, JL; Smith, EE; Reeves, MJ; Broderick, JP; Kleindorfer, DO; Sacco, RL; Olson, DM; Hernandez, AF; Peterson, ED; Schwamm, LH				Fonarow, Gregg C.; Pan, Wenqin; Saver, Jeffrey L.; Smith, Eric E.; Reeves, Mathew J.; Broderick, Joseph P.; Kleindorfer, Dawn O.; Sacco, Ralph L.; Olson, DaiWai M.; Hernandez, Adrian F.; Peterson, Eric D.; Schwamm, Lee H.			Comparison of 30-Day Mortality Models for Profiling Hospital Performance in Acute Ischemic Stroke With vs Without Adjustment for Stroke Severity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-FAILURE; MEDICARE BENEFICIARIES; SCALE SCORE; PREDICTORS; OUTCOMES; QUALITY; RISK; RECLASSIFICATION; PROGRAM; CARE	Context There is increasing interest in reporting risk-standardized outcomes for Medicare beneficiaries hospitalized with acute ischemic stroke, but whether it is necessary to include adjustment for initial stroke severity has not been well studied. Objective To evaluate the degree to which hospital outcome ratings and potential eligibility for financial incentives are altered after including initial stroke severity in a claims-based risk model for hospital 30-day mortality for acute ischemic stroke. Design, Setting, and Patients Data were analyzed from 782 Get With The Guidelines-Stroke participating hospitals on 127 950 fee-for-service Medicare beneficiaries with ischemic stroke who had a score documented for the National Institutes of Health Stroke Scale (NIHSS, a 15-item neurological examination scale with scores from 0 to 42, with higher scores indicating more severe stroke) between April 2003 and December 2009. Performance of claims-based hospital mortality risk models with and without inclusion of NIHSS scores for 30-day mortality was evaluated and hospital rankings from both models were compared. Main Outcomes Measures Model discrimination, hospital 30-day mortality outcome rankings, and value-based purchasing financial incentive categories. Results Across the study population, the mean (SD) NIHSS score was 8.23 (8.11) (median, 5; interquartile range, 2-12). There were 18 186 deaths (14.5%) within the first 30 days, including 7430 deaths (5.8%) during the index hospitalization. The hospital mortality model with NIHSS scores had significantly better discrimination than the model without (C statistic, 0.864; 95% CI, 0.861-0.867, vs 0.772; 95% CI, 0.769-0.776; P < .001). Among hospitals ranked in the top 20% or bottom 20% of performers by the claims model without NIHSS scores, 26.3% were ranked differently by the model with NIHSS scores. Of hospitals initially classified as having "worse than expected" mortality, 57.7% were reclassified to "as expected" by the model with NIHSS scores. The net reclassification improvement (93.1%; 95% CI, 91.6%-94.6%; P < .001) and integrated discrimination improvement (15.0%; 95% CI, 14.6%-15.3%; P < .001) indexes both demonstrated significant enhancement of model performance after the addition of NIHSS. Explained variance and model calibration was also improved with the addition of NIHSS scores. Conclusion Adding stroke severity as measured by the NIHSS to a hospital 30-day risk model based on claims data for Medicare beneficiaries with acute ischemic stroke was associated with considerably improved model discrimination and change in mortality performance rankings for a substantial portion of hospitals.	[Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA; [Saver, Jeffrey L.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Pan, Wenqin; Olson, DaiWai M.; Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Res Ctr, Durham, NC USA; [Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary, AB, Canada; [Reeves, Mathew J.] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA; [Broderick, Joseph P.; Kleindorfer, Dawn O.] Univ Cincinnati, Dept Neurol, Acad Hlth Ctr, Cincinnati, OH USA; [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Duke University; University of Calgary; Michigan State University; University System of Ohio; University of Cincinnati; University of Miami; Harvard University; Massachusetts General Hospital	Fonarow, GC (corresponding author), Ronald Reagan UCLA Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, 10833 LeConte Ave,Room 47-123 CHS, Los Angeles, CA 90095 USA.	gfonarow@mednet.ucla.edu	Olson, DaiWai/I-5932-2019; Fonarow, Gregg C/D-5988-2014; Hernandez, Adrian F/A-7818-2016; Peterson, Eric David/ABF-5033-2021; Sacco, Ralph/Y-9278-2019; Smith, Eric E/C-5443-2012	Olson, DaiWai/0000-0002-9280-078X; Fonarow, Gregg C/0000-0002-3192-8093; Hernandez, Adrian F/0000-0003-3387-9616; Smith, Eric E/0000-0003-3956-1668; Saver, Jeffrey/0000-0001-9141-2251; Schwamm, Lee/0000-0003-0592-9145	National Institutes of Health; Michigan Stroke Registry; National Institute of Neurological Disorders and Stroke (NINDS); AHA Pharmaceutical Roundtable grant; Johnson Johnson; Amylin; Eli Lilly; Janssen Pharmaceuticals; Janssen Pharmaceutical Companies of Johnson Johnson; Boehringer-Ingelheim; Merck; Bristol-Myers Squib/Sanofi Pharmaceutical; AHA Pharmaceutical Roundtable	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michigan Stroke Registry; National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); AHA Pharmaceutical Roundtable grant; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Amylin; Eli Lilly(Eli Lilly); Janssen Pharmaceuticals(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Janssen Pharmaceutical Companies of Johnson Johnson; Boehringer-Ingelheim(Boehringer Ingelheim); Merck(Merck & Company); Bristol-Myers Squib/Sanofi Pharmaceutical; AHA Pharmaceutical Roundtable(American Heart Association)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Fonarow reported serving as a member of the Get With The Guidelines (GWTG) Steering Committee and receiving research support from the National Institutes of Health and is an employee of the University of California, which holds a patent on retriever devices for stroke. Dr Pan is a member of the Duke Clinical Research Institute (DCRI), which serves as the American Heart Association (AHA) GWTG data coordinating center. Dr Saver reported serving as a member of the GWTG Science Subcommittee and as a scientific consultant regarding trial design and conduct to Covidien, CoAxia, Talacris, Brainsgate, Sygnis, and Ev3 and is an employee of the University of California, which holds a patent on retriever devices for stroke. Dr Smith reported having served on an advisory board to Genentech and is on the data safety and monitoring board for the MR Witness trial. Dr Reeves reported receiving salary support from the Michigan Stroke Registry and serving as a member of the AHA GWTG Quality Improvement Subcommittee. Dr Broderick reported receiving funding from the National Institute of Neurological Disorders and Stroke (NINDS) for multiple ongoing trials; receiving study medications from Genentech for 2 ongoing NINDS studies and having received payment as a consultant to Genentech; and having been reimbursed for travel to meetings by Genentech. Dr Sacco is immediate past president of the AHA. Dr Olson is a member of the DCRI, which serves as the AHA GWTG data coordinating center, and reported serving as a consultant to Bristol Myers Squibb/Sanofi. Dr Hernandez is a member of the DCRI, which serves as the AHAGWTG data coordinating center, and reported being a recipient of an AHA Pharmaceutical Roundtable grant and having received research support from Johnson & Johnson and Amylin. Dr Peterson reported serving as principal investigator of the Data Analytic Center for AHA GWTG; reported receiving research grants from Johnson & Johnson, Eli Lilly, and Janssen Pharmaceuticals; and reported serving as a consultant to Boehringer Ingelheim, Johnson & Johnson, Medscape, Merck, Novartis, Ortho-McNeil-Janssen, Pfizer, Westat, the Cardiovascular Research Foundation, WebMD, and United Healthcare. Dr Schwamm reported serving as chair of the AHA GWTG Steering Committee and as a consultant to the Massachusetts Department of Public Health. No other disclosures were reported.; The GWTG-Stroke program is provided by the AHA/American Stroke Association. The GWTG-Stroke program is currently supported in part by a charitable contribution from Janssen Pharmaceutical Companies of Johnson & Johnson. GWTG-Stroke has been funded in the past through support from Boehringer-Ingelheim, Merck, Bristol-Myers Squib/Sanofi Pharmaceutical Partnership, and the AHA Pharmaceutical Roundtable. The industry sponsors of GWTG-Stroke had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.	Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126; American Hospital Association, 2009, AM HOSP ASS HOSP STA; [Anonymous], FED REG; Centers for Medicare and Medicaid Services (CMS) HHS, 2011, Fed Regist, V76, P51476; Cook NR, 2009, ANN INTERN MED, V150, P795, DOI 10.7326/0003-4819-150-11-200906020-00007; Fonarow GC, 2012, J AM HEART ASSOC, V1, P42, DOI 10.1161/JAHA.111.000034; Fonarow GC, 2011, STROKE, V42, P159, DOI 10.1161/STROKEAHA.110.601831; Fonarow GC, 2010, CIRCULATION, V121, P879, DOI 10.1161/CIRCULATIONAHA.109.892497; Hammill BG, 2011, CIRC-CARDIOVASC QUAL, V4, P60, DOI 10.1161/CIRCOUTCOMES.110.954693; Hammill BG, 2009, AM HEART J, V157, P995, DOI 10.1016/j.ahj.2009.04.002; Huang IC, 2005, MED DECIS MAKING, V25, P20, DOI 10.1177/0272989X04273138; Jha AK, 2005, NEW ENGL J MED, V353, P265, DOI 10.1056/NEJMsa051249; Kelly A, 2008, STROKE, V39, P3367, DOI 10.1161/STROKEAHA.108.518738; Krumholz HM, 2008, CIRCULATION, V118, P1394, DOI 10.1161/CIRCULATIONAHA.108.804880; Krumholz HM, 2007, HEALTH AFFAIR, V26, P75, DOI 10.1377/hlthaff.26.1.75; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Krumholz HM, 2006, CIRCULATION, V113, P456, DOI 10.1161/CIRCULATIONAHA.105.170769; Leifer D, 2011, STROKE, V42, P849, DOI 10.1161/STR.0b013e318208eb99; Lichtman JH, 2011, NEUROLOGY, V76, P1976, DOI 10.1212/WNL.0b013e31821e54f3; Lichtman JH, 2010, STROKE, V41, P2525, DOI 10.1161/STROKEAHA.110.599159; Lindenauer Peter K, 2010, J Hosp Med, V5, pE12, DOI 10.1002/jhm.822; Nedeltchev K, 2010, SWISS MED WKLY, V140, P254, DOI smw-12919; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Reeves MJ, 2012, STROKE, V43, P44, DOI 10.1161/STROKEAHA.111.626978; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Smith EE, 2010, CIRCULATION, V122, P1496, DOI 10.1161/CIRCULATIONAHA.109.932822; Weimar C, 2004, STROKE, V35, P158, DOI 10.1161/01.STR.0000106761.94985.8B	27	136	140	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2012	308	3					257	264		10.1001/jama.2012.7870	http://dx.doi.org/10.1001/jama.2012.7870			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975AC	22797643				2022-12-28	WOS:000306477900026
J	Angell, SY; Cobb, LK; Curtis, CJ; Konty, KJ; Silver, LD				Angell, Sonia Y.; Cobb, Laura K.; Curtis, Christine J.; Konty, Kevin J.; Silver, Lynn D.			Change in Trans Fatty Acid Content of Fast-Food Purchases Associated With New York City's Restaurant Regulation A Pre-Post Study	ANNALS OF INTERNAL MEDICINE			English	Article							REFORMULATIONS; DISEASE	Background: Dietary trans fat increases risk for coronary heart disease. In 2006, New York City (NYC) passed the first regulation in the United States restricting trans fat use in restaurants. Objective: To assess the effect of the NYC regulation on the trans and saturated fat content of fast-food purchases. Design: Cross-sectional study that included purchase receipts matched to available nutritional information and brief surveys of adult lunchtime restaurant customers conducted in 2007 and 2009, before and after implementation of the regulation. Setting: 168 randomly selected NYC restaurant locations of 11 fast-food chains. Participants: Adult restaurant customers interviewed in 2007 and 2009. Measurements: Change in mean grams of trans fat, saturated fat, trans plus saturated fat, and trans fat per 1000 kcal per purchase, overall and by chain type. Results: The final sample included 6969 purchases in 2007 and 7885 purchases in 2009. Overall, mean trans fat per purchase decreased by 2.4 g (95% CI, -2.8 to -2.0 g; P < 0.001), whereas saturated fat showed a slight increase of 0.55 g (CI, 0.1 to 1.0 g; P = 0.011). Mean trans plus saturated fat content decreased by 1.9 g overall (CI, -2.5 to -1.2 g; P < 0.001). Mean trans fat per 1000 kcal decreased by 2.7 g per 1000 kcal (CI, -3.1 to -2.3 g per 1000 kcal; P < 0.001). Purchases with zero grams of trans fat increased from 32% to 59%. In a multivariate analysis, the poverty rate of the neighborhood in which the restaurant was located was not associated with changes. Limitation: Fast-food restaurants that were included may not be representative of all NYC restaurants. Conclusion: The introduction of a local restaurant regulation was associated with a substantial and statistically significant decrease in the trans fat content of purchases at fast-food chains, without a commensurate increase in saturated fat. Restaurant patrons from high-and low-poverty neighborhoods benefited equally. However, federal regulation will be necessary to fully eliminate population exposure to industrial trans fat sources.	[Curtis, Christine J.] New York City Dept Hlth & Mental Hyg, Gotham Ctr, CN24,42-09 28th St,9th Floor, Long Isl City, NY 11101 USA	New York City Department of Health & Mental Hygiene	Curtis, CJ (corresponding author), New York City Dept Hlth & Mental Hyg, Gotham Ctr, CN24,42-09 28th St,9th Floor, Long Isl City, NY 11101 USA.	cjohnso8@health.nyc.gov		Silver, Lynn/0000-0002-2680-7393	City of New York; Robert Wood Johnson Foundation Healthy Eating Research program [65839]	City of New York; Robert Wood Johnson Foundation Healthy Eating Research program(Robert Wood Johnson Foundation (RWJF))	The initial study to evaluate calorie labeling was funded by the City of New York and the Robert Wood Johnson Foundation Healthy Eating Research program (grant 65839). The secondary analysis on trans fat reported here was funded solely by the City of New York.	Agricultural Research Service, 2010, AW HOM PERC SEL NUTR; American Heart Association, 2009, POL POS STAT REG LEG; Angell SY, 2009, ANN INTERN MED, V151, P129, DOI 10.7326/0003-4819-151-2-200907210-00010; [Anonymous], 2011, LOCAL           0317; [Anonymous], 2009, CBC NEWS; Ascherio A, 1999, NEW ENGL J MED, V340, P1994, DOI 10.1056/NEJM199906243402511; Bassett MT, 2008, AM J PUBLIC HEALTH, V98, P1457, DOI 10.2105/AJPH.2008.135020; Carlesso J, 2011, HARFORD COURANT 0315; Center for Science in the Public Interest, 2012, TRANSF BANS REST; Dorfman B, 2008, CANADA REUTERS  0523; Dumanovsky T, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4464; Karpati A., 2004, HLTH DISPARITIES NEW; Leth T, 2006, ATHEROSCLEROSIS SUPP, V7, P53, DOI 10.1016/j.atherosclerosissup.2006.04.019; Mozaffarian D, 2006, NEW ENGL J MED, V354, P1601, DOI 10.1056/NEJMra054035; Mozaffarian D, 2010, NEW ENGL J MED, V362, P2037, DOI 10.1056/NEJMc1001841; Ratnayake WMN, 2009, EUR J CLIN NUTR, V63, P808, DOI 10.1038/ejcn.2008.39; Severson K, 2005, NY TIMES; U.S. Food and Drug Administration, 2003, FDA CONSUMER MA 0224	18	67	67	1	31	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2					81	+		10.7326/0003-4819-157-2-201207170-00004	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801670				2022-12-28	WOS:000307787900013
J	Chatterjee, S				Chatterjee, Saurav			Review: DPP-4 inhibitors are less effective than metformin for reducing HbA(1c) in type 2 diabetes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Maimonides Hosp, Brooklyn, NY 11219 USA	Maimonides Medical Center	Chatterjee, S (corresponding author), Maimonides Hosp, Brooklyn, NY 11219 USA.							Frederich R, 2010, POSTGRAD MED, V122, P16, DOI 10.3810/pgm.2010.05.2138; Lasserson D, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e1213; National Institute for Health and Clinical Excellence, 2009, TYP 2 DIAB NEW AG BL	3	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2							JC2-13	10.7326/0003-4819-157-2-201207170-02013	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-02013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801704				2022-12-28	WOS:000307787900012
J	Pokala, S				Pokala, Suma			Gastric bypass or biliopancreatic diversion increases remission from type 2 diabetes in obese adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Texas A&M Hlth Sci Ctr, Cent Texas Vet Healthcare Syst, Temple, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Pokala, S (corresponding author), Texas A&M Hlth Sci Ctr, Cent Texas Vet Healthcare Syst, Temple, TX USA.							Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724	1	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2							JC2-12	10.7326/0003-4819-157-2-201207170-02012	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-02012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801703				2022-12-28	WOS:000307787900011
J	Rugg-Gunn, FJ; Sander, JW				Rugg-Gunn, Fergus J.; Sander, Josemir W.			Management of chronic epilepsy	BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED-TRIAL; ANTIEPILEPTIC DRUGS; REFRACTORY EPILEPSY; ACTIVE EPILEPSY; LONG-TERM; TOPIRAMATE; VALPROATE; SEIZURES; OXCARBAZEPINE; CARBAMAZEPINE		[Rugg-Gunn, Fergus J.; Sander, Josemir W.] UCL Inst Neurol, Dept Clin & Expt Epilepsy, London WC14 3BG, England; [Rugg-Gunn, Fergus J.; Sander, Josemir W.] Epilepsy Soc, Gerrards Cross, England; [Sander, Josemir W.] SEIN Epilepsy Inst Netherlands Fdn, Heemstede, Netherlands	University of London; University College London	Sander, JW (corresponding author), UCL Inst Neurol, Dept Clin & Expt Epilepsy, Box 29, London WC14 3BG, England.	l.sander@ucl.ac.uk	Sander, Josemir W/C-1576-2008	Sander, Josemir W/0000-0001-6041-9661; Duncan, John S/0000-0002-1373-0681				ALBRIGHT P, 1985, ARCH NEUROL-CHICAGO, V42, P797, DOI 10.1001/archneur.1985.04210090065017; ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; Chaves J, 2005, EPILEPSIA, V46, P133, DOI 10.1111/j.1528-1167.2005.00325.x; COCKERELL OC, 1994, LANCET, V344, P918, DOI 10.1016/S0140-6736(94)92270-5; DUNCAN JS, 1990, EPILEPSIA, V31, P324, DOI 10.1111/j.1528-1157.1990.tb05383.x; Gilliam F, 2002, NEUROLOGY, V58, pS9, DOI 10.1212/WNL.58.8_suppl_5.S9; Hosking PG, 2002, SEIZURE-EUR J EPILEP, V11, P494, DOI 10.1016/S1059-1311(02)00137-1; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Leone MA, 2006, NEUROLOGY, V67, P2227, DOI 10.1212/01.wnl.0000249309.80510.63; Lhatoo SD, 2001, ANN NEUROL, V49, P336; Luciano AL, 2007, ANN NEUROL, V62, P375, DOI 10.1002/ana.21064; MacDonald BK, 2000, ANN NEUROL, V48, P833, DOI 10.1002/1531-8249(200012)48:6<833::AID-ANA3>3.0.CO;2-U; Marson A, 2005, LANCET, V365, P2007, DOI 10.1016/S0140-6736(05)66694-9; Marson AG, 1997, EPILEPSIA, V38, P859, DOI 10.1111/j.1528-1157.1997.tb01251.x; Marson AG, 2001, EPILEPSY RES, V46, P259, DOI 10.1016/S0920-1211(01)00287-X; Marson AG, 2007, LANCET, V369, P1016, DOI 10.1016/S0140-6736(07)60461-9; Marson AG, 2007, LANCET, V369, P1000, DOI 10.1016/S0140-6736(07)60460-7; Meador KJ, 2009, NEW ENGL J MED, V360, P1597, DOI 10.1056/NEJMoa0803531; Meador KJ, 2003, NEUROLOGY, V60, P1483, DOI 10.1212/01.WNL.0000063308.22506.19; National Institute for Health and Clinical Excellence, 2012, CLIN GUID, V137; Ngugi AK, 2011, NEUROLOGY, V77, P1005, DOI 10.1212/WNL.0b013e31822cfc90; Smith D, 1999, QJM-INT J MED, V92, P15, DOI 10.1093/qjmed/92.1.15; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501	23	15	15	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 17	2012	345								e4576	10.1136/bmj.e4576	http://dx.doi.org/10.1136/bmj.e4576			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	978LQ	22807075				2022-12-28	WOS:000306742900001
J	Bowen, A; Hesketh, A; Patchick, E; Young, A; Davies, L; Vail, A; Long, AF; Watkins, C; Wilkinson, M; Pearl, G; Ralph, MAL; Tyrrell, P				Bowen, Audrey; Hesketh, Anne; Patchick, Emma; Young, Alys; Davies, Linda; Vail, Andy; Long, Andrew F.; Watkins, Caroline; Wilkinson, Mo; Pearl, Gill; Ralph, Matthew A. Lambon; Tyrrell, Pippa			Effectiveness of enhanced communication therapy in the first four months after stroke for aphasia and dysarthria: a randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LANGUAGE THERAPY; SPEECH; SERVICE; CARERS	Objective To assess the effectiveness of enhanced communication therapy in the first four months after stroke compared with an attention control (unstructured social contact). Design Externally randomised, pragmatic, parallel, superiority trial with blinded outcome assessment. Setting Twelve UK hospital and community stroke services. Participants 170 adults (mean age 70 years) randomised within two weeks of admission to hospital with stroke (December 2006 to January 2010) whom speech and language therapists deemed eligible, and 135 carers. Interventions Enhanced, agreed best practice, communication therapy specific to aphasia or dysarthria, offered by speech and language therapists according to participants' needs for up to four months, with continuity from hospital to community. Comparison was with similarly resourced social contact (without communication therapy) from employed visitors. Outcome measures Primary outcome was blinded, functional communicative ability at six months on the Therapy Outcome Measure (TOM) activity subscale. Secondary outcomes (unblinded, six months): participants' perceptions on the Communication Outcomes After Stroke scale (COAST); carers' perceptions of participants from part of the Carer COAST; carers' wellbeing on Carers of Older People in Europe Index and quality of life items from Carer COAST; and serious adverse events. Results Therapist and visitor contact both had good uptake from service users. An average 22 contacts (intervention or control) over 13 weeks were accepted by users. Impairment focused therapy was the approach most often used by the speech and language therapists. Visitors most often provided general conversation. In total, 81/85 of the intervention group and 72/85 of the control group completed the primary outcome measure. Both groups improved on the TOM activity subscale. The estimated six months group difference was not statistically significant, with 0.25 (95% CI-0.19 to 0.69) points in favour of therapy. Sensitivity analyses that adjusted for chance baseline imbalance further reduced this difference. Per protocol analyses rejected a possible dilution of treatment effect from controls declining their allocation and receiving usual care. There was no added benefit of therapy on secondary outcome measures, subgroup analyses (such as aphasia), or serious adverse events, although the latter were less common after intervention (odds ratio 0.42 (95% CI 0.16 to 1.1)). Conclusions Communication therapy had no added benefit beyond that from everyday communication in the first four months after stroke. Future research should evaluate reorganised services that support functional communication practice early in the stroke pathway. This project was funded by the NIHR Health Technology Assessment programme (project No 02/11/04) and is published in full in Health Technology Assessment 2012;16(26):1-160.	[Bowen, Audrey; Hesketh, Anne; Patchick, Emma; Wilkinson, Mo] Univ Manchester, MAHSC, HCD, Manchester M13 9PL, Lancs, England; [Davies, Linda] Univ Manchester, Hlth Sci Res Grp Hlth Econ, MAHSC, Manchester M13 9PL, Lancs, England; [Vail, Andy] Univ Manchester, R&D Support Unit, Salford Royal NHS Fdn Trust, MAHSC, Salford M6 8HD, Lancs, England; [Long, Andrew F.] Univ Leeds, Sch Healthcare, Leeds LS2 9UT, W Yorkshire, England; [Watkins, Caroline] Univ Cent Lancashire, Clin Practice Res Unit, Preston PR1 2HE, Lancs, England; [Pearl, Gill] Speakeasy, Bolton BL6 4JF, England; [Ralph, Matthew A. Lambon] Univ Manchester, NARU, MAHSC, Manchester M13 9PL, Lancs, England	University of Manchester; University of Manchester; Salford Royal NHS Foundation Trust; University of Manchester; University of Leeds; University of Central Lancashire; University of Manchester	Bowen, A (corresponding author), Univ Manchester, MAHSC, HCD, Ellen Wilkinson Bldg, Manchester M13 9PL, Lancs, England.	audrey.bowen@manchester.ac.uk	Ralph, Matthew A Lambon/A-1695-2009; Bowen, Audrey/K-5544-2012; Watkins, Caroline L/E-6898-2013; Young, Alys/R-5348-2019	Ralph, Matthew A Lambon/0000-0001-5907-2488; Watkins, Caroline L/0000-0002-9403-3772; Young, Alys/0000-0001-8551-5078; Davies, Linda/0000-0001-8801-3559; /0000-0002-4198-5761; Bowen, Audrey/0000-0003-4075-1215; Hesketh, Anne/0000-0003-0583-0217; Vail, Andy/0000-0001-8274-2726; Tyrrell, Pippa/0000-0001-9609-1231	NIHR Health Technology Assessment programme [02/11/04]; NIHR Health Technology Assessment programme; UK's NIHR Health Technology Assessment Programme [02/1104]; Department of Health central subvention and the Stroke Association; National Institute for Health Research [02/11/04] Funding Source: researchfish	NIHR Health Technology Assessment programme(National Institute for Health Research (NIHR)); NIHR Health Technology Assessment programme(National Institute for Health Research (NIHR)); UK's NIHR Health Technology Assessment Programme; Department of Health central subvention and the Stroke Association; National Institute for Health Research(National Institute for Health Research (NIHR))	This project was funded by the NIHR Health Technology Assessment programme (project No 02/11/04) and is published in full in Health Technology Assessment 2012;16(26):1-160.; This project was funded by the NIHR Health Technology Assessment programme and is published in full in Health Technology Assessment 2012: 16(26) ISSN 1366-5278; ACT NoW was commissioned and funded by the UK's NIHR Health Technology Assessment Programme (ref 02/1104), with partial funding for participating NHS trusts' excess treatment costs provided by a Department of Health central subvention and the Stroke Association. An independent Trial Steering Committee and a Data Monitoring and Ethics Committee were appointed by the NIHR. The researchers were independent of the study funders, although several have served on their advisory or funding committees (AB, PT, CW, AH, LD, AV).	[Anonymous], 2010, NAT SENT STROK AUD O; Bakheit AMO, 2007, CLIN REHABIL, V21, P885, DOI 10.1177/0269215507078486; Bowen A, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16260; Brady MC, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000425.pub4, 10.1002/14651858.CD000425.pub3]; Brumfitt S, 1998, Int J Lang Commun Disord, V33 Suppl, P116; Collin C, 1988, Int Disabil Stud, V10, P61; DAVID R, 1982, J NEUROL NEUROSUR PS, V45, P957, DOI 10.1136/jnnp.45.11.957; ENDERBY P, 1989, BRIT J DISORD COMMUN, V24, P301; Enderby P., 2009, THERAPY OUTCOME MEAS; Enderby P M, 1987, Int Rehabil Med, V8, P166; French B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006073.pub2; Gillham S, 2011, PSYCHOL CARE STROKE; Godecke E, 2012, INT J STROKE, V7, P635, DOI 10.1111/j.1747-4949.2011.00631.x; Hesketh A, 2008, APHASIOLOGY, V22, P970, DOI 10.1080/02687030801952709; Hilari K, 2010, CLIN REHABIL, V24, P181, DOI 10.1177/0269215509346090; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Laska AC, 2011, CEREBROVASC DIS EXTR, V1, P66, DOI 10.1159/000329835; Lewin Simon, 2009, BMJ, V339, pb3496, DOI 10.1136/bmj.b3496; Long AF, 2008, CLIN REHABIL, V22, P1083, DOI 10.1177/0269215508090091; Long A, 2009, CLIN REHABIL, V23, P846, DOI 10.1177/0269215509336055; Matrix Evidence, 2010, EC EV SPEECH LANG TH; McKee KJ, 2003, AGING MENT HEALTH, V7, P39, DOI 10.1080/1360786021000006956; National Audit Office, 2010, PROGR IMPR STROK CAR; National Clinical Guideline Centre, 2011, STROK REH C IN PRESS; Pettitt DA, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c5972; Royal College of Physicians, 2011, NAT SENT STROK CLIN; Royal College of Physicians (Intercollegiate Stroke Working Party), 2008, NAT CLIN GUID STROK; Royal College of Speech and Language Therapists, 2009, RCSLT RES MAN COMM P; Scottish Intercollegiate Guideline Network, 2010, MAN PAT STROK 591 RE; Sellars C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002088.pub2; Thomas SA, 2006, BRIT J CLIN PSYCHOL, V45, P49, DOI 10.1348/014466505X34183; University of Manchester School of Psychological Sciences, ASS COMM THER N W AC; Young A, CLIN REHABI IN PRESS	33	53	55	1	85	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	2012	345								e4407	10.1136/bmj.e4407	http://dx.doi.org/10.1136/bmj.e4407			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975NX	22797843	Green Submitted, Green Published, hybrid, Green Accepted			2022-12-28	WOS:000306519100001
J	Nguyen, TD; Ehrenfreund, E; Vardeny, ZV				Nguyen, Tho D.; Ehrenfreund, Eitan; Vardeny, Z. Valy			Spin-Polarized Light-Emitting Diode Based on an Organic Bipolar Spin Valve	SCIENCE			English	Article							CHARGE-LIMITED CURRENT; INTERFACE; SEMICONDUCTORS; INJECTION; POLYMER; DEVICES; FILMS	The spin-polarized organic light-emitting diode (spin-OLED) has been a long-sought device within the field of organic spintronics. We designed, fabricated, and studied a spin-OLED with ferromagnetic electrodes that acts as a bipolar organic spin valve (OSV), based on a deuterated derivative of poly(phenylene-vinylene) with small hyperfine interaction. In the double-injection limit, the device shows similar to 1% spin valve magneto-electroluminescence (MEL) response, which follows the ferromagnetic electrode coercive fields and originates from the bipolar spin-polarized space charge-limited current. In stark contrast to the response properties of homopolar OSV devices, the MEL response in the double-injection device is practically independent of bias voltage, and its temperature dependence follows that of the ferromagnetic electrode magnetization. Our findings provide a pathway for organic displays controlled by external magnetic fields.	[Nguyen, Tho D.; Ehrenfreund, Eitan; Vardeny, Z. Valy] Univ Utah, Dept Phys & Astron, Salt Lake City, UT 84112 USA; [Ehrenfreund, Eitan] Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel; [Ehrenfreund, Eitan] Technion Israel Inst Technol, Inst Solid State, IL-32000 Haifa, Israel	Utah System of Higher Education; University of Utah; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Vardeny, ZV (corresponding author), Univ Utah, Dept Phys & Astron, Salt Lake City, UT 84112 USA.	val@physics.utah.edu	Ehrenfreund, Eitan/AAN-3555-2021		NSF [DMR-1104495]; MRSEC program at the UoU [DMR-1121252]; Israel Science Foundation [ISF 472/11]; Israel-USA BSF [2010135]; U.S. Department of Energy [DE-FG02-04ER46109]	NSF(National Science Foundation (NSF)); MRSEC program at the UoU; Israel Science Foundation(Israel Science Foundation); Israel-USA BSF; U.S. Department of Energy(United States Department of Energy (DOE))	Supported by NSF grant DMR-1104495 and MRSEC, DMR-1121252 program at the UoU (T.D.N. and Z.V.V.), Israel Science Foundation grant ISF 472/11 (E. E.), and Israel-USA BSF grant 2010135 (Z.V.V. and E. E.). The D-DOO-PPV polymer synthesis was supported by U.S. Department of Energy grant DE-FG02-04ER46109. We thank X.-G. Li (USTC) for providing the LSMO substrates. The authors declare no conflict of interest associated with this work. A patent disclosure related to the spin-OLED invention was recently filed with the University of Utah, disclosure no. 5249, which has been filed as a provisional patent application.	Barraud C, 2010, NAT PHYS, V6, P615, DOI 10.1038/NPHYS1688; Bergenti I, 2004, ORG ELECTRON, V5, P309, DOI 10.1016/j.orgel.2004.10.004; Davis AH, 2003, J APPL PHYS, V93, P7358, DOI 10.1063/1.1540174; Dediu V, 2002, SOLID STATE COMMUN, V122, P181, DOI 10.1016/S0038-1098(02)00090-X; Dediu V, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.115203; Dediu VA, 2009, NAT MATER, V8, P707, DOI [10.1038/NMAT2510, 10.1038/nmat2510]; Ishii H, 1997, IEEE T ELECTRON DEV, V44, P1295, DOI 10.1109/16.605471; JULLIERE M, 1975, PHYS LETT A, V54, P225, DOI 10.1016/0375-9601(75)90174-7; Kalinowski J, 2003, CHEM PHYS LETT, V380, P710, DOI 10.1016/j.cplett.2003.09.086; Majumdar S, 2006, J ALLOY COMPD, V423, P169, DOI 10.1016/j.jallcom.2005.12.104; Mermer O, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.205202; MURGATROYD PN, 1970, J PHYS D APPL PHYS, V3, P151, DOI 10.1088/0022-3727/3/2/308; Nguyen TD, 2010, NAT MATER, V9, P345, DOI [10.1038/nmat2633, 10.1038/NMAT2633]; Park JH, 1998, PHYS REV LETT, V81, P1953, DOI 10.1103/PhysRevLett.81.1953; PARMENTER RH, 1959, J APPL PHYS, V30, P1548, DOI 10.1063/1.1734999; Salis G, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.085203; Schulz L, 2011, NAT MATER, V10, P39, DOI 10.1038/NMAT2912; Sun DL, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.236602; Vinzelberg H, 2008, J APPL PHYS, V103, DOI 10.1063/1.2924435; Wang FJ, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.245324; Wohlgenannt M, 2001, NATURE, V409, P494, DOI 10.1038/35054025; Xiong ZH, 2004, NATURE, V427, P821, DOI 10.1038/nature02325; Yoo JW, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.205207; Yunus M, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2988273; Zhan YQ, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3078274	25	199	201	9	371	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2012	337	6091					204	209		10.1126/science.1223444	http://dx.doi.org/10.1126/science.1223444			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798608				2022-12-28	WOS:000306323500051
J	Junquera, L; Gallego, L				Junquera, Luis; Gallego, Lorena			Denervation Atrophy of the Tongue after Hypoglossal-Nerve Injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Junquera, Luis; Gallego, Lorena] Univ Cent Hosp, Oviedo, Asturias, Spain	University of Barcelona	Junquera, L (corresponding author), Univ Cent Hosp, Oviedo, Asturias, Spain.	junquera@uniovi.es							0	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2					156	156		10.1056/NEJMicm1114751	http://dx.doi.org/10.1056/NEJMicm1114751			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972IO	22784118				2022-12-28	WOS:000306270800012
J	Klass, P				Klass, Perri			Zen and the Art of Pediatric Health Maintenance	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NYU, New York, NY 10003 USA	New York University	Klass, P (corresponding author), NYU, New York, NY 10003 USA.								0	0	0	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2					103	105		10.1056/NEJMp1204035	http://dx.doi.org/10.1056/NEJMp1204035			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972IO	22784114				2022-12-28	WOS:000306270800006
J	Schiermeier, Q				Schiermeier, Quirin			I was sued for libel under an unjust law	NATURE			English	Editorial Material												q.schiermeier@nature.com						2008, NATURE, V456, P432	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2012	487	7406					141	141		10.1038/487141a	http://dx.doi.org/10.1038/487141a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	972LP	22785275	Bronze			2022-12-28	WOS:000306278900004
J	Waitukaitis, SR; Jaeger, HM				Waitukaitis, Scott R.; Jaeger, Heinrich M.			Impact-activated solidification of dense suspensions via dynamic jamming fronts	NATURE			English	Article							SUPERCOOLED LIQUIDS; COLLOIDAL DISPERSIONS; SHEAR; DILATANCY; SPHERES	Although liquids typically flow around intruding objects, a counterintuitive phenomenon occurs in dense suspensions of micrometre-sized particles: they become liquid-like when perturbed lightly, but harden when driven strongly(1-5). Rheological experiments have investigated how such thickening arises under shear, and linked it to hydrodynamic interactions(1,3) or granular dilation(2,4). However, neither of these mechanisms alone can explain the ability of suspensions to generate very large, positive normal stresses under impact. To illustrate the phenomenon, such stresses can be large enough to allow a person to run across a suspension without sinking, and far exceed the upper limit observed under shear or extension(2,4,6,7). Here we show that these stresses originate from an impact-generated solidification front that transforms an initially compressible particle matrix into a rapidly growing jammed region, ultimately leading to extraordinary amounts of momentum absorption. Using high-speed videography, embedded force sensing and X-ray imaging, we capture the detailed dynamics of this process as it decelerates a metal rod hitting a suspension of cornflour (cornstarch) in water. We develop a model for the dynamic solidification and its effect on the surrounding suspension that reproduces the observed behaviour quantitatively. Our findings suggest that prior interpretations of the impact resistance as dominated by shear thickening need to be revisited.	[Waitukaitis, Scott R.; Jaeger, Heinrich M.] Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; [Waitukaitis, Scott R.; Jaeger, Heinrich M.] Univ Chicago, Dept Phys, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Waitukaitis, SR (corresponding author), Univ Chicago, James Franck Inst, 5640 S Ellis Ave, Chicago, IL 60637 USA.	swaitukaitis@uchicago.edu		Waitukaitis, Scott/0000-0002-2299-3176	NSF through MRSEC programme [DMR-0820054]; US Army Research Office [W911NF-12-1-0182]; Millikan fellowship	NSF through MRSEC programme; US Army Research Office; Millikan fellowship	We thank E. Brown, J. Burton, J. Ellowitz, Q. Guo, W. Irvine, M. Miskin, S. Nagel, C. Orellana, V. Vitelli, T. Witten and W. Zhang for discussions and J. Burton for his PIV code. This work was supported by NSF through its MRSEC programme (DMR-0820054) and by the US Army Research Office through grant number W911NF-12-1-0182. S. R. W. acknowledges support from a Millikan fellowship.	Bi DP, 2011, NATURE, V480, P355, DOI 10.1038/nature10667; BRADY JF, 1988, ANNU REV FLUID MECH, V20, P111, DOI 10.1146/annurev.fl.20.010188.000551; Brennen C., 1982, REV ADDED MASS FLUID; Brown E, 2012, J RHEOL, V56, P875, DOI 10.1122/1.4709423; Brown E, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.031408; Brown E, 2010, NAT MATER, V9, P220, DOI [10.1038/NMAT2627, 10.1038/nmat2627]; Brown E, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.086001; Cates ME, 2005, J PHYS-CONDENS MAT, V17, pS2517, DOI 10.1088/0953-8984/17/24/010; Cheng X, 2011, SCIENCE, V333, P1276, DOI 10.1126/science.1207032; DAVIS RH, 1986, J FLUID MECH, V163, P479, DOI 10.1017/S0022112086002392; Debenedetti PG, 2001, NATURE, V410, P259, DOI 10.1038/35065704; Ediger MD, 1996, J PHYS CHEM-US, V100, P13200, DOI 10.1021/jp953538d; Fall A, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.018301; Fedorchenko AI, 2004, PHYS FLUIDS, V16, P1349, DOI 10.1063/1.1652061; Glasheen JW, 1996, PHYS FLUIDS, V8, P2078, DOI 10.1063/1.869010; Gomez LR, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.058001; GRAHAM DJ, 1995, J PHYS CHEM-US, V99, P4757, DOI 10.1021/j100013a053; HOCKING LM, 1973, J ENG MATH, V7, P207, DOI 10.1007/BF01535282; Liu AJ, 1998, NATURE, V396, P21, DOI 10.1038/23819; Liu B., 2010, PHYS REV LETT, V105; Maranzano BJ, 2001, J CHEM PHYS, V114, P10514, DOI 10.1063/1.1373687; Merkt FS, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.184501; MOGHISI M, 1981, J FLUID MECH, V108, P133, DOI 10.1017/S0022112081002036; Papoular M, 1999, PHYS REV E, V60, P2408, DOI 10.1103/PhysRevE.60.2408; RICHARDSON EG, 1948, P PHYS SOC LOND, V61, P352, DOI 10.1088/0959-5309/61/4/308; Royer JR, 2005, NAT PHYS, V1, P164, DOI 10.1038/nphys175; Smith MI, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1119; von Kann S, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.060401; Wagner NJ, 2009, PHYS TODAY, V62, P27, DOI 10.1063/1.3248476; White EEB, 2010, RHEOL ACTA, V49, P119, DOI 10.1007/s00397-009-0415-3	30	182	192	11	174	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2012	487	7406					205	209		10.1038/nature11187	http://dx.doi.org/10.1038/nature11187			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972LP	22785316				2022-12-28	WOS:000306278900033
J	Morris, RK; Riley, RD; Doug, M; Deeks, JJ; Kilby, MD				Morris, R. K.; Riley, R. D.; Doug, M.; Deeks, J. J.; Kilby, M. D.			Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROTEIN/CREATININE RATIO; HYPERTENSIVE PREGNANCY; WOMEN; QUANTITATION; URINALYSIS; DISORDERS; PREDICTOR; SAMPLES; TESTS	Objective To determine the diagnostic accuracy of two "spot urine" tests for significant proteinuria or adverse pregnancy outcome in pregnant women with suspected pre-eclampsia. Design Systematic review and meta-analysis. Data sources Searches of electronic databases 1980 to January 2011, reference list checking, hand searching of journals, and contact with experts. Inclusion criteria Diagnostic studies, in pregnant women with hypertension, that compared the urinary spot protein to creatinine ratio or albumin to creatinine ratio with urinary protein excretion over 24 hours or adverse pregnancy outcome. Study characteristics, design, and methodological and reporting quality were objectively assessed. Data extraction Study results relating to diagnostic accuracy were extracted and synthesised using multivariate random effects meta-analysis methods. Results Twenty studies, testing 2978 women (pregnancies), were included. Thirteen studies examining protein to creatinine ratio for the detection of significant proteinuria were included in the multivariate analysis. Threshold values for protein to creatinine ratio ranged between 0.13 and 0.5, with estimates of sensitivity ranging from 0.65 to 0.89 and estimates of specificity from 0.63 to 0.87; the area under the summary receiver operating characteristics curve was 0.69. On average, across all studies, the optimum threshold (that optimises sensitivity and specificity combined) seems to be between 0.30 and 0.35 inclusive. However, no threshold gave a summary estimate above 80% for both sensitivity and specificity, and considerable heterogeneity existed in diagnostic accuracy across studies at most thresholds. No studies looked at protein to creatinine ratio and adverse pregnancy outcome. For albumin to creatinine ratio, meta-analysis was not possible. Results from a single study suggested that the most predictive result, for significant proteinuria, was with the DCA 2000 quantitative analyser (> 2 mg/mmol) with a summary sensitivity of 0.94 (95% confidence interval 0.86 to 0.98) and a specificity of 0.94 (0.87 to 0.98). In a single study of adverse pregnancy outcome, results for perinatal death were a sensitivity of 0.82 (0.48 to 0.98) and a specificity of 0.59 (0.51 to 0.67). Conclusion The maternal "spot urine" estimate of protein to creatinine ratio shows promising diagnostic value for significant proteinuria in suspected pre-eclampsia. The existing evidence is not, however, sufficient to determine how protein to creatinine ratio should be used in clinical practice, owing to the heterogeneity in test accuracy and prevalence across studies. Insufficient evidence is available on the use of albumin to creatinine ratio in this area. Insufficient evidence exists for either test to predict adverse pregnancy outcome.	[Morris, R. K.; Kilby, M. D.] Univ Birmingham, Res Sect Reprod Genes & Dev, Sch Clin & Expt Med, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England; [Morris, R. K.; Kilby, M. D.] Birmingham Womens Hosp NHS Fdn Trust, Fetal Med Ctr, Birmingham, England; [Riley, R. D.; Deeks, J. J.] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England; [Doug, M.] Birmingham Womens Hosp NHS Fdn Trust, R&D Dept, Birmingham, England	University of Birmingham; Birmingham Women's Hospital; University of Birmingham; Birmingham Women's Hospital	Kilby, MD (corresponding author), Univ Birmingham, Res Sect Reprod Genes & Dev, Sch Clin & Expt Med, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.	m.d.kilby@bham.ac.uk	Riley, Richard David/ABE-5877-2020; Riley, Richard/G-2406-2011; Deeks, Jon/AAV-5745-2020; FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020	Riley, Richard David/0000-0001-8699-0735; Deeks, Jon/0000-0002-8850-1971; FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Morris, Katie/0000-0003-1247-429X	National Institute for Health; Medical Research Council Hub for Trials Methodology Research at the University of Birmingham (MRC) [G0800808]; Medical Research Council [G0800808, G0700526] Funding Source: researchfish; National Institute for Health Research [CL-2010-09-003] Funding Source: researchfish; MRC [G0700526, G0800808] Funding Source: UKRI	National Institute for Health; Medical Research Council Hub for Trials Methodology Research at the University of Birmingham (MRC); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	RKM is funded by a National Institute for Health Research clinical lectureship. RR and JD are supported by funding from the Medical Research Council Hub for Trials Methodology Research at the University of Birmingham (MRC grant ID G0800808).	Aggarwal N, 2008, Medscape J Med, V10, P98; Al RA, 2009, CLIN EXP OBSTET GYN, V36, P169; Al RA, 2004, OBSTET GYNECOL, V104, P367, DOI 10.1097/01.AOG.0000134788.01016.2a; Bachmann LM, 2006, BRIT MED J, V332, P1127, DOI 10.1136/bmj.38793.637789.2F; Bossuyt PM, 2006, BRIT MED J, V332, P1089, DOI 10.1136/bmj.332.7549.1089; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Brown MA, 2001, HYPERTENS PREGNANCY, V20, pIX, DOI 10.1081/PRG-100104165; Confidential Enquiry into Maternal and Child Health (CEMACH), 2005, 7 CEMACH; Cote AM, 2008, BRIT MED J, V336, P1003, DOI 10.1136/bmj.39532.543947.BE; Cote AM, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.009; Deeks JJ, 2001, BRIT MED J, V323, P157, DOI 10.1136/bmj.323.7305.157; Deeks JJ, 1996, BAILLIERE CLIN OB GY, V10, P613, DOI 10.1016/S0950-3552(96)80008-3; Durnwald C, 2003, AM J OBSTET GYNECOL, V189, P848, DOI 10.1067/S0002-9378(03)00849-4; Dwyer BK, 2008, J PERINATOL, V28, P461, DOI 10.1038/jp.2008.4; Freidman EA, 1976, HYPERTENS PREGNANCY, P13; Gangaram R, 2009, INT J GYNECOL OBSTET, V107, P19, DOI 10.1016/j.ijgo.2009.05.023; Gangaram R, 2009, EUR J OBSTET GYN R B, V144, P146, DOI 10.1016/j.ejogrb.2009.03.010; GINSBERG JM, 1983, NEW ENGL J MED, V309, P1543, DOI 10.1056/NEJM198312223092503; GUIDOTTI R, 1988, AM J OBSTET GYNECOL, V158, P80; Hamza TH, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-73; Hennessy A, 2011, NEPHROLOGY, V16, P134, DOI 10.1111/j.1440-1797.2010.01411.x; Honest H, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-4; Irwig L, 2002, BRIT MED J, V324, P669, DOI 10.1136/bmj.324.7338.669; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9; Khan KS, 2001, EUR J OBSTET GYN R B, V95, P6, DOI 10.1016/S0301-2115(00)00463-2; KUO VS, 1992, AM J OBSTET GYNECOL, V167, P723, DOI 10.1016/S0002-9378(11)91578-6; Leanos-Miranda A, 2007, CLIN CHEM, V53, P1623, DOI 10.1373/clinchem.2007.089334; MEYER NL, 1994, AM J OBSTET GYNECOL, V170, P137; MONTAN S, 1987, CLIN EXP HYPERTENS B, V6, P337, DOI 10.3109/10641958709023484; National Institute for Health and Clinical Excellence, 2008, NICE CLIN GUID, V66, P87; Nisell H, 2006, ACTA OBSTET GYN SCAN, V85, P1327, DOI 10.1080/00016340600808747; Papanna R, 2008, OBSTET GYNECOL, V112, P135, DOI 10.1097/AOG.0b013e3181778cfc; Ramos JGL, 1999, HYPERTENS PREGNANCY, V18, P209, DOI 10.3109/10641959909016194; Reitsma JB, 2005, J CLIN EPIDEMIOL, V58, P982, DOI 10.1016/j.jclinepi.2005.02.022; Riley RD, 2007, STAT MED, V26, P78, DOI 10.1002/sim.2524; Riley RD, 2009, J R STAT SOC A STAT, V172, P789, DOI 10.1111/j.1467-985X.2008.00593.x; Robert M, 1997, OBSTET GYNECOL, V90, P893, DOI 10.1016/S0029-7844(97)00536-X; Rochiguez-Thompson D, 2001, AM J OBSTET GYNECOL, V185, P808; Rodby RA, 1995, AM J KIDNEY DIS, V26, P904, DOI 10.1016/0272-6386(95)90054-3; Sankey SS, 1996, COMMUN STAT SIMULAT, V25, P1031, DOI 10.1080/03610919608813357; Saudan PJ, 1997, BRIT J OBSTET GYNAEC, V104, P1159, DOI 10.1111/j.1471-0528.1997.tb10940.x; Schubert FP, 2006, J REPROD MED, V51, P709; Shahbazian Nahid, 2008, Iran J Kidney Dis, V2, P127; Skweres Tomasz, 2006, Ginekol Pol, V77, P415; STEINHAUSLIN F, 1995, CLIN NEPHROL, V43, P110; Taherian A.A., 2006, J RES MED SCI, V11, P6; Thangaratinam S, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-10; The Cochrane Collaboration Diagnostic Test Accuracy Working Group, 2011, HDB DTA REV; Waugh J, 2005, HYPERTENS PREGNANCY, V24, P291, DOI 10.1080/10641950500281019; Waugh JJS, 2005, BJOG-INT J OBSTET GY, V112, P412, DOI 10.1111/j.1471-0528.2004.00455.x; Wheeler TL, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.10.892; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Whiting Penny F, 2006, BMC Med Res Methodol, V6, P9, DOI 10.1186/1471-2288-6-9; Yamasmit Waralak, 2004, J Matern Fetal Neonatal Med, V16, P275	56	93	99	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 9	2012	345								e4342	10.1136/bmj.e4342	http://dx.doi.org/10.1136/bmj.e4342			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975NR	22777026	Green Published, hybrid			2022-12-28	WOS:000306518500002
J	Baleta, A				Baleta, Adele			Profile: South African medical school celebrates a centenary	LANCET			English	Editorial Material																			0	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 30	2012	379	9835					2416	2416		10.1016/S0140-6736(12)61051-4	http://dx.doi.org/10.1016/S0140-6736(12)61051-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	967NV	22764374				2022-12-28	WOS:000305915900012
J	Mariner, WK; Glantz, LH; Annas, GJ				Mariner, Wendy K.; Glantz, Leonard H.; Annas, George J.			Reframing Federalism - The Affordable Care Act (and Broccoli) in the Supreme Court	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Mariner, Wendy K.; Glantz, Leonard H.; Annas, George J.] Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Mariner, WK (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Glantz, Leonard/0000-0003-4591-2305; Annas, George/0000-0001-5836-7831; Mariner, Wendy/0000-0001-5176-5917				[Anonymous], 2010, VITAL HLTH STAT, V249, P1; Centers for Medicare and Medicaid Services, 1960, NAT HLTH EXP DAT TYP; Chemerinsky E., 2011, CONSTITUTIONAL LAW P; Hensley S, 2012, MEDICAID EXPANSION W; Katz Olson, 2010, POLITICS MEDICAID; Mariner WK, 2011, NEW ENGL J MED, V364, P201, DOI 10.1056/NEJMp1014367; Romney M., 2006, WALL STREET J   0411, pA16; TRIBE LAURENCE H., 2000, AM CONSTITUTIONAL LA, P3	8	10	10	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 20	2012	367	12					1154	1158		10.1056/NEJMhle1208437	http://dx.doi.org/10.1056/NEJMhle1208437			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	007AS	22809363	Green Published			2022-12-28	WOS:000308861800015
J	Claesson, MJ; Jeffery, IB; Conde, S; Power, SE; O'Connor, EM; Cusack, S; Harris, HMB; Coakley, M; Lakshminarayanan, B; O'Sullivan, O; Fitzgerald, GF; Deane, J; O'Connor, M; Harnedy, N; O'Connor, K; O'Mahony, D; van Sinderen, D; Wallace, M; Brennan, L; Stanton, C; Marchesi, JR; Fitzgerald, AP; Shanahan, F; Hill, C; Ross, RP; O'Toole, PW				Claesson, Marcus J.; Jeffery, Ian B.; Conde, Susana; Power, Susan E.; O'Connor, Eibhlis M.; Cusack, Siobhan; Harris, Hugh M. B.; Coakley, Mairead; Lakshminarayanan, Bhuvaneswari; O'Sullivan, Orla; Fitzgerald, Gerald F.; Deane, Jennifer; O'Connor, Michael; Harnedy, Norma; O'Connor, Kieran; O'Mahony, Denis; van Sinderen, Douwe; Wallace, Martina; Brennan, Lorraine; Stanton, Catherine; Marchesi, Julian R.; Fitzgerald, Anthony P.; Shanahan, Fergus; Hill, Colin; Ross, R. Paul; O'Toole, Paul W.			Gut microbiota composition correlates with diet and health in the elderly	NATURE			English	Article							PHYLOGENETIC MICROARRAY; FECAL MICROBIOTA; SEQUENCES; UNIFRAC; INDEX; AGE	Alterations in intestinal microbiota composition are associated with several chronic conditions, including obesity and inflammatory diseases. The microbiota of older people displays greater inter-individual variation than that of younger adults. Here we show that the faecal microbiota composition from 178 elderly subjects formed groups, correlating with residence location in the community, day-hospital, rehabilitation or in long-term residential care. However, clustering of subjects by diet separated them by the same residence location and microbiota groupings. The separation of microbiota composition significantly correlated with measures of frailty, co-morbidity, nutritional status, markers of inflammation and with metabolites in faecal water. The individual microbiota of people in long-stay care was significantly less diverse than that of community dwellers. Loss of community-associated microbiota correlated with increased frailty. Collectively, the data support a relationship between diet, microbiota and health status, and indicate a role for diet-driven microbiota alterations in varying rates of health decline upon ageing.	[Claesson, Marcus J.; Jeffery, Ian B.; Power, Susan E.; O'Connor, Eibhlis M.; Cusack, Siobhan; Harris, Hugh M. B.; Fitzgerald, Gerald F.; Deane, Jennifer; van Sinderen, Douwe; Hill, Colin; O'Toole, Paul W.] Univ Coll Cork, Dept Microbiol, Cork, Ireland; [Claesson, Marcus J.; Jeffery, Ian B.; O'Connor, Eibhlis M.; Fitzgerald, Gerald F.; van Sinderen, Douwe; Stanton, Catherine; Shanahan, Fergus; Hill, Colin; Ross, R. Paul; O'Toole, Paul W.] Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland; [Conde, Susana; Fitzgerald, Anthony P.] Univ Coll Cork, Dept Stat, Cork, Ireland; [Coakley, Mairead; Lakshminarayanan, Bhuvaneswari; O'Sullivan, Orla; Stanton, Catherine; Ross, R. Paul] TEAGASC, Moorepk Food Res Ctr, Fermoy, Cork, Ireland; [O'Connor, Michael; Harnedy, Norma; O'Mahony, Denis] Cork Univ Hosp, Cork, Ireland; [O'Connor, Michael; Harnedy, Norma; O'Connor, Kieran; O'Mahony, Denis] St Finbarrs Hosp, Cork, Ireland; [O'Connor, Kieran] Mercy Univ Hosp, Cork, Ireland; [O'Connor, Kieran; O'Mahony, Denis] Victoria Univ Hosp, South Infirm, Cork, Ireland; [Wallace, Martina; Brennan, Lorraine] Univ Coll Dublin, Inst Food & Hlth, Dublin, Ireland; [Marchesi, Julian R.] Cardiff Univ, Sch Biosci, Cardiff CF10 3AT, S Glam, Wales; [Fitzgerald, Anthony P.] Univ Coll Cork, Dept Epidemiol & Publ Hlth, Cork, Ireland; [Shanahan, Fergus] Univ Coll Cork, Dept Med, Cork, Ireland	University College Cork; University College Cork; University College Cork; Teagasc; University College Cork; University College Cork; University College Dublin; Cardiff University; University College Cork; University College Cork	O'Toole, PW (corresponding author), Univ Coll Cork, Dept Microbiol, Cork, Ireland.	pwotoole@ucc.ie	Jeffery, Ian/I-4010-2013; Shanahan, Fergus/ABF-2390-2020; Claesson, Marcus/AAE-4145-2019; Claesson, Marcus/K-7639-2015; Marchesi, Julian/AAC-9021-2020; Stanton, Catherine/A-9549-2015; Marchesi, Julian/D-3731-2009; O'Connor, Eibhlís/F-8851-2013; Wallace, Martina/B-9441-2013; Van Sinderen, Douwe/A-6778-2015; Ross, Paul/A-7584-2015; O'Toole, Paul W/G-1593-2012; Fitzgerald, Tony/AAB-5331-2020; O'Sullivan, Orla/ABE-5980-2020; Hill, Colin/A-5611-2012	Shanahan, Fergus/0000-0003-0467-0936; Claesson, Marcus/0000-0002-5712-0623; Claesson, Marcus/0000-0002-5712-0623; Stanton, Catherine/0000-0002-6724-7011; Marchesi, Julian/0000-0002-7994-5239; O'Connor, Eibhlís/0000-0001-6727-6499; Van Sinderen, Douwe/0000-0003-1823-7957; Ross, Paul/0000-0003-4876-8839; O'Toole, Paul W/0000-0001-5377-0824; O'Sullivan, Orla/0000-0002-4332-1109; Hill, Colin/0000-0002-8527-1445; Brennan, Lorraine/0000-0002-7711-7499; Deane, Jennifer/0000-0002-4058-3568; Jeffery, Ian/0000-0001-9183-7292; Wallace, Martina/0000-0001-8272-5678	Government of Ireland National Development Plan; Health Research Board FHRI; Science Foundation Ireland; Health Research Board of Ireland	Government of Ireland National Development Plan; Health Research Board FHRI; Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board of Ireland	This work was supported by the Government of Ireland National Development Plan by way of a Department of Agriculture Food and Marine, and Health Research Board FHRI award to the ELDERMET project, as well as by a Science Foundation Ireland award to the Alimentary Pharmabiotic Centre. M.J.C. is funded by a fellowship from the Health Research Board of Ireland. We thank K. O'Donovan and P. Egan for clinical assistance, staff in Cork City and County hospitals for facilitating subject recruitment, S. Wong and B. Clayton for supercomputer access.	Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Bauer JM, 2008, NUTR CLIN PRACT, V23, P388, DOI 10.1177/0884533608321132; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Biagi E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010667; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Caporaso JG, 2010, BIOINFORMATICS, V26, P266, DOI 10.1093/bioinformatics/btp636; Chevreux B, 2004, GENOME RES, V14, P1147, DOI 10.1101/gr.1917404; Claesson MJ, 2011, P NATL ACAD SCI USA, V108, P4586, DOI 10.1073/pnas.1000097107; Claesson MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006669; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Dabney A, 2010, Q VALUE ESTIMATION F; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; de Groot V, 2003, J CLIN EPIDEMIOL, V56, P221, DOI 10.1016/S0895-4356(02)00585-1; Drescher LS, 2007, J NUTR, V137, P647, DOI 10.1093/jn/137.3.647; European Commission, 2011, POP STRUCT AG; Faith JJ, 2011, SCIENCE, V333, P101, DOI 10.1126/science.1206025; Feng XD, 2011, BIOMETRIKA, V98, P995, DOI 10.1093/biomet/asr052; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Garrett WS, 2010, CELL, V140, P859, DOI 10.1016/j.cell.2010.01.023; Guigoz Y, 2008, CURR OPIN CLIN NUTR, V11, P13, DOI 10.1097/MCO.0b013e3282f2bfdf; Hamady M, 2010, ISME J, V4, P17, DOI 10.1038/ismej.2009.97; Harrington J, 2011, PUBLIC HEALTH NUTR, V14, P2166, DOI 10.1017/S136898001100098X; Hildebrandt MA, 2009, GASTROENTEROLOGY, V137, P1716, DOI 10.1053/j.gastro.2009.08.042; Jansson J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006386; Jeffery IB, 2012, GUT, V61, P997, DOI 10.1136/gutjnl-2011-301501; Kassinen A, 2007, GASTROENTEROLOGY, V133, P24, DOI 10.1053/j.gastro.2007.04.005; Kau AL, 2011, NATURE, V474, P327, DOI 10.1038/nature10213; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; Kinsella K, 2009, AGING WORLD 2008; KOENKER R, 1978, ECONOMETRICA, V46, P33, DOI 10.2307/1913643; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Lilburn TG, 2004, INT J SYST EVOL MICR, V54, P7, DOI 10.1099/ijs.0.02749-0; Lovat LB, 1996, GUT, V38, P306, DOI 10.1136/gut.38.3.306; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; MAHONEY F I, 1965, Md State Med J, V14, P61; Mai V, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-49; MCCANCE RA, 2002, COMPOSITION FOODS; Muegge BD, 2011, SCIENCE, V332, P970, DOI 10.1126/science.1198719; Namiki T., 2011, ACM C BIOINF COMP BI; Noguchi H, 2006, NUCLEIC ACIDS RES, V34, P5623, DOI 10.1093/nar/gkl723; Nyamundanda G, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-571; O'Sullivan A, 2011, AM J CLIN NUTR, V93, P314, DOI 10.3945/ajcn.110.000950; O'Toole PW, 2010, INT DAIRY J, V20, P281, DOI 10.1016/j.idairyj.2009.11.010; Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490; Pryde SE, 2002, FEMS MICROBIOL LETT, V217, P133, DOI 10.1016/S0378-1097(02)01106-0; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rajilic-Stojanovic M, 2009, ENVIRON MICROBIOL, V11, P1736, DOI 10.1111/j.1462-2920.2009.01900.x; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; van Tongeren SP, 2005, APPL ENVIRON MICROB, V71, P6438, DOI 10.1128/AEM.71.10.6438-6442.2005; Walker AW, 2011, ISME J, V5, P220, DOI 10.1038/ISMEJ.2010.118; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344	55	1925	2028	26	686	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 9	2012	488	7410					178	+		10.1038/nature11319	http://dx.doi.org/10.1038/nature11319			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	985LE	22797518				2022-12-28	WOS:000307267000026
J	Higgins, SI; Scheiter, S				Higgins, Steven I.; Scheiter, Simon			Atmospheric CO2 forces abrupt vegetation shifts locally, but not globally	NATURE			English	Article							AFRICAN SAVANNA; CLIMATE-CHANGE; FOREST; VARIABILITY; RESILIENCE; GRASSLANDS; MECHANISM; DIEBACK; TREES; CYCLE	It is possible that anthropogenic climate change will drive the Earth system into a qualitatively different state(1). Although different types of uncertainty limit our capacity to assess this risk(2), Earth system scientists are particularly concerned about tipping elements, large-scale components of the Earth system that can be switched into qualitatively different states by small perturbations. Despite growing evidence that tipping elements exist in the climate system(1,3), whether large-scale vegetation systems can tip into alternative states is poorly understood(4). Here we show that tropical grassland, savanna and forest ecosystems, areas large enough to have powerful impacts on the Earth system, are likely to shift to alternative states. Specifically, we show that increasing atmospheric CO2 concentration will force transitions to vegetation states characterized by higher biomass and/or woody-plant dominance. The timing of these critical transitions varies as a result of between-site variance in the rate of temperature increase, as well as a dependence on stochastic variation in fire severity and rainfall. We further show that the locations of bistable vegetation zones (zones where alternative vegetation states can exist) will shift as climate changes. We conclude that even though large-scale directional regime shifts in terrestrial ecosystems are likely, asynchrony in the timing of these shifts may serve to dampen, but not nullify, the shock that these changes may represent to the Earth system.	[Higgins, Steven I.] Goethe Univ Frankfurt, Inst Phys Geog, Altenhoferallee 1, D-60438 Frankfurt, Germany; [Scheiter, Simon] Senckenberg Gesell Nat Forsch, Biodivers & Climate Res Ctr BiK F, D-60325 Frankfurt, Germany	Goethe University Frankfurt; Senckenberg Biodiversitat & Klima- Forschungszentrum (BiK-F); Senckenberg Gesellschaft fur Naturforschung (SGN)	Higgins, SI (corresponding author), Goethe Univ Frankfurt, Inst Phys Geog, Altenhoferallee 1, D-60438 Frankfurt, Germany.	higgins@em.uni-frankfurt.de	Scheiter, Simon/G-5048-2012; Higgins, Steven I/A-5138-2012	Scheiter, Simon/0000-0002-5449-841X; Higgins, Steven I/0000-0001-5695-9665	Deutsche Forschungsgemeinschaft; Hesse's Landes-Offensive zur Entwicklung Wissenschaftlich-okonomischer Exzellenz (LOEWE) programme	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Hesse's Landes-Offensive zur Entwicklung Wissenschaftlich-okonomischer Exzellenz (LOEWE) programme	We thank D. Bennu and T. Hickler for helping us improve the manuscript. Financial support was provided by the Deutsche Forschungsgemeinschaft and Hesse's Landes-Offensive zur Entwicklung Wissenschaftlich-okonomischer Exzellenz (LOEWE) programme.	[Anonymous], 2007, TERRESTRIAL ECOSYSTE, DOI [10.1007/978-3-540-32730-1, DOI 10.1007/978-3-540-32730-1_15]; Bond WJ, 2008, ANNU REV ECOL EVOL S, V39, P641, DOI 10.1146/annurev.ecolsys.39.110707.173411; Bond WJ, 2000, GLOBAL CHANGE BIOL, V6, P865, DOI 10.1046/j.1365-2486.2000.00365.x; Bowman DMJS, 2010, LANDSCAPE ECOL, V25, P1247, DOI 10.1007/s10980-010-9496-8; Buitenwerf R, 2012, GLOBAL CHANGE BIOL, V18, P675, DOI 10.1111/j.1365-2486.2011.02561.x; CARPENTER SR, 1992, AM NAT, V140, P781, DOI 10.1086/285440; Clark JS, 2001, SCIENCE, V293, P657, DOI 10.1126/science.293.5530.657; Cox PM, 2004, THEOR APPL CLIMATOL, V78, P137, DOI 10.1007/s00704-004-0049-4; Drake BG, 1997, ANNU REV PLANT PHYS, V48, P609, DOI 10.1146/annurev.arplant.48.1.609; Ehleringer JR, 1997, OECOLOGIA, V112, P285, DOI 10.1007/s004420050311; Higgins SI, 2000, J ECOL, V88, P213, DOI 10.1046/j.1365-2745.2000.00435.x; Hirota M, 2011, SCIENCE, V334, P232, DOI 10.1126/science.1210657; Kgope BS, 2010, AUSTRAL ECOL, V35, P451, DOI 10.1111/j.1442-9993.2009.02046.x; Lenton TM, 2008, P NATL ACAD SCI USA, V105, P1786, DOI 10.1073/pnas.0705414105; Lenton TM, 2011, NAT CLIM CHANGE, V1, P201, DOI [10.1038/NCLIMATE1143, 10.1038/NCLIMATE143]; Liu ZY, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL028062; Malhi Y, 2009, P NATL ACAD SCI USA, V106, P20610, DOI 10.1073/pnas.0804619106; New M, 2002, CLIMATE RES, V21, P1, DOI 10.3354/cr021001; Peel MC, 2007, HYDROL EARTH SYST SC, V11, P1633, DOI 10.5194/hess-11-1633-2007; Prentice IC, 2011, NEW PHYTOL, V189, P988, DOI 10.1111/j.1469-8137.2010.03620.x; Rammig A, 2010, NEW PHYTOL, V187, P694, DOI 10.1111/j.1469-8137.2010.03318.x; Roeckner E., 2005, IPCC DDC AR4 ECHAM5; Scheffer M, 2001, NATURE, V413, P591, DOI 10.1038/35098000; Scheffer M, 2003, TRENDS ECOL EVOL, V18, P648, DOI 10.1016/j.tree.2003.09.002; Scheiter S, 2007, AM NAT, V170, P587, DOI 10.1086/521317; Scheiter S, 2009, GLOBAL CHANGE BIOL, V15, P2224, DOI 10.1111/j.1365-2486.2008.01838.x; Scholes RJ, 1997, ANNU REV ECOL SYST, V28, P517, DOI 10.1146/annurev.ecolsys.28.1.517; Staver AC, 2011, SCIENCE, V334, P230, DOI 10.1126/science.1210465; Walter H., 1971, ECOLOGY TROPICAL SUB; Wigley BJ, 2010, GLOBAL CHANGE BIOL, V16, P964, DOI 10.1111/j.1365-2486.2009.02030.x	30	262	264	8	214	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 9	2012	488	7410					209	212		10.1038/nature11238	http://dx.doi.org/10.1038/nature11238			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	985LE	22763447				2022-12-28	WOS:000307267000033
J	Sarma, AV; Wei, JT				Sarma, Aruna V.; Wei, John T.			Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL PROGRESSION; OVERACTIVE BLADDER; SAW PALMETTO; MEN; ASSOCIATION; CANCER; MULTICENTER; DUTASTERIDE; FINASTERIDE; PLACEBO	A 59-year-old man with a history of benign prostatic hyperplasia and lower urinary tract symptoms comes for care. He has been receiving doxazosin at a dose of 4 mg daily (his only medication) for the past 2 years, with minimal improvement. He continues to have nocturia, a weak urinary stream, and urinary frequency (voiding eight times per day). How would you manage this case?	[Wei, John T.] Univ Michigan, Dept Urol, Dow Div Urol HSR, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Wei, JT (corresponding author), Univ Michigan, Dept Urol, Dow Div Urol HSR, 2800 Plymouth Rd,Bldg 520,Rm 3192, Ann Arbor, MI 48109 USA.	jtwei@umich.edu	Wei, John T/E-8967-2012		Sanofi-Aventis	Sanofi-Aventis(Sanofi-Aventis)	Dr. Wei reports receiving grant support to his institution from Sanofi-Aventis and payment for proctoring GreenLight laser surgery from American Medical Systems. No other potential conflict of interest relevant to this article was reported.	Andersson KE, 2011, NEUROUROL URODYNAM, V30, P292, DOI 10.1002/nau.20999; Andersson KE, 2004, PHYSIOL REV, V84, P935, DOI 10.1152/physrev.00038.2003; Andersson KE, 2004, LANCET NEUROL, V3, P46, DOI 10.1016/S1474-4422(03)00622-7; Andriole GL, 2010, NEW ENGL J MED, V362, P1192, DOI 10.1056/NEJMoa0908127; Barry MJ, 2011, JAMA-J AM MED ASSOC, V306, P1344, DOI 10.1001/jama.2011.1364; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; BARRY MJ, 1995, J UROLOGY, V154, P1770, DOI 10.1016/S0022-5347(01)66780-6; Bartsch G, 2000, EUR UROL, V37, P367, DOI 10.1159/000020181; Bent S, 2006, NEW ENGL J MED, V354, P557, DOI 10.1056/NEJMoa053085; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; Chapple C, 2009, EUR UROL, V56, P534, DOI 10.1016/j.eururo.2008.11.026; CHUTE CG, 1993, J UROLOGY, V150, P85, DOI 10.1016/S0022-5347(17)35405-8; Crawford ED, 2006, J UROLOGY, V175, P1422, DOI 10.1016/S0022-5347(05)00708-1; FAWZY A, 1995, J UROLOGY, V154, P105, DOI 10.1016/S0022-5347(01)67240-9; GIOVANNUCCI E, 1994, AM J EPIDEMIOL, V140, P989, DOI 10.1093/oxfordjournals.aje.a117206; Grossfeld GD, 2001, AM FAM PHYSICIAN, V63, P1145; Huggins C, 1940, J EXP MED, V72, P747, DOI 10.1084/jem.72.6.747; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; Kaplan SA, 2007, JAMA-J AM MED ASSOC, V297, P1195; Kristal AR, 2007, J UROLOGY, V177, P1395, DOI 10.1016/j.juro.2006.11.065; Lepor H, 1998, UROLOGY, V51, P892, DOI 10.1016/S0090-4295(98)00126-5; LEPOR H, 1995, UROLOGY, V45, P406, DOI 10.1016/S0090-4295(99)80008-9; Litwin MS, 2012, NIH PUBLICATION, P46; Lukacs B, 2012, EUR UROL, V61, P1165, DOI 10.1016/j.eururo.2012.01.052; MacDiarmid SA, 2008, MAYO CLIN PROC, V83, P1002, DOI 10.4065/83.9.1002; MacDonald R, 2012, BJU INT, V109, P1756, DOI 10.1111/j.1464-410X.2012.11172.x; Madersbacher S, 2004, EUR UROL, V46, P547, DOI 10.1016/j.eururo.2004.07.016; Marberger M, 2012, BJU INT, V109, P1162, DOI 10.1111/j.1464-410X.2011.10373.x; McConnell JD, 2003, NEW ENGL J MED, V349, P2387, DOI 10.1056/NEJMoa030656; McNeill SA, 2001, UROLOGY, V57, P459, DOI 10.1016/S0090-4295(00)01021-9; McVary KT, 2007, J UROLOGY, V177, P1401, DOI 10.1016/j.juro.2006.11.037; McVary KT, 2011, J UROLOGY, V185, P1793, DOI 10.1016/j.juro.2011.01.074; Milsom I, 2001, BJU INT, V87, P760, DOI 10.1046/j.1464-410x.2001.02228.x; Neuhouser ML, 2004, UROLOGY, V64, P201, DOI 10.1016/j.urology.2004.04.025; Nickel JC, 2011, BJU INT, V108, P388, DOI 10.1111/j.1464-410X.2011.10195.x; Parsons JK, 2009, J UROLOGY, V182, P1463, DOI 10.1016/j.juro.2009.06.038; Platz EA, 1998, ARCH INTERN MED, V158, P2349, DOI 10.1001/archinte.158.21.2349; Roehrborn CG, 1997, UROLOGY, V49, P548, DOI 10.1016/S0090-4295(97)00031-9; Roehrborn CG, 1999, UROLOGY, V53, P581, DOI 10.1016/S0090-4295(98)00655-4; Roehrborn CG, 2008, J UROLOGY, V180, P1228, DOI 10.1016/j.juro.2008.06.079; Roehrborn CG, 2011, MED CLIN N AM, V95, P87, DOI 10.1016/j.mcna.2010.08.013; Roehrborn CG, 2010, EUR UROL, V58, P801, DOI 10.1016/j.eururo.2010.07.035; Rohrmann S, 2007, PROSTATE, V67, P1693, DOI 10.1002/pros.20659; Sarma AV, 2012, UROLOGY, V79, P102, DOI 10.1016/j.urology.2011.08.065; Sauver JLS, 2008, UROLOGY, V71, P475, DOI 10.1016/j.urology.2007.11.155; Sauver JLS, 2009, AM J EPIDEMIOL, V169, P1281, DOI 10.1093/aje/kwp085; Schwinn DA, 2008, INT J UROL, V15, P193, DOI 10.1111/j.1442-2042.2007.01956.x; Seckiner I, 2006, UROL INT, V76, P139, DOI 10.1159/000090877; St Sauver JL, 2006, AM J EPIDEMIOL, V164, P760, DOI 10.1093/aje/kwj258; Sullivan MP, 1996, J UROLOGY, V155, P1995, DOI 10.1016/S0022-5347(01)66073-7; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; YALLA SV, 1981, J UROLOGY, V125, P677, DOI 10.1016/S0022-5347(17)55161-7	52	91	105	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2012	367	3					248	257		10.1056/NEJMcp1106637	http://dx.doi.org/10.1056/NEJMcp1106637			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	22808960				2022-12-28	WOS:000306522900009
J	Horton, R; Peterson, HB				Horton, Richard; Peterson, Herbert B.			The rebirth of family planning	LANCET			English	Editorial Material									[Peterson, Herbert B.] Univ N Carolina, Dept Maternal & Child Hlth, Gillings Sch Global Publ Hlth, Dept Obstet & Gynecol,Sch Med, Chapel Hill, NC 27599 USA; [Horton, Richard] The Lancet, London NW1 7BY, England	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Peterson, HB (corresponding author), Univ N Carolina, Dept Maternal & Child Hlth, Gillings Sch Global Publ Hlth, Dept Obstet & Gynecol,Sch Med, Chapel Hill, NC 27599 USA.	herbert_peterson@unc.edu							0	13	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2012	380	9837					77	77		10.1016/S0140-6736(12)61026-5	http://dx.doi.org/10.1016/S0140-6736(12)61026-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784538				2022-12-28	WOS:000306359100005
J	Berk, V; Fong, JCN; Dempsey, GT; Develioglu, ON; Zhuang, XW; Liphardt, J; Yildiz, FH; Chu, S				Berk, Veysel; Fong, Jiunn C. N.; Dempsey, Graham T.; Develioglu, Omer N.; Zhuang, Xiaowei; Liphardt, Jan; Yildiz, Fitnat H.; Chu, Steven			Molecular Architecture and Assembly Principles of Vibrio cholerae Biofilms	SCIENCE			English	Article							OPTICAL RECONSTRUCTION MICROSCOPY; RUGOSE COLONY MORPHOLOGY; BACTERIAL BIOFILMS; ANTIBIOTIC-RESISTANCE; PATHOGENESIS; DISPERSAL; MATRIX	In their natural environment, microbes organize into communities held together by an extracellular matrix composed of polysaccharides and proteins. We developed an in vivo labeling strategy to allow the extracellular matrix of developing biofilms to be visualized with conventional and superresolution light microscopy. Vibrio cholerae biofilms displayed three distinct levels of spatial organization: cells, clusters of cells, and collections of clusters. Multiresolution imaging of living V. cholerae biofilms revealed the complementary architectural roles of the four essential matrix constituents: RbmA provided cell-cell adhesion; Bap1 allowed the developing biofilm to adhere to surfaces; and heterogeneous mixtures of Vibrio polysaccharide, RbmC, and Bap1 formed dynamic, flexible, and ordered envelopes that encased the cell clusters.	[Berk, Veysel; Liphardt, Jan] Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; [Fong, Jiunn C. N.; Yildiz, Fitnat H.] Univ Calif Santa Cruz, Dept Microbiol & Environm Toxicol, Santa Cruz, CA 95064 USA; [Dempsey, Graham T.; Zhuang, Xiaowei] Harvard Univ, Biophys Program, Cambridge, MA 02138 USA; [Zhuang, Xiaowei] Harvard Univ, Dept Phys, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; [Zhuang, Xiaowei] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; [Develioglu, Omer N.] Taksim Training & Res Hosp, Dept Otorhinolaryngol, Istanbul, Turkey; [Liphardt, Jan] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA; [Chu, Steven] US DOE, Washington, DC 20585 USA	University of California System; University of California Berkeley; University of California System; University of California Santa Cruz; Harvard University; Harvard University; Harvard University; Howard Hughes Medical Institute; Istanbul Gaziosmanpasa Taksim Training & Research Hospital; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE)	Berk, V (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.	vberk@berkeley.edu; fyildiz@ucsc.edu	Develioglu, Omer N/AAA-6587-2020; develioglu, omer n/GQB-5341-2022	Develioglu, Omer N/0000-0001-6725-1013; Liphardt, Jan/0000-0003-2835-5025; Dempsey, Graham/0000-0002-9273-7506	NSF [PHY-0647161]; NIH [AI055987, GM096450, GM068518]; U.S. Department of Energy Office of Basic Energy Sciences (FWP SISGRKN); Lawrence Berkeley National Laboratory; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055987, R56AI055987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM096450, R01GM068518] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Energy Office of Basic Energy Sciences (FWP SISGRKN); Lawrence Berkeley National Laboratory(United States Department of Energy (DOE)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank B. Huang for providing image processing software and D. J. Wozniak, J. H. D. Cate, X. Nan, A. Arkin, and A. Yildiz for critical evaluation of the manuscript. This work is supported by the NSF [grant PHY-0647161 (J. L.)] and the NIH [grants AI055987 (F.H.Y.) and GM096450 and GM068518 (X.Z.)]. X.Z. is a HHMI Investigator. J. L. acknowledges support from the U.S. Department of Energy Office of Basic Energy Sciences (FWP SISGRKN) and Lawrence Berkeley National Laboratory.	Absalon C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002210; Anderson GG, 2008, CURR TOP MICROBIOL, V322, P85; Bates M, 2007, SCIENCE, V317, P1749, DOI 10.1126/science.1146598; Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344; Branda SS, 2005, TRENDS MICROBIOL, V13, P20, DOI 10.1016/j.tim.2004.11.006; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Flemming HC, 2010, NAT REV MICROBIOL, V8, P623, DOI 10.1038/nrmicro2415; Fong JCN, 2006, J BACTERIOL, V188, P1049, DOI 10.1128/JB.188.3.1049-1059.2006; Fong JCN, 2007, J BACTERIOL, V189, P2319, DOI 10.1128/JB.01569-06; Fong JCN, 2010, MICROBIOL-SGM, V156, P2757, DOI 10.1099/mic.0.040196-0; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; Hall-Stoodley L, 2005, TRENDS MICROBIOL, V13, P7, DOI 10.1016/j.tim.2004.11.004; Harmsen M, 2010, FEMS IMMUNOL MED MIC, V59, P253, DOI 10.1111/j.1574-695X.2010.00690.x; Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395; Hess ST, 2006, BIOPHYS J, V91, P4258, DOI 10.1529/biophysj.106.091116; Huang B, 2008, SCIENCE, V319, P810, DOI 10.1126/science.1153529; Karatan E, 2009, MICROBIOL MOL BIOL R, V73, P310, DOI 10.1128/MMBR.00041-08; Lieleg O, 2011, SOFT MATTER, V7, P3307, DOI 10.1039/c0sm01467b; Lopez D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000398; Masters B. R., 2008, J BIOMED OPT, V13, DOI DOI 10.1117/1.2911629; Moorthy S, 2004, MOL MICROBIOL, V52, P573, DOI 10.1111/j.1365-2958.2004.04000.x; Parsek MR, 2003, ANNU REV MICROBIOL, V57, P677, DOI 10.1146/annurev.micro.57.030502.090720; Reisner Andreas, 2005, V12, P114, DOI 10.1159/000081692; Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929; Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140-6736(01)05321-1; Sutherland IW, 2001, MICROBIOL-UK, V147, P3, DOI 10.1099/00221287-147-1-3; Yildiz FH, 2004, MOL MICROBIOL, V53, P497, DOI 10.1111/j.1365-2958.2004.04154.x	28	251	258	4	219	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2012	337	6091					236	239		10.1126/science.1222981	http://dx.doi.org/10.1126/science.1222981			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798614	Green Accepted			2022-12-28	WOS:000306323500059
J	Jucker, T; Coomes, DA				Jucker, Tommaso; Coomes, David A.			Comment on "Plant Species Richness and Ecosystem Multifunctionality in Global Drylands"	SCIENCE			English	Editorial Material							BIODIVERSITY; COMMUNITIES		[Jucker, Tommaso; Coomes, David A.] Univ Cambridge, Forest Ecol & Conservat Grp, Dept Plant Sci, Cambridge CB2 3EA, England	University of Cambridge	Jucker, T (corresponding author), Univ Cambridge, Forest Ecol & Conservat Grp, Dept Plant Sci, Downing St, Cambridge CB2 3EA, England.	tj272@cam.ac.uk	Jucker, Tommaso/S-4724-2017	Jucker, Tommaso/0000-0002-0751-6312; Coomes, David/0000-0002-8261-2582				Cardinale BJ, 2011, AM J BOT, V98, P572, DOI 10.3732/ajb.1000364; Hooper DU, 2005, ECOL MONOGR, V75, P3, DOI 10.1890/04-0922; Maestre FT, 2012, SCIENCE, V335, P214, DOI 10.1126/science.1215442; Maestre FT, 2010, PHILOS T R SOC B, V365, P2057, DOI 10.1098/rstb.2010.0016; Maestre FT, 2009, J ECOL, V97, P199, DOI 10.1111/j.1365-2745.2008.01476.x; Paquette A, 2011, GLOBAL ECOL BIOGEOGR, V20, P170, DOI 10.1111/j.1466-8238.2010.00592.x; Reiss J, 2009, TRENDS ECOL EVOL, V24, P505, DOI 10.1016/j.tree.2009.03.018	7	16	17	6	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2012	337	6091								10.1126/science.1220473	http://dx.doi.org/10.1126/science.1220473			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798584				2022-12-28	WOS:000306323500024
J	Mackenzie, IS; MacDonald, TM; Thompson, A; Morant, S; Wei, L				Mackenzie, Isla S.; MacDonald, Thomas M.; Thompson, Alastair; Morant, Steve; Wei, Li			Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTIHYPERTENSIVE MEDICATION; FOLLOW-UP; HYPERTENSION; ASSOCIATION; DRUGS	Objective To investigate whether exposure to spironolactone treatment affects the risk of incident breast cancer in women over 55 years of age. Design Retrospective, matched cohort study. Setting General Practice Research Database, a primary care anonymised database representative of the general population in the United Kingdom. Participants 1 290 625 female patients, older than 55 years and with no history of breast cancer, from 557 general practices with a total follow-up time of 8.4 million patient years. We excluded patients with poor quality data and those with no contacts with their general practitioner after their current registration date. Intervention Exposed cohort included women who received at least two prescriptions of spironolactone after age 55 years, who were followed up from the first prescription (index date). We randomly selected two unexposed female controls for every exposed patient, matched by practice, year of birth, and socioeconomic scores (if information was available), and followed up from the same date. Main outcome measure New cases of breast cancer, using Read codes to confirm diagnoses. Results Index dates for study patients ranged from 1987 to 2010, and 29 491 new cases of breast cancer were recorded in the study population (incidence rate 0.35% per year). The exposed cohort of 28 032 patients and control cohort of 55 961 patients had unadjusted incidence rates of 0.39% and 0.38% per year, respectively, over a mean follow-up time of 4.1 years. Time-to-event analysis, adjusting for potential risk factors, provided no evidence of an increased incidence of breast cancer in patients exposed to spironolactone (hazard ratio 0.99, 95% confidence interval 0.87 to 1.12). Conclusions These data suggest that the long term management of cardiovascular conditions with spironolactone does not increase the risk of breast cancer in women older than 55 years with no history of the disease.	[Mackenzie, Isla S.; MacDonald, Thomas M.; Morant, Steve; Wei, Li] Univ Dundee, Med Monitoring Unit MEMO, Dundee DD1 9SY, Scotland; [Thompson, Alastair] Dundee Canc Ctr, Dundee, Scotland	University of Dundee; University of Dundee	Mackenzie, IS (corresponding author), Univ Dundee, Med Monitoring Unit MEMO, Dundee DD1 9SY, Scotland.	i.s.mackenzie@dundee.ac.uk		Morant, Steven/0000-0001-5674-3784; Mackenzie, Isla/0000-0002-3680-7127; MacDonald, Thomas/0000-0001-5189-6669	University of Dundee; MRC [G106/1249] Funding Source: UKRI; Medical Research Council [G106/1249] Funding Source: researchfish	University of Dundee; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	No specific funding was received for this study. The study was sponsored by the University of Dundee.	[Anonymous], 1974, LANCET, V2, P669; [Anonymous], 1988, Drug Ther Bull, V26, P88; ARMSTRONG B, 1974, LANCET, V2, P672; DANIELSON DA, 1982, AM J EPIDEMIOL, V116, P329, DOI 10.1093/oxfordjournals.aje.a113416; Fryzek JP, 2006, BREAST CANCER RES TR, V97, P231, DOI 10.1007/s10549-005-9091-x; GARDINER P, 1989, J CLIN PHARMACOL, V29, P342, DOI 10.1002/j.1552-4604.1989.tb03339.x; Gonzalez-Perez A, 2004, PHARMACOEPIDEM DR S, V13, P581, DOI 10.1002/pds.910; Goon PKY, 2006, J HUM HYPERTENS, V20, P722, DOI 10.1038/sj.jhh.1002053; IARC, 2012, IARC MON, V79, P319; JICK H, 1975, LANCET, V2, P368, DOI 10.1016/S0140-6736(75)92814-7; Largent JA, 2006, J HUM HYPERTENS, V20, P727, DOI 10.1038/sj.jhh.1002075; Li CI, 2003, CANCER, V98, P1504, DOI 10.1002/cncr.11663; LOUBE SD, 1975, LANCET, V1, P1428, DOI 10.1016/S0140-6736(75)92645-8; NICE, 2019, HYP AD DIAGN MAN; Parthasarathy HK, 2011, J HYPERTENS, V29, P980, DOI 10.1097/HJH.0b013e3283455ca5; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; SELBY JV, 1989, CANCER RES, V49, P5736; Shaw JC, 2002, J CUTAN MED SURG, V6, P541, DOI 10.1007/s10227-001-0152-4; STIERER M, 1990, ONKOLOGIE, V13, P128; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; Williams B, 2004, J HUM HYPERTENS, V18, P139, DOI 10.1038/sj.jhh.1001683	21	43	43	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	2012	345								e4447	10.1136/bmj.e4447	http://dx.doi.org/10.1136/bmj.e4447			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975NX	22797844	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000306519100002
J	Shea, SA				Shea, Steven A.			Obesity and Pharmacologic Control of the Body Clock	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CIRCADIAN BEHAVIOR; SHIFT WORK; METABOLISM		Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	Shea, SA (corresponding author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.			Shea, Steven/0000-0003-1949-0954				Antunes LC, 2010, NUTR RES REV, V23, P155, DOI 10.1017/S0954422410000016; Bass J, 2010, SCIENCE, V330, P1349, DOI 10.1126/science.1195027; Buxton OM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003200; Cho H, 2012, NATURE, V485, P123, DOI 10.1038/nature11048; Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030; Suwazono Y, 2008, OBESITY, V16, P1887, DOI 10.1038/oby.2008.298	6	12	12	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2					175	178		10.1056/NEJMcibr1204644	http://dx.doi.org/10.1056/NEJMcibr1204644			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972IO	22784121				2022-12-28	WOS:000306270800016
J	James, JR; Vale, RD				James, John R.; Vale, Ronald D.			Biophysical mechanism of T-cell receptor triggering in a reconstituted system	NATURE			English	Article							PATTERN-FORMATION; ACTIVATION; CD45; SEGREGATION; ANTIGEN; MICROCLUSTERS; THRESHOLDS; CLUSTERS; ADHESION; KINASES	A T-cell-mediated immune response is initiated by the T-cell receptor (TCR) interacting with peptide-bound major histocompatibility complex (pMHC) on an infected cell. The mechanism by which this interaction triggers intracellular phosphorylation of the TCR, which lacks a kinase domain, remains poorly understood. Here, we have introduced the TCR and associated signalling molecules into a non-immune cell and reconstituted ligand-specific signalling when these cells are conjugated with antigen-presenting cells. We show that signalling requires the differential segregation of a phosphatase and kinase in the plasma membrane. An artificial, chemically controlled receptor system generates the same effect as TCR-pMHC, demonstrating that the binding energy of an extracellular protein-protein interaction can drive the spatial segregation of membrane proteins without a transmembrane conformational change. This general mechanism may extend to other receptors that rely on extrinsic kinases, including, as we demonstrate, chimaeric antigen receptors being developed for cancer immunotherapy.	[James, John R.; Vale, Ronald D.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA; [James, John R.; Vale, Ronald D.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vale, RD (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, 600 16th St, San Francisco, CA 94158 USA.	vale@cmp.ucsf.edu	James, John/AAP-3607-2021; James, John R/B-5547-2008	James, John/0000-0003-1452-7578; James, John R/0000-0003-1452-7578	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Alakoskela JM, 2011, BIOPHYS J, V100, P2865, DOI 10.1016/j.bpj.2011.05.013; Aleksic M, 2010, IMMUNITY, V32, P163, DOI 10.1016/j.immuni.2009.11.013; Altan-Bonnet G, 2005, PLOS BIOL, V3, P1925, DOI 10.1371/journal.pbio.0030356; Au-Yeung BB, 2009, IMMUNOL REV, V228, P41, DOI 10.1111/j.1600-065X.2008.00753.x; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Burroughs NJ, 2002, BIOPHYS J, V83, P1784, DOI 10.1016/S0006-3495(02)73944-1; Campi G, 2005, J EXP MED, V202, P1031, DOI 10.1084/jem.20051182; Chen JL, 2005, J EXP MED, V201, P1243, DOI 10.1084/jem.20042323; Choudhuri K, 2005, NATURE, V436, P578, DOI 10.1038/nature03843; Coombs D, 2004, BIOPHYS J, V86, P1408, DOI 10.1016/S0006-3495(04)74211-3; Davis SJ, 2006, NAT IMMUNOL, V7, P803, DOI 10.1038/ni1369; Deindl S, 2007, CELL, V129, P735, DOI 10.1016/j.cell.2007.03.039; He X, 2002, EUR J IMMUNOL, V32, P2578, DOI 10.1002/1521-4141(200209)32:9<2578::AID-IMMU2578>3.0.CO;2-3; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; Holst J, 2008, NAT IMMUNOL, V9, P658, DOI 10.1038/ni.1611; Irles C, 2003, NAT IMMUNOL, V4, P189, DOI 10.1038/ni877; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; Johnson KG, 2000, P NATL ACAD SCI USA, V97, P10138, DOI 10.1073/pnas.97.18.10138; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Leupin O, 2000, CURR BIOL, V10, P277, DOI 10.1016/S0960-9822(00)00362-6; Lillemeier BF, 2010, NAT IMMUNOL, V11, P90, DOI 10.1038/ni.1832; Love PE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002485; Manza BN, 2011, P NATL ACAD SCI USA, V108, P9089, DOI 10.1073/pnas.1018771108; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Qi SY, 2001, P NATL ACAD SCI USA, V98, P6548, DOI 10.1073/pnas.111536798; Saunders AE, 2010, CELL SIGNAL, V22, P339, DOI 10.1016/j.cellsig.2009.10.003; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; van der Merwe PA, 2011, NAT REV IMMUNOL, V11, P47, DOI 10.1038/nri2887; Varma R, 2006, IMMUNITY, V25, P117, DOI 10.1016/j.immuni.2006.04.010; Weikl TR, 2004, BIOPHYS J, V87, P3665, DOI 10.1529/biophysj.104.045609; Xu CQ, 2008, CELL, V135, P702, DOI 10.1016/j.cell.2008.09.044; Yokosuka T, 2005, NAT IMMUNOL, V6, P1253, DOI 10.1038/ni1272	38	222	237	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 5	2012	487	7405					64	69		10.1038/nature11220	http://dx.doi.org/10.1038/nature11220			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968LM	22763440	Green Accepted, Green Submitted			2022-12-28	WOS:000305982900050
J	Campbell, RJ; Gill, SS; Bronskill, SE; Paterson, JM; Whitehead, M; Bell, CM				Campbell, Robert J.; Gill, Sudeep S.; Bronskill, Susan E.; Paterson, J. Michael; Whitehead, Marlo; Bell, Chaim M.			Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MACULAR DEGENERATION; COHORT ANALYSIS; RANIBIZUMAB; BEVACIZUMAB; THERAPY; SAFETY; PHARMACOKINETICS; MORTALITY; CANCER; RISKS	Objective To assess the risk of systemic adverse events associated with intravitreal injections of vascular endothelial growth factor inhibiting drugs. Design Population based nested case-control study. Setting Ontario, Canada. Participants 91 378 older adults with a history of physician diagnosed retinal disease identified between 1 April 2006 and 31 March 2011. Cases were 1477 patients admitted to hospital for ischaemic stroke, 2229 admitted for an acute myocardial infarction, 1059 admitted or assessed in an emergency department for venous thromboembolism, and 2623 admitted for congestive heart failure. Event-free controls (at a ratio of 5: 1) were matched to cases on the basis of year of birth, sex, history of the outcome in the previous 5 years, and diabetes. Main exposure measure Exposure to vascular endothelial growth factor inhibiting drugs identified within 180 days before the index date. Results After adjustment for potential confounders, participants who had ischaemic stroke, acute myocardial infarction, congestive heart failure, or venous thromboembolism were not more likely than control participants to have been exposed to either bevacizumab (adjusted odds ratios of 0.95 (95% confidence interval 0.68 to 1.34) for ischaemic stroke, 1.04 (0.77 to 1.39) for acute myocardial infarction, 0.81 (0.49 to 1.34) for venous thromboembolism, and 1.21 (0.91 to 1.62) for congestive heart failure) or ranibizumab (adjusted odds ratios 0.87 (0.68 to 1.10) for ischaemic stroke, 0.90 (0.72 to 1.11) for acute myocardial infarction, 0.88 (0.67 to 1.16) for venous thromboembolism, and 0.87 (0.70 to 1.07) for congestive heart failure). Similarly, a secondary analysis of exclusive users of bevacizumab or ranibizumab showed no differences in risk between the two drugs (adjusted odds ratios for bevacizumab relative to ranibizumab of 1.03 (0.67 to 1.60) for ischaemic stroke, 1.23 (0.85 to 1.77) for acute myocardial infarction, 0.92 (0.51 to 1.69) for venous thromboembolism, and 1.35 (0.93 to 1.95) for congestive heart failure). These findings were consistent for all but one outcome in subgroup analyses. Conclusions Intravitreal injections of bevacizumab and ranibizumab were not associated with significant risks of ischaemic stroke, acute myocardial infarction, congestive heart failure, or venous thromboembolism.	[Campbell, Robert J.] Queens Univ, Dept Ophthalmol, Kingston, ON, Canada; [Campbell, Robert J.] Hotel Dieu & Kingston Gen Hosp, Dept Ophthalmol, Kingston, ON, Canada; [Gill, Sudeep S.] Queens Univ, Div Geriatr Med, Kingston, ON, Canada; [Gill, Sudeep S.] St Marys Lake Hosp, Div Geriatr Med, Kingston, ON, Canada; [Bronskill, Susan E.; Paterson, J. Michael] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Paterson, J. Michael] McMaster Univ, Dept Family Med, Hamilton, ON L8S 4L8, Canada; [Bell, Chaim M.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Bell, Chaim M.] St Michaels Hosp, Dept Med, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Bell, Chaim M.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada	Queens University - Canada; Queens University - Canada; University of Toronto; McMaster University; University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Campbell, RJ (corresponding author), Hop Hotel Dieu, Dept Ophthalmol, 166 Brock St, Kingston, ON K7L 5G2, Canada.	rob.campbell@queensu.ca	Bell, Chaim/C-4611-2015	Bell, Chaim/0000-0002-3778-9469	Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Ontario Ministry of Health and Long-Term Care's (MOHLTC); Southeastern Ontario Academic Medical Organization; CIHR from the Institute of Aging; Canadian Patient Safety Institute chair in patient safety and continuity of care; CIHR; Ontario MOHLTC; MOHLTC	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); Ontario Ministry of Health and Long-Term Care's (MOHLTC)(Ministry of Health and Long-Term Care, Ontario); Southeastern Ontario Academic Medical Organization; CIHR from the Institute of Aging(Canadian Institutes of Health Research (CIHR)); Canadian Patient Safety Institute chair in patient safety and continuity of care; CIHR(Canadian Institutes of Health Research (CIHR)); Ontario MOHLTC(Ministry of Health and Long-Term Care, Ontario); MOHLTC(Ministry of Health and Long-Term Care, Ontario)	We thank Erica Campbell for assistance with project management, creation of tables, and manuscript editing. She is funded through research grants from the Canadian Institutes of Health Research and the Ontario Ministry of Health and Long-Term Care. We also thank Brogan Inc, Ottawa, Canada, for use of their drug product and therapeutic class database.; This study was funded by the Canadian Institutes of Health Research (CIHR) and the Ontario Ministry of Health and Long-Term Care's (MOHLTC) drug innovation fund. RJC is supported by a clinician scientist award from the Southeastern Ontario Academic Medical Organization. SSG and SEB are supported by CIHR new investigator awards from the Institute of Aging. CMB is supported by a CIHR and Canadian Patient Safety Institute chair in patient safety and continuity of care. The sponsors of this study had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit for publication. The authors are affiliated with the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario MOHLTC. The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.; All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: RJC is supported by a Clinician Scientist Award from the Southeastern Ontario Academic Medical Organization, which receives funding from the Ontario Ministry of Health and Long-Term Care (MOHLTC) and holds research grants from the Canadian Institutes of Health Research (CIHR) and the MOHLTC for related work; SSG and SEB are supported by CIHR new investigator awards from the Institute of Aging; CMB is supported by a CIHR and Canadian Patient Safety Institute chair in patient safety and continuity of care; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; SSG is a member of the Ontario MOHLTC Committee to Evaluate Drugs, which provides advice to the Ontario MOHLTC on drug related matters (such as drugs to list on provincial formulary), and RJC is an adviser to the Ontario MOHLTC Committee to Evaluate Drugs (in these roles, neither has reviewed bevacizumab or ranibizumab); no other relationships or activities that could appear to have influenced the submitted work.	Al-Qureshi S, 2012, CLIN EXP OPHTHALMOL, V40, P3, DOI 10.1111/j.1442-9071.2011.02739.x; [Anonymous], 2012, ANN REPORT 2011, P66; Bell CM, 2009, JAMA-J AM MED ASSOC, V301, P1991, DOI 10.1001/jama.2009.683; Berkrot B, 2011, REUTERS US EDITI SEP; Breslow N, 1987, FITTING MODELS CONTI, P178; BRESLOW NE, 1983, J AM STAT ASSOC, V78, P1, DOI 10.2307/2287093; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Campbell RJ, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2941; Campbell RJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P359, DOI 10.1001/archophthalmol.2010.19; Chakravarthy U, 2012, OPHTHALMOLOGY; Choueiri TK, 2011, J CLIN ONCOL, V29, P632, DOI 10.1200/JCO.2010.31.9129; Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153; Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014; Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223; Essebag Vidal, 2005, BMC Med Res Methodol, V5, P5, DOI 10.1186/1471-2288-5-5; Ferner RE, 2010, BMJ-BRIT MED J, V340, P245; Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7; French DD, 2011, RETINA-J RET VIT DIS, V31, P1036, DOI 10.1097/IAE.0b013e31821dc66f; Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601; Gill SS, 2009, ARCH INTERN MED, V169, P867, DOI 10.1001/archinternmed.2009.43; Gower EW, 2011, ADVERSE EVENT RATES; Gruneir A, 2010, J AM GERIATR SOC, V58, P510, DOI 10.1111/j.1532-5415.2010.02736.x; Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512; Institute for Clinical Evaluative Sciences, ONT STROK EV REP 201; Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012; Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537; Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0; Juurlink D, 2006, CANADIAN I HLTH INFO; Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813; Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069; Lee DS, 2005, MED CARE, V43, P182, DOI 10.1097/00005650-200502000-00012; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; LIDDELL FDK, 1977, J R STAT SOC A STAT, V140, P469, DOI 10.2307/2345280; Liew G, 2007, NEW ENGL J MED, V356, P747; Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673; Martin DF, 2012, OPHTHALMOLOGY; Medicare Payment Advisory Commission, 2010, DAT BOOK HEALTHC SPE; MITKA M, 2011, JAMA-J AM MED ASSOC, V306, P1073; Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507; Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656; National Institute for Health and Clinical Excellence, 2010, BEV AV EYE COND REP; National Institute for Health and Clinical Excellence, 2010, NICES REP FEAS APPR; Pollack A, 2011, NY TIMES        1004; Public Health Agency of Canada Canadian Institute for Health Information Canadian Stroke Network Heart and Stroke Foundation of Canada Statistics Canada, 2009, TRACK HEART DIS STRO; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334; Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Snider KL, 2009, TARGET ONCOL, V4, P67, DOI 10.1007/s11523-009-0106-0; Suissa S, 2005, NOVEL APPROACHES PHA, P811; Tu Karen, 2007, Open Med, V1, pe18; Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459; Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003; Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046; Vandenbroucke JP, 2008, JAMA-J AM MED ASSOC, V300, P2417, DOI 10.1001/jama.2008.723; White RH, 2003, CIRCULATION, V107, pI4, DOI 10.1161/01.CIR.0000078468.11849.66; Williams JI, 1996, PATTERNS HLTH CARE O, P339	57	54	55	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 4	2012	344								e4203	10.1136/bmj.e4203	http://dx.doi.org/10.1136/bmj.e4203			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972KE	22763393	Green Published, hybrid			2022-12-28	WOS:000306275200002
J	Dunlay, SM; Weston, SA; Killian, JM; Bell, MR; Jaffe, AS; Roger, VL				Dunlay, Shannon M.; Weston, Susan A.; Killian, Jill M.; Bell, Malcolm R.; Jaffe, Allan S.; Roger, Veronique L.			Thirty-Day Rehospitalizations After Acute Myocardial Infarction A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; HEART-DISEASE; READMISSION; TRENDS; MORTALITY; FAILURE; CARE	Background: Rehospitalization is a quality-of-care indicator, yet little is known about its occurrence and predictors after myocardial infarction (MI) in the community. Objective: To examine 30-day rehospitalizations after incident MI. Design: Retrospective cohort study. Setting: Population-based registry in Olmsted County, Minnesota. Patients: 3010 patients who were hospitalized in Olmsted County with first-ever MI from 1987 to 2010 and survived to hospital discharge. Measurements: Diagnoses, therapies, and complications during incident and subsequent hospitalizations were identified. Manual chart review was performed to determine the cause of all rehospitalizations. The hazard ratios and cumulative incidence of 30-day rehospitalizations were determined by using Cox proportional hazards regression models. Results: Among 3010 patients (mean age, 67 years; 40.5% female) with incident MI (31.2% ST-segment elevation), 643 rehospitalizations occurred within 30 days in 561 (18.6%) patients. Overall, 30.2% of rehospitalizations were unrelated to the incident MI and 42.6% were related; the relationship was unclear in 27.2% of rehospitalizations. Angiography was performed in 153 (23.8%) rehospitalizations. Revascularization was performed in 103 (16.0%) rehospitalizations, of which 46 (44.7%) had no revascularization during the index hospitalization. After adjustment for potential confounders, diabetes, chronic obstructive pulmonary disease, anemia, higher Killip class, longer length of stay during the index hospitalization, and a complication of angiography or reperfusion or revascularization were associated with increased rehospitalization risk. The 30-day incidence of rehospitalization was 35.3% in patients who experienced a complication of angiography during the index MI hospitalization and 31.6% in those who experienced a complication of reperfusion or revascularization during the index MI hospitalization, compared with 16.8% in patients who had reperfusion or revascularization without complications. Limitation: This study represents the experiences of a single community. Conclusion: Comorbid conditions, longer length of stay, and complications of angiography and revascularization or reperfusion are associated with increased 30-day rehospitalization risk after MI. Many rehospitalizations seem to be unrelated to the incident MI.	[Roger, Veronique L.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA	Mayo Clinic	Roger, VL (corresponding author), Mayo Clin, Dept Hlth Sci Res, 200 1st St SW, Rochester, MN 55905 USA.	roger.veronique@mayo.edu	Roger, Veronique/AAV-5951-2020		National Institutes of Health [RO1-HL59205]; Rochester Epidemiology Project from the National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01-AR30582]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG034676] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rochester Epidemiology Project from the National Institute of Arthritis and Musculoskeletal and Skin Diseases; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	National Institutes of Health.; By grants from the National Institutes of Health (RO1-HL59205) and the Rochester Epidemiology Project (R01-AR30582, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases).	ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Axon RN, 2011, JAMA-J AM MED ASSOC, V305, P504, DOI 10.1001/jama.2011.72; Curtis JP, 2009, J AM COLL CARDIOL, V54, P903, DOI 10.1016/j.jacc.2009.04.076; Dunlay SM, 2009, J AM COLL CARDIOL, V54, P1695, DOI 10.1016/j.jacc.2009.08.019; Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935; Fried TR, 2008, J AM GERIATR SOC, V56, P1839, DOI 10.1111/j.1532-5415.2008.01923.x; Gershon AS, 2010, ARCH INTERN MED, V170, P560, DOI 10.1001/archinternmed.2010.17; Gorodeski EZ, 2010, NEW ENGL J MED, V363, P297, DOI 10.1056/NEJMc1001882; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Kors JA, 2000, AM J EPIDEMIOL, V151, P790, DOI 10.1093/oxfordjournals.aje.a010279; Kostis WJ, 2010, CIRC-CARDIOVASC QUAL, V3, P581, DOI 10.1161/CIRCOUTCOMES.110.957803; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Miller WL, 2006, EUR HEART J, V27, P1061, DOI 10.1093/eurheartj/ehi760; NCDR, 2008, NCDR CATHPCI REG V4; Parikh CR, 2008, ARCH INTERN MED, V168, P987, DOI 10.1001/archinte.168.9.987; Rihal CS, 2002, CIRCULATION, V105, P2259, DOI 10.1161/01.CIR.0000016043.87291.33; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Roger VL, 2010, CIRCULATION, V121, P863, DOI 10.1161/CIRCULATIONAHA.109.897249; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; Smith SC, 2001, CIRCULATION, V103, P3019, DOI 10.1161/01.CIR.103.24.3019; Thygesen K, 2007, EUR HEART J, V28, P2525; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; Zhang X, 2011, COMPUT METH PROG BIO, V101, P87, DOI 10.1016/j.cmpb.2010.07.005	26	81	84	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2012	157	1					11	U46		10.7326/0003-4819-157-1-201207030-00004	http://dx.doi.org/10.7326/0003-4819-157-1-201207030-00004			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992NS	22751756	Green Accepted			2022-12-28	WOS:000307784900002
J	Toll, E				Toll, Elizabeth			The Cost of Technology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Toll, Elizabeth] Brown Univ, Warren Alpert Med Sch, Dept Pediat, Providence, RI 02912 USA; [Toll, Elizabeth] Brown Univ, Warren Alpert Med Sch, Dept Internal Med, Providence, RI 02912 USA	Brown University; Brown University	Toll, E (corresponding author), Brown Univ, Warren Alpert Med Sch, Dept Pediat, Providence, RI 02912 USA.	etoll@lifespan.org							0	68	69	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2012	307	23					2497	2498		10.1001/jama.2012.4946	http://dx.doi.org/10.1001/jama.2012.4946			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	960MB	22797449				2022-12-28	WOS:000305391400025
J	Rosenstiel, TN; Shortlidge, EE; Melnychenko, AN; Pankow, JF; Eppley, SM				Rosenstiel, Todd N.; Shortlidge, Erin E.; Melnychenko, Andrea N.; Pankow, James F.; Eppley, Sarah M.			Sex-specific volatile compounds influence microarthropod-mediated fertilization of moss	NATURE			English	Article							FOLSOMIA-CANDIDA COLLEMBOLA; FLORAL SCENT; LAND PLANTS; EVOLUTION; SPERM; PREFERENCES; BRYOPHYTES; DIMORPHISM; DIVERSITY; PATTERNS	Sexual reproduction in non-vascular plants requires unicellular free-motile sperm to travel from male to female reproductive structures across the terrestrial landscape(1). Recent data suggest that microarthropods can disperse sperm in mosses(2). However, little is known about the chemical communication, if any, that is involved in this interaction or the relative importance of microarthropod dispersal compared to abiotic dispersal agents in mosses. Here we show that tissues of the cosmopolitan moss Ceratodon purpureus emit complex volatile scents, similar in chemical diversity to those described in pollination mutualisms between flowering plants and insects, that the chemical composition of C. purpureus volatiles are sex-specific, and that moss-dwelling microarthropods are differentially attracted to these sex-specific moss volatile cues. Furthermore, using experimental microcosms, we show that microarthropods significantly increase moss fertilization rates, even in the presence of water spray, highlighting the important role of microarthropod dispersal in contributing to moss mating success. Taken together, our results indicate the presence of a scent-based 'plant-pollinator-like' relationship that has evolved between two of Earth's most ancient terrestrial lineages, mosses and microarthropods.	[Rosenstiel, Todd N.; Shortlidge, Erin E.; Melnychenko, Andrea N.; Eppley, Sarah M.] Portland State Univ, Dept Biol, Portland, OR 97201 USA; [Rosenstiel, Todd N.; Shortlidge, Erin E.; Melnychenko, Andrea N.; Eppley, Sarah M.] Portland State Univ, Ctr Life Extreme Environm, Portland, OR 97201 USA; [Pankow, James F.] Portland State Univ, Dept Chem, Portland, OR 97201 USA; [Pankow, James F.] Portland State Univ, Dept Civil & Environm Engn, Portland, OR 97201 USA	Portland State University; Portland State University; Portland State University; Portland State University	Eppley, SM (corresponding author), Portland State Univ, Dept Biol, 1719 SW 10th Ave, Portland, OR 97201 USA.	eppley@pdx.edu	Shortlidge, Erin/ABA-9548-2021		3M Corporation; National Science Foundation [DEB-0743461, IOS-0719570]	3M Corporation(3M); National Science Foundation(National Science Foundation (NSF))	We are grateful to W. Luo and L. Isabelle for analytical assistance, to C. Rupert for assistance with the preference assays, and to L. Stark and N. McLetchie for plant material. Funding was provided by the 3M Corporation and the National Science Foundation (DEB-0743461 to S. M. E. and IOS-0719570 to T.N.R).	Andrew NR, 2003, J BIOGEOGR, V30, P731, DOI 10.1046/j.1365-2699.2003.00849.x; Ashman TL, 2009, FUNCT ECOL, V23, P852, DOI 10.1111/j.1365-2435.2009.01590.x; BENGTSSON G, 1988, SOIL BIOL BIOCHEM, V20, P25, DOI 10.1016/0038-0717(88)90122-8; Bisang I, 2005, J BRYOL, V27, P207, DOI 10.1179/174328205X69959; CREPET WL, 1984, ANN MO BOT GARD, V71, P607, DOI 10.2307/2399041; Cronberg N, 2006, SCIENCE, V313, P1255, DOI 10.1126/science.1128707; Fountain MT, 2005, ANNU REV ENTOMOL, V50, P201, DOI 10.1146/annurev.ento.50.071803.130331; Hemborg AM, 2005, BIOL J LINN SOC, V85, P97, DOI 10.1111/j.1095-8312.2005.00477.x; JOHNSON DL, 1980, RES POPUL ECOL, V22, P339, DOI 10.1007/BF02530855; Kenrick P, 1997, NATURE, V389, P33, DOI 10.1038/37918; KNUDSEN JT, 1993, PHYTOCHEMISTRY, V33, P253, DOI 10.1016/0031-9422(93)85502-I; Lawton E., 1971, MOSS FLORA PACIFIC N; LONGTON R E, 1976, Journal of the Hattori Botanical Laboratory, V41, P205; MISHLER BD, 1990, SYST BOT, V15, P86, DOI 10.2307/2419019; Muggoch H, 1942, PROC R SOC SER B-BIO, V130, P448, DOI 10.1098/rspb.1942.0012; Nickrent DL, 2000, MOL BIOL EVOL, V17, P1885, DOI 10.1093/oxfordjournals.molbev.a026290; Pankow J. F., 2011, ATMOS MEAS TECH, V4, P3647, DOI DOI 10.5194/AMTD-4-3647-2011; PAOLILLO DJ, 1981, BIOSCIENCE, V31, P367, DOI 10.2307/1308401; Raguso RA, 2008, ANNU REV ECOL EVOL S, V39, P549, DOI 10.1146/annurev.ecolsys.38.091206.095601; Raspotnig G, 2005, J CHEM ECOL, V31, P419, DOI 10.1007/s10886-005-1350-0; Rosenstiel TN, 2009, BIOL LETTERS, V5, P857, DOI 10.1098/rsbl.2009.0380; Sadaka-Laulan N, 1998, EUR J SOIL BIOL, V34, P179, DOI 10.1016/S1164-5563(00)86660-1; SAS Institute, 2012, JMP WIND REL 10 0 0; Schiestl FP, 2010, ECOL LETT, V13, P643, DOI 10.1111/j.1461-0248.2010.01451.x; SHAW AJ, 1993, AM J BOT, V80, P584, DOI 10.2307/2445376; Shaw AJ, 2000, BRYOPHYTE BIOL, P369; Shortlidge EE, 2012, NEW PHYTOL, V194, P741, DOI 10.1111/j.1469-8137.2012.04106.x; Staaden S, 2011, SOIL BIOL BIOCHEM, V43, P1411, DOI 10.1016/j.soilbio.2010.10.002; Stark LR, 2010, BRYOLOGIST, V113, P788, DOI 10.1639/0007-2745-113.4.788; Steidle JLM, 1997, J INSECT BEHAV, V10, P331, DOI 10.1007/BF02765601; THIMM T, 1995, BIOL FERT SOILS, V19, P266, DOI 10.1007/BF00336171; van Dam NM, 2008, PLANT BIOLOGY, V10, P29, DOI 10.1055/s-2007-964961; Varga S, 2008, AM J BOT, V95, P1225, DOI 10.3732/ajb.0800068; VERHOEF HA, 1977, J INSECT PHYSIOL, V23, P1009, DOI 10.1016/0022-1910(77)90128-7; Voigt CC, 2005, J MAMMAL, V86, P745, DOI 10.1644/1545-1542(2005)086[0745:BBABSS]2.0.CO;2; Xu J, 2009, INSECT SCI, V16, P57, DOI 10.1111/j.1744-7917.2009.00254.x	36	42	44	3	145	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 20	2012	489	7416					431	U118		10.1038/nature11330	http://dx.doi.org/10.1038/nature11330			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AK	22810584				2022-12-28	WOS:000308860900045
J	Hallal, PC; Andersen, LB; Bull, FC; Guthold, R; Haskell, W; Ekelund, U				Hallal, Pedro C.; Andersen, Lars Bo; Bull, Fiona C.; Guthold, Regina; Haskell, William; Ekelund, Ulf		Lancet Phys Activity Series Workin	Global physical activity levels: surveillance progress, pitfalls, and prospects	LANCET			English	Article							CORONARY-HEART-DISEASE; ACTIVITY QUESTIONNAIRE IPAQ; ALL-CAUSE MORTALITY; LEISURE-TIME; UNITED-STATES; SECULAR TRENDS; RISK-FACTOR; SHORT-FORM; CARDIOVASCULAR RISK; VIGOROUS EXERCISE	To implement effective non-communicable disease prevention programmes, policy makers need data for physical activity levels and trends. In this report, we describe physical activity levels worldwide with data for adults (15 years or older) from 122 countries and for adolescents (13-15-years-old) from 105 countries. Worldwide, 31.1% (95% CI 30.9-31.2) of adults are physically inactive, with proportions ranging from 17.0% (16.8-17.2) in southeast Asia to about 43% in the Americas and the eastern Mediterranean. Inactivity rises with age, is higher in women than in men, and is increased in high-income countries. The proportion of 13-15-year-olds doing fewer than 60 min of physical activity of moderate to vigorous intensity per day is 80.3% (80.1-80.5); boys are more active than are girls. Continued improvement in monitoring of physical activity would help to guide development of policies and programmes to increase activity levels and to reduce the burden of non-communicable diseases.	[Hallal, Pedro C.] Univ Fed Pelotas, Pelotas, Brazil; [Andersen, Lars Bo] Univ So Denmark, Ctr Res Childhood Hlth, Dept Exercise Epidemiol, Odense, Denmark; [Bull, Fiona C.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia; [Guthold, Regina] WHO, Dept Chron Dis & Hlth Promot, Geneva, Switzerland; [Haskell, William] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; [Ekelund, Ulf] MRC, Epidemiol Unit, Cambridge, England; [Andersen, Lars Bo; Ekelund, Ulf] Norwegian Sch Sport Sci, Dept Sport Med, Oslo, Norway	Universidade Federal de Pelotas; University of Southern Denmark; University of Western Australia; World Health Organization; Stanford University; Norwegian School of Sport Sciences	Hallal, PC (corresponding author), Rua Marechal Deodoro 1160, BR-96020220 Pelotas, RS, Brazil.	prchallal@gmail.com	Hallal, Pedro C/A-3249-2011; Reis, Rodrigo/F-7447-2012; lobelo, felipe/B-9148-2013; Lambert, Estelle/ABF-1268-2020; Guthold, Regina/AAD-9998-2021; Sarmiento, Olga L/AAS-4165-2020; Ekelund, Ulf/AAE-8471-2019; Martin, Brian W/H-3241-2012; Kahlmeier, Sonja/B-8141-2014; Bull, Fiona C/G-4148-2012; Owen, Neville/K-5986-2012; Sallis, James F/D-3001-2014; Parra, Diana/D-7633-2013; Katzmarzyk, Peter/N-1974-2017; Loos, Ruth/Q-2862-2016; Wells, Jonathan/A-4604-2009	Hallal, Pedro C/0000-0003-1470-6461; Reis, Rodrigo/0000-0002-9872-9865; Lambert, Estelle/0000-0003-4315-9153; Guthold, Regina/0000-0003-3073-6468; Sarmiento, Olga L/0000-0002-9190-3568; Ekelund, Ulf/0000-0003-2115-9267; Kahlmeier, Sonja/0000-0001-6905-9244; Owen, Neville/0000-0003-2784-4820; Sallis, James F/0000-0003-2555-9452; Parra, Diana/0000-0002-9797-6231; Goenka, Shifalika/0000-0001-6993-2883; Katzmarzyk, Peter/0000-0002-9280-6022; Loos, Ruth/0000-0002-8532-5087; Wells, Jonathan/0000-0003-0411-8025	Medical Research Council [MC_U106188470, MC_U106179473] Funding Source: Medline; MRC [MC_U106188470, MC_U106179473] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ainsworth BE, 2006, MED SCI SPORT EXER, V38, P1584, DOI 10.1249/01.mss.0000229457.73333.9a; Andersen LB, 2009, SCAND J MED SCI SPOR, V19, P406, DOI 10.1111/j.1600-0838.2008.00803.x; Andersen LB, 2011, J PHYS ACT HEALTH, V8, P1025, DOI 10.1123/jpah.8.8.1025; Andersen LB, 2000, ARCH INTERN MED, V160, P1621, DOI 10.1001/archinte.160.11.1621; [Anonymous], 2009, GLOBAL HEALTH RISKS: MORTALITY AND BURDEN OF DISEASE ATTRIBUTABLE TO SELECTED MAJOR RISKS, P1; [Anonymous], INT PHYS ACT QUEST; Armstrong Timothy, 2003, Ethn Dis, V13, pS13; Assah FK, 2011, DIABETES CARE, V34, P491, DOI 10.2337/dc10-0990; Baptista F, 2012, MED SCI SPORT EXER, V44, P466, DOI 10.1249/MSS.0b013e318230e441; Bassett DR, 2008, J PHYS ACT HEALTH, V5, P795, DOI 10.1123/jpah.5.6.795; Bauman A, 2011, AM J PREV MED, V41, P228, DOI 10.1016/j.amepre.2011.05.003; Bauman A, 2009, J PHYS ACT HEALTH, V6, pS5, DOI 10.1123/jpah.6.s1.s5; Bell AC, 2006, ASIA-PAC J PUBLIC HE, V18, P62, DOI 10.1177/10105395060180011001; Booth FW, 2008, EUR J APPL PHYSIOL, V102, P381, DOI 10.1007/s00421-007-0606-5; Brownson RC, 2005, ANNU REV PUBL HEALTH, V26, P421, DOI 10.1146/annurev.publhealth.26.021304.144437; Buliung RN, 2009, PREV MED, V48, P507, DOI 10.1016/j.ypmed.2009.03.001; Bull F.C., 2004, PHYS INACTIVITY, V1, P729; Bull FC, 2011, J HEALTH COMMUN, V16, P13, DOI 10.1080/10810730.2011.601226; Bull FC, 2009, J PHYS ACT HEALTH, V6, P790, DOI 10.1123/jpah.6.6.790; Centers for Disease Control and Prevention National Center for Health Statistics, 2012, NAT HLTH NUTR EX SUR; Central Statistics Office Ireland, 2006, 2006 CENS TRAV WORK; Chen IJ, 2008, NURS ECON, V26, P263; Cooper AR, 2008, PREV MED, V47, P324, DOI 10.1016/j.ypmed.2008.06.009; Cooper AR, 2006, MED SCI SPORT EXER, V38, P1724, DOI 10.1249/01.mss.0000229570.02037.1d; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Danish Ministry of Transport and Energy, 2007, MOR BIK SAF ROADS DE; de Nazelle A, 2011, ENVIRON INT, V37, P766, DOI 10.1016/j.envint.2011.02.003; Department for Transport, 2006, UK NAT TRAV SURV; Department of Transport, 2004, TRANSP STAT B NAT TR; Dumith SC, 2011, PREV MED, V53, P24, DOI 10.1016/j.ypmed.2011.02.017; Eaton Danice K., 2012, Morbidity and Mortality Weekly Report, V61, P1; Ekelund U, 2006, PUBLIC HEALTH NUTR, V9, P258, DOI 10.1079/PHN2005840; Ekelund U, 2011, BRIT J SPORT MED, V45, P859, DOI 10.1136/bjsports-2011-090190; Federal Office for Spatial Development Federal Statistical Office Switzerland, MICR TRAV BEH; Florindo AA, 2009, J PHYS ACT HEALTH, V6, P625, DOI 10.1123/jpah.6.5.625; Florindo AA, 2009, REV SAUDE PUBL, V43, P65, DOI 10.1590/S0034-89102009000900009; Gordon-Larsen P, 2009, ARCH INTERN MED, V169, P1216, DOI 10.1001/archinternmed.2009.163; Grize L, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-28; Guthold R, 2011, AM J PREV MED, V41, P52, DOI 10.1016/j.amepre.2011.03.008; Guthold R, 2010, J PEDIATR-US, V157, P43, DOI 10.1016/j.jpeds.2010.01.019; Hagstromer M, 2007, MED SCI SPORT EXER, V39, P1502, DOI 10.1249/mss.0b013e3180a76de5; Hagstromer M, 2010, AM J EPIDEMIOL, V171, P1055, DOI 10.1093/aje/kwq069; Hallal Pedro C., 2005, Cad. Saúde Pública, V21, P573, DOI 10.1590/S0102-311X2005000200024; Hallal Pedro C, 2011, Rev. bras. epidemiol., V14, P53, DOI 10.1590/S1415-790X2011000500006; Hallal PC, 2006, SPORTS MED, V36, P1019, DOI 10.2165/00007256-200636120-00003; Hallal PC, 2010, J PHYS ACT HEALTH, V7, pS259, DOI 10.1123/jpah.7.s2.s259; Hamer M, 2008, PREV MED, V46, P9, DOI 10.1016/j.ypmed.2007.03.006; Hansen BH, 2012, MED SCI SPORT EXER, V44, P266, DOI 10.1249/MSS.0b013e31822cb354; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; Hu FB, 1999, JAMA-J AM MED ASSOC, V282, P1433, DOI 10.1001/jama.282.15.1433; Hu G, 2003, DIABETOLOGIA, V46, P322, DOI 10.1007/s00125-003-1031-x; Hu G, 2004, CIRCULATION, V110, P666, DOI 10.1161/01.CIR.0000138102.23783.94; Ingram DK, 2000, MED SCI SPORT EXER, V32, P1623; Inoue S, 2011, MED SCI SPORT EXER, V43, P1913, DOI 10.1249/MSS.0b013e31821a5225; Juneau CE, 2010, PREV MED, V51, P384, DOI 10.1016/j.ypmed.2010.09.002; Knuth AG, 2009, J PHYS ACT HEALTH, V6, P548, DOI 10.1123/jpah.6.5.548; Knuth AG, 2010, J EPIDEMIOL COMMUN H, V64, P591, DOI 10.1136/jech.2009.088526; Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9; Lee PH, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-115; Lee PH, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-81; Lee SA, 2007, MED SCI SPORT EXER, V39, P1700, DOI 10.1249/mss.0b013e3181238a52; Levine JA, 2005, SCIENCE, V307, P584, DOI 10.1126/science.1106561; Lindstrom M, 2008, PREV MED, V46, P22, DOI 10.1016/j.ypmed.2007.07.012; Lynam D, 2005, EXTENDED STUDY DEV R; Manson JE, 1999, NEW ENGL J MED, V341, P650, DOI 10.1056/NEJM199908263410904; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; Manson JE, 2002, NEW ENGL J MED, V347, P716, DOI 10.1056/NEJMoa021067; Matsudo VKR, 2010, MED SCI SPORT EXER, V42, P2231, DOI 10.1249/MSS.0b013e3181e1fe8e; Matthews CE, 2007, AM J EPIDEMIOL, V165, P1343, DOI 10.1093/aje/kwm088; McDonald NC, 2007, AM J PREV MED, V32, P509, DOI 10.1016/j.amepre.2007.02.022; Melkevik O, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-46; Meschik M, RADVERKEHR ZAHLEN DA; Mobilitat in Deutschland, 2012, NAT TRANSP SURV ACT, P1; Monteiro Carlos A., 2003, Rev Panam Salud Publica, V14, P246, DOI 10.1590/S1020-49892003000900005; Morris JN, 1997, SPORTS MED, V23, P306, DOI 10.2165/00007256-199723050-00004; MORRIS JN, 1953, LANCET, V265, P1053; Ogilvie D, 2007, BMJ-BRIT MED J, V334, P1204, DOI 10.1136/bmj.39198.722720.BE; Oja P, 2011, SCAND J MED SCI SPOR, V21, P496, DOI 10.1111/j.1600-0838.2011.01299.x; Ostergaard L, 2011, J PHYS ACT HEALTH; Owen N, 2010, EXERC SPORT SCI REV, V38, P105, DOI 10.1097/JES.0b013e3181e373a2; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; Palacios-Cena D, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-799; Pratt M, 2012, LANCET, V380, P282, DOI 10.1016/S0140-6736(12)60736-3; Pucher J, 2011, AM J PUBLIC HEALTH, V101, pS310, DOI 10.2105/AJPH.2010.300067; Pucher J, 2011, TRANSPORT RES A-POL, V45, P451, DOI 10.1016/j.tra.2011.03.001; Pucher J, 2010, AM J PUBLIC HEALTH, V100, P1986, DOI 10.2105/AJPH.2009.189324; Pucher J, 2010, PREV MED, V50, pS106, DOI 10.1016/j.ypmed.2009.07.028; Raustorp A, 2007, ACTA PAEDIATR, V96, P1824, DOI 10.1111/j.1651-2227.2007.00525.x; Riddoch CJ, 2004, MED SCI SPORT EXER, V36, P86, DOI 10.1249/01.MSS.0000106174.43932.92; Rzewnicki R, 2003, PUBLIC HEALTH NUTR, V6, P299, DOI 10.1079/PHN2002427; Schnohr P, 2007, EUR J CARDIOV PREV R, V14, P72, DOI 10.1097/HJR.0b013e3280144470; Schnohr P, 2012, EUR J PREV CARDIOL, V19, P73, DOI 10.1177/1741826710393196; Sherar LB, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-485; Sigmundova D, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-731; Simpson ME, 2003, AM J PREV MED, V25, P95, DOI 10.1016/S0749-3797(03)00112-0; Sjol A, 2003, SCAND J MED SCI SPOR, V13, P224, DOI 10.1034/j.1600-0838.2003.00310.x; Stamatakis E, 2008, BRIT J SPORT MED, V42, P901, DOI 10.1136/bjsm.2008.048082; Statistics Canada, 2001, CAN WORK THEY GET TH; Statistics Netherlands, 2008, NAT TRAV SURV; Steffen LM, 2006, MED SCI SPORT EXER, V38, P1716, DOI 10.1249/01.mss.0000227407.83851.ba; Stigell E, 2011, THESIS, P1; Sullivan R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024898; Thompson AM, 2009, PREV MED, V49, P407, DOI 10.1016/j.ypmed.2009.09.009; Tin ST, 2009, INT J BEHAV NUTR PHY, V6, DOI 10.1186/1479-5868-6-64; Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3; Trost SG, 2002, MED SCI SPORT EXER, V34, P350, DOI 10.1097/00005768-200202000-00025; Wagner A, 2001, INT J OBESITY, V25, P940, DOI 10.1038/sj.ijo.0801635; Wen LM, 2008, PREV MED, V46, P29, DOI 10.1016/j.ypmed.2007.08.009; Weuve J, 2004, JAMA-J AM MED ASSOC, V292, P1454, DOI 10.1001/jama.292.12.1454; WHO, 2010, SCREENING DONATED BLOOD FOR TRANSFUSION: TRANSMISSIBLE INFECTIONS, P1; WHO, 2011, GLOB STAT REP NONC D; WHO, 2011, GLOB PHYS ACT SURV; WHO Europe, 2008, IN YOUNG PEOPL HLTH; WHO Regional Office for Europe, 2008, IN YOUNG PEOPL HLTH; World Health Organization, 2004, GLOB STRAT DIET PHYS; World Health Organization, 2011, GLOB HLTH OBS DAT RE; World Health Organization, 2011, GLOB SCH BAS STUD HL; Yang Lin, 2010, BMJ, V341, pc5293, DOI 10.1136/bmj.c5293	119	3150	3314	27	84	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2012	380	9838					247	257		10.1016/S0140-6736(12)60646-1	http://dx.doi.org/10.1016/S0140-6736(12)60646-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976TV	22818937	Green Submitted			2022-12-28	WOS:000306609200034
J	Sessa, B				Sessa, Ben			Shaping the renaissance of psychedelic research	LANCET			English	Editorial Material							ASSISTED PSYCHOTHERAPY; PSILOCYBIN		CAMHS Team, Taunton TA2 7PQ, Somerset, England		Sessa, B (corresponding author), CAMHS Team, Fdn House,Wellsprings Rd, Taunton TA2 7PQ, Somerset, England.	bensessa@gmail.com						Carhart-Harris RL, 2012, BRIT J PSYCHIAT, V200, P238, DOI 10.1192/bjp.bp.111.103309; Griffiths RR, 2006, PSYCHOPHARMACOLOGY, V187, P268, DOI 10.1007/s00213-006-0457-5; Grob CS, 2011, ARCH GEN PSYCHIAT, V68, P71, DOI 10.1001/archgenpsychiatry.2010.116; Krupitsky EM, 2007, J PSYCHOACTIVE DRUGS, V39, P13, DOI 10.1080/02791072.2007.10399860; MALLESON N, 1971, BRIT J PSYCHIAT, V118, P229, DOI 10.1192/bjp.118.543.229; Mithoefer MC, 2011, J PSYCHOPHARMACOL, V25, P439, DOI 10.1177/0269881110378371; Moreno FA, 2006, J CLIN PSYCHIAT, V67, P1735, DOI 10.4088/JCP.v67n1110; Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4; Sessa B, 2005, BRIT J PSYCHIAT, V186, P457, DOI 10.1192/bjp.186.6.457; Sessa B, 2011, PROG NEUROL PSYCHIAT, V15, P4, DOI 10.1002/pnp.216; Sewell RA, 2006, NEUROLOGY, V66, P1920, DOI 10.1212/01.wnl.0000219761.05466.43; Wade D, 2006, BRIT J PSYCHIAT, V189, P229, DOI 10.1192/bjp.bp.105.017236; Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856	13	36	36	1	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2012	380	9838					200	201		10.1016/S0140-6736(12)60600-X	http://dx.doi.org/10.1016/S0140-6736(12)60600-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976TV	22817963				2022-12-28	WOS:000306609200011
J	Andrault, D; Petitgirard, S; Lo Nigro, G; Devidal, JL; Veronesi, G; Garbarino, G; Mezouar, M				Andrault, Denis; Petitgirard, Sylvain; Lo Nigro, Giacomo; Devidal, Jean-Luc; Veronesi, Giulia; Garbarino, Gaston; Mezouar, Mohamed			Solid-liquid iron partitioning in Earth's deep mantle	NATURE			English	Article							POST-PEROVSKITE; SILICATE PEROVSKITE; MELTING EXPERIMENTS; MAGMA OCEAN; PERIDOTITE; CONSTRAINTS; SIGNATURE; BOUNDARY; ELEMENTS; SYSTEM	Melting processes in the deep mantle have important implications for the origin of the deep-derived plumes believed to feed hotspot volcanoes such as those in Hawaii(1). They also provide insight into how the mantle has evolved, geochemically and dynamically, since the formation of Earth(2). Melt production in the shallow mantle is quite well understood, but deeper melting near the core-mantle boundary remains controversial. Modelling the dynamic behaviour of deep, partially molten mantle requires knowledge of the density contrast between solid and melt fractions. Although both positive and negative melt buoyancies can produce major chemical segregation between different geochemical reservoirs, each type of buoyancy yields drastically different geodynamical models. Ascent or descent of liquids in a partially molten deep mantle should contribute to surface volcanism or production of a deep magma ocean, respectively. We investigated phase relations in a partially molten chondritic-type material under deep-mantle conditions. Here we show that the iron partition coefficient between aluminium-bearing (Mg,Fe)SiO3 perovskite and liquid is between 0.45 and 0.6, so iron is not as incompatible with deep-mantle minerals as has been reported previously(3). Calculated solid and melt density contrasts suggest that melt generated at the core-mantle boundary should be buoyant, and hence should segregate upwards. In the framework of the magma oceans induced by large meteoritic impacts on early Earth, our results imply that the magma crystallization should push the liquids towards the surface and form a deep solid residue depleted in incompatible elements.	[Andrault, Denis; Lo Nigro, Giacomo; Devidal, Jean-Luc] Univ Blaise Pascal, CNRS, IRD, Lab Magmas & Volcans, F-63038 Clermont Ferrand, France; [Petitgirard, Sylvain; Veronesi, Giulia; Garbarino, Gaston; Mezouar, Mohamed] European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Clermont Auvergne (UCA); European Synchrotron Radiation Facility (ESRF)	Andrault, D (corresponding author), Univ Blaise Pascal, CNRS, IRD, Lab Magmas & Volcans, F-63038 Clermont Ferrand, France.	d.andrault@opgc.univ-bpclermont.fr	Garbarino, Gaston L/D-1807-2013; ANDRAULT, Denis/N-8843-2016	ANDRAULT, Denis/0000-0002-9921-4572; Veronesi, Giulia/0000-0001-9228-6082	French National Centre for Scientific Research's National Institute for Earth Sciences and Astronomy; ESRF; European C2C programme	French National Centre for Scientific Research's National Institute for Earth Sciences and Astronomy; ESRF; European C2C programme	We thank N. Bolfan-Casanova, M. A. Bouhifd, T. Druitt, T. Hammouda and J.-M. Henot for help and discussions. This work is supported by the French National Centre for Scientific Research's National Institute for Earth Sciences and Astronomy, the ESRF and the European C2C programme. This is Laboratory of Excellence ClerVolc contribution no. 26.	Andrault D, 2011, EARTH PLANET SC LETT, V304, P251, DOI 10.1016/j.epsl.2011.02.006; Andrault D, 2010, EARTH PLANET SC LETT, V293, P90, DOI 10.1016/j.epsl.2010.02.026; Auzende AL, 2008, EARTH PLANET SC LETT, V269, P164, DOI 10.1016/j.epsl.2008.02.001; Buffett BA, 2000, SCIENCE, V290, P1338, DOI 10.1126/science.290.5495.1338; Corgne A, 2005, GEOCHIM COSMOCHIM AC, V69, P485, DOI 10.1016/j.gca.2004.06.041; Davaille A, 1999, NATURE, V402, P756, DOI 10.1038/45461; Fiquet G, 2010, SCIENCE, V329, P1516, DOI 10.1126/science.1192448; Funamori N, 2010, EARTH PLANET SC LETT, V295, P435, DOI 10.1016/j.epsl.2010.04.021; Hammersley J., 1996, FIT2D USER MANUAL; Hernlund JW, 2010, EARTH PLANET SC LETT, V296, P1, DOI 10.1016/j.epsl.2010.04.027; Hirose K, 2004, PHYS EARTH PLANET IN, V146, P249, DOI 10.1016/j.pepi.2002.11.001; Ito E, 2004, PHYS EARTH PLANET IN, V143, P397, DOI 10.1016/j.pepi.2003.09.016; Kobayashi Y, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023257; Labrosse S, 2007, NATURE, V450, P866, DOI 10.1038/nature06356; Laporte D, 2004, CONTRIB MINERAL PETR, V146, P463, DOI 10.1007/s00410-003-0509-3; Larson AC, 1988, GSAS MANUAL; Lay T, 2004, PHYS EARTH PLANET IN, V146, P441, DOI 10.1016/j.pepi.2004.04.004; Liebske C, 2005, CONTRIB MINERAL PETR, V149, P113, DOI 10.1007/s00410-004-0641-8; Litasov K, 2002, PHYS EARTH PLANET IN, V134, P105, DOI 10.1016/S0031-9201(02)00152-8; Manning CE, 2008, EARTH PLANET SC LETT, V272, P730, DOI 10.1016/j.epsl.2008.06.004; Mayanovic RA, 2012, J PHYS CHEM C, V116, P2218, DOI 10.1021/jp2067793; McNamara AK, 2010, EARTH PLANET SC LETT, V299, P1, DOI 10.1016/j.epsl.2010.07.042; Miyajima N, 1999, PHYS EARTH PLANET IN, V116, P117, DOI 10.1016/S0031-9201(99)00127-2; Mosenfelder JL, 2009, J GEOPHYS RES-SOL EA, V114, DOI 10.1029/2008JB005900; Murakami M, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021956; Nomura R, 2011, NATURE, V473, P199, DOI 10.1038/nature09940; Ohtani E, 1998, PHYS EARTH PLANET IN, V107, P75, DOI 10.1016/S0031-9201(97)00125-8; Petitgirard S, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.3680573; Petitgirard S, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3100202; Rost S, 2005, NATURE, V435, P666, DOI 10.1038/nature03620; Sakai T, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026868; Sanchez-Valle C, 2003, AM MINERAL, V88, P978, DOI 10.2138/am-2003-0705; Sata N, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.104114; Solomatov V.S., 2000, ORIGIN EARTH MOON, P323; Stixrude L, 2009, EARTH PLANET SC LETT, V278, P226, DOI 10.1016/j.epsl.2008.12.006; Tronnes RG, 2002, EARTH PLANET SC LETT, V197, P117, DOI 10.1016/S0012-821X(02)00466-1; Walter MJ, 2004, GEOCHIM COSMOCHIM AC, V68, P4267, DOI 10.1016/j.gca.2004.03.014; Wilke M, 2010, J SYNCHROTRON RADIAT, V17, P669, DOI 10.1107/S0909049510023654; Wood BJ, 1996, SCIENCE, V273, P1522, DOI 10.1126/science.273.5281.1522; ZHANG JZ, 1994, J GEOPHYS RES-SOL EA, V99, P17729, DOI 10.1029/94JB01406	40	106	107	1	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 19	2012	487	7407					354	+		10.1038/nature11294	http://dx.doi.org/10.1038/nature11294			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JB	22810700				2022-12-28	WOS:000306506500040
J	Shirani, A; Zhao, YS; Karim, ME; Evans, C; Kingwell, E; van der Kop, ML; Oger, J; Gustafson, P; Petkau, J; Tremlett, H				Shirani, Afsaneh; Zhao, Yinshan; Karim, Mohammad Ehsanul; Evans, Charity; Kingwell, Elaine; van der Kop, Mia L.; Oger, Joel; Gustafson, Paul; Petkau, John; Tremlett, Helen			Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE-MODIFYING DRUGS; IMMORTAL TIME BIAS; NATURAL-HISTORY; BRITISH-COLUMBIA; HEALTH-CARE; DELAYING PROGRESSION; LIFE EXPECTANCY; ONSET MS; TRIALS; IMPAIRMENT	context Interferon beta is widely prescribed to treat multiple sclerosis (MS); however, its relationship with disability progression has yet to be established. Objective To investigate the association between interferon beta exposure and disability progression in patients with relapsing-remitting MS. Design, Setting, and Patients Retrospective cohort study based on prospectively collected data (1985-2008) from British Columbia, Canada. Patients with relapsing-remitting MS treated with interferon beta (n=868) were compared with untreated contemporary (n=829) and historical (n=959) cohorts. Main Outcome Measures The main outcome measure was time from interferon beta treatment eligibility (baseline) to a confirmed and sustained score of 6 (requiring a cane to walk 100 m; confirmed at >150 days with no measurable improvement) on the Expanded Disability Status Scale (EDSS) (range, 0-10, with higher scores indicating higher disability). A multivariable Cox regression model with interferon beta treatment included as a time-varying covariate was used to assess the hazard of disease progression associated with interferon beta treatment. Analyses also included propensity score adjustment to address confounding by indication. Results The median active follow-up times (first to last EDSS measurement) were as follows: for the interferon beta-treated cohort, 5.1 years (interquartile range [IQR], 3.0-7.0 years); for the contemporary control cohort, 4.0 years (IQR, 2.1-6.4 years); and for the historical control cohort, 10.8 years (IQR, 6.3-14.7 years). The observed outcome rates for reaching a sustained EDSS score of 6 were 10.8%, 5.3%, and 23.1% in the 3 cohorts, respectively. After adjustment for potential baseline confounders (sex, age, disease duration, and EDSS score), exposure to interferon beta was not associated with a statistically significant difference in the hazard of reaching an EDSS score of 6 when either the contemporary control cohort (hazard ratio, 1.30; 95% CI, 0.92-1.83; P=.14) or the historical control cohort (hazard ratio, 0.77; 95% CI, 0.58-1.02; P=.07) were considered. Further adjustment for comorbidities and socioeconomic status, where possible, did not change interpretations, and propensity score adjustment did not substantially change the results. Conclusion Among patients with relapsing-remitting MS, administration of interferon beta was not associated with a reduction in progression of disability. JAMA. 2012;308(3):247-256 www.jama.com	[Zhao, Yinshan] Univ British Columbia, Div Neurol, MS MRI Res Grp, Dept Med, Vancouver, BC V6T 2B5, Canada; [Shirani, Afsaneh; Evans, Charity; Kingwell, Elaine; van der Kop, Mia L.; Oger, Joel; Tremlett, Helen] Univ British Columbia, Dept Med, Brain Res Ctr, Vancouver, BC V6T 2B5, Canada; [Shirani, Afsaneh; Evans, Charity; Kingwell, Elaine; van der Kop, Mia L.; Oger, Joel; Tremlett, Helen] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Vancouver, BC V6T 2B5, Canada; [Karim, Mohammad Ehsanul; Gustafson, Paul; Petkau, John] Univ British Columbia, Dept Stat, Vancouver, BC V6T 2B5, Canada	University of British Columbia; University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia	Tremlett, H (corresponding author), Univ British Columbia, Dept Med, Div Neurol, UBC Hosp, Room S178,2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.	helen.tremlett@ubc.ca	Zhao, Yinshan/K-4789-2014; Tremlett, Helen/AAE-7983-2020; Karim, Ehsan/I-1803-2018	Zhao, Yinshan/0000-0001-5433-4637; Tremlett, Helen/0000-0001-5804-2535; Karim, Ehsan/0000-0002-0346-2871; Kingwell, Elaine/0000-0002-1956-1700	endMS Research and Training Network; European Committee for Treatment and Research in Multiple Sclerosis; International Society for Pharmacoepidemiology; Bayer Schering Pharma; Aventis; Bayer; Biogen-Idec; BioMS; Corixa; Genentech; Novartis; Serono; Shering; Talecris; Teva-Neurosciences; Biogen Idec; Bayer Pharma; Bayer Canada; Bayhill Therapeutics; BTG International; Merck-Serono; Consortium of MS Centres; US National MS Society; Swiss Multiple Sclerosis Society; University of British Columbia Multiple Sclerosis Research Program; Bayer Pharmaceuticals; Teva Pharmaceuticals; Canadian Institutes of Health Research (CIHR) [MOP-93646]; National Multiple Sclerosis Society (NMSS) [RG 4202-A-2]; Multiple Sclerosis Society of Canada; CIHR [MOP-93646]; NMSS [RG 4202-A-2]; Michael Smith Foundation for Health Research; Christopher Foundation; University of British Columbia (UBC); Medical Services Commission of British Columbia; Natural Sciences and Engineering Research Council of Canada; Multiple Sclerosis Society of Canada (Don Paty Career Development Award); UK Multiple Sclerosis Trust; NMSS; Donald Paty	endMS Research and Training Network; European Committee for Treatment and Research in Multiple Sclerosis; International Society for Pharmacoepidemiology; Bayer Schering Pharma(Bayer AG); Aventis(Sanofi-Aventis); Bayer(Bayer AG); Biogen-Idec(Biogen); BioMS; Corixa; Genentech(Roche HoldingGenentech); Novartis(Novartis); Serono(Merck & Company); Shering; Talecris; Teva-Neurosciences(Teva Pharmaceutical Industries); Biogen Idec(Biogen); Bayer Pharma; Bayer Canada(Bayer AG); Bayhill Therapeutics; BTG International; Merck-Serono(Merck & Company); Consortium of MS Centres; US National MS Society(National Multiple Sclerosis Society); Swiss Multiple Sclerosis Society; University of British Columbia Multiple Sclerosis Research Program; Bayer Pharmaceuticals(Bayer AG); Teva Pharmaceuticals(Teva Pharmaceutical Industries); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); National Multiple Sclerosis Society (NMSS)(National Multiple Sclerosis Society); Multiple Sclerosis Society of Canada; CIHR(Canadian Institutes of Health Research (CIHR)); NMSS(National Multiple Sclerosis Society); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); Christopher Foundation; University of British Columbia (UBC); Medical Services Commission of British Columbia; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Multiple Sclerosis Society of Canada (Don Paty Career Development Award); UK Multiple Sclerosis Trust; NMSS(National Multiple Sclerosis Society); Donald Paty	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Shirani reports receiving travel grants to present at and attend conferences from the endMS Research and Training Network and the European Committee for Treatment and Research in Multiple Sclerosis. Mr Karim reports having had travel and accommodation costs covered to present at a conference from the endMS Research and Training Network. Dr Evans reports receiving travel grants to present at and attend conferences from the endMS Research and Training Network and the European Committee for Treatment and Research in Multiple Sclerosis. Dr Kingwell reports having had travel and accommodation costs covered to present at and attend conferences from the endMS Research and Training Network, the International Society for Pharmacoepidemiology, and Bayer Schering Pharma. Dr Oger reports receiving speaker honoraria, consulting fees, travel grants, research grants, and/or educational grants from Aventis, Bayer, Biogen-Idec, BioMS, Corixa, Genentech, Novartis, Serono, Shering, Talecris, and Teva-Neurosciences. He receives fees for services from Bayer, Novartis, and Biogen Idec to serve on advisory committees. Dr Petkau reports having received research funds from Bayer Pharma and consulting fees and/or fees for service on data safety monitoring boards from Bayer Canada, Bayer Pharma, Bayhill Therapeutics, BTG International, Merck-Serono, and Novartis. Dr Tremlett reports having received speaker honoraria and/or travel expenses to speak at conferences from the Consortium of MS Centres, US National MS Society, Swiss Multiple Sclerosis Society, University of British Columbia Multiple Sclerosis Research Program, Bayer Pharmaceuticals (invited speaker, honoraria declined), and Teva Pharmaceuticals (invited speaker). Unless otherwise stated, all speaker honoraria are either donated to an MS charity or to an unrestricted grant for use by her research group. No other disclosures were reported.; This study was supported by grant MOP-93646 from the Canadian Institutes of Health Research (CIHR; principal investigator: Dr Tremlett) and grant RG 4202-A-2 from the National Multiple Sclerosis Society (NMSS; principal investigator: Dr Tremlett). Dr Shirani is funded through a postdoctoral fellowship from the Multiple Sclerosis Society of Canada and grants from the CIHR (MOP-93646) and the NMSS (RG 4202-A-2). Dr Zhao receives research funding from the CIHR, the Multiple Sclerosis Society of Canada, and the NMSS. Dr Evans is funded through grants from the CIHR (MOP-93646), the NMSS (RG 4202-A-2), and the Michael Smith Foundation for Health Research. Dr Kingwell is supported by postdoctoral fellowships from the Multiple Sclerosis Society of Canada and the Michael Smith Foundation for Health Research. Dr Oger receives support from the Christopher Foundation and the University of British Columbia (UBC). He receives fees for service from the Medical Services Commission of British Columbia. Dr Gustafson is supported by the Natural Sciences and Engineering Research Council of Canada. Dr Petkau holds research grants from the CIHR, the Multiple Sclerosis Society of Canada, the NMSS, and the Natural Sciences and Engineering Research Council of Canada. Dr Tremlett is funded by the Multiple Sclerosis Society of Canada (Don Paty Career Development Award), is a Michael Smith Foundation for Health Research Scholar, and is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis. She has also received research support from the NMSS, CIHR, and UK Multiple Sclerosis Trust. The BCMS database has been funded from various sources (including the above) and also by an unrestricted grant from Donald Paty, MD, FRCPC, University of British Columbia, and the MS/MRI Research Group.	Arbizu T, 2000, ACTA NEUROL SCAND, V102, P209, DOI 10.1034/j.1600-0404.2000.102004209.x; Berkman L, 2008, NEW ENGL J MED, V358, P2509, DOI 10.1056/NEJMe0802773; Boggild M, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4677; Brenner SR, 2008, NEUROLOGY, V71, P615, DOI 10.1212/01.wnl.0000324708.37575.5c; Brown MG, 2007, NEUROLOGY, V69, P1498, DOI 10.1212/01.wnl.0000271884.11129.f3; Coppola G, 2006, EUR J NEUROL, V13, P1014, DOI 10.1111/j.1468-1331.2006.01422.x; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Dimick JB, 2010, ARCH SURG-CHICAGO, V145, P927, DOI 10.1001/archsurg.2010.223; Ebers GC, 2008, NEUROLOGY, V71, P624, DOI 10.1212/01.wnl.0000313034.46883.16; Ebers GC, 2010, J NEUROL NEUROSUR PS, V81, P907, DOI 10.1136/jnnp.2009.204123; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Filippini G, 2003, LANCET, V361, P545, DOI 10.1016/S0140-6736(03)12512-3; Giovannoni G, 2002, J NEUROL NEUROSUR PS, V73, P465, DOI 10.1136/jnnp.73.5.465; Gout O, 2008, ANN NEUROL, V63, P126, DOI 10.1002/ana.21186; Haut ER, 2011, JAMA-J AM MED ASSOC, V305, P2462, DOI 10.1001/jama.2011.822; Haynes B, 1999, BRIT MED J, V319, P652, DOI 10.1136/bmj.319.7211.652; Kappos L, 2006, NEUROLOGY, V67, P944, DOI 10.1212/01.wnl.0000237994.95410.ce; Kappos L, 2009, LANCET NEUROL, V8, P987, DOI 10.1016/S1474-4422(09)70237-6; Koch M, 2008, ANN NEUROL, V63, P125, DOI 10.1002/ana.21185; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Liu C, 2000, J NEUROL NEUROSUR PS, V68, P450, DOI 10.1136/jnnp.68.4.450; Milanese C, 2003, J NEUROL NEUROSUR PS, V74, P1689, DOI 10.1136/jnnp.74.12.1689; Multiple Sclerosis Society of Canada, TREATM MOD DIS COURS; Noseworthy JH, 2006, NEUROLOGY, V67, P930, DOI 10.1212/01.wnl.0000241080.31577.df; Paolillo A, 2002, EUR J NEUROL, V9, P645, DOI 10.1046/j.1468-1331.2002.00476.x; Pozzilli C, 2005, NEUROL SCI, V26, pS174, DOI 10.1007/s10072-005-0510-x; Renoux C, 2008, ANN NEUROL, V64, P109, DOI 10.1002/ana.21352; Rosenbaum P., 1987, STAT SCI, V2, P292, DOI [DOI 10.1214/SS/1177013232, 10.2307/2245766]; SADOVNICK AD, 1992, NEUROLOGY, V42, P991, DOI 10.1212/WNL.42.5.991; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Shirani A, 2012, MULT SCLER J, V18, P442, DOI 10.1177/1352458511422097; Skoog B, 2012, BRAIN, V135, P900, DOI 10.1093/brain/awr336; Sturmer T, 2011, EPIDEMIOLOGY, V22, P298, DOI 10.1097/EDE.0b013e318212640c; Suissa S, 2007, PHARMACOEPIDEM DR S, V16, P241, DOI 10.1002/pds.1357; SWEENEY VP, 1986, CAN J NEUROL SCI, V13, P47, DOI 10.1017/S0317167100035782; Tremlett H, 2008, J NEUROL NEUROSUR PS, V79, P1368, DOI 10.1136/jnnp.2008.145805; Tremlett H, 2005, NEUROLOGY, V65, P1919, DOI 10.1212/01.wnl.0000188880.17038.1d; Tremlett H, 2006, NEUROLOGY, V66, P172, DOI 10.1212/01.wnl.0000194259.90286.fe; Tremlett H, 2009, NEUROLOGY, V73, P1616, DOI 10.1212/WNL.0b013e3181c1e44f; Tremlett H, 2008, MULT SCLER J, V14, P314, DOI 10.1177/1352458507084264; Tremlett H, 2006, NEUROLOGY, V67, P954, DOI 10.1212/01.wnl.0000237475.01655.9d; Trojano M, 2003, MULT SCLER J, V9, P451, DOI 10.1191/1352458503ms948oa; Trojano M, 2007, ANN NEUROL, V61, P300, DOI 10.1002/ana.21102; Uitdehaag Bernard, 2011, Ther Adv Neurol Disord, V4, P3, DOI 10.1177/1756285610391693; Wilkins R., 2002, HLTH REP S, V13, P1; WILLOUGHBY EW, 1988, NEUROLOGY, V38, P1793, DOI 10.1212/WNL.38.11.1793	46	202	203	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2012	308	3					247	256		10.1001/jama.2012.7625	http://dx.doi.org/10.1001/jama.2012.7625			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975AC	22797642	Bronze			2022-12-28	WOS:000306477900025
J	Diehl, AK				Diehl, Andrew K.			Individual-patient meta-analysis: Daily aspirin reduces risk for incident cancer with distant metastasis	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Diehl, Andrew K.] Univ Texas Hlth Sci Ctr, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio	Diehl, AK (corresponding author), Univ Texas Hlth Sci Ctr, San Antonio, TX USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2							JC2-3	10.7326/0003-4819-157-2-201207170-02003	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-02003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801695				2022-12-28	WOS:000307787900002
J	Watts, G				Watts, Geoff			Amy Tsui: population expert for whom people count	LANCET			English	Biographical-Item																			0	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2012	380	9837					100	100		10.1016/S0140-6736(12)61164-7	http://dx.doi.org/10.1016/S0140-6736(12)61164-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22794232				2022-12-28	WOS:000306359100021
J	Lee, SW; Markham, PF; Coppo, MJC; Legione, AR; Markham, JF; Noormohammadi, AH; Browning, GF; Ficorilli, N; Hartley, CA; Devlin, JM				Lee, Sang-Won; Markham, Philip F.; Coppo, Mauricio J. C.; Legione, Alistair R.; Markham, John F.; Noormohammadi, Amir H.; Browning, Glenn F.; Ficorilli, Nino; Hartley, Carol A.; Devlin, Joanne M.			Attenuated Vaccines Can Recombine to Form Virulent Field Viruses	SCIENCE			English	Article							INFECTIOUS LARYNGOTRACHEITIS VIRUS		[Lee, Sang-Won; Markham, Philip F.; Coppo, Mauricio J. C.; Legione, Alistair R.; Browning, Glenn F.; Ficorilli, Nino; Hartley, Carol A.; Devlin, Joanne M.] Univ Melbourne, Fac Vet Sci, Asia Pacific Ctr Anim Hlth, Parkville, Vic 3010, Australia; [Noormohammadi, Amir H.] Univ Melbourne, Asia Pacific Ctr Anim Hlth, Fac Vet Sci, Werribee, Vic 3030, Australia; [Markham, John F.] Univ Melbourne, Sch Engn, Dept Elect & Elect Engn, Natl ICT Australia NICTA Victoria Res Lab, Melbourne, Vic 3010, Australia	University of Melbourne; University of Melbourne; NICTA; University of Melbourne	Devlin, JM (corresponding author), Univ Melbourne, Fac Vet Sci, Asia Pacific Ctr Anim Hlth, Parkville, Vic 3010, Australia.	devlinj@unimelb.edu.au	Browning, Glenn Francis/P-4459-2014; Legione, Alistair/AAX-6064-2020; Legione, Alistair/L-9102-2015	Browning, Glenn Francis/0000-0002-0903-2469; Legione, Alistair/0000-0003-2407-4496; Legione, Alistair/0000-0003-2407-4496; Hartley, Carol/0000-0001-6174-7341; Coppo, Mauricio/0000-0002-4344-9532; NOORMOHAMMADI, AMIR/0000-0003-3459-2692; Devlin, Joanne/0000-0003-0400-9670; Markham, John/0000-0002-5738-3861	Rural Industries Research and Development Corporation, Australia; NICTA; Australian government; Australian Research Council through the ICT Centre of Excellence program	Rural Industries Research and Development Corporation, Australia; NICTA(NICTA); Australian government(Australian GovernmentCGIAR); Australian Research Council through the ICT Centre of Excellence program(Australian Research Council)	The Rural Industries Research and Development Corporation, Australia, funded this study. This work is supported by NICTA, which is funded by the Australian government as represented by the Department of Broadband, Communications and the Digital Economy and the Australian Research Council through the ICT Centre of Excellence program. Sequence data for the class 8 and 9 viruses have been deposited in GenBank under accession nos. JN804826 and JN804827, respectively. The three reference sequences are Serva, GenBank accession no. HQ_630064; SA2, GenBank accession no. JN596962; A20, GenBank accession no. JN596963.	Bagust TJ, 2000, REV SCI TECH OIE, V19, P483, DOI 10.20506/rst.19.2.1229; Blacker HP, 2011, AUST VET J, V89, P89, DOI 10.1111/j.1751-0813.2010.00665.x; Devlin JM, 2011, VACCINE, V29, P5699, DOI 10.1016/j.vaccine.2011.06.002; Kirkpatrick NC, 2006, AVIAN DIS, V50, P28, DOI 10.1637/7414-072205R.1; Lee SW, 2011, VACCINE, V29, P9583, DOI 10.1016/j.vaccine.2011.10.055; Thiry E, 2005, REV MED VIROL, V15, P89, DOI 10.1002/rmv.451	6	135	145	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2012	337	6091					188	188		10.1126/science.1217134	http://dx.doi.org/10.1126/science.1217134			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798607				2022-12-28	WOS:000306323500047
J	Rangel, TF				Rangel, Thiago F.			Amazonian Extinction Debts	SCIENCE			English	Editorial Material							BRAZILIAN AMAZON; CONSERVATION; FUTURE; DEFORESTATION; BIODIVERSITY; FORESTS; BASIN		Univ Fed Goias, Dept Ecol, BR-74970001 Goiania, Go, Brazil	Universidade Federal de Goias	Rangel, TF (corresponding author), Univ Fed Goias, Dept Ecol, CxP 131, BR-74970001 Goiania, Go, Brazil.	thiagorangel@icb.ufg.br	Rangel, Thiago F/H-8708-2012	Rangel, Thiago F/0000-0002-2001-7382				Chazdon RL, 2008, SCIENCE, V320, P1458, DOI 10.1126/science.1155365; Chazdon RL, 2009, CONSERV BIOL, V23, P1406, DOI 10.1111/j.1523-1739.2009.01338.x; Davidson EA, 2012, NATURE, V481, P321, DOI 10.1038/nature10717; FAITH DP, 1992, BIOL CONSERV, V61, P1, DOI 10.1016/0006-3207(92)91201-3; Gomez-Pompa A, 1999, P NATL ACAD SCI USA, V96, P5982, DOI 10.1073/pnas.96.11.5982; Kuussaari M, 2009, TRENDS ECOL EVOL, V24, P564, DOI 10.1016/j.tree.2009.04.011; Laurance WF, 2001, SCIENCE, V291, P438, DOI 10.1126/science.291.5503.438; Metzger JP, 2010, NAT CONSERVACAO, V8, P92, DOI 10.4322/natcon.00801017; Nepstad D, 2009, SCIENCE, V326, P1350, DOI 10.1126/science.1182108; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; Pimm SL, 2000, NATURE, V403, P843, DOI 10.1038/35002708; Soares BS, 2006, NATURE, V440, P520, DOI 10.1038/nature04389; Soares B, 2010, P NATL ACAD SCI USA, V107, P10821, DOI 10.1073/pnas.0913048107; Wearn OR, 2012, SCIENCE, V337, P228, DOI 10.1126/science.1219013	14	9	9	7	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2012	337	6091					162	163		10.1126/science.1224819	http://dx.doi.org/10.1126/science.1224819			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798589				2022-12-28	WOS:000306323500031
J	Janssen, MA				Janssen, Marco A.			Elinor Ostrom (1933-2012) OBITUARY	NATURE			English	Biographical-Item									Arizona State Univ, Sch Human Evolut & Social Change, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Janssen, MA (corresponding author), Arizona State Univ, Sch Human Evolut & Social Change, Tempe, AZ 85287 USA.	marco.janssen@asu.edu						OSTROM E, PUBLICATION LIST	1	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2012	487	7406					172	172		10.1038/487172a	http://dx.doi.org/10.1038/487172a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972LP	22785305	Bronze			2022-12-28	WOS:000306278900021
J	Berg, MG; Singh, LN; Younis, I; Liu, Q; Pinto, AM; Kaida, D; Zhang, ZX; Cho, SC; Sherrill-Mix, S; Wan, LL; Dreyfuss, G				Berg, Michael G.; Singh, Larry N.; Younis, Ihab; Liu, Qiang; Pinto, Anna Maria; Kaida, Daisuke; Zhang, Zhenxi; Cho, Sungchan; Sherrill-Mix, Scott; Wan, Lili; Dreyfuss, Gideon			U1 snRNP Determines mRNA Length and Regulates Isoform Expression	CELL			English	Article							POLY(A) SITE-SELECTION; SPLICING-INDEPENDENT RECRUITMENT; POLYMERASE CHAIN-REACTION; 3' UNTRANSLATED REGIONS; ALTERNATIVE POLYADENYLATION; II TRANSCRIPTION; FACTOR CSTF-64; GENES; CELLS; CLEAVAGE	U1 snRNP (U1), in addition to its splicing role, protects pre-mRNAs from drastic premature termination by cleavage and polyadenylation (PCPA) at cryptic polyadenylation signals (PASs) in introns. Here, a high-throughput sequencing strategy of differentially expressed transcripts (HIDE-seq) mapped PCPA sites genome wide in divergent organisms. Surprisingly, whereas U1 depletion terminated most nascent gene transcripts within similar to 1 kb, moderate functional U1 level decreases, insufficient to inhibit splicing, dose-dependently shifted PCPA downstream and elicited mRNA 30 UTR shortening and proximal 3 ' exon switching characteristic of activated immune and neuronal cells, stem cells, and cancer. Activated neurons' signature mRNA shortening could be recapitulated by U1 decrease and antagonized by U1 overexpression. Importantly, we show that rapid and transient transcriptional upregulation inherent to neuronal activation physiology creates U1 shortage relative to pre-mRNAs. Additional experiments suggest cotranscriptional PCPA counteracted by U1 association with nascent transcripts, a process we term telescripting, ensuring transcriptome integrity and regulating mRNA length.	[Berg, Michael G.; Singh, Larry N.; Younis, Ihab; Liu, Qiang; Pinto, Anna Maria; Kaida, Daisuke; Zhang, Zhenxi; Cho, Sungchan; Sherrill-Mix, Scott; Wan, Lili; Dreyfuss, Gideon] Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; [Berg, Michael G.; Singh, Larry N.; Younis, Ihab; Liu, Qiang; Pinto, Anna Maria; Kaida, Daisuke; Zhang, Zhenxi; Cho, Sungchan; Sherrill-Mix, Scott; Wan, Lili; Dreyfuss, Gideon] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.	gdreyfuss@hhmi.upenn.edu	Singh, Larry N./AAG-6880-2021; Younis, Ihab/M-1849-2019; Pinto, Anna Maria/AAB-6172-2020; Pinto, Anna Maria/K-5846-2016; wan, li/GRY-7634-2022	Singh, Larry N./0000-0002-2478-5864; Younis, Ihab/0000-0003-3329-5979; Pinto, Anna Maria/0000-0001-6259-6901; Pinto, Anna Maria/0000-0001-6259-6901; Kaida, Daisuke/0000-0003-4014-5231; Sherrill-Mix, Scott/0000-0002-8955-8072	Association Francaise Contre les Myopathies (AFM)	Association Francaise Contre les Myopathies (AFM)(Association Francaise contre les Myopathies)	We are grateful to the members of our laboratory for helpful discussions, especially Drs. Pilong Li, Jeongsik Yong, Kazuhiro Fukumura, and Lauren Brady. We thank the University of Pennsylvania Genomics core facility for 454 sequencing and Dr. Bin Tian for help with PAS analysis. This work was supported by the Association Francaise Contre les Myopathies (AFM). G.D. is an Investigator of the Howard Hughes Medical Institute.	Ashe MP, 2000, RNA, V6, P170, DOI 10.1017/S1355838200991957; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; Brody Y, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000573; Buratowski S, 2009, MOL CELL, V36, P541, DOI 10.1016/j.molcel.2009.10.019; Calvo O, 2003, GENE DEV, V17, P1321, DOI 10.1101/gad.1093603; Chuvpilo S, 1999, IMMUNITY, V10, P261, DOI 10.1016/S1074-7613(00)80026-6; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; Das R, 2007, MOL CELL, V26, P867, DOI 10.1016/j.molcel.2007.05.036; Di Giammartino DC, 2011, MOL CELL, V43, P853, DOI 10.1016/j.molcel.2011.08.017; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Flavell SW, 2008, NEURON, V60, P1022, DOI 10.1016/j.neuron.2008.11.029; Fortes P, 2003, P NATL ACAD SCI USA, V100, P8264, DOI 10.1073/pnas.1332669100; Glover-Cutter K, 2008, NAT STRUCT MOL BIOL, V15, P71, DOI 10.1038/nsmb1352; Gunderson SI, 1998, MOL CELL, V1, P255, DOI 10.1016/S1097-2765(00)80026-X; Guo JG, 2011, MOL CELL BIOL, V31, P639, DOI 10.1128/MCB.00919-10; Gurskaya NG, 1996, ANAL BIOCHEM, V240, P90, DOI 10.1006/abio.1996.0334; Hartmann B, 2009, CURR OPIN CELL BIOL, V21, P377, DOI 10.1016/j.ceb.2009.02.006; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hu J, 2005, RNA, V11, P1485, DOI 10.1261/rna.2107305; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Ji Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008419; Kaida D, 2007, NAT CHEM BIOL, V3, P576, DOI 10.1038/nchembio.2007.18; Kaida D, 2010, NATURE, V468, P664, DOI 10.1038/nature09479; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; Loebrich S, 2009, PHYSIOL REV, V89, P1079, DOI 10.1152/physrev.00013.2009; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; LUKYANOV KA, 1995, ANAL BIOCHEM, V229, P198, DOI 10.1006/abio.1995.1402; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Mayer A, 2010, NAT STRUCT MOL BIOL, V17, P1272, DOI 10.1038/nsmb.1903; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Mueller CL, 2004, MOL CELL, V14, P447, DOI 10.1016/S1097-2765(04)00257-6; Niibori Y, 2007, NEUROSCI RES, V57, P399, DOI 10.1016/j.neures.2006.11.014; Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394; Pan ZH, 2006, GENE, V366, P325, DOI 10.1016/j.gene.2005.09.024; Patel SB, 2007, J CELL BIOL, V178, P937, DOI 10.1083/jcb.200706134; Sala C, 2003, J NEUROSCI, V23, P6327; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; SAUTERER RA, 1988, EXP CELL RES, V176, P344, DOI 10.1016/0014-4827(88)90336-9; Shell SA, 2005, J BIOL CHEM, V280, P39950, DOI 10.1074/jbc.M508848200; Spiluttini B, 2010, J CELL SCI, V123, P2084, DOI 10.1242/jcs.061358; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; Tian B, 2007, GENOME RES, V17, P156, DOI 10.1101/gr.5532707; Vagner S, 2000, RNA, V6, P178, DOI 10.1017/S1355838200991854; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Zhang HB, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-12-r100	52	299	302	0	41	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 6	2012	150	1					53	64		10.1016/j.cell.2012.05.029	http://dx.doi.org/10.1016/j.cell.2012.05.029			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770214	Bronze, Green Accepted			2022-12-28	WOS:000306115000006
J	Bininda-Emonds, ORP; Purvis, A				Bininda-Emonds, Olaf R. P.; Purvis, Andy			Comment on "Impacts of the Cretaceous Terrestrial Revolution and KPg Extinction on Mammal Diversification"	SCIENCE			English	Editorial Material									[Bininda-Emonds, Olaf R. P.] Carl von Ossietzky Univ Oldenburg, Inst Biol & Environm Sci, Fac 5, AG Systemat & Evolutionary Biol, D-26111 Oldenburg, Germany; [Purvis, Andy] Univ London Imperial Coll Sci Technol & Med, Div Ecol & Evolut, Ascot SL5 7PY, Berks, England	Carl von Ossietzky Universitat Oldenburg; Imperial College London	Bininda-Emonds, ORP (corresponding author), Carl von Ossietzky Univ Oldenburg, Inst Biol & Environm Sci, Fac 5, AG Systemat & Evolutionary Biol, Carl von Ossietzky Str 9-11, D-26111 Oldenburg, Germany.	olaf.bininda@uni-oldenburg.de; a.purvis@imperial.ac.uk	Bininda-Emonds, Olaf/P-6718-2019; Purvis, Andy/A-7529-2008; Bininda-Emonds, Olaf R.P:/C-5405-2008	Purvis, Andy/0000-0002-8609-6204; Bininda-Emonds, Olaf R.P:/0000-0003-4432-224X				Bininda-Emonds ORP, 2008, NATURE, V456, P274, DOI 10.1038/nature07347; Bininda-Emonds ORP, 2007, NATURE, V446, P507, DOI 10.1038/nature05634; Meredith RW, 2011, SCIENCE, V334, P521, DOI 10.1126/science.1211028; Purvis A, 2011, PHILOS T R SOC B, V366, P2462, DOI 10.1098/rstb.2011.0025; Stadler T, 2011, P NATL ACAD SCI USA, V108, P6187, DOI 10.1073/pnas.1016876108; Wood S.N., 2017, GEN ADDITIVE MODELS, V2nd, DOI 10.1201/9781315370279	6	5	6	0	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2012	337	6090								10.1126/science.1220012	http://dx.doi.org/10.1126/science.1220012			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	969KC	22767912				2022-12-28	WOS:000306053100028
J	Hawkes, N				Hawkes, Nigel			The NHS must change or die	BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes1@btinternet.com							0	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 4	2012	344								e4478	10.1136/bmj.e4478	http://dx.doi.org/10.1136/bmj.e4478			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972KE	22763396				2022-12-28	WOS:000306275200012
J	van de Kerkhof, PCM				van de Kerkhof, Peter C. M.			Apremilast: a step forward in the treatment of psoriasis?	LANCET			English	Editorial Material							MODERATE		Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van de Kerkhof, PCM (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, NL-6500 HB Nijmegen, Netherlands.	p.vandekerkhof@derma.umcn.nl	van de Kerkhof, P.C.M./H-8059-2014					Bohm D, 2012, J EUR ACAD DERMATOL, DOI 10. 1111/j. 1468-3083. 2012. 04451; Christophers E, 2006, J EUR ACAD DERMATOL, V20, P921, DOI 10.1111/j.1468-3083.2006.01667.x; Davidovici BB, 2010, J INVEST DERMATOL, V130, P1785, DOI 10.1038/jid.2010.103; Fonia A, 2010, BRIT J DERMATOL, V163, P807, DOI 10.1111/j.1365-2133.2010.09944.x; Griffiths CEM, 2007, LANCET, V370, P263, DOI 10.1016/S0140-6736(07)61128-3; Leavy O., 2012, NAT REV IMMUNOL, V12, P322; Papp K, 2012, LANCET; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Pathirana D, 2009, J EUR ACAD DERMATOL, V23, P1, DOI 10.1111/j.1468-3083.2009.03389.x; Reich K, 2012, BRIT J DERMATOL, V166, P179, DOI 10.1111/j.1365-2133.2011.10583.x; Schafer PH, 2010, BRIT J PHARMACOL, V159, P842, DOI 10.1111/j.1476-5381.2009.00559.x; van Lumig PPM, 2012, J EUR ACAD DERMATOL, V26, P283, DOI 10.1111/j.1468-3083.2011.04044.x	12	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 25	2012	380	9843					708	709		10.1016/S0140-6736(12)60896-4	http://dx.doi.org/10.1016/S0140-6736(12)60896-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995IK	22748703				2022-12-28	WOS:000308001300006
J	Webb, N; Cseh, D; Lenc, E; Godet, O; Barret, D; Corbel, S; Farrell, S; Fender, R; Gehrels, N; Heywood, I				Webb, Natalie; Cseh, David; Lenc, Emil; Godet, Olivier; Barret, Didier; Corbel, Stephane; Farrell, Sean; Fender, Robert; Gehrels, Neil; Heywood, Ian			Radio Detections During Two State Transitions of the Intermediate-Mass Black Hole HLX-1	SCIENCE			English	Article							X-RAY SOURCE; GALAXY ESO 243-49; FUNDAMENTAL PLANE; JETS; EMISSION; OUTBURST; MODELS	Relativistic jets are streams of plasma moving at appreciable fractions of the speed of light. They have been observed from stellar-mass black holes (similar to 3 to 20 solar masses, M-circle dot) as well as supermassive black holes (similar to 10(6) to 10(9) M-circle dot) found in the centers of most galaxies. Jets should also be produced by intermediate-mass black holes (similar to 10(2) to 10(5) M-circle dot), although evidence for this third class of black hole has, until recently, been weak. We report the detection of transient radio emission at the location of the intermediate-mass black hole candidate ESO 243-49 HLX-1, which is consistent with a discrete jet ejection event. These observations also allow us to refine the mass estimate of the black hole to be between similar to 9 x 10(3) M-circle dot and similar to 9 x 10(4) M-circle dot.	[Webb, Natalie; Godet, Olivier; Barret, Didier] Univ Toulouse, UPS OMP, IRAP, F-31028 Toulouse, France; [Webb, Natalie; Godet, Olivier; Barret, Didier] CNRS, IRAP, F-31028 Toulouse 4, France; [Cseh, David; Corbel, Stephane] Univ Paris Diderot, Lab Astrophys Interact Multiechelles UMR 7158, CEA DSM CNRS, CEA Saclay, F-91191 Gif Sur Yvette, France; [Lenc, Emil] CSIRO Astron & Space Sci, Australia Telescope Natl Facil, Epping, NSW 1710, Australia; [Lenc, Emil; Farrell, Sean] Univ Sydney, Sydney Inst Astron, Sch Phys, Sydney, NSW 2006, Australia; [Farrell, Sean] Univ Leicester, Dept Phys & Astron, Leicester LE1 7RH, Leics, England; [Fender, Robert] Univ Southampton, Sch Phys & Astron, Southampton SO17 1BJ, Hants, England; [Gehrels, Neil] NASA, Astroparticle Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; [Heywood, Ian] Univ Oxford, Dept Phys, Oxford OX1 3RH, England	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Sydney; University of Leicester; University of Southampton; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Oxford	Webb, N (corresponding author), Univ Toulouse, UPS OMP, IRAP, F-31028 Toulouse, France.	natalie.webb@irap.omp.eu	Barret, Didier/AAV-2771-2020	barret, didier/0000-0002-0393-9190; Heywood, Ian/0000-0001-6864-5057; Lenc, Emil/0000-0002-9994-1593	European Community [ITN 215212]; UK Science and Technology Facilities Council; Australian Research Council; Commonwealth of Australia;  [DP110102889]; Science and Technology Facilities Council [ST/J001600/1] Funding Source: researchfish; STFC [ST/J001600/1] Funding Source: UKRI	European Community(European Commission); UK Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Australian Research Council(Australian Research Council); Commonwealth of Australia(Australian Government); ; Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	Supported by the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement number ITN 215212 "Black Hole Universe" (D. C. and S. C.), the UK Science and Technology Facilities Council (S. F.), and an Australian Research Council postdoctoral fellowship funded by grant DP110102889 (S. F.). The Australia Telescope is funded by the Commonwealth of Australia for operation as a national facility managed by CSIRO; the data can be accessed at http://atoa.atnf.csiro.au/query.jsp. This work made use of data supplied by the UK Swift Science Data Centre at the University of Leicester (www.swift.ac.uk/swift_portal).	Begelman MC, 2002, ASTROPHYS J, V568, pL97, DOI 10.1086/340457; Brocksopp C, 2002, MON NOT R ASTRON SOC, V331, P765, DOI 10.1046/j.1365-8711.2002.05230.x; Burrows DN, 2005, SPACE SCI REV, V120, P165, DOI 10.1007/s11214-005-5097-2; Corbel S, 2004, ASTROPHYS J, V617, P1272, DOI 10.1086/425650; Cseh D, 2012, ASTROPHYS J, V749, DOI 10.1088/0004-637X/749/1/17; Davis SW, 2011, ASTROPHYS J, V734, DOI 10.1088/0004-637X/734/2/111; Farrell SA, 2009, NATURE, V460, P73, DOI 10.1038/nature08083; Fender RP, 2009, MON NOT R ASTRON SOC, V396, P1370, DOI 10.1111/j.1365-2966.2009.14841.x; Fender RP, 2004, MON NOT R ASTRON SOC, V355, P1105, DOI 10.1111/j.1365-2966.2004.08384.x; Freeland M, 2006, MON NOT R ASTRON SOC, V372, P630, DOI 10.1111/j.1365-2966.2006.10750.x; Gladstone JC, 2009, MON NOT R ASTRON SOC, V397, P1836, DOI 10.1111/j.1365-2966.2009.15123.x; Godet O, 2009, ASTROPHYS J LETT, V705, pL109, DOI 10.1088/0004-637X/705/2/L109; Guedes J, 2009, ASTROPHYS J, V702, P890, DOI 10.1088/0004-637X/702/2/890; Heinz S, 2003, MON NOT R ASTRON SOC, V343, pL59, DOI 10.1046/j.1365-8711.2003.06918.x; Kaaret P, 2003, SCIENCE, V299, P365, DOI 10.1126/science.1079610; King AR, 2001, ASTROPHYS J, V552, pL109, DOI 10.1086/320343; Kording E, 2002, ASTRON ASTROPHYS, V382, pL13, DOI 10.1051/0004-6361:20011776; Kording E, 2005, ASTRON ASTROPHYS, V436, P427, DOI 10.1051/0004-6361:20042452; Merloni A, 2003, MON NOT R ASTRON SOC, V345, P1057, DOI 10.1046/j.1365-2966.2003.07017.x; Miller MC, 2004, INT J MOD PHYS D, V13, P1, DOI 10.1142/S0218271804004426; Miller NA, 2005, ASTROPHYS J, V623, pL109, DOI 10.1086/430112; Servillat M, 2011, ASTROPHYS J, V743, DOI 10.1088/0004-637X/743/1/6; Soria R, 2010, MON NOT R ASTRON SOC, V405, P870, DOI 10.1111/j.1365-2966.2010.16517.x; Webb NA, 2010, ASTROPHYS J LETT, V712, pL107, DOI 10.1088/2041-8205/712/1/L107; Wiersema K, 2010, ASTROPHYS J LETT, V721, pL102, DOI 10.1088/2041-8205/721/2/L102	28	107	107	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 3	2012	337	6094					554	556		10.1126/science.1222779	http://dx.doi.org/10.1126/science.1222779			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982PU	22767898	Green Submitted			2022-12-28	WOS:000307058700037
J	Esbjornsson, J; Mansson, F; Kvist, A; Isberg, PE; Nowroozalizadeh, S; Biague, AJ; da Silva, ZJ; Jansson, M; Fenyo, EM; Norrgren, H; Medstrand, P				Esbjornsson, Joakim; Mansson, Fredrik; Kvist, Anders; Isberg, Per-Erik; Nowroozalizadeh, Salma; Biague, Antonio J.; da Silva, Zacarias J.; Jansson, Marianne; Fenyo, Eva Maria; Norrgren, Hans; Medstrand, Patrik			Inhibition of HIV-1 Disease Progression by Contemporaneous HIV-2 Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; WEST-AFRICA; GUINEA-BISSAU; VIRAL LOAD; PROTECTION; DIVERSITY; EVOLUTION; INDIVIDUALS; ACTIVATION; SENEGAL	BACKGROUND Progressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in most persons with untreated infection with human immunodeficiency virus type 1 (HIV-1) but in only approximately 20 to 30% of persons infected with HIV type 2 (HIV-2); among persons infected with both types, the natural history of disease progression is poorly understood. METHODS We analyzed data from 223 participants who were infected with HIV-1 after enrollment (with either HIV-1 infection alone or HIV-1 and HIV-2 infection) in a cohort with a long follow-up duration (approximately 20 years), according to whether HIV-2 infection occurred first, the time to the development of AIDS (time to AIDS), CD4+ and CD8+ T-cell counts, and measures of viral evolution. RESULTS The median time to AIDS was 104 months (95% confidence interval [CI], 75 to 133) in participants with dual infection and 68 months (95% CI, 60 to 76) in participants infected with HIV-1 only (P = 0.003). CD4+ T-cell levels were higher and CD8+ T-cell levels increased at a lower rate among participants with dual infection, reflecting slower disease progression. Participants with dual infection with HIV-2 infection preceding HIV-1 infection had the longest time to AIDS and highest levels of CD4+ T-cell counts. HIV-1 genetic diversity was significantly lower in participants with dual infections than in those with HIV-1 infection alone at similar time points after infection. CONCLUSIONS Our results suggest that HIV-1 disease progression is inhibited by concomitant HIV-2 infection and that dual infection is associated with slower disease progression. The slower rate of disease progression was most evident in participants with dual infection in whom HIV-2 infection preceded HIV-1 infection. These findings could have implications for the development of HIV-1 vaccines and therapeutics. (Funded by the Swedish International Development Cooperation Agency-Swedish Agency for Research Cooperation with Developing Countries and others.)	[Esbjornsson, Joakim; Medstrand, Patrik] Lund Univ, Sect Mol Virol, Dept Expt Med Sci, SE-22184 Lund, Sweden; [Kvist, Anders] Lund Univ, Dept Clin Sci, Sect Oncol, SE-22184 Lund, Sweden; [Kvist, Anders] Skane Univ Hosp, Lund, Sweden; [Isberg, Per-Erik] Lund Univ, Dept Stat, Sch Econ & Management, SE-22184 Lund, Sweden; [Jansson, Marianne; Fenyo, Eva Maria] Lund Univ, Dept Lab Med Lund, Div Med Microbiol, SE-22184 Lund, Sweden; [Norrgren, Hans] Lund Univ, Dept Clin Sci, Div Infect Med, SE-22184 Lund, Sweden; [Mansson, Fredrik] Lund Univ, Dept Clin Sci Malmo, Infect Dis Res Unit, Malmo, Sweden; [Medstrand, Patrik] Lund Univ, Dept Lab Med Malmo, Malmo, Sweden; [Nowroozalizadeh, Salma; Jansson, Marianne] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Biague, Antonio J.; da Silva, Zacarias J.] Natl Publ Hlth Lab, Bissau, Guinea Bissau	Lund University; Lund University; Lund University; Skane University Hospital; Lund University; Lund University; Lund University; Lund University; Lund University; Karolinska Institutet	Esbjornsson, J (corresponding author), Lund Univ, Sect Mol Virol, Dept Expt Med Sci, BMC C13,Solvegatan 19, SE-22184 Lund, Sweden.	joakim.esbjornsson@med.lu.se	Esbjörnsson, Joakim/H-3219-2019	Esbjornsson, Joakim/0000-0002-6088-7796; Jansson, Marianne/0000-0001-6536-8146; Norrgren, Hans/0000-0001-5780-530X; Esbjornsson, Joakim/0000-0002-3822-4953; Kvist, Anders/0000-0002-1358-0695	Swedish International Development Cooperation Agency-Swedish Agency for Research Cooperation with Developing Countries; Swedish Research Council; Crafoord Foundation; Royal Physiographic Society; Lars Hierta Memorial Foundation; Konsul Thure Carlsson Fund for Medical Research; Tegger Foundation; Medical Faculty of Lund University; Region Skane	Swedish International Development Cooperation Agency-Swedish Agency for Research Cooperation with Developing Countries; Swedish Research Council(Swedish Research CouncilEuropean Commission); Crafoord Foundation; Royal Physiographic Society; Lars Hierta Memorial Foundation; Konsul Thure Carlsson Fund for Medical Research; Tegger Foundation; Medical Faculty of Lund University; Region Skane	Supported by grants from the Swedish International Development Cooperation Agency-Swedish Agency for Research Cooperation with Developing Countries, the Swedish Research Council, the Crafoord Foundation, the Royal Physiographic Society, the Lars Hierta Memorial Foundation, Konsul Thure Carlsson Fund for Medical Research, the Tegger Foundation, the Medical Faculty of Lund University, and the regional agreement on medical training and clinical research between Region Skane and the Medical Faculty of Lund University.	Akimoto H, 1998, IMMUNOLOGY, V95, P214, DOI 10.1046/j.1365-2567.1998.00537.x; Al-Harthi L, 1998, AIDS RES HUM RETROV, V14, P59, DOI 10.1089/aid.1998.14.59; Andersson S, 1997, AIDS, V11, P1815, DOI 10.1097/00002030-199715000-00005; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Arya SK, 1996, P NATL ACAD SCI USA, V93, P4486, DOI 10.1073/pnas.93.9.4486; Bello G, 2007, AIDS RES HUM RETROV, V23, P1242, DOI 10.1089/aid.2007.0074; Cavaleiro R, 2000, AIDS, V14, P2679, DOI 10.1097/00002030-200012010-00007; de Silva Thushan I., 2010, HIV Therapy, V4, P305, DOI 10.2217/HIV.10.26; DECOCK KM, 1994, JAMA-J AM MED ASSOC, V271, P196; Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333; Esbjornsson J, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-23; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; Giorgi JV, 2002, J ACQ IMMUN DEF SYND, V29, P346, DOI 10.1097/00126334-200204010-00004; Greenberg AE, 2001, AIDS, V15, P2319, DOI 10.1097/00002030-200111230-00015; Hamel DJ, 2007, AIDS RES HUM RETROV, V23, P1189, DOI 10.1089/aid.2007.0037; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; Kokkotou EG, 2000, P NATL ACAD SCI USA, V97, P6797, DOI 10.1073/pnas.97.12.6797; Lee HY, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000240; Lemey P, 2007, PLOS COMPUT BIOL, V3, P282, DOI 10.1371/journal.pcbi.0030029; Mansson F, 2009, AIDS, V23, P1575, DOI 10.1097/QAD.0b013e32832cedfb; Markham RB, 1998, P NATL ACAD SCI USA, V95, P12568, DOI 10.1073/pnas.95.21.12568; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019; Otten RA, 2004, AIDS, V18, P1127, DOI 10.1097/00002030-200405210-00006; PUTKONEN P, 1990, AIDS, V4, P783, DOI 10.1097/00002030-199008000-00010; Sahin GO, 2012, J VIROL, V86, P961, DOI 10.1128/JVI.06315-11; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; TRAVERS K, 1995, SCIENCE, V268, P1833; TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936; Troyer RM, 2005, J VIROL, V79, P9006, DOI 10.1128/JVI.79.14.9006-9018.2005; WEISS RA, 1988, AIDS, V2, P95, DOI 10.1097/00002030-198804000-00004; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; World Health Organisation, 2007, WHO CAS DEF HIV SURV; Zheng NN, 2007, J VIROL, V81, P9061, DOI 10.1128/JVI.00117-07; Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004	40	68	68	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2012	367	3					224	232		10.1056/NEJMoa1113244	http://dx.doi.org/10.1056/NEJMoa1113244			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975PI	22808957				2022-12-28	WOS:000306522900006
J	Xiao, CH; Fujita, N; Miyasaka, K; Sakamoto, Y; Terasaki, O				Xiao, Changhong; Fujita, Nobuhisa; Miyasaka, Keiichi; Sakamoto, Yasuhiro; Terasaki, Osamu			Dodecagonal tiling in mesoporous silica	NATURE			English	Article							SQUARE-TRIANGLE TILINGS; QUASI-CRYSTALS; ORDER; 12-FOLD; PHASE	Recent advances in the fabrication of quasicrystals in soft matter systems have increased the length scales for quasicrystals(1) into the mesoscale range (20 to 500 angstroms). Thus far, dendritic liquid crystals(2), ABC-star polymers(3), colloids(4) and inorganic nanoparticles(5) have been reported to yield quasicrystals. These quasicrystals offer larger length scales than intermetallic quasicrystals (a few angstroms)(1,6), thus potentially leading to optical applications through the realization of a complete photonic bandgap induced via multiple scattering of light waves in virtually all directions(7-9). However, the materials remain far from structurally ideal, in contrast to their intermetallic counterparts, and fine control over the structure through a self-organization process has yet to be attained. Here we use the well-established self-assembly of surfactant micelles to produce a new class of mesoporous silicas, which exhibit 12-fold (dodecagonal) symmetry in both electron diffraction and morphology. Each particle reveals, in the 12-fold cross-section, an analogue of dodecagonal quasicrystals in the centre surrounded by 12 fans of crystalline domains in the peripheral part. The quasicrystallinity has been verified by selected-area electron diffraction and quantitative phason strain analyses on transmission electron microscope images obtained from the central region. We argue that the structure forms through a non-equilibrium growth process, wherein the competition between different micellar configurations has a central role in tuning the structure. A simple theoretical model successfully reproduces the observed features and thus establishes a link between the formation process and the resulting structure.	[Xiao, Changhong; Miyasaka, Keiichi; Sakamoto, Yasuhiro; Terasaki, Osamu] Stockholm Univ, Bezelii Ctr EXSELENT Porous Mat, Dept Mat & Environm Chem, S-10691 Stockholm, Sweden; [Fujita, Nobuhisa] Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 9808577, Japan; [Miyasaka, Keiichi; Terasaki, Osamu] Korea Adv Inst Sci & Technol, Grad Sch EEWS WCU, Taejon 305701, South Korea; [Sakamoto, Yasuhiro] Osaka Prefecture Univ, Nanosci & Nanotechnol Res Ctr, Sakai, Osaka 5998570, Japan	Stockholm University; Tohoku University; Korea Advanced Institute of Science & Technology (KAIST); Osaka Metropolitan University	Terasaki, O (corresponding author), Stockholm Univ, Bezelii Ctr EXSELENT Porous Mat, Dept Mat & Environm Chem, S-10691 Stockholm, Sweden.	terasaki@mmk.su.se	Terasaki, Osamu/Y-1137-2018; Sakamoto, Yasuhiro/G-8289-2012; Fujita, Nobuhisa/AAC-5392-2019	Terasaki, Osamu/0000-0001-5803-0817; Fujita, Nobuhisa/0000-0003-4797-1675; Miyasaka, Keiichi/0000-0002-2722-7024	Swedish Research Council (VR); Japan Science and Technology Agency (JST); Berzelii EXSELENT; Knut and Alice Wallenberg Foundation; WCU programme, Korea [R-31-2008-000-10055-0]; JSPS [23710132]; MEXT, Japan	Swedish Research Council (VR)(Swedish Research Council); Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)); Berzelii EXSELENT; Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); WCU programme, Korea; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank K. Niizeki, T. Dotera, A. E. Garcia-Bennett, S. Che and C. Gao for discussions, O. M. Yaghi and M. O'Keeffe for critical reading of the manuscript, and J. Shen for encouragement and support. This work was supported by the Swedish Research Council (VR), the Japan Science and Technology Agency (JST) and Berzelii EXSELENT. SEM and TEM studies were performed at the Electron Microscopy Center (EMC) at Stockholm University, which is supported by the Knut and Alice Wallenberg Foundation. Support from the WCU programme, Korea (R-31-2008-000-10055-0; K.M. and O.T.), Grants-in-Aid for Young Scientists (B) of JSPS (no. 23710132; Y.S.), and Special Coordination Funds for Promoting Science and Technology of MEXT, Japan (Y.S.) is also acknowledged.	BAAKE M, 1992, PHYSICA A, V191, P554, DOI 10.1016/0378-4371(92)90582-B; BERGMAN G, 1954, ACTA CRYSTALLOGR, V7, P857, DOI 10.1107/S0365110X54002605; BOREN B, 1933, ARKIV FOER KEMI MI A, V0011; Chan YS, 1998, PHYS REV LETT, V80, P956, DOI 10.1103/PhysRevLett.80.956; COCKAYNE E, 1994, PHYS REV B, V49, P5896, DOI 10.1103/PhysRevB.49.5896; Durian DJ, 2010, PHYS TODAY, V63, P62, DOI 10.1063/1.3431341; Eden M., 1958, S INFORMATION THEORY, P359; Fischer S, 2011, P NATL ACAD SCI USA, V108, P1810, DOI 10.1073/pnas.1008695108; FRANK FC, 1959, ACTA CRYSTALLOGR, V12, P483, DOI 10.1107/S0365110X59001499; Gao CB, 2008, CHEM-EUR J, V14, P11423, DOI 10.1002/chem.200800766; Grunbaum B., 1986, TILINGS PATTERNS; Hayashida K, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.195502; ISHIMASA T, 1985, PHYS REV LETT, V55, P511, DOI 10.1103/PhysRevLett.55.511; Kusner R., 1996, KELVIN PROBLEM FOAM, P71; LEUNG PW, 1989, PHYS REV B, V39, P446, DOI 10.1103/PhysRevB.39.446; Man WN, 2005, NATURE, V436, P993, DOI 10.1038/nature03977; MEAKIN P, 1988, PHYS REV A, V38, P418, DOI 10.1103/PhysRevA.38.418; Miyasaka K., 2006, ANGEW CHEM, V118, P6666; SHECHTMAN D, 1984, PHYS REV LETT, V53, P1951, DOI 10.1103/PhysRevLett.53.1951; STAMPFLI P, 1986, HELV PHYS ACTA, V59, P1260; Steurer W, 2004, Z KRISTALLOGR, V219, P391, DOI 10.1524/zkri.219.7.391.35643; Sullivan JM, 1998, FOAMS EMULSIONS NATO, V354, P379; Talapin DV, 2009, NATURE, V461, P964, DOI 10.1038/nature08439; WEAIRE D, 1994, PHIL MAG LETT, V69, P107, DOI 10.1080/09500839408241577; Yamamoto A, 1996, ACTA CRYSTALLOGR A, V52, P509, DOI 10.1107/S0108767396000967; YE HQ, 1984, ACTA CRYSTALLOGR B, V40, P461, DOI 10.1107/S0108768184002482; Zeng XB, 2004, NATURE, V428, P157, DOI 10.1038/nature02368; Ziherl P, 2001, J PHYS CHEM B, V105, P10147, DOI 10.1021/jp010944q; Zoorob ME, 2000, NATURE, V404, P740, DOI 10.1038/35008023	30	110	114	5	248	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 19	2012	487	7407					349	353		10.1038/nature11230	http://dx.doi.org/10.1038/nature11230			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JB	22810699				2022-12-28	WOS:000306506500039
J	Osotimehin, B				Osotimehin, Babatunde			Family planning save lives, yet investments falter	LANCET			English	Editorial Material									United Nations Populat Fund, New York, NY 10158 USA	United Nations Population Fund	Osotimehin, B (corresponding author), United Nations Populat Fund, New York, NY 10158 USA.	osotimehin@unfpa.org						Ahmed S., 2012, LANCET; [Anonymous], 1994, INT C POP DEV CAIR 5; Canning D, 2012, LANCET, DOI http://dx.doi.org/SO140-6736(12)60827-7; Center for Reproductive Rights United Nations Population Fund (UNFPA), 2010, RIGHT CONTR INF SERV; Cleland J, 2012, LANCET; Cleland J, 2006, LANCET, V368, P1810, DOI 10.1016/S0140-6736(06)69480-4; Cottingham J, 2012, LANCET; Ezeh AC, 2012, LANCET, DOI http://dx.doi.org/10.1016/S0140-6736(12)60696-5; O'Neill BC, 2012, LANCET, DOI http://dx.doi.org/ SO140-6736(12)60958-1; Shiffman J, 2012, LANCET; Singh S, 2012, ADDING IT COSTS BENE; World Health Organization (WHO), 2012, TRENDS MAT MORT 1990	12	14	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2012	380	9837					82	83		10.1016/S0140-6736(12)60906-4	http://dx.doi.org/10.1016/S0140-6736(12)60906-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784541				2022-12-28	WOS:000306359100008
J	He, XM; Aizenberg, M; Kuksenok, O; Zarzar, LD; Shastri, A; Balazs, AC; Aizenberg, J				He, Ximin; Aizenberg, Michael; Kuksenok, Olga; Zarzar, Lauren D.; Shastri, Ankita; Balazs, Anna C.; Aizenberg, Joanna			Synthetic homeostatic materials with chemo-mechano-chemical self-regulation	NATURE			English	Article								Living organisms have unique homeostatic abilities, maintaining tight control of their local environment through interconversions of chemical and mechanical energy and self-regulating feedback loops organized hierarchically across many length scales(1-7). In contrast, most synthetic materials are incapable of continuous self-monitoring and self-regulating behaviour owing to their limited single-directional chemomechanical(7-12) or mechanochemical(13,14) modes. Applying the concept of homeostasis to the design of autonomous materials(15) would have substantial impacts in areas ranging from medical implants that help stabilize bodily functions to 'smart' materials that regulate energy usage(2,16,17). Here we present a versatile strategy for creating self-regulating, self-powered, homeostatic materials capable of precisely tailored chemo-mechanochemical feedback loops on the nano- or microscale. We design a bilayer system with hydrogel-supported, catalyst-bearing microstructures, which are separated from a reactant-containing 'nutrient' layer. Reconfiguration of the gel in response to a stimulus induces the reversible actuation of the microstructures into and out of the nutrient layer, and serves as a highly precise 'on/off' switch for chemical reactions. We apply this design to trigger organic, inorganic and biochemical reactions that undergo reversible, repeatable cycles synchronized with the motion of the microstructures and the driving external chemical stimulus. By exploiting a continuous feedback loop between various exothermic catalytic reactions in the nutrient layer and the mechanical action of the temperature-responsive gel, we then create exemplary autonomous, self-sustained homeostatic systems that maintain a user-defined parameter-temperature-in a narrow range. The experimental results are validated using computational modelling that qualitatively captures the essential features of the self-regulating behaviour and provides additional criteria for the optimization of the homeostatic function, subsequently confirmed experimentally. This design is highly customizable owing to the broad choice of chemistries, tunable mechanics and its physical simplicity, and may lead to a variety of applications in autonomous systems with chemo-mechano-chemical transduction at their core.	[He, Ximin; Aizenberg, Joanna] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [He, Ximin; Aizenberg, Michael; Aizenberg, Joanna] Harvard Univ, Wyss Inst Biologically Inspired Engn, Cambridge, MA 02138 USA; [Kuksenok, Olga; Balazs, Anna C.] Univ Pittsburgh, Dept Chem & Petr Engn, Pittsburgh, PA 15260 USA; [Zarzar, Lauren D.; Shastri, Ankita; Aizenberg, Joanna] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Harvard University; Harvard University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University	Aizenberg, J (corresponding author), Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.	jaiz@seas.harvard.edu	Kuksenok, Olga/L-9234-2018; Zarzar, Lauren D./C-4239-2019; He, Ximin/D-3533-2017	Kuksenok, Olga/0000-0002-1895-5206; Balazs, Anna/0000-0002-5555-2692; Zarzar, Lauren/0000-0002-3287-3602; He, Ximin/0000-0001-8845-4637; Aizenberg, Michael/0000-0002-2901-7012	US DOE [DE-SC0005247]; US NSF [CMMI-1124839]	US DOE(United States Department of Energy (DOE)); US NSF(National Science Foundation (NSF))	We thank P. Kim for assistance with the gel formulation, M. Khan for microstructure fabrication, R. S. Friedlander for assistance with confocal imaging, M. Kolle and A. Ehrlicher for technical assistance, and A. Grinthal for help with manuscript preparation. The work was supported by the US DOE under award DE-SC0005247 (experiment) and by the US NSF under award CMMI-1124839 (computational modelling).	Ariga K, 2011, CHEM SCI, V2, P195, DOI 10.1039/c0sc00300j; Bao G, 2010, CELL MOL BIOENG, V3, P91, DOI 10.1007/s12195-010-0109-z; Das M, 2006, ADV MATER, V18, P80, DOI 10.1002/adma.200501043; Fratzl P, 2009, NATURE, V462, P442, DOI 10.1038/nature08603; Fritz J, 2000, SCIENCE, V288, P316, DOI 10.1126/science.288.5464.316; Guyton A. C., 1997, HUMAN PHYSL MECH DIS, P3; Harris TJ, 1999, J PROCESS CONTR, V9, P1, DOI 10.1016/S0959-1524(98)00031-6; Hess H, 2011, ANNU REV BIOMED ENG, V13, P429, DOI 10.1146/annurev-bioeng-071910-124644; Horvath J, 2011, SOFT MATTER, V7, P8462, DOI 10.1039/c1sm05226h; Koga S, 2011, NAT CHEM, V3, P720, DOI [10.1038/NCHEM.1110, 10.1038/nchem.1110]; Kovacs K, 2009, J PHYS CHEM A, V113, P146, DOI 10.1021/jp807840g; Kuksenok O, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.041406; Lahann J, 2005, MRS BULL, V30, P185, DOI 10.1557/mrs2005.50; Li DB, 2009, MRS BULL, V34, P671, DOI 10.1557/mrs2009.179; Maeda S, 2007, ADV MATER, V19, P3480, DOI 10.1002/adma.200700625; Murthy N, 2003, P NATL ACAD SCI USA, V100, P4995, DOI 10.1073/pnas.0930644100; Nayak S, 2004, J AM CHEM SOC, V126, P10258, DOI 10.1021/ja0474143; OKANO T, 1990, J CONTROL RELEASE, V11, P255, DOI 10.1016/0168-3659(90)90138-J; Paxton WF, 2006, ANGEW CHEM INT EDIT, V45, P5420, DOI 10.1002/anie.200600060; Prosser BL, 2011, SCIENCE, V333, P1440, DOI 10.1126/science.1202768; Richter A, 2008, SENSORS-BASEL, V8, P561, DOI 10.3390/s8010561; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R; Sidorenko A, 2007, SCIENCE, V315, P487, DOI 10.1126/science.1135516; Siegel RA, 2009, NATO SCI PEACE SEC A, P175, DOI 10.1007/978-90-481-2993-5_7; SPAET TH, 1966, BLOOD-J HEMATOL, V28, P112, DOI 10.1182/blood.V28.1.112.112; Stuart MAC, 2010, NAT MATER, V9, P101, DOI [10.1038/NMAT2614, 10.1038/nmat2614]; Todres Z. V, 2006, ORGANIC MECHANOCHEMI, P170, DOI DOI 10.1201/9781420005882; Vanag VK, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.016201; Yashin VV, 2006, SCIENCE, V314, P798, DOI 10.1126/science.1132412; Yashin VV, 2010, PROG POLYM SCI, V35, P155, DOI 10.1016/j.progpolymsci.2009.10.003; Yerushalmi R, 2005, J MATER CHEM, V15, P4480, DOI 10.1039/b505212b; Zarzar LD, 2011, ADV MATER, V23, P1442, DOI 10.1002/adma.201004231	33	340	344	24	575	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2012	487	7406					214	218		10.1038/nature11223	http://dx.doi.org/10.1038/nature11223			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972LP	22785318	Green Submitted			2022-12-28	WOS:000306278900035
J	Sheppard, JP; Singh, S; Fletcher, K; McManus, RJ; Mant, J				Sheppard, J. P.; Singh, S.; Fletcher, K.; McManus, R. J.; Mant, J.			Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LIPID-LOWERING THERAPY; CORONARY-HEART-DISEASE; RISK-FACTORS; VASCULAR EVENTS; TIME TRENDS; OLDER; TRIAL; HYPERTENSION; ATORVASTATIN; INDIVIDUALS	Objectives To establish the impact of age and sex on primary preventive treatment for cardiovascular disease in a typical primary care population. Design Cross sectional study of anonymised patient records. Participants All 41 250 records of patients aged >= 40 registered at 19 general practices in the West Midlands, United Kingdom, were extracted and analysed. Main outcome measures Patients' demographics, risk factors for cardiovascular disease (blood pressure, total cholesterol concentration), and prescriptions for primary preventive drugs were extracted from patients' records. Patients were subdivided into five year age bands up to 85 (patients aged >= 85 were analysed as one group) and prescribing trends across the population were assessed by estimating the proportion of patients prescribed with antihypertensive drug or statin drug, or both, in each group. Results Of the 41 250 records screened in this study, 36 679 (89%) patients did not have a history of cardiovascular disease and therefore could be considered for primary preventive treatment. The proportion receiving antihypertensive drugs increased with age (from 5% (378/6978) aged 40-44 to 57% (621/1092) aged >= 85) as did the proportion taking statins up to the age of 74 (from 3% (201/6978) aged 40-44 to 29% (675/2367) aged 70-74). In those aged 75 and above, the odds of a receiving prescription for a statin (relative to the 40-44 age group) decreased with every five year increment in age (odds ratio 12.9 (95% confidence interval 10.8 to 15.3) at age 75-79 to 5.7 (4.6 to 7.2) at age >= 85; P<0.001). There were no consistent differences in prescribing trends by sex. Conclusions Previously described undertreatment of women in secondary prevention of cardiovascular disease was not observed for primary prevention. Low use of statins in older people highlights the need for a stronger evidence base and clearer guidelines for people aged over 75.	[McManus, R. J.] Univ Oxford, NIHR Sch Primary Care Res, Oxford OX33 6GG, England; [Sheppard, J. P.; Singh, S.; Fletcher, K.] Univ Birmingham, NIHR Sch Primary Care Res, Birmingham B15 2TT, W Midlands, England; [Mant, J.] Univ Cambridge, Primary Care Unit, Cambridge CB2 0SR, England	University of Oxford; University of Birmingham; University of Cambridge	McManus, RJ (corresponding author), Univ Oxford, NIHR Sch Primary Care Res, Oxford OX33 6GG, England.	richard.mcmanus@phc.ox.ac.uk	Sheppard, James/AAR-6793-2021	Sheppard, James/0000-0002-4461-8756; Mant, Jonathan/0000-0002-9531-0268	National Institute for Health Research [RP-PG-0606-1153]; National Institute for Health Research Birmingham and Black Country Collaboration for Leadership in Applied Health Research and Care; NIHR; University of Birmingham; National Institute for Health Research [CDF/01/017] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research Birmingham and Black Country Collaboration for Leadership in Applied Health Research and Care; NIHR(National Institute for Health Research (NIHR)); University of Birmingham; National Institute for Health Research(National Institute for Health Research (NIHR))	This work forms part of a larger programme on stroke prevention in primary care supported by the National Institute for Health Research (RP-PG-0606-1153). JPS and SS are funded by the National Institute for Health Research Birmingham and Black Country Collaboration for Leadership in Applied Health Research and Care. RJMcM holds an NIHR career development fellowship. The views and opinions expressed are those of the authors and do not necessarily reflect those of the NHS, NIHR, or the Department of Health.; The University of Birmingham acted as the study sponsor. They were responsible for the overall conduct of the study and ensured the relevant contracts, insurance and approvals were in place prior to the start of the study. They had no active role in the study design, data collection, analysis or dissemination.	Aarabi M, 2008, EUR J CARDIOV PREV R, V15, P59, DOI 10.1097/HJR.0b013e3282f07973; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; Aresu M, 2010, HLTH SURVEY ENGLAND, V1; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Beckett NS, 2008, NEW ENGL J MED, V358, P1887, DOI 10.1056/NEJMoa0801369; British Medical Association NHS Employers, 2009, EGUI05501 BRIT MED A; Chamnan P, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1693; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Collier DJ, 2011, J HYPERTENS, V29, P592, DOI 10.1097/HJH.0b013e328342c8f7; Collins GS, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2442; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Dahlof B, 2005, LANCET, V366, P895, DOI 10.1016/S0140-6736(05)67185-1; de Ruijter W, 2010, BRIT J GEN PRACT, V60, P47, DOI 10.3399/bjgp10X482103; Department of Health, 2008, PUTT PREV 1 VASC CHE; Driscoll A, 2011, INTERN MED J, V41, P730, DOI 10.1111/j.1445-5994.2011.02534.x; Glynn RJ, 2010, ANN INTERN MED, V152, P488, DOI 10.7326/0003-4819-152-8-201004200-00005; Gnavi R, 2007, EUR J PUBLIC HEALTH, V17, P492, DOI 10.1093/eurpub/ckm005; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hippisley-Cox J, 2008, BMJ-BRIT MED J, V336, P1475, DOI 10.1136/bmj.39609.449676.25; Holt TA, 2008, BRIT J GEN PRACT, V58, P495, DOI 10.3399/bjgp08X319468; Khunti K, 2011, BRIT MED J, V342, DOI 10.1136/bmj.c6312; Ko DT, 2004, JAMA-J AM MED ASSOC, V291, P1864, DOI 10.1001/jama.291.15.1864; Lawson KD, 2010, HEART, V96, P208, DOI 10.1136/hrt.2009.177204; Lemaitre RN, 1998, ARCH INTERN MED, V158, P1761, DOI 10.1001/archinte.158.16.1761; Marshall T, 2006, BRIT J GEN PRACT, V56, P600; Messerli FH, 2008, NEW ENGL J MED, V359, P972; Nakamura H, 2006, LANCET, V368, P1155, DOI 10.1016/S0140-6736(06)69472-5; National Institute for Health and Clinical Excellence, 2008, CG067 NAT I HLTH CLI; National Institute for Health and Clinical Excellence, 2006, CG034 NAT I HLTH CLI; National Institute for Health and Clinical Excellence, 2011, CG127 NAT I HLTH CLI; NHS Health Check Programme, 2009, PUTT PREV 1 NHS HLTH; Office for National Statistics, 2010, MIDY POP EST AG FAST; Office for National Statistics, 2010, OFF NAT STAT SER; Reckless JPD, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d201; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Robinson JG, 2007, STROKE, V38, P441, DOI 10.1161/01.STR.0000254602.58896.d2; Robinson JG, 2009, DRUG AGING, V26, P917, DOI 10.2165/11318270-000000000-00000; Rothwell PM, 2005, LANCET, V366, P1773, DOI 10.1016/S0140-6736(05)67702-1; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Vulic D, 2010, AM J CARDIOVASC DRUG, V10, P109, DOI 10.2165/11535240-000000000-00000; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Whincup PH, 2002, HEART, V88, P25, DOI 10.1136/heart.88.1.25; Wood D, 2005, HEART, V91, P1, DOI 10.1136/hrt.2005.079988; World Health Organization, 2007, PREV CARD DIS GUID A; Yusuf S, 2009, LANCET, V373, P1341, DOI 10.1016/S0140-6736(09)60611-5	46	40	41	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 12	2012	345								e4535	10.1136/bmj.e4535	http://dx.doi.org/10.1136/bmj.e4535			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975NW	22791787	Green Published, hybrid			2022-12-28	WOS:000306519000003
J	Elliott, C				Elliott, Carl			Justice for Injured Research Subjects	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Minnesota, Ctr Bioeth, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Elliott, C (corresponding author), Univ Minnesota, Ctr Bioeth, Minneapolis, MN 55455 USA.							Pike ER, 2012, AM J LAW MED, V38, P7, DOI 10.1177/009885881203800101; Presidential Commission for the Study of Bioethical Issues, 2011, MOR SCI PROT PART HU; Stark L., 2011, CLOSED DOORS IRBS MA; The Lewin Group, 2005, TASK ORD PR IN PRESS	4	17	18	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					6	8		10.1056/NEJMp1205623	http://dx.doi.org/10.1056/NEJMp1205623			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	968KJ	22762312				2022-12-28	WOS:000305979400016
J	Morrow, M; Harris, JR; Schnitt, SJ				Morrow, Monica; Harris, Jay R.; Schnitt, Stuart J.			Surgical Margins in Lumpectomy for Breast Cancer - Bigger Is Not Better	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							20-YEAR FOLLOW-UP; ESTROGEN-RECEPTOR; CONSERVING THERAPY; PROGESTERONE-RECEPTOR; RADICAL-MASTECTOMY; ADJUVANT BREAST; RECURRENCE; WOMEN; RADIATION; EXCISION		[Morrow, Monica] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Harris, Jay R.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Harris, Jay R.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Schnitt, Stuart J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Harris, Jay R.; Schnitt, Stuart J.] Harvard Univ, Sch Med, Boston, MA USA	Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Morrow, M (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.							Abdulkarim BS, 2011, J CLIN ONCOL, V29, P2852, DOI 10.1200/JCO.2010.33.4714; Anderson SJ, 2009, J CLIN ONCOL, V27, P2466, DOI 10.1200/JCO.2008.19.8424; Arriagada R, 1996, J CLIN ONCOL, V14, P1558, DOI 10.1200/JCO.1996.14.5.1558; Azu M, 2010, ANN SURG ONCOL, V17, P558, DOI 10.1245/s10434-009-0765-1; Blichert-Toft M, 1992, J Natl Cancer Inst Monogr, P19; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; Fisher B, 1996, J CLIN ONCOL, V14, P1982, DOI 10.1200/JCO.1996.14.7.1982; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Gage I, 1996, CANCER-AM CANCER SOC, V78, P1921, DOI 10.1002/(SICI)1097-0142(19961101)78:9<1921::AID-CNCR12>3.0.CO;2-#; Giuliano AE, 2011, JAMA-J AM MED ASSOC, V305, P569, DOI 10.1001/jama.2011.90; Ho AY, 2012, CANCER          0305; HOLLAND R, 1990, J CLIN ONCOL, V8, P113, DOI 10.1200/JCO.1990.8.1.113; HOLLAND R, 1985, CANCER, V56, P979, DOI 10.1002/1097-0142(19850901)56:5<979::AID-CNCR2820560502>3.0.CO;2-N; Houssami N, 2008, J CLIN ONCOL, V26, P3248, DOI 10.1200/JCO.2007.15.2108; Houssami N, 2010, EUR J CANCER, V46, P3219, DOI 10.1016/j.ejca.2010.07.043; Hwang N, 2009, ANN SURG ONCOL, V16, P3000, DOI 10.1245/s10434-009-0607-1; Kyndi M, 2008, J CLIN ONCOL, V26, P1419, DOI 10.1200/JCO.2007.14.5565; Mamounas EP, 2010, J CLIN ONCOL, V28, P1677, DOI 10.1200/JCO.2009.23.7610; McCahill LE, 2012, JAMA-J AM MED ASSOC, V307, P467, DOI 10.1001/jama.2012.43; Millar EKA, 2009, J CLIN ONCOL, V27, P4701, DOI 10.1200/JCO.2008.21.7075; Morrow M, 2012, JAMA-J AM MED ASSOC, V307, P509, DOI 10.1001/jama.2012.74; Morrow M, 2009, JAMA-J AM MED ASSOC, V302, P1551, DOI 10.1001/jama.2009.1450; Nguyen PL, 2008, J CLIN ONCOL, V26, P2373, DOI 10.1200/JCO.2007.14.4287; Nguyen PL, 2008, J CLIN ONCOL, V26, P3110; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Poggi MM, 2003, CANCER, V98, P697, DOI 10.1002/cncr.11580; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; SCHNITT SJ, 1987, CANCER, V59, P675, DOI 10.1002/1097-0142(19870215)59:4<675::AID-CNCR2820590402>3.0.CO;2-U; Solin LJ, 2008, J CLIN ONCOL, V26, P386, DOI 10.1200/JCO.2006.09.5448; Taghian A, 2005, ANN SURG, V241, P629, DOI 10.1097/01.sla.0000157272.04803.1b; van Dongen JA, 2000, JNCI-J NATL CANCER I, V92, P1143, DOI 10.1093/jnci/92.14.1143; Veronesi U, 2002, NEW ENGL J MED, V347, P1227, DOI 10.1056/NEJMoa020989; VICINI F, 1991, ANN SURG, V214, P200, DOI 10.1097/00000658-199109000-00002; Vicini FA, 2004, INT J RADIAT ONCOL, V60, P86, DOI 10.1016/j.ijrobp.2004.02.002	35	132	134	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					79	82		10.1056/NEJMsb1202521	http://dx.doi.org/10.1056/NEJMsb1202521			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968KJ	22762325				2022-12-28	WOS:000305979400013
J	Pearle, MS				Pearle, Margaret S.			Shock-Wave Lithotripsy for Renal Calculi	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TO-STONE DISTANCE; DIABETES-MELLITUS; RISK-FACTORS; FOLLOW-UP; COMPUTED-TOMOGRAPHY; COST-EFFECTIVENESS; RANDOMIZED-TRIAL; KIDNEY-STONES; NEPHROLITHIASIS; MANAGEMENT	A 42-year-old man without a history of kidney stones had intermittent left flank pain for several weeks before being seen by his primary care doctor. Urinalysis revealed microhematuria. Computed tomography (CT) of the abdomen and pelvis without contrast enhancement identified a calcification 12 mm in diameter in the left renal pelvis, associated with mild hydronephrosis and a normal-caliber ureter. The attenuation coefficient of the stone was 790 Hounsfield units, and the skin-to-stone distance was 8.5 cm. He was referred to a urologist, who reviewed the CT scan and recommended treatment with extracorporeal shock-wave lithotripsy.	Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Pearle, MS (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Urol, 5323 Harry Hines Blvd,J8-106, Dallas, TX 75390 USA.	margaret.pearle@utsouthwestern.edu			Cook Medical; Olympus America; Storz Endoscopy; Coloblast	Cook Medical; Olympus America; Storz Endoscopy; Coloblast	Dr. Pearle reports receiving consulting fees from Cook Medical, lecture fees from Olympus America, Storz Endoscopy, and Coloblast, and royalties from Informa Healthcare, Springer Publishing, and Oakstone Medical Publishing. No other potential conflict of interest relevant to this article was reported.	Albala DM, 2001, J UROLOGY, V166, P2072, DOI 10.1016/S0022-5347(05)65508-5; Albala DM, 2002, J UROLOGY, V167, P1805, DOI DOI 10.1016/S0022-5347(05)65508-5.ERRATUM; BAUMGARTNER BR, 1987, RADIOLOGY, V163, P531, DOI 10.1148/radiology.163.2.3562837; Borghi L, 1996, J UROLOGY, V155, P839, DOI 10.1016/S0022-5347(01)66321-3; Borghi L, 2002, NEW ENGL J MED, V346, P77, DOI 10.1056/NEJMoa010369; Brown J, 2006, INT UROL NEPHROL, V38, P87, DOI 10.1007/s11255-005-3622-6; CARLSSON P, 1992, SCAND J UROL NEPHROL, V26, P257, DOI 10.3109/00365599209180879; CRUM LA, 1988, J UROLOGY, V140, P1587, DOI 10.1016/S0022-5347(17)42132-X; de Cogain M, 2012, UROLOGY, V79, P298, DOI 10.1016/j.urology.2011.07.1430; Dhar NB, 2004, J UROLOGY, V172, P2271, DOI 10.1097/01.ju.0000143459.03836.2d; DRETLER SP, 1988, J UROLOGY, V139, P1124, DOI 10.1016/S0022-5347(17)42801-1; Evan AP, 2002, J UROLOGY, V168, P1556, DOI 10.1016/S0022-5347(05)64520-X; Georgiev MI, 2011, UROLOGY, V78, P1023, DOI 10.1016/j.urology.2011.01.073; Gerber R, 2005, J UROLOGY, V173, P2013, DOI 10.1097/01.ju.0000158042.41319.c4; Gravina GL, 2005, UROLOGY, V66, P24, DOI 10.1016/j.urology.2005.01.013; Hyams ES, 2011, J UROLOGY, V186, P2270, DOI 10.1016/j.juro.2011.07.079; KIM SC, 1991, J UROLOGY, V145, P489; KNAPP PM, 1988, J UROLOGY, V139, P700, DOI 10.1016/S0022-5347(17)42604-8; Krambeck AE, 2011, J UROLOGY, V185, P1161; Krambeck AE, 2006, J UROLOGY, V175, P1742, DOI 10.1016/S0022-5347(05)00989-4; Krambeck AE, 2011, J UROLOGY, V185, P164, DOI 10.1016/j.juro.2010.09.033; Laopaiboon M, 2009, COCHRANE DB SYST REV, V4; LINGEMAN JE, 1990, JAMA-J AM MED ASSOC, V263, P1789, DOI 10.1001/jama.263.13.1789; Lotan Y, 2005, UROL RES, V33, P223, DOI 10.1007/s00240-005-0463-9; Madbouly K, 2002, J UROLOGY, V167, P1239, DOI 10.1016/S0022-5347(05)65273-1; Makhlouf AA, 2009, UROLOGY, V73, P4, DOI 10.1016/j.urology.2008.07.066; NEWMAN LH, 1991, UROLOGY, V38, P35, DOI 10.1016/0090-4295(91)80009-V; Ogan K, 2005, MINIMALLY INVASIVE U, P614; Pareek G, 2005, UROLOGY, V66, P941, DOI 10.1016/j.urology.2005.05.011; Pearle MS, 2005, J UROLOGY, V173, P848, DOI 10.1097/01.ju.0000152082.14384.d7; Pearle MS, 2005, J UROLOGY, V173, P2005, DOI 10.1097/01.ju.0000158458.51706.56; Perks AE, 2008, UROLOGY, V72, P765, DOI 10.1016/j.urology.2008.05.046; Portis AJ, 2003, J UROLOGY, V169, P58, DOI 10.1016/S0022-5347(05)64034-7; Preminger GM, 2005, J UROLOGY, V173, P1991, DOI 10.1097/01.ju.0000161171.67806.2a; Saigal CS, 2005, KIDNEY INT, V68, P1808, DOI 10.1111/j.1523-1755.2005.00599.x; Sato Y, 2008, UROLOGY, V71, P586, DOI 10.1016/j.urology.2007.10.072; SAW KC, 1999, AUA UPDATE SERIES, V20, P154; Sayed MAB, 2001, BJU INT, V88, P675, DOI 10.1046/j.1464-4096.2001.02435.x; Sheir KZ, 2003, J UROLOGY, V170, P389, DOI 10.1097/01.ju.0000075080.58359.46; Sorensen C, 2002, J UROLOGY, V168, P35, DOI 10.1016/S0022-5347(05)64826-4; Soygur T, 2002, J ENDOUROL, V16, P149, DOI 10.1089/089277902753716098; Stamatelou KK, 2003, KIDNEY INT, V63, P1817, DOI 10.1046/j.1523-1755.2003.00917.x; Turk C, 2011, GUIDELINES UROLITHIA; Willis LR, 1997, J ENDOUROL, V11, P27, DOI 10.1089/end.1997.11.27; Wolf JS, 2008, J UROLOGY, V180, P2262; Wolf JS, 2008, J UROLOGY, V179, P1379, DOI [10.1016/j.juro.2008.01.068, 10.1016/S0022-5347(08)62119-9]; Zehnder P, 2011, EUR UROL, V59, P637, DOI 10.1016/j.eururo.2011.01.026; Zhong P, 2001, ULTRASOUND MED BIOL, V27, P119, DOI 10.1016/S0301-5629(00)00322-7	48	31	31	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					50	57		10.1056/NEJMct1103074	http://dx.doi.org/10.1056/NEJMct1103074			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968KJ	22762318				2022-12-28	WOS:000305979400005
J	Kripalani, S; Roumie, CL; Dalal, AK; Cawthon, C; Businger, A; Eden, SK; Shintani, A; Sponsler, KC; Harris, LJ; Theobald, C; Huang, RL; Scheurer, D; Hunt, S; Jacobson, TA; Rask, KJ; Vaccarino, V; Gandhi, TK; Bates, DW; Williams, MV; Schnipper, JL				Kripalani, Sunil; Roumie, Christianne L.; Dalal, Anuj K.; Cawthon, Courtney; Businger, Alexandra; Eden, Svetlana K.; Shintani, Ayumi; Sponsler, Kelly Cunningham; Harris, L. Jeff; Theobald, Cecelia; Huang, Robert L.; Scheurer, Danielle; Hunt, Susan; Jacobson, Terry A.; Rask, Kimberly J.; Vaccarino, Viola; Gandhi, Tejal K.; Bates, David W.; Williams, Mark V.; Schnipper, Jeffrey L.		PILL-CVD Pharmacist Intervent Low	Effect of a Pharmacist Intervention on Clinically Important Medication Errors After Hospital Discharge A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE DRUG EVENTS; PATIENTS AFTER-DISCHARGE; LOW-LITERACY; CARE; RECONCILIATION; PREVALENCE; INPATIENT	Background: Clinically important medication errors are common after hospital discharge. They include preventable or ameliorable adverse drug events (ADEs), as well as medication discrepancies or nonadherence with high potential for future harm (potential ADEs). Objective: To determine the effect of a tailored intervention on the occurrence of clinically important medication errors after hospital discharge. Design: Randomized, controlled trial with concealed allocation and blinded outcome assessors. (ClinicalTrials.gov registration number: NCT00632021) Setting: Two tertiary care academic hospitals. Patients: Adults hospitalized with acute coronary syndromes or acute decompensated heart failure. Intervention: Pharmacist-assisted medication reconciliation, inpatient pharmacist counseling, low-literacy adherence aids, and individualized telephone follow-up after discharge. Measurements: The primary outcome was the number of clinically important medication errors per patient during the first 30 days after hospital discharge. Secondary outcomes included preventable or ameliorable ADEs, as well as potential ADEs. Results: Among 851 participants, 432 (50.8%) had 1 or more clinically important medication errors; 22.9% of such errors were judged to be serious and 1.8% life-threatening. Adverse drug events occurred in 258 patients (30.3%) and potential ADEs in 253 patients (29.7%). The intervention did not significantly alter the per-patient number of clinically important medication errors (unadjusted incidence rate ratio, 0.92 [95% CI, 0.77 to 1.10]) or ADEs (unadjusted incidence rate ratio, 1.09 [CI, 0.86 to 1.39]). Patients in the intervention group tended to have fewer potential ADEs (unadjusted incidence rate ratio, 0.80 [CI, 0.61 to 1.04]). Limitation: The characteristics of the study hospitals and participants may limit generalizability. Conclusion: Clinically important medication errors were present among one half of patients after hospital discharge and were not significantly reduced by a health-literacy-sensitive, pharmacist-delivered intervention.	Vanderbilt Univ, Vanderbilt Ctr Hlth Serv Res, Vet Affairs Tennessee Valley Geriatr Res Educ Cli, Hlth Serv Res & Dev Serv,Targeted Res Enhancement, Nashville, TN USA; Clin Res Ctr Excellence, Nashville, TN USA; Harvard Univ, Brigham & Womens Hosp, Brigham & Womens Hosp Hospitalist Serv, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA; Med Univ S Carolina, Charleston, SC 29425 USA; Univ Washington, Hospitalist Serv, Seattle, WA 98195 USA; Emory Univ, Sch Med, Atlanta, GA USA; Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; NW Univ Feinberg, Sch Med, Chicago, IL USA	Geriatric Research Education & Clinical Center; Vanderbilt University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Medical University of South Carolina; University of Washington; University of Washington Seattle; Emory University; Emory University; Rollins School Public Health; Northwestern University; Feinberg School of Medicine	Kripalani, S (corresponding author), Vanderbilt Univ, Dept Med, Med Ctr E, 1215 21st Ave S,Suite 6000, Nashville, TN 37232 USA.	sunil.kripalani@vanderbilt.edu	Rask, Kimberly/L-5742-2019; Jacobson, Terry/AAK-4757-2020; Bates, David/AAE-7283-2019; rask, kimberly/M-8001-2016; , Viola/AAW-5600-2020	Rask, Kimberly/0000-0001-6806-4666; Jacobson, Terry/0000-0002-9926-2179; Harris, Leonard/0000-0002-4967-4618; Reyes, Harry/0000-0001-7774-2561; Williams, Mark V/0000-0001-6107-0457	National Heart, Lung, and Blood Institute; National Heart, Lung, and Blood Institute grant [R01 HL089755, K23 HL077597, K08 HL072806]; Veterans Affairs Career Development Award [04-342-2]; National Center for Research Resources grant [UL1 RR024975]; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024977, TL1RR024978, UL1RR024975] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL072806, R01HL089755, K23HL077597] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Heart, Lung, and Blood Institute grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs Career Development Award; National Center for Research Resources grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	National Heart, Lung, and Blood Institute.; By National Heart, Lung, and Blood Institute grant R01 HL089755 (Dr. Kripalani) and in part by National Heart, Lung, and Blood Institute grant K23 HL077597 (Dr. Kripalani); National Heart, Lung, and Blood Institute grant K08 HL072806 (Dr. Schnipper); Veterans Affairs Career Development Award 04-342-2 (Dr. Roumie); and National Center for Research Resources grant UL1 RR024975 (Dr. Bernard).	BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Borson S, 2005, J AM GERIATR SOC, V53, P871, DOI 10.1111/j.1532-5415.2005.53269.x; Coleman EA, 2005, ARCH INTERN MED, V165, P1842, DOI 10.1001/archinte.165.16.1842; Cua YM, 2008, ANN ACAD MED SINGAP, V37, P136; Davis TC, 2006, ANN INTERN MED, V145, P887, DOI 10.7326/0003-4819-145-12-200612190-00144; Elhai JD, 2008, PSYCHIAT RES, V160, P129, DOI 10.1016/j.psychres.2007.07.003; Forster AJ, 2005, J GEN INTERN MED, V20, P317, DOI 10.1111/j.1525-1497.2005.30390.x; Forster AJ, 2004, CAN MED ASSOC J, V170, P345; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Kaboli PJ, 2006, ARCH INTERN MED, V166, P955, DOI 10.1001/archinte.166.9.955; Kripalani S, 2008, MAYO CLIN PROC, V83, P529, DOI 10.4065/83.5.529; Kripalani S, 2007, J HOSP MED, V2, P314, DOI 10.1002/jhm.228; Kripalani S, 2007, PATIENT EDUC COUNS, V66, P368, DOI 10.1016/j.pec.2007.01.020; Little RJA, 2002, STAT ANAL MISSING DA, p[85, 209]; Marvanova M, 2011, J HOSP MED, V6, P488, DOI 10.1002/jhm.925; McCullagh P., 1999, GEN LINEAR MODELS; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Paasche-Orlow MK, 2005, J GEN INTERN MED, V20, P175, DOI 10.1111/j.1525-1497.2005.40245.x; Parker RM, 1998, SHORT TEST FUNCTIONA; Poon EG, 2006, ANN INTERN MED, V145, P426, DOI 10.7326/0003-4819-145-6-200609190-00006; Rask KJ, 2005, AM J MANAG CARE, V11, P145; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; Schnipper JL, 2011, J AM MED INFORM ASSN, V18, P309, DOI 10.1136/amiajnl-2010-000040; Schnipper JL, 2010, CIRC-CARDIOVASC QUAL, V3, P212, DOI 10.1161/CIRCOUTCOMES.109.921833; Schnipper JL, 2009, ARCH INTERN MED, V169, P771, DOI 10.1001/archinternmed.2009.51; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Schnipper JL, 2010, J HOSP MED S1, V68, P68; van Buuren S, 2000, MULTIVARIATE IMPUTAT; Walker PC, 2009, ARCH INTERN MED, V169, P2003, DOI 10.1001/archinternmed.2009.398; [No title captured], DOI DOI 10.1016/J.JACC.2007.02.013	33	190	191	0	28	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2012	157	1					1	U35		10.7326/0003-4819-157-1-201207030-00003	http://dx.doi.org/10.7326/0003-4819-157-1-201207030-00003			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	992NS	22751755	Green Accepted			2022-12-28	WOS:000307784900001
J	Ghiringhelli, G; Le Tacon, M; Minola, M; Blanco-Canosa, S; Mazzoli, C; Brookes, NB; De Luca, GM; Frano, A; Hawthorn, DG; He, F; Loew, T; Sala, MM; Peets, DC; Salluzzo, M; Schierle, E; Sutarto, R; Sawatzky, GA; Weschke, E; Keimer, B; Braicovich, L				Ghiringhelli, G.; Le Tacon, M.; Minola, M.; Blanco-Canosa, S.; Mazzoli, C.; Brookes, N. B.; De Luca, G. M.; Frano, A.; Hawthorn, D. G.; He, F.; Loew, T.; Sala, M. Moretti; Peets, D. C.; Salluzzo, M.; Schierle, E.; Sutarto, R.; Sawatzky, G. A.; Weschke, E.; Keimer, B.; Braicovich, L.			Long-Range Incommensurate Charge Fluctuations in (Y,Nd)Ba2Cu3O6+x	SCIENCE			English	Article							HIGH-TEMPERATURE SUPERCONDUCTOR; FERMI-SURFACE; STRIPE ORDER; PSEUDOGAP; PHASE; SYMMETRY	The concept that superconductivity competes with other orders in cuprate superconductors has become increasingly apparent, but obtaining direct evidence with bulk-sensitive probes is challenging. We have used resonant soft x-ray scattering to identify two-dimensional charge fluctuations with an incommensurate periodicity of similar to 3.2 lattice units in the copper-oxide planes of the superconductors (Y,Nd)Ba2Cu3O6+x, with hole concentrations of 0.09 to 0.13 per planar Cu ion. The intensity and correlation length of the fluctuation signal increase strongly upon cooling down to the superconducting transition temperature (T-c); further cooling below T-c abruptly reverses the divergence of the charge correlations. In combination with earlier observations of a large gap in the spin excitation spectrum, these data indicate an incipient charge density wave instability that competes with superconductivity.	[Ghiringhelli, G.; Minola, M.; Mazzoli, C.; Braicovich, L.] Consorzio Nazl Interuniv Sci Fis Materia, CNR SPIN, I-20133 Milan, Italy; [Ghiringhelli, G.; Minola, M.; Mazzoli, C.; Braicovich, L.] Politecn Milan, Dipartimento Fis, I-20133 Milan, Italy; [Le Tacon, M.; Blanco-Canosa, S.; Frano, A.; Loew, T.; Peets, D. C.; Keimer, B.] Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany; [Brookes, N. B.; Sala, M. Moretti] ESRF, F-38043 Grenoble, France; [De Luca, G. M.; Salluzzo, M.] CNR SPIN, I-80126 Naples, Italy; [Frano, A.; Schierle, E.; Weschke, E.] Helmholtz Zentrum Berlin Mat & Energie, D-12489 Berlin, Germany; [Hawthorn, D. G.] Univ Waterloo, Dept Phys & Astron, Waterloo, ON N2L 3G1, Canada; [He, F.; Sutarto, R.] Univ Saskatchewan, Canadian Light Source, Saskatoon, SK S7N 0X4, Canada; [Sutarto, R.; Sawatzky, G. A.] Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z4, Canada	Consiglio Nazionale delle Ricerche (CNR); Istituto Superconduttori, Materiali e Dispositivi Innovativi (SPIN-CNR); Polytechnic University of Milan; Max Planck Society; European Synchrotron Radiation Facility (ESRF); Consiglio Nazionale delle Ricerche (CNR); Istituto Superconduttori, Materiali e Dispositivi Innovativi (SPIN-CNR); Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB); University of Waterloo; University of Saskatchewan; University of British Columbia	Ghiringhelli, G (corresponding author), Consorzio Nazl Interuniv Sci Fis Materia, CNR SPIN, Piazza Leonardo da Vinci 32, I-20133 Milan, Italy.	giacomo.ghiringhelli@fisi.polimi.it; b.keimer@fkf.mpg.de	Weschke, Eugen/J-4404-2013; Mazzoli, Claudio/J-4360-2012; Sala, Marco Moretti/H-1034-2014; Mazzoli, Claudio/GWR-0931-2022; Ghiringhelli, Giacomo/D-1159-2014; Blanco-Canosa, Santiago/A-2928-2015; He, Feizhou/G-8493-2015; Schierle, Enrico/J-4356-2013; Hawthorn, David G/I-6491-2012; , Le Tacon Matthieu/D-8023-2011; Brookes, Nicholas B/C-6718-2019; salluzzo, marco/C-5919-2009; Moretti, Marco/AAF-9255-2019; Peets, Darren/T-5090-2017	Weschke, Eugen/0000-0002-2141-0944; Sala, Marco Moretti/0000-0002-9744-9976; Mazzoli, Claudio/0000-0001-9774-1507; Ghiringhelli, Giacomo/0000-0003-0867-7748; Blanco-Canosa, Santiago/0000-0002-4437-5846; He, Feizhou/0000-0002-3125-1406; Schierle, Enrico/0000-0002-6981-2301; Hawthorn, David G/0000-0002-7002-0416; , Le Tacon Matthieu/0000-0002-5838-3724; Brookes, Nicholas B/0000-0002-1342-9530; salluzzo, marco/0000-0001-8372-6963; Moretti, Marco/0000-0002-9744-9976; Peets, Darren/0000-0002-5456-574X; Minola, Matteo/0000-0003-4084-0664; Braicovich, Lucio/0000-0001-6548-9140; Keimer, Bernhard/0000-0001-5220-9023	European Commission [226716]; European project "SOPRANO" under Marie Curie actions [PITNGA-2008-214040]; German Science Foundation [SFB/TRR 80]; Italian Ministry of Research [Ministero dell'Istruzione, Universita e Ricerca (MIUR)] [PRIN-20094W2LAY]; Natural Sciences and Engineering Research Council of Canada; National Research Council; Canadian Institutes of Health Research; Univ. of Saskatchewan; CNR Institute; European Union Community	European Commission(European CommissionEuropean Commission Joint Research Centre); European project "SOPRANO" under Marie Curie actions; German Science Foundation(German Research Foundation (DFG)); Italian Ministry of Research [Ministero dell'Istruzione, Universita e Ricerca (MIUR)]; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); National Research Council; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Univ. of Saskatchewan; CNR Institute; European Union Community(European Commission)	This work was performed partly at the Advanced Resonant Spectroscopies (ADRESS) beamline of the Swiss Light Source, using the Super Advanced X-ray Emission Spectrometer (SAXES) instrument jointly built by Paul Scherrer Institut (Villigen, Switzerland), Politecnico di Milano (Italy), and Ecole Polytechnique Federale de Lausanne (Switzerland); partly at the ID08 beam line of the ESRF (Grenoble, France); partly at the UE46-PGM1 beamline of Bessy-II (Helmholtz-Zentrum Berlin fur Materialien und Energie, Germany); and partly at the Resonant Elastic and Inelastic X-ray Scattering (REIXS) beamine at the Canadian Light Source (CLS; Saskatoon, Saskatchewan, Canada). Part of this research project has been supported by the European Commission under the 7th Framework Programme: Research Infrastructures (grant agreement number 226716), the European project "SOPRANO" under Marie Curie actions (grant no. PITNGA-2008-214040), the German Science Foundation under SFB/TRR 80, and by the Italian Ministry of Research [Ministero dell'Istruzione, Universita e Ricerca (MIUR), grant no. PRIN-20094W2LAY]. The research at the CLS is supported by the Natural Sciences and Engineering Research Council of Canada, the National Research Council, the Canadian Institutes of Health Research, and the Univ. of Saskatchewan. We gratefully thank S. Kivelson, T. Devereaux, S. Sebastian, M.-H. Julien, and G. Khaliullin for discussions; T. Schmitt, K. Zhou, and C. Monney for support at the ADRESS beamline; and V. Hinkov, C. Lin, M. Bakr, M. Raichle, and D. Haug for preparation of some of the single-crystal samples. M.S. acknowledges additional funding from the CNR Institute and from the European Union Community.	Abbamonte P, 2005, NAT PHYS, V1, P155, DOI 10.1038/nphys178; Ament LJP, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.117003; Andersen NH, 1999, PHYSICA C, V317, P259, DOI 10.1016/S0921-4534(99)00066-0; ANDERSEN OK, 1991, PHYSICA C, V185, P147, DOI 10.1016/0921-4534(91)91964-6; Birgeneau RJ, 2006, J PHYS SOC JPN, V75, DOI 10.1143/JPSJ.75.111003; Braicovich L, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.077002; CASTELLANI C, 1995, PHYS REV LETT, V75, P4650, DOI 10.1103/PhysRevLett.75.4650; Coneri F, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.104507; Dai PC, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.054525; Daou R, 2010, NATURE, V463, P519, DOI 10.1038/nature08716; Doiron-Leyraud N, 2007, NATURE, V447, P565, DOI 10.1038/nature05872; Fong HF, 2000, PHYS REV B, V61, P14773, DOI 10.1103/PhysRevB.61.14773; Ghiringhelli G, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.117406; Harrison N, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.226402; Haug D, 2010, NEW J PHYS, V12, DOI 10.1088/1367-2630/12/10/105006; Hawthorn DG, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.075125; He RH, 2011, SCIENCE, V331, P1579, DOI 10.1126/science.1198415; Hinkov V, 2007, NAT PHYS, V3, P780, DOI 10.1038/nphys720; Hoffman JE, 2002, SCIENCE, V295, P466, DOI 10.1126/science.1066974; Howald C, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.014533; Hucker M, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.104506; Laliberte F, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1440; Le Tacon M, 2011, NAT PHYS, V7, P725, DOI [10.1038/nphys2041, 10.1038/NPHYS2041]; Liang RX, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.180505; Moretti Sala M, 2011, NEW J PHYS, V13, DOI 10.1088/1367-2630/13/4/043026; Parker CV, 2010, NATURE, V468, P677, DOI 10.1038/nature09597; Rigamonti A, 1998, REP PROG PHYS, V61, P1367, DOI 10.1088/0034-4885/61/10/002; Salluzzo M, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.134521; Stock C, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.024522; Strempfer J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.157007; Sun XF, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.107001; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; Vojta M, 2009, ADV PHYS, V58, P699, DOI 10.1080/00018730903122242; Wilkins SB, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.195101; Wise WD, 2008, NAT PHYS, V4, P696, DOI 10.1038/nphys1021; Wu T, 2011, NATURE, V477, P191, DOI 10.1038/nature10345; Yao H, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.012507	40	814	823	8	348	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 17	2012	337	6096					821	825		10.1126/science.1223532	http://dx.doi.org/10.1126/science.1223532			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	989BQ	22798406	Green Submitted			2022-12-28	WOS:000307535600037
J	Altman, D; Aggleton, P; Williams, M; Kong, T; Reddy, V; Harrad, D; Reis, T; Parker, R				Altman, Dennis; Aggleton, Peter; Williams, Michael; Kong, Travis; Reddy, Vasu; Harrad, David; Reis, Toni; Parker, Richard			Men who have sex with men: stigma and discrimination	LANCET			English	Editorial Material							GAY		[Altman, Dennis] La Trobe Univ, Sch Social Sci, Fac Humanities & Social Sci, Bundoora, Vic 3086, Australia; [Aggleton, Peter] Univ New S Wales, Natl Ctr HIV Social Res, Sydney, NSW, Australia; [Williams, Michael] Monash Univ, Michael Kirby Ctr Publ Hlth & Human Rights, Melbourne, Vic 3004, Australia; [Kong, Travis] Univ Hong Kong, Pokfulam, Hong Kong, Peoples R China; [Reddy, Vasu] Human Sci Res Council, Pretoria, South Africa; [Harrad, David] Grp Dignidade, Curitiba, Parana, Brazil; [Reis, Toni] Assoc Brasileira Lesb Gays Bissexuais Travestis &, Curitiba, Parana, Brazil; [Parker, Richard] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA	La Trobe University; University of New South Wales Sydney; Monash University; University of Hong Kong; Human Sciences Research Council-South Africa; Columbia University	Altman, D (corresponding author), La Trobe Univ, Sch Social Sci, Fac Humanities & Social Sci, Bundoora, Vic 3086, Australia.	d.altman@latrobe.edu.au		Altman, Dennis/0000-0001-7823-5326; Aggleton, Peter/0000-0001-5966-4969				Adam B, 1998, SEXUALITIES, V1, P387, DOI DOI 10.1177/136346098001004001; AIDS Accountability International, AIDS ACC SCOR LGBTI; Altman Dennis, 2000, HUMAN RIGHTS GENDER, P211; Altman Dennis, 1971, HOMOSEXUAL OPPRESSIO; Amory D, 1998, BOY WIVES FEMALE HUS; Anderson E, 2009, ROUTL RES GEND SOC, P81; [Anonymous], 2011, AGENCE FRANCE P 1030; Ayala G, 2011, WHAT UN LEARN GAY AC; Azimi N, 2006, NY TIMES MAGAZINE; Berkman A, 2005, AM J PUBLIC HEALTH, V95, P1162, DOI 10.2105/AJPH.2004.054593; Berry C, 2001, J HOMOSEXUAL, V40, P211, DOI 10.1300/J082v40n03_11; Beyrer C, 2012, LANCET; Bleys Rudi, 1996, GEOGRAPHY PERVERSION; Boellstorff T, 2004, ETHNOS, V69, P471; Boellstorff T, 2011, CULT ANTHROPOL, V26, P287, DOI 10.1111/j.1548-1360.2011.01100.x; Breyrer B, 2011, GLOBAL HIV EPIDEMICS; Campbell DE, 2008, PUBLIC OPIN QUART, V72, P399, DOI 10.1093/poq/nfn032; Conselho Nacional de Combate a Discriminacao/Ministerio da Saude (Brasil), 2004, BRAS SEM HOM PROGR C; Corr?a S., 2008, SEXUALITY HLTH HUMAN; Corrales Javier, 2010, POLITICS SEXUALITY L; Currier A, 2010, GENDER SOC, V24, P110, DOI 10.1177/0891243209354275; Dowsett G, 2009, MORAL PANICS SEX PAN, P130; Eshaghian T, 2008, BE OTHERS; Gao G, 1995, CHINESE SOC ANTHROP, V27, P71; Gettleman J, 2011, NY TIMES        0330; Herek GM, 2009, J COUNS PSYCHOL, V56, P32, DOI 10.1037/a0014672; Hinsch Bret, 1990, PASSIONS CUT SLEEVE; Human Rights Watch, 2009, WANT US EXT MURD TOR; International Lesbian Gay Trans and Intersex Association, 2010, LESB GAY RIGHTS WORL; Itaborahy LP, 2012, STAT SPONS HOM WORLD; Jackson, 2006, FEMINIST THEORY, V7, P105, DOI [10.1177/1464700106061462, DOI 10.1177/1464700106061462]; Kim YG, 2006, CULT HEALTH SEX, V8, P59, DOI 10.1080/13691050500159720; Kong TSK, 2010, CHINESE MALE HOMOSEX, P154; McLelland MJ, 2000, MALE HOMOSEXULITY MO; Ministerio da Saude (Brasil), 2008, DIR HUM HIV AIDS AV; Ministerio da Saude (Brasil), 2001, 4392BR BIRD; Mkhize Nonhlanhla, 2010, COUNTRY WE WANT LIVE, DOI DOI 10.1080/10894160.2011.604837; Myers S, 2011, NY TIMES        0330; Parker R, 2003, SOC SCI MED, V57, P13, DOI 10.1016/S0277-9536(02)00304-0; Pew Global Attitudes Project, RIS ENV CONC 47 NAT; Pew Research Center for the People and the Press, 2011, MOST SAY HOM SHOULD; Plummer D., 1999, ONE BOYS MASCULINITY; Politica Nacional de DST/AIDS: Principios Diretrizes e Estrategias, 1999, COORD NAC DST AIDS; Reddy V., 2002, SO AFR LINGUIST APPL, V20, P163, DOI DOI 10.2989/16073610209486308; Rice X, 2011, GUARDIAN        0529; Rich Adrienne, 1994, BLOOD BREAD POETRY S; Rivers I, 2011, HOMOPHOBIC B; Roberts B, 2008, HSRC REV, V6, P9; Rofel L, 2007, DESIRING CHINA EXPT, P3; Rofel L, 2010, POSITIONS-E ASIA CUL, V18, P425, DOI 10.1215/10679847-2010-009; Sang Tze-lan D., 1999, TOKENS EXCHANGE PROB, P276; The Joint United Nations Programme on HIV/AIDS (UNAIDS), 2008, KEEP SCOR 2 PROGR RE; The Joint United Nations Programme on HIV/AIDS (UNAIDS), 2009, HIV PREV HAMP HOM; Thoreson R, 2011, NOWHERE TURN BLACKMA; UN Political Declaration on HIV/AIDS, INT OUR EFF EL HIV A; UNESCO, 2011, RIO STAT HOM B ED AL; Virkkunen J, 2010, POLITICS PRIDE ETHNO; Weinberg G, 1972, SOC HLTH HOMOSEXUAL, P4; Whittaker B, 2006, UNSPEAKABLE LOVE GAY; Williamson IR, 2000, HEALTH EDUC RES, V15, P97, DOI 10.1093/her/15.1.97	60	111	118	1	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 28	2012	380	9839					439	445		10.1016/S0140-6736(12)60920-9	http://dx.doi.org/10.1016/S0140-6736(12)60920-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819652				2022-12-28	WOS:000306842800041
J	Paton, NI; Goodall, RL; Dunn, DT; Franzen, S; Collaco-Moraes, Y; Gazzard, BG; Williams, IG; Fisher, MJ; Winston, A; Fox, J; Orkin, C; Herieka, EA; Ainsworth, JG; Post, FA; Wansbrough-Jones, M; Kelleher, P				Paton, Nicholas I.; Goodall, Ruth L.; Dunn, David T.; Franzen, Samuel; Collaco-Moraes, Yolanda; Gazzard, Brian G.; Williams, Ian G.; Fisher, Martin J.; Winston, Alan; Fox, Julie; Orkin, Chloe; Herieka, Elbushra A.; Ainsworth, Jonathan G.; Post, Frank A.; Wansbrough-Jones, Mark; Kelleher, Peter			Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL-ACTIVATION; LYMPHOCYTE-ACTIVATION; INHIBITION; CHLOROQUINE; REPLICATION; INFECTIVITY; DIDANOSINE; MECHANISM; APOPTOSIS; MARKERS	Context Therapies to decrease immune activation might be of benefit in slowing HIV disease progression. Objective To determine whether hydroxychloroquine decreases immune activation and slows CD4 cell decline. Design, Setting, and Patients Randomized, double-blind, placebo-controlled trial performed at 10 HIV outpatient clinics in the United Kingdom between June 2008 and February 2011. The 83 patients enrolled had asymptomatic HIV infection, were not taking antiretroviral therapy, and had CD4 cell counts greater than 400 cells/mu L. Intervention Hydroxychloroquine, 400 mg, or matching placebo once daily for 48 weeks. Main Outcome Measures The primary outcome measure was change in the proportion of activated CD8 cells (measured by the expression of CD38 and HLA-DR surface markers), with CD4 cell count and HIV viral load as secondary outcomes. Analysis was by intention to treat using mixed linear models. Results There was no significant difference in CD8 cell activation between the 2 groups (-4.8% and -4.2% in the hydroxychloroquine and placebo groups, respectively, at week 48; difference, -0.6%; 95% CI, -4.8% to 3.6%; P = .80). Decline in CD4 cell count was greater in the hydroxychloroquine than placebo group (-85 cells/mu L vs -23 cells/mu L at week 48; difference, -62 cells/mu L; 95% CI, -115 to -8; P = .03). Viral load increased in the hydroxychloroquine group compared with placebo (0.61 log(10) copies/mL vs 0.23 log(10) copies/mL at week 48; difference, 0.38 log(10) copies/mL; 95% CI, 0.13 to 0.63; P = .003). Antiretroviral therapy was started in 9 patients in the hydroxychloroquine group and 1 in the placebo group. Trial medication was well tolerated, but more patients reported influenza-like illness in the hydroxychloroquine group compared with the placebo group (29% vs 10%; P = .03). Conclusion Among HIV-infected patients not taking antiretroviral therapy, the use of hydroxychloroquine compared with placebo did not reduce CD8 cell activation but did result in a greater decline in CD4 cell count and increased viral replication.	[Paton, Nicholas I.; Goodall, Ruth L.; Dunn, David T.; Collaco-Moraes, Yolanda] MRC Clin Trials Unit, London WC2B 6NH, England; [Franzen, Samuel; Kelleher, Peter] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Immunol Sect, London SW7 2AZ, England; [Gazzard, Brian G.; Kelleher, Peter] Chelsea & Westminster NHS Fdn, NHS Trust, London, England; [Williams, Ian G.] Mortimer Market Ctr, London, England; [Fisher, Martin J.] Brighton & Sussex Univ Hosp, NHS Trust, Brighton, E Sussex, England; [Winston, Alan] St Marys Hosp, London, England; [Fox, Julie] St Thomas Hosp, London, England; [Orkin, Chloe] Barts & London NHS Trust, London, England; [Herieka, Elbushra A.] Royal Bournemouth Hosp, Bournemouth, Dorset, England; [Ainsworth, Jonathan G.] N Middlesex Univ Hosp, London, England; [Post, Frank A.] Kings Coll Hosp London, London, England; [Post, Frank A.] Kings Coll London, London, England; [Wansbrough-Jones, Mark] St George Hosp, London, England	Medical Research Council Clinical Trials Unit; Imperial College London; Brighton and Sussex University Hospitals NHS Trust; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; Barts Health NHS Trust; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; St Georges University London	Paton, NI (corresponding author), MRC Clin Trials Unit, Aviat House,125 Kingsway, London WC2B 6NH, England.	nick.paton@ctu.mrc.ac.uk	Angus, Brian/L-9246-2019; Winston, Alan/AGZ-3015-2022	Angus, Brian/0000-0003-3598-7784; Winston, Alan/0000-0002-5847-8416; Dunn, David/0000-0003-1836-4446; Metcalf, Rebecca/0000-0002-6810-8937; fox, Julie/0000-0002-0583-8019; Goodall, Ruth/0000-0003-0622-5035; Arenas-Pinto, Alejandro/0000-0002-3368-5005; Greathead, Louise/0000-0002-0781-4408; Franzen, Samuel/0000-0002-8080-1865	Wellcome Trust; National Institute for Health Research, through the UK Clinical Research Network; MRC [MC_U122886352] Funding Source: UKRI; Medical Research Council [MC_U122886352] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); National Institute for Health Research, through the UK Clinical Research Network; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The trial was funded by The Wellcome Trust and supported by the National Institute for Health Research, through the UK Clinical Research Network.	Avina-Zubieta JA, 1998, ANN RHEUM DIS, V57, P582, DOI 10.1136/ard.57.10.582; Beirne P, 2009, EUR RESPIR J, V34, P1376, DOI 10.1183/09031936.00028209; Bofill M, 1996, AIDS, V10, P827, DOI 10.1097/00002030-199607000-00005; Chiang G, 1996, CLIN THER, V18, P1080, DOI 10.1016/S0149-2918(96)80063-4; Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333; ESDAILE JM, 1995, AM J MED, V98, P156; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002; Gilman AL, 1996, BONE MARROW TRANSPL, V17, P1069; Gilman AL, 2000, BIOL BLOOD MARROW TR, V6, P327, DOI 10.1016/S1083-8791(00)70058-9; GIORGI JV, 1994, J INFECT DIS, V170, P775, DOI 10.1093/infdis/170.4.775; Goldman FD, 2000, BLOOD, V95, P3460, DOI 10.1182/blood.V95.11.3460.011k26_3460_3466; Gougeon ML, 1996, J IMMUNOL, V156, P3509; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203; Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003; Longo DL, 1999, CLIN IMMUNOL, V90, P173, DOI 10.1006/clim.1998.4637; Martinson JA, 2010, ANTIMICROB AGENTS CH, V54, P871, DOI 10.1128/AAC.01246-09; Mildvan D, 2004, J INFECT DIS, V189, P1811, DOI 10.1086/383277; Murray SM, 2010, J VIROL, V84, P12082, DOI 10.1128/JVI.01466-10; Nixon DE, 2010, CURR OPIN HIV AIDS, V5, P498, DOI 10.1097/COH.0b013e32833ed6f4; Ooi EE, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-39; Paton NI, 2005, HIV MED, V6, P13, DOI 10.1111/j.1468-1293.2005.00259.x; Paton NI, 2002, LANCET, V359, P1667, DOI 10.1016/S0140-6736(02)08557-4; Paton NI, 2011, LANCET INFECT DIS, V11, P677, DOI 10.1016/S1473-3099(11)70065-2; Piconi S, 2011, BLOOD, V118, P3263, DOI 10.1182/blood-2011-01-329060; Savarino A, 2001, AIDS, V15, P2221, DOI 10.1097/00002030-200111230-00002; SPERBER K, 1995, CLIN THER, V17, P622, DOI 10.1016/0149-2918(95)80039-5; SPERBER K, 1993, AIDS RES HUM RETROV, V9, P91, DOI 10.1089/aid.1993.9.91; Sperber K, 1997, CLIN THER, V19, P913, DOI 10.1016/S0149-2918(97)80045-8; SPERBER K, 1993, J RHEUMATOL, V20, P803; TSAI WP, 1990, AIDS RES HUM RETROV, V6, P481, DOI 10.1089/aid.1990.6.481; WHO, ANT THER HIV INF AD; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	34	121	130	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					353	361		10.1001/jama.2012.6936	http://dx.doi.org/10.1001/jama.2012.6936			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820788	Green Accepted, Bronze			2022-12-28	WOS:000306685500023
J	Deeks, SG; Barre-Sinoussi, F				Deeks, Steven G.; Barre-Sinoussi, Francoise			Towards a cure for HIV	NATURE			English	Editorial Material									[Deeks, Steven G.] Univ Calif San Francisco, San Francisco, CA 94110 USA; [Barre-Sinoussi, Francoise] Inst Pasteur, Inst Natl Sante & Rech Med, F-75724 Paris, France	University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Deeks, SG (corresponding author), Univ Calif San Francisco, San Francisco, CA 94110 USA.	sdeeks@php.ucsf.edu	Barre-Sinoussi, Françoise/G-8355-2011					[Anonymous], NATURE REV IN PRESS; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Schwartlander B, 2011, LANCET, V377, P2031, DOI 10.1016/S0140-6736(11)60702-2	3	17	17	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 19	2012	487	7407					293	294		10.1038/487293a	http://dx.doi.org/10.1038/487293a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	975JB	22810677	Bronze			2022-12-28	WOS:000306506500015
J	Ebran, JP; Khan, E; Niksic, T; Vretenar, D				Ebran, J. -P.; Khan, E.; Niksic, T.; Vretenar, D.			How atomic nuclei cluster	NATURE			English	Article							RADII	Nucleonic matter displays a quantum-liquid structure, but in some cases finite nuclei behave like molecules composed of clusters of protons and neutrons. Clustering is a recurrent feature in light nuclei, from beryllium to nickel(1-3). Cluster structures are typically observed as excited states close to the corresponding decay threshold; the origin of this phenomenon lies in the effective nuclear interaction, but the detailed mechanism of clustering in nuclei has not yet been fully understood. Here we use the theoretical framework of energy-density functionals(4,5), encompassing both cluster and quantum liquid-drop aspects of nuclei, to show that conditions for cluster formation can in part be traced back to the depth of the confining nuclear potential. For the illustrative example of neon-20, we show that the depth of the potential determines the energy spacings between single-nucleon orbitals in deformed nuclei, the localization of the corresponding wavefunctions and, therefore, the degree of nucleonic density clustering. Relativistic functionals, in particular, are characterized by deep single-nucleon potentials. When compared to non-relativistic functionals that yield similar ground-state properties (binding energy, deformation, radii), they predict the occurrence of much more pronounced cluster structures. More generally, clustering is considered as a transitional phenomenon between crystalline and quantum-liquid phases of fermionic systems.	[Khan, E.] Univ Paris 11, CNRS, IN2P3, Inst Phys Nucl, F-91406 Orsay, France; [Ebran, J. -P.] CEA DAM DIF, F-91297 Arpajon, France; [Niksic, T.; Vretenar, D.] Univ Zagreb, Fac Sci, Dept Phys, Zagreb 10000, Croatia	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Universite Paris Saclay; CEA; University of Zagreb	Khan, E (corresponding author), Univ Paris 11, CNRS, IN2P3, Inst Phys Nucl, F-91406 Orsay, France.	khan@ipno.in2p3.fr	Vretenar, Dario/N-8158-2013; Niksic, Tamara/L-7343-2013	Vretenar, Dario/0000-0002-2097-6567; Ebran, Jean-Paul/0000-0002-2386-654X	Institut Universitaire de France; Croatian Ministry of Science, Education and Sport [1191005-1010]	Institut Universitaire de France; Croatian Ministry of Science, Education and Sport(Ministry of Science, Education and Sports, Republic of Croatia)	This work was supported by the Institut Universitaire de France and by the Croatian Ministry of Science, Education and Sport-project 1191005-1010. The authors thank J. Margueron, M. Milin, T. Neff, N. Van Giai and P. Schuck for comments and suggestions.	Arumugam P, 2005, PHYS REV C, V71, DOI 10.1103/PhysRevC.71.064308; Bender M, 2003, REV MOD PHYS, V75, P121, DOI 10.1103/RevModPhys.75.121; Chabanat E, 1998, NUCL PHYS A, V635, P231, DOI 10.1016/S0375-9474(98)00180-8; Chulkov L, 1996, NUCL PHYS A, V603, P219, DOI 10.1016/0375-9474(96)00160-1; Cohen-Tannoudji C., 1973, MECANIQUE QUANTIQUE; FELDMEIER H, 1995, NUCL PHYS A, V586, P493, DOI 10.1016/0375-9474(94)00792-L; FRICKE G, 1992, PHYS REV C, V45, P80, DOI 10.1103/PhysRevC.45.80; Fynbo HOU, 2005, NATURE, V433, P136, DOI 10.1038/nature03219; GIROD M, 1983, PHYS REV C, V27, P2317, DOI 10.1103/PhysRevC.27.2317; Greiner W., 1995, NUCL MOL; Ichikawa T, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.112501; Ikeda K., 1968, PROG THEOR PHYS SUPP, V464, P464; Kanada-En'yo Y, 2001, PROG THEOR PHYS SUPP, P205, DOI 10.1143/PTPS.142.205; Lalazissis GA, 2005, PHYS REV C, V71, DOI 10.1103/PhysRevC.71.024312; Maruhn JA, 2006, PHYS REV C, V74, DOI 10.1103/PhysRevC.74.044311; Mottelson B., 1996, HOUCH SESS 66 TRENDS, P25; Neff T, 2003, NUCL PHYS A, V713, P311, DOI 10.1016/S0375-9474(02)01307-6; Nilsson SG., 1955, MAT FYS MEDD DAN VID, V29, P1; Okolowicz J., 2012, PREPRINT; Pines D., 1966, THEORY QUANTUM LIQUI; Reinhard PG, 2011, PHYS REV C, V83, DOI 10.1103/PhysRevC.83.034312; Robledo LM, 2011, PHYS REV C, V84, DOI 10.1103/PhysRevC.84.054302; ROSE HJ, 1984, NATURE, V307, P245, DOI 10.1038/307245a0; Stoitsov MV, 2005, COMPUT PHYS COMMUN, V167, P43, DOI 10.1016/j.cpc.2005.01.001; Tohsaki A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.192501; von Oertzen W, 2006, PHYS REP, V432, P43, DOI 10.1016/j.physrep.2006.07.001; Vretenar D, 2005, PHYS REP, V409, P101, DOI 10.1016/j.physrep.2004.10.001; Walecka J.D., 2004, THEORETICAL NUCL SUB, DOI 10.1142/5500; Weizsacker C F V, 1938, NATURWISSENSCHAFTEN, V26, P209; Wheeler JA, 1937, PHYS REV, V52, P1107, DOI 10.1103/PhysRev.52.1107	30	102	107	2	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 19	2012	487	7407					341	344		10.1038/nature11246	http://dx.doi.org/10.1038/nature11246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JB	22810698	Green Submitted			2022-12-28	WOS:000306506500037
J	Peters, D; Bloom, G				Peters, David; Bloom, Gerald			Bring order to unregulated health markets	NATURE			English	Editorial Material									[Peters, David] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Hlth Syst Program, Baltimore, MD 21205 USA; [Bloom, Gerald] Univ Sussex, Inst Dev Studies, Brighton BN1 9RE, E Sussex, England	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Sussex	Peters, D (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Hlth Syst Program, Baltimore, MD 21205 USA.	dpeters@jhsph.edu; g.bloom@ids.ac.uk		Peters, David/0000-0001-8377-3444; Bloom, Gerald/0000-0002-7047-2412	ESRC [ES/I021620/1] Funding Source: UKRI; Economic and Social Research Council [ES/I021620/1] Funding Source: researchfish	ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		Bloom G., TRANSFORMIN IN PRESS; Newton PN, 2008, PLOS MED, V5, P209, DOI 10.1371/journal.pmed.0050032; Paina L, 2011, HLTH POLICY PLAN; Peters DH, 2009, DIR DEV, P1, DOI 10.1596/978-0-8213-7888-5; WHO, 2009, MED US PRIM CAR DEV; World Health Organization (WHO), 2006, WORLD HLTH REP 2006	6	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2012	487	7406					163	165		10.1038/487163a	http://dx.doi.org/10.1038/487163a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	972LP	22785295	Bronze			2022-12-28	WOS:000306278900013
J	Neoptolemos, JP; Moore, MJ; Cox, TF; Valle, JW; Palmer, DH; McDonald, AC; Carter, R; Tebbutt, NC; Dervenis, C; Smith, D; Glimelius, B; Charnley, RM; Lacaine, F; Scarfe, AG; Middleton, MR; Anthoney, A; Ghaneh, P; Halloran, CM; Lerch, MM; Olah, A; Rawcliffe, CL; Verbeke, CS; Campbell, F; Buchler, MW				Neoptolemos, John P.; Moore, Malcolm J.; Cox, Trevor F.; Valle, Juan W.; Palmer, Daniel H.; McDonald, Alexander C.; Carter, Ross; Tebbutt, Niall C.; Dervenis, Christos; Smith, David; Glimelius, Bengt; Charnley, Richard M.; Lacaine, Francois; Scarfe, Andrew G.; Middleton, Mark R.; Anthoney, Alan; Ghaneh, Paula; Halloran, Christopher M.; Lerch, Markus M.; Olah, Attila; Rawcliffe, Charlotte L.; Verbeke, Caroline S.; Campbell, Fiona; Buechler, Markus W.		European Study Grp Pancreatic Canc	Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PANCREATIC-CANCER; AMPULLARY CARCINOMA; PROGNOSTIC-FACTORS; TRACT CANCER; PANCREATICODUODENECTOMY; CHEMORADIOTHERAPY; DIFFERENTIATION	Context Patients with periampullary adenocarcinomas undergo the same resectional surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant chemotherapy has been shown to have a survival benefit for pancreatic cancer, there have been no randomized trials for periampullary adenocarcinomas. Objective To determine whether adjuvant chemotherapy (fluorouracil or gemcitabine) provides improved overall survival following resection. Design, Setting, and Patients The European Study Group for Pancreatic Cancer (ESPAC)-3 periampullary trial, an open-label, phase 3, randomized controlled trial (July 2000-May 2008) in 100 centers in Europe, Australia, Japan, and Canada. Of the 428 patients included in the primary analysis, 297 had ampullary, 96 had bile duct, and 35 had other cancers. Interventions One hundred forty-four patients were assigned to the observation group, 143 patients to receive 20 mg/m(2) of folinic acid via intravenous bolus injection followed by 425 mg/m(2) of fluorouracil via intravenous bolus injection administered 1 to 5 days every 28 days, and 141 patients to receive 1000 mg/m(2) of intravenous infusion of gemcitabine once a week for 3 of every 4 weeks for 6 months. Main Outcome Measures The primary outcome measure was overall survival with chemotherapy vs no chemotherapy; secondary measures were chemotherapy type, toxic effects, progression-free survival, and quality of life. Results Eighty-eight patients (61%) in the observation group, 83 (58%) in the fluorouracil plus folinic acid group, and 73 (52%) in the gemcitabine group died. In the observation group, the median survival was 35.2 months (95%% CI, 27.2-43.0 months) and was 43.1 (95%, CI, 34.0-56.0) in the 2 chemotherapy groups (hazard ratio, 0.86; (95% CI, 0.66-1.11; chi(2)=1.33; P=.25). After adjusting for independent prognostic variables of age, bile duct cancer, poor tumor differentiation, and positive lymph nodes and after conducting multiple regression analysis, the hazard ratio for chemotherapy compared with observation was 0.75 (95% CI, 0.57-0.98; Wald chi(2)=4.53, P=.03). Conclusions Among patients with resected periampullary adenocarcinoma, adjuvant chemotherapy, compared with observation, was not associated with a significant survival benefit in the primary analysis; however, multivariable analysis adjusting for prognostic variables demonstrated a statistically significant survival benefit associated with adjuvant chemotherapy	[Neoptolemos, John P.; Cox, Trevor F.; Ghaneh, Paula; Halloran, Christopher M.; Rawcliffe, Charlotte L.; Campbell, Fiona] Univ Liverpool, Canc Res United Kingdom Ctr, Liverpool Canc Trials Unit, Inst Translat Med, Liverpool L69 3GA, Merseyside, England; [Moore, Malcolm J.] Princess Margaret Hosp, Dept Med, Div Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada; [Valle, Juan W.] Univ Manchester, Sch Canc & Enabling Sci, Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 9PL, Lancs, England; [Palmer, Daniel H.] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Sch Canc Sci, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England; [McDonald, Alexander C.] Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Carter, Ross] Glasgow Royal Infirm, Dept Surg, Glasgow G4 0SF, Lanark, Scotland; [Tebbutt, Niall C.] Austin Hlth, Ludwig Oncol Unit, Melbourne, Vic, Australia; [Dervenis, Christos] Agia Olga Hosp, Dept Surg, Athens, Greece; [Smith, David] Clatterbridge Ctr Oncol, Bebington, Merseyside, England; [Glimelius, Bengt] Uppsala Univ, Akad Sjukhuset, Dept Oncol, Uppsala, Sweden; [Charnley, Richard M.] Freeman Rd Hosp, Dept Surg, Newcastle Upon Tyne, Tyne & Wear, England; [Lacaine, Francois] Hop Tenon, Serv Chirurg Digest & Viscerale, F-75970 Paris, France; [Scarfe, Andrew G.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; [Middleton, Mark R.] Oxford Univ Hosp NHS Trust, Churchill Hosp, Dept Oncol, Oxford, England; [Anthoney, Alan] St James Univ Hosp, Dept Oncol, Leeds, W Yorkshire, England; [Lerch, Markus M.] Ernst Moritz Arndt Univ Greifswald, Dept Med, Greifswald, Germany; [Olah, Attila] Petz Aladar Hosp, Dept Surg, Gyor, Hungary; [Verbeke, Caroline S.] Karolinska Univ Hosp, Dept Pathol, Stockholm, Sweden; [Buechler, Markus W.] Heidelberg Univ, Dept Surg, D-6900 Heidelberg, Germany	University of Liverpool; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Christie NHS Foundation Trust; University of Manchester; Cancer Research UK; University of Birmingham; Beatson Oncology Centre; University of Glasgow; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; General Hospital of N. Ionia Agia Olga; Clatterbridge Cancer Centre; Uppsala University; Uppsala University Hospital; Newcastle Freeman Hospital; Newcastle University - UK; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Alberta; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Saint James's University Hospital; Ernst Moritz Arndt Universitat Greifswald; Karolinska Institutet; Karolinska University Hospital; Ruprecht Karls University Heidelberg	Neoptolemos, JP (corresponding author), Univ Liverpool, Canc Res United Kingdom Ctr, Liverpool Canc Trials Unit, Inst Translat Med, UCD Bldg,Daulby St,5th Floor, Liverpool L69 3GA, Merseyside, England.	j.p.neoptolemos@liverpool.ac.uk	Imanova, Mehriban M/F-9290-2016; Lerch, Markus M./E-2206-2016; Ibrahimov, Vagif R/U-2211-2017; Cox, Trevor F/E-5567-2013; Neoptolemos, John/HGU-7742-2022; Ibrahimov, Vagif/M-3971-2019; Ibrahimov, Vagif/Q-1537-2015; Valle, Juan W/J-3571-2015; Wyld, David/B-8893-2015	Imanova, Mehriban M/0000-0002-5383-8216; Lerch, Markus M./0000-0002-9643-8263; Ibrahimov, Vagif R/0000-0002-9148-4711; Ibrahimov, Vagif/0000-0002-9148-4711; Valle, Juan W/0000-0002-1999-0863; Halloran, Christopher/0000-0002-5471-4178; Segersvard, Ralf/0000-0002-5702-7971; Cox, Trevor/0000-0003-3045-5594; Spry, Nigel/0000-0001-8659-5065; Katsourakis, Anastasios/0000-0002-5151-9449; Oza, Amit/0000-0002-9510-8641; Wyld, David/0000-0001-9523-4333; Madhusudan, Srinivasan/0000-0002-5354-5480; Middleton, Gary/0000-0001-5695-3474; Neoptolemos, John/0000-0002-6201-7399; Foukakis, Theodoros/0000-0001-8952-9987	Cancer Research United Kingdom; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia; Cancer Council of New South Wales; Cancer Council of Queensland; Cancer Council of Victoria; Cancer Council of South Australia; Australasian Gastro-Intestinal Trials Group; Liverpool NIHR Pancreas Biomedical Research Unit; Oxford NIHR Biomedical Research Centre; Cancer Research UK [8968, 11883] Funding Source: researchfish; National Institute for Health Research [08/29/02, NF-SI-0510-10126] Funding Source: researchfish	Cancer Research United Kingdom(Cancer Research UK); National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia; Cancer Council of New South Wales(Cancer Council New South Wales); Cancer Council of Queensland(Cancer Council Queensland); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Cancer Council of South Australia(Cancer Council South Australia); Australasian Gastro-Intestinal Trials Group; Liverpool NIHR Pancreas Biomedical Research Unit; Oxford NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	The study was supported by Cancer Research United Kingdom; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia, Cancer Councils of New South Wales, Queensland, Victoria and South Australia and The Australasian Gastro-Intestinal Trials Group. JPN is part funded Liverpool NIHR Pancreas Biomedical Research Unit. MM is part funded Oxford NIHR Biomedical Research Centre.	Albores-Saavedra J, 2009, J SURG ONCOL, V100, P598, DOI 10.1002/jso.21374; [Anonymous], 1997, J CLIN PATHOL; Berberat PO, 2009, EJSO-EUR J SURG ONC, V35, P187, DOI 10.1016/j.ejso.2008.01.030; Carter R, 2009, INT J CANCER, V124, P2960, DOI 10.1002/ijc.24270; COX DR, 1972, J R STAT SOC B, V34, P187; de Castro SMM, 2004, J GASTROINTEST SURG, V8, P775, DOI 10.1016/j.gassur.2004.08.006; Ehehalt F, 2011, ANN SURG, V254, P302, DOI 10.1097/SLA.0b013e31821994a8; Hatzaras I, 2010, ANN SURG ONCOL, V17, P991, DOI 10.1245/s10434-009-0883-9; Henson DE, 2009, ARCH PATHOL LAB MED, V133, P67, DOI 10.1043/1543-2165-133.1.67; Hruban RH, 2010, WHO CLASSIFICATION T, P87; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; O'Connell JB, 2008, ANN SURG ONCOL, V15, P1820, DOI 10.1245/s10434-008-9886-1; Pedrazzoli Sergio, 1999, Digestive Surgery, V16, P337, DOI 10.1159/000018744; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Riall TS, 2006, SURGERY, V140, P764, DOI 10.1016/j.surg.2006.04.006; Riall TS, 2005, J GASTROINTEST SURG, V9, P1191, DOI 10.1016/j.gassur.2005.08.034; Schonleben F, 2009, J GASTROINTEST SURG, V13, P1510, DOI 10.1007/s11605-009-0917-4; Sessa F, 2007, VIRCHOWS ARCH, V451, P649, DOI 10.1007/s00428-007-0444-1; Showalter TN, 2011, J GASTROINTEST SURG, V15, P1411, DOI 10.1007/s11605-011-1518-6; Smith RA, 2008, J GASTROINTEST SURG, V12, P1422, DOI 10.1007/s11605-008-0554-3; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Westgaard A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-5; Westgaard A, 2009, HISTOPATHOLOGY, V54, P337, DOI 10.1111/j.1365-2559.2009.03227.x; Winter JM, 2010, J GASTROINTEST SURG, V14, P379, DOI 10.1007/s11605-009-1080-7	28	380	397	1	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2012	308	2					147	156		10.1001/jama.2012.7352	http://dx.doi.org/10.1001/jama.2012.7352			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971QS	22782416				2022-12-28	WOS:000306219500028
J	Spence, D				Spence, Des			Take down the BMJ pay wall	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						Groves T, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4383	1	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 11	2012	345								e4735	10.1136/bmj.e4735	http://dx.doi.org/10.1136/bmj.e4735			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NU	22786941	Bronze			2022-12-28	WOS:000306518800009
J	Marshall, IJ; Wolfe, CDA; McKevitt, C				Marshall, Iain J.; Wolfe, Charles D. A.; McKevitt, Christopher			Lay perspectives on hypertension and drug adherence: systematic review of qualitative research	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HIGH BLOOD-PRESSURE; AFRICAN-AMERICANS; ANTIHYPERTENSIVE DRUGS; MEDICATION ADHERENCE; FOLK ILLNESS; BELIEFS; PERCEPTIONS; HEALTH; EXPERIENCE; COMMUNITY	Objective To synthesise the findings from individual qualitative studies on patients' understanding and experiences of hypertension and drug taking; to investigate whether views differ internationally by culture or ethnic group and whether the research could inform interventions to improve adherence. Design Systematic review and narrative synthesis of qualitative research using the 2006 UK Economic and Social Research Council research methods programme guidance. Data sources Medline, Embase, the British Nursing Index, Social Policy and Practice, and PsycInfo from inception to October 2011. Study selection Qualitative interviews or focus groups among people with uncomplicated hypertension (studies principally in people with diabetes, established cardiovascular disease, or pregnancy related hypertension were excluded). Results 59 papers reporting on 53 qualitative studies were included in the synthesis. These studies came from 16 countries (United States, United Kingdom, Brazil, Sweden, Canada, New Zealand, Denmark, Finland, Ghana, Iran, Israel, Netherlands, South Korea, Spain, Tanzania, and Thailand). A large proportion of participants thought hypertension was principally caused by stress and produced symptoms, particularly headache, dizziness, and sweating. Participants widely intentionally reduced or stopped treatment without consulting their doctor. Participants commonly perceived that their blood pressure improved when symptoms abated or when they were not stressed, and that treatment was not needed at these times. Participants disliked treatment and its side effects and feared addiction. These findings were consistent across countries and ethnic groups. Participants also reported various external factors that prevented adherence, including being unable to find time to take the drugs or to see the doctor; having insufficient money to pay for treatment; the cost of appointments and healthy food; a lack of health insurance; and forgetfulness. Conclusions Non-adherence to hypertension treatment often resulted from patients' understanding of the causes and effects of hypertension; particularly relying on the presence of stress or symptoms to determine if blood pressure was raised. These beliefs were remarkably similar across ethnic and geographical groups; calls for culturally specific education for individual ethnic groups may therefore not be justified. To improve adherence, clinicians and educational interventions must better understand and engage with patients' ideas about causality, experiences of symptoms, and concerns about drug side effects.	[Marshall, Iain J.; Wolfe, Charles D. A.; McKevitt, Christopher] Kings Coll London, Div Hlth & Social Care Res, London SE1 3QD, England; [Wolfe, Charles D. A.] Guys & St Thomas NHS Fdn Trust, Natl Inst Hlth Res Comprehens, Biomed Res Ctr, London, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Marshall, IJ (corresponding author), Kings Coll London, Div Hlth & Social Care Res, London SE1 3QD, England.	iain.marshall@kcl.ac.uk	mckevitt, christopher/AAN-7271-2021	MCKEVITT, CHRISTOPHER/0000-0002-5290-4613; Wolfe, Charles/0000-0001-8264-0981; Marshall, Iain/0000-0003-2594-2654	National Institute for Health Research [RP-PG-0407-10184]; National Institute for Health Research [NF-SI-0510-10060] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: IJM was employed as a clinical editor for Clinical Evidence at BMJ Group from 2008 to March 2010; no other financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. This article presents independent research commissioned by the National Institute for Health Research under its programme grants for applied research funding scheme (RP-PG-0407-10184). The views expressed in this article are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.	Antikainen RL, 2010, J HUM HYPERTENS, V24, P439, DOI 10.1038/jhh.2009.85; Araujo Sadala ML, 1998, RECH SOINS INFIRM, P50; Bane C, 2007, PHARM WORLD SCI, V29, P534, DOI 10.1007/s11096-007-9099-x; Benson J, 2006, FAM PRACT, V23, P80, DOI 10.1093/fampra/cmi081; Benson J, 2002, BRIT MED J, V325, P873, DOI 10.1136/bmj.325.7369.873; Beune E, 2004, HUISARTS WET, V47, P25; Beune EJAJ, 2006, J HUM HYPERTENS, V20, P946, DOI 10.1038/sj.jhh.1002094; Beune EJAJ, 2008, J HYPERTENS, V26, P648, DOI 10.1097/HJH.0b013e3282f4d20b; BLUMHAGEN D, 1980, CULT MED PSYCHIAT, V4, P197, DOI 10.1007/BF00048414; Bosworth HB, 2006, AM J MED, V119, P791, DOI 10.1016/j.amjmed.2006.02.013; Boutain DM, 2001, J NURS SCHOLARSHIP, V33, P225, DOI 10.1111/j.1547-5069.2001.00225.x; Boutain DM, 2008, J HOLIST NURS, V26, P173, DOI 10.1177/0898010108315187; Boutin-Foster C, 2007, ETHNIC DIS, V17, P29; Bury M, 1994, Health Care Anal, V2, P23, DOI 10.1007/BF02251332; Cantillon P, 1997, J HUM HYPERTENS, V11, P221, DOI 10.1038/sj.jhh.1000432; Machado LRC, 2007, REV ESC ENFERM USP, V41, P573, DOI 10.1590/S0080-62342007000400006; CHATELLIER G, 1982, EUR HEART J, V3, P45, DOI 10.1093/eurheartj/3.suppl_C.45; Connell P, 2005, BRIT J GEN PRACT, V55, P357; Costa RD, 2008, REV LAT-AM ENFERM, V16, P871, DOI 10.1590/S0104-11692008000500012; Silva MEDCE, 2008, REV BRAS ENFERM, V61, P500, DOI 10.1590/S0034-71672008000400017; dela Cruz FA, 2008, J AM ACAD NURSE PRAC, V20, P118, DOI 10.1111/j.1745-7599.2007.00301.x; Dickinson HO, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004935.pub2; Dixon-Woods M, 2004, QUAL SAF HEALTH CARE, V13, P223, DOI 10.1136/qshc.2003.008714; Dixon-Woods M., 2006, QUAL RES, V6, P27, DOI [10.1177/1468794106058867, DOI 10.1177/1468794106058867]; Dixon-Woods Mary, 2005, J Health Serv Res Policy, V10, P45, DOI 10.1258/1355819052801804; Falaschetti E, 2009, HYPERTENSION, V53, P480, DOI 10.1161/HYPERTENSIONAHA.108.125617; Firmo Josélia Oliveira Araújo, 2004, Cad. Saúde Pública, V20, P1029, DOI 10.1590/S0102-311X2004000400018; Fongwa MN, 2008, VASC HEALTH RISK MAN, V4, P157, DOI 10.2147/vhrm.2008.04.01.157; Ford C. D., 2009, Ethnicity & Disease, V19, P407; Garro L C, 1988, Arctic Med Res, V47 Suppl 1, P70; GARRO LC, 1988, AM ETHNOL, V15, P98, DOI 10.1525/ae.1988.15.1.02a00070; Gascon JJ, 2004, FAM PRACT, V21, P125, DOI 10.1093/fampra/cmh202; Glynn L, 2011, CLIN EVID, Vii, P0220; Gohar F, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-4; GREENFIELD SF, 1987, CULT MED PSYCHIAT, V11, P79, DOI 10.1007/BF00055010; Greer TM, 2010, J HEALTH CARE POOR U, V21, P251, DOI 10.1353/hpu.0.0265; Hart PD, 2004, AM J MED, V117, P62, DOI 10.1016/j.amjmed.2004.04.003; HEURTINROBERTS S, 1992, AM J HYPERTENS, V5, P787, DOI 10.1093/ajh/5.11.787; HEURTINROBERTS S, 1993, SOC SCI MED, V37, P285, DOI 10.1016/0277-9536(93)90260-B; HIBBERT GA, 1984, BRIT J PSYCHIAT, V144, P618, DOI 10.1192/bjp.144.6.618; Higginbottom G, 2008, J RES NURS, V13, P89, DOI 10.1177/1744987108088636; Higginbottom GMA, 2006, SOCIOL HEALTH ILL, V28, P583, DOI 10.1111/j.1467-9566.2006.00508.x; Horne R, 2005, CONCORDANCE ADHERENC; Horowitz CR, 2004, J HEALTH CARE POOR U, V15, P631, DOI 10.1353/hpu.2004.0061; Hunt K, 2001, INT J EPIDEMIOL, V30, P442, DOI 10.1093/ije/30.3.442; Jensen J, 1999, AM J HYPERTENS, V12, P271, DOI 10.1016/S0895-7061(98)00225-8; Jhalani J, 2005, BLOOD PRESS MONIT, V10, P317, DOI 10.1097/00126097-200512000-00006; Johnson M J, 1999, Clin Nurs Res, V8, P318, DOI 10.1177/10547739922158331; Joint Formulary Committee, 2001, RAM; Joint Formulary Committee, 2011, PROPR HYDR; Kjellgren KI, 1997, SCAND J PRIM HEALTH, V15, P188, DOI 10.3109/02813439709035026; KOTTKE TE, 1979, INT J EPIDEMIOL, V8, P355, DOI 10.1093/ije/8.4.355; Lahdenpera TS, 2001, J ADV NURS, V34, P189, DOI 10.1046/j.1365-2648.2001.01744.x; Lawlor DA, 2003, AM J PUBLIC HEALTH, V93, P266, DOI 10.2105/AJPH.93.2.266; Lee Sok-Goo, 2008, J Prev Med Public Health, V41, P255, DOI 10.3961/jpmph.2008.41.4.255; Lewis LM, 2011, J GERONTOL NURS, V37, P35, DOI 10.3928/00989134-20100201-02; Lewis LM, 2010, J CARDIOVASC NURS, V25, P199, DOI 10.1097/JCN.0b013e3181c7ccde; Lisper L, 1997, PATIENT EDUC COUNS, V32, P147, DOI 10.1016/S0738-3991(97)00033-5; Lukoschek P, 2003, J HEALTH CARE POOR U, V14, P566; MEYER D, 1985, HEALTH PSYCHOL, V4, P115, DOI 10.1037/0278-6133.4.2.115; Mohammadi Eesa, 2002, Int J Nurs Pract, V8, P324, DOI 10.1046/j.1440-172X.2002.00386.x; Morecroft Charles, 2006, Res Social Adm Pharm, V2, P186, DOI 10.1016/j.sapharm.2006.02.006; MORGAN M, 1988, SOCIOL HEALTH ILL, V10, P561, DOI 10.1111/1467-9566.ep10837256; MORGAN M, 1995, INT J EPIDEMIOL, V24, pS79, DOI 10.1093/ije/24.Supplement_1.S79; Ogedegbe G, 2004, J NATL MED ASSOC, V96, P442; Ogedegbe G, 2004, ETHNIC DIS, V14, P3; Organisation W.H., 2010, ADHERENCE LONG TERM; Panpakdee O, 2003, THAI J NURSING RES, V7, P121; Peres DS, 2003, REV SAUDE PUBL, V37, P635, DOI 10.1590/S0034-89102003000500014; Popay J, 2010, GUIDANCE CONDUCT NAR; Pound P, 2005, SOC SCI MED, V61, P133, DOI 10.1016/j.socscimed.2004.11.063; Proulx M, 2007, PATIENT EDUC COUNS, V68, P98, DOI 10.1016/j.pec.2007.05.014; Rose LE, 2000, J ADV NURS, V32, P587, DOI 10.1046/j.1365-2648.2000.01538.x; Sangren H, 2009, PATIENT EDUC COUNS, V74, P236, DOI 10.1016/j.pec.2008.08.007; Schoenberg NE, 2002, MED ANTHROPOL Q, V16, P458, DOI 10.1525/maq.2002.16.4.458; Schroeder K, 2004, ARCH INTERN MED, V164, P722, DOI 10.1001/archinte.164.7.722; SHARKNESS CM, 1992, AM J PREV MED, V8, P141, DOI 10.1016/S0749-3797(18)30821-3; Shaw Rachel L, 2004, BMC Med Res Methodol, V4, P5, DOI 10.1186/1471-2288-4-5; Silva C, 2008, REV MIN ENFERMAGEM, V12, P346; Sims J, 1999, PATIENT EDUC COUNS, V38, P185, DOI 10.1016/S0738-3991(98)00126-8; Sparrenberger F, 2009, J HUM HYPERTENS, V23, P12, DOI 10.1038/jhh.2008.74; Spencer J, 2005, ETHNIC DIS, V15, P748; Strahl Hilde, 2003, Anthropol Med, V10, P309, DOI 10.1080/1364847032000133834; Svensson S, 2000, INT J CARDIOL, V76, P157, DOI 10.1016/S0167-5273(00)00374-0; van Wissen K, 1998, J ADV NURS, V27, P567, DOI 10.1046/j.1365-2648.1998.00556.x; Vermeire E, 2001, J CLIN PHARM THER, V26, P331, DOI 10.1046/j.1365-2710.2001.00363.x; Viswanathan Hema, 2005, Res Social Adm Pharm, V1, P21, DOI 10.1016/j.sapharm.2004.12.007; Wai KC, 2010, J PRIM HEALTH CARE, V2, P217; Weaver NF, 2006, FAM PRACT, V23, P637, DOI 10.1093/fampra/cml039; Wexler R, 2009, J NATL MED ASSOC, V101, P597, DOI 10.1016/S0027-9684(15)30947-0; WHO, 2011, WORLD MALARIA REPORT 2011, P1; Wright JM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001841.pub2; Ziebland S, 2006, MED EDUC, V40, P405, DOI 10.1111/j.1365-2929.2006.02467.x	93	175	178	1	55	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 9	2012	345								e3953	10.1136/bmj.e3953	http://dx.doi.org/10.1136/bmj.e3953			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NR	22777025	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000306518500001
J	Gaston, KJ				Gaston, Kevin J.			ECOLOGY The importance of being rare	NATURE			English	Editorial Material									Univ Exeter, Environm & Sustainabil Inst, Penryn TR10 9EZ, England	University of Exeter	Gaston, KJ (corresponding author), Univ Exeter, Environm & Sustainabil Inst, Penryn TR10 9EZ, England.	k.j.gaston@exeter.ac.uk		Gaston, Kevin J./0000-0002-7235-7928				Cardinale BJ, 2012, NATURE, V486, P59, DOI 10.1038/nature11148; Duffy JE, 2009, FRONT ECOL ENVIRON, V7, P437, DOI 10.1890/070195; Gaston KJ, 2011, BIOSCIENCE, V61, P354, DOI 10.1525/bio.2011.61.5.4; Hubbell Stephen P., 2001, V32, pi; Mi XC, 2012, AM NAT, V180, pE17, DOI 10.1086/665999	5	29	32	2	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2012	487	7405					46	47		10.1038/487046a	http://dx.doi.org/10.1038/487046a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	968LM	22763551				2022-12-28	WOS:000305982900044
J	Landrum, ML; Neumann, C; Cook, C; Chukwuma, U; Ellis, MW; Hospenthal, DR; Murray, CK				Landrum, Michael L.; Neumann, Charlotte; Cook, Courtney; Chukwuma, Uzo; Ellis, Michael W.; Hospenthal, Duane R.; Murray, Clinton K.			Epidemiology of Staphylococcus aureus Blood and Skin and Soft Tissue Infections in the US Military Health System, 2005-2010	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE UNITS; METHICILLIN-RESISTANT; STREAM INFECTIONS; STATES; HOSPITALIZATIONS; HOSPITALS; STRAINS; DISEASE; TRIAL; RISK	Context Rates of hospital-onset methicillin-resistant Staphylococcus aureus (MRSA) infections are reported as decreasing, but recent rates of community-onset S aureus infections are less known. Objectives To characterize the overall and annual incidence rates of community-onset and hospital-onset S aureus bacteremia and skin and soft tissue infections (SSTIs) in a national health care system and to evaluate trends in the incidence rates of S aureus bacteremia and SSTIs and the proportion due to MRSA. Design, Setting, and Participants Observational study of all Department of Defense TRICARE beneficiaries from January 2005 through December 2010. Medical record databases were used to identify and classify all annual first-positive S aureus blood and wound or abscess cultures as methicillin-susceptible S aureus or MRSA, and as community-onset or hospital-onset infections (isolates collected >3 days after hospital admission). Main Outcome Measures Unadjusted incidence rates per 100 000 person-years of observation, the proportion of infections that was due to MRSA, and annual trends for 2005 through 2010 (examined using the Spearman rank correlation test or the Mantel-Haenszel chi(2) test for linear trend). Results During 56 million person-years (nonactive duty: 47 million person-years; active duty: 9 million person-years), there were 2643 blood and 80 281 wound or abscess annual first-positive Saureus cultures. Annual incidence rates varied from 3.6 to 6.0 per 100 000 person-years for S aureus bacteremia and 122.7 to 168.9 per 100 000 person-years for S aureus SSTIs. The annual incidence rates for community-onset MRSA bacteremia decreased from 1.7 per 100 000 person-years (95% CI, 1.5-2.0 per 100 000 person-years) in 2005 to 1.2 per 100 000 person-years (95% CI, 0.9-1.4 per 100 000 person-years) in 2010 (P=.005 for trend). The annual incidence rates for hospital-onset MRSA bacteremia also decreased from 0.7 per 100 000 person-years (95% CI, 0.6-0.9 per 100 000 person-years) in 2005 to 0.4 per 100 000 person-years (95% CI, 0.3-0.5 per 100 000 person-years) in 2010 (P=.005 for trend). Concurrently, the proportion of community-onset SSTI due to MRSA peaked at 62% in 2006 before decreasing annually to 52% in 2010 (P<.001 for trend). Conclusion In the Department of Defense population consisting of men and women of all ages from across the United States, the rates of both community-onset and hospital-onset MRSA bacteremia decreased in parallel, while the proportion of community-onset SSTIs due to MRSA has more recently declined. JAMA. 2012;308(1):50-59 www.jama.com	[Landrum, Michael L.; Hospenthal, Duane R.; Murray, Clinton K.] San Antonio Military Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA; [Landrum, Michael L.] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA; [Ellis, Michael W.] Uniformed Serv Univ Hlth Sci, Div Infect Dis, Bethesda, MD 20814 USA; [Neumann, Charlotte; Cook, Courtney; Chukwuma, Uzo] Navy & Marine Corps Public Hlth Ctr, EpiData Ctr Dept, Portsmouth, VA USA; [Landrum, Michael L.] Bellin Hlth, Green Bay, WI USA	San Antonio Military Medical Center; Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA	Murray, CK (corresponding author), San Antonio Military Med Ctr, Infect Dis Serv, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	clinton.murray@amedd.army.mil			National Institute of Allergy and Infectious Diseases, National Institutes of Health [Y1-AI-5072]; Global Emerging Infections Surveillance and Response Program; Armed Forces Health Surveillance Center; Navy and Marine Corps Public Health Center (NMCPHC); Postgraduate Research Participation Program at the Navy and Marine Corps Public Health Center; IDCRP, a Department of Defense program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI005072] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Global Emerging Infections Surveillance and Response Program; Armed Forces Health Surveillance Center; Navy and Marine Corps Public Health Center (NMCPHC); Postgraduate Research Participation Program at the Navy and Marine Corps Public Health Center; IDCRP, a Department of Defense program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under interagency agreement Y1-AI-5072. Support for this work was leveraged from grants provided by the Global Emerging Infections Surveillance and Response Program, Armed Forces Health Surveillance Center to the EpiData Center Department, Navy and Marine Corps Public Health Center (NMCPHC). Additional support was also provided in part by an appointment to the Postgraduate Research Participation Program at the Navy and Marine Corps Public Health Center administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the NMCPHC. At the time of the research for this study and writing of this article, Dr Landrum was an employee of the Infectious Disease Clinical Research Program (IDCRP). As such, he received support for this work provided by the IDCRP, a Department of Defense program executed through the Uniformed Services University of the Health Sciences.	Army Medical Surveillance Activity, 2006, MED SURVEILLANCE MON, V12, P208; Burton DC, 2009, JAMA-J AM MED ASSOC, V301, P727, DOI 10.1001/jama.2009.153; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P992; Chambers HF, 2009, NAT REV MICROBIOL, V7, P629, DOI 10.1038/nrmicro2200; Cohen AL, 2008, INFECT CONT HOSP EP, V29, P901, DOI 10.1086/591741; Crum NF, 2006, AM J MED, V119, P943, DOI 10.1016/j.amjmed.2006.01.004; El Atrouni WI, 2009, CLIN INFECT DIS, V49, pE130, DOI 10.1086/648442; Ellis MW, 2007, ANTIMICROB AGENTS CH, V51, P3591, DOI 10.1128/AAC.01086-06; Fridkin SK, 2005, NEW ENGL J MED, V352, P1436, DOI 10.1056/NEJMoa043252; Halsell JS, 2003, JAMA-J AM MED ASSOC, V289, P3283, DOI 10.1001/jama.289.24.3283; Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593; Hersh AL, 2008, ARCH INTERN MED, V168, P1585, DOI 10.1001/archinte.168.14.1585; Hidron AI, 2011, AIDS, V25, P1001, DOI 10.1097/QAD.0b013e328343c595; Jain R, 2011, NEW ENGL J MED, V364, P1419, DOI 10.1056/NEJMoa1007474; Jenkins TC, 2009, INFECT CONT HOSP EP, V30, P233, DOI 10.1086/595963; Kallen AJ, 2010, JAMA-J AM MED ASSOC, V304, P641, DOI 10.1001/jama.2010.1115; Kazakova SV, 2005, NEW ENGL J MED, V352, P468, DOI 10.1056/NEJMoa042859; Kern WV, 2010, CURR OPIN INFECT DIS, V23, P346, DOI 10.1097/QCO.0b013e32833bcc8a; Klein E, 2007, EMERG INFECT DIS, V13, P1840, DOI 10.3201/eid1312.070629; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Klevens RM, 2006, CLIN INFECT DIS, V42, P389, DOI 10.1086/499367; Kuehnert MJ, 2005, EMERG INFECT DIS, V11, P868; Laupland KB, 2008, J INFECT DIS, V198, P336, DOI 10.1086/589717; Liu C, 2008, CLIN INFECT DIS, V46, P1637, DOI 10.1086/587893; Marconi VC, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-14; Popovich KJ, 2011, 49 ANN M INF DIS SOC; Roalfe AK, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-275; Seybold U, 2006, CLIN INFECT DIS, V42, P647, DOI 10.1086/499815; Stenehjem E, 2011, 49 ANN M INF DIS SOC; US Department of Defense, TRICARE POL ACC CAR; Velasco D, 2005, J ANTIMICROB CHEMOTH, V55, P379, DOI 10.1093/jac/dki017; Whitman TJ, 2010, INFECT CONT HOSP EP, V31, P1207, DOI 10.1086/657136	32	155	165	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2012	308	1					50	59		10.1001/jama.2012.7139	http://dx.doi.org/10.1001/jama.2012.7139			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971DD	22760291				2022-12-28	WOS:000306183000023
J	Ranieri, VM; Rubenfeld, GD; Thompson, BT; Ferguson, ND; Caldwell, E; Fan, E; Camporota, L; Slutsky, AS				Ranieri, V. Marco; Rubenfeld, Gordon D.; Thompson, B. Taylor; Ferguson, Niall D.; Caldwell, Ellen; Fan, Eddy; Camporota, Luigi; Slutsky, Arthur S.		ARDS Definition Task Force	Acute Respiratory Distress Syndrome The Berlin Definition	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE LUNG INJURY; PULMONARY-ARTERY; INTEROBSERVER VARIABILITY; CLINICAL-TRIAL; MORTALITY; ARDS; EPIDEMIOLOGY; PRESSURE; CATHETER; OUTCOMES	The acute respiratory distress syndrome (ARDS) was defined in 1994 by the American-European Consensus Conference (AECC); since then, issues regarding the reliability and validity of this definition have emerged. Using a consensus process, a panel of experts convened in 2011 (an initiative of the European Society of Intensive Care Medicine endorsed by the American Thoracic Society and the Society of Critical Care Medicine) developed the Berlin Definition, focusing on feasibility, reliability, validity, and objective evaluation of its performance. A draft definition proposed 3 mutually exclusive categories of ARDS based on degree of hypoxemia: mild (200 mm Hg<PaO2/FIO2 <= 300 mmHg), moderate (100 mm Hg<PaO2/FIO2 <= 200 mm Hg), and severe (PaO2/FIO2 <= 100 mm Hg) and 4 ancillary variables for severe ARDS: radiographic severity, respiratory system compliance (<= 40 mL/cm H2O), positive end-expiratory pressure (>= 10 cm H2O), and corrected expired volume per minute (>= 10 L/min). The draft Berlin Definition was empirically evaluated using patient-level meta-analysis of 4188 patients with ARDS from 4 multicenter clinical data sets and 269 patients with ARDS from 3 single-center data sets containing physiologic information. The 4 ancillary variables did not contribute to the predictive validity of severe ARDS for mortality and were removed from the definition. Using the Berlin Definition, stages of mild, moderate, and severe ARDS were associated with increased mortality (27%; 95% CI, 24%-30%; 32%; 95% CI, 29%-34%; and 45%; 95% CI, 42%-48%, respectively; P < .001) and increased median duration of mechanical ventilation in survivors (5 days; inter-quartile [IQR], 2-11; 7 days; IQR, 4-14; and 9 days; IQR, 5-17, respectively; P < .001). Compared with the AECC definition, the final Berlin Definition had better predictive validity for mortality, with an area under the receiver operating curve of 0.577 (95% CI, 0.561-0.593) vs 0.536 (95% CI, 0.520-0.553; P < .001). This updated and revised Berlin Definition for ARDS addresses a number of the limitations of the AECC definition. The approach of combining consensus discussions with empirical evaluation may serve as a model to create more accurate, evidence-based, critical illness syndrome definitions and to better inform clinical care, research, and health services planning. JAMA. 2012; 307(23):2526-2533 Published online May 21, 2012. doi: 10.1001/jama.2012.5669 www.jama.com	[Rubenfeld, Gordon D.] Univ Toronto, Program Trauma Emergency & Crit Care, Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Ranieri, V. Marco] Univ Turin, Dept Anesthesia & Intens Care Med, Turin, Italy; [Thompson, B. Taylor; Caldwell, Ellen] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON M4N 3M5, Canada; [Ferguson, Niall D.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Ferguson, Niall D.] Harvard Univ, Sch Med, Boston, MA USA; [Caldwell, Ellen; Camporota, Luigi] Univ Hlth Network, Dept Med, Toronto, ON, Canada; [Caldwell, Ellen; Camporota, Luigi] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Fan, Eddy] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA USA; [Camporota, Luigi] Guys & St Thomas NHS Fdn Trust, Dept Crit Care, Kings Hlth Partners, London, England; [Slutsky, Arthur S.] Univ Toronto, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Interdept Div Crit Care Med,St Michaels Hosp, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Turin; University of Toronto; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Washington; University of Washington Seattle; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Rubenfeld, GD (corresponding author), Univ Toronto, Program Trauma Emergency & Crit Care, Sunnybrook Hlth Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	gordon.rubenfeld@sunnybrook.ca	Ranieri, Marco/AFX-8152-2022; Pesenti, Antonio/H-7483-2012; Ferguson, Niall/D-7619-2019; Camporota, Luigi/G-2390-2017; Rhodes, Andrew/G-4265-2011; Beale, Richard J/J-7831-2013; Slutsky, Arthur/M-3325-2019	Pesenti, Antonio/0000-0003-2593-729X; Ferguson, Niall/0000-0002-6213-5264; Camporota, Luigi/0000-0001-5600-1676; Rhodes, Andrew/0000-0002-8737-574X; Gattinoni, Luciano/0000-0001-5380-2494; Vincent, Jean-Louis/0000-0001-6011-6951	Maquet; Hemodec; Ikaria; Faron; Cerus; US Biotest; Sirius Genetics; sanofi-aventis; Immunetrics; Abbott; Eli Lilly; National Heart, Lung, and Blood Institute; GlaxoSmithKline; Tarix; European Society of Intensive Care Medicine; National Institutes of Health [R01HL067939]; Canadian Institutes of Health Research New Investigator Award (Ottawa, Canada); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067939] Funding Source: NIH RePORTER	Maquet; Hemodec; Ikaria; Faron; Cerus; US Biotest; Sirius Genetics; sanofi-aventis(Sanofi-Aventis); Immunetrics; Abbott(Abbott Laboratories); Eli Lilly(Eli Lilly); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); GlaxoSmithKline(GlaxoSmithKline); Tarix; European Society of Intensive Care Medicine; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research New Investigator Award (Ottawa, Canada)(Canadian Institutes of Health Research (CIHR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ranieri reported receiving consulting fees or honoraria from Maquet and Hemodec and board membership from Faron. Dr Rubenfeld reported receiving consulting fees or honoraria from Ikaria, Faron, and Cerus. Dr Thompson reported receiving support for travel from European Society of Intensive Care Medicine; being an advisory board member of Hemodec and AstraZeneca; receiving consultancy fees from US Biotest, Sirius Genetics, sanofi-aventis, Immunetrics, Abbott, and Eli Lilly; and receiving grants from the National Heart, Lung, and Blood Institute. Dr Slutsky reported receiving support for travel expenses from European Society of Intensive Care Medicine; board membership from Ikaria; receiving consultancy fees from GlaxoSmithKline and Tarix; having stock/stock options with Apeiron and Tarix; and sitting on advisory boards for Maquet Medical and NovaLung and steering committees for HemoDec and Eli Lilly. No other authors reported any financial disclosures.; This work was supported by the European Society of Intensive Care Medicine and grant R01HL067939 from the National Institutes of Health (Dr Rubenfeld). Dr Ferguson is supported by a Canadian Institutes of Health Research New Investigator Award (Ottawa, Canada).	ASHBAUGH DG, 1967, LANCET, V2, P319; Bellani G, 2011, AM J RESP CRIT CARE, V183, P1193, DOI 10.1164/rccm.201008-1318OC; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bersten AD, 2002, AM J RESP CRIT CARE, V165, P443, DOI 10.1164/ajrccm.165.4.2101124; Britos M, 2011, CRIT CARE MED, V39, P2025, DOI 10.1097/CCM.0b013e31821cb774; Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6; Cooke CR, 2008, CRIT CARE MED, V36, P1412, DOI 10.1097/CCM.0b013e318170a375; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Ferguson ND, 2004, INTENS CARE MED, V30, P1111, DOI 10.1007/s00134-004-2163-2; Ferguson ND, 2002, INTENS CARE MED, V28, P1073, DOI 10.1007/s00134-002-1354-y; Gattinoni L, 2001, AM J RESP CRIT CARE, V164, P1701, DOI 10.1164/ajrccm.164.9.2103121; Gowda MS, 1997, CRIT CARE MED, V25, P41, DOI 10.1097/00003246-199701000-00010; Hager DN, 2005, AM J RESP CRIT CARE, V172, P1241, DOI 10.1164/rccm.200501-048CP; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; Katzenstein A L, 1976, Am J Pathol, V85, P209; KOMADINA KH, 1991, CHEST, V100, P1647, DOI 10.1378/chest.100.6.1647; Li GX, 2011, AM J RESP CRIT CARE, V183, P59, DOI 10.1164/rccm.201003-0436OC; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; Meade MO, 2000, AM J RESP CRIT CARE, V161, P85, DOI 10.1164/ajrccm.161.1.9809003; Needham DM, 2006, CRIT CARE, V10, DOI 10.1186/cc3948; Nuckton TJ, 2002, NEW ENGL J MED, V346, P1281, DOI 10.1056/NEJMoa012835; Phua J, 2008, CRIT CARE MED, V36, P2912, DOI 10.1097/CCM.0b013e31817d20bd; Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Rubenfeld GD, 1999, CHEST, V116, P1347, DOI 10.1378/chest.116.5.1347; Rubenfeld GD, 2003, CRIT CARE MED, V31, pS276, DOI 10.1097/01.CCM.0000057904.62683.2B; Spragg RG, 2010, AM J RESP CRIT CARE, V181, P1121, DOI 10.1164/rccm.201001-0024WS; Streiner DL, 2015, HLTH MEASUREMENT SCA, DOI [10.1891/1521-0987.17.3.150, DOI 10.1891/1521-0987.17.3.150]; Terragni PP, 2007, AM J RESP CRIT CARE, V175, P160, DOI 10.1164/rccm.200607-915OC; Terragni PP, 2009, ANESTHESIOLOGY, V111, P826, DOI 10.1097/ALN.0b013e3181b764d2; Villar J, 2007, AM J RESP CRIT CARE, V176, P795, DOI 10.1164/rccm.200610-1534OC; WEXLER HR, 1981, CAN ANAESTH SOC J, V28, P370, DOI 10.1007/BF03007805; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213	33	5591	5925	31	410	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2012	307	23					2526	2533		10.1001/jama.2012.5669	http://dx.doi.org/10.1001/jama.2012.5669			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	960MB	22797452	Green Published			2022-12-28	WOS:000305391400029
J	Gordon-Larsen, P; Jones-Smith, J				Gordon-Larsen, Penny; Jones-Smith, Jessica			Challenges in ameliorating hunger while preventing obesity	LANCET			English	Editorial Material							CHILD UNDERNUTRITION; TRANSITION; GROWTH; HEALTH; CASH		[Gordon-Larsen, Penny] Univ N Carolina, Carolina Populat Ctr, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC 27516 USA; [Jones-Smith, Jessica] Univ Calif San Francisco, Ctr Hlth & Community, San Francisco, CA 94143 USA; [Jones-Smith, Jessica] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Gordon-Larsen, P (corresponding author), Univ N Carolina, Carolina Populat Ctr, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC 27516 USA.	pglarsen@unc.edu		Jones-Smith, Jessica/0000-0001-8962-1695	NHLBI NIH HHS [R01 HL108427] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL108427] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 2005, PREV CHRON DIS VIT I; Bhutta ZA, 2008, LANCET, V371, P417, DOI 10.1016/S0140-6736(07)61693-6; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; Fernald LCH, 2008, J NUTR, V138, P2250, DOI 10.3945/jn.108.090506; Fernald LCH, 2008, LANCET, V371, P828, DOI 10.1016/S0140-6736(08)60382-7; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; Heckman JJ, 2006, SCIENCE, V312, P1900, DOI 10.1126/science.1128898; Jones-Smith JC, 2011, AM J EPIDEMIOL, V173, P667, DOI 10.1093/aje/kwq428; Koletzko B, 2011, AM J CLIN NUTR, V94, p2036S, DOI 10.3945/ajcn.111.018903; Oliveira V., 2015, EIB134 USDA EC RES S; Popkin BM, 2012, NUTR REV, V70, P3, DOI 10.1111/j.1753-4887.2011.00456.x; Schmidt M. I., 2011, Lancet (British edition), V377, P1949, DOI 10.1016/S0140-6736(11)60135-9; Stevens GA, 2012, LANCET; Uauy R, 2002, PUBLIC HEALTH NUTR, V5, P223, DOI 10.1079/PHN2001297; Victora CG, 2011, LANCET, V377, P2042, DOI 10.1016/S0140-6736(11)60055-X; Victora CG, 2010, PEDIATRICS, V125, pE473, DOI 10.1542/peds.2009-1519	16	7	8	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 1	2012	380	9844					787	789		10.1016/S0140-6736(12)60909-X	http://dx.doi.org/10.1016/S0140-6736(12)60909-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	000OP	22770477				2022-12-28	WOS:000308396300007
J	Havlir, D; Beyrer, C				Havlir, Diane; Beyrer, Chris			The Beginning of the End of AIDS?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HIV-1 INFECTION		[Havlir, Diane] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; [Havlir, Diane] San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Beyrer, Chris] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, Baltimore, MD USA; [Beyrer, Chris] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Ctr AIDS Res, Baltimore, MD USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Havlir, D (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI094189] Funding Source: NIH RePORTER; NIAID NIH HHS [P30 AI094189] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Schwartlander B, 2011, LANCET, V377, P2031, DOI 10.1016/S0140-6736(11)60702-2	5	41	41	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 23	2012	367	8					685	687		10.1056/NEJMp1207138	http://dx.doi.org/10.1056/NEJMp1207138			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	992CX	22809362	Bronze			2022-12-28	WOS:000307754200001
J	Prosser, AT; Tang, T; Hall, HI				Prosser, Adria Tassy; Tang, Tian; Hall, H. Irene			HIV in Persons Born Outside the United States, 2007-2010	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOREIGN-BORN; SURVEILLANCE DATA; MEXICAN MIGRANTS; MENTAL-HEALTH; NATIVE-BORN; HIV/AIDS; INFECTION; EPIDEMIC; CARE; IMMIGRANTS	Context Persons born outside the United States comprise about 13% of the US population, and the challenges these persons face in accessing health care may lead to poorer human immunodeficiency virus (HIV) disease outcomes. Objective To describe the epidemiology of HIV among persons born outside the United States and among US-born persons diagnosed in the United States. Design, Setting, and Participants Analysis of the estimated number of US-born persons and persons born outside the United States diagnosed with HIV from 2007 through 2010 in 46 states and 5 US territories, the demographic characteristics, and the HIV transmission risk factors reported to the National HIV Surveillance System. Foreign-born persons were defined as persons born outside the United States and its territories, inclusive of naturalized citizens. Main Outcome Measure Diagnosis of HIV infection. Results From 2007 through 2010, HIV was diagnosed in 191 697 persons in the US population; of these, 16.2% (95% CI, 16.0%-16.3%) (n=30 995) were born outside the United States. Of the 25 255 persons with a specified country or region of birth outside the United States, 14.5% (n=3656) were from Africa, 41.0% (n=10 343) were from Central America (including Mexico), and 21.5% (n=5418) were from the Caribbean. The 4 states (California, Florida, New York, and Texas) reporting the highest numbers of persons born outside the United States and diagnosed with HIV were also the top 4 reporters of HIV cases overall. Among persons born outside the United States with HIV, 73.5% (n=22 773) were male. Among whites, 1841 of 55 574 (3.3%) of HIV diagnoses were in persons born outside the United States; in blacks, 8614 of 86 547 diagnoses (10.0%); in Hispanics, 17 913 of 42 431 diagnoses (42.2%); and in Asians, 1987 of 3088 diagnoses (64.3%). The percentage infected through heterosexual contact was 39.4% among persons born outside the United States vs 27.2% for US-born persons. Conclusions Among persons in 46 US states and 5 US territories who received a diagnosis of HIV from 2007 through 2010, 16.2% were born outside the United States. Compared with US-born persons diagnosed with HIV, persons born outside the United States had different epidemiologic characteristics. JAMA. 2012;308(6):601-607 Published online July 22, 2012. doi:10.1001/jama.2012.9046	[Prosser, Adria Tassy; Hall, H. Irene] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA; [Tang, Tian] ICF Int Inc, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Prosser, AT (corresponding author), CDC, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-47, Atlanta, GA 30333 USA.	ahp8@cdc.gov			Centers for Disease Control and Prevention	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	The Centers for Disease Control and Prevention funds all states and the District of Columbia to conduct HIV surveillance and selected areas to conduct HIV incidence surveillance and provides technical assistance to all funded areas.	Akinsete OO, 2007, AIDS PATIENT CARE ST, V21, P356, DOI 10.1089/apc.2006.0074; Aynalem G, 2004, AIDS BEHAV, V8, P25, DOI 10.1023/B:AIBE.0000017523.39818.88; Beckwith CG, 2009, INT J INFECT DIS, V13, P186, DOI 10.1016/j.ijid.2008.06.004; Bouckenooghe Alain R, 2002, J Immigr Health, V4, P81, DOI 10.1023/A:1014546525310; Centers for Disease Control and Prevention, TERMS DEF CALC US CD; Centers for Disease Control and Prevention, DIST PUBL HLTH RES P; Centers for Disease Control and Prevention, HIV SURV REP; Centers for Disease Control and Prevention, 2009, TECHN APP 2 HIVECON; Centers for Disease Control and Prevention, SURV BRIEF SURV SYST; Centers for Disease Control & Prevention, 2011, DIAGN HIV INF AIDS U; Centres for Disease Control and Prevention, SURV BRIEF TERMS DEF; Cunningham SA, 2008, HEALTH PLACE, V14, P623, DOI 10.1016/j.healthplace.2007.12.002; DECOSAS J, 1995, LANCET, V346, P826, DOI 10.1016/S0140-6736(95)91631-8; Department of Health and Human Services; Assistant Secretary for Planning and Evaluation; Office of Human Services Policy, SUMM IMM EL RESTR CU; Department of Homeland Security, 2011, YB IMM STAT 2011; Derose KP, 2009, MED CARE RES REV, V66, P355, DOI 10.1177/1077558708330425; Foley EE, 2005, AIDS CARE, V17, P1030, DOI 10.1080/09540120500100890; Frisbie WP, 2001, AM J EPIDEMIOL, V153, P372, DOI 10.1093/aje/153.4.372; George C, 2007, AIDS CARE, V19, P9, DOI 10.1080/09540120600909398; Green TA, 1998, STAT MED, V17, P143, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt;143::AID-SIM757&gt;3.0.CO;2-Y; Grieco E, 2010, US CENSUS BUREAU AM; Gushulak B D, 2000, J Immigr Health, V2, P67, DOI 10.1023/A:1009581817682; Haag D, TRENDS HIV POSITIVE; Harawa NT, 2002, AM J PUBLIC HEALTH, V92, P1958, DOI 10.2105/AJPH.92.12.1958; Harrison KM, 2008, PUBLIC HEALTH REP, V123, P618, DOI 10.1177/003335490812300512; Johnson AS, 2010, PUBLIC HEALTH REP, V125, P61, DOI 10.1177/00333549101250S410; Kerani RP, 2008, JAIDS-J ACQ IMM DEF, V49, P102, DOI 10.1097/QAI.0b013e3181831806; MacPherson DW, 2006, EMERG INFECT DIS, V12, P612; Magis-Rodriguez C, 2009, JAIDS-J ACQ IMM DEF, V51, pS21, DOI 10.1097/QAI.0b013e3181a26433; Mali Sonja, 2009, Morbidity and Mortality Weekly Report, V58, P1; Marc LG, 2010, AIDS, V24, P2089, DOI 10.1097/QAD.0b013e32833bedff; Moreno A, 2003, JAIDS-J ACQ IMM DEF, V34, P251, DOI 10.1097/00126334-200310010-00022; Othieno J, 2007, J HEALTH CARE POOR U, V18, P170; Passel JS, PORTRAIT UNAUTHORIZE; Pence BW, 2009, J ANTIMICROB CHEMOTH, V63, P636, DOI 10.1093/jac/dkp006; Prosser A, 2010, 17 C RETR OPP INF FE; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; Sanchez MA, 2004, JAIDS-J ACQ IMM DEF, V37, pS204, DOI 10.1097/01.qai.0000141253.54217.24; Schafer JL., 1997, ANAL INCOMPLETE MULT, DOI 10.1201/9781439821862; Serrano MT, 1997, AM J TROP MED HYG, V57, P678, DOI 10.4269/ajtmh.1997.57.678; Shedlin MG, 2006, J URBAN HEALTH, V83, P43, DOI 10.1007/s11524-005-9006-5; Singh GK, 2006, INT J EPIDEMIOL, V35, P903, DOI 10.1093/ije/dyl089; Steel Jennifer, 2003, Transcult Psychiatry, V40, P91, DOI 10.1177/1363461503401006; Thompson A, 2005, HOUS J HLTH L POL, V5, P145; Torian Lucia V., 2011, Morbidity and Mortality Weekly Report, V60, P985; UNAIDS, 2009, WORLD REG SUMM; US Census Bureau, SCHED C COUNTR COD D; US Citizenship and Immigration Services, IMM MED EX; Whetten K, 2008, PSYCHOSOM MED, V70, P531, DOI 10.1097/PSY.0b013e31817749dc; World Health Organization, WHO UNAIDS UNICEF GL; Zaidi IF, 2005, AIDS EDUC PREV, V17, P405, DOI 10.1521/aeap.2005.17.5.405	51	73	73	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 8	2012	308	6					601	607		10.1001/jama.2012.9046	http://dx.doi.org/10.1001/jama.2012.9046			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	984YA	22820630	Bronze			2022-12-28	WOS:000307228400027
J	Reaves, ML; Sinha, S; Rabinowitz, JD; Kruglyak, L; Redfield, RJ				Reaves, Marshall Louis; Sinha, Sunita; Rabinowitz, Joshua D.; Kruglyak, Leonid; Redfield, Rosemary J.			Absence of Detectable Arsenate in DNA from Arsenate-Grown GFAJ-1 Cells	SCIENCE			English	Article								A strain of Halomonas bacteria, GFAJ-1, has been claimed to be able to use arsenate as a nutrient when phosphate is limiting and to specifically incorporate arsenic into its DNA in place of phosphorus. However, we have found that arsenate does not contribute to growth of GFAJ-1 when phosphate is limiting and that DNA purified from cells grown with limiting phosphate and abundant arsenate does not exhibit the spontaneous hydrolysis expected of arsenate ester bonds. Furthermore, mass spectrometry showed that this DNA contains only trace amounts of free arsenate and no detectable covalently bound arsenate.	[Sinha, Sunita; Redfield, Rosemary J.] Univ British Columbia, Dept Zool, Vancouver, BC, Canada; [Kruglyak, Leonid] Princeton Univ, Lewis Sigler Inst Integrat Genom, Howard Hughes Med Inst, Princeton, NJ 08544 USA; [Reaves, Marshall Louis] Univ British Columbia, Dept Mol Biol, Vancouver, BC V5Z 1M9, Canada; [Rabinowitz, Joshua D.] Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; [Kruglyak, Leonid] Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA	University of British Columbia; Howard Hughes Medical Institute; Princeton University; University of British Columbia; Princeton University; Princeton University	Redfield, RJ (corresponding author), Univ British Columbia, Dept Zool, Vancouver, BC, Canada.	redfield@zoology.ubc.ca	Redfield, Rosemary/K-5633-2012; Rabinowitz, Joshua/GPP-4019-2022	Redfield, Rosemary/0000-0001-8940-587X; Rabinowitz, Joshua/0000-0002-1247-4727	National Science Foundation; Canadian Institutes of Health Research	National Science Foundation(National Science Foundation (NSF)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	M.L.R. is supported by a Graduate Research Fellowship from the National Science Foundation. J.D.R. is supported by the CAREER Award from the National Science Foundation. L.K. is an Investigator of the Howard Hughes Medical Institute and a James S. McDonnell Foundation Centennial Fellow. R.J.R. thanks the Canadian Institutes of Health Research for funding and J. Blum and R. Oremland for providing strain GFAJ-1; M. Khoshnoodi for the trace-element mix; the Charles Thompson lab for use of their BioScreen Analyzer; and S. Silver and C. Rensing for helpful discussions. We also thank the ICP Laboratory in the Department of Geosciences at Princeton University for assistance with ICP-MS analysis.	Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BAER CD, 1981, INORG CHEM, V20, P905, DOI 10.1021/ic50217a052; Cotner JB, 2010, FRONT MICROBIOL, V1, DOI 10.3389/fmicb.2010.00132; Hess DC, 2006, PLOS BIOL, V4, P2012, DOI 10.1371/journal.pbio.0040351; Lebrun E, 2003, MOL BIOL EVOL, V20, P686, DOI 10.1093/molbev/msg071; Lu WY, 2010, ANAL CHEM, V82, P3212, DOI 10.1021/ac902837x; Schoepp-Cothenet B, 2011, SCIENCE, V332, DOI 10.1126/science.1201438; Wang LR, 2011, P NATL ACAD SCI USA, V108, P2963, DOI 10.1073/pnas.1017261108; Wolfe-Simon F., 2011, SCIENCE, V332, P1149; Wolfe-Simon F, 2011, SCIENCE, V332, P1163, DOI 10.1126/science.1197258; Zimmermann MT, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-264	11	82	83	1	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 27	2012	337	6093					470	473		10.1126/science.1219861	http://dx.doi.org/10.1126/science.1219861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979FS	22773140	Green Submitted, Green Accepted			2022-12-28	WOS:000306802300044
J	Keller, MJ; Burk, RD; Xie, XH; Anastos, K; Massad, LS; Minkoff, H; Xue, XN; D'Souza, G; Watts, DH; Levine, AM; Castle, PE; Colie, C; Palefsky, JM; Strickler, HD				Keller, Marla J.; Burk, Robert D.; Xie, Xianhong; Anastos, Kathryn; Massad, L. Stewart; Minkoff, Howard; Xue, Xiaonan; D'Souza, Gypsyamber; Watts, D. Heather; Levine, Alexandra M.; Castle, Philip E.; Colie, Christine; Palefsky, Joel M.; Strickler, Howard D.			Risk of Cervical Precancer and Cancer Among HIV-Infected Women With Normal Cervical Cytology and No Evidence of Oncogenic HPV Infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-PAPILLOMAVIRUS INFECTION; INTERAGENCY HIV; PREVENTION; DNA	Context US cervical cancer screening guidelines for human immunodeficiency virus (HIV)-uninfected women 30 years or older have recently been revised, increasing the suggested interval between Papanicolaou (Pap) tests from 3 years to 5 years among those with normal cervical cytology (Pap test) results who test negative for oncogenic human papillomavirus (HPV). Whether a 3- year or 5-year screening interval could be used in HIV-infected women who are cytologically normal and oncogenic HPV-negative is unknown. Objective To determine the risk of cervical precancer or cancer defined cytologically (high-grade squamous intraepithelial lesions or greater [HSIL+]) or histologically (cervical intraepithelial neoplasia 2 or greater [CIN-2+]), as 2 separate end points, in HIV-infected women and HIV-uninfected women who at baseline had a normal Pap test result and were negative for oncogenic HPV. Design, Setting, and Participants Participants included 420 HIV-infected women and 279 HIV-uninfected women with normal cervical cytology at their enrollment in a multi-institutional US cohort of the Women's Interagency HIV Study, between October 1, 2001, and September 30, 2002, with follow-up through April 30, 2011. Semiannual visits at 6 clinical sites included Pap testing and, if indicated, cervical biopsy. Cervicovaginal lavage specimens from enrollment were tested for HPV DNA using polymerase chain reaction. The primary analysis was truncated at 5 years of follow-up. Main Outcome Measure Five-year cumulative incidence of cervical precancer and cancer. Results No oncogenic HPV was detected in 369 (88%[95% CI, 84%-91%]) HIV-infected women and 255 (91% [95% CI, 88%-94%]) HIV-uninfected women with normal cervical cytology at enrollment. Among these oncogenic HPV-negative women, 2 cases of HSIL+ were observed; an HIV-uninfected woman and an HIV-infected woman with a CD4 cell count of 500 cells/mu L or greater. Histologic data were obtained from 4 of the 6 clinical sites. There were 6 cases of CIN-2+ in 145 HIV-uninfected women(cumulative incidence, 5% [95% CI, 1%-8%]) and 9 cases in 219 HIV-infected women (cumulative incidence, 5% [95% CI, 2%-8%]). This included 1 case of CIN-2+ in 44 oncogenic HPV-negative HIV-infected women with CD4 cell count less than 350 cells/mu L (cumulative incidence, 2% [95% CI, 0%-7%]), 1 case in 47 women with CD4 cell count of 350 to 499 cells/mu L (cumulative incidence, 2% [95% CI, 0%-7%]), and 7 cases in 128 women with CD4 cell count of 500 cells/mu L or greater (cumulative incidence, 6% [95% CI, 2%-10%]). One HIV-infected and 1 HIV-uninfected woman had CIN-3, but none had cancer. Conclusion The 5-year cumulative incidence of HSIL+ and CIN-2+ was similar in HIV-infected women and HIV-uninfected women who were cytologically normal and oncogenic HPV-negative at enrollment.	[Keller, Marla J.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Massad, L. Stewart] Washington Univ, Sch Med, St Louis, MO USA; [Minkoff, Howard] Maimonides Hosp, Brooklyn, NY 11219 USA; [D'Souza, Gypsyamber] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA; [Watts, D. Heather] NICHHD, Bethesda, MD 20892 USA; [Levine, Alexandra M.] City Hope Natl Med Ctr, Duarte, CA 91010 USA; [Castle, Philip E.] Amer Soc Clin Pathologists, Washington, DC USA; [Colie, Christine] Georgetown Univ, Med Ctr, Washington, DC 20007 USA; [Palefsky, Joel M.] Univ Calif San Francisco, San Francisco, CA 94143 USA	Yeshiva University; Albert Einstein College of Medicine; Washington University (WUSTL); Maimonides Medical Center; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); City of Hope; Georgetown University; University of California System; University of California San Francisco	Keller, MJ (corresponding author), Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave,Mazer Bldg,Room 512, Bronx, NY 10461 USA.	marla.keller@einstein.yu.edu	Castle, Philip/AAP-6395-2020	Castle, Philip/0000-0003-1082-6554	Merck Sharp Dohme; National Institute of Allergy and Infectious Diseases [U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, U01-AI-42590]; Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI) [UL1 RR024131]; Einstein-Montefiore Center for AIDS Research [P30-AI-51519]; Institute for Clinical and Translational Research [UL1 RR025750]; National Institutes of Health (NIH);  [R01-CA-085178];  [R33-AI079763]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U01HD032632] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA085178] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025750, UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI042590, U01AI031834, U01AI034994, U01AI034993, P30AI051519, P30AI027763, U01AI035004, U01AI034989, R33AI079763] Funding Source: NIH RePORTER	Merck Sharp Dohme(Merck & Company); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute on Deafness and Other Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); National Center for Research Resources (UCSF-CTSI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Einstein-Montefiore Center for AIDS Research; Institute for Clinical and Translational Research(Ohio State University); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Castle reported receiving fees from Merck Sharp & Dohme for serving as a member of a data and safety monitoring board. Dr Palefsky reported receiving grant support, as well as travel support and fees for review activities, through his institution from Merck Sharp & Dohme; receiving fees through his institution for serving as a board member and consultant and providing expert testimony for Merck Sharp & Dohme; and serving as a member of the scientific advisory board of Pharmajet. No other authors reported disclosures.; Support for this study, including HPV DNA testing, was provided through R01-CA-085178. Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (principal investigators) at New York City/Bronx Consortium (Dr Anastos); Brooklyn, New York (Dr Minkoff); Washington, DC, Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Dr Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, and U01-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) (U01-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI grant UL1 RR024131). Additional support was provided by R33-AI079763, the Einstein-Montefiore Center for AIDS Research (P30-AI-51519), and the Institute for Clinical and Translational Research (UL1 RR025750).; The WIHS is a National Institutes of Health (NIH)-funded multicenter cohort study. Thus, the funding sources had a role in the overall WIHS study design but not the design of the current ancillary study; one coauthor, Dr Watts, is an employee of NICHD/NIH, and as an author had a role in the interpretation of the current data, and she reviewed and approved the submitted manuscript.	Bacon MC, 2005, CLIN DIAGN LAB IMMUN, V12, P1013, DOI 10.1128/CDLI.12.9.1013-1019.2005; Barkan SE, 1998, EPIDEMIOLOGY, V9, P117, DOI 10.1097/00001648-199803000-00004; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Brown LD, 2001, STAT SCI, V16, P101, DOI 10.1214/ss/1009213286; Burk RD, 1996, J INFECT DIS, V174, P679, DOI 10.1093/infdis/174.4.679; Chaturvedi AK, 2009, JNCI-J NATL CANCER I, V101, P1120, DOI 10.1093/jnci/djp205; Guiguet M, 2009, LANCET ONCOL, V10, P1152, DOI 10.1016/S1470-2045(09)70282-7; Harris TG, 2005, JAMA-J AM MED ASSOC, V293, P1471, DOI 10.1001/jama.293.12.1471; JIANG G, 1995, BIOTECHNIQUES, V19, P566; Kaplan Jonathan E., 2009, Morbidity and Mortality Weekly Report, V58, P1; Leung KM, 1997, ANNU REV PUBL HEALTH, V18, P83, DOI 10.1146/annurev.publhealth.18.1.83; Moyer VA, 2012, ANN INTERN MED, V156, P880, DOI 10.7326/0003-4819-156-12-201206190-00424; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Palefsky JM, 1999, JNCI-J NATL CANCER I, V91, P226, DOI 10.1093/jnci/91.3.226; Qu WM, 1997, J CLIN MICROBIOL, V35, P1304, DOI 10.1128/JCM.35.6.1304-1310.1997; Saslow D, 2012, J LOW GENIT TRACT DI, V16, P175, DOI 10.1097/LGT.0b013e31824ca9d5; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Stout NK, 2008, ARCH INTERN MED, V168, P1881, DOI 10.1001/archinte.168.17.1881; Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073; VERMUND SH, 1989, AM J OBSTET GYNECOL, V160, P304, DOI 10.1016/0002-9378(89)90430-4; Wheeler CM, 1996, OBSTET GYNECOL, V88, P261, DOI 10.1016/0029-7844(96)00120-2; Whitlock EP, 2011, ANN INTERN MED, V155, P687, DOI 10.7326/0003-4819-155-10-201111150-00376; Wright Thomas C Jr, 2007, J Low Genit Tract Dis, V11, P201, DOI 10.1097/LGT.0b013e3181585870	23	51	52	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					362	369		10.1001/jama.2012.5664	http://dx.doi.org/10.1001/jama.2012.5664			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820789	Green Accepted			2022-12-28	WOS:000306685500024
J	Mermin, J; Fenton, KA				Mermin, Jonathan; Fenton, Kevin A.			The Future of HIV Prevention in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COST-EFFECTIVENESS; INFECTION		[Mermin, Jonathan] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA; [Mermin, Jonathan; Fenton, Kevin A.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Mermin, J (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Mailstop E-21,1600 Clifton Rd, Atlanta, GA 30333 USA.	jhm7@cdc.gov	Mermin, Jonathan/J-9847-2012					[Anonymous], DIV HIV AIDS PREV AN; [Anonymous], 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003255, DOI 10.1002/14651858.CD003255]; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Haukoos JS, 2010, JAMA-J AM MED ASSOC, V304, P284, DOI 10.1001/jama.2010.953; Holtgrave DR, 2012, AIDS BEHAV, V16, P1365, DOI 10.1007/s10461-012-0207-0; Hutchinson AB, 2012, JAIDS-J ACQ IMM DEF, V59, P281, DOI 10.1097/QAI.0b013e31823e5bee; Koppenhaver RT, 2011, JAIDS-J ACQ IMM DEF, V58, pE51, DOI 10.1097/QAI.0b013e31822b74fe; Long EF, 2010, ANN INTERN MED, V153, P778, DOI 10.7326/0003-4819-153-12-201012210-00004; Steele CB, 2007, HLTH DISPARITIES HIV	10	30	30	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					347	348		10.1001/jama.2012.8693	http://dx.doi.org/10.1001/jama.2012.8693			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820785				2022-12-28	WOS:000306685500020
J	Behrmann, E; Muller, M; Penczek, PA; Mannherz, HG; Manstein, DJ; Raunser, S				Behrmann, Elmar; Mueller, Mirco; Penczek, Pawel A.; Mannherz, Hans Georg; Manstein, Dietmar J.; Raunser, Stefan			Structure of the Rigor Actin-Tropomyosin-Myosin Complex	CELL			English	Article							MUSCLE THIN-FILAMENTS; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; CROSS-BRIDGE CYCLE; F-ACTIN; SKELETAL-MUSCLE; ELECTRON CRYOMICROSCOPY; ACTOMYOSIN COMPLEX; HELICAL FILAMENTS; MOTOR FUNCTIONS; N-TERMINUS	Regulation of myosin and filamentous actin interaction by tropomyosin is a central feature of contractile events in muscle and nonmuscle cells. However, little is known about molecular interactions within the complex and the trajectory of tropomyosin movement between its "open" and "closed" positions on the actin filament. Here, we report the 8 angstrom resolution structure of the rigor (nucleotide-free) actin-tropomyosin-myosin complex determined by cryo-electron microscopy. The pseudoatomic model of the complex, obtained from fitting crystal structures into the map, defines the large interface involving two adjacent actin monomers and one tropomyosin pseudorepeat per myosin contact. Severe forms of hereditary myopathies are linked to mutations that critically perturb this interface. Myosin binding results in a 23 angstrom shift of tropomyosin along actin. Complex domain motions occur in myosin, but not in actin. Based on our results, we propose a structural model for the tropomyosin-dependent modulation of myosin binding to actin.	[Mueller, Mirco; Manstein, Dietmar J.] Hannover Med Sch, Inst Biophys Chem, D-30625 Hannover, Germany; [Behrmann, Elmar; Mannherz, Hans Georg; Raunser, Stefan] Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany; [Penczek, Pawel A.] Univ Texas Houston, Houston Med Sch, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Mannherz, Hans Georg] Ruhr Univ Bochum, Dept Anat & Mol Embryol, D-44801 Bochum, Germany	Hannover Medical School; Max Planck Society; University of Texas System; University of Texas Health Science Center Houston; Ruhr University Bochum	Manstein, DJ (corresponding author), Hannover Med Sch, Inst Biophys Chem, D-30625 Hannover, Germany.	manstein.dietmar@mh-hannover.de; raunser@mpi-dortmund.mpg.de	Manstein, Dietmar J. J/M-1034-2013; Behrmann, Elmar/I-5808-2015; Manstein, Dietmar J./AAG-2640-2019; Mannherz, Hans Georg/HHM-2867-2022; Raunser, Stefan/AHE-1573-2022	Manstein, Dietmar J. J/0000-0003-0763-0147; Behrmann, Elmar/0000-0001-6794-3669; Manstein, Dietmar J./0000-0003-0763-0147; Raunser, Stefan/0000-0001-9373-3016; Mannherz, Hans Georg/0000-0001-8158-5722	Deutsche Forschungsgemeinschaft [RA 1781/1-1, MA 807/17-2, MA 1081/11-2]; Fonds der chemischen Industrie [684052]; European Union [228971]; NIH [GM U54 094598, GM R01 60635]; Max Planck Society; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060635, U54GM094598] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fonds der chemischen Industrie(Fonds der Chemischen IndustrieEuropean Commission); European Union(European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Max Planck Society(Max Planck SocietyFoundation CELLEX); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to R.S. Goody for continuous support and thank him and C. Ungermann for useful comments on the manuscript. We thank O. Hofnagel for assistance at the electron microscope and I. Vetter for help with the installation of SPARX. We are grateful to G. Schroder for helpful comments on the use of DireX and W. Lehman for providing the tropomyosin model in the B state. We thank K. Chinthalapudi, R. Diensthuber, S.M. Heissler, and M. Taft for providing purified proteins. This work was supported by the "Deutsche Forschungsgemeinschaft" Grants RA 1781/1-1 (to S.R.), MA 807/17-2 (to H.G.M.), MA 1081/11-2 (to. D.J.M.), the "Fonds der chemischen Industrie" Grant 684052 (to E. B.), funding from the European Union Seventh Framework Programme (FP7/2007-2011) under grant agreement number 228971 (Molecular Motors-based Nano Devices-MONAD) (to D.J.M.), the NIH Grants GM U54 094598 and GM R01 60635 (to P.A.P.), and the Max Planck Society (to S.R. and E.B.).	Behrmann E, 2012, J STRUCT BIOL, V177, P302, DOI 10.1016/j.jsb.2011.12.020; Bonne G, 1998, CIRC RES, V83, P580, DOI 10.1161/01.RES.83.6.580; Conibear PB, 2003, NAT STRUCT BIOL, V10, P831, DOI 10.1038/nsb986; Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; Durrwang U, 2006, J CELL SCI, V119, P550, DOI 10.1242/jcs.02774; EATON BL, 1976, SCIENCE, V192, P1337, DOI 10.1126/science.131972; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; Egelman EH, 2000, ULTRAMICROSCOPY, V85, P225, DOI 10.1016/S0304-3991(00)00062-0; Fujii T, 2010, NATURE, V467, P724, DOI 10.1038/nature09372; Furch M, 2000, BIOCHEMISTRY-US, V39, P11602, DOI 10.1021/bi000985x; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Galkin VE, 2010, NAT STRUCT MOL BIOL, V17, P1318, DOI 10.1038/nsmb.1930; GEEVES MA, 1986, PROC R SOC SER B-BIO, V229, P85, DOI 10.1098/rspb.1986.0076; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; Giese KC, 1997, BIOCHEMISTRY-US, V36, P8465, DOI 10.1021/bi963141f; Goodson HV, 1999, J MOL BIOL, V287, P173, DOI 10.1006/jmbi.1999.2565; Grant BJ, 2006, BIOINFORMATICS, V22, P2695, DOI 10.1093/bioinformatics/btl461; Hansen JE, 2000, BIOCHEMISTRY-US, V39, P1792, DOI 10.1021/bi991873c; Hohn M, 2007, J STRUCT BIOL, V157, P47, DOI 10.1016/j.jsb.2006.07.003; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; Holmes KC, 2008, J MUSCLE RES CELL M, V29, P213, DOI 10.1007/s10974-008-9157-6; Holthauzen LMF, 2004, J BIOL CHEM, V279, P15204, DOI 10.1074/jbc.M308904200; Houdusse A, 2000, P NATL ACAD SCI USA, V97, P11238, DOI 10.1073/pnas.200376897; HUXLEY HE, 1980, NATURE, V284, P140, DOI 10.1038/284140a0; Irving M, 2000, NAT STRUCT BIOL, V7, P482, DOI 10.1038/75890; Joel PB, 2001, J BIOL CHEM, V276, P2998, DOI 10.1074/jbc.M006930200; Kim E, 2002, BIOCHEMISTRY-US, V41, P86, DOI 10.1021/bi0113824; Klein JC, 2008, P NATL ACAD SCI USA, V105, P12867, DOI 10.1073/pnas.0802286105; Kollmar M, 2002, EMBO J, V21, P2517, DOI 10.1093/emboj/21.11.2517; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; Li XC, 2011, BIOPHYS J, V100, P1005, DOI 10.1016/j.bpj.2010.12.3697; Li XC, 2010, J STRUCT BIOL, V170, P313, DOI 10.1016/j.jsb.2010.01.016; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P16557, DOI 10.1021/bi962388+; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; Milligan RA, 1996, P NATL ACAD SCI USA, V93, P21, DOI 10.1073/pnas.93.1.21; Mindell JA, 2003, J STRUCT BIOL, V142, P334, DOI 10.1016/S1047-8477(03)00069-8; Murphy CT, 1999, BIOCHEMISTRY-US, V38, P3785, DOI 10.1021/bi9826815; Oda T, 2009, NATURE, V457, P441, DOI 10.1038/nature07685; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Reubold TF, 2003, NAT STRUCT BIOL, V10, P826, DOI 10.1038/nsb987; Sasaki N, 1999, J BIOL CHEM, V274, P37840, DOI 10.1074/jbc.274.53.37840; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; Schroder GF, 2007, STRUCTURE, V15, P1630, DOI 10.1016/j.str.2007.09.021; Sparrow JC, 2003, NEUROMUSCULAR DISORD, V13, P519, DOI 10.1016/S0960-8966(03)00101-9; Splettstoesser T, 2011, PROTEINS, V79, P2033, DOI 10.1002/prot.23017; Sweeney HL, 2010, ANNU REV BIOPHYS, V39, P539, DOI 10.1146/annurev.biophys.050708.133751; Van Dijk J, 1999, BIOCHEMISTRY-US, V38, P15078, DOI 10.1021/bi991595h; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; Volkmann N, 2003, P NATL ACAD SCI USA, V100, P3227, DOI 10.1073/pnas.0536510100	53	246	248	2	65	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 20	2012	150	2					327	338		10.1016/j.cell.2012.05.037	http://dx.doi.org/10.1016/j.cell.2012.05.037			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817895	Green Accepted, Bronze			2022-12-28	WOS:000306595700012
J	Li, JX; McQuade, T; Siemer, AB; Napetschnig, J; Moriwaki, K; Hsiao, YS; Damko, E; Moquin, D; Walz, T; McDermott, A; Chan, FKM; Wu, H				Li, Jixi; McQuade, Thomas; Siemer, Ansgar B.; Napetschnig, Johanna; Moriwaki, Kenta; Hsiao, Yu-Shan; Damko, Ermelinda; Moquin, David; Walz, Thomas; McDermott, Ann; Chan, Francis Ka-Ming; Wu, Hao			The RIP1/RIP3 Necrosome Forms a Functional Amyloid Signaling Complex Required for Programmed Necrosis	CELL			English	Article							RECEPTOR-INTERACTING PROTEIN; NF-KAPPA-B; HOMOTYPIC INTERACTION MOTIF; INNATE IMMUNE-RESPONSE; SOLID-STATE NMR; CELL-DEATH; TNF-ALPHA; RIP3; APOPTOSIS; DOMAIN	RIP1 and RIP3 kinases are central players in TNF-induced programmed necrosis. Here, we report that the RIP homotypic interaction motifs (RHIMs) of RIP1 and RIP3 mediate the assembly of heterodimeric filamentous structures. The fibrils exhibit classical characteristics of beta-amyloids, as shown by Thioflavin T (ThT) and Congo red (CR) binding, circular dichroism, infrared spectroscopy, X-ray diffraction, and solid-state NMR. Structured amyloid cores are mapped in RIP1 and RIP3 that are flanked by regions of mobility. The endogenous RIP1/RIP3 complex isolated from necrotic cells binds ThT, is ultrastable, and has a fibrillar core structure, whereas necrosis is partially inhibited by ThT, CR, and another amyloid dye, HBX. Mutations in the RHIMs of RIP1 and RIP3 that are defective in the interaction compromise cluster formation, kinase activation, and programmed necrosis in vivo. The current study provides insight into the structural changes that occur when RIP kinases are triggered to execute different signaling outcomes and expands the realm of amyloids to complex formation and signaling.	[Li, Jixi; Napetschnig, Johanna; Damko, Ermelinda; Wu, Hao] Weill Cornell Med Coll, Dept Biochem, New York, NY 10065 USA; [McQuade, Thomas; Moriwaki, Kenta; Moquin, David; Chan, Francis Ka-Ming] Univ Massachusetts, Sch Med, Program Immunol & Virol, Dept Pathol, Worcester, MA 01655 USA; [Siemer, Ansgar B.; McDermott, Ann] Columbia Univ, Dept Chem, New York, NY 10027 USA; [Hsiao, Yu-Shan; Walz, Thomas] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Walz, Thomas] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Cornell University; University of Massachusetts System; University of Massachusetts Worcester; Columbia University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Wu, H (corresponding author), Childrens Hosp Boston, Immune Dis Inst, Program Cellular & Mol Med, Boston, MA 02115 USA.	hao.wu@childrens.harvard.edu	Chan, Francis/ABB-1895-2021; Chan, Francis Ka-Ming/E-9647-2014	Chan, Francis Ka-Ming/0000-0002-4803-8353; Moriwaki, Kenta/0000-0002-8724-4715; Walz, Thomas/0000-0003-2606-2835; McDermott, Ann/0000-0002-9249-1649	NIH [T32 AI07349];  [AI083497];  [AI088502];  [AI045937]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007349, R01AI045937, R01AI083497, R21AI088502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank L. Cohen-Gould for help with EM imaging at the Weill Cornell Microscopy Facility, S.M. Damo for initial work on this project, Q. Li for insect cell expression, V. Kumar for ThT measurement of endogenous complexes, and D. Porter (Novartis) for the generous gift of LBW242. This work was supported by grants to F.K.C. (AI083497 and AI088502) and H.W. (AI045937). F.K.C. is a member of the UMass DERC (DK32520). J.N. is an Irvington Institute postdoctoral fellow of the Cancer Research Institute, and D.M. is supported by NIH training grant T32 AI07349. T.W. is an investigator in the Howard Hughes Medical Institute.	Alavez S, 2011, NATURE, V472, P226, DOI 10.1038/nature09873; Avila J, 2010, BIOCHEM SOC T, V38, P977, DOI 10.1042/BST0380977; Balbirnie M, 2001, P NATL ACAD SCI USA, V98, P2375, DOI 10.1073/pnas.041617698; Challa S, 2010, J VIROL, V84, P10467, DOI 10.1128/JVI.00983-10; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Cho Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023209; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Detken A, 2002, CHEM PHYS LETT, V356, P298, DOI 10.1016/S0009-2614(02)00335-4; Eisenberg D, 2012, CELL, V148, P1188, DOI 10.1016/j.cell.2012.02.022; Feng SS, 2007, CELL SIGNAL, V19, P2056, DOI 10.1016/j.cellsig.2007.05.016; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gaither A, 2007, CANCER RES, V67, P11493, DOI 10.1158/0008-5472.CAN-07-5173; He SD, 2011, P NATL ACAD SCI USA, V108, P20054, DOI 10.1073/pnas.1116302108; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Hou FJ, 2011, CELL, V146, P448, DOI 10.1016/j.cell.2011.06.041; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Kaiser WJ, 2005, J IMMUNOL, V174, P4942, DOI 10.4049/jimmunol.174.8.4942; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Li ZL, 2010, J ELECTRON MICROSC, V59, P53, DOI 10.1093/jmicro/dfp036; Lin SC, 2010, NATURE, V465, P885, DOI 10.1038/nature09121; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Mack C, 2008, P NATL ACAD SCI USA, V105, P3094, DOI 10.1073/pnas.0800168105; Meng FL, 2010, BIOCHEMISTRY-US, V49, P8127, DOI 10.1021/bi100939a; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Moquin D, 2010, TRENDS BIOCHEM SCI, V35, P434, DOI 10.1016/j.tibs.2010.03.001; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Oueslati A, 2010, PROG BRAIN RES, V183, P115, DOI 10.1016/S0079-6123(10)83007-9; Ramshini H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016075; Rebsamen M, 2009, EMBO REP, V10, P916, DOI 10.1038/embor.2009.109; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Sambashivan S, 2005, NATURE, V437, P266, DOI 10.1038/nature03916; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Sawaya MR, 2007, NATURE, V447, P453, DOI 10.1038/nature05695; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Sun XQ, 2002, J BIOL CHEM, V277, P9505, DOI 10.1074/jbc.M109488200; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013; Takegoshi K, 2001, CHEM PHYS LETT, V344, P631, DOI 10.1016/S0009-2614(01)00791-6; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Upton JW, 2012, CELL HOST MICROBE, V11, P290, DOI [10.1016/j.chom.2012.01.016, 10.1016/j.chom.2019.09.004]; Upton JW, 2010, CELL HOST MICROBE, V7, P302, DOI 10.1016/j.chom.2010.03.006; Verel R, 2001, J MAGN RESON, V150, P81, DOI 10.1006/jmre.2001.2310; Walczak H, 2011, IMMUNOL REV, V244, P9, DOI 10.1111/j.1600-065X.2011.01066.x; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wang LW, 2010, NAT STRUCT MOL BIOL, V17, P1324, DOI 10.1038/nsmb.1920; Welz PS, 2011, NATURE, V477, P330, DOI 10.1038/nature10273; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Yu PW, 1999, CURR BIOL, V9, P539, DOI 10.1016/S0960-9822(99)80239-5; Zandomeneghi G, 2004, PROTEIN SCI, V13, P3314, DOI 10.1110/ps.041024904; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhang HB, 2011, NATURE, V471, P373, DOI 10.1038/nature09878; Zhao J., 2012, P NATL ACAD SCI US	59	738	764	8	142	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 20	2012	150	2					339	350		10.1016/j.cell.2012.06.019	http://dx.doi.org/10.1016/j.cell.2012.06.019			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	976PB	22817896	Green Accepted, Bronze			2022-12-28	WOS:000306595700013
J	Gordin, FM; Masur, H				Gordin, Fred M.; Masur, Henry			Current Approaches to Tuberculosis in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV-INFECTED ADULTS; LATENT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; ANTIRETROVIRAL THERAPY; PULMONARY TUBERCULOSIS; MOXIFLOXACIN; RIFAPENTINE; OUTBREAK; TESTS; IDENTIFICATION	Tuberculosis is a major threat to global health, infecting a third of the world's population. In the United States, however, control of tuberculosis has been increasingly successful. Only 3.2% of the US population is estimated to have latent tuberculosis and there are only 11 000 cases annually of active disease. More than half the cases in this country occur in individuals born outside the United States. Human immunodeficiency virus coinfection is not a major factor in the United States, since only approximately 10% of cases are coinfected. Drug resistance is also uncommon in this country. Because the United States has more resources for the diagnosis, therapy, and public health control of tuberculosis than many regions of the world, and because many hospitals have more cases of clinically significant nontuberculous mycobacteria than tuberculosis, the management approaches to tuberculosis need to be quite different in this country than in other regions. The resurgence in interest in developing new tools and the investment in public health infrastructure will hopefully be sustained in the United States so that the effect of tuberculosis on the US population will continue to diminish, and these new tools and approaches can be adapted to both high and low prevalence areas to meet the global challenge. JAMA. 2012;308(3):283-289 www.jama.com	[Masur, Henry] Natl Inst Hlth Clin Ctr, Dept Crit Care Med, Bethesda, MD 20892 USA; [Gordin, Fred M.] Vet Affairs Med Ctr, Washington, DC 20422 USA; [Gordin, Fred M.] George Washington Univ, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); US Department of Veterans Affairs; Veterans Health Administration (VHA); George Washington University	Masur, H (corresponding author), Natl Inst Hlth Clin Ctr, Dept Crit Care Med, 10 Ctr Dr,Room 2C145, Bethesda, MD 20892 USA.	hmasur@nih.gov			CLC NIH HHS [NIH0010192010] Funding Source: Medline	CLC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603; Anonymous, 2009, Morbidity and Mortality Weekly Report, V58, P7; [Anonymous], 2000, Am J Respir Crit Care Med, V161, pS221; [Anonymous], 2010, MULTIDRUG EXTENSIVEL; Barnes RFW, 2011, ANN EPIDEMIOL, V21, P791, DOI 10.1016/j.annepidem.2011.07.002; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Benator D, 2002, LANCET, V360, P528, DOI 10.1016/S0140-6736(02)09742-8; Blanc FX, 2011, NEW ENGL J MED, V365, P1471, DOI 10.1056/NEJMoa1013911; Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847; Burman WJ, 2006, AM J RESP CRIT CARE, V174, P331, DOI 10.1164/rccm.200603-360OC; Burman WJ, 2010, CLIN INFECT DIS, V50, pS165, DOI 10.1086/651487; Centers for Disease Control and Prevention, 2012, TUB FACT SHEET TREND; Centers for Disease Control and Prevention, TUB DAT STAT; Centers for disease control and prevention, 2008, REP TUB US; Centers for Disease Control and Prevention, 2011, REP TUB US 2010; Centers for Disease Control and Prevention, 2011, TRENDS TUB US; Conde MB, 2009, LANCET, V373, P1183, DOI 10.1016/S0140-6736(09)60333-0; de Perio MA, 2009, ARCH INTERN MED, V169, P179, DOI 10.1001/archinternmed.2008.524; Diacon AH, 2009, NEW ENGL J MED, V360, P2397, DOI 10.1056/NEJMoa0808427; Dinnes J, 2007, HEALTH TECHNOL ASSES, V11, P1, DOI 10.3310/hta11030; Dorman SE, 2009, AM J RESP CRIT CARE, V180, P273, DOI 10.1164/rccm.200901-0078OC; Flores LL, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-55; Geng E, 2002, NEW ENGL J MED, V346, P1453, DOI 10.1056/NEJMoa012972; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607; Horsburgh CR, 2011, NEW ENGL J MED, V364, P1441, DOI 10.1056/NEJMcp1005750; Horsburgh CR, 2004, NEW ENGL J MED, V350, P2060, DOI 10.1056/NEJMsa031667; ISKRANT A P, 1953, Public Health Rep, V68, P911, DOI 10.2307/4588588; Jereb John A., 2011, Morbidity and Mortality Weekly Report, V60, P1650; Karim SSA, 2011, NEW ENGL J MED, V365, P1492, DOI 10.1056/NEJMoa1014181; Koul A, 2011, NATURE, V469, P483, DOI 10.1038/nature09657; Ma ZK, 2010, LANCET, V375, P2100, DOI 10.1016/S0140-6736(10)60359-9; Martinson NA, 2011, NEW ENGL J MED, V365, P11, DOI 10.1056/NEJMoa1005136; Mazurek Gerald H., 2010, Morbidity and Mortality Weekly Report, V59, P1; Mitruka K, 2011, EMERG INFECT DIS, V17, P425, DOI 10.3201/eid1703.101550; Miyazaki E, 1999, ANTIMICROB AGENTS CH, V43, P2126, DOI 10.1128/AAC.43.9.2126; Nuermberger EL, 2004, AM J RESP CRIT CARE, V169, P421, DOI 10.1164/rccm.200310-1380OC; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; Rosenthal IM, 2007, PLOS MED, V4, P1931, DOI 10.1371/journal.pmed.0040344; Saleeb PG, 2011, J CLIN MICROBIOL, V49, P1790, DOI 10.1128/JCM.02135-10; Saukkonen JJ, 2006, AM J RESP CRIT CARE, V174, P935, DOI 10.1164/rccm.200510-1666ST; Schechter M, 2006, AM J RESP CRIT CARE, V173, P922, DOI 10.1164/rccm.200512-1953OC; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; Snider GL, 1997, ANN INTERN MED, V126, P237, DOI 10.7326/0003-4819-126-3-199702010-00011; Sterling TR, 2011, NEW ENGL J MED, V365, P2155, DOI 10.1056/NEJMoa1104875; Sterling TR, 2006, AM J RESP CRIT CARE, V173, P927, DOI 10.1164/rccm.200510-1563OC; Styblo K, 1980, Adv Tuberc Res, V20, P1; WEHRLE PF, 1970, B WORLD HEALTH ORGAN, V43, P669; Weyer K, 2011, J INFECT DIS, V204, pS1196, DOI 10.1093/infdis/jir452; Wilson ML, 2011, CLIN INFECT DIS, V52, P1350, DOI 10.1093/cid/cir146; Yee D, 2003, AM J RESP CRIT CARE, V167, P1472, DOI 10.1164/rccm.200206-626OC; Zelazny AM, 2005, J CLIN MICROBIOL, V43, P1051, DOI 10.1128/JCM.43.3.1051-1058.2005	53	16	17	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2012	308	3					283	289		10.1001/jama.2012.7505	http://dx.doi.org/10.1001/jama.2012.7505			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975AC	22797646	Green Accepted			2022-12-28	WOS:000306477900029
J	Landon, BE; Keating, NL; Barnett, ML; Onnela, JP; Paul, S; O'Malley, AJ; Keegan, T; Christakis, NA				Landon, Bruce E.; Keating, Nancy L.; Barnett, Michael L.; Onnela, Jukka-Pekka; Paul, Sudeshna; O'Malley, A. James; Keegan, Thomas; Christakis, Nicholas A.			Variation in Patient-Sharing Networks of Physicians Across the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE; SOCIAL NETWORKS; REGIONAL-VARIATIONS; QUALITY; COOPERATION; SPECIALIST; CHOICE	Context Physicians are embedded in informal networks that result from their sharing of patients, information, and behaviors. Objectives To identify professional networks among physicians, examine how such networks vary across geographic regions, and determine factors associated with physician connections. Design, Setting, and Participants Using methods adopted from social network analysis, Medicare administrative data from 2006 were used to study 4 586 044 Medicare beneficiaries seen by 68 288 physicians practicing in 51 hospital referral regions (HRRs). Distinct networks depicting connections between physicians (defined based on shared patients) were constructed for each of the 51 HRRs. Main Outcomes Measures Variation in network characteristics across HRRs and factors associated with physicians being connected. Results The number of physicians per HRR ranged from 135 in Minot, North Dakota, to 8197 in Boston, Massachusetts. There was substantial variation in network characteristics across HRRs. For example, the mean (SD) adjusted degree (number of other physicians each physician was connected to per 100 Medicare beneficiaries) across all HRRs was 27.3 (range, 11.7-54.4); also, primary care physician relative centrality (how central primary care physicians were in the network relative to other physicians) ranged from 0.19 to 1.06, suggesting that primary care physicians were more than 5 times more central in some markets than in others. Physicians with ties to each other were far more likely to be based at the same hospital (69.2% of unconnected physician pairs vs 96.0% of connected physician pairs; adjusted rate ratio, 0.12 [95% CI, 0.12-0.12]; P < .001), and were in closer geographic proximity (mean office distance of 21.1 km for those with connections vs 38.7 km for those without connections, P < .001). Connected physicians also had more similar patient panels in terms of the race or illness burden than unconnected physicians. For instance, connected physician pairs had an average difference of 8.8 points in the percentage of black patients in their 2 patient panels compared with a difference of 14.0 percentage points for unconnected physician pairs (P < .001). Conclusions Network characteristics vary across geographic areas. Physicians tend to share patients with other physicians with similar physician-level and patient-panel characteristics. JAMA. 2012;308(3):265-273 www.jama.com	[Landon, Bruce E.; Keating, Nancy L.; Barnett, Michael L.; Paul, Sudeshna; O'Malley, A. James; Keegan, Thomas; Christakis, Nicholas A.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02215 USA; [Landon, Bruce E.; Keating, Nancy L.; Barnett, Michael L.; Paul, Sudeshna; O'Malley, A. James; Keegan, Thomas; Christakis, Nicholas A.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Cambridge, MA 02138 USA; [Onnela, Jukka-Pekka] Harvard Univ, Sch Publ Hlth, Dept Biostat, Cambridge, MA 02138 USA; [Onnela, Jukka-Pekka] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA; [Christakis, Nicholas A.] Harvard Univ, Dept Sociol, Fac Arts & Sci, Cambridge, MA 02138 USA; [Christakis, Nicholas A.] Harvard Univ, Dept Sociol, Fac Arts & Sci, Boston, MA 02215 USA; [Landon, Bruce E.; Christakis, Nicholas A.] Beth Israel Deaconess Med Ctr, Dept Med, Div Primary Care & Gen Internal Med, Boston, MA 02215 USA; [Keating, Nancy L.; Barnett, Michael L.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	Landon, BE (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02215 USA.	landon@hcp.med.harvard.edu	Keating, Nancy L/I-9968-2019; Barnett, Michael/AAF-4017-2019; Barnett, Michael/ABA-4159-2021	Keating, Nancy L/0000-0002-8274-4681; Barnett, Michael/0000-0002-4884-6609; Barnett, Michael/0000-0002-4884-6609	National Institute on Aging [P-01 AG-031093]; Doris Duke Charitable Foundation Clinical Research Fellowship; Harvard Medical School Research Fellowship; NATIONAL INSTITUTE ON AGING [P01AG031093] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Doris Duke Charitable Foundation Clinical Research Fellowship(Doris Duke Charitable Foundation (DDCF)); Harvard Medical School Research Fellowship; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grant P-01 AG-031093 from the National Institute on Aging. Dr Barnett was supported by a Doris Duke Charitable Foundation Clinical Research Fellowship and a Harvard Medical School Research Fellowship.	[Anonymous], 2005, MODELS METHODS SOCIA, DOI [10.1017/cbo9780511811395.004, DOI 10.1017/CBO9780511811395.004]; Apicella CL, 2012, NATURE, V481, P497, DOI 10.1038/nature10736; Baldwin LM, 2002, MED CARE, V40, P82; Barnett ML, 2012, J GEN INTERN MED, V27, P506, DOI 10.1007/s11606-011-1861-z; Barnett ML, 2012, MED CARE, V50, P152, DOI 10.1097/MLR.0b013e31822dcef7; Barnett ML, 2011, HEALTH SERV RES, V46, P1592, DOI 10.1111/j.1475-6773.2011.01262.x; BREIGER RL, 1974, SOC FORCES, V53, P181, DOI 10.2307/2576011; Bynum JPW, 2007, HEALTH SERV RES, V42, P45, DOI 10.1111/j.1475-6773.2006.00633.x; Coleman J. S., 1966, MED INNOVATION DIFFU; Dartmouth Medical School Center for the Evaluative Clinical Sciences, 1998, DARTM ATL HLTH CAR; DesRoches CM, 2008, NEW ENGL J MED, V359, P50, DOI 10.1056/NEJMsa0802005; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; FRUCHTERMAN TMJ, 1991, SOFTWARE PRACT EXPER, V21, P1129, DOI 10.1002/spe.4380211102; Ingenix Inc, WHAT AR ETGS; Iwashyna TJ, 2009, CHEST, V135, P827, DOI 10.1378/chest.08-1052; Keating NL, 2007, J GEN INTERN MED, V22, P794, DOI 10.1007/s11606-007-0190-8; Keating NL, 1998, JAMA-J AM MED ASSOC, V280, P900, DOI 10.1001/jama.280.10.900; Kinchen KS, 2004, ANN FAM MED, V2, P245, DOI 10.1370/afm.68; McPherson M, 2001, ANNU REV SOCIOL, V27, P415, DOI 10.1146/annurev.soc.27.1.415; Pham HH, 2009, ANN INTERN MED, V150, P236, DOI 10.7326/0003-4819-150-4-200902170-00004; Pollack CE, 2012, HEALTH SERV RES, V47, P380, DOI 10.1111/j.1475-6773.2011.01331.x; Pope GC, RISK ADJUSTMENT MEDI; Rand DG, 2011, P NATL ACAD SCI USA, V108, P19193, DOI 10.1073/pnas.1108243108; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; Wasserman S., 1994, NETWORK ANAL METHODS; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102	28	171	171	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2012	308	3					265	273		10.1001/jama.2012.7615	http://dx.doi.org/10.1001/jama.2012.7615			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975AC	22797644	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000306477900027
J	Pettitt, DA; Molajo, A; McArthur, P				Pettitt, David A.; Molajo, Adeyinka; McArthur, Paul			A human bite	BRITISH MEDICAL JOURNAL			English	Editorial Material							EAR		[Pettitt, David A.] Univ Liverpool, Liverpool L69 3BX, Merseyside, England; [Molajo, Adeyinka; McArthur, Paul] Whiston Hosp, Mersey Reg Plast Surg Unit, Liverpool, Merseyside, England	University of Liverpool; Whiston Hospital	Pettitt, DA (corresponding author), Univ Liverpool, Liverpool L69 3BX, Merseyside, England.	dapettitt@doctors.org.uk						Department of Health, 2006, IMM INF DIS GREEB BO; Deshpande AK, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-16; GOLDSTEIN EJC, 1989, J AM ACAD DERMATOL, V21, P1275, DOI 10.1016/S0190-9622(89)70343-1; Hanif J, 2001, BRIT MED J, V322, P906, DOI 10.1136/bmj.322.7291.906; Health Protection Agency, 2005, GUID MAN HUM BIT INJ; Joint Formulary Committee, 2021, BRIT NATL FORMULARY; Kerins M, 2004, EUR J EMERG MED, V11, P223, DOI 10.1097/01.mej.0000127652.61705.1d; Liston Peter N., 2001, New Zealand Dental Journal, V97, P58; MEDEIROS I, 2001, COCHRANE DB SYST REV, V2; NHS Evidence, CLIN KNOWL SUMM BIT; Oelzner S, 2003, J AM ACAD DERMATOL, V49, P720, DOI 10.1067/S0190-9622(03)00482-1; Perron AD, 2002, AM J EMERG MED, V20, P114, DOI 10.1053/ajem.2002.31146; RICHMAN KM, 1993, J ACQ IMMUN DEF SYND, V6, P402; Talan DA, 1999, NEW ENGL J MED, V340, P85, DOI 10.1056/NEJM199901143400202; Thomas N, 2011, EXPERT REV ANTI-INFE, V9, P215, DOI 10.1586/ERI.10.162; Vogelin E, 1998, BRIT J PLAST SURG, V51, P359, DOI 10.1054/bjps.1997.0033	16	2	2	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 17	2012	345								e4798	10.1136/bmj.e4798	http://dx.doi.org/10.1136/bmj.e4798			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	978LQ	22807077				2022-12-28	WOS:000306742900003
J	Shiffman, J; Quissell, K				Shiffman, Jeremy; Quissell, Kathryn			Family planning: a political issue	LANCET			English	Editorial Material							POPULATION-POLICY; MOVEMENT; HEALTH		[Shiffman, Jeremy; Quissell, Kathryn] American Univ, Sch Publ Affairs, Dept Publ Adm & Policy, Washington, DC 20016 USA	American University	Shiffman, J (corresponding author), American Univ, Sch Publ Affairs, Dept Publ Adm & Policy, 4400 Massachusetts Ave NW, Washington, DC 20016 USA.	jshiffma@american.edu		Shiffman, Jeremy/0000-0002-1693-4671				Bill & Melinda Gates Foundation, 2012, FAM PLANN OV; Blanc AK, 2005, STUD FAMILY PLANN, V36, P263, DOI 10.1111/j.1728-4465.2005.00069.x; Bongaarts J, 2008, STUD FAMILY PLANN, V39, P105, DOI 10.1111/j.1728-4465.2008.00157.x; Canning D, 2012, LANCET, DOI http://dx.doi.org/SO140-6736(12)60827-7; CLELAND J, 1987, POP STUD-J DEMOG, V41, P5, DOI 10.1080/0032472031000142516; Cleland J, 2012, LANCET; Conference, 2011, C POP DEV PLAN FAM A; Cottingham J, 2012, LANCET; Crane BB, 2004, REPROD HEALTH MATTER, V12, P128, DOI 10.1016/S0968-8080(04)24140-4; Crichton J, 2008, HEALTH POLICY PLANN, V23, P339, DOI 10.1093/heapol/czn020; Department for International Development, 2010, NEW FOC FAM PLANN; Department for International Development, FAM PLANN UK HOST SU; DONALDSON PJ, 1990, POPUL BULL, V45, P1; Donaldson PJ, 2002, POP STUD-J DEMOG, V56, P97, DOI 10.1080/00324720213793; Ezeh AC, 2012, LANCET, DOI http://dx.doi.org/10.1016/S0140-6736(12)60696-5; FINKLE JL, 1975, POPUL DEV REV, V1, P87, DOI 10.2307/1972272; Guttmacher Institute UNFPA, 2009, ADD IT COSTS BEN INV; GWATKIN DR, 1979, POPUL DEV REV, V5, P29, DOI 10.2307/1972317; Hodgson D, 1997, POPUL DEV REV, V23, P469, DOI 10.2307/2137570; Hulme D, 2010, 105 BWPI U MANCH; O'Neill BC, 2012, LANCET, DOI http://dx.doi.org/ SO140-6736(12)60958-1; PAI, 2012, PRES BUDG REQ REST I; Pelletier DL, 2012, HEALTH POLICY PLANN, V27, P19, DOI 10.1093/heapol/czr011; Petchesky RP, 1995, REPROD HEALTH MATTER, V3, P152; Potts M, 1999, BRIT MED J, V319, P933, DOI 10.1136/bmj.319.7215.933; Ravishankar N, 2009, LANCET, V373, P2113, DOI 10.1016/S0140-6736(09)60881-3; Robinson RS, 2012, POPUL RES POLICY REV, V31, P267, DOI 10.1007/s11113-011-9222-5; Sanhueza H., 2007, GLOBAL FAMILY PLANNI, P105120; SIDA, 2003, SEX REPR HLTH RIGHTS; SIMMONS R, 1983, POPUL DEV REV, V9, P457, DOI 10.2307/1973318; Solo J, 2008, FAMILY PLANNING RWAN; UN Department of Economic and Social Affairs Population Division, 2010, WORLD POP POL 2009; UNFPA, 2011, FIN RES FLOWS POP AC; United States Government, 1974, 200 US GOV; USAID, 2010, INT ALL LAUNCH SUPP; WEST MO, 1994, SOC HIST MED, V7, P447, DOI 10.1093/shm/7.3.447	36	12	12	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2012	380	9837					181	185		10.1016/S0140-6736(12)60782-X	http://dx.doi.org/10.1016/S0140-6736(12)60782-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784537				2022-12-28	WOS:000306359100046
J	Lugner, AK; van Boven, M; de Vries, R; Postma, MJ; Wallinga, J				Lugner, Anna K.; van Boven, Michiel; de Vries, Robin; Postma, Maarten J.; Wallinga, Jacco			Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis	BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; TRANSMISSION PARAMETERS; MITIGATION STRATEGIES; ECONOMIC-EVALUATION; SOCIAL CONTACTS; NETHERLANDS; DISEASE; IMPACT; AGE; EPIDEMIC	Objective To investigate whether a single optimal vaccination strategy exists across countries to deal with a future influenza pandemic by comparing the cost effectiveness of different strategies in various pandemic scenarios for three European countries. Design Economic and epidemic modelling study. Settings General populations in Germany, the Netherlands, and the United Kingdom. Data sources Country specific patterns of social contact and demographic data. Model An age structured susceptible-exposed-infected-recovered transmission model that describes how an influenza A virus will spread in the populations of Germany, the Netherlands, and the United Kingdom. Interventions Comparison of four vaccination strategies: no vaccination, blanket vaccination, vaccination of elderly people (>= 65 years), and vaccination of high transmitters (5-19 years). The four strategies were evaluated for scenarios in which a vaccine became available early or at the peak of the pandemic, and in which either everyone was initially susceptible or older age groups had pre-existing immunity. Main outcome measure Cost per quality adjusted life years (QALYs) gained. Results All vaccination strategies were cost effective (incremental cost per QALY gained, comparing intervention with non-intervention). In scenarios where the vaccine became available at the peak of the pandemic and there was pre-existing immunity among elderly people the incremental cost effectiveness ratios for vaccinating high transmitters were (sic)7325 (5815; pound $10 470) per QALY gained for Germany, (sic)10 216 per QALY gained for the Netherlands, and (sic)7280 per QALY gained for the United Kingdom. The most cost effective strategy not only differed across the pandemic scenarios but also between countries. Specifically, when the vaccine was available early in the pandemic and there was no pre-existing immunity, in Germany it would be most cost effective to vaccinate elderly people ((sic)940 per QALY gained), whereas it would be most cost effective to vaccinate high transmitters in both the Netherlands ((sic)525 per QALY gained) and the United Kingdom ((sic)163 per QALY gained). This difference in optimal strategies was due to differences in the demographic characteristics of the countries: Germany has a significantly higher proportion of elderly people compared with the Netherlands and the United Kingdom. Conclusions No single vaccination strategy was most cost effective across countries. With aging populations, pre-existing immunity in particular could be of crucial importance for the cost effectiveness of options to mitigate a future influenza pandemic.	[Lugner, Anna K.; van Boven, Michiel; Wallinga, Jacco] Natl Inst Publ Hlth & Environm, Epidemiol & Surveillance Unit, Ctr Infect Dis Control Netherlands, NL-3720 BA Bilthoven, Netherlands; [de Vries, Robin; Postma, Maarten J.] Univ Groningen, Unit PharmacoEpidemiol & PharmacoEcon, Dept Pharm, Groningen, Netherlands; [de Vries, Robin] Roche Nederland, Commercial Affairs, Woerden, Netherlands; [Wallinga, Jacco] Julius Ctr Hlth Sci & Primary Care, Univ Med Ctr Utrecht, Utrecht, Netherlands	Netherlands National Institute for Public Health & the Environment; University of Groningen; Utrecht University; Utrecht University Medical Center	Lugner, AK (corresponding author), Natl Inst Publ Hlth & Environm, Epidemiol & Surveillance Unit, Ctr Infect Dis Control Netherlands, POB 1, NL-3720 BA Bilthoven, Netherlands.	anna.lugner@rivm.nl	Wallinga, Jacco/C-4382-2018	Wallinga, Jacco/0000-0003-1725-5627; Postma, Maarten/0000-0002-6306-3653	Quantitative Immunization and Vaccine-Related Research (QUIVER) grant from the World Health Organization; Pfizer; GlaxoSmithKline; Sanofi Pasteur MSD; MapiValues	Quantitative Immunization and Vaccine-Related Research (QUIVER) grant from the World Health Organization; Pfizer(Pfizer); GlaxoSmithKline(GlaxoSmithKline); Sanofi Pasteur MSD; MapiValues	This research was partly funded by a Quantitative Immunization and Vaccine-Related Research (QUIVER) grant from the World Health Organization. The study sponsor had no influence on the study design; collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that: no support from any organisation for the submitted work; RdV is an employee of Roche Nederland (since completing this paper) that might have an interest in the submitted work in the previous three years, MJP has been on advisory boards of, or received grants from Pfizer, GlaxoSmithKline, Sanofi Pasteur MSD, and MapiValues, that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.	Aballea S, 2007, VALUE HEALTH, V10, P98, DOI 10.1111/j.1524-4733.2006.00157.x; Baguelin M, 2010, VACCINE, V28, P2370, DOI 10.1016/j.vaccine.2010.01.002; Baltussen RMPM, 1998, EPIDEMIOL INFECT, V121, P129, DOI 10.1017/S0950268898008966; Boelle PY, 2011, INFLUENZA OTHER RESP, V5, P306, DOI 10.1111/j.1750-2659.2011.00234.x; Boersma C, 2010, VALUE HEALTH, V13, P853, DOI 10.1111/j.1524-4733.2010.00736.x; Casparie A F, 1998, Ned Tijdschr Geneeskd, V142, P2075; CBS, 2009, STAT NETH STATL; Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; Fukuda K, 2004, INACTIVATED INFLUENZ; Germann TC, 2006, P NATL ACAD SCI USA, V103, P5935, DOI 10.1073/pnas.0601266103; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; JORDAN WS, 1958, AM J HYG, V68, P190, DOI 10.1093/oxfordjournals.aje.a119962; KOOPMANSCHAP MA, 1995, J HEALTH ECON, V14, P171, DOI 10.1016/0167-6296(94)00044-5; Longini IM, 2004, AM J EPIDEMIOL, V159, P623, DOI 10.1093/aje/kwh092; Longini IM, 2005, SCIENCE, V309, P1083, DOI 10.1126/science.1115717; Lugner AK, 2010, HEALTH ECON, V19, P518, DOI 10.1002/hec.1485; Medicijnkosten, DRUG COSTS; Medlock J, 2009, SCIENCE, V325, P1705, DOI 10.1126/science.1175570; Melse JM, 2000, AM J PUBLIC HEALTH, V90, P1241, DOI 10.2105/AJPH.90.8.1241; Meltzer MI, 1999, EMERG INFECT DIS, V5, P659, DOI 10.3201/eid0505.990507; MILLER M, 2009, PLOS INFLUENZA, pN1013; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; MULDER J, 1958, LANCET, V1, P810; Mylius SD, 2008, VACCINE, V26, P3742, DOI 10.1016/j.vaccine.2008.04.043; National Institute for Health and Clinical Excellence, SOC VAL JUDG PRINC D, V2nd; National Institute for Health and Clinical Excellence, 2009, GUID MAN 2009; Nohynek H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033536; Oostenbrink J, 2004, HANDLEIDING KOSTENON; Partinen M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033723; Postma MJ, 2005, VACCINE, V23, P5365, DOI 10.1016/j.vaccine.2005.06.007; Postma MJ, 1999, PHARMACOECONOMICS, V16, P33, DOI 10.2165/00019053-199916001-00005; Prosser LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022308; Sander B, 2006, PHARMACOECONOMICS, V24, P373, DOI 10.2165/00019053-200624040-00007; Sander B, 2010, VACCINE, V28, P6210, DOI 10.1016/j.vaccine.2010.07.010; Sander B, 2009, VALUE HEALTH, V12, P226, DOI 10.1111/j.1524-4733.2008.00437.x; SPRENGER MJW, 1993, INT J EPIDEMIOL, V22, P334, DOI 10.1093/ije/22.2.334; van Genugten MLL, 2003, EMERG INFECT DIS, V9, P531; Wallinga J, 2007, P ROY SOC B-BIOL SCI, V274, P599, DOI 10.1098/rspb.2006.3754; Wallinga J, 2006, AM J EPIDEMIOL, V164, P936, DOI 10.1093/aje/kwj317; Wallinga J, 2010, P NATL ACAD SCI USA, V107, P923, DOI 10.1073/pnas.0908491107; [No title captured]	42	25	26	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 12	2012	345								e4445	10.1136/bmj.e4445	http://dx.doi.org/10.1136/bmj.e4445			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NW	22791791	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000306519000001
J	Wiggins, NM				Wiggins, Natasha M.			Stop using military metaphors for disease	BRITISH MEDICAL JOURNAL			English	Editorial Material									Essex Cty Hosp, Dept Oncol, Colchester CO3 3NB, Essex, England		Wiggins, NM (corresponding author), Essex Cty Hosp, Dept Oncol, Colchester CO3 3NB, Essex, England.	natasha.wiggins@ic.ac.uk						Armstrong S., 2006, WAR TERROR; Benson J., 2010, I DO NOT BATTLE MY C; Pickering N, 1999, THEOR MED BIOETH, V20, P361, DOI 10.1023/A:1005403411725; Pirandello L., 1922, MAN FLOWER HIS MOUTH	4	17	17	1	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 12	2012	345								e4706	10.1136/bmj.e4706	http://dx.doi.org/10.1136/bmj.e4706			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NW	22791794				2022-12-28	WOS:000306519000008
J	Black, ME				Black, Mary E.			Winners and losers	BRITISH MEDICAL JOURNAL			English	Editorial Material												drmaryblack@gmail.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 11	2012	345								e4699	10.1136/bmj.e4699	http://dx.doi.org/10.1136/bmj.e4699			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NU	22786940				2022-12-28	WOS:000306518800008
J	Radwan, R; Ram, AD; Huddart, SN				Radwan, Rami; Ram, Ashok Daya; Huddart, Simon N.			CASE REPORT A few hours from disaster	BRITISH MEDICAL JOURNAL			English	Editorial Material							INTESTINAL MALROTATION; INFANTS		[Radwan, Rami; Ram, Ashok Daya; Huddart, Simon N.] Univ Wales Hosp, Cardiff CF14 4XW, S Glam, Wales	Cardiff University	Radwan, R (corresponding author), Univ Wales Hosp, Cardiff CF14 4XW, S Glam, Wales.	ramiradwan@hotmail.com	Radwan, Rami W/ABD-6950-2020					[Anonymous], 2001, BMJ BEST PRACTICE; Applegate KE, 2006, RADIOGRAPHICS, V26, P1485, DOI 10.1148/rg.265055167; Bass KD, 1998, J PEDIATR SURG, V33, P279, DOI 10.1016/S0022-3468(98)90447-X; Ingoe Renee, 2007, AORN J, V85, P300, DOI 10.1016/S0001-2092(07)60040-4; Kimura K, 2000, AM FAM PHYSICIAN, V61, P2791; Ladd WE, 1936, NEW ENGL J MED, V215, P705, DOI 10.1056/NEJM193610152151604; Lampl B, 2009, PEDIATR RADIOL, V39, P359, DOI 10.1007/s00247-009-1168-y; Millar A J W, 2003, Semin Pediatr Surg, V12, P229, DOI 10.1053/j.sempedsurg.2003.08.003; Nehra D, 2011, SURGERY, V149, P386, DOI 10.1016/j.surg.2010.07.004; Strouse PJ, 2004, PEDIATR RADIOL, V34, P837, DOI 10.1007/s00247-004-1279-4; TORRES AM, 1993, WORLD J SURG, V17, P326, DOI 10.1007/BF01658699	11	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 9	2012	345								e4441	10.1136/bmj.e4441	http://dx.doi.org/10.1136/bmj.e4441			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NR	22777027				2022-12-28	WOS:000306518500003
J	Carter, RM; Bowling, DL; Reeck, C; Huettel, SA				Carter, R. McKell; Bowling, Daniel L.; Reeck, Crystal; Huettel, Scott A.			A Distinct Role of the Temporal-Parietal Junction in Predicting Socially Guided Decisions	SCIENCE			English	Article							HUMAN BRAIN; MIND; GAME; COGNITION; BEHAVIOR	To make adaptive decisions in a social context, humans must identify relevant agents in the environment, infer their underlying strategies and motivations, and predict their upcoming actions. We used functional magnetic resonance imaging, in conjunction with combinatorial multivariate pattern analysis, to predict human participants' subsequent decisions in an incentive-compatible poker game. We found that signals from the temporal-parietal junction provided unique information about the nature of the upcoming decision, and that information was specific to decisions against agents who were both social and relevant for future behavior.	[Carter, R. McKell; Bowling, Daniel L.; Reeck, Crystal; Huettel, Scott A.] Duke Univ, Ctr Cognit Neurosci, Durham, NC 27708 USA; [Carter, R. McKell; Bowling, Daniel L.] Duke Univ, Dept Neurobiol, Durham, NC 27710 USA; [Carter, R. McKell; Huettel, Scott A.] Duke Univ, Brain Imaging & Anal Ctr, Durham, NC 27710 USA; [Reeck, Crystal; Huettel, Scott A.] Duke Univ, Dept Psychol & Neurosci, Durham, NC 27708 USA	Duke University; Duke University; Duke University; Duke University	Huettel, SA (corresponding author), Duke Univ, Ctr Cognit Neurosci, Durham, NC 27708 USA.	scott.huettel@duke.edu		Bowling, Daniel/0000-0002-5303-5472; Carter, R. McKell/0000-0003-2235-6529	National Institute of Mental Health (NIMH) [R01-70685, R01-86712]; National Institute of Neurological Disorders and Stroke [P01-41328]; NSF; Duke Institute for Brain Sciences;  [5T32-NS051156-04]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH086712, R01MH070685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS051156, P01NS041328] Funding Source: NIH RePORTER	National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NSF(National Science Foundation (NSF)); Duke Institute for Brain Sciences; ; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank P. Kragel and J. Pearson for assistance with analyses; D. Murty for assistance with data collection; and N. Clement, L. Harris, K. LaBar, M. Platt, V. Venkatraman, K. Watson, and A. Winecoff for comments on the manuscript. This project was supported by National Institute of Mental Health (NIMH) grant R01-70685, NIMH R01-86712, and National Institute of Neurological Disorders and Stroke P01-41328. R. M. C. was supported by 5T32-NS051156-04. C. R. was supported by an NSF Graduate Research Fellowship. S. A. H. was supported by an Incubator Award from the Duke Institute for Brain Sciences.	ASCH SE, 1955, SCI AM, V193, P31, DOI 10.1038/scientificamerican1155-31; Behrens TEJ, 2008, NATURE, V456, P245, DOI 10.1038/nature07538; Behrens TEJ, 2009, SCIENCE, V324, P1160, DOI 10.1126/science.1169694; Bhatt MA, 2010, P NATL ACAD SCI USA, V107, P19720, DOI 10.1073/pnas.1009625107; Blakemore SJ, 2003, CEREB CORTEX, V13, P837, DOI 10.1093/cercor/13.8.837; Bonaccio S, 2006, ORGAN BEHAV HUM DEC, V101, P127, DOI 10.1016/j.obhdp.2006.07.001; Clithero JA, 2009, NEUROIMAGE, V45, P1329, DOI 10.1016/j.neuroimage.2008.12.074; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Danchin E, 2004, SCIENCE, V305, P487, DOI 10.1126/science.1098254; Decety J, 2007, NEUROSCIENTIST, V13, P580, DOI 10.1177/1073858407304654; Festinger L, 1954, HUM RELAT, V7, P117, DOI 10.1177/001872675400700202; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; GOREN CC, 1975, PEDIATRICS, V56, P544; Hampton AN, 2007, P NATL ACAD SCI USA, V104, P1377, DOI 10.1073/pnas.0606297104; Harris LT, 2009, EUR REV SOC PSYCHOL, V20, P192, DOI 10.1080/10463280902954988; Heider F, 1944, AM J PSYCHOL, V57, P243, DOI 10.2307/1416950; Kameda T, 1997, J PERS SOC PSYCHOL, V73, P296, DOI 10.1037/0022-3514.73.2.296; Krach S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002597; Lee D, 2008, NAT NEUROSCI, V11, P404, DOI 10.1038/nn2065; Mitchell JP, 2008, CEREB CORTEX, V18, P262, DOI 10.1093/cercor/bhm051; Mitchell JP, 2011, J COGNITIVE NEUROSCI, V23, P857, DOI 10.1162/jocn.2010.21479; Olsson A, 2008, TRENDS COGN SCI, V12, P65, DOI 10.1016/j.tics.2007.11.010; Raafat RM, 2009, TRENDS COGN SCI, V13, P420, DOI 10.1016/j.tics.2009.08.002; Rapoport A, 1997, ORGAN BEHAV HUM DEC, V69, P31, DOI 10.1006/obhd.1996.2670; Rendell L, 2010, SCIENCE, V328, P208, DOI 10.1126/science.1184719; Ro T, 2001, PSYCHOL SCI, V12, P94, DOI 10.1111/1467-9280.00317; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; Shepherd SV, 2006, CURR BIOL, V16, pR119, DOI 10.1016/j.cub.2006.02.013; Tankersley D, 2007, NAT NEUROSCI, V10, P150, DOI 10.1038/nn1833; Yoshida W, 2010, J NEUROSCI, V30, P10744, DOI 10.1523/JNEUROSCI.5895-09.2010	30	152	153	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2012	337	6090					109	111		10.1126/science.1219681	http://dx.doi.org/10.1126/science.1219681			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	969KC	22767930	Green Accepted			2022-12-28	WOS:000306053100055
J	van den Broek, IVF; van Bergen, JEAM; Brouwers, EEHG; Fennema, JSA; Gotz, HM; Hoebe, CJPA; Koekenbier, RH; Kretzschmar, M; Over, EAB; Schmid, BV; Pars, LL; van Ravesteijn, SM; van der Sande, MAB; de Wit, GA; Low, N; Op de Coul, ELM				van den Broek, Ingrid V. F.; van Bergen, Jan E. A. M.; Brouwers, Elfi E. H. G.; Fennema, Johannes S. A.; Gotz, Hannelore M.; Hoebe, Christian J. P. A.; Koekenbier, Rik H.; Kretzschmar, Mirjam; Over, Eelco A. B.; Schmid, Boris V.; Pars, Lydia L.; van Ravesteijn, Sander M.; van der Sande, Marianne A. B.; de Wit, G. Ardine; Low, Nicola; Op de Coul, Eline L. M.			Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PELVIC-INFLAMMATORY-DISEASE; NATIONAL PROBABILITY SURVEY; TRACHOMATIS; PROGRAM; INFECTION; POPULATION; PREVALENCE; PREVENTION; INTERNET; PARTICIPANTS	Objective To evaluate the effectiveness of register based, yearly chlamydia screening. Design Controlled trial with randomised stepped wedge implementation in three blocks. Setting Three regions of the Netherlands: Amsterdam, Rotterdam, and South Limburg. Participants 317 304 women and men aged 16-29 years listed on municipal registers at start of trial. Intervention From March 2008 to February 2011, the Chlamydia Screening Implementation programme offered yearly chlamydia screening tests. Postal invitations asked people to use an internet site to request a kit for self collection of samples, which would then be sent to regional laboratories for testing. Treatment and partner notification were done by the general practitioner or at a sexually transmitted infection clinic. Main outcome measures Primary outcomes were the percentage of chlamydia tests positive (positivity), percentage of invitees returning a specimen (uptake), and estimated chlamydia prevalence. Secondary outcomes were positivity according to sex, age, region, and sociodemographic factors; adherence to screening invitations; and incidence of self reported pelvic inflammatory disease. Results The participation rate was 16.1% (43 358/269 273) after the first invitation, 10.8% after the second, and 9.5% after the third, compared with 13.0% (6223/48 031) in the control block invited at the end of round two of the intervention. Chlamydia positivity in the intervention blocks at the first invitation was the same as in the control block (4.3%) and 0.2% lower at the third invitation (odds ratio 0.96 (95% confidence interval 0.83 to 1.10)). No substantial decreases in positivity were seen after three screening rounds in any region or sociodemographic group. Among the people who participated three times (2.8% of all invitees), positivity fell from 5.9% to 2.9% (odds ratio 0.49 (0.47 to 0.50)). Conclusions There was no statistical evidence of an impact on chlamydia positivity rates or estimated population prevalence from the Chlamydia Screening Implementation programme after three years at the participation levels obtained. The current evidence does not support a national roll out of this register based chlamydia screening programme.	[van den Broek, Ingrid V. F.; Kretzschmar, Mirjam; Schmid, Boris V.; van der Sande, Marianne A. B.; Op de Coul, Eline L. M.] RIVM Ctr Infect Dis Control Netherlands, Unit Epidemiol & Surveillance, NL-3720 BA Bilthoven, Netherlands; [van Bergen, Jan E. A. M.] Univ Amsterdam, NL-1012 WX Amsterdam, Netherlands; [van Bergen, Jan E. A. M.; Pars, Lydia L.] STI AIDS Netherlands, NL-1016 GB Amsterdam, Netherlands; [Brouwers, Elfi E. H. G.; Hoebe, Christian J. P. A.] S Limburg Publ Hlth Serv, NL-6160 HA Geleen, Netherlands; [Fennema, Johannes S. A.; Koekenbier, Rik H.] Amsterdam Publ Hlth Serv, NL-1018 WT Amsterdam, Netherlands; [Gotz, Hannelore M.] Municipal Publ Hlth Serv Rotterdam Rijnmond, Dept Infect Dis Control, NL-3000 LP Rotterdam, Netherlands; [Kretzschmar, Mirjam; van der Sande, Marianne A. B.; de Wit, G. Ardine] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3584 CX Utrecht, Netherlands; [Over, Eelco A. B.; de Wit, G. Ardine] RIVM Netherlands, Ctr Prevent & Hlth Serv Res, Bilthoven, Netherlands; [van Ravesteijn, Sander M.] Municipal Publ Hlth Serv Rotterdam Rijnmond, NL-3011 EN Rotterdam, Netherlands; [Low, Nicola] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland	University of Amsterdam; Public Health Service Amsterdam; Utrecht University; Utrecht University Medical Center; Netherlands National Institute for Public Health & the Environment; University of Bern	van den Broek, IVF (corresponding author), RIVM Ctr Infect Dis Control Netherlands, Unit Epidemiol & Surveillance, POB 1, NL-3720 BA Bilthoven, Netherlands.	Ingrid.van.den.Broek@rivm.nl	Schmid, Boris V./P-9013-2016; Low, Nicola/H-4718-2019	Schmid, Boris V./0000-0003-0452-623X; Low, Nicola/0000-0003-4817-8986; Hoebe, Christian/0000-0003-1815-0974; Kretzschmar, Mirjam/0000-0002-4394-7697; van der Sande, Marianne AB/0000-0002-4778-6739; de Wit, G. Ardine/0000-0002-1375-7657; Gotz, Hannelore Martha/0000-0002-1236-6224	Dutch organisation for Health Research and Development (ZonMW) [12.400.001]	Dutch organisation for Health Research and Development (ZonMW)(Netherlands Organization for Health Research and Development)	The Chlamydia Screening Implementation was carried out on request of the Ministry of Health, Welfare and Sport. The Dutch organisation for Health Research and Development (ZonMW, project number 12.400.001) funded the project.	ADDISS DG, 1993, SEX TRANSM DIS, V20, P28, DOI 10.1097/00007435-199301000-00006; Andersen B, 2006, SEX TRANSM DIS, V33, P407, DOI 10.1097/01.olq.0000200609.77577.3f; [Anonymous], 1998, CMOS EXPERT ADVISORY; Bakker F, 2009, SEXUAL HLTH NETHERLA; Batteiger BE, 2010, J INFECT DIS, V201, pS178, DOI 10.1086/652400; Chai SJ, 2010, SEX TRANSM DIS, V37, P756, DOI 10.1097/OLQ.0b013e3181e3d771; de Coul EO, 2011, SEX TRANSM INFECT, V87, pA343, DOI 10.1136/sextrans-2011-050108.599; Dokkum NFB, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-176; Dutch Health Council, 2004, SCREEN CHLAM; Gaydos CA, 2007, SEX TRANSM DIS, V34, P625, DOI 10.1097/OLQ.0b013e3180f62f6a; Gaydos CA, 2009, SEX TRANSM DIS, V36, P577, DOI 10.1097/OLQ.0b013e3181a7482f; Gotz HM, 2011, SEX TRANSM INFECT, V87, pA21, DOI 10.1136/sextrans-2011-050109.3; Gotz HM, 2005, SEX TRANSM INFECT, V81, P24, DOI 10.1136/sti.2004.010181; Greenland KE, 2011, SEX TRANSM DIS, V38, P467, DOI 10.1097/OLQ.0b013e318204546e; Health Protection Agency, 2010, NAT CHLAM SCREEN PRO; Heijne JCM, 2010, AM J PREV MED, V39, P243, DOI 10.1016/j.amepre.2010.05.011; HERRMANN BF, 1991, SEX TRANSM DIS, V18, P233, DOI 10.1097/00007435-199110000-00007; HILLIS SD, 1995, FAM PLANN PERSPECT, V27, P108, DOI 10.2307/2136107; Hocking J, 2011, SEX TRANSM INFECT, V87, pA202, DOI 10.1136/sextrans-2011-050108.240; Kretzschmar M, 2009, SEX TRANSM INFECT, V85, P359, DOI 10.1136/sti.2009.036251; Low N, 2007, HEALTH TECHNOL ASSES, V11, P1, DOI 10.3310/hta11080; Low N, 2006, SEX TRANSM INFECT, V82, P212, DOI 10.1136/sti.2005.017186; Low N, 2011, EUR J PUBLIC HLTH; Low N, 2007, BMJ-BRIT MED J, V334, P725, DOI 10.1136/bmj.39154.378079.BE; Low N, 2009, INT J EPIDEMIOL, V38, P435, DOI 10.1093/ije/dyn222; Macleod J, 2005, BRIT MED J, V330, P940, DOI 10.1136/bmj.38413.663137.8F; Mercer CH, 2009, INT J EPIDEMIOL, V38, P206, DOI 10.1093/ije/dyn216; National Chlamydia Screening Programme, 2011, AUG 2011 ENEWSLETTER; National Chlamydia Screening Programme, 2011, BIGG PICT NAT CHLAM; Oakeshott P, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1642; Op de Coul ELM, 2012, SEX TRANSM DIS, V39, P97, DOI 10.1097/OLQ.0b013e3182383097; Op de Coul ELM, 2011, 210261006 RIVM; Ostergaard L, 2000, CLIN INFECT DIS, V31, P951, DOI 10.1086/318139; Riha J, 2011, SEX TRANSM INFECT, V87, P306, DOI 10.1136/sti.2010.047027; Schmid B, 2011, SEX TRANSM INFECT, V87, pA344, DOI 10.1136/sextrans-2011-050108.601; Schmid BV, 2011, SEX TRANSM INFECT, V87, pA45, DOI 10.1136/sextrans-2011-050109.52; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; Szczepura A, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-346; Turner KME, 2006, SEX TRANSM INFECT, V82, P496, DOI 10.1136/sti.2005.019067; UK National Screening Committee, 2011, UK SCREEN PORT PROGR; Ukoumunne OC, 1999, BRIT MED J, V319, P376, DOI 10.1136/bmj.319.7206.376; van Bergen J, 2005, SEX TRANSM INFECT, V81, P17, DOI 10.1136/sti.2004.010173; van Bergen JEAM, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-293; Van den Broek I, 2010, 25 IUSTI EUR C SEPT; van den Broek IVF, 2011, SEX TRANSM INFECT, V87, pA200, DOI 10.1136/sextrans-2011-050108.236; van den Broek IVF, 2012, SEX TRANSM INFECT, V88, P205, DOI 10.1136/sextrans-2011-050219; van den Broek IVF, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-89; Vriend HJ, 2011, 210261009 RIVM; WESTROM L, 1995, VENEREOLOGY, V8, P219; Woodhall SC, 2011, SEX TRANSM INFECT, V87, pA113, DOI 10.1136/sextrans-2011-050108.35; Workowski Kimberly A, 2010, MMWR Recomm Rep, V59, P1	51	98	99	0	34	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 5	2012	344								e4316	10.1136/bmj.e4316	http://dx.doi.org/10.1136/bmj.e4316			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972KH	22767614	hybrid, Green Published			2022-12-28	WOS:000306275500002
J	Leventhal, JM; Krugman, RD				Leventhal, John M.; Krugman, Richard D.			"The Battered-Child Syndrome" 50 Years Later Much Accomplished, Much Left to Do	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ABUSE; TRIAL		[Leventhal, John M.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; [Krugman, Richard D.] Univ Colorado, Sch Med, Aurora, CO USA	Yale University; University of Colorado System; University of Colorado Anschutz Medical Campus	Leventhal, JM (corresponding author), Yale Univ, Sch Med, Dept Pediat, POB 208064,333 Cedar St, New Haven, CT 06520 USA.	john.leventhal@yale.edu						Chaffin M, 2012, PEDIATRICS, V129, P509, DOI 10.1542/peds.2011-1840; Fang XM, 2012, CHILD ABUSE NEGLECT, V36, P156, DOI 10.1016/j.chiabu.2011.10.006; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Finkelhor D., 2009, UPDATED TRENDS CHILD; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; Leventhal JM, 2012, PED AC SOC ANN M APR; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; Trickett PK, 2011, DEV PSYCHOPATHOL, V23, P453, DOI 10.1017/S0954579411000174; US Department of Health and Human Services, CHILD MALTR 2010; Widom CS, UPDATE CYCLE VIOLENC	10	7	7	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2012	308	1					35	36		10.1001/jama.2012.6416	http://dx.doi.org/10.1001/jama.2012.6416			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971DD	22760286				2022-12-28	WOS:000306183000018
J	Lo, B				Lo, Bernard			Euthanasia in the Netherlands: what lessons for elsewhere?	LANCET			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; LIFE DECISION-MAKING; PALLIATIVE SEDATION; COUNTRIES; CARE		[Lo, Bernard] Greenwall Fdn, New York, NY USA; [Lo, Bernard] Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Lo, B (corresponding author), Greenwall Fdn, New York, NY USA.	bernie@medicine.ucsf.edu						Alpers A, 1999, ARCH FAM MED, V8, P200, DOI 10.1001/archfami.8.3.200; Brennan T, 2002, LANCET, V359, P520, DOI 10.1016/s0140-6736(02)07684-5; Buiting HM, 2010, J MED ETHICS, V36, P24, DOI 10.1136/jme.2009.030155; Cohen J, 2008, J MED ETHICS, V34, P247, DOI 10.1136/jme.2006.020297; Li D, 2008, J PAIN, V9, P2, DOI 10.1016/j.jpain.2007.08.009; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Onwuteaka-Philipsen BD, 2012, LANCET; Quill TE, 2009, ANN INTERN MED, V151, P421, DOI 10.7326/0003-4819-151-6-200909150-00007; Regional euthanasia review committees, ANN REP 2010; Schweickert WD, 2008, CRIT CARE, V12, DOI 10.1186/cc6151; Smets T, 2012, EUR J PUBLIC HEALTH, V22, P19, DOI 10.1093/eurpub/ckq180; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6	13	6	7	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 8	2012	380	9845					869	870		10.1016/S0140-6736(12)61128-3	http://dx.doi.org/10.1016/S0140-6736(12)61128-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	002QL	22789500				2022-12-28	WOS:000308547300009
J	Parsons, MW; Levi, CR				Parsons, Mark W.; Levi, Christopher R.			Reperfusion trials for acute ischaemic stroke	LANCET			English	Editorial Material							INTRAVENOUS THROMBOLYSIS; COMPUTED-TOMOGRAPHY		[Parsons, Mark W.; Levi, Christopher R.] Univ Newcastle, Dept Neurol, John Hunter Hosp, Hunter Med Res Inst, Newcastle, NSW 2305, Australia	Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle	Parsons, MW (corresponding author), Univ Newcastle, Dept Neurol, John Hunter Hosp, Hunter Med Res Inst, Newcastle, NSW 2305, Australia.	mark.parsons@hnehealth.nsw.gov.au	Parsons, Mark W./G-3750-2014	Levi, Christopher/0000-0002-9474-796X				Barber PA, 1999, STROKE, V30, P2059, DOI 10.1161/01.STR.30.10.2059; Mlynash M, 2011, STROKE, V42, P1270, DOI 10.1161/STROKEAHA.110.601609; Muir KW, 2007, STROKE, V38, P2485, DOI 10.1161/STROKEAHA.107.484592; Parsons M, 2012, NEW ENGL J MED, V366, P1099, DOI 10.1056/NEJMoa1109842; Parsons MW, 2011, STROKE, V42, P2666, DOI 10.1161/STROKEAHA.111.621771; Parsons MW, 2010, J CEREBR BLOOD F MET, V30, P1214, DOI 10.1038/jcbfm.2010.3; Parsons MW, 2005, ANN NEUROL, V58, P672, DOI 10.1002/ana.20638; Rha JH, 2007, STROKE, V38, P967, DOI 10.1161/01.STR.0000258112.14918.24; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Saqqur M, 2007, STROKE, V38, P948, DOI 10.1161/01.STR.0000257304.21967.ba; Zinkstok SM, 2012, LANCET	11	1	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 25	2012	380	9843					706	708		10.1016/S0140-6736(12)61043-5	http://dx.doi.org/10.1016/S0140-6736(12)61043-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995IK	22748819				2022-12-28	WOS:000308001300005
J	Zinkstok, SM; Roos, YB				Zinkstok, Sanne M.; Roos, Yvo B.		ARTIS Investigators	Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial	LANCET			English	Article							RT-PA THROMBOLYSIS; ANTIPLATELET THERAPY; INTRAVENOUS THROMBOLYSIS; CLINICAL DETERIORATION; ARTERIAL REOCCLUSION; RECANALIZATION; COMBINATION; RATIONALE; DESIGN; SAFETY	Background Thrombolysis with intravenous alteplase is the only approved treatment for acute ischaemic stroke. After alteplase-induced recanalisation, reocclusion occurs in 14-34% of patients, probably because of platelet activation. Early administration of antiplatelet therapy after alteplase could reduce the risk of reocclusion and improve outcome. We compared the effects of early addition of intravenous aspirin to alteplase with standard alteplase without aspirin. Methods In this multicentre, randomised, open-label trial with blind-endpoint assessment, patients with acute ischaemic stroke treated with alteplase were randomly assigned to 300 mg intravenous aspirin within 90 min after start of alteplase treatment or to no additional treatment. In both groups, oral antiplatelet therapy was started 24 h after alteplase treatment. The primary endpoint was favourable outcome, defined as a score of 0-2 on the modified Rankin scale at 3 months. This trial is registered with the Netherlands Trial Register (NTR822). Findings Between July 29, 2008, and April 20, 2011, 642 patients (322 patients aspirin, 320 patients standard treatment) of the targeted 800 patients were enrolled. At that time, the trial was terminated prematurely because of an excess of symptomatic intracranial haemorrhage (SICH) and no evidence of benefit in the aspirin group. At 3 months, 174 (54.0%) patients in the aspirin group versus 183 (57.2%) patients in the standard treatment group had a favourable outcome (absolute difference -3.2%, 95% CI -10.8 to 4.2; crude relative risk 0.94, 0.82 to 1.09, p=0.42). Adjusted odds ratio was 0.91 (95% CI 0.66-1.26, p=0.58). SICH occurred more often in the aspirin group (14 [4.3%] patients) than in the standard treatment group (five [1.6%]; absolute difference 2.8%, 95% CI 0.2-5.4; p=0.04). SICH was more often the cause of poor outcome in the aspirin group compared with the standard treatment group (11 vs 1, p=0.006). Interpretation Early administration of intravenous aspirin in patients with acute ischaemic stroke treated with alteplase does not improve outcome at 3 months and increases the risk of SICH. The results of this trial do not support a change of the current guidelines, which advise to start antiplatelet therapy 24 h after alteplase.	[Zinkstok, Sanne M.; Roos, Yvo B.] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Roos, YB (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, H2-214,POB 22660, NL-1100 DD Amsterdam, Netherlands.	y.b.roos@amc.uva.nl	Roos, Yvo BWEM/B-9843-2013		Dutch Heart Foundation [2005B118]	Dutch Heart Foundation(Netherlands Heart Foundation)	The Dutch Heart Foundation.; The trial was funded by a grant from the Dutch Heart Foundation (2005B118). We thank Simone Dierckx for coordinating the trial from January, 2007, to January, 2008; all patients, nurses, secretaries, neurologists, and residents who contributed to the ARTIS trial; and the research nurses Nadine Fleitour, Anick Gorissen, and Mineke Ek for their administrative support and outcome assessment.	Alexandrov AV, 2002, NEUROLOGY, V59, P862, DOI 10.1212/WNL.59.6.862; [Anonymous], 1988, LANCET, V2, P349; BOCHNER F, 1988, EUR J CLIN PHARMACOL, V35, P287, DOI 10.1007/BF00558267; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; CANDELISE L, 1995, LANCET, V346, P1509; Diedler J, 2010, STROKE, V41, P288, DOI 10.1161/STROKEAHA.109.559724; Grotta JC, 2001, STROKE, V32, P661, DOI 10.1161/01.STR.32.3.661; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; Hacke W, 2004, LANCET, V363, P768; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Lansberg MG, 2012, CHEST, V141, pE601S, DOI 10.1378/chest.11-2302; Leopold JA, 1995, CORONARY ARTERY DIS, V6, P923; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Nordt TK, 1998, THROMB HAEMOSTASIS, V80, P881; Parsons M, 2012, NEW ENGL J MED, V366, P1099, DOI 10.1056/NEJMoa1109842; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Rha JH, 2007, STROKE, V38, P967, DOI 10.1161/01.STR.0000258112.14918.24; Ringleb AP, 2011, EUROPEAN HDB NEUROLO, V1, P101; Rubiera M, 2005, STROKE, V36, P1452, DOI 10.1161/01.STR.0000170711.43405.81; Sanak D, 2012, EUR NEUROL, V67, P52, DOI 10.1159/000333064; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Saqqur M, 2007, STROKE, V38, P69, DOI 10.1161/01.STR.0000251800.01964.f6; Schoenfeld DA, 2005, CRIT CARE, V9, P34, DOI 10.1186/cc3013; Schulz KF, 2005, LANCET, V365, P1657, DOI 10.1016/S0140-6736(05)66516-6; Uyttenboogaart M, 2008, ARCH NEUROL-CHICAGO, V65, P607, DOI 10.1001/archneur.65.5.noc70077; Wardlaw JM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub2; Wilson JTL, 2002, STROKE, V33, P2243, DOI 10.1161/01.STR.0000027437.22450.BD; Zinkstok SM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-51; Zinkstok SM, 2010, CEREBROVASC DIS, V29, P79, DOI 10.1159/000256651	29	151	162	1	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 25	2012	380	9843					731	737		10.1016/S0140-6736(12)60949-0	http://dx.doi.org/10.1016/S0140-6736(12)60949-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995IK	22748820				2022-12-28	WOS:000308001300030
J	Liu, C; Placais, PY; Yamagata, N; Pfeiffer, BD; Aso, Y; Friedrich, AB; Siwanowicz, I; Rubin, GM; Preat, T; Tanimoto, H				Liu, Chang; Placais, Pierre-Yves; Yamagata, Nobuhiro; Pfeiffer, Barret D.; Aso, Yoshinori; Friedrich, Anja B.; Siwanowicz, Igor; Rubin, Gerald M.; Preat, Thomas; Tanimoto, Hiromu			A subset of dopamine neurons signals reward for odour memory in Drosophila	NATURE			English	Article							TARGETED GENE-EXPRESSION; MUSHROOM BODY; BRAIN; FLY; HYDROXYLASE; OCTOPAMINE; SEROTONIN; BEHAVIOR; REVEALS; AROUSAL	Animals approach stimuli that predict a pleasant outcome(1). After the paired presentation of an odour and a reward, Drosophila melanogaster can develop a conditioned approach towards that odour(2,3). Despite recent advances in understanding the neural circuits for associative memory and appetitive motivation(4), the cellular mechanisms for reward processing in the fly brain are unknown. Here we show that a group of dopamine neurons in the protocerebral anterior medial (PAM) cluster signals sugar reward by transient activation and inactivation of target neurons in intact behaving flies. These dopamine neurons are selectively required for the reinforcing property of, but not a reflexive response to, the sugar stimulus. In vivo calcium imaging revealed that these neurons are activated by sugar ingestion and the activation is increased on starvation. The output sites of the PAM neurons are mainly localized to the medial lobes of the mushroom bodies (MBs), where appetitive olfactory associative memory is formed(5,6). We therefore propose that the PAM cluster neurons endow a positive predictive value to the odour in the MBs. Dopamine in insects is known to mediate aversive reinforcement signals(5,7-11). Our results highlight the cellular specificity underlying the various roles of dopamine and the importance of spatially segregated local circuits within the MBs.	[Liu, Chang; Yamagata, Nobuhiro; Aso, Yoshinori; Friedrich, Anja B.; Siwanowicz, Igor; Tanimoto, Hiromu] Max Planck Inst Neurobiol, D-82152 Martinsried, Germany; [Liu, Chang] Chinese Acad Sci, Kunming Inst Zool, Lab Primate Cognit Neurosci, Kunming 650223, Yunnan, Peoples R China; [Liu, Chang] Chinese Acad Sci, Grad Univ, Beijing 100049, Peoples R China; [Placais, Pierre-Yves; Preat, Thomas] Ecole Super Phys & Chim Ind Ville Paris, CNRS, Neurobiol Unit, F-75005 Paris, France; [Pfeiffer, Barret D.; Aso, Yoshinori; Rubin, Gerald M.] Howard Hughes Med Inst, Ashburn, VA 20147 USA	Max Planck Society; Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Howard Hughes Medical Institute	Tanimoto, H (corresponding author), Max Planck Inst Neurobiol, D-82152 Martinsried, Germany.	hiromut@neuro.mpg.de	Tanimoto, Hiromu/J-6810-2016; Aso, Yoshinori/ACJ-9439-2022	Rubin, Gerald/0000-0001-8762-8703; Preat, Thomas/0000-0001-9976-1763	Max-Planck-Gesellschaft; Chinese Academy of Sciences; Deutscher Akademischer Austausch Dienst; Alexander von Humboldt Foundation; Region Ile-de-France; Agence Nationale pour la Recherche; Howard Hughes Medical Institute; Bundesministerium fur Bildung und Forschung; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH081982] Funding Source: NIH RePORTER	Max-Planck-Gesellschaft(Max Planck Society); Chinese Academy of Sciences(Chinese Academy of Sciences); Deutscher Akademischer Austausch Dienst(Deutscher Akademischer Austausch Dienst (DAAD)); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); Region Ile-de-France(Region Ile-de-France); Agence Nationale pour la Recherche(French National Research Agency (ANR)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank L. Bracker, M. Feind, C. Murphy, C. Schnaitmann and T. Templier for technical assistance and experiments that inspired this study; P. Garrity, the Kyoto Drosophila Genetic Resource Center and the Bloomington Stock Center for fly stocks; and Y.Y. Ma, Z. Q. Meng, R. Menzel, A. Thum, S. Waddell and the members of the Tanimoto laboratory for discussion and/or critical reading of the manuscript. C.L., Y.A., N.Y. and P.-Y.P. were sponsored by a Chinese-European doctoral training program from Max-Planck-Gesellschaft and the Chinese Academy of Sciences, the Deutscher Akademischer Austausch Dienst, the Alexander von Humboldt Foundation, and the Region Ile-de-France, respectively. This work was supported by the Agence Nationale pour la Recherche (T.P.), the Howard Hughes Medical Institute (G.M.R.), Bernstein Focus Learning from the Bundesministerium fur Bildung und Forschung and the Max-Planck-Gesellschaft (H.T.).	Aso Y, 2010, CURR BIOL, V20, P1445, DOI 10.1016/j.cub.2010.06.048; Bromberg-Martin ES, 2010, NEURON, V68, P815, DOI 10.1016/j.neuron.2010.11.022; Busch S, 2009, J COMP NEUROL, V513, P643, DOI 10.1002/cne.21966; Claridge-Chang A, 2009, CELL, V139, P405, DOI 10.1016/j.cell.2009.08.034; Cole SH, 2005, J BIOL CHEM, V280, P14948, DOI 10.1074/jbc.M414197200; Friggi-Grelin F, 2003, J NEUROBIOL, V54, P618, DOI 10.1002/neu.10185; Hamada FN, 2008, NATURE, V454, P217, DOI 10.1038/nature07001; HAMMER M, 1993, NATURE, V366, P59, DOI 10.1038/366059a0; Kaun KR, 2011, NAT NEUROSCI, V14, P612, DOI 10.1038/nn.2805; Kim YC, 2007, J NEUROSCI, V27, P7640, DOI 10.1523/JNEUROSCI.1167-07.2007; Kitamoto T, 2001, J NEUROBIOL, V47, P81, DOI 10.1002/neu.1018; Krashes MJ, 2009, CELL, V139, P416, DOI 10.1016/j.cell.2009.08.035; Kume K, 2005, J NEUROSCI, V25, P7377, DOI 10.1523/JNEUROSCI.2048-05.2005; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Li H, 2000, CURR BIOL, V10, P211, DOI 10.1016/S0960-9822(00)00340-7; Mao ZM, 2009, FRONT NEURAL CIRCUIT, V3, DOI 10.3389/neuro.04.005.2009; Marella S, 2006, NEURON, V49, P285, DOI 10.1016/j.neuron.2005.11.037; Mizunami M, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00172; Monastirioti M, 1996, J NEUROSCI, V16, P3900; Pfeiffer BD, 2008, P NATL ACAD SCI USA, V105, P9715, DOI 10.1073/pnas.0803697105; Pfeiffer BD, 2010, GENETICS, V186, P735, DOI 10.1534/genetics.110.119917; Riemensperger T, 2005, CURR BIOL, V15, P1953, DOI 10.1016/j.cub.2005.09.042; Robinson IM, 2002, NATURE, V418, P336, DOI 10.1038/nature00915; Schnaitmann C, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00010; Schroll C, 2006, CURR BIOL, V16, P1741, DOI 10.1016/j.cub.2006.07.023; Schultz W, 2006, ANNU REV PSYCHOL, V57, P87, DOI 10.1146/annurev.psych.56.091103.070229; Schwaerzel M, 2003, J NEUROSCI, V23, P10495, DOI 10.1523/jneurosci.23-33-10495.2003; Sejourne J, 2011, NAT NEUROSCI, V14, P903, DOI 10.1038/nn.2846; Selcho M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005897; Sitaraman D, 2008, P NATL ACAD SCI USA, V105, P5579, DOI 10.1073/pnas.0710168105; Tanaka NK, 2008, J COMP NEUROL, V508, P711, DOI 10.1002/cne.21692; TEMPEL BL, 1983, P NATL ACAD SCI-BIOL, V80, P1482, DOI 10.1073/pnas.80.5.1482; Tian L, 2009, NAT METHODS, V6, P875, DOI 10.1038/nmeth.1398; Trannoy S, 2011, CURR BIOL, V21, P1647, DOI 10.1016/j.cub.2011.08.032; Van Swinderen B, 2011, P ROY SOC B-BIOL SCI, V278, P906, DOI 10.1098/rspb.2010.2564; Waddell S, 2010, TRENDS NEUROSCI, V33, P457, DOI 10.1016/j.tins.2010.07.001; Yarali A, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00189	37	338	344	3	146	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 23	2012	488	7412					512	+		10.1038/nature11304	http://dx.doi.org/10.1038/nature11304			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	992FS	22810589				2022-12-28	WOS:000307761600037
J	Bartlett, S				Bartlett, Stephanie			Very heavy, very humble-the Higgs is (probably) here	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Bartlett, S (corresponding author), The Lancet, London NW1 7BY, England.	s.bartlett@lancet.com						CERN, LARG HADR COLL; Department of Energy and the Human Genome Project, HUM GEN PROJ INF; Science and Technology Facilities Council, LHC WHO BEN	3	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2012	380	9837					92	92		10.1016/S0140-6736(12)61138-6	http://dx.doi.org/10.1016/S0140-6736(12)61138-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22794229				2022-12-28	WOS:000306359100014
J	Bonilla, LL; Carpio, A				Bonilla, Luis L.; Carpio, Ana			Driving Dislocations in Graphene	SCIENCE			English	Editorial Material									[Bonilla, Luis L.] Univ Carlos III Madrid, Fluid Dynam Nanosci & Ind Math Inst, Leganes 28911, Spain; [Carpio, Ana] Univ Complutense Madrid, E-28040 Madrid, Spain	Universidad Carlos III de Madrid; Complutense University of Madrid	Bonilla, LL (corresponding author), Univ Carlos III Madrid, Fluid Dynam Nanosci & Ind Math Inst, Leganes 28911, Spain.	bonilla@ing.uc3m.es; ana_carpio@mat.ucm.es	Bonilla, Luis L./B-6658-2008; carpio, ana/AGX-3411-2022	Bonilla, Luis L./0000-0002-7687-8595; carpio, ana/0000-0001-8623-6521				Bulatov V., 2006, COMPUTER SIMULATIONS; Carpio A, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.085406; Chen S, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.214103; Gomez-Navarro C, 2010, NANO LETT, V10, P1144, DOI 10.1021/nl9031617; Guinea F, 2010, NAT PHYS, V6, P30, DOI 10.1038/NPHYS1420; Gunlycke D, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.136806; Hirth J. P., 1972, THEORY DISLOCATIONS; Kotakoski J, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.245420; Levy N, 2010, SCIENCE, V329, P544, DOI 10.1126/science.1191700; Meyer JC, 2008, NANO LETT, V8, P3582, DOI 10.1021/nl801386m; Nair RR, 2012, NAT PHYS, V8, P199, DOI [10.1038/NPHYS2183, 10.1038/nphys2183]; Warner JH, 2012, SCIENCE, V337, P209, DOI 10.1126/science.1217529	12	17	18	2	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2012	337	6091					161	162		10.1126/science.1224681	http://dx.doi.org/10.1126/science.1224681			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973AN	22798588				2022-12-28	WOS:000306323500030
J	Roberts, L				Roberts, Leslie			HIV/AIDS In America	SCIENCE			English	Editorial Material																			0	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2012	337	6091					167	167		10.1126/science.337.6091.167	http://dx.doi.org/10.1126/science.337.6091.167			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	973AN	22798592				2022-12-28	WOS:000306323500034
J	Hunt, DP; Becker, AE; Guimaraes, AR; Stemmer-Rachamimov, A; Misdraji, J				Hunt, Daniel P.; Becker, Anne E.; Guimaraes, Alexander R.; Stemmer-Rachamimov, Anat; Misdraji, Joseph			Case 21-2012: A 27-Year-Old Man with Fatigue, Weakness, Weight Loss, and Decreased Libido	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANOREXIA-NERVOSA; SPONTANEOUS PNEUMOMEDIASTINUM; EATING-DISORDERS; PREVALENCE; RESTRICTION; MANAGEMENT; STARVATION; NEUROPATHY; EMPHYSEMA; SURGERY		[Hunt, Daniel P.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Becker, Anne E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Guimaraes, Alexander R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Stemmer-Rachamimov, Anat; Misdraji, Joseph] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Hunt, Daniel P.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Becker, Anne E.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Guimaraes, Alexander R.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Stemmer-Rachamimov, Anat; Misdraji, Joseph] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Hunt, DP (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.		Misdraji, Joseph/AAD-4588-2019; Misdraji, Joseph/AGX-4779-2022	Becker, Anne/0000-0001-9129-6510				ABARBANEL JM, 1987, NEUROLOGY, V37, P196, DOI 10.1212/WNL.37.2.196; Al-Mufarrej F, 2008, J CARDIOTHORAC SURG, V3, DOI 10.1186/1749-8090-3-59; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th; [Anonymous], 2010, DSM 5 PROP DIAGN CRI; Attia E, 2009, NEW ENGL J MED, V360, P500, DOI 10.1056/NEJMct0805569; Biffl WL, 2010, PATIENT SAF SURG, V4, DOI 10.1186/1754-9493-4-1; Caceres M, 2008, ANN THORAC SURG, V86, P962, DOI 10.1016/j.athoracsur.2008.04.067; DENNYBROWN D, 1947, MEDICINE, V26, P41, DOI 10.1097/00005792-194702000-00002; Elias WJ, 2006, J NEUROSURG, V105, P631, DOI 10.3171/jns.2006.105.4.631; Filosso PL, 2010, J THORAC CARDIOV SUR, V139, pE79, DOI 10.1016/j.jtcvs.2008.04.037; Hudson JI, 2007, BIOL PSYCHIAT, V61, P348, DOI 10.1016/j.biopsych.2006.03.040; Hutter G, 2009, INT J EAT DISORDER, V42, P293, DOI 10.1002/eat.20610; Iyer VN, 2009, MAYO CLIN PROC, V84, P417, DOI 10.1016/S0025-6196(11)60560-0; Jensen GL, 2010, JPEN-PARENTER ENTER, V34, P156, DOI 10.1177/0148607110361910; Karim A, 2003, INT J EAT DISORDER, V33, P104, DOI 10.1002/eat.10114; Kotler DP, 2000, ANN INTERN MED, V133, P622, DOI 10.7326/0003-4819-133-8-200010170-00015; Kumar N, 2007, NEUROL CLIN, V25, P209, DOI 10.1016/j.ncl.2006.11.001; Lin LY, 2005, INT J EAT DISORDER, V38, P277, DOI 10.1002/eat.20170; LINDBOE CF, 1982, ACTA NEUROPATHOL, V56, P299, DOI 10.1007/BF00691262; Lo Russo L, 2008, ORAL DIS, V14, P479, DOI 10.1111/j.1601-0825.2007.01422.x; Machado PPP, 2007, INT J EAT DISORDER, V40, P212, DOI 10.1002/eat.20358; MACKENZIE JR, 1989, ARCH PHYS MED REHAB, V70, P827; Mehler PS, 2003, J WOMEN HEALTH GEN-B, V12, P331, DOI 10.1089/154099903765448844; Miura Hiroyuki, 2003, Ann Thorac Cardiovasc Surg, V9, P188; OVERBY KJ, 1988, PEDIATRICS, V81, P134; Ozawa Y, 1998, INTERNAL MED, V37, P32, DOI 10.2169/internalmedicine.37.32; Rautou PE, 2008, GASTROENTEROLOGY, V135, P840, DOI 10.1053/j.gastro.2008.05.055; Rosenbaum K, 2000, JPEN-PARENTER ENTER, V24, P52, DOI 10.1177/014860710002400252; Stoving RK, 1999, J PSYCHIATR RES, V33, P139, DOI 10.1016/S0022-3956(98)00049-1; Strumia R, 2005, AM J CLIN DERMATOL, V6, P165, DOI 10.2165/00128071-200506030-00003; Tajiri K, 2006, INT J EAT DISORDER, V39, P616, DOI 10.1002/eat.20326; Treasure J, 2010, LANCET, V375, P583, DOI 10.1016/S0140-6736(09)61748-7; van Veelen I, 2008, EUR J PEDIATR, V167, P171, DOI 10.1007/s00431-007-0444-9; Yager J, 2005, NEW ENGL J MED, V353, P1481, DOI 10.1056/NEJMcp050187	34	13	13	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2					157	169		10.1056/NEJMcpc1110053	http://dx.doi.org/10.1056/NEJMcpc1110053			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972IO	22784119				2022-12-28	WOS:000306270800013
J	Reshef, R; Luger, SM; Hexner, EO; Loren, AW; Frey, NV; Nasta, SD; Goldstein, SC; Stadtmauer, EA; Smith, J; Bailey, S; Mick, R; Heitjan, DF; Emerson, SG; Hoxie, JA; Vonderheide, RH; Porter, DL				Reshef, Ran; Luger, Selina M.; Hexner, Elizabeth O.; Loren, Alison W.; Frey, Noelle V.; Nasta, Sunita D.; Goldstein, Steven C.; Stadtmauer, Edward A.; Smith, Jacqueline; Bailey, Sarah; Mick, Rosemarie; Heitjan, Daniel F.; Emerson, Stephen G.; Hoxie, James A.; Vonderheide, Robert H.; Porter, David L.			Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMATOPOIETIC-CELL TRANSPLANTATION; CHEMOKINE RECEPTOR CCR5; HEMATOLOGIC MALIGNANCIES; MARROW-TRANSPLANTATION; PREPARATIVE REGIMENS; CLINICAL-TRIALS; ACUTE GVHD; T-CELLS; RISK; MARAVIROC	BACKGROUND Graft-versus-host disease (GVHD) is a major barrier to successful allogeneic hematopoietic stem-cell transplantation (HSCT). The chemokine receptor CCR5 appears to play a role in alloreactivity. We tested whether CCR5 blockade would be safe and limit GVHD in humans. METHODS We tested the in vitro effect of the CCR5 antagonist maraviroc on lymphocyte function and chemotaxis. We then enrolled 38 high-risk patients in a single-group phase 1 and 2 study of reduced-intensity allogeneic HSCT that combined maraviroc with standard GVHD prophylaxis. RESULTS Maraviroc inhibited CCR5 internalization and lymphocyte chemotaxis in vitro without impairing T-cell function or formation of hematopoietic-cell colonies. In 35 patients who could be evaluated, the cumulative incidence rate (+/- SE) of grade II to IV acute GVHD was low at 14.7 +/- 6.2% on day 100 and 23.6 +/- 7.4% on day 180. Acute liver and gut GVHD were not observed before day 100 and remained uncommon before day 180, resulting in a low cumulative incidence of grade III or IV GVHD on day 180 (5.9 +/- 4.1%). The 1-year rate of death that was not preceded by disease relapse was 11.7 +/- 5.6% without excessive rates of relapse or infection. Serum from patients receiving maraviroc prevented CCR5 internalization by CCL5 and blocked T-cell chemotaxis in vitro, providing evidence of antichemotactic activity. CONCLUSIONS In this study, inhibition of lymphocyte trafficking was a specific and potentially effective new strategy to prevent visceral acute GVHD. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00948753.)	[Reshef, Ran; Luger, Selina M.; Hexner, Elizabeth O.; Loren, Alison W.; Frey, Noelle V.; Nasta, Sunita D.; Goldstein, Steven C.; Stadtmauer, Edward A.; Smith, Jacqueline; Bailey, Sarah; Emerson, Stephen G.; Hoxie, James A.; Vonderheide, Robert H.; Porter, David L.] Univ Penn, Perelman Sch Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA; [Reshef, Ran; Luger, Selina M.; Hexner, Elizabeth O.; Loren, Alison W.; Frey, Noelle V.; Nasta, Sunita D.; Goldstein, Steven C.; Stadtmauer, Edward A.; Smith, Jacqueline; Bailey, Sarah; Emerson, Stephen G.; Hoxie, James A.; Vonderheide, Robert H.; Porter, David L.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Reshef, Ran; Vonderheide, Robert H.] Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Mick, Rosemarie; Heitjan, Daniel F.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Hoxie, James A.] Univ Penn, Perelman Sch Med, Ctr AIDS Res, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Reshef, R (corresponding author), Univ Penn, Perelman Sch Med, Div Hematol & Oncol, 2-PCAM,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	ran.reshef@uphs.upenn.edu; david.porter@uphs.upenn.edu	Hexner, Elizabeth/AAC-1442-2020	Hexner, Elizabeth/0000-0002-1125-4060; Reshef, Ran/0000-0003-2185-9546	Pfizer; Leukemia and Lymphoma Society; National Institutes of Health [P30-CA16520, K24-CA117879, U01-HL069286]; Abramson Cancer Center; American Society of Hematology Scholar Award; American Society of Clinical Oncology Young Investigator Award; Bristol-Myers Squibb; Celgene; Millennium; NATIONAL CANCER INSTITUTE [K24CA117879, P30CA016520] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL069286, U01HL069286] Funding Source: NIH RePORTER	Pfizer(Pfizer); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Abramson Cancer Center; American Society of Hematology Scholar Award; American Society of Clinical Oncology Young Investigator Award; Bristol-Myers Squibb(Bristol-Myers Squibb); Celgene(Bristol-Myers SquibbCelgene Corporation); Millennium(Takeda Pharmaceutical Company Ltd); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by Pfizer; a Specialized Center of Research grant (to Drs. Porter and Vonderheide) and a Special Fellow in Clinical Research Award (to Dr. Reshef) from the Leukemia and Lymphoma Society; grants (P30-CA16520, to Drs. Vonderheide, Stadtmauer, and Heitjan and Ms. Mick; K24-CA117879, to Dr. Porter; and U01-HL069286, to Drs. Porter and Stadtmauer) from the National Institutes of Health; a Pilot Project Grant from the Abramson Cancer Center (to Drs. Reshef, Vonderheide, and Porter); and an American Society of Hematology Scholar Award and an American Society of Clinical Oncology Young Investigator Award (both to Dr. Reshef). Dr. Reshef is a fellow of the Institute for Translational Medicine and Therapeutics, University of Pennsylvania.; Dr. Frey reports receiving lecture fees from Pfizer; Dr. Stadtmauer, consulting fees from Pfizer; Dr. Vonderheide, grant support from Pfizer; and Dr. Porter, consulting fees from Bristol-Myers Squibb and lecture fees from Celgene and Millennium. No other potential conflict of interest relevant to this article was reported.	Alousi AM, 2009, BLOOD, V114, P511, DOI 10.1182/blood-2009-03-212290; Alyea EP, 2005, BLOOD, V105, P1810, DOI 10.1182/blood-2004-05-1947; BEATTY PG, 1993, BLOOD, V81, P249; Bogunia-Kubik K, 2006, HAEMATOLOGICA, V91, P1628; Carlson MJ, 2009, BLOOD, V113, P1365, DOI 10.1182/blood-2008-06-162420; Choi SW, 2007, BLOOD, V110, P3447, DOI 10.1182/blood-2007-05-087403; Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005; Fatkenheuer G, 2008, NEW ENGL J MED, V359, P1442, DOI 10.1056/NEJMoa0803154; Fatkenheuer G, 2005, NAT MED, V11, P1170, DOI 10.1038/nm1319; Ferrara J L, 1999, Biol Blood Marrow Transplant, V5, P347, DOI 10.1016/S1083-8791(99)70011-X; Filipovich AH, 2005, BIOL BLOOD MARROW TR, V11, P945, DOI 10.1016/j.bbmt.2005.09.004; Fischereder M, 2001, LANCET, V357, P1758, DOI 10.1016/S0140-6736(00)04898-4; Flowers MED, 2011, BLOOD, V117, P3214, DOI 10.1182/blood-2010-08-302109; Giralt S, 2001, BLOOD, V97, P631, DOI 10.1182/blood.V97.3.631; Gulick RM, 2008, NEW ENGL J MED, V359, P1429, DOI 10.1056/NEJMoa0803152; Heidenhain C, 2009, ANN TRANSPL, V14, P36; Jagasia M, 2012, BLOOD, V119, P296, DOI 10.1182/blood-2011-06-364265; Johnston L, 2008, BEST PRACT RES CL HA, V21, P177, DOI 10.1016/j.beha.2008.02.006; Levine JE, 2010, BIOL BLOOD MARROW TR, V16, P1693, DOI 10.1016/j.bbmt.2010.05.019; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Luger SM, 2012, BONE MARROW TRANSPL, V47, P203, DOI 10.1038/bmt.2011.69; Ma Q, 2010, BIOL BLOOD MARROW TR, V16, P132, DOI 10.1016/j.bbmt.2009.05.017; Matte CC, 2004, NAT MED, V10, P987, DOI 10.1038/nm1089; McDermott DH, 2010, BLOOD, V115, P2311, DOI 10.1182/blood-2009-08-237768; McSweeney PA, 2001, BLOOD, V97, P3390, DOI 10.1182/blood.V97.11.3390; Mielcarek M, 2003, BLOOD, V102, P756, DOI 10.1182/blood-2002-08-2628; Murai M, 1999, J CLIN INVEST, V104, P49, DOI 10.1172/JCI6642; Murai M, 2003, NAT IMMUNOL, V4, P154, DOI 10.1038/ni879; Murai M, 2003, NAT IMMUNOL, V4, P497, DOI 10.1038/ni0503-497; Nash RA, 2000, BLOOD, V96, P2062; New JY, 2002, BONE MARROW TRANSPL, V29, P979, DOI 10.1038/sj.bmt.1703563; Nikolic B, 2000, J CLIN INVEST, V105, P1289, DOI 10.1172/JCI7894; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Ringden O, 2009, J CLIN ONCOL, V27, P4570, DOI 10.1200/JCO.2008.20.9692; Sackstein R, 2006, BIOL BLOOD MARROW TR, V12, P2, DOI 10.1016/j.bbmt.2005.09.015; Schetelig J, 2002, HAEMATOLOGICA, V87, P299; Serody JS, 2000, BLOOD, V96, P2973; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Slavin S, 1998, BLOOD, V91, P756, DOI 10.1182/blood.V91.3.756.756_756_763; Sorror ML, 2005, BLOOD, V106, P2912, DOI 10.1182/blood-2005-05-2004; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213; Weisdorf Daniel, 2007, Hematology Am Soc Hematol Educ Program, P62; Welniak LA, 2006, BLOOD, V107, P410, DOI 10.1182/blood-2004-11-4565; Welniak LA, 2004, EXP HEMATOL, V32, P318, DOI 10.1016/j.exphem.2003.12.003; Wysocki CA, 2004, J IMMUNOL, V173, P845, DOI 10.4049/jimmunol.173.2.845; Yi TS, 2009, BLOOD, V114, P3101, DOI 10.1182/blood-2009-05-219402; Zhang Y, 2002, J CLIN INVEST, V109, P1335, DOI 10.1172/JCI200214989; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	49	179	190	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2					135	145		10.1056/NEJMoa1201248	http://dx.doi.org/10.1056/NEJMoa1201248			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972IO	22784116	Bronze, Green Accepted			2022-12-28	WOS:000306270800010
J	Heath, I				Heath, Iona			In praise of young doctors	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Coll Gen Practitioners, London, England		Heath, I (corresponding author), Royal Coll Gen Practitioners, London, England.	iona.heath22@yahoo.co.uk						Beauchamp TL, 2008, PRINCIPLES BIOMEDICA, V6th; Fish D., 2010, ANN ROY COLL SURG, V92, P80, DOI [10.1308/rcsann.2010.92.1.80a, DOI 10.1308/RCSANN.2010.92.1.80A]; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; KASSIRER JP, 1993, NEW ENGL J MED, V328, P1268, DOI 10.1056/NEJM199304293281710	4	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 11	2012	345								e4549	10.1136/bmj.e4549	http://dx.doi.org/10.1136/bmj.e4549			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975NU	22786935				2022-12-28	WOS:000306518800002
J	Pasternak, B; Svanstrom, H; Molgaard-Nielsen, D; Krause, TG; Emborg, HD; Melbye, M; Hviid, A				Pasternak, Bjorn; Svanstrom, Henrik; Molgaard-Nielsen, Ditte; Krause, Tyra G.; Emborg, Hanne-Dorthe; Melbye, Mads; Hviid, Anders			Risk of Adverse Fetal Outcomes Following Administration of a Pandemic Influenza A(H1N1) Vaccine During Pregnancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							H1N1 INFLUENZA; WOMEN; COHORT	Context Assessment of the fetal safety of vaccination against influenza A(H1N1) pdm09 in pregnancy has been limited. Objective To investigate whether exposure to an adjuvanted influenza A(H1N1) pdm09 vaccine during pregnancy was associated with increased risk of adverse fetal outcomes. Design, Setting, and Participants Registry-based cohort study based on all live-born singleton infants in Denmark, delivered between November 2, 2009, and September 30, 2010. In propensity score-matched analyses, we estimated prevalence odds ratios (PORs) of adverse fetal outcomes, comparing infants exposed and unexposed to an AS03-adjuvanted influenza A(H1N1) pdm09 vaccine during pregnancy. Main Outcome Measures Major birth defects, preterm birth, and small size for gestational age. Results From a cohort of 53 432 infants (6989 [13.1%] exposed to the influenza A[H1N1] pdm09 vaccine during pregnancy [345 in the first trimester and 6644 in the second or third trimester]), 660 (330 exposed) were included in propensity score-matched analyses of adverse fetal outcomes associated with first-trimester exposure. For analysis of small size for gestational age after second-or third-trimester exposure, 13 284 (6642 exposed) were included; for analyses of preterm birth, 12 909 (6543 exposed) were included. A major birth defect was diagnosed in 18 of 330 infants (5.5%) exposed to the vaccine in the first trimester, compared with 15 of 330 unexposed infants (4.5%) (POR, 1.21; 95% CI, 0.60-2.45). Preterm birth occurred in 31 of 330 infants (9.4%) exposed in the first trimester, compared with 24 of 330 unexposed infants (7.3%) (POR, 1.32; 95% CI, 0.76-2.31), and in 302 of 6543 infants (4.6%) with second- or third-trimester exposure, compared with 295 of 6366 unexposed infants (4.6%) (POR, 1.00; 95% CI, 0.84-1.17). Small size for gestational age was observed in 25 of 330 infants (7.6%) with first-trimester exposure compared with 31 of 330 unexposed infants (9.4%) (POR, 0.79; 95% CI, 0.46-1.37), and in 641 of 6642 infants (9.7%) with second-or third-trimester exposure, compared with 657 of 6642 unexposed infants (9.9%) (POR, 0.97; 95% CI, 0.87-1.09). Conclusions In this Danish cohort, exposure to an adjuvanted influenza A(H1N1) pdm09 vaccine during pregnancy was not associated with a significantly increased risk of major birth defects, preterm birth, or fetal growth restriction. JAMA. 2012;308(2):165-174	[Pasternak, Bjorn; Svanstrom, Henrik; Molgaard-Nielsen, Ditte; Melbye, Mads; Hviid, Anders] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark	Statens Serum Institut	Pasternak, B (corresponding author), Statens Serum Inst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen S, Denmark.	bjp@ssi.dk	Hviid, Anders/AAH-4319-2020; Emborg, Hanne-Dorthe/GRS-8769-2022; Pasternak, Bjorn/H-5739-2012	Hviid, Anders/0000-0002-7509-9127; Pasternak, Bjorn/0000-0002-2097-8466; melbye, mads/0000-0001-8264-6785	Danish Medical Research Council [11-115854]	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by the Danish Medical Research Council (grant 11-115854 to Dr Pasternak).	Ahluwalia Indu B., 2012, Morbidity and Mortality Weekly Report, V61, P113; Andersen TF, 1999, DAN MED BULL, V46, P263; Bone A, 2010, VACCINE, V28, P8157, DOI 10.1016/j.vaccine.2010.09.096; Boyd HA, 2009, AM J EPIDEMIOL, V170, P1358, DOI 10.1093/aje/kwp324; Buhimschi CS, 2009, OBSTET GYNECOL, V113, P166, DOI 10.1097/AOG.0b013e31818d6788; Danish National Board of Health, REC VACC PERS RISK S; EUROCAT Central Registry, EUR GUID 1 3 REF DOC; EUROCAT Central Registry, PREV TABL; European Medicines Agency, 11 PAND PHARM WEEKL; European Medicines Agency, 22 PAND PHARM UPD; Folkenberg M, 2011, VACCINE, V29, P1180, DOI 10.1016/j.vaccine.2010.12.008; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Huang WT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0023049, 10.1371/journal.pone.0023829]; Jorgensen Finn Stener, 2003, Ugeskr Laeger, V165, P4409; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Knudsen LB, 1998, DAN MED BULL, V45, P320; Lacroix I, 2011, VACCINE, V29, P1357, DOI 10.1016/j.vaccine.2010.12.011; Lambert LC, 2010, NEW ENGL J MED, V363, P2036, DOI 10.1056/NEJMra1002842; Louie JK, 2010, NEW ENGL J MED, V362, P27, DOI 10.1056/NEJMoa0910444; Mackenzie IS, 2012, BRIT J CLIN PHARMACO, V73, P801, DOI 10.1111/j.1365-2125.2011.04142.x; Mak TK, 2008, LANCET INFECT DIS, V8, P44, DOI 10.1016/S1473-3099(07)70311-0; Moro PL, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.047; Mosby LG, 2011, AM J OBSTET GYNECOL, V205, P10, DOI 10.1016/j.ajog.2010.12.033; Omon E, 2011, VACCINE, V29, P9649, DOI 10.1016/j.vaccine.2011.10.034; Pasternak B, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2794; Pasternak B, 2010, JAMA-J AM MED ASSOC, V304, P859, DOI 10.1001/jama.2010.1206; Pedersen CB, 2006, DAN MED BULL, V53, P441; Pierce M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3214; Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479; Skowronski DM, 2009, VACCINE, V27, P4754, DOI 10.1016/j.vaccine.2009.03.079; Tamma PD, 2009, AM J OBSTET GYNECOL, V201, P547, DOI 10.1016/j.ajog.2009.09.034; Tavares F, 2011, VACCINE, V29, P6358, DOI 10.1016/j.vaccine.2011.04.114; Tsatsaris V, 2011, ANN INTERN MED, V155, P733, DOI 10.7326/0003-4819-155-11-201112060-00005; Walter D, 2011, VACCINE, V29, P4008, DOI 10.1016/j.vaccine.2011.03.069; [No title captured]	35	105	105	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2012	308	2					165	174		10.1001/jama.2012.6131	http://dx.doi.org/10.1001/jama.2012.6131			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971QS	22782418	Bronze			2022-12-28	WOS:000306219500030
J	Surani, A; Tischler, J				Surani, Azim; Tischler, Julia			STEM CELLS A sporadic super state	NATURE			English	Editorial Material							MOUSE; PLURIPOTENCY; NANOG		[Surani, Azim; Tischler, Julia] Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QN, England	University of Cambridge	Surani, A (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QN, England.	a.surani@gurdon.cam.ac.uk		Surani, Azim/0000-0002-8640-4318	Medical Research Council [G0800784B] Funding Source: researchfish; MRC [G0800784] Funding Source: UKRI; Medical Research Council [G0800784] Funding Source: Medline; Wellcome Trust [092096, 079249] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Canham MA, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000379; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Hayashi K, 2008, CELL STEM CELL, V3, P391, DOI 10.1016/j.stem.2008.07.027; Kalmar T, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000149; Macfarlan TS, 2012, NATURE, V487, P57, DOI 10.1038/nature11244; Miyanari Y, 2012, NATURE, V483, P470, DOI 10.1038/nature10807; Peaston AE, 2004, DEV CELL, V7, P597, DOI 10.1016/j.devcel.2004.09.004; Rossant J, 2009, DEVELOPMENT, V136, P701, DOI 10.1242/dev.017178; Toyooka Y, 2008, DEVELOPMENT, V135, P909, DOI 10.1242/dev.017400; Zalzman M, 2010, NATURE, V464, P858, DOI 10.1038/nature08882	10	10	11	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 5	2012	487	7405					43	45		10.1038/487043a	http://dx.doi.org/10.1038/487043a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	968LM	22763548				2022-12-28	WOS:000305982900042
J	Ghander, C; Tenenbaum, F; Tissier, F; Silvera, S; Lalej, D; Dousset, B; Groussin, L				Ghander, Cecile; Tenenbaum, Florence; Tissier, Frederique; Silvera, Stephane; Lalej, Dalila; Dousset, Bertrand; Groussin, Lionel			When adrenal Cushing's and phaeochromocytoma meet	LANCET			English	Editorial Material									[Ghander, Cecile; Groussin, Lionel] Univ Paris 05, Hop Cochin, Dept Endocrinol, Paris, France; [Tenenbaum, Florence] Univ Paris 05, Hop Cochin, Dept Nucl Med, Paris, France; [Tissier, Frederique] Univ Paris 05, Hop Cochin, Dept Pathol, Paris, France; [Silvera, Stephane] Univ Paris 05, Hop Cochin, Dept Radiol, Paris, France; [Dousset, Bertrand] Univ Paris 05, Hop Cochin, Dept Endocrine Surg, Paris, France; [Tissier, Frederique; Groussin, Lionel] Inst Cochin Genet Mol, Inst Natl Sante, F-75014 Paris, France; [Tissier, Frederique; Groussin, Lionel] Inst Cochin Genet Mol, Rech Med Unite, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Groussin, L (corresponding author), Univ Paris 05, Cochin Teaching Hosp, Dept Endocrinol, F-7503 Paris, France.	lionel.groussin@cch.aphp.fr		Dousset, Bertrand/0000-0003-2526-7345; Groussin, Lionel/0000-0003-1476-475X					0	6	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 10	2012	380	9854					1683	1683		10.1016/S0140-6736(12)60438-3	http://dx.doi.org/10.1016/S0140-6736(12)60438-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	035MN	22796131				2022-12-28	WOS:000310951400030
J	Buckley, BA; Burkhart, KB; Gu, SG; Spracklin, G; Kershner, A; Fritz, H; Kimble, J; Fire, A; Kennedy, S				Buckley, Bethany A.; Burkhart, Kirk B.; Gu, Sam Guoping; Spracklin, George; Kershner, Aaron; Fritz, Heidi; Kimble, Judith; Fire, Andrew; Kennedy, Scott			A nuclear Argonaute promotes multigenerational epigenetic inheritance and germline immortality	NATURE			English	Article							DOUBLE-STRANDED-RNA; C-ELEGANS; CAENORHABDITIS-ELEGANS; GENE; INTERFERENCE; PROTEIN; MEMORY; PIRNAS; RDE-1	Epigenetic information is frequently erased near the start of each new generation(1). In some cases, however, epigenetic information can be transmitted from parent to progeny (multigenerational epigenetic inheritance)(2). A particularly notable example of this type of epigenetic inheritance is double-stranded RNA-mediated gene silencing in Caenorhabditis elegans. This RNA-mediated interference (RNAi) can be inherited for more than five generations(3-8). To understand this process, here we conduct a genetic screen for nematodes defective in transmitting RNAi silencing signals to future generations. This screen identified the heritable RNAi defective 1 (hrde-1) gene. hrde-1 encodes an Argonaute protein that associates with small interfering RNAs in the germ cells of progeny of animals exposed to double-stranded RNA. In the nuclei of these germ cells, HRDE-1 engages the nuclear RNAi defective pathway to direct the trimethylation of histone H3 at Lys 9 (H3K9me3) at RNAi-targeted genomic loci and promote RNAi inheritance. Under normal growth conditions, HRDE-1 associates with endogenously expressed short interfering RNAs, which direct nuclear gene silencing in germ cells. In hrde-1- or nuclear RNAi-deficient animals, germline silencing is lost over generational time. Concurrently, these animals exhibit steadily worsening defects in gamete formation and function that ultimately lead to sterility. These results establish that the Argonaute protein HRDE-1 directs gene-silencing events in germ-cell nuclei that drive multigenerational RNAi inheritance and promote immortality of the germ-cell lineage. We propose that C. elegans use the RNAi inheritance machinery to transmit epigenetic information, accrued by past generations, into future generations to regulate important biological processes.	[Buckley, Bethany A.; Burkhart, Kirk B.; Spracklin, George; Fritz, Heidi; Kimble, Judith; Kennedy, Scott] Univ Wisconsin, Lab Genet, Madison, WI 53706 USA; [Gu, Sam Guoping; Fire, Andrew] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Gu, Sam Guoping; Fire, Andrew] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Kershner, Aaron; Fritz, Heidi] Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; [Kershner, Aaron; Kimble, Judith] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; Stanford University; Stanford University; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kennedy, S (corresponding author), Univ Wisconsin, Lab Genet, Madison, WI 53706 USA.	sgkennedy@wisc.edu		Fire, Andrew/0000-0001-6217-8312; Kennedy, Scott/0000-0002-7974-8155; Spracklin, George/0000-0001-7352-7354	Pew scholar's program; Shaw scholar's program; National Institutes of Health [GM88289, GM37706, GM069454]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088289, R01GM069454, R01GM037706, R01GM104232] Funding Source: NIH RePORTER	Pew scholar's program; Shaw scholar's program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank P. Anderson, H. Opalicious and D. Wassarman for discussions. We thank S. Ahmed and members of the Ahmed laboratory for sharing unpublished data concerning the role of nrde-1 in germline immortality. This work was supported by grants from the Pew and Shaw scholar's programs, and the National Institutes of Health, GM88289 (S. K.), GM37706 (A. F.) and GM069454 (J.K).	Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Alcazar RM, 2008, GENETICS, V180, P1275, DOI 10.1534/genetics.108.089433; Ashe A, 2012, CELL, V150, P88, DOI 10.1016/j.cell.2012.06.018; Bagijn M.P., 2012, SCIENCE; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; Burkhart KB, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002249; Burton NO, 2011, P NATL ACAD SCI USA, V108, P19683, DOI 10.1073/pnas.1113310108; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Gu SG, 2012, NAT GENET, V44, P157, DOI 10.1038/ng.1039; Gu WF, 2009, MOL CELL, V36, P231, DOI 10.1016/j.molcel.2009.09.020; Guang S, 2008, SCIENCE, V321, P537, DOI 10.1126/science.1157647; Guang SH, 2010, NATURE, V465, P1097, DOI 10.1038/nature09095; Jablonka E, 2009, Q REV BIOL, V84, P131, DOI 10.1086/598822; Pak J, 2007, SCIENCE, V315, P241, DOI 10.1126/science.1132839; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Shirayama M, 2012, CELL, V150, P65, DOI 10.1016/j.cell.2012.06.015; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Vastenhouw NL, 2006, NATURE, V442, P882, DOI 10.1038/442882a; Yigit E, 2006, CELL, V127, P747, DOI 10.1016/j.cell.2006.09.033	21	303	310	0	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 20	2012	489	7416					447	451		10.1038/nature11352	http://dx.doi.org/10.1038/nature11352			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AK	22810588	Green Accepted			2022-12-28	WOS:000308860900049
J	Alexander, CMO; Bowden, R; Fogel, ML; Howard, KT; Herd, CDK; Nittler, LR				Alexander, C. M. O'D.; Bowden, R.; Fogel, M. L.; Howard, K. T.; Herd, C. D. K.; Nittler, L. R.			The Provenances of Asteroids, and Their Contributions to the Volatile Inventories of the Terrestrial Planets	SCIENCE			English	Article							TAGISH LAKE METEORITE; OXYGEN-ISOTOPE; SOLAR NEBULA; CARBONACEOUS CHONDRITES; ORGANIC-MATTER; LOW-MASS; ORIGIN; WATER; CONSTRAINTS; MIGRATION	Determining the source(s) of hydrogen, carbon, and nitrogen accreted by Earth is important for understanding the origins of water and life and for constraining dynamical processes that operated during planet formation. Chondritic meteorites are asteroidal fragments that retain records of the first few million years of solar system history. The deuterium/hydrogen (D/H) values of water in carbonaceous chondrites are distinct from those in comets and Saturn's moon Enceladus, implying that they formed in a different region of the solar system, contrary to predictions of recent dynamical models. The D/H values of water in carbonaceous chondrites also argue against an influx of water ice from the outer solar system, which has been invoked to explain the nonsolar oxygen isotopic composition of the inner solar system. The bulk hydrogen and nitrogen isotopic compositions of CI chondrites suggest that they were the principal source of Earth's volatiles.	[Alexander, C. M. O'D.; Nittler, L. R.] Carnegie Inst Sci, Dept Terr Magnetism, Washington, DC 20015 USA; [Bowden, R.; Fogel, M. L.] Carnegie Inst Sci, Geophys Lab, Washington, DC 20015 USA; [Howard, K. T.] Nat Hist Museum, London SW7 5BD, England; [Howard, K. T.] CUNY, Kingsborough Community Coll, Brooklyn, NY 11235 USA; [Herd, C. D. K.] Univ Alberta, Dept Earth & Atmospher Sci, Edmonton, AB T6G 2E3, Canada	Carnegie Institution for Science; Carnegie Institution for Science; Natural History Museum London; City University of New York (CUNY) System; University of Alberta	Alexander, CMO (corresponding author), Carnegie Inst Sci, Dept Terr Magnetism, 5241 Broad Branch Rd NW, Washington, DC 20015 USA.	alexander@dtm.ciw.edu	Alexander, Conel M. O'D./N-7533-2013	Alexander, Conel M. O'D./0000-0002-8558-1427; Herd, Christopher/0000-0001-5210-4002	NASA [NNX11AG67G]; NASA Astrobiology Institute; Carnegie Canada; Natural Sciences and Engineering Research Council of Canada; W.M. Keck Foundation; UK Cosmochemical Analysis Network	NASA(National Aeronautics & Space Administration (NASA)); NASA Astrobiology Institute; Carnegie Canada; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); W.M. Keck Foundation(W.M. Keck Foundation); UK Cosmochemical Analysis Network	All the data reported in this paper are presented in the supplementary materials. This work was partially funded by NASA Cosmochemistry grant NNX11AG67G (C.M.O'D.A.), the NASA Astrobiology Institute (C.M.O'D.A., R. B., M. L. F., L.R.N.), Carnegie Canada (C.M.O'D.A., C. D. K. H., L.R.N.), the Natural Sciences and Engineering Research Council of Canada (C. D. K. H.), the W.M. Keck Foundation (M. L. F., R. B.), and the UK Cosmochemical Analysis Network (K. T. H.). For supplying the many samples that were necessary for this work, we thank the members of the Meteorite Working Group, C. Satterwhite and K. Righter (NASA, Johnson Space Center), T. McCoy and L. Welzenbach (Smithsonian Museum for Natural History), L. Garvie (Arizona State University), S. Russell, C. Smith, and D. Cassey (Natural History Museum, London).	Brearley A. J., 2006, METEORITES EARLY SOL, VII, P584; Clayton RN, 1999, GEOCHIM COSMOCHIM AC, V63, P2089, DOI 10.1016/S0016-7037(99)00090-3; Coutens A, 2012, ASTRON ASTROPHYS, V539, DOI 10.1051/0004-6361/201117627; Drouart A, 1999, ICARUS, V140, P129, DOI 10.1006/icar.1999.6137; Gounelle M, 2006, METEORIT PLANET SCI, V41, P135, DOI 10.1111/j.1945-5100.2006.tb00198.x; Haack H., 2011, LUNAR PLANET SCI, V43, P9100; Herd CDK, 2011, SCIENCE, V332, P1304, DOI 10.1126/science.1203290; Hiroi T, 2001, SCIENCE, V293, P2234, DOI 10.1126/science.1063734; Jewitt D, 2012, ASTRON J, V143, DOI 10.1088/0004-6256/143/3/66; Levison HF, 2003, NATURE, V426, P419, DOI 10.1038/nature02120; Liu FC, 2011, ASTRON ASTROPHYS, V527, DOI 10.1051/0004-6361/201015519; Lyons JR, 2005, NATURE, V435, P317, DOI 10.1038/nature03557; Marty B, 2012, EARTH PLANET SC LETT, V313, P56, DOI 10.1016/j.epsl.2011.10.040; McCanta MC, 2008, GEOCHIM COSMOCHIM AC, V72, P5757, DOI 10.1016/j.gca.2008.07.034; McKeegan KD, 2011, SCIENCE, V332, P1528, DOI 10.1126/science.1204636; Messenger S, 2000, NATURE, V404, P968, DOI 10.1038/35010053; Mousis O, 2000, ICARUS, V148, P513, DOI 10.1006/icar.2000.6499; Raymond SN, 2009, ICARUS, V203, P644, DOI 10.1016/j.icarus.2009.05.016; STEVENSON DJ, 1988, ICARUS, V75, P146, DOI 10.1016/0019-1035(88)90133-9; Waite JH, 2009, NATURE, V460, P487, DOI 10.1038/nature08153; Warren PH, 2011, EARTH PLANET SC LETT, V311, P93, DOI 10.1016/j.epsl.2011.08.047; Young ED, 1999, SCIENCE, V286, P1331, DOI 10.1126/science.286.5443.1331; Yurimoto H, 2004, SCIENCE, V305, P1763, DOI 10.1126/science.1100989	28	418	422	7	199	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 10	2012	337	6095					721	723		10.1126/science.1223474	http://dx.doi.org/10.1126/science.1223474			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986PE	22798405				2022-12-28	WOS:000307354500051
J	Van Damme, L; Corneli, A; Ahmed, K; Agot, K; Lombaard, J; Kapiga, S; Malahleha, M; Owino, F; Manongi, R; Onyango, J; Temu, L; Monedi, MC; Mak'Oketch, P; Makanda, M; Reblin, I; Makatu, SE; Saylor, L; Kiernan, H; Kirkendale, S; Wong, C; Grant, R; Kashuba, A; Nanda, K; Mandala, J; Fransen, K; Deese, J; Crucitti, T; Mastro, TD; Taylor, D				Van Damme, Lut; Corneli, Amy; Ahmed, Khatija; Agot, Kawango; Lombaard, Johan; Kapiga, Saidi; Malahleha, Mookho; Owino, Fredrick; Manongi, Rachel; Onyango, Jacob; Temu, Lucky; Monedi, Modie Constance; Mak'Oketch, Paul; Makanda, Mankalimeng; Reblin, Ilse; Makatu, Shumani Elsie; Saylor, Lisa; Kiernan, Haddie; Kirkendale, Stella; Wong, Christina; Grant, Robert; Kashuba, Angela; Nanda, Kavita; Mandala, Justin; Fransen, Katrien; Deese, Jennifer; Crucitti, Tania; Mastro, Timothy D.; Taylor, Douglas		FEM-PrEP Study Grp	Preexposure Prophylaxis for HIV Infection among African Women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Preexposure prophylaxis with antiretroviral drugs has been effective in the prevention of human immunodeficiency virus (HIV) infection in some trials but not in others. Methods In this randomized, double-blind, placebo-controlled trial, we assigned 2120 HIV-negative women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily. The primary objective was to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety. Results HIV infections occurred in 33 women in the TDF-FTC group (incidence rate, 4.7 per 100 person-years) and in 35 in the placebo group (incidence rate, 5.0 per 100 person-years), for an estimated hazard ratio in the TDF-FTC group of 0.94 (95% confidence interval, 0.59 to 1.52; P = 0.81). The proportions of women with nausea, vomiting, or elevated alanine aminotransferase levels were significantly higher in the TDF-FTC group (P = 0.04, P < 0.001, and P = 0.03, respectively). Rates of drug discontinuation because of hepatic or renal abnormalities were higher in the TDF-FTC group (4.7%) than in the placebo group (3.0%, P = 0.051). Less than 40% of the HIV-uninfected women in the TDF-FTC group had evidence of recent pill use at visits that were matched to the HIV-infection window for women with seroconversion. The study was stopped early, on April 18, 2011, because of lack of efficacy. Conclusions Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo. Despite substantial counseling efforts, drug adherence appeared to be low. (Supported by the U. S. Agency for International Development and others; FEM-PrEP ClinicalTrials.gov number, NCT00625404.)	[Van Damme, Lut; Corneli, Amy; Saylor, Lisa; Kiernan, Haddie; Kirkendale, Stella; Wong, Christina; Nanda, Kavita; Mandala, Justin; Deese, Jennifer; Mastro, Timothy D.; Taylor, Douglas] FHI 360, Res Triangle Pk, NC USA; [Kashuba, Angela] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA; [Ahmed, Khatija; Malahleha, Mookho; Monedi, Modie Constance; Makatu, Shumani Elsie] Setshaba Res Ctr, Pretoria, South Africa; [Lombaard, Johan; Makanda, Mankalimeng; Reblin, Ilse] JOSHA Res, Bloemfontein, South Africa; [Agot, Kawango; Owino, Fredrick; Onyango, Jacob; Mak'Oketch, Paul] Impact Res & Dev Org, Kisumu, Kenya; [Kapiga, Saidi; Manongi, Rachel; Temu, Lucky] Kilimanjaro Christian Med Ctr, Moshi, Tanzania; [Kapiga, Saidi] London Sch Hyg & Trop Med, London, England; [Grant, Robert] Univ Calif San Francisco, Gladstone Inst, San Francisco, CA 94143 USA; [Fransen, Katrien; Crucitti, Tania] Inst Trop Med, B-2000 Antwerp, Belgium	FHI 360; University of North Carolina; University of North Carolina Chapel Hill; Kilimanjaro Christian Medical Centre; University of London; London School of Hygiene & Tropical Medicine; University of California System; University of California San Francisco; The J David Gladstone Institutes; Institute of Tropical Medicine (ITM)	Van Damme, L (corresponding author), FHI 360, 1825 Connecticut Ave NW, Washington, DC 20009 USA.	lvandamme@fhi360.org	Crucitti, Tania/AAB-9967-2019; Crucitti, Tania/AAH-1902-2021; Crucitti, Tania/AEQ-9792-2022	Crucitti, Tania/0000-0002-2235-6038; Crucitti, Tania/0000-0002-2235-6038; Kapiga, Saidi/0000-0003-1753-4060; Ojwang, Frank/0000-0002-6001-3298; Andreasen, Aura/0000-0003-0664-7342; ahmed, khatija/0000-0003-0309-1641; Corneli, Amy/0000-0002-4629-4329; deese, jennifer/0000-0003-1535-1076; Grant, Robert/0000-0002-0851-7085	U.S. Agency for International Development; Bill and Melinda Gates Foundation; MRC [G0901756] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI095031, P30AI027763, P30AI050410] Funding Source: NIH RePORTER; Medical Research Council [G0901756] Funding Source: researchfish	U.S. Agency for International Development(United States Agency for International Development (USAID)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by grants from the U.S. Agency for International Development and the Bill and Melinda Gates Foundation. Gilead Sciences provided the study drugs.	Abdool Karim S., 2012, INT MICR C SYDN APR; Anderson Peter D, 2012, J Pharm Pract, V25, P5, DOI 10.1177/0897190011431143; [Anonymous], 2008, EAST SOFTW ADV CLIN; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Donnell D, 2012, 19 C RETR OPP INF SE; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Kashuba AD, 2011, LANCET; Mascolini M., 2012, FDA PANEL ENDORSES T; Microbicide Trial Network, 2011, MTN STAT DEC DISC US; National Institute of Allergy and Infectious Diseases, 2004, DIV AIDS TABL GRAD S; Patterson KB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003174; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Weir S., 2005, PRIORITIES LOCAL AID	13	1108	1127	0	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2012	367	5					411	422		10.1056/NEJMoa1202614	http://dx.doi.org/10.1056/NEJMoa1202614			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981VZ	22784040	Green Accepted, Green Published			2022-12-28	WOS:000307001900006
J	Mayer, KH; Bekker, LG; Stall, R; Grulich, AE; Colfax, G; Lama, JR				Mayer, Kenneth H.; Bekker, Linda-Gail; Stall, Ron; Grulich, Andrew E.; Colfax, Grant; Lama, Javier R.			Comprehensive clinical care for men who have sex with men: an integrated approach	LANCET			English	Article							SEXUALLY-TRANSMITTED INFECTIONS; PSYCHOSOCIAL HEALTH-PROBLEMS; HUMAN-IMMUNODEFICIENCY-VIRUS; CLUB-DRUG-USE; HOMOSEXUAL-MEN; RISK-FACTORS; ALCOHOL-USE; HIV-INFECTION; GAY MEN; CIGARETTE-SMOKING	Men who have sex with men (MSM) have unique health-care needs, not only because of biological factors such as an increased susceptibility to infection with HIV and sexually transmitted infections associated with their sexual behaviour, but also because of internalisation of societal stigma related to homosexuality and gender non-conformity, resulting in depression, anxiety, substance use, and other adverse outcomes. Successful responses to the global HIV/AIDS epidemic will require the development of culturally sensitive clinical care programmes for MSM that address these health disparities and root causes of maladaptive behaviour (eg, societal homophobia). Health-care providers need to become familiar with local outreach agencies, hotlines, and media that can connect MSM with positive role models and social opportunities. Research is needed to understand how many MSM lead resilient and productive lives in the face of discrimination to develop assets-based interventions that build on community support. Optimum clinical care for sexual and gender minorities is a fundamental human right. MSM deserve to be treated with respect, and health-care providers need to interact with them in ways that promote disclosure of actionable health information.	[Mayer, Kenneth H.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Fenway Hlth, Boston, MA 02215 USA; [Bekker, Linda-Gail] Univ Cape Town, Desmond Tutu AIDS Fdn, ZA-7925 Cape Town, South Africa; [Stall, Ron] Univ Pittsburgh, Pittsburgh, PA USA; [Grulich, Andrew E.] Univ New S Wales, Kirby Inst, Sydney, NSW, Australia; [Colfax, Grant] San Francisco Hlth Dept, San Francisco, CA USA; [Lama, Javier R.] Impacta, Lima, Peru	Fenway Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Cape Town; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of New South Wales Sydney; Kirby Institute	Mayer, KH (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Fenway Hlth, 1340 Boylston St, Boston, MA 02215 USA.	khmayer@gmail.com	Bekker, Linda-Gail/AAZ-8929-2020	BEKKER, LINDA-GAIL/0000-0002-0755-4386	Gilead Sciences; Bristol-Myers Squibb; Merck; CSL, the Australian distributor of Gardisil; Harvard Center for AIDS Research [P30AI-06354]; National Institute of Allergy and Infectious Diseases Clinical Trial Unit for HIV Prevention and Microbicide Research [UM1AI069480]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI060354, UM1AI069480] Funding Source: NIH RePORTER	Gilead Sciences(Gilead Sciences); Bristol-Myers Squibb(Bristol-Myers Squibb); Merck(Merck & Company); CSL, the Australian distributor of Gardisil; Harvard Center for AIDS Research; National Institute of Allergy and Infectious Diseases Clinical Trial Unit for HIV Prevention and Microbicide Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	KHM has received unrestricted research and educational grants from Gilead Sciences, Bristol-Myers Squibb, and Merck. AEG has received honoraria and conference travel support from Merck and research funding from CSL, the Australian distributor of Gardisil. All other authors declare that they have no conflicts of interest.; We would like to thank Andrea Karis for assistance in the preparation of the manuscript and Amy Herrick for preparation of the figure. KHM would also like to thank Rodney Vanderwarker, Harvey Makadon, Judith Bradford, Steven Safren, Matthew Mimiaga, Sean Cahill, Conall O'Cleirigh, and Stephen Boswell at Fenway Health, who assisted in thinking through the approach to many of the key issues discussed in this article. KHM is supported by the Harvard Center for AIDS Research (grant number P30AI-06354) and the National Institute of Allergy and Infectious Diseases Clinical Trial Unit for HIV Prevention and Microbicide Research (UM1AI069480).	Abdolrasouli A, 2009, SEX HEALTH, V6, P185, DOI 10.1071/SH08084; Almeida J, 2009, J YOUTH ADOLESCENCE, V38, P1001, DOI 10.1007/s10964-009-9397-9; Applebaum J, 2008, FENWAY GUIDE LESBIAN, P135; Arnold LM, 2001, AM J PUBLIC HEALTH, V91, P1731, DOI 10.2105/AJPH.91.11.1731; Berg CJ, 2011, NICOTINE TOB RES, V13, P29, DOI 10.1093/ntr/ntq193; Beyrer C, 2008, SEX TRANSM INFECT, V84, P410, DOI 10.1136/sti.2008.033290; Beyrer C, 2010, EPIDEMIOL REV, V32, P137, DOI 10.1093/epirev/mxq011; Blashill AJ, 2010, BODY IMAGE, V7, P310, DOI 10.1016/j.bodyim.2010.07.006; Bolding G, 2002, ADDICTION, V97, P195, DOI 10.1046/j.1360-0443.2002.00031.x; Bostwick WB, 2010, AM J PUBLIC HEALTH, V100, P468, DOI 10.2105/AJPH.2008.152942; Buchacz K, 2004, AIDS, V18, P2075, DOI 10.1097/00002030-200410210-00012; Butler AH, 2008, J HOMOSEXUAL, V55, P223, DOI 10.1080/00918360802129485; Butler LM, 2009, JAIDS-J ACQ IMM DEF, V50, P162, DOI 10.1097/QAI.0b013e31819388a9; Celum Connie L, 2010, Top HIV Med, V18, P138; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P985; Chin-Hong PV, 2005, JNCI-J NATL CANCER I, V97, P896, DOI 10.1093/jnci/dji163; Cochran BN, 2007, SUBST USE MISUSE, V42, P161, DOI 10.1080/10826080601094207; Cohen CE, 2004, SEX TRANSM INFECT, V80, P469, DOI 10.1136/sti.2004.011171; Coleman E, 2011, AIDS BEHAV, V15, pS18, DOI 10.1007/s10461-011-9909-y; Colfax G, 2006, CLIN INFECT DIS, V42, P1463, DOI 10.1086/503259; Colfax G, 2010, LANCET, V376, P458, DOI 10.1016/S0140-6736(10)60753-2; Colfax GN, 2011, ARCH GEN PSYCHIAT, V68, P1168, DOI 10.1001/archgenpsychiatry.2011.124; Cranston RD, 2008, SEX TRANSM INFECT, V84, P417, DOI 10.1136/sti.2008.032508; D'Augelli A.R., 2002, CLIN CHILD PSYCHOL P, V7, P439, DOI [10.1177/1359104502007003010, DOI 10.1177/1359104502007003010, 10.1177/ 1359104502007003010]; Daskalakis D, 2009, CLIN INFECT DIS, V48, P1609, DOI 10.1086/598979; Doolan DM, 2006, NURS RES, V55, pS29, DOI 10.1097/00006199-200607001-00005; Drasin H, 2008, J HOMOSEXUAL, V54, P381, DOI 10.1080/00918360801991372; Drumright LN, 2006, SUBST USE MISUSE, V41, P1551, DOI 10.1080/10826080600847894; Dube EM, 1999, DEV PSYCHOL, V35, P1389, DOI 10.1037/0012-1649.35.6.1389; Durazzo TC, 2007, ALCOHOL, V41, P489, DOI 10.1016/j.alcohol.2007.07.007; Fenton KA, 2005, INFECT DIS CLIN N AM, V19, P311, DOI 10.1016/j.idc.2005.04.004; Fierer Daniel S., 2011, Morbidity and Mortality Weekly Report, V60, P945; Glynn JR, 2009, AIDS, V23, P1595, DOI 10.1097/QAD.0b013e32832e15e8; Golden MR, 2008, JAIDS-J ACQ IMM DEF, V49, P212, DOI 10.1097/QAI.0b013e31818455e8; Gonser P A, 2000, J Cult Divers, V7, P72; Greenwood GL, 2005, AM J PUBLIC HEALTH, V95, P145, DOI 10.2105/AJPH.2003.021451; Greenwood GL, 2002, AM J PUBLIC HEALTH, V92, P1964, DOI 10.2105/AJPH.92.12.1964; Grierson J, 2011, HIV MED, V12, P562, DOI 10.1111/j.1468-1293.2011.00928.x; Grov C, 2006, J SEX RES, V43, P115, DOI 10.1080/00224490609552306; Grulich AE, 2003, AUST NZ J PUBL HEAL, V27, P155, DOI 10.1111/j.1467-842X.2003.tb00803.x; Gunn RA, 2007, SEX TRANSM DIS, V34, P663, DOI 10.1097/01.olq.0000258306.20287.a7; Halkitis PN, 2007, DRUG ALCOHOL DEPEN, V89, P153, DOI 10.1016/j.drugalcdep.2006.12.028; Hall HI, 2010, JAIDS-J ACQ IMM DEF, V55, P271, DOI 10.1097/QAI.0b013e3181e8f90c; Harrison TW, 2003, J SCHOOL HEALTH, V73, P107, DOI 10.1111/j.1746-1561.2003.tb03584.x; Hart GJ, 2010, CURR OPIN INFECT DIS, V23, P39, DOI 10.1097/QCO.0b013e328334feb1; Heffelfinger JD, 2007, AM J PUBLIC HEALTH, V97, P1076, DOI 10.2105/AJPH.2005.070417; Institute of Medicine, HLTH LESB GAY BIS TR; Irwin TW, 2005, J URBAN HEALTH, V82, pI127, DOI 10.1093/jurban/jti032; Jin F, 2007, SEX TRANSM INFECT, V83, P113, DOI 10.1136/sti.2006.021915; Jin FY, 2010, AIDS, V24, P907, DOI 10.1097/QAD.0b013e3283372d90; Jin FY, 2009, AIDS, V23, P243, DOI 10.1097/QAD.0b013e32831fb51a; Justice AC, 2006, MED CARE, V44, pS52, DOI 10.1097/01.mlr.0000228003.08925.8c; Kaplan Jonathan E., 2009, Morbidity and Mortality Weekly Report, V58, P1; Kent CK, 2005, CLIN INFECT DIS, V41, P67, DOI 10.1086/430704; Kim JJ, 2010, LANCET INFECT DIS, V10, P845, DOI 10.1016/S1473-3099(10)70219-X; Kippax S, 1997, AIDS, V11, P191, DOI 10.1097/00002030-199702000-00009; Koblin BA, 2006, AIDS, V20, P731, DOI 10.1097/01.aids.0000216374.61442.55; Larance B, 2008, DRUG ALCOHOL REV, V27, P679, DOI 10.1080/09595230802392568; Lee SJ, 2003, J ADDICT DIS, V22, P47, DOI 10.1300/J069v22n04_05; Lombardi Emilia, 2007, J LGBT Health Res, V3, P37, DOI 10.1300/J463v03n02_05; Mackesy-Amiti ME, 2010, DRUG ALCOHOL DEPEN, V110, P38, DOI 10.1016/j.drugalcdep.2010.01.016; Makadon H, 2008, FENWAY GUIDE LESBIAN; Mansergh G, 2008, SEX TRANSM INFECT, V84, P509, DOI 10.1136/sti.2008.031807; Mansergh G, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000329; Mathers BM, 2010, LANCET, V375, P1014, DOI 10.1016/S0140-6736(10)60232-2; Mausbach BT, 2007, DRUG ALCOHOL DEPEN, V87, P249, DOI 10.1016/j.drugalcdep.2006.08.026; Mayer K, 2001, AM J PUBLIC HEALTH, V91, P892, DOI 10.2105/AJPH.91.6.892; Mayer KH, 2008, AM J PUBLIC HEALTH, V98, P989, DOI 10.2105/AJPH.2007.127811; McCabe SE, 2012, ARCH SEX BEHAV, V41, P649, DOI 10.1007/s10508-011-9768-7; McClintock MK, 1996, CURR DIR PSYCHOL SCI, V5, P178, DOI 10.1111/1467-8721.ep11512422; McNally LP, 2008, CLIN INFECT DIS, V47, pE25, DOI 10.1086/589299; Mercer CH, 2004, AIDS, V18, P1453, DOI 10.1097/01.aids.0000131331.36386.de; Mills TC, 2004, AM J PSYCHIAT, V161, P278, DOI 10.1176/appi.ajp.161.2.278; Mimiaga MJ, 2008, AIDS PATIENT CARE ST, V22, P745, DOI 10.1089/apc.2007.0243; Mimiaga MJ, 2009, AIDS PATIENT CARE ST, V23, P825, DOI 10.1089/apc.2009.0086; Moreira ED, 2011, HUM VACCINES, V7, P768, DOI 10.4161/hv.7.7.15579; Morgenstern J, 2007, J CONSULT CLIN PSYCH, V75, P72, DOI 10.1037/0022-006X.75.1.72; Morgenstern J, 2009, J CONSULT CLIN PSYCH, V77, P645, DOI 10.1037/a0015588; Morineau G, 2011, AIDS BEHAV, V15, P1033, DOI 10.1007/s10461-009-9590-6; Morris SR, 2008, SEX TRANSM INFECT, V84, P290, DOI 10.1136/sti.2008.030163; Murdock TB, 2005, PSYCHOL SCHOOLS, V42, P159, DOI 10.1002/pits.20054; Mustanski B, 2007, ANN BEHAV MED, V34, P37, DOI 10.1007/BF02879919; NEWMAN BS, 1993, ADOLESCENCE, V28, P213; Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6; Ostrow DG, 2009, JAIDS-J ACQ IMM DEF, V51, P349, DOI 10.1097/QAI.0b013e3181a24b20; Parsons JT, 2005, AIDS, V19, pS13, DOI 10.1097/01.aids.0000167348.15750.9a; Paul JP, 2001, CHILD ABUSE NEGLECT, V25, P557, DOI 10.1016/S0145-2134(01)00226-5; Prestage G, 2005, AUST NZ J PUBL HEAL, V29, P530, DOI 10.1111/j.1467-842X.2005.tb00245.x; Reback CJ, 2003, AIDS CARE, V15, P775, DOI 10.1080/09540120310001618621; REMAFEDI G, 1987, PEDIATRICS, V79, P326; Safren SA, 1999, J CONSULT CLIN PSYCH, V67, P859, DOI 10.1037/0022-006X.67.6.859; Sanchez Travis, 2006, Morbidity and Mortality Weekly Report, V55, P1; Sandfort TGM, 2006, AM J PUBLIC HEALTH, V96, P1119, DOI 10.2105/AJPH.2004.058891; Schachter J, 2008, SEX TRANSM DIS, V35, P637, DOI 10.1097/OLQ.0b013e31817bdd7e; Sell Randall L, 2008, J LGBT Health Res, V4, P27, DOI 10.1080/15574090802615703; Shoptaw S, 2008, J SUBST ABUSE TREAT, V35, P285, DOI 10.1016/j.jsat.2007.11.004; Stall R, 2003, AM J PUBLIC HEALTH, V93, P939, DOI 10.2105/AJPH.93.6.939; Stall R, 2001, ADDICTION, V96, P1589, DOI 10.1046/j.1360-0443.2001.961115896.x; Stall R., 2000, AIDS BEHAV, V4, P181, DOI [10.1023/A:1009516608672, DOI 10.1023/A:1009516608672]; Stall R, 2008, UNEQUAL OPPORTUNITY, P252; Stall RD, 1999, AM J PUBLIC HEALTH, V89, P1875, DOI 10.2105/AJPH.89.12.1875; Szumowski JD, 2009, CLIN INFECT DIS, V49, P118, DOI 10.1086/599608; Taylor LE, 2011, CLIN INFECT DIS, V52, P812, DOI 10.1093/cid/ciq201; Templeton DJ, 2010, SEX TRANSM INFECT, V86, P90, DOI 10.1136/sti.2009.036814; Tohme RA, 2010, HEPATOLOGY, V52, P1497, DOI 10.1002/hep.23808; TROIDEN RR, 1979, PSYCHIATRY, V42, P362, DOI 10.1080/00332747.1979.11024039; Truong HHM, 2006, SEX TRANSM INFECT, V82, P461, DOI 10.1136/sti.2006.019950; Van de Ven P, 2002, AIDS CARE, V14, P471, DOI 10.1080/09540120208629666; van Griensven F, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-13; Velasquez MM, 2009, J CONSULT CLIN PSYCH, V77, P657, DOI 10.1037/a0015519; Wolitski RJ, 2011, AIDS BEHAV, V15, pS9, DOI 10.1007/s10461-011-9901-6; Workowski Kimberly A, 2010, MMWR Recomm Rep, V59, P1	112	112	114	0	47	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 28	2012	380	9839					378	387		10.1016/S0140-6736(12)60835-6	http://dx.doi.org/10.1016/S0140-6736(12)60835-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819653	Green Accepted			2022-12-28	WOS:000306842800036
J	Smith, JM				Smith, Jeanette M.			HIV/AIDS-Increasing Evidence, Advancing Ahead	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMMUNE ACTIVATION; HIV; INFLAMMATION; THERAPY; RISK					jeanette.smith@jamanetwork.org						Camus Albert, 1962, PLAGUE; Fauci AS, 2012, JAMA-J AM MED ASSOC, V308, P343, DOI 10.1001/jama.2012.8142; Kaiser Family Foundation, 2012, JAMA, V308, P330, DOI 10.1001/jama.2012.8700; Keller MJ, 2012, JAMA-J AM MED ASSOC, V308, P362, DOI 10.1001/jama.2012.5664; Limketkai BN, 2012, JAMA-J AM MED ASSOC, V308, P370, DOI 10.1001/jama.2012.7844; Mateen FJ, 2012, JAMA-J AM MED ASSOC, V308, P349, DOI 10.1001/jama.2012.8538; Mermin J, 2012, JAMA-J AM MED ASSOC, V308, P347, DOI 10.1001/jama.2012.8693; Paton NI, 2012, JAMA-J AM MED ASSOC, V308, P353, DOI 10.1001/jama.2012.6936; Reitz MS, 2010, RETROVIRUSES: MOLECULAR BIOLOGY, GENOMICS AND PATHOGENESIS, P417; Stein JH, 2012, JAMA-J AM MED ASSOC, V308, P405, DOI 10.1001/jama.2012.8488; Steinbrook R, 2012, JAMA-J AM MED ASSOC, V308, P345, DOI 10.1001/jama.2012.7855; Subramanian S, 2012, JAMA-J AM MED ASSOC, V308, P379, DOI 10.1001/jama.2012.6698; Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961	13	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					407	408		10.1001/jama.2012.8648	http://dx.doi.org/10.1001/jama.2012.8648			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820795				2022-12-28	WOS:000306685500030
J	Yehia, BR; Fleishman, JA; Metlay, JP; Moore, RD; Gebo, KA				Yehia, Baligh R.; Fleishman, John A.; Metlay, Joshua P.; Moore, Richard D.; Gebo, Kelly A.			Sustained Viral Suppression in HIV-Infected Patients Receiving Antiretroviral Therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PREVENTION; CARE		[Yehia, Baligh R.; Metlay, Joshua P.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Fleishman, John A.] Agcy Healthcare Res & Qual, Ctr Financing Access & Cost Trends, Rockville, MD USA; [Moore, Richard D.; Gebo, Kelly A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	University of Pennsylvania; Pennsylvania Medicine; Agency for Healthcare Research & Quality; Johns Hopkins University	Yehia, BR (corresponding author), Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.	byehia@upenn.edu	Gebo, Kelly/AHA-7533-2022	Gebo, Kelly/0000-0003-4010-398X	NIAAA NIH HHS [R01 AA016893, R01 AA 16893] Funding Source: Medline; NIAID NIH HHS [K24 AI073957, U01 AI069918] Funding Source: Medline; NIDA NIH HHS [K24 DA 00432, R01DA11602, R01 DA011602, K24 DA000432] Funding Source: Medline; PHS HHS [290-01-0012] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069918, K24AI073957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA016893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011602, K24DA000432] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cohen Stacy M., 2011, Morbidity and Mortality Weekly Report, V60, P1618; Gill VS, 2010, CLIN INFECT DIS, V50, P98, DOI 10.1086/648729; Moore RD, 2011, CLIN INFECT DIS, V53, P600, DOI 10.1093/cid/cir467; Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG HIV 1; Thompson MA, 2012, ANN INTERN MED, V156, P817, DOI 10.7326/0003-4819-156-11-201206050-00419	6	66	66	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2012	308	4					339	342		10.1001/jama.2012.5927	http://dx.doi.org/10.1001/jama.2012.5927			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977SR	22820781	Green Accepted			2022-12-28	WOS:000306685500016
J	Kohler, M; Marin-Moratalla, N; Jordana, X; Aanes, R				Koehler, Meike; Marin-Moratalla, Nekane; Jordana, Xavier; Aanes, Ronny			Seasonal bone growth and physiology in endotherms shed light on dinosaur physiology	NATURE			English	Article							AMPRINOS RULE; REINDEER; DEER; HYPOMETABOLISM; HISTOLOGY; HORMONES; FOOD	Cyclical growth leaves marks in bone tissue that are in the forefront of discussions about physiologies of extinct vertebrates(1). Ectotherms show pronounced annual cycles of growth arrest that correlate with a decrease in body temperature and metabolic rate; endotherms are assumed to grow continuously until they attain maturity because of their constant high body temperature and sustained metabolic rate(1,2). This apparent dichotomy has driven the argument that zonal bone denotes ectotherm-like physiologies, thus fuelling the controversy on dinosaur thermophysiology and the evolution of endothermy in birds and mammal-like reptiles(1-4). Here we show, from a comprehensive global study of wild ruminants from tropical to polar environments, that cyclical growth is a universal trait of homoeothermic endotherms. Growth is arrested during the unfavourable season concurrently with decreases in body temperature, metabolic rate and bone-growth-mediating plasma insulin-like growth factor-1 levels, forming part of a plesiomorphic thermometabolic strategy for energy conservation. Conversely, bouts of intense tissue growth coincide with peak metabolic rates and correlated hormonal changes at the beginning of the favourable season, indicating an increased efficiency in acquiring and using seasonal resources. Our study supplies the strongest evidence so far that homeothermic endotherms arrest growth seasonally, which precludes the use of lines of arrested growth as an argument in support of ectothermy. However, high growth rates are a distinctive trait of mammals, suggesting the capacity for endogenous heat generation. The ruminant annual cycle provides an extant model on which to base inferences regarding the thermophysiology of dinosaurs and other extinct taxa.	[Koehler, Meike] Univ Autonoma Barcelona, ICREA, Inst Catala Paleontol Miquel Crusafont, Bellaterra 08193, Spain; [Aanes, Ronny] Norwegian Polar Res Inst, Fram Ctr, NO-9296 Tromso, Norway; [Aanes, Ronny] Norwegian Directorate Nat Management, NO-7047 Trondheim, Norway	Autonomous University of Barcelona; ICREA; Institut Catala de Paleontologia Miquel Crusafont (ICP); Norwegian Polar Institute	Kohler, M (corresponding author), Univ Autonoma Barcelona, ICREA, Inst Catala Paleontol Miquel Crusafont, Bellaterra 08193, Spain.	meike.kohler@icp.cat	Jordana, Xavier/L-9301-2014; Jordana, Xavier/G-7537-2017	Jordana, Xavier/0000-0001-8990-4388; Jordana, Xavier/0000-0002-6016-6630; Kohler, Meike/0000-0001-9228-3164; Kohler, Meike/0000-0002-6816-6651	Spanish Ministry of Science and Innovation [CGL2008-06204/BTE, CGL2011-24685, BES-2009-02641, JCI-2010-08157]; Norwegian Research Council [NORKLIMA 178561/S30]; ICREA Funding Source: Custom	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Norwegian Research Council(Research Council of NorwayEuropean Commission); ICREA(ICREA)	We thank Th. Kaiser for permission to cut femora of skeletons from the Oboussier collections and from zoological material housed at the Zoological Institute and Museum of the University of Hamburg; W. Arnold for providing alpine red deer material, and A. Kubber for preparing and sending it; R. Garcia Gonzalez for providing red deer femora from Jaca (Spanish Pyrenees) and Capra ibex from Alfarc (Tarragona, Spain); all the people that helped collect the Svalbard material, and R. Garcia for preparation of the thin sections; and J. Horner, H. Woodward, S. Moya-Sola, T. Bromage and J. Cubo for comments on the manuscript. This work was supported by the Spanish Ministry of Science and Innovation (CGL2008-06204/BTE, 2012: CGL2011-24685, M.K.; BES-2009-02641, N.M.-M.; JCI-2010-08157, X.J.); the work was partly funded by the Norwegian Research Council (NORKLIMA 178561/S30, R.A.). The material is tabulated in the Supporting Online Material and archived at the Institut Catala de Paleontologia, Catalonia, Spain.	Aanes R, 2000, ECOGRAPHY, V23, P437, DOI 10.1034/j.1600-0587.2000.230406.x; Arnold W, 2004, AM J PHYSIOL-REG I, V286, pR174, DOI 10.1152/ajpregu.00593.2002; Bennett A.F., 1986, P207; Bubenik GA, 1998, COMP BIOCHEM PHYS C, V120, P307, DOI 10.1016/S0742-8413(98)10010-5; Chinsamy A, 2004, DINOSAURIA, 2ND EDITION, P643; Chinsamy A, 2012, ANAT REC, V295, P610, DOI 10.1002/ar.22428; Courtland HW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014762; de Margerie E, 2002, CR BIOL, V325, P221, DOI 10.1016/S1631-0691(02)01429-4; Fastovsky D. E., 2009, DINOSAURS CONCISE NA; Gruber A., 2008, 128 WCRP WORLD MET O; Hetem RS, 2010, J COMP PHYSIOL B, V180, P1111, DOI 10.1007/s00360-010-0480-z; Klein N, 2008, PALEOBIOLOGY, V34, P247, DOI 10.1666/0094-8373(2008)034[0247:OSITLB]2.0.CO;2; Klevezal G., 1996, RECORDING STRUCTURES; Lawler James P., 1997, Rangifer, V17, P135; McNab B.K, 2002, PHYSL ECOLOGY VERTEB, DOI DOI 10.1643/0045-8511(2002)002[1170:]2.0.CO;2; McNab BK, 2010, OECOLOGIA, V164, P13, DOI 10.1007/s00442-010-1621-5; Montes L, 2010, ANIM BIOL, V60, P25, DOI 10.1163/157075610X12610595764093; Ostrowski S, 2006, PHYSIOL BIOCHEM ZOOL, V79, P810, DOI 10.1086/504614; Padian K, 2004, DINOSAURIA, 2ND EDITION, P660; Peel MC, 2007, HYDROL EARTH SYST SC, V11, P1633, DOI 10.5194/hess-11-1633-2007; Piccione G, 2009, BIOL RHYTHM RES, V40, P455, DOI 10.1080/09291010802568848; REID REH, 1984, GEOL MAG, V121, P589, DOI 10.1017/S0016756800030739; REIMERS E, 1984, Rangifer, V4, P16; RINGBERG T, 1979, ACTA PHYSIOL SCAND, V105, P268, DOI 10.1111/j.1748-1716.1979.tb06341.x; Sander PM, 2006, PALAEONTOGR ABT A, V277, P143; Signer C, 2011, FUNCT ECOL, V25, P537, DOI 10.1111/j.1365-2435.2010.01806.x; SUTTIE JM, 1995, AM ZOOL, V35, P215; Todini L, 2007, ANIMAL, V1, P997, DOI 10.1017/S1751731107000262; Turbill C, 2011, J EXP BIOL, V214, P963, DOI 10.1242/jeb.052282; Tyler N. J. C., 1990, Rangifer, P211	30	149	149	2	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 19	2012	487	7407					358	361		10.1038/nature11264	http://dx.doi.org/10.1038/nature11264			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JB	22763443				2022-12-28	WOS:000306506500041
J	Franklin, BA				Franklin, Barry A.			Multifactorial cardiac rehabilitation did not reduce mortality or morbidity after acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Beaumont Hlth Syst, Royal Oak, MI USA	Beaumont Health	Franklin, BA (corresponding author), Beaumont Hlth Syst, Royal Oak, MI USA.							Heran BS, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800.pub2, 10.1002/14651858.CD001800.pub3]; Smith SC, 2011, CIRCULATION, V124, P2458, DOI 10.1161/CIR.0b013e318235eb4d; Taylor RS, 2004, AM J MED, V116, P682, DOI 10.1016/j.amjmed.2004.01.009	3	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2							JC2-11	10.7326/0003-4819-157-2-201207170-02011	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-02011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801702				2022-12-28	WOS:000307787900010
J	Moyer, VA				Moyer, Virginia A.		US Preventive Serv Task Force	Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement	ANNALS OF INTERNAL MEDICINE			English	Article							ANDROGEN DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; RADICAL PROSTATECTOMY; FOLLOW-UP; CONSERVATIVE MANAGEMENT; ANTIGEN LEVELS; MORTALITY; MEN; OUTCOMES; BIOPSY	Description: Update of the 2008 U.S. Preventive Services Task Force (USPSTF) recommendation statement on screening for prostate cancer. Methods: The USPSTF reviewed new evidence on the benefits and harms of prostate-specific antigen (PSA)-based screening for prostate cancer, as well as the benefits and harms of treatment of localized prostate cancer. Recommendation: The USPSTF recommends against PSA-based screening for prostate cancer (grade D recommendation). This recommendation applies to men in the general U.S. population, regardless of age. This recommendation does not include the use of the PSA test for surveillance after diagnosis or treatment of prostate cancer; the use of the PSA test for this indication is outside the scope of the USPSTF.	[Moyer, Virginia A.] Baylor Coll Med, Houston, TX 77030 USA; [Moyer, Virginia A.; US Preventive Serv Task Force] US Prevent Serv Task Force, Rockville, MD USA	Baylor College of Medicine	Moyer, VA (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.				USPSTF	USPSTF	The USPSTF is an independent, voluntary body. The U.S. Congress mandates that the Agency for Healthcare Research and Quality support the operations of the USPSTF.	Albertsen PC, 2005, JAMA-J AM MED ASSOC, V293, P2095, DOI 10.1001/jama.293.17.2095; American Cancer Society, 2011, CANC FACTS FIG 2011; Andriole GL, 2012, J NATL CANCER I, V104, P125, DOI 10.1093/jnci/djr500; Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696; Bach PB, 2011, J CLIN ONCOL, V29, pE387, DOI 10.1200/JCO.2011.34.9027; Bill-Axelson A, 2008, J NATL CANCER I, V100, P1144, DOI 10.1093/jnci/djn255; Bill-Axelson A, 2011, NEW ENGL J MED, V364, P1708, DOI 10.1056/NEJMoa1011967; Carroll P, 2009, PROSTATE SPECIFIC AN; Catalona WJ, 2011, 107 ANN M AM UR ASS; Chou R, 2011, AHRQ PUBLICATION; Chou R, 2011, ANN INTERN MED, V155, P762, DOI 10.7326/0003-4819-155-11-201112060-00375; Collin SM, 2008, BJU INT, V102, P1400, DOI 10.1111/j.1464-410X.2008.07817.x; Cooperberg MR, 2010, J CLIN ONCOL, V28, P1117, DOI 10.1200/JCO.2009.26.0133; Crawford ED, 2011, J CLIN ONCOL, V29, P355, DOI 10.1200/JCO.2010.30.5979; Croswell JM, 2009, ANN FAM MED, V7, P212, DOI 10.1370/afm.942; Draisma G, 2003, J NATL CANCER I, V95, P868, DOI 10.1093/jnci/95.12.868; Dubben HH, 2009, LANCET ONCOL, V10, P294, DOI 10.1016/S1470-2045(09)70066-X; Fowler FJ, 2006, J GEN INTERN MED, V21, P715, DOI 10.1111/j.1525-1497.2006.00464.x; Fransson P, 2009, SCAND J UROL NEPHROL, V43, P119, DOI 10.1080/00365590802519396; Ganz PA, 2012, ANN INTERN MED, V156, P591, DOI [10.7326/0003-4819-156-8-201204170-00401, 10.7326/0003-4819-156-8-201204170-00010]; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Howlader N, 2011, SEER CANC STAT REV 1; Hu JC, 2009, JAMA-J AM MED ASSOC, V302, P1557, DOI 10.1001/jama.2009.1451; Hugosson J, 2010, LANCET ONCOL, V11, P725, DOI 10.1016/S1470-2045(10)70146-7; IVERSEN P, 1995, SCAND J UROL NEPHROL, P65; Johansson E, 2011, LANCET ONCOL, V12, P891, DOI 10.1016/S1470-2045(11)70162-0; Kiellman A, 2009, J UROLOGY, V181, P1615, DOI 10.1016/j.juro.2008.11.115; Kilpelainen TP, 2010, BRIT J CANCER, V102, P469, DOI 10.1038/sj.bjc.6605512; Labrie F, 2004, PROSTATE, V59, P311, DOI 10.1002/pros.20017; Lim LS, 2008, AM J PREV MED, V34, P164, DOI 10.1016/j.amepre.2007.10.003; Lin K, 2011, AHRO PUBLICATION; Lin K, 2008, ANN INTERN MED, V149, P192, DOI 10.7326/0003-4819-149-3-200808050-00009; Loeb S, 2011, J UROLOGY, V186, P1830, DOI 10.1016/j.juro.2011.06.057; Lu-Yao G, 2004, J UROLOGY, V171, P2285, DOI 10.1097/01.ju.0000127740.96006.1a; Lu-Yao GL, 2008, JAMA-J AM MED ASSOC, V300, P173, DOI 10.1001/jama.300.2.173; Lu-Yao GL, 2009, JAMA-J AM MED ASSOC, V302, P1202, DOI 10.1001/jama.2009.1348; McNaughton-Collins M, 2004, AM J MED, V117, P719, DOI 10.1016/j.amjmed.2004.06.036; Miller AB, 2012, NEW ENGL J MED, V366, P1047, DOI 10.1056/NEJMe1200185; Moore AL, 2009, BJU INT, V104, P1592, DOI 10.1111/j.1464-410X.2009.08652.x; Newschaffer CJ, 2000, JNCI-J NATL CANCER I, V92, P613, DOI 10.1093/jnci/92.8.613; Nguyen PL, 2011, JAMA-J AM MED ASSOC, V306, P2359, DOI 10.1001/jama.2011.1745; Raaijmakers R, 2002, UROLOGY, V60, P826, DOI 10.1016/S0090-4295(02)01958-1; Rosario DJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d7894; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; Sandblom G, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1539; Schroder FH, 2012, NEW ENGL J MED, V366, P981, DOI 10.1056/NEJMoa1113135; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084; Theoret MR, 2011, NEW ENGL J MED, V365, P97, DOI 10.1056/NEJMp1106783; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Thompson IM, 2005, JAMA-J AM MED ASSOC, V294, P66, DOI 10.1001/jama.294.1.66; US Preventive Serv Task Force, 2008, ANN INTERN MED, V149, P185, DOI 10.7326/0003-4819-149-3-200808050-00008; Vickers AJ, 2011, J NATL CANCER I, V103, P462, DOI 10.1093/jnci/djr028; Welch HG, 2010, J NATL CANCER I, V102, P605, DOI 10.1093/jnci/djq099; Welch HG, 2009, J NATL CANCER I, V101, P1325, DOI 10.1093/jnci/djp278; Welch HG, 2005, J NATL CANCER I, V97, P1132, DOI 10.1093/jnci/dji205; Widmark A, 2011, 53 ANN M AM SOC THER; Wilt TJ, 2008, ANN INTERN MED, V148, P435, DOI 10.7326/0003-4819-148-6-200803180-00209; Wilt TJ, 2009, CONTEMP CLIN TRIALS, V30, P81, DOI 10.1016/j.cct.2008.08.002; Wilt TJ, 2011, 107 ANN M AM UR ASS; Wolf AMD, 2010, CA-CANCER J CLIN, V60, P70, DOI 10.3322/caac.20066; Woloshin S, 2010, JAMA-J AM MED ASSOC, V303, P164, DOI 10.1001/jama.2009.2007; Wolters T, 2010, INT J CANCER, V126, P2387, DOI 10.1002/ijc.24870	62	1498	1526	3	103	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2					120	+		10.7326/0003-4819-157-2-201207170-00459	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00459			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801674				2022-12-28	WOS:000307787900017
J	Singh, AK; Kari, JA				Singh, Ajay K.; Kari, Jameela A.			24-hour isotonic sodium choloride was better than 7-hour sodium bicarbonate for preventing CIN	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Singh, Ajay K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [Kari, Jameela A.] King Abdulaziz Univ, Fac Med, Jeddah 21413, Saudi Arabia	Harvard University; Brigham & Women's Hospital; Harvard Medical School; King Abdulaziz University	Singh, AK (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.		Singh, Ajay/AAF-4414-2020					Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Merten GJ, 2004, JAMA-J AM MED ASSOC, V291, P2328, DOI 10.1001/jama.291.19.2328	2	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2							JC2-9	10.7326/0003-4819-157-2-201207170-02009	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-02009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22801700				2022-12-28	WOS:000307787900008
J	Sepkowitz, KA				Sepkowitz, Kent A.			Finland, Weinstein, and the Birth of Antibiotic Regret	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Sepkowitz, Kent A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Sepkowitz, Kent A.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Sepkowitz, KA (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.							BROWN C, 1953, JAMA-J AM MED ASSOC, V152, P206, DOI 10.1001/jama.1953.03690030006002; FINLAND M, 1953, NEW ENGL J MED, V248, P220, DOI 10.1056/NEJM195302052480602; MOSER RH, 1956, NEW ENGL J MED, V255, P606, DOI 10.1056/NEJM195609272551306; SMITH DT, 1952, ANN INTERN MED, V37, P1135, DOI 10.7326/0003-4819-37-6-1135	4	6	8	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2					102	103		10.1056/NEJMp1205847	http://dx.doi.org/10.1056/NEJMp1205847			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972IO	22784113				2022-12-28	WOS:000306270800005
J	Jaques, R; Loosemore, M				Jaques, Rod; Loosemore, Mike			Sports and exercise medicine in undergraduate training	LANCET			English	Editorial Material							10-YEAR FOLLOW-UP; BREAST-CANCER; PHYSICAL-ACTIVITY; RANDOMIZED-TRIAL; HIP FRACTURE; PREVENTION; WOMEN; RISK; OUTCOMES		[Jaques, Rod] Fac Sport & Exercise Med UK, Edinburgh EH8 9DR, Midlothian, Scotland; [Loosemore, Mike] Univ Coll London Hosp, London, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Jaques, R (corresponding author), Fac Sport & Exercise Med UK, Edinburgh EH8 9DR, Midlothian, Scotland.	rod.jaques@eis2win.co.uk						Babyak M, 2000, PSYCHOSOM MED, V62, P633, DOI 10.1097/00006842-200009000-00006; Blair SN, 2009, BRIT J SPORT MED, V43, P1; Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2; Feskanich D, 2002, JAMA-J AM MED ASSOC, V288, P2300, DOI 10.1001/jama.288.18.2300; Ford I, 2007, NEW ENGL J MED, V357, P1477, DOI 10.1056/NEJMoa065994; Friedenreich CM, 2002, J NUTR, V132, p3456S, DOI 10.1093/jn/132.11.3456S; Hackshaw A, 2011, J CLIN ONCOL, V29, P1657, DOI 10.1200/JCO.2010.32.2933; Hambrecht R, 2004, CIRCULATION, V109, P1371, DOI 10.1161/01.CIR.0000121360.31954.1F; Holmes MD, 2005, JAMA-J AM MED ASSOC, V293, P2479, DOI 10.1001/jama.293.20.2479; Lee DC, 2010, J PSYCHOPHARMACOL, V24, P27, DOI 10.1177/1359786810382057; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; Moradi T, 2002, INT J CANCER, V100, P76, DOI 10.1002/ijc.10447; National Health Service, FRESH APPR 2012; Oluwajana F, 2010, BRIT J SPORT MED, V44, pi6; Pigozzi F, 2009, BRIT J SPORT MED, V43, P1085, DOI 10.1136/bjsm.2008.055350; Royal College of General Practitioners-Birmingham Research Unit, ANN PREV REP 2006; Wei M, 1999, ANN INTERN MED, V130, P89, DOI 10.7326/0003-4819-130-2-199901190-00002; YOUNG A, 1983, MED EDUC, V17, P369, DOI 10.1111/j.1365-2923.1983.tb01122.x	19	14	15	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 7	2012	380	9836					4	5		10.1016/S0140-6736(12)60992-1	http://dx.doi.org/10.1016/S0140-6736(12)60992-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	970GK	22770445				2022-12-28	WOS:000306115900005
J	Samstein, RM; Josefowicz, SZ; Arvey, A; Treuting, PM; Rudensky, AY				Samstein, Robert M.; Josefowicz, Steven Z.; Arvey, Aaron; Treuting, Piper M.; Rudensky, Alexander Y.			Extrathymic Generation of Regulatory T Cells in Placental Mammals Mitigates Maternal-Fetal Conflict	CELL			English	Article							IMPRINTED GENE; IMMUNE-SYSTEM; FOXP3 GENE; TGF-BETA; PROTEIN; AUTOIMMUNITY; PREGNANCY; RETROTRANSPOSON; EXPRESSION; INTERFACE	Regulatory T (Treg) cells, whose differentiation and function are controlled by X chromosome-encoded transcription factor Foxp3, are generated in the thymus (tTreg) and extrathymically (peripheral, pTreg), and their deficiency results in fatal autoimmunity. Here, we demonstrate that a Foxp3 enhancer, conserved noncoding sequence 1 (CNS1), essential for pTreg but dispensable for tTreg cell generation, is present only in placental mammals. CNS1 is largely composed of mammalian-wide interspersed repeats (MIR) that have undergone retrotransposition during early mammalian radiation. During pregnancy, pTreg cells specific to a model paternal alloantigen were generated in a CNS1-dependent manner and accumulated in the placenta. Furthermore, when mated with allogeneic, but not syngeneic, males, CNS1-deficient females showed increased fetal resorption accompanied by increased immune cell infiltration and defective remodeling of spiral arteries. Our results suggest that, during evolution, a CNS1-dependent mechanism of extrathymic differentiation of Treg cells emerged in placental animals to enforce maternal-fetal tolerance.	[Samstein, Robert M.; Josefowicz, Steven Z.; Arvey, Aaron; Rudensky, Alexander Y.] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10065 USA; [Samstein, Robert M.; Josefowicz, Steven Z.; Arvey, Aaron; Rudensky, Alexander Y.] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10065 USA; [Treuting, Piper M.] Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Washington; University of Washington Seattle	Rudensky, AY (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10065 USA.	rudenska@mskcc.org	Treuting, Piper M./AAB-2721-2019	Treuting, Piper M./0000-0002-1812-1519; Samstein, Robert/0000-0001-6860-2401; josefowicz, steven/0000-0001-7453-779X; Arvey, Aaron/0000-0002-8789-0290	NIH [DK091968, R37 AI21609]; MSTP [GM07739]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F30DK091968] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MSTP; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We would like to thank J. Gerard, Y. Liang, D. Canner, and M. Samstein; Z. Williams for helpful discussion; S. Gelber for review of histology; and P. Samollow and J. Vandeberg for providing opossum genomic DNA. R.M.S. was supported by NIH DK091968 and MSTP grant GM07739. A.Y.R. was supported by NIH grant R37 AI21609. A.Y.R. is an investigator with the Howard Hughes Medical Institute.	Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Arruvito L, 2009, J REPROD IMMUNOL, V82, P158, DOI 10.1016/j.jri.2009.04.010; Avagliano L, 2011, J CLIN PATHOL, V64, P1064, DOI 10.1136/jclinpath-2011-200092; Bejerano G, 2006, NATURE, V441, P87, DOI 10.1038/nature04696; Blois SM, 2007, NAT MED, V13, P1450, DOI 10.1038/nm1680; BROSIUS J, 1992, P NATL ACAD SCI USA, V89, P10706, DOI 10.1073/pnas.89.22.10706; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Collins MK, 2009, J CLIN INVEST, V119, P2062, DOI 10.1172/JCI38714; Darmochwal-Kolarz D, 2012, J REPROD IMMUNOL, V93, P75, DOI 10.1016/j.jri.2012.01.006; Dupressoir A, 2011, P NATL ACAD SCI USA, V108, pE1164, DOI 10.1073/pnas.1112304108; Erlebacher A, 2007, J CLIN INVEST, V117, P1399, DOI 10.1172/JCI28214; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Grubin CE, 1997, IMMUNITY, V7, P197, DOI 10.1016/S1074-7613(00)80523-3; Hall JA, 2011, IMMUNITY, V35, P13, DOI 10.1016/j.immuni.2011.07.002; Heikkinen J, 2004, CLIN EXP IMMUNOL, V136, P373, DOI 10.1111/j.1365-2249.2004.02441.x; Hunt JS, 1997, J IMMUNOL, V158, P4122; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; JURKA J, 1995, NUCLEIC ACIDS RES, V23, P170, DOI 10.1093/nar/23.1.170; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Littman DR, 2010, CELL, V140, P845, DOI 10.1016/j.cell.2010.02.021; Margulies EH, 2007, GENOME RES, V17, P760, DOI 10.1101/gr.6034307; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; Mikkelsen TS, 2007, NATURE, V447, P167, DOI 10.1038/nature05805; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munoz-Suano A, 2011, IMMUNOL REV, V241, P20, DOI 10.1111/j.1600-065X.2011.01002.x; Nikolaev S, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030002; Ono R, 2006, NAT GENET, V38, P101, DOI 10.1038/ng1699; Petroff MG, 2010, AM J REPROD IMMUNOL, V63, P506, DOI 10.1111/j.1600-0897.2010.00841.x; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Quintana FJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009478; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; Renaud SJ, 2011, J IMMUNOL, V186, P1799, DOI 10.4049/jimmunol.1002679; Rowe JH, 2011, CELL HOST MICROBE, V10, P54, DOI 10.1016/j.chom.2011.06.005; Sekita Y, 2008, NAT GENET, V40, P243, DOI 10.1038/ng.2007.51; Shima T, 2010, J REPROD IMMUNOL, V85, P121, DOI 10.1016/j.jri.2010.02.006; Simpson H, 2002, PLACENTA, V23, P44, DOI 10.1053/plac.2001.0746; SMIT AFA, 1995, NUCLEIC ACIDS RES, V23, P98, DOI 10.1093/nar/23.1.98; Somerset DA, 2004, IMMUNOLOGY, V112, P38, DOI 10.1111/j.1365-2567.2004.01869.x; Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Winger EE, 2011, AM J REPROD IMMUNOL, V66, P320, DOI 10.1111/j.1600-0897.2011.00992.x; Xu LL, 2010, IMMUNITY, V33, P313, DOI 10.1016/j.immuni.2010.09.001; Zheng SG, 2004, J IMMUNOL, V172, P5213, DOI 10.4049/jimmunol.172.9.5213; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750	51	426	438	2	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 6	2012	150	1					29	38		10.1016/j.cell.2012.05.031	http://dx.doi.org/10.1016/j.cell.2012.05.031			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	970GB	22770213	Green Accepted, Bronze			2022-12-28	WOS:000306115000004
J	Truog, RD; Kesselheim, AS; Joffe, S				Truog, Robert D.; Kesselheim, Aaron S.; Joffe, Steven			Paying Patients for Their Tissue: The Legacy of Henrietta Lacks	SCIENCE			English	Editorial Material									[Truog, Robert D.] Childrens Hosp Boston, Boston, MA 02115 USA; [Kesselheim, Aaron S.] Brigham & Womens Hosp, Boston, MA 02120 USA; [Joffe, Steven] Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute	Truog, RD (corresponding author), Childrens Hosp Boston, Boston, MA 02115 USA.	robert.truog@childrens.harvard.edu	Joffe, Steven/H-3941-2019; Kesselheim, Aaron/R-6793-2017	Joffe, Steven/0000-0002-0667-7384; Kesselheim, Aaron/0000-0002-8867-2666	AHRQ HHS [K08 HS018465, K08HS18465-01] Funding Source: Medline; NCRR NIH HHS [UL1 RR025758, 1 UL1 RR025758-01] Funding Source: Medline; AHRQ [5K08HS018465-04] Funding Source: Federal RePORTER; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS018465] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Charo RA, 2006, NEW ENGL J MED, V355, P1517, DOI 10.1056/NEJMp068192; Grady C, 2005, J CLIN INVEST, V115, P1681, DOI 10.1172/JCI25694; Murray T. H., 1986, DISCOVER, V7, P90; Sandel Michael, 2012, WHAT MONEY CANT BUY, P93; Skloot R., 2011, IMMORTAL LIFE HENRIE; Skloot Rebecca, 2006, N Y Times Mag, P38	6	31	31	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2012	337	6090					37	38		10.1126/science.1216888	http://dx.doi.org/10.1126/science.1216888			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	969KC	22767914	Green Accepted			2022-12-28	WOS:000306053100032
J	Sagan, SD				Sagan, Scott D.			A call for global nuclear disarmament	NATURE			English	Editorial Material									Stanford Univ, Ctr Int Secur & Cooperat, Stanford, CA 94305 USA	Stanford University	Sagan, SD (corresponding author), Stanford Univ, Ctr Int Secur & Cooperat, Stanford, CA 94305 USA.	ssagan@stanford.edu						Brands H, 2011, INT SECURITY, V36, P133, DOI 10.1162/ISEC_a_00047; Braut-Hegghammer M, 2011, INT SECURITY, V36, P101, DOI 10.1162/ISEC_a_00046; Dobbs M., 2008, ONE MINUTE MIDNIGHT, p[191, 258, 276]; Lister T., 2011, CNN WORLD       0622; Miller S. E., 2012, 141 AAAS; Muller H., 2011, NONPROLIFERATION REV, P219; Palkki D., 2011, SADDAM TAPES, P223; Sagan S. D., 2010, 113 AAAS; Sagan S. D., 1993, LIMITS SAFETY ORG AC, P81; Sanger D. E., 2009, INHERITANCE WORLD OB, P220; SCIOLINO E, 2007, NY TIMES        0201; U.S. Department of Defense, 2011, NUCL POST REV REP, pix	12	6	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 5	2012	487	7405					30	32		10.1038/487030a	http://dx.doi.org/10.1038/487030a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	968LM	22763534	Bronze			2022-12-28	WOS:000305982900016
J	Clack, A; Lledo-Weber, P				Clack, Alice; Lledo-Weber, Patricia			Ensuring that women have access to safe abortion is "pro-life"	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Clack, Alice] Hillingdon Hosp, Uxbridge UB8 3NN, Middx, England		Clack, A (corresponding author), Hillingdon Hosp, Uxbridge UB8 3NN, Middx, England.	aclack@doctors.org.uk							0	2	2	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 4	2012	344								e4391	10.1136/bmj.e4391	http://dx.doi.org/10.1136/bmj.e4391			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972KE	22763395				2022-12-28	WOS:000306275200009
J	Koretz, RL				Koretz, Ronald L.			Review: Proton-pump inhibitors are associated with increased risk for Clostridium difficile infection	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CLOPIDOGREL		Olive View UCLA Med Ctr, Sylmar, CA 91342 USA	University of California System; University of California Los Angeles	Koretz, RL (corresponding author), Olive View UCLA Med Ctr, 14445 Olive View Dr, Sylmar, CA 91342 USA.							Bhatt DL, 2010, NEW ENGL J MED, V363, P1909, DOI 10.1056/NEJMoa1007964; Ho PM, 2009, JAMA-J AM MED ASSOC, V301, P937, DOI 10.1001/jama.2009.261	2	1	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 21	2012	157	4							JC4-13	10.7326/0003-4819-157-4-201208210-02013	http://dx.doi.org/10.7326/0003-4819-157-4-201208210-02013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992XG	22910967				2022-12-28	WOS:000307813200012
J	Gewin, V				Gewin, Virginia			THE SEQUENCING MACHINE	NATURE			English	News Item							HUMAN MICROBIOME; GUT MICROBIOME; BODY HABITATS; COMMUNITIES											Caporaso JG, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-5-r50; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Costello EK, 2010, ISME J, V4, P1375, DOI 10.1038/ismej.2010.71; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Fierer N, 2010, P NATL ACAD SCI USA, V107, P6477, DOI 10.1073/pnas.1000162107; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; KNIGHT RD, 2001, GENOME BIOL, V2; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Muegge BD, 2011, SCIENCE, V332, P970, DOI 10.1126/science.1198719; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Yatsunenko T, 2012, NATURE	13	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2012	487	7406					156	158		10.1038/487156a	http://dx.doi.org/10.1038/487156a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	972LP	22816112	Bronze			2022-12-28	WOS:000306278900011
J	Koretz, RL				Koretz, Ronald L.			Invitation to screening with colonoscopy had lower participation but similar yield as CT colonography	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							COLORECTAL-CANCER		Olive View UCLA Med Ctr, Sylmar, CA 91342 USA	University of California System; University of California Los Angeles	Koretz, RL (corresponding author), Olive View UCLA Med Ctr, 14445 Olive View Dr, Sylmar, CA 91342 USA.							Atkin WS, 2010, LANCET, V375, P1624, DOI 10.1016/S0140-6736(10)60551-X; Baxter NN, 2009, ANN INTERN MED, V150, P1, DOI 10.7326/0003-4819-150-1-200901060-00306; Brenner H, 2011, ANN INTERN MED, V154, P22, DOI 10.7326/0003-4819-154-1-201101040-00004; Hewitson P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001216.pub2; Quintero E, 2012, NEW ENGL J MED, V366, P697, DOI [10.1056/NEJMoa1108895, 10.1056/NEJMx150040]	5	1	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2							JC2-5	10.7326/0003-4819-157-2-201207170-02005	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-02005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22910967				2022-12-28	WOS:000307787900004
J	Powell, K				Powell, Kendall			Egg-making stem cells found in adult ovaries	NATURE			English	News Item																		Johnson J, 2004, NATURE, V428, P145, DOI 10.1038/nature02316; White Y. A. R., 2012, NATURE MED; Zou K, 2009, NAT CELL BIOL, V11, P631, DOI 10.1038/ncb1869	3	11	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 1	2012	483	7387					16	17		10.1038/483016a	http://dx.doi.org/10.1038/483016a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	900HP	22382955	Bronze			2022-12-28	WOS:000300877900018
